PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ARAGAY, AM; KATZ, A; SIMON, MI				ARAGAY, AM; KATZ, A; SIMON, MI			THE G-ALPHA-Q AND G-ALPHA-11 PROTEINS COUPLE THE THYROTROPIN-RELEASING-HORMONE RECEPTOR TO PHOSPHOLIPASE-C IN GH3 RAT PITUITARY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; INOSITOL TRISPHOSPHATE FORMATION; REGULATORY PROTEINS; PERTUSSIS-TOXIN; SUBUNITS; HYDROLYSIS; MEMBRANES; PURIFICATION; DISTINCT; ACTIVATION	Thyrotropin-releasing hormone stimulates the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) in GH3 cell membranes. The stimulation of the phosphoinositide phospholipase C (PI/PLC) activity can be blocked by incubation of GH3 membranes with polyclonal antibodies directed against a peptide derived from the C-terminal region of Galphaq and Galpha11. Antibodies directed against the C-terminal region of other Galpha-subunits had no detectable effect. The inhibition was specific since addition of the peptide that was used to prepare the antibody completely reversed the inhibition. Further evidence for the coupling of the TRH receptor to Galpha(q) or Galpha11 comes from a reconstitution experiment in which human embryonic kidney cells were transiently transfected with cDNAs corresponding to the TRH receptor, Galpha(q) or Galpha11. The PIP2 hydrolysis detected with membranes from cells that over-expressed the TRH receptor alone was low, however, co-expression with the Galpha(q) or Galpha11 subunits produced a synergistic stimulation of PI-PLC activity. In contrast, co-expression of these alpha-subunits with the M2 muscarinic acetylcholine receptor induced a weak stimulation of PIP2 hydrolysis. The results presented here suggest that the TRH-dependent stimulation of PI-PLC in GH3 cells is mediated through the G-protein alpha-subunits, Galpha(q) and/or Galpha11.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Katz, Arieh/F-5836-2012; Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126	NIGMS NIH HHS [GM 34236] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; AUB DL, 1987, J BIOL CHEM, V262, P9521; AUB DL, 1986, J BIOL CHEM, V261, P9333; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HINKLE PM, 1984, J BIOL CHEM, V259, P3445; HINKLE PM, 1984, P NATL ACAD SCI-BIOL, V81, P6183, DOI 10.1073/pnas.81.19.6183; HINKLE PM, 1973, J BIOL CHEM, V248, P6180; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; IMAI A, 1985, J BIOL CHEM, V260, P536; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCAS DO, 1985, BIOCHEM BIOPH RES CO, V132, P721, DOI 10.1016/0006-291X(85)91192-1; MARTIN MW, 1985, BIOCHEM J, V229, P539, DOI 10.1042/bj2290539; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; OFFERMANNS S, 1989, EUR J BIOCHEM, V180, P283, DOI 10.1111/j.1432-1033.1989.tb14645.x; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARK D, 1992, J BIOL CHEM, V267, P16048; PAULSSEN EJ, 1991, MOL CELL ENDOCRINOL, V76, P45, DOI 10.1016/0303-7207(91)90258-T; RYU SH, 1987, J BIOL CHEM, V262, P12511; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; STRAUB RE, 1986, J BIOL CHEM, V261, P2712; STRAUB RE, 1991, P NATL ACAD SCI USA, V87, P9414; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; UI M, 1990, ADP RIBOSYLATING TOX, P45; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1992, J BIOL CHEM, V267, P1811	40	140	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24983	24988						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334076				2022-12-25	WOS:A1992KB60300014
J	BOOTMAN, MD; TAYLOR, CW; BERRIDGE, MJ				BOOTMAN, MD; TAYLOR, CW; BERRIDGE, MJ			THE THIOL REAGENT, THIMEROSAL, EVOKES CA2+ SPIKES IN HELA-CELLS BY SENSITIZING THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; CELLULAR GLUTATHIONE; CA-2+ SEQUESTRATION; CHROMAFFIN CELLS; TUMOR PROMOTER; OSCILLATIONS; HEPATOCYTES; RELEASE; INHIBITION; STORES	The thiol reagent, thimerosal, has been shown to cause an increase in intracellular Ca2+ concentration ([Ca2+]i) in several cell types, and to cause Ca2+ spikes in unfertilized hamster eggs. Using single cell video-imaging we have shown that thimerosal evokes repetitive Ca2+ spikes in intact Fura-2-loaded HeLa cells that were similar in shape to those stimulated by histamine. Both thimerosal- and histamine-stimulated Ca2+ spikes occurred in the absence of extracellular (Ca2+o), suggesting that they result from mobilization of Ca2+ from intracellular stores. Whereas histamine stimulated formation of inositol phosphates, thimerosal, at concentrations that caused sustained Ca2+ spiking, inhibited basal and histamine-stimulated formation of inositol phosphates. Thimerosal-evoked Ca2+ spikes are therefore not due to the stimulated production of inositol 1,4,5-trisphosphate (InsP3). The effects of thimerosal on Ca2+ spiking were probably due to alkylation of thiol groups on intracellular proteins because the spiking was reversed by the thiol-reducing compound dithiothreitol, and the latency between addition of thimerosal and a rise in [Ca2+]i was greatly shortened in cells where the intracellular reduced glutathione concentration had been decreased by preincubation with DL-buthionine (S,R)-sulfoximine. In permeabilized cells, thimerosal caused a concentration-dependent inhibition of Ca2+ accumulation, which was entirely due to inhibition of Ca2+ uptake into stores because thimerosal did not affect unidirectional Ca-45(2+) efflux from stores preloaded with Ca-45(2+). Thimerosal also caused a concentration-dependent sensitization of InSP3-induced Ca2+ mobilization: half-maximal mobilization of Ca2+ stores occurred with 161 +/- 20 nM InsP3 in control cells and with 62 +/- 5 nM InsP3 after treatment with 10 muM thimerosal. We conclude that thimerosal can mimic the effects of histamine on intracellular Ca2+ spiking without stimulating the formation of InsP3 and, in light of our results with permeabilized cells, suggest that thimerosal stimulates spiking by sensitizing cells to basal InsP3 levels.	DEPT ZOOL,AFRC,MOLEC SIGNALLING LAB,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND; DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge			Bootman, Martin/AAB-3330-2019; Taylor, Colin/G-2447-2010	Bootman, Martin/0000-0002-6447-3451; Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLOMO G, 1983, FEBS LETT, V163, P136, DOI 10.1016/0014-5793(83)81180-6; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CAPIOD T, 1991, BIOCHEM J, V275, P277, DOI 10.1042/bj2750277; CARROLL J, 1992, J BIOL CHEM, V267, P11196; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; GUILLEMETTE G, 1988, MOL ENDOCRINOL, V2, P1249, DOI 10.1210/mend-2-12-1249; HATZELMANN A, 1990, BIOCHEM PHARMACOL, V39, P559, DOI 10.1016/0006-2952(90)90064-R; HECKER M, 1989, BIOCHEM BIOPH RES CO, V159, P961, DOI 10.1016/0006-291X(89)92202-X; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JONES DP, 1983, J BIOL CHEM, V258, P6390; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PRUIJN FB, 1990, BIOCHEM PHARMACOL, V40, P1947, DOI 10.1016/0006-2952(90)90223-8; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; RICE GC, 1986, CANCER RES, V46, P6105; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SAUVE R, 1987, J MEMBRANE BIOL, V96, P199, DOI 10.1007/BF01869302; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; STRAUSS WL, 1984, MEMBRANES DETERGENTS, P85; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725	42	261	264	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25113	25119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334081				2022-12-25	WOS:A1992KB60300033
J	WESTON, BW; SMITH, PL; KELLY, RJ; LOWE, JB				WESTON, BW; SMITH, PL; KELLY, RJ; LOWE, JB			MOLECULAR-CLONING OF A 4TH MEMBER OF A HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE FAMILY - MULTIPLE HOMOLOGOUS SEQUENCES THAT DETERMINE EXPRESSION OF THE LEWIS-X, SIALYL LEWIS-X, AND DIFUCOSYL SIALYL LEWIS-X EPITOPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; D-GALACTOSIDE 2-ALPHA-L-FUCOSYLTRANSFERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; LEUKOCYTE ADHESION MOLECULE-1; BLOOD-GROUP ANTIGENS; GDP-L-FUCOSE; EMBRYONIC ANTIGEN; HUMAN ALPHA-3-FUCOSYLTRANSFERASES; CARBOHYDRATE LIGANDS; LEX DETERMINANT	We and others have previously described the isolation of three human alpha(1,3)fucosyltransferase genes which form the basis of a nascent glycosyltransferase gene family. We now report the molecular cloning and expression of a fourth homologous human alpha(1,3)fucosyltransferase gene. When transfected into mammalian cells, this fucosyltransferase gene is capable of directing expression of the Lewis x (Galbeta1-->4[Fucalpha1-->3] GlcNAc), sialyl Lewis x (NeuNAcalpha2-->3Galbeta1-->4 [Fucalpha1-->3]GlcNAc),and difucosyl sialyl Lewis x (NeuNAcalpha2-->3Galbeta1-->4[Fucalpha1-->3]GlcNAcbeta1-->3Galbeta1-->4[Fucalpha1-->3]GlcNAc) epitopes. The enzyme shares 85% amino acid sequence identity with Fuc-TIII and 89% identity with Fuc-TV but differs substantially in its acceptor substrate requirements. Polymerase chain reaction analyses demonstrate that the gene is syntenic to Fuc-TIII and Fuc-TV on chromosome 19. Southern blot analyses of human genomic DNA demonstrate that these four alpha(1,3)fucosyltransferase genes account for all DNA sequences that cross-hybridize at low stringency with the Fuc-TIII catalytic domain. Using similar methods, a catalytic domain probe from Fuc-TIV identifies a new class of DNA fragments which do not cross-hybridize with the chromosome 19 fucosyltransferase probes. These results extend the molecular definition of a family of human alpha(1,3)fucosyltransferase genes and provide tools for examining fucosyltransferase gene expression.	HOWARD HUGHES MED INST, DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL, MED SCI RES BLDG I,RM 3510, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan			/L-2667-2019		NIGMS NIH HHS [GM47455, GM14279] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014279, R01GM047455] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL SP, 1991, ANN HUM GENET, V55, P225, DOI 10.1111/j.1469-1809.1991.tb00417.x; BERG EL, 1991, J BIOL CHEM, V266, P14869; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CAILLARD T, 1988, EXP CLIN IMMUNOGENET, V5, P15; COLLINS FS, 1987, SCIENCE, V235, P1046, DOI 10.1126/science.2950591; COUILLIN P, 1991, CYTOGENET CELL GENET, V56, P108, DOI 10.1159/000133061; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; FEIZI T, 1987, BIOCHEM J, V245, P1; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; FOX N, 1983, CANCER RES, V43, P669; FUKUSHI Y, 1985, CANCER RES, V45, P3711; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HOFF SD, 1990, ARCH SURG-CHICAGO, V125, P206; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; JOHNSON PH, 1981, BIOCHEM BIOPH RES CO, V100, P1611, DOI 10.1016/0006-291X(81)90703-8; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KIM YS, 1988, CANCER RES, V48, P475; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LOWE JB, 1993, IN PRESS HDB IMMUNOP; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; Maniatis T, 1989, MOL CLONING; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MOLLICONE R, 1988, BLOOD, V71, P1113; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; MUROI K, 1992, BLOOD, V79, P713; ORNTOFT TF, 1991, BLOOD, V77, P1389; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; POTVIN B, 1990, J BIOL CHEM, V265, P1615; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SAKAMOTO J, 1986, CANCER RES, V46, P1553; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TETTEROO PAT, 1987, J BIOL CHEM, V262, P15984; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	74	313	339	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24575	24584						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1339443				2022-12-25	WOS:A1992KA26300065
J	GRINSTEIN, S; WOODSIDE, M; SARDET, C; POUYSSEGUR, J; ROTIN, D				GRINSTEIN, S; WOODSIDE, M; SARDET, C; POUYSSEGUR, J; ROTIN, D			ACTIVATION OF THE NA+/H+ ANTIPORTER DURING CELL-VOLUME REGULATION - EVIDENCE FOR A PHOSPHORYLATION-INDEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; GROWTH-FACTORS; PH REGULATION; OKADAIC ACID; EXCHANGE; FIBROBLASTS	A variety of cell types regulate their volume in anisotonic media by stimulating Na+/H+ exchange. Like growth factors, osmotic challenge activates the Na+/H+ antiport by increasing its sensitivity to intracellular [H+]. To investigate the molecular mechanism underlying this shift in pH sensitivity, the antiporter of P-32-labeled human bladder carcinoma cells and of Chinese hamster ovary cells was immunoprecipitated using antibodies raised against the cytosolic domain of the NHE-1 isoform of the Na+/H+ exchanger. Unlike the effects of growth promoters, activation of the antiport during volume regulation was not associated with increased phosphorylation. The possible coexistence of multiple antiporter isoforms was considered. The cytosolic alkalosis normally elicited by hypertonic media was found to be absent in Na+/H+ exchange-deficient fibroblasts. Responsiveness to osmotic challenge was restored by stable transfection of these cells with the cDNA encoding NHE-1. In these transfectants, phosphorylation of the antiporter was also unaffected during osmotic activation. The unchanged phosphate content of the antiporter might be explained by dephosphorylation of one site with concomitant phosphorylation at a different site. However, this possibility appears unlikely since phosphoamino acid analysis revealed that serine was the only residue phosphorylated in immunoprecipitated antiports of both control and osmotically stimulated cells. Moreover, phosphopeptide maps of control and hypertonically activated antiports were identical. These findings reveal a novel mode of activation of Na+/H+ exchange not requiring direct phosphorylation of the antiporter. We propose the existence of dual control of Na+/H+ exchange by phosphorylation-dependent and -independent mechanisms.	UNIV NICE PARC VALROSE,CNRS,CTR BIOCHIM,F-06034 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	GRINSTEIN, S (corresponding author), HOSP SICK CHILDREN,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; CALA PM, 1980, J GEN PHYSIOL, V76, P683, DOI 10.1085/jgp.76.6.683; CASSEL D, 1986, J BIOL CHEM, V261, P5460; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS BA, 1992, AM J PHYSIOL, V262, pC533, DOI 10.1152/ajpcell.1992.262.2.C533; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1986, J BIOL CHEM, V261, P8009; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; Hille B., 1992, IONIC CHANNELS EXCIT; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; ROTIN D, 1989, CANCER RES, V49, P205; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424	24	224	226	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23823	23828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331102				2022-12-25	WOS:A1992JZ23900060
J	BLANK, JL; BRATTAIN, KA; EXTON, JH				BLANK, JL; BRATTAIN, KA; EXTON, JH			ACTIVATION OF CYTOSOLIC PHOSPHOINOSITIDE PHOSPHOLIPASE-C BY G-PROTEIN BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; MUSCARINIC K+-CHANNEL; ALPHA-SUBUNITS; ADENYLYL CYCLASE; BOVINE BRAIN; IMMUNOLOGICAL IDENTIFICATION; AFFINITY-CHROMATOGRAPHY; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; PERTUSSIS TOXIN	Bovine liver cytosol contains a phosphoinositide phospholipase C (PLC(cyt)) that is activated by guanosine 5'-O-(3-thio)triphosphate (GTPgammaS)-activated G-proteins from liver plasma membranes. Heparin-Sepharose chromatography indicated that PLC(cyt) was immunologically distinct from PLC-beta1, PLC-gamma1, or PLC-delta1 from brain. Initial purification of the GTPgammaS-activated G-proteins that stimulated PLC(cyt) indicated that the betagamma complex was responsible. G-proteins were subsequently extracted from liver membranes as heterotrimers and purified in the presence of AlCl3, MgCl2, and NaF to allow reversible activation. Immunoblot analysis with an antiserum selective for the beta subunit showed that the stimulatory activity corresponded with the presence of this protein at every chromatographic step. When liver betagamma complex was purified and separated from all detectable alpha subunits, as shown by immunoblotting and silver staining, it strongly stimulated PLC(cyt) after removal of the activating ligand [AlF4]- by gel filtration. Betagamma prepared from brain was approximately equipotent with that from liver. Betagamma was half-maximally effective at 33 nM and produced a maximal 50-fold activation of the PLC. Under identical conditions, betagamma had no effect on brain PLC-gamma1 or PLC-delta1 and produced a 2-fold stimulation of PLC-beta1 activity. Addition of purified GDP-bound alpha(o) which had no effect by itself, completely reversed the betagamma activation of PLC(cyt), confirming that betagamma was the active species. These data provide evidence for a novel mechanism by which betagamma subunits of pertussis toxin-sensitive or -insensitive G-proteins activate phospholipase C.	VANDERBILT UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University								AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOURNE HR, 1987, NATURE, V325, P296, DOI 10.1038/325296a0; BOURNE HR, 1989, NATURE, V337, P504, DOI 10.1038/337504a0; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HARDEN TK, 1990, AM REV RESPIR DIS, V141, pS119, DOI 10.1164/ajrccm/141.3_Pt_2.S119; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRIZ R, 1990, CIBA F SYMP, V150, P112; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PRICE SR, 1989, BIOCHEMISTRY-US, V28, P3803, DOI 10.1021/bi00435a027; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAW K, 1992, BIOCHEMISTRY-US, V31, P6347, DOI 10.1021/bi00142a026; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; THOMAS GMH, 1991, EMBO J, V10, P2507, DOI 10.1002/j.1460-2075.1991.tb07790.x; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1992, J BIOL CHEM, V267, P1811; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	65	171	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23069	23075						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331076				2022-12-25	WOS:A1992JY16300057
J	MIRAYLOPEZ, R; JARAMILLO, S; WAXMAN, S				MIRAYLOPEZ, R; JARAMILLO, S; WAXMAN, S			REDUNDANT REGULATION OF UROKINASE PLASMINOGEN-ACTIVATOR TRANSCRIPTION BY THE 2 MAJOR ISOZYMES OF CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; AMP RECEPTOR PROTEINS; CYCLIC-AMP; CATALYTIC SUBUNIT; RETINOIC ACID; ADENOSINE-MONOPHOSPHATE; SELECTIVE ACTIVATION; GENE-TRANSCRIPTION; MOLECULAR-CLONING; CARCINOMA-CELLS	The regulation of urokinase plasminogen activator (uPA) gene expression by the two major cAMP-dependent protein kinase isozymes was studied in SC115 mouse mammary carcinoma cells using the site-selective cAMP analog approach. SC115 cells expressed both type I and type II cAMP-dependent protein kinase holoenzyme (at a ratio of 2:3), and selective, partial activation of each holoenzyme could be demonstrated in vitro using appropriate combinations of cAMP analogs. When cells were exposed to the same analog combinations, uPA expression was upregulated 2- to 4-fold when either holoenzyme I or holoenzyme II was targeted. For comparison, a high concentration (1 mM) of 8-bromo-cAMP, an analog that does not discriminate between kinase isoforms, up-regulated uPA 10-fold. These findings suggest that there are two pathways of cAMP-dependent regulation of uPA, one mediated by holoenzyme I, the other by holoenzyme II, and that the end result of activation of each pathway is the same. Differences in the mechanism whereby each pathway regulates uPA were searched for but not found. Both pathways were shown to be dependent on catalytically active enzyme, to be potentiated by retinoic acid treatment, and to regulate uPA transcriptionally. The most likely interpretation of these findings is that uPA transcription is mediated solely by the action of the common catalytic subunit, regardless of whether it originated from holoenzyme I or holoenzyme II.			MIRAYLOPEZ, R (corresponding author), CUNY MT SINAI SCH MED,DEPT MED,DIV MED ONCOL,BOX 1178,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NATIONAL CANCER INSTITUTE [R29CA054273, R01CA054273] Funding Source: NIH RePORTER; NCI NIH HHS [CA54273] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BEEBE SJ, 1987, MOL ENDOCRINOL, V1, P639, DOI 10.1210/mend-1-9-639; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CHOCHUNG YS, 1989, JNCI-J NATL CANCER I, V81, P982, DOI 10.1093/jnci/81.13.982; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COLLART MA, 1987, J IMMUNOL, V139, P949; CORBIN JD, 1982, EUR J BIOCHEM, V125, P259, DOI 10.1111/j.1432-1033.1982.tb06677.x; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; HUNZICKERDUNN M, 1981, J BIOL CHEM, V256, P2185; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; LIVESEY SA, 1985, CANCER RES, V45, P5734; LIVESEY SA, 1988, METHOD ENZYMOL, V159, P105; LU X, 1990, GENE, V86, P185, DOI 10.1016/0378-1119(90)90278-Y; Maniatis T, 1989, DECONTAMINATION DILU; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MIRAYLOPEZ R, 1991, J CELL PHYSIOL, V147, P46, DOI 10.1002/jcp.1041470107; NAKAGAWA J, 1988, J BIOL CHEM, V263, P2460; NG KW, 1983, CANCER RES, V43, P794; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; PLET A, 1982, J BIOL CHEM, V257, P889; ROGELJ S, 1984, EUR J BIOCHEM, V139, P351, DOI 10.1111/j.1432-1033.1984.tb08013.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TORTORA G, 1990, J BIOL CHEM, V265, P18067; TOURNIER S, 1991, J BIOL CHEM, V266, P19018; UHLER MD, 1986, J BIOL CHEM, V261, P5360; WALTER U, 1977, J BIOL CHEM, V252, P6494; WU JC, 1989, J BIOL CHEM, V264, P9989; ZAJAC JD, 1986, ENDOCRINOLOGY, V118, P2059, DOI 10.1210/endo-118-5-2059	38	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23063	23068						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331075				2022-12-25	WOS:A1992JY16300056
J	MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R				MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R			LUMINAL CA2+ CONTROLS THE ACTIVATION OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR BY CYTOSOLIC CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CALCIUM RELEASE; ACINAR-CELLS; CA-2+ STORES; RAT; TRISPHOSPHATE; ENTRY; OSCILLATIONS; HEPATOCYTES; PHOSPHATES	Luminal Ca2+-controls the sensitivity of the intracellular Ca2+ stores to inositol 1,4,5-trisphosphate (Ins(1,4,5)P3). Ins(1,4 5)P3-induced Ca2+ release is also controlled by cytosolic Ca2+; low concentrations of Ca2+ stimulate the release. The aim of this work was to investigate whether luminal Ca2+ would affect the stimulation of the Ins(1,4,5)P3 receptor by cytosolic Ca2+ in permeabilized A7r5 smooth muscle cells. We also report that the Ins(1,4,5)P3, receptor in A7r5 cells is activated by low concentrations of cytosolic Ca2+. Cytoplasmic Ca2+ increases the Ins(1,4,5)P3 sensitivity without affecting the cooperativity. The increase in Ins(1,4,5)P3 sensitivity becomes relatively more pronounced when the Ca2+ content of the stores decreases. This modulatory effect of luminal Ca2+ on the responsiveness to cytosolic Ca2+ is an intrinsic property of the Ins(1,4 5)P3 receptor.			MISSIAEN, L (corresponding author), CATHOLIC UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CASTEELS R, 1981, PFLUG ARCH EUR J PHY, V392, P139, DOI 10.1007/BF00581262; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1992, MOL PHARMACOL, V41, P115; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189	34	93	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22961	22966						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331072				2022-12-25	WOS:A1992JY16300041
J	SAVARESE, DMF; RUSSELL, JT; FATATIS, A; LIOTTA, LA				SAVARESE, DMF; RUSSELL, JT; FATATIS, A; LIOTTA, LA			TYPE-IV COLLAGEN STIMULATES AN INCREASE IN INTRACELLULAR CALCIUM - POTENTIAL ROLE IN TUMOR-CELL MOTILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; INOSITOL TRISPHOSPHATE; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DICTYOSTELIUM-DISCOIDEUM; NEUTROPHIL CHEMOTAXIS; CYCLIC METABOLITE; PEPTIDE RECEPTOR; PLASMA-MEMBRANE	Type IV collagen (Coll IV), a component of the extracellular matrix, stimulates motility in the A2058 human melanoma cell line, a response that is inhibited by pertussis toxin (PT). Fibronectin (FN)-induced chemotaxis in this cell line is not affected by PT. To understand the mechanism of cellular signaling, single cell intracellular Ca2+ responses to Coll IV and FN were studied using Fura-2 and digital imaging fluorescence microscopy. Coll IV, at a dose that stimulates motility (100 mug/ml, 185 nM), induces a significant rise in cytosolic free Ca2+ concentration ([Ca2+]i) within 100 s. This response is not inhibited by PT. Treatment of the cells with FN 30 mug/ml (70 nM), a dose that stimulates near-maximal chemotaxis, does not increase [Ca2+]i appreciably. Removal of extracellular Ca2+ fails to inhibit the Coll IV-stimulated rise in Ca2+ in all cells. Depletion of extracellular Ca2+ and pretreatment of cells with Ca2+ channel blockers only partially inhibits Coll IV-induced motility. Depletion of intracellular Ca2+ inhibits both chemotaxis and the Coll IV-induced increase in intracellular Ca2+. Coll IV does not stimulate membrane phosphoinositide hydrolysis. We conclude that Coll IV treatment induces an inositol 1,4,5-trisphosphate-independent release of intracellular Ca2+ stores which appears to play a necessary role in the chemotactic response of A2058 cells but is not mediated by a PT-sensitive G-protein. This response is not seen in cells exposed to FN, suggesting different intracellular signaling mechanisms for stimulated motility between these two extracellular matrix molecules.	NCI,MED BRANCH,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892; NICHHD,DEV NEUROBIOL LAB,BETHESDA,MD 20892; POLICLIN NAPLES 2,IST FARMACOL,NAPLES,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Universita della Campania Vanvitelli								AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOUCEK MM, 1976, SCIENCE, V193, P905, DOI 10.1126/science.948752; CHIEN JL, 1988, INT J PANCREATOL, V3, P113; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CYBULSKY AV, 1990, AM J PHYSIOL, V259, pF326, DOI 10.1152/ajprenal.1990.259.2.F326; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; ELFERINK JGR, 1985, BIOCHIM BIOPHYS ACTA, V846, P364, DOI 10.1016/0167-4889(85)90007-2; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GODFRAIND T, 1981, J PHARMACOL EXP THER, V217, P510; GODFRAIND T, 1981, FED PROC, V40, P2866; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUIRGUIS R, 1987, NATURE, V329, P261, DOI 10.1038/329261a0; HALL AL, 1989, DEV BIOL, V136, P517, DOI 10.1016/0012-1606(89)90277-7; HARRIS H, 1987, NATURE, V330, P310, DOI 10.1038/330310a0; IMAI A, 1986, BIOCHEM J, V240, P341, DOI 10.1042/bj2400341; JEAN T, 1986, J BIOL CHEM, V261, P6414; KOHN EC, 1990, BIOCHEM BIOPH RES CO, V166, P757, DOI 10.1016/0006-291X(90)90874-M; KORCZAK B, 1989, CANCER RES, V49, P2597; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LAM WC, 1981, AM J PATHOL, V104, P69; LASSING I, 1988, EXP CELL RES, V174, P1, DOI 10.1016/0014-4827(88)90136-X; LEE HC, 1989, J BIOL CHEM, V264, P1608; LESTER BR, 1989, CANCER RES, V49, P5940; LEVY AT, 1991, CANCER RES, V51, P439; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; LIOTTA LA, 1986, CANCER RES, V46, P1; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MESHULAM T, 1986, J IMMUNOL, V137, P1954; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NAKANO T, 1987, J BIOCHEM-TOKYO, V101, P1169, DOI 10.1093/oxfordjournals.jbchem.a121981; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SCHACHT J, 1976, J NEUROCHEM, V27, P1119, DOI 10.1111/j.1471-4159.1976.tb00318.x; SEZZI ML, 1985, ANTICANCER RES, V5, P265; SMITH CD, 1985, J BIOL CHEM, V260, P5875; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; TSIEN RY, 1982, J CELL BIOL, V94, P324; Varani J, 1982, Cancer Metastasis Rev, V1, P17, DOI 10.1007/BF00049478; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; ZABRENETZKY V, 1988, BIOCHEM J, V255, P1037, DOI 10.1042/bj2551037; ZIGMOND SH, 1988, CELL MOTIL CYTOSKEL, V9, P184, DOI 10.1002/cm.970090210	52	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21928	21935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328249				2022-12-25	WOS:A1992JV01100103
J	FUJITAYOSHIGAKI, J; YOKOYAMA, S; SHINDOOKADA, N; NISHIMURA, S				FUJITAYOSHIGAKI, J; YOKOYAMA, S; SHINDOOKADA, N; NISHIMURA, S			AZATYROSINE INHIBITS NEURITE OUTGROWTH OF PC12 CELLS INDUCED BY ONCOGENIC RAS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; H-RAS; DIFFERENTIATION; PHOSPHORYLATION; MICROINJECTION; EXPRESSION; MOUSE; P21; ANTIBODY	An antibiotic, azatyrosine [L-beta-(5-hydroxy-2-pyridyl) alanine], specifically converts ras-, raf- or c-erbB2 (neu)-transformed NIH3T3 cells to apparently normal phenotype. The reversion induced by azatyrosine is permanent, and the phenotype of the revertant cells does not change even after prolonged culture in the absence of azatyrosine [N. Shindo-Okada, O. Manabe, H. Nagahara & S. Nishimura (1989). Mol. Carcinogen., 2, 159-167]. In the present study, we found that neurite outgrowth of PC12 cells induced by expression of either the ras or raf oncogenes was inhibited by addition of azatyrosine to the medium. Azatyrosine also inhibited neurite outgrowth induced by microinjection of oncogenic Ras protein into PC12 cells. The dose dependency was much the same for the two systems, inhibition of neurite outgrowth of PC12 cells and reversion of the transformed NIH3T3 cells. Microinjection of azatyrosine into the cells was as effective as addition to the medium, indicating that the target of azatyrosine is intracellular. In contrast, neurite outgrowth induced by nerve growth factor, which has been shown to be mediated by normal Ras [N. Hagag, S. Halegouna & M. Viola (1986). Nature, 319, 680-682], was found to be resistant to azatyrosine. Azatyrosine also showed no effect on neurite outgrowth induced by a membrane-permeant cyclic AMP analog through another pathway. These findings suggest that azatyrosine sensitivity is the result of abnormal signal transduction by oncogenic Ras. It was shown that azatyrosine also inhibited differentiation-associated growth arrest of PC12 cells induced by oncogenic Ras. In Ras-induced neurite outgrowth, the azatyrosine-sensitive process was found to be completed in the first 6-9 h, and is probably essential for the commitment of PC12 cells to differentiation rather than to growth.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; NATL CANC CTR,RES INST,CHUO KU,TOKYO 104,JAPAN	University of Tokyo; University of Tokyo; National Cancer Center - Japan			Yoshigaki, Junko/AAE-6702-2020; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; INOUYE S, 1975, CHEM PHARM BULL, V23, P2669; IZAWA M, 1992, IN PRESS CANCER RES; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; MIURA K, 1986, JPN J CANCER RES, V77, P45; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SHIROUZU M, 1992, ONCOGENE, V7, P475; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	33	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2019	2024						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328988				2022-12-25	WOS:A1992JP42400016
J	QURESHI, SA; ALEXANDROPOULOS, K; RIM, M; JOSEPH, CK; BRUDER, JT; RAPP, UR; FOSTER, DA				QURESHI, SA; ALEXANDROPOULOS, K; RIM, M; JOSEPH, CK; BRUDER, JT; RAPP, UR; FOSTER, DA			EVIDENCE THAT HA-RAS MEDIATES 2 DISTINGUISHABLE INTRACELLULAR SIGNALS ACTIVATED BY V-SRC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHORBOL 12-MYRISTATE 13-ACETATE; NIH 3T3 CELLS; GENE-EXPRESSION; PHOSPHOLIPASE-D; EARLY RESPONSE; TRANSFORMATION; GTPASE; TRANSDUCTION; ONCOGENES	v-Src activates promoters under the control of 12-O-tetradecanoylphorbol-13-acetate (TPA) response elements (TREs) and serum response elements (SREs) via two distinguishable intracellular signaling mechanisms. The induction of TRE- and SRE-mediated gene expression by v-Src could be distinguished by a differential sensitivity to depleting cells of protein kinase C (PKC) and to a dominant negative Raf-1 mutant. Thus, PKC depletion and the dominant negative Raf-1 mutant were able to distinguish two intracellular signaling mechanisms activated by v-Src. Both of these v-Src-induced intracellular signals were sensitive to a dominant negative mutant of Ha-Ras. These data suggest that Ha-Ras functions to coordinately regulate multiple intracellular signaling mechanisms activated by v-Src.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BISHOP JM, 1984, RNA TUMOR VIRUSES, P999; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MARONEY AC, 1992, ONCOGENE, V7, P1207; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; QURESHI SA, 1992, ONCOGENE, V7, P121; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Treisman R, 1990, Semin Cancer Biol, V1, P47; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	50	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17635	17639						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325443				2022-12-25	WOS:A1992JM22300027
J	SAKODA, T; KAIBUCHI, K; KISHI, K; KISHIDA, S; DOI, K; HOSHINO, M; HATTORI, S; TAKAI, Y				SAKODA, T; KAIBUCHI, K; KISHI, K; KISHIDA, S; DOI, K; HOSHINO, M; HATTORI, S; TAKAI, Y			SMG/RAP-1/KREV-1 P21S INHIBIT THE SIGNAL PATHWAY TO THE C-FOS PROMOTER ENHANCER FROM C-KI-RAS P21 BUT NOT FROM C-RAF-1 KINASE IN NIH3T3-CELLS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEOTIDE EXCHANGE-REACTION; PUTATIVE EFFECTOR DOMAIN; SERUM-RESPONSE ELEMENT; BOVINE BRAIN; MAMMALIAN-CELLS; GROWTH-FACTOR; SMG P21; CATALYZED PHOSPHORYLATION; TYROSINE PHOSPHORYLATION	smg/rap1A/Krev-1 p21 cDNA is known to inhibit v-Kiras p21-induced cell transformation in NIH3T3 cells, but the inhibitory mechanism is not clear at present. In the present study, we examined the effect of smg p21s on the c-fos promoter/enhancer linked to the luciferase reporter gene (c-fos-luciferase). After transfection of c-fos-luciferase into NIH3T3 cells constitutively expressing c-Ki-ras(val-12) p21 or activated c-raf-1 kinase, expression of c-fos-luciferase was much higher than after transfection into control NIH3T3 cells. Addition of platelet-derived growth factor (PDGF), 12-O-tetradecanoyl phorbol 13-acetate (TPA) or dibutyryl cyclic AMP (Bt2cAMP) to the control NIH3T3 cells stimulated c-fos-luciferase expression. Transfection of the smg p21 cDNAs inhibited the activated ras p21-, PDGF- or TPA-stimulated c-fos-luciferase expression, but did not inhibit the activated c-raf-1 kinase- or Bt2cAMP-stimulated reaction. These results indicate that smg p21s inhibit the signal pathways from the PDGF receptor, protein kinase C, and ras p21s to the c-fos promoter/enhancer, but not those from c-raf-1 kinase and cyclic AMP-dependent protein kinase to the c-fos promoter/enhancer.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; UNIV TOKYO,COLL ARTS & SCI,DEPT PURE & APPL SCI,TOKYO 153,JAPAN	Kobe University; University of Tokyo				kishida, shosei/0000-0003-0405-851X				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOSCH HVD, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; ITOH T, 1991, BIOCHEM BIOPH RES CO, V177, P1319, DOI 10.1016/0006-291X(91)90685-Z; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MITSUNOBU F, 1989, ONCOGENE, V4, P437; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OKU N, 1990, FEBS LETT, V269, P148, DOI 10.1016/0014-5793(90)81141-A; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RAPP UR, 1991, ONCOGENE, V6, P495; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZIPSER D, 1981, P NATL ACAD SCI-BIOL, V78, P6276, DOI 10.1073/pnas.78.10.6276	67	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1705	1711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323817				2022-12-25	WOS:A1992JJ37600005
J	HU, RM; LEVIN, ER; PEDRAM, A; FRANK, HJL				HU, RM; LEVIN, ER; PEDRAM, A; FRANK, HJL			ATRIAL-NATRIURETIC-PEPTIDE INHIBITS THE PRODUCTION AND SECRETION OF ENDOTHELIN FROM CULTURED ENDOTHELIAL-CELLS - MEDIATION THROUGH THE C-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION SYSTEM; SMOOTH-MUSCLE CELLS; HEART-FAILURE; MESSENGER-RNAS; GENE; RAT; ANGIOTENSIN; STIMULATION; HYDROLYSIS; EXPRESSION	Atrial natriuretic peptide (ANP) and endothelin-1 (ET-1) are vasoactive peptides produced in cells of the cardiovascular system. We examined the effects of ANP on ET-1 transcription, production (translation), and secretion in cultured bovine aortic endothelial cells (BAEC). ANP and C-ANP 4-23 (a specific ligand for the C or non-guanylate cyclase receptor) equipotently inhibited the synthesis of prepro-ET-1 and ET-1 proteins in BAEC by at least 50%. Both of these forms of ANP and another C receptor specific ligand, nanopiperazine ANP (11-15)-NH2, inhibited ET-1 secretion by as much as 55%. LY 83583, an inhibitor of ANP-induced cGMP generation, failed to reverse the ANP-induced inhibition of ET-1 secretion. This further indicated that the guanylate cyclase-linked B receptor is not involved. The decreased ET-1 secretion caused by C-ANP 4-23 was reversed by 8-bromo-cAMP or amiloride, which prevents ANP-induced inhibition of cAMP. We also found that ANP and C-ANP 4-23 augmented ET-1 mRNA levels in BAEC by prolonging the mRNA half-life. ANP or cycloheximide comparably inhibited ET-1 translation while increasing ET-1 mRNA levels, suggesting that the two events are related. These results indicate that ANP inhibits ET-1 protein production and secretion while stabilizing the ET-1 mRNA. The effects of ANP are mediated through the C receptor and are probably the result of ANP inhibiting the generation of cAMP. These findings suggest a potentially important new function for this receptor to mediate, in part, the interactions of ANP and ET in the vasculature.	LONG BEACH VET HOSP,MED SERV 111I,5901 E 7TH ST,LONG BEACH,CA 90822; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHARMACOL,IRVINE,CA 92717	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine			Levin, Ellis/J-5402-2013		NICHD NIH HHS [HD-24401] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024401] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANANDSRIVASTAVA MB, 1991, BIOCHEM J, V278, P211, DOI 10.1042/bj2780211; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; AUSBEL FM, 1989, CURRENT PROTOCOLS MO; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BOULANGER CM, 1991, J CARDIOVASC PHARM, V17, pS264, DOI 10.1097/00005344-199100177-00075; CAVERO PG, 1990, AM J PHYSIOL, V259, pF312, DOI 10.1152/ajprenal.1990.259.2.F312; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CLEVELAND D W, 1989, New Biologist, V1, P121; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; EMORI T, 1991, HYPERTENSION, V18, P165, DOI 10.1161/01.HYP.18.2.165; GELFAND R, 1991, AM J PHYSIOL, V261, pR453; GOETZ KL, 1988, AM J PHYSIOL, V254, pE1, DOI 10.1152/ajpendo.1988.254.1.E1; HATTORI Y, 1991, METABOLISM, V40, P65; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; INOUE A, 1989, J BIOL CHEM, V264, P14954; JOHNSON BG, 1991, J PHARMACOL EXP THER, V257, P720; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KOHNO M, 1991, J CLIN INVEST, V87, P1999, DOI 10.1172/JCI115228; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LEVIN E R, 1991, Molecular and Cellular Neuroscience, V2, P189, DOI 10.1016/1044-7431(91)90044-O; LEVIN ER, 1991, ENDOCRINOLOGY, V128, P2925, DOI 10.1210/endo-128-6-2925; LEVIN ER, 1991, AM J PHYSIOL, V261, pE183; LEVIN ER, 1989, BIOCHEM BIOPH RES CO, V160, P807; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; ODONNELL ME, 1986, J BIOL CHEM, V261, P5461; OKOLICANY J, 1990, KIDNEY INT, V37, P342; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SAIJONMAA O, 1990, BIOCHEM BIOPH RES CO, V173, P514, DOI 10.1016/S0006-291X(05)80064-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIBINGER RJ, 1990, ENDOCRINOLOGY, V127, P119; SHAW G, 1986, CELL, V55, P1115; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; TSUNODA K, 1988, CIRC RES, V62, P155, DOI 10.1161/01.RES.62.1.155; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	38	125	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17384	17389						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324935				2022-12-25	WOS:A1992JL05300097
J	GERWINS, P; FREDHOLM, BB				GERWINS, P; FREDHOLM, BB			ATP AND ITS METABOLITE ADENOSINE ACT SYNERGISTICALLY TO MOBILIZE INTRACELLULAR CALCIUM VIA THE FORMATION OF INOSITOL 1,4,5-TRISPHOSPHATE IN A SMOOTH-MUSCLE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; FRTL-5 THYROID-CELLS; SIGNAL TRANSDUCTION SYSTEMS; PERTUSSIS TOXIN; PHOSPHOLIPASE-C; CYCLIC-AMP; PHOSPHOINOSITIDE TURNOVER; EXTRACELLULAR ATP; ADENYLATE-CYCLASE; CEREBRAL-CORTEX	Interactions between ATP and adenosine on the formation of inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and mobilization of intracellular calcium were investigated in the smooth muscle cell line DDT1 MF-2. Activation of adenosine A1 receptors with adenosine or cyclopentyladenosine (CPA) or of nucleotide receptors with ATP increased both Ins(1,4,5)P3 formation and intracellular calcium concentrations. The A1 receptor-induced Ins(1,4,5)P3 formation (EC50) 10 nM) was antagonized by the A1 antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) and by pretreatment of the cells with pertussis toxin (PTX). ATP-stimulated Ins(1,4,5)P3 formation (EC50 21-mu-m) was attenuated, but still present, after PTX treatment. ATP and CPA had supraadditive effects on Ins(1,4,5)P3 accumulation and CPA increased ATP-induced Ins(1,4,5)P3 accumulation in a concentration-dependent manner with an EC50 of 3 nM, a concentration which per se had little or no effect on Ins(1,4,5)P3 accumulation. ATP (EC50 4-mu-M) and CPA (EC50 4 nM) both increased intracellular calcium levels. The effect of ATP was partially sensitive to PTX treatment, whereas the effect of CPA was blocked both by PTX and by DPCPX. Concentrations of ATP and CPA that by themselves were insufficient to raise intracellular calcium were able to do so when combined. The synergy between ATP and CPA on the mobilization of intracellular calcium was abolished after treatment of cells with PTX or when DPCPX was included in the experiment. Since ATP was metabolized by ecto-enzymes to ADP, AMP, and adenosine, we also examined whether adenosine formed from ATP could enhance the ATP effects on Ins(1,4,5)P3 accumulation. Indeed, the addition of the A1 receptor antagonist DPCPX or removal of endogenous adenosine by inclusion of adenosine deaminase in the experimental medium significantly attenuated the ATP response, and the two treatments did not have additive effects. The present study thus demonstrates that in a clonal cell line two types of receptors increase phospholipase C activity, but via different pathways; nucleotide receptors appeared to act via partially PTX-insensitive, and Al receptors via PTX-sensitive G-proteins. ATP and CPA are not only able per se to induce formation of Ins(1,4,5)P3 and mobilize intracellular calcium, but they also act synergistically. Finally, it is demonstrated that endogenous adenosine, possibly formed from the rapid breakdown of ATP, can significantly enhance some ATP effects.			GERWINS, P (corresponding author), KAROLINSKA INST, DEPT PHARMACOL, BOX 60400, S-10401 STOCKHOLM 60, SWEDEN.							ALEXANDER SPH, 1989, BRIT J PHARMACOL, V98, P1241, DOI 10.1111/j.1476-5381.1989.tb12670.x; ALI H, 1990, J BIOL CHEM, V265, P745; AREND LJ, 1988, AM J PHYSIOL, V255, pC581, DOI 10.1152/ajpcell.1988.255.5.C581; AREND LJ, 1989, AM J PHYSIOL, V256, pF1067, DOI 10.1152/ajprenal.1989.256.6.F1067; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOUSCAREL B, 1988, J BIOL CHEM, V263, P14913; BOYER JL, 1989, J BIOL CHEM, V264, P884; BRASS LF, 1986, J BIOL CHEM, V261, P6838; BRUNS RF, 1990, BIOL ACTIONS EXTRACE, V603, P211; BURNATOWSKAHLEDIN MA, 1991, AM J PHYSIOL, V260, pC143, DOI 10.1152/ajpcell.1991.260.1.C143; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; ELETR M, 1989, J NEUROSCI, V9, P1473; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; GERWINS P, 1991, MOL PHARMACOL, V40, P149; GERWINS P, 1990, MOL PHARMACOL, V38, P660; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGGBLAD J, 1987, NEUROSCI LETT, V82, P211, DOI 10.1016/0304-3940(87)90132-7; HILL SJ, 1987, BRIT J PHARMACOL, V91, P661, DOI 10.1111/j.1476-5381.1987.tb11260.x; HOITING B, 1990, EUR J PHARM-MOLEC PH, V189, P31, DOI 10.1016/0922-4106(90)90227-O; HOLLINGSWORTH EB, 1986, EUR J PHARMACOL, V122, P45, DOI 10.1016/0014-2999(86)90156-1; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; KENDALL DA, 1990, BRIT J PHARMACOL, V100, P37, DOI 10.1111/j.1476-5381.1990.tb12048.x; KENDALL DA, 1988, J NEUROCHEM, V50, P497, DOI 10.1111/j.1471-4159.1988.tb02939.x; KOHL C, 1990, BRIT J PHARMACOL, V101, P829, DOI 10.1111/j.1476-5381.1990.tb14165.x; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LINDEN J, 1989, TRENDS PHARMACOL SCI, V10, P114, DOI 10.1016/0165-6147(89)90209-5; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; NANOFF C, 1990, BRIT J PHARMACOL, V100, P63, DOI 10.1111/j.1476-5381.1990.tb12052.x; NAZAREA M, 1991, EUR J PHARM-MOLEC PH, V206, P47, DOI 10.1016/0922-4106(91)90145-8; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; NORRIS JS, 1974, NATURE, V248, P422, DOI 10.1038/248422a0; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; OKAJIMA F, 1990, J BIOL CHEM, V265, P21741; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OKAJIMA F, 1989, FEBS LETT, V248, P145, DOI 10.1016/0014-5793(89)80450-8; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PALMER S, 1990, METHODS INOSITIDE RE, P127; PFEILSCHIFTER J, 1990, CELL SIGNAL, V2, P129; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; POBINER BF, 1985, J BIOL CHEM, V260, P6200; RAMKUMAR V, 1990, MOL PHARMACOL, V37, P149; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHWABE U, 1983, ADENOSINE ADENINE NU, P3; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x; VONKUGELGEN I, 1991, TRENDS PHARMACOL SCI, V12, P319, DOI 10.1016/0165-6147(91)90587-I; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WATSON S, 1991, TRENDS PHARMACOL SCI, V12, P25	58	118	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16081	16087						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322890				2022-12-25	WOS:A1992JJ45800018
J	COOK, WJ; JEFFREY, LC; SULLIVAN, ML; VIERSTRA, RD				COOK, WJ; JEFFREY, LC; SULLIVAN, ML; VIERSTRA, RD			3-DIMENSIONAL STRUCTURE OF A UBIQUITIN-CONJUGATING ENZYME (E2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR CRYSTALLOGRAPHY; SACCHAROMYCES-CEREVISIAE; ALZHEIMERS-DISEASE; CARRIER PROTEIN; RAD6; GENE; ENCODES; DEGRADATION; RESOLUTION; REFINEMENT	The x-ray crystal structure of a recombinant ubiquitin-conjugating enzyme (E2) encoded by the UBC1 gene of the plant Arabidopsis thaliana has been determined with the use of multiple isomorphous replacement techniques and refined at 2.4-angstrom resolution by simulated annealing and restrained least-squares. This E2 is an alpha/beta-protein, with four alpha-helices and a four-stranded antiparallel beta-sheet. The NH2 and COOH termini, which may be important for interaction with other enzymes and substrates in the ubiquitin-conjugation pathway, are on the opposite side of the molecule from the cysteine residue that binds to the COOH terminus of ubiquitin. This structure should now allow for the rational analysis of E2 function by in vitro mutagenesis and facilitate the effective design of E2s with unique specificities or catalytic functions.	UNIV ALABAMA,CTR MACROMOLEC CRYSTALLOG,BIRMINGHAM,AL 35294; UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706	University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison	COOK, WJ (corresponding author), UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294, USA.				NINDS NIH HHS [NS-30374] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030374] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BERLETH ES, 1990, BIOCHEM BIOPH RES CO, V171, P705, DOI 10.1016/0006-291X(90)91203-5; BLOW DM, 1959, ACTA CRYSTALLOGR, V12, P794, DOI 10.1107/S0365110X59002274; BONNER WM, 1988, UBIQUITIN, P157; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; COOK WJ, 1992, J MOL BIOL, V223, P1183, DOI 10.1016/0022-2836(92)90270-T; DUNIGAN DD, 1988, VIROLOGY, V165, P310, DOI 10.1016/0042-6822(88)90691-5; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Rechsteiner M., 1988, UBIQUITIN; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SULLIVAN ML, 1989, P NATL ACAD SCI USA, V86, P9861, DOI 10.1073/pnas.86.24.9861; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; VANNOCKER S, 1991, P NATL ACAD SCI USA, V88, P10297, DOI 10.1073/pnas.88.22.10297; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	88	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15116	15121						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321826				2022-12-25	WOS:A1992JF08800090
J	PICKLES, RJ; CUTHBERT, AW				PICKLES, RJ; CUTHBERT, AW			FAILURE OF THAPSIGARGIN TO ALTER ION-TRANSPORT IN HUMAN SWEAT GLAND EPITHELIA WHILE INTRACELLULAR CA2+ CONCENTRATION IS RAISED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; DIVALENT-CATION ENTRY; ADRENAL CHROMAFFIN CELLS; CYSTIC-FIBROSIS TISSUES; PLASMA-MEMBRANE; CALCIUM ENTRY; INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; CYTOSOLIC CALCIUM; TUMOR PROMOTER	Ca(i) in cultured human sweat gland epithelial monolayers was measured using Fura-2 fluorescence. Thapsigargin (Tg) caused a sustained increase in Ca(i), the rate of rise being slower but the magnitude greater than with the agonists lysylbradykinin and ATP. Tg caused an irreversible change such that even after it was removed Ca(i) was dependent on the ambient calcium concentration, consistent with the hypothesis that Ca2+ entry is controlled by the state of the intracellular stores. Calcium entry after Tg was not modified by nimodipine, omega-conotoxin, or BAY K8644 but could be blocked by low concentrations (0.5 mM) of La3+. High concentrations of La3+ (2 mM) caused an increase in the response to Tg, suggesting that membrane ATPase exerts a major Ca(i) lowering effect. Intracellular Ca2+ ion chelation with 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid significantly blunted the response to Tg. Finally, Mn2+ entry rate into epithelial cells was doubled by Tg. In spite of the evidence that Tg raises Ca(i) to values greater and for longer than calcium requiring agonists only the latter affected transepithelial transport processes. It is shown that Tg neither affects transepithelial sodium transport nor chloride conductance, both of which increase in response to lysylbradykinin or ATP. It is concluded that spatio-temporal patterns of Ca(i) increase after Tg and other agonists are different.	UNIV CAMBRIDGE,DEPT PHARMACOL,TENNIS COURT RD,CAMBRIDGE CB2 1QJ,ENGLAND	University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BOND M, 1984, J PHYSIOL-LONDON, V355, P677, DOI 10.1113/jphysiol.1984.sp015445; BRAYDEN DJ, 1989, BRIT J PHARMACOL, V98, P809, DOI 10.1111/j.1476-5381.1989.tb14609.x; BRAYDEN DJ, 1988, J PHYSIOL-LONDON, V405, P657, DOI 10.1113/jphysiol.1988.sp017354; BRAYDEN DJ, 1991, BRIT J PHARMACOL, V102, P57, DOI 10.1111/j.1476-5381.1991.tb12132.x; BRAYDEN DJ, 1990, BRIT J CLIN PHARMACO, V29, P235, DOI 10.1111/j.1365-2125.1990.tb03625.x; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; CLANCY JP, 1990, AM J PHYSIOL, V258, pL25, DOI 10.1152/ajplung.1990.258.2.L25; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENDERSON RM, 1991, PFLUG ARCH EUR J PHY, V418, P271, DOI 10.1007/BF00370526; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KWAN CY, 1990, J BIOL CHEM, V265, P678; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LARSEN EH, 1990, J PHYSIOL-LONDON, V424, P109, DOI 10.1113/jphysiol.1990.sp018058; LEE CM, 1984, J CELL SCI, V72, P259; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PICKLES RJ, 1991, EUR J PHARMACOL, V199, P77, DOI 10.1016/0014-2999(91)90639-8; PUTNEY JW, 1987, AM J PHYSIOL, V252, pG149, DOI 10.1152/ajpgi.1987.252.2.G149; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Quinton PM, 1987, KIDNEY INT S, V21, pS102; RANDRIAMAMPITA C, 1991, PFLUG ARCH EUR J PHY, V417, P633, DOI 10.1007/BF00372962; RASHATWAR SS, 1987, P NATL ACAD SCI USA, V84, P5685, DOI 10.1073/pnas.84.16.5685; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358	37	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14818	14825						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321817				2022-12-25	WOS:A1992JF08800049
J	DEGUCHI, Y; THEVENIN, C; KEHRL, JH				DEGUCHI, Y; THEVENIN, C; KEHRL, JH			STABLE EXPRESSION OF HB24, A DIVERGED HUMAN HOMEOBOX GENE, IN LYMPHOCYTES-T INDUCES GENES INVOLVED IN T-CELL ACTIVATION AND GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHAIN GENE; LEUKEMIA-VIRUS; TRANSCRIPTION FACTOR; HOMEOTIC GENES; PROTO-ONCOGENE; BETA-ACTIN; B-CELLS; PROTEINS; DROSOPHILA; SEQUENCE	A diverged homeobox gene, HB24, which is known to be induced following lymphocyte activation, was introduced into Jurkat T cells under the control of a constitutive promoter. Stable transfectants of HB24 were established that expressed high levels of HB24 mRNA and possessed an altered phenotype suggestive of activated T cells. A number of genes known to be induced following T cell activation and associated with cell growth were increased in the transfectants, including c-fos, c-myc, c-myb, HLA-DR, lck, NF-kappa-B, interleukin-2 and interleukin-2 receptor-alpha (IL-2R-alpha). Analysis of IL-2R-alpha-expression by transient transfection of IL-2R-alpha-promoter constructs into the HB24 transfectants revealed constitutive expression (about 60% of phytohemagglutinin- and phorbol ester-activated Jurkat cells) that was dependent on the kappa-B site in the IL-2R-alpha-promoter. Furthermore, as a consequence of the increased HB24 mRNA levels, the Jurkat HB24 transfectants proliferated more rapidly than control cell lines. Thus, stable expression of HB24 confers an activation phenotype on a human T cell line, implicating this gene as an important transcriptional factor during T cell activation and growth.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BARAD M, 1988, EMBO J, V7, P2151, DOI 10.1002/j.1460-2075.1988.tb03054.x; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURILLA AM, 1989, J EXP MED, V170, P105, DOI 10.1084/jem.170.1.105; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEGUCHI Y, 1991, NEW BIOL, V3, P353; DEGUCHI Y, 1991, BLOOD, V78, P323; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DORSETT DL, 1983, J VIROL, V48, P218, DOI 10.1128/JVI.48.1.218-228.1983; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; Favaloro J, 1980, Methods Enzymol, V65, P718; FREEDMAN AS, 1987, LEUKEMIA, V1, P9; FU SM, 1978, J EXP MED, V148, P1423, DOI 10.1084/jem.148.5.1423; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LEVINE M, 1984, CELL, V38, P667, DOI 10.1016/0092-8674(84)90261-7; LIN BB, 1990, MOL CELL BIOL, V10, P850, DOI 10.1128/MCB.10.2.850; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Maniatis T., 1982, MOL CLONING; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PASCO DS, 1988, J BIOL CHEM, V263, P8671; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	53	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8222	8229						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349016				2022-12-25	WOS:A1992HQ18500041
J	WIELAND, HA; LUDDENS, H; SEEBURG, PH				WIELAND, HA; LUDDENS, H; SEEBURG, PH			A SINGLE HISTIDINE IN GABA-A RECEPTORS IS ESSENTIAL FOR BENZODIAZEPINE AGONIST BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINOBUTYRIC ACIDA RECEPTOR; INVERSE AGONIST; SITE; SUBUNIT; PHARMACOLOGY; ANTAGONIST; CELLS; RAT; DNA	Benzodiazepines (BZ) modulate neurotransmitter-evoked chloride currents at the gamma-aminobutyric acid type A (GABA(A)) receptor, the major inhibitory ion channel in the mammalian brain. This receptor is composed of structurally distinct subunits whose numerous molecular variants underlie the observed diversity in the properties of the BZ site. Pharmacologically distinct BZ sites can be recreated by the recombinant coexpression of any one of six a subunits, a beta-subunit variant, and the gamma-2 subunit. In these receptors the a variant determines the affinity for ligand binding of the BZ site. Notably, the alpha-1 and alpha-6-variants impart on alpha(x)beta-2-gamma-2 receptors high and negligible affinity, respectively, to BZ ligands with sedative as well as anxiolytic activities. By exchanging domains between the alpha-1 and alpha-6 variants, we show that a portion of the large extracellular domain determines sensitivity toward these ligands. Furthermore, we identify a single histidine residue in the alpha-1 variant, replaced by an arginine in alpha-6, as a major determinant for high affinity binding of BZ agonists. This residue also plays a role in determining high affinity binding for BZ antagonists. Hence, this histidine present in the alpha-1, alpha-2, alpha-3, and alpha-5-subunits appears to be a key residue for the action of clinically used BZ ligands.	UNIV HEIDELBERG,CTR MOLEC BIOL,MOLEC NEUROENDOCRINOL LAB,INF 282,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								ALLEN MS, 1990, J MED CHEM, V33, P2343, DOI 10.1021/jm00171a007; ARBILLA S, 1985, N-S ARCH PHARMACOL, V330, P248, DOI 10.1007/BF00572441; BENKE D, 1991, J BIOL CHEM, V266, P4478; BURCH TP, 1981, P NATL ACAD SCI-BIOL, V78, P3945, DOI 10.1073/pnas.78.6.3945; CHANGEUX JP, 1987, TRENDS NEUROSCI, V10, P245, DOI 10.1016/0166-2236(87)90167-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; Costa E, 1988, Adv Biochem Psychopharmacol, V45, P367; DIAZARAUZO H, 1991, LIFE SCI, V49, P207, DOI 10.1016/0024-3205(91)90005-V; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAEFELY W, 1990, TRENDS PHARMACOL SCI, V11, P452, DOI 10.1016/0165-6147(90)90126-S; HAEFELY W, 1981, HDB EXPT PHARMACOLOG, V55, P13; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; IZQUIERDO I, 1989, TRENDS PHARMACOL SCI, V10, P473, DOI 10.1016/0165-6147(89)90040-0; KAO PN, 1986, J BIOL CHEM, V261, P8085; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; LAMBOLEZ B, 1989, NEUROCHEM INT, V15, P145, DOI 10.1016/0197-0186(89)90093-4; LUDDENS H, 1991, TRENDS PHARMACOL SCI, V12, P49, DOI 10.1016/0165-6147(91)90495-E; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MAKSAY G, 1991, MOL PHARMACOL, V39, P725; MATSUMOTO RR, 1989, BRAIN RES REV, V14, P203, DOI 10.1016/0165-0173(89)90001-5; MOHLER H, 1984, EUR J PHARMACOL, V102, P191, DOI 10.1016/0014-2999(84)90358-3; NIELSEN M, 1980, NATURE, V286, P606, DOI 10.1038/286606a0; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1986, RECEPTOR BIOCH METHO, V5, P1; PAUL SM, 1982, PHARMACOL BIOCHEM BE, V17, P37, DOI 10.1016/0091-3057(82)90508-1; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1990, COLD SPRING HARB SYM, V55, P651; SNODGRASS S R, 1990, FASEB Journal, V4, P2775; SQUIRES RF, 1979, PHARMACOL BIOCHEM BE, V10, P825, DOI 10.1016/0091-3057(79)90341-1; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; STEPHENSON FA, 1990, BIOCHEM J, V264, P199; SUZDAK PD, 1986, SCIENCE, V234, P1243, DOI 10.1126/science.3022383; VILLAR HO, 1991, LIFE SCI, V48, P593, DOI 10.1016/0024-3205(91)90533-H	40	383	388	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1426	1429						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346133				2022-12-25	WOS:A1992HA48500007
J	HIROYA, K; ISHIGOOKA, M; SHIMIZU, T; HATANO, M				HIROYA, K; ISHIGOOKA, M; SHIMIZU, T; HATANO, M			ROLE OF GLU318 AND THR319 IN THE CATALYTIC FUNCTION OF CYTOCHROME-P450D (P4501A2) - EFFECTS OF MUTATIONS ON THE METHANOL HYDROXYLATION	FASEB JOURNAL			English	Note						CYTOCHROME-P450; SITE-DIRECTED MUTAGENESIS; METHANOL; DISTAL SITE	MICROSOMAL CYTOCHROME-P-450; OXIDATION; ETHANOL; SYSTEM; FORMS; RATS; PURIFICATION; ACTIVATION; RADICALS; OXIDASE	Polar amino acids in the (putative) distal site are well conserved in P450s. For example, Glu318 for P450d is well conserved as either Glu or Asp for P450s, and Thr319 for P450d is also conserved for P450s. We have studied how mutations at Glu318 and Thr319 of P450d influence the catalytic activity toward methanol associated with the activation of O2. Catalytic activities of Glu318Asp, Glu318Ala, and Thr319Ala mutants toward methanol were 60, 25, and 38%, respectively, compared with that of the wild type. O2 consumption and NADPH oxidation rates of each mutants varied corresponding to the catalytic activities. However, surprisingly, efficiency (16-40%) of incorporated O to the substrate vs. consumed O2 for the Glu318Ala and Thr319Ala mutants were higher than that (9%) of the wild type. In addition, H2O2, which is produced from uncoupling for the wild-type P450d, was not observed for reaction of the Glu318Ala and Thr319Ala mutants. It seemed that consumed O2 was partially reduced to 2 mol of H2O by 4-electron transfer from NADPH for the wild-type and Thr319Ala mutant. However, for the two Glu318 mutants, it appeared that the consumed O2 was not reduced in the same way. It was thus suggested that the conserved Glu318 and Thr319 of P450d are not essential for the activation Of O2 in the methanol oxidation. Role of the water molecule or the methanol molecule in the catalytic function was implied.	TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN	Tohoku University								CEDERBAUM AI, 1979, BIOCHEM BIOPH RES CO, V91, P747, DOI 10.1016/0006-291X(79)91943-0; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUENGERICH FP, 1978, J BIOL CHEM, V253, P7931; HIROYA K, 1991, CHEM LETT, P973, DOI 10.1246/cl.1991.973; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; INGELMANSUNDBERG M, 1984, J BIOL CHEM, V259, P6447; KRAINEV AG, 1991, BIOCHEMISTRY-US, V30, P11206, DOI 10.1021/bi00111a003; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MIWA GT, 1978, ARCH BIOCHEM BIOPHYS, V187, P464, DOI 10.1016/0003-9861(78)90058-9; MORGAN ET, 1982, J BIOL CHEM, V257, P3951; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1988, J BIOL CHEM, V263, P6038; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; RAAG R, IN PRESS BIOCHEMISTR; RYAN DE, 1980, J BIOL CHEM, V255, P7941; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P4659, DOI 10.1021/bi00233a004; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P1490, DOI 10.1021/bi00220a007; WINSTON GW, 1983, J BIOL CHEM, V258, P1514	24	26	26	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					749	751		10.1096/fasebj.6.2.1347023	http://dx.doi.org/10.1096/fasebj.6.2.1347023			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1347023				2022-12-25	WOS:A1992GZ44000017
J	NISHIOKA, J; SUZUKI, K				NISHIOKA, J; SUZUKI, K			THE ROLE OF THE COOH-TERMINAL REGION OF ANTITHROMBIN-III - EVIDENCE THAT THE COOH-TERMINAL REGION OF THE INHIBITOR ENHANCES THE REACTIVITY OF THROMBIN AND FACTOR-XA WITH THE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY ABNORMAL ANTITHROMBIN; HEPARIN-BINDING; ANTI-THROMBIN; PROTEIN-C; ACTIVE-SITE; IDENTIFICATION; SUBSTITUTION; MUTATION; VARIANT; DOMAIN	To elucidate the role of the COOH-terminal region of antithrombin III, we studied the effects of synthetic peptides corresponding to its sequence on the amidolytic and proteolytic activities of thrombin and Factor Xa in the presence or absence of the inhibitor, antithrombin III. The peptides ANRPFLVFI and IIFMGRVANP corresponding to residues Ala404 to Ile412 and Ile420 to Pro429, respectively, blocked the inhibition by antithrombin III. The effect of IIFMGRVANP was reduced in the presence of heparin. Both peptides at a concentration of 1 mM blocked complex formation between antithrombin III and thrombin or Factor Xa. The two peptides, particularly IIFMGRVANP, directly enhanced the amidolytic activity of thrombin and Factor Xa on the synthetic substrate Boc-Ala-Gly-Arg-MCA (where Boc is t-butoxycarbonyl and MCA is 4-methylcoumarin), which corresponds to residues P3-P1 of the reactive site of antithrombin III, and also on other substrates due to increased V(max). IIFMGRVANP also shortened the thrombin-induced fibrinogen clotting time, whereas ANRPFLVFI inhibited the thrombin-catalyzed activation of protein C both in the presence and absence of thrombomodulin. The direct effect of ANRPFLVFI and IIFMGRVANP on thrombin was confirmed by enhancement of the incorporation of dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide into thrombin. These findings suggest that the COOH-terminal region of antithrombin III interacts with thrombin and Factor Xa to increase the reactivity of the enzyme, which may enhance acyl-bond formation between the inhibitor and the enzyme.	MIE UNIV,SCH MED,DEPT MOLEC BIOL GENET DIS,TSU,MIE 514,JAPAN	Mie University								ASAKURA S, 1990, J BIOL CHEM, V265, P5135; ASAKURA S, 1989, J BIOL CHEM, V264, P13736; AUSTIN RC, 1991, BLOOD, V77, P2185; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1982, J BIOL CHEM, V257, P2406; BOCK SC, 1988, BIOCHEMISTRY-US, V27, P6171, DOI 10.1021/bi00416a052; BOCK SC, 1989, THROMB HAEMOSTASIS, V62, P494; BRUNEL F, 1987, AM J HEMATOL, V25, P223, DOI 10.1002/ajh.2830250214; CHANDRA T, 1983, P NATL ACAD SCI-BIOL, V80, P1845, DOI 10.1073/pnas.80.7.1845; CHANG JY, 1986, J BIOL CHEM, V261, P1174; DUCHANGE N, 1987, THROMB RES, V45, P115, DOI 10.1016/0049-3848(87)90263-5; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; Furie B.C., 1976, Methods Enzymol, V45, P191; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P368, DOI 10.1021/bi00647a020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDBLAD RL, 1975, BIOCHEM BIOPH RES CO, V66, P482, DOI 10.1016/0006-291X(75)90536-7; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NAKAGAWA M, 1991, THROMB RES, V64, P101, DOI 10.1016/0049-3848(91)90209-F; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; OLDS RJ, 1989, NUCLEIC ACIDS RES, V17, P10511, DOI 10.1093/nar/17.24.10511; OLDS RJ, 1992, BLOOD, V79, P1206, DOI 10.1182/blood.V79.5.1206.bloodjournal7951206; OWEN MC, 1987, BLOOD, V69, P1275; PERRY DJ, 1991, FEBS LETT, V285, P248, DOI 10.1016/0014-5793(91)80809-H; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PEWARCHUK WJ, 1990, THROMB RES, V59, P793, DOI 10.1016/0049-3848(90)90061-G; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; STEPHENS AW, 1987, J BIOL CHEM, V262, P1044; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; SUZUKI K, 1991, J BIOL CHEM, V266, P18498; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255	37	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22224	22229						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331047				2022-12-25	WOS:A1992JW71900038
J	GAESTEL, M; BENNDORF, R; HAYESS, K; PRIEMER, E; ENGEL, K				GAESTEL, M; BENNDORF, R; HAYESS, K; PRIEMER, E; ENGEL, K			DEPHOSPHORYLATION OF THE SMALL HEAT-SHOCK PROTEIN HSP25 BY CALCIUM CALMODULIN-DEPENDENT (TYPE-2B) PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; EHRLICH ASCITES TUMOR; CATALYTIC SUBUNIT; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; STRESS PROTEINS; ALPHA; PHOSPHORYLATION; CALCINEURIN; CELLS	The dephosphorylation of the mouse small heat shock protein hsp25 within an extract obtained from Ehrlich ascites tumor cells is inhibited by the calcium chelator EGTA and at concentrations of microcystin-LR which are characteristic for inhibition of calcium/calmodulin-dependent (2B type) protein phosphatases. Furthermore, the dephosphorylation of hsp25 in the cell-free system derived from Ehrlich ascites tumor could be increased specifically by addition of the calcium/calmodulin-dependent (2B type) protein phosphatase calcineurin. Dephosphorylation of the heat shock protein hsp25 is also obtained in an in vitro system containing phosphorylated recombinant hsp25, 1 mM Ca2+, calmodulin, and calcineurin specifying hsp25 as the direct substrate for this enzyme. The expression of two isoforms of the catalytic subunit of the mouse calcium/calmodulin-dependent (2B type) protein phosphatases in Ehrlich ascites tumor cells is demonstrated by polymerase chain reaction using specific oligonucleotide primers to the catalytic and calmodulin-binding domain, respectively. Northern blot analysis using the amplified fragments as probes shows that the mRNA of one isoform of the mouse calcium/calmodulin-dependent protein phosphatase is of medium abundance in EAT cells. These data suggest a calcium/calmodulin-dependent dephosphorylation of the small stress protein in EAT cells also in vivo. Since it is known that heat shock increases the intracellular calcium level and that thermotolerance is influenced by calcium chelators, ionophores, and anti-calmodulin drugs, the changes in the degree of hsp25 phosphorylation induced by thermal stress resulting in an altered thermoresistance could be explained at least partially by the calcium/calmodulin-dependent dephosphorylation through protein phosphatases 2B.			GAESTEL, M (corresponding author), MAX DELBRUCK CTR MOLEC MED,R ROSSLE STR 10,O-1115 BERLIN,GERMANY.		Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652				ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1992, IN PRESS BIOCH BIOPH; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; CHIESA R, 1989, BIOCHEM BIOPH RES CO, V162, P1494, DOI 10.1016/0006-291X(89)90843-7; CHIESA R, 1990, FEBS LETT, V268, P222, DOI 10.1016/0014-5793(90)81013-E; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; ERIKSON E, 1988, 2ND MESSENGERS PHOSP, V12, P135; EVANS DP, 1990, J CELL PHYSIOL, V142, P615, DOI 10.1002/jcp.1041420323; EVANS DP, 1991, RADIAT RES, V127, P261, DOI 10.2307/3577940; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GUPTA RC, 1990, MOL CELL BIOCHEM, V97, P53; GUPTA RC, 1992, MOL CELL BIOCHEM, V267, P1846; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KITAMURA K, 1991, J BIOCHEM-TOKYO, V109, P307; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1988, RADIAT RES, V113, P426, DOI 10.2307/3577240; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MALHOTRA A, 1986, J CELL PHYSIOL, V128, P279, DOI 10.1002/jcp.1041280220; MURAMATSU T, 1992, P NATL ACAD SCI USA, V89, P529, DOI 10.1073/pnas.89.2.529; NOVER L, 1991, HEAT SHOCK RESPONSE, P41; OESTERREICH S, 1990, BIOMED BIOCHIM ACTA, V49, P219; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PEZZI L, 1989, INT J BIOCHEM, V21, P791, DOI 10.1016/0020-711X(89)90212-7; POSAS F, 1989, NUCLEIC ACIDS RES, V17, P8369, DOI 10.1093/nar/17.20.8369; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; STEVENSON MA, 1986, BIOCHEM BIOPH RES CO, V137, P826, DOI 10.1016/0006-291X(86)91154-X; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	40	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21607	21611						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328240				2022-12-25	WOS:A1992JV01100055
J	KOHEN, R; KAKUNDA, A; RUBINSTEIN, A				KOHEN, R; KAKUNDA, A; RUBINSTEIN, A			THE ROLE OF CATIONIZED CATALASE AND CATIONIZED GLUCOSE-OXIDASE IN MUCOSAL OXIDATIVE DAMAGE INDUCED IN THE RAT JEJUNUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; POLYETHYLENE-GLYCOL; ENDOTHELIAL-CELLS; FREE-RADICALS; PROTECTION; PERMEABILITY; ANTIOXIDANT; ARTHRITIS; TRANSPORT	The successful prevention of hydrogen peroxide-induced damage to the rat jejunal mucosa by cationized catalase is described in this study. Biological damage was induced in a closed circulating intestinal loop of the rat by hydrogen peroxide and by hydroxyl radicals induced in situ via the metal-mediated Haber-Wiess reaction. The mucosal activity of lactate dehydrogenase and the amount of potassium ions were used to quantitatively characterize the tissue damage. Catalase was cationized by reacting it with N,N'-dimethyl-1,3-propanediamine to give a soluble product or with polyhistidine to give an insoluble product. The activity of the modified enzymes was assessed, and their ability to protect the rat jejunal mucosa against oxidative stress was studied. It was found that in all cases the cationized enzymes were superior to the native catalase in their shield capability. A significant protection against Fe(II)/H2O2 and ascorbie acid/copper ion-mediated damage was obtained when the cationized enzymes were used. In the presence of glucose, native glucose oxidase failed to cause damage in the rat jejunal mucosa; however, the cationized enzyme caused profound tissue injury. These findings indicate the potential therapeutic merit of cationized enzymes for the treatment of pathological processes in the intestine, whenever oxidative stress is involved.	HEBREW UNIV JERUSALEM,SCH PHARM,DAVID R BLOOM CTR PHARM,POB 12065,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem				Rubinstein, Abraham/0000-0001-6212-3725; Kohn, Ron/0000-0001-7268-9845				AMES BN, 1985, DIET HUMAN CARCINOGE, P25; BABBS CF, 1990, FREE RADICAL BIO MED, V8, P191, DOI 10.1016/0891-5849(90)90091-V; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CROSS CE, 1984, LANCET, V1, P1328; DANON D, 1972, J ULTRA MOL STRUCT R, V38, P500, DOI 10.1016/0022-5320(72)90087-1; FLIGIEL SEG, 1984, AM J PATHOL, V115, P375; GIBBS D, 1989, INFLAMMATION, V13, P465, DOI 10.1007/BF00914929; GINSBURG I, 1987, INFLAMMATION, V11, P489, DOI 10.1007/BF00915991; GRAF E, 1985, CANCER-AM CANCER SOC, V56, P717, DOI 10.1002/1097-0142(19850815)56:4<717::AID-CNCR2820560402>3.0.CO;2-4; GRANGER DN, 1986, VIEWPOINTS DIG DIS, V18, P13; GREENWALD RA, 1990, FREE RADICAL BIO MED, V8, P201, DOI 10.1016/0891-5849(90)90092-W; GRISHAM MB, 1990, INFLAMMATION, V14, P669, DOI 10.1007/BF00916370; GRISHAM MB, 1987, AM J PHYSIOL, V253, pG93, DOI 10.1152/ajpgi.1987.253.1.G93; HALLIWELL B, 1990, FREE RADICAL RES COM, V9, P1, DOI 10.3109/10715769009148569; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HIGSON FK, 1988, FREE RADICAL RES COM, V5, P107, DOI 10.3109/10715768809066918; ITOH M, 1985, GASTROENTEROLOGY, V88, P1162, DOI 10.1016/S0016-5085(85)80075-5; LEWIS LD, 1975, GASTROENTEROLOGY, V68, P1509; NAVOK T, 1984, BIOCHEM BIOPH RES CO, V122, P297, DOI 10.1016/0006-291X(84)90474-1; SCHALKWIJK J, 1985, J CLIN INVEST, V76, P198, DOI 10.1172/JCI111946; SHINAR E, 1983, J BIOL CHEM, V258, P1478; SMITH KR, 1989, PHARM RES-DORDR, V6, P466, DOI 10.1023/A:1015960205409; STOCKS SJ, 1986, ANAL BIOCHEM, V154, P232, DOI 10.1016/0003-2697(86)90520-8; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; TRIGUERO D, 1989, P NATL ACAD SCI USA, V86, P4761, DOI 10.1073/pnas.86.12.4761; TURRENS JF, 1984, J CLIN INVEST, V73, P87, DOI 10.1172/JCI111210; VANDENBERG WB, 1984, J CLIN INVEST, V74, P1850, DOI 10.1172/JCI111604; VARANI J, 1985, LAB INVEST, V53, P656; WARD PA, 1983, J CLIN INVEST, V72, P789, DOI 10.1172/JCI111050; WEISS SJ, 1981, J CLIN INVEST, V68, P714, DOI 10.1172/JCI110307; WOLFGANG GHI, 1991, TOXICOL APPL PHARM, V108, P321, DOI 10.1016/0041-008X(91)90121-T	32	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21349	21354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328230				2022-12-25	WOS:A1992JV01100017
J	LEMARCHAND, P; VAGLIO, M; MAUEL, J; MARKERT, M				LEMARCHAND, P; VAGLIO, M; MAUEL, J; MARKERT, M			TRANSLOCATION OF A SMALL CYTOSOLIC CALCIUM-BINDING PROTEIN (MRP-8) TO PLASMA-MEMBRANE CORRELATES WITH HUMAN NEUTROPHIL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; PHORBOL-MYRISTATE ACETATE; CELL-FREE SYSTEM; NADPH OXIDASE; INTRACELLULAR CALCIUM; ARACHIDONIC-ACID; KINASE-C; COMPONENTS; PURIFICATION	To further understand the mechanisms involved in phagocyte activation in general and in NADPH oxidase activation in particular, a polyclonal antibody was raised in rabbit against a partially purified oxidase preparation. The enzyme was solubilized from zymosan-activated human neutrophils and resting cells and separated by preparative isoelectric focusing electrophoresis. A polyclonal antibody was raised in rabbit against the pI 5.0 fraction, which had the maximum superoxide-producing capacity. Analysis of the polyclonal antibody revealed marked differences between activated and resting neutrophils. The antibody recognized in particular an 8-kDa protein (pS) in resting human neutrophil cytosol and in the membrane of zymosan-activated cells. A polyclonal antibody (anti-p8) was raised against the pure cytosolic p8 protein. This anti-p8 reacted not only with p8, but also with cytosolic proteins of 14 kDa and 6 kDa. N-terminal amino acid sequence analysis of p8 revealed homology with the calcium-binding myeloid related protein (MRP-8). Upon neutrophil activation, translocation of the 8- and 14-kDa proteins to the membrane was observed with stimuli known to depend on extracellular calcium. In calcium-depleted medium, the absence of translocation correlated with a depression of superoxide production, supporting a role for the calcium-binding protein in cellular activation.	BIOCHEM INST,CH-1066 EPALINGES,SWITZERLAND		LEMARCHAND, P (corresponding author), CHU VAUDOIS,CENT LAB CLIN CHEM,CH-1011 LAUSANNE,SWITZERLAND.		lemarchand, patricia/C-3247-2011	lemarchand, patricia/0000-0002-5330-2008				AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; BABIOR BM, 1987, TRENDS BIOCHEM SCI, V12, P241, DOI 10.1016/0968-0004(87)90118-6; BALSINDE J, 1990, J IMMUNOL, V144, P4298; BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1987, J BIOL CHEM, V262, P4065; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; DOUSSIERE J, 1990, BIOCHEMISTRY-US, V29, P2225, DOI 10.1021/bi00461a004; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; EDGEWORTH J, 1989, NATURE, V342, P189, DOI 10.1038/342189a0; FUJIMOTO S, 1989, J BIOL CHEM, V264, P21629; GABIG TG, 1990, J IMMUNOL, V145, P945; HEIERLI C, 1988, NEPHROL DIAL TRANSPL, V3, P773; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; MARKERT M, 1985, P NATL ACAD SCI USA, V82, P3144, DOI 10.1073/pnas.82.10.3144; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MURAO S, 1989, J BIOL CHEM, V264, P8356; NAKAMURA K, 1985, ANAL BIOCHEM, V148, P311, DOI 10.1016/0003-2697(85)90234-9; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; SHAAG D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P405, DOI 10.1016/0167-4838(90)90044-G; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V677, P512, DOI 10.1016/0304-4165(81)90267-1; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; TANAKA T, 1990, J BIOL CHEM, V265, P18717; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WILKINSON MM, 1988, J CELL SCI, V91, P221; WOLFSON M, 1985, J IMMUNOL, V135, P2057; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	39	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19379	19382						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326551				2022-12-25	WOS:A1992JP59300056
J	JI, C; MARNETT, LJ				JI, C; MARNETT, LJ			OXYGEN RADICAL-DEPENDENT EPOXIDATION OF (7S,8S)-DIHYDROXY-7,8-DIHYDROBENZO[A]PYRENE IN MOUSE SKIN INVIVO - STIMULATION BY PHORBOL ESTERS AND INHIBITION BY ANTIINFLAMMATORY STEROIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR PROMOTER 12-O-TETRADECANOYLPHORBOL-13-ACETATE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; POLYCYCLIC AROMATIC-HYDROCARBONS; ANTIOXIDANT PROOXIDANT STATUS; METABOLIC-ACTIVATION; SUPEROXIDE-DISMUTASE; CHEMI-LUMINESCENCE; TOPICAL TREATMENT; EPIDERMAL-CELLS; DIOL-EPOXIDES	(7S,8S) - Dihydroxy - 7,8 - dihydrobenzo[a]pyrene ((+)-BP-7,8-diol) is epoxidized to (7S,8R)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((+)-syn-BPDE) by cytochrome P-450 isoenzymes and to (7S,8R)-dihydroxy-(9R,10S)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((-)-anti-BPDE) by peroxyl free radicals. P-32 postlabeling analysis of the diastereomeric BPDE-DNA adducts was used to investigate the pathways of (+)-BP-7,8-diol oxidation in mouse skin in vivo. The pattern of deoxynucleoside 3',5'-bisphosphate adducts in epidermal scrapings from female CD-1 mice indicated that cytochrome P-450 was the major oxidant. Similar results were obtained when the tumor-promoting phorbol ester tetradecanoylphorbolacetate (TPA) was coadministered with (+)-BP-7,8-diol. However, when animals were pretreated with TPA 24 h before coadminsitration of TPA and (+)-BP-7,8-diol, the pattern of BPDE-DNA adducts indicated that peroxyl radicals made a major contribution to (+)-BP-7,8-diol epoxidation. Peroxyl radical-dependent epoxidation was maximal when the time between the two TPA administrations was 24-72 h. No increase in (-)-anti-BPDE-DNA was observed when the non-tumor-promoting phorbol ester 4-O-methyl-TPA was substituted for TPA. The calcium ionophore A23187 stimulated peroxyl radical generation when substituted for the first, but not the second, TPA treatment. The antiinflammatory steroid fluocinolone acetonide inhibited (-)-anti-BPDE-DNA adduct formation when coadministered with the first but not the second TPA treatment. These findings demonstrate the existence of two independent pathways of metabolic activation of (+)-BP-7,8-diol in mouse epidermis, one dependent on cytochrome P-450 and the other dependent on peroxyl free radicals. The results also suggest that repetitive topical administration of tumor-promoting phorbol esters remodels epidermal metabolism leading to a significant increase in free radical generation.	VANDERBILT UNIV, MED CTR,SCH MED,CTR MOLEC TOXICOL,DEPT BIOCHEM, AB HANCOCK JR MEM LAB CANC RES, NASHVILLE, TN 37232 USA	Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD WM, 1971, CANCER RES, V31, P1434; BIRNBOIM HC, 1986, CARCINOGENESIS, V7, P495, DOI 10.1093/carcin/7.3.495; Boutwel R. K., 1978, CARCINOGENESIS, V2, P49; BOYD JA, 1982, CANCER RES, V42, P2628; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BYCZKOWSKI JZ, 1989, BIOCHEM BIOPH RES CO, V159, P1199, DOI 10.1016/0006-291X(89)92237-7; CANELLA K, 1991, CARCINOGENESIS, V12, P1109, DOI 10.1093/carcin/12.6.1109; CATALANO CE, 1987, BIOCHEMISTRY-US, V26, P8373, DOI 10.1021/bi00399a052; DEUTSCH J, 1978, P NATL ACAD SCI USA, V75, P3123, DOI 10.1073/pnas.75.7.3123; Dipple A., 1984, CHEM CARCINOGENS, P41; DIX TA, 1981, J AM CHEM SOC, V103, P6744, DOI 10.1021/ja00412a037; ELING T, 1986, CARCINOGENESIS, V7, P1957, DOI 10.1093/carcin/7.12.1957; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; FISCHER SM, 1985, CANCER RES, V45, P3130; FISCHER SM, 1986, CARCINOGENESIS, V7, P915, DOI 10.1093/carcin/7.6.915; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GOLDSTEIN BD, 1981, CANCER LETT, V11, P257, DOI 10.1016/0304-3835(81)90117-8; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; GUPTA RC, 1985, CANCER RES, V45, P5656; HUBERMAN E, 1976, P NATL ACAD SCI USA, V73, P607, DOI 10.1073/pnas.73.2.607; KAPITULNIK J, 1978, CANCER RES, V38, P354; KENSLER T W, 1989, P233; KENSLER TW, 1987, TOXICOL APPL PHARM, V90, P337, DOI 10.1016/0041-008X(87)90341-3; KENSLER TW, 1986, ADV FREE RADICAL BIO, V2, P347, DOI 10.1016/S8755-9668(86)80019-9; MALLET WG, 1991, CARCINOGENESIS, V12, P521, DOI 10.1093/carcin/12.3.521; MARKS F, 1981, CANCER RES, V41, P696; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; MARNETT LJ, 1987, CARCINOGENESIS, V8, P1365, DOI 10.1093/carcin/8.10.1365; MARNETT LJ, 1979, FEBS LETT, V106, P13, DOI 10.1016/0014-5793(79)80684-5; MARNETT LJ, 1979, J BIOL CHEM, V254, P5077; MARNETT LJ, 1985, PLATELETS PHYSL PHAR, P187; METCALF JA, 1986, LABORATORY MANUAL NE, P150; MILLER JA, 1970, CANCER RES, V30, P559; MIYASAKI KT, 1991, ANAL BIOCHEM, V193, P38, DOI 10.1016/0003-2697(91)90040-Z; PANTHANANICKAL A, 1981, CHEM-BIOL INTERACT, V33, P239, DOI 10.1016/0009-2797(81)90044-2; PERCHELLET EM, 1989, CANCER RES, V49, P6193; POUND AW, 1967, AUST J EXP BIOL MED, V45, P507, DOI 10.1038/icb.1967.49; PRUESSSCHWARTZ D, 1989, CANCER RES, V49, P1732; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; REDDY AP, 1992, CHEM RES TOXICOL, V5, P26, DOI 10.1021/tx00025a006; REDDY AP, 1992, CHEM RES TOXICOL, V5, P19, DOI 10.1021/tx00025a005; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; REED GA, 1981, THESIS WAYNE STATE U; REINERS JJ, 1991, CARCINOGENESIS, V12, P2345, DOI 10.1093/carcin/12.12.2345; REINERS JJ, 1991, CARCINOGENESIS, V12, P2337, DOI 10.1093/carcin/12.12.2337; ROBINSON JM, 1984, BIOCHEM BIOPH RES CO, V122, P734, DOI 10.1016/S0006-291X(84)80095-9; RODRIGUES AD, 1991, CHEM RES TOXICOL, V4, P281, DOI 10.1021/tx00021a004; SCHWARZ JA, 1977, CHEM-BIOL INTERACT, V17, P331, DOI 10.1016/0009-2797(77)90096-5; SELIGER HH, 1982, PHOTOCHEM PHOTOBIOL, V36, P359, DOI 10.1111/j.1751-1097.1982.tb04387.x; SIMS P, 1974, NATURE, V252, P326, DOI 10.1038/252326a0; Sims P, 1974, Adv Cancer Res, V20, P165, DOI 10.1016/S0065-230X(08)60111-6; SIVARAJAH K, 1979, FEBS LETT, V106, P17, DOI 10.1016/0014-5793(79)80685-7; SLAGA TJ, 1982, J CELL BIOCHEM, V18, P99, DOI 10.1002/jcb.1982.240180109; SLAGA TJ, 1983, MODULATION MEDIATION, P10; Slaga TJ, 1978, CARCINOGENESIS, V2, P173; SOLANKI V, 1981, CARCINOGENESIS, V2, P1141, DOI 10.1093/carcin/2.11.1141; TAFFE BG, 1989, CARCINOGENESIS, V10, P1261, DOI 10.1093/carcin/10.7.1261; THAKKER DR, 1977, CHEM-BIOL INTERACT, V16, P281, DOI 10.1016/0009-2797(77)90108-9; THOMPSON S, 1976, J INVEST DERMATOL, V66, P108, DOI 10.1111/1523-1747.ep12481449; TROLL W, 1985, ANNU REV PHARMACOL, V25, P509, DOI 10.1146/annurev.pharmtox.25.1.509; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; TRUSH MA, 1985, P NATL ACAD SCI USA, V82, P5194, DOI 10.1073/pnas.82.15.5194; TRUSH MA, 1992, IN PRESS FOOD CHEM T; WEI HC, 1991, CANCER RES, V51, P4443; WOOD AW, 1976, J BIOL CHEM, V251, P4882	66	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17842	17848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325452				2022-12-25	WOS:A1992JM22300057
J	ZANG, LY; MISRA, HP				ZANG, LY; MISRA, HP			SUPEROXIDE RADICAL PRODUCTION DURING THE AUTOXIDATION OF 1-METHYL-4-PHENYL-2,3-DIHYDROPYRIDINIUM PERCHLORATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIGROSTRIATAL TOXIN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; MONOAMINE-OXIDASE; SUBSTANTIA NIGRA; MPTP; METABOLITE; ION; PARKINSONISM; OXIDATION; N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; BIOACTIVATION	1-Methyl-4-phenyl-2,3-dihydropyridinium perchlorate (MPDP+), an intermediate in the metabolism of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, was found to generate superoxide radicals during its autoxidation process. The generation of superoxide radicals was detected by their ability to reduce ferricytochrome c. Superoxide dismutase inhibited this reduction in a dose-dependent manner. The rate of reduction of ferricytochrome c was dependent not only on the concentration of MPDP+ but also on the pH of the system. Thus, the rate of autoxidation of MPDP+ and the sensitivity of this autoxidation to superoxide dismutase-inhibitable ferricytochrome c reduction were both augmented, as the pH was raised from 7.0 to 10.5. The rate constant (K(c)) for the reaction of superoxide radical with ferricytochrome c to form ferricytochrome c was found to be 3.48 x 10(5) m-1 s-1. The rate constant (K(MPDP+)) for the reaction of MPDP+ with ferricytochrome3+ c was found to be only 4.86 m-1 s-1. These results, in conjunction with complexities in the kinetics, lead to the proposal that autoxidation of MPDP+ proceeds by at least two distinct pathways, one of which involves the production of superoxide radicals and hence is inhibitable by superoxide dismutase. It is possible that the free radicals so generated could induce oxidative injury which may be central to the MPTP/MPDP+-induced neuropathy.	VIRGINIA POLYTECH INST & STATE UNIV, VIRGINIA MARYLAND REG COLL VET MED, DEPT BIOMED SCI, BLACKSBURG, VA 24061 USA; CHINESE ACAD SCI, BEIJING, PEOPLES R CHINA	Virginia Polytechnic Institute & State University; Chinese Academy of Sciences								BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CAPELLOS C, 1972, KINETIC SYSTEMS, P6; CHACON JN, 1987, BIOCHEM BIOPH RES CO, V144, P957, DOI 10.1016/S0006-291X(87)80057-8; CHEVALET J, 1972, J ELECTROANAL CHEM, V39, P201, DOI 10.1016/S0022-0728(72)80488-1; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHIBA K, 1985, DRUG METAB DISPOS, V13, P342; CZAPSKI G, 1964, J PHYS CHEM-US, V68, P1169, DOI 10.1021/j100787a034; GESSNER W, 1985, FEBS LETT, V183, P345, DOI 10.1016/0014-5793(85)80807-3; GORDON S, 1963, J AM CHEM SOC, V85, P1375, DOI 10.1021/ja00893a002; GORDON S, 1964, J PHYS CHEM-US, V68, P1262, DOI 10.1021/j100787a520; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; KORTYTOWSKI W, 1987, BIOCHEM BIOPH RES CO, V144, P692, DOI 10.1016/S0006-291X(87)80020-7; KORYTOWSKI W, 1987, BIOCHEM BIOPH RES CO, V147, P354, DOI 10.1016/S0006-291X(87)80129-8; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, NEUROSCI LETT, V48, P87, DOI 10.1016/0304-3940(84)90293-3; LEUNG L, 1989, J ORG CHEM, V54, P1052, DOI 10.1021/jo00266a011; LEWIN R, 1984, SCIENCE, V225, P1460, DOI 10.1126/science.6433484; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; NAIMAN N, 1990, CHEM RES TOXICOL, V3, P133, DOI 10.1021/tx00014a008; PETERSON LA, 1985, J MED CHEM, V28, P1432, DOI 10.1021/jm00148a010; POIRIER J, 1985, BIOCHEM BIOPH RES CO, V131, P1284, DOI 10.1016/0006-291X(85)90230-X; POIRIER J, 1985, BIOCHEM BIOPH RES CO, V128, P25, DOI 10.1016/0006-291X(85)91639-0; RABANI J, 1969, J PHYS CHEM-US, V73, P3736, DOI 10.1021/j100845a030; SIMIC MG, 1975, BIOCHEM BIOPH RES CO, V62, P161, DOI 10.1016/S0006-291X(75)80118-5; TREVOR AJ, 1987, LIFE SCI, V40, P713, DOI 10.1016/0024-3205(87)90298-0; TREVOR AJ, 1988, TOXICOLOGY, V49, P513, DOI 10.1016/0300-483X(88)90037-6; WU E, 1988, CHEM RES TOXICOL, V1, P186, DOI 10.1021/tx00003a010; WU EY, 1986, LIFE SCI, V39, P1695, DOI 10.1016/0024-3205(86)90167-0; YONG VW, 1986, NEUROSCI LETT, V63, P56, DOI 10.1016/0304-3940(86)90012-1	32	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17547	17552						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325439				2022-12-25	WOS:A1992JM22300014
J	NARAYANAN, CS; FUJIMOTO, J; GERASRAAKA, E; GERSHENGORN, MC				NARAYANAN, CS; FUJIMOTO, J; GERASRAAKA, E; GERSHENGORN, MC			REGULATION BY THYROTROPIN-RELEASING-HORMONE (TRH) OF TRH RECEPTOR MESSENGER-RNA DEGRADATION IN RAT PITUITARY GH3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; IRON-RESPONSIVE ELEMENT; STABILITY INVITRO; GENE-EXPRESSION; BINDING-PROTEIN; DOWN-REGULATION; PHORBOL ESTER; FREE SYSTEM; GM-CSF; DECAY	In rat pituitary GH3 cells, thyrotropin-releasing hormone (TRH) down-regulates TRH receptor (TRH-R) mRNA (Fujimoto, J., Straub, R. E., and Gershengorn, M. C. (1991) Mol. Endocrinol. 5, 1527-1532), at least in part, by stimulating its degradation (Fujimoto, J., Narayanan, C. S., Benjamin, J. E., Heinflink, M., and Gershengorn, M. C. (1992) Endocrinology 130, 1879-1884). Here we show that TRH regulates RNase activity in GH3 cells and that specific mRNA sequences are needed for in vivo regulation of TRH-R mRNA by TRH. TRH affected RNase activity in a biphasic manner with rapid stimulation (by 10 min) followed by a decrease to a rate slower than in control lysates within 6 h. This time course paralleled the effects of TRH on degradation of TRH-R mRNA in vivo. The regulated RNase activity was in a polysome-free fraction of the lysates and was not specific for TRH-R RNA. A truncated form of TRH-R RNA that was missing the entire 3'-untranslated region (TRHR-R5) was more stable than full-length TRH-R RNA (TRHR-WT). In contrast to TRHR-WT mRNA, TRHR-R5 mRNA and TRHR-D9 mRNA, which was missing the 143 nucleotides 5' of the poly(A) tail, were not down-regulated by TRH in stably transfected GH3 cells as their rates of degradation were not increased. These data show that TRH regulates RNase activity in GH3 cells, that the 3'-untranslated region bestows decreased stability on TRH-R mRNA and that the 3' end of the mRNA is necessary for regulation by TRH of TRH-R mRNA degradation. We present an hypothesis that explains specific regulation of TRH-R mRNA degradation by TRH in GH3 pituitary cells.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV MOLEC BIOL,RM A328,1300 YORK AVE,NEW YORK,NY 10021; NEW YORK HOSP,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043036] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BINDER R, 1989, J BIOL CHEM, V264, P16910; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; DEUTSCHER MP, 1988, TRENDS BIOCHEM SCI, V13, P136, DOI 10.1016/0968-0004(88)90070-9; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; FUJIMOTO J, 1991, MOL ENDOCRINOL, V5, P1527, DOI 10.1210/mend-5-10-1527; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1879, DOI 10.1210/en.130.4.1879; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GERSHENGORN MC, 1978, J CLIN INVEST, V62, P937, DOI 10.1172/JCI109222; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HINKLE PM, 1975, BIOCHEMISTRY-US, V14, P3845, DOI 10.1021/bi00688a017; IMAI A, 1987, METHOD ENZYMOL, V141, P100; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P45, DOI 10.1093/nar/12.1Part1.45; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAVERRIERE JN, 1983, EMBO J, V2, P1493, DOI 10.1002/j.1460-2075.1983.tb01613.x; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MAYER JE, 1983, J BIOL CHEM, V258, P5340; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; ORON Y, 1987, SCIENCE, V238, P1406, DOI 10.1126/science.2825350; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PELTZ SW, 1987, MOL CELL BIOL, V7, P4345, DOI 10.1128/MCB.7.12.4345; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1987, J BIOL CHEM, V262, P9374; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORENSON CM, 1991, NUCLEIC ACIDS RES, V19, P4459, DOI 10.1093/nar/19.16.4459; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	52	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17296	17303						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324930				2022-12-25	WOS:A1992JL05300085
J	MURPHY, BJ; CATTERALL, WA				MURPHY, BJ; CATTERALL, WA			PHOSPHORYLATION OF PURIFIED RAT-BRAIN NA+ CHANNEL RECONSTITUTED INTO PHOSPHOLIPID-VESICLES BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-DEPENDENT PHOSPHORYLATION; SENSITIVE SODIUM-CHANNELS; SCORPION TOXIN BINDING; ALPHA-SUBUNIT; EXPRESSION; MODULATION; PURIFICATION; NEURONS; SITE	Phosphorylation of voltage-sensitive Na+ channels in neurons by protein kinase C slows Na+ channel inactivation and reduces peak Na+ currents. Na+ channels purified from rat brain and reconstituted into phospholipid vesicles under conditions that restore Na+ channel function were rapidly phosphorylated by protein kinase C on their 260-kDa alpha-subunit. The phosphorylation reaction required Ca2+, diolein, and phosphatidylserine for activation of protein kinase C, and the rate of phosphorylation of reconstituted Na+ channels was 3- to 4-fold faster than for Na+ channels in detergent solution. Phosphorylation was on serine residues in three distinct tryptic phosphopeptides designated A, B, and C. Up to 2.5 mol of phosphate were incorporated per mol of Na+ channel. Following maximum phosphorylation by protein kinase C, cAMP-dependent protein kinase was able to incorporate more than 2.25 mol of phosphate per mol of Na+ channel indicating that these two kinases phosphorylate distinct sites. However, prior phosphorylation by cAMP-dependent protein kinase prevented phosphorylation of phosphopeptide B indicating that both kinases phosphorylate the site in this peptide. Phosphopeptide B shown here to be phosphorylated by protein kinase C and phosphopeptide 7 previously shown to be phosphorylated by cAMP-dependent protein kinase co-migrate on two-dimensional phosphopeptide maps and evidently are identical. The reduction in peak Na+ currents caused by both protein kinase C and cAMP-dependent protein kinase may result from phosphorylation of this single common site.			MURPHY, BJ (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PHARMACOL, SEATTLE, WA 98195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGNEW WS, 1984, ANNU REV PHYSIOL, V46, P517; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P445; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; FELLER DJ, 1985, J BIOL CHEM, V260, P1542; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARTSHORNE RP, 1985, P NATL ACAD SCI USA, V82, P240, DOI 10.1073/pnas.82.1.240; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LI M, 1991, J CELL BIOL, V115, pA495; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; ROSSIE S, 1987, ENZYMES, V18, P335; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; TAMKUN MM, 1984, J BIOL CHEM, V259, P1676; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	33	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16129	16134						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322892				2022-12-25	WOS:A1992JJ45800025
J	WILDEN, PA; KAHN, CR; SIDDLE, K; WHITE, MF				WILDEN, PA; KAHN, CR; SIDDLE, K; WHITE, MF			INSULIN-RECEPTOR KINASE DOMAIN AUTOPHOSPHORYLATION REGULATES RECEPTOR ENZYMATIC FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; TYROSINE KINASE; BETA-SUBUNIT; PHOSPHORYLATION SITES; HYBRID RECEPTORS; SIGNAL TRANSDUCTION; TRANSFECTED CELLS; PROTEIN; REPLACEMENT; INVITRO	We have studied a series of insulin receptor molecules in which the 3 tyrosine residues which undergo autophosphorylation in the kinase domain of the beta-subunit (Tyr1158, Tyr1162, and Tyr1163) were replaced individually, in pairs, or all together with phenylalanine or serine by in vitro mutagenesis. A single-Phe replacement at each of these three positions reduced insulin-stimulated autophosphorylation of solubilized receptor by 45-60% of that observed with wild-type receptor. The double-Phe replacements showed a 60-70% reduction, and substitution of all 3 tyrosine residues with Phe or Ser reduced insulin-stimulated tyrosine autophosphorylation by >80%. Phosphopeptide mapping each mutant revealed that all remaining tyrosine autophosphorylation sites were phosphorylated normally following insulin stimulation, and no new sites appeared. The single-Phe mutants showed insulin-stimulated kinase activity toward a synthetic peptide substrate of 50-75% when compared with wild-type receptor kinase activity. Insulin-stimulated kinase activity was further reduced in the double-Phe mutants and barely detectable in the triple-Phe mutants. In contrast to the wild-type receptor, all of the mutant receptor kinases showed a significant reduction in activation following in vitro insulin-stimulated autophosphorylation. When studied in intact Chinese hamster ovary cells, insulin-stimulated receptor autophosphorylation and tyrosine phosphorylation of the cellular substrate pp185 in the single-Phe and double-Phe mutants was progressively lower with increased tyrosine replacement and did not exceed the basal levels in the triple-Phe mutants. However, all the mutant receptors, including the triple-Phe mutant, retained the ability to undergo insulin-stimulated Ser and Thr phosphorylation. Thus, full activation of the insulin receptor tyrosine kinase is dependent on insulin-stimulated Tris phosphorylation of the kinase domain, and the level of autophosphorylation in the kinase domain provides a mechanism for modulating insulin receptor kinase activity following insulin stimulation. By contrast, insulin stimulation of receptor phosphorylation on Ser and Thr residues by cellular serine/threonine kinases can occur despite markedly reduced tyrosine autophosphorylation.	HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School	WILDEN, PA (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 33201, DK 36836, DK 38712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038712, P30DK036836, R29DK038712, R55DK038712, R01DK033201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GOLDSTEIN BJ, 1991, ADV PROTEIN PHOSPHAT, V6; GOREN HJ, 1987, BIOCHEMISTRY-US, V26, P2374, DOI 10.1021/bi00382a044; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HERRERA R, 1986, J BIOL CHEM, V261, P1980; ISSAD T, 1991, BIOCHEM J, V275, P15, DOI 10.1042/bj2750015; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KING MJ, 1990, BIOCHEM J, V266, P251, DOI 10.1042/bj2660251; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1991, J BIOL CHEM, V266, P10616; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RODBARD D, 1980, CANCER, V46, P2907, DOI 10.1002/1097-0142(19801215)46:12+<2907::AID-CNCR2820461433>3.0.CO;2-6; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SALE GJ, 1991, INSULIN RECEPTOR PHO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SBRACCIA P, 1991, DIABETES, V40, P295, DOI 10.2337/diabetes.40.2.295; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1989, J BIOL CHEM, V264, P18951; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAVARE JM, 1991, BIOCHEM J, V274, P173, DOI 10.1042/bj2740173; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WHITE MF, 1991, J BIOENERG BIOMEMBR, V23, P63; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; ZHANG B, 1991, J BIOL CHEM, V266, P990	53	123	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16660	16668						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322912				2022-12-25	WOS:A1992JJ45800102
J	MENON, AK; STEVENS, VL				MENON, AK; STEVENS, VL			PHOSPHATIDYLETHANOLAMINE IS THE DONOR OF THE ETHANOLAMINE RESIDUE LINKING A GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR TO PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VARIANT SURFACE GLYCOPROTEINS; GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; MEMBRANE-DERIVED OLIGOSACCHARIDES; SACCHAROMYCES-CEREVISIAE; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; STRUCTURAL CHARACTERIZATION; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS	Numerous cell surface glycoproteins from eukaryotic organisms including African trypanosomes and budding yeast (Saccharomyces cerevisiae), are anchored to the lipid bilayer by a glycophospholipid, glycosylphosphatidylinositol, covalently linked to the carboxyl terminus of the protein via a phosphoethanolamine bridge. In this paper we describe metabolic labeling experiments aimed at identifying the biosynthetic origin of the ethanolamine residue in the phosphoethanolamine bridge. Using yeast mutants generated by disruption of the ethanolaminephosphotransferase (EPT1) and cholinephosphotransferase (CPT1) genes, we report data consistent with the proposal that the ethanolamine residue is derived from phosphatidylethanolamine.	EMORY UNIV,ROLLINS RES CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University	MENON, AK (corresponding author), ROCKEFELLER UNIV,MOLEC PARASITOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.			Menon, Anant Kumar/0000-0001-6924-2698	NIAID NIH HHS [AI28858, AI21531] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021531, R01AI028858] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BENNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKENHAGEN L, 1961, J BIOL CHEM, V236, pPC28; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CONZELMANN A, 1991, CELL BIOL INT REP, V15, P863, DOI 10.1016/0309-1651(91)90038-K; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, J BIOL CHEM, V266, P8392; HIGGINS JA, 1989, BIOCHEM J, V259, P913, DOI 10.1042/bj2590913; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; JACKSON BJ, 1983, J BIOL CHEM, V258, P2394; KAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47; KENNEDY EP, 1961, FED PROC, V20, P934; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MALGAT M, 1986, J LIPID RES, V27, P251; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MILLER KJ, 1987, J BACTERIOL, V169, P682, DOI 10.1128/jb.169.2.682-686.1987; MULLER G, 1991, EUR J BIOCHEM, V202, P299, DOI 10.1111/j.1432-1033.1991.tb16376.x; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SINGH N, 1991, MOL CELL BIOL, V11, P391, DOI 10.1128/MCB.11.1.391; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VAI M, 1990, BIOCHIM BIOPHYS ACTA, V1038, P277, DOI 10.1016/0167-4838(90)90237-A; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027	51	122	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15277	15280						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322394				2022-12-25	WOS:A1992JG11300006
J	CHAU, CMA; EVANS, MJ; SCARPULLA, RC				CHAU, CMA; EVANS, MJ; SCARPULLA, RC			NUCLEAR RESPIRATORY FACTOR-I ACTIVATION SITES IN GENES ENCODING THE GAMMA-SUBUNIT OF ATP SYNTHASE, EUKARYOTIC INITIATION FACTOR-2-ALPHA, AND TYROSINE AMINOTRANSFERASE - SPECIFIC INTERACTION OF PURIFIED NRF-1 WITH MULTIPLE TARGET GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CYTOCHROME-C; TRANSCRIPTION FACTOR; DNA-BINDING; PROCESSED PSEUDOGENES; SEQUENCE; EXPRESSION; RNA; UPSTREAM; PROMOTER; PROTEIN	Transcription factor nuclear respiratory factor 1 (NRF-1) was originally identified as an activator of the cytochrome c gene and subsequently found to stimulate transcription through specific sites in other nuclear genes whose products function in the mitochondria. These include subunits of the cytochrome oxidase and reductase complexes and a component of the mitochondrial DNA replication machinery. Here we establish that a functional recognition site for NRF-1 is present in the ATP synthase gamma-subunit gene extending the proposed respiratory role of NRF-1 to complex V. In addition, biologically active NRF-1 sites are found in genes encoding the eukaryotic translation initiation factor 2-alpha-subunit and tyrosine aminotransferase, both of which participate in the rate-limiting step of their respective pathways of protein biosynthesis and tyrosine catabolism. The recognition sites from each of these genes form identical complexes with NRF-1 as established by competition binding assays, methylation interference footprinting, and UV-induced DNA cross-linking. Cloned oligomers of each NRF-1 binding site also stimulate the activity of a truncated cytochrome c promoter in transfected cells. The NRF-1 binding activities for the various target sites copurified approximately 33,000-fold and resided in a single protein of 68 kDa. These observations further support a role for NRF-1 in the expression of nuclear respiratory genes and suggest it may help coordinate respiratory metabolism with other biosynthetic and degradative pathways.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM032525, R01GM032525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32525-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BASU A, 1991, J BIOL CHEM, V266, P15450; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYER MR, 1989, BIOCHEMISTRY-US, V28, P3670, DOI 10.1021/bi00435a008; EVANS MJ, 1988, P NATL ACAD SCI USA, V85, P9625, DOI 10.1073/pnas.85.24.9625; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; JACOB WF, 1989, J BIOL CHEM, V264, P20372; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Maxam A M, 1980, Methods Enzymol, V65, P499; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; OHTA S, 1988, J BIOL CHEM, V263, P11257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARPULLA RC, 1984, MOL CELL BIOL, V4, P2279, DOI 10.1128/MCB.4.11.2279; STRYER L, 1988, BIOCHEMISTRY-US, P479; SUSKE G, 1988, DNA-J MOLEC CELL BIO, V7, P163, DOI 10.1089/dna.1988.7.163; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; SUZUKI H, 1989, BIOCHEM BIOPH RES CO, V161, P371, DOI 10.1016/0006-291X(89)91607-0; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1990, NUCLEIC ACIDS RES, V18, P6581, DOI 10.1093/nar/18.22.6581; VIRBASIUS JV, 1988, J BIOL CHEM, V263, P6791	33	112	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6999	7006						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348057				2022-12-25	WOS:A1992HM05300083
J	TANG, BL; WONG, SH; LOW, SH; HONG, WJ				TANG, BL; WONG, SH; LOW, SH; HONG, WJ			RETENTION OF A TYPE-II SURFACE-MEMBRANE PROTEIN IN THE ENDOPLASMIC-RETICULUM BY THE LYS-ASP-GLU-LEU SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; IDENTIFICATION; SIGNAL; ER	Soluble luminal proteins of the endoplasmic reticulum (ER) are known to be retained by a tetrapeptide retention signal KDEL. We report in this communication that the KDEL sequence when appended to the carboxy terminus of a cell surface membrane protein, dipeptidyl peptidase IV (DPPIV), resulted in its retention in the endoplasmic reticulum of transfected Madin-Darby canine kidney cells as assessed by indirect immunofluorescence. Selective surface biotinylation revealed that about 90-95% of the expressed DPPIV was retained in the ER. Appendance of the sequence KDEV did not, however, result in ER retention, illustrating the functional specificity of the retention signal. The ER retention was not due to misfolding of the mutant protein, as the mutant proteins remained enzymatically active. Our data suggest that the KDEL receptor is able to recognize and recycle type II membrane proteins containing a carboxyl-terminal KDEL sequence and postulates the existence of such yet to be identified endogenous proteins.			TANG, BL (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.		Tang, Bor Luen/E-4548-2012; HONG, Wanjin/E-9927-2010	Tang, Bor Luen/0000-0002-1925-636X; 				ANDRES DA, 1991, J BIOL CHEM, V266, P14277; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; DAHLLOF B, 1991, J BIOL CHEM, V26, P1804; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAUGEJORDEN SM, 1991, J BIOL CHEM, V266, P6015; HONG WJ, 1989, BIOCHEMISTRY-US, V28, P8474, DOI 10.1021/bi00447a030; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LOW SH, 1991, J BIOL CHEM, V266, P13391; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAGATSU T, 1976, ANAL BIOCHEM, V74, P466, DOI 10.1016/0003-2697(76)90227-X; OGATA S, 1989, J BIOL CHEM, V264, P3596; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633	20	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7072	7076						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348058				2022-12-25	WOS:A1992HM05300094
J	KOLLMAR, R; LINDSTROM, MJ; FARNHAM, PJ				KOLLMAR, R; LINDSTROM, MJ; FARNHAM, PJ			HEAT SENSITIVITY AND SP1 ACTIVATION OF COMPLEX-FORMATION AT THE SYRIAN-HAMSTER CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING) ASPARTATE CARBAMOYLTRANSFERASE DIHYDROOROTASE PROMOTER INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SV40 EARLY PROMOTER; WHOLE-CELL EXTRACT; ACCURATE TRANSCRIPTION; CAD GENE; DNA-BINDING; INITIATION; UPSTREAM; TATA; SEQUENCES	To study the regulation of transcription of the carbamoyl-phosphate synthase (glutamine-hydrolyzing)/aspartate carbamoyltransferase/dihydroorotase (CAD) gene from the Syrian hamster, Mesocricetus auratus, we developed a homologous in vitro transcription system on the basis of nuclear extract from Syrian hamster kidney cells. We optimized the reaction temperature and the concentrations of DNA template, KCl, and MgCl2 simultaneously with the response surface method and found an unusually low temperature optimum of 20-degrees-C. We therefore investigated whether CAD transcription in vitro depended on a heat-labile component of nuclear extract. Preincubating extract alone at 30-degrees-C reduced transcription from the CAD promoter but not from the major late promoter of adenovirus 2. The formation of stable initiation complexes at the CAD promoter was diminished in heat-treated extract; run-off transcripts, however, accumulated at the same rate as in untreated extract. The heat sensitivity of complex formation correlated with the heat sensitivity of DNA binding by transcription factor Sp1, which binds to two sites in the CAD promoter; moreover, both preformed initiation complexes and DNA-bound Sp1 were heat-resistant. Adding purified Spl to heat-treated extract restored complex formation. We propose that Sp1 activates CAD transcription by stabilizing initiation complexes at the CAD promoter.	UNIV WISCONSIN, MCARDLE LAB CANC RES, 1400 UNIV AVE, MADISON, WI 53706 USA; UNIV WISCONSIN, MCARDLE LAB CANC RES, CTR BIOSTAT, MADISON, WI 53706 USA; UNIV WISCONSIN, MCARDLE LAB CANC RES, PROGRAM CELL & MOLEC BIOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [P30CA007175, P01CA023076, P30CA014520] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA14520, CA23076, CA07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI T, 1982, J BIOL CHEM, V257, P432; BEIN K, 1991, J BIOL CHEM, V266, P3791; BORRELLI MJ, 1987, EXP CELL RES, V170, P363, DOI 10.1016/0014-4827(87)90313-2; BOX GEP, 1954, BIOMETRICS, V10, P16, DOI 10.2307/3001663; BOX GEP, 1987, EMPIRICAL MODEL BUIL, P375; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; FARNHAM PJ, 1990, CELL GROWTH DIFFER, V1, P179; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FARNHAM PJ, 1991, GENE EXPRESSION, V1, P137; FIRE A, 1984, J BIOL CHEM, V259, P2509; GISSINGER F, 1974, BIOCHIMIE, V56, P319, DOI 10.1016/S0300-9084(74)80139-2; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES ME, 1972, CURR TOP CELL REGUL, V6, P227; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LIAO WSL, 1986, J BIOL CHEM, V261, P5577; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAO GN, 1987, MOL CELL BIOL, V7, P1961, DOI 10.1128/MCB.7.5.1961; RAO GN, 1988, EXP CELL RES, V178, P449, DOI 10.1016/0014-4827(88)90413-2; RAO GN, 1988, DNA-J MOLEC CELL BIO, V7, P423, DOI 10.1089/dna.1.1988.7.423; Record Jr M. T., 1990, BIOL NONSPECIFIC DNA, P33; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TYLER BM, 1985, P NATL ACAD SCI USA, V82, P5450, DOI 10.1073/pnas.82.16.5450; VERDIER JM, 1990, NUCLEIC ACIDS RES, V18, P7033, DOI 10.1093/nar/18.23.7033; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WEIL PA, 1979, CELL, V18, P469; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x; WOONTNER M, 1990, J BIOL CHEM, V265, P8979	45	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					385	391						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1346130				2022-12-25	WOS:A1992GY43900063
J	GEORGE, DJ; BLACKSHEAR, PJ				GEORGE, DJ; BLACKSHEAR, PJ			MEMBRANE ASSOCIATION OF THE MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) PROTEIN APPEARS TO INVOLVE MYRISTATE-DEPENDENT BINDING IN THE ABSENCE OF A MYRISTOYL PROTEIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PHORBOL ESTERS; CELLULAR SUBSTRATE; PLASMA-MEMBRANE; GENE-PRODUCT; PHOSPHORYLATION; FIBROBLASTS; ACTIVATION; EXPRESSION; PP60V-SRC	The myristoylated alanine-rich C kinase substrate, or MARCKS protein, has been implicated in several cellular processes, yet its physiological function remains unknown. We have studied the molecular basis of its membrane association in a cell-free system in order to help elucidate its regulation and function. First, we showed that the MARCKS protein incorporated [H-3]myristate when its mRNA was translated in vitro in reticulocyte lysates. The myristoylated protein bound rapidly to freshly fractionated cell membranes, while a nonmyristoylated mutant associated to a much lesser extent (<15% of wild type). To determine whether this binding was due to a specific cytoplasmic-face protein "receptor," as is seen with pp60v-src, we pretreated the membranes in several ways. Prior treatment of membranes with heat (100-degrees-C for 3 min) or trypsin did not affect subsequent MARCKS binding. Binding was markedly decreased in 50 mM EDTA, 0.5 M NaCl, or 1.0% Triton X-100; it was restored to normal after removal of the NaCl and EDTA but was still decreased after removal of the Triton X-100. These findings argued against the existence of a protein receptor for the MARCKS protein on cellular membranes. Finally, MARCKS protein phosphorylated in vitro with protein kinase C bound to the cell membranes to the same extent as the nonphosphorylated protein; this binding was also unaffected by an excess of a synthetic peptide corresponding to the phosphorylation site domain of the protein. We conclude that, at least in this in vitro system, the membrane association of the MARCKS protein is primarily dependent on the amino-terminal myristate moiety and does not appear to involve a specific cytoplasmic-face protein receptor.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,POB 3897,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL METAB & NUTR,DIABET & METAB SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GRAFF JM, 1989, J BIOL CHEM, V264, P2181; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JAMES G, 1989, J BIOL CHEM, V264, P20928; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; NIEDEL J E, 1986, P47; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]	33	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24879	24885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332970				2022-12-25	WOS:A1992KA26300107
J	FLANAGAN, CA; THORNER, J				FLANAGAN, CA; THORNER, J			PURIFICATION AND CHARACTERIZATION OF A SOLUBLE PHOSPHATIDYLINOSITOL 4-KINASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; BOVINE BRAIN; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; INOSITOL TRISPHOSPHATE; 2ND MESSENGERS; RAT-LIVER; GENE; RECEPTOR	A phosphatidylinositol (PI) 4-kinase was purified 25,000-fold from the cytosolic fraction of extracts from the yeast Saccharomyces cerevisiae. The purification consisted of an ammonium sulfate fractionation followed by chromatography on sulfonated-agarose (S-Sepharose), phosphocellulose, threonine-agarose, and quaternary amino (Mono Q), and sulfonated (Mono S) beads. Major contaminants in the purification, Hsc82 and Hsp82 (yeast homologs of the mammalian heat shock protein Hsp90), were eliminated by using a combination of molecular genetics (to construct a null mutation in HSC82), altered growth conditions (to minimize expression from the inducible HSP82 gene), and high ionic strength fractionation conditions (to remove the residual Hsp82). The purified enzyme had an apparent subunit molecular weight of 125,000, much larger than any other well characterized PI-4-kinase reported previously. Like mammalian PI-4-kinases, the yeast enzyme specifically phosphorylated PI on position 4 of the inositol ring and was stimulated by Triton X-100. However, activity was not inhibited by adenosine, a potent inhibitor of certain (type II) mammalian PI-4-kinases. The enzyme displayed typical Michaelis-Menten kinetics with apparent K(m) values of 100 muM for ATP and 50 muM for PI. To date, this yeast enzyme is the first soluble PI-4-kinase purified from any source.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,RM 401,BARKER HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NCI NIH HHS [CA09041] Funding Source: Medline; NIGMS NIH HHS [GM21841, GM07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P87; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CULBERTSON MR, 1975, GENETICS, V80, P23; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAHL JS, 1985, BIOCHEM BIOPH RES CO, V133, P844, DOI 10.1016/0006-291X(85)91211-2; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FIELDS FO, 1992, THESIS U CALIFORNIA; FLANAGAN CA, 1991, THESIS U CALIFORNIA; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HOU WM, 1988, BIOCHIM BIOPHYS ACTA, V959, P67; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LI YS, 1989, BIOCHEM BIOPH RES CO, V160, P202, DOI 10.1016/0006-291X(89)91641-0; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; MICHELL RH, 1967, BIOCHIM BIOPHYS ACTA, V144, P649, DOI 10.1016/0005-2760(67)90053-7; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PORTER FD, 1988, J BIOL CHEM, V263, P8989; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SKOLNIK EY, 1991, CELL, V65, P75; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1974, BIOCHIM BIOPHYS ACTA, V360, P306, DOI 10.1016/0005-2760(74)90060-5; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TUAZON PT, 1987, METHOD ENZYMOL, V141, P210; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WHEELER GE, 1972, BIOCHEM J, V127, pP64; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	60	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24117	24125						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331109				2022-12-25	WOS:A1992JZ23900103
J	HOFFMAN, L; PRATT, G; RECHSTEINER, M				HOFFMAN, L; PRATT, G; RECHSTEINER, M			MULTIPLE FORMS OF THE 20-S MULTICATALYTIC AND THE 26-S UBIQUITIN ATP-DEPENDENT PROTEASES FROM RABBIT RETICULOCYTE LYSATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; OXIDANT-DAMAGED HEMOGLOBIN; SODIUM DODECYL-SULFATE; RAT SKELETAL-MUSCLE; RED BLOOD-CELLS; CLASS-II REGION; PROTEINASE COMPLEX; NEUTRAL ENDOPEPTIDASE; LINKED LMP; HUMAN MHC	We have used native gel electrophoresis followed by fluorogenic peptide overlay to identify multiple forms of rabbit reticulocyte multicatalytic protease (MCP) or 20 S protease, and two forms of rabbit 26 S ubiquitin/ATP-dependent protease. An abundant, fast-migrating 20 S complex (20 S(F)) possesses modest ability to hydrolyze the fluorogenic peptide succinyl-Leu-Leu-Val-Tyr-4-methyl-coumaryl-7-amide. In contrast, two minor, slower migrating species cleave the peptide at high rates. A unique 30-kDa polypeptide is associated with one of the active MCPs, and a 160-kDa subunit is associated with the other. Two electrophoretically distinct 26 S proteases can also be isolated from rabbit reticulocyte lysate. The faster migrating form, 26 S(F), is more resistant to inactivation by ATP depletion. Despite the differential response to nucleotides and the distinctive electrophoretic mobilities of 26 S(F) and 26 S(S), we have not identified any subunit differences between the two enzymes. In addition to active 26 S proteases, we have discovered and purified a proteolytically inactive particle that contains subunits characteristic of the 26 S protease (e.g. molecular masses between 30 and 110 kDa). Incubation of this protein complex with purified MCP and ATP results in the formation of the 26 S proteases.	UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NIGMS NIH HHS [GM37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DJABALLAH H, 1991, BIOCH SOC T S, V19, P291; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LINGRELL J, 1972, PROTEIN BIOSYNTHESIS, P234; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MYKLES DL, 1991, ARCH BIOCHEM BIOPHYS, V288, P543, DOI 10.1016/0003-9861(91)90233-9; MYKLES DL, 1989, ARCH BIOCHEM BIOPHYS, V274, P216, DOI 10.1016/0003-9861(89)90433-5; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P5211; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SACCHETTA P, 1990, BIOCHIM BIOPHYS ACTA, V1037, P337, DOI 10.1016/0167-4838(90)90035-E; SEELIG A, 1991, BIOCHEM J, V280, P225, DOI 10.1042/bj2800225; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YAMAMOTO K, 1987, BIOCHEM BIOPH RES CO, V148, P267, DOI 10.1016/0006-291X(87)91105-3; ZOLFAGHARI R, 1987, ARCH BIOCHEM BIOPHYS, V258, P42, DOI 10.1016/0003-9861(87)90320-1	41	229	231	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22362	22368						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331052				2022-12-25	WOS:A1992JW71900060
J	XIA, ZX; DAI, WW; XIONG, JP; HAO, ZP; DAVIDSON, VL; WHITE, S; MATHEWS, FS				XIA, ZX; DAI, WW; XIONG, JP; HAO, ZP; DAVIDSON, VL; WHITE, S; MATHEWS, FS			THE 3-DIMENSIONAL STRUCTURES OF METHANOL DEHYDROGENASE FROM 2 METHYLOTROPHIC BACTERIA AT 2.6-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOBACTERIUM-EXTORQUENS AM1; NUCLEOTIDE-SEQUENCE; MACROMOLECULAR CRYSTALLOGRAPHY; PARACOCCUS-DENITRIFICANS; REFINEMENT; GENE; OXIDATION; SUBUNIT; SYSTEM; ERRORS	The structures of methanol dehydrogenase (MEDH) from two closely related methylotrophic bacteria, Methylophilus methylotrophus and W3A1, have been determined at 2.6-angstrom resolution. The molecule, a quinoprotein of molecular mass of about 138 kDa, contains two heavy (H) and two light (L) subunits of unknown sequence and two molecules of noncovalently associated pyrroloquinoline quinone. The two enzymes crystallize isomorphously in space group P2(1) with one H-2L2 heterotetramer in the asymmetric unit. The electron density map of the M. methylophilus enzyme was obtained by multiple isomorphous replacement with anomalous scattering and improved by solvent leveling and electron density averaging. For model building, the amino acid sequence of MEDH from Paracoccus denitrificans for the H subunit and from Methylobacterium extorquens AM1 for the L subunit were used to represent the unknown amino acid sequence. At the present time, 579 and 57 amino acid residues for the large and small subunits, respectively, have been fitted into the map. The phases for MEDH from M. methylophilus were used directly to analyze the W3A1 structure, and both structures were refined to R-factors (where R = SIGMA\F(o) - F(c)\/SIGMAF(o)) of 0.277 and 0.266, respectively. The L subunit contains a long alpha-helix and an extended N-terminal segment, both lying on the molecular surface of the H subunit. The H subunit contains eight antiparallel beta-sheets, each consisting of four strands arranged topologically like the letter W. The eight Ws are arranged circularly, forming the main disc-shaped body of the subunit, with some short helices and loops connecting the consecutive Ws, as well as some excursions within and between some of the Ws. The pyrroloquinoline quinone prosthetic group is located in the central channel of the large subunit near the surface of the molecule. The topology of the eight-W folding unit is similar to those of the six- and seven W folding units previously reported for three other proteins, neuraminidase, methylamine dehydrogenase, and galactose oxidase.	ACAD SINICA,SHANGHAI INST ORGAN CHEM,SHANGHAI 200032,PEOPLES R CHINA; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; University of Mississippi; University of Mississippi Medical Center; Washington University (WUSTL)			White, Scott/C-6684-2008	Davidson, Victor/0000-0002-1966-7302; White, Scott/0000-0002-0202-6154	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031611, R01GM041574, R37GM041574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41574, GM31611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1988, J BACTERIOL, V170, P2254, DOI 10.1128/jb.170.5.2254-2262.1988; ANDERSON DJ, 1990, GENE, V90, P173, DOI 10.1016/0378-1119(90)90457-3; ANTHONY C, 1967, BIOCHEM J, V104, P960, DOI 10.1042/bj1040960; ANTHONY C, 1990, FEMS MICROBIOL LETT, V87, P209, DOI 10.1016/0378-1097(90)90456-Z; ANTHONY C, 1986, ADV MICROB PHYSIOL, V27, P113, DOI 10.1016/S0065-2911(08)60305-7; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; CHEN LY, 1992, PROTEINS, V14, P288, DOI 10.1002/prot.340140214; COX JM, 1992, BIOCHIM BIOPHYS ACTA, V1119, P97, DOI 10.1016/0167-4838(92)90240-E; DUINE JA, 1989, ANNU REV BIOCHEM, V58, P403; DUINE JA, 1980, EUR J BIOCHEM, V108, P187, DOI 10.1111/j.1432-1033.1980.tb04711.x; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HARMS N, 1987, J BACTERIOL, V169, P3969, DOI 10.1128/jb.169.9.3969-3975.1987; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; INOUE T, 1989, J BACTERIOL, V171, P3115, DOI 10.1128/jb.171.6.3115-3122.1989; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONGEJAN JA, 1989, PQQ AND QUINOPROTEINS, P205; LIM LW, 1986, J MOL BIOL, V191, P141, DOI 10.1016/0022-2836(86)90431-6; MACHLIN SM, 1988, J BACTERIOL, V170, P4739, DOI 10.1128/jb.170.10.4739-4747.1988; MATTHEWS BW, 1975, ACTA CRYSTALLOGR A, V31, P480, DOI 10.1107/S0567739475001040; MCINTIRE WS, 1991, SCIENCE, V252, P981; NUNN DN, 1989, BIOCHEM J, V260, P857, DOI 10.1042/bj2600857; NUNN DN, 1988, BIOCHEM J, V256, P673, DOI 10.1042/bj2560673; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; VANSPANNING RJM, 1991, J BACTERIOL, V173, P6948, DOI 10.1128/jb.173.21.6948-6961.1991; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; XIA ZX, 1989, FEBS LETT, V258, P175, DOI 10.1016/0014-5793(89)81644-8	38	116	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22289	22297						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331050				2022-12-25	WOS:A1992JW71900048
J	KIM, RA; WANG, JC				KIM, RA; WANG, JC			IDENTIFICATION OF THE YEAST TOP3 GENE-PRODUCT AS A SINGLE STRAND-SPECIFIC DNA TOPOISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MITOTIC RECOMBINATION; BINDING-PROTEIN; OMEGA-PROTEIN; S-CEREVISIAE; SEQUENCES; CLONING; VECTORS; RDNA	The TOP3 gene of the yeast Saccharomyces cerevisiae was postulated to encode a DNA topoisomerase, based on its sequence homology to Escherichia coli DNA topoisomerase I and the suppression of the poor growth phenotype of top3 mutants by the expression of the E. coli enzyme (Wallis, J. W., Chrebet, G., Brodsky, G., Golfe, M., and Rothstein, R. (1989) Cell 58, 409-419). We have purified the yeast TOP3 gene product to near homogeneity as a 74-kDa protein from yeast cells lacking DNA topoisomerase I and overexpressing a plasmid-borne TOP3 gene linked to a phosphate-regulated yeast PHO5 gene promoter. The purified protein possesses a distinct DNA topoisomerase activity: similar to E. coli DNA topoisomerases I and III, it partially relaxes negatively but not positively supercoiled DNA. Several experiments, including the use of a negatively supercoiled heteroduplex DNA containing a 29-nucleotide single-stranded loop, indicate that the activity has a strong preference for single-stranded DNA. A protein-DNA covalent complex in which the 74-kDa protein is linked to a 5' DNA phosphoryl group has been identified, and the nucleotide sequences of 30 sites of DNA-protein covalent complex formation have been determined. These sequences differ from those recognized by E. coli DNA topoisomerase I but resemble those recognized by E. coli DNA topoisomerase III. Based on these results, the yeast TOP3 gene product can formally be termed S. cerevisiae DNA topoisomerase III. Analysis of supercoiling of intracellular yeast plasmids in various DNA topoisomerase mutants indicates that yeast DNA topoisomerase III has at most a weak activity in relaxing negatively supercoiled double-stranded DNA in vivo, in accordance with the characteristics of the purified enzyme.			KIM, RA (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NATIONAL CANCER INSTITUTE [R01CA047958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER; NCI NIH HHS [CA47958] Funding Source: Medline; NIGMS NIH HHS [GM 24544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIMA K, 1983, NUCLEIC ACIDS RES, V11, P1657, DOI 10.1093/nar/11.6.1657; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DEAN F, 1983, COLD SPRING HARB SYM, V47, P769; DEAN F, 1984, THESIS U CHICAGO; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DUPLAY P, 1984, J BIOL CHEM, V259, P606; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KUNG VT, 1977, J BIOL CHEM, V252, P5398; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; RADMAN M, 1991, BIOCHIMIE, V73, P357, DOI 10.1016/0300-9084(91)90101-6; RAYMOND W, 1990, THESIS HARVARD U; ROTHSTEIN R, 1987, MOL CELL BIOL, V7, P1198, DOI 10.1128/MCB.7.3.1198; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TSE YC, 1980, J BIOL CHEM, V255, P5560; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1971, J MOL BIOL, V55, P532; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	33	112	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17178	17185						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324925				2022-12-25	WOS:A1992JL05300070
J	QUELLE, FW; QUELLE, DE; WOJCHOWSKI, DM				QUELLE, FW; QUELLE, DE; WOJCHOWSKI, DM			INTERLEUKIN-3, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, AND TRANSFECTED ERYTHROPOIETIN RECEPTORS MEDIATE TYROSINE PHOSPHORYLATION OF A COMMON CYTOSOLIC PROTEIN (PP100) IN FDC-ER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; EXPRESSION CLONING; RAPID PHOSPHORYLATION; CYTOPLASMIC REGION; KINASE-ACTIVITY; BETA-CHAIN; GM-CSF; GROWTH; ACTIVATION; LINES	Receptors for the hematopoietic growth factors erythropoietin, interleukin 3 (IL-3), and granulocyte-macrophage colony-stimulating factor (GM-CSF) are members of a structurally related receptor superfamily. Interestingly, while none of these receptors encode tyrosine kinase activities, induced tyrosine phosphorylation has been observed in various responsive cells stimulated with each factor. Toward defining possible common transduction pathways which are activated by these three cytokines, we have studied induced protein phosphorylation in murine myeloid FDC-P1 cells stably transfected with an erythropoietin receptor cDNA (FDC-ER cells). FDC-ER cells proliferate in response to erythropoietin (Quelle, D. E., and Wojchowski, D. M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4801-4805), and presently are shown to rapidly phosphorylate a M(r) 100,000 cytosolic protein (pp100) at tyrosine residues in response to this factor. Phosphorylation of pp100 also is induced in FDC-P1 and FDC-ER cells in response to IL-3 or GM-CSF. Importantly, quantitative analyses showed identical concentration dependencies for factor-induced pp100 phosphorylation and induced cell proliferation. Moreover, a selective loss of proliferative responsiveness to GM-CSF in FDC-ER cells was associated with a reduced capacity of GM-CSF to induce pp100 phosphorylation. Finally, limited differences in tryptic phosphopeptide maps of pp100 as isolated following exposure to erythropoietin, IL-3, or GM-CSF were observed, suggesting that these factors also may preferentially induce phosphorylation of pp100 at distinct sites. These findings are consistent with a role for pp100 as a common cytosolic transducer in the apparently convergent pathways of erythropoietin-, IL-3-, and GM-CSF-induced proliferation of myeloid progenitor cells.	PENN STATE UNIV, DEPT MOLEC & CELL BIOL, UNIV PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University				Quelle, Dawn/0000-0001-8776-0122; Quelle, Frederick/0000-0002-1184-6170	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040242] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44491] Funding Source: Medline; NIDDK NIH HHS [R29-DK40242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GORDON JA, 1991, METHOD ENZYMOL, V201, P110; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IHLE JN, 1982, J IMMUNOL, V129, P1377; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1990, BLOOD, V76, P706; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SALTZMAN EM, 1990, J BIOL CHEM, V265, P10138; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SORENSEN PHB, 1989, BLOOD, V73, P406; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TUNER B, 1991, P NATL ACAD SCI USA, V88, P1227; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	44	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17055	17060						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324920				2022-12-25	WOS:A1992JL05300051
J	MISEK, DE; SALTIEL, AR				MISEK, DE; SALTIEL, AR			AN INOSITOL PHOSPHATE GLYCAN DERIVED FROM A TRYPANOSOMA-BRUCEI GLYCOSYL-PHOSPHATIDYLINOSITOL MIMICS SOME OF THE METABOLIC ACTIONS OF INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR HEAD GROUP; VARIANT SURFACE GLYCOPROTEIN; DEPENDENT PROTEIN-KINASE; HEPATIC PLASMA-MEMBRANES; HORMONE-SENSITIVE LIPASE; EPIDERMAL GROWTH-FACTOR; FRUCTOSE 2,6-BISPHOSPHATE; RAT HEPATOCYTES; PYRUVATE-DEHYDROGENASE; OKADAIC ACID	Some of the acute actions of insulin may be mediated by an enzyme-modulating inositol phosphate glycan, produced by the insulin-sensitive hydrolysis of glycosyl-phosphatidylinositol (GPI) that is structurally similar to a membrane protein anchor. An inositol glycan fragment from the structurally characterized Trypanosoma brucei variant surface glycoprotein GPI anchor is evaluated for insulin-mimetic antilipolytic activity. The fragment specifically and dose-dependently inhibits isoproterenol-stimulated lipolysis. Like the effect of insulin, glycan-induced antilipolysis is blocked by the low K(m) cAMP phosphodiesterase inhibitor imazodan (CI-914) and the serine/threonine phosphatase inhibitor, okadaic acid, suggesting that the activation of both cAMP phosphodiesterase and serine/threonine protein phosphatases are necessary. Moreover, this fragment causes a specific and dose-dependent inhibition of both microsomal glucose-6-phosphatase (EC 3.1.3.9) and cytosolic fructose-1,6-bisphosphatase (EC 3.1.3.11) activity. Additionally, direct addition of the glycan to hepatocytes caused marked inhibition of glucose production from pyruvate. These results suggest that the direct modification of the activities of these two gluconeogenic enzymes by an inositol glycan may play a role in the inhibition of glucose output by insulin and provide the first evidence for the insulin-mimetic properties of a chemically characterized inositol glycan.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA	University of Michigan System; University of Michigan; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033804, R23DK033804] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33804] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEMANY S, 1987, NATURE, V330, P77, DOI 10.1038/330077a0; ALVAREZ JF, 1987, BIOCHEM BIOPH RES CO, V147, P765, DOI 10.1016/0006-291X(87)90996-X; ALVAREZ L, 1991, MOL ENDOCRINOL, V5, P1062, DOI 10.1210/mend-5-8-1062; ASSIMACOPOULOSJEANNET F, 1990, J BIOL CHEM, V265, P7202; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRUNI P, 1990, BIOCHEM BIOPH RES CO, V166, P765, DOI 10.1016/0006-291X(90)90875-N; BUTCHER RW, 1966, J BIOL CHEM, V241, P1651; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; ELMAGHRABI MR, 1988, P NATL ACAD SCI USA, V85, P8430, DOI 10.1073/pnas.85.22.8430; ELMAGHRABI MR, 1991, J BIOL CHEM, V266, P2115; Ferguson M.A.J., 1987, NATO ASI Series Series H Cell Biology, V11, P19; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; Fleischer S, 1974, Methods Enzymol, V31, P6; GAULTON GN, 1991, DIABETES, V40, P1297, DOI 10.2337/diabetes.40.10.1297; GETTYS TW, 1990, SEC MESS PHOSPHOPROT, V13, P37; GOTTSCHALK WK, 1988, ARCH BIOCHEM BIOPHYS, V261, P175, DOI 10.1016/0003-9861(88)90116-6; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HAMER MJ, 1990, BIOCHEM J, V269, P685, DOI 10.1042/bj2690685; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; IGARASHI Y, 1987, BIOCHEM BIOPH RES CO, V145, P249, DOI 10.1016/0006-291X(87)91313-1; KELLY KL, 1986, FEBS LETT, V209, P238, DOI 10.1016/0014-5793(86)81119-X; KELLY KL, 1987, P NATL ACAD SCI USA, V84, P6404, DOI 10.1073/pnas.84.18.6404; KELLY KL, 1987, J BIOL CHEM, V262, P15285; KOJIMA I, 1990, J BIOL CHEM, V265, P16846; KONO T, 1973, J BIOL CHEM, V248, P7417; LARNER J, 1988, BIOCHEM BIOPH RES CO, V151, P1416, DOI 10.1016/S0006-291X(88)80520-5; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MANGANIELLO VC, 1990, 2ND MESSENGERS PHOSP, P147; MARTINY L, 1990, CELL SIGNAL, V2, P21, DOI 10.1016/0898-6568(90)90029-A; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; MATO JM, 1987, J BIOL CHEM, V262, P2131; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MENON AK, 1988, J BIOL CHEM, V263, P1970; MERIDA I, 1988, FEBS LETT, V236, P251, DOI 10.1016/0014-5793(88)80325-9; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MILLER TB, 1973, J BIOL CHEM, V248, P3483; MOR MA, 1981, FEBS LETT, V136, P131; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; PILKIS SJ, 1975, J BIOL CHEM, V250, P6328; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PONTREMOLI S, 1982, ARCH BIOCHEM BIOPHYS, V218, P609, DOI 10.1016/0003-9861(82)90386-1; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROMERO G, 1990, P NATL ACAD SCI USA, V87, P1476, DOI 10.1073/pnas.87.4.1476; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SALTIEL AR, 1987, BIOCHEM BIOPH RES CO, V149, P1084, DOI 10.1016/0006-291X(87)90519-5; SALTIEL AR, 1988, AM J PHYSIOL, V255, pC1, DOI 10.1152/ajpcell.1988.255.1.C1; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; SALTIEL AR, 1988, PHILOS T ROY SOC B, V320, P345, DOI 10.1098/rstb.1988.0081; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SHIBATA H, 1991, J BIOL CHEM, V266, P17948; SOLEY M, 1987, ARCH BIOCHEM BIOPHYS, V255, P136, DOI 10.1016/0003-9861(87)90303-1; SPAGNOLI D, 1983, ARCH BIOCHEM BIOPHYS, V226, P182, DOI 10.1016/0003-9861(83)90283-7; SPETH M, 1981, BIOCHEM BIOPH RES CO, V99, P134, DOI 10.1016/0006-291X(81)91723-X; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; SUZUKI S, 1984, BIOCHEM BIOPH RES CO, V118, P40, DOI 10.1016/0006-291X(84)91064-7; TAKETA K, 1965, J BIOL CHEM, V240, P651; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VARGAS AM, 1990, J BIOL CHEM, V265, P15368; VILLALBA M, 1988, BIOCHIM BIOPHYS ACTA, V968, P69, DOI 10.1016/0167-4889(88)90045-6; WIELAND O, 1957, BIOCHEM Z, V329, P313; Williams J.M., 1975, ADV CARBOHYD CHEM, V31, P9, DOI [10.1016/S0065-2318(08)60294-2, DOI 10.1016/S0065-2318(08)60294-2]; WITTERS LA, 1988, J BIOL CHEM, V263, P8027; WITTERS LA, 1988, BIOCHEM BIOPH RES CO, V153, P992, DOI 10.1016/S0006-291X(88)81326-3	72	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16266	16273						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322896				2022-12-25	WOS:A1992JJ45800044
J	SPEAR, DH; KUTSUNAI, SY; CORRELL, CC; EDWARDS, PA				SPEAR, DH; KUTSUNAI, SY; CORRELL, CC; EDWARDS, PA			MOLECULAR-CLONING AND PROMOTER ANALYSIS OF THE RAT-LIVER FARNESYL DIPHOSPHATE SYNTHASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; PYROPHOSPHATE SYNTHETASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A SYNTHASE; COORDINATE REGULATION; BINDING PROTEINS; MEVALONIC ACID; MESSENGER-RNA; SEQUENCE; DNA; TRANSCRIPTION	The isolation and characterization of the rat genomic clone encoding the cholesterogenic enzyme farnesyl diphosphate (FPP) synthase is reported. The gene is localized on a 15-kilobase (kb) genomic fragment, spans approximately 12 kb and contains eight exons. Sequences containing from 3.9 kb to 132 base pairs (bp) of the putative promoter were joined to the coding region of the bacterial reporter gene chloramphenicol acetyltransferase (CAT). The CAT activities or CAT mRNA levels of the hybrid genes were determined following either transient transfections into human hepatoma HepG2 cells or stable transfections into Chinese hamster ovary cells. The transient transfections identified a 319-bp fragment that was required for a 4-fold induction in the absence of sterols. Sequence analysis of this region showed it contained five potential copies of the sterol regulatory element (SRE-1) (Smith, J. R., Osborne, T. F., Brown, M. S., Goldstein, J. L., and Gil, G. (1988) J. Biol. Chem. 263, 18480-18487) previously identified in the promoters of the 3-hydroxy-3-methyl-coenzyme A (HMG-CoA) reductase, HMG-CoA synthase, and low density lipoprotein receptor genes. Further mutational and deletion analysis of the FPP synthase promoter-CAT constructs followed by stable transfection and primer extension of the CAT mRNA levels indicated that these potential SRE-1 regulatory elements were not involved in the sterol-mediated transcriptional regulation of the gene. Our analyses have identified a 115-bp region that is required for the transcriptional induction of FPP synthase in the absence of sterols. These results suggest that the FPP synthase gene may be regulated at the transcriptional level by a different mechanism than other sterol regulated genes.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIGMS NIH HHS [GMO7185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ASHBY MN, 1989, J BIOL CHEM, V264, P635; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FAUST JR, 1980, J BIOL CHEM, V255, P6546; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEINZMANN C, 1989, GENOMICS, V5, P493, DOI 10.1016/0888-7543(89)90015-3; JAMES MJ, 1980, J BIOL CHEM, V255, P16; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; LEVIN MS, 1989, BIOCHIM BIOPHYS ACTA, V1003, P293, DOI 10.1016/0005-2760(89)90235-X; Maniatis T., 1982, MOL CLONING; NIELSEN DA, 1983, P NATL ACAD SCI USA, V80, P1598; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, V1, P162; RILLING HC, 1985, STEROLS BILE ACIDS, P17; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; WOLDA SL, 1988, J BIOL CHEM, V263, P5997	33	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14462	14469						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321149				2022-12-25	WOS:A1992JD32500102
J	LEMOSY, EK; ERICKSON, HP; BEYER, WF; RADEK, JT; JEONG, JM; MURTHY, SNP; LORAND, L				LEMOSY, EK; ERICKSON, HP; BEYER, WF; RADEK, JT; JEONG, JM; MURTHY, SNP; LORAND, L			VISUALIZATION OF PURIFIED FIBRONECTIN-TRANSGLUTAMINASE COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; FACTOR-XIII; TISSUE TRANSGLUTAMINASE; PURIFICATION; FIBRINOGEN; TENASCIN; PROTEINS; PLASMA	It has been reported previously (Turner, P. M., and Lorand, L. (1989) Biochemistry 28, 628-635) that human erythrocyte transglutaminase forms a noncovalent complex with human plasma fibronectin near its collagen-binding domain. In the present study, we show by nondenaturing electrophoresis that guinea pig liver transglutaminase, similarly to the erythrocyte enzyme, forms a complex with human fibronectin. Studies of anisotropic shifts of fluorescein-labeled liver and erythrocyte transglutaminases, upon addition of fibronectin, indicated that both transglutaminases bind to fibronectin with a stoichiometry of about 2:1. Polymerization of fibrinogen by human erythryocyte transglutaminase was inhibited after complex formation with fibronectin. Complexes of fibronectin with either erythrocyte or liver transglutaminase were isolated by glycerol gradient zone sedimentation and examined by rotary shadowing electron microscopy. The globular transglutaminase could be readily identified binding to the thin fibronectin strand. The binding site for transglutaminase was within 5-10 nm of the N terminus of fibronectin, consistent with its proximity to the collagen-binding domain. Under some experimental conditions, the complex of fibronectin with erythrocyte transglutaminase appeared as a ring-shaped structure in which two transglutaminase molecules had probably dimerized. The molecular weight of the erythrocyte transglutaminase was determined by sedimentation equilibrium to be 71,440 +/- 830.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Duke University; Northwestern University	LEMOSY, EK (corresponding author), DUKE UNIV, MED CTR, DEPT CELL BIOL, BOX 3011, DURHAM, NC 27710 USA.			LeMosy, Ellen/0000-0001-5192-2804	NCI NIH HHS [CA 47056] Funding Source: Medline; NHLBI NIH HHS [HL 03512, HL 02212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047056, R37CA047056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL002212, K06HL003512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUKHIL I, 1990, MATRIX, V10, P98, DOI 10.1016/S0934-8832(11)80176-9; BRENNER SC, 1978, BIOCHIM BIOPHYS ACTA, V522, P74, DOI 10.1016/0005-2744(78)90323-6; CARRELL NA, 1989, J BIOL CHEM, V264, P551; CHURCHICH JE, 1967, BIOCHIM BIOPHYS ACTA, V147, P511, DOI 10.1016/0005-2795(67)90010-4; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; ERICKSON HP, 1981, J CELL BIOL, V91, P673, DOI 10.1083/jcb.91.3.673; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FOLK JE, 1966, J BIOL CHEM, V241, P5518; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FREYSSINET JM, 1978, BIOCHEM J, V169, P403, DOI 10.1042/bj1690403; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LORAND L, 1988, P NATL ACAD SCI USA, V85, P1057, DOI 10.1073/pnas.85.4.1057; LORAND L, 1979, ANAL BIOCHEM, V93, P453, DOI 10.1016/S0003-2697(79)80178-5; LORAND L, 1981, METHOD ENZYMOL, V80, P333; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIHALYI E, 1968, BIOCHEMISTRY-US, V7, P208, DOI 10.1021/bi00841a026; MORROW JS, 1981, J SUPRAMOL STR CELL, V17, P275, DOI 10.1002/jsscb.380170308; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; MURTHY SNP, 1990, P NATL ACAD SCI USA, V87, P9679, DOI 10.1073/pnas.87.24.9679; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; RADEK J T, 1991, Biophysical Journal, V59, p478A; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SVEDBERG T, 1940, ULTRACENTRIFUGE, P48; TAYLOR HC, 1989, J CELL BIOCHEM, V41, P71, DOI 10.1002/jcb.240410204; TURNER PM, 1989, BIOCHEMISTRY-US, V28, P628, DOI 10.1021/bi00428a032; WEBER K, 1969, J BIOL CHEM, V244, P4406	30	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7880	7885						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348509				2022-12-25	WOS:A1992HN48500095
J	BEEBE, SJ; SALOMONSKY, P; JAHNSEN, T; LI, YX				BEEBE, SJ; SALOMONSKY, P; JAHNSEN, T; LI, YX			THE C-GAMMA SUBUNIT IS A UNIQUE ISOZYME OF THE CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; INHIBITOR PROTEIN; MOLECULAR-CLONING; RAT TESTIS; CELLS; FORM; IDENTIFICATION; PURIFICATION; MECHANISM; ISOFORMS	There are at least three isozymes (Calpha, Cbeta, and Cgamma) of the mammalian catalytic (C) subunit of cAMP-dependent protein kinase (PKA) (Beebe, S., Oyen, O., Sandberg, M., Froysa, A., Hansson, V., and Jahnsen, T. (1990) Mol. Endocrinol. 4, 465-475). To compare the Cgamma and Calpha isozymes, the respective cDNAs were expressed in permanently transformed Kin-8 PKA-deficient Y1 adrenal cells using the mouse metallothionein promoter. The recombinant C subunits were characterized as immunoreactive, zinc-inducible, cAMP-dependent kinase activities. In contrast to Calpha, histone was a better substrate than Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide) for Cgamma. Furthermore, Cgamma histone kinase activity was not inhibited by the protein kinase inhibitor peptide (5-24 amide), which has been widely used as a PKA-specific inhibitor. The major Cgamma peak (type I) eluted from DEAE-Sepharose at a higher NaCl concentration (120 mM) than the Calpha type I eluted (70 mM). Cgamma and Calpha type II eluted between 220 and 240 mM NaCl. Cgamma required higher concentrations of cAMP than Calpha did for dissociation from the mutant type I holoenzyme. These differences provided a basis for the separation of the mutant RI-associated isozymes on DEAE-Sepharose. Both Calpha (41-42 kDa) and Cgamma (39-40 kDa) were identified by a C subunit antibody after sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot analysis. Zinc induced the PKA-mediated rounding phenotype in Cgamma and Calpha clones, thereby restoring the cells to the parent Y1 adrenal cell phenotype. Collectively, these data indicate that Cgamma is an active PKA C subunit but suggest that Cgamma and Calpha have different protein and peptide recognition determinants.	EASTERN VIRGINIA MED SCH, PEDIAT RES CTR, DEPT PEDIAT, NORFOLK, VA 23501 USA; UNIV OSLO, DEPT MED BIOCHEM, N-0317 OSLO, NORWAY; UNIV OSLO, RIKSHOSP, N-0317 OSLO, NORWAY; EASTERN VIRGINIA MED SCH, PEDIAT RES CTR, DEPT PHYSIOL, NORFOLK, VA 23501 USA	Eastern Virginia Medical School; University of Oslo; University of Oslo; National Hospital Norway; Eastern Virginia Medical School				Oyen, Ole/0000-0001-6615-3542	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044777] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44777] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY CD, 1973, J BIOL CHEM, V248, P1255; BEALE EG, 1977, J BIOL CHEM, V252, P6322; BEEBE SJ, 1984, MOL CELL ENDOCRINOL, V36, P67, DOI 10.1016/0303-7207(84)90086-8; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEEBE SJ, 1992, DEV BIOL, V151, P48, DOI 10.1016/0012-1606(92)90212-Y; BEEBE SJ, 1986, ENZYMES, V17, P43; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG HC, 1986, J BIOL CHEM, V261, P989; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; FOSS KB, 1992, CYTOGENET CELL GENET, V60, P22, DOI 10.1159/000133286; GLASS DB, 1986, J BIOL CHEM, V261, P2166; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; OLSON M, 1991, END SOC ABSTR, V622, P186; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; REED J, 1983, ARCH BIOCHEM BIOPHYS, V222, P276, DOI 10.1016/0003-9861(83)90525-8; ROBINSONSTEINER A, 1984, J BIOL CHEM, V250, P10596; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WIEMANN S, 1991, J BIOL CHEM, V266, P5140; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	36	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25505	25512						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334096				2022-12-25	WOS:A1992KB60300089
J	ANDERSON, GL; WILLIAMS, J; HILLE, R				ANDERSON, GL; WILLIAMS, J; HILLE, R			THE PURIFICATION AND CHARACTERIZATION OF ARSENITE OXIDASE FROM ALCALIGENES-FAECALIS, A MOLYBDENUM-CONTAINING HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ELECTRON-SPIN-RESONANCE; ESCHERICHIA-COLI; XANTHINE-OXIDASE; PSEUDOMONAS-PUTIDA; ADP-ARSENATE; RESISTANCE; CENTERS; SYSTEMS; CLUSTER	The purification and initial characterization of arsenite oxidase from Alcaligenes faecalis are described. The enzyme consists of a monomer of 85 kDa containing one molybdenum, five or six irons, and inorganic sulfide. In the presence of denaturants arsenite oxidase releases a fluorescent material with specral properties identical to the pterin cofactor released by the hydroxylase class of molybdenum-containing enzymes. Azurin and a c-type cytochrome, both isolated from A. faecalis, each serves as an electron acceptor to arsenite oxidase and may form a periplasmic electron transfer pathway for arsenite detoxification. Full reduction of arsenite oxidase requires 3-4 reducing equivalents, using either arsenite or dithionite as the electron source. Below 20 K, oxidized arsenite oxidase exhibits an EPR signal with g values of 2.03, 2.01, and 2.00, which integrates to approximately 0.4 spins/protein. Since enrichment in Fe-57 results in broadening of this EPR signal, the center giving rise to this signal must contain iron. The most plausible candidates are a [4Fe-4S] high potential iron protein center or a [3Fe-4S] center. The EPR signal observed in oxidized arsenite oxidase disappears upon reduction of the protein with either arsenite or dithionite. Concomitantly, a rhombic EPR signal (g = 2.03, 1.89, 1.76) appears which is similar to that of Rieske-type [2Fe-2S] clusters and spin quantifies to one spin/protein.	OHIO STATE UNIV,DEPT MED BIOCHEM,1645 NEIL AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL PHARM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004882] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 04882] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; ANTANAITIS BC, 1983, J BIOL CHEM, V258, P3166; Bard A. J., 1985, STANDARD POTENTIALS; BENKO V, 1977, ENVIRON RES, V13, P386; CHANDRASEKAR R, 1986, J BIOL CHEM, V261, P3616; CODDINGTON K, 1986, TOXICOL ENVIRON CHEM, V11, P281, DOI 10.1080/02772248609357139; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; CRANE RK, 1953, J BIOL CHEM, V201, P235; DAVIS JC, 1982, P NATL ACAD SCI-BIOL, V79, P4623, DOI 10.1073/pnas.79.15.4623; FEE JA, 1984, J BIOL CHEM, V259, P124; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOX BG, 1988, J BIOL CHEM, V263, P10553; GEARY PJ, 1984, BIOCHEM J, V217, P667, DOI 10.1042/bj2170667; Goyer R.A., 1986, CASARETT DOULLS TOXI, P582; Green H. H., 1918, REP DIR VET RES S AF, V5, P593; GRESSER MJ, 1981, J BIOL CHEM, V256, P5981; GUTTERIDGE S, 1978, BIOCHEM J, V175, P887, DOI 10.1042/bj1750887; HEMMERICH P, 1964, HELV CHIM ACTA, V47, P464, DOI 10.1002/hlca.19640470214; Hille R., 1985, Metal Ions in Biology, V7, P443; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; ISHINISHI N, 1986, HDB TOXICOLOGY METAL, P43; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1988, METHOD ENZYMOL, V158, P371, DOI 10.1016/0076-6879(88)58069-2; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KNOWLES FC, 1983, TRENDS BIOCHEM SCI, V8, P178, DOI 10.1016/0968-0004(83)90168-8; KOMAI H, 1969, J BIOL CHEM, V244, P1692; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPIN AG, 1979, J AM CHEM SOC, V101, P2302, DOI 10.1021/ja00503a009; LEGGE JW, 1954, AUST J BIOL SCI, V7, P504, DOI 10.1071/BI9540504; LEGGE JW, 1954, AUST J BIOL SCI, V7, P496, DOI 10.1071/BI9540496; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALKIN R, 1978, BIOCHIM BIOPHYS ACTA, V505, P147, DOI 10.1016/0304-4173(78)90011-3; MAYHEW SG, 1969, J BIOL CHEM, V244, P803; MITRA S, 1982, P NATL ACAD SCI USA, V79, P6907; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; MOORE SA, 1983, J BIOL CHEM, V258, P6266; OEHME FW, 1972, TOXICOLOGY, V5, P215; OSBORNE FH, 1976, J APPL BACTERIOL, V41, P295, DOI 10.1111/j.1365-2672.1976.tb00633.x; PALMER G, 1975, ENZYMES, V12, P1; PHILLIPS SE, 1976, APPL ENVIRON MICROB, V32, P392, DOI 10.1128/AEM.32.3.392-399.1976; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; RIESKE JS, 1964, BIOCHEM BIOPH RES CO, V15, P338, DOI 10.1016/0006-291X(64)90171-8; RINDERLE SJ, 1984, FED PROC, V43, P2060; ROSENBERG H, 1977, J BACTERIOL, V131, P505, DOI 10.1128/JB.131.2.505-511.1977; RYDEN L, 1984, COPPER PROTEINS COPP, V1, P157; SAUBER K, 1977, EUR J BIOCHEM, V74, P89, DOI 10.1111/j.1432-1033.1977.tb11370.x; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; SILVER S, 1981, J BACTERIOL, V146, P983, DOI 10.1128/JB.146.3.983-996.1981; SILVER S, 1982, P NATL ACAD SCI-BIOL, V79, P6114, DOI 10.1073/pnas.79.20.6114; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; TURNER AW, 1954, AUST J BIOL SCI, V7, P479, DOI 10.1071/BI9540479; TURNER AW, 1954, AUST J BIOL SCI, V7, P452, DOI 10.1071/BI9540452; TURNER AW, 1949, NATURE, V164, P76, DOI 10.1038/164076a0; TWILFER H, 1981, EUR J BIOCHEM, V119, P595, DOI 10.1111/j.1432-1033.1981.tb05649.x; VAHTER M, 1983, ENVIRON RES, V32, P13; WILLIAMS JW, 1986, FASEB J, V45, P1660; WILLSKY GR, 1980, J BACTERIOL, V144, P366, DOI 10.1128/JB.144.1.366-374.1980; WILLSKY GR, 1980, J BACTERIOL, V144, P356, DOI 10.1128/JB.144.1.356-365.1980; [No title captured]	61	225	247	3	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23674	23682						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331097				2022-12-25	WOS:A1992JZ23900040
J	JANETZKY, B; LEHLE, L				JANETZKY, B; LEHLE, L			TY4, A NEW RETROTRANSPOSON FROM SACCHAROMYCES-CEREVISIAE, FLANKED BY TAU-ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; AMINO-ACID-SEQUENCE; TRANSCRIPTION TERMINATION; REVERSE TRANSCRIPTION; NUCLEOTIDE-SEQUENCE; YEAST; RNA; PROTEINS; TRANSPOSON; GENES	We have isolated and sequenced a genomic clone from Saccharomyces cerevisiae that shows structural features of a novel retrotransposon, designated Ty4. The element is 6.2 kilobases in length, and its genetic organization of the deduced functional domains is similar to Ty1 and Ty2 and thus different from Ty3. In contrast to hitherto known Ty elements from yeast, Ty4 is flanked by long terminal tau-element repeats instead of delta or sigma sequences. Ty4 contains two overlapping open reading frames. The first open reading frame, TYA4, is 1230 base pairs long and encodes a protein with a motif found in the nucleic acid-binding gag-protein of retroviruses. The second 4395-base pair open reading frame, TYB4, encodes a polyprotein that has domains with significant homology to retroviral protease, integrase, reverse transcriptase, and RNase H, structurally arranged in that order. The deduced amino acid sequence shows the greatest similarity with Ty2 and Ty1. The overall identity of the deduced functional protein domains is 28% with Ty2, 25% with Ty1, 19% with copia from Drosophila, and 18% with Ty3. Examination of genomic DNA from several laboratory strains indicates that Ty4 is present in two to four copies. Ty4 mRNA is of low abundance as compared to other Ty retrotransposons. At the 3' end of Ty4, two "solo" delta-elements, a full length and an overlapping, truncated one, are associated.			JANETZKY, B (corresponding author), UNIV REGENSBURG,INST ZELLBIOL,W-8400 REGENSBURG,GERMANY.							ADAMS SE, 1987, CELL, V49, P111, DOI 10.1016/0092-8674(87)90761-6; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; BOEKE JD, 1989, MOBILE DNA, P335; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CLARE J, 1985, P NATL ACAD SCI USA, V82, P2828; CLARK DJ, 1988, J BIOL CHEM, V263, P1413; COPELAND TD, 1984, VIROLOGY, V133, P137, DOI 10.1016/0042-6822(84)90432-X; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; ELDER RT, 1980, COLD SPRING HARB SYM, V45, P581; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; FARABAUGH PJ, 1980, NATURE, V286, P352, DOI 10.1038/286352a0; FINK GR, 1986, TRENDS GENET, V2, P118, DOI 10.1016/0168-9525(86)90200-3; GAFNER J, 1980, NATURE, V286, P414, DOI 10.1038/286414a0; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; GENBAUFFE FS, 1984, J BIOL CHEM, V259, P518; GRANDBASTIEN MA, 1992, TRENDS GENET, V8, P103, DOI 10.1016/0168-9525(92)90198-D; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HAUBER J, 1985, NUCLEIC ACIDS RES, V13, P2745, DOI 10.1093/nar/13.8.2745; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KINGSMAN AJ, 1988, CELL, V53, P333, DOI 10.1016/0092-8674(88)90151-1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIAO XB, 1987, P NATL ACAD SCI USA, V84, P8520, DOI 10.1073/pnas.84.23.8520; MCCLUSKEY K, 1990, CURR GENET, V18, P385, DOI 10.1007/BF00318221; MELLOR J, 1985, NATURE, V318, P583, DOI 10.1038/318583a0; MELLOR J, 1985, NUCLEIC ACIDS RES, V13, P6249, DOI 10.1093/nar/13.17.6249; MELLOR J, 1985, NATURE, V313, P243, DOI 10.1038/313243a0; MULLER F, 1987, MOL GEN GENET, V207, P421, DOI 10.1007/BF00331610; MULLER F, 1991, MOL GEN GENET, V226, P145, DOI 10.1007/BF00273598; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; Sambrook J, 1989, MOL CLONING LABORATO; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; Sherman F., 1986, METHODS YEAST GENETI; STUCKA R, 1986, CURR GENET, V11, P193, DOI 10.1007/BF00420606; VARMUS HE, 1977, P NATL ACAD SCI USA, V74, P911; WARMINGTON JR, 1985, NUCLEIC ACIDS RES, V13, P6679, DOI 10.1093/nar/13.18.6679; YOSHINAKA Y, 1977, CELL, V12, P709, DOI 10.1016/0092-8674(77)90271-9; YOUNGREN SD, 1988, MOL CELL BIOL, V8, P1421, DOI 10.1128/MCB.8.4.1421; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	46	17	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19798	19805						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328182				2022-12-25	WOS:A1992JR85800010
J	HORI, H; MASUYA, F; TSUBAKI, M; YOSHIKAWA, S; ICHIKAWA, Y				HORI, H; MASUYA, F; TSUBAKI, M; YOSHIKAWA, S; ICHIKAWA, Y			ELECTRONIC AND STEREOCHEMICAL CHARACTERIZATIONS OF INTERMEDIATES IN THE PHOTOLYSIS OF FERRIC CYTOCHROME P450SCC NITROSYL COMPLEXES - EFFECTS OF CHOLESTEROL AND ITS ANALOGS ON LIGAND-BINDING STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; PARAMAGNETIC RESONANCE; CRYSTAL-STRUCTURE; ELECTROMAGNETIC PROPERTIES; C OXIDASE; HEMOPROTEINS; PREGNENOLONE; CONVERSION; MYOGLOBIN; RAMAN	Low temperature photolysis of nitric oxide from the nitrosyl complexes of ferric cytochrome P450scc was examined by EPR spectroscopy to elucidate the stereochemical interaction between heme-bound ligand and side-chain of cholesterol or its hydroxylated analogues at the substrate-binding site. The photoproducts of the NO complexes trapped at 5 K exhibited new EPR absorptions providing information on the steric crowding of the distal heme moiety. Without substrate, the photoproduct exhibited a broad EPR absorption at g approximately 8 due to magnetic dipole-dipole interaction between the photodissociated NO (S = 1/2) and the ferric iron (S = 5/2). This indicates that the photo-dissociated NO can move far away from the heme iron in the less restricted distal heme moiety of the substrate-free cytochrome P450scc. In the presence of substrates, such as cholesterol, 20(S)-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, and 25-hydroxycholesterol, the EPR spectra of the photoproducts exhibited many variations having broad g approximately 8 absorptions and/or the widespread signals together with zero-field absorption. Among the steroid complexes used, 20(S)-hydroxycholesterol complex exhibited a conspicuously widespread EPR signal with a distinct zero-field absorption due to a spin-coupled interaction between the ferric iron (S = 5/2) and the photolyzed NO (S = 1/2). These results indicate that the 20(S)-hydroxycholesterol complex has restricted substrate-binding structure and that the hydroxylation of the cholesterol side-chain at the 22R position is necessary to proceed the side-chain cleavage reaction properly in cytochrome P450scc.	HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN; KAGAWA MED SCH,DEPT BIOCHEM,MIKI,KAGAWA 76107,JAPAN	University of Hyogo; Kagawa University	HORI, H (corresponding author), OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN.							BENKO B, 1983, P NATL ACAD SCI USA, V80, P7042, DOI 10.1073/pnas.80.22.7042; BURSTEIN S, 1976, STEROIDS, V28, P115, DOI 10.1016/0039-128X(76)90131-8; BURSTEIN S, 1975, J BIOL CHEM, V250, P9028; COOPER CE, 1992, J BIOL CHEM, V267, P280; DUNHAM WR, 1983, BIOCHIM BIOPHYS ACTA, V748, P73, DOI 10.1016/0167-4838(83)90029-8; ENEMARK JH, 1974, COORDIN CHEM REV, V13, P339, DOI 10.1016/S0010-8545(00)80259-3; HAGEN WR, 1982, BIOCHIM BIOPHYS ACTA, V708, P82, DOI 10.1016/0167-4838(82)90206-0; HENDRICH MP, 1989, BIOPHYS J, V56, P489, DOI 10.1016/S0006-3495(89)82696-7; HOFFMAN BM, 1978, P NATL ACAD SCI USA, V75, P21, DOI 10.1073/pnas.75.1.21; HORI H, 1981, J BIOL CHEM, V256, P7849; HORI H, 1990, J BIOL CHEM, V265, P15028; HORI H, 1982, BIOCHEMISTRY-US, V21, P1431, DOI 10.1021/bi00535a050; HORI H, 1980, NATURE, V288, P501, DOI 10.1038/288501a0; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; HUME R, 1984, EUR J BIOCHEM, V140, P583, DOI 10.1111/j.1432-1033.1984.tb08142.x; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; KOBAYASHI K, 1980, J BIOL CHEM, V255, P2239; MORISAKI M, 1976, FEBS LETT, V72, P337, DOI 10.1016/0014-5793(76)80999-4; ORMEJOHNSON NR, 1979, J BIOL CHEM, V254, P2103; PICIULO PL, 1974, J AM CHEM SOC, V96, P5293, DOI 10.1021/ja00823a067; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; POULOS TL, 1987, J MOL BIOL, V195, P678; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; SCHEIDT WR, 1984, J AM CHEM SOC, V106, P3191, DOI 10.1021/ja00323a022; TSUBAKI M, 1986, BIOCHIM BIOPHYS ACTA, V870, P564, DOI 10.1016/0167-4838(86)90266-9; TSUBAKI M, 1986, BIOCHEMISTRY-US, V25, P3563, DOI 10.1021/bi00360a014; TSUBAKI M, 1987, BIOCHEMISTRY-US, V26, P4527, DOI 10.1021/bi00388a054; YONETANI T, 1972, J BIOL CHEM, V247, P2447	30	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18377	18381						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326522				2022-12-25	WOS:A1992JN50200024
J	HAYASHI, Y; CHAN, J; NAKABAYASHI, H; HASHIMOTO, T; TAMAOKI, T				HAYASHI, Y; CHAN, J; NAKABAYASHI, H; HASHIMOTO, T; TAMAOKI, T			IDENTIFICATION AND CHARACTERIZATION OF 2 ENHANCERS OF THE HUMAN ALBUMIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; TISSUE-SPECIFIC EXPRESSION; LIVER-SPECIFIC FACTOR; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVATORS; PROMOTER REGIONS; MOUSE; UPSTREAM; DNA; ELEMENTS	A 12.5-kilobase pair (kb) segment upstream of the human albumin gene was analyzed for transcription enhancing activity using transient transfection analysis, gel mobility shift assays, DNase I footprinting, and site-specific mutagenesis. Two enhancer regions were identified, one 1.7 kb upstream of the transcription initiation site (E1.7) and the other 6 kb upstream (E6). In E1.7, a nuclear protein from HuH-7 hepatoma cells binds to an AT-rich sequence, GTTACTAATTGAC. Competition gel mobility shift assays suggested that this protein is HNF-1, which regulates the promoter of the albumin gene and several other liver-specific genes. A 60-base pair E1.7 fragment carrying the AT-rich sequence stimulates a heterologous (alpha-fetoprotein) promoter in a dose-dependent manner. In E6, a HuH-7 nuclear protein binds to a GT-rich sequence, TGTTTGGC. A 27-base pair E6 fragment carrying this sequence is able to stimulate the SV40 promoter in an orientation-independent manner. An alteration of this sequence by site-specific mutagenesis resulted in the loss of transcriptional activity as well as binding to the HuH-7 nuclear protein. Competition gel mobility shift assays showed that homologous elements exist in the albumin promoter. These results show that the promoter and enhancer of the human albumin gene are regulated by two common transcription factors through two shared cis-acting elements, one AT-rich and the other GT-rich.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary			Chan, Jeannie/B-5060-2013					BABISS LE, 1987, GENE DEV, V1, P256, DOI 10.1101/gad.1.3.256; BACH I, 1990, GENOMICS, V8, P155, DOI 10.1016/0888-7543(90)90238-P; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; FRAIN M, 1990, MOL CELL BIOL, V10, P991, DOI 10.1128/MCB.10.3.991; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; JOSEESTANYOL M, 1988, J BIOL CHEM, V263, P10865; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NAKABAYASHI H, 1989, J BIOL CHEM, V264, P266; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; SAWADAISHI K, 1988, MOL CELL BIOL, V8, P5179, DOI 10.1128/MCB.8.12.5179; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; TRONCHE F, 1990, MOL BIOL MED, V7, P173; URANO Y, 1986, J BIOL CHEM, V261, P3244; WATANABE K, 1987, J BIOL CHEM, V262, P4812; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	36	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14580	14585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321810				2022-12-25	WOS:A1992JF08800016
J	MAKINEN, KK; MAKINEN, PL; SYED, SA				MAKINEN, KK; MAKINEN, PL; SYED, SA			PURIFICATION AND SUBSTRATE-SPECIFICITY OF AN ENDOPEPTIDASE FROM THE HUMAN ORAL SPIROCHETE TREPONEMA-DENTICOLA ATCC-35405, ACTIVE ON FURYLACRYLOYL-LEU-GLY-PRO-ALA AND BRADYKININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYMOTRYPSINLIKE PROTEASE; PERIODONTAL-DISEASE; SUBGINGIVAL PLAQUE; BASEMENT-MEMBRANE; RAT-BRAIN; ENZYME; METALLOENDOPEPTIDASE; COLLAGENASES; INHIBITION; THERMOLYSIN	An endopeptidase was purified to homogeneity from the cell extracts of Treponema denticola ATCC 35405 (a human oral spirochete) by a procedure that comprised dialysis, anion exchange fast protein liquid chromatography (FPLC), hydroxylapatite FPLC, immobilized metal affinity FPLC, FPLC chromatofocusing, and two consecutive gel permeation FPLC steps. The enzyme is a 62-kDa protein with an isoelectric point of 6.5-7.0. Experiments with enzyme inhibitors suggest that this enzyme is a metallopeptidase and that its activity is not dependent on sulfhydryl or serine residues. The enzyme is active on furylacryloyl-Leu-Gly-Pro-Ala (FALGPA; pH optimum near 6.25), bradykinin (Bk), and several Bk-related peptides. In FALGPA, the cleavage site is the Leu-Gly bond. An imino acid is absolutely necessary in position P'2. The shortest hydrolyzed peptide was FALGPA, the hydrolysis of which is strongly and competitively inhibited by Bk (K(i) = 5.0-mu-M). The pyrophosphate ion and phosphoramidon also inhibited the hydrolysis of FALGPA. The enzyme does not hydrolyze all typical synthetic collagenase substrates, Azocoll, Azocasein, or Type I and Type IV collagens, or any other proteins tested. In Bk-related peptides, the hydrolyzed bond was Phe5-Ser6. Since a Bk antagonist and a Bk-potentiating pentapeptide also were good substrates, it is possible that the enzyme hydrolyzes Bks and related peptides only because of the coincidental, specific amino acid sequence of those substrates. A proposal is made that since a substantial portion of the amino acid sequence of FALGPA is present in collagen (and additionally acknowledging that the furylacryloyl residue structurally resembles that of proline), the natural substrates of this enzyme may be small, soluble collagen fragments produced by other enzymes from periodontal connective tissue, and that such peptides are important for the nutrition and pathogenicity of T. denticola.			MAKINEN, KK (corresponding author), UNIV MICHIGAN,SCH DENT,DEPT BIOL & MAT SCI,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008664] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08664-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARRETT AJ, 1991, BIOCHEM SOC T, V19, P707, DOI 10.1042/bst0190707; BOEHRINGER H, 1984, INFECT IMMUN, V45, P155, DOI 10.1128/IAI.45.1.155-159.1984; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3077, DOI 10.1021/bi00308a035; BREDDAM K, 1979, BIOCHEMISTRY-US, V18, P1563, DOI 10.1021/bi00575a028; CANALEPAROLA E, 1977, BACTERIOL REV, V41, P181, DOI 10.1128/MMBR.41.1.181-204.1977; CHAVIRA R, 1984, ANAL BIOCHEM, V136, P446, DOI 10.1016/0003-2697(84)90242-2; CHENG SL, 1983, J PERIODONTAL RES, V18, P362, DOI 10.1111/j.1600-0765.1983.tb00371.x; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; DOI E, 1981, ANAL BIOCHEM, V118, P173, DOI 10.1016/0003-2697(81)90175-5; Erdos E., 1979, HDB EXPT PHARM S, VXXV, P427; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FELBER JP, 1962, BIOCHEMISTRY-US, V1, P231, DOI 10.1021/bi00908a006; FOURNIEZALUSKI MC, 1963, J MED CHEM, V26, P60; GRENIER D, 1990, INFECT IMMUN, V58, P347, DOI 10.1128/IAI.58.2.347-351.1990; HARRIS DL, 1972, VET MED SM ANIM CLIN, V67, P61; HARWOOD CS, 1984, ANNU REV MICROBIOL, V38, P161, DOI 10.1146/annurev.mi.38.100184.001113; HOLMQUIST B, 1974, J BIOL CHEM, V249, P4601; HOLT S C, 1991, Critical Reviews in Oral Biology and Medicine, V2, P177; KAM CM, 1979, BIOCHEMISTRY-US, V18, P3032, DOI 10.1021/bi00581a019; KIKUCHI M, 1988, BIOCHIM BIOPHYS ACTA, V965, P176, DOI 10.1016/0304-4165(88)90054-2; LISTGARTEN MA, 1978, J CLIN PERIODONTOL, V5, P115, DOI 10.1111/j.1600-051X.1978.tb01913.x; Loesche W. J., 1982, HOST PARASITE INTERA, P62; LOESCHE WJ, 1987, J PERIODONTOL, V58, P266, DOI 10.1902/jop.1987.58.4.266; LOESCHE WJ, 1985, J PERIODONTOL, V56, P447, DOI 10.1902/jop.1985.56.8.447; MAKINEN KK, 1987, CURR MICROBIOL, V14, P341; MAKINEN KK, 1978, BIOCHEM J, V175, P1051; MAKINEN KK, 1990, MOL MICROBIOL, V4, P1413, DOI 10.1111/j.1365-2958.1990.tb00721.x; MAKINEN KK, 1990, CURR MICROBIOL, V20, P69, DOI 10.1007/BF02094028; MAKINEN KK, 1988, ORAL MICROBIOL IMMUN, V3, P121, DOI 10.1111/j.1399-302X.1988.tb00096.x; MAKINEN PL, 1989, J BIOL CHEM, V264, P3325; MALKINEN KK, 1987, J BIOL CHEM, V262, P12488; MCDERMOTT JR, 1987, BIOCHEM BIOPH RES CO, V146, P154, DOI 10.1016/0006-291X(87)90704-2; MOORE WEC, 1985, INFECT IMMUN, V48, P507, DOI 10.1128/IAI.48.2.507-519.1985; MOORE WM, 1986, BIOCHEMISTRY-US, V25, P5189, DOI 10.1021/bi00366a031; NITZAN D, 1978, ARCH ORAL BIOL, V23, P465, DOI 10.1016/0003-9969(78)90078-X; OHTA K, 1986, INFECT IMMUN, V53, P213, DOI 10.1128/IAI.53.1.213-220.1986; OLSEN I, 1984, SCAND J DENT RES, V92, P55; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1981, BIOCHEMISTRY-US, V20, P4942, DOI 10.1021/bi00520a021; PASTER BJ, 1982, APPL ENVIRON MICROB, V43, P686, DOI 10.1128/AEM.43.3.686-693.1982; PASTER BJ, 1985, APPL ENVIRON MICROB, V50, P212, DOI 10.1128/AEM.50.2.212-219.1985; QUE XC, 1990, INFECT IMMUN, V58, P4099, DOI 10.1128/IAI.58.12.4099-4105.1990; REGOLI D, 1990, TRENDS PHARMACOL SCI, V11, P156, DOI 10.1016/0165-6147(90)90067-I; RUDOLPH AH, 1988, J AM ACAD DERMATOL, V18, P1121, DOI 10.1016/S0190-9622(88)80015-X; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SEPPA HEJ, 1978, J INVEST DERMATOL, V70, P84, DOI 10.1111/1523-1747.ep12541221; SIMONSON LG, 1988, INFECT IMMUN, V56, P726, DOI 10.1128/IAI.56.4.726-728.1988; STEWART JM, 1971, BIOCHEM PHARMACOL, V20, P1557, DOI 10.1016/0006-2952(71)90284-X; THOMAS DD, 1988, P NATL ACAD SCI USA, V85, P3608, DOI 10.1073/pnas.85.10.3608; UITTO VJ, 1988, ORAL MICROBIOL IMMUN, V3, P97, DOI 10.1111/j.1399-302X.1988.tb00092.x; UMEZAWA S, 1972, Tetrahedron Letters, V1, P97; VANWART HE, 1981, ANAL BIOCHEM, V113, P356, DOI 10.1016/0003-2697(81)90089-0; WEINBERG A, 1990, INFECT IMMUN, V58, P1720, DOI 10.1128/IAI.58.6.1720-1729.1990; WOLZ RL, 1990, ANAL BIOCHEM, V191, P314; WUNSCH E, 1963, H-S Z PHYSIOL CHEM, V333, P149, DOI 10.1515/bchm2.1963.333.1.149; ZOLFAGHARI R, 1986, ENZYME, V36, P165, DOI 10.1159/000469289; ZOLLNER H, 1989, HDB ENZYME INHIBITOR, P334	57	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14285	14293						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321141				2022-12-25	WOS:A1992JD32500077
J	RABBANI, SA; MAZAR, AP; BERNIER, SM; HAQ, M; BOLIVAR, I; HENKIN, J; GOLTZMAN, D				RABBANI, SA; MAZAR, AP; BERNIER, SM; HAQ, M; BOLIVAR, I; HENKIN, J; GOLTZMAN, D			STRUCTURAL REQUIREMENTS FOR THE GROWTH-FACTOR ACTIVITY OF THE AMINO-TERMINAL DOMAIN OF UROKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; PRO-UROKINASE; CELL-SURFACE; ENDOTHELIAL-CELLS; RIBONUCLEIC-ACID; RECEPTOR; DEGRADATION; EXPRESSION; MECHANISM; MONOCYTES	High molecular weight urokinase-type plasminogen activator (uPA) in which proteolytic activity was inactivated (diisopropyl fluorophosphate (DFP)-uPA), its amino-terminal fragment (ATF, amino acids (aa) 1143), and fucosylated and defucosylated growth factor domains (GFD, aa 4-43) were tested for growth-promoting effects and binding in human SaOS-2 osteosarcoma cells and U-937 lymphoma cells. DFP-uPA, ATF, and both the fucosylated and defucosylated GFD were capable of competing with I-125-ATF for binding to both SaOS-2 and U-937 cells. DFP-uPA, ATF, and fucosylated GFD were also mitogenic in SaOS-2 cells and increased cell numbers. However, defucosylated GFD was nonmitogenic in SaOS-2 cells and did not stimulate cell proliferation, even though it bound to these cells in a manner equivalent to the fucosylated GFD. A nonglycosylated high molecular weight uPA expressed and purified from Escherichia coli inhibited I-125-ATF binding to SaOS-2 cells but was also nonmitogenic. No mitogenic activity was observed in U-937 cells treated with the uPA forms capable of eliciting a mitogenic response in SaOS-2 cells. Proteolytically prepared kringle domain (aa 47-135) and low molecular weight uPA (aa 144-411) did not compete for I-125-ATF binding and did not elicit any mitogenic response in either of the cell lines tested. In addition, tissue plasminogen activator (tPA), which has been shown to be homologous to uPA in its growth factor domain and is also fucosylated, did not inhibit I-125-ATF binding nor elicit any mitogenic response. These results demonstrate that the GFD, implicated in binding to the uPA receptor, is also responsible for growth factor like activity in SaOS-2 cells and that the fucosylation at Thr18 within this domain may serve as a molecular trigger in eliciting this response.	ABBOTT LABS,DIV PHARMACEUT PROD,THROMBOLYT VENTURE,ABBOTT PK,IL 60064; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT PHYSIOL,MONTREAL H3A 1A1,QUEBEC,CANADA	Abbott Laboratories; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital				rabbani, shafaat/0000-0001-5594-3899	NCI NIH HHS [R01 CA37126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BOYD D, 1988, CANCER RES, V48, P3112; BUKO AM, 1991, P NATL ACAD SCI USA, V88, P3992, DOI 10.1073/pnas.88.9.3992; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUDEWICZ PW, 1987, BIOCHEM BIOPH RES CO, V147, P1176, DOI 10.1016/S0006-291X(87)80193-6; GUREWICH V, 1984, J CLIN INVEST, V73, P1731, DOI 10.1172/JCI111381; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HE CJ, 1991, BIOCHEM BIOPH RES CO, V176, P1408, DOI 10.1016/0006-291X(91)90443-B; HEARING VJ, 1988, CANCER RES, V48, P1270; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KIRCHHEIMER J, 1984, BIOCHIM BIOPHYS ACTA, V797, P256, DOI 10.1016/0304-4165(84)90129-6; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; KOUTSILIERIS M, 1987, J ENDOCRINOL, V115, P447, DOI 10.1677/joe.0.1150447; LO KM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P217; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MARCOTTE PA, 1992, FIBRINOLYSIS, V6, P57, DOI 10.1016/0268-9499(92)90095-Y; MAZAR AP, 1992, FIBRINOLYSIS, V6, P49, DOI 10.1016/0268-9499(92)90094-X; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; NOVOKHATNY V, 1992, IN PRESS J BIOL CHEM, V267; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; PANNELL R, 1986, BLOOD, V67, P1215; PLOUG M, 1991, J BIOL CHEM, V266, P1926; RABBANI SA, 1990, BIOCHEM BIOPH RES CO, V173, P1058, DOI 10.1016/S0006-291X(05)80893-9; ROBBIATI F, 1990, FIBRINOLYSIS, V4, P53, DOI 10.1016/S0268-9499(05)80041-4; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3574, DOI 10.1021/bi00875a028; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STUMP DC, 1986, J BIOL CHEM, V261, P7120; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; ULRICH A, 1984, EMBO J, V3, P361; ZAMARRON C, 1984, THROMB HAEMOSTASIS, V52, P27	40	233	242	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14151	14156						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321137				2022-12-25	WOS:A1992JD32500058
J	LOHSE, MJ; ANDEXINGER, S; PITCHER, J; TRUKAWINSKI, S; CODINA, J; FAURE, JP; CARON, MG; LEFKOWITZ, RJ				LOHSE, MJ; ANDEXINGER, S; PITCHER, J; TRUKAWINSKI, S; CODINA, J; FAURE, JP; CARON, MG; LEFKOWITZ, RJ			RECEPTOR-SPECIFIC DESENSITIZATION WITH PURIFIED PROTEINS - KINASE DEPENDENCE AND RECEPTOR SPECIFICITY OF BETA-ARRESTIN AND ARRESTIN IN THE BETA-2-ADRENERGIC RECEPTOR AND RHODOPSIN SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL S-ANTIGEN; NUCLEOTIDE-BINDING-PROTEIN; ROD OUTER SEGMENTS; ADRENERGIC-RECEPTOR; HETEROLOGOUS DESENSITIZATION; PHOSPHORYLATION SITES; DISTINCT PATHWAYS; LIGHT-SCATTERING; 48-KDA PROTEIN; ACTIVATION	Homologous desensitization of beta-adrenergic receptors, as well as adaptation of rhodopsin, are thought to be triggered by specific phosphorylation of the receptor proteins. However, phosphorylation alone seems insufficient to inhibit receptor function, and it has been proposed that the inhibition is mediated, following receptor phosphorylation, by the additional proteins beta-arrestin in the case of beta-adrenergic receptors and arrestin in the case of rhodopsin. In order to test this hypothesis with isolated proteins, beta-arrestin and arrestin were produced by transient overexpression of their cDNAs in COS7 cells and purified to apparent homogeneity. Their functional effects were assessed in reconstituted receptor/G protein systems using either beta-2-adrenergic receptors with G(s) or rhodopsin with G(t). Prior to the assays, beta-2-receptors and rhodopsin were phosphorylated by their specific kinases beta-adrenergic receptor kinase (beta-ARK) and rhodopsin kinase, respectively. Beta-arrestin was a potent inhibitor of the function of beta-ARK-phosphorylated beta-2-receptors. Half-maximal inhibition occurred at a beta-arrestin:beta-2-receptor stoichiometry of about 1:1. More than 100-fold higher concentrations of arrestin were required to inhibit beta-2-receptor function. Conversely, arrestin caused half-maximal inhibition of the function of rhodopsin kinase-phosphorylated rhodopsin when present in concentrations about equal to those of rhodopsin, whereas beta-arrestin at 100-fold higher concentrations had little inhibitory effect. The potency of beta-arrestin in inhibiting beta-2-receptor function was increased over 10-fold following phosphorylation of the receptors by beta-ARK, but was not affected by receptor phosphorylation using protein kinase A. This suggests that beta-arrestin plays a role in beta-ARK-mediated homologous, but not in protein kinase A-mediated heterologous desensitization of beta-adrenergic receptors. It is concluded that even though arrestin and beta-arrestin are similar proteins, they display marked specificity for their respective receptors and that phosphorylation of the receptors by the receptor-specific kinases serves to permit the inhibitory effects of the "arresting" proteins by allowing them to bind to the receptors and thereby inhibit their signaling properties. Furthermore, it is shown that this mechanism of receptor inhibition can be reproduced with isolated purified proteins.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV PARIS 06,INSERM,F-75270 PARIS 06,FRANCE	Duke University; Howard Hughes Medical Institute; Baylor College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	LOHSE, MJ (corresponding author), UNIV MUNICH,MAX PLANCK INST BIOCHEM,MOLEC BIOL LAB,W-8033 MARTINSRIED,GERMANY.		Pitcher, Julie/ABH-2078-2020; Lohse, Martin J/A-7160-2012; Lefkowitz, Robert/AAW-2649-2021	Lohse, Martin J/0000-0002-0599-3510; 	NHLBI NIH HHS [HL 16037] Funding Source: Medline; NIDDK NIH HHS [DK 19318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019318, R37DK019318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1986, NATURE, V322, P869; BLAKE AD, 1987, BIOCHEM BIOPH RES CO, V147, P168, DOI 10.1016/S0006-291X(87)80102-X; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CODINA J, 1984, J BIOL CHEM, V259, P5871; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; DOREY C, 1982, OPHTHALMIC RES, V14, P249, DOI 10.1159/000265199; FAURE JP, 1984, CURR EYE RES, V3, P867, DOI 10.3109/02713688409000800; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LIGGETT SB, 1989, MOL PHARMACOL, V36, P343; LOHSE MJ, 1986, MOL PHARMACOL, V30, P403; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOHSE MJ, 1992, SIGNAL TRANSMISSION; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SHICHI H, 1984, VISION RES, V24, P1523, DOI 10.1016/S0042-6989(84)80001-2; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6875; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STIEMER RH, 1992, IN PRESS J AUTOIMMUN; WAGNER R, 1988, FEBS LETT, V235, P103, DOI 10.1016/0014-5793(88)81242-0; WAGNER R, 1988, FEBS LETT, V234, P44, DOI 10.1016/0014-5793(88)81299-7; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZIGLER JS, 1984, INVEST OPHTH VIS SCI, V25, P977	43	284	288	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8558	8564						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349018				2022-12-25	WOS:A1992HQ18500090
J	VOGEL, LK; SPIESS, M; SJOSTROM, H; NOREN, O				VOGEL, LK; SPIESS, M; SJOSTROM, H; NOREN, O			EVIDENCE FOR AN APICAL SORTING SIGNAL ON THE ECTODOMAIN OF HUMAN AMINOPEPTIDASE-N	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELL; MICROVILLUS AMINOPEPTIDASE; ENDOPLASMIC-RETICULUM; MEMBRANE; PROTEINS; INSERTION; SURFACE; BIOSYNTHESIS	In polarized epithelial cells aminopeptidase N is targeted to the apical membrane. The aim of this study was to determine whether a sorting signal is necessary for its correct transport to the apical membrane and, if so, to localize this sorting signal to one of the domains of the transmembrane protein. Anchor-minus aminopeptidase N, consisting of the hemagglutinin signal peptide including its cleavage site, and the ectoplasmic domain of human aminopeptidase N were stably expressed in Madin-Darby canine kidney cells cultured on polycarbonate filters. By measurement of the enzymatic activity it was found that the anchor-minus aminopeptidase N was secreted in a polarized manner to the apical side. As a reference the secretion of the secretory granule protein, cystatin C, was likewise studied. Cystatin C was found to be secreted in a nonpolarized manner to both domains. Our data thus show that human aminopeptidase N carries an apical sorting signal and that it is localized on the ectodomain of the enzyme.	UNIV BASEL, BIOCTR, DEPT BIOCHEM, CH-4056 BASEL, SWITZERLAND	University of Basel	VOGEL, LK (corresponding author), UNIV COPENHAGEN, PANUM INST, DEPT BIOCHEM C, BLEGDAMSVEJ 3, DK-2200 COPENHAGEN, DENMARK.			Vogel, Lotte K./0000-0001-9920-0982; Spiess, Martin/0000-0001-7139-0550				ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; DANIELSEN EM, 1985, EUR J BIOCHEM, V152, P493, DOI 10.1111/j.1432-1033.1985.tb09223.x; FINIDORI J, 1987, J CELL BIOL, V104, P1705, DOI 10.1083/jcb.104.6.1705; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GRUBB A, 1985, SCAND J CLIN LAB INV, V45, P7; HANSEN GH, 1988, MAMMALIAN BRUSH BORD, P29; HUSSAIN MM, 1981, BIOCHEM J, V199, P179, DOI 10.1042/bj1990179; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH MG, 1989, ANNU REV PHYSIOL, V51, P797; Sambrook J, 1989, MOL CLONING LABORATO; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SJOSTROM H, 1978, EUR J BIOCHEM, V88, P503, DOI 10.1111/j.1432-1033.1978.tb12476.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WANDINGERNESS A, 1991, INTRACELLULAR TRAFFI, P575; WESSELS HP, 1989, J BIOL CHEM, V264, P17; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	30	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2794	2797						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346396				2022-12-25	WOS:A1992HB53200101
J	SAXENA, A; ALI, IU				SAXENA, A; ALI, IU			INCREASED EXPRESSION OF GENES FROM GROWTH-FACTOR SIGNALING PATHWAYS IN GLIOBLASTOMA CELL-LINES	ONCOGENE			English	Article							MESSENGER RIBONUCLEIC-ACID; FACTOR-ALPHA; TRANSFORMED-CELLS; FACTOR RECEPTOR; BREAST-CANCER; DNA-SEQUENCE; FACTOR-BETA; FACTOR CDNA; AMPLIFICATION; RNAS	The concept of autocrine stimulation of cell proliferation postulates growth autonomy by acquisition of the ability to produce and respond to growth factors. Overproduction of several growth factors in a variety of human tumors and cell lines derived from these tumors has been reported. We have screened several cell lines derived from glioblastomas for anomalies in the expression of genes encoding transforming growth factor alpha (TGF-alpha), TGF-beta, basic fibroblast growth factor (bFGF) and its high-affinity receptor, flg. Compared with normal human brain tissue, we observed a generalized elevation in the levels of expression of these genes in glioblastoma cell lines and an SV40-transformed human astroglial cell line. Overexpression of these genes does not appear to be merely a reflection of the proliferative state of transformed cells since some other human tumor cell lines, when analysed for the expression of TGF-beta and bFGF, did not show a significant increase in these transcripts. The specificity of the elevated transcription of TGF-alpha, TGF-beta, bFGF and flg in glioblastoma cell lines is further suggested by the fact that the transcription of the proto-oncogene c-erbB2, which is overproduced in breast tumor cell lines, was not elevated in glioblastoma cell lines. Increased expression of growth factors, which are potent mitogens and angiogens, and/or their receptors may have critical roles in autonomous proliferation as well as neovascularization of glioblastomas.	NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ALI IU, 1989, ONCOGENE, V4, P89; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BIARD A, 1987, BIOCHEM BIOPH RES CO, V142, P428; BLAM SB, 1988, ONCOGENE, V3, P129; BREM S, 1972, J NATL CANCER I, V48, P347; CLARK GM, 1991, CANCER RES, V51, P944; DERYNCK R, 1987, CANCER RES, V47, P707; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; KERNOHAN JW, 1952, ATLAS TUMOR PATHOLOG; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KRAUS MH, 1989, CANCER CEL, V7, P303; KUROKAWA T, 1987, FEBS LETT, V213, P189, DOI 10.1016/0014-5793(87)81489-8; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MAXWELL M, 1991, CANCER RES, V51, P1345; MURPHY PR, 1988, MOL ENDOCRINOL, V2, P591, DOI 10.1210/mend-2-7-591; MYELLO JH, 1988, PROSTATE, V13, P241; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NISTER M, 1988, CANCER RES, V48, P3910; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUSHDI A, 1983, SCIENCE, V222, P390; Russell D., 1989, PATHOLOGY TUMORS NER; SANETO RP, 1985, DEV NEUROSCI-BASEL, V7, P340, DOI 10.1159/000112301; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHLEGEL U, 1990, ONCOGENE, V5, P1839; Sporn M B, 1987, Important Adv Oncol, P75; STERNFELD MD, 1988, J CELL PHYSIOL, V136, P297, DOI 10.1002/jcp.1041360212; TAKAHASHI JA, 1991, BIOCHEM BIOPH RES CO, V177, P1, DOI 10.1016/0006-291X(91)91939-A; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEIBEL M, 1985, INT J DEV NEUROSCI, V3, P617, DOI 10.1016/0736-5748(85)90052-8; WESTERMARK B, 1973, INT J CANCER, V12, P438, DOI 10.1002/ijc.2910120215; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; ZAGZAG D, 1990, CANCER RES, V50, P7393	47	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					243	247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1347915				2022-12-25	WOS:A1992HG98200006
J	VANIWAARDEN, JF; VANSTRIJP, JAG; VISSER, H; HAAGSMAN, HP; VERHOEF, J; VANGOLDE, LMG				VANIWAARDEN, JF; VANSTRIJP, JAG; VISSER, H; HAAGSMAN, HP; VERHOEF, J; VANGOLDE, LMG			BINDING OF SURFACTANT PROTEIN-A (SP-A) TO HERPES-SIMPLEX VIRUS TYPE 1-INFECTED CELLS IS MEDIATED BY THE CARBOHYDRATE MOIETY OF SP-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG SURFACTANT; PULMONARY SURFACTANT; ALVEOLAR PROTEINOSIS; II CELLS; GLYCOPROTEINS; PHAGOCYTOSIS; COMPLEMENT; PNEUMONIA; MACROPHAGES; EXPRESSION	Pulmonary surfactant protein A (SP-A) has been shown to act as an opsonin in the phagocytosis of viruses by alveolar macrophages. To determine whether SP-A binds to viral proteins and which part of the SP-A molecule is involved in this interaction, binding studies were undertaken. SP-A was labeled with fluorescein isothiocyanate, and its binding to herpes simplex virus type 1-infected HEp-2 cells, as a model for virus-infected cells in general, was studied using flow cytometry. The binding of SP-A to virus-infected cells was saturable, reversible, and both time- and concentration-dependent, reaching a maximal level after 30 min at an SP-A concentration of 10 mug/ml. An approximately 4-fold increase in binding of SP-A to infected cells over control cells was observed. Yeast mannan, a mannose homopolysaccharide, did not influence the binding. However, heparin inhibited binding of SP-A in a concentration-dependent manner. In addition, heparin could also dissociate cell-bound SP-A, indicating that polyanionic oligosaccharides are involved in the binding of SP-A to virus-infected cells. Deglycosylated SP-A, obtained by digestion with N-glycosidase F, did not bind to infected cells. Heparin or deglycosylation of SP-A had no effect on the stimulation of alveolar macrophages by SP-A. It is concluded that the carbohydrate moiety of SP-A is involved in the recognition of viruses by SP-A and may play a role in the antiviral defenses of the lung.	UNIV UTRECHT, EIJKMAN WINKLER LAB MED MICROBIOL, 3508 TD UTRECHT, NETHERLANDS	Utrecht University	VANIWAARDEN, JF (corresponding author), UNIV UTRECHT, VET BIOCHEM LAB, 3508 TD UTRECHT, NETHERLANDS.		Haagsman, Henk P/F-8919-2010; van Strijp, Jos A.G./J-9549-2014	van Strijp, Jos A.G./0000-0001-6253-0830				BHATTACHARYYA SN, 1984, ARCH BIOCHEM BIOPHYS, V231, P72, DOI 10.1016/0003-9861(84)90364-3; BOBAK DA, 1987, J IMMUNOL, V138, P1150; CAL WH, 1988, J VIROL, V62, P2596, DOI 10.1128/JVI.62.8.2596-2604.1988; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; FRIEDMAN HM, 1984, NATURE, V309, P633, DOI 10.1038/309633a0; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAAGSMAN HP, 1991, ANNU REV PHYSIOL, V53, P441, DOI 10.1146/annurev.ph.53.030191.002301; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; JENNINGS SR, 1987, J VIROL, V61, P104, DOI 10.1128/JVI.61.1.104-112.1987; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LJUNGMAN P, 1990, J INFECT DIS, V162, P244, DOI 10.1093/infdis/162.1.244; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; MUNAKATA H, 1982, BIOCHEM BIOPH RES CO, V108, P1401, DOI 10.1016/S0006-291X(82)80062-4; OLOFSSON S, 1981, ARCH VIROL, V70, P321, DOI 10.1007/BF01320247; PHELPS DS, 1991, AM REV RESPIR DIS, V143, P1072, DOI 10.1164/ajrccm/143.5_Pt_1.1072; PIZER LI, 1980, J VIROL, V34, P142, DOI 10.1128/JVI.34.1.142-153.1980; RAMSEY PG, 1982, ANN INTERN MED, V97, P813, DOI 10.7326/0003-4819-97-6-813; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; SAWITZKY D, 1990, J GEN VIROL, V71, P1221, DOI 10.1099/0022-1317-71-5-1221; SPEAR PG, 1985, HERPESVIRUSES, V3, P315; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; VAHERI A, 1964, ACTA PATHOL MIC SC, P7; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1987, AM REV RESPIR DIS, V136, P426, DOI 10.1164/ajrccm/136.2.426; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	37	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25039	25043						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334078				2022-12-25	WOS:A1992KB60300022
J	DIRENZO, MF; OLIVERO, M; FERRO, S; PRAT, M; BONGARZONE, I; PILOTTI, S; BELFIORE, A; COSTANTINO, A; VIGNERI, R; PIEROTTI, MA; COMOGLIO, PM				DIRENZO, MF; OLIVERO, M; FERRO, S; PRAT, M; BONGARZONE, I; PILOTTI, S; BELFIORE, A; COSTANTINO, A; VIGNERI, R; PIEROTTI, MA; COMOGLIO, PM			OVEREXPRESSION OF THE C-MET HGF RECEPTOR GENE IN HUMAN THYROID CARCINOMAS	ONCOGENE			English	Note							HEPATOCYTE GROWTH-FACTOR; POORLY DIFFERENTIATED CARCINOMA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TYROSINE KINASE ONCOGENES; ACTIVATED RAS ONCOGENES; PROTO-ONCOGENE; SCATTER FACTOR; HUMAN-BREAST; CELL-LINE	The receptor for Hepatocyte Growth Factor is a transmembrane tyrosine kinase encoded by the c-MET oncogene. We have previously shown that the Met protein is expressed in several human epithelial tissues. The receptor is barely detectable, however, in normal thyroids and in specimens from patients affected by nonneoplastic thyroid diseases. Now we report that the expression of the Met/HGF receptor is increased a hundred fold in 22 out of 41 human carcinomas derived from the thyroid follicular epithelium. A comprehensive analysis of 15 cases showed that the overexpressing carcinomas belong to histotype variants correlated with negative prognosis and in all but one case there were evidences of locally advanced disease and/or distant metastases. The 11 benign adenomas and the 5 medullary carcinomas tested were negative. Western blot analysis with monoclonal antibodies directed against either the intracellular or the extracellular receptor domains failed to reveal major structural alterations. Southern blot analysis also demonstrated that the c-MET gene was not amplified nor rearranged. These data suggest a role for the overexpression of c-MET oncogene in the pathogenesis and progression of thyroid tumors derived from the follicular epithelium.	NATL CANC INST,DEPT EXPTL ONCOL A,MILAN,ITALY; NATL CANC INST,DEPT PATHOL,MILAN,ITALY; UNIV CATANIA,SCH MED,DEPT ENDOCRINOL,I-95124 CATANIA,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Catania	DIRENZO, MF (corresponding author), UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10124 TURIN,ITALY.		DI RENZO, Maria Flavia/B-6091-2012; Belfiore, Antonino/B-4652-2011; olivero, martina/J-4811-2018; Bongarzone, Italia/B-9544-2017; Vigneri, Riccardo/M-3968-2017	DI RENZO, Maria Flavia/0000-0002-5093-3373; Belfiore, Antonino/0000-0002-6181-4193; olivero, martina/0000-0002-6815-3498; Bongarzone, Italia/0000-0003-2530-9170; Comoglio, Paolo/0000-0002-7056-5328; Vigneri, Riccardo/0000-0002-4401-3140; Pierotti, Marco Alessandro/0000-0002-7431-8332				ADNANE J, 1991, ONCOGENE, V6, P659; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BERCHUCK A, 1990, CANCER RES, V50, P4087; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COHEN JA, 1989, ONCOGENE, V4, P81; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEDIGAR C, 1988, HISTOLOGICAL TYPING; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; Hermanek P, 1987, TNM CLASSIFICATION M; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; JOHNSON TL, 1988, AM J SURG PATHOL, V12, P22, DOI 10.1097/00000478-198801000-00003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LEMOINE NR, 1988, CANCER RES, V48, P4459; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P442; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK JB, 1989, CANCER RES, V49, P6605; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOBRINHOSIMOES M, 1988, AM J CLIN PATHOL, V89, P264, DOI 10.1093/ajcp/89.2.264; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1988, ONCOGENE, V2, P403; SUAREZ HG, 1990, ONCOGENE, V5, P565; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WEIDNER KM, 1990, J CELL BIOL, V111, P2907; WEIDNER U, 1990, CANCER RES, V50, P4504; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1986, CANCER RES, V46, P414; YONEMURA Y, 1991, CANCER RES, V51, P1034; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252	54	333	353	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2549	2553						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334253				2022-12-25	WOS:A1992KA85600024
J	ELMOATASSIM, C; DUBYAK, GR				ELMOATASSIM, C; DUBYAK, GR			A NOVEL PATHWAY FOR THE ACTIVATION OF PHOSPHOLIPASE-D BY P(2Z) PURINERGIC RECEPTORS IN BAC1.2F5 MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PHORBOL-MYRISTATE ACETATE; EXTRACELLULAR ATP; PHOSPHATIDYLCHOLINE HYDROLYSIS; ADENOSINE 5'-TRIPHOSPHATE; PHOSPHATIDIC-ACID; PLASMA-MEMBRANE; GROWTH-FACTOR; CELL-LINE; GUANINE-NUCLEOTIDES	Macrophages express two distinct types of nucleotide (P2 purinergic) receptors for extracellular ATP: one type induces a Ca2+-mobilizing response via the activation of phosphatidylinositol-phospholipase C (PI-PLC) while the second type induces the rapid formation of nonselective pores which are permeated by ions and small (<1 kDa) organic molecules. We have confirmed the presence of these two ATP receptor types in the BAC1.2F5 murine macrophage cell line and have identified 3'-O-(4-benzoyl)benzoyl-ATP (BzATP) as a selective and potent agonist for the so-called P2z or pore-forming ATP receptor type. Several lines of evidence indicated that occupation of these P2z receptors is also accompanied by a rapid and large increase in the activity of a phosphatidylcholine-selective phospholipase D (PLD) effector enzyme. In cells metabolically labeled with [H-3]oleic acid or [H-3]glycerol and stimulated in the presence of ethanol, ATP and BzATP induced a severalfold increase in the rate and extent of [H-3]phosphatidylethanol (PEt) accumulation. These responses were stimulated only by ATP, BzATP, and ATPgammaS (adenosine 5'-O-(3-thiotriphosphate) with the rank order of potency: BzATP >> ATP > ATPgammaS; there was no response to other adenine nucleotides or to non-adenine nucleotides. Significantly, the ability Of P2z receptor agonists to stimulate this PLD activity was not dependent on the presence of extracellular [Ca2+] or elevation of cytosolic [Ca2+]. The inability of ionomycin, gramicidin, digitonin, UTP, platelet-activating factor, or phorbol ester to quantitatively mimic these nucleotide effects suggested that activation of this PLD by P2z receptor agonists was not a secondary response due to: 1) enhanced Ca2+ influx; 2) membrane depolarization; 3) nonselective permeabilization of the plasma membrane; 4) stimulation of Ca2+-mobilizing ATP receptors; 5) stimulation of a primary PI-PLC pathway; or 6) activation of protein kinase C. These findings suggest that activation of a novel PLD-based signaling pathway may play an important role in the modulation of macrophage function by pore-forming P2z receptors for extracellular ATP.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University				Dubyak, George/0000-0001-9720-4226	NIGMS NIH HHS [GM-36387] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BALSINDE J, 1991, J BIOL CHEM, V266, P18726; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOYER JL, 1990, J BIOL CHEM, V265, P13515; BOYER JL, 1989, MOL PHARMACOL, V36, P831; BOYER JL, 1989, J BIOL CHEM, V264, P884; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CHAREST R, 1985, J BIOL CHEM, V260, P5789; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P23147; COCKCROFT S, 1980, BIOCHEM J, V188, P789, DOI 10.1042/bj1880789; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; DURONIO V, 1989, BIOCHEM BIOPH RES CO, V164, P804, DOI 10.1016/0006-291X(89)91530-1; ELMOATASSIM C, 1987, BIOCHIM BIOPHYS ACTA, V927, P437, DOI 10.1016/0167-4889(87)90110-8; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; EXTON JH, 1990, J BIOL CHEM, V265, P1; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/pnas.87.21.8267; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; GOMPERTS BD, 1985, TRENDS BIOCHEM SCI, V10, P414, DOI 10.1016/0968-0004(85)90020-9; GONZALEZ FA, 1989, J CELL PHYSIOL, V139, P109, DOI 10.1002/jcp.1041390116; GONZALEZ FA, 1990, P NATL ACAD SCI USA, V87, P9717, DOI 10.1073/pnas.87.24.9717; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HEPPEL LA, 1985, J MEMBRANE BIOL, V86, P189, DOI 10.1007/BF01870597; HUANG R, 1991, J BIOL CHEM, V266, P1652; IRVING HR, 1987, J BIOL CHEM, V262, P3440; KINSKY SC, 1989, BIOCHEM BIOPH RES CO, V162, P788, DOI 10.1016/0006-291X(89)92379-6; LASSEGUE B, 1991, BIOCHEM J, V276, P19, DOI 10.1042/bj2760019; MARTIN TW, 1990, BIOCHIM BIOPHYS ACTA, V1053, P162, DOI 10.1016/0167-4889(90)90009-3; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; PAI JK, 1988, J BIOL CHEM, V263, P12472; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; ROZENGURT E, 1979, J BIOL CHEM, V254, P708; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; STEINBERG TH, 1989, METHOD CELL BIOL, V31, P45; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; UHING RJ, 1989, J BIOL CHEM, V264, P9224; WEISMAN GA, 1989, METHOD ENZYMOL, V171, P857; WILLIAMS N, 1986, METHOD ENZYMOL, V126, P667; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; XING MZ, 1992, J BIOL CHEM, V267, P6602; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545	62	141	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23664	23673						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331096				2022-12-25	WOS:A1992JZ23900039
J	VONAKIS, BM; VANDERHOEK, JY				VONAKIS, BM; VANDERHOEK, JY			15-HYDROXYEICOSATETRAENOIC ACID (15-HETE) RECEPTORS - INVOLVEMENT IN THE 15-HETE-INDUCED STIMULATION OF THE CRYPTIC 5-LIPOXYGENASE IN PT-18 MAST/BASOPHIL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTE RECEPTORS; MAST BASOPHIL CELLS; ARACHIDONIC-ACID; ENDOTHELIAL-CELLS; 15-LIPOXYGENASE PRODUCTS; LIPOXYGENASE PATHWAY; HUMAN-NEUTROPHILS; BINDING; LEUKOTRIENE-B4; METABOLISM	The mechanism of stimulation of the inactive 5-lipoxygenase in mast/basophil PT-18 cells by muM 15-hydroxyeicosatetraenoic acid (15-HETE) was investigated. Treatment of PT-18 cells with pM 15-[H-3]HETE at 4-degrees for 3 h resulted in the cell association of 10% of the ligand: two-thirds was incorporated into cellular lipids and a third was bound to specific 15-HETE cellular binding sites. Binding data analysis indicated a single class of 15-HETE binding sites with a K(d) of 162 nm and a B(max) of 7.1 x 10(5) sites/cell. Unlabeled 15-HETE, 12-HETE, and 5,15-diHETE inhibited the binding of 15-[H-3]HETE to cells, whereas LTB, and PGF2alpha were relatively ineffective. 2.4 muM 15-HETE (unlabeled) prevented 50% 15-[H-3]HETE incorporation. Examination of the effects of 15-HETE methyl ester, 12-HETE, 5,15-diHETE, and pertussis toxin on both the 15-HETE-induced 5-lipoxygenase activation and 15-HETE cell association processes indicated a preponderant correlation of this activation process with specific 15-HETE binding rather than 15-HETE incorporation into phospholipids. In addition, 5,15-diHETE itself stimulated the inactive 5-lipoxygenase and eight times more [H-3]diHETE was bound to cells than became incorporated into cellular lipids. The results support the involvement of low affinity 15-HETE receptors, rather than 15-HETE incorporation into cellular lipids, in the 15-HETE-induced stimulation of the 5-lipoxygenase in PT-18 cells.			VONAKIS, BM (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20037, USA.			Vanderhoek, Jack/0000-0002-2051-2236; Vonakis, Becky/0000-0003-4174-6514				BORNESTEIN DG, 1987, ARTHRITIS RHEUM, V30, pS65; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; COSTELLO PB, 1991, INFLAMMATION, V15, P269, DOI 10.1007/BF00917312; DAHLEN SE, 1991, LIPOXYGENASES THEIR, P235; DUELL EA, 1988, J INVEST DERMATOL, V91, P446, DOI 10.1111/1523-1747.ep12476562; GOETZL EJ, 1983, J EXP MED, V158, P731, DOI 10.1084/jem.158.3.731; GOLDMAN DW, 1986, J IMMUNOL, V136, P4631; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; GOLDMAN DW, 1987, FASEB J, V46, P200; GROSS E, 1990, J INVEST DERMATOL, V94, P446, DOI 10.1111/1523-1747.ep12874543; HAAS TA, 1988, BIOCHIM BIOPHYS ACTA, V961, P153, DOI 10.1016/0005-2760(88)90108-7; HALUSHKA PV, 1987, FASEB J, V46, P149; HAMBERG M, 1980, ACTA PHYSIOL SCAND, V110, P219, DOI 10.1111/j.1748-1716.1980.tb06656.x; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; JOHNSON HG, 1985, AM REV RESPIR DIS, V131, P917; Kates M., 1986, TECHNIQUES LIPIDOLOG; KUHN H, 1985, PROSTA LEUKOTR MED, V17, P291, DOI 10.1016/0262-1746(85)90118-0; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; LIN AH, 1984, PROSTAGLANDINS, V28, P837, DOI 10.1016/0090-6980(84)90038-8; MAGHNI K, 1991, J PHARMACOL EXP THER, V258, P784; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MEXMAIN S, 1985, J IMMUNOL, V135, P1361; MEXMAIN S, 1984, PROSTA LEUKOTR MED, V13, P93, DOI 10.1016/0262-1746(84)90108-2; NICHOLS RC, 1991, BIOCHIM BIOPHYS ACTA, V1085, P77, DOI 10.1016/0005-2760(91)90234-9; PAWLOWSKI NA, 1982, J EXP MED, V155, P1653, DOI 10.1084/jem.155.6.1653; RABIER M, 1988, BIOCHEM BIOPH RES CO, V152, P1179, DOI 10.1016/S0006-291X(88)80409-1; ROSSI GL, 1990, AGENTS ACTIONS, V31, P257, DOI 10.1007/BF01997617; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; TURK J, 1982, J BIOL CHEM, V257, P7068; VANDERHOEK JY, 1985, BIOCHIM BIOPHYS ACTA, V837, P119, DOI 10.1016/0005-2760(85)90234-6; VANDERHOEK JY, 1982, J BIOL CHEM, V257, P2191	34	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23625	23631						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331094				2022-12-25	WOS:A1992JZ23900033
J	BULLESBACH, EE; YANG, S; SCHWABE, C				BULLESBACH, EE; YANG, S; SCHWABE, C			THE RECEPTOR-BINDING SITE OF HUMAN RELAXIN-II - A DUAL PRONG-BINDING MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE RELAXIN; INSULIN; SEQUENCE; CHAIN; BRAIN; GENE	Recent structure/function studies on human relaxin II have led to the conclusion that the arginines B13 and/or B17 are important for biological activity. These studies have been confirmed and extended with the help of chemically synthesized derivatives, i.e. dicitrulline (B13, B17), two monocitrulline (B13 and B17), a dilysine (B13,17), and alanine (B17) relaxins. The CD spectra of synthetic human relaxin and of the derivatives are indistinguishable. Yet, only the native human relaxin II is biologically active and binds strongly to relaxin receptor preparations in vitro. The inactivation is strictly due to side chain functions, in particular the replacement of either or both arginines in the positions B13 or B17. Binding is mediated by a two-prong electrostatic and hydrogen-binding interaction via arginines B13 and B17. Neither B13 nor B17 alone are sufficient and a positive charge equidistant from the B chain helix is equally insufficient. This binding mechanism appears to be unique, as concerns hormone receptor interaction.			BULLESBACH, EE (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,CHARLESTON,SC 29425, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038348] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 23877] Funding Source: Medline; NIDDK NIH HHS [DK 38348] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler A J, 1973, Methods Enzymol, V27, P675; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; BERNATOWICZ MS, 1986, INT J PEPT PROT RES, V28, P107; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; CRAWFORD RJ, 1989, J MOL ENDOCRINOL, V3, P169, DOI 10.1677/jme.0.0030169; DODSON GG, 1982, INT J BIOL MACROMOL, V4, P399, DOI 10.1016/0141-8130(82)90083-6; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; ISAACS N, 1978, NATURE, V271, P278, DOI 10.1038/271278a0; LEE YA, 1992, ENDOCRINOLOGY, V130, P1165, DOI 10.1210/en.130.3.1165; MORODER L, 1976, H-S Z PHYSIOL CHEM, V357, P1651, DOI 10.1515/bchm2.1976.357.2.1651; OSHEROFF PL, 1990, J BIOL CHEM, V265, P9396; OSHEROFF PL, 1992, P NATL ACAD SCI USA, V89, P2384, DOI 10.1073/pnas.89.6.2384; OSHEROFF PL, 1991, P NATL ACAD SCI USA, V88, P6413, DOI 10.1073/pnas.88.15.6413; SCHWABE C, 1977, BIOCHEM BIOPH RES CO, V75, P503, DOI 10.1016/0006-291X(77)91070-1; SCHWABE C, 1989, J BIOL CHEM, V264, P940; SCHWABE C, 1990, COMP BIOCHEM PHYS B, V96, P15, DOI 10.1016/0305-0491(90)90335-Q; SHIRE SJ, 1991, BIOCHEMISTRY-US, V30, P7703, DOI 10.1021/bi00245a006; STEINETZ BG, 1960, ENDOCRINOLOGY, V67, P102, DOI 10.1210/endo-67-1-102; STEWART DR, 1991, ENDOCRINOLOGY, V129, P375, DOI 10.1210/endo-129-1-375; STULTS JT, 1990, BIOMED ENVIRON MASS, V19, P655, DOI 10.1002/bms.1200191105; WOODS AS, 1991, INT J MASS SPECTROM, V111, P77, DOI 10.1016/0168-1176(91)85049-R; YANG S, 1992, ENDOCRINOLOGY, V130, P179, DOI 10.1210/en.130.1.179	24	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22957	22960						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331071				2022-12-25	WOS:A1992JY16300040
J	ROSEN, ED; ODONNELL, AL; KOENIG, RJ				ROSEN, ED; ODONNELL, AL; KOENIG, RJ			LIGAND-DEPENDENT SYNERGY OF THYROID-HORMONE AND RETINOID X-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RESPONSE ELEMENT; GROWTH-HORMONE; NUCLEAR-PROTEIN; GENE-EXPRESSION; BETA GENE; BINDING; MUTATIONS; ACID; IDENTIFICATION; SUPERFAMILY	The binding of thyroid hormone receptors to DNA is enhanced by heterodimerization with nuclear proteins. One such heterodimerization partner has recently been characterized as the retinoid X receptor. 9-cis-Retinoic acid has been identified as a natural ligand for retinoid X receptors, suggesting a potential receptor-mediated interaction between thyroid hormone and 9-cis-retinoic acid in the regulation of thyroid hormone-responsive genes. A transient cotransfection assay was used to test for such an interaction. When a complex thyroid hormone response element composed of both direct and inverted repeat hexamers was tested, these two ligands activated gene expression synergistically. In contrast, when the response element consisted only of directly repeated hexamers, unliganded retinoid X receptors enhanced thyroid hormone responsiveness, but 9-cis-retinoic acid induced no additional activation. The results suggest a unique mechanism to achieve differential thyroid hormone sensitivity of thyroid hormone-responsive genes within a cell. Genes with appropriate response elements will show amplification of the thyroid hormone response by 9-cis-retinoic acid in the presence of retinoid X receptors; other thyroid hormone-responsive genes will be influenced by retinoid X receptors, but not 9-cis-retinoic acid.	UNIV MICHIGAN,MED CTR,DIV ENDOCRINOL,1150 W MED CTR DR,5560 MSRB2,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDDK NIH HHS [DK44195] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DOZIN B, 1985, BIOCHEMISTRY-US, V24, P5581, DOI 10.1021/bi00341a044; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEE YP, 1965, J BIOL CHEM, V240, P1427; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; TAKEDA K, 1991, J CLIN INVEST, V87, P496, DOI 10.1172/JCI115023; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	32	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22010	22013						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331043				2022-12-25	WOS:A1992JW71900007
J	BOYLAN, JF; GUDAS, LJ				BOYLAN, JF; GUDAS, LJ			THE LEVEL OF CRABP-I EXPRESSION INFLUENCES THE AMOUNTS AND TYPES OF ALL-TRANS-RETINOIC ACID METABOLITES IN F9 TERATOCARCINOMA STEM-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BINDING-PROTEIN CRABP; MOLECULAR-CLONING; DIFFERENTIATION; MOUSE; MALFORMATIONS; EMBRYOGENESIS; PREVENTION; RECEPTORS; RATS	The CRABP-I and CRABP-II proteins are high affinity cytoplasmic retinoic acid-binding proteins. In undifferentiated F9 teratocarcinoma stem cells, only the CRABP-I protein is expressed at detectable levels. We have previously shown that overexpression of the CRABP-I protein in stably transfected F9 stem cell lines results in a lower sensitivity to a given external concentration of retinoic acid relative to that of untransfected F9 cells; in contrast, reduced CRABP-I expression in CRABP-I cDNA anti-sense transfected lines is associated with increased sensitivity of these lines to retinoic acid. These three types of cell lines were cultured in the presence of 50 nM [H-3]retinoic acid, and the metabolism of retinoic acid was followed over the next 24 h. The results demonstrate that CRABP-I has the ability to alter both the levels and types of RA metabolites produced in the cytoplasm of differentiating embryonic stem cells. Moreover, the level of CRABP-I determines the rate of RA metabolism to 4-oxo-RA such that the higher the CRABP-I level, the faster the metabolism of [H-3]retinoic acid. This is the first reported connection between the level of CRABP-I expression and intracellular RA metabolism.	CORNELL UNIV,MED CTR,COLL MED,DEPT PHARMACOL,RM 409-E,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Cornell University; Cornell University					NATIONAL CANCER INSTITUTE [F32CA009251, R01CA043796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010389] Funding Source: NIH RePORTER; NCI NIH HHS [1F32 CA09251-01, CA43796] Funding Source: Medline; NIDCR NIH HHS [DE10389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; DE LUCA LM, 1991, FASEB J, V5, P2924; DENCKER L, 1990, DEVELOPMENT, V110, P343; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; FROLIK CA, 1984, RETINOIDS, V2, P177; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GUBLER ML, 1985, J BIOL CHEM, V260, P9552; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; MADEN M, 1990, DEVELOPMENT, V109, P75; MOON RC, 1990, BASIC LIFE SCI, V52, P213; MORRISSKAY G, 1991, SEMINARS DEV BIOL, V2, P211; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; POLLARD M, 1991, CANCER RES, V51, P3610; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; SHENEFELT RE, 1972, TERATOLOGY, V5, P103, DOI 10.1002/tera.1420050115; SHUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645, DOI 10.1073/pnas.84.16.5645; STONER CM, 1989, CANCER RES, V49, P1497; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUNDELIN J, 1985, J BIOL CHEM, V260, P6494; VAESSEN MJ, 1990, DEVELOPMENT, V110, P371; VANWAUWE JP, 1990, J PHARMACOL EXP THER, V252, P365; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658	28	246	254	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21486	21491						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328234				2022-12-25	WOS:A1992JV01100036
J	LIU, HL; CHAO, W; OLSON, MS				LIU, HL; CHAO, W; OLSON, MS			REGULATION OF THE SURFACE EXPRESSION OF THE PLATELET-ACTIVATING-FACTOR RECEPTOR IN IC-21 PERITONEAL-MACROPHAGES - EFFECTS OF LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT KUPFFER CELLS; PROTEIN-KINASE-C; GLYCERYL ETHER PHOSPHORYLCHOLINE; COLONY-STIMULATING FACTOR; ACUTE PHASE REACTANT; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN-NEUTROPHILS; BINDING-PROTEIN; RABBIT PLATELETS; GENE-EXPRESSION	The effect of bacterial lipopolysaccharide (LPS) on the expression of the receptor for platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; AGEPC) was examined in cultured IC-21 peritoneal macrophages. AGEPC binding to its receptors reached saturation within 20 min at 25-degree-C and was reversible. Scatchard analysis revealed a single class of AGEPC receptors with a B(max) of approximately 170 fmol/mg cellular protein and a K(d) of 0.25 nM. Preincubation of IC-21 cells with LPS (0.01-1,000 ng/ml) induced an increase in the surface expression of AGEPC receptors in a time- and concentration-dependent fashion. The maximal effect of LPS on the AGEPC receptor was observed between 5 and 8 h, with a typical increase between 150 and 200%. Scatchard analysis indicated that LPS treatment of IC-21 cells increased the number of AGEPC receptors on the cell surface without any apparent change in the affinity of the receptor for the ligand. The effect of LPS on the surface expression of the AGEPC receptor was nearly abolished by cycloheximide (0.1 mM) and by actinomycin D (3 muM), suggesting the involvement of enhanced receptor protein synthesis and mRNA production in this event. Moreover, LPS treatment increased the capability of the IC-21 cell to respond to AGEPC addition by elevating intracellular free Ca2+ without causing an increase in the basal level of intracellular Ca2+. The present study demonstrates that IC-21 peritoneal macrophages possess high affinity AGEPC receptors and provides the evidence that the number of functional AGEPC receptors on a cell can be increased significantly upon exposure to LPS.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio				Chao, Wei/0000-0002-2505-1360	NIADDK NIH HHS [AM-33538] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM033538] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AMANO F, 1985, FEBS LETT, V82, P263; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Braquet P, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P822; CHAO W, 1989, J BIOL CHEM, V264, P13591; CHAO W, 1990, ARCH BIOCHEM BIOPHYS, V282, P188, DOI 10.1016/0003-9861(90)90103-6; CHAO W, 1989, J BIOL CHEM, V264, P20448; CHEN BDM, 1983, J IMMUNOL, V130, P2256; DING AH, 1989, J BIOL CHEM, V264, P3924; FOREHAND JR, 1989, J CLIN INVEST, V83, P74, DOI 10.1172/JCI113887; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILBERT LJ, 1984, J IMMUNOL METHODS, V73, P17, DOI 10.1016/0022-1759(84)90027-9; HANAHAN DJ, 1980, J BIOL CHEM, V255, P5514; HOLTER W, 1987, J IMMUNOL, V138, P2917; HOMMA H, 1987, J BIOL CHEM, V262, P10582; HWANG SB, 1983, BIOCHEMISTRY-US, V22, P4756, DOI 10.1021/bi00289a022; KLOPROGGE E, 1984, BIOCHEM J, V223, P901, DOI 10.1042/bj2230901; MCMANUS LM, 1981, J CLIN INVEST, V67, P903, DOI 10.1172/JCI110108; NISHIJIMA M, 1985, P NATL ACAD SCI USA, V82, P282, DOI 10.1073/pnas.82.2.282; OFLAHERTY JT, 1986, J CLIN INVEST, V78, P381, DOI 10.1172/JCI112588; OFLAHERTY JT, 1981, AM J PATHOL, V103, P70; OFLAHERTY JT, 1989, J BIOL CHEM, V264, P6836; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PRPIC V, 1988, J CELL BIOL, V107, P363, DOI 10.1083/jcb.107.1.363; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; REATZ CRH, 1990, ANNU REV BIOCHEM, V59, P129; SASAKI M, 1987, TRENDS PHARM RES PLA, P108; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANNENBAUM CS, 1988, J IMMUNOL, V140, P3640; TERASHITA Z, 1985, EUR J PHARMACOL, V109, P257, DOI 10.1016/0014-2999(85)90427-3; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; VALONE FH, 1982, J IMMUNOL, V129, P1637; VALONE FH, 1988, J IMMUNOL, V140, P2389; VALONE FH, 1983, IMMUNOLOGY, V48, P141; VOSBECK K, 1990, J LEUKOCYTE BIOL, V47, P97, DOI 10.1002/jlb.47.2.97; WAHL SM, 1987, J IMMUNOL, V139, P1342; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YAMAZAKI M, 1989, P NATL ACAD SCI USA, V86, P5791, DOI 10.1073/pnas.86.15.5791	45	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20811	20819						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328211				2022-12-25	WOS:A1992JT97800048
J	PORRAS, A; NEBREDA, AR; BENITO, M; SANTOS, E				PORRAS, A; NEBREDA, AR; BENITO, M; SANTOS, E			ACTIVATION OF RAS BY INSULIN IN 3T3-L1 CELLS DOES NOT INVOLVE GTPASE-ACTIVATING PROTEIN-PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TRK PROTOONCOGENE PRODUCT; SERINE THREONINE KINASES; SIGNAL-TRANSDUCTION; TYROSINE KINASE; PC12 CELLS; P21RAS ACTIVATION; GENE-EXPRESSION; XENOPUS OOCYTES; MAP KINASES	Insulin-induced differentiation of 3T3 L1 cells to adipocytes can be mimicked by the expression of transfected ras oncogenes but not of the tyrosine-kinase oncogenes src and trk. Expression of two different transfected, dominant inhibitory ras mutants resulted in significant inhibition of insulin-induced differentiation, suggesting that endogenous Ras proteins are mediators of insulin signaling in these cells. Exposure of untransfected 3T3 L1 cells to insulin resulted in significant formation of the active Ras.GTP complex, at levels comparable with those resulting from exposure to platelet-derived growth factor. However, whereas exposure of the same cells to platelet-derived growth factor resulted in significant tyrosine phosphorylation of the p21ras GTPase-activating protein (GAP), insulin-treated cells did not show any detectable levels of de novo GAP tyrosine phosphorylation. Interestingly, insulin caused tyrosine phosphorylation of the p62 polypeptide coprecipitated with GAP by anti-GAP antibodies. Insulin-induced activation of cytosolic MAP kinase activity in untransfected 3T3 L1 cells was also mimicked by Ras expression (in the absence of insulin) in the same cells transfected with an inducible ras construct. These results confirm that Ras proteins participate in insulin signaling pathways in these mammalian cells and indicate that activation of cytosolic MAP kinases is an early event occurring downstream from Ras activation. However, tyrosine phosphorylation of GAP appears not to be a significant upstream regulatory event in the activation of Ras by insulin.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,RM 1D28,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Porras, Almudena/N-2121-2015; Nebreda, Angel Rodriguez/R-9594-2019; Benito, Manuel/J-5637-2014	Porras, Almudena/0000-0002-6495-3308; Benito, Manuel/0000-0002-7218-406X				AHN NG, 1990, J BIOL CHEM, V265, P11487; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERIKSON AK, 1990, J BIOL CHEM, V265, P19728; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HRESKO RC, 1988, P NATL ACAD SCI USA, V85, P8835, DOI 10.1073/pnas.85.23.8835; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN X, 1991, MOL CELL BIOL, V11, P2511; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; PEARSE AG, 1968, HISTOCHEMISTRY; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	66	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21124	21131						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328223				2022-12-25	WOS:A1992JT97800095
J	LEBONNIEC, BF; GUINTO, ER; ESMON, CT				LEBONNIEC, BF; GUINTO, ER; ESMON, CT			INTERACTION OF THROMBIN DES-ETW WITH ANTITHROMBIN-III, THE KUNITZ INHIBITORS, THROMBOMODULIN AND PROTEIN-C - STRUCTURAL LINK BETWEEN THE AUTOLYSIS LOOP AND THE TYR-PRO-PRO-TRP INSERTION OF THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; BINDING-SITE; ACTIVE-SITE; HUMAN-PROTHROMBIN; CLOTTING ACTIVITY; HIRUDIN COMPLEX; ACTIVATION; RESIDUES	X-ray diffraction studies of human thrombin revealed that compared with trypsin, two insertions (B and C) potentially limit access to the active site groove. When amino acids Glu146, Thr147, and Trp148, adjacent to the C-insertion (autolysis loop), are deleted the resulting thrombin (des-ETW) has dramatically altered interaction with serine protease inhibitors. Whereas des-ETW resists antithrombin III inactivation with a rate constant (K(on)) almost-equal-to 350-fold slower than for thrombin, des-ETW is remarkably sensitive to the Kunitz inhibitors, with inhibition constants (K(i)) decreased from 2.6 muM to 34 nM for the soybean trypsin inhibitor and from 52 muM to 1.8 muM for the bovine pancreatic trypsin inhibitor. The affinity for hirudin (K(i) = 5.6 pm) is weakened at least 30-fold compared with recombinant thrombin. The mutation affects the charge stabilizing system and the primary binding pocket of thrombin as depicted by a decrease in K(on) for diisopropylfluorophosphate (9.5-fold) and for N(alpha)-p-tosyl-L-lysine-chloromethyl ketone (51-fold) and a 39-fold increase in the K(i) for benzamidine. With peptidyl p-nitroanilide substrates, the des-ETW deletion results in changes in the Michaelis (K(m)) and/or catalytic (k(cat)) constants, worsened as much as 85-fold (K(m)) or 100-fold (k(cat)). The specific clotting activity of des-ETW is less than 5% that of thrombin and the k(cat)/K(m) for protein C activation in the absence of cofactor less than 2%. Thrombomodulin binds to des-ETW with a dissociation constant of almost-equal-to 2.5 nM and partially restores its ability to activate protein C since, in the presence of the cofactor, k(cat)/K(m) rises to 6.5% that of thrombin. This study suggests that the ETW motif of thrombin prevents (directly or indirectly) its interaction with the two Kunitz inhibitors and is not essential for the thrombomodulin-mediated enhancement of protein C activation.	OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center			Le Bonniec, Bernard/ABA-1366-2020; Le Bonniec, Bernard/S-5756-2016	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL29807, R37-HL30340] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; ASCENZI P, 1988, BIOCHIM BIOPHYS ACTA, V956, P156, DOI 10.1016/0167-4838(88)90262-2; BANNER DW, 1991, J BIOL CHEM, V266, P20085; BERLINER LJ, 1986, ANN NY ACAD SCI, V485, P80, DOI 10.1111/j.1749-6632.1986.tb34570.x; BETZ A, 1991, BIOCHEMISTRY-US, V30, P9848, DOI 10.1021/bi00105a006; BEZEAUD A, 1988, J BIOL CHEM, V263, P3576; BEZEAUD A, 1985, EUR J BIOCHEM, V153, P491, DOI 10.1111/j.1432-1033.1985.tb09328.x; BING DH, 1977, J BIOL CHEM, V252, P8027; BLOW DM, 1974, NATURE, V249, P55, DOI 10.1038/249054a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; BREZNIAK DV, 1990, BIOCHEMISTRY-US, V29, P3536, DOI 10.1021/bi00466a017; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHANG JY, 1986, BIOCHEM J, V240, P797, DOI 10.1042/bj2400797; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CHASE T, 1970, METHOD ENZYMOL, V19, P21; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; IRWIN DM, 1986, THESIS U BRIT COLUMB; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KAWABATA S, 1985, J BIOCHEM, V97, P325, DOI 10.1093/oxfordjournals.jbchem.a135057; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAZAR JB, 1991, J BIOL CHEM, V266, P685; LEATHERBARROW RJ, 1987, ENZFITTER PROGRAM NO; LEBONNIEC B, 1988, ANAL BIOCHEM, V174, P280, DOI 10.1016/0003-2697(88)90547-7; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LONGSTAFF C, 1990, BIOCHEMISTRY-US, V29, P7339, DOI 10.1021/bi00483a025; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NOE G, 1988, J BIOL CHEM, V263, P11729; OLSON ST, 1982, J BIOL CHEM, V257, P4891; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STONE SR, 1991, BIOCHEMISTRY-US, V30, P3950, DOI 10.1021/bi00230a021; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUZUKI K, 1990, J BIOL CHEM, V265, P13263; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALLIS RB, 1988, TRENDS PHARMACOL SCI, V9, P425, DOI 10.1016/0165-6147(88)90124-1; WALZ DA, 1986, ANN NY ACAD SCI, V485, P323, DOI 10.1111/j.1749-6632.1986.tb34594.x; Williams J W, 1979, Methods Enzymol, V63, P437; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775	67	76	76	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19341	19348						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326550				2022-12-25	WOS:A1992JP59300050
J	MUALLEM, S; ZHANG, BX; LOESSBERG, PA; STAR, RA				MUALLEM, S; ZHANG, BX; LOESSBERG, PA; STAR, RA			SIMULTANEOUS RECORDING OF CELL-VOLUME CHANGES AND INTRACELLULAR PH OR CA2+ CONCENTRATION IN SINGLE OSTEOSARCOMA CELLS UMR-106-01	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECTURUS GALLBLADDER EPITHELIUM; PANCREATIC ACINAR-CELLS; ASCITES TUMOR-CELLS; REGULATORY MECHANISMS; HCO3 TRANSPORTERS; NA+/H+ EXCHANGER; LINE UMR-106-01; KIDNEY-CELLS; MEMBRANE; OSTEOBLASTS	We present a new technique for the simultaneous measurement of cell volume changes and intracellular ionic activities in single cells. The technique uses measurement of changes in the concentration of intracellularly trapped fluorescent dyes to report relative cell volume. By using pH- or Ca2+-sensitive dyes and recording at the ion-sensitive and -insensitive (isosbestic) wavelengths, the method can measure both cell volume changes and intracellular ionic activities. The technique was used to study the mechanisms of regulatory volume decrease (RVD) in the osteosarcoma cell line UMR-106-01 grown on cover slips. Swelling cells in 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES)-buffered hypotonic medium was followed by stable cytosolic acidification and a decrease in cell volume back toward normal. The recovery of cell volume could be blocked by depolarization, treatment with ouabain, or depletion of cell Cl-. These suggest the conductive efflux of K+ and Cl- during RVD. The cytosolic acidification that accompanied cell swelling was not blocked by amiloride, bafilomycin A, or removal of Cl- and could not be reproduced by depletion of cellular ATP. These findings exclude Na+/H+ and Cl-/HCO3- exchange, intracellularly generated acid, or increased metabolism, respectively, as the cause of the acidification. The cell swelling-induced acidification was inhibited by depolarization, suggesting the involvement of an electrogenic pathway. The acidification, as well as RVD, was inhibited by short incubation with deoxyglucose, and these effects could not be reversed by valinomycin. Thus, the anionic pathway(s) participating in RVD and the acidification are sensitive to the cellular level of ATP. Together, these studies indicate that RVD in UMR-106-01 cells in HEPES-buffered medium is mediated by the conductive efflux of K+, Cl-, and OH-.	UNIV TEXAS,SW MED CTR,DEPT MED,DIV NEPHROL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MUALLEM, S (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39245] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; COTTON CU, 1991, J GEN PHYSIOL, V97, P667, DOI 10.1085/jgp.97.4.667; EVELOFF JL, 1987, AM J PHYSIOL, V252, pF1, DOI 10.1152/ajprenal.1987.252.1.F1; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FURLONG TJ, 1990, AM J PHYSIOL, V258, pC1016; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; GREEN J, 1988, J GEN PHYSIOL, V92, P239, DOI 10.1085/jgp.92.2.239; GREEN J, 1988, J BIOL CHEM, V263, P5012; GREEN J, 1990, J GEN PHYSIOL, V95, P121, DOI 10.1085/jgp.95.1.121; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; GRONOWICZ G, 1986, J BONE MINER RES, V1, P441; HOFFMANN EK, 1986, J MEMBRANE BIOL, V91, P227, DOI 10.1007/BF01868816; KAJI D, 1986, J GEN PHYSIOL, V88, P719, DOI 10.1085/jgp.88.6.719; KHADEMAZAD M, 1991, AM J PHYSIOL, V261, pC441, DOI 10.1152/ajpcell.1991.261.3.C441; LEWIS SA, 1990, NEWS PHYSIOL SCI, V5, P112; LOPES AG, 1988, P NATL ACAD SCI USA, V85, P2873, DOI 10.1073/pnas.85.8.2873; MCCARTY NA, 1990, AM J PHYSIOL, V259, pF950, DOI 10.1152/ajprenal.1990.259.6.F950; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; MUALLEM S, 1990, J BIOL CHEM, V265, P12813; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; PIERCE SK, 1990, ANNU REV PHYSIOL, V52, P27, DOI 10.1146/annurev.ph.52.030190.000331; REDHEAD CR, 1988, J PHYSIOL-LONDON, V401, P455, DOI 10.1113/jphysiol.1988.sp017172; REUSS L, 1985, P NATL ACAD SCI USA, V82, P6014, DOI 10.1073/pnas.82.17.6014; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; ROY G, 1987, J MEMBRANE BIOL, V100, P83, DOI 10.1007/BF02209143; STAR RA, 1990, J CLIN INVEST, V86, P1172, DOI 10.1172/JCI114823; STAR RA, 1992, J BIOL CHEM, V267, P17665; STONE DK, SEMIN NEPHROL, V10, P159; TANIGUCHI J, 1989, AM J PHYSIOL, V257, pF347, DOI 10.1152/ajprenal.1989.257.3.F347; TAUC M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P278, DOI 10.1016/0167-4889(90)90222-Y; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; UBL J, 1988, PFLUG ARCH EUR J PHY, V412, P551, DOI 10.1007/BF00582547; WALL SM, 1988, AM J PHYSIOL, V255, pF331, DOI 10.1152/ajprenal.1988.255.2.F331; XIE XS, 1989, J BIOL CHEM, V264, P18870; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P4383	38	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17658	17664						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325444				2022-12-25	WOS:A1992JM22300030
J	TOKUNAGA, M; KAWAMURA, A; KOHNO, K				TOKUNAGA, M; KAWAMURA, A; KOHNO, K			PURIFICATION AND CHARACTERIZATION OF BIP KAR2 PROTEIN FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA PLASMID PGKL1; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; ESCHERICHIA-COLI; ESSENTIAL COMPONENT; PRECURSOR PROTEINS; UNCOATING PROTEIN; YEAST; TRANSLOCATION; BINDING	Using specific anti-BiP/Kar2 antibody as the probe, we have developed an efficient purification method of BiP/Kar2 protein from the total cell extract of Saccharomyces cerevisiae. Overproduction of BiP/Kar2 protein was achieved by the cloning of the KAR2 gene on multicopy plasmids and the treatment of cells harboring the cloned KAR2 gene with tunicamycin. Freeze-thaw treatment, hydroxyapatite high pressure liquid chromatography, and ATP-agarose column chromatography of crude extract yielded homogeneous BiP/Kar2 protein (including less than 0.2% of degradative derivative) with a 430-fold purification and 28% recovery. Edman degradation of purified BiP/Kar2 suggests that the mature protein corresponds to a processed product with the removal of a 42-amino acid presequence. It is active as a homodimer and exhibits ATPase activity with a specific activity of 2 pmol/min/mu-g of protein. Protease susceptibility indicated that the ADP form of BiP/Kar2 is more resistant than the ATP form to the chymotrypsin digestion and that BiP/Kar2 required the presence of ATP to avoid the irreversible denaturation. Synthesis of BiP/Kar2 was induced by the inducible expression of an aberrant heterologous protein, yeast killer prepro-signal mouse alpha-amylase fusion protein.	OSAKA UNIV, DEPT MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN	Osaka University	TOKUNAGA, M (corresponding author), MITSUBISHI KASEI INST LIFE SCI, MOLEC GENET LAB, 11 MINAMIOOYA, MACHIDA, TOKYO 194, JAPAN.		Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICHOLSON RC, 1990, P NATL ACAD SCI USA, V87, P1159, DOI 10.1073/pnas.87.3.1159; NICOLET CM, 1991, METHOD ENZYMOL, V194, P710; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OMORI A, 1990, Journal of Protein Chemistry, V9, P250; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SCHEKMAN R, 1982, TRENDS BIOCHEM SCI, V7, P243, DOI 10.1016/0968-0004(82)90034-2; SCHEKMAN R, 1985, ANNU REV CELL BIOL, V1, P115, DOI 10.1146/annurev.cellbio.1.1.115; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHIU RPC, 1979, BIOCHIM BIOPHYS ACTA, V576, P141, DOI 10.1016/0005-2795(79)90493-8; TAJIMA M, 1986, MOL CELL BIOL, V6, P246, DOI 10.1128/MCB.6.1.246; TOKUNAGA M, 1990, J BIOL CHEM, V265, P17274; TOKUNAGA M, 1988, NUCLEIC ACIDS RES, V16, P7499, DOI 10.1093/nar/16.15.7499; TOKUNAGA M, 1989, NUCLEIC ACIDS RES, V17, P3435, DOI 10.1093/nar/17.9.3435; TOKUNAGA M, 1987, BIOCHEM BIOPH RES CO, V144, P613, DOI 10.1016/S0006-291X(87)80010-4; TOKUNAGA M, 1992, EUR J BIOCHEM, V203, P415, DOI 10.1111/j.1432-1033.1992.tb16565.x; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885	50	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17553	17559						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325440				2022-12-25	WOS:A1992JM22300015
J	STEUER, B; STOPPLER, H; BREUER, B; ALONSO, A				STEUER, B; STOPPLER, H; BREUER, B; ALONSO, A			TRANSCRIPTION OF BPV-1 GENES IN TRANSFECTED F9 CELLS	ONCOGENE			English	Article							BOVINE PAPILLOMAVIRUS TYPE-1; MURINE TERATOCARCINOMA CELLS; EMBRYONAL CARCINOMA-CELLS; STEM-CELLS; DNA; DIFFERENTIATION; EXPRESSION; KERATINOCYTES; ANTIGEN; INVITRO	In F9 cells transformed with bovine papillomavirus type 1 (BPV-1) sequences two different phenotypes can be recognized. One cell type shows the characteristics of the parental stem cell line, whereas the other comprises cells with spindle-like morphology that do not adhere to each other, similar to retinoic acid-treated F9 embryonal carcinoma cells. The phenotypically altered cells plate more efficiently than the stem cells, grow well in soft agar and show an extended lifespan in the differentiated stage. Both types of cells contain BPV-1 DNA sequences as episomes, but only the non-stem-like cells have RNA transcripts for the unspliced E5 reading frame as well as for the spliced E6/E4.	GERMAN CANC RES CTR,NEUENHEIMER FELD 280,W-6900 HEIDELBERG 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								BREUER B, 1989, GENE, V81, P307, DOI 10.1016/0378-1119(89)90191-1; DURST M, 1987, ONCOGENE, V1, P251; Hogan B. L. M, 1983, CANCER SURV, V2, P115; LAMBERT PF, 1988, ANNU REV GENET, V22, P235, DOI 10.1146/annurev.ge.22.120188.001315; LAW MF, 1981, P NATL ACAD SCI-BIOL, V78, P2727, DOI 10.1073/pnas.78.5.2727; LEVINE RA, 1984, MOL CELL BIOL, V4, P2142, DOI 10.1128/MCB.4.10.2142; LINNENBACH A, 1980, P NATL ACAD SCI-BIOL, V77, P4875, DOI 10.1073/pnas.77.8.4875; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; ROSENSTRAUS MJ, 1982, DEV BIOL, V89, P516, DOI 10.1016/0012-1606(82)90340-2; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SWARTZENDRUBER DE, 1975, J CELL PHYSIOL, V85, P179, DOI 10.1002/jcp.1040850204; TIENARI J, 1987, DEV BIOL, V123, P566, DOI 10.1016/0012-1606(87)90415-5; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	18	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1875	1878						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323821				2022-12-25	WOS:A1992JJ37600025
J	ROTH, EJ; KURZ, B; LIANG, LM; HANSEN, CL; DAMERON, CT; WINGE, DR; SMOTKIN, D				ROTH, EJ; KURZ, B; LIANG, LM; HANSEN, CL; DAMERON, CT; WINGE, DR; SMOTKIN, D			METAL THIOLATE COORDINATION IN THE E7 PROTEINS OF HUMAN PAPILLOMA VIRUS-16 AND COTTONTAIL RABBIT PAPILLOMA-VIRUS AS EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; COPPER METALLOTHIONEIN; CERVICAL-CARCINOMA; DNA-SEQUENCE; TYPE-16; CELLS; IDENTIFICATION; TRANSCRIPTION; COMPLEXES; PHOTOLUMINESCENCE	The oncogenic E7 proteins of human papilloma virus (HPV 16) and of cottontail rabbit papilloma virus (CRPV) have been purified from an expression system in Escherichia coli. The proteins as purified from E. coli contain one tightly bound Zn(II) ion per molecule. The metal site shows facile exchange with either Cd(II) or Cu(I). The HPV 16 E7 maximally bound one Cd(II) or two Cu(I) ions, while the CRPV E7 bound two Cd(II) or three Cu(I) ions. The Cd(II) and Cu(I) E7 molecules exhibited optical transitions in the ultraviolet suggestive of metal:thiolate coordination. E7 proteins from HPV 16 and CRPV contain 7 and 8 cysteines/molecule, respectively. Reaction of the E7 proteins with the sulfhydryl reagent, dithiodipyridine, revealed that all the cysteinyl sulfurs are present in the reduced thiol state. Cu(I)-E7 molecules are luminescent with maximal emission at 570 nm. The observed emission at room temperature is indicative of metal coordination within a compact protein environment shielded from solvent interactions. The emission maxima occurs at the same wavelength (570 nm) as Cu(I)-cysteinyl sulfur clusters in Cu(I)-metallothioneins. The single Zn(II) atom in each protein can be removed from E7 in the presence of EDTA. The resulting apoE7 molecules remain soluble and can be partially reconstituted with Cd(II) to regain the ultraviolet charge transfer transitions.	UNIV UTAH, DEPT OBSTET & GYNECOL, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [P30CA042014, R29CA047127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA42014, CA47127] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; BARBOSA MS, 1988, VIROLOGY, V165, P134, DOI 10.1016/0042-6822(88)90666-6; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BAUMGARTNER MR, 1990, THESIS U ZURICH; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BELTRAMINI M, 1989, BIOCHEM J, V260, P189, DOI 10.1042/bj2600189; BUTT TR, 1989, P NATL ACAD SCI USA, V86, P2540, DOI 10.1073/pnas.86.8.2540; BYRD J, 1988, J BIOL CHEM, V263, P6688; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; Dalgarno D C, 1984, Adv Inorg Biochem, V6, P113; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; DANOS O, 1982, EMBO J, V1, P231, DOI 10.1002/j.1460-2075.1982.tb01152.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; GEORGE GN, 1988, J BIOL CHEM, V263, P8199; GIRI I, 1985, P NATL ACAD SCI USA, V82, P1580, DOI 10.1073/pnas.82.6.1580; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HENARY M, 1989, J AM CHEM SOC, V111, P7407, DOI 10.1021/ja00201a020; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; LYTLE FE, 1970, APPL SPECTROSC, V24, P319, DOI 10.1366/000370270774371651; MCMILLIN DR, 1985, COORDIN CHEM REV, V64, P83, DOI 10.1016/0010-8545(85)80043-6; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNGER K, 1989, J VIROL, V63, P4417; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NASSERI M, 1984, J VIROL, V51, P706, DOI 10.1128/JVI.51.3.706-712.1984; NASSERI M, 1989, VIROLOGY, V170, P321, DOI 10.1016/0042-6822(89)90388-7; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; SCHNEIDER G, 1983, P NATL ACAD SCI-BIOL, V80, P5289, DOI 10.1073/pnas.80.17.5289; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUTH TL, 1990, METAL ION INDUCED RE, V8, P199; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VOGLER A, 1986, J AM CHEM SOC, V108, P7211, DOI 10.1021/ja00283a012; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	41	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16390	16395						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322900				2022-12-25	WOS:A1992JJ45800064
J	BU, GJ; MORTON, PA; SCHWARTZ, AL				BU, GJ; MORTON, PA; SCHWARTZ, AL			IDENTIFICATION AND PARTIAL CHARACTERIZATION BY CHEMICAL CROSS-LINKING OF A BINDING-PROTEIN FOR TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) ON RAT HEPATOMA-CELLS - A PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1-INDEPENDENT T-PA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY THROMBOLYSIS; MEDIATED ENDOCYTOSIS; EXTRACELLULAR-MATRIX; LIPOPROTEIN RECEPTOR; HIGH-AFFINITY; LINE HEP-G2; CATABOLISM; UROKINASE; PURIFICATION; HEPATOCYTES	Plasma tissue-type plasminogen activator (t-PA) is cleared rapidly in vivo by the liver. Previous studies with the human hepatoma cell line HepG2 have identified a clearance system for t-PA modulated by plasminogen activator inhibitor type 1 (PAI-1). In the present study, a rat hepatoma cell line MH1C1 is shown to contain a PAI-1-independent t-PA clearance system. At 4-degrees-C, binding of I-125-t-PA to MH1C1 cells was rapid, specific, and saturable. Scatchard analysis of the binding data yielded a mean estimate of 105,000 high affinity binding sites per cell (K(d) = 4.1 nM). When the bound ligand was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the majority (about 90%) of the specific binding was in the form of uncomplexed I-125-t-PA. This is in contrast to HepG2 cells in which specific binding was mainly in the form of a sodium dodecyl sulfate-stable I-125-PA.PAI-1 complex. When availability of matrix-associated PAI-1 was blocked by preincubation with anti-PAI-1 antibody or removed by elastase treatment, specific I-125-t-PA binding to MH1C1 cells was unaffected, whereas most of the specific I-125-t-PA binding to HepG2 cells was abolished. Furthermore, when the active site of t-PA was inactivated with diisopropyl fluorophosphate, the diisopropyl fluorophosphate-t-PA specifically competed for binding of I-125-t-PA to MH1C1 cells, but failed to block specific I-125-t-PA binding to HepG2 cells. At 37-degrees-C, PAI-1-independent t-PA binding to MH1C1 cells was followed by ligand uptake and degradation with kinetics similar to that seen in HepG2 cells. Chemical cross-linking of t-PA to MH1C1 cells revealed a specific t-PA binding protein with a molecular mass of about 500,000 daltons. Ligand-receptor complexes generated by chemical cross-linking were immunoprecipitable by anti-t-PA antibody but not by anti-PAI-1 antibody, further supporting the finding that binding of t-PA to MH1C1 cells is PAI-1-independent.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DIV PEDIAT HEMATOL ONCOL,ST LOUIS,MO 63178	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKHIT C, 1987, J BIOL CHEM, V262, P8716; BEEBE DP, 1986, THROMB RES, V43, P663, DOI 10.1016/0049-3848(86)90103-9; BERGMANN SR, 1983, SCIENCE, V220, P1181; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOUNAMEAUX H, 1985, THROMBOLYSIS BIOL TH, P85; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEVRIES S R, 1987, Fibrinolysis, V1, P17, DOI 10.1016/0268-9499(87)90027-0; EMEIS JJ, 1985, THROMB HAEMOSTASIS, V54, P661; FUCHS HE, 1985, BLOOD, V65, P539; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; KORNINGER C, 1981, THROMB HAEMOSTASIS, V46, P658; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORTON PA, 1990, J BIOL CHEM, V265, P14093; MORTON PA, 1989, J BIOL CHEM, V264, P7228; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; OWENSBY DA, 1991, J BIOL CHEM, V266, P4334; PLOUG M, 1991, J BIOL CHEM, V266, P1926; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RIJKEN DC, 1986, BIOCHEM J, V238, P643, DOI 10.1042/bj2380643; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDEWERF F, 1984, NEW ENGL J MED, V310, P609; VERSTRAETE M, 1985, J PHARMACOL EXP THER, V235, P506; WING LR, 1991, FEBS LETT, V278, P95, DOI 10.1016/0014-5793(91)80092-H; WUN TC, 1989, J BIOL CHEM, V264, P7862; 1985, NEW ENGL J MED, V310, P609	32	65	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15595	15602						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322401				2022-12-25	WOS:A1992JG11300055
J	VASSBOTN, FS; OSTMAN, A; SIEGBAHN, A; HOLMSEN, H; HELDIN, CH				VASSBOTN, FS; OSTMAN, A; SIEGBAHN, A; HOLMSEN, H; HELDIN, CH			NEOMYCIN IS A PLATELET-DERIVED GROWTH-FACTOR (PDGF) ANTAGONIST THAT ALLOWS DISCRIMINATION OF PDGF ALPHA-RECEPTOR AND BETA-RECEPTOR SIGNALS IN CELLS EXPRESSING BOTH RECEPTOR TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; B-TYPE RECEPTOR; HUMAN-FIBROBLASTS; MONOCLONAL-ANTIBODY; DIFFERENT ISOFORMS; KINASE ACTIVATION; DNA-SYNTHESIS; A-CHAIN; BINDING; IDENTIFICATION	The aminoglycoside neomycin has recently been found to affect certain platelet-derived growth factor (PDGF) responses in C3H/10T1/2 C18 fibroblasts. Using porcine aortic endothelial cells transfected with PDGF alpha- or beta-receptors, we explored the possibility that neomycin interferes with the interaction between the different PDGF isoforms and their receptors. We found that neomycin (5 mM) inhibited the binding of I-125-PDGF-BB to the alpha-receptor with only partial effect on the binding of I-125-PDGF-AA; in contrast, the binding of I-125-PDGF-BB to the beta-receptor was not affected by the aminoglycoside. Scatchard analyses showed that neomycin (5 mM) decreased the number of binding sites for PDGF-BB on alpha-receptor-expressing cells by 87%. Together with cross-competition studies with I-125-labeled PDGF homodimers, the effect of neomycin indicates that PDGF-AA and PDGF-BB bind to both common and unique structures on the PDGF alpha-receptor. Neomycin specifically inhibited the autophosphorylation of the alpha-receptor by PDGF-BB, with less effect on the phosphorylation induced by PDGF-AA and no effect on the phosphorylation of the beta-receptor by PDGF-BB. Thus, neomycin is a PDGF isoform- and receptor-specific antagonist that provides a possibility to compare the signal transduction pathways of alpha- and beta-receptors in cells expressing both receptor types. This approach was used to show that activation of PDGF beta-receptors by PDGF-BB mediated a chemotactic response in human fibroblasts, whereas activation of alpha-receptors by the same ligand inhibited chemotaxis.	LUDWIG INST CANC RES,CTR BIOMED,BOX 595,S-75124 UPPSALA,SWEDEN; UNIV BERGEN,DEPT BIOCHEM,N-5009 BERGEN,NORWAY; UNIV HOSP UPPSALA,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research; University of Bergen; Uppsala University; Uppsala University Hospital								BAR RS, 1989, ENDOCRINOLOGY, V124, P1841, DOI 10.1210/endo-124-4-1841; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DUAN DSR, 1991, J BIOL CHEM, V266, P413; EK B, 1984, J BIOL CHEM, V259, P1145; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ERIKSSON A, 1991, J BIOL CHEM, V266, P21138; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; HELDIN CH, 1981, EXP CELL RES, V136, P255, DOI 10.1016/0014-4827(81)90003-3; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; JOSEPHS SF, 1984, SCIENCE, V223, P487, DOI 10.1126/science.6318322; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; LANGELAND N, 1987, J VIROL, V61, P3388, DOI 10.1128/JVI.61.11.3388-3393.1987; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; TYSNES OB, 1991, BIOCHEM J, V273, P241, DOI 10.1042/bj2730241; VASSBOTN FS, 1990, BIOCHIM BIOPHYS ACTA, V1054, P207, DOI 10.1016/0167-4889(90)90242-6; VASSBOTN FS, 1990, BIOCHIM BIOPHYS ACTA, V1054, P246, DOI 10.1016/0167-4889(90)90248-C; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WILKINSON PC, 1982, CHEMOTAXIS INFLAMMAT, P35; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	54	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15635	15641						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322402				2022-12-25	WOS:A1992JG11300060
J	GUNASEKERA, A; EBRIGHT, YW; EBRIGHT, RH				GUNASEKERA, A; EBRIGHT, YW; EBRIGHT, RH			DNA-SEQUENCE DETERMINANTS FOR BINDING OF THE ESCHERICHIA-COLI CATABOLITE GENE ACTIVATOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; RECOGNITION SEQUENCE; NUCLEIC-ACIDS; OPERATOR DNA; CAP; SITE; SPECIFICITY; REPRESSOR; RESOLUTION; COMPLEX	The consensus DNA site for binding of the Escherichia coli catabolite gene activator protein (CAP) is 22 base pairs in length and is 2-fold symmetric: 5'-AAATGTGATCTAGATCACATTT-3'. Positions 4 to 8 of each half of the consensus DNA half-site are the most strongly conserved. In this report, we analyze the effects of substitution of DNA base pairs at positions 4 to 8, the effects of substitution of thymine by uracil and by 5-methylcytosine at positions 4, 6, and 8, and the effect of dam methylation of the 5'-GATC-3' sequence at positions 7 to 10. All DNA sites having substitutions of DNA base pairs at positions 4 to 8 exhibit lower affinities for CAP than does the consensus DNA site, consistent with the proposal that the consensus DNA site is the ideal DNA site for CAP. Specificity for T:A at position 4 appears to be determined solely by the thymine 5-methyl group. Specificity for T:A at position 6 and specificity for A:T at position 8 appear to be determined in part, but not solely, by the thymine 5-methyl group. dam methylation has little effect on CAP . DNA complex formation. The thermodynamically defined consensus DNA site spans 28 base pairs. All, or nearly all, DNA determinants required for maximal affinity for CAP and for maximal thermodynamically defined CAP-DNA ion pair formation are contained within a 28-base pair DNA fragment that has the 22-base pair consensus DNA site at its center. The quantitative data in this report provide base-line thermodynamic data required for detailed investigations of amino acid-base pair and amino acid-phosphate contacts in this protein-DNA complex.	RUTGERS STATE UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855; RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AIBA H, 1989, GENE, V85, P91; BARBER AM, 1990, J BIOMOL STRUCT DYN, V8, P213, DOI 10.1080/07391102.1990.10507803; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; CHEUNG S, 1984, P NATL ACAD SCI-BIOL, V81, P3665, DOI 10.1073/pnas.81.12.3665; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; EBRIGHT RH, 1990, NUCLEIC ACIDS RES, V18, P1457, DOI 10.1093/nar/18.6.1457; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; EBRIGHT RH, 1984, P NATL ACAD SCI-BIOL, V81, P7274, DOI 10.1073/pnas.81.23.7274; EBRIGHT RH, 1986, PROTEIN STRUCTURE FO, P207; EBRIGHT RH, 1986, THESIS HARVARD U; EILEN E, 1978, BIOCHEMISTRY-US, V17, P2469, DOI 10.1021/bi00606a001; FELSENFELD GARY, 1965, J MOL BIOL, V13, P407; FISHER EF, 1979, NUCLEIC ACIDS RES, V7, P401, DOI 10.1093/nar/7.2.401; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GUNASEKERA A, 1990, NUCLEIC ACIDS RES, V18, P6853, DOI 10.1093/nar/18.23.6853; JANSEN C, 1987, BIOCHEM J, V246, P227, DOI 10.1042/bj2460227; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLELLAND M, 1988, GENE, V74, P291, DOI 10.1016/0378-1119(88)90305-8; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; MORITA T, 1988, NUCLEIC ACIDS RES, V16, P7315, DOI 10.1093/nar/16.15.7315; OLMSTED MC, 1989, P NATL ACAD SCI USA, V86, P7766, DOI 10.1073/pnas.86.20.7766; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PASTAN I, 1976, BACTERIOL REV, V40, P527, DOI 10.1128/MMBR.40.3.527-551.1976; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1978, BIOPOLYMERS, V17, P159, DOI 10.1002/bip.1978.360170112; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROSENBERG JM, 1982, DNA-J MOLEC CELL BIO, V1, P117, DOI 10.1089/dna.1.1982.1.117; SAENGER W, 1986, NATURE, V324, P385, DOI 10.1038/324385a0; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STORMO GD, 1989, P NATL ACAD SCI USA, V86, P1183, DOI 10.1073/pnas.86.4.1183; TAKAHASHI M, 1983, J MOL BIOL, V167, P895, DOI 10.1016/S0022-2836(83)80118-1; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TAKEDA Y, 1983, SCIENCE, V221, P1020, DOI 10.1126/science.6308768; TUNIS MJB, 1968, BIOPOLYMERS, V6, P1345, DOI 10.1002/bip.1968.360060909; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; ZHANG XP, 1990, P NATL ACAD SCI USA, V87, P4717, DOI 10.1073/pnas.87.12.4717	49	112	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14713	14720						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321815				2022-12-25	WOS:A1992JF08800035
J	HIRAISHI, H; TERANO, A; RAZANDI, M; SUGIMOTO, T; HARADA, T; IVEY, KJ				HIRAISHI, H; TERANO, A; RAZANDI, M; SUGIMOTO, T; HARADA, T; IVEY, KJ			ROLE OF CELLULAR SUPEROXIDE-DISMUTASE AGAINST REACTIVE OXYGEN METABOLITE INJURY IN CULTURED BOVINE AORTIC ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE REDOX CYCLE; GASTRIC-MUCOSAL INJURY; HYDROGEN-PEROXIDE; FREE-RADICALS; HYDROXYL RADICALS; CYTO-TOXICITY; XANTHINE DEHYDROGENASE; HEMORRHAGIC-SHOCK; REDUCING AGENTS; RAT	We examined the protective effect of cellular superoxide dismutase against extracellular hydrogen-peroxide in cultured bovine aortic endothelial cells. Cr-51-labeled cells were exposed to hydrogen peroxide generated by glucose oxidase/glucose. Glucose oxidase caused a dose-dependent increase of Cr-51 release. Pretreatment with diethyldithiocarbamate enhanced injury induced by glucose oxidase, corresponding with the degree of inhibition of endogenous superoxide dismutase activity. Inhibition of cellular superoxide dismutase by diethyldithiocarbamate was not associated either with alteration of other antioxidant defenses or with potentiation of nonoxidant injury. Enhanced glucose oxidase damage by diethyldithiocarbamate was prevented by chelating cellular iron. Inhibition of cellular xanthine oxidase neither prevented lysis by hydrogen peroxide nor diminished enhanced susceptibility by diethyldithiocarbamate. These results suggest that, in cultured endothelial cells: 1) cellular superoxide is involved in mediating hydrogen peroxide-induced damage; 2) superoxide, which would be generated upon exposure to excess hydrogen peroxide independently of cellular xanthine oxidase, promotes the Haber-Weiss reaction by initiating reduction of stored iron (Fe3+) to Fe2+; 3) cellular iron catalyzes the production of a more toxic species from these two oxygen metabolites; 4) cellular superoxide dismutase plays a critical role in preventing hydrogen peroxide damage by scavenging superoxide and consequently by inhibiting the generation of the toxic species.	VET AFFAIRS MED CTR, DEPT MED, LONG BEACH, CA 90822 USA; UNIV CALIF IRVINE, DEPT CHEM, IRVINE, CA 92717 USA; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 2, TOKYO 113, JAPAN; DOKKYO UNIV, SCH MED, MIBU, TOCHIGI 32102, JAPAN	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of Tokyo; Dokkyo Medical University								BACON BR, 1984, SEMIN LIVER DIS, V4, P181, DOI 10.1055/s-2008-1041769; BAUGHMAN RP, 1986, J LAB CLIN MED, V107, P233; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Beutler E., 1975, RED CELL METABOLISM, P69; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CHB, 1986, P NATL ACAD SCI USA, V83, P7147, DOI 10.1073/pnas.83.19.7147; CHOPRA J, 1987, LAB INVEST, V57, P578; CUNNINGHAM SK, 1977, IRISH J MED SCI, V146, P136, DOI 10.1007/BF03030948; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FREEMAN BA, 1983, J BIOL CHEM, V258, P2534; FREEMAN BA, 1982, LAB INVEST, V47, P412; FUCHS HJR, 1983, BIOCHEM BIOPH RES CO, V116, P1107, DOI 10.1016/S0006-291X(83)80256-3; GARDNER TJ, 1983, SURGERY, V94, P423; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; Grisham MB, 1986, PHYSL OXYGEN RADICAL, P01; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; HALLIWELL B, 1989, FREE RADICAL BIO MED, V7, P645, DOI 10.1016/0891-5849(89)90145-7; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HALLIWELL B, 1982, BIOCHEM J, V205, P461, DOI 10.1042/bj2050461; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; Heikkila R.E., 1985, HDB METHODS OXYGEN R, P387; HEIKKILA RE, 1976, J BIOL CHEM, V251, P2182; HIRAISHI H, 1987, AM J PHYSIOL, V253, pG40, DOI 10.1152/ajpgi.1987.253.1.G40; HOMANMULLER JWT, 1975, J LAB CLIN MED, V85, P198; ITOH T, 1986, STROKE, V17, P1284, DOI 10.1161/01.STR.17.6.1284; JONES CE, 1968, AM J PHYSIOL, V214, P1374, DOI 10.1152/ajplegacy.1968.214.6.1374; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; KELNER MJ, 1986, J BIOL CHEM, V261, P1636; KELNER MJ, 1989, FREE RADICAL BIO MED, V6, P355, DOI 10.1016/0891-5849(89)90079-8; Korthuis R., 1986, PHYSL OXYGEN RADICAL, P217; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; KYLE ME, 1988, J BIOL CHEM, V263, P3784; MARGOLIASH E, 1958, BIOCHEM J, V68, P468, DOI 10.1042/bj0680468; MARKEY BA, 1990, FREE RADICAL BIO MED, V9, P307, DOI 10.1016/0891-5849(90)90005-4; MARUBAYASHI S, 1986, SURGERY, V99, P184; MCCORD JM, 1982, CAN J PHYSIOL PHARM, V60, P1346, DOI 10.1139/y82-201; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MICHIELS C, 1990, J CELL PHYSIOL, V144, P295, DOI 10.1002/jcp.1041440216; MOLDOW CF, 1984, METHOD ENZYMOL, V105, P378; ODY C, 1985, P SOC EXP BIOL MED, V180, P103; PALLER MS, 1986, AM J PHYSIOL, V251, pF839, DOI 10.1152/ajprenal.1986.251.5.F839; PARKS DA, 1988, AM J PHYSIOL, V254, pG768, DOI 10.1152/ajpgi.1988.254.5.G768; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SMITH SM, 1987, GASTROENTEROLOGY, V93, P466, DOI 10.1016/0016-5085(87)90907-3; SMITH SM, 1987, GASTROENTEROLOGY, V92, P950, DOI 10.1016/0016-5085(87)90969-3; STARKE PE, 1985, J BIOL CHEM, V260, P99; SUTTORP N, 1986, AM J PHYSIOL, V251, pC671, DOI 10.1152/ajpcell.1986.251.5.C671; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; Taylor A E, 1983, Physiologist, V26, P152; TROMBETTA LD, 1988, TOXICOL APPL PHARM, V93, P154, DOI 10.1016/0041-008X(88)90035-X; VANSTEVENINCK J, 1985, BIOCHEM J, V232, P309, DOI 10.1042/bj2320309; VERCELLOTTI GM, 1988, P SOC EXP BIOL MED, V187, P181; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; WINTERBOURN CC, 1979, BIOCHEM J, V182, P625, DOI 10.1042/bj1820625; YOKOYAMA Y, 1988, GASTROENTEROLOGY, V94, pA607	65	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14812	14817						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321816				2022-12-25	WOS:A1992JF08800048
J	WANG, YB; DEMAYO, JL; HAHN, TM; FINEGOLD, MJ; KONECKI, DS; LICHTERKONECKI, U; WOO, SLC				WANG, YB; DEMAYO, JL; HAHN, TM; FINEGOLD, MJ; KONECKI, DS; LICHTERKONECKI, U; WOO, SLC			TISSUE-SPECIFIC AND DEVELOPMENT-SPECIFIC EXPRESSION OF THE HUMAN PHENYLALANINE-HYDROXYLASE CHLORAMPHENICOL ACETYLTRANSFERASE FUSION GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTITRYPSIN GENE; ACTING PROMOTER ELEMENTS; ALBUMIN GENE; NUCLEOTIDE-SEQUENCE; BINDING-PROTEINS; NUCLEAR FACTOR; MESSENGER-RNA; HUMAN LIVER; TRANSCRIPTION; PHENYLKETONURIA	Human phenylalanine hydroxylase (PAH) catalyzes the conversion Of L-phenylalanine to L-tyrosine. Deficiency of this enzyme results in phenylketonuria, a common genetic disorder of amino acid metabolism that causes severe mental retardation. In primates, PAH is expressed specifically in the liver, while in rodents PAH activity is also present in kidney, although at a much lower level. A 9-kilobase genomic DNA fragment at the 5' end of the hPAH gene (hPAH) was fused to the bacterial chloramphenicol acetyltransferase (CAT) gene. The hPAH/CAT minigene was used to generate multiple transgenic mouse lines. In all expressing lines, CAT activity was detected predominantly in the liver and at much lower levels in the kidney. By immunohistochemical staining, CAT expression was localized to hepatocytes and renal epithelial cells, both of which also express the endogenous mouse PAH enzyme. Furthermore, both the transgene and the endogenous mouse PAH were activated at about the same stage of embryonic development in the mouse liver. These results suggest that the 9-kilobase DNA fragment flanking the 5' end of the human PAH gene contains all the necessary cis-acting elements to direct tissue- and developmental-specific expression in vivo.	BAYLOR COLL MED,DEPT CELL BIOL,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; UNIV HEIDELBERG,KINDERKLIN,W-6900 HEIDELBERG,GERMANY	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Ruprecht Karls University Heidelberg				Wang, Yibin/0000-0003-0852-0767	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017711, R37HD017711] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-17711] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; BANERJI J, 1983, NATURE, V323, P731; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRINSTER RL, 1983, NATURE, V306, P332, DOI 10.1038/306332a0; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; COSTA RH, 1990, P NATL ACAD SCI USA, V87, P6589, DOI 10.1073/pnas.87.17.6589; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DILELLA AG, 1988, LANCET, V1, P497; DILELLA AG, 1986, BIOCHEMISTRY-US, V25, P743, DOI 10.1021/bi00352a001; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EISENSMITH RC, 1992, IN PRESS HUM MUT, V1; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GILHAM PT, 1964, J AM CHEM SOC, V86, P4982, DOI 10.1021/ja01076a049; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAYSON DR, 1988, SCIENCE, V239, P786, DOI 10.1126/science.3257586; GREENGARD O, 1977, PEDIATR RES, V11, P669, DOI 10.1203/00006450-197705000-00009; HSIEH MC, 1979, J EXP ZOOL, V208, P161, DOI 10.1002/jez.1402080204; Kaufman S., 1976, ADV NEUROCHEM, P1; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEDLEY FD, 1985, SCIENCE, V228, P77, DOI 10.1126/science.3856322; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIDSKY AS, 1985, P NATL ACAD SCI USA, V82, P6221, DOI 10.1073/pnas.82.18.6221; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MCGEE MM, 1972, BIOCHEM J, V127, P669, DOI 10.1042/bj1270669; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; RAIHA NCR, 1973, PEDIATR RES, V7, P1; RAO DN, 1986, J BIOL CHEM, V261, P8866; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROBSON KJH, 1982, P NATL ACAD SCI-BIOL, V79, P4701, DOI 10.1073/pnas.79.15.4701; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SCRIVER CR, 1980, ANNU REV GENET, V14, P179, DOI 10.1146/annurev.ge.14.120180.001143; SHEN RF, 1987, NUCLEIC ACIDS RES, V15, P8399, DOI 10.1093/nar/15.20.8399; SIFERS RN, 1987, NUCLEIC ACIDS RES, V15, P1459, DOI 10.1093/nar/15.4.1459; SIMONE VD, 1987, EMBO J, V6, P2759; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; TOURIAN A, 1969, J CELL PHYSIOL, V73, P159, DOI 10.1002/jcp.1040730210; TRONCHE F, 1990, MOL BIOL MED, V7, P173; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YEOH GCT, 1988, DIFFERENTIATION, V38, P42, DOI 10.1111/j.1432-0436.1988.tb00590.x	48	29	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15105	15110						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321825				2022-12-25	WOS:A1992JF08800088
J	BRENNER, B; WILDHARDT, G; SCHNEIDER, S; ROYERPOKORA, B				BRENNER, B; WILDHARDT, G; SCHNEIDER, S; ROYERPOKORA, B			RNA-POLYMERASE CHAIN-REACTION DETECTS DIFFERENT LEVELS OF 4 ALTERNATIVELY SPLICED WT1 TRANSCRIPTS IN WILMS-TUMORS	ONCOGENE			English	Note							ENZYMATIC AMPLIFICATION; HUMAN CHROMOSOME-11; PHYSICAL MAP; PROTEIN; LOCUS; GENE	A Wilms' tumor susceptibility gene (WT1) localized to 11p13 was recently isolated and shown to be altered in some sporadic Wilms' tumors. This gene encodes a DNA-binding protein with four zinc fingers (ZFs) in the carboxy-terminal region and a glutamine/proline (Gln/Pro)-rich domain near the 5' end. Two alternative splice sites were described, splice I in the Gln/Pro-rich domain (51 bp) and splice II between ZFs 3 and 4 (9 bp). Using RNA polymerase chain reaction (PCR) we show that Wilms' tumors contain all four possible transcripts, which are also identified in normal adult and embryonic kidney cells. The transcripts containing the 9-bp ZF insert were always predominant in tumors and normal cells. The presence of all four WT1 transcripts in tumors and expressing tissues suggests that each encoded protein isoform has an important role for the function of the WT1 gene.	UNIV HEIDELBERG,INST HUMAN GENET & ANTHROPOL,NEUENHEIMER FELD 328,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; GESSLER M, 1989, GENOMICS, V5, P43, DOI 10.1016/0888-7543(89)90084-0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980	14	43	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1431	1433						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320246				2022-12-25	WOS:A1992HZ97100023
J	MURAKAMI, T; NISHIYAMA, T; SHIROTANI, T; SHINOHARA, Y; KAN, M; ISHII, K; KANAI, F; NAKAZURU, S; EBINA, Y				MURAKAMI, T; NISHIYAMA, T; SHIROTANI, T; SHINOHARA, Y; KAN, M; ISHII, K; KANAI, F; NAKAZURU, S; EBINA, Y			IDENTIFICATION OF 2 ENHANCER ELEMENTS IN THE GENE ENCODING THE TYPE-1 GLUCOSE TRANSPORTER FROM THE MOUSE WHICH ARE RESPONSIVE TO SERUM, GROWTH-FACTOR, AND ONCOGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; INDUCE EXPRESSION; MESSENGER-RNA; SARCOMA-VIRUS; FOS GENE; DNA; TRANSFORMATION; ACTIVATION	The type 1 glucose transporter (GLUT1) gene encodes an integral membrane glycoprotein responsible for facilitating transfer of glucose across plasma membrane and is rapidly activated by serum, growth factors, and by oncogenic transformation. To elucidate the molecular mechanisms of regulation of GLUT1 gene expression, we isolated and characterized the mouse GLUT1 gene. DNA elements regulating transcription of the gene were analyzed in transient expression assays after transfection of NIH/3T3 cells with a low background chloramphenicol acetyltransferase (CAT) vector system pSVOOCAT. We identified two enhancer elements; the first one is located 2.7 kilobases upstream of the cap site of the gene which contains the homologous sequences with two 12-O-tetradecanoylphorbol-13-acetate-responsive elements (TREs), a serum response element, a cyclic AMP-responsive element (CRE) and three GC boxes, and the second one is located in the second intron of the gene which contains the homologous sequences with two TREs and one CRE. With the promoter alone the transcription of the gene is activated by src, only slightly activated by ras and is not activated by serum and platelet-derived growth factor. When the gene is accompanied by one of these enhancers, the transcription is activated by all these stimuli.	UNIV TOKUSHIMA,INST ENZYME RES,DEPT ENZYME GENET,KURAMOTO CHO,TOKUSHIMA 770,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT METAB MED,KUMAMOTO 860,JAPAN; UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,DEPT UROL,TOKUSHIMA 770,JAPAN	Tokushima University; Kumamoto University; Tokushima University; Tokushima University			Ishii, Kazuo/N-9946-2019; Ishii, Kazuo/M-3099-2016; ishii, kazuo/K-7428-2014	Ishii, Kazuo/0000-0002-8363-8266; ishii, kazuo/0000-0001-7801-1891				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BIRNBAUM MJ, 1987, SCIENCE, V235, P1492; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FUKUMOTO H, 1988, DIABETES, V37, P657, DOI 10.2337/diabetes.37.5.657; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATANAKA M, 1974, BIOCHIM BIOPHYS ACTA, V355, P77, DOI 10.1016/0304-419X(74)90008-0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HIRAKI Y, 1989, MOL ENDOCRINOL, V3, P1470, DOI 10.1210/mend-3-9-1470; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HIRAKI Y, 1989, P NATL ACAD SCI USA, V86, P8252, DOI 10.1073/pnas.86.21.8252; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIYAZAKI J, 1989, GENE, V79, P269; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHUTZBANK T, 1982, CELL, V30, P481, DOI 10.1016/0092-8674(82)90245-8; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	47	119	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9300	9306						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1339457				2022-12-25	WOS:A1992HR85400091
J	LEGOUX, R; DELPECH, B; DUMONT, X; GUILLEMOT, JC; RAMOND, P; SHIRE, D; CAPUT, D; FERRARA, P; LOISON, G				LEGOUX, R; DELPECH, B; DUMONT, X; GUILLEMOT, JC; RAMOND, P; SHIRE, D; CAPUT, D; FERRARA, P; LOISON, G			CLONING AND EXPRESSION IN ESCHERICHIA-COLI OF THE GENE ENCODING ASPERGILLUS-FLAVUS URATE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ALPHA-ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; ALCOHOL-DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; PROTEINS; YEAST; NIDULANS; SPECIFICITY; PEROXISOMES	Amino acid sequencing of peptides obtained after proteolytic hydrolysis of Aspergillus flavus urate oxidase (uricase) permitted the design of oligodeoxynucleotide probes that were used to obtain 1.2- and 5-kilobase pair DNA fragments from A. flavus cDNA and genomic libraries, respectively. The cDNA fragment contained the entire coding region for uricase, and comparison with the genomic fragment revealed the presence of two short introns in the coding region of the gene. A. flavus uricase has around 40% overall identity with uricases from higher organisms but with many conserved amino acids. Hitherto highly conserved consensus patterns found in other uricases were found to be modified in the A. flavus enzyme, notably the sequence Val-Leu-Lys-Thr-Thr-Gln-Ser near position 150, which in the filamentous fungus is uniquely modified to Val-Leu-Lys-Ser-Thr-Asn-Ser. Silent mutations were introduced by cassette mutagenesis near the 5'-extremity of the coding sequence in order to conform with Escherichia coli codon usage, and the uricase was expressed in the E. coli cytoplasm in a completely soluble, biologically active form.	SANOFI ELF BIORECH,VOIE 1 INNOPOLE,BP 137,F-31676 LABEGE,FRANCE	Sanofi-Aventis								ALVARES K, 1989, BIOCHEM BIOPH RES CO, V158, P991, DOI 10.1016/0006-291X(89)92820-9; Arst HN, 1985, GENE MANIPULATIONS F, P309; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunaud M, 1969, Therapie, V24, P785; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CONLEY TG, 1980, BIOCHEM J, V187, P727, DOI 10.1042/bj1870727; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOY CH, 1985, DNA-J MOLEC CELL BIO, V4, P105, DOI 10.1089/dna.1985.4.105; ELION GB, 1968, AM J MED, V45, P69, DOI 10.1016/0002-9343(68)90008-9; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FRIEDMAN TB, 1985, COMP BIOCHEM PHYS B, V81, P653, DOI 10.1016/0305-0491(85)90381-5; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; LABOUREUR P, 1968, B SOC CHIM BIOL, V50, P811; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEE FJS, 1989, J BIOL CHEM, V264, P12339; MELLOR J, 1989, MOL CELL BIOL YEASTS, P1; MOTOJIMA K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P116, DOI 10.1016/0167-4781(89)90178-4; NGUYEN T, 1985, P NATL ACAD SCI USA, V82, P5040, DOI 10.1073/pnas.82.15.5040; PATEMAN JA, 1983, PROC R SOC SER B-BIO, V217, P243, DOI 10.1098/rspb.1983.0009; PESTANA A, 1975, BIOCHEMISTRY-US, V14, P1404, DOI 10.1021/bi00678a010; RAMBOSEK J, 1987, CRIT REV BIOTECHNOL, V6, P357, DOI 10.3109/07388558709089387; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCAZZOCC.C, 1968, BIOCHIM BIOPHYS ACTA, V166, P557, DOI 10.1016/0005-2787(68)90243-8; SEALYLEWIS HM, 1978, MOL GEN GENET, V164, P303, DOI 10.1007/BF00333161; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SHIRE D, 1990, GENE, V93, P183, DOI 10.1016/0378-1119(90)90223-E; SUZUKI H, 1991, PLANT PHYSIOL, V95, P384, DOI 10.1104/pp.95.2.384; WALLRATH LL, 1990, MOL CELL BIOL, V10, P5114, DOI 10.1128/MCB.10.10.5114; WU XW, 1989, P NATL ACAD SCI USA, V86, P9412, DOI 10.1073/pnas.86.23.9412; YOSHIDA A, 1972, J BIOL CHEM, V247, P952; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153; ZOLLER M, 1985, DNA NY, V3, P479	38	70	85	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8565	8570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1339455				2022-12-25	WOS:A1992HQ18500091
J	ROSS, L; HASSMAN, F; MOLONY, L				ROSS, L; HASSMAN, F; MOLONY, L			INHIBITION OF MOLT-4-ENDOTHELIAL ADHERENCE BY SYNTHETIC PEPTIDES FROM THE SEQUENCE OF ICAM-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-1; HUMAN ENDOTHELIAL-CELLS; LEUKOCYTE ADHESION; SURFACE RECEPTORS; LFA-1; INTEGRIN; LYMPHOCYTES; MECHANISMS; EXPRESSION	Previous studies have shown that inflammatory pathologies are mediated by lymphocyte adhesion to endothelium and subsequent transmigration through the endothelial monolayer. Lymphocyte-endothelial adherence is, in part, caused by the leukocyte integrin LFA-1 binding to ICAM-1, its ligand on endothelial cells. Synthetic peptides based on specific amino acid sequences of human ICAM-1 inhibit the adherence of a lymphocytic cell line, Molt-4, to cytokine-stimulated endothelial cells. A total of 26 peptides spanning the extracellular domains of ICAM-1 were evaluated for their inhibitory activity in two cell adhesion assays. Binding of fluorescently labeled Molt-4 cells to TNF-stimulated human umbilical vein endothelial cells was inhibited reproducibly by peptides ICAM1-20, ICAM26-50 ICAM40-64, ICAM132-146, and ICAM345-375. Three overlapping sequences of the peptide ICAM40-64, KELLLPGNNRKVYELSNVQEDSQPM, were synthesized and tested as well, and the sequence KELLLPGNNRKV showed the greatest inhibition. The inhibitory activity of these peptides was confirmed using a second assay, inhibition of aggregation of the Epstein-Barr virus-transformed B-lymphoblast line JY. Polyclonal antibodies were developed in rabbits by immunization with two of the peptides and characterized for their ability to inhibit lymphocyte-endothelial adherence. These studies predict potential sites for interaction of the integrin receptor, LFA-1, with its ligand, ICAM-1. Thus lymphocyte-endothelial interaction, and resulting inflammation, may be partially mediated by the association of ICAM-1 with LFA-1 at the specific molecular locations identified in this study.	GLAXO RES INST, DEPT CELL BIOL, RES TRIANGLE PK, NC 27709 USA; GLAXO RES INST, DEPT STRUCT CHEM, RES TRIANGLE PK, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline								ADAMS DH, 1989, LANCET, V2, P1122; ALTIERI DC, 1990, J IMMUNOL, V145, P662; ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CARLOS TM, 1990, BLOOD, V76, P965; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GIRANDA VL, 1990, PROTEINS, V7, P227, DOI 10.1002/prot.340070304; GRIFFITHS CEM, 1989, AM J PATHOL, V135, P1045; HALE LP, 1989, ARTHRITIS RHEUM, V32, P22, DOI 10.1002/anr.1780320105; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LEEUWENBERG JFM, 1990, CLIN EXP IMMUNOL, V81, P496; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MILESKI WJ, 1990, SURGERY, V108, P206; NICKOLOFF BJ, 1990, J INVEST DERMATOL, V94, pS151, DOI 10.1111/1523-1747.ep12876134; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PLUMB JA, 1989, CANCER RES, V49, P4435; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0	38	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8537	8543						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349017				2022-12-25	WOS:A1992HQ18500088
J	SHIMABUKU, AM; NISHIMOTO, T; UEDA, K; KOMANO, T				SHIMABUKU, AM; NISHIMOTO, T; UEDA, K; KOMANO, T			P-GLYCOPROTEIN - ATP HYDROLYSIS BY THE N-TERMINAL NUCLEOTIDE-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTIDRUG-RESISTANCE; GENE; CELLS; PURIFICATION; MUTATIONS; F1-ATPASE; PROTEINS; SUBUNITS; SITE; DNA	Two ATP-binding domains are found in members of the family of ATP-dependent transport proteins, which includes P-glycoprotein and cystic fibrosis transmembrane conductance regulator. To investigate the involvement of the two ATP-binding domains in the ATPase activity of P-glycoprotein, full-length and the 5'-half of human MDR1 cDNA, which encodes P-glycoprotein, were fused with the Escherichia coli lacZ gene and expressed in NIH3T3 cells. Immunoprecipitated full-length P-glycoprotein beta-galactosidase showed ATPase activity with apparent specific activity of 180 nmol/mg/min, a value higher than previously reported, in the presence of phospholipids, suggesting that stabilization of the transmembrane domains is necessary for ATP hydrolysis. N-terminal half P-glycoprotein-beta-galactosidase also showed ability to hydrolyze ATP but with slightly lower specific activity. Both ATPase activities showed similar characteristics when the effect of several inhibitors was analyzed, indicating that the N-terminal ATP-binding domain contains all residues necessary to hydrolyze ATP without interacting with the C-terminal ATP-binding domain.	KYOTO UNIV,DEPT AGR CHEM,BIOCHEM LAB,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Ueda, Kazumitsu/0000-0003-2980-6078				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERMINO J, 1984, P NATL ACAD SCI-BIOL, V81, P4692, DOI 10.1073/pnas.81.15.4692; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HAMADA H, 1988, CANCER RES, V48, P4296; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HIGGINS CF, 1988, BIOESSAYS, V8, P111, DOI 10.1002/bies.950080406; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUFMAN RJ, 1986, P NATL ACAD SCI USA, V83, P3136, DOI 10.1073/pnas.83.10.3136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Miller JH., 1972, EXPT MOL GENETICS; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHIMABUKU AM, 1991, AGR BIOL CHEM TOKYO, V55, P1075, DOI 10.1080/00021369.1991.10870709; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	26	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4308	4311						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1347041				2022-12-25	WOS:A1992HF64200009
J	METZ, T; GRAF, T				METZ, T; GRAF, T			THE NUCLEAR ONCOGENES V-ERBA AND V-ETS COOPERATE IN THE INDUCTION OF AVIAN ERYTHROLEUKEMIA	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; CHICKEN ERYTHROID-CELLS; MONOCLONAL-ANTIBODIES; LEUKEMIA VIRUSES; MYELOID CELLS; GROWTH-FACTOR; PROTEIN; DIFFERENTIATION; TRANSFORMATION; GENE	The nuclear oncogenes v-erbA and v-ets are known to cooperate with other viral oncogenes in the induction of avian erythroleukemia. Thus, in the case of avian erythroblastosis virus (AEV), v-erbA enhances the effect of the tyrosine kinase-encoding v-erbB oncogene by blocking the terminal differentiation of erythroid cells. In the case of E26 virus a fusion of the product from v-ets to that of the nuclear oncogene v-myb is a prerequisite for leukemogenicity. Here we show that an artificial virus carrying both v-erbA and v-ets induces a rapid, acute erythroleukemia phenotypically similar to that induced by AEV. In contrast, virus constructs containing either v-erbA or v-ets alone are non-leukemogenic, although they are capable of transforming erythroid cells in vitro. Analysis of in vitro-transformed cells showed that v-erbA induces a block of differentiation without abrogating dependence on anemic serum, while v-ets predominantly causes anemic serum independence. As expected, cells transformed by both oncogenes exhibit an increased proliferative potential, are blocked in differentiation and are anemic serum independent. These data demonstrate that two separately expressed nuclear oncoproteins can complement each other in vitro and in vivo. They also show that the v-Ets protein on its own can contribute to leukemogenesis.			METZ, T (corresponding author), EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY.		Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Frykberg L, 1988, Oncogene Res, V3, P313; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAI MMC, 1980, VIROLOGY, V100, P475, DOI 10.1016/0042-6822(80)90537-1; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PAPAS TS, 1986, CANCER INVEST, V4, P555, DOI 10.3109/07357908609039835; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	42	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					597	605						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347919				2022-12-25	WOS:A1992HK00500030
J	KELLENBERGER, S; MALHERBE, P; SIGEL, E				KELLENBERGER, S; MALHERBE, P; SIGEL, E			FUNCTION OF THE ALPHA-1-BETA-2-GAMMA-2S GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR IS MODULATED BY PROTEIN-KINASE-C VIA MULTIPLE PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-BRAIN; GABAA RECEPTOR; ALPHA-SUBUNIT; CYCLIC-AMP; XENOPUS-OOCYTES; BETA-SUBUNIT; 2 FORMS; EXPRESSION; ACTIVATION; CAMP	Activation of protein kinase C (PKC) results in down-modulation of the gamma-aminobutyric acid type A (GABA(A)) receptor. In this study, the recombinant subunit combination alpha1beta2gamma2S was expressed in Xenopus oocytes. The resulting channel was shown to be modulated by 2 muM oleoylacetylglycerol or, stereo-specifically, by low concentrations (10 nM) of the phorbol ester 4beta-phorbol 12-myristate 13-acetate. By site-specific mutagenesis, we altered the serine or threonine residues of consensus phosphorylation sites for PKC in the large, intracellular domain of alpha1, beta2, and gamma2S. Mutant subunits were co-expressed with wild type subunits to yield alpha1beta2gamma2S combinations. All of the tested 14 mutations did not affect the level of expression of GABA current. Two of these mutations, Ser-410 in beta2 and Ser-327 in gamma2S, resulted in a significant reduction of the effect of the activator of PKC, 4beta-phorbol 12-myristate 13-acetate, on the GABA current amplitude. Thus, we have identified two single serine residues, Ser-410 in the subunit beta2 and Ser-327 in gamma2S, as phosphorylation sites of a PKC endogenous to Xenopus oocytes. Co-expression of the mutant subunits suggests that phosphorylation of both sites is required for a full, PKC-mediated down-regulation of GABA currents.	UNIV BERN, INST PHARMAKOL, DEPT PHARMACOL, FRIEDBUHLSTR 49, CH-3010 BERN, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, PHARMA PRECLIN RES, CH-4002 BASEL, SWITZERLAND	University of Bern; Roche Holding	SIGEL, E (corresponding author), UNIV BERN, INST PHARMAKOL, DEPT PHARMACOL, FRIEDBUHLSTR 49, CH-3010 BERN, SWITZERLAND.		Sigel, Erwin/F-7736-2015	Kellenberger, Stephan/0000-0003-1755-6198				BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; HARRISON NL, 1989, NEUROSCI LETT, V105, P137, DOI 10.1016/0304-3940(89)90025-6; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; MORAN O, 1989, MOL BRAIN RES, V5, P193, DOI 10.1016/0169-328X(89)90035-1; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SIGEL E, 1991, FEBS LETT, V291, P150, DOI 10.1016/0014-5793(91)81124-Q; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TEHRANI MHJ, 1989, SYNAPSE, V4, P126, DOI 10.1002/syn.890040206; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966	30	116	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25660	25663						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334482				2022-12-25	WOS:A1992KD07300011
J	RUBARTELLI, A; BAJETTO, A; ALLAVENA, G; WOLLMAN, E; SITIA, R				RUBARTELLI, A; BAJETTO, A; ALLAVENA, G; WOLLMAN, E; SITIA, R			SECRETION OF THIOREDOXIN BY NORMAL AND NEOPLASTIC-CELLS THROUGH A LEADERLESS SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR; PROTEIN; EXPORT; LEUKEMIA; SIGNAL; CDNA	Thioredoxin, despite its function as an intracellular disulfide reducing enzyme and its lack of a signal sequence, has been found to play some roles extracellularly. Here we show that thioredoxin is actively secreted by a variety of normal and transformed cells, including fibroblasts, airway epithelial cells, and activated B and T lymphocytes. Neither brefeldin A nor dinitrophenol, two drugs that block transport through the exocytic pathway, inhibit secretion of thioredoxin, indicating that the latter does not follow the classical ER-Golgi route. The secretory mechanism for thioredoxin shares several features with the alternative pathway described for interleukin-1beta, such as the potentiating effect on secretion of several unrelated drugs and the sensitivity to methylamine. However, unlike interleukin-1beta, thioredoxin is not detected in membrane-bound compartments of secreting cells. In addition, when COS7 are transfected with plasmids encoding pro-interleukin-1beta or thioredoxin, only the latter is detectable extracellularly.	INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE; IST SCI SAN RAFFAELE,I-20132 MILAN,ITALY	UNICANCER; Gustave Roussy; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	RUBARTELLI, A (corresponding author), IST NAZL RIC CANC,PATOL CLIN,VIALE BENEDETTO 15 10,I-16132 GENOA,ITALY.		Rubartelli, Anna/AAA-1259-2021	Sitia, Roberto/0000-0001-7086-4152				CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COSULICH ME, 1987, P NATL ACAD SCI USA, V84, P4205, DOI 10.1073/pnas.84.12.4205; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; GUAZZI S, 1989, LEUKEMIA RES, V13, P1105, DOI 10.1016/0145-2126(89)90156-2; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Sambrook J, 1989, MOL CLONING LABORATO; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447	24	407	425	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24161	24164						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332947				2022-12-25	WOS:A1992KA26300004
J	ZANG, LY; MISRA, HP				ZANG, LY; MISRA, HP			EPR KINETIC-STUDIES OF SUPEROXIDE RADICALS GENERATED DURING THE AUTOXIDATION OF 1-METHYL-4-PHENYL-2,3-DIHYDROPYRIDINIUM, A BIOACTIVATED INTERMEDIATE OF PARKINSONIAN-INDUCING NEUROTOXIN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; NIGROSTRIATAL TOXIN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; TRAP 5,5-DIMETHYL-1-PYRROLINE-1-OXIDE DMPO; CUTANEOUS PHOTOSENSITIZING AGENTS; MONOAMINE-OXIDASE; MOLECULAR MECHANISM; MELANIN PRECURSORS; LIPID-PEROXIDATION; HYDROXYL RADICALS; SUBSTANTIA NIGRA	1-Methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), a metabolic product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), has been shown to generate superoxide radicals during its autoxidation process. The generation of superoxide radicals was detected as a 5,5-dimethyl-1-pyrroline-N-oxide (DMPO).O2- spin adduct by spin trapping in combination with EPR techniques. The rate of formation of spin adduct was dependent not only on the concentrations of MPDP+ and oxygen but also on the pH of the system. Superoxide dismutase inhibited the spin adduct formation in a dose-dependent manner. The ability of DMPO to trap superoxide radicals, generated during the autoxidation of MPDP+, and of superoxide dismutase to effectively compete with this reaction for the available O2-, has been used as a convenient competition reaction to quantitatively determine various kinetic parameters. Thus, using this technique the rate constant for scavenging of superoxide radical by superoxide dismutase was found to be 7.56 x 10(9) M-1 s-1. The maximum rate of superoxide generation at a fixed spin trap concentration using different amounts of MPDP+ was found to be 4.48 x 10(-10) M s-1. The rate constant (K1) for MPDP+ making superoxide radical was found to be 3.97 x 10(-6) s-1. The secondary order rate constant (K(DMPO)) for DMPO-trapping superoxide radicals was found to be 10.2 M-1 s-1. The lifetime of superoxide radical at pH 10.0 was calculated to be 1.25 s. These values are in close agreement to the published values obtained using different experimental techniques. These results indicate that superoxide radicals are produced during spontaneous oxidation of MPDP+ and that EPR spin trapping can be used to determine the rate constants and lifetime of free radicals generated in aqueous solutions. It appears likely that the nigrostriatal toxicity of MPTP/MPDP+ leading to Parkinson's disease may largely be due to the reactivity of these radicals.	VIRGINIA POLYTECH INST & STATE UNIV, VIRGINIA MARYLAND REG COLL VET MED, DEPT BIOMED SCI, BLACKSBURG, VA 24061 USA; ACAD SINICA, INST BIOPHYS, BEIJING 100080, PEOPLES R CHINA	Virginia Polytechnic Institute & State University; Chinese Academy of Sciences; Institute of Biophysics, CAS								ARROYO CM, 1990, FREE RADICAL BIO MED, V9, P191, DOI 10.1016/0891-5849(90)90027-G; ASADA K, 1974, AGR BIOL CHEM TOKYO, V38, P471, DOI 10.1080/00021369.1974.10861178; BENHUR E, 1985, INT J RADIAT BIOL, V48, P837, DOI 10.1080/09553008514551931; BUETTNER GR, 1978, BIOCHEM BIOPH RES CO, V83, P69, DOI 10.1016/0006-291X(78)90398-4; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CARMICHAEL AJ, 1985, PHOTOCHEM PHOTOBIOL, V41, P635, DOI 10.1111/j.1751-1097.1985.tb03616.x; CHEVALET J, 1972, J ELECTROANAL CHEM, V39, P201, DOI 10.1016/S0022-0728(72)80488-1; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHIBA K, 1985, DRUG METAB DISPOS, V13, P342; FARHATAZIZ E, 1977, NATL STAND REF DATA, V59, P37; Fee J.A., 1977, SUPEROXIDE SUPEROXID, P19; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; FRIDOVICH I, 1977, SUPEROXIDE SUPEROXID, P551; GESSNER W, 1985, FEBS LETT, V183, P345, DOI 10.1016/0014-5793(85)80807-3; GORDON S, 1963, J AM CHEM SOC, V85, P1375, DOI 10.1021/ja00893a002; HARBOUR JR, 1978, J PHYS CHEM-US, V82, P1397, DOI 10.1021/j100501a015; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; JAMESON DM, 1984, FLUORESCEIN HAPTEN I, P23; JANZEN EG, 1984, METHOD ENZYMOL, V105, P188; JANZEN EG, 1973, J MAGN RESON, V9, P510, DOI 10.1016/0022-2364(73)90194-7; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; KALYANARAMAN B, 1982, PHOTOCHEM PHOTOBIOL, V36, P5, DOI 10.1111/j.1751-1097.1982.tb04332.x; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; KORTYTOWSKI W, 1987, BIOCHEM BIOPH RES CO, V144, P692, DOI 10.1016/S0006-291X(87)80020-7; KORYTOWSKI W, 1986, BIOCHIM BIOPHYS ACTA, V882, P145, DOI 10.1016/0304-4165(86)90149-2; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, NEUROSCI LETT, V48, P87, DOI 10.1016/0304-3940(84)90293-3; LEUNG L, 1989, J ORG CHEM, V54, P1052, DOI 10.1021/jo00266a011; LEWIN R, 1984, SCIENCE, V225, P1460, DOI 10.1126/science.6433484; MAKINO K, 1986, BIOCHEM BIOPH RES CO, V141, P381, DOI 10.1016/S0006-291X(86)80380-1; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; MONTE DD, 1988, DRUG METAB DISPOS, V16, P250; MOTTEN AG, 1985, PHOTOCHEM PHOTOBIOL, V42, P9, DOI 10.1111/j.1751-1097.1985.tb03540.x; PETERSON LA, 1985, J MED CHEM, V28, P1432, DOI 10.1021/jm00148a010; RABANI J, 1969, J PHYS CHEM-US, V73, P3736, DOI 10.1021/j100845a030; RESZKA K, 1983, PHOTOCHEM PHOTOBIOL, V38, P281, DOI 10.1111/j.1751-1097.1983.tb02673.x; TREVOR AJ, 1987, LIFE SCI, V40, P713, DOI 10.1016/0024-3205(87)90298-0; TREVOR AJ, 1988, TOXICOLOGY, V49, P513, DOI 10.1016/0300-483X(88)90037-6; TURNER MJ, 1986, J MED CHEM, V29, P2439, DOI 10.1021/jm00162a004; WU E, 1988, CHEM RES TOXICOL, V1, P186, DOI 10.1021/tx00003a010; WU EY, 1986, LIFE SCI, V39, P1695, DOI 10.1016/0024-3205(86)90167-0; YONG VW, 1986, NEUROSCI LETT, V63, P56, DOI 10.1016/0304-3940(86)90012-1; ZANG LY, 1992, J BIOL CHEM, V267, P17547; ZANG LY, 1992, IN PRESS PHOTOCHEM P, V54	45	51	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23601	23608						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331093				2022-12-25	WOS:A1992JZ23900030
J	PAGES, F; DETERRE, P; PFISTER, C				PAGES, F; DETERRE, P; PFISTER, C			ENHANCED GTPASE ACTIVITY OF TRANSDUCIN WHEN BOUND TO CGMP PHOSPHODIESTERASE IN BOVINE RETINAL RODS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OUTER SEGMENTS; INTRINSIC FLUORESCENCE; MOLECULAR MECHANISM; GUANYLATE-CYCLASE; ALPHA-SUBUNIT; G-PROTEIN; DEACTIVATION; ACTIVATION; HYDROLYSIS; LIGHT	The generation of the physiological response of a retinal rod cell to an incident photon involves activation of a cGMP phosphodiesterase (PDE) by a GTP-binding protein, transducin (T). This activation has been shown to occur by formation of a membrane-bound Talpha(GTP)-PDE complex (Clerc, A., and Bennett, N. (1992) J. Biol. Chem. 267,6620-6627; Catty, P., Pfister, C., Bruckert, F., and Deterre, P. (1992) J. Biol. Chem 267, 19489-19493). The recovery of the response involves turning-off of T by its intrinsic GTPase activity. We show here that the formation of the membrane-bound Talpha(GTP)-PDE complex correlates with an enhanced rate of GTP hydrolysis. In vivo, this would provide an appropriate mechanism for fast turn-off of cGMP hydrolysis.	CEN,BIOPHYS MOLEC & CELLULAIRE LAB,DEPT BIOL MOLEC & STRUCT,BP 85-X,F-38041 GRENOBLE,FRANCE				Deterre, Philippe/O-8984-2017	Deterre, Philippe/0000-0001-9303-0791				ARCHAVSKY VY, 1989, FEBS LETT, V250, P353; ARCHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARCHAVSKY VY, 1992, NATURE, V357, P416; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BRUCKERT F, 1992, IN PRESS BIOPHYS J; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHABRE M, 1990, ACTIVATION DESENSI H, V44, P215; CLERC A, 1992, J BIOL CHEM, V267, P6620; COMPTON SJ, 1985, ANAL BIOCHEM, V151, P369, DOI 10.1016/0003-2697(85)90190-3; DETERRE P, 1984, FEBS LETT, V178, P228, DOI 10.1016/0014-5793(84)80606-7; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; PEPE IM, 1986, FEBS LETT, V203, P73, DOI 10.1016/0014-5793(86)81439-9; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SITARAMAYYA A, 1988, BIOCHEMISTRY-US, V27, P4880, DOI 10.1021/bi00413a044; STRYER L, 1991, J BIOL CHEM, V266, P10711; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VUONG TM, 1990, NATURE, V346, P71, DOI 10.1038/346071a0; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039	31	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22018	22021						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331045				2022-12-25	WOS:A1992JW71900009
J	HOMMA, Y; TAKENAWA, T				HOMMA, Y; TAKENAWA, T			INHIBITORY EFFECT OF SRC HOMOLOGY (SH) 2/SH3 FRAGMENTS OF PHOSPHOLIPASE C-GAMMA ON THE CATALYTIC ACTIVITY OF PHOSPHOLIPASE-C ISOFORMS - IDENTIFICATION OF A NOVEL PHOSPHOLIPASE-C INHIBITOR REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PHOSPHORYLATION; PROTEIN; ASSOCIATION; SEQUENCE; BINDING; CELLS; PURIFICATION; HYDROLYSIS; PI3-KINASE	In order to study the regulatory mechanisms of phospholipase C-gamma (PLC-gamma) via the intrinsic SH2/SH3 region (Z region), two recombinant Z proteins, rP45Z and rP38Z, derived from rat PLC-gamma1 and PLC-gamma2, respectively, were purified from the inclusion bodies of Escherichia coli. We examined their direct effects on phosphoinositide hydrolysis induced by four different PLC isoforms purified from bovine brain and thymus, and found that both of these Z proteins suppress the enzyme activity of all four PLC isoforms in a dose-dependent manner. This suppressive effect is very potent and stoichiometric. The kinetics studies indicate that the suppression is non-competitive. This suppression is eliminated by treatment with proteases but is not affected by heat treatment at 95-degrees-C for 15 min, indicating that the primary structure might be important for the action of Z proteins. Comparative studies suggested that two Z proteins but not Src and phosphatidylinositol 3-kinase possess, adjacent to their SH2 and SH3 motifs, a phospholipase C inhibitor (PCI) region that strongly suppresses their phosphatidylinositol 4,5-bisphosphate (PIP2)-hydrolyzing activity. A series of synthetic peptides identical with the sequence of the proposed PCI region, including an octamer, YRKMRLRY, inhibited PIP2 hydrolysis induced by four different phospholipase C isoforms. These results demonstrate that both types of phospholipase C-gamma contain the PCI sequence which is responsible for the inhibition of PIP2 hydrolysis, indicating that phospholipase C-gamma is a self-regulating enzyme.	UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo	HOMMA, Y (corresponding author), TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,35-2 SAKAE,TOKYO 173,JAPAN.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HOMMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P1402, DOI 10.1016/0006-291X(92)91889-X; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; HOMMA Y, 1992, J BIOL CHEM, V267, P3778; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM UH, 1991, J BIOL CHEM, V266, P1359; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P47; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; Sambrook J, 1989, MOL CLONING LABORATO; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218	30	59	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21844	21849						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328245				2022-12-25	WOS:A1992JV01100090
J	LI, L; LIN, K; PILKIS, J; CORREIA, JJ; PILKIS, SJ				LI, L; LIN, K; PILKIS, J; CORREIA, JJ; PILKIS, SJ			HEPATIC 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE - THE ROLE OF SURFACE LOOP BASIC RESIDUES IN SUBSTRATE BINDING TO THE FRUCTOSE-2,6-BISPHOSPHATASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FRUCTOSE-6-PHOSPHATE 2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; RAT TESTES FRUCTOSE-6-PHOSPHATE; 5' FLANKING SEQUENCE; FRUCTOSE 2,6-BISPHOSPHATASE; PHOSPHORYLATION SITES; MOLECULAR-CLONING; LIVER; DNA; GLUCONEOGENESIS	Lys-356 has been implicated as a critical residue for binding the C-6 phospho group of fructose 2,6-bisphosphate to the fructose-2,6-bisphosphatase domain of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (Li, L., Lin, K., Correia, J., and Pilkis, S. J. (1992) J. Biol. Chem. 267, 16669-16675). To ascertain whether the three other basic residues (Arg-352, Arg-358, and Arg-360), which are located in a surface loop (residues 331-362) which contains Lys-356, are important in substrate binding, these arginyl residues were mutated to Ala, and each arginyl mutant was expressed in Escherichia coli and purified to homogeneity. The far UV circular dichroism spectra of the mutants were identical to that of the wild-type enzyme. The kinetic parameters of 6-phosphofructo-2-kinase of the mutants revealed only small changes. However, the K(m) for fructose 2,6-bisphosphate, K(i) for fructose 6-phosphate, and K(a) for inorganic phosphate of fructose-2,6-bisphosphatase for Arg352Ala were, respectively, 2,800-, 4,500-, and 1,500-fold higher than those for the wild-type enzyme, whereas there was no change in the maximal velocity or the K(i) for inorganic phosphate. The K(m) for fructose 2,6-bisphosphate and K(i) for inorganic phosphate of Arg360Ala were 10- and 12-fold higher, respectively, than those of the wild-type enzyme, whereas the maximal velocity and K(i) for fructose 6-phosphate were unchanged. In addition, substrate inhibition was not observed with Arg352Ala and greatly reduced with Arg360Ala. The properties of the Arg358Ala mutant were identical to those of the wild-type enzyme. The results demonstrate that in addition to Lys-356, Arg-352 is another critical residue in fructose-2,6-bisphosphatase for binding the C-6 phospho group of fructose 2,6-bisphosphate and that Arg-360 binds the C-2 phospho group of fructose 2,6-bisphosphate in the phosphoenzyme.fructose 2,6-bis-phosphate complex. The results also provide support for Arg-352, Lys-356, and Arg-360 constituting a specificity pocket for fructose-2,6-bisphosphatase.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Mississippi; University of Mississippi Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P57; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1982, BIOCHEM BIOPH RES CO, V106, P794, DOI 10.1016/0006-291X(82)91780-6; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3096; HERS HG, 1982, BIOCHEM J, V206, P1; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KRETSCHMER M, 1991, BIOCHEMISTRY-US, V30, P10663, DOI 10.1021/bi00108a009; LANGE AJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P258, DOI 10.1016/0003-9861(91)90617-R; LANGE AJ, 1990, NUCLEIC ACIDS RES, V18, P3652, DOI 10.1093/nar/18.12.3652; LI L, 1992, J BIOL CHEM, V267, P4386; LI L, 1992, J BIOL CHEM, V267, P16669; LIN K, 1992, J BIOL CHEM, V267, P6556; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1982, MOL CELL ENDOCRINOL, V25, P245, DOI 10.1016/0303-7207(82)90082-X; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; PILKIS SJ, 1990, FRUCTOSE 2 6 BISPHOS; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STEWART HB, 1986, J BIOL CHEM, V261, P8793; STRICKLAND EH, 1987, CRC HDB BIOCH MOL BI, V3, P141; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1990, J BIOL CHEM, V265, P15617; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VENTURA F, 1992, J BIOL CHEM, V267, P17939	38	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21588	21594						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328239				2022-12-25	WOS:A1992JV01100052
J	RAMARAO, CS; DENKER, JMK; PEREZ, DM; GAIVIN, RJ; RIEK, RP; GRAHAM, RM				RAMARAO, CS; DENKER, JMK; PEREZ, DM; GAIVIN, RJ; RIEK, RP; GRAHAM, RM			GENOMIC ORGANIZATION AND EXPRESSION OF THE HUMAN ALPHA-1B-ADRENERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P RECEPTOR; RNA POLYMERASE-II; MOLECULAR-CLONING; MESSENGER-RNAS; ALPHA-2-ADRENERGIC RECEPTOR; CHROMOSOME LOCALIZATION; ADRENERGIC-RECEPTOR; GENE; TRANSCRIPTION; CDNA	Alpha1-adrenergic receptors (ARs) are members of the guanine nucleotide-binding protein-coupled receptor superfamily. The genes for all ARs described thus far are intronless. We report here the cloning and the nucleotide sequence of the gene for the human alpha1B-AR. It consists of two exons and a single large intron of at least 20 kilobases which interrupts the coding region at the end of the putative sixth transmembrane domain. The deduced amino acid sequence of the encoded receptor has a high degree of homology to the cloned hamster, rat, and dog alpha1B-ARs. To characterize the encoded protein, a fusion gene constructed by splicing together exon 1 and exon 2 was expressed transiently in COS-1 cells. The transfected gene fusion product resulted in the production of an alpha1B-AR with ligand binding characteristics indistinguishable from those of the expressed hamster alpha1B cDNA. Evidence that the human alpha1B-AR gene we have isolated is indeed transcribed is the finding of similar sized (2.8-kilobase) transcripts in human heart and other tissues by Northern blot analysis when either exon 1 or exon 2 is used as a probe. Moreover, using primers designed to span the exon 1/exon 2 boundary, a polymerase chain reaction product generated from single-stranded DNA prepared from human heart mRNA had the exact size and nucleotide sequence predicted for a transcript in which exon 1 is spliced to exon 2. The 5'-flanking region (924 base pairs (bp)) of exon 1 contains neither a TATA box nor a CAAT box but is high in GC content (70%) and contains several Sp1 binding sites (GC boxes), consistent with promoters described for housekeeping genes. The 5'-untranslated region also contains a putative cyclic AMP response element. Primer extension studies and RNase protection assays suggested that there are several potential transcription start sites in most tissues with a predominant site located 173 bp upstream from the translation start site. The 3'-flanking region contains a putative polyadenylation signal (ATTAAA) 492 bp downstream from the stop codon. The genomic organization of the human alpha1B-AR with a single large intron interrupting its coding region differs from those of other ARs as well as muscarinic and 5-hydroxy-tryptamine receptors, which are intronless. The location of the intron in the human alpha1B-AR gene is also unique among those members of the G-protein-coupled receptor family that do possess introns. Availability of this gene will now allow further studies on the transcriptional control of human alpha1B-AR expression.	CLEVELAND CLIN FDN, RES INST,DEPT HEART & HYPERTENS RES,FF3-20, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NIGMS NIH HHS [GM45985] Funding Source: Medline; NINDS NIH HHS [NS19583, NS09056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019583, F32NS009056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLQUIST RP, 1948, AM J PHYSIOL, V153, P586, DOI 10.1152/ajplegacy.1948.153.3.586; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; COLLINS J, 1980, COLD SPRING HARB SYM, V45, P409, DOI 10.1101/SQB.1981.045.01.055; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; GERARD NP, 1991, BIOCHEMISTRY-US, V30, P10640, DOI 10.1021/bi00108a006; GERARD NP, 1990, J BIOL CHEM, V265, P20455; HAGENBUCHLE O, 1980, CELL, V21, P179, DOI 10.1016/0092-8674(80)90125-7; HARRISON JK, 1991, TRENDS PHARMACOL SCI, V12, P62, DOI 10.1016/0165-6147(91)90499-I; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; JOB D, 1991, EUR J BIOCHEM, V195, P831, DOI 10.1111/j.1432-1033.1991.tb15772.x; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RAYMOND JR, 1990, HYPERTENSION, V15, P119, DOI 10.1161/01.HYP.15.2.119; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STALKER DM, 1981, ICN UCLA S MOL CELL, V22, P113; TOSO RD, 1989, EMBO J, V8, P4025; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; VOIGT MM, 1990, NUCLEIC ACIDS RES, V18, P1053, DOI 10.1093/nar/18.4.1053; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILLIAMS WL, 1987, J MOL BIOL, V196, P743	46	158	171	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21936	21945						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328250				2022-12-25	WOS:A1992JV01100104
J	FEDOROV, S; UYEDA, K				FEDOROV, S; UYEDA, K			OSCILLATION IN FRUCTOSE 2,6-BISPHOSPHATE LEVELS AND IN THE PHOSPHORYLATION STATES OF FRUCTOSE 6-PHOSPHATE,2-KINASE-FRUCTOSE-2,6-BISPHOSPHATASE IN ISCHEMIC RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOTIDE CYCLE; CATALYZES HYDROLYSIS; INSULIN-SECRETION; MUSCLE EXTRACTS; ENZYME; GLYCOLYSIS; FORMS; AMP; FRUCTOSE-2,6-BISPHOSPHATE; PHOSPHOFRUCTOKINASE-2	In order to determine the role of fructose (Fru) 2,6-P2 in stimulation of phosphofructokinase in ischemic liver, tissue contents of Fru-2,6-P2, hexose-Ps, adenine nucleotides, and Fru-6-P,2-kinase:Fru-2,6-bisphosphatase were investigated during the first few minutes of ischemia. The Fru-2,6-P2 concentration in the liver changed in an oscillatory manner. Within 7 s after the initiation of ischemia, Fru-2,6-P2 increased from 6 to 21 nmol/g liver and decreased to 5 nmol/g liver within 30 s. Subsequently, it reached the maximum value at 50, 80, and 100 s and decreased to the basal concentration at 60, 90, and 120 s. Oscillatory patterns were also observed with Glc-6-P and Fru-6-P, but the ATP/ADP ratio decreased monotonically. Determination of Fru-6-P,2-kinase activity and the phosphorylation states of Fru-6-P,2-kinase:Fru-2,6-bisphosphatase demonstrated that at 7 and 50 s, where Fru-2,6-P2 was the highest, the enzyme was activated and mostly in a dephosphorylated form. On the other hand, at 0, 30, and 300 s, the enzyme was predominantly in the phosphorylated form. The concentration of cAMP in the liver also changed in an oscillatory manner between 0.5 to 1.3 nmol/g with varying frequency of 10 to 40 s. These results indicated that: (a) Fru-2,6-P2 was important in rapid activation of phosphofructokinase in the first few seconds and up to 2-3 min, and (b) the oscillation of Fru-2,6-P2 concentration was the result of activation and inhibition of Fru-6-P,2-kinase:Fru-2,6-bisphosphatase, which was caused by changes in the phosphorylation state of the enzyme.	DEPT VET AFFAIRS MED CTR,PRECLIN SCI UNIT,4500 S LANCASTER RD,DALLAS,TX 75216; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75216	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGSTROM RW, 1989, AM J PHYSIOL, V257, pE479, DOI 10.1152/ajpendo.1989.257.4.E479; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P585, DOI 10.1016/0003-9861(65)90404-2; BRADFORD MM, 1976, ANAL BIOCHEM, V28, P216; CHANCE B, 1965, J BIOL CHEM, V240, P3170; CHOU HF, 1990, DIABETES, V39, P112, DOI 10.2337/diabetes.39.1.112; CONGO EA, 1991, J BIOL CHEM, V266, P9314; Corbin J D, 1974, Methods Enzymol, V38, P287; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ELMAGHRABI MR, 1981, BIOCHEM BIOPH RES CO, V101, P1071, DOI 10.1016/0006-291X(81)91858-1; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; FURUYA E, 1982, BIOCHEM BIOPH RES CO, V105, P264, DOI 10.1016/S0006-291X(82)80040-5; FURUYA E, 1982, P NATL ACAD SCI-BIOL, V79, P325, DOI 10.1073/pnas.79.2.325; FURUYA E, 1981, J BIOL CHEM, V256, P7109; HESS B, 1971, ANNU REV BIOCHEM, V40, P237, DOI 10.1146/annurev.bi.40.070171.001321; HUE L, 1982, BIOCHEM J, V206, P359, DOI 10.1042/bj2060359; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowry O. H., 1972, FLEXIBLE SYSTEM ENZY, P146; LOWRY OH, 1964, J BIOL CHEM, V239, P18; OGUSHI S, 1990, J BIOL CHEM, V265, P10943; RAPP PE, 1987, PROG NEUROBIOL, V29, P261, DOI 10.1016/0301-0082(87)90023-2; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; STALMANS W, 1975, EUR J BIOCHEM, V54, P341, DOI 10.1111/j.1432-1033.1975.tb04144.x; THOMAS H, 1986, ANAL BIOCHEM, V154, P50, DOI 10.1016/0003-2697(86)90494-X; THOMAS H, 1986, FED PROC, V45, P1013; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; TORNHEIM K, 1988, J BIOL CHEM, V263, P2619; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; UYEDA K, 1982, MOL CELL BIOCHEM, V48, P97; UYEDA K, 1978, J BIOL CHEM, V253, P8319; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V101, P1078; VEECH RL, 1973, J NEUROCHEM, V20, P183, DOI 10.1111/j.1471-4159.1973.tb12115.x	37	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20826	20830						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328212				2022-12-25	WOS:A1992JT97800050
J	FRATTALI, AL; TREADWAY, JL; PESSIN, JE				FRATTALI, AL; TREADWAY, JL; PESSIN, JE			TRANSMEMBRANE SIGNALING BY THE HUMAN INSULIN-RECEPTOR KINASE - RELATIONSHIP BETWEEN INTRAMOLECULAR BETA-SUBUNIT TRANS-AUTOPHOSPHORYLATION AND CIS-AUTOPHOSPHORYLATION AND SUBSTRATE KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; COOH-TERMINAL TRUNCATION; EXPRESSION SYSTEM; TYROSINE KINASE; PROTEIN-KINASE; DEPENDENT COVALENT; CYTOPLASMIC DOMAIN; POSSIBLE MECHANISM; TRANSFECTED CELLS; HYBRID RECEPTORS	To examine the role of intramolecular beta subunit trans- and cis-autophosphorylation in signal transduction, the vaccinia virus/bacteriophage T7 expression system was used to generate insulin holoreceptors composed of a kinase-defective half-receptor precursor (alphabeta(A/K) or alphabeta(A/K.DELTACT)) and a kinase-active half-receptor precursor (alphabeta(DELTACT) or alphabeta(WT)). In the alphabeta(A/K-alphabeta(DELTACT) hybrid insulin receptor, insulin stimulated a 20-fold increase in intramolecular beta subunit trans-phosphorylation, whereas cis-phosphorylation increased only 3-fold over the basal state. Similarly, in the alphabeta(WT)-alphabeta(A/K.DELTACT) hybrid insulin receptor, insulin stimulated trans-phosphorylation approximately 30-fold and cis-phosphorylation only 3-fold over the basal state. Although cis-phosphorylation of the kinase-functional alphabeta half-receptor was observed within these hybrid receptor species, this was not sufficient to stimulate exogenous substrate kinase activity. These data demonstrate that insulin primarily activates an intramolecular beta subunit trans-phosphorylation reaction within the insulin holoreceptor and suggest that this reaction is necessary for activation of the holoreceptor. Furthermore, our results suggest a molecular basis for the dominant-negative phenotype observed in insulin-resistant patients possessing one kinase-defective insulin receptor allele.			FRATTALI, AL (corresponding author), UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242, USA.				NIDDK NIH HHS [DK01822, DK33823, DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823, K04DK001822, P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1991, J BIOL CHEM, V266, P434; ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BOYLE TR, 1985, J BIOL CHEM, V260, P8593; CHIN JE, 1991, J BIOL CHEM, V266, P15587; COBB MH, 1989, J BIOL CHEM, V264, P18701; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRATTALI AL, 1992, J CELL BIOCHEM, V48, P43, DOI 10.1002/jcb.240480108; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; HAYES GR, 1991, DIABETES, V40, P300, DOI 10.2337/diabetes.40.2.300; HERRERA R, 1988, J BIOL CHEM, V263, P5560; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; OHARE T, 1988, BIOCHEMISTRY-US, V27, P5693, DOI 10.1021/bi00415a045; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; SHIA MA, 1983, J BIOL CHEM, V258, P4450; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1989, J BIOL CHEM, V264, P15136; VANOBBERGHENSCHILLING EE, 1981, J CLIN INVEST, V68, P1356, DOI 10.1172/JCI110383; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P785, DOI 10.1021/bi00428a056; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	44	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19521	19528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326556				2022-12-25	WOS:A1992JP59300076
J	GHALAYINI, AJ; ANDERSON, RE				GHALAYINI, AJ; ANDERSON, RE			ACTIVATION OF BOVINE ROD OUTER SEGMENT PHOSPHOLIPASE-C BY ARRESTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIGHT-MEDIATED BREAKDOWN; 48-KDA PROTEIN; S-ANTIGEN; IMMUNOCYTOCHEMICAL EVIDENCE; PHOTOEXCITED RHODOPSIN; GUANYLATE-CYCLASE; RETINAL RODS; BINDING; CALCIUM	Phospholipase C (PLC) enzyme activity in rod outer segment (ROS) membranes bleached in the presence of ATP and GTP was assayed using exogenously added [H-3]phosphatidylinositol 4,5-bisphosphate vesicles as substrate. The addition of the soluble ROS protein arrestin (also known as S-antigen or 48K protein) to ROS membranes activated PLC 2-3.4-fold. This activation was dose-dependent, and maximal activation was observed at an arrestin concentration of congruent-to 110-220 nM. PLC activation by arrestin was dependent on ROS protein concentration and free Ca2+. Soluble PLC (s-PLC) enzyme activity present in hypotonic extracts of bleached ROS was also activated 2-4-fold by arrestin. Maximum activation of s-PLC by arrestin was observed at free Ca2+ of 80 nM. Arrestin activation of s-PLC was not affected by urea-treated and extensively washed ROS membranes, suggesting that rhodopsin was not required for the observed effect of arrestin on s-PLC. The results are indicative of a direct interaction of arrestin with s-PLC, resulting in the activation of the latter. Based on these results and the documented binding of arrestin to bleached and phosphorylated rhodopsin, a model for the light activation of PLC in ROS is proposed.			GHALAYINI, AJ (corresponding author), BAYLOR COLL MED,CULLEN EYE INST,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL EYE INSTITUTE [P30EY002520, R01EY004149, R01EY000871] Funding Source: NIH RePORTER; NEI NIH HHS [EY04149, EY00871, EY02520] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GEHM BD, 1990, BIOCHEMISTRY-US, V29, P5447, DOI 10.1021/bi00475a006; GEHM BD, 1991, BIOCHEMISTRY-US, V30, P11302, DOI 10.1021/bi00111a016; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLITSCHER W, 1989, FEBS LETT, V256, P101, DOI 10.1016/0014-5793(89)81726-0; GLITSCHER W, 1991, FEBS LETT, V282, P431, DOI 10.1016/0014-5793(91)80530-G; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; HUPPERTZ B, 1990, J BIOL CHEM, V265, P9470; JEANSONNE NE, 1991, J BIOL CHEM, V266, P14675; KAPOOR CL, 1987, EXP EYE RES, V45, P545, DOI 10.1016/S0014-4835(87)80065-9; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KORF H, 1987, CANCER, V60, P1763, DOI 10.1002/1097-0142(19871015)60:8<1763::AID-CNCR2820600815>3.0.CO;2-3; Kuhn H., 1980, Neurochemistry International, V1, P269, DOI 10.1016/0197-0186(80)90066-2; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITOSCH I, 1991, J BIOL CHEM, V266, P4764; MATHEWS HR, 1988, NATURE, V3334, P67; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; MIRSHAHI M, 1989, FEBS LETT, V258, P240, DOI 10.1016/0014-5793(89)81663-1; MIRSHAHI M, 1991, C R ACD SCI PARIS, V312, P1441; MORRIS AJ, 1990, G PROTEINS SIGNAL TR, V81, P61; NAKAMURA S, 1990, P NATL ACAD SCI USA, V87, P6413, DOI 10.1073/pnas.87.16.6413; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; OLIVER J, 1987, CR ACAD SCI III-VIE, V305, P485; PANFOLI I, 1990, BIOCHEM BIOPH RES CO, V173, P283, DOI 10.1016/S0006-291X(05)81054-X; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SAGIEISENBERG R, 1989, CELL SIGNAL, V1, P519, DOI 10.1016/0898-6568(89)90036-3; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1988, PROGR RETINAL RES, V8, P51; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRYER L, 1991, J BIOL CHEM, V266, P10711; TARVER AP, 1988, EXP EYE RES, V46, P29, DOI 10.1016/S0014-4835(88)80090-3; TAYLOR SJ, 1991, NATURE, V350, P512; USUDA N, 1991, J CELL BIOL, V112, P1241, DOI 10.1083/jcb.112.6.1241; WACKER WB, 1977, J IMMUNOL, V119, P1949; WANG P, 1987, J BIOCHEM-TOKYO, V102, P1275, DOI 10.1093/oxfordjournals.jbchem.a122166; WEYAND I, 1990, EUR J BIOCHEM, V193, P459, DOI 10.1111/j.1432-1033.1990.tb19360.x; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; WISTOW GJ, 1986, FEBS LETT, V196, P23, DOI 10.1016/0014-5793(86)80207-1	48	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17977	17982						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325454				2022-12-25	WOS:A1992JM22300076
J	FILATOV, D; INGEMARSON, R; GRASLUND, A; THELANDER, L				FILATOV, D; INGEMARSON, R; GRASLUND, A; THELANDER, L			THE ROLE OF HERPES-SIMPLEX VIRUS RIBONUCLEOTIDE REDUCTASE SMALL SUBUNIT CARBOXYL TERMINUS IN SUBUNIT INTERACTION AND FORMATION OF IRON-TYROSYL CENTER STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SYNTHETIC PEPTIDES; R2 SUBUNIT; TYPE-1; INHIBITION; PURIFICATION; PROTEIN; DNA; TRANSFORMATION; EXPRESSION	Herpes simplex virus ribonucleotide reductase consists of two nonidentical subunits, proteins R1 and R2, which are required together for activity. Active R2 protein contains a tyrosyl free radical and a binuclear iron center. A truncated form of the R2 subunit, lacking 7 amino acid residues in the carboxyl terminus, was constructed, overexpressed in Escherichia coli and purified to homogeneity. In the presence of ferrous iron and oxygen, the truncated protein readily generated similar amounts of tyrosyl free radical as the intact protein. However, the radical showed differences in EPR characteristics in the truncated protein compared with the normal one, indicating an altered structural arrangement of the radical relative to the iron center. The truncated R2* protein was completely devoid of binding affinity to the R1 protein, demonstrating that the subunit interaction is totally dependent on the 7 outermost carboxyl-terminal amino acids of protein R2.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN	Umea University								AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BACCHETTI S, 1986, J VIROL, V57, P1177, DOI 10.1128/JVI.57.3.1177-1181.1986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, IN PRESS BIOCHEMISTR; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; COSENTINO G, 1991, BIOCHEM CELL BIOL, V69, P79, DOI 10.1139/o91-011; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FRAME MC, 1985, J GEN VIROL, V66, P1581, DOI 10.1099/0022-1317-66-7-1581; FURLONG J, 1991, VIROLOGY, V182, P846, DOI 10.1016/0042-6822(91)90627-N; GAUDREAU P, 1987, J BIOL CHEM, V262, P12413; GAUDREAU P, 1990, J MED CHEM, V33, P723, DOI 10.1021/jm00164a040; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; INGEMARSON R, 1989, J VIROL, V63, P3769, DOI 10.1128/JVI.63.9.3769-3776.1989; INGEMARSON R, 1987, VIROLOGY, V156, P417, DOI 10.1016/0042-6822(87)90422-3; INGEMARSON R, 1989, UMEA U MED DISSERTAT, V4, P1; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LANKINEN H, 1982, J VIROL, V41, P893, DOI 10.1128/JVI.41.3.893-900.1982; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MCLAUCHLAN J, 1983, J GEN VIROL, V64, P997, DOI 10.1099/0022-1317-64-5-997; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PARADIS H, 1991, J BIOL CHEM, V266, P9647; PARADIS H, 1988, J BIOL CHEM, V263, P16045; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5542; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; YANG FD, 1990, FEBS LETT, V272, P61, DOI 10.1016/0014-5793(90)80449-S	36	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15816	15822						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322407				2022-12-25	WOS:A1992JG11300085
J	SAINTRUF, C; VIEGASPEQUIGNOT, E; ALFANI, E; CLEMENTI, M; DUTRILLAUX, B; CARLONI, G				SAINTRUF, C; VIEGASPEQUIGNOT, E; ALFANI, E; CLEMENTI, M; DUTRILLAUX, B; CARLONI, G			COAMPLIFICATION OF TRANSCRIPTIONALLY ACTIVE EPIDERMAL GROWTH-FACTOR RECEPTOR AND RIBOSOMAL GENES IN THE HUMAN HEPATOMA-CELL LINE LI7A	ONCOGENE			English	Article							HOMOGENEOUSLY STAINING REGIONS; BREAST-CANCER; SQUAMOUS-CELL; INVERTED DUPLICATION; ENHANCED EXPRESSION; ORGANIZER REGIONS; MAMMARY-CARCINOMA; HIGH-AFFINITY; SINGLE-COPY; A431 CELLS	A high level of expression of the functional product of the epidermal growth factor receptor (EGFR) gene was detected in the human hepatocarcinoma cell line Li7A and it was found to correlate with gene amplification. The karyotype was paratriploid, with 15 rearranged chromosomes, several of which contained abnormally banded regions (ABRs). The search for DNA sequences co-amplified with the EGFR gene, using the in-gel renaturation technique, allowed us to detect an amplified DNA band (La1) of about 30 kb. This DNA was used as a probe for in situ hybridization on chromosomes, to locate the amplified segment. In normal lymphocytes, the DNA of band La1 hybridized to chromosome regions in which repetitive DNAs are located, i.e. on juxtacentromeric regions, the site of alphoid and CCATT satellite DNA, and on the short arms of acrocentrics, the site of ribosomal RNA (RNR) genes. In Li7A cells, it hybridized to the same regions and, in addition, to several chromosome arms corresponding to ABRs. The same ABRs hybridized to EGFR and RNR probes, but neither Alu sequences nor various probes for other repetitive sequences were recognized. They also exhibited nucleolus organizer region staining characterizing functionally active (RNR) genes. It was concluded that transcriptionally active genes were co-amplified in the same ABRs, although they originated from different chromosomes, i.e. chromosome 7 for EGFR and acrocentrics for RNR genes.	INST CURIE,BIOL SECT,CNRS,URA 620,26 RUE ULM,F-75231 PARIS 05,FRANCE; CNR,IST MED SPERIMENTALE,ROME,ITALY; IST SUPER SANITA,BIOL CELLULAIRE LAB,I-00161 ROME,ITALY; UNIV ANCONA,IST MICROBIOL,I-60100 ANCONA,ITALY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Consiglio Nazionale delle Ricerche (CNR); Istituto Superiore di Sanita (ISS); Marche Polytechnic University			Clementi, Massimo/F-6646-2013	Clementi, Massimo/0000-0002-7461-5898				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BERTICS PJ, 1985, J BIOL CHEM, V260, P14643; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARLIN CR, 1988, MOL CELL BIOL, V8, P25, DOI 10.1128/MCB.8.1.25; CARLONI G, 1988, VIRAL HEPATITIS HEPA, P501; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CLEMENTI M, 1989, FEBS LETT, V249, P297, DOI 10.1016/0014-5793(89)80645-3; CORNEO G, 1970, J MOL BIOL, V48, P319, DOI 10.1016/0022-2836(70)90163-4; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; DUTRILLAUX B, 1981, PRATIQUE ANAL CHROMO, P7; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; FUKUMOTO M, 1988, P NATL ACAD SCI USA, V85, P6846, DOI 10.1073/pnas.85.18.6846; GIL GN, 1981, NATURE, V293, P305; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; HOLDEN JJA, 1985, CANCER GENET CYTOGEN, V14, P131, DOI 10.1016/0165-4608(85)90224-9; HUNTS J, 1985, JPN J CANCER RES, V76, P663; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KNOWLES AF, 1985, BIOCHEM BIOPH RES CO, V126, P8, DOI 10.1016/0006-291X(85)90564-9; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LAFAGE M, 1990, GENE CHROMOSOME CANC, V2, P171, DOI 10.1002/gcc.2870020302; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAVOLPE A, 1985, J MOL BIOL, V183, P213, DOI 10.1016/0022-2836(85)90214-1; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LOONEY JE, 1987, MOL CELL BIOL, V7, P569, DOI 10.1128/MCB.7.2.569; MADEN BEH, 1987, BIOCHEM J, V246, P519, DOI 10.1042/bj2460519; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MILLER OJ, 1979, CHROMOSOMA, V71, P183, DOI 10.1007/BF00292822; MILLER OJ, 1981, GENES CHROMOSOMES NE, P253; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; PASSANANTI C, 1987, EMBO J, V6, P1697, DOI 10.1002/j.1460-2075.1987.tb02420.x; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RIEHMAN RA, 1976, P NATL ACAD SCI USA, V73, P3589; Roninson I B, 1987, Methods Enzymol, V151, P332, DOI 10.1016/S0076-6879(87)51028-X; SAINTRUF C, 1990, GENE CHROMOSOME CANC, V2, P18, DOI 10.1002/gcc.2870020105; SAINTRUF C, 1991, CANCER GENET CYTOGEN, V52, P27, DOI 10.1016/0165-4608(91)90050-5; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P666; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWARZACHER HG, 1983, HUM GENET, V63, P89, DOI 10.1007/BF00291525; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; STURANI E, 1988, MOL CELL BIOL, V8, P1345, DOI 10.1128/MCB.8.3.1345; THEILLET C, 1990, ONCOGENE, V5, P147; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; VIEGASPEQUIGNOT E, 1990, CANCER GENET CYTOGEN, V49, P37, DOI 10.1016/0165-4608(90)90162-4; WAYE JS, 1987, MOL CELL BIOL, V7, P349, DOI 10.1128/MCB.7.1.349	56	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1557	1565						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321403				2022-12-25	WOS:A1992JE81300012
J	ODENWALLER, R; MADDIPATI, KR; MARNETT, LJ				ODENWALLER, R; MADDIPATI, KR; MARNETT, LJ			DETECTION OF A HIGHER OXIDATION-STATE OF MANGANESE-PROSTAGLANDIN ENDOPEROXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR GLAND MICROSOMES; ELECTRON-PARAMAGNETIC-RES; H SYNTHASE; PEROXIDASE-ACTIVITIES; CYCLOOXYGENASE; BIOSYNTHESIS; PURIFICATION; SYNTHETASE; HEME; HYDROPEROXIDE	Addition of arachidonic acid or 5-phenyl-4-pentenylhydroperoxide to manganese-prostaglandin endoperoxide synthase (Mn-PGH synthase) produced a species with an absorbance maximum at 418 nm. This maximum is distinct from those of resting enzyme (3 7 2 and 468 nm) or reduced enzyme (434 nm). The formation of the 418 nm-absorbing species was observed immediately after the addition of hydroperoxide to enzyme but only after a 10-s lag period following addition of arachidonate. Mn-PGH synthase exhibited a peroxidase activity that was 0.8% that of Fe-PGH synthase. Addition of peroxidase reducing substrates to the oxidized form of Mn-PGH synthase diminished the absorbance at 418 nm. In the case of N,N,N',N'-tetramethylphenylenediamine, reduction of the 418 nm-absorbing species was accompanied by an increase in absorbance at 610 nm due to the oxidized form of the amine. Thus, the spectral and chemical properties of the 418 nm-absorbing species are consistent with its existence as a higher oxidation state of Mn-PGH synthase. Kinetic analysis indicated that formation of the higher oxidation state preceded or was coincident with oxygenation of the fatty acid substrate, eicosa-11, 14-dienoic acid. The cyclooxygenase activity of Mn-PGH synthase was inhibited by the combination of glutathione and human plasma glutathione peroxidase at a glutathione peroxidase concentration 227-fold lower than the concentration that inhibited Fe-PGH synthase. The results suggest that Mn-PGH synthase forms a higher oxidation state following reaction with hydroperoxides added exogenously or generated endogenously from polyunsaturated fatty acid substrates. This higher oxidation state functions in the peroxidase catalytic cycle of Mn-PGH synthase, and its formation appears to be essential for activation of the cyclooxygenase catalytic cycle.	VANDERBILT UNIV, MED CTR,SCH MED,DEPT BIOCHEM, AB HANCOCK JR MEM LAB CANC RES,CTR MOLEC TOXICOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT CHEM, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University			Maddipati, Krishna Rao/H-3569-2019	Maddipati, Krishna Rao/0000-0003-1445-791X	NCI NIH HHS [CA-47479] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAZZARD JT, 1991, J AM CHEM SOC, V113, P8956, DOI 10.1021/ja00023a059; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; HORI H, 1987, BIOCHIM BIOPHYS ACTA, V912, P74, DOI 10.1016/0167-4838(87)90249-4; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1985, BIOCHEM BIOPH RES CO, V130, P918, DOI 10.1016/0006-291X(85)90504-2; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1991, DEV ONCOL, V67, P205; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS W, 1971, ANN NY ACAD SCI, V180, P107, DOI 10.1111/j.1749-6632.1971.tb53190.x; Lands WE, 1984, FREE RADICAL BIO MED, P39; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MADDIPATI KR, 1987, J BIOL CHEM, V262, P17398; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; O'Brien P J, 1980, Adv Prostaglandin Thromboxane Res, V6, P145; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; OGINO N, 1978, J BIOL CHEM, V253, P5061; PORTER NA, 1986, ACCOUNTS CHEM RES, V19, P262, DOI 10.1021/ar00129a001; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; ROTH GJ, 1981, J BIOL CHEM, V256, P18; RUF HH, 1984, FEBS LETT, V165, P293, DOI 10.1016/0014-5793(84)80189-1; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SMITH WL, 1991, ACTA LIPIDS LIPID ME, V1083, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WELLER PE, 1985, ARCH BIOCHEM BIOPHYS, V243, P633, DOI 10.1016/0003-9861(85)90541-7; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YONETANI T, 1969, J BIOL CHEM, V244, P4580; YONETANI T, 1968, J BIOL CHEM, V243, P3996	45	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13863	13869						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321128				2022-12-25	WOS:A1992JD32500015
J	KUMAR, G; SHARMA, AK; JAYARAMAN, K				KUMAR, G; SHARMA, AK; JAYARAMAN, K			INCORPORATION OF BRDU IN A DNA FRAGMENT MAY AFFECT PROTEIN DNA INTERACTIONS IN A SITE-DEPENDENT MANNER	ONCOGENE			English	Article							BINDING	DNA in which BrdU has been randomly incorporated is used to identify specific DNA-binding proteins. We show here that the location of BrdU incorporation in a DNA fragment can significantly affect specific protein-DNA interactions and thereby identification of DNA-binding proteins. We suggest that a radioactive labeled unmodified DNA, rather than BrdU-incorporated DNA, be used for identifying DNA-binding proteins by UV cross-linking.	WAYNE STATE UNIV,SCH MED,CTR MOLEC BIOL,DETROIT,MI 48201; EASTMAN KODAK CO,RES LABS,NEW YORK,NY 14601	Wayne State University; Eastman Kodak	KUMAR, G (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,540 E CANFIELD,DETROIT,MI 48201, USA.			Sharma, Arun/0000-0002-2777-8731	NIGMS NIH HHS [GM 38228, GM 08167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN JK, 1989, J VIROL, V63, P5425, DOI 10.1128/JVI.63.12.5425-5439.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; KUMAR G, 1984, J ORG CHEM, V49, P4905, DOI 10.1021/jo00199a032; SHARMA AK, 1991, FEBS LETT, V281, P272, DOI 10.1016/0014-5793(91)80409-V	7	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1453	1455						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320247				2022-12-25	WOS:A1992HZ97100027
J	THEROUX, SJ; TAGLIENTISIAN, C; NAIR, N; COUNTAWAY, JL; ROBINSON, HL; DAVIS, RJ				THEROUX, SJ; TAGLIENTISIAN, C; NAIR, N; COUNTAWAY, JL; ROBINSON, HL; DAVIS, RJ			INCREASED ONCOGENIC POTENTIAL OF ERBB IS ASSOCIATED WITH THE LOSS OF A COOH-TERMINAL DOMAIN SERINE PHOSPHORYLATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR RECEPTOR; TISSUE-SPECIFIC TRANSFORMATION; C-ERBB; KINASE-ACTIVITY; TYROSINE; VIRUS; EXPRESSION; SEQUENCES; DNA	The erbB oncogene encodes an altered form of the epidermal growth factor (EGF) receptor that lacks the extracellular ligand binding domain. This oncogene is exclusively leukemogenic. However, an increase in oncogenic potential and a broadening of the tissue specificity of tumor formation occurs after retroviral transduction of erbB. The increased oncogenic potential correlates with structural alterations within the erbB gene. One common event is the deletion of a serine phosphorylation site located within the COOH-terminal domain. This site of phosphorylation has been demonstrated to be required for EGF-induced desensitization of signaling by the EGF receptor (Countaway, J. L., Nairn, A. C., and Davis, R. J. (1992) J. Biol. Chem. 267, 1129-1140). Here we show that the mutation of erbB at this negative regulatory serine phosphorylation site causes fibroblast transformation in vitro and is associated with an increased oncogenic potential in vivo.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT PATHOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT MOLEC GENET & MICROBIOL,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA27223, CA53396, CA39240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027223, P01CA039240, R03CA053396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; ISRAEL MA, 1979, J VIROL, V29, P990, DOI 10.1128/JVI.29.3.990-996.1979; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; THEROUX SJ, 1992, NUCLEIC ACIDS RES, V20, P915, DOI 10.1093/nar/20.4.915; TRACY SE, 1985, J VIROL, V54, P304, DOI 10.1128/JVI.54.2.304-310.1985; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	19	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7967	7970						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349014				2022-12-25	WOS:A1992HQ18500003
J	FISHER, MT; STADTMAN, ER				FISHER, MT; STADTMAN, ER			OXIDATIVE MODIFICATION OF ESCHERICHIA-COLI GLUTAMINE-SYNTHETASE - DECREASES IN THE THERMODYNAMIC STABILITY OF PROTEIN-STRUCTURE AND SPECIFIC CHANGES IN THE ACTIVE-SITE CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-FUNCTION OXIDATION; LIMITED PROTEOLYSIS; BINDING-SITE; DIVALENT CATIONS; OXYGEN RADICALS; DEGRADATION; INACTIVATION; TURNOVER; MODEL	Metal catalyzed oxidation of specific amino acid residues has been proposed to be an important physiological mechanism of marking proteins for proteolytic degradation. After initial oxidative inactivation of dodecameric Escherichia coli glutamine synthetase (GS), the integrity of the GS active site and protein structure was assessed by monitoring ATP binding, observing a susceptibility of GS to tryptic cleavage, and comparative thermodynamic analysis. The tryptic cleavage rates of an active site linked central loop were significantly accelerated for the oxidized conformer. This tryptic cleavage was essentially prevented in the presence of glutamate for native GS but not for the oxidized conformer. The integrity of the ATP binding site in the oxidized GS was substantially altered as indicated by the reduction in fluorescence enhancement associated with ATP binding. Decreases in the free energies of quaternary protein structure and subunit interactions due to oxidative modification were determined by temperature and urea induced unfolding equilibrium measurements. Comparative thermal stability measurements of a partial unfolding transition indicated that the loss in stabilization free energy for the oxidized GS conformer was 1.3 kcal/mol dodecamer. Under alkaline conditions, the urea-induced disruption of quaternary and tertiary structures of oxidized and native GS were examined. This comparative analysis revealed that the free energies of the subunit interactions and unfolding of the dissociated monomers for oxidized GS were decreased by 1.5 and 1.7 kcal/mol, respectively. Our results suggest that small free energy decreases in GS protein structural stability of only 1-2 kcal/mol may be responsible for the selective proteolytic turnover of the oxidized GS.	NHLBI, BIOCHEM LAB, ENZYMES SECT, BLDG 3, RM 222, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ABELL LM, 1989, BIOCHEMISTRY-US, V28, P1940; ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; ATKINS WM, 1991, BIOCHEMISTRY-US, V30, P3406, DOI 10.1021/bi00228a008; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; CIARDI JE, 1973, BIOCHEMISTRY-US, V12, P4321, DOI 10.1021/bi00746a004; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; DAUTRYVARSAT A, 1979, J BIOL CHEM, V254, P3124; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DELGADO CJ, 1972, BIOCHIM BIOPHYS ACTA, V268, P121, DOI 10.1016/0005-2744(72)90205-7; FARBER JM, 1986, J BIOL CHEM, V261, P4574; FISHER MT, 1990, FASEB J, V4, P1996; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FULKS RM, 1985, BIOCHIM BIOPHYS ACTA, V843, P214, DOI 10.1016/0304-4165(85)90142-4; GINSBURG A, 1991, BIOCHEMISTRY-US, V30, P9421, DOI 10.1021/bi00103a005; Ginsburg A., 1972, ADV PROTEIN CHEM, V26, P1; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HUNT JB, 1972, BIOCHEMISTRY-US, V11, P3723, DOI 10.1021/bi00770a010; HUNT JB, 1975, ARCH BIOCHEM BIOPHYS, V166, P102, DOI 10.1016/0003-9861(75)90370-7; HUNT JB, 1980, J BIOL CHEM, V255, P590; LEE YS, 1988, J BIOL CHEM, V263, P6643; LEI M, 1979, J BIOL CHEM, V254, P3129; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; MERKLER DJ, 1987, BIOCHEMISTRY-US, V26, P7805, DOI 10.1021/bi00398a041; MILLER RE, 1974, ARCH BIOCHEM BIOPHYS, V163, P155, DOI 10.1016/0003-9861(74)90465-2; MONROE DM, 1984, BIOCHEMISTRY-US, V23, P4565, DOI 10.1021/bi00315a009; MOSS J, 1990, J BIOL CHEM, V265, P21056; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; Oliver CN, 1982, EXPERIENCES BIOCH PE, P233; OLIVER CN, 1981, THESIS J HOPKINS U B; PINKOFSKY HB, 1984, J BIOL CHEM, V259, P9616; POLLACK S, 1977, BIOCHIM BIOPHYS ACTA, V497, P481, DOI 10.1016/0304-4165(77)90205-7; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; RHEE SG, 1989, ADV ENZYMOL RAMB, V62, P37; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; ROGERS SW, 1988, J BIOL CHEM, V263, P19850; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; SEGAL A, 1972, ARCH BIOCHEM BIOPHYS, V152, P367, DOI 10.1016/0003-9861(72)90226-3; Shapiro B., 1970, METHOD ENZYMOL, V17A, P910, DOI 10.1016/0076-6879(71)17305-3; SHRAKE A, 1989, BIOCHEMISTRY-US, V28, P6281, DOI 10.1021/bi00441a021; SPENCER RD, 1970, J CHEM PHYS, V52, P1654, DOI 10.1063/1.1673201; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; TIMMONS RB, 1974, BIOCHEMISTRY-US, V13, P4479, DOI 10.1021/bi00719a002; WOOLFOLK CA, 1966, ARCH BIOCHEM BIOPHYS, V116, P177, DOI 10.1016/0003-9861(66)90026-9; WOOLFOLK CA, 1967, ARCH BIOCHEM BIOPHYS, V122, P174, DOI 10.1016/0003-9861(67)90137-3; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681	50	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1872	1880						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346137				2022-12-25	WOS:A1992HA48500074
J	CHOUDHURY, K; SUNDARAMOORTHY, M; MAURO, JM; POULOS, TL				CHOUDHURY, K; SUNDARAMOORTHY, M; MAURO, JM; POULOS, TL			CONVERSION OF THE PROXIMAL HISTIDINE LIGAND TO GLUTAMINE RESTORES ACTIVITY TO AN INACTIVE MUTANT OF CYTOCHROME-C PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ELECTRON-TRANSFER; RADICAL SITE; COMPOUND-I; TRYPTOPHAN-51; MUTAGENESIS; REDUCTION; KINETICS; ES	Using site-directed mutagenesis, a double mutant in yeast cytochrome c peroxidase (CCP) has been constructed where the proximal ligand, His175, has been converted to glutamine and the neighboring Trp191 has been converted to phenylalanine. The refined 2.4-angstrom crystal structure of the double mutant shows that the Gln175 side chain is within coordination distance of the heme iron atom and that Phe191 occupies the same position as Trp191 in the native enzyme with very little rearrangement outside the immediate vicinity of the mutations. Consistent with earlier work, we find that the single mutant, His175 --> Gln, is fully active under steady state assay conditions and that as reported earlier (Mauro et al., 1988), the Trp191 --> Phe mutant exhibits only <0.05% activity. However, the double mutant, His175 --> Gln/Phe191 --> Phe, exhibits 20% wild type activity. Since it is known that the Trp191 --> Phe mutant is inactive because it can no longer transfer electrons from ferrocytochrome c, changing the nature of the proximal ligand is able to restore this activity. These results raise interesting questions regarding the mechanism of interprotein electron transfer reactions.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT BIOCHEM & MOLEC BIOL,IRVINE,CA 92717; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; GEORGE WASHINGTON UNIV,DEPT GENET,WASHINGTON,DC 20052	University of California System; University of California Irvine; University of California System; University of California Irvine; George Washington University	POULOS, TL (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.				NIGMS NIH HHS [GM 42614] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042614] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEUNG E, 1986, P NATL ACAD SCI USA, V83, P1330, DOI 10.1073/pnas.83.5.1330; CONKLIN KT, 1988, J AM CHEM SOC, V110, P3345, DOI 10.1021/ja00219a001; DARWISH K, 1991, PROTEIN ENG, V4, P701, DOI 10.1093/protein/4.6.701; EDWARDS SE, 1991, J BIOL CHEM, V265, P2588; ERMAN JE, 1975, BIOCHIM BIOPHYS ACTA, V393, P343, DOI 10.1016/0005-2795(75)90060-4; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; HAZZARD JT, 1987, BIOCHEMISTRY-US, V26, P2836, DOI 10.1021/bi00384a027; HAZZARD JT, 1991, J AM CHEM SOC, V113, P3856; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MCLENDON G, 1985, J AM CHEM SOC, V107, P7811, DOI 10.1021/ja00312a002; PURCELL WL, 1976, J AM CHEM SOC, V98, P7033, DOI 10.1021/ja00438a049; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SPANGLER BD, 1986, BIOCHIM BIOPHYS ACTA, V872, P155; SUNDARAMOORTHY M, 1991, J AM CHEM SOC, V113, P7755, DOI 10.1021/ja00020a044; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; Yonetani T., 1976, ENZYMES, P345; [No title captured]	21	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25656	25659						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334481				2022-12-25	WOS:A1992KD07300010
J	SETH, A; GONZALEZ, FA; GUPTA, S; RADEN, DL; DAVIS, RJ				SETH, A; GONZALEZ, FA; GUPTA, S; RADEN, DL; DAVIS, RJ			SIGNAL TRANSDUCTION WITHIN THE NUCLEUS BY MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DNA-BINDING ACTIVITY; C-MYC ONCOGENE; MYELIN BASIC-PROTEIN; CELL-CYCLE; TRANSCRIPTION FACTOR; MESSENGER-RNA; PHOSPHORYLATION SITE; TYROSINE KINASE; GENE-PRODUCT	The nucleus is an important target of signal transduction by growth factor receptors that stimulate mitogen-activated protein (MAP) kinases. We tested the hypothesis that MAP kinases have a signaling role within the nucleus by examining the effect of the expression of a human MAP kinase isoform (p41mapk) in tissue culture cells. The expressed p41mapk was found to be localized in both the cytoplasmic and nuclear compartments of the cells. Significantly, the expression of p41mapk caused an increase in the phosphorylation of a nuclear substrate: Ser62 of c-Myc. Phosphorylation at Ser62 stimulated the activity of the NH2-terminal transactivation domain of c-Myc. Thus, p41mapk causes the phosphorylation and regulation of a physiologically significant nuclear target of signal transduction. These data establish that at least one MAP kinase isoform has a nuclear role during signal transduction.	UNIV MASSACHUSETTS, SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED, 373 PLANTAT ST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA58396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DEAN M, 1986, J BIOL CHEM, V261, P9161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FONG YL, 1989, J BIOL CHEM, V264, P16759; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Penn L J, 1990, Semin Cancer Biol, V1, P69; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAKSELA K, 1992, ONCOGENE, V7, P347; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SYMONDS G, 1989, ONCOGENE, V4, P285; THEROUX SJ, 1992, NUCLEIC ACIDS RES, V20, P915, DOI 10.1093/nar/20.4.915; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAITZ W, 1991, ONCOGENE, V6, P29; WATERS CM, 1991, ONCOGENE, V6, P797; WELLS KS, 1989, HANDBOOK OF BIOLOGICAL CONFOCAL MICROSCOPY, REVISED EDITION, P27; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	89	322	322	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24796	24804						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332967				2022-12-25	WOS:A1992KA26300096
J	YEO, EJ; WAGNER, C				YEO, EJ; WAGNER, C			PURIFICATION AND PROPERTIES OF PANCREATIC GLYCINE N-METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE BINDING-PROTEIN; RAT-LIVER CYTOSOL; METABOLISM; CDNA	Glycine N-methyltransferase (GNMT) regulates the ratio of S-adenosylmethionine to S-adenosylhomocysteine. It is very abundant in liver cytosol and earlier studies have shown it to be present in high concentrations in the pancreas. We have previously reported that liver GNMT is allosterically inhibited by 5-methyltetrahydrofolate pentaglutamate (5-CH3-H4PteGlu5), and proposed that this represents a metabolic control mechanism which links the de novo synthesis of methyl groups to the methylating ability of the liver. We now report that pancreatic GNMT also contains bound folate in vivo. Purified pancreatic GNMT is inhibited by reduced folate polyglutamates in vitro. The K(I) for the synthetic (R,S)5-CH3-H4PteGlu5 is 2.4 x 10(-7) M. The natural (S) form of 5-CH3-H4PteGlu5 is tightly bound and has a K(d) of 1.3 x 10(-7) M. One mole is bound per enzyme tetramer. These studies suggest that GNMT is important in the regulation of methyl group metabolism in the pancreas as well as in the liver.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37212 USA; VET AFFAIRS MED CTR, NASHVILLE, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System					NIDDK NIH HHS [DK15289] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015289, R01DK015289] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALAGHI M, 1992, J NUTR, V122, P1391, DOI 10.1093/jn/122.7.1391; BALINSKY BI, 1970, INTRO EMBRYOLOGY, P528; BLUMENSTEIN J, 1960, BIOCHEM BIOPH RES CO, V3, P259, DOI 10.1016/0006-291X(60)90235-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK RJ, 1981, ARCH BIOCHEM BIOPHYS, V208, P358, DOI 10.1016/0003-9861(81)90520-8; COOK RJ, 1989, J NUTR, V119, P612, DOI 10.1093/jn/119.4.612; DELISLE RC, 1984, AM J PHYSIOL, V246, pG411, DOI 10.1152/ajpgi.1984.246.4.G411; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; HOOVER KL, 1986, J NUTR, V116, P1569, DOI 10.1093/jn/116.8.1569; KERR SJ, 1972, J BIOL CHEM, V247, P4248; KRUMDIECK CL, 1983, VITAM HORM, V40, P45, DOI 10.1016/S0083-6729(08)60432-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; OGAWA H, 1982, J BIOL CHEM, V257, P3447; OGAWA H, 1984, BIOCHEM BIOPH RES CO, V124, P44, DOI 10.1016/0006-291X(84)90913-6; PARSA I, 1970, AM J PATHOL, V59, P1; SUZUKI N, 1980, ARCH BIOCHEM BIOPHYS, V199, P236, DOI 10.1016/0003-9861(80)90277-5; WAGNER C, 1989, J BIOL CHEM, V264, P9638; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; WAGNER C, 1985, NUTR REV, V43, P293; WAGNER C, 1984, P NATL ACAD SCI USA, V81, P3631; WALZEM RL, 1988, J NUTR, V118, P1343, DOI 10.1093/jn/118.11.1343; WITTWER AJ, 1980, P NATL ACAD SCI-BIOL, V77, P4484, DOI 10.1073/pnas.77.8.4484; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZAPPIA V, 1983, METHOD ENZYMOL, V94, P57	27	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24669	24674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332963				2022-12-25	WOS:A1992KA26300078
J	MATSUMURA, M; SAITO, Y; JACKSON, MR; SONG, ES; PETERSON, PA				MATSUMURA, M; SAITO, Y; JACKSON, MR; SONG, ES; PETERSON, PA			INVITRO PEPTIDE BINDING TO SOLUBLE EMPTY CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES ISOLATED FROM TRANSFECTED DROSOPHILA-MELANOGASTER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA MOLECULES; IMMUNOGENIC PEPTIDES; ANTIGENIC PEPTIDES; SELF-PEPTIDES; MHC MOLECULES; HEAVY-CHAIN; T-CELLS; BETA-2-MICROGLOBULIN; REGION; GENE	A soluble form of a mouse class I major histocompatibility antigen (H-2K(b)) has been expressed in transfected Drosophila melanogaster cells. These molecules were efficiently secreted (up to 4 mg/liter) as noncovalent heterodimers and purified to homogeneity from cell supernatants. The isolated soluble K(b) molecules were devoid of endogenous peptides. Using these molecules, we have characterized the K(b) heavy chain-beta2-microglobulin (beta2m) assembly as well as peptide binding in vitro. In detergent-free solution the heavy chains readily re-assembled with beta2m even in the absence of peptides. Kinetic analyses showed that the peptide binding is rapid and reversible and dependent on the heavy chains being assembled with beta2m. Likewise, peptide dissociated from K(b) molecules without the displacement of beta2m. Equilibrium binding experiments using various peptides confirmed that octapeptides bind to K(b) molecules with the highest affinity and form the most stable complexes. However, in contrast to earlier studies, the amino-terminal positioning of peptide to K(b) molecules was more crucial than the carboxyl-terminal positioning and amidation of the peptide carboxylate did not affect the binding. Soluble K(b) molecules could selectively bind allele-specific peptides among a mixture of randomly synthesized octapeptides in vitro; however, no dominant residue was observed at the carboxyl terminus of bound peptides. This suggests that the previously observed hydrophobic residues at the carboxyl terminus of peptides may reflect the specificity of enzyme(s) or protein(s) involved in peptide processing in vivo.			MATSUMURA, M (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA97489] Funding Source: Medline; NIAID NIH HHS [AI31965] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031965] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HARLOW E, 1988, ANTIBODIES LABORATOR; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY F, 1990, INT IMMUNOL, V2, P995, DOI 10.1093/intimm/2.10.995; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MULLER R, 1983, METHOD ENZYMOL, V92, P589; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; PARKER KC, 1992, J BIOL CHEM, V267, P5451; REYES AA, 1982, P NATL ACAD SCI-BIOL, V79, P3270, DOI 10.1073/pnas.79.10.3270; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002	48	135	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23589	23595						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331092				2022-12-25	WOS:A1992JZ23900028
J	ALLAN, GF; LENG, XH; TSAI, SY; WEIGEL, NL; EDWARDS, DP; TSAI, MJ; OMALLEY, BW				ALLAN, GF; LENG, XH; TSAI, SY; WEIGEL, NL; EDWARDS, DP; TSAI, MJ; OMALLEY, BW			HORMONE AND ANTIHORMONE INDUCE DISTINCT CONFORMATIONAL-CHANGES WHICH ARE CENTRAL TO STEROID-RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; HUMAN PROGESTERONE-RECEPTOR; CELL GLUCOCORTICOID RECEPTOR; DNA-BINDING STATE; ESTROGEN-RECEPTOR; DEPENDENT PHOSPHORYLATION; DEOXYRIBONUCLEIC-ACID; GENE-TRANSCRIPTION; RESPONSE ELEMENT; BREAST-CANCER	Antihormones are potent antagonists of hormone action in vivo, but the mechanism underlying this antagonism is not understood. Several steroid hormones transform (activate) their receptors from a cytosolic, non-DNA binding 8 S sedimentation form to a nuclear, DNA binding 4 S form. Transformation is accompanied by the loss of associated heat shock proteins. We have previously demonstrated that an additional hormone-dependent step, separate from heat shock protein removal, is required for activation of the human progesterone receptor. We have devised an assay in which the human progesterone receptor translated in vitro binds to its specific response element in a hormone-dependent manner. As assessed by limited proteolytic digestion, hormone treatment of the nascent receptor induces a dramatic conformational change within the protein. The conformational change occurs in the absence of DNA and renders the entire ligand binding domain resistant to digestion by proteases. A number of antiprogestins, including RU486, induce an equally dramatic, but distinct, structural alteration of the ligand binding domain. The distinction centers upon the final 30 to 40 amino acids at the carboxyl terminus. The conformational change can be induced by ligand prior to dissociation of the 8 S complex and is not induced by heat shock protein removal in the absence of hormone. Remarkably, virtually identical hormone-induced conformational changes were detected following proteolytic analysis of in vitro translated retinoic acid receptors. Our data indicate that the sole necessary event in the activation of steroid receptors is conformational modification by the ligand. Furthermore, we conclude that transcriptional inactivation of steroid receptors by antihormones involves the induction of an inappropriate structural conformation at the extreme carboxyl terminus of the ligand binding domain.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262	Baylor College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; BAGCHI MK, 1991, MOL CELL BIOL, V11, P4998, DOI 10.1128/MCB.11.10.4998; BAKKER GH, 1990, J STEROID BIOCHEM, V37, P789, DOI 10.1016/0960-0760(90)90421-G; Baulieu E E, 1971, Recent Prog Horm Res, V27, P351; BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENIS M, 1989, J BIOL CHEM, V264, P6005; DENNER LA, 1987, J STEROID BIOCHEM, V27, P235, DOI 10.1016/0022-4731(87)90315-3; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DOUGHERTY JJ, 1982, J BIOL CHEM, V257, P4226; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HORWITZ KB, 1985, DNA-J MOLEC CELL BIO, V4, P451, DOI 10.1089/dna.1985.4.451; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LOGEAT F, 1985, BIOCHEM BIOPH RES CO, V131, P421, DOI 10.1016/0006-291X(85)91819-4; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; NEEF G, 1984, STEROIDS, V44, P349, DOI 10.1016/S0039-128X(84)80027-6; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1988, J BIOL CHEM, V263, P267; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TSAI SY, 1990, J BIOL CHEM, V265, P17055; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	67	310	319	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19513	19520						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326555				2022-12-25	WOS:A1992JP59300075
J	NAKAMURA, T; SUGINO, K; KUROSAWA, N; SAWAI, M; TAKIO, K; ETO, Y; IWASHITA, S; MURAMATSU, M; TITANI, K; SUGINO, H				NAKAMURA, T; SUGINO, K; KUROSAWA, N; SAWAI, M; TAKIO, K; ETO, Y; IWASHITA, S; MURAMATSU, M; TITANI, K; SUGINO, H			ISOLATION AND CHARACTERIZATION OF ACTIVIN RECEPTOR FROM MOUSE EMBRYONAL CARCINOMA-CELLS - IDENTIFICATION OF ITS SERINE THREONINE TYROSINE PROTEIN-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; FOLLICULAR GRANULOSA-CELL; FSH-RELEASING PROTEIN; BINDING PROTEIN; FACTOR EDF; INHIBIN; LEUKEMIA; MESODERM; GROWTH; BETA	The activin receptor protein was isolated from the mouse embryonal carcinoma (EC) cell line P 19 by three cycles of affinity chromatography on an activin A-immobilized column. The purified receptor had a specific and high affinity for activins A, AB, and B (K(d) = 345 pM), but not for transforming growth factor-beta. The purified activin receptor was identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and ligand blotting analysis as a single protein of 70 kDa. The amino acid sequence of the first 18 NH2-terminal residues revealed that the receptor is a member of the activin receptor family. The purified receptor phosphorylated itself and exogenous substrate proteins on serine, threonine, and tyrosine residues, indicating that the activin receptor is a transmembrane serine/threonine/tyrosine protein kinase. These results suggest that signal transduction of activin employs a novel pathway via a new class of cellular receptor in EC P19 cells.	INST PHYS & CHEM RES, FRONTIER RES PROGRAM, WAKU, SAITAMA 35101, JAPAN; AJINOMOTO CO INC, CENT RES LABS, KAWASAKI KU, KAWASAKI, KANAGAWA 210, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; UNIV TOKYO, FAC MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN; FUJITA HLTH UNIV, SCH MED, TOYOAKE, AICHI 47011, JAPAN	RIKEN; Ajinomoto Co Inc; University of Tokyo; Fujita Health University				Kurosawa, Nobuyuki/0000-0002-1548-4541; Iwashita, Shintaro/0000-0001-8086-9192				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BILLESTRUP N, 1990, MOL ENDOCRINOL, V4, P356, DOI 10.1210/mend-4-2-356; BROXMEYER HE, 1988, P NATL ACAD SCI USA, V85, P9052, DOI 10.1073/pnas.85.23.9052; BURGER HG, 1988, ENDOCRINOLOGY, V122, P1701; CAMPEN CA, 1988, BIOCHEM BIOPH RES CO, V157, P844, DOI 10.1016/S0006-291X(88)80326-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HASEGAWA Y, 1986, ENDOCRINOL JAPON, V33, P645; HASHIMOTO M, 1992, J BIOL CHEM, V267, P7203; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HINO M, 1989, J BIOL CHEM, V264, P10309; HSUEH AJW, 1987, P NATL ACAD SCI USA, V84, P5082, DOI 10.1073/pnas.84.14.5082; HUTCHINSON LA, 1987, BIOCHEM BIOPH RES CO, V146, P1405, DOI 10.1016/0006-291X(87)90806-0; KITAOKA M, 1988, BIOCHEM BIOPH RES CO, V157, P48, DOI 10.1016/S0006-291X(88)80009-3; KONDO S, 1989, BIOCHEM BIOPH RES CO, V161, P1267, DOI 10.1016/0006-291X(89)91379-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; MURATA M, 1988, BIOCHEM BIOPH RES CO, V151, P230, DOI 10.1016/0006-291X(88)90583-9; NAKAMURA T, 1992, J BIOL CHEM, V267, P16385; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SUGINO H, 1988, BIOCHEM BIOPH RES CO, V153, P281, DOI 10.1016/S0006-291X(88)81219-1; SUGINO H, 1988, J BIOL CHEM, V263, P15249; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	42	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18924	18928						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326537				2022-12-25	WOS:A1992JN50200101
J	MITSUI, T; INAGAKI, M; IKEBE, M				MITSUI, T; INAGAKI, M; IKEBE, M			PURIFICATION AND CHARACTERIZATION OF SMOOTH-MUSCLE MYOSIN-ASSOCIATED PHOSPHATASE FROM CHICKEN GIZZARDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; DEPENDENT PROTEIN-KINASE; LIGHT CHAIN KINASE; CELLULAR-REGULATION; OKADAIC ACID; PHOSPHORYLATION SITES; CALMODULIN BINDING; MAMMALIAN-TISSUES; CATALYTIC SUBUNIT; CALDESMON	Myosin light chain phosphatase associated with smooth muscle myosin (MAPP) was isolated from chicken gizzard. The MAPP was tightly associated with myosin and was not dissociated from myosin under the physiological ionic conditions. The phosphatase was dissociated from myosin in the presence of high MgCl2, i.e. 80 mM MgCl2. The binding site of the enzyme on the myosin molecule was the subfragment-2 region, since the enzyme did bind to the myosin rod and heavy meromyosin but not to the subfragment-1 affinity column. MAPP was purified with a heparin-Sepharose 6B column, and two activity peaks were obtained, i.e. MAPP I and MAPP II. The major activity peak, MAPP I, was further purified to homogeneity by thiophosphorylated myosin light chain-Sepharose 4B column chromatography. MAPP I was a tetramer composed of four 34-kDa subunits. The enzyme preferentially dephosphorylated the beta-subunit of phosphorylase kinase and was strongly inhibited by the heat- and acid-stable protein phosphatase inhibitor-1, whereas it was partially inhibited by the inhibitor-2. The IC50 (concentration of inhibitor giving 50% inhibition) value for the inhibition of the enzyme by okadaic acid was 70 nM which was about eight times higher than skeletal muscle type-1 and 390 times higher than type-2 protein phosphatase. These results demonstrate that the MAPP I is a type-1-like protein phosphatase, although the properties are not the same as type-I phosphatase. The properties of the myosin-associated phosphatase were distinct from the phosphatases reported previously, although some properties were similar to smooth muscle phosphatase-IV. Therefore, it is concluded that MAPP I is a novel smooth muscle protein phosphatase. Since it strongly associated with smooth muscle myosin, it is likely that MAPP I is responsible for the dephosphorylation of smooth muscle myosin in situ.	CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University			Inagaki, Masaki/B-9920-2016; Mitsui, Toshiaki/N-9773-2017	Mitsui, Toshiaki/0000-0002-9165-8830				BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V971, P163, DOI 10.1016/0167-4889(88)90188-7; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V968, P392, DOI 10.1016/0167-4889(88)90032-8; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CONTI MA, 1981, J BIOL CHEM, V256, P3178; COOKE R, 1981, CELL MUSCLE MOTILITY, V1, P99; DISALVO J, 1988, ADV PROTEIN PHOSPHAT, V1, P327; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P432; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P11242, DOI 10.1021/bi00503a013; IKEBE M, 1988, J BIOL CHEM, V263, P10698; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P2713, DOI 10.1021/bi00463a014; IKEBE M, 1991, ARCH BIOCHEM BIOPHYS, V288, P538, DOI 10.1016/0003-9861(91)90232-8; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1988, J BIOL CHEM, V263, P6432; IKEBE M, 1990, J BIOL CHEM, V265, P17607; INAGAKI M, 1990, BIOPHYS J, V57, pA145; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; ISHIHARA H, 1989, BIOPHYS J, V55, pA475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P301, DOI 10.1016/0022-2836(73)90375-6; ONISHI H, 1982, J BIOCHEM, V91, P265, DOI 10.1093/oxfordjournals.jbchem.a133684; ONISHI H, 1979, J BIOCHEM, V85, P457, DOI 10.1093/oxfordjournals.jbchem.a132352; PATO MD, 1985, J BIOL CHEM, V260, P2359; PATO MD, 1990, ARCH BIOCHEM BIOPHYS, V276, P116, DOI 10.1016/0003-9861(90)90017-S; PATO MD, 1983, EUR J BIOCHEM, V132, P283, DOI 10.1111/j.1432-1033.1983.tb07360.x; PATO MD, 1983, J BIOL CHEM, V258, P7047; PATO MD, 1983, J BIOL CHEM, V258, P7055; PATO MD, 1988, BIOCHEM J, V256, P283; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; TAKAI A, 1989, BIOCHEM J, V262, P617, DOI 10.1042/bj2620617; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WERTH DK, 1982, J BIOL CHEM, V257, P7036; YOSHIDA M, 1988, J BIOCHEM-TOKYO, V103, P380, DOI 10.1093/oxfordjournals.jbchem.a122278	47	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16727	16735						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322916				2022-12-25	WOS:A1992JJ45800111
J	ZHANG, BX; ZHAO, H; LOESSBERG, P; MUALLEM, S				ZHANG, BX; ZHAO, H; LOESSBERG, P; MUALLEM, S			ACTIVATION OF THE PLASMA-MEMBRANE CA2+ PUMP DURING AGONIST STIMULATION OF PANCREATIC ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM POOL; DEPENDENT PROTEIN-KINASE; VASCULAR SMOOTH-MUSCLE; CA-2+ PUMP; CYTOSOLIC CALCIUM; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; INOSITOL PHOSPHATES; MOBILIZING HORMONES; RAT HEPATOCYTES	The role of internal stores and plasma membrane Ca2+ pumps in controlling [Ca2+]i during agonist stimulation and their regulation by agonists are not well understood. We report here measurements of intracellular ([Ca2+]i) and extracellular ([Ca2+]o) Ca2+ concentrations in agonist-stimulated pancreatic acini in an effort to directly address these questions. Stimulation of acini suspended in Ca2+-free or Ca2+-containing medium with Ca2+ mobilizing agonists resulted in a typical transient increase in [Ca2+]i. Thapsigargin, a specific inhibitor of internal Ca2+ pumps, inhibited the rate of [Ca2+]i reduction after agonist stimulation by approximately 40%. Under the same conditions, thapsigargin had no effect on the rate of the unidirectional Ca2+ efflux across the plasma membrane as revealed by measurements of [Ca2+]o. These findings suggest that internal Ca2+ pumps actively remove Ca2+ from the cytosol during continued agonist stimulation. The correlation between the reduction in [Ca2+]i and the increase in [Ca2+]o showed that Ca2+ efflux from cells stimulated with agonist and thapsigargin represent Ca2+ efflux across the plasma membrane. Inhibition of cells exposed to agonist and thapsigargin with a specific antagonist sharply reduced the rates of the [Ca2+]i decrease and the accompanied [Ca2+]o increase. Hence, at comparable [Ca2+]i, Ca2+ efflux from stimulated cells was about 3-fold faster than that from resting cells, indicating that agonists directly activate the plasma membrane Ca2+ pump. To study the role of [Ca2+]i increase in plasma membrane Ca2+ pump activation the acini were loaded with 1,2-bis-(2-aminophenoxyethane-N,N',N')-tetraacetic acid (BAPTA), and [Ca2+]o Was measured during agonist stimulation. Surprisingly, although BAPTA completely prevented the increase in [Ca2+]i, Ca2+ efflux rate was reduced by only 34%. These findings provide the first evidence for Ca2+-independent activation of the plasma membrane Ca2+ pump by Ca2+ mobilizing agonists.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK38938] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANSAH TA, 1984, J BIOL CHEM, V259, P3442; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOINK JL, 1991, J BIOL CHEM, V266, P18206; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHEEK TR, 1989, CELL CALCIUM, V10, P213, DOI 10.1016/0143-4160(89)90004-3; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; ELY JA, 1991, J BIOL CHEM, V266, P18635; FODER B, 1981, BIOCHIM BIOPHYS ACTA, V649, P367, DOI 10.1016/0005-2736(81)90426-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; HEILMANN C, 1989, CELL CALCIUM, V10, P275, DOI 10.1016/0143-4160(89)90054-7; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KURTZ A, 1989, P NATL ACAD SCI USA, V86, P3423, DOI 10.1073/pnas.86.9.3423; LEW VL, 1982, NATURE, V298, P478, DOI 10.1038/298478a0; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MINTA A, 1989, J BIOL CHEM, V264, P8171; MUALLEM S, 1989, AM J PHYSIOL, V257, pG917, DOI 10.1152/ajpgi.1989.257.6.G917; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1989, BIOCHEM J, V263, P333, DOI 10.1042/bj2630333; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1987, BIOCHEM BIOPH RES CO, V149, P213, DOI 10.1016/0006-291X(87)91626-3; MUALLEM S, 1988, J MEMBRANE BIOL, V102, P153, DOI 10.1007/BF01870453; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; MUALLEM S, 1981, BIOCHIM BIOPHYS ACTA, V647, P73, DOI 10.1016/0005-2736(81)90296-0; NEYSES L, 1985, J BIOL CHEM, V260, P283; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1990, CELL CALCIUM, V11, P477, DOI 10.1016/0143-4160(90)90080-E; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PETERSEN OH, 1990, INTRACELLULAR CALCIU, P77; POLLOCK WK, 1987, FEBS LETT, V210, P132, DOI 10.1016/0014-5793(87)81322-4; PONAPPA BC, 1981, LIFE SCI, V28, P2395; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REEVES JP, 1990, INTRACELLULAR CALCIU, P305; RICHARDSON AE, 1984, BIOCHEM J, V219, P679, DOI 10.1042/bj2190679; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SATO K, 1988, J PHARMACOL EXP THER, V246, P294; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STUENKEL EL, 1990, AM J PHYSIOL, V258, pC289, DOI 10.1152/ajpcell.1990.258.2.C289; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; THERENOD F, 1989, J MEMBRANE BIOL, V109, P173; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WILLIAMS JA, 1980, CELL TISSUE RES, V210, P295; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819; YOSKIDA K, 1987, J BIOL CHEM, V262, P16048; ZHAO H, 1990, J BIOL CHEM, V265, P20856	59	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15419	15425						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322397				2022-12-25	WOS:A1992JG11300027
J	HEYES, MP; SAITO, K; JACOBOWITZ, D; MARKEY, SP; TAKIKAWA, O; VICKERS, JH				HEYES, MP; SAITO, K; JACOBOWITZ, D; MARKEY, SP; TAKIKAWA, O; VICKERS, JH			POLIOVIRUS INDUCES INDOLEAMINE-2,3-DIOXYGENASE AND QUINOLINIC ACID SYNTHESIS IN MACAQUE BRAIN	FASEB JOURNAL			English	Article						ENTEROVIRUS; INFLAMMATION; NEURODEGENERATION; EXCITOTOXIN; KYNURENINE PATHWAY; INDOLEAMINE 2,3-DIOXYGENASE; CYTOKINES	CENTRAL NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; INTERFERON-GAMMA; KYNURENIC ACID; INDOLEAMINE 2,3-DIOXYGENASE; HUNTINGTONS-DISEASE; RAT-BRAIN; ALZHEIMERS-DISEASE; RHESUS MACAQUES; REGIONAL BRAIN	Accumulation of the neurotoxin quinolinic acid within the brain occurs in a broad spectrum of patients with inflammatory neurologic disease and may be of neuropathologic significance. The production of quinolinic acid was postulated to reflect local induction of indoleamine 2,3-dioxygenase by cytokines in reactive cells and inflammatory cell infiltrates within the central nervous system. To test this hypothesis, macaques received an intraspinal injection of poliovirus as a model of localized inflammatory neurologic disease. Seventeen days later, spinal cord indoleamine 2,3-dioxygenase activity and quinolinic acid concentrations in spinal cord and cerebrospinal fluid were both increased in proportion to the degree of inflammatory responses and neurologic damage in the spinal cord, as well as the severity of motor paralysis. The absolute concentrations of quinolinic acid achieved in spinal cord and cerebrospinal fluid exceeded levels reported to kill spinal cord neurons in vitro. Smaller increases in indoleamine 2,3-dioxygenase activity and quinolinic acid concentrations also occurred in parietal cortex, a poliovirus target area. In frontal cortex, which is not a target for poliovirus, indoleamine 2,3-dioxygenase was not affected. A monoclonal antibody to human indoleamine 2,3-dioxygenase was, used to visualize indoleamine 2,3-dioxygenase predominantly in grey matter of poliovirus-infected spinal cord, in conjunction with local inflammatory lesions. Macrophage/monocytes in vitro synthesized [C-13(6)]quinolinic acid from [C-13(6)]L-tryptophan, particularly when stimulated by interferon-gamma. Spinal cord slices from poliovirus-inoculated macaques in vitro also converted [C-13(6)]L-tryptophan to [C-13(6)]quinolinic acid. We conclude that local synthesis of quinolinic acid from L-tryptophan within the central nervous system follows the induction of indoleamine-2,3-dioxygenase, particularly within macrophage/microglia. In view of this link between immune stimulation and the synthesis of neurotoxic amounts of quinolinic acid, we propose that attenuation of local inflammation, strategies to reduce the synthesis of neuroactive kynurenine pathway metabolites, or drugs that interfere with the neurotoxicity of quinolinic acid offer new approaches to therapy in inflammatory neurologic disease.	NIMH, CLIN SCI LAB, HISTOPHARMACOL SECT, BETHESDA, MD 20892 USA; OSAKA BIOSCI INST, DEPT CELL BIOL, OSAKA 565, JAPAN; US FDA, CTR BIOL EVALUAT & RES, PATHOBIOL & PRIMATOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); US Food & Drug Administration (FDA)	HEYES, MP (corresponding author), NIMH, CLIN SCI LAB, ANALYT BIOCHEM SECT, BLDG 10, ROOM 3D40, BETHESDA, MD 20892 USA.							ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; ARYA SC, 1977, J BIOL STAND, V5, P275, DOI 10.1016/S0092-1157(77)80012-7; BEAL MF, 1990, J NEUROCHEM, V55, P1327, DOI 10.1111/j.1471-4159.1990.tb03143.x; BIANCHI M, 1988, BIOCHEM BIOPH RES CO, V152, P237, DOI 10.1016/S0006-291X(88)80705-8; BOEGMAN RJ, 1990, ANN NY ACAD SCI, V585, P261, DOI 10.1111/j.1749-6632.1990.tb28059.x; BROUWERS P, 1991, 7TH INT C AIDS FLOR, P190; CARLIN JM, 1989, EXPERIENTIA, V45, P535, DOI 10.1007/BF01990503; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; FOSTER AC, 1984, NEUROSCI LETT, V48, P273, DOI 10.1016/0304-3940(84)90050-8; FREI K, 1988, J EXP MED, V168, P449, DOI 10.1084/jem.168.1.449; GAGNON J, 1989, SUPERANOVA ABACUS CO; GLIGHT AR, 1991, J NEUROL SCI, V103, P156; GOGATE N, 1991, J NEUROIMMUNOL, V31, P19, DOI 10.1016/0165-5728(91)90082-I; GRIFFIN DE, 1991, NEUROLOGY, V41, P69, DOI 10.1212/WNL.41.1.69; HALPERIN JJ, 1992, NEUROLOGY, V42, P43, DOI 10.1212/WNL.42.1.43; HEYES MP, 1990, J CHROMATOGR-BIOMED, V530, P108, DOI 10.1016/S0378-4347(00)82308-7; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HEYES MP, 1992, BRAIN RES, V570, P237, DOI 10.1016/0006-8993(92)90587-Y; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1991, NEUROSCI LETT, V122, P265, DOI 10.1016/0304-3940(91)90874-S; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1988, BIOMED ENVIRON MASS, V15, P291, DOI 10.1002/bms.1200150509; HEYES MP, 1988, J NEUROCHEM, V51, P1446, DOI 10.1111/j.1471-4159.1988.tb01183.x; HEYES MP, 1990, BRAIN RES, V531, P148, DOI 10.1016/0006-8993(90)90768-7; HEYES MP, 1988, NEUROCHEM INT, V13, P405, DOI 10.1016/0197-0186(88)90015-0; HEYES MP, 1990, J CEREBR BLOOD F MET, V10, P660, DOI 10.1038/jcbfm.1990.119; HEYES MP, 1990, J NEUROCHEM, V55, P338, DOI 10.1111/j.1471-4159.1990.tb08857.x; HEYES MP, 1990, ANN NEUROL, V27, P666, DOI 10.1002/ana.410270614; HEYES MP, 1991, FIDIA RES F S SERIES, P353; HEYES MP, IN PRESS J NEUROIMMU; HEYES MP, 1992, IN PRESS BRAIN; HOLMES EW, 1988, ANAL BIOCHEM, V172, P518, DOI 10.1016/0003-2697(88)90478-2; LJUNGDAHL A, 1989, J NEUROSCI RES, V24, P451, DOI 10.1002/jnr.490240316; MARTIN A, 1992, IN PRESS J NEUROPSYC; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORONI F, 1986, NEUROBIOL AGING, V7, P249, DOI 10.1016/0197-4580(86)90003-5; MOURDIAN MM, 1989, NEUROSCI LETT, V105, P233, DOI 10.1016/0304-3940(89)90043-8; OGRA PL, 1973, INFECT IMMUN, V8, P931, DOI 10.1128/IAI.8.6.931-937.1973; PERKINS MN, 1985, EXP NEUROL, V88, P570, DOI 10.1016/0014-4886(85)90072-X; PERKINS MN, 1983, BRAIN RES, V259, P172, DOI 10.1016/0006-8993(83)91084-3; PFEFFERKORN ER, 1986, MOL BIOCHEM PARASIT, V20, P215, DOI 10.1016/0166-6851(86)90101-5; PRETUS HA, 1989, J TRAUMA, V29, P1152, DOI 10.1097/00005373-198908000-00014; SAITO K, 1991, BRAIN RES, V546, P151, DOI 10.1016/0006-8993(91)91171-V; SAITO K, 1991, BRAIN RES, V540, P353, DOI 10.1016/0006-8993(91)90536-5; SAITO K, 1992, IN PRESS NEUROSCIENC; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SCHWARCZ R, 1988, ANN NEUROL, V24, P580, DOI 10.1002/ana.410240417; SPECIALE C, 1989, NEUROSCI LETT, V104, P345, DOI 10.1016/0304-3940(89)90601-0; STEINMAN L, 1990, PATHOPHYSIOLOGY BLOO, P453; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; TURSKI WA, 1989, J NEUROCHEM, V52, P1629, DOI 10.1111/j.1471-4159.1989.tb09218.x; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5; WOOD MJ, 1988, NEUROLOGICAL INFECTI; YAMAZAKI F, 1985, BIOCHEM J, V230, P635, DOI 10.1042/bj2300635	55	99	102	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1992	6	11					2977	2989		10.1096/fasebj.6.11.1322853	http://dx.doi.org/10.1096/fasebj.6.11.1322853			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1322853				2022-12-25	WOS:A1992JJ66500012
J	RANDALL, SK; KELLY, TJ				RANDALL, SK; KELLY, TJ			THE FATE OF PARENTAL NUCLEOSOMES DURING SV40 DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CHROMATIN ASSEMBLY INVITRO; NEWLY SYNTHESIZED HISTONES; NUCLEAR FACTOR-I; HYPERSENSITIVE SITES; GEL-ELECTROPHORESIS; CELL-EXTRACTS; SEGREGATION; PURIFICATION; INITIATION	The fate of parental nucleosomes during the replication of chromatin templates was studied using a modification of the cell-free SV40 DNA replication system. Plasmid DNA molecules containing the SV40 origin were assembled into chromatin with purified core histones and fractionated assembly factors derived from HeLa cells. When these templates were replicated in vitro, the resulting progeny retained a nucleosomal organization. To determine whether the nucleosomes associated with the progeny molecules resulted from displacement of parental histones during replication followed by reassembly, the replication reactions were performed in the presence of control templates. It was observed that the progeny genomes resulting from the replication of chromatin templates retained a nucleosomal structure, whereas the progeny of the control DNA molecules were not assembled into chromatin. Additional experiments, involving direct addition of histones to the replication reaction mixtures, confirmed that the control templates were not sequestered in some form which made them unavailable for nucleosome assembly. Thus, our data demonstrate that parental nucleosomes remain associated with the replicating molecules and are transferred to the progeny molecules without displacement into solution. We propose a simple model in which nucleosomes ahead of the fork are transferred intact to the newly synthesized daughter duplexes.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,PCTB RM 605,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					NCI NIH HHS [CA09139, CA40414] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040414, R01CA040414, T32CA009139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; ANNUNZIATO AT, 1984, NUCLEIC ACIDS RES, V12, P6179, DOI 10.1093/nar/12.15.6179; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; COTTEN M, 1985, NUCLEIC ACIDS RES, V13, P401, DOI 10.1093/nar/13.2.401; CUSICK ME, 1981, BIOCHEMISTRY-US, V20, P6648, DOI 10.1021/bi00526a020; CUSICK ME, 1984, J MOL BIOL, V178, P249, DOI 10.1016/0022-2836(84)90143-8; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DILWORTH SM, 1988, BIOESSAYS, V9, P44, DOI 10.1002/bies.950090203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOTEDAR R, 1989, P NATL ACAD SCI USA, V86, P6459, DOI 10.1073/pnas.86.17.6459; FOWLER E, 1982, NUCLEIC ACIDS RES, V10, P735, DOI 10.1093/nar/10.2.735; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JACKSON V, 1988, BIOCHEMISTRY-US, V27, P2109, DOI 10.1021/bi00406a044; JACKSON V, 1987, BIOCHEMISTRY-US, V26, P2315, DOI 10.1021/bi00382a037; JACKSON V, 1985, BIOCHEMISTRY-US, V24, P6930, DOI 10.1021/bi00345a027; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEFFAK IM, 1977, CELL, V12, P837, DOI 10.1016/0092-8674(77)90282-3; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MULLER U, 1978, SCIENCE, V201, P406, DOI 10.1126/science.208155; PALTER KB, 1979, J BIOL CHEM, V254, P1160; POSPELOV V, 1982, J MOL BIOL, V156, P79, DOI 10.1016/0022-2836(82)90460-0; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SEALE RL, 1976, CELL, V9, P423, DOI 10.1016/0092-8674(76)90087-8; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TACK LC, 1981, J BIOL CHEM, V256, P8821; TOOZE J, 1980, DNA TUMOR VIRUSES, P801; TSURIMOTO T, 1990, NATURE, V346, P1023; van Holde K. E., 1989, CHROMATIN, P1; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WEINTRAUB H, 1976, CELL, V9, P419, DOI 10.1016/0092-8674(76)90086-6; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	58	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14259	14265						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321140				2022-12-25	WOS:A1992JD32500073
J	LOUIS, NA; WITTERS, LA				LOUIS, NA; WITTERS, LA			GLUCOSE REGULATION OF ACETYL-COA CARBOXYLASE IN HEPATOMA AND ISLET CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COENZYME-A CARBOXYLASE; STIMULATED INSULIN-SECRETION; FATTY-ACID SYNTHESIS; MALONYL-COA; REVERSIBLE PHOSPHORYLATION; TISSUE DISTRIBUTION; GLYCOGEN-SYNTHASE; RAT-LIVER; ENZYMES	The regulation of acetyl-CoA carboxylase (ACC) by glucose and other fuel molecules has been examined in Fao Reuber hepatoma cells and Syrian hamster insulin tumor (HIT) cells in order to determine whether lipogenic substrates acutely alter ACC activity and to examine the mechanism of such regulation. In Fao cells, preincubated in simple medium without substrates, glucose addition results in a rapid activation of ACC. This effect, mimicked by other fuels such as lactate, is characterized by an increase in enzyme V(max) and a decrease in the activation constant for citrate. Several lines of evidence indicate that this activation of ACC is due to enzyme dephosphorylation, including the kinetic changes observed, the persistence of enzyme activation through ACC isolation, the necessity of inclusion of sodium fluoride/EDTA in the cell lysis buffer for preservation of the glucose-induced change, and the direct demonstration of diminished P-32-labeling of ACC after glucose exposure. Identical effects of glucose are also observed in HIT cells, although the ACC activation is smaller in magnitude and less sensitive than that observed in Fao cells. Other insulin secretagogues such as glutamine, lactate, and isobutylmethylxanthine are also found to activate HIT ACC. Others have suggested that glucose-induced changes in malonyl-CoA in beta-cells may be linked to glucose-induced insulin secretion. However, studies conducted in late passage HIT cells, which fail to secrete insulin in response to glucose stimulation, reveal the same glucose-induced activation seen in early passage, secretion-competent HIT cells, suggesting that glucose-induced ACC activation is not by itself sufficient to provoke insulin secretion. Taken together, these findings indicate that glucose and other fuel molecules can play a major role in the rapid regulation of the fatty acid synthesis pathway. The activation of fatty acid synthesis by substrate-induced ACC dephosphorylation insures ultimate fuel storage of glucose-derived carbon as fatty acid, while substrate-induced increases in the ACC product, malonyl CoA, would serve to simultaneously limit the rate of fatty acid oxidation through its allosteric regulation of carnitine palmitoyltransferase I.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,DIV ENDOCRINE METAB,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756	Dartmouth College; Dartmouth College			Louis, Nancy/G-5163-2011	Louis, Nancy/0000-0001-7092-8136	NIDDK NIH HHS [DK 35712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; EASOM RA, 1984, BIOCHEM J, V220, P733, DOI 10.1042/bj2200733; EVANS JL, 1989, BIOCHEM J, V259, P821, DOI 10.1042/bj2590821; GIFFHORN S, 1984, BIOCHEM J, V221, P343, DOI 10.1042/bj2210343; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; JAMIL H, 1987, J BIOL CHEM, V262, P638; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; MABROUK GM, 1990, J BIOL CHEM, V265, P6330; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MEGLASSON MD, 1987, DIABETES, V36, P477, DOI 10.2337/diabetes.36.4.477; MOIR AMB, 1990, BIOCHEM J, V272, P511, DOI 10.1042/bj2720511; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; SPENCE JT, 1985, BIOCHEM J, V227, P939, DOI 10.1042/bj2270939; THAMPY KG, 1988, J BIOL CHEM, V263, P6454; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; VAGELOS PR, 1963, J BIOL CHEM, V238, P533; WINDER WW, 1990, AM J PHYSIOL, V259, pE266, DOI 10.1152/ajpendo.1990.259.2.E266; WINDER WW, 1989, J APPL PHYSIOL, V67, P2230, DOI 10.1152/jappl.1989.67.6.2230; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WITTERS LA, 1983, J BIOL CHEM, V258, P5643; WITTERS LA, 1978, BIOCHEMISTRY-US, V17, P406, DOI 10.1021/bi00596a004; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	35	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2287	2293						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346395				2022-12-25	WOS:A1992HB53200029
J	XI, D; VANDOLAH, FM; RAMSDELL, JS				XI, D; VANDOLAH, FM; RAMSDELL, JS			MAITOTOXIN INDUCES A CALCIUM-DEPENDENT MEMBRANE DEPOLARIZATION IN GH4C1 PITUITARY-CELLS VIA ACTIVATION OF TYPE-L VOLTAGE-DEPENDENT CALCIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE BREAKDOWN; GAMBIERDISCUS-TOXICUS; CA-2+ TRANSPORT; BETA-SUBUNIT; DINOFLAGELLATE; MECHANISMS; RELEASE; SYNAPTOSOMES; CURRENTS; AGONIST	Maitotoxin (MTX) is a water-soluble polyether, isolated from the marine dinoflagellate Gambierdiscus toxicus, that stimulates hormone release and Ca2+ influx. We have investigated the action by which MTX induces Ca2+ influx and stimulates prolactin (PRL) release from GH4C1 rat pituitary cells. PRL release elicited by MTX is abolished in a concentration-dependent manner by nimodipine, a dihydropyridine (DHP) antagonist of type L voltage-dependent calcium channels (L-VDCC), indicating that MTX-enhanced PRL release occurs via activation of type L-VDCC. As an initial approach to determine whether MTX interacts directly with VDCC, we examined whether MTX affects the binding of [H-3]PN 200-110, a DHP class antagonist, in intact GH4C1 cells. MTX increased the B(max) of [H-3]PN 200-110 binding to intact GH4C1 cells from 4.6 +/- 0.03 to 12.5 +/- 2.2 fmol/10(6) cells, without changing the K(d). This indicates that MTX does not bind to the DHP site, but rather suggests that MTX may have an allosteric interaction with the DHP binding site. The effect of MTX on DHP binding was largely (65%) calcium-dependent. We next examined whether MTX alters the membrane potential of GH4C1 cells using the potential sensitive fluorescent dye bisoxonol. Addition of 100 ng/ml MTX to GH4C1 cells caused a membrane depolarization within 2.5 min which reached a plateau at 5 min. The MTX-induced depolarization was not prevented by substitution of impermeant choline ions for Na+. It was similarly unaffected by K+ channel blockers or by depleting the K+ chemical concentration gradient with gramicidin, a monovalent cation pore-forming agent. By contrast, low extracellular Ca2+ totally abolished the depolarization response, and nimodipine at 100 nM substantially reduced the MTX-induced membrane depolarization. These results indicate that the predominant effect of MTX on depolarization is Ca2+ influx through L-VDCC. Taken together, our results indicate that MTX-enhanced PRL release occurs exclusively via activation of type L-VDCC in GH4C1 Cells. We suggest that MTX induces an initial slow calcium conductance, possibly via an allosteric interaction with a component of the VDCC complex, which, in turn, initiates a positive feedback mechanism involving calcium-dependent membrane depolarization and voltage-dependent activation of calcium channels.	MED UNIV S CAROLINA,221 FT JOHNSON RD,CHARLESTON,SC 29412; NATL MARINE FISHERIES SERV,CHARLESTON LAB,CHARLESTON,SC 29412	Medical University of South Carolina; National Oceanic Atmospheric Admin (NOAA) - USA					NIDDK NIH HHS [DK 43107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADEN DG, 1989, FASEB J, V3, P1807, DOI 10.1096/fasebj.3.7.2565840; BARROS F, 1984, J BIOL CHEM, V259, P9404; CONN PM, 1987, MOL ENDOCRINOL, V1, P154, DOI 10.1210/mend-1-2-154; DUBINSKY JM, 1984, J GEN PHYSIOL, V83, P309, DOI 10.1085/jgp.83.3.309; ENYEART JJ, 1985, AM J PHYSIOL, V248, pC510, DOI 10.1152/ajpcell.1985.248.5.C510; GUSOVSKY F, 1989, FEBS LETT, V243, P307, DOI 10.1016/0014-5793(89)80151-6; GUSOVSKY F, 1990, J PHARMACOL EXP THER, V252, P466; GUSOVSKY F, 1990, BIOCHEM PHARMACOL, V39, P1633, DOI 10.1016/0006-2952(90)90105-T; HAMILTON SL, 1985, SCIENCE, V229, P182, DOI 10.1126/science.3160111; HOLMES MJ, 1990, TOXICON, V28, P1159, DOI 10.1016/0041-0101(90)90116-O; KACZOROWSKI GJ, 1984, J BIOL CHEM, V259, P9395; KOBAYASHI M, 1987, BRIT J PHARMACOL, V92, P665, DOI 10.1111/j.1476-5381.1987.tb11370.x; KOCH BD, 1988, J BIOL CHEM, V263, P216; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEGRAND AM, 1984, J MOL CELL CARDIOL, V16, P663, DOI 10.1016/S0022-2828(84)80630-6; LOGIN IS, 1990, ENDOCRINOLOGY, V127, P1948, DOI 10.1210/endo-127-4-1948; MCPHERSON GA, 1985, J PHARMACOL METHOD, V13, P125, DOI 10.1016/0160-5402(85)90056-7; MURATA M, 1991, TOXICON, V29, P1085, DOI 10.1016/0041-0101(91)90206-7; SCHETTINI G, 1984, AM J PHYSIOL, V247, pE520, DOI 10.1152/ajpendo.1984.247.4.E520; SLADECZEK F, 1988, EUR J BIOCHEM, V174, P663, DOI 10.1111/j.1432-1033.1988.tb14149.x; SOERGEL DG, 1990, J PHARMACOL EXP THER, V255, P1360; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; TAGLIALATELA M, 1990, BIOCHIM BIOPHYS ACTA, V1026, P126, DOI 10.1016/0005-2736(90)90342-L; TAKAHASHI M, 1982, J BIOL CHEM, V257, P7287; TAN KN, 1984, J BIOL CHEM, V259, P418; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; UEDA H, 1986, NEUROSCI LETT, V67, P141, DOI 10.1016/0304-3940(86)90387-3; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WU CH, 1988, ANNU REV PHARMACOL, V28, P141; YASUMOTO T, 1988, J SYNTH ORG CHEM JPN, V40, P478; YOKOYAMA A, 1988, J BIOCHEM-TOKYO, V104, P184, DOI 10.1093/oxfordjournals.jbchem.a122438; YOSHII M, 1987, BRAIN RES, V424, P119, DOI 10.1016/0006-8993(87)91200-5	32	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25025	25031						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334077				2022-12-25	WOS:A1992KB60300020
J	SAIDO, TC; SHIBATA, M; TAKENAWA, T; MUROFUSHI, H; SUZUKI, K				SAIDO, TC; SHIBATA, M; TAKENAWA, T; MUROFUSHI, H; SUZUKI, K			POSITIVE REGULATION OF MU-CALPAIN ACTION BY POLYPHOSPHOINOSITIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CALMODULIN-BINDING PROTEIN; PHOSPHATIDYLINOSITOL KINASE; CA-2+-DEPENDENT PROTEASE; ACIDIC PHOSPHOLIPIDS; PLASMA-MEMBRANE; PHORBOL ESTER; CALCIUM; FODRIN; NEOMYCIN	Whether calcium is the only major intracellular activator of calpain has not yet been established. Here we demonstrate that polyphosphoinositides may play critical roles in the activation process of mu-calpain. Experiments with purified enzyme, substrate (fodrin), and phospholipids show that only polyphosphoinositides but not other lipids significantly promote calpain action in the physiological intracellular calcium range of 10(-7) to 10(-6) M. The effect of polyphosphoinositide is exerted through both a reduction in the calcium concentration required for calpain autolysis and an increase in the V(max) of the proteolytic reaction. Neomycin, a polyphosphoinositide-binding antibiotic, inhibits both polyphosphoinositide-assisted proteolysis in test tubes and calcium-induced calpain activation coupled with substrate proteolysis in intact cells. This implies that the presence of polyphosphoinositides may actually be a prerequisite for calpain activation inside cells.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,TOKYO 173,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Gerontology; University of Tokyo	SAIDO, TC (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN.		Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BURGOYNE RD, 1987, NATURE, V326, P448, DOI 10.1038/326448a0; BURNS NR, 1985, NATURE, V313, P178, DOI 10.1038/313178b0; CARLIN RK, 1983, J CELL BIOL, V96, P443, DOI 10.1083/jcb.96.2.443; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHOWDHURY MIH, 1990, VIROLOGY, V176, P126; COHEN P, 1971, J CLIN INVEST, V50, P762, DOI 10.1172/JCI106547; COLLICAN SA, 1986, J BIOL CHEM, V261, P4170; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; CROALL ED, 1990, INTRACELLULAR CALCIU, P103; Dixon M., 1979, ENZYMES, P47; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FOX JEB, 1987, BLOOD, V69, P537; GLENNEY JR, 1982, CELL, V28, P843, DOI 10.1016/0092-8674(82)90063-0; GOLL ED, 1990, INTRACELLULAR CALCIU, P103; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HATHAWAY DR, 1990, INTRACELLULAR CALCIU, P91; HENDRICKSON H S, 1971, Biochemical and Biophysical Research Communications, V44, P1258; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; IMAJOH S, 1986, J BIOCHEM-TOKYO, V99, P1281, DOI 10.1093/oxfordjournals.jbchem.a135593; INOMATA M, 1983, J BIOCHEM-TOKYO, V93, P291, DOI 10.1093/oxfordjournals.jbchem.a134166; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KOSOWER NS, 1990, INTRACELLULAR CALCIU, P163; KUBOKI M, 1987, BIOCHIM BIOPHYS ACTA, V929, P164, DOI 10.1016/0167-4889(87)90172-8; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; MATSUOKA K, 1988, SCIENCE, V239, P640; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCGOWAN EB, 1989, BIOCHEM BIOPH RES CO, V158, P432, DOI 10.1016/S0006-291X(89)80065-8; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MEIRI KF, 1990, J NEUROSCI, V10, P256; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; PALMER FBSC, 1981, J LIPID RES, V22, P1296; PONTREMOLI S, 1985, BIOCHEM BIOPH RES CO, V128, P331, DOI 10.1016/0006-291X(85)91683-3; PRENTKI M, 1986, FEBS LETT, V197, P285, DOI 10.1016/0014-5793(86)80343-X; PRPIC V, 1988, J CELL BIOL, V107, P363, DOI 10.1083/jcb.107.1.363; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; Shoeman RL, 1990, INTRACELLULAR CALCIU, P191; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SIMAN R, 1985, NATURE, V313, P225, DOI 10.1038/313225a0; SIMAN R, 1990, J NEUROSCI, V10, P2400; SIMAN R, 1990, FID RES FDN, V4, P145; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1991, BIOMED BIOCHIM ACTA, V50, P483; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; TYSNES OB, 1988, EUR J BIOCHEM, V177, P219, DOI 10.1111/j.1432-1033.1988.tb14365.x; WANG CY, 1988, BIOCHEMISTRY-US, V27, P1254, DOI 10.1021/bi00404a027; WANG CY, 1987, J BIOL CHEM, V262, P14716; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218	67	216	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24585	24590						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332961				2022-12-25	WOS:A1992KA26300066
J	WU, QY; TSIANG, M; SADLER, JE				WU, QY; TSIANG, M; SADLER, JE			LOCALIZATION OF THE SINGLE-STRANDED-DNA BINDING-SITE IN THE THROMBIN ANION-BINDING EXOSITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; HEPARIN COFACTOR-II; PROTEIN-C; BLOOD-COAGULATION; ANTICOAGULANT ACTIVITY; HUMAN THROMBOMODULIN; CRYSTAL-STRUCTURE; LYSYL RESIDUES; HIRUDIN; ACTIVATION	Single-stranded DNA molecules containing a 15-nucleotide consensus sequence have been reported to inhibit thrombin activity. The mechanism of the inhibition was studied using a consensus 15-mer oligonucleotide and two recombinant mutant thrombins: the anion-binding exosite mutant thrombin R70E, and thrombin K154A, in which the mutation was located in a surface loop outside of the exosite. The consensus 15-mer oligonucleotide inhibited both fibrinogen-clotting and platelet-activation activities of plasma-derived thrombin, recombinant wild type thrombin, and mutant thrombin K154A in a sequence-specific and dose-dependent manner, whereas it did not inhibit either activity of mutant thrombin R70E. The 15-mer oligonucleotide also inhibited thrombomodulin-dependent protein C activation by plasma-derived thrombin. In competition equilibrium binding experiments, binding of I-125-labeled diisopropyl phosphoryl-thrombin to thrombomodulin was completely inhibited by the consensus 15-mer oligonucleotide with a K(d) value of 2.68 +/- 0.16 nM. These results suggest that Arg-70 in the anion-binding exosite of thrombin is a key determinant for interaction with specific single-stranded DNA molecules, and that binding of single-stranded DNA molecules to the exosite prevents the interaction of thrombin with fibrinogen, the platelet thrombin receptor, and thrombomodulin.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	WU, QY (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED, HOWARD HUGHES MED INST,660 S EUCLID AVE, BOX 8022, ST LOUIS, MO 63110 USA.		Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X; Wu, Qingyu/0000-0003-0561-9315	NHLBI NIH HHS [HLBI14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baenziger N L, 1974, Methods Enzymol, V31, P149; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH FC, 1988, FEBS LETT, V237, P26, DOI 10.1016/0014-5793(88)80164-9; DITTMAN WA, 1990, BLOOD, V75, P329; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1989, ANN NY ACAD SCI, V556, P158; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; MANN KG, 1990, BLOOD, V76, P1; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; NOE G, 1988, J BIOL CHEM, V263, P11729; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SALEM HH, 1984, J BIOL CHEM, V259, P2246; SHEEHAN JP, 1991, BLOOD S, V78, pA277; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1992, J BIOL CHEM, V267, P7083; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	41	73	74	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24408	24412						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332957				2022-12-25	WOS:A1992KA26300043
J	HAHN, TJ; GOOCHEE, CF				HAHN, TJ; GOOCHEE, CF			GROWTH-ASSOCIATED GLYCOSYLATION OF TRANSFERRIN SECRETED BY HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM TRANSFERRIN; HAMSTER-KIDNEY CELLS; ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLGLUCOSAMINYLTRANSFERASE-V; CONCANAVALIN-A-SEPHAROSE; TRANSFORMED-CELLS; DEPENDENT CHANGES; SUGAR CHAINS; OVARY CELLS; GLYCOPEPTIDES	Growth-associated alterations in the oligosaccharide structures of transferrin secreted by HepG2 cells were examined by concanavalin A-crossed affinoimmunoelectrophoresis. Slowly dividing, confluent cultures produced transferrin with a approximately 4.5-fold greater proportion of biantennary complex-type oligosaccharides than rapidly dividing, subconfluent cultures. The activity of N-acetylglucosaminyltransferase V (GlcNAc-T V) and galactosyltransferase were measured in cell extracts from subconfluent and confluent cultures. While the activity of galactosyltransferare remained relatively constant, the activity of GIcNAc-T V was approximately 3.2-fold lower in confluent cultures than in subconfluent cultures. These results suggest that the growth-associated alteration in the oligosaccharides of transferrin is due, at least in part, to the regulation of GlcNAc-T V activity.	STANFORD UNIV, DEPT CHEM ENGN, STAUFFER BLDG 3, STANFORD, CA 94305 USA	Stanford University								BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BATES GW, 1967, J BIOL CHEM, V242, P2810; BUCK CA, 1971, BIOCHEMISTRY-US, V10, P2176, DOI 10.1021/bi00787a034; BUCK CA, 1971, SCIENCE, V172, P169, DOI 10.1126/science.172.3979.169; BUCK CA, 1970, BIOCHEMISTRY-US, V9, P4567, DOI 10.1021/bi00825a016; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPION B, 1989, EUR J BIOCHEM, V184, P405, DOI 10.1111/j.1432-1033.1989.tb15032.x; CECCARINI C, 1975, P NATL ACAD SCI USA, V72, P3139, DOI 10.1073/pnas.72.8.3139; CECCARINI C, 1975, P NATL ACAD SCI USA, V72, P2687, DOI 10.1073/pnas.72.7.2687; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EASTON EW, 1991, J BIOL CHEM, V266, P21674; Freshney R. I., 1987, CULTURE ANIMAL CELLS, P137; GREEN ED, 1988, J BIOL CHEM, V263, P25; HAHN TJ, 1991, ANAL BIOCHEM, V199, P243, DOI 10.1016/0003-2697(91)90097-D; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HEEGAARD NHH, 1989, ELECTROPHORESIS, V10, P836, DOI 10.1002/elps.1150101207; IBER H, 1990, EUR J CELL BIOL, V52, P236; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; KRUSIUS T, 1976, FEBS LETT, V71, P117, DOI 10.1016/0014-5793(76)80911-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EU, 1989, J BIOL CHEM, V264, P13848; LO JT, 1979, J BIOL CHEM, V254, P6710; MACDONALD DJ, 1978, CLIN CHIM ACTA, V87, P367, DOI 10.1016/0009-8981(78)90180-8; MACGILLIVRAY RTA, 1983, J BIOL CHEM, V258, P3543; MATLIN KS, 1988, J BIOL CHEM, V263, P11478; MEEZAN E, 1969, BIOCHEMISTRY-US, V8, P2518, DOI 10.1021/bi00834a039; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MONTREUIL J, 1975, PROTEINS IRON STORAG, P27; MURAMATSU T, 1973, J MOL BIOL, V80, P781, DOI 10.1016/0022-2836(73)90210-6; MUSGROVE E, 1987, EXP CELL RES, V172, P65, DOI 10.1016/0014-4827(87)90093-0; NILSSON LA, 1983, SCAND J IMMUNOL S, V10, P57; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; OGATA SI, 1976, NATURE, V259, P580, DOI 10.1038/259580a0; ONEIL P, 1983, ADV ENG MATH, P1054; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PAUL B, 1984, CARBOHYD RES, V126, P27, DOI 10.1016/0008-6215(84)85124-1; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PIERCE M, 1986, J BIOL CHEM, V261, P772; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; POTVIN B, 1990, J BIOL CHEM, V265, P1615; SALIER JP, 1980, ELECTROPHORESIS, V1, P193; SANTER UV, 1979, BIOCHEMISTRY-US, V18, P2533, DOI 10.1021/bi00579a016; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SIMON D, 1982, INT J CANCER, V30, P27, DOI 10.1002/ijc.2910300106; SRIVASTAVA OP, 1988, CARBOHYD RES, V179, P137, DOI 10.1016/0008-6215(88)84115-6; Trinder P., 1969, ANN CLIN BIOCHEM, V6, P24, DOI DOI 10.1177/000456326900600108; WARREN L, 1972, NATURE, V235, P276, DOI 10.1038/235275a0; WEEKE B, 1973, SCAND J IMMUNOL, V2, P37, DOI 10.1111/j.1365-3083.1973.tb03777.x; YAKIN HM, 1982, ELECTROPHORESIS, V3, P244, DOI 10.1002/elps.1150030503; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834	53	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23982	23987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331106				2022-12-25	WOS:A1992JZ23900082
J	CHANG, CN; SKALSKI, V; ZHOU, JH; CHENG, YC				CHANG, CN; SKALSKI, V; ZHOU, JH; CHENG, YC			BIOCHEMICAL PHARMACOLOGY OF (+)-2',3'-DIDEOXY-3'-THIACYTIDINE AND (-)-2',3'-DIDEOXY-3'-THIACYTIDINE AS ANTIHEPATITIS B-VIRUS AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; INVITRO; CELLS; REPLICATION; 2',3'-DIDEOXYCYTIDINE; INHIBITION; DNA	2',3'-Dideoxy-3'-thiacytidine (cis-(+/-)-SddC) was found to have potent activity against hepatitis B virus and human immunodeficiency viruses in culture. Recent studies by us identified (-)-SddC as the stereoisomer responsible for the antiviral effect and showed that the cytotoxicity was mainly caused by (+)-SddC. Metabolism studies showed that these drugs were converted to their monophosphates, diphosphates, and triphosphates. The enzyme responsible for the formation of monophosphates was identified to be cytoplasmic deoxycytidine kinase in CEM cells. Uptake studies showed that the intracellular concentration of (-)SddC and its metabolites was approximately 5-fold higher than that of (+)-SddC metabolites. (-)-SddCTP was more potent than (+)-SddCTP in inhibiting hepatitis B virus replication; (+)- and (-)-SddCTP exhibited minimal inhibition on polymerases alpha and delta, more inhibition on beta, and strong inhibition on gamma. In all cases, (+)SddCTP was found to be more inhibitory than (-)SddCTP to all four polymerases. (+)-SddCMP competed with dCTP for incorporation into DNA by DNA polymerase gamma and beta and served as a chain terminator; however, similar incorporation was not detected using other polymerases. The selective inhibition of DNA synthesis in isolated mitochondria by (+)- and (-)SddCTP suggests a stereospecificity on the mitochondrial uptake of deoxynucleoside triphosphates.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University					NATIONAL CANCER INSTITUTE [R35CA044358] Funding Source: NIH RePORTER; NCI NIH HHS [CA44358] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKISEI S, 1991, J INFECT DIS, V164, P843, DOI 10.1093/infdis/164.5.843; Ayoola E.A., 1988, B WORLD HEALTH ORGAN, V66, P443; BEACH JW, 1992, J ORG CHEM, V57, P2217, DOI 10.1021/jo00034a006; BEASLEY RP, 1981, LANCET, V2, P1129; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; CHANG CN, 1992, J BIOL CHEM, V267, P13938; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CHENG YC, 1977, BIOCHIM BIOPHYS ACTA, V481, P481, DOI 10.1016/0005-2744(77)90281-9; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; MILLER RH, 1986, P NATL ACAD SCI USA, V83, P2531, DOI 10.1073/pnas.83.8.2531; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; STARNES MC, 1987, J BIOL CHEM, V262, P988; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330	19	198	214	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22414	22420						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331054				2022-12-25	WOS:A1992JW71900067
J	DEVARAJAN, P; GILMOREHEBERT, M; BENZ, EJ				DEVARAJAN, P; GILMOREHEBERT, M; BENZ, EJ			DIFFERENTIAL TRANSLATION OF THE NA,K-ATPASE SUBUNIT MESSENGER-RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; ALPHA-SUBUNIT; RAT-BRAIN; 5'-UNTRANSLATED REGION; EUKARYOTIC RIBOSOMES; MOLECULAR-CLONING; BETA-SUBUNIT; AMINO-ACID; EXPRESSION; NA+	Expression of the Na,K-ATPase alpha and beta subunit genes is influenced by a complex series of regulatory pathways. For example, unequal amounts of subunit mRNAs are detected in several tissues, both at rest and upon mRNA induction, even though equal quantities of subunit proteins exist. We therefore studied mRNA stability and translational efficiency of wild type, deletion mutant, and chimeric subunit mRNAs in a cell-free translation system, to examine the possible role of post-transcriptional events in regulating subunit expression. Alpha1 mRNA translated less efficiently than beta1 mRNA and competed less efficiently for rate-limiting translation factors. Deletion of the 5'-untranslated region of alpha1 mRNA significantly increased its translation efficiency. Conversely, the alpha1 5'-untranslated region impaired translation of beta1 mRNA when attached upstream of the beta1 coding sequence. This region is G/C-rich, and has a complex mRNA secondary structure. We propose that differential translational efficiency may contribute to the equal biosynthesis of subunit proteins in those tissues in which subunit mRNAs either exist in unequal amounts or are differentially induced.	YALE UNIV, DEPT PEDIAT, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT INTERNAL MED, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University; Yale University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044430, R01HL024385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44430, HL-24385] Funding Source: Medline; NICHD NIH HHS [HD-22297] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; CAYANIS E, 1990, J BIOL CHEM, V265, P10829; CHAMBERS SK, 1992, IN PRESS BLOOD; GICK GG, 1988, J BIOL CHEM, V263, P16610; GICK GG, 1988, NAPLUS KPLUS PUMP B, P277; GILMOREHEBERT M, 1989, J CLIN INVEST, V84, P347, DOI 10.1172/JCI114161; GILMOREHEBERT M, 1988, NA K PUMP B, P71; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HORIUCHI T, 1990, J BIOL CHEM, V265, P6521; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ISMAILBEIGI F, 1971, J GEN PHYSIOL, V57, P710, DOI 10.1085/jgp.57.6.710; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAZ T, 1987, TRANSLATIONAL REGULA, P413; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MACKNIGHT ADC, 1977, PHYSIOL REV, V57, P510, DOI 10.1152/physrev.1977.57.3.510; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MERCER RW, 1988, NA K PUMP, P119; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; ORLOWSKI J, 1988, J BIOL CHEM, V263, P17817; OZAWA K, 1988, J BIOL CHEM, V263, P10922; PAVLAKIS GN, 1980, CELL, V19, P91, DOI 10.1016/0092-8674(80)90391-8; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; PHILIPSON KD, 1985, ANNU REV PHYSIOL, V47, P561; PRESSLEY TA, 1988, AM J PHYSIOL, V255, pC252, DOI 10.1152/ajpcell.1988.255.2.C252; SCHNEIDER JW, 1985, P NATL ACAD SCI USA, V82, P6357, DOI 10.1073/pnas.82.18.6357; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; ULLRICH KJ, 1979, ANNU REV PHYSIOL, V41, P181, DOI 10.1146/annurev.ph.41.030179.001145; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	42	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22435	22439						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331056				2022-12-25	WOS:A1992JW71900070
J	DOMENGET, C; LEPRINCE, D; PAIN, B; PEYROL, S; LI, RP; STEHELIN, D; SAMARUT, J; JURDIC, P				DOMENGET, C; LEPRINCE, D; PAIN, B; PEYROL, S; LI, RP; STEHELIN, D; SAMARUT, J; JURDIC, P			THE VARIOUS DOMAINS OF V-MYB AND V-ETS ONCOGENES OF E26 RETROVIRUS CONTRIBUTE DIFFERENTLY, BUT COOPERATIVELY, IN TRANSFORMATION OF HEMATOPOIETIC LINEAGES	ONCOGENE			English	Article							AVIAN LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; DNA-BINDING ACTIVITY; C-MYB; NUCLEOTIDE-SEQUENCE; TRANSCRIPTIONAL ACTIVATION; MITOGENIC STIMULATION; MYELOBLASTOSIS VIRUS; CELLULAR PROGENITOR; PROTO-ONCOGENE	The genome of the avian leukemia virus E26 is a unique example of association between two transcription factors which appear as a fused composite nuclear oncoprotein, P135gag-myb-ets. Previous studies with E26 have shown that v-myb and v-ets must cooperate to fully transform both erythrocytic and myelomonocytic precursor cells in vivo and in vitro. To analyse further the contribution of the individual domains involved in the transformation of various hematopoietic lineages, we have constructed several mutant viruses expressing a fusion protein with deletions in either v-myb or v-ets. We show here that integrity of the v-ets oncogene is necessary for transformation of the erythrocytic cells but that neither the DNA-binding domain nor the trans-activating domain of v-myb is required for this transformation. The DNA-binding domain of v-ets is necessary to transform myelomonocytic cells. Furthermore, we show that E26 oncoprotein also transforms granulocytic cells. The v-ets DNA-binding domain is not necessary to transform them, whereas deleting the v-myb DNA-binding domain strongly reduces transformation of these cells. These data show that the v-myb and v-ets DNA-binding domains provide quite different contributions to the transformation of various hematopoietic lineages by E26.	ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 13,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE; INST PASTEUR,F-69007 LYON,FRANCE; INST PASTEUR,ONCOL MOLEC LAB,CNRS,U1160,INSERM,UNITE 186,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Samarut, Jacques/AAD-2587-2019; Pain, Bertrand/A-7686-2015	Pain, Bertrand/0000-0002-1210-8444; Leprince, Dominique/0000-0002-1999-0775				AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENDAVID Y, 1991, CELL, V66, P381; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; CHEN JH, 1985, MOL CELL BIOL, V5, P2933; ENERBACK L, 1986, MAST CELL DIFFERENTI; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frykberg L, 1988, Oncogene Res, V3, P313; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GEGONNE A, 1992, IN PRESS NEW BIOL; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JURDIC P, 1987, J VIROL, V61, P3058, DOI 10.1128/JVI.61.10.3058-3065.1987; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LI RP, 1989, ONCOGENE RES, V5, P137; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSCOVICI MG, 1989, J VIROL, V63, P2335, DOI 10.1128/JVI.63.5.2335-2339.1989; MUSCENSKI ML, 1991, CELL, V65, P677; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAMARUT J, 1980, J CELL PHYSIOL, V105, P553, DOI 10.1002/jcp.1041050320; SCHNEIKERT J, 1992, IN PRESS ONCOGENE; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SENECA S, 1991, ONCOGENE, V6, P357; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZOBEL A, 1991, ONCOGENE, V6, P1397	65	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2231	2241						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331935				2022-12-25	WOS:A1992JW66500015
J	BRITTEN, CJ; ZHEN, RG; KIM, EJ; REA, PA				BRITTEN, CJ; ZHEN, RG; KIM, EJ; REA, PA			RECONSTITUTION OF TRANSPORT FUNCTION OF VACUOLAR H+-TRANSLOCATING INORGANIC PYROPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANT TONOPLAST; RED BEET; ATPASE; PURIFICATION; RESOLUTION; MEMBRANE; PROTEINS; SUBUNIT; VESICLES; CELL	A procedure for reconstitution of the transport function of the vacuolar H+-translocating inorganic pyrophosphatase H+-PPase; EC 3.6.1.1) prepared from etiolated hypocotyls of Vigna radiata (mung bean) is described. The method entails sequential extraction of isolated vacuolar membrane (tonoplast) vesicles with deoxycholate and CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate), combination of CHAPS-solubilized protein with phospholipid-cholesterol mixtures, diaLysis, and glycerol density gradient centrifugation. The final proteoliposome preparation is 9-fold enriched for PPase activity and active in pyrophosphate (PP(i))-energized electrogenic H+-translocation. Since both PP(i) hydrolysis and PP(i)-dependent H+-translocation by the proteoliposomes are indistinguishable from the corresponding activities of native tonoplast vesicles, the functional integrity of the H+-PPase appears to be conserved during solubilization and reconstitution. The high transport capacity and amenability of the reconstituted enzyme to both radiometric membrane filtration and fluorimetric H+-translocation assays, on the other hand, demonstrate its applicability to a broad range of transport studies. SDS-polyacrylamide gel electrophoresis of the proteoliposomes reveals selective enrichment of the M(r) 66,000, substrate-binding subunit of the H+-PPase and two additional polypeptides of M(r) 21,000 and 20,000. Although the M(r) 21,000 and 20,000 polypeptides have not been described previously, all attempts to reconstitute H+-PPase lacking these components were unsuccessful. It is therefore tentatively proposed that the M(r) 21,000 and 20,000 polypeptides, as well as the M(r) 66,000 subunit, are required for the productive reconstitution of PP(i)-dependent H+-translocation.	UNIV PENN,DEPT BIOL,INST PLANT SCI,PHILADELPHIA,PA 19104	University of Pennsylvania								Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BRITTEN CJ, 1989, FEBS LETT, V256, P200, DOI 10.1016/0014-5793(89)81748-X; DAVIES JM, 1991, FEBS LETT, V278, P66, DOI 10.1016/0014-5793(91)80085-H; DZANDU JK, 1984, P NATL ACAD SCI-BIOL, V81, P1733, DOI 10.1073/pnas.81.6.1733; KAESTNER KH, 1987, PLANT PHYSIOL, V83, P483, DOI 10.1104/pp.83.3.483; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KURKDJIAN A, 1988, EMBO J, V7, P3661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI S, 1991, J BIOL CHEM, V266, P16078; LAI SP, 1988, J BIOL CHEM, V263, P16731; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rea P.A., 1990, METHODS PLANT BIOCH, V3, P385, DOI DOI 10.1016/B978-0-12-461013-2.50035-6; REA PA, 1987, J BIOL CHEM, V262, P14745; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; REA PA, 1987, BIOCHIM BIOPHYS ACTA, V904, P1, DOI 10.1016/0005-2736(87)90080-0; REA PA, 1986, PLANT PHYSIOL, V81, P126, DOI 10.1104/pp.81.1.126; REA PA, 1985, PLANT PHYSIOL, V77, P46, DOI 10.1104/pp.77.1.46; REA PA, 1992, TRANSPORT AND RECEPTOR PROTEINS OF PLANT MEMBRANES, P25; REA PA, 1992, IN PRESS PLANT PHYSL, V100; SARAFIAN V, 1989, PLANT PHYSIOL, V91, P34, DOI 10.1104/pp.91.1.34; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SHIMMEN T, 1987, PROTOPLASMA, V136, P205, DOI 10.1007/BF01276370; WARD JM, 1992, IN PRESS PLANT PHYSL, V100	29	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21850	21855						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328246				2022-12-25	WOS:A1992JV01100091
J	MCCARTHY, SA; BICKNELL, R				MCCARTHY, SA; BICKNELL, R			RESPONSES OF PERTUSSIS TOXIN-TREATED MICROVASCULAR ENDOTHELIAL-CELLS TO TRANSFORMING GROWTH FACTOR-BETA-1 - NO EVIDENCE FOR PERTUSSIS-SENSITIVE G-PROTEIN INVOLVEMENT IN TGF-BETA SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; AKR-2B CELLS; INHIBITION; PROLIFERATION; RECEPTOR; ACTIVATION; BINDING; PROMOTER; PATHWAYS; PHOSPHORYLATION	Responses of bovine adrenal capillary endothelial cells (BACE) on treatment with transforming growth factor beta1 (TGF-beta1) have been characterized and tested for sensitivity to inactivation of pertussis toxin-sensitive G-proteins. TGF-beta1 elicited growth inhibition, monolayer remodeling, elevation of steady state mRNA levels for collagen type 1 (alpha1(1) and alpha2(1)) and TGF-beta1, and inhibition of p34cdc2 histone H1 kinase activity in BACE cells. Pertussis toxin treatment enhanced both inhibition of BACE cell [H-3]methylthymidine uptake and remodeling of BACE monolayers by TGF-beta1. These findings contrast with studies of mink lung epithelial cells, in which TGF-beta1 growth inhibition has been shown to be pertussis-sensitive. Further investigation revealed that pertussis toxin treatment of BACE cells had no effect on TGF-beta1-stimulated elevation of steady state mRNA levels for collagen type 1 (alpha1(1) or alpha2(1)) or for TGF-beta1. Analysis of p34cdc2 activity in BACE cells revealed potent inhibition of p34cdc2 histone H1 kinase activity by TGF-beta1. Pertussis toxin treatment also abolished the increase in p34cdc2 activity, however, precluding the determination of the pertussis toxin sensitivity of this response to TGF-beta1. Consistent with suppression of p34cdc2 activation, pertussis toxin also caused substantial inhibition of mitogen-stimulated BACE cell [H-3]methylthymidine uptake. It is concluded that TGF-beta1 signal transduction in this cell type does not involve G-proteins of the pertussis toxin-sensitive class and that, in view of its potent effects on DNA synthesis and p34cdc2 activation, the use of pertussis toxin to determine G-protein involvement in cytokine signalling pathways should be approached with caution.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford			McCarthy, Sarah/HCI-8963-2022	Bicknell, Roy/0000-0002-0941-8919				BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BIRNBAUMER L, 1990, ADP RIBOSYLATING TOX, P225; BIRNBAUMER L, 1990, FASEB J, V4, P3068; BOYD FT, 1989, J BIOL CHEM, V264, P2272; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; FAWCETT J, 1991, BIOCHEM BIOPH RES CO, V174, P903, DOI 10.1016/0006-291X(91)91503-5; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; HOWE PH, 1990, BIOCHEM J, V266, P537, DOI 10.1042/bj2660537; HOWE PH, 1989, CANCER RES, V49, P6024; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KUZU I, 1992, J CLIN PATHOL, V45, P143, DOI 10.1136/jcp.45.2.143; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RAYCHAUDHURY A, 1991, J CELL BIOCHEM, V47, P224, DOI 10.1002/jcb.240470307; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, P421; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; UI M, 1990, ADP RIBOSYLATING TOX, P45; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WANG XF, 1991, CELL, V67, P796; YANG LJ, 1991, J BIOL CHEM, V266, P22451	43	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21617	21622						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328241				2022-12-25	WOS:A1992JV01100057
J	RAUFMAN, JP; SINGH, L; SINGH, G; ENG, J				RAUFMAN, JP; SINGH, L; SINGH, G; ENG, J			TRUNCATED GLUCAGON-LIKE PEPTIDE-1 INTERACTS WITH EXENDIN RECEPTORS ON DISPERSED ACINI FROM GUINEA-PIG PANCREAS - IDENTIFICATION OF A MAMMALIAN ANALOG OF THE REPTILIAN PEPTIDE EXENDIN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; HELODERMA-HORRIDUM VENOM; PERFUSED RAT PANCREAS; ADENYLATE-CYCLASE; BINDING-SITES; CELL-LINE; HYPOTHALAMIC POLYPEPTIDE; PREPROGLUCAGON CONTAINS; AMYLASE RELEASE	To find mammalian analogues of exendin-4, a peptide from Helodermatidae venoms that interacts with newly discovered exendin receptors on dispersed acini from guinea pig pancreas, we examined the actions of recent additions to the vasoactive intestinal peptide/secretin/glucagon family of regulatory peptides. In every respect tested, the truncated form of glucagon-like peptide-1, GLP-1(7-36)NH2, mimicked the actions of exendin-4. Like exendin-4, GLP-1(7-36)NH2 caused an increase in acinar cAMP without stimulating amylase release. GLP-1(7-36)NH2-induced increases in cAMP were inhibited progressively by increasing concentrations of the specific exendin-receptor antagonist, exendin(9-39)NH2. In dispersed acini from guinea pig and rat pancreas, concentrations of GLP-1(7-36)NH2 that stimulated increases in cAMP caused potentiation of cholecystokinin-induced amylase release. Binding of I-125-[Y39]exendin-4 or I-125-GLP-1(7-36)NH2 to dispersed acini from guinea pig pancreas was inhibited by adding increasing concentrations of unlabeled exendin-4 or GLP-1(7-36)NH2. We conclude that the mammalian peptide GLP-1(7-36)NH2 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Exendin(9-39)NH2, a competitive antagonist of the actions of GLP-1(7-36)NH2 in pancreatic acini, may be a useful tool for examining the physiological actions of this peptide.	VET AFFAIRS MED CTR, SOLOMON A BERSON RES LAB, BRONX, NY 10468 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	RAUFMAN, JP (corresponding author), SUNY HLTH SCI CTR, DEPT MED, DIV DIGEST DIS, 450 CLARKSON AVE, BOX 1196, BROOKLYN, NY 11203 USA.							BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; BELL GI, 1983, NATURE, V304, P368, DOI 10.1038/304368a0; BUSCAIL L, 1990, FEBS LETT, V262, P77, DOI 10.1016/0014-5793(90)80158-F; CAUVIN A, 1990, PEPTIDES, V11, P773, DOI 10.1016/0196-9781(90)90194-A; CESKA M, 1969, CLIN CHIM ACTA, V26, P437, DOI 10.1016/0009-8981(69)90071-0; CHRISTOPHE JP, 1976, J BIOL CHEM, V251, P4629; COLLEN MJ, 1982, AM J PHYSIOL, V242, pG423, DOI 10.1152/ajpgi.1982.242.4.G423; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; ENG J, 1990, J BIOL CHEM, V265, P20259; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1991, BIOCHIM BIOPHYS ACTA, V1091, P356, DOI 10.1016/0167-4889(91)90200-H; FEHMANN HC, 1990, PANCREAS, V5, P361, DOI 10.1097/00006676-199005000-00019; GARDNER JD, 1982, AM J PHYSIOL, V242, pG547, DOI 10.1152/ajpgi.1982.242.6.G547; GARDNER JD, 1979, BIOCHIM BIOPHYS ACTA, V583, P491, DOI 10.1016/0304-4165(79)90066-7; GARDNER JD, 1981, PHYSL GASTROINTESTIN, P831; GOKE R, 1991, EUR J CLIN INVEST, V21, P135, DOI 10.1111/j.1365-2362.1991.tb01802.x; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; HEINRICH G, 1984, J BIOL CHEM, V259, P4082; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOOSEIN NM, 1984, FEBS LETT, V178, P83, DOI 10.1016/0014-5793(84)81245-4; KOMATSU R, 1989, DIABETES, V38, P902, DOI 10.2337/diabetes.38.7.902; KREYMANN B, 1988, FEBS LETT, V242, P167, DOI 10.1016/0014-5793(88)81008-1; KREYMANN B, 1987, LANCET, V2, P1300; LEMEUTH V, 1991, AM J PHYSIOL, V260, pG265, DOI 10.1152/ajpgi.1991.260.2.G265; LOPEZ LC, 1983, P NATL ACAD SCI-BIOL, V80, P5485, DOI 10.1073/pnas.80.18.5485; MALHOTRA R, 1991, Gastroenterology, V100, pA653; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MOJSOV S, 1990, J BIOL CHEM, V265, P8001; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; OHTAKI T, 1990, BIOCHEM BIOPH RES CO, V171, P838, DOI 10.1016/0006-291X(90)91222-E; ORSKOV C, 1988, ENDOCRINOLOGY, V123, P2009, DOI 10.1210/endo-123-4-2009; ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467, DOI 10.1210/endo-119-4-1467; PATZELT C, 1984, P NATL ACAD SCI-BIOL, V81, P5007, DOI 10.1073/pnas.81.16.5007; PEIKIN SR, 1978, AM J PHYSIOL, V235, pE743, DOI 10.1152/ajpendo.1978.235.6.E743; RAUFMAN JP, 1991, J BIOL CHEM, V266, P2897; RAUFMAN JP, 1991, REGUL PEPTIDES, V36, P121, DOI 10.1016/0167-0115(91)90200-Z; RAUFMAN JP, 1986, REGUL PEPTIDES, V14, P93, DOI 10.1016/0167-0115(86)90208-9; ROBBERECHT P, 1991, AM J PHYSIOL, V260, pG97, DOI 10.1152/ajpgi.1991.260.1.G97; SCHJOLDAGER BTG, 1989, DIGEST DIS SCI, V34, P703, DOI 10.1007/BF01540341; SCHMIDT WE, 1985, DIABETOLOGIA, V28, P704, DOI 10.1007/BF00291980; SCHMIDTLER J, 1991, AM J PHYSIOL, V260, pG940, DOI 10.1152/ajpgi.1991.260.6.G940; SHIMIZU I, 1987, ENDOCRINOLOGY, V121, P1076, DOI 10.1210/endo-121-3-1076; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C	43	102	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21432	21437						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328231				2022-12-25	WOS:A1992JV01100029
J	REINHART, J; MERTZ, LM; CATT, KJ				REINHART, J; MERTZ, LM; CATT, KJ			MOLECULAR-CLONING AND EXPRESSION OF CDNA-ENCODING THE MURINE GONADOTROPIN-RELEASING-HORMONE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LUTEINIZING-HORMONE; PITUITARY GONADOTROPHS; CELL-LINES; PROTEIN; MEMBRANE; BINDING; SITES; LOCALIZATION; METABOLISM; RESPONSES	The primary structure of the gonadotropin-releasing hormone (GnRH) receptor was determined by sequencing a functional receptor cDNA isolated by expression cloning from an immortalized murine gonadotroph (alphaT3) cell line. Positive clone pools from a cDNA library were detected by screening expressed RNA in aequorin-injected Xenopus laevis oocytes, in which receptor-mediated calcium responses were monitored as light emission during stimulation by GnRH. The isolated receptor cDNA encodes a 327-amino acid protein that has seven putative transmembrane regions and is unique among G protein-coupled receptors in that the predicted sequence lacks a carboxyl-terminal cytoplasmic domain. COS-7 cells transfected with the receptor cDNA expressed high affinity binding sites for GnRH and its agonist and antagonist analogs and exhibited calcium responses to GnRH stimulation. These, and the prominent calcium responses of Xenopus oocytes injected with receptor RNA, were inhibited by GnRH antagonists. Northern blot analysis revealed two mRNAs (1.6 and 3.5 kilobases) in alphaT3 cells and in the mouse pituitary gland, and both transcripts were shown to encode functional GnRH receptors when expressed in Xenopus oocytes. In contrast, a single 4.6-kilobase receptor mRNA was present in rat anterior pituitary gland, ovary, and Leydig cells. The absence of a carboxyl-terminal cytoplasmic domain indicates the importance of other regions of the GnRH receptor in agonist-induced signal transduction, and possibly in receptor desensitization and sequestration.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, BLDG 10, RM B1-L400, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BURGUS R, 1972, P NATL ACAD SCI USA, V69, P278, DOI 10.1073/pnas.69.1.278; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHANG JP, 1986, J BIOL CHEM, V261, P9105; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CLAYTON RN, 1979, NATURE, V282, P90, DOI 10.1038/282090a0; CLAYTON RN, 1980, P NATL ACAD SCI-BIOL, V77, P4459, DOI 10.1073/pnas.77.8.4459; CLAYTON RN, 1981, ENDOCR REV, V2, P186, DOI 10.1210/edrv-2-2-186; CLAYTON RN, 1989, J ENDOCRINOL, V120, P11, DOI 10.1677/joe.0.1200011; CURRIE AJ, 1981, BIOCHEM BIOPH RES CO, V99, P332, DOI 10.1016/0006-291X(81)91749-6; EIDNE KA, 1987, J CLIN ENDOCR METAB, V64, P425, DOI 10.1210/jcem-64-3-425; EIDNE KA, 1988, J MOL ENDOCRINOL, V1, pR9; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUARDABASSO V, 1987, AM J PHYSIOL, V252, pE357, DOI 10.1152/ajpendo.1987.252.3.E357; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAZUM E, 1981, ENDOCRINOLOGY, V109, P1281, DOI 10.1210/endo-109-4-1281; HIROTA K, 1985, J BIOL CHEM, V260, P3243; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; IWASHITA M, 1988, J MOL ENDOCRINOL, V1, P187, DOI 10.1677/jme.0.0010187; IWASHITA M, 1986, J CLIN ENDOCR METAB, V62, P127, DOI 10.1210/jcem-62-1-127; IWASHITA M, 1985, ENDOCRINOLOGY, V117, P738, DOI 10.1210/endo-117-2-738; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOUMAYE E, 1984, J BIOL CHEM, V259, P2663; LOUMAYE E, 1982, SCIENCE, V215, P983, DOI 10.1126/science.6296998; LOUMAYE E, 1982, SCIENCE, V218, P1323, DOI 10.1126/science.6293058; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MERELLI F, 1992, ENDOCRINOLOGY, V131, P925, DOI 10.1210/en.131.2.925; Millan M, 1986, Methods Enzymol, V124, P590; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NUSSENZVEIG DR, 1992, 74TH END SOC M; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PAHWA GS, 1989, BIOCHEM BIOPH RES CO, V161, P1086, DOI 10.1016/0006-291X(89)91354-5; PERRIN MH, 1989, ENDOCRINOLOGY, V124, P798, DOI 10.1210/endo-124-2-798; Sambrook J, 1989, MOL CLONING LABORATO, P1881; SANDBERG K, 1988, FEBS LETT, V241, P177, DOI 10.1016/0014-5793(88)81055-X; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALLY AV, 1971, J BIOL CHEM, V246, P7230; SEALFON SC, 1990, MOL ENDOCRINOL, V4, P119, DOI 10.1210/mend-4-1-119; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEGERSON TP, 1992, 74TH END SOC M SAN A; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	50	230	233	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21281	21284						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328228				2022-12-25	WOS:A1992JV01100003
J	SUH, K; GABEL, CA; BERGMANN, JE				SUH, K; GABEL, CA; BERGMANN, JE			IDENTIFICATION OF A NOVEL MECHANISM FOR THE REMOVAL OF GLUCOSE RESIDUES FROM HIGH MANNOSE-TYPE OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; VIRUS-G-PROTEIN; ROUGH ENDOPLASMIC-RETICULUM; ALPHA-D-MANNOSIDASE; SECRETORY GLYCOPROTEINS; VIRAL GLYCOPROTEIN; PROCESSING ENZYME; GOLGI-COMPLEX; RAT-LIVER; 1-DEOXYNOJIRIMYCIN	The role of glucosylated oligosaccharides in the biogenesis of the glycoprotein (G protein) of vesicular stomatitis virus was studied in PhaR2.7, a mouse lymphoma cell line deficient in glucosidase II activity. As expected, the great majority of cell-associated G protein remained glucosylated in PhaR2.7, and the G protein was rapidly deglucosylated in BW5147, the parental cell line. Despite these differences in glucosylation, the rates of G protein trimerization and transport to the cell surface were as rapid and efficient in the PhaR2.7 mutant as in BW5147. Surprisingly, greater than 73% of the oligosaccharides on G proteins recovered from released virions were complex-type units. The efficient processing of the G protein oligosaccharides coincided with the efficient removal of glucose residues from its oligosaccharides. After treatment with deoxynojirimycin, an inhibitor of endoplasmic reticulum (ER) glucosidases I and II, the total percentage of G protein-associated high mannose-type oligosaccharides increased more in the parental cells than in the mutant cells. Furthermore, when the G protein was retained in the ER of PhaR2.7 cells by depletion of the cellular ATP pools with carbonyl cyanide m-chlorophenylhydrazone, its oligosaccharides remained glucosylated. Under identical conditions, BW5147 cells removed the glucose residues from > 90% of the retained G protein's oligosaccharides. Thus, PhaR2.7 cells efficiently remove glucose residues from high mannose-type oligosaccharides of selected proteins using a deoxynojirimycin-insensitive enzyme located in a post-ER compartment. The existence of a second mechanism for the deglucosylation of N-linked oligosaccharides provides evidence for the important role of glucose removal in glycoprotein maturation.	COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032617, R01GM033342] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33342, GM32617] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; DATEMA R, 1981, J BIOL CHEM, V256, P1191; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; GABEL CA, 1985, J CELL BIOL, V101, P460, DOI 10.1083/jcb.101.2.460; HETTKAMP H, 1982, BIOSCIENCE REP, V2, P899, DOI 10.1007/BF01114896; HICKMAN S, 1984, J CELL BIOL, V98, P407, DOI 10.1083/jcb.98.2.407; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; KABCENELL AK, 1985, J CELL BIOL, V101, P1270, DOI 10.1083/jcb.101.4.1270; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMANSKY P, 1984, J BIOL CHEM, V259, P13129; LI E, 1978, J BIOL CHEM, V253, P7762; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MCELDUFF A, 1986, BIOCHEM J, V239, P679, DOI 10.1042/bj2390679; MICHAEL JM, 1980, ARCH BIOCHEM BIOPHYS, V199, P249, DOI 10.1016/0003-9861(80)90278-7; PARENT JB, 1986, MOL CELL BIOCHEM, V72, P21; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; REITMAN ML, 1982, J BIOL CHEM, V257, P357; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SCHLESINGER S, 1984, J BIOL CHEM, V259, P7597; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; STANELONI RJ, 1980, EUR J BIOCHEM, V105, P275, DOI 10.1111/j.1432-1033.1980.tb04498.x; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411	35	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21671	21677						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328242				2022-12-25	WOS:A1992JV01100065
J	ROESLER, WJ; MCFIE, PJ; DAUVIN, C				ROESLER, WJ; MCFIE, PJ; DAUVIN, C			THE LIVER-ENRICHED TRANSCRIPTION FACTOR D-SITE-BINDING PROTEIN ACTIVATES THE PROMOTER OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE IN HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; RAT-LIVER; REGULATORY REGION; GTP GENE; C/EBP; CAMP; IDENTIFICATION; ELEMENTS; DBP; PHOSPHORYLATION	It has been previously demonstrated that the CCAAT/enhancer-binding protein (C/EBP) trans-activates the gene coding for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) (PEPCK) and binds to several sites along the promoter. The additional observations that C/EBP is expressed in liver and follows the same developmental profile as PEPCK suggests that C/EBP plays an important role in the regulation of PEPCK gene expression. However, since C/EBP is expressed at high levels in lung, a tissue in which PEPCK is not expressed, it appears that other mechanisms are involved to provide PEPCK with high level expression in liver. We now show that the albumin promoter D-site-binding protein (DBP), a transcription factor whose expression is limited to the liver, is also able to trans-activate the PEPCK promoter through sequence-specific binding. Both recombinant DBP and C/EBP bind with highest affinity to regions located at positions -85 and -245 in the promoter, but display differences in their binding properties at other sites. Using eukaryotic expression vectors for both C/EBP and DBP, we found that with 5'-deletion mutants of the PEPCK promoter, both C/EBP and DBP exerted their effects through similar regions of the promoter. However, the use of internal deletion mutants of the promoter identified distinct differences in the mechanism of activation by C/EBP and DBP. In particular, a region of the promoter between positions -86 and -117 significantly attenuated the level of trans-activation by DBP, but not by C/EBP. Evidence presented also supports a model whereby the relative ratios of C/EBP and DBP in the cell fine-tune the expression of the PEPCK gene. These results demonstrate that DBP and C/EBP, while having similar DNA binding specificities, have distinct functional differences in the context of the PEPCK promoter. These differences, along with the developmental profiles of C/EBP and DBP, may provide a mechanistic explanation for the liver-specific as well as the developmental profile of PEPCK gene expression.			ROESLER, WJ (corresponding author), UNIV SASKATCHEWAN,COLL MED,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA.							BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; RUIZ J P G, 1978, Proceedings of the National Academy of Sciences of the United States of America, V75, P4189, DOI 10.1073/pnas.75.9.4189; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SHORT JM, 1986, J BIOL CHEM, V261, P9721; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	35	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21235	21243						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328227				2022-12-25	WOS:A1992JT97800112
J	ROUXEL, FP; HILLY, M; MAUGER, JP				ROUXEL, FP; HILLY, M; MAUGER, JP			CHARACTERIZATION OF A RAPIDLY DISSOCIATING INOSITOL 1,4,5-TRISPHOSPHATE-BINDING SITE IN LIVER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE; RAT-LIVER; CA-2+ RELEASE; TRISPHOSPHATE RECEPTOR; BINDING; HEPATOCYTES; PHOSPHATES; INHIBITION; MECHANISM; VESICLES	The binding of inositol 1,4,5-trisphosphate (InsP3) to a specific receptor induces the release of Ca2+ from an intracellular store. In the liver, the K(D) of a low affinity state of the receptor (R(L)) found at low Ca2+ concentration ([Ca2+]) is in close agreement with the EC50 of the InsP3-induced Ca2+ release. We have developed an experimental procedure for measuring the rate of dissociation of this low affinity [P-32]InsP3-receptor complex in less than 1 s. When the receptor was in the R(L) state, two kinetic components, R(L1) and R(L2), were identified with respective rate constants (k(off)) of 1-2 s-1 and 0.03-0.06 s-1. Increasing the [Ca2+] up to 1-muM transformed the receptor into the high affinity state (R(H)) and decreased the dissociation rate constant to 2.10(-2) min-1. We also investigated the time course of the transformation of the receptor from the high affinity (R(H)) to the low affinity state (R(L)) after decreasing the [Ca2+] to less than 10 nM. This reversion was dramatically dependent on temperature: at 4-degrees-C, the receptor was locked in the R(H) state, whereas at 37-degrees-C the receptor reverted to the R(L) state with a half-time of less than 1 s. The reversion from the R(H) state to the R(L) one is associated to a recovery of InSP3-induced Ca-45(2+) release on permeabilized hepatocytes. The rapid and reversible transformation of the InsP3 receptor from an active to an inactive state may be a key event in the Ca2+ release process in intact cells.	UNIV PARIS 11,INSERM,U274,BATIMENT 443,F-91405 ORSAY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHILVERS ER, 1990, BRIT J PHARMACOL, V99, P297, DOI 10.1111/j.1476-5381.1990.tb14698.x; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HINGORANI SR, 1991, ANAL BIOCHEM, V194, P204, DOI 10.1016/0003-2697(91)90169-T; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOSEPH SK, 1986, J BIOL CHEM, V261, P4658; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NILSSON T, 1988, FEBS LETT, V229, P211, DOI 10.1016/0014-5793(88)80829-9; NUNN DL, 1990, BIOCHEM J, V265, P393, DOI 10.1042/bj2650393; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PIETRI F, 1990, CELL SIGNAL, V2, P253, DOI 10.1016/0898-6568(90)90053-D; PIETRI F, 1990, J BIOL CHEM, V265, P17478; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SPAT A, 1986, BIOCHEM J, V233, P929; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; VARNEY MA, 1990, BIOCHEM J, V269, P211, DOI 10.1042/bj2690211; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	30	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20017	20023						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328191				2022-12-25	WOS:A1992JR85800044
J	PARYS, JB; SERNETT, SW; DELISLE, S; SNYDER, PM; WELSH, MJ; CAMPBELL, KP				PARYS, JB; SERNETT, SW; DELISLE, S; SNYDER, PM; WELSH, MJ; CAMPBELL, KP			ISOLATION, CHARACTERIZATION, AND LOCALIZATION OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR PROTEIN IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM RELEASE CHANNEL; SKELETAL-MUSCLE; TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; RYANODINE RECEPTOR; SMOOTH-MUSCLE; FUNCTIONAL-CHARACTERIZATION; MOUSE CEREBELLUM; SEA-URCHIN	Inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) induces Ca2+ oscillations and waves in Xenopus laevis oocytes. Microsomes from oocytes exhibit high-affinity binding for Ins(1,4,5)P3, and demonstrate Ins(1,4,5)P3-induced Ca2+ release. The Ins(1,4,5)P3 receptor (InsP3R) was purified from oocyte microsomes as a large tetrameric complex and shown to have a monomer molecular mass of 256 kDa, compared with 273 kDa for the brain InSP3R. Binding to the oocyte receptor is highly specific for Ins(1,4,5)P3 and is inhibited by heparin (IC50, 2-mu-g/ml). Immunoblot analysis revealed that an antibody against the C-terminal sequence of the brain receptor recognized the oocyte receptor. These results, in addition to the difference in pattern obtained after limited proteolysis, suggest that the oocyte InsP3R is a new shorter isoform of the mammalian brain type I InsP3R. Immunofluorescence experiments indicated the presence of the InsP3R in the cortical layer and the perinuclear endoplasmic reticulum of the oocyte. However, immunological and biochemical experiments did not reveal the presence of the ryanodine receptor. The presence of an InsP3R and the absence of a ryanodine receptor support the importance of Ins(1,4,5)P3 in Ca2+ handling by oocytes and particularly in the induction of Ca2+ oscillations and waves.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, 400 ECKSTEIN MED RES BLDG, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa				Parys, Jan/0000-0002-3591-4967; Welsh, Michael/0000-0002-1646-6206; Campbell, Kevin/0000-0003-2066-5889				ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1990, J REPROD FERTIL, P155; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DELISLE S, 1991, CELL CALCIUM, V12, P217, DOI 10.1016/0143-4160(91)90022-7; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DELISLE S, 1992, AM J PHYSIOL, V262, pC1456, DOI 10.1152/ajpcell.1992.262.6.C1456; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERGUSON JE, 1991, EXP CELL RES, V192, P352, DOI 10.1016/0014-4827(91)90052-V; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HAN JK, 1990, J CELL BIOL, V110, P1103, DOI 10.1083/jcb.110.4.1103; HENSON JH, 1989, J CELL BIOL, V109, P149, DOI 10.1083/jcb.109.1.149; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JAFFE LF, 1983, DEV BIOL, V99, P265, DOI 10.1016/0012-1606(83)90276-2; JORGENSEN AO, 1984, J CELL BIOL, V98, P1597, DOI 10.1083/jcb.98.4.1597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1991, J PHYSIOL-LONDON, V433, P207, DOI 10.1113/jphysiol.1991.sp018422; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	55	245	247	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18776	18782						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326534				2022-12-25	WOS:A1992JN50200080
J	WIEGMANN, K; SCHUTZE, S; KAMPEN, E; HIMMLER, A; MACHLEIDT, T; KRONKE, M				WIEGMANN, K; SCHUTZE, S; KAMPEN, E; HIMMLER, A; MACHLEIDT, T; KRONKE, M			HUMAN 55-KDA RECEPTOR FOR TUMOR-NECROSIS-FACTOR COUPLED TO SIGNAL TRANSDUCTION CASCADES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; PROTEIN-KINASE-C; CELL-SURFACE RECEPTORS; NATURAL-KILLER-CELLS; MOLECULAR-CLONING; FACTOR-ALPHA; MONOCLONAL-ANTIBODIES; BINDING PROTEIN; DOWN-REGULATION; SOLUBLE FORM	The numerous biological activities of tumor necrosis factor (TNF) appear mediated by two types of receptors of 55 kDa (TR55) and 75 kDa (TR75) molecular mass. To test TR55 for its individual role in signaling across the membrane, a cDNA coding for the human TR55 was stably expressed in murine 70Z/3 pre-B cells, which lack binding sites for, and proved nonresponsive to human TNF. The transfected TR55 showed high affinity ligand binding and active internalization. It is demonstrated that the TNF signaling cascade, i.e. stimulation of protein kinase C, sphingomyelinase, and phospholipase A2, production of the second messengers diacylglycerol and ceramide, can occur completely through exclusive binding of TNF to TR55. The p55 TNF-binding site functions as an autonomous TNF receptor that mediates key signal transduction pathways, which may control the majority of TNF actions.	TECH UNIV MUNICH,INST MED MIKROBIOL & HYG,TROGERSTR 4A,W-8000 MUNICH 80,GERMANY; BENDER & CO GMBH,ERNST BOEHRINGER INST,A-1121 VIENNA,AUSTRIA	Technical University of Munich			Schütze, Stefan/C-8596-2011					AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEHRL JH, 1988, J CLIN INVEST, V81, P200, DOI 10.1172/JCI113295; KIM MY, 1991, J BIOL CHEM, V266, P484; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LE TBT, 1986, J IMMUNOL, V139, P1550; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIN JX, 1987, J BIOL CHEM, V262, P11908; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAUME B, 1991, J IMMUNOL, V146, P3045; NEALE ML, 1988, IMMUNOLOGY, V64, P81; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; RALPH P, 1984, J IMMUNOL, V133, P2442; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1988, J IMMUNOL, V140, P3000; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TSUDO M, 1987, P NATL ACAD SCI USA, V84, P5394, DOI 10.1073/pnas.84.15.5394; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; YOSHIE O, 1986, J BIOCHEM-TOKYO, V100, P531, DOI 10.1093/oxfordjournals.jbchem.a121744; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	43	194	205	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17997	18001						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325455				2022-12-25	WOS:A1992JM22300079
J	FARRANCE, IKG; MAR, JH; ORDAHL, CP				FARRANCE, IKG; MAR, JH; ORDAHL, CP			M-CAT BINDING-FACTOR IS RELATED TO THE SV40 ENHANCER BINDING-FACTOR, TEF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC TRANSCRIPTION; MYOGENIC CELL-LINE; CARDIAC ACTIN GENE; TROPONIN-T-GENE; UPSTREAM REGIONS; EXPRESSION; SEQUENCE; SKELETAL; PROMOTER; MOTIF	M-CAT binding factor (MCBF) governs the activity of the cardiac troponin T gene promoter. M-CAT motifs have also been implicated recently in the regulation of other contractile protein genes which, like cardiac troponin T, do not require direct interaction with MyoD1 or related factors for activity. Mutational analysis of the M-CAT motif revealed that it can be functionally replaced by a regulatory motif of the SV40 enhancer which binds human transcription factor TEF-1. Biochemical analyses show that MCBF from muscle nuclei is indistinguishable from TEF-1 in terms of specificity of binding site recognition, fractionation on DNA-agarose, and apparent molecular weight. In addition, antibodies raised against amino- and carboxyl-terminal regions of human TEF-1 also bind to MCBF from chicken muscle. We conclude, therefore, that MCBF is closely related to TEF-1. Finally, MCBF/TEF-1 is highly enriched in the nuclei of striated muscle, as compared with other tissues, consistent with a role in muscle-specific promoter regulation.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; ANTIN PB, 1991, DEV BIOL, V143, P122, DOI 10.1016/0012-1606(91)90059-C; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRICHNIK JM, 1986, NUCLEIC ACIDS RES, V14, P1683, DOI 10.1093/nar/14.4.1683; HERRERA VLM, 1990, J BIOL CHEM, V265, P9555; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; NER SS, 1988, DNA-J MOLEC CELL BIO, V7, P127, DOI 10.1089/dna.1988.7.127; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; UETSUKI T, 1990, MOL CELL BIOL, V10, P2562, DOI 10.1128/MCB.10.6.2562; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	34	147	148	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17234	17240						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324927				2022-12-25	WOS:A1992JL05300077
J	NICKELS, JT; BUXEDA, RJ; CARMAN, GM				NICKELS, JT; BUXEDA, RJ; CARMAN, GM			PURIFICATION, CHARACTERIZATION, AND KINETIC-ANALYSIS OF A 55-KDA FORM OF PHOSPHATIDYLINOSITOL 4-KINASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; MIXED MICELLES; GEL-ELECTROPHORESIS; CELL-PROLIFERATION; TRITON X-100; PHOSPHATIDATE PHOSPHATASE; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; KINASE; PHOSPHOLIPASE-A2	A 55-kDa form of membrane-associated phosphatidylinositol 4-kinase (ATP:phosphatidylinositol 4-phosphotransferase, EC 2.7.1.67) was purified 10,166-fold from Saccharomyces cerevisiae. The purification procedure included solubilization of microsome membranes with 1% Triton X-100 followed by chromatography with DE52, hydroxylapatite I, Q-Sepharose, Mono Q, and hydroxylapatite II. The procedure resulted in a nearly homogeneous 55-kDa phosphatidylinositol 4-kinase preparation. The 55-kDa phosphatidylinositol 4-kinase and the previously purified 45-kDa phosphatidylinositol 4-kinase differed with respect to their amino acid composition, isoelectric points, and peptide maps. Furthermore, the two forms of phosphatidylinositol 4-kinase did not show an immunological relationship. Maximum 55-kDa phosphatidylinositol 4-kinase activity was dependent on magnesium (10 mM) or manganese (0.5 mM) ions and Triton X-100 at the pH optimum of 7.0. The activation energy for the reaction was 12 kcal/mol, and the enzyme was labile above 30-degrees-C. The enzyme was inhibited by thioreactive agents, MgADP, and calcium ions. A detailed kinetic analysis of the purified enzyme was performed using Triton X-100/phosphatidylinositol-mixed micelles. 55-kDa phosphatidylinositol 4-kinase activity followed saturation kinetics with respect to the bulk and surface concentrations of phosphatidylinositol and followed surface dilution kinetics. The interfacial Michaelis constant (K(m)) and the dissociation constant (K(s)) for phosphatidylinositol in the Triton X-100 micelle surface were 1.3 mol % and 0.035 mM, respectively. The K(m) for MgATP was 0.36 mM. 55-kDa phosphatidylinositol 4-kinase catalyzed a sequential reaction mechanism as indicated by the results of kinetic and isotopic exchange reactions. The enzyme bound to phosphatidylinositol before ATP and released phosphatidylinositol 4-phosphate before ADP. The enzymological and kinetic properties of the 55-kDa phosphatidylinositol 4-kinase differed significantly from those of the 45-kDa phosphatidylinositol 4-kinase. This may suggest that the two forms of phosphatidylinositol 4-kinase from S. cerevisiae are regulated differentially in vivo.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM-35655] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; Cleland W. W, 1970, ENZYMES, V2, P1; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLODZIN M, 1965, J BIOL CHEM, V240, P3771; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL JS, 1985, BIOCHEM BIOPH RES CO, V133, P844, DOI 10.1016/0006-291X(85)91211-2; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Dennis EA, 1983, ENZYMES, P307; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; DUBOIS EL, 1978, MOL GEN GENET, V164, P275, DOI 10.1007/BF00333157; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GREENBERG ML, 1983, J BACTERIOL, V153, P791, DOI 10.1128/JB.153.2.791-799.1983; HAID A, 1983, METHOD ENZYMOL, V96, P192; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; HOLLAND KM, 1988, J BACTERIOL, V170, P828, DOI 10.1128/jb.170.2.828-833.1988; JENKINS GH, 1991, BIOCHIM BIOPHYS ACTA, V1080, P11, DOI 10.1016/0167-4838(91)90105-9; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATO H, 1989, J BIOL CHEM, V264, P3116; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KUCERA GL, 1988, J BIOL CHEM, V263, P12964; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LESTER RL, 1968, J BIOL CHEM, V243, P4889; LIN YP, 1990, J BIOL CHEM, V265, P166; MCKENZIE MA, 1983, J BACTERIOL, V156, P421, DOI 10.1128/JB.156.1.421-423.1983; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; MCKENZIE MA, 1982, PARTIAL PURIFICATION; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; POOLE MA, 1985, J BACTERIOL, V161, P772, DOI 10.1128/JB.161.2.772-774.1985; PORTER FD, 1988, J BIOL CHEM, V263, P8989; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; SALTIEL AR, 1987, BIOCHEM J, V241, P759, DOI 10.1042/bj2410759; SCHOLZ G, 1991, EUR J BIOCHEM, V201, P249, DOI 10.1111/j.1432-1033.1991.tb16281.x; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1974, BIOCHIM BIOPHYS ACTA, V360, P306, DOI 10.1016/0005-2760(74)90060-5; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WETZKER R, 1991, EUR J BIOCHEM, V200, P179, DOI 10.1111/j.1432-1033.1991.tb21065.x; YAMAKAWA A, 1988, J BIOL CHEM, V263, P17555	52	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16297	16304						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322897				2022-12-25	WOS:A1992JJ45800049
J	VOZNESENSKY, AI; SCHENKMAN, JB				VOZNESENSKY, AI; SCHENKMAN, JB			THE CYTOCHROME-P450 2B4-NADPH CYTOCHROME-P450 REDUCTASE ELECTRON-TRANSFER COMPLEX IS NOT FORMED BY CHARGE-PAIRING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; WATER-SOLUBLE CARBODIIMIDE; P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; RAT-LIVER; CHEMICAL MODIFICATION; IONIC-STRENGTH; B5; MECHANISM; MEMBRANE	Attempts to covalently link NADPH-cytochrome P450 reductase to cytochrome P450 2B4 using a water-soluble carbodiimide, 1-ethyl-3-(3-dimethylisopropyl)carbodiimide, were unsuccessful, despite the fact that under the same conditions about 30% of P450 2B4 could be covalently linked with cytochrome b5 in a functionally active complex (Tamburini, P. P., and Schenkman, J. B. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 11-15). This suggested that the functional electron transfer complex between P450 2B4 and reductase is not stabilized by electrostatic forces. Raising the ionic strength of the medium is disruptive to salt bridges and was used to further test whether P450 2B4 and the reductase form charge-pairing complexes. Instead of inhibiting electron transfer, high ionic strength increased the apparent fast phase rate constant and the fraction of P450 2B4 reduced in the fast phase. The possibility that electron transfer between NADPH-cytochrome P450 reductase and P450 2B4 is diminished by charge repulsion was examined. Consistent with this hypothesis, the K(m) of P450 2B4 for reductase was decreased 26-fold by increasing the ionic strength from 10 to 100 mM sodium phosphate without affecting the V(max). The rate of benzphetamine N-demethylation also was increased by elevation of the ionic strength. Electron transfer from the reductase to other charged redox acceptors, e.g. cytochrome c and ferricyanide, was also stimulated by increased ionic strength. However, no similar stimulation was observed with the uncharged acceptor 1,4-benzoquinone. Polylysine, a polypeptide that binds to anionic sites, enhanced electron transfer from NADPH to ferricyanide and the apparent fast phase of reduction of cytochrome P450. The results are consistent with the hypothesis that charges on NADPH-cytochrome P450 reductase and cytochrome P450 decrease the stability of the electron transfer complex.	UNIV CONNECTICUT,CTR HLTH,DEPT PHARMACOL,FARMINGTON,CT 06030	University of Connecticut					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026114] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26114] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKES WL, 1989, J BIOL CHEM, V264, P6252; BACKES WL, 1992, ARCH BIOCHEM BIOPHYS, V293, P231; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BERNHARDT R, 1988, BIOMED BIOCHIM ACTA, V47, P581; BILIMORIA MH, 1973, ANN NY ACAD SCI, V212, P428, DOI 10.1111/j.1749-6632.1973.tb47612.x; BLACK SD, 1979, BIOCHEM BIOPH RES CO, V91, P1528, DOI 10.1016/0006-291X(79)91238-5; BLACK SD, 1982, FLAVINS FLAVOPROTEIN, P710; BOSTERLING B, 1982, J BIOL CHEM, V257, P4783; CHEDDAR G, 1990, ARCH BIOCHEM BIOPHYS, V278, P264; DIGNAM JD, 1975, BIOCHEM BIOPH RES CO, V63, P845, DOI 10.1016/0006-291X(75)90644-0; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; GEMZIK B, 1990, J STEROID BIOCHEM, V35, P429, DOI 10.1016/0022-4731(90)90251-M; GUM J R, 1979, Journal of Biological Chemistry, V254, P4177; HACKETT CS, 1984, J BIOL CHEM, V259, P3275; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HAZZARD JT, 1988, BIOCHEMISTRY-US, V27, P2002, DOI 10.1021/bi00406a029; JANSSON I, 1975, MOL PHARMACOL, V11, P450; JANSSON I, 1985, DRUG METAB DISPOS, V13, P453; KOPPENOL WH, 1980, BIOPHYS J, V29, P493, DOI 10.1016/S0006-3495(80)85148-4; KUNZ BC, 1991, BIOCHIM BIOPHYS ACTA, V1063, P226, DOI 10.1016/0005-2736(91)90375-I; KUNZ BC, 1983, FEBS LETT, V161, P311, DOI 10.1016/0014-5793(83)81031-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE R, 1980, EUR J BIOCHEM, V107, P441; MAUK MR, 1989, EUR J BIOCHEM, V186, P473, DOI 10.1111/j.1432-1033.1989.tb15231.x; MEANS GE, 1971, CHEM MODIFICATION PR, P144; NADLER SG, 1988, ARCH BIOCHEM BIOPHYS, V261, P418, DOI 10.1016/0003-9861(88)90358-X; NISIMOTO Y, 1985, ARCH BIOCHEM BIOPHYS, V241, P386, DOI 10.1016/0003-9861(85)90561-2; OMURA T, 1964, J BIOL CHEM, V239, P2379; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; RAW I, 1959, J BIOL CHEM, V234, P1867; SCHELLENBERG KA, 1958, J BIOL CHEM, V231, P547; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; STROBEL HW, 1989, DRUG METAB REV, V20, P519, DOI 10.3109/03602538909103558; TAMBURINI PP, 1986, ARCH BIOCHEM BIOPHYS, V245, P512, DOI 10.1016/0003-9861(86)90244-4; TAMBURINI PP, 1986, MOL PHARMACOL, V30, P178; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; TAMBURINI PP, 1986, BIOCHEM BIOPH RES CO, V134, P519, DOI 10.1016/S0006-291X(86)80451-X; TAMBURINI PP, 1984, BIOCHEMISTRY-US, V23, P4526, DOI 10.1021/bi00315a004; VERMILION JL, 1978, J BIOL CHEM, V253, P2694	41	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14669	14676						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321814				2022-12-25	WOS:A1992JF08800029
J	HAZUDA, DJ; PERRY, HC; MCCLEMENTS, WL				HAZUDA, DJ; PERRY, HC; MCCLEMENTS, WL			COOPERATIVE INTERACTIONS BETWEEN REPLICATION ORIGIN-BOUND MOLECULES OF HERPES-SIMPLEX VIRUS ORIGIN-BINDING PROTEIN ARE MEDIATED VIA THE AMINO TERMINUS OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; VIRAL-DNA REPLICATION; HELICASE-PRIMASE; GENE-PRODUCTS; TYPE-1 ORIGIN; IDENTIFICATION; COMPLEMENTATION; OVEREXPRESSION; SEQUENCE; HSV-1	The virally encoded origin binding protein (OBP) of herpes simplex virus (HSV) is required for viral DNA synthesis. OBP binds at the replication origin to initi-multienzyme replication complex (Challberg, M. D., and Kelly, T. J. (1989) Annu Rev. Biochem. 58, 671-717). OBP binds to two sites at the replication origin. The sequence-specific interaction of OBP with each binding site is localized to the major groove, and in both HSV origins the two interaction surfaces are in phase, aligned on the same face of the helix (Hazuda, D.J., Perry, H. C., Naylor, A. M., and McClements, W. L. (1991) J. Biol. Chem. 261, 24621-24625). Using native gel electrophoresis, we now demonstrate that OBP binding to the origin is highly cooperative and that cooperativity requires the putative NH2-terminal leucine zipper. Neither the phase nor orientation of the binding sites affect cooperativity, suggesting that the interaction promotes wrapping of origin DNA around the OBP multimer. A comparison of OBP DNase I footprints with the DNase I footprints of a truncated protein defective in cooperativity demonstrates that the interaction between OBPs bound at sites I and II affects the conformation of the intervening DNA, particularly when the phase or orientation of the two sites is different from wild type. OBP may elicit a unique nucleoprotein structure which facilitates unwinding of the origin and/or assembly of the replication complex. We also demonstrate that OBP can exchange binding sites, forming interduplex complexes. This property may be important for reinitiation of DNA replication.			HAZUDA, DJ (corresponding author), MERCK SHARP & DOHME LTD,DEPT VIRUS & CELL BIOL,W POINT,PA 19486, USA.							BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DABROWSKI CE, 1991, J VIROL, V65, P3140, DOI 10.1128/JVI.65.6.3140-3150.1991; DEB S, 1989, NUCLEIC ACIDS RES, V17, P2733, DOI 10.1093/nar/17.7.2733; DEB S, 1991, J VIROL, V65, P4359; DODSON MS, 1989, J BIOL CHEM, V264, P20835; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HAZUDA DJ, 1991, J BIOL CHEM, V261, P24621; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOFF A, 1988, J VIROL, V62, P4096, DOI 10.1128/JVI.62.11.4096-4103.1988; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; MARCHETTI ME, 1988, J VIROL, V62, P715, DOI 10.1128/JVI.62.3.715-721.1988; MARTIN DW, 1991, J VIROL, V65, P4359, DOI 10.1128/JVI.65.8.4359-4369.1991; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; RHODES D, 1989, PROTEIN FUNCTION PRA, P177; SCHAFFER PA, 1973, VIROLOGY, V52, P57, DOI 10.1016/0042-6822(73)90398-X; STOW ND, 1982, EMBO J, V1, P863, DOI 10.1002/j.1460-2075.1982.tb01261.x; STOW ND, 1985, J GEN VIROL, V66, P31, DOI 10.1099/0022-1317-66-1-31; STOW ND, 1983, VIROLOGY, V130, P427, DOI 10.1016/0042-6822(83)90097-1; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; WELLER SK, 1983, VIROLOGY, V130, P290, DOI 10.1016/0042-6822(83)90084-3; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	40	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14309	14315						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321142				2022-12-25	WOS:A1992JD32500080
J	SEABRA, MC; GOLDSTEIN, JL; SUDHOF, TC; BROWN, MS				SEABRA, MC; GOLDSTEIN, JL; SUDHOF, TC; BROWN, MS			RAB GERANYLGERANYL TRANSFERASE - A MULTISUBUNIT ENZYME THAT PRENYLATES GTP-BINDING PROTEINS TERMINATING IN CYS-X-CYS OR CYS-CYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; FARNESYL	Rab proteins are membrane-bound prenylated GTP-binding proteins required for the targeted movement of membrane vesicles from one organelle to another. In the current paper we have characterized and purified an enzyme that attaches geranylgeranyl residues to Rab proteins that bear the COOH-terminal sequence Cys-X-Cys (such as Rab3A) and Cys-Cys (such as Rab1A). This enzyme is designated Rab geranylgeranyl transferase (Rab GG transferase). At high salt concentrations, Rab GG transferase from rat brain cytosol separates into two components, designated A and B, both of which are required for activity. We purified Component B to apparent homogeneity and found that it contains two peptides of 60 and 38 kDa. The purified Rab GG transferase did not attach geranylgeranyl to p21H-ras-CVLL, which is prenylated by a GG transferase of the CAAX type that resembles the CAAX farnesyltransferase. Rab GG transferase was strongly inhibited by Zn2+, a cation that is absolutely required by farnesyltransferase. The Rab GG transferase was also inhibited by NaCl concentrations in excess of 100 mM. Together with previous data, the current findings indicate that mammalian cells possess at least three protein prenyltransferases (CAAX farnesyltransferase, CAAX GG transferase, and Rab GG transferase) that are specific for different classes of low molecular weight GTP-binding proteins and other proteins.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SEABRA, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; 	NHLBI NIH HHS [HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GIANNAKOURS TO, 1992, IN PRESS LIPID MODIF; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	26	299	304	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14497	14503						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321151				2022-12-25	WOS:A1992JD32500107
J	BERSTEIN, G; BLANK, JL; SMRCKA, AV; HIGASHIJIMA, T; STERNWEIS, PC; EXTON, JH; ROSS, EM				BERSTEIN, G; BLANK, JL; SMRCKA, AV; HIGASHIJIMA, T; STERNWEIS, PC; EXTON, JH; ROSS, EM			RECONSTITUTION OF AGONIST-STIMULATED PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS USING PURIFIED M1 MUSCARINIC RECEPTOR, GQ/11, AND PHOSPHOLIPASE C-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; GUANINE-NUCLEOTIDE-BINDING; ADENYLATE-CYCLASE ACTIVITY; REGULATORY COMPONENT; G-PROTEIN; ALPHA-SUBUNITS; BOVINE BRAIN; ACETYLCHOLINE-RECEPTOR; GTPASE ACTIVITY; PURIFICATION	We describe the reconstitution using purified proteins of the m1 muscarinic cholinergic pathway that activates phosphatidylinositol 4,5-bisphosphate-specific phospholipase C via the G protein G(q/11). Recombinant m1 muscarinic receptor was co-reconstituted in lipid vesicles with either hepatic G(q/11) or with cerebral alpha(q/11) and beta-gamma-subunits. The rate of [S-35]GTP-gamma-S binding to the reconstituted vesicles was stimulated 20-50-fold by agonist. Maximal receptor-catalyzed binding was 7 mol of GTP-gamma-S bound per mol of receptor. The m2 muscarinic receptor was a poor activator of G(q/11). The binding of [alpha-P-32]GTP and [gamma-P-32]GTP to m1/G(q/11) vesicles indicated that the receptor could maintain up to 40% of the total coupled G(q/11) in the GTP bound state. The rate of hydrolysis of bound GTP, 0.8 min-1, is consistent with the rate predicted from the GTP binding data but is 3-5-fold lower than rates reported for other trimeric G proteins. Agonist-stimulated photoaffinity labeling with gamma-(4-azidoanilido)-[alpha-P-32]GTP indicated that the receptor catalyzed binding to both alpha(q) and alpha-11 with about equal efficiency. Receptor-catalyzed activation of G(q/11) by GTP-gamma-S, measured as the ability to activate purified phospholipase C-beta-1, paralleled receptor-catalyzed [S-35]GTP-gamma-S binding. Co-reconstitution of receptor, G(q/11), and phospholipase C-beta-1 restored GTP-gamma-S-dependent carbachol-stimulated hydrolysis of phosphatidylinositol 4,5-bisphosphate. The m1 receptor, G(q/11), and phospholipase C-beta-1 are thus sufficient to initiate the hormonal inositol trisphosphate/diacylglycerol signaling pathway without additional proteins.	UNIV TEXAS, SW MED CTR, SW GRAD SCH BIOMED SCI, DEPT PHARMACOL, DALLAS, TX 75235 USA; VANDERBILT UNIV, MED CTR,SCH MED,SCH MED,HOWARD HUGHES MED INST, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Vanderbilt University					FOGARTY INTERNATIONAL CENTER [F05TW004475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, F32GM014489] Funding Source: NIH RePORTER; FIC NIH HHS [F05-TW04475] Funding Source: Medline; NIGMS NIH HHS [S32-GM14489, R01-GM30355] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1984, J BIOL CHEM, V259, P9351; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERSTEIN G, 1990, CURRENT ASPECTS NEUR, V1, P245; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BUJO H, 1988, FEBS LETT, V240, P95, DOI 10.1016/0014-5793(88)80346-6; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CERIONE RA, 1986, J BIOL CHEM, V261, P9514; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEDER D, 1986, EMBO J, V5, P1509, DOI 10.1002/j.1460-2075.1986.tb04390.x; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLEMING JW, 1980, J CYCLIC NUCL PROT, V6, P407; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAGA K, 1985, J BIOL CHEM, V260, P7927; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P3597; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MAY DC, 1985, J BIOL CHEM, V260, P5829; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEDERSEN SE, 1985, J BIOL CHEM, V260, P4150; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; THOMAS R, 1991, METHOD ENZYMOL, V195, P280; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	58	291	293	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8081	8088						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1341877				2022-12-25	WOS:A1992HQ18500021
J	KORNILOVA, ES; TAVERNA, D; HOECK, W; HYNES, NE				KORNILOVA, ES; TAVERNA, D; HOECK, W; HYNES, NE			SURFACE EXPRESSION OF ERBB-2 PROTEIN IS POSTTRANSCRIPTIONALLY REGULATED IN MAMMARY EPITHELIAL-CELLS BY EPIDERMAL GROWTH-FACTOR AND BY THE CULTURE DENSITY	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; BETA-CASEIN GENE; FACTOR-RECEPTOR; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; POLYACRYLAMIDE GELS; C-ERBB-2 PROTEIN; KINASE-ACTIVITY; NEU ONCOGENE; A431 CELLS	The control of expression of the erbB-2 protein was examined in two mammary epithelial cells lines, HC11 and 31E. The erbB-2 protein content varied dramatically depending upon cell density and upon the presence of epidermal growth factor (EGF) in the culture medium. The changes in protein content were not due to variation in the erbB-2 mRNA level. Analysis of the metabolic turnover of the erbB-2 protein showed that its rate of degradation was two- to threefold higher in cells growing at low density than in cells confluent for 2 days. The addition of EGF to the culture medium caused an increase in the phosphoamino acid content and an increase in the turnover of the erbB-2 protein. Cell fractionation experiments were performed, and a shift in the cellular localization of the erbB-2 protein towards the lysosomal compartment in EGF-treated HC11 cells was found. This is reflected by an increase in the degradation rate of the erbB-2 protein. These findings suggest that in mammary epithelial cells the stability of the erbB-2 protein is an important regulatory control point in determining the level of the protein. The degradation rate is sensitive to cell confluency and is controlled by EGF receptor activity.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND; ACAD SCI USSR,INST CYTOL,LENINGRAD,USSR	Friedrich Miescher Institute for Biomedical Research; Russian Academy of Sciences			taverna, daniela/J-8358-2016; Kornilova, Elena Sergeevna/AAB-5559-2021	taverna, daniela/0000-0002-6365-527X; Kornilova, Elena/0000-0002-2951-6292; Hoeck, Wolfgang/0000-0001-9142-7103				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DATI C, 1990, ONCOGENE, V5, P1001; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GAMOU S, 1987, J BIOL CHEM, V262, P6708; GORMAN RM, 1987, J CELL PHYSIOL, V131, P158, DOI 10.1002/jcp.1041310204; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULTEKIN H, 1988, ANAL BIOCHEM, V172, P320, DOI 10.1016/0003-2697(88)90451-4; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KORNILOVA ES, 1987, TSITOLOGIYA+, V29, P904; LACROIX H, 1989, ONCOGENE, V4, P145; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MUNSON PJ, 1990, CANCER RES, V50, P3947; REDMOND SMS, 1988, ONCOGENE, V2, P259; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RICHARDS J, 1982, EXP CELL RES, V141, P433, DOI 10.1016/0014-4827(82)90231-2; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; RIZZINO A, 1988, CANCER RES, V48, P4266; SAINSBURY JRC, 1987, LANCET, V1, P1398; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; TAKETANI Y, 1983, FEBS LETT, V152, P256, DOI 10.1016/0014-5793(83)80391-3; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	46	62	64	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					511	519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347917				2022-12-25	WOS:A1992HK00500017
J	SCHROEDER, C; GIBSON, L; ZENKE, M; BEUG, H				SCHROEDER, C; GIBSON, L; ZENKE, M; BEUG, H			MODULATION OF NORMAL ERYTHROID-DIFFERENTIATION BY THE ENDOGENOUS THYROID-HORMONE AND RETINOIC ACID RECEPTORS - A POSSIBLE TARGET FOR V-ERBA ONCOGENE ACTION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; CELLS-INVITRO; C-ERBA; GENE-EXPRESSION; GROWTH; TRANSFORMATION; PHENOTYPE; PROTEIN; PROLIFERATION; FIBROBLASTS	The v-erbA oncogene, a mutated version of the thyroid hormone receptor alpha (c-erbA/TR-alpha), inhibits erythroid differentiation and constitutively represses transcription of certain erythrocyte genes, suggesting a normal function of the proto-oncogene c-erbA in erythropoiesis. Here we demonstrate that the endogenous thyroid hormone receptor alpha (c-erbA/TR-alpha) and the closely related retinoic acid receptor alpha (RAR-alpha) play a role in the regulation of normal erythroid differentiation. Retinoic acid (RA) distinctly modulated the erythroid differentiation program of normal erythroid progenitors and erythroblasts reversibly transformed by a conditional tyrosine kinase oncogene. When added pulsewise to immature cells, differentiation was accelerated while more mature cells underwent premature cell death. Thyroid hormone (T3) alone caused similar but weaker effects. Interestingly, T3 strongly enhanced the action of RA, suggesting cooperative action of the two receptors in modulating erythroid differentiation. Expression of the human RAR-alpha in receptor-negative erythroblasts conferred RA-induced regulation of differentiation to the otherwise unresponsive cells, thus showing that the RAR-alpha is essential for the RA effect. Likewise, enhanced expression of exogenous c-erbA/TR-alpha in erythroblasts rendered them susceptible to modulation of differentiation by T3, suggesting a similar function of both receptors.	INST MOLEC PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Gibson, Leonie/AAM-5917-2021	Gibson, Leonie/0000-0002-0904-8145				BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; CAMPBELL A, 1985, J CLIN INVEST, V75, P2085, DOI 10.1172/JCI111928; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAINIAK N, 1986, BLOOD, V68, P1289; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOUER D, 1982, J CLIN INVEST, V69, P1039, DOI 10.1172/JCI110507; FEIN HG, 1975, MED CLIN N AM, V59, P1133, DOI 10.1016/S0025-7125(16)31963-0; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GARG LC, 1983, DIFFERENTIATION, V25, P79; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HORTON L, 1976, Q J MED, V45, P101; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOEFFLER HP, 1985, CIBA F SYMP, V113, P252; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; Maniatis T., 1982, MOL CLONING; MULDOWNEY FP, 1957, CLIN SCI, V16, P309; NAGLER A, 1986, EXP HEMATOL, V14, P60; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REIMANN J, 1979, EXP HEMATOL, V7, P45; ROBERTS RA, 1987, J CELL PHYSIOL, V132, P203, DOI 10.1002/jcp.1041320204; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	52	90	91	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					217	227						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1347914				2022-12-25	WOS:A1992HG98200003
J	POST, SR; MIYAZAKI, H; TAGER, HS				POST, SR; MIYAZAKI, H; TAGER, HS			IDENTIFICATION OF A MG2+-DEPENDENT AND GUANYL NUCLEOTIDE-DEPENDENT GLUCAGON RECEPTOR CYCLE BY USE OF PERMEABILIZED CANINE HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SLOWLY REVERSIBLE BINDING; ADENYLATE-CYCLASE; G-PROTEINS; GUANINE-NUCLEOTIDES; PLASMA-MEMBRANES; RAT-LIVER; FUNCTIONAL INTERACTIONS; REGULATORY COMPONENT; N-ETHYLMALEIMIDE	We have investigated (by use of intact and saponin-permeabilized canine hepatocytes) the roles of Mg2+ and guanyl nucleotides in regulating glucagon-receptor interactions. In contrast to intact cells, saponin-permeabilized hepatocytes bind [[I-125]iodo-Tyr10]glucagon according to a single first-order process and exhibit a single apparent dissociation constant for glucagon binding during steady-state incubations. Further analysis of the permeabilized cell system demonstrated (a) the temperature-sensitive action of Mg2+ to enhance the extent and affinity of glucagon-receptor interactions at steady-state, (b) the conversion of Mg2+-independent hormone-receptor complexes to Mg2+-dependent complexes, (c) the effect of guanyl nucleotides to inhibit specifically the Mg2+-dependent component of glucagon-receptor interactions, (d) the more rapid association of glucagon with receptor during cell incubations occurring in the presence of guanyl nucleotides or in the absence of Mg2+, and (e) the ability of guanyl nucleotides to induce both high and low affinity states of glucagon-receptor interactions. Additional experiments identified an effect of cell incubations in the presence of glucagon to limit the subsequent binding of hormone, the ability of GDP, GTP, or guanosine-5'-3-O-(thio)triphosphate (GTP-gammaS) to dissociate previously bound glucagon, and a specific requirement for GDP to re-activate the glucagon receptor for additional cycles of hormone binding. A model is presented in which (a) glucagon binds to receptor in a Mg2+-independent fashion, (b) glucagon-receptor complexes are converted to a Mg2+-dependent state, (c) guanyl nucleotide exchange initiates both an alteration in glucagon-receptor affinity and the subsequent dissociation of hormone, and (d) in the context of the intact cell, G protein-mediated hydrolysis of GTP to GDP is required to reinitialize the system.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago	TAGER, HS (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.			Post, Steven/0000-0002-4711-1723	NIDDK NIH HHS [DK20595, DK18347] Funding Source: Medline; NIGMS NIH HHS [GM07183] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018347, P60DK020595, R01DK018347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BHARUCHA DB, 1990, J BIOL CHEM, V265, P3070; BIRD SJ, 1978, J BIOL CHEM, V253, P8826; BIRNBAUMER L, 1971, J BIOL CHEM, V246, P1857; BOND M, 1987, J BIOL CHEM, V262, P15630; BONNEVIENIELSEN V, 1983, J BIOL CHEM, V258, P1313; BONNEVIENIELSEN V, 1982, P NATL ACAD SCI-BIOL, V79, P2167, DOI 10.1073/pnas.79.7.2167; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; CODINA J, 1984, J BIOL CHEM, V259, P1408; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ENGLAND RD, 1983, BIOCHEMISTRY-US, V22, P1722, DOI 10.1021/bi00276a031; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FISKUM G, 1985, CELL CALCIUM, V6, P25, DOI 10.1016/0143-4160(85)90032-6; FRANDSEN EK, 1987, BIOCHIM BIOPHYS ACTA, V929, P74, DOI 10.1016/0167-4889(87)90242-4; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOPALAKRISHNAN V, 1988, ENDOCRINOLOGY, V123, P922, DOI 10.1210/endo-123-2-922; GRADY T, 1987, J BIOL CHEM, V262, P15514; HAGOPIAN WA, 1987, J BIOL CHEM, V262, P15506; HAGOPIAN WA, 1984, J BIOL CHEM, V259, P8986; HEIDENREICH KA, 1982, J BIOL CHEM, V257, P804; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HORWITZ EM, 1985, J BIOL CHEM, V260, P9307; IYENGAR R, 1980, J BIOL CHEM, V255, P312; IYENGAR R, 1982, P NATL ACAD SCI-BIOL, V79, P5179, DOI 10.1073/pnas.79.17.5179; LAD PM, 1977, J BIOL CHEM, V252, P5942; LEFKOWITZ RJ, 1976, J BIOL CHEM, V251, P4686; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; MANDEL P, 1964, PROG NUCLEIC ACID RE, V3, P299, DOI 10.1016/S0079-6603(08)60744-8; MASON JC, 1985, P NATL ACAD SCI USA, V82, P6835, DOI 10.1073/pnas.82.20.6835; MICK GJ, 1988, J BIOL CHEM, V263, P10667; MUKHERJEE C, 1975, J BIOL CHEM, V250, P4869; MUKHERJEE XG, 1976, J BIOL CHEM, V251, P4686; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; PADRELL E, 1987, ENDOCRINOLOGY, V120, P2316, DOI 10.1210/endo-120-6-2316; POHL SL, 1971, J BIOL CHEM, V246, P1849; RODBELL M, 1971, J BIOL CHEM, V246, P1861; RODBELL M, 1974, J BIOL CHEM, V249, P59; ROJAS FJ, 1983, ENDOCRINOLOGY, V113, P711, DOI 10.1210/endo-113-2-711; ROJAS FJ, 1985, J BIOL CHEM, V260, P7829; ROMANI A, 1991, J BIOL CHEM, V266, P24376; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SONNE O, 1978, J BIOL CHEM, V253, P3203; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WILLIAMS LT, 1978, J BIOL CHEM, V253, P2984; WILLIAMS LT, 1977, J BIOL CHEM, V252, P7207; WYBORSKI RJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P532, DOI 10.1016/0003-9861(88)90405-5; ZHAO H, 1990, J BIOL CHEM, V265, P14822	56	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25776	25785						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334486				2022-12-25	WOS:A1992KD07300032
J	GOMEZFOIX, AM; COATS, WS; BAQUE, S; ALAM, T; GERARD, RD; NEWGARD, CB				GOMEZFOIX, AM; COATS, WS; BAQUE, S; ALAM, T; GERARD, RD; NEWGARD, CB			ADENOVIRUS-MEDIATED TRANSFER OF THE MUSCLE GLYCOGEN-PHOSPHORYLASE GENE INTO HEPATOCYTES CONFERS ALTERED REGULATION OF GLYCOGEN-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; SEQUENCE-ANALYSIS; EXPRESSION; ACTIVATION; TISSUE; DNA; SYNTHASE; KINASE; TYPE-5; CELLS	The muscle isozyme of glycogen phosphorylase is potently activated by the allosteric ligand AMP, whereas the liver isozyme is not. In this study we have investigated the metabolic impact of expression of muscle phosphorylase in liver cells. To this end, we constructed a replication-defective, recombinant adenovirus containing the muscle glycogen phosphorylase cDNA (termed AdCMV-MGP) and used this system to infect hepatocytes in culture. AMP-activatable glycogen phosphorylase activity was increased 46-fold 6 days after infection of primary liver cells with AdCMV-MGP. Despite large increases in phosphorylase activity, glycogen levels were only slightly reduced in AdCMV-MGP-infected liver cells compared to uninfected cells or cells infected with wild-type adenovirus. The lack of correlation of phosphorylase activity and glycogen content suggests that the liver cell environment can inhibit the muscle phosphorylase isozyme. This inhibition can be overcome, however, by addition of carbonyl cyanide m-chlorophenylhydrazone (CCCP), which increases AMP levels by 30-fold and causes a much larger decrease in glycogen levels in AdCMV-MGP-infected cells than in uninfected or wild-type adenovirus-infected controls. CCCP treatment also caused a preferential decrease in glycogen content relative to glucagon treatment in AdCMV-MGP-infected hepatocytes (74% versus 11%, respectively), even though the two drugs caused equal increases in phosphorylase alpha activity. Introduction of muscle phosphorylase into hepatocytes therefore confers a capacity for glycogenolytic response to effectors that is not provided by the endogenous liver phosphorylase isozyme. The remarkable efficiency of adenovirus-mediated gene transfer into primary hepatocytes and the demonstration of altered regulation of glycogen metabolism as a consequence of expression of a non-cognate phosphorylase isozyme may have implications for gene therapy of glycogen storage diseases.	UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas					NIDDK NIH HHS [R29-DK40734] Funding Source: Medline; PHS HHS [FU90 37284920] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040734] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; CARABAZA A, 1986, ARCH BIOCHEM BIOPHYS, V250, P469, DOI 10.1016/0003-9861(86)90751-4; CARABAZA A, 1990, J BIOL CHEM, V265, P2724; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CLARK D, 1988, CURR TOP CELL REGUL, V29, P217; COATS WS, 1991, J BIOL CHEM, V266, P16113; COHEN PTW, 1973, FEBS LETT, V29, P113; FLETTERICK RJ, 1982, ACCOUNTS CHEM RES, V15, P361, DOI 10.1021/ar00083a004; GLASER T, 1989, GENOMICS, V5, P510, DOI 10.1016/0888-7543(89)90017-7; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GOMEZFOIX AM, 1991, BIOCHEM J, V276, P607, DOI 10.1042/bj2760607; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KOBAYASHI M, 1982, J BIOL CHEM, V257, P4041; LEBO RV, 1984, SCIENCE, V225, P57, DOI 10.1126/science.6587566; LEDERER B, 1976, BIOCHEM J, V159, P689, DOI 10.1042/bj1590689; LEDLEY FD, 1990, J INHERIT METAB DIS, V13, P597, DOI 10.1007/BF01799515; LIU TJ, 1992, SOMAT CELL MOLEC GEN, V18, P89, DOI 10.1007/BF01233451; LYON JB, 1963, J BIOL CHEM, V238, P1; MADSEN NB, 1961, BIOCHEM BIOPH RES CO, V6, P310, DOI 10.1016/0006-291X(61)90385-0; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; NAKANO K, 1986, FEBS LETT, V204, P283, DOI 10.1016/0014-5793(86)80829-8; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; NEWGARD CB, 1988, J BIOL CHEM, V263, P3850; NEWGARD CB, 1987, AM J HUM GENET, V40, P351; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; NEWGARD CB, 1992, BIO-TECHNOL, V10, P1112, DOI 10.1038/nbt1092-1112; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; NEWGARD CB, 1991, BIOCHIM BIOPHYS ACTA, V1090, P333, DOI 10.1016/0167-4781(91)90198-U; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SEN A, 1988, J BIOL CHEM, V263, P19132; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; VANDEBROECK A, 1988, BIOCHEM J, V256, P685, DOI 10.1042/bj2560685; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437	40	247	317	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25129	25134						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334082				2022-12-25	WOS:A1992KB60300035
J	HEIM, R; IWATA, T; ZVARITCH, E; ADAMO, HP; RUTISHAUSER, B; STREHLER, EE; GUERINI, D; CARAFOLI, E				HEIM, R; IWATA, T; ZVARITCH, E; ADAMO, HP; RUTISHAUSER, B; STREHLER, EE; GUERINI, D; CARAFOLI, E			EXPRESSION, PURIFICATION, AND PROPERTIES OF THE PLASMA-MEMBRANE CA2+ PUMP AND OF ITS N-TERMINALLY TRUNCATED 105-KDA FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; CALMODULIN-BINDING DOMAIN; ION MOTIVE ATPASES; PIG SMOOTH-MUSCLE; CALCIUM-PUMP; CA-2+ PUMP; MOLECULAR-CLONING; FUNCTIONAL DOMAINS; CA-2+-TRANSPORTING ATPASE; DIRECTED MUTAGENESIS	Isoform 4b of the human plasma membrane Ca2+ pump was expressed in COS cells and in the baculovirus system (Sf9 cells). A 105-kDa pump fragment lacking the first two transmembrane domains and the so-called transduction domain was also expressed. The expression level was 2-4 times the background in COS cells and at least 7 times in the baculovirus system. Tests on membranes from both systems showed that the expressed pump was active. The expressed pump and the 105-kDa fragment were isolated from Sf9 cell membranes by calmodulin affinity chromatography. The pump had Ca2+-dependent ATPase activity with a calmodulin stimulation factor of 3, formed a La3+-stabilized phosphoenzyme, and had a K(M) (Ca2+) in the presence of calmodulin of about 1 muM. The 105-kDa fragment, assayed by the phosphoenzyme test on COS or Sf9 cell membranes or by ATPase measurements after isolation from Sf9 cells, pro-ed inactive. Laser confocal microscopy on Sf9 cells showed that both the pump and the 105-kDa fragment were apparently associated with the plasma membrane. The expressed pump in COS and Sf9 cells and the endogenous pump in a number of other cell lines had a slower gel mobility (i.e. a higher apparent molecular mass) than the erythrocyte pump.	SWISS FED INST TECHNOL,INST BIOCHEM,UNIV STR 16,CH-8092 ZURICH,SWITZERLAND; MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55901; SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND	ETH Zurich; Mayo Clinic; ETH Zurich			Adamo, Hugo Pedro/ABB-8338-2021; Carafoli, Ernesto/K-5192-2016	Adamo, Hugo Pedro/0000-0002-1712-8049; Carafoli, Ernesto/0000-0002-7826-0094				BORKE JL, 1987, J CLIN INVEST, V80, P1225, DOI 10.1172/JCI113196; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CURRIE JR, 1991, J NEUROSCI RES, V30, P687, DOI 10.1002/jnr.490300413; DEJAEGERE S, 1990, BIOCHEM J, V271, P655, DOI 10.1042/bj2710655; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GREEB J, 1989, J BIOL CHEM, V264, P18569; GREEN NM, 1989, BIOCHEM SOC T, V17, P819, DOI 10.1042/bst0170819; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HOLZER KP, 1989, J BIOL CHEM, V264, P14389; JAMES P, 1989, J BIOL CHEM, V264, P8289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; NIGGLI V, 1987, METHOD ENZYMOL, V139, P791; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Sambrook J, 1989, MOL CLONING LABORATO; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Schatzmann H J, 1978, Ann N Y Acad Sci, V307, P125, DOI 10.1111/j.1749-6632.1978.tb41939.x; SCHATZMANN HJ, 1982, MEMBRANE TRANSPORT C, P41; SCULLY SP, 1982, CELL CALCIUM, V3, P515, DOI 10.1016/0143-4160(82)90042-2; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; Summers MD, 1987, TEXAS AGR EXPT STATI; SZASZ I, 1978, BIOCHIM BIOPHYS ACTA, V512, P331, DOI 10.1016/0005-2736(78)90257-2; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1991, J BIOL CHEM, V266, P22; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	47	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24476	24484						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332959				2022-12-25	WOS:A1992KA26300053
J	ORNING, L; GIERSE, J; DUFFIN, K; BILD, G; KRIVI, G; FITZPATRICK, FA				ORNING, L; GIERSE, J; DUFFIN, K; BILD, G; KRIVI, G; FITZPATRICK, FA			MECHANISM-BASED INACTIVATION OF LEUKOTRIENE-A4 HYDROLASE AMINOPEPTIDASE BY LEUKOTRIENE-A4 - MASS-SPECTROMETRIC AND KINETIC CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; HUMAN-ERYTHROCYTES; ZINC METALLOENZYME; MOLECULAR-CLONING; EPOXIDE HYDROLASE; BIOSYNTHESIS; PURIFICATION; INHIBITION; METABOLISM; LEUKOCYTES	"Suicide" inactivation of leukotriene (LT) A4 hydrolase/aminopeptidase occurs via an irreversible mechanism-based process which is saturable, of pseudo first-order, and dependent upon catalysis. Data obtained with either recombinant enzyme or enzyme purified from human leukocytes were similar. Apparent binding constants and inactivation rate constants are equivalent, compatible with a single type of substrate-enzyme complex which partitions between two fates, turnover and inactivation. Both catalytic functions are inactivated, consistent with an overlapping active site for this bifunctional enzyme. The partition ratio (turnover/inactivation) for the LTA4-enzyme complex is 129 +/- 16 for LTA4 hydrolase activity and 124 +/- 10 for aminopeptidase activity. The pH dependence for turnover and inactivation are indistinguishable with a maximum at pH 8. L-Proline p-nitroanilide, a weak substrate with a high K(m) for the aminopeptidase affords only partial protection against inactivation by LTA4. However, two potent competitive inhibitors, bestatin and captopril, protect both catalytic processes from inactivation, consistent with an active-site specificity for the suicide event. Electrospray ionization mass spectrometry indicates that the molecular weight of pure recombinant enzyme is 69,399 +/- 4 and that covalent modification accompanies catalysis, producing an LTA4:enzyme adduct with a molecular weight 69,717 +/- 4 and a 1:1 stoichiometry. In agreement with kinetic data, electrospray ionization mass spectrometry shows that bestatin inhibits the covalent modification of enzyme by LTA4 and that the extent of modification is proportional to the loss of enzymatic activity.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; MONSANTO CO,CORP RES,ST LOUIS,MO 63167	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Monsanto					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLB PO1 34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRENNER DG, 1981, BIOCHEMISTRY-US, V20, P3682; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; EVANS JF, 1985, J BIOL CHEM, V260, P966; EVANS JF, 1992, FEBS LETT, V297, P139, DOI 10.1016/0014-5793(92)80345-H; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FITZPATRICK F, 1984, J BIOL CHEM, V259, P1403; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; JAKSCHIK BA, 1983, PROSTAG OTH LIPID M, V25, P767, DOI 10.1016/0090-6980(83)90002-3; KITZ R, 1962, J BIOL CHEM, V237, P3245; MALFROY B, 1989, BIOCHEM BIOPH RES CO, V161, P236, DOI 10.1016/0006-291X(89)91586-6; MATHEWS WR, 1988, ANAL CHEM, V60, P349, DOI 10.1021/ac00155a016; MCGEE J, 1985, J BIOL CHEM, V260, P2832; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MEDINA JF, 1990, EUR J BIOCHEM, V191, P27, DOI 10.1111/j.1432-1033.1990.tb19089.x; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V173, P620, DOI 10.1016/S0006-291X(05)80080-4; ORNING L, 1990, J BIOL CHEM, V265, P14911; ORNING L, 1991, J BIOL CHEM, V266, P16507; ORNING L, 1991, J BIOL CHEM, V266, P1375; ORNING L, 1992, BIOCHEMISTRY-US, V31, P4218, DOI 10.1021/bi00132a010; RADMARK O, 1984, J BIOL CHEM, V259, P2339; RADMARK O, 1990, ADV PROSTAG THROMB L, V20, P35; RAJASHEKHAR B, 1984, J BIOL CHEM, V259, P6925; SUN FF, 1984, BIOCHIM BIOPHYS ACTA, V794, P56, DOI 10.1016/0005-2760(84)90297-2; TOH H, 1990, BIOCHEM BIOPH RES CO, V171, P216, DOI 10.1016/0006-291X(90)91379-7; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WETTERHOLM A, 1991, BIOCHIM BIOPHYS ACTA, V1080, P96, DOI 10.1016/0167-4838(91)90134-L	32	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22733	22739						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331064				2022-12-25	WOS:A1992JY16300009
J	THEODOROU, ME; CORNEL, FA; DUFF, SMG; PLAXTON, WC				THEODOROU, ME; CORNEL, FA; DUFF, SMG; PLAXTON, WC			PHOSPHATE STARVATION-INDUCIBLE SYNTHESIS OF THE ALPHA-SUBUNIT OF THE PYROPHOSPHATE-DEPENDENT PHOSPHOFRUCTOKINASE IN BLACK MUSTARD SUSPENSION CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE-6-PHOSPHATE PHOSPHOTRANSFERASE; FRUCTOSE 2,6-BISPHOSPHATE; PYROPHOSPHATE-FRUCTOSE-6-PHOSPHATE PHOSPHOTRANSFERASE; CHENOPODIUM-RUBRUM; GLYCOLYTIC ENZYME; POTATO-TUBERS; 1-PHOSPHOTRANSFERASE; TISSUES; FRUCTOSE-2,6-BISPHOSPHATE; PURIFICATION	PP(i)-dependent phosphofructokinase (PFP) activity, measured in the forward direction, increased approximately 19-fold when suspension cell cultures of black mustard (Brassica nigra) were subjected to 18 days of P(i) deprivation. Fructose 2,6-bisphosphate (2 muM) elicited a 10-fold activation of PFP from P(i)-deficient cells, compared to only a 2-fold activation of the enzyme from nutrient-sufficient cells. Also, PFP from P(i)-starved cells exhibited a greater affinity for the activator (K(a) = 0.09 muM) than the enzyme from nutrient-sufficient cells (K(a) = 0.32 muM). Western blots of extracts from P(i)-deficient cells were probed with rabbit anti-(potato tuber PFP) immune serum and revealed equal intensity staining immunoreactive polypeptides of M(r) 66,000 (alpha-subunit) and 60,000 (beta-subunit) that co-migrated with the alpha- and beta-subunits of homogeneous potato tuber PFP. By contrast, only the M(r) 60,000 beta-subunit was observed on immunoblots of extracts prepared from nutrient-sufficient cells. Quantification of immunoblots indicated that in black mustard cells experiencing transition from P(i) sufficiency to deficiency or vice versa, the relative amount of immunoreactive alpha-subunit correlated with the degree of activation of PFP by fructose 2,6-bisphosphate. These observations provide additional evidence that (i) plant PFP is an adaptive enzyme that may function in glycolysis during P(i) deprivation, and (ii) the alpha-subunit acts as a regulatory protein in controlling the catalytic activity of the beta-subunit and its regulation by fructose 2,6-bisphosphate.	QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada; Queens University - Canada			Plaxton, William C/O-3353-2013	Plaxton, William C/0000-0002-8447-7249				APREES T, 1985, BIOCHEM J, V227, P299, DOI 10.1042/bj2270299; APREES T, 1985, CARBOHYDRATE PARTITI, P129; BLACK CC, 1987, PHYSIOL PLANTARUM, V69, P387, DOI 10.1111/j.1399-3054.1987.tb04305.x; BOTHA AM, 1990, PLANT PHYSIOL, V93, P683, DOI 10.1104/pp.93.2.683; BOTHA AM, 1991, PLANT CELL PHYSIOL, V32, P1299; BOTHA AM, 1991, PLANT PHYSIOL, V96, P1185, DOI 10.1104/pp.96.4.1185; BOTHA FC, 1988, PLANT CELL PHYSIOL, V29, P223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLISLE SM, 1990, J BIOL CHEM, V265, P18366; CHENG HF, 1990, J BIOL CHEM, V265, P2173; DANCER JE, 1989, J PLANT PHYSIOL, V135, P197, DOI 10.1016/S0176-1617(89)80177-4; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; DUFF SMG, 1991, P NATL ACAD SCI USA, V88, P9538, DOI 10.1073/pnas.88.21.9538; DUFF SMG, 1989, PLANT PHYSIOL, V90, P734, DOI 10.1104/pp.90.2.734; DUFF SMG, 1989, PLANT PHYSIOL, V90, P1275, DOI 10.1104/pp.90.4.1275; EDWARDS J, 1986, PHYTOCHEMISTRY, V25, P2033, DOI 10.1016/0031-9422(86)80062-0; FAHRENDORF T, 1987, PLANT PHYSIOL, V84, P182, DOI 10.1104/pp.84.1.182; GOLDSTEIN AH, 1989, PLANT MOL BIOL REP, V7, P7; HAJIREZAEI M, 1991, PLANT SCI, V77, P177, DOI 10.1016/0168-9452(91)90086-N; HATZFELD WD, 1990, PLANTA, V180, P198, DOI 10.1007/BF00193996; HATZFELD WD, 1990, PLANTA, V180, P205, DOI 10.1007/BF00193997; HATZFELD WD, 1989, FEBS LETT, V254, P215, DOI 10.1016/0014-5793(89)81042-7; HUBER SC, 1986, PLANT PHYSIOL, V81, P1008, DOI 10.1104/pp.81.4.1008; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; KRUGER NJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P273, DOI 10.1016/0003-9861(87)90446-2; LEFEBVRE DD, 1990, PLANT PHYSL BETHESDA, V93, P505; MAHAJAN R, 1989, PLANT PHYSIOL, V91, P421, DOI 10.1104/pp.91.1.421; MERTENS E, 1991, FEBS LETT, V285, P1, DOI 10.1016/0014-5793(91)80711-B; Moorhead G B, 1991, Protein Expr Purif, V2, P29, DOI 10.1016/1046-5928(91)90005-4; MOORHEAD GBG, 1990, BIOCHEM J, V269, P133, DOI 10.1042/bj2690133; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; STITT M, 1989, PLANT PHYSIOL, V89, P628, DOI 10.1104/pp.89.2.628; STITT M, 1990, ANNU REV PLANT PHYS, V41, P153, DOI 10.1146/annurev.pp.41.060190.001101; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; WEINER H, 1987, BIOCHIM BIOPHYS ACTA, V893, P13, DOI 10.1016/0005-2728(87)90143-5; WONG JH, 1990, PLANT PHYSIOL, V94, P499, DOI 10.1104/pp.94.2.499; WU FS, 1984, ANAL BIOCHEM, V139, P100, DOI 10.1016/0003-2697(84)90394-4; XU DP, 1989, PLANT PHYSIOL, V90, P635, DOI 10.1104/pp.90.2.635; YAN TFJ, 1984, J BIOL CHEM, V259, P5087	40	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21901	21905						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328248				2022-12-25	WOS:A1992JV01100098
J	HUNG, DT; WONG, YH; VU, TKH; COUGHLIN, SR				HUNG, DT; WONG, YH; VU, TKH; COUGHLIN, SR			THE CLONED PLATELET THROMBIN RECEPTOR COUPLES TO AT LEAST 2 DISTINCT EFFECTORS TO STIMULATE PHOSPHOINOSITIDE HYDROLYSIS AND INHIBIT ADENYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; HAMSTER FIBROBLASTS; BINDING PROTEIN; ACTIVATION; MOBILIZATION; ACCUMULATION; CLONING; CELLS; GI	Thrombin both stimulates phosphoinositide hydrolysis and inhibits adenylyl cyclase in a variety of cell types. Whether the cloned human platelet thrombin receptor accounts for both of these signaling events is unknown. We report that thrombin receptor agonist peptide causes both phosphoinositide hydrolysis and inhibition of adenylyl cyclase in naturally thrombin-responsive CCL-39 cells. To exclude the possibility that the agonist peptide or thrombin itself may activate these pathways via distinct receptors and to circumvent a lack of suitable thrombin receptor-null cells, we utilized a designed "enterokinase receptor," a thrombin receptor with its thrombin cleavage recognition sequence LDPR replaced by DDDDK, the enterokinase cleavage recognition sequence. Transfection of enterokinase-unresponsive cells with this construct conferred both enterokinase-sensitive phosphoinositide hydrolysis and inhibition of adenylyl cyclase. The phosphoinositide hydrolysis response was largely insensitive to pertussis toxin, whereas the adenylyl cyclase response was completely blocked by pertussis toxin. These data show that the cloned thrombin receptor can effect both phosphoinositide hydrolysis and inhibition of adenylyl cyclase via at least two distinct effectors, most likely G(q)-like and G(i)-like G-proteins.	UNIV CALIF SAN FRANCISCO, DEPT LAB MED, BOX 0524, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL44907, HL0248-01] Funding Source: Medline; NIGMS NIH HHS [GM27800] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1986, J BIOL CHEM, V261, P6838; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JONES LG, 1989, MOL PHARMACOL, V36, P142; KROLL MH, 1989, BLOOD, V74, P1181; LIU LW, 1991, J BIOL CHEM, V266, P16977; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	22	247	254	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20831	20834						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328213				2022-12-25	WOS:A1992JT97800051
J	AMLAIKY, N; RAMBOZ, S; BOSCHERT, U; PLASSAT, JL; HEN, R				AMLAIKY, N; RAMBOZ, S; BOSCHERT, U; PLASSAT, JL; HEN, R			ISOLATION OF A MOUSE 5HT1E-LIKE SEROTONIN RECEPTOR EXPRESSED PREDOMINANTLY IN HIPPOCAMPUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; NEURONS; PROTEIN; BRAIN	Using a strategy based on amino acid sequence homology between 5-hydroxytryptamine (5-HT) receptors that interact with G proteins, we have isolated from a mouse brain library a cDNA encoding a new serotonin receptor, the 5HT1Ebeta receptor. Amino acid sequence comparisons revealed that its closest relatives were the recently characterized 5HT1E receptor (S31) and the 5HT1B and 5HT1D receptors. When expressed transiently in Cos-7 cells, the 5HT1Ebeta receptor displayed a high affinity for the nonspecific serotonergic radioligand 2-[I-125]iodolysergic acid diethylamide (K(d) = 980 pM). The pharmacological profile of the 5HT1Ebeta receptor resembled that of previously reported 5HT1E sites that have a low affinity for 5-carboxamidotryptamine and that have been found in human and rat brain. When stably expressed in NIH-3T3 cells, the 5HT1Ebeta receptor was negatively coupled to adenylate cyclase. In situ hybridization experiments revealed that the 5HT1Ebeta transcripts were detected only in the CA1, CA2, and CA3 layers of the hippocampus. Our results therefore demonstrate that the 5HT1E receptors constitute a heterogeneous family of receptors.	FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ASARCH KB, 1985, LIFE SCI, V36, P1265, DOI 10.1016/0024-3205(85)90271-1; BEER MS, 1992, EUR J PHARMACOL, V213, P193, DOI 10.1016/0014-2999(92)90681-S; COLINO A, 1987, NATURE, V328, P73, DOI 10.1038/328073a0; CONN PJ, 1985, J PHARMACOL EXP THER, V234, P15; DELEAN A, 1982, MOL PHARMACOL, V22, P290; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAFEN E, 1983, EMBO J, V2, P617, DOI 10.1002/j.1460-2075.1983.tb01472.x; HAMBLIN MW, 1991, MOL PHARMACOL, V40, P143; HARTIG PR, 1992, TRENDS PHARMACOL SCI, V13, P152, DOI 10.1016/0165-6147(92)90053-9; HEN R, 1992, TRENDS PHARMACOL SCI, V13, P160, DOI 10.1016/0165-6147(92)90054-A; HEURING RE, 1986, EUR J PHARMACOL, V122, P279, DOI 10.1016/0014-2999(86)90114-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; LEONHARDT S, 1989, J NEUROCHEM, V53, P465, DOI 10.1111/j.1471-4159.1989.tb07357.x; LEVY FO, 1992, FEBS LETT, V296, P201, DOI 10.1016/0014-5793(92)80379-U; MAHLE CD, 1991, EUR J PHARMACOL, V205, P323, DOI 10.1016/0014-2999(91)90919-H; MAROTEAUX L, 1992, P NATL ACAD SCI USA, V89, P3020, DOI 10.1073/pnas.89.7.3020; MCALLISTER G, 1992, P NATL ACAD SCI USA, V89, P5517, DOI 10.1073/pnas.89.12.5517; MILLER KJ, 1992, NEUROSCI LETT, V136, P223, DOI 10.1016/0304-3940(92)90054-B; Peroutka S. J., 1991, SEROTONIN RECEPTOR S, P65; PEROUTKA SJ, 1991, BRAIN RES, V553, P206, DOI 10.1016/0006-8993(91)90826-H; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; SAUDOU F, 1992, EMBO J, V11, P7, DOI 10.1002/j.1460-2075.1992.tb05021.x; SUMNER MJ, 1989, BRIT J PHARMACOL, V98, P29, DOI 10.1111/j.1476-5381.1989.tb16856.x; WAEBER C, 1990, NEUROCHEM RES, V15, P567, DOI 10.1007/BF00973745; WEISBERG E, 1992, DRUG DEVELOP RES, V26, P225, DOI 10.1002/ddr.430260303; Wilkinson LO, 1991, SEROTONIN RECEPTOR S, P147; YAKEL JL, 1988, J NEUROSCI, V8, P1273	30	88	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19761	19764						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328180				2022-12-25	WOS:A1992JR85800003
J	DESBARATS, L; LAM, TY; WONG, LM; SIU, CH				DESBARATS, L; LAM, TY; WONG, LM; SIU, CH			IDENTIFICATION OF A UNIQUE CAMP-RESPONSE ELEMENT IN THE GENE ENCODING THE CELL-ADHESION MOLECULE GP80 IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION PATHWAYS; ALPHA PROTEIN SUBUNITS; SITE-A GLYCOPROTEIN; CYCLIC-AMP; MULTICELLULAR DEVELOPMENT; MONOCLONAL-ANTIBODIES; AGGREGATION STAGE; SEQUENCE ELEMENT; INDUCIBLE GENE; ACTIN GENE	Extracellular cAMP serves as a chemoattractant as well as a signal which regulates gene expression during development of Dictyostelium discoideum. The cell adhesion molecule gp80 is expressed at the aggregation stage, between 6 and 10 h of development, and is known to be under cAMP regulation. Transcription of the gp80 gene is first turned on at a low, basal level at the preaggregation stage and is then greatly augmented by pulses of low levels of cAMP at the aggregation stage. Using cloned cDNA sequences, we have isolated genomic DNA fragments encompassing the gp80 gene. The gp80 gene has a single open reading frame, with multiple transcription start sites located downstream from a putative TATA box. Several short, repeated sequences in the upstream sequence have also been identified. The cloned 1.3-kilobase upstream DNA was sufficient to confer proper temporal and cAMP regulation on a gp80 minigene reporter in Dictyostelium cells. Deletional analysis of this 5'-flanking DNA led to the mapping of a cAMP-response element (CRE) in the gp80 gene to sequences between -306 and -289 base pairs upstream of the translational start site. Present within this region is a sequence we refer to as box 1 (TGGTGTG). The gp80 box 1-CRE binds specifically to a protein present in nuclear extracts, but binding is abolished when mutations are introduced in the box 1 sequence. The gp80 box 1-CRE shows little sequence homology to CREs of late developmental genes and the expression of gp80 may involve a distinct signal transduction pathway.	UNIV TORONTO,CHARLES H BEST INST,DEPT BIOCHEM,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto								BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRODIE C, 1983, CELL, V32, P1115, DOI 10.1016/0092-8674(83)90295-7; CHOI AHC, 1987, J CELL BIOL, V104, P1375, DOI 10.1083/jcb.104.5.1375; COCUCCI SM, 1970, J CELL BIOL, V45, P399, DOI 10.1083/jcb.45.2.399; COFFMAN DS, 1982, DEV BIOL, V93, P422, DOI 10.1016/0012-1606(82)90129-4; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; DATTA S, 1987, MOL CELL BIOL, V7, P149, DOI 10.1128/MCB.7.1.149; DRISCOLL DM, 1988, DEV GENET, V9, P455, DOI 10.1002/dvg.1020090423; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1989, NUCLEIC ACIDS RES, V17, P6473; FIRTEL RA, 1991, TRENDS GENET, V7, P381, DOI 10.1016/0168-9525(91)90260-W; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P3047; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HARIBABU B, 1986, MOL CELL BIOL, V6, P2402, DOI 10.1128/MCB.6.7.2402; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HJORTH A, 1988, DEV GENET, V9, P435, DOI 10.1002/dvg.1020090422; HJORTH AL, 1989, GENE DEV, V3, P747, DOI 10.1101/gad.3.6.747; HJORTH AL, 1990, GENE DEV, V4, P419, DOI 10.1101/gad.4.3.419; KAMBOJ RK, 1988, BIOCHIM BIOPHYS ACTA, V951, P78, DOI 10.1016/0167-4781(88)90027-9; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LAM TY, 1981, DEV BIOL, V83, P127, DOI 10.1016/S0012-1606(81)80015-2; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MA PCC, 1990, MOL CELL BIOL, V10, P3297, DOI 10.1128/MCB.10.7.3297; Maniatis T., 1982, MOL CLONING; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; MANN SKO, 1988, DEV BIOL, V130, P294, DOI 10.1016/0012-1606(88)90435-6; MAY T, 1989, MOL CELL BIOL, V9, P4653, DOI 10.1128/MCB.9.11.4653; MAY T, 1991, MECH DEVELOP, V33, P147, DOI 10.1016/0925-4773(91)90081-G; MCNEIL JB, 1986, J MOL BIOL, V187, P363, DOI 10.1016/0022-2836(86)90439-0; MULLER K, 1978, NATURE, V274, P445, DOI 10.1038/274445a0; MURRAY BA, 1981, J SUPRAMOL STR CELL, V17, P197, DOI 10.1002/jsscb.380170302; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NELLEN W, 1986, EMBO J, V5, P3367, DOI 10.1002/j.1460-2075.1986.tb04652.x; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; OYAMA M, 1986, P NATL ACAD SCI USA, V83, P4819, DOI 10.1073/pnas.83.13.4819; PAVLOVIC J, 1989, MOL CELL BIOL, V9, P4660, DOI 10.1128/MCB.9.11.4660; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; PEARS CJ, 1987, EMBO J, V6, P195, DOI 10.1002/j.1460-2075.1987.tb04738.x; POOLE SJ, 1984, J MOL BIOL, V172, P203, DOI 10.1016/S0022-2836(84)80038-8; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; SACE CL, 1991, DEV GENET, V12, P6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXE CL, 1991, GENE DEV, V5, P1, DOI 10.1101/gad.5.1.1; SCHAAP P, 1985, EXP CELL RES, V159, P388, DOI 10.1016/S0014-4827(85)80012-4; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIU CH, 1988, BIOCHIM BIOPHYS ACTA, V968, P283, DOI 10.1016/0167-4889(88)90019-5; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; VAUTI F, 1990, MOL CELL BIOL, V10, P4080, DOI 10.1128/MCB.10.8.4080; WONG LM, 1986, P NATL ACAD SCI USA, V83, P4248, DOI 10.1073/pnas.83.12.4248; WONG LM, 1988, THESIS U TORONTO	57	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19655	19664						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326559				2022-12-25	WOS:A1992JP59300095
J	KUKOLJ, G; DUBOW, MS				KUKOLJ, G; DUBOW, MS			INTEGRATION HOST FACTOR ACTIVATES THE NER-REPRESSED EARLY PROMOTER OF TRANSPOSABLE MU-LIKE PHAGE-D108	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA BENDING PROTEIN; ESCHERICHIA-COLI; BACTERIOPHAGE-MU; GENE-EXPRESSION; STRAND TRANSFER; BINDING; TRANSCRIPTION; SITE; TRANSPOSITION; SEQUENCES	The lytic-lysogenic switch in transposable, Mu-like bacteriophage D108 is governed by two divergent and slightly overlapping transcription units originating from the Pe and Pc promoters. DNase I footprinting and in vivo mutational analysis suggest that lysogeny is maintained by c-repressor occupancy of the O2 operator, which precludes RNA polymerase from binding to Pe. Lytic development is controlled by the Ner repressor, which binds to a site symmetrically situated between the converging promoters and, in the absence of other factors, prevents RNA polymerase from binding to either Pc or Pe. DNase I protection and potassium permanganate hypersensitivity in the presence of integration host factor (IHF), which binds and alters the DNA structure upstream of Pe, revealed that RNA polymerase was able to bind Pe irrespective of the Ner.DNA-bound complex, and partially unwind the Pe "-10 region." Ner repression of Pe transcription in vitro was significantly more effective in the absence of IHF. Using a cloned D108 early region-lacZ fusion in IHF-deficient and -proficient backgrounds, we also demonstrate this host factor's affect on ner-repressed Pe in vivo, and generate a system for isolating mutants in the regulatory genes and sites controlling this genetic switch. D108 lytic growth is proposed to occur through IHF-mediated activation of the phage Ner-repressed early operon.	MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2B4,QUEBEC,CANADA	McGill University								ADHYA S, 1990, J BIOL CHEM, V265, P10797; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BECK CF, 1988, MICROBIOL REV, V52, P318, DOI 10.1128/MMBR.52.3.318-326.1988; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; DEVARGAS LM, 1989, SCIENCE, V244, P1457; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FIEDLER S, 1988, ANAL BIOCHEM, V170, P38, DOI 10.1016/0003-2697(88)90086-3; FLAMM EL, 1985, J MOL BIOL, V183, P117, DOI 10.1016/0022-2836(85)90206-2; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GILADI H, 1990, J MOL BIOL, V213, P109, DOI 10.1016/S0022-2836(05)80124-X; GIPHARTGASSLER M, 1979, COLD SPRING HARB SYM, V43, P1179, DOI 10.1101/SQB.1979.043.01.133; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOOSEN N, 1984, GENE, V30, P41, DOI 10.1016/0378-1119(84)90103-3; GOOSEN N, 1986, J BACTERIOL, V167, P503, DOI 10.1128/jb.167.2.503-507.1986; GOOSEN N, 1984, GENE, V32, P419, DOI 10.1016/0378-1119(84)90017-9; GRIFFO G, 1989, J MOL BIOL, V209, P55, DOI 10.1016/0022-2836(89)90169-1; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUANG L, 1990, J BACTERIOL, V172, P5293, DOI 10.1128/jb.172.9.5293-5298.1990; HULL RA, 1978, J VIROL, V27, P513, DOI 10.1128/JVI.27.3.513-518.1978; KINCADE JM, 1991, GENE, V97, P7, DOI 10.1016/0378-1119(91)90003-T; KONIG U, 1988, VIROLOGY, V164, P75, DOI 10.1016/0042-6822(88)90621-6; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KRAUSE HM, 1983, NUCLEIC ACIDS RES, V11, P5483, DOI 10.1093/nar/11.16.5483; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUKOLJ G, 1991, NUCLEIC ACIDS RES, V19, P5949, DOI 10.1093/nar/19.21.5949; KUKOLJ G, 1989, EMBO J, V8, P3141, DOI 10.1002/j.1460-2075.1989.tb08467.x; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; LEVIN DB, 1989, MOL GEN GENET, V217, P392, DOI 10.1007/BF02464909; LEVIN DB, 1987, FEBS LETT, V222, P199, DOI 10.1016/0014-5793(87)80219-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; MILLER HI, 1984, COLD SPRING HARB SYM, V49, P691, DOI 10.1101/SQB.1984.049.01.078; MILLER HI, 1977, DNA INSERTION ELEMEN, P349; Miller J.H., 1972, EXPT MOL GENETICS; MIZUUCHI M, 1986, NUCLEIC ACIDS RES, V14, P3813, DOI 10.1093/nar/14.9.3813; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PATO ML, 1984, CELL, V36, P197, DOI 10.1016/0092-8674(84)90089-8; PEREIRA RF, 1988, NUCLEIC ACIDS RES, V16, P5973, DOI 10.1093/nar/16.13.5973; Ptashne M., 1986, A GENETIC SWITCH; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STENZEL TT, 1991, GENE DEV, V5, P1453, DOI 10.1101/gad.5.8.1453; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; Symonds N., 1987, PHAGE MU; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TOLIAS PP, 1986, VIROLOGY, V148, P298, DOI 10.1016/0042-6822(86)90327-2; TOLIAS PP, 1985, EMBO J, V4, P3031, DOI 10.1002/j.1460-2075.1985.tb04040.x; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; TSUI P, 1991, J BACTERIOL, V173, P5800, DOI 10.1128/jb.173.18.5800-5807.1991; VANRIJN PA, 1988, NUCLEIC ACIDS RES, V16, P4595, DOI 10.1093/nar/16.10.4595; VOGEL JL, 1991, J BACTERIOL, V173, P6568, DOI 10.1128/jb.173.20.6568-6577.1991; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	65	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17827	17835						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325451				2022-12-25	WOS:A1992JM22300055
J	BRAULKE, T; MIESKES, G				BRAULKE, T; MIESKES, G			ROLE OF PROTEIN PHOSPHATASES IN INSULIN-LIKE GROWTH FACTOR-II (IGF-II)-STIMULATED MANNOSE 6-PHOSPHATE/IGF-II RECEPTOR REDISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; LIGHT CHAIN KINASE; OKADAIC ACID; TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; LYSOSOMAL-ENZYMES; GLUCOSE-TRANSPORT; CELL-SURFACE; 6-PHOSPHATE-SPECIFIC RECEPTOR; INTRACELLULAR MOVEMENT	The regulated expression of mannose 6-phosphate/insulin-like growth factor II (M6P/IGF II) receptors in plasma membranes has previously been shown to be accompanied by marked changes in the phosphorylation state of the receptors (Corvera, S., Folander, K., Clairmont, K. B., and Czech, M. P. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7567-7571). In the present study we show that protein phosphatase 2A dephosphorylates the human M6P/IGF II receptor in vitro. Incubation of human fibroblasts with okadaic acid, a specific inhibitor of this phosphatase, resulted in a depletion of M6P/IGF II receptors at the cell surface without affecting their internalization kinetics. The phosphorylation state of the remaining cell surface receptors was 3-fold increased. Thus, the endocytosis rate of M6P/IGF II receptors appears to be unaltered by increased phosphorylation. While the decreased cell surface expression of receptors was reversible upon removal of okadaic acid the IGF II-induced redistribution of M6P/IGF II receptors to the plasma membrane (Braulke, T., Tippmer, S., Neher, E., and von Figura, K. (1989) EMBO J. 8,681-686) was irreversibly inhibited by the phosphatase inhibitor. Receptor redistribution in response to protein kinase C activation was not affected by okadaic acid. These results suggest that the cell surface expression of M6P/IGF II receptor can be regulated by phosphatase-dependent and -independent pathways. In addition, the phosphorylation state and the steady-state cell surface number of transferrin receptors were not affected by okadaic acid, whereas it impaired the IGF II-stimulated receptor redistribution similarly as for M6P/IGF II receptors. The data indicate that okadaic acid-sensitive protein phosphatases may play a general role in terms of IGF II-modulated receptor recycling.	UNIV GOTTINGEN,DEPT CLIN BIOCHEM,W-3400 GOTTINGEN,GERMANY	University of Gottingen	BRAULKE, T (corresponding author), UNIV GOTTINGEN,INST BIOCHEM 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY.		Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BRAULKE T, 1992, BIOCHIM BIOPHYS ACTA, V1138, P334, DOI 10.1016/0925-4439(92)90012-C; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BRAULKE T, 1990, EUR J BIOCHEM, V189, P609, DOI 10.1111/j.1432-1033.1990.tb15529.x; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; BRAULKE T, 1990, J BIOL CHEM, V265, P6650; BRAULKE T, 1991, BIOCHEM BIOPH RES CO, V179, P108, DOI 10.1016/0006-291X(91)91341-9; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CORVERA S, 1985, P NATL ACAD SCI USA, V82, P7314, DOI 10.1073/pnas.82.21.7314; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAMKE H, 1992, BIOCHEM J, V281, P225, DOI 10.1042/bj2810225; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; HU KQ, 1990, J BIOL CHEM, V265, P13864; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEE EYC, 1981, COLD SPRING HARBOR C, V8, P425; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OPPENHEIMER CL, 1983, J BIOL CHEM, V258, P4824; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; ROGERS SA, 1989, J BIOL CHEM, V264, P4273; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TALLANT EA, 1983, METHOD ENZYMOL, V102, P244; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TUNG HYL, 1984, EUR J BIOCHEM, V138, P635, DOI 10.1111/j.1432-1033.1984.tb07962.x; VONFIGURA K, 1985, BIOCHEM J, V225, P543, DOI 10.1042/bj2250543	44	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17347	17353						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324932				2022-12-25	WOS:A1992JL05300092
J	LANGE, AJ; ESPINET, C; HALL, R; ELMAGHRABI, MR; VARGAS, AM; MIKSICEK, RJ; GRANNER, DK; PILKIS, SJ				LANGE, AJ; ESPINET, C; HALL, R; ELMAGHRABI, MR; VARGAS, AM; MIKSICEK, RJ; GRANNER, DK; PILKIS, SJ			REGULATION OF GENE-EXPRESSION OF RAT SKELETAL-MUSCLE LIVER 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE - ISOLATION AND CHARACTERIZATION OF A GLUCOCORTICOID RESPONSE ELEMENT IN THE 1ST INTRON OF THE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; CELL LINE; RECEPTOR; DNA; ENHANCER; BINDING; IDENTIFICATION; INDUCTION; PROTEINS; SEQUENCE	At least two genes encode isoenzymes of rat 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Alternative splicing of one of these genes generates a skeletal muscle-specific transcript from an upstream promoter and a liver-specific transcript from a downstream promoter. A potent glucocorticoid response element was identified in the first intron of the gene, i.e. between liver exon I and exon II. The element is approximately 3.5 kilobase pairs (kb) downstream of the liver isoenzyme transcription start site and 13 kb upstream of exon II of the gene and confers dexamethasone-sensitive expression of chloramphenicol acetyltransferase (CAT) activity from a heterologous thymidine kinase promoter and from both homologous 5'-flanking regions of the gene. This glucocorticoid response element also exhibits androgen- but not estrogen-sensitive expression of CAT activity in HeLa cells cotransfected with the appropriate receptor expression vector. DNase footprint and sequence analysis revealed that the element is comprised minimally of two adjacent 15-mer glucocorticoid receptor dimer binding sites situated in opposite orientations. Glucocorticoid regulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression in liver and skeletal muscle is mediated by a single complex glucocorticoid response element located in the first intron of the skeletal muscle/liver gene.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL,STONY BROOK,NY 11794; VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vanderbilt University	LANGE, AJ (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794, USA.		Miksicek, Richard/AAC-7319-2020; Vargas, Ana/GSE-1963-2022; Espinet, Carme/A-7950-2010	EspinetMestre, Carme/0000-0001-7172-3407	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43384] Funding Source: Medline; NIDDK NIH HHS [DK-38354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P5643; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; ELMAGHRABI MR, 1991, J BIOL CHEM, V266, P2115; ELMAGHRABI MR, 1990, LIVER 6 PHOSPHOFRUCT, P87; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GEY GO, 1952, CANCER RES, V12, P264; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IVARIE RD, 1978, CELL, V13, P41, DOI 10.1016/0092-8674(78)90136-8; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUMMEL L, 1990, BIOCHEM BIOPH RES CO, V169, P406, DOI 10.1016/0006-291X(90)90346-O; LANGE AJ, 1989, BIOCHEM BIOPH RES CO, V162, P753, DOI 10.1016/0006-291X(89)92374-7; LEMAIGRE FP, 1991, MOL CELL BIOL, V11, P1099, DOI 10.1128/MCB.11.2.1099; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARKER AJ, 1989, J BIOL CHEM, V264, P7000; Maxam A M, 1980, Methods Enzymol, V65, P499; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MOORE EE, 1982, J CELL PHYSIOL, V111, P1, DOI 10.1002/jcp.1041110102; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NITSCH D, 1991, HORMONAL CONTROL REG, P223; NORRIS JS, 1974, NATURE, V248, P422, DOI 10.1038/248422a0; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PRESTRIDGE DS, 1991, SIGNALSCAN VERSION 2; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TSAI MJ, 1991, HORMONAL REGULATION, P101; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P205	45	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15673	15680						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1339434				2022-12-25	WOS:A1992JG11300065
J	PATEL, SS; ROSENBERG, AH; STUDIER, FW; JOHNSON, KA				PATEL, SS; ROSENBERG, AH; STUDIER, FW; JOHNSON, KA			LARGE-SCALE PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF T7-PRIMASE HELICASE PROTEINS - EVIDENCE FOR HOMODIMER AND HETERODIMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; LAGGING STRAND SYNTHESIS; PRIMED DNA-SYNTHESIS; GENE-4 PROTEIN; ESCHERICHIA-COLI; REPLICATION INVITRO; ADENOSINE-TRIPHOSPHATASE; PRIMASE-HELICASE; ATP HYDROLYSIS	A rapid purification procedure produces milligram amounts of the T7 gene 4A' primase/helicase, 4B helicase, and the wild-type 4AB proteins expressed from the clones described in the accompanying paper (Rosenberg, A. H., Patel, S. S., Johnson, K. A., and Studier, F. W. (1992) J. Biol. Chem. 267, 15005-15012). Purified 4A' protein (in which the wild-type methionine at amino acid 64 has been replaced by leucine to eliminate the 4B initiation codon) appears to be equivalent to the wild-type 4A protein in primase, helicase, and NTPase activities. Gel filtration chromatography and polyacrylamide gel electrophoresis of native proteins indicate that the 4A' and 4B proteins form homodimers and heterodimers in solution. Heterodimer formation presumably accounts for an observed 3-fold increase in the primase activity of 4A' upon addition of 4B that lacks primase activity of its own. Steady-state k(cat) and K(m) values for hydrolysis of the nucleoside triphosphates ATP, dATP, dTTP, and dGTP were measured for 4A', 4B, 4A'B (1:1), and wild-type 4AB (1:2) proteins. The dependence of the dNTPase activities on the concentration was hyperbolic, suggesting single or noncooperative binding sites, whereas ATPase activity was sigmoidal, suggesting more than one ATP binding site. The k(cat)/K(m) ratios for hydrolysis of the dNTPs by the four protein preparations were within a factor of 6 of each other. The 1:1 mixture of 4A'B had the highest k(cat)/K(m) ratios, with a preference for dATP and dTTP.	PENN STATE UNIV,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; United States Department of Energy (DOE); Brookhaven National Laboratory					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613, F32GM013135, R01GM021872] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13135, GM44613, GM21872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5247; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CAMPBELL JL, 1986, ANNU REV BIOCHEM, V55, P733, DOI 10.1146/annurev.bi.55.070186.003505; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; DUNN JJ, 1984, J MOL BIOL, V175, P111; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FISCHER H, 1980, J BIOL CHEM, V255, P7956; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HINKLE DC, 1975, J BIOL CHEM, V250, P5523; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; KORNBERG A, 1991, DNA REPLIATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MILLER H, 1987, METHOD ENZYMOL, V152, P145; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RICHARDSON CC, 1983, REPLICATION VIRAL CE, P163; RICHARDSON CC, 1987, UCLA S MOL CELL BIOL, V47, P151; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; VENKATESAN M, 1982, J BIOL CHEM, V257, P124; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YARRANTON GT, 1979, J BIOL CHEM, V254, P1997	43	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15013	15021						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321824				2022-12-25	WOS:A1992JF08800076
J	AMEMIYA, K; TRAUB, R; DURHAM, L; MAJOR, EO				AMEMIYA, K; TRAUB, R; DURHAM, L; MAJOR, EO			ADJACENT NUCLEAR FACTOR-I AND ACTIVATOR PROTEIN-BINDING SITES IN THE ENHANCER OF THE NEUROTROPIC JC VIRUS - A COMMON CHARACTERISTIC OF MANY BRAIN-SPECIFIC GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOMEGALO-VIRUS; RNA POLYMERASE-II; POLYOMAVIRUS-JC; DNA-BINDING; GLUCOCORTICOID RECEPTOR; OSTEOCALCIN GENE; NERVOUS-SYSTEM; CYCLIC-AMP; BK VIRUS; C-JUN	JC virus is a neurotropic virus that causes the demyelinating disease progressive multifocal leukoencephalopathy in humans. In order to understand the neurotropic nature of this virus, we examined the binding of nuclear proteins to the viral regulatory region. A close association of nuclear factor-1 (NF-1) and Jun protein binding sites was found. These binding sites were either adjacent or overlapped each other. Depending on the order of binding, there was some interference of binding of the NF-1 protein by Jun even at a non-Jun binding site. This suggests that there may be a direct interaction between these proteins. Examination of the regulatory region of a number of genes expressed in the central and peripheral nervous systems revealed that many of these genes apparently have adjacent NF-1 and activator protein binding sites immediately upstream from the the mRNA start site. Since it had been demonstrated that nuclear proteins from brain and non-brain cells could interact with these sites, it is probable that the NF-1- and Jun-related proteins which interact at these sites are involved in the basal activity of these genes. It appears that adjacent binding sites for NF-1 and Jun immediately upstream from the mRNA start site may be a characteristic of many genes expressed in the nervous system.	IGEN INC,ROCKVILLE,MD 20852		AMEMIYA, K (corresponding author), NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,MOLEC VIROL & GENET SECT,BLDG 36,BETHESDA,MD 20892, USA.							ALLORE RJ, 1990, J BIOL CHEM, V265, P15537; AMEMIYA K, 1989, J BIOL CHEM, V264, P7025; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BESNARD F, 1991, J BIOL CHEM, V266, P18877; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COMB M, 1988, EMBO J, V7, P3797; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HENNIGHAUSEN L, 1986, EMBO J, V5, P1367, DOI 10.1002/j.1460-2075.1986.tb04368.x; JEANG KT, 1987, J VIROL, V61, P1559, DOI 10.1128/JVI.61.5.1559-1570.1987; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONT C, 1990, CELL, V62, P1189; KAMHOLZ J, 1988, J NEUROSCI RES, V21, P62, DOI 10.1002/jnr.490210110; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KERR D, 1991, J BIOL CHEM, V266, P15876; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARKOWITZ RB, 1991, J VIROL, V65, P4515, DOI 10.1128/JVI.65.8.4515-4519.1991; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORGELLO S, 1987, HUM PATHOL, V18, P289, DOI 10.1016/S0046-8177(87)80012-6; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; NAVE KA, 1991, J NEUROSCI, V11, P3060; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PADGETT BL, 1977, INFECT IMMUN, V15, P656, DOI 10.1128/IAI.15.2.656-662.1977; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SALZMAN NP, 1986, PAPOVAVIRIDAE, V1, P27; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STAMMINGER T, 1990, J GEN VIROL, V71, P105, DOI 10.1099/0022-1317-71-1-105; SUNDSFJORD A, 1990, J VIROL, V64, P3864, DOI 10.1128/JVI.64.8.3864-3871.1990; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; VINTERS HV, 1989, BRAIN, V112, P245, DOI 10.1093/brain/112.1.245; WILEY CA, 1986, J NEUROPATH EXP NEUR, V45, P127, DOI 10.1097/00005072-198603000-00003; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	59	99	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14204	14211						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321139				2022-12-25	WOS:A1992JD32500065
J	BEGGS, AH; BYERS, TJ; KNOLL, JHM; BOYCE, FM; BRUNS, GAP; KUNKEL, LM				BEGGS, AH; BYERS, TJ; KNOLL, JHM; BOYCE, FM; BRUNS, GAP; KUNKEL, LM			CLONING AND CHARACTERIZATION OF 2 HUMAN SKELETAL-MUSCLE ALPHA-ACTININ GENES LOCATED ON CHROMOSOME-1 AND CHROMOSOME-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; MUSCULAR-DYSTROPHY; BETA-SPECTRIN; DMD GENE; SEQUENCE; PROTEIN; CDNA; EXPRESSION; LOCALIZATION; MOUSE	Conserved sequences of dystrophin, beta-spectrin, and alpha-actinin were used to plan a set of degenerate oligonucleotide primers with which we amplified a portion of a human alpha-actinin gene transcript. Using this short clone as a probe, we isolated and characterized full-length cDNA clones for two human alpha-actinin genes (ACTN2 and ACTN3). These genes encode proteins that are structurally similar to known alpha-actinins with approximately 80% amino acid identity to each other and to the previously characterized human nonmuscle gene. ACTN2 is the human homolog of a previously characterized chicken gene while ACTN3 represents a novel gene product. Northern blot analysis demonstrated that ACTN2 is expressed in both skeletal and cardiac muscle, but ACTN3 expression is limited to skeletal muscle. As with other muscle-specific isoforms, the EF-hand domains in ACTN2 and ACTN3 are predicted to be incapable of binding calcium, suggesting that actin binding is not calcium sensitive. ACTN2 was mapped to human chromosome 1q42-q43 and ACTN3 to 11q13-q14 by somatic cell hybrid panels and fluorescent in situ hybridization. These results demonstrate that rome of the isoform diversity of alpha-actinins is the result of transcription from different genetic loci.	HARVARD UNIV,SCH MED,DIV GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	BEGGS, AH (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,BOSTON,MA 02115, USA.			Beggs, Alan/0000-0001-8818-0568; Knoll, Joan/0000-0001-6691-1710	NICHD NIH HHS [HD18658] Funding Source: Medline; NINDS NIH HHS [NS23740] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD018658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023740] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARIMURA C, 1988, EUR J BIOCHEM, V177, P649, DOI 10.1111/j.1432-1033.1988.tb14419.x; BARON MD, 1987, J BIOL CHEM, V262, P17623; BARON MD, 1987, J BIOL CHEM, V262, P2558; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BEGGS AH, 1990, HUM GENET, V86, P45; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BRUNS G, 1987, HUM GENET, V76, P58; BRUNS GAP, 1979, BIOCHEM GENET, V17, P1031, DOI 10.1007/BF00504344; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DEGROUCHY J, 1978, ANNU REV GENET, V12, P289; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; EBASHI S, 1965, J BIOCHEM-TOKYO, V58, P7, DOI 10.1093/oxfordjournals.jbchem.a128167; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; GEIGER B, 1981, J CELL BIOL, V91, P614, DOI 10.1083/jcb.91.3.614; HAMMONDS RG, 1987, CELL, V51, P1, DOI 10.1016/0092-8674(87)90002-X; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HOFFMAN EP, 1989, J CELL BIOL, V108, P503, DOI 10.1083/jcb.108.2.503; HUEBNER K, 1985, P NATL ACAD SCI USA, V82, P3790, DOI 10.1073/pnas.82.11.3790; JOCKUSCH BM, 1980, EXP CELL RES, V127, P409, DOI 10.1016/0014-4827(80)90445-0; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KOBAYASHI R, 1983, EUR J BIOCHEM, V133, P607, DOI 10.1111/j.1432-1033.1983.tb07505.x; KOBAYASHI R, 1989, EUR J BIOCHEM, V185, P297, DOI 10.1111/j.1432-1033.1989.tb15115.x; KOBAYASHI R, 1984, EUR J BIOCHEM, V143, P125, DOI 10.1111/j.1432-1033.1984.tb08351.x; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kretsinger R H, 1980, Ann N Y Acad Sci, V356, P14, DOI 10.1111/j.1749-6632.1980.tb29594.x; LAING NG, 1992, AM J HUM GENET, V50, P576; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; LEINWAND LA, 1983, SCIENCE, V221, P766, DOI 10.1126/science.6879174; LEVINE BA, 1990, FEBS LETT, V263, P159, DOI 10.1016/0014-5793(90)80728-2; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIMURA N, 1987, J BIOL CHEM, V262, P4717; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; OLSEN DR, 1989, AM J HUM GENET, V44, P876; SAEZ LJ, 1987, NUCLEIC ACIDS RES, V15, P5443, DOI 10.1093/nar/15.13.5443; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHAT FH, 1985, J CELL BIOL, V101, P1001, DOI 10.1083/jcb.101.3.1001; SINGH I, 1977, BIOCHIM BIOPHYS ACTA, V491, P29, DOI 10.1016/0005-2795(77)90038-1; SOMMER R, 1989, NUCLEIC ACIDS RES, V17, P6749, DOI 10.1093/nar/17.16.6749; SUZUKI A, 1973, BIOCHIM BIOPHYS ACTA, V295, P188, DOI 10.1016/0005-2795(73)90087-1; VANDEKERCKHOVE J, 1978, EUR J BIOCHEM, V90, P451, DOI 10.1111/j.1432-1033.1978.tb12624.x; WALLRAFF E, 1986, EMBO J, V5, P61, DOI 10.1002/j.1460-2075.1986.tb04178.x; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	55	246	259	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9281	9288						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1339456				2022-12-25	WOS:A1992HR85400088
J	KIM, H; PATEL, MS				KIM, H; PATEL, MS			CHARACTERIZATION OF 2 SITE-SPECIFICALLY MUTATED HUMAN DIHYDROLIPOAMIDE DEHYDROGENASES (HIS-452-]GLN AND GLU-457-]GLN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; LIPOAMIDE DEHYDROGENASE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; CATALYTIC MECHANISM; PIG HEART; RESOLUTION; COMPLEXES; ENZYME	Two site-specifically mutated human dihydrolipoamide dehydrogenases (His-452 --> Gln and Glu-457 --> Gln) were expressed in pyruvate dehydrogenase complex-deletion mutant Escherichia coli JRG1342. The expressed mutant E3s were purified to near homogeneity using DEAE-Sephacel and hydroxyapatite columns. The initial velocity measurements in the absence of products for the Gln-452 mutant E3 in the direction of NAD+ reduction showed parallel lines in double-reciprocal plots, indicating that the mutant E3, like wild-type enzyme, catalyzed E3 reaction via a ping-pong mechanism. The specific activity of the Gln-452 mutant E3 was about 0.2% of that of wild-type enzyme. Its K(m) for dihydrolipoamide was dramatically increased by 63-fold. The substitution of His-452 to Gln resulted in a destabilization of the transition state of human E3 catalysis by about 6.4 kcal mol-1. The Gln-457 mutant E3, unlike wild-type enzyme, catalyzed E3 reaction via a sequential mechanism in the direction of NAD+ reduction based on the intersecting lines shown on double-reciprocal plots. Its specific activity decreased to 28% of that of wild-type enzyme. Its K(m) for dihydrolipoamide increased about 4.3-fold. The substitution of Glu-457 to Gln resulted in a destabilization of the transition state by about 1.7 kcal mol-1. These results indicate that His-452, which is a possible proton acceptor/donor in human E3 reaction, is critical to human E3 catalysis and that the local environment around His-452 and Glu-457, which are suggested to be hydrogen-bonded, is important in the binding of dihydrolipoamide to the enzyme.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, 2109 ABINGTON RD, CLEVELAND, OH 44106 USA	Case Western Reserve University					NIDDK NIH HHS [DK20478, DK42885] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478, R01DK042885] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON N, 1988, BIOCHEM J, V256, P741, DOI 10.1042/bj2560741; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9602, DOI 10.1021/bi00451a008; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KIM HJ, 1991, J BIOL CHEM, V266, P9367; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MANNERVIK B, 1973, BIOCHEM BIOPH RES CO, V53, P1151, DOI 10.1016/0006-291X(73)90585-8; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MATTHEWS RG, 1977, J BIOL CHEM, V252, P3199; PAI EF, 1983, J BIOL CHEM, V258, P1752; PONS G, 1988, P NATL ACAD SCI USA, V85, P1422, DOI 10.1073/pnas.85.5.1422; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; STAAL GEJ, 1969, BIOCHIM BIOPHYS ACTA, V185, P49, DOI 10.1016/0005-2744(69)90281-2; THEKKUMKARA TJ, 1989, ANN NY ACAD SCI, V573, P113, DOI 10.1111/j.1749-6632.1989.tb14990.x; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; WALKER JL, 1986, J BIOL CHEM, V261, P2214; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Williams CH., 1976, ENZYMES, P89; Williams Jr C.H., 1989, ANN N Y ACAD SCI, V573, P55; YOUNG JF, 1983, P NATL ACAD SCI-BIOL, V80, P6105, DOI 10.1073/pnas.80.19.6105	24	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5128	5132						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1347528				2022-12-25	WOS:A1992HH74700022
J	HIBI, K; TAKAHASHI, T; YAMAKAWA, K; UEDA, R; SEKIDO, Y; ARIYOSHI, Y; SUYAMA, M; TAKAGI, H; NAKAMURA, Y; TAKAHASHI, T				HIBI, K; TAKAHASHI, T; YAMAKAWA, K; UEDA, R; SEKIDO, Y; ARIYOSHI, Y; SUYAMA, M; TAKAGI, H; NAKAMURA, Y; TAKAHASHI, T			3 DISTINCT REGIONS INVOLVED IN 3P DELETION IN HUMAN LUNG-CANCER	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; SHORT ARM; DNA-SEQUENCE; CHROMOSOME-3; HETEROZYGOSITY; GENE; ADENOCARCINOMA; EXPRESSION; MYC; ABNORMALITIES	The 3p deletion was first noted by cytogenetic analysis and was later confirmed by several independent studies using restriction fragment length polymorphism (RFLP) probes. As an initial step towards positional cloning (reverse genetics) of the tumor-suppressor gene(s) on 3p, a detailed analysis of the minimum deleted region(s) on 3p was performed with 13 RFLP probes and 48 paired human lung cancer samples. All nine small-cell lung cancer cases (100%) and 31 of 39 non-small-cell lung cancer cases (79%) showed allelic loss at one or more loci mapped on 3p. We show here that three distinct regions on 3p appear to be frequently deleted in lung cancer. These regions include 3p25, 3p21.3 and 3p14-cen. The present study should warrant future work focusing on these chromosomal regions on 3p, and may ultimately lead to the isolation of tumor-suppressor genes involved in the pathogenesis of lung cancer.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT SURG 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; JAPANESE FDN CANC RES,INST CANC,BIOCHEM LAB,TOSHIMA KU,TOKYO 170,JAPAN; AICHI CANC CTR,DEPT SURG,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center; Nagoya University; Nagoya University; Japanese Foundation for Cancer Research; Aichi Cancer Center; Aichi Cancer Center			Takahashi, Takashi/I-7262-2014; Yamakawa, Kazuhiro/N-5050-2015	Takahashi, Takashi/0000-0003-0615-7001; Yamakawa, Kazuhiro/0000-0002-1478-4390; Sekido, Yoshitaka/0000-0002-2428-3848				BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1991, ONCOGENE, V6, P2291; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; NAU M, 1985, P NATL ACAD SCI USA, V83, P1092; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SEKIDO Y, 1991, CANCER RES, V51, P2416; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	34	278	283	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					445	449						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347916				2022-12-25	WOS:A1992HK00500007
J	ARTEMYEV, NO; RARICK, HM; MILLS, JS; SKIBA, NP; HAMM, HE				ARTEMYEV, NO; RARICK, HM; MILLS, JS; SKIBA, NP; HAMM, HE			SITES OF INTERACTION BETWEEN ROD G-PROTEIN ALPHA-SUBUNIT AND CGMP-PHOSPHODIESTERASE GAMMA-SUBUNIT - IMPLICATIONS FOR THE PHOSPHODIESTERASE ACTIVATION MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; AMINO-ACID SEQUENCE; OUTER SEGMENTS; INHIBITORY SUBUNIT; CDNA SEQUENCE; RETINAL RODS; TRANSDUCIN; BOVINE; CASCADE	In photoreceptor cells of vertebrates light activates a series of protein-protein interactions resulting in activation of a cGMP-phosphodiesterase (PDE). Interaction between the GTP-bound form of rod G-protein alpha-subunit (alpha(t)) and PDE inhibitory gamma-subunit (Pgamma) is a key event for effector enzyme activation. This interaction has been studied using Pgamma labeled with the fluorescent probe, lucifer yellow vinyl sulfone, at Cys-68 (PgammaLY) and sites of interaction on alpha(t) and Pgamma have been investigated. Addition of alpha(t)GTPgammaS to PgammaLY produced a 3.2-fold increase in the fluorescence of PgammaLY. The K(d) for alpha(t)GTPgammaS.PgammaLY interaction was 36 nM. Addition of 1 muM alpha(t)GDP had no effect, but in the presence of AlF4-, alpha(t)GDP increased PgammaLY fluorescence by 85%. When PgammaLY was reconstituted with Palphabeta to form fluorescent holo-PDE, alpha(t)GTPgammaS increased the fluorescence of holo-PDE with a K0.5 = 0.7 muM. Also, alpha(t)GTPgammaS stimulated the activity of this PDE over an identical range of concentrations with a similar K0.5 (0.6 muM). alpha(t)GTPgammaS enhanced the fluorescence of a COOH-terminal Pgamma fragment, PgammaLY-46-87, as well (K(d) = 1.5 muM). We demonstrate that an alpha(t) peptide, alpha(t)-293-314, which activated PDE (Rarick, H. M., Artemyev, N. O., and Hamm, H. E. (1992) Science 256, 1031-1033), mediates PDE activation by interacting with the Pgamma-46-87 region. Peptide alpha(t)-293-314 bound to PgammaLY (K0.5 = 1.2 muM) as well as to the carboxyl-terminal Pgamma fragment, PgammaLY-46-87 (K0.5 = 1.7 muM) as measured by fluorescence increase, while other alpha(t) peptides had no effect. A peptide from the Pgamma central region, Pgamma-24-46, blocked the interaction between alpha(t)GTPgammaS and PgammaLY. The K(d) for alpha(t)GTPgammaS.Pgamma-24-46 interaction was 0.7 muM. On the other hand, Pgamma-24-46 had no effect on alpha(t)-293-314 interaction with PgammaLY. Our data suggest that there are at least two distinct sites of interaction between alpha(t)GTPgammaS and Pgamma. The interaction between alpha(t)-293-314 and Pgamma-46-87 is important for PDE activation. A second site of interaction involves the Pgamma-24-46 region and an as yet unknown region on the alpha(t) subunit. We suggest that the initial step of PDE activation by alpha(t) includes the binding of alpha(t) to the COOH-terminal region of Pgamma with the formation of an intermediate complex, alpha(t)-Pgamma-Palphabeta in which Pgamma is still bound to Palphabeta through its central region. An alpha(t)-induced conformational change in the Pgamma-24-46 region may result in a decreased affinity of Pgamma for Palphabeta and an increased affinity for alpha(t).	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, BOX 6998, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-06062] Funding Source: Medline; NHLBI NIH HHS [T32HL07692] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006062] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007692] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONNY B, 1990, FEBS LETT, V268, P277, DOI 10.1016/0014-5793(90)81027-L; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; ERICKSON JW, 1991, BIOCHEMISTRY-US, V30, P7112, DOI 10.1021/bi00243a011; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; HINGORANI VN, 1988, J BIOL CHEM, V263, P19804; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; KROLL S, 1989, J BIOL CHEM, V264, P4490; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MALINSKI JA, 1992, IN PRESS BIOCHEMISTR; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; STEWART WW, 1981, J AM CHEM SOC, V103, P7615, DOI 10.1021/ja00415a033; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	34	75	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25067	25072						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334079				2022-12-25	WOS:A1992KB60300026
J	ASTROM, A; PETTERSSON, U; VOORHEES, JJ				ASTROM, A; PETTERSSON, U; VOORHEES, JJ			STRUCTURE OF THE HUMAN CELLULAR RETINOIC ACID-BINDING PROTEIN-II GENE - EARLY TRANSCRIPTIONAL REGULATION BY RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT TERATOCARCINOMA CELLS; CHAIN-TERMINATING INHIBITORS; PROMOTER-SPECIFIC ACTIVATION; SELECTIVE RESPONSE ELEMENTS; COMPLEMENTARY-DNA SEQUENCE; CARCINOMA PCC4.AZA1R CELLS; MESSENGER-RNA EXPRESSION; SKIN FIBROBLASTS INVITRO; GROWTH-POTENTIAL INVITRO; RECEPTOR-BETA GENES	The gene for human cellular retinoic acid-binding protein II (CRABP-II) has been cloned. It was isolated from a human placenta genomic library and is contained within one bacteriophage clone. The gene spans 6 kilobases and consists of 4 exons. One major transcription initiation site was mapped to an A residue 137 nucleotides upstream of the ATG initiation codon. The upstream region contains a TATA box and potential AP2, Sp1, and Krox-24 binding sites, as well as a direct repeat with homology to a retinoic acid-responsive element. The CRABP-II mRNA was rapidly induced within 2-6 h in cultured human skin fibroblasts by retinoic acid, reaching a plateau after 6 h of treatment. The rapid increase of CRABP-II message was mainly due to an increased rate of transcription as determined by nuclear run-on experiments. Increased transcription could be detected as early as 1 h after addition of retinoic acid, peaked at 2 h, and returned to basal levels within 6 h. On-going protein synthesis was required for this transient increase of transcription, since the induction was blocked by cycloheximide. These data suggest that the human CRABP-II gene is transcriptionally regulated by a newly synthesized regulatory protein.			ASTROM, A (corresponding author), UNIV MICHIGAN,DEPT DERMATOL,KRESGE I,R6558,ANN ARBOR,MI 48109, USA.							ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ASSELINEAU D, 1989, DEV BIOL, V133, P322, DOI 10.1016/0012-1606(89)90037-7; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CLEVELAND D W, 1989, New Biologist, V1, P121; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; ELDER JT, 1990, J INVEST DERMATOL, V94, P19, DOI 10.1111/1523-1747.ep12873313; EWARDS SA, 1991, DEV BIOL, V148, P165; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARPER RA, 1979, SCIENCE, V204, P526, DOI 10.1126/science.432659; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NERVI C, 1990, CELL GROWTH DIFFER, V1, P535; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SPORN MB, 1983, CANCER RES, V43, P3034; STONER CM, 1989, CANCER RES, V49, P1497; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	43	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25251	25255						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334086				2022-12-25	WOS:A1992KB60300053
J	KOSUGI, S; OKAJIMA, F; BAN, T; HIDAKA, A; SHENKER, A; KOHN, LD				KOSUGI, S; OKAJIMA, F; BAN, T; HIDAKA, A; SHENKER, A; KOHN, LD			MUTATION OF ALANINE 623 IN THE 3RD CYTOPLASMIC LOOP OF THE RAT THYROTROPIN (TSH) RECEPTOR RESULTS IN A LOSS IN THE PHOSPHOINOSITIDE BUT NOT CAMP SIGNAL INDUCED BY TSH AND RECEPTOR AUTOANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-DIRECTED MUTAGENESIS; THYROID-CELLS; CYCLIC-AMP; STIMULATION; ASSIGNMENT; DOMAINS; BINDING; REGIONS; GENE	Thyrotropin (TSH) and IgG preparations from patients with Graves' disease increase inositol phosphate as well as cAMP formation in Cos-7 cells transfected with rat TSH receptor cDNA. Mutation of alanine 623 in the carboxyl end of the third cytoplasmic loop of the TSH receptor, to lysine or glutamic acid, results in the loss of TSH- and Graves' IgG-stimulated inositol phosphate formation but not in stimulated cAMP formation. There is no effect of the mutations on basal or P2-purinergic receptor-mediated inositol phosphate formation. The mutations do not affect transfection efficiency or the synthesis, processing, or membrane integration of the receptor, as evidenced by the unchanged amount and composition of the TSH receptor forms on Western blots of membranes from transfected cells. The mutations increase the affinity of the TSH receptor for [I-125]TSH and decrease B(max); however, cells with an equivalently decreased B(max) as a result of transfection with lower levels of wild type receptor do not lose either TSH-induced inositol phosphate formation or cAMP signaling activity. Thus, in addition to discriminating between ligand-induced phosphatidylinositol bisphosphate and cAMP signals, the mutation appears to cause an altered receptor conformation which affects ligand binding to its large extracellular domain.	NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	KOSUGI, S (corresponding author), NIDDKD,CELL REGULAT SECT,BIOCHEM & METAB LAB,BETHESDA,MD 20892, USA.		KOSUGI, Shinji/GYR-2946-2022					AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; BAN T, 1992, ENDOCRINOLOGY, V131, P815, DOI 10.1210/en.131.2.815; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CORDA D, 1985, J BIOL CHEM, V260, P9230; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DICERBO A, 1992, J CLIN ENDOCR METAB, V74, P585, DOI 10.1210/jc.74.3.585; FIELD JB, 1987, BIOCHEM J, V247, P519, DOI 10.1042/bj2470519; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; JI IH, 1991, J BIOL CHEM, V266, P14953; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1992, MOL ENDOCRINOL, V6, P166; LAURENT E, 1991, J CLIN INVEST, V87, P1634, DOI 10.1172/JCI115178; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ROUSSEAUMERCK MF, 1990, GENOMICS, V8, P233, DOI 10.1016/0888-7543(90)90276-Z; SHO K, 1991, J BIOL CHEM, V266, P12180; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; TAHARA K, 1991, J BIOL CHEM, V266, P440; THOMPSON EB, 1992, MOL ENDOCRINOL, V6, P501, DOI 10.1210/me.6.4.501; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q	23	141	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24153	24156						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332945				2022-12-25	WOS:A1992KA26300002
J	KANAHO, Y; TAKAHASHI, K; TOMITA, U; IIRI, T; KATADA, T; UI, M; NOZAWA, Y				KANAHO, Y; TAKAHASHI, K; TOMITA, U; IIRI, T; KATADA, T; UI, M; NOZAWA, Y			A PROTEIN-KINASE-C INHIBITOR, STAUROSPORINE, ACTIVATES PHOSPHOLIPASE-D VIA A PERTUSSIS TOXIN-SENSITIVE GTP-BINDING PROTEIN IN RABBIT PERITONEAL NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 GRANULOCYTES; CHEMOTACTIC PEPTIDE; SIGNAL TRANSDUCTION; PHORBOL ESTERS; ALPHA-SUBUNITS; COMPOUND 48/80; MAST-CELLS; WASP VENOM; PHOSPHATIDYLCHOLINE; MASTOPARAN	In rabbit peritoneal neutrophils prelabeled with [H-3] lyso platelet-activating factor, a protein kinase C inhibitor, staurosporine (> 1 muM), increased [H-3]phosphatidylethanol ([H-3]PEt) level in the presence of ethanol in a concentration- and time-dependent manner, providing evidence for staurosporine activation of phospholipase D (PLD). The staurosporine activation of the enzyme absolutely required both extracellular calcium and cytochalasin B, and was almost completely inhibited by pretreatment of the cells with pertussis toxin (IAP). In a reconstituted system where the purified G(i1) had been incorporated into phospholipid vesicles, staurosporine activated GTPase activity of G(i1) in a concentration-dependent fashion, with a maximal 4-5-fold effect. ADP-ribosylation by IAP of G(i1) in vesicles significantly suppressed the staurosporine activation. As with the GTPase activity of G(i1), GTPase activities of other purified IAP-sensitive G proteins, such as G(i2)) and G(o), were significantly stimulated by staurosporine, but the cholera toxin substrate G(s) was appreciably less sensitive to the staurosporine stimulation. The staurosporine activation of GTPase was also observed in rabbit neutrophil membranes from control cells, but not in membranes from IAP-treated neutrophils. From these results, we conclude that the staurosporine activation of PLD in rabbit neutrophils is attributed to the direct activation of an IAP-sensitive G protein in a similar manner to receptors occupied by agonists. By contrast, staurosporine failed to activate phosphoinositide-specific phospholipase C (PI-PLC) under the conditions in which it activated PLD, indicating that there exists a PLD activation pathway independent of PI-PLC. Furthermore, it was found that N-acetyl-beta-glucosaminidase release from the granules of intact neutrophils was evoked by staurosporine to almost the same extent as by fMLP (100 nM), but O2- generation was not affected. These results suggest a possibility that PLD pathway plays an important role in enzyme release, but is not sufficient for O2- generation, in rabbit peritoneal neutrophils.	TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN	Tokyo Institute of Technology; University of Tokyo	KANAHO, Y (corresponding author), GIFU UNIV,SCH MED,DEPT BIOCHEM,TSUKASAMACHI 40,GIFU 500,JAPAN.							AGWU DE, 1989, J BIOL CHEM, V264, P1405; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BECKER EL, 1979, AM J PATHOL, V95, P81; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; CATT KJ, 1973, NATURE-NEW BIOL, V244, P219, DOI 10.1038/newbio244219a0; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DECKMYN H, 1991, G PROTEINS, P429; EXTON JH, 1990, J BIOL CHEM, V265, P1; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; HALENDA SP, 1990, BIOCHEM J, V267, P479, DOI 10.1042/bj2670479; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HUANG R, 1991, J BIOL CHEM, V266, P1652; KANAHO Y, 1992, J IMMUNOL, V149, P622; KANAHO Y, 1989, CELL SIGNAL, V1, P553, DOI 10.1016/0898-6568(89)90063-6; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KANAHO Y, 1991, FEBS LETT, V279, P249, DOI 10.1016/0014-5793(91)80160-5; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OKANO Y, 1985, FEBS LETT, V188, P363, DOI 10.1016/0014-5793(85)80403-8; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PAI JK, 1988, J BIOL CHEM, V263, P12472; SEISHIMA M, 1988, BIOCHEM BIOPH RES CO, V156, P1077, DOI 10.1016/S0006-291X(88)80742-3; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOMITA U, 1991, J BIOCHEM-TOKYO, V109, P184, DOI 10.1093/oxfordjournals.jbchem.a123342; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WONG K, 1992, BIOCHEM J, V283, P499, DOI 10.1042/bj2830499; YANG SF, 1967, J BIOL CHEM, V242, P477	40	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23554	23559						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331088				2022-12-25	WOS:A1992JZ23900023
J	VILEN, BJ; PENTA, JF; TING, JPY				VILEN, BJ; PENTA, JF; TING, JPY			STRUCTURAL CONSTRAINTS WITHIN A TRIMERIC TRANSCRIPTIONAL REGULATORY REGION - CONSTITUTIVE AND INTERFERON-GAMMA-INDUCIBLE EXPRESSION OF THE HLA-DRA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II GENES; INVARIANT CHAIN GENE; ACTIVATED T-CELLS; ALPHA GENE; ANTIGEN PRESENTATION; IMMUNE INTERFERON; BINDING PROTEINS; NUCLEAR PROTEINS; IA-ANTIGEN	Constitutive and inducible transcription of the major histocompatability class II HLA-DRA gene involves the upstream S element and the conserved X and Y elements. In this report we have addressed the roles of spatial constraints and stereospecific alignment between the upstream S and X elements, and the X and Y elements, in both constitutive and interferon-gamma (gamma-IFN)-induced expression. Analysis of the constitutive expression in B cell lines (B-LCL) has previously shown that the X and Y elements must be stereo-aligned. Further study reveals that any spacing changes between S and X, regardless of the helical alignment of these two elements, is not tolerated. These same restraints are involved in an inducible system, because the response to gamma-IFN treatment requires both stereo alignment between the X and Y elements and precise spacing between the S and X elements. Neither constitutive nor inducible expression can be restored by correcting the distance and spacing between only the S and Y elements with misalignment of X. These results reveal a common pathway for constitutive and inducible expression that may require either direct or indirect protein complex formation among proteins bound to three highly conserved regulatory elements. We have also evaluated the role of the A/T-rich sequence located immediately 5' of the Y element and show that it exerts little effect on constitutive and gamma-IFN induced DRA expression.	UNIV CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA 48185] Funding Source: Medline; PHS HHS [P32-A1-07273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON G, 1990, J IMMUNOL, V145, P3456; BASHAM TY, 1983, J IMMUNOL, V130, P1492; BASTA PV, 1987, J IMMUNOL, V138, P1275; BASTA PV, 1988, P NATL ACAD SCI USA, V85, P8618, DOI 10.1073/pnas.85.22.8618; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BLACKMAN MA, 1989, SCIENCE, V244, P214, DOI 10.1126/science.2784868; BOTTAZZO GF, 1983, LANCET, V2, P1115; BROWN AM, 1991, J IMMUNOL, V146, P3183; COGSWELL JP, 1991, CRIT REV IMMUNOL, V11, P87; COGSWELL JP, 1990, P NATL ACAD SCI USA, V87, P7703, DOI 10.1073/pnas.87.19.7703; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; FIERZ W, 1985, J IMMUNOL, V134, P3785; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; HAMMERLING GJ, 1976, TRANSPLANT REV, V30, P64; HARVEY C, 1991, MOL ENDOCRINOL, V5, P836, DOI 10.1210/mend-5-6-836; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P6269, DOI 10.1093/nar/19.22.6269; HOOD L, 1983, ANNU REV IMMUNOL, V1, P529, DOI 10.1146/annurev.iy.01.040183.002525; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KORMAN AJ, 1985, IMMUNOL REV, V85, P45, DOI 10.1111/j.1600-065X.1985.tb01130.x; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; MASSA PT, 1987, P NATL ACAD SCI USA, V84, P4219, DOI 10.1073/pnas.84.12.4219; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIWA K, 1987, P NATL ACAD SCI USA, V84, P4939, DOI 10.1073/pnas.84.14.4939; MOSES H, 1992, J IMMUNOL, V148, P3643; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PETERLIN BM, 1990, IMMUNOL RES, V9, P164, DOI 10.1007/BF02918176; POBER JS, 1983, J EXP MED, V157, P1339, DOI 10.1084/jem.157.4.1339; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; ROBBINS PA, 1988, J IMMUNOL, V141, P1281; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAKURAI M, 1988, P NATL ACAD SCI USA, V85, P6909, DOI 10.1073/pnas.85.18.6909; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SERVENIUS B, 1987, J BIOL CHEM, V262, P8759; SHERMAN PA, 1989, MOL CELL BIOL, V9, P50, DOI 10.1128/MCB.9.1.50; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4254, DOI 10.1073/pnas.84.12.4254; SLOAN JH, 1992, J IMMUNOL, V148, P2591; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TANESE N, 1991, ENES DEV, V5, P2212; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; WAIBEL F, 1990, NATURE, V346, P199, DOI 10.1038/346199a0; WILLMAN CL, 1989, J EXP MED, V170, P1559, DOI 10.1084/jem.170.5.1559; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WU L, 1988, GENE DEV, V2, P403, DOI 10.1101/gad.2.4.403; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873	56	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23728	23734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331098				2022-12-25	WOS:A1992JZ23900047
J	DEGROOT, RP; SASSONECORSI, P				DEGROOT, RP; SASSONECORSI, P			ACTIVATION OF JUN/AP-1 BY PROTEIN KINASE-A	ONCOGENE			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CLONED PLACENTAL CDNA; DNA-BINDING PROTEINS; C-FOS GENE; CYCLIC-AMP; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; POSITIVE REGULATION; ENHANCER ELEMENTS; MAMMALIAN-CELLS	The product of the c-jun proto-oncogene is the major component of the 12-O-tetradecanoyl phorbol 13-acetate (TPA)-inducible transcription factor AP-1. Jun binds to the TPA-responsive elements (TREs) present in a large number of TPA-inducible genes, thereby regulating their expression in response to activation of protein kinase C. Previously we have shown that Jun/AP-1 can also activate cAMP-responsive elements (CREs), indicating the existence of cross-talk in signal transduction at the transcriptional level. Here we show that Jun/AP-1 is activated by the cAMP-dependent protein kinase A (PKA). In transient transfection experiments, TRE activation by Jun is strongly enhanced by co-transfection of the catalytic subunit of PKA or forskolin treatment, although not in all cell types studied. Jun activity can be significantly inhibited by co-transfection of the regulatory subunit of PKA. Furthermore, we show a cell-specific increase in AP-1 binding in response to forkolin treatment. However, since direct phosphorylation of Jun by PKA does not occur, we suggest an indirect activation mechanism.	FAC MED STRASBOURG, GENET MOLEC EUCARYOTES LAB,CNRS,U184,INSERM, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AUWERX J, 1992, IN PRESS ONCOGENE; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRELLI E, 1992, IN PRESS CRC REV ONC; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DEGROOT RP, 1992, IN PRESS ONCOGENE; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	52	68	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2281	2286						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331936				2022-12-25	WOS:A1992JW66500021
J	SZEBERENYI, J; ERHARDT, P; CAI, H; COOPER, GM				SZEBERENYI, J; ERHARDT, P; CAI, H; COOPER, GM			ROLE OF RAS IN SIGNAL TRANSDUCTION FROM THE NERVE GROWTH-FACTOR RECEPTOR - RELATIONSHIP TO PROTEIN-KINASE-C, CALCIUM AND CYCLIC-AMP	ONCOGENE			English	Article							PC12 CELLS; TRK PROTOONCOGENE; ADENYLATE-CYCLASE; ONCOGENE PRODUCT; PHOSPHOLIPASE-C; 3T3 CELLS; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; INHIBITION	A dominant inhibitory ras mutant (Ha-ras Asn-17) has been used to investigate the role of Ras in nerve growth factor (NGF)-mediated signal transduction in PC12 cells. Expression of Ha-Ras Asn-17 blocks neuronal differentiation of these cells in response to NGF treatment. The Ha-Ras Asn-17 block was bypassed by treatment with NGF plus dibutyryl cAMP or NGF plus the Ca2+ ionophore ionomycin, but not by NGF plus 12-tetradecanoyl phorbol acetate (TPA). Direct stimulation of the cAMP or Ca2+ pathways thus appeared to act synergistically with a Ras-independent NGF signaling pathway. This Ras-independent pathway was also distinct from protein kinase C, since its activity was not affected by protein kinase C down-regulation. It thus appears that NGF stimulation generates a Ras-independent intracellular signal that contributes to neuronal differentiation independently of the cAMP, Ca2+ or protein kinase C second messenger systems Since TPA did not bypass the Ha-Ras Asn-17 block to differentiation, protein kinase C also did not appear to be sufficient for Ras-dependent pathways mediating NGF-induced differentiation. Down-regulation experiments further indicated that protein kinase C was not required for NGF induction of early response genes via either Ras-dependent or Ras-independent pathways. Moreover, the formation of inositol phosphates and mobilization of intracellular calcium in response to NGF was not inhibited in PC12 cells expressing the Ha-Ras Asn-17 protein. Therefore, although calcium was able to bypass the Ha-Ras Asn-17 block to PC12 differentiation, Ras activity was not required for activation of phospholipase C in response to NGF. It thus appears that both Ras-dependent and Ras-independent signaling pathways contribute to NGF-induced PC12 cell differentiation independently of the cAMP, calcium and protein kinase C second messenger systems.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADY MJ, 1990, J NEUROCHEM, V54, P1034, DOI 10.1111/j.1471-4159.1990.tb02354.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; COPELAND NG, 1979, CELL, V16, P347, DOI 10.1016/0092-8674(79)90011-4; CREMINS J, 1986, J CELL BIOL, V103, P887, DOI 10.1083/jcb.103.3.887; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1984, TRENDS NEUROSCI, V7, P91, DOI 10.1016/S0166-2236(84)80164-2; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HORWITZ J, 1987, METHOD ENZYMOL, V141, P169; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUGIMOTO Y, 1988, J BIOL CHEM, V263, P12102; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VICENTINI LM, 1986, BIOCHEM J, V234, P555, DOI 10.1042/bj2340555; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	51	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2105	2113						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331931				2022-12-25	WOS:A1992JW66500002
J	MOUILLAC, B; CARON, M; BONIN, H; DENNIS, M; BOUVIER, M				MOUILLAC, B; CARON, M; BONIN, H; DENNIS, M; BOUVIER, M			AGONIST-MODULATED PALMITOYLATION OF BETA-2-ADRENERGIC RECEPTOR IN SF9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; INFECTED INSECT CELLS; PHOSPHORYLATION SITES; TRANSFERRIN RECEPTOR; EXPRESSION VECTORS; C-MYC; PROTEIN; DESENSITIZATION; PALMITYLATION; BINDING	The palmitoylation of the human beta2-adrenergic receptor (beta2-AR) was studied in recombinant baculo-virus-infected insect Sf9 cells. At 48 h post-infection, a high level expression of an epitope-tagged beta2-AR (10-25 pmol/mg protein) was detected by [I-125]iodocyanopindolol ([I-125]CYP) binding assays. The identity of the receptor was confirmed both by photoaffinity labeling and immunoblotting. The fusion receptor displayed typical beta2-AR pharmacological properties and conferred a beta-adrenergic sensitive adenylyl cyclase activity to the Sf9 cells. Moreover, exposure of the Sf9 cells to the beta-adrenergic agonist isoproterenol induced a rapid desensitization of the receptor-stimulated adenylyl cyclase activity. Purification of the epitope-tagged beta2-AR by immunoprecipitation as well as by alprenolol-Sepharose affinity chromatography revealed that the receptor is covalently modified with palmitic acid in the insect cells as is observed in mammalian cells. In addition, short-term incubation of the cells with isoproterenol led to a specific increase in the incorporation of [H-3]palmitate in the receptor, consistent with a rapid agonist-modulated turnover of the beta2-AR-attached palmitic acid. These results suggest that agonist-mediated regulation of beta2-AR post-translational palmitoylation could represent an other regulatory process for G protein-coupled receptors.	UNIV MONTREAL,DEPT BIOCHEM,POB 6128,STN A,MONTREAL H3C 3J7,QUEBEC,CANADA; BIOTECHNOL RES INST,MONTREAL H4P 2R2,QUEBEC,CANADA	Universite de Montreal; National Research Council Canada			MOUILLAC, Bernard/M-3896-2014; Bouvier, Michel/H-2758-2014	MOUILLAC, Bernard/0000-0002-3906-8673; Bouvier, Michel/0000-0003-1128-0100				ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOUVIER M, 1987, MOL PHARMACOL, V33, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CIERNIEWSKI CS, 1989, J BIOL CHEM, V264, P12158; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PARKER EM, 1991, J BIOL CHEM, V266, P519; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RANDS E, 1990, J BIOL CHEM, V265, P10759; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SKANE JHP, 1989, J CELL BIOL, V108, P613; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WONG SKF, 1990, J BIOL CHEM, V265, P6219	32	178	181	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21733	21737						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328244				2022-12-25	WOS:A1992JV01100074
J	HOU, JZ; KAN, M; WANG, F; XU, JM; NAKAHARA, M; MCBRIDE, G; MCKEEHAN, K; MCKEEHAN, WL				HOU, JZ; KAN, M; WANG, F; XU, JM; NAKAHARA, M; MCBRIDE, G; MCKEEHAN, K; MCKEEHAN, WL			SUBSTITUTION OF PUTATIVE HALF-CYSTINE RESIDUES IN HEPARIN-BINDING FIBROBLAST GROWTH-FACTOR RECEPTORS - LOSS OF BINDING-ACTIVITY IN BOTH 2-LOOP AND 3-LOOP ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; PROTEINS; CLONING; FAMILY; COMMON; CELL	Alternate use of an exon coding for an 89-residue NH2 terminal immunoglobulin-like disulfide loop results in isoforms of the heparin-binding fibroblast growth factor receptor (FGF-R) with three (FGF-R-alpha) and two (FGF-R-beta) Ig-like loops in the extracellular domain. Both FGF-R-alpha and FGF-R-beta isoforms exhibit qualitatively similar ligand-binding activities. In this report, we show by site-directed mutagenesis and analysis of ligand-binding activity in transfected cells that substitution of a cysteine that potentially forms an intra-loop disulfide in either juxtamembrane Loop II or III disrupted maturation and formation of the ligand-binding site in both FGF-R-alpha and FGF-R-beta isoforms. Neither three loop FGF-R-alpha constructions coding for intact Loops I and II adjacent to defective Loop III nor intact Loops I and III separated by defective Loop II exhibited ligand-binding activity. In addition, a two-loop molecule of tandem Loops I and III was inactive. The results suggest that single Loops I, II, or III of FGF-R are insufficient to form a ligand-binding site. Loop I does not form an independent ligand-binding site with either Loop II or III, but interacts with a common ligand-binding site formed by Loops II and III (Xu, J., Nakahara, M., Crabb, J. W., Shi, E., Matuo, Y., Fraser, M., Kan, M., Hou, J., and McKeehan, W. L. (1992) J. Biol. Chem. 267, 17792-17803, 1992).	W ALTON JONES CELL SCI CTR, 10 OLD BARN RD, LAKE PLACID, NY 12946 USA						NCI NIH HHS [CA37589] Funding Source: Medline; NIDDK NIH HHS [DK40739, DK35310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040739, R01DK035310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN M, 1988, J BIOL CHEM, V263, P11306; KAN M, 1991, METHOD ENZYMOL, V198, P158; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PINNA LA, 1990, PEPT PROT PHOSPH, P145; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUDIKOFF S, 1986, P NATL ACAD SCI USA, V83, P7875, DOI 10.1073/pnas.83.20.7875; SHI E, 1991, J BIOL CHEM, V266, P5774; SHI E, 1991, Journal of Cell Biology, V115, p416A; SHI E, 1991, Journal of Cell Biology, V115, p417A; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; XU JM, 1992, J BIOL CHEM, V267, P17792	20	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17804	17808						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325450				2022-12-25	WOS:A1992JM22300052
J	KATO, A; GORES, GJ; LARUSSO, NF				KATO, A; GORES, GJ; LARUSSO, NF			SECRETIN STIMULATES EXOCYTOSIS IN ISOLATED BILE-DUCT EPITHELIAL-CELLS BY A CYCLIC AMP-MEDIATED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL RAT-LIVER; INTRACELLULAR PH; PLASMA-MEMBRANE; ENDOCYTOSIS; VESICLES; FLUORESCENCE; MICROTUBULES; HEPATOCYTES; ACIDOSIS; CULTURE	Intrahepatic bile duct epithelial cells, or cholangiocytes, contribute to bile secretion in response to hormones, including secretin. However, the mechanism by which secretin stimulates ductular bile flow is unknown. Since recent data in nonhepatic epithelia have suggested a role for exocytosis in fluid secretion, we tested the hypothesis that secretin stimulates exocytosis by isolated cholangiocytes. Cholangiocytes were isolated from normal rat liver by a newly described method employing enzymatic digestion and mechanical disruption followed by immunomagnetic separation using specific monoclonal antibodies, and exocytosis was measured using a fluorescence unquenching assay employing acridine orange. Secretin caused a dose-dependent (10(-12)-10(-7) M) increase in acridine orange fluorescence by acridine orange-loaded cholangiocytes with a peak response at 10 min; the half-maximal concentration of secretin was 7 x 10(-9) M. The secretin effect was inhibited by preincubation of cholangiocytes with colchicine (30% inhibition, p < 0.05) or trypsin (90% inhibition, p < 0.001); no inhibition was seen with lumicolchicine and heat-inactivated trypsin. Cholecystokinin, insulin, and somatostatin had no effect on fluorescence of acridine orange-loaded cholangiocytes; secretin had no effect on fluorescence of acridine orange-loaded hepatocytes or hepatic endothelial cells. Exposure of isolated cholangiocytes to secretin at doses that stimulated exocytosis caused a dose-dependent increase in cyclic AMP levels (218% maximal increase, p < 0.05); moreover, an analogue of cyclic AMP stimulated exocytosis by cholangiocytes. Secretin had no effect on intracellular calcium concentration using Fura-2-loaded cholangiocytes assessed by digitized video microscopy. Our results demonstrate, for the first time, that secretin stimulates exocytosis by rat cholangiocytes. The effect is cell- and hormone-specific, dependent on intact microtubules, on a protein(s) on the external surface of cholangiocytes, and on changes in cellular levels of cyclic AMP. The results are consistent with the hypothesis that secretin-induced changes in bile flow may involve an exocytic process.	MAYO MED SCH CLIN & FDN,CTR BASIC RES DIGEST DIS,DEPT INTERNAL MED,ROCHESTER,MN 55905; MAYO MED SCH CLIN & FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024031, R37DK024031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-24031, DK-45331] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPINI G, 1988, J CLIN INVEST, V81, P569, DOI 10.1172/JCI113355; ALVARO D, 1991, HEPATOLOGY, V14, pA152; ARGENT BE, 1986, Q J EXP PHYSIOL CMS, V71, P633, DOI 10.1113/expphysiol.1986.sp003023; BAFFER BM, 1990, GASTROENTEROLOGY, V98, pA218; BJERKNES R, 1984, SCAND J HAEMATOL, V33, P197; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; BUANES T, 1987, ACTA PHYSIOL SCAND, V131, P55, DOI 10.1111/j.1748-1716.1987.tb08205.x; BUANES T, 1988, GASTROENTEROLOGY, V95, P417, DOI 10.1016/0016-5085(88)90499-4; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CASE RM, 1986, EXOCRINE PANCREAS BI, P213; ERLINGER S, 1988, LIVER BIOL PATHOBIOL, P643; FAROUK M, 1990, HEPATOLOGY, V12, P917; FORKER EL, 1967, J CLIN INVEST, V46, P1189, DOI 10.1172/JCI105612; FORTE JG, 1989, HDB PHYSL, V3, P207; GOLDFARB S, 1963, J LAB CLIN MED, V62, P608; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GORES GJ, 1986, HEPATOLOGY, V6, P511, DOI 10.1002/hep.1840060331; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; GRAY EG, 1975, PROC R SOC SER B-BIO, V190, P369, DOI 10.1098/rspb.1975.0100; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENDERSO.PJ, 1969, BIOCHEM J, V111, P521, DOI 10.1042/bj1110521; HUBEL KA, 1972, GASTROENTEROLOGY, V62, P318; ISHII M, 1990, J HISTOCHEM CYTOCHEM, V38, P515, DOI 10.1177/38.4.2319122; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; ISHII M, 1990, GASTROENTEROLOGY, V98, P1284, DOI 10.1016/0016-5085(90)90346-3; JONES AL, 1990, HEPATOLOGY TXB LIVER, P3; KEMPSON SA, 1989, J BIOL CHEM, V264, P18451; KUIJPERS GAJ, 1989, J BIOL CHEM, V264, P698; LACY PE, 1975, LAB INVEST, V33, P570; LENZEN R, 1990, HEPATOLOGY, V12, P810; LUKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P258; NORTHRUP TE, 1979, AM J PHYSIOL, V236, pE649, DOI 10.1152/ajpendo.1979.236.6.E649; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; OLSSON GM, 1990, ANAL CELL PATHOL, V2, P179; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PLATTNER H, 1982, J CELL BIOL, V92, P368, DOI 10.1083/jcb.92.2.368; STUENKEL EL, 1990, PFLUG ARCH EUR J PHY, V416, P652, DOI 10.1007/BF00370610; TAVOLONI N, 1987, SEMIN LIVER DIS, V7, P280, DOI 10.1055/s-2008-1040583; TIETZ P S, 1992, Gastroenterology, V102, pA901; TOMODA H, 1989, J BIOL CHEM, V264, P15445; TRIMBLE ER, 1987, P NATL ACAD SCI USA, V84, P3146, DOI 10.1073/pnas.84.10.3146; VEEL T, 1990, ACTA PHYSIOL SCAND, V139, P603, DOI 10.1111/j.1748-1716.1990.tb08965.x; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; WARNOCK DG, 1982, AM J PHYSIOL, V242, pF733, DOI 10.1152/ajprenal.1982.242.6.F733; WHEELER HO, 1966, AM J PHYSIOL, V210, P1153, DOI 10.1152/ajplegacy.1966.210.5.1153; WILSON L, 1986, BIOCHEMISTRY-US, V5, P2463	47	151	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15523	15529						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322400				2022-12-25	WOS:A1992JG11300043
J	DO, MS; FITZERATTAS, C; GUBBAY, J; GREENFELD, L; FELDMAN, M; EISENBACH, L				DO, MS; FITZERATTAS, C; GUBBAY, J; GREENFELD, L; FELDMAN, M; EISENBACH, L			MOUSE PLATELET-DERIVED GROWTH FACTOR-ALPHA RECEPTOR - SEQUENCE, TISSUE-SPECIFIC EXPRESSION AND CORRELATION WITH METASTATIC PHENOTYPE	ONCOGENE			English	Article							TUMOR-CELL LINES; PDGF-RECEPTOR; TYROSINE KINASE; SARCOMA-VIRUS; STRUCTURAL SIMILARITY; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; TRANSFORMING GENE; PROTEIN-KINASE	High- and low-metastatic cells derived from metastatic murine tumors were screened for the differential expression of proto-oncogenes which may code for cell-surface receptors to growth factors. We found that metastatic clones of 3LL carcinoma and T10 sarcoma but not non-metastatic clones of these tumors express a 6.5-kb mRNA that is recognized by a v-fms probe containing a tyrosine kinase domain. The cloning and sequence analysis of a full-length cDNA clone corresponding to the v-fms-related 6.5-kb transcript showed that this transcript is the murine homolog of platelet-derived growth factor alpha (PDGF-alpha) receptor. The cDNA contains an open reading frame that predicts a 1089 amino acid protein. Comparison with the human and rat PDGF-alpha receptor reveals an overall amino acid sequence identity of 91% and 94% respectively. Northern blot analysis shows that this gene is preferentially expressed in the high-metastatic clones and is also selectively expressed in normal mouse tissues. Immunoprecipitation using anti-PDGF-alpha receptor serum shows that 185-kDa and 170-kDa proteins were specifically precipitated from cells of the high-metastatic D122 but not from the low-metastatic A9 cells. The possibility that overexpression of PDGF-alpha receptor in high-metastatic clones may contribute to an increase in the capacity of tumor cells to generate metastases in the lung is discussed.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Eisenbach, Lea R/0000-0002-4816-1968; Fitzer-Attas, Cheryl/0000-0002-8709-1384	NCI NIH HHS [CA28139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BEVEREN CV, 1981, NATURE, V289, P258; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEBAETSELIER P, 1980, NATURE, V288, P179; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; EISENBACH L, 1986, NATO ASI SER, V121, P57; EISENBACH L, 1983, J CANCER, V32, P3293; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FRANCHINI G, 1982, MOL CELL BIOL, V2, P1014, DOI 10.1128/MCB.2.8.1014; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Hart I R, 1982, Cancer Metastasis Rev, V1, P5, DOI 10.1007/BF00049477; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MALIK R, 1991, CANCER RES, V51, P5626; Maniatis T., 1982, MOL CLONING; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORI S, 1991, J BIOL CHEM, V266, P21158; MOSHIER JA, 1987, GENE, V58, P19, DOI 10.1016/0378-1119(87)90025-4; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NISTER M, 1991, MOL BASIS HUMAN CANC, P62; Paget S, 1889, LANCET, V133, P571, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; Sjolund M, 1990, GROWTH FACTORS, V3, P191, DOI 10.3109/08977199009043904; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SUGIURA K, 1955, CANCER RES, V15, P38; TARIN D, 1984, CANCER RES, V44, P3584; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; WANG JL, 1990, INT J CANCER, V46, P772, DOI 10.1002/ijc.2910460504; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	64	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1567	1575						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321404				2022-12-25	WOS:A1992JE81300013
J	KIM, SJ; KIM, KY; TAPSCOTT, SJ; WINOKUR, TS; PARK, K; FUJIKI, H; WEINTRAUB, H; ROBERTS, AB				KIM, SJ; KIM, KY; TAPSCOTT, SJ; WINOKUR, TS; PARK, K; FUJIKI, H; WEINTRAUB, H; ROBERTS, AB			INHIBITION OF PROTEIN PHOSPHATASES BLOCKS MYOGENESIS BY 1ST ALTERING MYOD BINDING-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; OKADAIC ACID; TUMOR-PROMOTER; MUSCLE DIFFERENTIATION; NUCLEAR FACTOR; GENE FAMILY; PHOSPHORYLATION; CELLS; ACTIVATION; EXPRESSION	To examine the role of protein phosphatases in skeletal muscle differentiation, C2C12 myoblasts were treated with okadaic acid, a potent in vitro inhibitor of protein phosphatases 1 and 2A which regulate various cellular events in intact cells. We now show that okadaic acid treatment of the mouse myoblast C2C12 cell line reversibly altered the morphology of the cells and blocked differentiation. At a molecular level, it extinguished expression of the myogenic determination genes, MyoD1 and myogenin, but induced the expression of an inhibitor of differentiation, Id. Analysis of the MyoD1 promoter showed that inhibition of MyoD1 expression by okadaic acid occurs at the transcriptional level. These changes occur 10-20 h after okadaic acid treatment. However, within 1 h of treatment the ability of muscle extracts to support a specific MyoD-dependent gel mobility shift using a MyoD DNA binding site is lost. These data suggest that protein phosphatases play an important role during myogenic differentiation.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; NATL CANC CTR,RES INST,TOKYO 104,JAPAN	Fred Hutchinson Cancer Center; National Cancer Center - Japan	KIM, SJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.			Winokur, Thomas/0000-0002-6785-2991				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIALOJAN C, 1988, BIOCHEM J, V256, P248; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ERDODI F, 1988, BIOCHEM BIOPH RES CO, V153, P156, DOI 10.1016/S0006-291X(88)81202-6; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PARK K, 1992, J BIOL CHEM, V267, P10810; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; THEVENIN C, 1990, New Biologist, V2, P793; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WICE B, 1987, J BIOL CHEM, V262, P1810; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	43	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15140	15145						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321827				2022-12-25	WOS:A1992JF08800093
J	HASHIMOTO, N; FEENER, EP; ZHANG, WR; GOLDSTEIN, BJ				HASHIMOTO, N; FEENER, EP; ZHANG, WR; GOLDSTEIN, BJ			INSULIN-RECEPTOR PROTEIN-TYROSINE PHOSPHATASES - LEUKOCYTE COMMON ANTIGEN-RELATED PHOSPHATASE RAPIDLY DEACTIVATES THE INSULIN-RECEPTOR KINASE BY PREFERENTIAL DEPHOSPHORYLATION OF THE RECEPTOR REGULATORY DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-PLACENTA; BETA-SUBUNIT; CLONING; AUTOPHOSPHORYLATION; FAMILY; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; MEMBER; SITES	A number of protein-tyrosine phosphatase(s) (PTPases) have been shown to dephosphorylate the insulin receptor in vitro; however, it is not known whether any individual PTPase has specificity for certain phosphotyrosine residues of the receptor that regulate its intrinsic tyrosine kinase activity. We evaluated the deactivation of the insulin receptor kinase by three candidate enzymes that are expressed in insulin-sensitive rat tissues, including the receptor-like PTPases LAR and LRP, and the intracellular enzyme, PTPase1B. Purified insulin receptors were activated by insulin and receptor dephosphorylation, and kinase activity was quantitated after incubation with recombinant PTPases from an Escherichia coli expression system. When related to the level of overall receptor dephosphorylation, LAR deactivated the receptor kinase 3.1 and 2.1 times more rapidly than either PTPase1B or LRP, respectively (p < 0.03). To assess whether these effects were associated with preferential dephosphorylation of the regulatory (Tyr-1150) domain of the receptor beta-subunit, we performed tryptic mapping of the insulin receptor beta-subunit after dephosphorylation by PTPases. Relative to the rate of initial loss of P-32 from receptor C-terminal sites, LAR dephosphorylated the Tris-phosphorylated Tyr-1150 domain 3.5 and 3.7 times more rapidly than either PTPase1B or LRP, respectively (p < 0.01). The accelerated deactivation of the insulin receptor kinase by LAR and its relative preference for regulatory phosphotyrosine residues further support a potential role for this transmembrane PTPase in the physiological regulation of insulin receptors in intact cells.	BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK043396] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36836, DK43396] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1990, HDB EXPT PHARM, V92, P313; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJEE S, 1992, PEPTIDES CHEM BIOL, P553; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GOLDSTEIN BJ, 1992, J CELL BIOCHEM, V48, P33, DOI 10.1002/jcb.240480107; GOLDSTEIN BJ, 1992, MOL CELL BIOCHEM, V109, P107; GOLDSTEIN BJ, 1991, ADV PROTEIN PHOSPHAT, V6, P1; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HASHIMOTO N, 1992, IN PRESS BIOCH J, V284; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASUGA M, 1985, METHOD ENZYMOL, V109, P609; KING MJ, 1991, BIOCHEM J, V275, P413, DOI 10.1042/bj2750413; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MYERS MG, 1991, J BIOL CHEM, V266, P10616; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SALE GJ, 1991, ADV PROTEIN PHOSPHAT, V6, P159; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAPPIA PS, 1991, BIOCHEM J, V278, P69, DOI 10.1042/bj2780069; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WOODFORD TA, 1991, ADV PROTEIN PHOSPHAT, V6, P503; ZHANG WR, 1991, BIOCHEM BIOPH RES CO, V178, P1291, DOI 10.1016/0006-291X(91)91034-A	42	100	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13811	13814						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321126				2022-12-25	WOS:A1992JD32500006
J	LIEBL, U; PEZENNEC, S; RIEDEL, A; KELLNER, E; NITSCHKE, W				LIEBL, U; PEZENNEC, S; RIEDEL, A; KELLNER, E; NITSCHKE, W			THE RIESKE FES CENTER FROM THE GRAM-POSITIVE BACTERIUM PS3 AND ITS INTERACTION WITH THE MENAQUINONE POOL STUDIED BY EPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIOBACTERIUM-CHLORUM; ISOPRENOID QUINONE; ELECTRON-TRANSPORT; MEMBRANE; STIGMATELLIN; OXIDATION; BINDING; CYTOCHROMES; INHIBITION; RESONANCE	The Rieske 2Fe2S center from Bacillus PS3, a Gram-positive thermophilic eubacterium, has been studied by EPR spectroscopy. Its redox midpoint potential at pH 7.0 was determined to be +165 +/- 10 mV and was found to decrease with an apparent slope of -80 mV/pH unit above pH 7.9. The Q(o)-site inhibitor stigmatellin induced spectral changes analogous to those reported for Rieske centers from mitochondria and chloroplasts. The redox midpoint potential of the PS3 Rieske cluster was not affected by stigmatellin. The orientation of the g tensor was similar to other Rieske centers (g(z) and g(y) are oriented parallel, g(x) is oriented perpendicular to the membrane plane). The shape of the EPR spectrum of the Rieske cluster from PS3 changed as a function of the redox state of the menaquinone (MK) pool. This permitted the redox midpoint potential of the MK pool to be determined in the membrane. Values of -60 +/- 20 mV at pH 7.0 and of -130 +/- 20 mV at pH 8.0 were obtained. The results are compared with already published data from other Rieske centers. It is proposed that all Rieske centers that function in electron transport chains using MK as pool quinone show common features that distinguish them from Rieske centers operating in ubiquinone- or plastoquinone-based electron transfer chains.	INST BIOL PHYSICO CHIM,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE; CENS,DEPT BIOL CELLULAIRE & MOLEC,CNRS,URA 1290,BIOENERGET SECT,F-91191 GIF SUR YVETTE,FRANCE; UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,W-8400 REGENSBURG,GERMANY	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Regensburg			Nitschke, Wolfgang/C-4812-2012	Pezennec, Stephane/0000-0003-1265-8048; Nitschke, Wolfgang/0000-0003-2084-3032; LIEBL, Ursula/0000-0003-0869-4388				BLASIE JK, 1978, BIOCHIM BIOPHYS ACTA, V501, P33, DOI 10.1016/0005-2728(78)90093-2; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HIRAISHI A, 1989, ARCH MICROBIOL, V151, P378, DOI 10.1007/BF00406568; HURT EC, 1984, FEBS LETT, V168, P149, DOI 10.1016/0014-5793(84)80225-2; Kagawa Y, 1979, Methods Enzymol, V55, P781; KNAFF DB, 1976, BIOCHIM BIOPHYS ACTA, V430, P24; Kroger A., 1985, COENZYME Q, P285; KUILA D, 1986, J BIOL CHEM, V261, P2768; KUTOH E, 1988, J BIOL CHEM, V263, P9020; LEWIS RJ, 1981, J BIOL CHEM, V256, P543; LIEBL U, 1990, FEBS LETT, V261, P427, DOI 10.1016/0014-5793(90)80608-L; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; NITSCHKE W, 1989, BIOCHIM BIOPHYS ACTA, V974, P223, DOI 10.1016/S0005-2728(89)80376-7; OETTMEIER W, 1985, BIOCHIM BIOPHYS ACTA, V807, P216, DOI 10.1016/0005-2728(85)90125-2; PRINCE RC, 1976, FEBS LETT, V65, P117, DOI 10.1016/0014-5793(76)80634-5; REDFEARN ER, 1968, BIOCHEM J, V106, P50; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VENTUROLI G, 1990, HIGHLIGHTS IN UBIQUINONE RESEARCH, P116; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; ZANNONI D, 1985, FEBS LETT, V193, P93, DOI 10.1016/0014-5793(85)80086-7	28	62	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14068	14072						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321134				2022-12-25	WOS:A1992JD32500046
J	HANSON, S; ADELMAN, J; ULLMAN, B				HANSON, S; ADELMAN, J; ULLMAN, B			AMPLIFICATION AND MOLECULAR-CLONING OF THE ORNITHINE DECARBOXYLASE GENE OF LEISHMANIA-DONOVANI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; RESISTANT LEISHMANIA; ALPHA-DIFLUOROMETHYLORNITHINE; DNA AMPLIFICATION; TRYPANOSOMA-BRUCEI; INTRACELLULAR DEGRADATION; EXTRACHROMOSOMAL CIRCLES; DIHYDROFOLATE REDUCTASE; PLASMODIUM-FALCIPARUM; MESSENGER-RNA	A strain of Leishmania donovani has been described that is resistant to DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODCase) activity, and contains 15-fold greater amounts of ODCase activity and protein than the wild type strain from which it was derived (Coons, T., Hanson, S., Bitonti, A. J., McCann, P. P., and Ullman, B. (1990) Mol. Biochem. Pharmacol. 39, 77-90). From this mutant strain, another ODCase overproducing L. donovani strain, DFMO16, was generated by virtue of its ability to proliferate under even higher concentrations of DFMO. To investigate the mechanism by which DFMO-resistant cells overexpress ODCase, the leishmanial ODCase gene was isolated by hybridization to a fragment of the L. donovani ODCase gene that was generated by the polymerase chain reaction. The nucleotide sequence of a 4.5-kilobase DNA fragment encompassed an open reading frame encoding 707 amino acids (M(r) = 77,350). The leishmanial protein contained an extra approximately 200 amino acid NH2-terminal extension and lacked the COOH terminus of the mammalian ODCase. Northern blot analysis revealed two leishmanial ODCase transcripts of 4.8 and 6.5 kilobases, both of which were amplified 10-20-fold in the DFMO16 cells. Genomic Southern blot analysis established that the augmented amount of ODCase activity and ODCase mRNA in the DFMO16 strain could be attributed to a approximately 10-20-fold amplification of the ODCase gene copy number. DFMO16 cells exhibited an unstable phenotype in that the amplification of the ODCase gene, the increased amount of ODCase transcript, the overproduction of ODCase activity, and the DFMO-resistance growth phenotype all reverted synchronously in the absence of selective pressure.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023682, R37AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALHONENHONGISTO L, 1985, BIOCHEM BIOPH RES CO, V126, P734, DOI 10.1016/0006-291X(85)90246-3; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; Battey, 1986, BASIC METHODS MOL BI; BELLOFATTO V, 1987, MOL BIOCHEM PARASIT, V25, P227, DOI 10.1016/0166-6851(87)90086-7; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIRNS BR, 1989, P NATL ACAD SCI USA, V86, P7682, DOI 10.1073/pnas.86.20.7682; Campbell W.C., 1986, CHEMOTHERAPY PARASIT; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; COOMBS GH, 1983, J ANTIMICROB CHEMOTH, V11, P151, DOI 10.1093/jac/11.2.151; COONS T, 1990, MOL BIOCHEM PARASIT, V39, P77, DOI 10.1016/0166-6851(90)90010-J; DETKE S, 1988, J BIOL CHEM, V263, P3418; DETKE S, 1989, EXP CELL RES, V180, P161, DOI 10.1016/0014-4827(89)90220-6; DOBERSTYN EB, 1984, EXPERIENTIA, V40, P1311, DOI 10.1007/BF01951884; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P13501; FONG D, 1988, MOL BIOCHEM PARASIT, V31, P97, DOI 10.1016/0166-6851(88)90149-1; FONZI WA, 1987, J BIOL CHEM, V262, P10127; GARVEY EP, 1986, SCIENCE, V233, P535, DOI 10.1126/science.3726545; GENSKE JE, 1991, MOL CELL BIOL, V11, P240, DOI 10.1128/MCB.11.1.240; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; GILLIN FD, 1983, J PROTOZOOL, V31, P161; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HANSON WL, 1983, J PARASITOL, V69, P446, DOI 10.2307/3281265; HANSON WL, 1982, AM J VET RES, V43, P1651; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; IOVANNISCI DM, 1984, MOL CELL BIOL, V4, P1013, DOI 10.1128/MCB.4.6.1013; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; IOVANNISCI DM, 1984, MOL BIOCHEM PARASIT, V12, P139, DOI 10.1016/0166-6851(84)90131-2; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATAKURA K, 1989, MOL BIOCHEM PARASIT, V34, P189, DOI 10.1016/0166-6851(89)90010-8; KAUR K, 1986, J PROTOZOOL, V33, P518, DOI 10.1111/j.1550-7408.1986.tb05654.x; KAUR K, 1988, J BIOL CHEM, V263, P7020; KINK JA, 1987, P NATL ACAD SCI USA, V84, P1253, DOI 10.1073/pnas.84.5.1253; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDFEAR SM, 1985, MOL BIOCHEM PARASIT, V15, P61, DOI 10.1016/0166-6851(85)90029-5; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LEINONEN P, 1987, BIOCHEM J, V242, P199, DOI 10.1042/bj2420199; LOOKER D, 1988, NUCLEIC ACIDS RES, V16, P7198, DOI 10.1093/nar/16.14.7198; McCann P. P., 1981, Advances in polyamine research., P97; MCCONLOGUE L, 1986, MOL CELL BIOL, V6, P2865, DOI 10.1128/MCB.6.8.2865; MCCONLOGUE L, 1983, J BIOL CHEM, V258, P2083; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MILLER SI, 1986, NUCLEIC ACIDS RES, V14, P7341, DOI 10.1093/nar/14.18.7341; MURPHY WJ, 1986, CELL, V47, P515; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PEGG AE, 1988, ISI ATLAS-BIOCHEM, V1, P11; PETERS W, 1985, PARASITOLOGY, V90, P705, DOI 10.1017/S003118200005232X; PHILLIPS MA, 1987, MOL BIOCHEM PARASIT, V22, P9, DOI 10.1016/0166-6851(87)90064-8; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; POHJANPELTO P, 1985, J BIOL CHEM, V260, P8532; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STACK SP, 1990, MOL CELL BIOL, V10, P6788; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TYAGI AK, 1981, J BIOL CHEM, V256, P2156; WANG CC, 1982, TRENDS BIOCHEM SCI, V7, P354, DOI 10.1016/0968-0004(82)90108-6; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WILSON K, 1991, J BIOL CHEM, V266, P1665; [No title captured]; 1982, B WORLD HEALTH ORGAN, V60, P821	74	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2350	2359						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1339439				2022-12-25	WOS:A1992HB53200038
J	YONEZAWA, K; UEDA, H; HARA, K; NISHIDA, K; ANDO, A; CHAVANIEU, A; MATSUBA, H; SHII, K; YOKONO, K; FUKUI, Y; CALAS, B; GRIGORESCU, F; DHAND, R; GOUT, I; OTSU, M; WATERFIELD, MD; KASUGA, M				YONEZAWA, K; UEDA, H; HARA, K; NISHIDA, K; ANDO, A; CHAVANIEU, A; MATSUBA, H; SHII, K; YOKONO, K; FUKUI, Y; CALAS, B; GRIGORESCU, F; DHAND, R; GOUT, I; OTSU, M; WATERFIELD, MD; KASUGA, M			INSULIN-DEPENDENT FORMATION OF A COMPLEX CONTAINING AN 85-KDA SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE AND TYROSINE-PHOSPHORYLATED INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PEPTIDE-SYNTHESIS; SIGNAL TRANSDUCTION; INTACT-CELLS; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; PROTEIN; BINDING; PURIFICATION; PHOSPHOTYROSINE; PI3-KINASE	Monoclonal antibodies raised against the 85-kDa subunit (p85) of bovine phosphatidylinositol (PI) 3-kinase were found to recognize uncomplexed p85 or p85 in the active PI 3-kinase. Immunoprecipitation studies of Chinese hamster ovary cells, which overexpress the human insulin receptor when treated with insulin, showed increased amounts of p85 and PI 3-kinase activity immunoprecipitable with monoclonal anti-p85 antibody and no increase in the tyrosine phosphorylation of p85. Insulin also induced an association of p85 with the tyrosine-phosphorylated insulin receptor substrate 1 (IRS-1) and other phosphorylated proteins ranging in size from 100 to 170 kDa but not with the activated insulin receptor. In vitro reconstitution studies were used to show p85 in the active PI 3-kinase associated with the tyrosine-phosphorylated IRS-1 but not with the activated insulin receptor. Competition studies using synthetic phosphopeptides corresponding to potential tyrosine phosphorylation sites of IRS-1 revealed that phosphopeptides containing YMXM motifs inhibited this association with different potencies, whereas nonphosphorylated analogues and a phosphopeptide containing the EYYE motif had no effect. Src homology region 2 domains of p85 expressed as glutathione S-transferase fusion proteins also bound to tyrosine-phosphorylated IRS-1. These results suggest that insulin causes the association of PI 3-kinase with IRS-1 via phosphorylated YMXM motifs of IRS-1 and Src homology region 2 domains of p85.	KOBE UNIV, SCH MED,DEPT INTERNAL MED 2,7-5-1 KUSUNOKI CHO, CHUO KU, KOBE 650, JAPAN; CNRS, UPR8402, CRBM, F-34033 MONTPELLIER, FRANCE; INSERM, U249, F-34100 MONTPELLIER, FRANCE; HYOGO INST CLIN RES, AKASHI 673, JAPAN; UNIV TOKYO, FAC AGR, DEPT AGR CHEM, BIOCHEM LAB, BUNKYO KU, TOKYO 113, JAPAN; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Kobe University; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Tokyo; Ludwig Institute for Cancer Research	KASUGA, M (corresponding author), KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, 7-5-1 KUSUNOKI CHO, CHUO KU, KOBE 650, JAPAN.		GRIGORESCU, FLORIN/C-2238-2013; Grigorescu, Florin/Q-3728-2019; Fukui, Yasuhisa/E-8806-2010; Chavanieu, Alain/A-2247-2013	GRIGORESCU, FLORIN/0000-0002-3095-5639; Grigorescu, Florin/0000-0002-3095-5639; Chavanieu, Alain/0000-0002-0512-5115				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BECKER AB, 1990, ANNU REV MED, V41, P99; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAVANIEU A, 1991, BIOORG MED CHEM LETT, V1, P299, DOI 10.1016/S0960-894X(01)80812-X; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KADOWAKI T, 1987, J BIOL CHEM, V262, P7324; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN DO, 1985, ENDOCRINOLOGY, V116, P1224, DOI 10.1210/endo-116-3-1224; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTH RA, 1982, P NATL ACAD SCI-BIOL, V79, P7312, DOI 10.1073/pnas.79.23.7312; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; YONEZAWA K, 1991, ADV EXP MED BIOL, V293, P227; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZARDENETA G, 1990, ANAL BIOCHEM, V190, P340, DOI 10.1016/0003-2697(90)90205-N	46	122	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25958	25965						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334490				2022-12-25	WOS:A1992KD07300057
J	DURAND, M; THUONG, NT; MAURIZOT, JC				DURAND, M; THUONG, NT; MAURIZOT, JC			BINDING OF NETROPSIN TO A DNA TRIPLE HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHIDIUM-BROMIDE; MINOR GROOVE; STRAND FORMATION; MAJOR GROOVE; OLIGONUCLEOTIDE; CONFORMATION; DISTAMYCIN; SEQUENCES; COMPLEXES; CLEAVAGE	The interaction of netropsin, a minor groove binding drug, with T-A-T triple helix and A-T double helix was studied using circular dichroism spectroscopy and thermal denaturation. The triple helix was made by an oligonucleotide (dA)12-x-(dT)12-x-(dT)12, where x is a hexaethylene glycol chain bridged between the 3' phosphate of one strand and the 5' phosphate of the following strand. This oligonucleotide is able to fold back on itself to form a very stable triplex. Changing the conditions allows the same oligonucleotide in a duplex form with a (dT)12 dangling arm. Circular dichroism spectroscopy demonstrates that netropsin can bind to the triple helical structure. Spectral analysis shows that the bound drug exhibits a conformation and an environment similar in double-stranded and in triple-stranded structure. However, the binding constant to the triple-stranded structure is found smaller than the binding constant to the double-stranded one. Thermal denaturation experiments demonstrate that netropsin destabilizes the triplex whereas it stabilizes the duplex.			DURAND, M (corresponding author), CTR BIOPHYS MOLEC 1A, F-45071 ORLEANS, FRANCE.							ARNOTT S, 1974, J MOL BIOL, V88, P523, DOI 10.1016/0022-2836(74)90499-9; ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; ARNOTT S, 1976, NUCLEIC ACIDS RES, V3, P2459, DOI 10.1093/nar/3.10.2459; CASSANI GR, 1969, BIOCHEMISTRY-US, V8, P3928, DOI 10.1021/bi00838a008; COLL M, 1989, BIOCHEMISTRY-US, V28, P310, DOI 10.1021/bi00427a042; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DURAND M, 1992, BIOCHEMISTRY-US, V31, P9197, DOI 10.1021/bi00153a012; DURAND M, 1990, NUCLEIC ACIDS RES, V18, P6353, DOI 10.1093/nar/18.21.6353; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1988, NUCLEIC ACIDS RES, V16, P11431, DOI 10.1093/nar/16.24.11431; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KIBLERHERZOG L, 1990, NUCLEIC ACIDS RES, V18, P3545, DOI 10.1093/nar/18.12.3545; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; LATT SA, 1967, BIOCHEMISTRY-US, V6, P3293, DOI 10.1021/bi00862a040; Le Pecq J B, 1971, Methods Biochem Anal, V20, P41, DOI 10.1002/9780470110393.ch2; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LEHRMAN EA, 1977, NUCLEIC ACIDS RES, V4, P1381, DOI 10.1093/nar/4.5.1381; LEPECQ J, 1965, CR HEBD ACAD SCI, V260, P7033; LUCK G, 1974, NUCLEIC ACIDS RES, V1, P503, DOI 10.1093/nar/1.3.503; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MARKY LA, 1989, BIOCHEMISTRY-US, V28, P9982, DOI 10.1021/bi00452a016; MERGNY JL, 1991, NUCLEIC ACIDS RES, V19, P1521, DOI 10.1093/nar/19.7.1521; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PATEL DJ, 1985, BIOCHIMIE, V67, P887, DOI 10.1016/S0300-9084(85)80181-4; PATEL DJ, 1982, P NATL ACAD SCI-BIOL, V79, P6424, DOI 10.1073/pnas.79.21.6424; PERROUAULT L, 1990, NATURE, V344, P358, DOI 10.1038/344358a0; PILCH DS, 1990, NUCLEIC ACIDS RES, V18, P5743, DOI 10.1093/nar/18.19.5743; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; POSVIC TJ, 1989, J AM CHEM SOC, V111, P3059; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; SCARIA PV, 1991, J BIOL CHEM, V266, P5417; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; SUN JS, 1991, J BIOMOL STRUCT DYN, V9, P425, DOI 10.1080/07391102.1991.10507926; SUTHERLAND JC, 1978, BIOCHEMISTRY-US, V17, P5088, DOI 10.1021/bi00617a003; UMEMOTO K, 1990, J AM CHEM SOC, V112, P4539, DOI 10.1021/ja00167a063; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WARING MJ, 1974, BIOCHEM J, V143, P483, DOI 10.1042/bj1430483; WARTELL RM, 1974, J BIOL CHEM, V249, P6719; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; ZASEDATELEV AS, 1974, MOL BIOL REP, V1, P337, DOI 10.1007/BF00309567; ZIMMER C, 1976, NUCLEIC ACIDS RES, V3, P1521, DOI 10.1093/nar/3.6.1521; ZIMMER C, 1972, EUR J BIOCHEM, V26, P81, DOI 10.1111/j.1432-1033.1972.tb01742.x; Zimmer C, 1975, Prog Nucleic Acid Res Mol Biol, V15, P285, DOI 10.1016/S0079-6603(08)60122-1; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2; ZIMMER C, 1971, J MOL BIOL, V58, P329, DOI 10.1016/0022-2836(71)90250-6	57	58	60	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24394	24399						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332955				2022-12-25	WOS:A1992KA26300041
J	FUNG, BKK; LIEBERMAN, BS; LEE, RH				FUNG, BKK; LIEBERMAN, BS; LEE, RH			A 3RD FORM OF THE G-PROTEIN BETA-SUBUNIT .2. PURIFICATION AND BIOCHEMICAL-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; AMINO-ACID SEQUENCE; GAMMA-SUBUNITS; CYCLIC-GMP; RETINAL CONES; ALPHA-SUBUNITS; TRANSDUCIN; DIVERSITY; BINDING; BRAIN	Visual excitation in cones is thought to involve a cone-specific G protein (cone transducin) that transduces the light signal detected by the cone visual pigment into an increase in the enzymatic activity of a cGMP phosphodiesterase. In the preceding paper, we have shown that the Gbeta3 isoform of G proteins is specifically localized in bovine cone photoreceptors and proposed that it might be a component of cone transducin. We reported here the purification from bovine retinal extract of a cone-specific Tbeta3gamma complex (where T is transducin), which is composed of a Gbeta3 subunit and an immunochemically distinct Ggamma subunit. Our purification of this complex is based on a two-stage procedure; the first stage consists of a series of column chromatographies that yield a mixture of purified Tbetagamma substantially enriched in Tbeta3gamma, and the second stage involves the removal of all of the rod-specific Tbeta1gamma from the mixture using an affinity column of immobilized monoclonal antibodies directed against the rod Tgamma subunit of transducin. Using this procedure, we were able to obtain sufficient amounts of Tbeta1gamma and Tbeta3gamma to begin a comparative study of their properties. We showed that Tbeta3gamma is distinguishable from Tbeta1gamma by isoelectric focusing under nondenaturing conditions. The Gbeta3 polypeptide of Tbeta3gamma also migrates slightly slower than the Gbeta1 polypeptide of Tbeta1gamma on denaturing polyacrylamide gels. Analysis of the interactions of Tbeta3gamma with other retinal proteins indicated that it has a lower affinity for the Talpha subunit of rod transducin but appears to complex with a phosducin-like protein. The differences in the intrinsic biochemical properties of Tbeta3gamma as compared to Tbeta1gamma may partially account for the lower light sensitivity of cones.	UNIV CALIF LOS ANGELES, SCH MED, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90024 USA; VET ADM MED CTR, MOLEC NEUROL LAB, SEPULVEDA, CA 91343 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA)	FUNG, BKK (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, JULES STEIN EYE INST, LOS ANGELES, CA 90024 USA.				NATIONAL EYE INSTITUTE [R01EY005895] Funding Source: NIH RePORTER; NEI NIH HHS [EY00395, EY05895] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATTWELL D, 1985, NATURE, V317, P14, DOI 10.1038/317014a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODEUR BR, 1984, J IMMUNOL METHODS, V71, P265, DOI 10.1016/0022-1759(84)90073-5; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; COBBS WH, 1985, NATURE, V317, P64, DOI 10.1038/317064a0; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FUNG BKK, 1983, J BIOL CHEM, V258, P10502; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HARWELL LW, 1984, J IMMUNOL METHODS, V66, P59, DOI 10.1016/0022-1759(84)90247-3; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HO Y-K, 1990, Investigative Ophthalmology and Visual Science, V31, P215; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KUO CH, 1989, MOL BRAIN RES, V6, P1, DOI 10.1016/0169-328X(89)90022-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEE R, 1989, Investigative Ophthalmology and Visual Science, V30, P171; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEE RH, 1990, EXP EYE RES, V51, P325, DOI 10.1016/0014-4835(90)90029-T; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P11035; MILAM AH, 1990, OPHTHALMOLOGY, V97, P1620; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NAKATANI K, 1989, J PHYSIOL-LONDON, V409, P525, DOI 10.1113/jphysiol.1989.sp017511; NAKATANI K, 1986, Investigative Ophthalmology and Visual Science, V27, P300; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NAVON SE, 1987, EXP EYE RES, V44, P115, DOI 10.1016/S0014-4835(87)80030-1; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OVCHINNIKOV YA, 1985, FEBS LETT, V179, P107, DOI 10.1016/0014-5793(85)80201-5; PUGH EN, 1986, VISION RES, V26, P1613, DOI 10.1016/0042-6989(86)90051-9; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STAHLI C, 1980, J IMMUNOL METHODS, V32, P297, DOI 10.1016/0022-1759(80)90194-5; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weizsacker E. V., 1992, BIOCHEM BIOPH RES CO, V183, P350; WOOLKALIS MJ, 1987, MOL PHARMACOL, V32, P1; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	48	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24782	24788						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332966				2022-12-25	WOS:A1992KA26300094
J	LOHSE, DL; LINHARDT, RJ				LOHSE, DL; LINHARDT, RJ			PURIFICATION AND CHARACTERIZATION OF HEPARIN LYASES FROM FLAVOBACTERIUM-HEPARINUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; ENZYMATIC DEGRADATION; SULFATE; HEPARITINASE; ENZYMES; BIOSYNTHESIS; PRODUCTS; PROTEINS; POLYMER; BINDING	Heparin lyase I has been purified from Flavobacterium heparinum and has been partially characterized (Yang, V. C., Linhardt, R. J., Berstein, H., Cooney, C. L., and Langer, R. (1985) J. Biol. Chem. 260, 1849-1857). There has been no report of the purification of the other polysaccharide lyases from this organism. Although all three of these heparin/heparan sulfate lyases are widely used, with the exception of heparin lyase I, there is no information on their purity or their physical and kinetic characteristics. The absence of pure heparin lyases and a lack of understanding of the optimal catalytic conditions and substrate specificity has stood in the way of the use of these enzymes as reagents for the specific depolymerization of heparin and heparan sulfate into oligosaccharides for structure and activity studies. This paper describes a single, reproducible scheme to simultaneously purify all three of the heparin lyases from F. heparinum to apparent homogeneity. Heparin lyase I (heparinase, EC 4.2.2.7), heparin lyase II (no EC number), and heparin lyase III (heparitinase, EC 4.2.2.8) have molecular weights (by sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and isoelectric points (by isoelectric focusing) of M(r) 42,800, pI 9.1-9.2, M(r) 84, 100, pI 8.9-9.1, M(r) 70,800, pI 9.9-10.1, respectively. Their amino acid analyses and peptide maps demonstrate that while these proteins are different gene products they are closely related. The kinetic properties of the heparin lyases have been determined as well as the conditions to optimize their activity and stability. These data should improve the application of these important enzymes in the study of heparin and heparan sulfate.	UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242	University of Iowa					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38060] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNICK CT, 1972, BIOCHEMISTRY-US, V11, P568; BOHMER LH, 1990, J BIOL CHEM, V265, P13609; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; COHEN DM, 1990, BIOPOLYMERS, V30, P733, DOI 10.1002/bip.360300708; DIETRICH CP, 1971, BIOCHIM BIOPHYS ACTA, V237, P430, DOI 10.1016/0304-4165(71)90260-1; DIETRICH CP, 1974, BIOCHIM BIOPHYS ACTA, V343, P34, DOI 10.1016/0304-4165(74)90237-2; DIETRICH CP, 1973, J BIOL CHEM, V248, P6408; DIETRICH CP, 1969, BIOCHEMISTRY-US, V8, P2089, DOI 10.1021/bi00833a046; GALLIHER PM, 1981, APPL ENVIRON MICROB, V41, P360, DOI 10.1128/AEM.41.2.360-365.1981; GALLIHER PM, 1982, EUR J APPL MICROBIOL, V15, P252, DOI 10.1007/BF00499966; HOVINGH P, 1970, J BIOL CHEM, V245, P6170; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER HH, 1986, ANAL CHEM, V58, P166, DOI 10.1021/ac00292a041; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1991, CHEM IND-LONDON, P45; LINHARDT RJ, 1984, APPL BIOCHEM BIOTECH, V9, P41, DOI 10.1007/BF02798373; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; LINHARDT RJ, 1988, BIOCHEM J, V254, P781, DOI 10.1042/bj2540781; LINHARDT RJ, 1985, INT J BIOCHEM, V17, P1179; LINKER A, 1965, J BIOL CHEM, V240, P3724; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; LOHSE DL, 1992, THESIS U IOWA; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; MCLEAN MW, 1985, 8TH P INT S GLYC, P73; MICHELACCI YM, 1974, BIOCHEM BIOPH RES CO, V56, P973, DOI 10.1016/S0006-291X(74)80284-6; MOFFAT CF, 1991, EUR J BIOCHEM, V197, P449, DOI 10.1111/j.1432-1033.1991.tb15931.x; NADER HB, 1990, J BIOL CHEM, V265, P16807; NAKAMURA T, 1988, J CLIN MICROBIOL, V26, P1070, DOI 10.1128/JCM.26.5.1070-1071.1988; OTOTANI N, 1979, CARBOHYD RES, V70, P295, DOI 10.1016/S0008-6215(00)87109-8; OTOTANI N, 1981, CARBOHYD RES, V88, P291, DOI 10.1016/S0008-6215(00)85542-1; OTOTANI N, 1978, J BIOCHEM-TOKYO, V84, P1005, DOI 10.1093/oxfordjournals.jbchem.a132181; OTOTANI N, 1981, 6TH P INT S GLYC TOK; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PAYZA AN, 1956, NATURE, V177, P88, DOI 10.1038/177088a0; PERELLA FW, 1988, ANAL BIOCHEM, V174, P437; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; SASISEKHARAN R, 1991, THESIS HARVARD U; SAYLERS AA, 1977, APPL ENVIRON MICROB, V33, P319; SILVA ME, 1976, BIOCHIM BIOPHYS ACTA, V437, P129, DOI 10.1016/0304-4165(76)90354-8; SILVA ME, 1974, BIOCHEM BIOPH RES CO, V56, P965, DOI 10.1016/S0006-291X(74)80283-4; YANG VC, 1985, CARBOHYD RES, V143, P294, DOI 10.1016/S0008-6215(00)90723-7; YANG VC, 1987, APPL BIOCHEM BIOTECH, V16, P35, DOI 10.1007/BF02798354; YANG VC, 1985, J BIOL CHEM, V260, P1849; YOSHIDA K, 1989, 10TH P ANN S GLYC; YOSHIDA K, 1991, 1991 INT S HEP REL P; ZIMMERMANN JJF, 1991, APPL BIOCHEM BIOTECH, V30, P137	51	196	230	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24347	24355						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332952				2022-12-25	WOS:A1992KA26300034
J	SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD				SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD			RECONSTITUTION OF TRANSCRIPTION WITH 5 PURIFIED INITIATION-FACTORS AND RNA POLYMERASE-II FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TFIIE; PREINITIATION COMPLEX; LARGE SUBUNIT; YEAST; PROMOTER; PURIFICATION; GENE; SEQUENCE; INVITRO; KINASE	Yeast RNA polymerase II initiation factors a, b, e, and g were isolated from whole cell extract and found to be sufficient, when combined with bacterially expressed yeast transcription factor (TF) IID, to enable RNA polymerase II to utilize nine different eukaryotic promoters in vitro, and to initiate transcription at sites used in vivo. The purified factors did not contain the previously described transcription factor IIA (TFIIA). TFIIA failed to substitute for any purified factor or to stimulate transcription with the complete set of factors, indicating that its function in crude extracts is primarily as an anti-inhibitor.			SAYRE, MH (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DONAHUE TF, 1982, GENE, V18, P47, DOI 10.1016/0378-1119(82)90055-5; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FURTERGRAVES EM, 1990, MOL GEN GENET, V223, P407, DOI 10.1007/BF00264447; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HENRY NL, 1992, J BIOL CHEM, V267, P23388; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555	52	110	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23376	23382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331084				2022-12-25	WOS:A1992JY16300101
J	SURYANARAYANA, S; VONZASTROW, M; KOBILKA, BK				SURYANARAYANA, S; VONZASTROW, M; KOBILKA, BK			IDENTIFICATION OF INTRAMOLECULAR INTERACTIONS IN ADRENERGIC-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIGAND-BINDING; PROTEIN	Adrenergic receptors are representative of a large family of plasma membrane receptors that interact with G proteins during the process of transmembrane signal transduction. G protein-coupled receptors have a primary structure that is homologous to bacteriorhodopsin and are proposed to have a similar three-dimensional structure; however, it has not yet been possible to examine this hypothesis experimentally. We have used a novel mutagenesis approach to identify intramolecular interactions. Our results indicate that specific amino acids in the seventh hydrophobic segment of alpha2 and beta2 adrenergic receptors lie adjacent to the first hydrophobic segment. These studies provide the first experimental evidence defining spatial relationships that exist in the three-dimensional structure of adrenergic receptors.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DIV CARDIOVASC MED,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER; NINDS NIH HHS [5 RO1 NS28471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		DAHL SG, 1991, P NATL ACAD SCI USA, V88, P8111, DOI 10.1073/pnas.88.18.8111; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; FINDLAY J, 1990, TRENDS PHARMACOL SCI, V11, P492, DOI 10.1016/0165-6147(90)90050-I; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; SURYANARAYANA S, 1991, METHODS, V3, P193; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530	15	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					21991	21994						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331041				2022-12-25	WOS:A1992JW71900002
J	CLOUGH, RC; MATTHIS, AL; BARNUM, SR; JAWORSKI, JG				CLOUGH, RC; MATTHIS, AL; BARNUM, SR; JAWORSKI, JG			PURIFICATION AND CHARACTERIZATION OF 3-KETOACYL-ACYL CARRIER PROTEIN SYNTHASE-III FROM SPINACH - A CONDENSING ENZYME UTILIZING ACETYL-COENZYME-A TO INITIATE FATTY-ACID SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OLERACEA LEAVES; SYNTHETASE; BIOSYNTHESIS; FORMS; SEEDS	The 3-ketoacyl-acyl carrier protein (ACP) synthase III from spinach was purified to homogeneity by an eight-step procedure that included an ACP-affinity column. The size of the native enzyme was M(r) = 63,000 based on gel filtration, and its subunit size was M(r) = 40,500 based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, suggesting that 3-ketoacyl-ACP synthase III may be a homodimer. The purified enzyme was highly specific for acetyl-CoA and malonyl-ACP. The K(m) for acetyl-CoA was 5 muM when assayed in the presence of 10 muM malonyl-CoA. Acetyl-, butyryl-, and hexanoyl-ACP would not substitute for acetyl-CoA as substrates. The specificity for acetyl-CoA suggested that the physiological function of 3-ketoacyl-ACP synthase is to catalyze the initial condensation reaction in fatty acid biosynthesis. The homogeneous 3-ketoacyl-ACP synthase was capable of catalyzing acetyl-CoA:ACP transacylation but at a rate about 90-fold slower than the condensation reaction with malonyl-ACP. The 3-ketoacyl-ACP synthase was inhibited 100% by 5 mM N-ethylmaleimide or 20 mM sodium arsenite.	MIAMI UNIV,DEPT CHEM,OXFORD,OH 45056; MIAMI UNIV,DEPT BOT,OXFORD,OH 45056	University System of Ohio; Miami University; University System of Ohio; Miami University			Jaworski, Jan/N-2255-2014	Jaworski, Jan/0000-0003-3309-4915				ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; ALBERTS AW, 1969, METHOD ENZYMOL, V14, P50; BLOCH K, 1977, ANNU REV BIOCHEM, V46, P263, DOI 10.1146/annurev.bi.46.070177.001403; CLOUGH RC, 1989, ANAL BIOCHEM, V176, P82, DOI 10.1016/0003-2697(89)90276-5; CRONAN JE, 1981, P NATL ACAD SCI-BIOL, V78, P5440, DOI 10.1073/pnas.78.9.5440; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P412, DOI 10.1016/0003-2697(88)90208-4; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JAWORSKI JG, 1989, PLANT PHYSIOL, V90, P41, DOI 10.1104/pp.90.1.41; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKINTHOMAS PL, 1986, J BIOL CHEM, V261, P4785; LOWE PN, 1988, BIOCHEM J, V250, P789, DOI 10.1042/bj2500789; MACKINTOSH RW, 1989, BIOCHIM BIOPHYS ACTA, V1002, P114, DOI 10.1016/0005-2760(89)90073-8; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RUTKOSKI A, 1978, ANAL BIOCHEM, V91, P370, DOI 10.1016/0003-2697(78)90854-0; SHIMAKATA T, 1982, ARCH BIOCHEM BIOPHYS, V217, P144, DOI 10.1016/0003-9861(82)90488-X; SHIMAKATA T, 1983, J BIOL CHEM, V258, P3592; SHIMAKATA T, 1982, PLANT PHYSIOL, V69, P1257, DOI 10.1104/pp.69.6.1257; SHIMAKATA T, 1983, ARCH BIOCHEM BIOPHYS, V220, P39, DOI 10.1016/0003-9861(83)90384-3; SHIMAKATA T, 1982, P NATL ACAD SCI-BIOL, V79, P5808, DOI 10.1073/pnas.79.19.5808; Stumpf P. K., 1987, Biochemistry of Plants, V9, P121; TSAY JT, 1992, J BIOL CHEM, V267, P6807; VOLPE JJ, 1973, ANNU REV BIOCHEM, V42, P21, DOI 10.1146/annurev.bi.42.070173.000321; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WALSH MC, 1990, PLANT LIPID BIOCHEMISTRY, STRUCTURE AND UTILIZATION, P114; WILLIAMS.IP, 1966, J BIOL CHEM, V241, P2326	29	97	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20992	20998						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328217				2022-12-25	WOS:A1992JT97800076
J	HIGUCHI, M; AGGARWAL, BB				HIGUCHI, M; AGGARWAL, BB			MODULATION OF 2 FORMS OF TUMOR-NECROSIS-FACTOR RECEPTORS AND THEIR CELLULAR-RESPONSE BY SOLUBLE RECEPTORS AND THEIR MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXIC RESPONSE; FACTOR TNF RECEPTOR; FACTOR-ALPHA; MOLECULAR-CLONING; DOWN-REGULATION; EXPRESSION; INTERLEUKIN-1; BINDING; CELLS; INTERNALIZATION	Recently, two different receptors for human tumor necrosis factor (TNF) with molecular masses of 60 kDa (p60) and 80 kDa (p80) have been identified. In this report, we investigated the effect of the soluble forms of these receptors and monoclonal antibodies against them on ligand interaction, receptor down-regulation, and mediation of cellular response in U-937 cells. Our results indicate that p60 and p80 constitute 20-30 and 60-80% of the total TNF-binding sites on U-937 cells, respectively. However, by cross-linking, only the p80 form of the receptor could be detected. In contrast to unlabeled TNF, the anti-p60 and anti-p80 antibodies together only partially inhibited ligand binding, and this inhibition was not additive. Lack of additive inhibition of binding was found to be not due to stereochemical hindrance. TNF binding to cells can be completely displaced by soluble forms of either the p60 or p80 receptor. However, 100-fold more of the p80 than the p60 form of the soluble receptor is needed for equivalent displacement. Under optimum conditions, TNF and the anti-p80 and anti-p60 antibodies down-regulated 30, 80, and 20% of the TNF receptors, respectively. The anti-p60 and anti-p80 antibodies down-regulated not only their own receptors, but also reciprocal receptors, suggesting a cross-communication between the p60 and p80 forms of the TNF receptor. In spite of inhibiting as much as 80% of TNF binding, none of the receptor antibodies significantly inhibited the cytotoxic response to TNF in U-937 cells. Soluble forms of both receptors, however, completely abrogated the cellular response to TNF. Thus, overall, our results indicate that the antibodies against both receptors together inhibit the majority of the receptor-ligand interaction without any significant effect on the biological response to TNF.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					AGGARWAL BB, 1987, J BIOL CHEM, V262, P10000; AGGARWAL BB, 1986, J BIOL CHEM, V261, P3652; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; AIYER RA, 1987, CRC HDB CYTOLYTIC LY, V2, P105; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DING AH, 1989, J BIOL CHEM, V264, P3924; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GOEDDEL DV, 1989, COLD SPRING HARB SYM, V1, P597; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIGUCHI M, 1992, ANAL BIOCHEM, V204, P53, DOI 10.1016/0003-2697(92)90138-W; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KULL FC, 1981, CANCER RES, V41, P4885; KULL FC, 1988, BIOCHEM BIOPH RES CO, V153, P402, DOI 10.1016/S0006-291X(88)81238-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE JM, 1987, LAB INVEST, V56, P234; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; POUTEU F, 1990, J EXP MED, V172, P599; RUGGIERO V, 1987, J IMMUNOL, V138, P661; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHEURICH P, 1989, J EXP MED, V170, P947; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH MR, 1990, J IMMUNOL, V144, P162; STAUBER GB, 1988, J BIOL CHEM, V263, P19098; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO M, 1987, J BIOCHEM-TOKYO, V102, P1571, DOI 10.1093/oxfordjournals.jbchem.a122206; TSUJIMOTO M, 1986, J IMMUNOL, V137, P2272	44	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20892	20899						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328214				2022-12-25	WOS:A1992JT97800060
J	POWELL, WS; GRAVELLE, F; GRAVEL, S				POWELL, WS; GRAVELLE, F; GRAVEL, S			METABOLISM OF 5(S)-HYDROXY-6,8,11,14-EICOSATETRAENOIC ACID AND OTHER 5(S)-HYDROXYEICOSANOIDS BY A SPECIFIC DEHYDROGENASE IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOHYDROXY-EICOSATETRAENOIC ACIDS; LEUKOTRIENE-B4 OMEGA-HYDROXYLASE; PRESSURE LIQUID-CHROMATOGRAPHY; ARACHIDONIC-ACID; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; PROSTAGLANDIN 9-KETOREDUCTASE; DIHYDRO METABOLITES; PORCINE LEUKOCYTES; FATTY-ACIDS; NEUTROPHILS	Human polymorphonuclear leukocytes (PMNL) convert 6-trans isomers of leukotriene B4 (LTB4) to dihydro metabolites (Powell, W. S., and Gravelle, F. (1988) J. Biol. Chem. 263, 2170-2177). In the present study we investigated the mechanism for the initial step in the formation of these products. We found that the 1,500 x g supernatant fraction from human PMNL converts 12-epi-6-trans-LTB4 to its 5-oxo metabolite which was identified by mass spectrometry and UV spectrophotometry. The latter compound was subsequently converted to the corresponding dihydro-oxo product, which was further metabolized to 6,11-dihydro-12-epi-6-trans-LTB4, which was the major product after longer incubation times. The 5-hydroxyeicosanoid dehydrogenase activity is localized in the microsomal fraction and requires NADP+ as a cofactor. These experiments therefore suggest that the initial step in the formation of dihydro metabolites of 6-trans isomers of LTB4 is oxidation of the 5-hydroxyl group by a microsomal dehydrogenase. Studies with a variety of substrates revealed that the microsomal dehydrogenase in human PMNL oxidizes the hydroxyl groups of a number of other eicosanoids which contain a 5(S)-hydroxyl group followed by a 6-trans double bond. There is little or no oxidation of hydroxyl groups in the 8-, 9-, 11-, 12-, or 15-positions of eicosanoids, or of the 5-hydroxyl group of LTB4, which has a 6-cis rather than a 6-trans double bond. The preferred substrate for this enzyme is 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid (5(S)-HETE) (K(m), 0.2-mu-M), which is converted to 5-oxo-6,8,11,14-eicosatetraenoic acid. Unlike 5(S)-HETE, 5(R)-HETE is a poor substrate for the 5(S)-hydroxyeicosanoid dehydrogenase, indicating that in addition to exhibiting a high degree of positional specificity, this enzyme is also highly stereospecific. In addition to 5(S)-HETE and 6-trans isomers of LTB4, 5,15-diHETE is also a good substrate for this enzyme, being converted to 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid (5-oxo-15-hydroxy-ETE). The oxidation of 5(S)-HETE to 5-oxo-ETE is reversible since human PMNL microsomes stereospecifically reduce 5-oxo-ETE to the 5(S)-hydroxy compound in the presence of NADPH. 5-Oxo-ETE is formed rapidly from 5(S)-HETE by intact human PMNL, but because of the reversibility of the reaction, its concentration only reaches about 25% that of 5(S)-HETE.			POWELL, WS (corresponding author), MCGILL UNIV,RESP HLTH NETWORK CTR EXCELLENCE,DEPT MED,MEAKINS CHRISTIE LABS,3626 ST URBAIN ST,MONTREAL H2X 2P2,QUEBEC,CANADA.		Powell, William/AAE-9000-2020	Powell, William/0000-0002-8507-4038				AGINS AP, 1987, AGENTS ACTIONS, V21, P397, DOI 10.1007/BF01966527; ANGGARD E, 1966, ARK KEMI, V25, P293; BADWEY JA, 1988, J BIOL CHEM, V263, P2779; BERGHOLTE JM, 1987, ARCH BIOCHEM BIOPHYS, V257, P444, DOI 10.1016/0003-9861(87)90589-3; BOEYNAEMS JM, 1980, ANAL BIOCHEM, V104, P259, DOI 10.1016/0003-2697(80)90073-1; BORGEAT P, 1981, PROSTAG LEUKOTR ESS, V6, P557, DOI 10.1016/0161-4630(81)90117-8; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; CHANG DGB, 1981, BIOCHEM BIOPH RES CO, V99, P745, DOI 10.1016/0006-291X(81)91806-4; CHANG DGB, 1981, BIOCHEM BIOPH RES CO, V101, P898, DOI 10.1016/0006-291X(81)91834-9; EARLES SM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P174, DOI 10.1016/0005-2760(91)90023-B; GOETZL EJ, 1980, J IMMUNOL, V125, P1789; GOETZL EJ, 1980, IMMUNOLOGY, V39, P491; JUBIZ W, 1982, J BIOL CHEM, V257, P6106; LEE SC, 1975, J BIOL CHEM, V250, P548; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; LINDGREN JA, 1981, FEBS LETT, V128, P329, DOI 10.1016/0014-5793(81)80110-X; MARCUS AJ, 1984, P NATL ACAD SCI-BIOL, V81, P903, DOI 10.1073/pnas.81.3.903; MARCUS AJ, 1988, J BIOL CHEM, V263, P2223; MASS RL, 1982, J BIOL CHEM, V257, P7056; MORITA E, 1990, J IMMUNOL, V144, P1893; OFLAHERTY JT, 1988, J IMMUNOL, V140, P4323; OFLAHERTY JT, 1986, J IMMUNOL, V137, P3277; OFLAHERTY JT, 1985, J CELL PHYSIOL, V122, P229, DOI 10.1002/jcp.1041220211; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1983, ANAL BIOCHEM, V128, P93, DOI 10.1016/0003-2697(83)90349-4; POWELL WS, 1988, J BIOL CHEM, V263, P2170; POWELL WS, 1990, J BIOL CHEM, V265, P9131; POWELL WS, 1990, BIOCHIM BIOPHYS ACTA, V1044, P147, DOI 10.1016/0005-2760(90)90230-U; POWELL WS, 1989, J BIOL CHEM, V264, P5364; POWELL WS, 1987, ANAL BIOCHEM, V164, P117, DOI 10.1016/0003-2697(87)90375-7; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; SOBERMAN RJ, 1987, J BIOL CHEM, V262, P12421; SOK DE, 1988, BIOCHEM BIOPH RES CO, V156, P524; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; SUMIMOTO H, 1988, EUR J BIOCHEM, V172, P315, DOI 10.1111/j.1432-1033.1988.tb13889.x; Tai H H, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P159; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P10126, DOI 10.1021/bi00495a017; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; WERMUTH B, 1981, J BIOL CHEM, V256, P1206; WONG PYK, 1984, J BIOL CHEM, V259, P2683	43	142	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19233	19241						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326548				2022-12-25	WOS:A1992JP59300036
J	STAR, RA; ZHANG, BX; LOESSBERG, PA; MUALLEM, S				STAR, RA; ZHANG, BX; LOESSBERG, PA; MUALLEM, S			REGULATORY VOLUME DECREASE IN THE PRESENCE OF HCO3- BY SINGLE OSTEOSARCOMA CELLS UMR-106-01	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+/OH-/HCO3 TRANSPORT; COUPLED ELECTROGENIC PROCESS; INTRACELLULAR PH REGULATION; PROXIMAL CONVOLUTED TUBULE; DIPHTHERIA-TOXIN ENTRY; BASOLATERAL MEMBRANE; NA+/H+ EXCHANGER; ANION TRANSPORT; LINE UMR-106-01; VERO CELLS	The technique for the simultaneous recording of cell volume changes and pH(i) in single cells was used to study the role of HCO3- in regulatory volume decrease (RVD) by the osteosarcoma cells UMR-106-01. In the presence of HCO3-, steady state pH(i) is regulated by Na+/H+ exchange, Na+(HCO3-)3 cotransport and Na+-independent Cl-/HCO3- exchange. Following swelling in hypotonic medium, pH(i) was reduced from 7.16 +/- 0.02 to 6.48 +/- 0.02 within 3.4 +/- 0.28 min. During this period of time, the cells performed RVD until cell volume was decreased by 31 +/- 5% beyond that of control cells (RVD overshoot). Subsequently, while the cells were still in hypotonic medium, pH(i) slowly increased from 6.48 +/- 0.02 to 6.75 +/- 0.02. This increase in pH(i) coincided with an increase in cell volume back to normal (recovery from RVD overshoot or hypotonic regulatory volume increase (RVI)). The same profound changes in cell volume and pH(i) after cell swelling were observed in the complete absence of Cl- or Na+, providing HCO3- was present. On the other hand, depolarizing the cells by increasing external K+ or by inhibition of K+ channels with quinidine, Ba2+ or tetraethylammonium prevented the changes in pH(i) and RVD. These findings suggest that in the presence of HCO3-, RVD in UMR-106-01 cells is largely mediated by the conductive efflux of K+ and HCO3-. Removal of external Na+ but not Cl- prevented the hypotonic RVI that occurred after the overshoot in RVD. Amiloride had no effect, whereas pretreatment with 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) strongly inhibited hypotonic RVI. Thus, hypotonic RVI is mediated by a Na(out)+-dependent, Cl--independent and DIDS-inhibitable mechanism, which is indicative of a Na+(HCO3-)3 cotransporter. This is the first evidence for the involvement of this transporter in cell volume regulation. The present results also stress the power of the new technique used in delineating complicated cell volume regulatory mechanisms in attached single cells.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MED,DIV NEPHROL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39245] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADORANTE JS, 1990, J GEN PHYSIOL, V96, P1153, DOI 10.1085/jgp.96.6.1153; ALPERN RJ, 1985, J GEN PHYSIOL, V86, P613, DOI 10.1085/jgp.86.5.613; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; FERRIER J, 1987, J CELL PHYSIOL, V130, P344, DOI 10.1002/jcp.1041300306; GREEN J, 1988, J GEN PHYSIOL, V92, P239, DOI 10.1085/jgp.92.2.239; GREEN J, 1988, J BIOL CHEM, V263, P5012; GREEN J, 1990, J GEN PHYSIOL, V95, P121, DOI 10.1085/jgp.95.1.121; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; JENTSCH TJ, 1985, J BIOL CHEM, V260, P795; KHADEMAZAD M, 1991, AM J PHYSIOL, V261, pC441, DOI 10.1152/ajpcell.1991.261.3.C441; LOPES AG, 1987, AM J PHYSIOL, V253, pF340, DOI 10.1152/ajprenal.1987.253.2.F340; LOPES AG, 1987, J MEMBRANE BIOL, V97, P117, DOI 10.1007/BF01869418; LOPES AG, 1988, P NATL ACAD SCI USA, V85, P2873, DOI 10.1073/pnas.85.8.2873; LUDT J, 1991, J MEMBRANE BIOL, V119, P179, DOI 10.1007/BF01871417; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; MUALLEM S, 1992, J BIOL CHEM, V267, P17658; OLSNES S, 1986, J BIOL CHEM, V261, P1553; OLSNES S, 1986, J BIOL CHEM, V261, P1562; PARIS S, 1986, J BIOL CHEM, V261, P6177; REDHEAD CR, 1988, J PHYSIOL-LONDON, V401, P455, DOI 10.1113/jphysiol.1988.sp017172; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SOLEIMANI M, 1991, J BIOL CHEM, V266, P8706; TONNESSEN TI, 1990, AM J PHYSIOL, V258, pC1117, DOI 10.1152/ajpcell.1990.258.6.C1117; VOLKL H, 1988, PFLUG ARCH EUR J PHY, V411, P514, DOI 10.1007/BF00582372; VOLKL H, 1988, PFLUG ARCH EUR J PHY, V412, P1; WENZL E, 1989, AM J PHYSIOL, V257, pG732, DOI 10.1152/ajpgi.1989.257.5.G732; WHISENANT N, 1991, AM J PHYSIOL, V261, pC433, DOI 10.1152/ajpcell.1991.261.3.C433; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P4383; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P197; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, pS121, DOI 10.1007/BF00581792	32	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17665	17669						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325445				2022-12-25	WOS:A1992JM22300031
J	ODA, K				ODA, K			CALCIUM DEPLETION BLOCKS PROTEOLYTIC CLEAVAGES OF PLASMA-PROTEIN PRECURSORS WHICH OCCUR AT THE GOLGI AND OR TRANS-GOLGI NETWORK - POSSIBLE INVOLVEMENT OF CA2+-DEPENDENT GOLGI ENDOPROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; ROUGH ENDOPLASMIC-RETICULUM; I HISTOCOMPATIBILITY MOLECULES; PROPROTEIN PROCESSING ENZYME; HEPATOMA SECRETORY PROTEINS; VESICULAR STOMATITIS-VIRUS; WEAKLY BASIC AMINES; BREFELDIN-A; SERUM-ALBUMIN; CELL-SURFACE	The effects of calcium depletion on the proteolytic cleavage and secretion of plasma protein precursors were investigated in primary cultured rat hepatocytes and HepG2 cells. When the cells were incubated with A23187, the calcium-specific ionophore, in a medium lacking CaCl2, precursors of serum albumin and the third and fourth components of complement, C3 and C4, respectively, were found to be released into the medium. The addition of ionomycin or EGTA to the medium inhibited the processing of pro-C3 as well. Blocking the secretory pathway either at the mixed endoplasmic reticulum/Golgi in the presence of brefeldin A or at the endoplasmic reticulum/tubular-vesicular structure at a reduced temperature caused accumulation of pro-C3 within hepatocytes or HepG2 cells, indicating that the cleavage of the precursor occurs at a later stage of the secretory pathway. Once the blockade was released by incubating the cells either in the brefeldin A-free medium or at 37-degrees-C, the secretion of plasma proteins resumed, irrespective of the presence of A23187. However, the processing of pro-C3 was almost completely inhibited in the presence of A23187, with only the precursor being released into the medium, implying that a decline in Ca2+ levels within the cell modulates the activity of a Golgi endoprotease responsible for the cleavage of pro-C3. When incubated with isolated Golgi membranes, pro-C3 secreted from Ca2+-depleted cells was cleaved in vitro into their subunits in the presence of Ca2+ but not in its absence, pointing to the involvement of a Ca2+-dependent Golgi endoprotease in the processing of pro-C3. These results collectively suggest that calcium depletion blocks the proteolytic cleavages of plasma protein precursors presumably by exhausting a Ca2+ pool available to the Ca2+-dependent processing enzyme(s) located at the Golgi and/or trans-Golgi network.			ODA, K (corresponding author), FUKUOKA UNIV,SCH MED,DEPT BIOCHEM,45-1 7-CHOME NANAKUMA,JONAN KU,FUKUOKA 81401,JAPAN.							ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHAN AC, 1983, J CLIN INVEST, V72, P1639, DOI 10.1172/JCI111123; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GELLER DM, 1972, BIOCHEM J, V127, P865, DOI 10.1042/bj1270865; GOLDBERGER G, 1980, NATURE, V286, P514, DOI 10.1038/286514a0; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V136, P603, DOI 10.1016/0006-291X(86)90483-3; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUTTON JC, 1987, BIOCHEM J, V244, P457, DOI 10.1042/bj2440457; IKEHARA Y, 1977, J BIOCHEM-TOKYO, V81, P1293; JOHNSON DC, 1980, VIROLOGY, V103, P407, DOI 10.1016/0042-6822(80)90200-7; JUDAH JD, 1976, TRENDS BIOCHEM SCI, V1, P107, DOI 10.1016/0968-0004(76)90017-7; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KLENK HD, 1984, EMBO J, V3, P2911, DOI 10.1002/j.1460-2075.1984.tb02231.x; KORIYAMA Y, 1989, BIOMED RES-TOKYO, V10, P341, DOI 10.2220/biomedres.10.341; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MORRIS KM, 1982, SCIENCE, V215, P399, DOI 10.1126/science.7199205; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; ODA K, 1988, J BIOL CHEM, V263, P12576; ODA K, 1978, BIOCHIM BIOPHYS ACTA, V536, P97, DOI 10.1016/0005-2795(78)90055-7; ODA K, 1990, J BIOCHEM-TOKYO, V108, P549, DOI 10.1093/oxfordjournals.jbchem.a123240; ODA K, 1986, J BIOCHEM-TOKYO, V100, P1669, DOI 10.1093/oxfordjournals.jbchem.a121876; ODA K, 1988, J BIOCHEM-TOKYO, V104, P159, DOI 10.1093/oxfordjournals.jbchem.a122432; ODA K, 1986, BIOCHEM J, V240, P739, DOI 10.1042/bj2400739; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; ODA K, 1985, EUR J BIOCHEM, V152, P605, DOI 10.1111/j.1432-1033.1985.tb09238.x; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; ODA K, 1991, BIOCHEM BIOPH RES CO, V175, P690, DOI 10.1016/0006-291X(91)91621-I; ODA K, 1979, BIOCHIM BIOPHYS ACTA, V552, P212, DOI 10.1016/0005-2736(79)90278-5; OGAWA Y, 1975, SEIKAGAKU JIKKEN KOZ, V15, P325; REDMAN CM, 1978, J CELL BIOL, V77, P400, DOI 10.1083/jcb.77.2.400; RUSSELL JH, 1975, J BIOL CHEM, V250, P3409; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPAETE RR, 1990, J VIROL, V64, P2922, DOI 10.1128/JVI.64.6.2922-2931.1990; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; UCHIDA N, 1979, P NATL ACAD SCI USA, V76, P1868, DOI 10.1073/pnas.76.4.1868; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; WILLIAMS DB, 1988, J BIOL CHEM, V263, P4549; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	67	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17465	17471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324939				2022-12-25	WOS:A1992JL05300109
J	VERKHOVSKAYA, M; VERKHOVSKY, M; WIKSTROM, M				VERKHOVSKAYA, M; VERKHOVSKY, M; WIKSTROM, M			PH-DEPENDENCE OF PROTON TRANSLOCATION BY ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OXIDOREDUCTASES; OXIDASE	Proton translocation in spheroplasts from Escherichia coli has been studied in two mutants, one of which expresses cytochrome o and the other cytochrome d as the terminal oxidase. Using the O2 pulse method, the H+/e- ratio of proton translocation associated with cytochrome o was confirmed to be near 2 at neutral pH, but was found to decrease considerably when the medium pH was raised above 8. At high pH there was an increase in H+/OH- permeability of the cell membrane, but this was not sufficient to explain the decline in proton ejection. The pH effect was confined to cytochrome o-linked activity. It was not present when cytochrome d generated the electrochemical proton gradient. This makes it improbable that the Na+/H+ antiporter is responsible. The most likely explanation for our finding is that there is a "slip" in the proton-pumping mechanism of cytochrome o at high pH.			VERKHOVSKAYA, M (corresponding author), UNIV HELSINKI,DEPT MED CHEM,HELSINKI BIOENERGET GRP,SILTAVUORENPENGER 10,SF-00170 HELSINKI 17,FINLAND.		Wikstrom, Marten KF/A-4403-2008	Verkhovskaya, Marina/0000-0001-8950-5256; Wikstrom, Marten/0000-0002-7527-4415				ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; AVETISYAN AV, 1991, BIOCHIM BIOPHYS ACTA, V1098, P95; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; GREEN GN, 1984, J BIOL CHEM, V259, P7994; KRULWICH TA, 1985, J BACTERIOL, V162, P768, DOI 10.1128/JB.162.2.768-772.1985; MACNAB RM, 1990, J BIOL CHEM, V265, P9247; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; WIKSTROM M, 1982, FEBS LETT, V144, P183, DOI 10.1016/0014-5793(82)80634-0; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8	14	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14559	14562						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321808				2022-12-25	WOS:A1992JF08800012
J	MOSS, SJ; DOHERTY, CA; HUGANIR, RL				MOSS, SJ; DOHERTY, CA; HUGANIR, RL			IDENTIFICATION OF THE CAMP-DEPENDENT PROTEIN-KINASE AND PROTEIN-KINASE-C PHOSPHORYLATION SITES WITHIN THE MAJOR INTRACELLULAR DOMAINS OF THE BETA-1-SUBUNIT, GAMMA-2S-SUBUNIT, AND GAMMA-2L-SUBUNIT OF THE GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GABAA RECEPTOR; MOLECULAR-BIOLOGY; SUBUNIT; EXPRESSION; CHANNEL; FORMS	Gamma-aminobutyric acid Type A (GABA(A)) receptors are the major sites of synaptic inhibition in the central nervous system. These receptors are thought to be pentameric complexes of homologous transmembrane glycoproteins. Molecular cloning has revealed a multiplicity of different GABA(A) receptor subunits divided into five classes, alpha, beta, gamma, delta, and rho, based on sequence homology. Within the proposed major intracellular domain of these subunits, there are numerous potential consensus sites for protein phosphorylation by a variety of protein kinases. We have used purified fusion proteins of the major intracellular domain of GABA(A) receptor subunits produced in Escherichia coli to examine the phosphorylation of these subunits by cAMP-dependent protein kinase (PKA) and protein kinase C (PKC). The purified fusion protein of the intracellular domain of the beta-1-subunit was an excellent substrate for both PKA and PKC. PKA and PKC phosphorylated the beta-1-subunit fusion protein on serine residues on a single tryptic phosphopeptide. Site-directed mutagenesis of serine 409 in the intracellular domain of the beta-1-subunit to an alanine residue eliminated the phosphorylation of the beta-1-subunit fusion protein by both protein kinases. The purified fusion proteins of the major intracellular domain of the gamma-2S and gamma-2L subunits of the GABA(A) receptor were rapidly and stoichiometrically phosphorylated by PKC but not by PKA. The phosphorylation of the gamma-2S subunit occurred on serine residues on a single tryptic phosphopeptide. Site-directed mutagenesis of serine 327 of the gamma-2S subunit fusion protein to an alanine residue eliminated the phosphorylation of the gamma-2S fusion protein by PKC. The gamma-2L subunit is an alternatively spliced form of the gamma-2S subunit that differs by the insertion of 8 amino acids (LLRMFSFK) within the major intracellular domain of the gamma-2S subunit. The PKC phosphorylation of the gamma-2L subunit occurred on serine residues on two tryptic phosphopeptides. Site-specific mutagenesis of serine 343 within the 8-amino acid insert to an alanine residue eliminated the PKC phosphorylation of the novel site in the gamma-2L subunit. No phosphorylation of a purified fusion protein of the major intracellular loop of the alpha-1-subunit was observed with either PKA or PKC. These results identify the specific amino acid residues within GABA(A) receptor subunits that are phosphorylated by PKA and PKC and suggest that protein phosphorylation of these sites may be important in regulating GABA(A) receptor function. In addition, these studies suggest that alternative splicing of the gamma-2 subunit may provide a novel mechanism for the differential regulation of GABA(A) receptors by PKC.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,725 N WOLFE ST,900 PCTB,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CHEN CY, 1986, DNA NY, V4, P165; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1983, P NATL ACAD SCI-BIOL, V80, P1130, DOI 10.1073/pnas.80.4.1130; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; MILES K, 1989, NEURON, V2, P1517, DOI 10.1016/0896-6273(89)90198-0; MOSS SJ, 1990, EUR J PHARM-MOLEC PH, V189, P77, DOI 10.1016/0922-4106(90)90232-M; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1986, BENZODIAZEPINE GABA, V5, P36; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; Sambrook J, 1989, MOL CLONING LABORATO; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SESSLER FM, 1989, BRAIN RES, V499, P27, DOI 10.1016/0006-8993(89)91132-3; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SIGEL E, 1991, FEBS LETT, V291, P150, DOI 10.1016/0014-5793(91)81124-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENSON FA, 1988, BIOCHEM J, V249, P21, DOI 10.1042/bj2490021; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; YMER S, 1989, EMBO J, V8, P1865	32	176	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14470	14476						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321150				2022-12-25	WOS:A1992JD32500103
J	RITTER, JK; CHEN, F; SHEEN, YY; TRAN, HM; KIMURA, S; YEATMAN, MT; OWENS, IS				RITTER, JK; CHEN, F; SHEEN, YY; TRAN, HM; KIMURA, S; YEATMAN, MT; OWENS, IS			A NOVEL COMPLEX LOCUS UGT1 ENCODES HUMAN BILIRUBIN, PHENOL, AND OTHER UDP-GLUCURONOSYLTRANSFERASE ISOZYMES WITH IDENTICAL CARBOXYL TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING; GENE; EXPRESSION; REGION; CELLS; CDNA	Two human liver UDP-glucuronosyltransferase (transferase) cDNAs, HUG-Br1 and HUG-Br2, were previously isolated (Ritter, J. K., Crawford, J. M., and Owens, I. S. (1991) J. Biol. Chem. 266, 1043-1047), and each was shown to encode a bilirubin transferase isozyme which catalyzes the formation of all physiological conjugates of bilirubin IX-alpha following expression in COS-1 cells. Sequence data showed that the cDNAs contained identical 3' ends (1469 base pairs in length) to each other and to that of the human phenol trans rase cDNA, HLUG P1 (Harding, D., Fournel-Gigleux, S., Jackson, M. R., and Burchell, B. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8381-8385). Here we report that the two corresponding bilirubin transferases and the phenol transferase are encoded by a novel locus, UGT1, which is also predicted to encode three other bilirubin transferase-like isozymes all having identical carboxyl termini. The transcriptional arrangement utilizes six nested promoter elements, each of which is positioned upstream of a unique exon 1. Each exon 1 encodes the NH2-terminal domain (286 amino acids) and confers the substrate specificity of the isoform. The 3' end of the locus contains 4 common exons which encode the identical carboxyl termini (246 amino acids). It is predicted that six nested primary transcripts are synthesized and that each exon 1 is differentially spliced to the 4 common exons to produce six unique, mature mRNAs. Although the gene organization is present as a single copy, it provides the flexibility of independent regulation of each isoform which is known to occur in the case of bilirubin and phenol transferase activities. With an understanding of the gene structure, lethal, as well as the nonlethal defects, associated with bilirubin transferase activity can now be determined.	NCI,MOLEC CARCINOGENESIS LAB,BLDG 10,RM 95 242,BETHESDA,MD 20892; NICHHD,HUMAN GENET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BALTIMORE D, 1981, CELL, V24, P592, DOI 10.1016/0092-8674(81)90082-9; CHOWDHURY JR, 1989, METABOLIC BASIS INHE, P1367; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; HARDING D, 1990, ANN HUM GENET, V54, P17, DOI 10.1111/j.1469-1809.1990.tb00356.x; HEILIG R, 1987, NUCLEIC ACIDS RES, V15, P9129, DOI 10.1093/nar/15.22.9129; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; NEBERT DW, 1979, CRC CR REV BIOCH MOL, V6, P401, DOI 10.3109/10409237909105427; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RITTER JK, 1990, J BIOL CHEM, V265, P7900; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; SATO H, 1990, BIOCHEM BIOPH RES CO, V169, P260, DOI 10.1016/0006-291X(90)91462-2; SCHMID R, 1966, GLUCURONIC ACID FREE, P493; VINCENT A, 1984, EMBO J, V3, P1003, DOI 10.1002/j.1460-2075.1984.tb01920.x	15	446	460	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3257	3261						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1339448				2022-12-25	WOS:A1992HD15400069
J	PHILLIPS, MA; STEWART, BE; RICE, RH				PHILLIPS, MA; STEWART, BE; RICE, RH			GENOMIC STRUCTURE OF KERATINOCYTE TRANSGLUTAMINASE - RECRUITMENT OF NEW EXON FOR MODIFIED FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ANCHORAGE REGION; AMINO-ACID-SEQUENCE; ERYTHROCYTE-MEMBRANE; EPIDERMAL-CELLS; CROSS-LINKING; GENE; DNA; FRAGMENTS	The gene for keratinocyte transglutaminase (TG(K)) spans 14 kilobase pairs and contains 15 exons. Many features of the TG(K) gene are very similar, if not identical, to those of the gene encoding the catalytic subunit of human clotting factor XIII: they have the same number of exons, corresponding introns always interrupt the coding region in the same phase of the codon, and most exons are of similar size (10 of 15 are exactly the same size). In these respects, the TG(K) and factor XIII catalytic subunit genes resemble each other more than either resembles the gene for erythrocyte band 4.2, a noncatalytic transglutaminase superfamily member. Exon II in both the TG(K) and factor XIII genes encodes an amino-terminal extension of nonhomologous sequence which in each protein confers a specialized function (membrane anchorage or activation of cross-linking, respectively). This suggests that the evolution of these genes included recruitment of a new exon to modify the enzyme action. Southern blots of genomic DNA reveal the presence of a TG(K)-like gene in birds, amphibians, and fish, but not in flies.	UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616	University of California System; University of California Davis			Rice, Robert/AAP-7813-2021		NCI NIH HHS [CA46928] Funding Source: Medline; NIAMS NIH HHS [AR27130] Funding Source: Medline; NIEHS NIH HHS [ES07059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATTAGLIA DE, 1988, J CELL BIOL, V107, P2447, DOI 10.1083/jcb.107.6.2447; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; LI WH, 1991, FUNDAMENTALS MOL EVO, P67; LICHTI U, 1985, J BIOL CHEM, V260, P1422; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; Sambrook J, 1989, MOL CLONING LABORATO; SEITZ J, 1990, HISTOCHEMISTRY, V93, P525, DOI 10.1007/BF00266412; SIGNORINI M, 1991, J PLANT PHYSIOL, V137, P547, DOI 10.1016/S0176-1617(11)80697-8; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R	34	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2282	2286						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346394				2022-12-25	WOS:A1992HB53200028
J	SCHROEDER, C; GIBSON, L; BEUG, H				SCHROEDER, C; GIBSON, L; BEUG, H			THE V-ERBA ONCOGENE REQUIRES COOPERATION WITH TYROSINE KINASES TO ARREST ERYTHROID-DIFFERENTIATION INDUCED BY LIGAND-ACTIVATED ENDOGENOUS C-ERBA AND RETINOIC ACID RECEPTOR	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; TISSUE-SPECIFIC EXPRESSION; GROWTH-FACTOR RECEPTOR; LEUKEMIA VIRUSES; GENE-EXPRESSION; CELLS; PROTEIN; TRANSFORMATION; TRANSCRIPTION	The v-erbA oncogene, a mutated version of the thyroid hormone receptor alpha (c-erbA/TR-alpha), cooperates with tyrosine kinase oncogenes in erythroblast transformation. Here we show that the ligand-activated, endogenous retinoic acid receptor (RAR-alpha), in cooperation with c-erbA/TR-alpha, efficiently reverses the transforming effect of kinase oncogenes, overcoming oncogene-induced self-renewal by triggering terminal differentiation of the transformed cells into healthy erythrocytes. This differentiation induction was accompanied by up-regulation of erythrocyte gene expression. Similarly, RAR-alpha and overexpressed exogenous c-erbA/TR-alpha efficiently abolished the differentiation arrest caused by v-erbA, while the low levels of endogenous TR-alpha had no effect. In contrast, transformation by v-erbA plus a kinase oncogene was not affected at all by ligand-activated endogenous or overexpressed exogenous TR-alpha and RAR-alpha. These results suggest that oncogene cooperation is required to protect leukemic erythroblasts from differentiation induction via endogenous, nuclear hormone receptors. Endogenous c-erbA/TR-alpha and RAR-alpha apparently cooperated in abolishing erythroblast self-renewal and inducing differentiation, since the respective ligands acted in a synergistic fashion, and overexpressed, non-ligand-bound c-erbA/TR-alpha suppressed endogenous RAR-alpha function in differentiation induction. Genetic evidence is presented that this functional cooperation requires the receptor dimerization domain, suggesting that TR-alpha/RAR-alpha heterodimers play a role in regulation of erythroid differentiation.	INST MOLEC PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Gibson, Leonie/AAM-5917-2021	Gibson, Leonie/0000-0002-0904-8145				BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1985, PROC R SOC SER B-BIO, V226, P121, DOI 10.1098/rspb.1985.0086; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; BEUG H, 1991, MYERS S NUCLEAR PROC, V15; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HOUSMAN D, 1980, COLD SPRING HARB SYM, V44, P1177, DOI 10.1101/SQB.1980.044.01.127; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; Maniatis T., 1982, MOL CLONING; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROSS J, 1976, CELL, V8, P513, DOI 10.1016/0092-8674(76)90219-1; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	48	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					203	216						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1347913				2022-12-25	WOS:A1992HG98200002
J	SATO, K; AKAIKE, T; KOHNO, M; ANDO, M; MAEDA, H				SATO, K; AKAIKE, T; KOHNO, M; ANDO, M; MAEDA, H			HYDROXYL RADICAL PRODUCTION BY H2O2 PLUS CU,ZN-SUPEROXIDE DISMUTASE REFLECTS THE ACTIVITY OF FREE COPPER RELEASED FROM THE OXIDATIVELY DAMAGED ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA ALPHA-1-PROTEINASE INHIBITOR; ZINC SUPEROXIDE-DISMUTASE; HUMAN NEUTROPHIL ELASTASE; HYDROGEN-PEROXIDE; OXYGEN RADICALS; PULSE RADIOLYSIS; DNA DAMAGE; INACTIVATION; MYELOPEROXIDASE; PROTEASE	To elaborate the catalytic activity of Cu2+ of Cu,Zn-superoxide dismutase (SOD) in the generation of hydroxyl radical (.OH) from H2O2, we investigated the mechanism of inactivation of alpha1-protease inhibitor (alpha1-PI), mediated by H2O2 and Cu,Zn-SOD. When alpha1-PI was incubated with 500 units/ml Cu,Zn-SOD and 1.0 mm H2O2, 60% of anti-elastase activity of alpha1-PI was lost within 90 min. ESR spin trapping using 5,5-dimethyl-1-pyrroline N-oxide showed that free .OH was indeed generated in the reaction of Cu,Zn-SOD/H2O2; this was substantiated by the almost complete eradication of .OH by either ethanol or dimethyl sulfoxide accompanied by the generation of carbon-centered radicals. .OH production and alpha1-PI inactivation in the H2O2/SOD system became apparent at 30 min or later. Dimethyl sulfoxide and 5,5-dimethyl-1-pyrroline N-oxide protected inactivation of alpha1-PI significantly in this system, indicating that alpha1-PI inactivation was mediated by .OH. SOD activity decreased rapidly during the reaction with H2O2 for the initial 30 min. Time-dependent changes in the ESR signal of SOD showed the destruction of ligands for Cu2+ in SOD by H2O2 within this initial period. Thus we conclude that inactivation of alpha1-PI is mediated in the H2O2/Cu,Zn-SOD system via the generation of .OH by free Cu2+ released from oxidatively damaged SOD.	KUMAMOTO UNIV, SCH MED, DEPT MICROBIOL, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT MED, KUMAMOTO 860, JAPAN; JEOL LTD, DIV ANALYT INSTRUMENTS, ELECTRON SPIN RESONANCE APPLICAT LAB, AKISHIMA 196, JAPAN	Kumamoto University; Kumamoto University; Jeol Ltd; JEOL Japan								AKAIKE T, 1992, ARCH BIOCHEM BIOPHYS, V294, P55, DOI 10.1016/0003-9861(92)90136-K; AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; ARUOMA OI, 1989, FEBS LETT, V244, P76, DOI 10.1016/0014-5793(89)81166-4; BLECH DM, 1983, ARCH BIOCHEM BIOPHYS, V224, P579, DOI 10.1016/0003-9861(83)90245-X; BORDERS CL, 1985, ARCH BIOCHEM BIOPHYS, V241, P472, DOI 10.1016/0003-9861(85)90572-7; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; CLARK RA, 1981, J BIOL CHEM, V256, P3348; DEAN RT, 1989, BIOCHEM BIOPH RES CO, V159, P821, DOI 10.1016/0006-291X(89)90068-5; DIZDAROGLU M, 1990, BIOCHEMISTRY-US, V29, P8447, DOI 10.1021/bi00488a035; DUCHESNE J, 1977, J THEOR BIOL, V66, P137, DOI 10.1016/0022-5193(77)90316-2; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GELVAN D, 1990, BIOCHIM BIOPHYS ACTA, V1035, P353, DOI 10.1016/0304-4165(90)90100-B; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HEIDTMANN H, 1986, PROTEINASE INHIBITOR, V12, P441; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; HUNT JV, 1988, BIOCHEM J, V250, P87, DOI 10.1042/bj2500087; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; JEWETT SL, 1989, EUR J BIOCHEM, V180, P569, DOI 10.1111/j.1432-1033.1989.tb14683.x; KAJIHARA J, 1988, BIOCH TOKYO, V104, P851; KLUG D, 1972, J BIOL CHEM, V247, P4839; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; KWON NS, 1990, AGENTS ACTIONS, V29, P388, DOI 10.1007/BF01966473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN RA, 1982, J BIOL CHEM, V257, P336; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHESON NR, 1981, BIOCHEMISTRY-US, V20, P331, DOI 10.1021/bi00505a016; MATHESON NR, 1979, BIOCHEM BIOPH RES CO, V88, P402, DOI 10.1016/0006-291X(79)92062-X; MATHESON NR, 1985, BIOCHEMISTRY-US, V24, P1941, DOI 10.1021/bi00329a021; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOLLA A, 1986, INFECT IMMUN, V53, P522, DOI 10.1128/IAI.53.3.522-529.1986; NOWAK D, 1990, EXP PATHOL-JENA, V38, P249, DOI 10.1016/S0232-1513(11)80236-7; ODA T, 1992, ARCH BIOCHEM BIOPHYS, V294, P38, DOI 10.1016/0003-9861(92)90133-H; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; SAGRIPANTI JL, 1989, J BIOL CHEM, V264, P1729; SALO DC, 1990, J BIOL CHEM, V265, P11919; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SINET PM, 1981, ARCH BIOCHEM BIOPHYS, V212, P411, DOI 10.1016/0003-9861(81)90382-9; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5; WARD PA, 1983, J CLIN INVEST, V72, P789, DOI 10.1172/JCI111050; WONG PS, 1980, BIOCHEM BIOPH RES CO, V96, P1449, DOI 10.1016/0006-291X(80)90113-8; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	48	150	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25371	25377						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334093				2022-12-25	WOS:A1992KB60300070
J	DEGRAY, JA; LASSMANN, G; CURTIS, JF; KENNEDY, TA; MARNETT, LJ; ELING, TE; MASON, RP				DEGRAY, JA; LASSMANN, G; CURTIS, JF; KENNEDY, TA; MARNETT, LJ; ELING, TE; MASON, RP			SPECTRAL-ANALYSIS OF THE PROTEIN-DERIVED TYROSYL RADICALS FROM PROSTAGLANDIN-H SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION; ENZYME	We have analyzed the low temperature EPR spectra of the protein-derived tyrosyl radicals detected upon addition of arachidonic acid or 5-phenyl-4-pentenyl-1-hydroperoxide (PPHP) to prostaglandin H synthase. With either arachidonic acid or PPHP the initial radical detected is a doublet (peak-to-trough = 35 Gauss) that disappears rapidly and is replaced by a broad singlet (peak-to-trough = 30 Gauss) followed by a narrow singlet (peak-to-trough = 26.5 Gauss). The relative amounts of these signals vary with time and concentration of arachidonic acid. The three tyrosyl radical signals were subjected to computer simulation and power saturation analysis. The data establish that there are only two distinct tyrosyl radical species, the doublet and the narrow singlet. The broad singlet seen at intermediate times and at low arachidonic acid concentrations is a composite of the doublet and the narrow singlet. The composition of the broad singlet in incubations of prostaglandin H synthase with 0.5 mM arachidonic acid is approximately 40% doublet and 60% singlet. The broad singlet signal does not represent a distinct tyrosyl radical species.	NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709; VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,CTR MOLEC TOXICOL,AB HANCOCK JR MEM LAB CANC RES,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CHEM,NASHVILLE,TN 37232	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University; Vanderbilt University			Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				BARRY BA, 1990, J BIOL CHEM, V265, P20139; DEGRAY JA, 1987, THESIS BROWN U PROVI; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; FASANELL.EL, 1969, P NATL ACAD SCI USA, V62, P299, DOI 10.1073/pnas.62.2.299; GRASLUND A, 1985, ENVIRON HEALTH PERSP, V64, P139, DOI 10.2307/3430005; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1990, ADV PROSTAGLANDIN TH, V21, P137; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; PACEASCIAK CR, 1983, ENZYMES, V16, P544; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; TSAI AL, 1992, J BIOL CHEM, V267, P17753	15	79	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23583	23588						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331091				2022-12-25	WOS:A1992JZ23900027
J	CLERC, A; CATTY, P; BENNETT, N				CLERC, A; CATTY, P; BENNETT, N			INTERACTION BETWEEN CGMP-PHOSPHODIESTERASE AND TRANSDUCIN ALPHA-SUBUNIT IN RETINAL RODS - A CROSS-LINKING STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; OUTER SEGMENTS; ACTIVATION MECHANISM; LIMITED PROTEOLYSIS; INHIBITORY SUBUNIT; GAMMA-SUBUNIT; BETA-SUBUNIT; MEMBRANES; PHOTORECEPTORS	Cross-linking of the different subunits of the retinal cGMP-phosphodiesterase (PDE) with its activator GalphaGTPgammaS (alpha subunit of the retinal G-protein transducin with GTPgammaS (guanosine 5'-O-(3-thiotriphosphate) bound) has been investigated using purified proteins, with a N-hydroxysuccinimide homobifunctional cross-linker, bis(sulfosuccinimidyl)suberate (BS3) and its cleavable analog 3,3'-dithiobis(sulfosuccinimidylpropionate) (DTSSP). Interaction of purified G-protein and PDE is achieved in the presence of lecithin vesicles, at protein concentrations sufficient for full PDE activation. Protein subunits linked with DTSSP are separated by cleavage of the disulfide bridge and identified by electrophoresis. Complexes of PDEalpha (PDEbeta) with 1 and 2 molecules of activator GalphaGTPgammaS are observed, providing direct evidence for an interaction or at least a close proximity between 2 molecules of activator Galpha and each of the catalytic PDE subunits in the activated state of PDE. The results also reveal symmetrical roles of PDEalpha and PDEbeta, with the existence of one site for PDEgamma and one site for Galpha on each catalytic subunit.	CEN,DBMS,BMC,BIOPHYS MOLEC & CELLULAIRE LAB,CNRS,UA 520,BP 85X,F-38041 GRENOBLE,FRANCE	Centre National de la Recherche Scientifique (CNRS)								BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BENNETT N, 1985, J BIOL CHEM, V260, P4156; BHOWN AS, 1980, ANAL BIOCHEM, V103, P184, DOI 10.1016/0003-2697(80)90254-7; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CLERC A, 1992, J BIOL CHEM, V267, P6620; COMPTON SJ, 1985, ANAL BIOCHEM, V151, P369, DOI 10.1016/0003-2697(85)90190-3; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DETERRE P, 1984, FEBS LETT, V178, P228, DOI 10.1016/0014-5793(84)80606-7; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1983, J BIOL CHEM, V258, P503; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; KROLL S, 1989, J BIOL CHEM, V264, P4490; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MURADOV KG, 1990, BIOL MEMBRANY, V7, P565; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; SCHLEGEL W, 1979, J BIOL CHEM, V254, P5168; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; TSUI FC, 1990, BIOPHYS J, V57, P85, DOI 10.1016/S0006-3495(90)82509-1; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539	37	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19948	19953						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328188				2022-12-25	WOS:A1992JR85800035
J	CATTY, P; PFISTER, C; BRUCKERT, F; DETERRE, P				CATTY, P; PFISTER, C; BRUCKERT, F; DETERRE, P			THE CGMP PHOSPHODIESTERASE-TRANSDUCIN COMPLEX OF RETINAL RODS - MEMBRANE-BINDING AND SUBUNITS INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENTS; ALPHA-SUBUNIT; G-PROTEIN; INHIBITORY SUBUNIT; MONOCLONAL-ANTIBODIES; ACTIVATION MECHANISM; LIMITED PROTEOLYSIS; ADENYLATE-CYCLASE; LIGHT-SCATTERING	cGMP-specific phosphodiesterase (PDE) of vertebrate retinal rod outer segments (ROS) is composed of two catalytic subunits (PDEalpha and PDEbeta) and two identical inhibitory subunits (PDEgamma). Native PDEalphabetagamma2 is peripherally bound to the membranes of ROS discs. We studied quantitatively its partition between soluble and membrane-bound fractions in ROS homogenates. In the presence of its activator, the alpha-subunit of transducin loaded with a triphosphate guanine nucleotide (Talpha*), PDE displayed a greatly enhanced membrane binding. Neither the purified PDEgamma.Talpha* complex, nor the PDEalphabeta and PDEalphabetagamma forms of active PDE, showed a membrane binding comparable to that of PDEalphabetagamma2 in the presence of Talpha*. The Talpha*-activated PDE is therefore an undissociated complex tightly bound to the ROS membranes. Using limited proteolysis, we showed that the membrane anchoring of the whole complex implies not only PDE (mainly by the C terminus of PDEbeta) but also both termini of Talpha*. The membrane binding of the purified PDEalphabeta species was also enhanced in the presence of Talpha*; a direct link would therefore exist between the activator and the catalytic subunits. From this work emerges a plausible structural model of the Talpha*-activated PDE, with its internal interactions and its sites of anchoring into the ROS membrane.	CEN, BIOPHYS MOLEC & CELLULAIRE LAB, CNRS, UA 520, F-38041 GRENOBLE, FRANCE	Centre National de la Recherche Scientifique (CNRS)			Deterre, Philippe/O-8984-2017	Deterre, Philippe/0000-0001-9303-0791				ANANT JS, 1992, J BIOL CHEM, V267, P687; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BRUCKERT F, 1988, EUR BIOPHYS J BIOPHY, V16, P207; CARETTA A, 1986, BIOCHEMISTRY-US, V25, P2335, DOI 10.1021/bi00357a006; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CLERC A, 1992, J BIOL CHEM, V267, P6620; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HINGORANI VN, 1990, J BIOL CHEM, V265, P19923; HINGORANI VN, 1987, FEBS LETT, V220, P15, DOI 10.1016/0014-5793(87)80867-0; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; JOURNOT L, 1991, P NATL ACAD SCI USA, V88, P10054, DOI 10.1073/pnas.88.22.10054; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; LIEBMAN PA, 1984, ADV CYCLIC NUCL PROT, V17, P215; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MORRIS D, 1990, BIOCHEMISTRY-US, V29, P9079, DOI 10.1021/bi00490a027; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, J BIOL CHEM, V262, P15746; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; STRYER L, 1991, J BIOL CHEM, V266, P10711; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028; VANDOP C, 1984, J BIOL CHEM, V259, P23; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539	48	59	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19489	19493						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326553				2022-12-25	WOS:A1992JP59300072
J	DRAYER, AL; VANHAASTERT, PJM				DRAYER, AL; VANHAASTERT, PJM			MOLECULAR-CLONING AND EXPRESSION OF A PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C OF DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL TRANSDUCTION; TYROSINE KINASE; COMPLETE CDNA; SEQUENCE; GENE; CHEMOATTRACTANT; DROSOPHILA; GROWTH; CELLS	A number of phosphoinositide-specific phospholipases C (PLC) of different species have recently been cloned. The predicted amino acid sequences of these isoforms contain two highly conserved domains. Here we report the identification of a PLC gene of Dictyostelium by using the polymerase chain reaction. Primers were designed coding for highly conserved amino acid regions located within one of the conserved domains of PLCs. Cloning and sequencing of the polymerase chain reaction product revealed one unique PLC-like sequence. This sequence was used to screen a library and isolate several overlapping cDNA clones. The complete cDNA was expressed in Dictyostelium cells resulting in increased basal levels of inositol 1,4,5-trisphosphate and enhanced PLC activity. The identified Dictyostelium PLC, DdPLC, encodes a protein with a calculated molecular mass of 91 kDa. The deduced amino acid sequence contains the two conserved domains found in other PLC isoforms, separated by a short variable region. The C-terminal part of the protein shows strong homology with the mammalian PLC-delta isoform. DdPLC is expressed at all stages of development, with an increase in transcription during starvation and in the culminating fruiting body.			DRAYER, AL (corresponding author), UNIV GRONINGEN,DEPT BIOCHEM,NIJENBORGH 4,9747 AG GRONINGEN,NETHERLANDS.							ALBERTS B, 1989, MOL BIOL CELL, P681; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOMINAAR AA, 1991, J CELL SCI, V100, P825; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EMORI Y, 1989, J BIOL CHEM, V264, P21885; EUROPEFINNER GN, 1987, J CELL SCI, V87, P513; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.bi.56.070187.004225; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TOMPKINS TA, 1991, J BIOL CHEM, V266, P4228; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; VANHAASTERT PJM, 1989, ANAL BIOCHEM, V177, P115, DOI 10.1016/0003-2697(89)90024-9; VANHAASTERT PJM, 1989, BIOCHEM J, V258, P577, DOI 10.1042/bj2580577; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171	35	73	74	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18387	18392						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326523				2022-12-25	WOS:A1992JN50200026
J	MA, ZM; GRUBB, JH; SLY, WS				MA, ZM; GRUBB, JH; SLY, WS			DIVALENT CATION-DEPENDENT STIMULATION OF LIGAND-BINDING TO THE 46-KDA MANNOSE 6-PHOSPHATE RECEPTOR CORRELATES WITH DIVALENT CATION-DEPENDENT TETRAMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; BETA-GLUCURONIDASE; EQUILIBRIUM; CLONING; FORMS	The quaternary structure and binding activity of the murine 46-kDa mannose 6-phosphate receptor (46MPR) were studied in semi-intact murine cells that overexpress the murine receptor. Chemical cross-linking studies showed that the murine 46MPR exists in monomer, dimer, and tetramer forms in membranes of overexpressing murine cells. Treatment of permeabilized cells with Mn2+ increased the tetramer form of 46MPR, and this tetramerization was reversed by removal of Mn2+. Thus, the divalent cations affected the distribution of receptor among the three forms, favoring tetramerization at the expense of dimer and monomer. Low temperature (4-degrees-C) also increases the fraction present as tetramer. The binding assay results show that Mn2+ is required for the 46MPR to achieve and retain the ability to bind ligand at 37-degrees-C but not at 4-degrees-C. Preincubation with Mn2+ produced a 3-fold increase in Man-6-P-specific binding of beta-glucuronidase which paralleled the 3-fold increase in tetramer seen during preincubation with Mn2+. The similarity of the effects of addition and removal of Mn2+ on enzyme binding to the effects of Mn2+ on favoring tetramer formation suggests that divalent cation-dependent tetramerization of the 46MPR contributes to the stimulation of ligand binding to the 46MPR by divalent cations.	ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104	Saint Louis University					NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034182, R37GM034182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA ZM, 1991, J BIOL CHEM, V266, P10589; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036	16	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					19017	19022						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326539				2022-12-25	WOS:A1992JN50200114
J	LECONTE, I; AUZAN, C; DEBANT, A; ROSSI, B; CLAUSER, E				LECONTE, I; AUZAN, C; DEBANT, A; ROSSI, B; CLAUSER, E			N-LINKED OLIGOSACCHARIDE CHAINS OF THE INSULIN RECEPTOR-BETA SUBUNIT ARE ESSENTIAL FOR TRANSMEMBRANE SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; ACETYLCHOLINE-RECEPTOR; GLYCOSYLATION MUTANTS; BINDING-ACTIVITY; CELLS; CARBOHYDRATE; BIOSYNTHESIS; REPLACEMENT; HYBRID	Insulin receptor (IR) is a glycoprotein possessing N-linked oligosaccharide side chains on both alpha and beta-subunits. The present study focusses for the first time on the potential contribution of N-linked oligosaccharides of the beta-subunit in the processing, structure, and function of the insulin receptor. To investigate this point, a receptor mutant (IR beta-N1234) was obtained by stable transfection into Chinese hamster ovary cells of an IR cDNA modified by site-directed mutagenesis on the four potential N-glycosylation sites (Asn-X-Ser/Thr) of the beta-subunit. The mutated receptor presents an alpha-subunit of 135 kDa, indistinguishable from the wild type alpha-subunit, but the beta-subunit has a reduced molecular mass (80 kDa instead of 95 kDa) most likely due to the absence of N-glycosylation. Metabolic labeling experiments indicate a normal processing and maturation of this mutated receptor which is normally expressed at the surface of the cells as demonstrated by indirect immunofluorescence. The affinity of the mutant for insulin (K(d) = 0.12 nM) is similar to that of the wild type receptor (K(d) = 0.12 nM). However, a major defect of the mutated IR tyrosine kinase was assessed both in vitro and in vivo by (i) the absence of insulin-stimulated phosphorylation of the poly(Glu-Tyr) substrate in vitro; (ii) the reduction of the insulin maximal stimulation of the mutated IR autophosphorylation in vitro (2-fold stimulation for the mutant receptor as compared to a 7-fold stimulation for the wild type); and (iii) a more complex alteration of the mutated receptor tyrosine autophosphorylation in vivo (3-fold increase of the basal phosphorylation and a 4-fold simulation of this phosphorylation as compared to the wild type receptor, the phosphorylation of which is stimulated 14-fold by insulin). The physiological consequences of this defect were tested on three classical insulin cellular actions; in Chinese hamster ovary IR beta-N1234, glucose transport, glycogen synthesis, and DNA synthesis were all unable to be stimulated by insulin indicating the absence of insulin transduction through this mutated receptor. These data provide the first direct evidence for a critical role of oligosaccharide side chains of the beta-subunit in the molecular events responsible for the IR enzymatic activation and signal transduction.	COLL FRANCE,CHAIRE MED EXPTL,INSERM,U36,3 RUE ULM,F-75005 PARIS,FRANCE; FAC MED PASTEUR,INSERM,U210,NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur								ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BREITFELD PP, 1984, J BIOL CHEM, V259, P414; CAPEAU J, 1980, FEBS LETT, V118, P25, DOI 10.1016/0014-5793(80)81210-5; CHERQUI G, 1983, BIOCHEM J, V214, P111, DOI 10.1042/bj2140111; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLLIER E, 1991, DIABETES, V40, P197, DOI 10.2337/diabetes.40.2.197; CUATRECASAS P, 1973, P NATL ACAD SCI USA, V70, P485, DOI 10.1073/pnas.70.2.485; CUATRECASAS P, 1972, INSULIN ACTION, P137; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; DURONIO V, 1988, J BIOL CHEM, V263, P5436; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EDGE ASB, 1990, ENDOCRINOLOGY, V127, P1887, DOI 10.1210/endo-127-4-1887; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1987, P NATL ACAD SCI USA, V84, P5101, DOI 10.1073/pnas.84.15.5101; FILIPOVIC I, 1989, J BIOL CHEM, V264, P8815; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HAYES GR, 1991, BIOCHEM BIOPH RES CO, V174, P735, DOI 10.1016/0006-291X(91)91479-V; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; HEIDENREICH KA, 1983, J BIOL CHEM, V258, P8527; HERZBERG VL, 1985, BIOCHEM BIOPH RES CO, V129, P789, DOI 10.1016/0006-291X(85)91961-8; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; KEATING MT, 1989, J BIOL CHEM, V264, P9129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PANZIO G, 1988, EMBO J, V6, P4111; PODSKALNY J, 1984, BIOCHEM BIOPH RES CO, V125, P70, DOI 10.1016/S0006-291X(84)80335-6; PONZIO G, 1987, EMBO J, V6, P333, DOI 10.1002/j.1460-2075.1987.tb04759.x; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; PRIVES J, 1983, J BIOL CHEM, V258, P1775; RANDS E, 1990, J BIOL CHEM, V265, P10759; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; RONNETT GV, 1981, J BIOL CHEM, V256, P4704; ROUILLER DG, 1986, ENDOCRINOLOGY, V118, P1159, DOI 10.1210/endo-118-3-1159; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SLIEKER LJ, 1988, BIOCHEM BIOPH RES CO, V153, P96, DOI 10.1016/S0006-291X(88)81194-X; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; SODORA DL, 1989, J VIROL, V63, P5184, DOI 10.1128/JVI.63.12.5184-5193.1989; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554	50	72	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17415	17423						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324936				2022-12-25	WOS:A1992JL05300102
J	DEAN, FB; BOROWIEC, JA; EKI, T; HURWITZ, J				DEAN, FB; BOROWIEC, JA; EKI, T; HURWITZ, J			THE SIMIAN VIRUS-40 T-ANTIGEN DOUBLE HEXAMER ASSEMBLES AROUND THE DNA AT THE REPLICATION ORIGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-TUMOR-ANTIGEN; SV40 ORIGIN; HELICASE ACTIVITY; BINDING ACTIVITY; ATPASE ACTIVITY; DUPLEX DNA; SITE-II; OLIGOMERIZATION; INITIATION; PHOSPHORYLATION	An initial step in the replication of simian virus (SV40) DNA is the ATP-dependent formation of a double hexamer of the SV40 large tumor (T) antigen at the SV40 DNA replication origin. In the absence of DNA, T antigen assembled into hexamers in the presence of magnesium and ATP. Hexameric T antigen was stable and could be isolated by glycerol gradient centrifugation. The ATPase activities of hexameric and monomeric T antigen isolated from parallel glycerol gradients were identical. However, while monomeric T antigen was active in the ATP-dependent binding, untwisting, unwinding, and replication of SV40 origin-containing DNA, hexameric T antigen was inactive in these reactions. Isolated hexamers incubated at 37-degrees-C in the presence of ATP remained intact, but dissociated into monomers when incubated at 37-degrees-0 in the absence of ATP. This dissociation restored the activity of these preparations in the DNA replication reaction, indicating that hexameric T antigen is not permanently inactivated but merely assembled into a nonproductive structure. We propose that the two hexamers of T antigen at the SV40 origin assemble around the DNA from monomer T antigen in solution. This complex untwists the DNA at the origin, melting specific DNA sequences. The resulting single-stranded regions may be utilized by the T antigen helicase activity to initiate DNA unwinding bidirectionally from the origin.	NYU MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA; RIKEN INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, GENE BANK, TSUKUBA, IBARAKI 305, JAPAN	New York University; RIKEN	DEAN, FB (corresponding author), SLOAN KETTERING MEM CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.			Dean, Frank/0000-0002-9416-4449	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034559] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM 34559] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBORN K, 1989, J VIROL, V63, P912, DOI 10.1128/JVI.63.2.912-918.1989; BAUMANN EA, 1982, J VIROL, V44, P78, DOI 10.1128/JVI.44.1.78-87.1982; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BRADLEY MK, 1987, P NATL ACAD SCI USA, V84, P4026, DOI 10.1073/pnas.84.12.4026; BRADLEY MK, 1990, J VIROL, V64, P4939, DOI 10.1128/JVI.64.10.4939-4947.1990; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BUCHMAN AR, 1980, DNA TUMOR VIRUSES, P799; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; BURGER C, 1983, VIROLOGY, V126, P19, DOI 10.1016/0042-6822(83)90459-2; CARROLL RB, 1974, P NATL ACAD SCI USA, V71, P3754, DOI 10.1073/pnas.71.9.3754; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB SP, 1988, BIOCHEM BIOPH RES CO, V153, P249, DOI 10.1016/S0006-291X(88)81215-4; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DODSON M, 1989, J BIOL CHEM, V264, P10719; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; GIACHERIO D, 1979, J BIOL CHEM, V254, P8113; GIDONI D, 1982, J VIROL, V42, P456, DOI 10.1128/JVI.42.2.456-466.1982; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GREENSPAN DS, 1981, P NATL ACAD SCI-BIOL, V78, P105, DOI 10.1073/pnas.78.1.105; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JONES KA, 1984, CELL, V36, P155, DOI 10.1016/0092-8674(84)90084-9; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KUCHINO T, 1975, J VIROL, V15, P1302, DOI 10.1128/JVI.15.6.1302-1307.1975; LOEBER G, 1989, J VIROL, V63, P94, DOI 10.1128/JVI.63.1.94-100.1989; LOEBER G, 1991, J VIROL, V65, P3167, DOI 10.1128/JVI.65.6.3167-3174.1991; MANOS MM, 1985, J VIROL, V53, P120, DOI 10.1128/JVI.53.1.120-127.1985; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOHR IJ, 1989, J VIROL, V63, P4181, DOI 10.1128/JVI.63.10.4181-4188.1989; MONTENARH M, 1987, FEBS LETT, V221, P199, DOI 10.1016/0014-5793(87)80925-0; MONTENARH M, 1984, J VIROL, V49, P658, DOI 10.1128/JVI.49.3.658-664.1984; MONTENARH M, 1983, J VIROL, V45, P531, DOI 10.1128/JVI.45.2.531-538.1983; MYERS RM, 1981, J MOL BIOL, V148, P347, DOI 10.1016/0022-2836(81)90180-7; OSBORN M, 1974, COLD SPRING HARB SYM, V39, P267, DOI 10.1101/SQB.1974.039.01.035; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; POTTER CW, 1969, J VIROL, V4, P574, DOI 10.1128/JVI.4.5.574-579.1969; PRIVES C, 1979, COLD SPRING HARB SYM, V44, P123, DOI 10.1101/SQB.1980.044.01.014; REYNISDOTTIR I, 1990, J VIROL, V64, P6234; ROBERTS JM, 1989, P NATL ACAD SCI USA, V86, P3939, DOI 10.1073/pnas.86.11.3939; RUNZLER R, 1987, J VIROL, V61, P2076, DOI 10.1128/JVI.61.7.2076-2083.1987; SCHEFFNER M, 1989, NUCLEIC ACIDS RES, V17, P93, DOI 10.1093/nar/17.1.93; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SCHICKEDANZ J, 1986, VIROLOGY, V148, P47, DOI 10.1016/0042-6822(86)90402-2; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SIMMONS DT, 1990, J VIROL, V64, P4858, DOI 10.1128/JVI.64.10.4858-4865.1990; SIMMONS DT, 1990, J VIROL, V64, P1973, DOI 10.1128/JVI.64.5.1973-1983.1990; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; WACHTER M, 1985, J VIROL, V56, P520, DOI 10.1128/JVI.56.2.520-526.1985; WANG EH, 1991, VIROLOGY, V184, P399, DOI 10.1016/0042-6822(91)90858-9; WIEKOWSKI M, 1987, J VIROL, V61, P411, DOI 10.1128/JVI.61.2.411-418.1987; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WUNKIM K, 1990, J VIROL, V64, P2014, DOI 10.1128/JVI.64.5.2014-2020.1990	72	141	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14129	14137						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321135				2022-12-25	WOS:A1992JD32500055
J	HOITINK, CWG; CANTERS, GW				HOITINK, CWG; CANTERS, GW			THE IMPORTANCE OF ASN(47) FOR STRUCTURE AND REACTIVITY OF AZURIN FROM ALCALIGENES-DENITRIFICANS AS STUDIED BY SITE-DIRECTED MUTAGENESIS AND SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE COPPER PROTEINS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; POPLAR PLASTOCYANIN; ESCHERICHIA-COLI; CYTOCHROME-C; REDUCTION; RESOLUTION; PSEUDOAZURIN; PURIFICATION	To study the importance of a rigid copper site for the structure and function of azurin, a mutant with a reduced number of internal hydrogen bonds around the copper has been prepared and characterized. To this purpose, the previously cloned azu gene from Alcaligenes denitrificans (Hoitink, C. W. G., Woudt, L. P., Turenhout, J. C. M., Van de Kamp, M., and Canters, G. W. (1990) Gene (Amst.) 90, 15-20) was expressed in Escherichia coli and an isolation and purification procedure for the azurin was developed. The azurin obtained after heterologous expression in E. coli appears spectroscopically indistinguishable from azurin derived from A. denitrificans. The hydrogen bonding network around the copper site was altered by replacing Asn47 by a leucine by means of site-directed mutagenesis. Asn47 is a conserved residue in all blue copper proteins of which the primary structure has been reported. Characterization of the mutant protein with UV-visible, electron spin resonance, and NMR spectroscopy, and comparison with the wild type azurin revealed that the structure of the copper site as well as the overall structure of the protein have been largely retained. The redox activity as measured by the electron self-exchange rate appears not to have changed either. However, the mutant differs from the wild type azurin with respect to stability and midpoint potential. Midpoint potentials of mutant and wild type azurin amount to 396 and 286 mV, respectively. The difference is due to sizable entropic and enthalpic contributions which to a large extent cancel. Possible explanations for the outcome of these experiments are discussed.	GORLAEUS LABS,POB 9502,2300 RA LEIDEN,NETHERLANDS									ADDISON AW, 1985, COPPER COORDINATION, P109; ADMAN ET, 1985, TOPICS MOL STRUCTU 1, P1; AINSCOUGH EW, 1987, BIOCHEMISTRY-US, V26, P71, DOI 10.1021/bi00375a011; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; AMBLER RP, 1985, BIOCHEM J, V232, P451, DOI 10.1042/bj2320451; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BASHFORD D, 1988, J MOL BIOL, V203, P507, DOI 10.1016/0022-2836(88)90016-2; BERGMAN C, 1977, BIOCHEM BIOPH RES CO, V77, P1052, DOI 10.1016/S0006-291X(77)80084-3; CANTERS GW, 1984, J MAGN RESON, V57, P1, DOI 10.1016/0022-2364(84)90230-0; CHOTHIA C, 1982, J MOL BIOL, V160, P309, DOI 10.1016/0022-2836(82)90178-4; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; CUTLER RL, 1989, BIOCHEMISTRY-US, V28, P3188, DOI 10.1021/bi00434a012; DENBLAAUWEN T, 1989, J BACTERIOL, V171, P1394, DOI 10.1128/jb.171.3.1394-1401.1989; ENGESETH HR, 1986, BIOCHEMISTRY-US, V25, P2448, DOI 10.1021/bi00357a023; GILSON MK, 1986, BIOPOLYMERS, V25, P2097, DOI 10.1002/bip.360251106; GOLDBERG M, 1976, BIOCHEMISTRY-US, V15, P4197, DOI 10.1021/bi00664a011; GROENEVELD CM, 1988, J MOL BIOL, V200, P189, DOI 10.1016/0022-2836(88)90343-9; GROENEVELD CM, 1987, J INORG BIOCHEM, V31, P143, DOI 10.1016/0162-0134(87)80059-4; GROENEVELD CM, 1988, J BIOL CHEM, V263, P167; GUSS JM, 1988, SCIENCE, V241, P806, DOI 10.1126/science.3406739; GUSS JM, 1983, J MOL BIOL, V169, P521; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HARVEY S, 1989, PROTEINS, V5, P68; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; HILL HAO, 1985, J ELECTROANAL CHEM, V187, P315; HOITINK CWG, 1990, GENE, V90, P15, DOI 10.1016/0378-1119(90)90434-S; KARLSSON BG, 1989, FEBS LETT, V253, P99, DOI 10.1016/0014-5793(89)80938-X; KORSZUN ZR, 1987, J MOL BIOL, V196, P413, DOI 10.1016/0022-2836(87)90701-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; NORRIS GE, 1979, J MOL BIOL, V135, P309, DOI 10.1016/0022-2836(79)90357-7; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; PETRATOS K, 1988, ACTA CRYSTALLOGR B, V44, P628, DOI 10.1107/S0108768188008912; RYDEN L, 1976, NATURE, V261, P344, DOI 10.1038/261344a0; Sambrook J, 1989, MOL CLONING LABORATO; SHEPARD WEB, 1990, J AM CHEM SOC, V112, P7817, DOI 10.1021/ja00177a065; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; VANBEEUMEN J, 1991, J BIOL CHEM, V266, P4869; VANDEKAMP M, 1990, EUR J BIOCHEM, V194, P109; VANDEKAMP M, 1990, BIOCHIM BIOPHYS ACTA, V1019, P283, DOI 10.1016/0005-2728(90)90206-J; VARADARAJAN R, 1989, SCIENCE, V243, P69, DOI 10.1126/science.2563171; WILLIAMS RJP, 1983, PURE APPL CHEM, V55, P35, DOI 10.1351/pac198355010035; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13836	13842						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321127				2022-12-25	WOS:A1992JD32500011
J	FAZIOLI, F; BOTTARO, DP; MINICHIELLO, L; AURICCHIO, A; WONG, WT; SEGATTO, O; DIFIORE, PP				FAZIOLI, F; BOTTARO, DP; MINICHIELLO, L; AURICCHIO, A; WONG, WT; SEGATTO, O; DIFIORE, PP			IDENTIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF NOVEL PUTATIVE SUBSTRATES FOR THE EPIDERMAL GROWTH-FACTOR RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; EGF RECEPTOR; INSULIN-RECEPTOR; PROTEIN; DOMAINS; CELLS; GAP	To gain insight into the mechanisms which control the mitogenic response to epidermal growth factor (EGF), we have partially purified and characterized several intracellular proteins which are phosphorylated on tyrosine residues following activation of the epidermal growth factor receptor (EGFR). Partial purification was achieved by immunoaffinity chromatography using immobilized anti-phosphotyrosine antibodies. Antisera generated against the partially purified proteins were used to identify at least five novel EGFR putative substrates, designated, on the basis of their apparent molecular weight, p97, p68, p61, p56, and p23. All of these proteins became specifically phosphorylated on tyrosine after EGF treatment of intact cells, as assessed by phosphoamino acid analysis, and none of them represented an EGFR degradation product. The phosphorylation of these proteins appeared to be relatively specific for the EGFR. In particular, an EGFR-related kinase, erbB-2 was much less efficient than EGFR at phosphorylating p97, p56, and p23 and incapable of phosphorylating p68. The identification of these novel EGFR putative substrates should lead to a better understanding of the mechanisms controlling the specificity of EGFR-mediated mitogenic signaling.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,RM 1D23,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bottaro, Donald P/AAF-3853-2020; Minichiello, Liliana/AAA-7190-2022; Di Fiore, Pier Paolo/K-2130-2012; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Di Fiore, Pier Paolo/0000-0002-2252-0950; Bottaro, Donald P/0000-0002-5057-5334; Segatto, Oreste/0000-0003-2561-1142; AURICCHIO, Alberto/0000-0002-0832-2472				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LONARDO F, 1990, New Biologist, V2, P992; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	46	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5155	5161						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1347529				2022-12-25	WOS:A1992HH74700026
J	SARKADI, B; PRICE, EM; BOUCHER, RC; GERMANN, UA; SCARBOROUGH, GA				SARKADI, B; PRICE, EM; BOUCHER, RC; GERMANN, UA; SCARBOROUGH, GA			EXPRESSION OF THE HUMAN MULTIDRUG RESISTANCE CDNA IN INSECT CELLS GENERATES A HIGH-ACTIVITY DRUG-STIMULATED MEMBRANE ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; P-GLYCOPROTEIN GENE; HAMSTER OVARY CELLS; MUTANTS; BINDING; PERMEABILITY; PURIFICATION; VINBLASTINE; COLCHICINE; ANTIBODIES	Drug-resistant tumor cells actively extrude a variety of chemotherapeutic agents by the action of the multidrug resistance (MDR1) gene product, the plasma membrane P-glycoprotein. In this report we show that the expression of the human MDR1 gene in cultured Sf9 insect cells via a baculovirus vector generates a high activity vanadate-sensitive membrane ATPase. This ATPase is markedly stimulated by drugs known to interact with the P-glycoprotein, such as vinblastine and verapamil, and the ability of the various drugs to stimulate the ATPase corresponds to their previously observed affinity for this transporter. The drug-stimulated ATPase is not present in uninfected or mock-infected Sf9 cells, and its appearance correlates with the appearance of the MDR1 gene product detected with a monoclonal anti-MDR protein antibody and by labeling with 8-azido-ATP. The drug-induced ATPase requires magnesium ions, does not utilize ADP or AMP as substrates, exhibits a half-maximal activation at about 0.5 mM MgATP, and its maximal activity (about 3-5-mu-mol/mg MDR protein/min) approaches that of the well characterized ion transport ATPases. These results provide the first direct demonstration of a high capacity drug-stimulated ATPase activity of the human multidrug resistance protein and offer a new and simple assay for the investigation of functional interactions of various drugs with this clinically important enzyme.	UNIV N CAROLINA, DEPT PHARMACOL, CB 7365 FLOB, CHAPEL HILL, NC 27599 USA; NATL INST HAEMATOL & BLOOD TRANSFUS, BUDAPEST, HUNGARY; NCI, BETHESDA, MD 20892 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill			Sarkadi, Balazs/I-5024-2013					BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BROXTERMAN HJ, 1988, FASEB J, V2, P2278, DOI 10.1096/fasebj.2.7.3350243; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1989, J BIOL CHEM, V264, P14880; INABA M, 1979, CANCER RES, V39, P2200; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; LING V, 1983, CANCER TREAT REP, V67, P869; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; PASTAN I, 1991, FASEB J, V5, P2523, DOI 10.1096/fasebj.5.11.1868977; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SARKADI B, 1977, BIOCHIM BIOPHYS ACTA, V464, P93, DOI 10.1016/0005-2736(77)90373-X; TSURUO T, 1983, CANCER RES, V43, P2905; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282	36	603	621	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4854	4858						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1347044				2022-12-25	WOS:A1992HF64200084
J	WITTERS, LA; KEMP, BE				WITTERS, LA; KEMP, BE			INSULIN ACTIVATION OF ACETYL-COA CARBOXYLASE ACCOMPANIED BY INHIBITION OF THE 5'-AMP-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COENZYME-A CARBOXYLASE; FATTY-ACID SYNTHESIS; EPIDIDYMAL ADIPOSE-TISSUE; PHASE PEPTIDE-SYNTHESIS; ISOLATED ADIPOCYTES; HEPATOMA-CELLS; POSTTRANSCRIPTIONAL REGULATION; PHOSPHORYLATION; EPINEPHRINE; SITES	The activity of acetyl-CoA carboxylase (ACC), a rate-limiting enzyme of fatty acid biosynthesis and malonyl-CoA production, can be regulated by several mechanisms, including multisite covalent phosphorylation, both in vitro and in intact cells. Evidence has been presented by others to indicate that a 5'-AMP-activated protein kinase (AMPK) is likely the major regulatory kinase active on ACC. While insulin is known to activate ACC in several cell types, accompanied by changes in ACC phosphorylation, the mechanism underlying this activation has been obscure. In the present study, we have examined, in Fao hepatoma cells, the effects of insulin on ACC and AMPK activity, the latter measured with a synthetic peptide corresponding to one of the phosphorylation sites on ACC for AMPK. Our results show that insulin leads to inhibition of kinase activity prior to the onset of ACC activation; the peak of maximal kinase inhibition (approximately 35% at 10 min) is seen to precede the onset of ACC activation (20 min). The inhibition of kinase activity due to insulin is observed both in the absence and presence of varying stimulating concentrations of added 5'-AMP. Both kinase inhibition and ACC activation display similar insulin sensitivity (A50 0.3 nM). Preservation of this insulin-induced kinase inhibition requires the presence of protein phosphatase inhibitors in the cell lysis buffer, suggesting that AMPK itself might be regulated by insulin-stimulated changes in kinase phosphorylation. Taken together, these data are consistent with the hypothesis that the 5'-AMP-activated protein kinase is a regulated component of the insulin signal transduction pathway and may be the major target for insulin regulation of ACC.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756; ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA	Dartmouth College; St. Vincent's Institute of Medical Research	WITTERS, LA (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756, USA.		Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORTHWICK AC, 1990, BIOCHEM J, V270, P795, DOI 10.1042/bj2700795; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSEY RW, 1984, BIOCHEM J, V218, P733, DOI 10.1042/bj2180733; BROWNSEY RW, 1982, BIOCHEM J, V202, P77, DOI 10.1042/bj2020077; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CRETTAZ M, 1988, BIOCHEMISTRY-US, V27, P495, DOI 10.1021/bi00401a071; CRETTAZ M, 1983, ENDOCRINOLOGY, V113, P1201, DOI 10.1210/endo-113-4-1201; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; HALESTRA.AP, 1973, BIOCHEM J, V132, P509, DOI 10.1042/bj1320509; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HAYSTEAD TAJ, 1986, BIOCHEM J, V234, P279, DOI 10.1042/bj2340279; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P339, DOI 10.1111/j.1432-1033.1988.tb14202.x; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; HODGES RS, 1975, ANAL BIOCHEM, V65, P241, DOI 10.1016/0003-2697(75)90509-6; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P275, DOI 10.1111/j.1432-1033.1983.tb07359.x; JAMIL H, 1987, J BIOL CHEM, V262, P638; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; LEE KH, 1973, BIOCHEM BIOPH RES CO, V54, P1133, DOI 10.1016/0006-291X(73)90810-3; MABROUK GM, 1990, J BIOL CHEM, V265, P6330; MOIR AMB, 1990, BIOCHEM J, V272, P511, DOI 10.1042/bj2720511; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; PARK KR, 1991, J BIOL CHEM, V266, P12249; PELECH SL, 1991, BIOCHEM J, V274, P759, DOI 10.1042/bj2740759; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; STEWART JM, 1966, SOLID PHASE PEPTIDE, P44; THAMPY KG, 1988, J BIOL CHEM, V263, P6454; TIPPER JP, 1983, ARCH BIOCHEM BIOPHYS, V227, P386, DOI 10.1016/0003-9861(83)90468-X; WITTERS LA, 1988, J BIOL CHEM, V263, P8027; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WITTERS LA, 1983, J BIOL CHEM, V258, P5643; WITTERS LA, 1981, BIOCHEM BIOPH RES CO, V100, P872, DOI 10.1016/S0006-291X(81)80254-9; WITTERS LA, 1986, ADV PROTEIN PHOSPHAT, V3, P201	36	172	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2864	2867						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1346611				2022-12-25	WOS:A1992HD15400008
J	KJELSBERG, MA; COTECCHIA, S; OSTROWSKI, J; CARON, MG; LEFKOWITZ, RJ				KJELSBERG, MA; COTECCHIA, S; OSTROWSKI, J; CARON, MG; LEFKOWITZ, RJ			CONSTITUTIVE ACTIVATION OF THE ALPHA-1B-ADRENERGIC RECEPTOR BY ALL AMINO-ACID SUBSTITUTIONS AT A SINGLE SITE - EVIDENCE FOR A REGION WHICH CONSTRAINS RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; BINDING; AGONIST; HYDROLYSIS; PROTEIN; DOMAINS; MUTAGENESIS; EXPRESSION; AFFINITY; GS	Mutations in an intracellular region of the alpha-1B-adrenergic receptor constitutively activate the receptor, resulting in G protein coupling in the absence of agonist, as evidenced by elevated levels of polyphosphoinositide hydrolysis. Remarkably, all 19 possible amino acid substitutions at a single site in this region (alanine 293) confer constitutive activity. This set of mutated receptors exhibits a graded range of elevated biological activities, apparently representing a spectrum of receptor conformations which mimic the "active" state of the wild type receptor. In addition to their constitutive activities, these mutated receptors all demonstrate a higher affinity for agonists, another primary characteristic of the "active" conformation of G protein-coupled receptors. The fact that all possible mutations at this particular site result in increased activity suggests that this region may function to constrain the G protein coupling of the receptor, a constraint which is normally relieved by agonist occupancy.	DUKE UNIV,MED CTR,DEPT MED,BOX 3821,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BURGISSER E, 1982, P NATL ACAD SCI-BIOL, V79, P1732, DOI 10.1073/pnas.79.6.1732; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1982, MOL PHARMACOL, V22, P290; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEVITZKI A, 1988, SCIENCE, V241, P800, DOI 10.1126/science.2841758; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3	27	527	551	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1430	1433						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346134				2022-12-25	WOS:A1992HA48500008
J	KONRAD, M				KONRAD, M			CLONING AND EXPRESSION OF THE ESSENTIAL GENE FOR GUANYLATE KINASE FROM YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENYLATE KINASE; SACCHAROMYCES-CEREVISIAE; X-RAY; PURIFICATION; DISRUPTION; SEQUENCE; PROTEINS; GTP	Guanylate kinase catalyzes the reversible transfer of the terminal phosphoryl group of ATP to the acceptor molecule GMP. Detailed analysis of the in vivo function of this enzyme has been limited by the lack of any genetic data. Using oligonucleotides based on amino acid sequence information of the yeast enzyme, the Saccharomyces cerevisiae gene, GUK1, was isolated and characterized. The gene is present in single copy and maps to chromosome IV. Insertional mutagenesis of the GUK1 locus caused recessive lethality, indicating that this enzyme is necessary for vegetative cell growth. Using inducible expression systems, guanylate kinase was produced in large amounts both in S. cerevisiae and in Escherichia coli.			KONRAD, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC GENET, POB 2841, W-3400 GOTTINGEN, GERMANY.							Agarwal K C, 1978, Methods Enzymol, V51, P483; Anderson E. P., 1973, ENZYMES, V8, P49; ANDREADIS A, 1984, J BIOL CHEM, V259, P8059; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BESSMAN MJ, 1959, J BIOL CHEM, V234, P2735; Boyer P.D, 1973, ENZYMES, P279; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; BUCCINO RJ, 1969, ARCH BIOCHEM BIOPHYS, V132, P49, DOI 10.1016/0003-9861(69)90337-3; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; ITO Y, 1980, EUR J BIOCHEM, V105, P85, DOI 10.1111/j.1432-1033.1980.tb04477.x; KONRAD M, 1990, NUCLEIC ACIDS RES, V18, P5320, DOI 10.1093/nar/18.17.5320; KONRAD M, 1988, J BIOL CHEM, V263, P19468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIECH RP, 1965, J BIOL CHEM, V240, P351; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OESCHGER MP, 1966, J BIOL CHEM, V241, P5452; PALL ML, 1988, J BIOL CHEM, V263, P11168; ROSE AB, 1990, METHOD ENZYMOL, V185, P234; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; VETTER IR, 1991, BIOCHEMISTRY-US, V30, P4137, DOI 10.1021/bi00231a005; WEBER G, 1992, ADV ENZYME REGUL, V32, P57; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	33	49	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25652	25655						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334480				2022-12-25	WOS:A1992KD07300009
J	TANG, LH; CHOKSHI, H; HU, CB; GORDON, MM; ALPERS, DH				TANG, LH; CHOKSHI, H; HU, CB; GORDON, MM; ALPERS, DH			THE INTRINSIC-FACTOR (IF)-COBALAMIN RECEPTOR-BINDING SITE IS LOCATED IN THE AMINO-TERMINAL PORTION OF IF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCOBALAMIN-I; ESCHERICHIA-COLI; RAT-KIDNEY; CDNA; VITAMIN-B12; RECOGNITION; LOCALIZATION; PURIFICATION; HAPTOCORRIN; TRANSLATION	Intrinsic factor has two binding sites, one each for cobalamin and for the ileal receptor recognizing the intrinsic factor-cobalamin complex. To obtain initial functional mapping of these domains, cDNAs encoding intact rat and human intrinsic factor or fragments thereof were expressed transiently in COS-1 cells or in an in vitro transcription/translation system. Deletion of as little as 12% of the amino acids from the carboxyl terminus resulted in loss of cobalamin binding activity. On the other hand, the receptor binding region of intrinsic factor appears localized to a restricted region in the amino-terminal portion of the protein. Only those transcription/translation fragments of rat or human intrinsic factor tested that contained amino acid residues 25 to 62 (out of 399) showed calcium-dependent binding to isolated kidney brush borders, the shortest sequence corresponding with 20 consecutive amino acids. In contrast, a 232-amino acid carboxyl-terminal fragment of rat intrinsic factor and 243- and 338-amino acid carboxyl-terminal fragments of human intrinsic factor showed no receptor binding activity.	WASHINGTON UNIV,SCH MED,DIV GASTROENTEROL,660 S EUCLID,BOX 8124,ST LOUIS,MO 63110	Washington University (WUSTL)					NIDDK NIH HHS [DK33487] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033487] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS ER, 1991, FEBS LETT, V281, P90, DOI 10.1016/0014-5793(91)80365-A; BORTZ JD, 1988, J CELL BIOL, V107, P811, DOI 10.1083/jcb.107.2.811; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P3129, DOI 10.1093/nar/17.8.3129; DIECKGRAEFE BK, 1988, P NATL ACAD SCI USA, V85, P46, DOI 10.1073/pnas.85.1.46; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; GORDON M, IN PRESS BIOCH BIOPH; GORDON MM, 1991, AM J PHYSIOL, V260, pG736, DOI 10.1152/ajpgi.1991.260.5.G736; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; HAGEDORN CH, 1977, GASTROENTEROLOGY, V73, P1019; HEWITT JE, 1990, EUR J BIOCHEM, V189, P125, DOI 10.1111/j.1432-1033.1990.tb15468.x; HEWITT JE, 1991, GENOMICS, V10, P432, DOI 10.1016/0888-7543(91)90329-D; HOOPER DC, 1973, J CLIN INVEST, V52, P3074, DOI 10.1172/JCI107506; HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249; JOHNSTON J, 1989, J BIOL CHEM, V264, P15754; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; PLATICA O, 1991, J BIOL CHEM, V266, P7860; SCHONER RG, 1985, BIO-TECHNOL, V3, P151, DOI 10.1038/nbt0285-151; SEETHARAM B, 1983, BIOCHEM BIOPH RES CO, V115, P238, DOI 10.1016/0006-291X(83)90995-6; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM B, 1990, HDB PHYSL INTESTINAL, P437; SMOLKA A, 1990, GASTROENTEROLOGY, V98, P607, DOI 10.1016/0016-5085(90)90279-A; STUPPERICH E, 1991, EUR J BIOCHEM, V199, P299, DOI 10.1111/j.1432-1033.1991.tb16124.x; 1989, PROMEGA PROTOCOLS AP, P42	25	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22982	22986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331073				2022-12-25	WOS:A1992JY16300044
J	GONG, MC; FUGLSANG, A; ALESSI, D; KOBAYASHI, S; COHEN, P; SOMLYO, AV; SOMLYO, AP				GONG, MC; FUGLSANG, A; ALESSI, D; KOBAYASHI, S; COHEN, P; SOMLYO, AV; SOMLYO, AP			ARACHIDONIC-ACID INHIBITS MYOSIN LIGHT CHAIN PHOSPHATASE AND SENSITIZES SMOOTH-MUSCLE TO CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; GTP-BINDING PROTEINS; RECEPTOR-MEDIATED ACTIVATION; PORCINE CORONARY-ARTERY; SKELETAL-MUSCLE; CA2+ SENSITIZATION; CA-2+ SENSITIVITY; PHOSPHOLIPASE-C; PHORBOL ESTER; PHOSPHORYLATION	Arachidonic acid (AA) increased, at constant Ca2+, the levels of force and 20-kDa myosin light chain (MLC20) phosphorylation in permeabilized smooth muscle, and slowed relaxation and MLC20 dephosphorylation. The Ca2+-sensitizing effect of AA was not inhibited by inhibitors of AA metabolism (indomethacin, nordihydroguaiaretic acid, or propyl gallate), of protein kinase C (pseudopeptide) or by guanosine-5'-O-(beta-thiodiphosphate) and was abolished by oxidation of AA in air. A non-metabolizable AA analog, 5,8,11,14-eicosatetraynoic acid) also had Ca2+-sensitizing effects. Extensive treatment with saponin abolished the Ca2+-sensitizing effects of phorbol 12,13-dibutyrate and guanosine-5'-O-(gamma-thiotriphosphate), but not that of AA. A purified, oligomeric MLC20 phosphatase isolated from gizzard smooth muscle was dissociated into subunits by AA, and its activity was inhibited toward heavy meromyosin but not phosphorylase. We conclude that AA may act as a messenger-promoting protein phosphorylation through direct inhibition of the form of protein phosphatase(s) that dephosphorylate MLC20 in vivo.	UNIV VIRGINIA, SCH MED, DEPT PHYSIOL, BOX 449, JORDAN HALL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV DUNDEE, DEPT BIOCHEM, MRC, PROT PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND	University of Virginia; University of Virginia; University of Virginia; University of Dundee				Alessi, Dario/0000-0002-2140-9185	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL19242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1992, IN PRESS EUR J BIOCH; ANDERSON KM, 1989, PROSTAG LEUKOTR ESS, V35, P231, DOI 10.1016/0952-3278(89)90006-9; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BUCKLEY BJ, 1991, BIOCHEM J, V280, P281, DOI 10.1042/bj2800281; BURCH RM, 1989, MOL NEUROBIOL, V3, P155, DOI 10.1007/BF02935629; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; CHATTERJEE M, 1986, AM J PHYSIOL, V251, pC356, DOI 10.1152/ajpcell.1986.251.3.C356; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1992, J MOL CELL CARDIOL, V24, pS31, DOI 10.1016/0022-2828(92)90935-S; COHEN P, 1991, METHOD ENZYMOL, V201, P389; DEMEY JG, 1982, CIRC RES, V51, P439, DOI 10.1161/01.RES.51.4.439; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENT P, 1992, IN PRESS EUR J BIOCH; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GONG MC, 1992, J BIOL CHEM, V267, P14662; GRILLONE LR, 1988, J BIOL CHEM, V263, P2658; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HIMPENS B, 1990, PFLUG ARCH EUR J PHY, V417, P21, DOI 10.1007/BF00370764; HIMPENS B, 1988, J GEN PHYSIOL, V92, P713, DOI 10.1085/jgp.92.6.713; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ITOH T, 1988, J PHYSIOL-LONDON, V397, P401, DOI 10.1113/jphysiol.1988.sp017008; JELSEMA CL, 1987, J BIOL CHEM, V262, P163; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KIGOSHI T, 1990, BIOCHEM BIOPH RES CO, V171, P369, DOI 10.1016/0006-291X(90)91403-F; KIKKAWA U, 1988, PHILOS T ROY SOC B, V320, P313, DOI 10.1098/rstb.1988.0079; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P1291, DOI 10.1016/0006-291X(90)91589-K; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1991, AM J PHYSIOL, V260, pC364, DOI 10.1152/ajpcell.1991.260.2.C364; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LAYCHOCK SG, 1989, CURR TOP CELL REGUL, V30, P203; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; NAKAJIMA T, 1991, FEBS LETT, V289, P239, DOI 10.1016/0014-5793(91)81079-N; NARASIMHAN V, 1990, J BIOL CHEM, V265, P1459; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NISHIMURA J, 1990, AM J PHYSIOL, V259, pH2, DOI 10.1152/ajpheart.1990.259.1.H2; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; PARK S, 1985, P NATL ACAD SCI USA, V82, P8835, DOI 10.1073/pnas.82.24.8835; Rainsford KD, 1988, PROSTAGLANDINS BIOL, P52; RUZYCKY AL, 1989, BRIT J PHARMACOL, V97, P391, DOI 10.1111/j.1476-5381.1989.tb11966.x; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIMADA T, 1992, J GEN PHYSIOL, V100, P27, DOI 10.1085/jgp.100.1.27; SINGER HA, 1983, J PHARMACOL EXP THER, V226, P790; SMITH JB, 1985, BIOCHIM BIOPHYS ACTA, V835, P344, DOI 10.1016/0005-2760(85)90290-5; SOMLYO AP, 1988, PHILOS T ROY SOC B, V320, P399, DOI 10.1098/rstb.1988.0084; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; SOMLYO AV, 1990, PROG CLIN BIOL RES, V327, P167; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; SUTTON TA, 1990, J BIOL CHEM, V265, P2749; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004	57	229	235	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21492	21498						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328235				2022-12-25	WOS:A1992JV01100037
J	OLIVER, KG; PUTNEY, JW; OBIE, JF; SHEARS, SB				OLIVER, KG; PUTNEY, JW; OBIE, JF; SHEARS, SB			THE INTERCONVERSION OF INOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE AND INOSITOL TETRAKISPHOSPHATES IN AR4-2J CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; LARGE INTESTINAL CANCER; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; 1,4,5-TRISPHOSPHATE 3-KINASE; RECEPTOR ACTIVATION; PANCREATOMA CELLS; PAROTID-GLAND; F344 RATS; METABOLISM; PENTAKISPHOSPHATE	Data from several cell types have indicated that activation of hormone receptors promotes the metabolism of inositol 1,3,4,5,6-pentakisphosphate (IP5) to inositol 3,4,5,6-tetrakisphosphate ((3,4,5,6)IP4). However, to date, metabolism of IP5 by cell-free preparations has resulted in the formation of only inositol 1,4,5,6-tetrakisphosphate ((1,4,5,6)IP4). Thus, the metabolic relationships of IP5 with various inositol tetrakisphosphate (IP4) isomers have been investigated in both intact cells and cell homogenates of the rat pancreatoma cell line, AR4-2J. The steady-state concentration of IP5 was estimated to be 65 muM, while the combined concentration of (3,4,5,6)IP4 and (1,4,5,6)IP4 was approximately 1.0 muM. AR4-2J cell homogenates converted (1,3,4,6)IP4, (3,4,5,6)IP4, and (1,4,5,6)IP4 to IP5. (1,4,5,6)IP4 previously has not been demonstrated to be a precursor of IP5. To alter steady-state levels of inositol phosphates that were maintained by phosphorylation-dephosphorylation cycles, intact cells were treated with 10 muM antimycin A which reduced ATP levels by >90% within 10 min. Following 2 h of treatment with antimycin A, there was a 6-fold increase in both (3,4,5,6)IP4 and (1,4,5,6)IP4, presumably derived from IP5. Experiments with cell-free systems determined that IP5 was dephosphorylated to (1,4,5,6)IP4 by a predominantly particulate Mg2+-independent, Li+-insensitive IP5 3-phosphatase. However, in the presence of 5 mM MgATP, IP5 also was metabolized to (3,4,5,6)IP4. Therefore, our data demonstrate novel and complex relationships between IP5, (3,4,5,6)IP4, and (1,4,5,6)IP4.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	OLIVER, KG (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,CALCIUM REGULAT SECT,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019; Shears, Stephen B/C-6335-2019	Putney, James W/0000-0002-3379-4789; Shears, Stephen B/0000-0001-7309-8916				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BALLA T, 1989, J BIOL CHEM, V264, P9386; BALLA T, 1989, J BIOL CHEM, V264, P13605; BARKER CJ, 1988, BIOCHEM SOC T, V16, P984, DOI 10.1042/bst0160984; BARRACO RA, 1989, EUR J PHARMACOL, V173, P75, DOI 10.1016/0014-2999(89)90010-1; BIRD GS, 1990, BIOCHEM J, V273, P541; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER D, 1989, BIOCHEM SOC T, V17, P3, DOI 10.1042/bst0170003; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; EUROPEFINNER GN, 1989, J CELL SCI, V93, P585; FRENCH PJ, 1988, BIOCHEM SOC T, V16, P985, DOI 10.1042/bst0160985; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; HUNYADY L, 1988, BIOCHEM BIOPH RES CO, V157, P1247, DOI 10.1016/S0006-291X(88)81008-8; KIRK CJ, 1991, PEPTIDE HORMONE ACTI, P151; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; Maslanski J. A., 1990, METHODS INOSITIDE RE, P113; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NICOLETTI F, 1989, J NEUROCHEM, V53, P1026, DOI 10.1111/j.1471-4159.1989.tb07390.x; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; NOGIMORI K, 1990, BIOCHEM J, V269, P195, DOI 10.1042/bj2690195; PHILLIPPY BQ, 1988, ANAL BIOCHEM, V175, P162, DOI 10.1016/0003-2697(88)90374-0; PITTET D, 1989, J BIOL CHEM, V264, P18489; POGGIOLI J, 1983, MOL PHARMACOL, V23, P71; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; Schacht J, 1981, Methods Enzymol, V72, P626; SHAMSUDDIN AM, 1988, CARCINOGENESIS, V9, P577, DOI 10.1093/carcin/9.4.577; SHAMSUDDIN AM, 1989, CARCINOGENESIS, V10, P625, DOI 10.1093/carcin/10.3.625; SHEARS SB, 1987, BIOCHEM J, V242, P393, DOI 10.1042/bj2420393; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1988, BIOCHEM J, V249, P283, DOI 10.1042/bj2490283; STEWART SJ, 1987, BIOCHEM BIOPH RES CO, V145, P895, DOI 10.1016/0006-291X(87)91049-7; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0	40	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21528	21534						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328236				2022-12-25	WOS:A1992JV01100043
J	KENDALL, RL; BRADSHAW, RA				KENDALL, RL; BRADSHAW, RA			ISOLATION AND CHARACTERIZATION OF THE METHIONINE AMINOPEPTIDASE FROM PORCINE LIVER RESPONSIBLE FOR THE COTRANSLATIONAL PROCESSING OF PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL METHIONINE; AMINO-ACID SEQUENCE; SALMONELLA-TYPHIMURIUM; BETA-CHAIN; HEMOGLOBIN; PURIFICATION; INITIATION; VARIANT; YEAST	A methionine aminopeptidase that specifically removes methionine residues from peptides with amino-terminal sequences of Met-Ala-, Met-Val-, Met-Ser-, Met-Gly-, and Met-Pro- but not Met-Leu- or Met-Lys- has been isolated to homogeneity from porcine liver by a procedure involving five chromatographic steps. The enzyme, whose specificity matches that predicted for the entity responsible for the co-translational amino-terminal processing of nascent polypeptide chains, has a measured molecular mass of 70,000 Da by SDS-polyacrylamide electrophoresis and 67,000 Da by gel chromatography (under nondenaturing conditions), suggesting the native molecule is a monomer. It is activated by Co2+ and inhibited by beta-mercaptoethanol and EDTA. With octapeptide substrates related to the amino-terminal portion of the beta-chain of human hemoglobin (with a histidine in position 3), the enzyme had a pH optimum of 6.0. With a synthetic peptide devoid of histidine, it showed no pH dependence from 6.0 to 8.0. This sensitivity may be due to the propensity of peptides with histidine in the third position to bind divalent cations such as Co2+. The measured K(m) and k(cat) values were affected by residues in the second position. The peptide corresponding to the natural sequence (Met-Val-His-) gave a k(cat)/K(m) value of 260 mM-1 s-1; substitution of alanine in the second position raised the k(cat)/K(m) to 1523 mM-1 s-1, but substitution of proline lowered the value to 130. The effects are primarily on the k(cat). The substitution of proline (for histidine) in the third position, the mutation found in hemoglobin Long Island, prevents the removal of the methionine residue, as occurs with the mutant protein. The porcine liver enzyme is similar to methionine aminopeptidases isolated from Escherichia coli, Salmonella typhimurium, and yeast in that it also is stimulated by Co2+. However, it is much larger than these enzymes and differs somewhat in specificity, particularly with the yeast enzyme.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032465] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32465] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARWICK RC, 1985, P NATL ACAD SCI USA, V82, P4602, DOI 10.1073/pnas.82.14.4602; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BLOUQUIT Y, 1984, FEBS LETT, V178, P315, DOI 10.1016/0014-5793(84)80624-9; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; BRADSHAW RA, 1968, J BIOL CHEM, V243, P3817; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CHANG YH, 1992, J BIOL CHEM, V267, P8007; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Delange R. J., 1971, ENZYMES, VIII, P81; EVERT RF, 1986, ANAL BIOCHEM, V154, P431; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HANSON H, 1976, METHODS ENZYMOLOGY B, V45, P504; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JACKSON R, 1970, NATURE, V227, P672, DOI 10.1038/227672a0; KENDALL RL, 1992, THESIS U CALIFORNIA; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALFROY B, 1989, BIOCHEM BIOPH RES CO, V161, P236, DOI 10.1016/0006-291X(89)91586-6; MILLER CG, 1987, P NATL ACAD SCI USA, V84, P2718, DOI 10.1073/pnas.84.9.2718; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; TERMIGNONI C, 1986, BIOCHEM J, V234, P469, DOI 10.1042/bj2340469; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; WACHSMUTH ED, 1966, BIOCHEMISTRY-US, V5, P169, DOI 10.1021/bi00865a022; WINGFIELD P, 1989, EUR J BIOCHEM, V180, P23, DOI 10.1111/j.1432-1033.1989.tb14610.x; YAMADA R, 1988, ENZYME, V40, P223, DOI 10.1159/000469167	29	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20667	20673						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328207				2022-12-25	WOS:A1992JT97800026
J	TIDBALL, JG				TIDBALL, JG			IDENTIFICATION AND DISTRIBUTION OF A NOVEL, COLLAGEN-BINDING PROTEIN IN THE DEVELOPING SUBEPICARDIUM AND ENDOMYSIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-B1 CHAIN REVEALS; PLASMA FIBRONECTIN; CELL ATTACHMENT; CONNECTIVE-TISSUE; CARDIAC-MUSCLE; MESSENGER-RNAS; RAT-HEART; SEQUENCE; HYPERTENSION; LOCALIZATION	A protein doublet (M(r) = 68,000) that copurifies with chicken cardiac collagen types I and III is purified and characterized in the present study. Peptide mapping and amino terminus sequencing for both 68-kDa polypeptides show they have similar structures. This is supported by amino terminus sequencing of a 39-kDa proteolytic fragment of each polypeptide. The 68-kDa polypeptides appear at pI 6.7-6.8 in two-dimensional gels. Under nonreducing, electrophoretic conditions, the doublet appears as a large multimer or aggregate. Amino acid sequencing of the protein shows that its amino terminus contains a heptapeptide (VCLXXGK) that appears in the heparin/fibrin-binding domain of fibronectin and the collagen-binding domain of laminin. Cardiac myocytes synthesize and secrete the protein in vitro onto cell surfaces and onto the substratum. Indirect immunofluorescence shows the protein first appears in the chicken subepicardium at approximately 10 days following fertilization. As collagen accumulates in the subepicardium and the volume of the subepicardial space increases, the 68-kDa protein is found predominantly at the interface between myocardial cells and the connective tissue and between epicardial cells and the connective tissue. In adult hearts, the protein is also present at lower concentrations in endomysial connective tissue. The 68-kDa protein is also present in the skeletal muscle endomysium of embryonic chickens. Electron microscopic immunocytochemistry shows the 68-kDa protein is located at the surface of subepicardial collagen fibers. In addition, a direct interaction between the 68-kDa protein and collagen are indicated by : 1) equilibrium gel filtration of the 68-kDa protein in the presence of gelatin, 2) gelatin affinity chromatography of the 68-kDa protein, and 3) comigration of type I collagen and the 68-kDa protein during gel filtration under reducing conditions. The 68-kDa protein exhibits no collagenase activity under native conditions or in zymograms. Together, the data indicate that the 68-kDa protein is a novel collagen-associated protein appearing in late epicardial development.	UNIV CALIF LOS ANGELES, JERRY LEWIS NEUROMUSCULAR RES CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	TIDBALL, JG (corresponding author), UNIV CALIF LOS ANGELES, DEPT PHYSIOL SCI, LOS ANGELES, CA 90024 USA.		Tidball, James/H-7970-2012	Tidball, James/0000-0003-1202-8038	NCRR NIH HHS [1 S10RR05554-01] Funding Source: Medline; NHLBI NIH HHS [HL-42227] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042227] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALIAN G, 1979, J BIOL CHEM, V254, P1429; BARTOSOV.D, 1969, J PHYSIOL-LONDON, V200, P285, DOI 10.1113/jphysiol.1969.sp008693; BING OHL, 1978, CIRC RES, V43, P632, DOI 10.1161/01.RES.43.4.632; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BORG TK, 1982, COLLAGEN REL RES, V2, P211; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPASSO JM, 1986, CIRC RES, V58, P445, DOI 10.1161/01.RES.58.4.445; CHIANG TM, 1982, J BIOL CHEM, V257, P7581; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COX JV, 1983, CELL, V35, P331, DOI 10.1016/0092-8674(83)90236-2; EGHBALI M, 1989, J MOL CELL CARDIOL, V21, P103, DOI 10.1016/0022-2828(89)91498-3; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FACTOR SM, 1990, CARDIAC MYOCYTE CONN, P130; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GARCIAPARDO A, 1983, J BIOL CHEM, V258, P2670; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GROVE D, 1969, CIRC RES, V25, P473, DOI 10.1161/01.RES.25.4.473; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HORMANN H, 1980, H-S Z PHYSIOL CHEM, V361, P1449; KLEBE RJ, 1974, NATURE, V250, P248, DOI 10.1038/250248a0; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND DD, 1979, CARDIOVASC RES, V13, P39, DOI 10.1093/cvr/13.1.39; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; NAGASE H, 1981, J BIOL CHEM, V256, P1951; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; OBRIEN LJ, 1966, EXPERIENTIA, V22, P845, DOI 10.1007/BF01897456; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARLMAN ES, 1982, LAB INVEST, V46, P158; POLINGER IS, 1970, EXP CELL RES, V63, P78, DOI 10.1016/0014-4827(70)90333-2; PURI EC, 1978, EXP CELL RES, V115, P159, DOI 10.1016/0014-4827(78)90413-5; RAO CN, 1982, J BIOL CHEM, V257, P9740; RUOSLAHTI E, 1979, J BIOL CHEM, V254, P6054; Sage H, 1982, Methods Enzymol, V82 Pt A, P96; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SKOSEY JL, 1972, CIRC RES, V31, P145, DOI 10.1161/01.RES.31.2.145; STRICKLIN GP, 1988, COLLAGEN, V1, P187; TIDBALL JG, 1992, ANAT EMBRYOL, V185, P155; VARTIO T, 1981, J BIOL CHEM, V256, P471; VARTIO T, 1983, EUR J BIOCHEM, V135, P203, DOI 10.1111/j.1432-1033.1983.tb07638.x; VARTIO T, 1989, FEBS LETT, V255, P285, DOI 10.1016/0014-5793(89)81107-X; VATER CA, 1978, BIOCHIM BIOPHYS ACTA, V539, P238, DOI 10.1016/0304-4165(78)90010-7; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber KT, 1987, CIRCULATION S1, V75, P140	49	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21211	21219						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328225				2022-12-25	WOS:A1992JT97800108
J	PARK, JW; BABIOR, BM				PARK, JW; BABIOR, BM			THE TRANSLOCATION OF RESPIRATORY BURST OXIDASE COMPONENTS FROM CYTOSOL TO PLASMA-MEMBRANE IS REGULATED BY GUANINE-NUCLEOTIDES AND DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROTEIN-KINASE-C; ADENINE-DINUCLEOTIDE PHOSPHATE; CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL NADPH OXIDASE; ARACHIDONIC-ACID; PHORBOL ESTER; ACTIVATION; GTP; DIRADYLGLYCEROL	The respiratory burst oxidase is a multimeric enzyme responsible for O2- production by stimulated neutrophils and a few other cell types. In the resting neutrophil, the oxidase is dormant, and its subunits are distributed between the cytosol, in which they appear to exist in the form of a multisubunit complex, and the plasma membrane; but, when the neutrophil is activated, the cytosolic complex translocates to the membrane to assemble the active enzyme. Using a cell-free system in which oxidase activity was elicited with SDS, we examined the effects of GTPgammaS and dioctanoylglycerol (DiC8) on both the activation of O2- production and the transfer of the cytosolic oxidase components p47phox and p67phox to the plasma membrane. GTP (added as undialyzed cytosol) and GTPgammaS augmented the transfer of the oxidase components to the plasma membrane and was essential for the acquisition of O2- producing activity by the oxidase. DiC8 also supported the SDS-mediated transfer of oxidase components to the membrane, but O2- production did not take place unless GTP or GTPgammaS was present. In the presence of these nucleotides, however, DiC8 augmented both translocation and O2- production. We interpreted these results in terms of a mechanism in which 2 membrane-binding sites are created during the activation of the cytosolic complex, one for diacylglycerol and the other for a second site on the membrane. Development of the second membrane-binding site depends upon the action of a G protein and is essential for the expression of oxidase activity. The results further suggested that the priming of the respiratory burst oxidase in intact neutrophils might be due to an increase in membrane diacylglycerol concentration that occurs in response to the priming stimulus. Because of the increased diacylglycerol content, a larger than usual amount of active respiratory burst oxidase could be assembled on the primed plasma membrane when the neutrophil is fully activated.			PARK, JW (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028479, R37AI024227, R01AI024227] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00833] Funding Source: Medline; NIAID NIH HHS [AI-24227, AI-28479] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1992, ADV ENZYMOL RELAT AR, V65, P49; BASS DA, 1988, J BIOL CHEM, V263, P19610; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BELL RM, 1991, J BIOL CHEM, V266, P4661; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DEWALD B, 1979, J CLIN INVEST, V63, P21, DOI 10.1172/JCI109273; DOUSSIERE J, 1988, BIOCHEM BIOPH RES CO, V152, P993, DOI 10.1016/S0006-291X(88)80382-6; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; OKAMURA N, 1990, J CLIN INVEST, V85, P1583, DOI 10.1172/JCI114608; PARK JW, 1992, J BIOL CHEM, V267, P17327; RANDO RR, 1989, FASEB J, V3, P2348; SCHONHARDT T, 1987, BIOCHEM BIOPH RES CO, V149, P769, DOI 10.1016/0006-291X(87)90434-7; SCHWARZ HP, 1985, BLOOD, V66, P1452; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UMEI T, 1991, J BIOL CHEM, V266, P6019; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	43	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19901	19906						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328185				2022-12-25	WOS:A1992JR85800027
J	PRIEST, JW; HAJDUK, SL				PRIEST, JW; HAJDUK, SL			CYTOCHROME-C REDUCTASE PURIFIED FROM CRITHIDIA-FASCICULATA CONTAINS AN ATYPICAL CYTOCHROME-C1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; AMINO-ACID SEQUENCE; EUGLENA-GRACILIS; COMPLEX-III; RESPIRATORY-CHAIN; NEUROSPORA-CRASSA; LEISHMANIA-TARENTOLAE; YEAST MITOCHONDRIA; PURIFICATION; BINDING	Cytochrome c reductase purified from the trypanosomatid Crithidia fasciculata retained antimycin A sensitivity and catalyzed the reduction of horse heart ferricytochrome c in the presence of reduced coenzyme Q10. The complex contained heme b and heme c1 in a ratio of 2:1. Nine major protein bands ranging in size from 55.3 to approximately 12.8 kDa were resolved by SDS-polyacrylamide gel electrophoresis. A 31.6-kDa protein was identified as cytochrome c1 by the presence of a covalently attached heme. A red shift in the alpha-absorbance band of the cytochrome c1 absolute absorbance spectrum, difference absorbance spectrum, and pyridine ferrohemochrome absorbance spectrum suggested that the heme prosthetic group of C. fasciculata cytochrome c1 is bound to the apoprotein through only one thioether bond. A fragment of the cytochrome c1 gene was amplified from C. fasciculata, Trypanosoma brucei, Leishmania tarentolae, and Bodo caudatus. The deduced heme binding site sequence of each of these kinetoplastid species, Phe-Ala-Pro-Cys-His, contains a phenylalanine rather that a cysteine at the first position so that only one thioether bond can be formed between heme and apoprotein. This phenylalanine substitution and the presence of a conserved proline in the sequence may represent compensatory changes that are necessary for optimal interaction of the cytochromes c1 with the atypical cytochromes c of these species.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL07631] Funding Source: Medline; NIAID NIH HHS [AI21401, AI08259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008259, R01AI021401, R21AI021401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASFORD RE, 1957, BIOCHIM BIOPHYS ACTA, V24, P107, DOI 10.1016/0006-3002(57)90152-X; BEATTIE DS, 1979, BIOCHEMISTRY-US, V18, P2400, DOI 10.1021/bi00578a040; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BERRY EA, 1991, J BIOL CHEM, V266, P9064; BHAT GJ, 1991, NUCLEIC ACIDS RES, V19, P398, DOI 10.1093/nar/19.2.398; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONSTRUP U, 1989, J BIOENERG BIOMEMBR, V21, P359, DOI 10.1007/BF00762727; CARTER KR, 1981, FEBS LETT, V132, P243, DOI 10.1016/0014-5793(81)81170-2; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EHRENBERG A, 1955, ACTA CHEM SCAND, V9, P1193, DOI 10.3891/acta.chem.scand.09-1193; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FINZEL BC, 1985, J MOL BIOL, V186, P627, DOI 10.1016/0022-2836(85)90135-4; GELLERFORS P, 1981, EUR J BIOCHEM, V115, P275, DOI 10.1111/j.1432-1033.1981.tb05234.x; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GREEN DE, 1961, ARCH BIOCHEM BIOPHYS, V92, P312, DOI 10.1016/0003-9861(61)90354-X; GROOT GSP, 1978, BIOCHIM BIOPHYS ACTA, V517, P457, DOI 10.1016/0005-2787(78)90212-5; HAMPSEY DM, 1986, J BIOL CHEM, V261, P3259; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HILL GC, 1975, EUR J BIOCHEM, V57, P265, DOI 10.1111/j.1432-1033.1975.tb02298.x; HILL GC, 1971, BIOCHIM BIOPHYS ACTA, V253, P78, DOI 10.1016/0005-2728(71)90235-0; HILL GC, 1971, BIOCHIM BIOPHYS ACTA, V243, P225, DOI 10.1016/0005-2795(71)90079-1; HILL GC, 1973, BIOCHIM BIOPHYS ACTA, V305, P590, DOI 10.1016/0005-2728(73)90078-9; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KATAN MB, 1976, EUR J BIOCHEM, V65, P95, DOI 10.1111/j.1432-1033.1976.tb10393.x; KUSEL JP, 1973, BIOCHIM BIOPHYS ACTA, V305, P570, DOI 10.1016/0005-2728(73)90076-5; KUSEL JP, 1969, ARCH BIOCHEM BIOPHYS, V133, P293, DOI 10.1016/0003-9861(69)90457-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LINKE P, 1986, METHOD ENZYMOL, V126, P201; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1985, BIOPHYS J, V47, pA196; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARTIN E, 1979, J BIOL CHEM, V254, P2192; MENDELHARTVIG I, 1983, J BIOENERG BIOMEMBR, V15, P289, DOI 10.1007/BF00744526; MOORE GR, 1990, CYTOCHROMES C EVOLUT, P116; MUKAI K, 1989, EUR J BIOCHEM, V178, P649, DOI 10.1111/j.1432-1033.1989.tb14494.x; MUKAI K, 1989, J BIOCHEM-TOKYO, V106, P479, DOI 10.1093/oxfordjournals.jbchem.a122877; Nelson B D, 1978, Methods Enzymol, V53, P80; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; PETTIGRE.GW, 1972, FEBS LETT, V22, P64, DOI 10.1016/0014-5793(72)80220-5; PETTIGREW GW, 1973, NATURE, V241, P531, DOI 10.1038/241531a0; PETTIGREW GW, 1975, BIOCHEM J, V147, P291, DOI 10.1042/bj1470291; RASSAM MB, 1986, MOL BIOCHEM PARASIT, V21, P1, DOI 10.1016/0166-6851(86)90072-1; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; Rieske JS, 1967, METHOD ENZYMOL, V10, P488, DOI DOI 10.1016/0076-6879(67)10081-5; ROMISCH J, 1987, EUR J BIOCHEM, V164, P111, DOI 10.1111/j.1432-1033.1987.tb11000.x; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1991, P NATL ACAD SCI USA, V19, P398; SHAW JM, 1989, EXP PARASITOL, V68, P443, DOI 10.1016/0014-4894(89)90129-X; SIDHU A, 1982, J BIOL CHEM, V257, P7879; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; TANAKA Y, 1988, J BIOCHEM-TOKYO, V104, P477, DOI 10.1093/oxfordjournals.jbchem.a122493; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TORRI AF, 1988, MOL CELL BIOL, V8, P4625, DOI 10.1128/MCB.8.11.4625; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; van Gelder B F, 1978, Methods Enzymol, V53, P125; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; WAKABAYASHI S, 1982, J BIOL CHEM, V257, P9335; WAN YP, 1975, BIOCHEM BIOPH RES CO, V63, P11, DOI 10.1016/S0006-291X(75)80003-9; WEISS H, 1976, BIOCHIM BIOPHYS ACTA, V456, P291, DOI 10.1016/0304-4173(76)90002-1; WEISS H, 1979, EUR J BIOCHEM, V99, P139, DOI 10.1111/j.1432-1033.1979.tb13240.x; WEISS H, 1978, EUR J BIOCHEM, V88, P17, DOI 10.1111/j.1432-1033.1978.tb12418.x; WRAY W, 1981, ANAL BIOCHEM, V118, P1697; YU CA, 1974, J BIOL CHEM, V249, P4905; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	71	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20188	20195						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328195				2022-12-25	WOS:A1992JR85800071
J	NAMBI, P; PULLEN, M; WU, HL; NUTHULAGANTI, P; ELSHOURBAGY, N; KUMAR, C				NAMBI, P; PULLEN, M; WU, HL; NUTHULAGANTI, P; ELSHOURBAGY, N; KUMAR, C			DEXAMETHASONE DOWN-REGULATES THE EXPRESSION OF ENDOTHELIN RECEPTORS IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES PHOSPHOLIPASE-C; MESANGIAL CELLS; CHROMOSOMAL ASSIGNMENT; GENE-EXPRESSION; BINDING-SITES; MESSENGER-RNA; UP-REGULATION; CLONING; GLUCOCORTICOIDS; AGONIST	Steroid hormones have been shown to modulate a number of physiological processes in addition to their potent antiinflammatory effects. Endothelin (ET) is a newly discovered vasoconstrictor that is synthesized and released by endothelial cells and acts on adjacent vascular smooth muscle cells by interacting with specific cell surface receptors. Proinflammatory agents such as thrombin and transforming growth factor beta have been shown to up-regulate ET gene expression in vascular endothelial cells. We wondered whether the anti-inflammatory steroids might have any regulatory effect on the ET receptors present in the vascular smooth muscle cells. Rat vascular smooth muscle cells (A-10 cell line, ATCC.CRL 1476) were used as a model system to study the effects of glucocorticoids on ET receptor expression and function. These cells display high density and high affinity ET receptors that belong to the ETA subtype. Pretreatment of these cells with dexamethasone reduced the number of ET receptors by 50-60% without changing the affinity. Of the steroids tested, dexamethasone was most effective followed by prednisolone and hydrocortisone. Aldosterone, a mineralocorticoid, was 5000-fold less potent than dexamethasone. This effect of dexamethasone was dependent on the time of pretreatment and concentration of the steroid used. This down-regulation of ET receptors was also accompanied by an attenuated response to ET-1 in dexamethasone-pretreated cells. The inhibitory effect of dexamethasone was selective for ET receptors because the vasopressin-mediated response was unaffected. In addition, dexamethasone pretreatment of these cells resulted in 50-60% reduction in the steady-state level of ETA receptor mRNA as revealed by Northern analysis. These results suggest that glucocorticoid pretreatment of smooth muscle cells resulted in the down-regulation of the ET(A) receptor at the mRNA level.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406	GlaxoSmithKline	NAMBI, P (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT PHARMACOL,UW2521,POB 1539,KING OF PRUSSIA,PA 19406, USA.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; AUGUET M, 1988, BIOCHEM BIOPH RES CO, V156, P186, DOI 10.1016/S0006-291X(88)80822-2; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BADR KF, 1989, BIOCHEM BIOPH RES CO, V161, P776, DOI 10.1016/0006-291X(89)92667-3; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BLOCH KD, 1989, J BIOL CHEM, V264, P18156; BURNSTEIN KL, 1989, ANNU REV PHYSIOL, V51, P683, DOI 10.1146/annurev.ph.51.030189.003343; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1988, J BIOL CHEM, V263, P9067; ELSHOURBAGY NA, 1992, MOL PHARMACOL, V41, P465; ELSHOURBAGY NA, 1991, CIRCULATION S2, V84, P1610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOETZ KL, 1988, AM J PHYSIOL, V255, pR1064, DOI 10.1152/ajpregu.1988.255.6.R1064; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIU JJ, 1989, BIOCHEM BIOPH RES CO, V164, P1220, DOI 10.1016/0006-291X(89)91799-3; LYSKO PG, 1991, NEUROPEPTIDES, V18, P83, DOI 10.1016/0143-4179(91)90005-4; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MARSDEN PA, 1989, BIOCHEM BIOPH RES CO, V158, P86, DOI 10.1016/S0006-291X(89)80180-9; MASUDA Y, 1989, FEBS LETT, V257, P208, DOI 10.1016/0014-5793(89)81535-2; MILLER WL, 1989, J CLIN INVEST, V83, P317, DOI 10.1172/JCI113876; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; NAMBI P, 1990, NEUROPEPTIDES, V16, P195, DOI 10.1016/0143-4179(90)90062-4; NAMBI P, 1989, CELL SIGNAL, V1, P241, DOI 10.1016/0898-6568(89)90041-7; NAMBI P, 1990, EUR J PHARMACOL, V187, P113, DOI 10.1016/0014-2999(90)90346-8; NAMBI P, 1989, 9TH INT WASH SPRING, P362; OHTA K, 1990, BIOCHEM BIOPH RES CO, V169, P578, DOI 10.1016/0006-291X(90)90370-3; RESINK TJ, 1988, BIOCHEM BIOPH RES CO, V157, P1360, DOI 10.1016/S0006-291X(88)81025-8; SAKAMOTO H, 1990, BIOCHEM BIOPH RES CO, V169, P462, DOI 10.1016/0006-291X(90)90354-P; SAKAUE M, 1991, J CLIN INVEST, V88, P385, DOI 10.1172/JCI115315; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SARKAR DD, 1988, GENE DEV, V2, P1144; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; TAKAYANAGI R, 1990, REGUL PEPTIDES, V27, P247, DOI 10.1016/0167-0115(90)90043-V; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; VANE JR, 1989, ENDOTHELIN J CARDI S, V13, pS1; VIGUERIE N, 1987, BIOCHEM BIOPH RES CO, V147, P942, DOI 10.1016/S0006-291X(87)80161-4; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	47	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19555	19559						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326558				2022-12-25	WOS:A1992JP59300080
J	JOHNSON, KF; KORNFELD, S				JOHNSON, KF; KORNFELD, S			A HIS-LEU-LEU SEQUENCE NEAR THE CARBOXYL TERMINUS OF THE CYTOPLASMIC DOMAIN OF THE CATION-DEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR IS NECESSARY FOR THE LYSOSOMAL-ENZYME SORTING FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; PLASMA-MEMBRANE; CATHEPSIN-D; CLATHRIN; CELLS; GOLGI; EXPRESSION; FORMS; INTERNALIZATION; PHOSPHORYLATION	The determinants on the cytoplasmic tail of the cation-dependent mannose 6-phosphate receptor (CD-MPR) required for lysosomal enzyme sorting have been analyzed. Mouse L cells deficient in the mannose 6-phosphate/insulin-like growth factor-II receptor were transfected with normal bovine CD-MPR cDNA or cDNAs containing mutations in the 67-amino acid cytoplasmic tail and assayed for their ability to target the lysosomal enzyme cathepsin D to lysosomes. Cells expressing the wild-type bovine CD-MPR sorted 67 +/- 2% of newly synthesized cathepsin D compared with the base-line value of 47 +/- 1%. The presence of mannose 6-phosphate in the medium did not affect the efficiency of cathepsin D sorting, indicating that the routing of the ligand-receptor complex is completely intracellular. Mutant receptors with the carboxyl-terminal His-Leu-Leu-Pro-Met67 residues deleted or replaced with alanines sorted cathepsin D below the baseline value. A mutant receptor with the outermost Pro-Met residues replaced with alanines sorted cathepsin D better than the wild-type receptor, indicating that the essential residues for sorting are the His-Leu-Leu sequence. Disruption of a putative casein kinase II phosphorylation site at Ser57 had no detectable effect on sorting. The mutant receptor with the five-amino acid deletion was able to bind to a phosphopentamannose affinity column, proving that its ligand binding site was grossly intact. Resialylation experiments showed that this mutant receptor recycled from the cell surface to the Golgi at a rate similar to the normal CD-MPR, indicating that the defect in sorting is at the level of the Golgi.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BENNETT G, 1981, J CELL BIOL, V88, P1, DOI 10.1083/jcb.88.1.1; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KORNFELD S, 1992, IN PRESS ANN REV BIO; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MA ZM, 1991, J BIOL CHEM, V266, P10589; MAHIN DT, 1970, CURRENT STATUS LIQUI; Maniatis T., 1982, MOL CLONING; MAYA E, 1991, CELL, V66, P257; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MESSNER DJ, 1989, J CELL BIOL, V108, P2149, DOI 10.1083/jcb.108.6.2149; NADIMPALLI SK, 1991, FEBS LETT, V280, P61, DOI 10.1016/0014-5793(91)80204-G; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	37	165	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17110	17115						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324923				2022-12-25	WOS:A1992JL05300060
J	LEE, CH; PARK, D; WU, DQ; RHEE, SG; SIMON, MI				LEE, CH; PARK, D; WU, DQ; RHEE, SG; SIMON, MI			MEMBERS OF THE GQ-ALPHA-SUBUNIT GENE FAMILY ACTIVATE PHOSPHOLIPASE-C BETA-ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENYLYL CYCLASE; G-PROTEINS; IDENTIFICATION; PURIFICATION; HYDROLYSIS; DIVERSITY; CELLS	The relative specificities of members of the G-alpha(q) family of GTP-binding proteins were tested for their ability to activate different phosphoinositide-specific phospholipase C (PI-PLC) beta-isozymes. Cos-7 cells were transfected with cDNA corresponding to G-alpha(q), G-alpha-11, G-alpha-14, and G-alpha-16. Most of the recombinant protein was bound to the cell membrane and these membranes were washed to elute endogenous PI-PLC activity. The membrane preparation was reconstituted with purified preparations of the PI-PLC beta-isozymes and guanosine 5'-O-thiotriphosphate (GTP-gamma-S)-stimulated enzyme activity was measured. All four proteins of the G-alpha(q) family were found to stimulate PI-PLC beta-1, with G-alpha(q) and G-alpha-11 being most efficient. On the other hand, G-alpha-16 was found to most effectively activate PI-PLC beta-2, while G-alpha(q), G-alpha-11, and G-alpha-14 showed less stimulation. Specific anti-G-alpha-16 antibody blocked the stimulation of both PI-PLC beta-1 and PI-PLC beta-2 in the enriched membrane fraction. We conclude that there is specificity in the interaction of different members of the G(q) family with different PI-PLC beta-effectors. This specificity may be important in generating tissue- or receptor-specific responses in vivo.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	California Institute of Technology; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1984, J GEN PHYSIOL, V84, P265, DOI 10.1085/jgp.84.2.265; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; PARK D, 1992, J BIOL CHEM, V267, P16048; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHATZMANN HJ, 1973, J PHYSIOL-LONDON, V235, P551, DOI 10.1113/jphysiol.1973.sp010403; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1990, ADP RIBOSYLATING TOX, P267; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1992, J BIOL CHEM, V267, P1811	24	270	274	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16044	16047						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322889				2022-12-25	WOS:A1992JJ45800011
J	STURZBECHER, HW; BRAIN, R; ADDISON, C; RUDGE, K; REMM, M; GRIMALDI, M; KEENAN, E; JENKINS, JR				STURZBECHER, HW; BRAIN, R; ADDISON, C; RUDGE, K; REMM, M; GRIMALDI, M; KEENAN, E; JENKINS, JR			A C-TERMINAL ALPHA-HELIX PLUS BASIC REGION MOTIF IS THE MAJOR STRUCTURAL DETERMINANT OF P53 TETRAMERIZATION	ONCOGENE			English	Article							LARGE T-ANTIGEN; TUMOR SUPPRESSOR PROTEIN; DNA-BINDING PROTEINS; MONOCLONAL-ANTIBODIES; WILD-TYPE; TRANSFORMED-CELLS; TRANS-ACTIVATION; CELLULAR PROTEIN; LEUCINE ZIPPER; SV40 ORIGIN	The p53 gene product has been implicated in both human and animal tumorigenesis. p53 forms heterologous complexes with the transforming proteins encoded by several different DNA tumor viruses. p53 also assembles into stable homo-oligomers. We demonstrate that the major structural determinant for the tetramerization of p53 is an alpha-helical plus basic region motif near the C-terminus of the protein. A monomeric p53 mutant adopts a conformation distinct from both `wild-type' and `mutant' form as defined by PAb1620 and PAb240 monoclonal antibody recognition. Nevertheless, monomeric and dimeric mutant p53 proteins retain the ability to suppress SV40 origin-directed DNA replication in vivo. Thus, p53-p53 interaction and expression of the PAb1620 epitope is not a prerequisite for such activity. We present data suggesting that suppression of replication by p53 may occur by a mechanism that is independent of detectable p53-T antigen association.	MARIE SKLODOWSKA CURIE MEM INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND; ESTONIAN BIOCTR,TARTU,ESTONIA,USSR	Estonian Biocentre			Remm, Maido/L-9072-2019	Remm, Maido/0000-0003-3966-8422				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ADDISON C, 1990, ONCOGENE, V5, P423; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNG MC, 1988, J VIROL METHODS, V19, P33, DOI 10.1016/0166-0934(88)90005-5; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122	53	247	254	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1513	1523						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321401				2022-12-25	WOS:A1992JE81300007
J	WEINSTEIN, SL; SANGHERA, JS; LEMKE, K; DEFRANCO, AL; PELECH, SL				WEINSTEIN, SL; SANGHERA, JS; LEMKE, K; DEFRANCO, AL; PELECH, SL			BACTERIAL LIPOPOLYSACCHARIDE INDUCES TYROSINE PHOSPHORYLATION AND ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; SEA STAR OOCYTES; HERBIMYCIN-A; MAP KINASE; INHIBITION; INSULIN; INVITRO; ERKS; RECEPTOR	Bacterial lipopolysaccharide (LPS) is a potent activator of antibacterial responses by macrophages. Following LPS stimulation, the tyrosine phosphorylation of several proteins is rapidly increased in macrophages, and this event appears to mediate some responses to LPS. We now report that two of these tyrosine phosphoproteins of 41 and 44 kDa are isoforms of mitogen-activated protein (MAP) kinase. Each of these proteins was reactive with anti-MAP kinase antibodies and comigrated with MAP kinase activity in fractions eluted from a MonoQ anion-exchange column. Following LPS stimulation, column fractions containing the tyrosine phosphorylated forms of p41 and p44 exhibited increased MAP kinase activity. Inhibition of LPS-induced tyrosine phosphorylation of these proteins was accompanied by inhibition of MAP kinase activity. Additionally, induction of p41/p44 tyrosine phosphorylation and MAP kinase activity by LPS appeared to be independent of activation of protein kinase C, even though phorbol esters also induced these responses. These results demonstrate that LPS induces the tyrosine phosphorylation and activation of at least two MAP kinase isozymes. Since MAP kinases appear to modulate cellular processes in response to extracellular signals, these kinases may be important targets for LPS action in macrophages.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; KINET BIOTECHNOL CORP, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES LAB, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of British Columbia; University of British Columbia					NIAID NIH HHS [AI20038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020038, R01AI020038] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARRIERE SL, 1991, PATIENT CARE, V25, P95; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1985, MOL CELL BIOL, V5, P3304, DOI 10.1128/MCB.5.11.3304; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Morrison D C, 1979, Adv Immunol, V28, P293; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; PABST MJ, 1989, HDB INFLAMMATION, V6, P361; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	33	408	414	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14955	14962						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321821				2022-12-25	WOS:A1992JF08800069
J	YANG, Y; FRUH, K; CHAMBERS, J; WATERS, JB; WU, L; SPIES, T; PETERSON, PA				YANG, Y; FRUH, K; CHAMBERS, J; WATERS, JB; WU, L; SPIES, T; PETERSON, PA			MAJOR HISTOCOMPATIBILITY COMPLEX (MHC)-ENCODED HAM2 IS NECESSARY FOR ANTIGENIC PEPTIDE LOADING ONTO CLASS-I MHC MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							H-2-DEFICIENT LYMPHOMA VARIANTS; MULTICATALYTIC PROTEINASE; REGION; TRANSPORTERS; PATHWAY; CELLS; GENE	The mutant murine lymphoma cell line RMA-S is unable to present endogenous antigens due to its inability to efficiently assemble class I major histocompatibility complex molecules and antigenic peptides. Therefore, it has been suggested that RMA-S cells are defective either in peptide generation or in peptide transport into the endoplasmic reticulum, where class I major histocompatibility complex molecule assembly is believed to occur. As proteasomes and the putative peptide transporters HAM1 and HAM2 have been implicated in class I antigen processing, we have investigated their expression in RMA-S and its wild-type counterpart RMA. Both proteasomes and HAM1 proteins are expressed at similar levels and show identical subcellular distributions in the two cell lines. However, only one copy of the HAM2 gene is present in RMA-S cells, and it contains a point mutation that leads to a premature stop codon. Thus, the HAM2 protein is absent from RMA-S cells. These data demonstrate that HAM2 is essential for peptide loading onto class I molecules.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	YANG, Y (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.			Frueh, Klaus/0000-0001-8014-3877				AMES FLG, 1992, IN PRESS FASEB J; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOBBERSTEIN B, 1992, NATURE, V355, P109, DOI 10.1038/355109a0; GLYME R, 1991, NATURE, V353, P357; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HYDE SC, 1990, NATURE, V346, P352; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; OHLEN C, 1990, EUR J IMMUNOL, V20, P1873, DOI 10.1002/eji.1830200837; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANG Y, 1992, IN PRESS P NATL ACAD	29	114	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11669	11672						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1339432				2022-12-25	WOS:A1992HY94700003
J	NELSON, C; RABB, H; ARNAOUT, MA				NELSON, C; RABB, H; ARNAOUT, MA			GENETIC CAUSE OF LEUKOCYTE ADHESION MOLECULE DEFICIENCY - ABNORMAL SPLICING AND A MISSENSE MUTATION IN A CONSERVED REGION OF CD18 IMPAIR CELL-SURFACE EXPRESSION OF BETA-2 INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIIA; POLYMERASE CHAIN-REACTION; AMINO-ACID-SEQUENCE; LEU-CAM DEFICIENCY; MESSENGER-RNA; FIBRONECTIN RECEPTOR; EPITHELIAL-CELLS; SUBUNIT; LFA-1; COMMON	Patients with leukocyte adhesion molecule (CD11/CD18, beta-2 integrins) deficiency have structural defects in the common beta-subunit (CD18), which prevent heterodimer formation and normal cell surface expression' of these receptors, leading to life-threatening bacterial infections. To elucidate the nature of these defects in a patient with partial (type II) deficiency, abnormal CD18 cDNA clones were isolated, using the polymerase chain reaction to amplify the patient's B cell-derived cDNAs. Sequence analysis revealed two mutant alleles. cDNA clones, representing a maternal allele, contained both a 12-base pair insertion resulting in an in-frame addition of four amino acids between P247 and E248 and a C1756 --> T nucleotide transition, resulting in an R586 --> W substitution in the normal CD18 protein. The in-frame insertion arose by a single nucleotide C --> A transversion in the 3' terminus of an intron, generating an aberrant splice acceptor site. Other cDNA clones contained an A1052 --> G nucleotide transition not present in either parent which resulted in an N351 --> S substitution. To determine the functional importance of these changes, cDNA encoding a normal alpha-chain (CD11b) was cotransfected into COS with CD18 cDNAs encoding for wild-type, maternal mutant allele, or CD18 containing N351 --> S substitution. Immunostaining of transfectants with anti-CD18 monoclonal antibodies revealed no cell surface expression of the maternal mutant CD18, and 22% surface expression of N351 --> S CD18. Both the insertion and the N351 --> S mutations occurred in a 250 amino acid extracellular region of CD18 that is highly conserved among beta-integrins supporting a role for this region in heterodimer formation.	MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,LEUKOCYTE BIOL & INFLAMMAT PROGRAM,RENAL UNIT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1988, J CELL PHYSIOL, V137, P305, DOI 10.1002/jcp.1041370214; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1984, J CLIN INVEST, V74, P1291, DOI 10.1172/JCI111539; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; BEATTY PG, 1983, J IMMUNOL, V131, P2913; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; Cannady W G, 1978, Prog Clin Pathol, V7, P239; CROWLEY CA, 1980, NEW ENGL J MED, V302, P1163, DOI 10.1056/NEJM198005223022102; DANA N, 1987, J CLIN INVEST, V79, P1010, DOI 10.1172/JCI112868; DANA N, 1984, J CLIN INVEST, V73, P153, DOI 10.1172/JCI111186; DANA N, 1988, BAILLIERE CLIN IMMUN, V2, P453; DESIMONE DW, 1988, J BIOL CHEM, V263, P5333; DIMANCHE MT, 1987, EUR J IMMUNOL, V17, P417, DOI 10.1002/eji.1830170318; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KISHIMOTO TK, 1989, J BIOL CHEM, V264, P3588; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KISHIMOTO TK, 1987, CELL, V50, P193, DOI 10.1016/0092-8674(87)90215-7; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Maniatis T, 1989, DECONTAMINATION DILU; MENTZER SJ, 1987, J CELL PHYSIOL, V130, P410, DOI 10.1002/jcp.1041300314; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	38	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3351	3357						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1346613				2022-12-25	WOS:A1992HD15400083
J	SLIGH, JE; HURWITZ, MY; ZHU, CM; ANDERSON, DC; BEAUDET, AL				SLIGH, JE; HURWITZ, MY; ZHU, CM; ANDERSON, DC; BEAUDET, AL			AN INITIATION CODON MUTATION IN CD18 IN ASSOCIATION WITH THE MODERATE PHENOTYPE OF LEUKOCYTE ADHESION DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; COMMON BETA-SUBUNIT; NON-AUG CODONS; MESSENGER-RNA; TRANSLATION INITIATION; P150,95 GLYCOPROTEINS; MAMMALIAN-CELLS; ALPHA-SUBUNIT; LFA-1; MAC-1	Leukocyte adhesion deficiency (LAD) is an autosomal recessive disease caused by mutations in the CD18 gene which codes for the beta-2 integrin subunit. We studied two patients, the first of which had a moderate LAD phenotype and expressed only 9% of CD11/CD18 on blood leukocytes. RNA from lymphoblasts was reverse-transcribed, and the cDNA was amplified, cloned, and sequenced. An ATG to AAG alteration in the initiation codon was detected in 39 of 45 (87%) cDNA clones. This mutation was detected in the father, but not in the mother. The maternal defect was shown to be a frameshift mutation with the deletion of a single T in the aspartic acid codon at position 690 (GAT), 11 amino acids N-terminal to the beginning of the transmembrane domain. This mutation predicts a polypeptide which would terminate without transmembrane or cytoplasmic domains. The frameshift mutation was also found in the second patient who had the severe phenotype of LAD (< 11% of CD11/CD18), indicating that this allele does not encode a functional protein. The partial expression in the patient with a moderate phenotype must be derived from the initiation codon mutation and may be due to a low level of initiation of translation of the CD18 mRNA at the second codon (CUG).	BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,HOWARD HUGHES MED INST,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,SPEROS P MARTEL LEUKOCYTE BIOL LAB,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	SLIGH, JE (corresponding author), BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019031, R01AI019031, R01AI023521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE009079] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 23521, AI 19031] Funding Source: Medline; NIDCR NIH HHS [DE09079] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANDERSON DC, 1984, J CLIN INVEST, V74, P536, DOI 10.1172/JCI111451; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; ATWEH GF, 1988, J CLIN INVEST, V82, P557, DOI 10.1172/JCI113632; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOJO SS, 1989, J BIOL CHEM, V264, P20839; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HO MK, 1983, J BIOL CHEM, V258, P2766; ISSEKUTZ AC, 1979, CLIN IMMUNOL IMMUNOP, V14, P1, DOI 10.1016/0090-1229(79)90119-3; JANKOVIC L, 1990, HEMOGLOBIN, V14, P169, DOI 10.3109/03630269009046958; JOHN SWM, 1989, AM J HUM GENET, V45, P905; KISHIMOTO TK, 1989, J BIOL CHEM, V264, P3588; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KISHIMOTO TK, 1987, CELL, V50, P193, DOI 10.1016/0092-8674(87)90215-7; KOBAYASHI K, 1990, J BIOL CHEM, V265, P11361; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MARLIN SD, 1986, J EXP MED, V164, P855, DOI 10.1084/jem.164.3.855; MITCHELL GA, 1988, J CLIN INVEST, V81, P630, DOI 10.1172/JCI113365; MOI P, 1987, J CLIN INVEST, V80, P1416, DOI 10.1172/JCI113220; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; NOZARI G, 1986, GENE, V43, P23, DOI 10.1016/0378-1119(86)90004-1; OLIVIERI NF, 1987, BLOOD, V70, P729; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; PIRASTU M, 1984, J BIOL CHEM, V259, P2315; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SASTRE L, 1986, J IMMUNOL, V137, P1060; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; TAIRA M, 1990, J BIOL CHEM, V265, P16491; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335	45	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					714	718						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1346132				2022-12-25	WOS:A1992GY96000009
J	MULLER, G; SCHUBERT, K; FIEDLER, F; BANDLOW, W				MULLER, G; SCHUBERT, K; FIEDLER, F; BANDLOW, W			THE CAMP-BINDING ECTOPROTEIN FROM SACCHAROMYCES-CEREVISIAE IS MEMBRANE-ANCHORED BY GLYCOSYL-PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; TRYPANOSOMA-BRUCEI; YEAST MITOCHONDRIA; PHOSPHOLIPASE-C; SUBMITOCHONDRIAL LOCALIZATION; INTRAMITOCHONDRIAL LOCATION; SYNERGISTIC CONTROL; PLASMA-MEMBRANE; PROTEIN; INSULIN	Saccharomyces cerevisiae contains an amphiphilic cAMP-binding glycoprotein at the outer face of the plasma membrane (M(r) = 54,000). It is converted to a hydrophilic form by treatment with glycosyl-phosphatidylinositol-specific phospholipases C and D (GPI-PLC/D), suggesting membrane anchorage by a covalently bound glycolipid. Determination of the constituents of the purified anchor by gas-liquid chromatography and amino acid analysis reveals the presence of glycerol, myo-inositol, glucosamine, galactose, mannose, ethanolamine, and asparagine (as the carboxyl-terminal amino acid of the Pronase-digested protein to which the anchor is attached). Complementary results are obtained by metabolic labeling, indicating that fatty acids and phosphorus are additional anchor constituents. The phosphorus is resistant to alkaline phosphatase, whereas approximately half is lost from the protein after treatment with GPI-PLD or nitrous acid, and all is removed by aqueous HF indicating the presence of two phosphodiester bonds. Inhibition of N-glycosylation by tunicamycin or removal of protein-bound glycan chains by N-glycanase or Pronase does not abolish radiolabeling of the anchor structure by any of the above compounds. Analysis of the products obtained after sequential enzymic and chemical degradation of the anchor agrees with the arrangement of constitutents in GPIs from higher eucaryotes. Evidence for anchorage of the yeast cAMP-binding protein by a GPI anchor is strengthened additionally by the reactivity of the GPI-PLC-cleaved anchor with antibodies directed against the cross-reacting determinant of trypanosomal variant surface glycoproteins.	UNIV MUNICH,INST GENET & MIKROBIOL,W-8000 MUNICH 19,GERMANY	University of Munich	MULLER, G (corresponding author), HOECHST AG,DIV PHARMACEUT RES,SBU METAB H825,POB 800320,W-6230 FRANKFURT 80,GERMANY.			Muller, Gunter/0000-0001-6178-8215				ACHSTETTER T, 1984, J BIOL CHEM, V259, P3334; ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; ANDERSON AJ, 1977, CARBOHYD RES, V57, pC7, DOI 10.1016/S0008-6215(00)81944-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULOW R, 1986, J BIOL CHEM, V261, P1918; CHAN BL, 1988, SCIENCE, V241, P1670, DOI 10.1126/science.2843987; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DOERING TL, 1990, J BIOL CHEM, V265, P611; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; FIEDLER F, 1987, SYST APPL MICROBIOL, V9, P16, DOI 10.1016/S0723-2020(87)80050-4; FISCHER W, 1973, BIOCHIM BIOPHYS ACTA, V296, P527, DOI 10.1016/0005-2760(73)90113-6; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Heller M, 1978, Adv Lipid Res, V16, P267; HERELD D, 1986, J BIOL CHEM, V261, P3813; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HOOPER NM, 1991, BIOCHEM J, V273, P301, DOI 10.1042/bj2730301; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; KLIP A, 1988, FEBS LETT, V238, P419, DOI 10.1016/0014-5793(88)80524-6; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9974; MULLER G, 1991, BIOCHEMISTRY-US, V30, P10181; MULLER G, 1987, YEAST, V3, P161, DOI 10.1002/yea.320030304; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9968; MULLER G, 1991, EUR J BIOCHEM, V202, P299, DOI 10.1111/j.1432-1033.1991.tb16376.x; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9957; MULLER G, 1987, EMBO J, V6, P2199; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RODEL G, 1985, J BACTERIOL, V161, P7; ROMERO G, 1988, SCIENCE, V240, P509, DOI 10.1126/science.3282305; SADEGHI H, 1988, P NATL ACAD SCI USA, V85, P5512, DOI 10.1073/pnas.85.15.5512; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; STIEGER S, 1991, BIOCHIMIE, V73, P1179, DOI 10.1016/0300-9084(91)90002-I; TAGUCHI R, 1987, J BIOCHEM-TOKYO, V102, P803, DOI 10.1093/oxfordjournals.jbchem.a122119; VAI M, 1990, BIOCHIM BIOPHYS ACTA, V1038, P277, DOI 10.1016/0167-4838(90)90237-A; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	51	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25337	25346						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334092				2022-12-25	WOS:A1992KB60300065
J	MURPHY, AC; ROZENGURT, E				MURPHY, AC; ROZENGURT, E			PASTEURELLA-MULTOCIDA TOXIN SELECTIVELY FACILITATES PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS BY BOMBESIN, VASOPRESSIN, AND ENDOTHELIN - REQUIREMENT FOR A FUNCTIONAL G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHOLIPASE-C ACTIVITY; KINASE-C; ALPHA-SUBUNITS; GUANINE-NUCLEOTIDE; POTENT MITOGEN; PHORBOL ESTERS; MONOCLONAL-ANTIBODIES; DERMONECROTIC TOXIN; BACTERIAL TOXINS	Treatment of Swiss 3T3 cells with a subsaturating concentration of recombinant Pasteurella multocida toxin (rPMT) markedly potentiated the production of inositol phosphates induced by bombesin, vasopressin, and endothelin but not by platelet-derived growth factor (PDGF) (AA and BB homodimers). Similarly, the neuropeptides but not PDGF caused a shift in the dose-dependent increase in inositol phosphates induced by rPMT. The rate of accumulation of inositol phosphates induced by bombesin was increased 2-fold by rPMT treatment while that of PDGF was unaffected. rPMT treatment also enhanced bombesin-induced inositol(1,4,5)trisphosphate, the direct product of phosphatidylinositol 4,5-bisphosphate hydrolysis. In contrast, treatment of cells with rPMT had no effect on the tyrosine phosphorylation of phospholipase Cgamma. Depletion of protein kinase C increased rPMT-induced inositol phosphates in a manner similar to that observed for bombesin but not PDGF. Thus, rPMT selectively potentiates neuropeptide-mediated inositol phosphate production. The action of rPMT on phosphatidylinositol 4,5-bisphosphate hydrolysis persisted in streptolysin O-permeabilized cells. Addition of guanosine 5'-O-(beta-thiodiphosphate) to permeabilized cells markedly reduced rPMT-induced inositol phosphates in a time- and dose-dependent manner. rPMT also increased the sensitivity of phospholipase C for free calcium. Our results strongly suggest that the action of rPMT facilitates the coupling of G protein to phospholipase C.	IMPERIAL CANC RES FUND, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BROWN KD, 1990, BIOCHEM J, V270, P557, DOI 10.1042/bj2700557; BROWN KD, 1987, BIOCHEM J, V245, P631, DOI 10.1042/bj2450631; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; BUYS WECM, 1990, NUCLEIC ACIDS RES, V18, P2815, DOI 10.1093/nar/18.9.2815; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANTER N, 1986, J GEN MICROBIOL, V132, P1089; COLLINS MKL, 1983, P NATL ACAD SCI-BIOL, V80, P1924, DOI 10.1073/pnas.80.7.1924; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABREGAT I, 1990, BIOCHEM BIOPH RES CO, V167, P161, DOI 10.1016/0006-291X(90)91745-E; FOGED NT, 1988, INFECT IMMUN, V56, P1901, DOI 10.1128/IAI.56.8.1901-1906.1988; FOGED NT, 1987, FEMS MICROBIOL LETT, V43, P45, DOI 10.1111/j.1574-6968.1987.tb02095.x; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KAMPS AMIE, 1990, FEMS MICROBIOL LETT, V67, P187, DOI 10.1111/j.1574-6968.1990.tb13860.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287-136-1-81; LAX AJ, 1990, FEBS LETT, V277, P59, DOI 10.1016/0014-5793(90)80809-W; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARTIN TFJ, 1989, J BIOL CHEM, V264, P20917; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NAKAI T, 1984, INFECT IMMUN, V46, P429, DOI 10.1128/IAI.46.2.429-434.1984; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PETERSEN SK, 1989, INFECT IMMUN, V57, P3907, DOI 10.1128/IAI.57.12.3907-3913.1989; PETERSEN SK, 1990, MOL MICROBIOL, V4, P821, DOI 10.1111/j.1365-2958.1990.tb00652.x; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, J CELL SCI, P43; RYU SH, 1990, J BIOL CHEM, V265, P17941; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHENKER A, 1991, SCIENCE, V266, P9309; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1	66	58	59	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25296	25303						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334089				2022-12-25	WOS:A1992KB60300059
J	PERLMAN, JH; NUSSENZVEIG, DR; OSMAN, R; GERSHENGORN, MC				PERLMAN, JH; NUSSENZVEIG, DR; OSMAN, R; GERSHENGORN, MC			THYROTROPIN-RELEASING-HORMONE BINDING TO THE MOUSE PITUITARY RECEPTOR DOES NOT INVOLVE IONIC INTERACTIONS - A MODEL FOR NEUTRAL PEPTIDE BINDING TO G-PROTEIN-COUPLED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; HIGH-AFFINITY; TUMOR-CELLS; GH3 CELLS; TRH; ACTIVATION; CULTURE; IDENTIFICATION; EXPRESSION	Thyrotropin-releasing hormone, TRH (<Glu-His-Proamide), and [N(tau)Me-His]TRH (MeTRH) are present as neutral and positively charged forms at physiologic pH, and it was possible that they bind to the TRH receptor (TRH-R) as charged (protonated) species. Binding affinities of TRH and MeTRH to endogenous rat TRH-Rs and to transfected wild type mouse TRH-Rs decreased below pH 7.1. Half-maximal decreases in binding occurred at the approximate pK(a) values of these ligands. Asp to Ala mutations in extracellular loop 1, TM-4, and TM-5 did not decrease binding affinity, but an Asp to Ala mutation in TM-2 caused the affinity to decrease 8-fold. The pH dependences of binding of MeTRH, however, were similar in wild type and all mutant receptors and were consistent with the protonated form of MeTRH binding less well. Thus, the binding of TRH to its receptor does not involve ionic interactions and may be a prototype for binding of neutral peptide ligands to G protein-coupled receptors.	CORNELL UNIV, MED CTR,NEW YORK HOSP,COLL MED,DEPT MED, DIV MOLEC MED,1300 YORK AVE, NEW YORK, NY 10021 USA; CUNY MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10029 USA	Cornell University; NewYork-Presbyterian Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIDDK NIH HHS [DK43036] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043036] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; DRUMMOND AH, 1985, BIOCHEM BIOPH RES CO, V127, P63, DOI 10.1016/S0006-291X(85)80126-1; DRUMMOND AH, 1989, ANN NY ACAD SCI, V553, P197; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FUJIMOTO J, 1991, MOL ENDOCRINOL, V5, P1527, DOI 10.1210/mend-5-10-1527; GERSHENGORN MC, 1986, ENDOCRINOLOGY, V119, P833, DOI 10.1210/endo-119-2-833; GERSHENGORN MC, 1991, ENDOCRINOLOGY, V128, P1204, DOI 10.1210/endo-128-2-1204; GERSHENGORN MC, 1978, J CLIN INVEST, V62, P937, DOI 10.1172/JCI109222; GERSHENGORN MC, 1983, MOL BASIS THYROID HO, P338; GOREN HJ, 1977, MOL PHARMACOL, V13, P606; GRANT G, 1972, BIOCHEMISTRY-US, V11, P3070, DOI 10.1021/bi00766a020; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HINKLE PM, 1984, J BIOL CHEM, V259, P3445; HINKLE PM, 1974, J BIOL CHEM, V249, P3085; HINKLE PM, 1973, J BIOL CHEM, V248, P6180; HINKLE PM, 1989, ANN NY ACAD SCI, V553, P176; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; IMAI A, 1987, METHOD ENZYMOL, V141, P100; JI IH, 1991, J BIOL CHEM, V266, P14953; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEVE KA, 1991, MOL PHARMACOL, V39, P733; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REYNOLDS WF, 1973, J AM CHEM SOC, V95, P328, DOI 10.1021/ja00783a006; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; Sambrook J, 1989, MOL CLONING LABORATO; SHARIF NA, 1987, NEUROSCI LETT, V81, P339, DOI 10.1016/0304-3940(87)90407-1; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; Vale W, 1973, Front Neuroendocrinol, V0, P375; WANG CD, 1991, MOL PHARMACOL, V40, P168; XIE YB, 1990, J BIOL CHEM, V265, P21411	31	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24413	24417						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332958				2022-12-25	WOS:A1992KA26300044
J	BARON, V; KALIMAN, P; GAUTIER, N; VANOBBERGHEN, E				BARON, V; KALIMAN, P; GAUTIER, N; VANOBBERGHEN, E			THE INSULIN-RECEPTOR ACTIVATION PROCESS INVOLVES LOCALIZED CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL-FREE SYSTEM; KINASE-ACTIVITY; BINDING-SITE; BETA-SUBUNIT; PHOSPHORYLATION; AUTOPHOSPHORYLATION; ATP; ANTIBODIES	The molecular process by which insulin binding to the receptor alpha-subunit induces activation of the receptor beta-subunit with ensuing substrate phosphorylation remains unclear. In this study, we aimed at approaching this molecular mechanism of signal transduction and at delineating the cytoplasmic domains implied in this process. To do this, we used antipeptide antibodies to the following sequences of the receptor beta-subunit: (i) positions 962-972 in the juxtamembrane domain, (ii) positions 1247-1261 at the end of the kinase domain, and (iii) positions 1294-1317 and (iv) positions 1309-1326, both in the receptor C terminus. We have previously shown that insulin binding to its receptor induces a conformational change in the beta-subunit C terminus. Here, we demonstrate that receptor autophosphorylation induces an additional conformational change. This process appears to be distinct from the one produced by ligand binding and can be detected in at least three different beta-subunit regions: the juxtamembrane domain, the kinase domain, and the C terminus. Hence, the cytoplasmic part of the receptor beta-subunit appears to undergo an extended conformational change upon autophosphorylation. By contrast, the insulin-induced change does not affect the juxtamembrane domain 962-972 nor the kinase domain 1247-1261 and may be limited to the receptor C terminus. Further, we show that the hormone-dependent conformational change is maintained in a kinase-deficient receptor due to a mutation at lysine 1018. Therefore, during receptor activation, the ligand-induced change could precede ATP binding and receptor autophosphorylation. We propose that insulin binding leads to a transient receptor form that may allow ATP binding and, subsequently, autophosphorylation. The second conformational change could unmask substrate-binding sites and stabilize the receptor in an active conformation.	FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE 2,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur								BARON V, 1989, BIOCHEM J, V260, P749, DOI 10.1042/bj2600749; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DONNER DB, 1983, J BIOL CHEM, V258, P9413; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; FREYCHET P, 1976, METHODS RECEPTOR RES, P384; HERRERA R, 1986, J BIOL CHEM, V261, P1980; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KEATING MT, 1988, J BIOL CHEM, V263, P12805; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PILCH PF, 1980, SCIENCE, V210, P1152, DOI 10.1126/science.7003712; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANOBBERGHEN E, 1982, FEBS LETT, V143, P179, DOI 10.1016/0014-5793(82)80094-X; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052	22	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23290	23294						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331080				2022-12-25	WOS:A1992JY16300089
J	ROMANIC, AM; ADACHI, E; HOJIMA, Y; ENGEL, J; PROCKOP, DJ				ROMANIC, AM; ADACHI, E; HOJIMA, Y; ENGEL, J; PROCKOP, DJ			POLYMERIZATION OF PNCOLLAGEN-I AND COPOLYMERIZATION OF PNCOLLAGEN-I WITH COLLAGEN-I - A KINETIC, THERMODYNAMIC, AND MORPHOLOGIC STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO TENDONS; FIBRIL FORMATION; PC-COLLAGEN; ELECTRON-MICROSCOPY; CONNECTIVE-TISSUE; V COLLAGEN; PROCOLLAGEN; DIAMETER; PROTEINASE; CLEAVAGE	Previous observations established that pNcollagen III copolymerized with collagen I and decreased the diameter of the fibrils formed (Romanic, A. M., Adachi, E., Kadler, K. E., Hojima, Y., and Prockop, D. J. (1991) J. Biol. Chem. 266, 12703-12709). Here, procollagen I alone or mixtures of procollagen I and pCcollagen I were incubated with procollagen C-proteinase to generate pNcollagen I or mixtures of pNcollagen I and collagen I. The results confirmed previous reports that pNcollagen I assembles into sheet-like structures. They also demonstrated that polymerization of pNcollagen I exhibits a lag period and a propagation phase similar to those seen with other protein self-assembly systems. In addition, the results demonstrated that pNcollagen I formed true copolymers with collagen I in that the presence of pNcollagen I increased the lag time, decreased the propagation rate, and increased the concentration of collagen I in solution at equilibrium. Copolymerization of pNcollagen I with collagen I, however, differed in two features from copolymerization of pNcollagen III with collagen I. One was that, in confirmation of previous work, copolymerization of pNcollagen I with collagen I markedly altered the circularity of the fibrils formed. The second difference was that the copolymerization increased the concentration in solution at equilibrium of pNcollagen I whereas copolymerization with collagen I was previously shown to decrease the concentration in solution of pNcollagen III. The increase in concentration in solution of pNcollagen I was explicable either by the assembly of soluble oligomers of pNcollagen I and collagen I, or by subtle changes in the activities of pNcollagen I and collagen I in the solid-phase. Comparison with previous data with pNcollagen III indicated that although pNcollagen I and pNcollagen III copolymerize with collagen I, there are marked differences in the two kinds of copolymers.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University					NIAMS NIH HHS [AR39740, AR38188] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, P01AR038188] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI E, 1985, COLLAGEN REL RES, V5, P225; ADACHI E, 1989, MATRIX, V9, P232, DOI 10.1016/S0934-8832(89)80055-1; ALAKOKKO L, 1989, BIOCHEM J, V260, P509, DOI 10.1042/bj2600509; BAILEY AJ, 1973, EUR J BIOCHEM, V34, P91, DOI 10.1111/j.1432-1033.1973.tb02732.x; BECKER U, 1976, BIOCHEMISTRY-US, V15, P2853, DOI 10.1021/bi00658a024; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P2201, DOI 10.1002/bip.360281212; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; FIEDLERNAGY C, 1982, J BIOL CHEM, V257, P9181; FLEISCHMAJER R, 1983, P NATL ACAD SCI-BIOL, V80, P3354, DOI 10.1073/pnas.80.11.3354; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FLEISCHMAJER R, 1988, J HISTOCHEM CYTOCHEM, V36, P1425, DOI 10.1177/36.11.3049791; FLEISCHMAJER R, 1990, MATRIX, V4, P224; GELMAN RA, 1979, J BIOL CHEM, V254, P180; HOFMANN H, 1980, J MOL BIOL, V141, P293, DOI 10.1016/0022-2836(80)90182-5; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLBROOK KA, 1982, J INVEST DERMATOL, V79, pS7, DOI 10.1111/1523-1747.ep12544609; HOLMES DF, 1991, J MOL BIOL, V220, P111, DOI 10.1016/0022-2836(91)90385-J; HULMES DJS, 1983, COLLAGEN REL RES, V3, P317; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; HULMES DJS, 1989, SPRINGER SERIES BIOP, V3, P81; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KADLER KE, 1988, J BIOL CHEM, V263, P10517; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; KEENE DR, 1987, J CELL BIOL, V105, P2393, DOI 10.1083/jcb.105.5.2393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; MIYAHARA M, 1983, COLLAGEN REL RES, V3, P279; MIYAHARA M, 1984, J BIOL CHEM, V259, P9891; MOORE WJ, 1972, PHYSICAL CHEM, P259; MOULD AP, 1990, J MOL BIOL, V211, P581, DOI 10.1016/0022-2836(90)90267-P; PARRY DAD, 1979, NATURE, V282, P213, DOI 10.1038/282213a0; PELTONEN L, 1980, P NATL ACAD SCI-BIOL, V77, P162, DOI 10.1073/pnas.77.1.162; PIERARD GE, 1986, COLLAGEN REL RES, V6, P481; POTSCHKA M, 1988, BIOCHEMISTRY-US, V27, P8481, DOI 10.1021/bi00422a028; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; TIMPL R, 1981, CLIN ORTHOP RELAT R, P224; VEIS A, 1973, P NATL ACAD SCI USA, V70, P1464, DOI 10.1073/pnas.70.5.1464; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	41	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22265	22271						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331049				2022-12-25	WOS:A1992JW71900044
J	ALLISON, RG; CHACONAS, G				ALLISON, RG; CHACONAS, G			ROLE OF THE A PROTEIN-BINDING SITES IN THE INVITRO TRANSPOSITION OF MU-DNA - A COMPLEX CIRCUIT OF INTERACTIONS INVOLVING THE MU-ENDS AND THE TRANSPOSITIONAL ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; STRAND-TRANSFER-REACTION; BACTERIOPHAGE-MU; A-PROTEIN; B-PROTEIN; PHAGE-MU; RECOMBINATION; MECHANISM; REPRESSOR; CLEAVAGE	To investigate the role of the A protein-binding sites at the Mu ends in the DNA strand transfer reaction, we constructed mutant mini-Mu molecules in which these sites were deleted (L3 or R3) or substituted (L2 or R2) to conserve the spacing arrangements at the adjacent sites. The single site mutants are poor substrates for phosphodiester bond hydrolysis at the Mu ends in Type 1 reactions in the absence of Escherichia coli integration host factor (IHF). Addition of IHF to the reaction stimulates Type 1 cleavage more than 10 times for the DELTA-R3, DELTA-L3, S-L2 mutants and more than five times in the case of the S-R2 mutant under alternate conditions. The site of IHF stimulation resides within the transpositional enhancer which implicates the end-binding sites L2, L3, R2, and R3 in interactions with the enhancer. At least two of the L2, L3, and R3 sites are required for proficient reaction in the presence of IHF. By combining the single site mutants with O1 or O2 partially deleted enhancer elements, we have tentatively localized some of the interactions to each side of the functional enhancer revealing a complex circuit of end-enhancer interactions. The R3 site is suggested to be involved in interactions only with O2 and the L3 site only with O1. The data also suggest the possibility that L2 and R2 may be involved in interactions with both O1 and O2. Finally, our working model predicts that the L3-O1 and R3-O2 interactions may be required contacts for discriminating between the Mu left and right ends in transpososome formation.			ALLISON, RG (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; GROENEN MAM, 1985, P NATL ACAD SCI USA, V82, P2087, DOI 10.1073/pnas.82.7.2087; GROENEN MAM, 1986, J MOL BIOL, V189, P597, DOI 10.1016/0022-2836(86)90490-0; HAFFTER P, 1988, EMBO J, V7, P3991, DOI 10.1002/j.1460-2075.1988.tb03287.x; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HEINKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI K, 1992, ANN REV BIOCH, V68, P1101; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHUMM JW, 1981, VIROLOGY, V114, P429, DOI 10.1016/0042-6822(81)90224-5; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VOGEL JL, 1991, J BACTERIOL, V173, P6568, DOI 10.1128/jb.173.20.6568-6577.1991; ZOU A, 1991, J BIOL CHEM, V266, P20476	36	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19963	19970						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328189				2022-12-25	WOS:A1992JR85800037
J	CORBETT, AH; DEVORE, RF; OSHEROFF, N				CORBETT, AH; DEVORE, RF; OSHEROFF, N			EFFECT OF CASEIN KINASE-II-MEDIATED PHOSPHORYLATION ON THE CATALYTIC CYCLE OF TOPOISOMERASE-II - REGULATION OF ENZYME-ACTIVITY BY ENHANCEMENT OF ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DNA TOPOISOMERASE; DROSOPHILA-MELANOGASTER; MITOTIC CHROMOSOMES; PHORBOL ESTER; CELL-CYCLE; CLEAVAGE; PROLIFERATION; LOCALIZATION; RECOMBINATION	The catalytic activity of topoisomerase II is stimulated approximately 2-3-fold following phosphorylation by casein kinase II (Ackerman, P., Glover, C. V. C., and Osheroff, N. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 3164-3168). In order to delineate the mechanism by which the activity of the enzyme is enhanced, the effects of casein kinase II-mediated phosphorylation on the individual steps of the catalytic cycle of Drosophila topoisomerase II were characterized. Phosphorylation did not affect reaction steps that preceded hydrolysis of the enzyme's high energy ATP cofactor. This included enzyme-DNA binding, pre-strand passage DNA cleavage/religation, the double-stranded DNA passage event, and post-strand passage DNA cleavage/religation. In contrast, the rate of topoisomerase II-mediated ATP hydrolysis was stimulated 2.7-fold following phosphorylation by casein kinase II. Since ATP hydrolysis is a prerequisite for enzyme turnover, it is concluded that phosphorylation modulates the overall catalytic activity of topoisomerase II by stimulating the enzyme's ATPase activity.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,621 LIGHT HALL,NASHVILLE,TN 37232	Vanderbilt University			Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09582] Funding Source: Medline; NIDDK NIH HHS [DK43325] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; BAE YS, 1988, P NATL ACAD SCI USA, V85, P5497; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BODLEY AL, 1987, NATL CANCER I MONOGR, V4, P31; CHARTRAND P, 1991, DNA TOPOISOMERASES C, P240; CHOW KC, 1987, MOL CELL BIOL, V7, P3119, DOI 10.1128/MCB.7.9.3119; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CRESPI MD, 1988, EXP CELL RES, V175, P206, DOI 10.1016/0014-4827(88)90267-4; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DUGET M, 1983, NUCLEIC ACIDS RES, V11, P1059; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GENOVESE JA, 1988, LIFE SCI, V43, P2137, DOI 10.1016/0024-3205(88)90364-5; GLOVER CVC, 1983, J BIOL CHEM, V258, P3259; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; HOLDEN JA, 1990, BIOCHEMISTRY-US, V29, P2127, DOI 10.1021/bi00460a024; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1988, CANCER RES, V48, P3230; HSIANG YH, 1989, MOL PHARMACOL, V36, P371; ISHIMI Y, 1992, J BIOL CHEM, V267, P462; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; LIU LF, 1983, J BIOL CHEM, V258, P5365; MATTHES E, 1990, ANTIVIR RES, V13, P273, DOI 10.1016/0166-3542(90)90012-V; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MISKIMINS R, 1983, EXP CELL RES, V146, P53, DOI 10.1016/0014-4827(83)90323-3; NELSON WG, 1987, CANCER RES, V47, P3246; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; OSHEROFF N, 1983, MECHANISMS DNA REPLI, P55; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1057; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; Sambrook J, 1989, MOL CLONING LABORATO; SANDER M, 1983, J BIOL CHEM, V258, P8421; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SULLIVAN DM, 1987, CANCER RES, V47, P3973; SULLIVAN DM, 1987, NATL CANCER I MONOGR, V4, P73; SUTCLIFFE JA, 1989, ANTIMICROB AGENTS CH, V33, P2027, DOI 10.1128/AAC.33.12.2027; TAUDOU G, 1984, FEBS LETT, V176, P431, DOI 10.1016/0014-5793(84)81212-0; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WYCOFF E, 1989, J MOL BIOL, V205, P1; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	68	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20513	20518						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328202				2022-12-25	WOS:A1992JR85800118
J	ROSS, TS; WANG, FP; MAJERUS, PW				ROSS, TS; WANG, FP; MAJERUS, PW			MAMMALIAN-CELLS THAT EXPRESS BACILLUS-CEREUS PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-C HAVE INCREASED LEVELS OF INOSITOL CYCLIC 1/2-PHOSPHATE, INOSITOL 1-PHOSPHATE, AND INOSITOL 2-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHATE 1-PHOSPHATASE; HUMAN-PLATELETS; PHOSPHATE; 2-INOSITOLPHOSPHOHYDROLASE; SEQUENCE; THROMBIN; ENZYMES; CLONING; BRAIN; LI+	Phosphatidylinositol-specific phospholipase C (Ptd-Ins-PLC) of Bacillus cereus catalyzes the conversion of PtdIns to inositol cyclic 1:2-phosphate and diacylglycerol. NIH 3T3, Swiss mouse 3T3, CV-1, and Cos-7 cells were transfected with a cDNA encoding this enzyme, and the metabolic and cellular consequences were investigated. Overexpression of PtdIns-PLC enzyme activity was associated with elevated levels of inositol cyclic 1:2-phosphate (2.5-70-fold), inositol 1-phosphate (2-20-fold), and inositol 2-phosphate (3-20-fold). The increases correlated with the levels of enzyme expression obtained in each cell type. The turnover of phosphatidylinositol (PtdIns) was also increased in transfected CV-1 cells by 13-fold 20 h after transfection. The levels of PtdIns, phosphatidic acid, diacylglycerol, or other inositol phosphates were not detectably altered. Expression of bacterial PtdIns-PLC decreased rapidly after 20 h implying that either the increased PtdIns turnover or the accumulation of inositol phosphates was detrimental to cells and that by some adaptive mechanism enzyme expression was suppressed.			ROSS, TS (corresponding author), WASHINGTON UNIV, DIV HEMATOL ONCOL, ST LOUIS, MO 63130 USA.		wang, fang/GYD-4295-2022	Ross, Theodora/0000-0002-9166-1802	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL016634, R01HL016634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI 14147, HLBI 16634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAMILLI A, 1991, J EXP MED, V173, P751, DOI 10.1084/jem.173.3.751; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; EISENBER.F, 1967, J BIOL CHEM, V242, P1375; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; INHORN RC, 1987, J BIOL CHEM, V262, P15946; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; Low M G, 1981, Methods Enzymol, V71 Pt C, P741; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; RAGAN CI, 1988, BIOCHEM J, V249, P143, DOI 10.1042/bj2490143; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1992, J BIOL CHEM, V267, P19924; ROSS TS, 1986, J BIOL CHEM, V261, P1119; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAGUCHI R, 1978, ARCH BIOCHEM BIOPHYS, V186, P196, DOI 10.1016/0003-9861(78)90480-0; WILSON DB, 1985, J BIOL CHEM, V260, P1046; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548	28	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19919	19923						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328186				2022-12-25	WOS:A1992JR85800030
J	SOZZANI, S; AGWU, DE; MCCALL, CE; OFLAHERTY, JT; SCHMITT, JD; KENT, JD; MCPHAIL, LC				SOZZANI, S; AGWU, DE; MCCALL, CE; OFLAHERTY, JT; SCHMITT, JD; KENT, JD; MCPHAIL, LC			PROPRANOLOL, A PHOSPHATIDATE PHOSPHOHYDROLASE INHIBITOR, ALSO INHIBITS PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL RESPIRATORY BURST; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CHRONIC GRANULOMATOUS-DISEASE; PHOSPHOLIPASE-D ACTIVATION; PHORBOL-MYRISTATE ACETATE; HUMAN-PLATELETS; NADPH OXIDASE; PHOSPHATIDYLCHOLINE HYDROLYSIS; SIGNAL TRANSDUCTION; POTENT INHIBITOR	Propranolol, a beta-adrenergic receptor antagonist, also inhibits phosphatidate phosphohydrolase, the enzyme that converts phosphatidic acid into diacylglycerol. This latter effect has prompted recent use of propranolol in studies examining the importance of diacylglycerol and phosphatidic acid in cellular signalling events. Here, we show that propranolol is also an inhibitor of protein kinase C. At concentrations greater-than-or-equal-to 20 muM, propranolol reduced [H-3]phorbol dibutyrate binding (IC50 = 200 muM) and phorbol myristate acetate-stimulated superoxide anion release (IC50 = 130 muM) in human neutrophils. Scatchard analysis showed that propranolol lowers the number of phorbol diester binding sites without significantly affecting their affinity. In vitro kinetic analysis, performed in a mixed micellar assay with protein kinase C purified from human neutrophils, suggested a competitive inhibition of propranolol with the cofactor phosphatidylserine. Complex kinetic patterns were observed with respect to diacylglycerol and ATP, approximating competitive and noncompetitive inhibition, respectively. Taken together, these results suggest that the drug interacts at the level of the regulatory domain of the enzyme. Fifty % inhibition occurred at approximately 150 muM propranolol. Similar levels of inhibition were obtained using exogenous (histone) and endogenous (p47- phox, a NADPH oxidase component) substrates. Protein kinase C-alpha and protein kinase C-beta, two protein kinase C isozymes present in human neutrophils, were inhibited by propranolol in a comparable manner. In the range of concentrations tested (30-1000 muM), neither cAMP-dependent protein kinase nor neutrophil protein tyrosine kinases were affected. The racemic form of propranolol and the (+) and the (-) stereoisomers were equally active, and other beta-adrenergic receptor antagonists (pindolol) and agonists (isoproterenol) were inactive. This suggests that the inhibitory action of propranolol on protein kinase C is related to the amphipathic nature of the drug rather than to its beta-adrenergic receptor blocking ability. Analogs of propranolol were synthesized and found to be more potent protein kinase C inhibitors, with IC50 values in the 10-20 muM range. We conclude that the ability of propranolol to inhibit both protein kinase C and PA phosphohydrolase complicates interpretation of results when this drug is used in signal transduction studies. In addition, propranolol may be a useful prototype for the synthesis of new protein kinase C inhibitors.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, MED CTR BLVD, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, INFECT DIS SECT, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center			Sozzani, Silvano/C-1447-2009; McPhail, Linda C/D-9505-2013	Sozzani, Silvano/0000-0002-3144-8743; McPhail, Linda C/0000-0002-8670-306X	NHLBI NIH HHS [HL-27799] Funding Source: Medline; NIAID NIH HHS [AI-09169, R01 AI022564, AI-22564] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI009169, R01AI009169, R01AI022564] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BISHOP WR, 1990, BIOCHEM J, V269, P465, DOI 10.1042/bj2690465; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DACHARYPRIGENT J, 1979, THROMB RES, V14, P15, DOI 10.1016/0049-3848(79)90020-3; DELLABIANCA V, 1991, BIOCHEM BIOPH RES CO, V177, P948, DOI 10.1016/0006-291X(91)90630-P; ENGLISH D, 1991, BLOOD, V77, P2746; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; EXTON JH, 1990, J BIOL CHEM, V265, P1; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GAY JC, 1991, BIOCHIM BIOPHYS ACTA, V1095, P236, DOI 10.1016/0167-4889(91)90105-7; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GROBECKER H, 1973, EUR J CLIN PHARMACOL, V5, P145, DOI 10.1007/BF00564894; HANNUN YA, 1988, J BIOL CHEM, V263, P5124; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, J BIOL CHEM, V264, P9960; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HARDY SJ, 1991, EUR J BIOCHEM, V198, P801, DOI 10.1111/j.1432-1033.1991.tb16084.x; HOLMSEN H, 1990, THROMB HAEMOSTASIS, V64, P307; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KATOH N, 1981, P NATL ACAD SCI-BIOL, V78, P4813, DOI 10.1073/pnas.78.8.4813; KOUL O, 1987, ARCH BIOCHEM BIOPHYS, V253, P453, DOI 10.1016/0003-9861(87)90199-8; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGSLET A, 1970, EUR J PHARMACOL, V13, P6, DOI 10.1016/0014-2999(70)90174-3; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LEE MH, 1986, J BIOL CHEM, V261, P4867; LIN PY, 1991, BIOCHEM PHARMACOL, V41, P1941, DOI 10.1016/0006-2952(91)90134-Q; LIN PY, 1991, J IMMUNOL, V146, P1609; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; METZ SA, 1991, BIOCHEM PHARMACOL, V41, pR1, DOI 10.1016/0006-2952(91)90470-P; MORI T, 1980, J BIOL CHEM, V255, P8378; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; MURRAY KT, 1990, J CLIN INVEST, V85, P836, DOI 10.1172/JCI114510; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P9146; PIRES EMV, 1977, BIOCHEM J, V167, P137, DOI 10.1042/bj1670137; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; QIAN Z, 1990, J BIOL CHEM, V265, P3607; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SCHATZMAN RC, 1981, BIOCHEM BIOPH RES CO, V98, P669, DOI 10.1016/0006-291X(81)91166-9; SHEARMAN MS, 1989, METHOD ENZYMOL, V168, P347; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; STILES GL, 1984, PHYSIOL REV, V64, P661, DOI 10.1152/physrev.1984.64.2.661; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; TURNER RS, 1985, PHOSPHOLIPIDS CELLUL, V2, P75; WISE BC, 1982, J BIOL CHEM, V257, P8489; WOLFSON M, 1985, J IMMUNOL, V135, P2057; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	72	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20481	20488						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328200				2022-12-25	WOS:A1992JR85800113
J	TROYER, D; PADILLA, R; SMITH, T; KREISBERG, J; GLASS, W				TROYER, D; PADILLA, R; SMITH, T; KREISBERG, J; GLASS, W			STIMULATION OF THE THROMBIN RECEPTOR OF HUMAN GLOMERULAR MESANGIAL CELLS BY SER-PHE-LEU-LEU-ARG-ASN-PRO-ASN-ASP-LYS-TYR-GLU-PRO-PHE PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION; PHOSPHOINOSITIDES; PROLIFERATION; VASOPRESSIN; METABOLISM; ELEVATION; CLONING; SHAPE	We have studied the effects of thrombin (alpha-thrombin) and Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe (SFLL), a peptide agonist of the platelet thrombin receptor in cultured human mesangial cells, and find that SFLL can reproduce the biochemical and morphological effects of thrombin. Treatment of mesangial cells with cAMP-elevating agents causes fragmentation of stress fibers, loss of the vitronectin receptor from sites of focal adhesion, and produces a change in shape from a flat to a more arborized configuration. These effects are prevented by both thrombin and SFLL. Thrombin and SFLL also initiate biochemical signaling events in mesangial cells by stimulating the metabolism of phospholipids. Both thrombin and SFLL stimulate release of inositol phosphates from [H-3]inositol-labeled cells, elevation of cytosolic calcium, the formation of [H-3]myristic acid-labeled diacylglycerol, an increase in the mass of diacylglycerol, P-32 incorporation into phospholipids, and release of unesterified [H-3]arachidonic acid from cells prelabeled with [H-3]arachidonic acid. When present together, the effects of SFLL and thrombin on diacylglycerol formation, arachidonic acid production, and inositol phosphate production were not additive. This suggested that SFLL and thrombin were acting on the same receptor. This was further supported by our observations that cells pretreated with SFLL and subsequently exposed to thrombin (or vice versa) did not show elevated cytosolic calcium. We also show that phospholipase D is activated by demonstrating production of radiolabeled phosphatidylethanol when cells are treated with SFLL in the presence of ethanol. These findings indicate that SFLL can be used to study the receptor-mediated effects of thrombin in mesangial cells, thereby avoiding thrombin's proteolytic actions.	UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	TROYER, D (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NCRR NIH HHS [RR 04194] Funding Source: Medline; NIDDK NIH HHS [DK 29787, DK 34234] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK034234, R01DK029787, R01DK034234] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARNEY DH, 1986, SEMIN THROMB HEMOST, V12, P231, DOI 10.1055/s-2007-1003559; GLASS WF, 1988, J CLIN INVEST, V82, P1992, DOI 10.1172/JCI113819; GLASS WF, 1991, AM J PHYSIOL, V261, pF336, DOI 10.1152/ajprenal.1991.261.2.F336; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JAFFER F, 1989, AM J PATHOL, V135, P261; KREISBERG JI, 1985, AM J PHYSIOL, V249, pF227, DOI 10.1152/ajprenal.1985.249.2.F227; KREISBERG JI, 1986, AM J PHYSIOL, V251, pC505, DOI 10.1152/ajpcell.1986.251.4.C505; MYERS PR, 1989, AM J PHYSIOL, V257, pH603, DOI 10.1152/ajpheart.1989.257.2.H603; PAI JK, 1988, J BIOL CHEM, V263, P12472; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SCHER W, 1987, LAB INVEST, V57, P607; SCHULTZ PJ, 1989, AM J PHYSIOL, V257, pF366; SEUWEN K, 1989, BLOOD CELLS ARTERIES, P217; TROYER DA, 1985, AM J PHYSIOL, V249, pF139, DOI 10.1152/ajprenal.1985.249.1.F139; TROYER DA, 1987, J BIOL CHEM, V262, P1614; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; VANDONGEN CJ, 1985, ANAL BIOCHEM, V144, P104, DOI 10.1016/0003-2697(85)90090-9; VILLAMEDIANA LM, 1990, KIDNEY INT, V38, P956, DOI 10.1038/ki.1990.297; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALZ DA, 1985, P SOC EXP BIOL MED, V180, P518	23	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20126	20131						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328194				2022-12-25	WOS:A1992JR85800061
J	HATCH, GM; JAMIL, H; UTAL, AK; VANCE, DE				HATCH, GM; JAMIL, H; UTAL, AK; VANCE, DE			ON THE MECHANISM OF THE OKADAIC ACID-INDUCED INHIBITION OF PHOSPHATIDYLCHOLINE BIOSYNTHESIS IN ISOLATED RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; HELA-CELLS; FATTY-ACIDS; PROTEIN PHOSPHATASES; PHOSPHORYLATION; LIVER; TRANSLOCATION; DIACYLGLYCEROL; CYTOSOL; CYTIDYLTRANSFERASE	The mechanism of inhibition of phosphatidylcholine biosynthesis by okadaic acid was investigated in suspension cultures of isolated rat hepatocytes. Cells were pulsed with [methyl-H-3]choline and chased in the absence or presence of 1-mu-M okadaic acid for up to 120 min. Phosphatidylcholine biosynthesis was inhibited after 15 min of chase. To see if okadaic acid altered the degree of phosphorylation of cytidylyltransferase (CT), hepatocytes were incubated with P-32(i) and chased in the absence or presence of okadaic acid. Okadaic acid caused a rapid (within 15 min) increase in the phosphorylation state of the cytosolic enzyme. Two-dimensional peptide map analysis revealed an increase in the phosphorylation of several peptides in okadaic acid-treated hepatocytes compared with controls. After 15 min of incubation of hepatocytes with okadaic acid, membrane CT activity was decreased and a corresponding increase in cytosolic CT activity was observed. In hepatocytes incubated with okadaic acid and oleate a correlation between membrane CT activity, diacylglycerol level, and phosphatidylcholine biosynthesis was observed. These data suggest that the concentration of diacylglycerol is responsible for the increase in membrane CT activity and subsequently phosphatidylcholine biosynthesis in oleate-treated cells. We postulate that the okadaic acid-induced decrease in phosphatidylcholine biosynthesis is due to an increase in the phosphorylation state of CT which promotes a translocation of CT activity from the membranes to the cytosol.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,328 HERITAGE MED RES CTR,EDMONTON T6G 2S2,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 252,ALBERTA,CANADA	University of Alberta; University of Alberta								BAISTED DJ, 1988, BIOCHEM J, V253, P693, DOI 10.1042/bj2530693; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOY PC, 1979, CAN J BIOCHEM CELL B, V57, P605, DOI 10.1139/o79-076; COHEN P, 1989, J BIOL CHEM, V264, P21435; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P37, DOI 10.1016/0005-2760(87)90215-3; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; HATCH GM, 1990, BIOCHIM BIOPHYS ACTA, V1042, P374, DOI 10.1016/0005-2760(90)90167-V; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JAMIL H, 1987, J BIOL CHEM, V262, P630; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; LIM P, 1986, BIOCHEM CELL BIOL, V64, P692, DOI 10.1139/o86-095; PADDON HB, 1977, BIOCHIM BIOPHYS ACTA, V448, P181; PELECH SL, 1982, J BIOL CHEM, V257, P4198; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1983, BIOCHEM J, V216, P129, DOI 10.1042/bj2160129; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE JE, 1988, J BIOL CHEM, V263, P5898; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	30	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15751	15758						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322404				2022-12-25	WOS:A1992JG11300076
J	MORHAM, SG; SHUMAN, S				MORHAM, SG; SHUMAN, S			COVALENT AND NONCOVALENT DNA-BINDING BY MUTANTS OF VACCINIA DNA TOPOISOMERSE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICKING-CLOSING ENZYME; ACTIVE-SITE TYROSINE; ESCHERICHIA-COLI; CAMPTOTHECIN; CLEAVAGE; IDENTIFICATION; SEQUENCE; COMPLEX	Analysis of vaccinia topoisomerase mutants that are impaired in DNA relaxation has allowed the identification of amino acid residues required for the transesterification step of catalysis. Missense mutations of wild-type residues Gly-132 --> Asp and Arg-223 --> Gln rendered the protein inert in formation of the covalent enzyme-DNA complex and hence completely inactive in DNA relaxation. Mutations of Thr-147 --> Ile and Gly-132 --> Ser caused severe defects in covalent adduct formation that correlated with the extent of inhibition of relaxation. None of these point mutations had an effect on noncovalent DNA binding sufficient to account for the defect in relaxation. Deletion of amino- or carboxyl-terminal portions of the polypeptide abrogated noncovalent DNA binding. Two distinct topoisomerase-DNA complexes were resolved by native gel electrophoresis. One complex, which was unique to those proteins competent in covalent adduct formation, contained topoisomerase bound to the 5'-portion of the incised DNA strand. The 3'-segment of the cleaved strand had dissociated spontaneously. This complex was isolated and shown to catalyze transfer of the covalently bound DNA to a heterologous acceptor oligonucleotide, thereby proving that the covalent adduct between protein and duplex DNA is a true intermediate in strand breakage and reunion. The role of the active site region of eukaryotic topoisomerase in determining sensitivity or resistance to camptothecin was examined by converting the active site region of the resistant vaccinia enzyme (SKRAY274) to that of the drug-sensitive yeast enzyme (SKINY). The SKINY mutation did not alter the resistance of the vaccinia enzyme to the cleavage-enhancing effects of camptothecin.	CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Cornell University	MORHAM, SG (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MCCONAUGHY BL, 1981, BIOCHIM BIOPHYS ACTA, V655, P1, DOI 10.1016/0005-2787(81)90059-9; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69	19	59	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15984	15992						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322412				2022-12-25	WOS:A1992JG11300108
J	SPIVAKKROIZMAN, T; ROTIN, D; PINCHASI, D; ULLRICH, A; SCHLESSINGER, J; LAX, I				SPIVAKKROIZMAN, T; ROTIN, D; PINCHASI, D; ULLRICH, A; SCHLESSINGER, J; LAX, I			HETERODIMERIZATION OF C-ERBB2 WITH DIFFERENT EPIDERMAL GROWTH-FACTOR RECEPTOR MUTANTS ELICITS STIMULATORY OR INHIBITORY RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PHOSPHOLIPASE-C-GAMMA; EGF RECEPTOR; NEU ONCOGENE; SIGNAL TRANSDUCTION; POINT MUTATION; PHORBOL ESTERS; KIT RECEPTOR; PROTEIN; PHOSPHORYLATION	Ligand-induced dimerization of growth factor receptors is crucial for stimulation of their intrinsic protein tyrosine kinase activity promoting receptor autophosphorylation by an intermolecular mechanism. Moreover, the suppressive and negative dominant action of defective epidermal growth factor receptor (EGFR) was shown to be caused by formation of inactive heterodimers with normal EGFR leading to diminished biological signaling. In this report we explore the structural requirements and functional significance of heterodimerization between EGFR and HER2. HER2 (also called c-erbB-2 or neu) is a member of the EGFR family whose natural ligand is still unknown. We show that in response to EGF, wild type EGFR and various EGFR mutants were able to undergo heterodimerization with HER2. Addition of EGF to transfected cells co-expressing HER2 with a kinase negative point mutant of EGFR (K721A) stimulated heterodimer formation, tyrosine phosphorylation of K721A and HER2, and tyrosine phosphorylation of one of their known substrates, phospholipase C-gamma. However, the binding of EGF to transfected cells co-expressing HER2 together with another EGFR mutant CD533 (a deletion mutant lacking most of the cytoplasmic domain of EGFR) caused heterodimerization and inhibition of tyrosine kinase activity. It appears therefore that EGF-induced heterodimerization of EGFR and HER2 can promote either stimulatory or inhibitory influences on kinase activity. We propose that the nature of receptor interactions on the cell surface can either activate or inhibit the initiation of growth factor-controlled cellular signaling.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society	SPIVAKKROIZMAN, T (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.							AKIYAMA T, 1988, MOL CELL BIOL, V8, P1010; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHOU OK, 1987, NATURE, V328, P820; COCHET C, 1988, J BIOL CHEM, V263, P3290; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KING AC, 1982, J BIOL CHEM, V257, P3053; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LI W, 1991, MOL BIOL CELL, V2, P641; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS B, 1990, SCIENCE, V248, P435; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; REDEMANN N, 1992, IN PRESS MOL CELL BI; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTIN D, 1992, IN PRESS EMBO J; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P549; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1982, BIOPHYS METHODS EXP, V20, P197; Schlessinger J., 1979, PHYSICAL CHEM ASPECT, P89; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SKOLNIK EY, 1991, CELL, V65, P85; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	45	102	107	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8056	8063						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349015				2022-12-25	WOS:A1992HQ18500018
J	CHESSLER, SD; BYERS, PH				CHESSLER, SD; BYERS, PH			DEFECTIVE FOLDING AND STABLE ASSOCIATION WITH PROTEIN DISULFIDE ISOMERASE/PROLYL HYDROXYLASE OF TYPE-I PROCOLLAGEN WITH A DELETION IN THE PRO-ALPHA-2(I) CHAIN THAT PRESERVES THE GLY-X-Y REPEAT PATTERN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LETHAL OSTEOGENESIS IMPERFECTA; TRIPLE-HELICAL DOMAIN; ENDOPLASMIC-RETICULUM; SUBSTITUTION; SECRETION; GLYCINE; GENE	We have studied the folding, processing, and association with two endoplasmic reticulum (ER) resident proteins of the abnormal type I procollagen molecules produced by a strain of fibroblasts harboring a 4.5 kilobase deletion in an allele of COL1A2 (Willing, M. C., Cohn, D. H., Starman, B. Holbrook, K. A., Greenberg, C. R., and Byers, P. H. (1988) J. Biol. Chem. 263, 8398-8404). By sequencing cDNA, we found that the mutant allele encodes pro-alpha-2(I) chains that are shortened by 180 amino acids but retain the Gly-X-Y repeat pattern crucial for collagen triple helix formation. The type I procollagen molecules that incorporated the shortened chain were retained intracellularly and were stable. The triple helical domain in these molecules did not attain a normal conformation and remained accessible to posttranslational modifying enzymes amino-terminal to the deletion site for a prolonged period. The abnormal molecules folded into a triple helical conformation more slowly than the normal molecules, and the amino-terminal ends of the pro-alpha-1(I) chains failed to become protease-resistant. While the abnormal procollagen molecules were not bound by the ER-resident protein BiP, they stably associated with protein disulfide isomerase, the beta-subunit of prolyl-4-hydroxylase. These results indicate that some mutations in type I collagen genes both transiently delay folding and permanently disrupt the structure of the triple helix and suggest that binding to prolyl-4-hydroxylase helps to retain certain abnormal procollagen molecules within the ER.	UNIV WASHINGTON,DEPT PATHOL,SM-30,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,CTR INHERITED DIS,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Byers, Peter H./0000-0001-7786-7030	NIAMS NIH HHS [AR21557] Funding Source: Medline; NIGMS NIH HHS [GM07266-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSUK JA, 1989, MATRIX, V9, P244, DOI 10.1016/S0934-8832(89)80057-5; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P241; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; Gething M J, 1990, Semin Cell Biol, V1, P65; KAO WWY, 1979, J BIOL CHEM, V254, P2234; KIVIRIKKO KI, 1985, ANN NY ACAD SCI, V460, P187, DOI 10.1111/j.1749-6632.1985.tb51167.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; OLDEN K, 1979, P NATL ACAD SCI USA, V76, P791, DOI 10.1073/pnas.76.2.791; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WALLIS GA, 1990, J BIOL CHEM, V265, P18628; WARREN G, 1990, CELL, V62, P1, DOI 10.1016/0092-8674(90)90229-8; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WILLING MC, 1988, J BIOL CHEM, V263, P8398	27	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7751	7757						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1339453				2022-12-25	WOS:A1992HN48500078
J	LI, W; MACDONALD, RG; HEXUM, TD				LI, W; MACDONALD, RG; HEXUM, TD			ROLE OF SULFHYDRYL-GROUPS IN Y2 NEUROPEPTIDE-Y RECEPTOR-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; RAT-BRAIN; PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; CROSS-LINKING; MEMBRANES; NPY; NEURONS; SITES; IMMUNOREACTIVITY	Benextramine, a tetramine disulfide, irreversibly inhibits neuropeptide Y (NPY) binding to the 50-kDa Y2 NPY receptor in bovine hippocampus (Li, W., MacDonald, R. G., and Hexum, T. D. (1991) Eur. J. Pharmacol. 207, 89-91). Evidence is presented that this inhibition occurs through a thiol-disulfide exchange. Treatment of bovine hippocampal membranes with benextramine inhibited NPY affinity cross-linking to the 50-kDa receptor. This inhibition of labeling was not affected by washing the membranes, but could be completely reversed by the addition of several thiol reducing reagents, including reduced glutathione, beta-mercaptoethanol, and cysteine. Benextramine inhibited 70% of NPY-specific labeling and was much more effective than other sulfhydryl reactive agents, such as oxidized glutathione, cystamine, and 5,5'-dithio-bis(2-nitrobenzoic acid). Furthermore, the sulfhydryl-modifying agents N-ethylmaleimide and p-chloromercuriphenyl-sulfonic acid specifically decreased NPY affinity labeling. Finally, NPY labeling of the 50-kDa receptor was reduced by the heavy metal ions Zn2+, Cu2+, and Hg2+. Preincubation with NPY prevented Y2 receptors from being inactivated by either 400-mu-M N-ethylmaleimide or 1 mM benextramine. These results suggest that one or more benextramine-sensitive sulfhydryl groups on the Y2 receptor are important for NPY binding activity.	UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, 600 S 42ND ST, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT BIOCHEM, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026479] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26479] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRIAN TE, 1983, NATURE, V306, P584, DOI 10.1038/306584a0; ALLEN JM, 1985, CLIN SCI, V68, P373, DOI 10.1042/cs0680373; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; CHANG RSL, 1985, LIFE SCI, V37, P2111, DOI 10.1016/0024-3205(85)90583-1; CHERDCHU C, 1989, EUR J PHARMACOL, V173, P115, DOI 10.1016/0014-2999(89)90507-4; CHRONWALL BM, 1984, NEUROSCI LETT, V52, P213, DOI 10.1016/0304-3940(84)90164-2; DOUGHTY MB, 1990, EUR J PHARMACOL, V185, P113, DOI 10.1016/0014-2999(90)90218-U; GIMPL G, 1990, J BIOL CHEM, V265, P18142; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HEXUM TD, 1989, NEUROPEPTIDES, V13, P35, DOI 10.1016/0143-4179(89)90019-X; HOKFELT T, 1983, NEUROSCI LETT, V36, P217, DOI 10.1016/0304-3940(83)90003-4; INUI A, 1989, ENDOCRINOLOGY, V124, P402, DOI 10.1210/endo-124-1-402; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1991, EUR J PHARM-MOLEC PH, V207, P89, DOI 10.1016/S0922-4106(05)80042-2; LI W, 1991, BRAIN RES, V553, P167, DOI 10.1016/0006-8993(91)90246-R; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P393, DOI 10.1111/j.1748-1716.1982.tb07157.x; MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo-128-1-413; MANNON PJ, 1989, AM J PHYSIOL, V256, pG637, DOI 10.1152/ajpgi.1989.256.3.G637; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MELCHIORRE C, 1981, TRENDS PHARMACOL SCI, V2, P209, DOI 10.1016/0165-6147(81)90315-1; NGUYEN TD, 1990, J BIOL CHEM, V265, P6416; POTTER EK, 1988, PHARMACOL THERAPEUT, V37, P251, DOI 10.1016/0163-7258(88)90028-9; SHEIKH SP, 1989, FEBS LETT, V245, P209, DOI 10.1016/0014-5793(89)80223-6; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SHEIKH SP, 1990, J BIOL CHEM, V265, P8304; SMITH Y, 1985, J COMP NEUROL, V236, P71, DOI 10.1002/cne.902360107; STANLEY BG, 1984, LIFE SCI, V35, P2635, DOI 10.1016/0024-3205(84)90032-8; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; TATEMOTO K, 1989, NEUROPEPTIDE Y, P13; UNDEN A, 1984, EUR J BIOCHEM, V145, P525, DOI 10.1111/j.1432-1033.1984.tb08588.x; WAHLESTEDT C, 1989, PROG NEURO-PSYCHOPH, V13, P31, DOI 10.1016/0278-5846(89)90003-1; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WALKER MW, 1988, MOL PHARMACOL, V34, P779; WALKER MW, 1988, J NEUROSCI, V8, P2438	35	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7570	7575						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348506				2022-12-25	WOS:A1992HN48500054
J	OGISO, M; IRIE, A; KUBO, H; HOSHI, M; KOMOTO, M				OGISO, M; IRIE, A; KUBO, H; HOSHI, M; KOMOTO, M			SENILE CATARACT-RELATED ACCUMULATION OF LEWIS(X) GLYCOLIPID IN HUMAN LENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTIGEN SSEA-1; CELL-ADHESION; SIALYL-LEX; GLYCOSPHINGOLIPIDS; RECOGNITION; CHROMATOGRAPHY; GANGLIOSIDES; CARBOHYDRATE; MECHANISMS; EMBRYOS	A glycosphingolipid that reacted positively to anti-stage-specific embryonic antigen-1 (SSEA-1) anti-serum accumulated in human lens in association with aging and senile cataract formation. Since this anti-serum recognizes Lewis(x) (Le(x)) structure, Gal-beta-1-4(Fuc-alpha-1-3)GlcNAc-, which is a typical tumor-associated and differentiation-related saccharide chain, the lens glycolipid was predicted to be a Le(x) antigen. The glycolipid purified from cataractous lens tissues was indeed a Le(x) glycolipid, Gal-beta-1-4(Fuc-alpha-1-3)GlcNAc-beta-1-3Gal-beta-1-4Glc-beta-1-1 ceramide. Enhanced expression of the Le(x) glycolipid may affect the organization of lens plasma membranes through Le(x)-Le(x) interactions, as suggested for compaction in mouse preimplantation embryos and embryonic teratocarcinomas, resulting in lens opacification, namely cataract.	TOHO UNIV,SCH MED,DEPT PHYSIOL & OPHTHALMOL,TOKYO 143,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN	Toho University; Tokyo Institute of Technology								ANDO S, 1976, BIOCHIM BIOPHYS ACTA, V424, P98; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; CHYLACK LT, 1984, OPHTHALMOLOGY, V91, P596; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; HAKOMORI S, 1981, BIOCHEM BIOPH RES CO, V100, P1578, DOI 10.1016/0006-291X(81)90699-9; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HIGASHI H, 1984, J BIOCHEM-TOKYO, V95, P1517, DOI 10.1093/oxfordjournals.jbchem.a134760; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; IRIE A, 1990, J BIOCHEM-TOKYO, V108, P531, DOI 10.1093/oxfordjournals.jbchem.a123237; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KANNAGI R, 1987, METHOD ENZYMOL, V138, P3, DOI 10.1016/0076-6879(87)38003-6; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KNOWLES BB, 1980, NATURE, V288, P615, DOI 10.1038/288615a0; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; LAINE RA, 1975, J LIPID RES, V16, P102; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LEDEEN RW, 1973, J NEUROCHEM, V21, P829, DOI 10.1111/j.1471-4159.1973.tb07527.x; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; OGISO M, 1990, INVEST OPHTH VIS SCI, V31, P243; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOLTER D, 1979, DEV BIOL, V70, P515, DOI 10.1016/0012-1606(79)90043-5; TAO R V P, 1983, Current Eye Research, V2, P427; TAO RVP, 1983, BIOCHIM BIOPHYS ACTA, V753, P89, DOI 10.1016/0005-2760(83)90102-9; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275	31	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6467	6470						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348055				2022-12-25	WOS:A1992HM05300005
J	MARTINEZBLANCO, H; REGLERO, A; FERNANDEZVALVERDE, M; FERRERO, MA; MORENO, MA; PENALVA, MA; LUENGO, JM				MARTINEZBLANCO, H; REGLERO, A; FERNANDEZVALVERDE, M; FERRERO, MA; MORENO, MA; PENALVA, MA; LUENGO, JM			ISOLATION AND CHARACTERIZATION OF THE ACETYL-COA SYNTHETASE FROM PENICILLIUM-CHRYSOGENUM - INVOLVEMENT OF THIS ENZYME IN THE BIOSYNTHESIS OF PENICILLINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ISOPENICILLIN-N SYNTHETASE; ACID TRANSPORT-SYSTEM; PHENYLACETYL-COA; ASPERGILLUS-NIDULANS; WIS 54-1255; HOMOCITRATE SYNTHASE; FATTY-ACIDS; PURIFICATION; ACYLTRANSFERASE	Acetyl-CoA synthetase (ACS) of Penicillium chrysogenum was purified to homogeneity (745-fold) from fungal cultures grown in a chemically defined medium containing acetate as the main carbon source. The enzyme showed maximal rate of catalysis when incubated in 50 mM HCl-Tris buffer, pH 8.0, at 37-degrees-C. Under these conditions, ACS showed hyperbolic behavior against acetate, CoA, and ATP; the K(m) values calculated for these substrates were 6.8, 0.18, and 17 mM, respectively. ACS recognized as substrates not only acetate but also several fatty acids ranging between C2 and Ca and some aromatic molecules (phenylacetic, 2-thiopheneacetic, and 3-thiopheneacetic acids). ATP can be replaced by ADP although, in this case, a lower activity was observed (37%). ACS is inhibited by some thiol reagents (5,5'-dithiobis(nitrobenzoic acid), N-ethylmaleimide, p-chloromercuribenzoate) and divalent cations (Zn2+, Cu2+, and Hg2+), whereas it was stimulated when the reaction mixtures contained 1 mM dithiothreitol, reduced glutathione, or 2-mercaptoethanol. The calculated molecular mass of ACS was 139 +/- 1 kDa, and the native enzyme is composed of two apparent identical subunits (70 kDa) in an alpha-2 oligomeric structure. ACS activity was regulated "in vivo" by carbon catabolite inactivation when glucose was taken up by cells in which the enzyme had been previously induced. This enzyme can be coupled "in vitro" to acyl-CoA:6-aminopenicillanic acid acyltransferase from P. chrysogenum, thus allowing the reconstitution of the functional enzymatic system which catalyzes the two latter reactions responsible for the biosynthesis of different penicillins. The ACS from Aspergillus nidulans can also be coupled to 6-aminopenicillanic acid acyltransferase to synthesize penicillins. These results strongly indicate that this enzyme can catalyze the activation (to their CoA thioesters) of some of the side-chain precursors required in these two fungi for the production of several penicillins. All these data are reported here for the first time.	UNIV LEON, FAC VET, DEPT BIOQUIM & BIOL MOLEC, E-24007 LEON, SPAIN; CONSEJO SUPER INVEST CIENTIFICAS, E-28006 MADRID, SPAIN; ANTIBIOT SA LEON, DEPT BIOQUIM, LEON, SPAIN	Universidad de Leon; Consejo Superior de Investigaciones Cientificas (CSIC)			Penalva, Miguel A/G-2295-2015; Luengo, Jose M./E-1935-2016	Penalva, Miguel A/0000-0002-3102-2806; Luengo, Jose M./0000-0002-4984-6256; Moreno Valle, Miguel Angel/0000-0002-1419-6898; Martinez Blanco, Honorina/0000-0003-4591-2321; Ferrero Garcia, Miguel Angel/0000-0002-4335-0372				ALONSO MJ, 1988, J ANTIBIOT, V41, P1074, DOI 10.7164/antibiotics.41.1074; BADOR H, 1984, BIOCHIMIE, V66, P223, DOI 10.1016/0300-9084(84)90066-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HD, 1975, J BACTERIOL, V121, P959, DOI 10.1128/JB.121.3.959-969.1975; Brunner R, 1975, Methods Enzymol, V43, P476; BURNETT JH, 1976, FUNDAMENTALS MYCOLOG, P238; CONNERTON IF, 1990, MOL MICROBIOL, V4, P451, DOI 10.1111/j.1365-2958.1990.tb00611.x; DEMAIN AL, 1974, J GEN MICROBIOL, V82, P143, DOI 10.1099/00221287-82-1-143; DUNTZE W, 1968, EUR J BIOCHEM, V3, P326, DOI 10.1111/j.1432-1033.1968.tb19533.x; Fawcett P, 1975, Methods Enzymol, V43, P471; FERNANDEZCANON JM, 1989, J ANTIBIOT, V42, P1410, DOI 10.7164/antibiotics.42.1410; FERNANDEZCANON JM, 1989, J ANTIBIOT, V42, P1398, DOI 10.7164/antibiotics.42.1398; FLOREY HW, 1949, ANTIBIOTICS, V2; FRENKEL EP, 1977, J BIOL CHEM, V252, P504; FRIEDRICH CG, 1977, J ANTIBIOT, V30, P760, DOI 10.7164/antibiotics.30.760; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GANCEDO C, 1976, ARCH MICROBIOL, V109, P221, DOI 10.1007/BF00446632; Gancedo C., 1989, YEASTS, V3, P205; GEISSLER JF, 1988, J BACTERIOL, V170, P1709, DOI 10.1128/jb.170.4.1709-1714.1988; GORTS CPM, 1969, BIOCHIM BIOPHYS ACTA, V184, P299, DOI 10.1016/0304-4165(69)90032-4; HOLZ G, 1974, METHOD ENZYMAT AN, V3, P1528; IMESCH E, 1984, INT J BIOCHEM, V16, P875, DOI 10.1016/0020-711X(84)90146-0; JETTEN MSM, 1989, J BACTERIOL, V171, P5430, DOI 10.1128/jb.171.10.5430-5435.1989; KESTON AS, 1956, 5TH M AM CHEM SOC DA, P310; KOGEKAR RG, 1983, INDIAN J BIOCHEM BIO, V20, P208; KONOMI T, 1979, BIOCHEM J, V184, P427, DOI 10.1042/bj1840427; LENZ AG, 1980, FEBS LETT, V109, P271, DOI 10.1016/0014-5793(80)81103-3; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LUENGO JM, 1986, BIO-TECHNOL, V4, P44, DOI 10.1038/nbt0186-44; LUENGO JM, 1986, J ANTIBIOT, V39, P1565, DOI 10.7164/antibiotics.39.1565; LUENGO JM, 1986, J ANTIBIOT, V39, P1754, DOI 10.7164/antibiotics.39.1754; LUENGO JM, 1980, J BACTERIOL, V144, P869, DOI 10.1128/JB.144.3.869-876.1980; MAGASANIK B, 1961, COLD SPRING HARB SYM, V26, P249, DOI 10.1101/SQB.1961.026.01.031; MARTINEZBLANCO H, 1989, J ANTIBIOT, V42, P1416, DOI 10.7164/antibiotics.42.1416; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MARTINVILLACORTA J, 1990, J ANTIBIOT, V43, P1559, DOI 10.7164/antibiotics.43.1559; MARTINVILLACORTA J, 1989, J ANTIBIOT, V42, P1502, DOI 10.7164/antibiotics.42.1502; MASUREKAR PS, 1972, CAN J MICROBIOL, V18, P1045, DOI 10.1139/m72-162; MATERN H, 1977, J BIOL CHEM, V252, P6399; MAZON MJ, 1982, EUR J BIOCHEM, V127, P605; OSULLIVAN J, 1979, BIOCHEM J, V184, P421, DOI 10.1042/bj1840421; RAMON D, 1987, GENE, V57, P171, DOI 10.1016/0378-1119(87)90120-X; RAMOS FR, 1985, ANTIMICROB AGENTS CH, V27, P380, DOI 10.1128/AAC.27.3.380; REVILLA G, 1986, J BACTERIOL, V168, P947, DOI 10.1128/jb.168.2.947-952.1986; ROMANO AH, 1969, PROC R SOC SER B-BIO, V173, P475, DOI 10.1098/rspb.1969.0072; SANDEMAN RA, 1989, MOL GEN GENET, V218, P87, DOI 10.1007/BF00330569; SMITH DJ, 1990, BIO-TECHNOL, V8, P39, DOI 10.1038/nbt0190-39; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; WALLACH D, 1976, J BIOL CHEM, V251, P5802; WEBER K, 1969, J BIOL CHEM, V244, P4406; WHITEMAN PA, 1990, FEBS LETT, V262, P342, DOI 10.1016/0014-5793(90)80224-7; Wrigley C.W., 1971, METHOD ENZYMOL, V22, P559	52	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5474	5481						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1347531				2022-12-25	WOS:A1992HH74700072
J	KANOH, H; IMAI, S; YAMADA, K; SAKANE, F				KANOH, H; IMAI, S; YAMADA, K; SAKANE, F			PURIFICATION AND PROPERTIES OF PHOSPHATIDIC-ACID PHOSPHATASE FROM PORCINE THYMUS MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DIACYLGLYCEROL KINASE; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; HUMAN-NEUTROPHILS; PHOSPHOLIPASE-D; PHOSPHOHYDROLASE ACTIVITIES; KINETIC-ANALYSIS; MIXED MICELLES	We purified phosphatidic acid phosphatase (EC 3.1.3.4) 2300-fold from porcine thymus membranes. The enzyme was solubilized with beta-octyl glucoside and Triton X-100 and fractionated with ammonium sulfate. The purification was then achieved by chromatography in the presence of Triton X-100 with Sephacryl S-300, hydroxylapatite, heparin-Sepharose, and Affi-Gel Blue. The final enzyme preparation gave a single band of M(r) = 83,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing and nonreducing conditions. The native enzyme, on the other hand, was eluted at M(r) = 218,000 in gel filtration chromatography with Superose 12 in the presence of Triton X-100. The enzyme was judged to be specific to phosphatidic acid, since excess amounts of dicetylphosphate or lysophosphatidic acid did not inhibit the enzyme activity. In this respect, the enzyme was inhibited by 1,2-diacylglycerol but not by 1- or 2-monoacylglycerol and triacylglycerol. The enzyme required Triton X-100 or deoxycholate for its activity. Although the enzyme appeared to be an integral membrane protein, we could not detect its phospholipid dependencies. The activity was independent of Mg2+, and other cations were strongly inhibitory. The specific enzyme activity was 15 mumol/min/mg of protein when assayed using phosphatidic acid as Triton X-100 mixed micelles. The K(m) for the surface concentration of phosphatidic acid was 0.30 mol %. The enzyme was inhibited by sphingosine and chlorpromazine, and less potently, by propranolol and NaF. The enzyme was insensitive to thio-reactive reagents like N-ethylmaleimide.			KANOH, H (corresponding author), SAPPORO MED COLL,DEPT BIOCHEM,WEST 17,SOUTH 1,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN.		Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377				ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BRINDLEY DN, 1988, PHOSPHATIDATE PHOSPH, V1, P1; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; EPAND RM, 1990, BIOCHEM BIOPH RES CO, V171, P487, DOI 10.1016/0006-291X(90)91419-S; EXTON JH, 1990, J BIOL CHEM, V265, P1; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; HII CST, 1991, J BIOL CHEM, V266, P20238; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; HOSAKA K, 1975, J BIOCHEM-TOKYO, V77, P501, DOI 10.1093/oxfordjournals.jbchem.a130751; IDE H, 1989, ARCH BIOCHEM BIOPHYS, V271, P177, DOI 10.1016/0003-9861(89)90268-3; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; MARTIN A, 1987, BIOCHEM J, V245, P347, DOI 10.1042/bj2450347; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; QIAN Z, 1990, J BIOL CHEM, V265, P3607; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WALTON PA, 1989, BIOCHEM J, V261, P673, DOI 10.1042/bj2610673; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMADA K, 1988, BIOCHEM J, V255, P601	42	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25309	25314						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334090				2022-12-25	WOS:A1992KB60300061
J	FOROOZAN, R; RUEDI, JM; BABIOR, BM				FOROOZAN, R; RUEDI, JM; BABIOR, BM			THE REDUCTION OF CYTOCHROME-B558 AND THE ACTIVITY OF THE RESPIRATORY BURST OXIDASE FROM HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE-GENERATING OXIDASE; FULLY SOLUBLE SYSTEM; NADPH OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES; ACTIVATION; PURIFICATION; GRANULOCYTES; KINETICS	It is known that in respiratory burst oxidase preparations engaged in O2- production, cytochrome b558, a characteristic oxidase component, is partly reduced. This result has been interpreted in terms of a mechanism in which cytochrome b558 functions as an electron-carrying component of the respiratory burst oxidase, its level of reduction reflecting a steady-state partitioning of the cytochrome between reduced and oxidized forms as it ferries electrons from. NADPH to oxygen. Kinetic arguments based on this interpretation have supported the proposal that the cytochrome is reduced at a rate sufficient to account for the rate of O2- production by activated neutrophils. We have confirmed the partial reduction of cytochrome b558 in neutrophil cytoplasts and in oxidase preparations exposed to NADPH, but have found that the reduction of the cytochrome bears no apparent relation to the activity of the oxidase, and can occur when NADPH is added to neutrophil membrane preparations that are unable to manufacture O2-. We therefore conclude that the NADPH-dependent reduction of cytochrome b558 seen in these preparations is unlikely to be a reflection of a catalysis-related steady state and that inferences drawn from such observations regarding the kinetic competence of the cytochrome may need to be reconsidered.			FOROOZAN, R (corresponding author), SCRIPPS RES INST, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024227, R37AI024227, R01AI030742, R21AI130742, R01AI028479] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24227, AI-28479, AI-30742] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BABIOR BM, 1992, ADV ENZYMOL, V65, P49; BABIOR BM, 1981, LEUKOCYTE FUNCTION, P35; BORREGAARD N, 1990, J CLIN INVEST, V85, P408, DOI 10.1172/JCI114453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; CROSS AR, 1984, BIOCHEM J, V223, P337, DOI 10.1042/bj2230337; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; GABIG TG, 1982, J BIOL CHEM, V257, P4114; GLASS GA, 1986, J BIOL CHEM, V261, P3247; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; HARPER AM, 1984, BIOCHEM J, V219, P519, DOI 10.1042/bj2190519; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; KORCHAK HM, 1983, P NATL ACAD SCI-BIOL, V80, P4968, DOI 10.1073/pnas.80.16.4968; LIGHT DR, 1981, BIOCHEMISTRY-US, V20, P1468, DOI 10.1021/bi00509a010; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; PICK E, 1987, J BIOL CHEM, V262, P16476; SEGAL AW, 1988, HEMATOL ONCOL CLIN N, V2, P213, DOI 10.1016/S0889-8588(18)30616-6; SEGER RA, 1983, BLOOD, V61, P423; SMITH RM, 1991, BLOOD, V77, P673; SWITZER R L, 1989, Biofactors, V2, P77; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	28	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24400	24407						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332956				2022-12-25	WOS:A1992KA26300042
J	LAHERTY, CD; HU, HM; OPIPARI, AW; WANG, F; DIXIT, VM				LAHERTY, CD; HU, HM; OPIPARI, AW; WANG, F; DIXIT, VM			THE EPSTEIN-BARR-VIRUS LMP1-GENE PRODUCT INDUCES A20-ZINC FINGER PROTEIN EXPRESSION BY ACTIVATING NUCLEAR FACTOR-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR NECROSIS FACTOR; HUMAN IMMUNODEFICIENCY VIRUS; FACTOR-ALPHA; INTERLEUKIN-1 STIMULATE; BNLF-1 ONCOGENE; GENE-EXPRESSION; CELL LINES; INFECTION; TRANSCRIPTION; INDUCTION	A20 is an inducible zinc finger protein that confers resistance to tumor necrosis factor alpha cytotoxicity. A survey of various cell lines revealed that A20 was constitutively expressed in Epstein-Barr virus (EBV)-immortalized B-cells. Transfection experiments demonstrated that the EBV latent membrane protein LMP1 induced A20 expression. LMP1 is a transforming protein of EBV that has dramatic effects on cell growth, activation, and survival. An integral membrane phosphoprotein, LMP1 bears no homology to other recognized membrane signaling molecules, and its signal transduction pathway is not known. However, studies using the A20 promoter demonstrated that LMP1 transcriptionally activates the A20 gene through cis-acting kappaB sites. In addition, electrophoretic mobility shift assays confirmed LMP1-inducible binding of an NF-kappaB-like factor to kappaB sequences within the A20 promoter. This is the first report implicating NF-kappaB in signaling by LMP1, a fundamentally important viral transforming protein.	UNIV MICHIGAN, SCH MED, CELLULAR & MOLEC BIOL PROGRAM, ANN ARBOR, MI 48109 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MOLEC GENET, BOSTON, MA 02115 USA	University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	LAHERTY, CD (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Hu, Hong-Ming/0000-0002-2206-3470	NHLBI NIH HHS [HL 45351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BAICHWAL VR, 1989, ONCOGENE, V4, P67; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; GAFFEY MJ, 1992, PATHOL ANNU, V27, P55; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; KIEFF E, 1990, VIROLOGY, P1889; KRANSOW SW, 1991, CYTOKINE, V3, P1; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MURRAY RJ, 1988, J VIROL, V62, P894, DOI 10.1128/JVI.62.3.894-901.1988; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	33	379	388	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24157	24160						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332946				2022-12-25	WOS:A1992KA26300003
J	BUCK, E; ZIMANYI, I; ABRAMSON, JJ; PESSAH, IN				BUCK, E; ZIMANYI, I; ABRAMSON, JJ; PESSAH, IN			RYANODINE STABILIZES MULTIPLE CONFORMATIONAL STATES OF THE SKELETAL-MUSCLE CALCIUM RELEASE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; NEGATIVELY CHARGED HOMOTETRAMER; CA-2+ RELEASE; TERMINAL CISTERNAE; RECEPTOR COMPLEX; FEET STRUCTURES; CARDIAC-MUSCLE; BINDING; PURIFICATION; RECONSTITUTION	Nanomolar to micromolar ryanodine alters the gating kinetics of the Ca2+ release channel from skeletal sarcoplasmic reticulum (SR) fused with bilayer lipid membranes (BLM). In the presence of asymmetric CsCl and 100 muM CaCl2 cis, ryanodine (RY) (5-40 nM) activates the channel, increasing the open probability (p(o);maximum 300% of control) without changing unitary conductance (468 picosiemens (pS)). Statistical analyses of gating kinetics reveal that open and closed dwell times exhibit biexponential distributions and are significantly modified by nanomolar RY. Altered channel gating kinetics with low nanomolar RY is fully reversible and correlates well with binding kinetics of nanomolar [H-3]RY with its high affinity site (K(d1) = 0.7 nM) under identical experimental conditions. RY (20-50 nM) induces occasional 1/2 conductance fluctuations which correlate with [H-3]RY binding to a second site having lower affinity (K(d2) = 23 nm). RY (5-50 nM) in the presence of 500 mM CsCl significantly enhances Ca2+-induced Ca2+ release from actively loaded SR vesicles. Ryanodine greater-than-or-equal-to 50 nM stabilizes the channel in a 234-pS subconductance which is not readily reversible. RY (greater-than-or-equal-to 70 muM) produces a unidirectional transition from the 1/2 to a 1/4 conductance fluctuation, whereas RY greater-than-or-equal-to 200 muM causes complete closure of the channel. The RY required for stabilizing 1/4 conductance transitions and channel closure do not quantitatively correlate with [H-3]RY equilibrium binding constants and is attributed to significant reduction in association kinetics with >200 nM [H-3]RY in the presence of 500 mM CsCl. These results demonstrate that RY stabilizes four discrete states of the SR release channel and supports the existence of multiple interacting RY effector sites on the channel protein.	UNIV CALIF DAVIS,DEPT VET PHARMACOL & TOXICOL,DAVIS,CA 95616; PORTLAND STATE UNIV,DEPT PHYS,PORTLAND,OR 97207	University of California System; University of California Davis; Portland State University			Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NIEHS NIH HHS [ES05002] Funding Source: Medline; NIGMS NIH HHS [GM 44337] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005002, R29ES005002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM044337] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750; ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CARROLL S, 1991, ARCH BIOCHEM BIOPHYS, V290, P239, DOI 10.1016/0003-9861(91)90615-P; CHU A, 1990, MOL PHARMACOL, V37, P735; CORONADO R, 1979, NATURE, V280, P807, DOI 10.1038/280807a0; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; HYMEL L, 1988, BIOCHEM BIOPH RES CO, V152, P308, DOI 10.1016/S0006-291X(88)80715-0; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; OGAWA Y, 1990, J BIOCHEM-TOKYO, V107, P887, DOI 10.1093/oxfordjournals.jbchem.a123143; PALADE P, 1987, J BIOL CHEM, V262, P6135; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SAITO A, 1988, J CELL BIOL, V107, P211, DOI 10.1083/jcb.107.1.211; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WATERHOUSE AL, 1984, J CHEM SOC CHEM COMM, P1265, DOI 10.1039/c39840001265; WYSKOVSKY W, 1990, EUR J BIOCHEM, V194, P549, DOI 10.1111/j.1432-1033.1990.tb15651.x; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938; ZIMANYI I, 1992, IN PRESS MOL PHARM	35	139	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23560	23567						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331089				2022-12-25	WOS:A1992JZ23900024
J	LELONGT, B; PIEDAGNEL, R; CHATELET, F; BAUDOUIN, B; BRENCHLEY, PEC; VERROUST, PJ; CASSINGENA, R; VANDEWALLE, A; RONCO, PM				LELONGT, B; PIEDAGNEL, R; CHATELET, F; BAUDOUIN, B; BRENCHLEY, PEC; VERROUST, PJ; CASSINGENA, R; VANDEWALLE, A; RONCO, PM			DRAMATIC CHANGES OF SULFATED PROTEOGLYCANS COMPOSITION IN A TUMORIGENIC SV-40-TRANSFORMED RENAL PROXIMAL-TUBULE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER HYDROLASES; HAMSTER-KIDNEY CELLS; ROUS-SARCOMA VIRUS; HEPARAN-SULFATE; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; GLYCOSAMINOGLYCAN SYNTHESIS; SKIN FIBROBLASTS; SIMIAN VIRUS-40; TRANSFORMATION	To characterize the sulfated proteoglycans (PGs) alterations associated with malignant transformation of epithelial cells in vitro, the localization, charge, size, and composition of cell-associated and secreted sulfated PGs have been compared in rabbit renal proximal-tubule cells in primary culture (Ronco et al., 1990) and in a derived SV-40 transformed cell line (RC.SV1) exhibiting a proximal phenotype and high tumor-inducing ability (Vandewalle et al., 1989). Both normal and transformed cells incorporated PGs into a thick basement membrane layer as shown by ruthenium red staining and immunodetection with a monoclonal antibody raised against the core protein of the bovine basement membrane heparan sulfate-PG (HS-PG). In primary cultures of normal cells, cell-associated PGs were almost identical to those extracted from renal tubule fractions in vivo by their size (K(av) = 0.27 vs. 0.26 on Sepharose CL-6B) and composition characterized by the exclusive presence of heparan sulfate glycosaminoglycan (HS-GAG) chains. In addition, the cells secreted a HS-PG with similar biochemical characteristics (K(av) = 0.29; 100% HS-GAG chains). The SV-40-transformed RC.SV1 cells also synthesized and secreted a unique PG with the same charge and K(av) values and apparently the same core protein (35 kDa) as in nontransformed cells, but three major differences were observed: (i) an increased proportion of PG-associated [S-35]sulfate radioactivity released into the culture medium (36 vs. 21%), (ii) the emergence of free GAG chains unincorporated into PGs and detected only in the cell-associated fraction, and (iii) a dramatic change in the composition of GAG chains in which chondroitin sulfate replaced heparan-sulfate. The latter finding is in keeping with the known chondroitin sulfate increase and heparan-sulfate decrease in epithelial tumors. The alterations of PGs observed in this study may play a role in the acquisition and/or maintenance of the malignant phenotype.	UER XAVIER BICHAT,U246,PARIS,FRANCE; HOP TENON,HISTOL & CYTOL PATHOL LAB,F-75970 PARIS 20,FRANCE; CNRS,UPR 42,F-94800 VILLEJUIF,FRANCE; ST MARYS HOSP,DEPT IMMUNOL,MANCHESTER M13 0JH,LANCS,ENGLAND	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); University of Manchester	LELONGT, B (corresponding author), HOP TENON,INSERM,U64,4 RUE CHINE,F-75970 PARIS 20,FRANCE.		Piedagnel, Remi/C-7427-2017; lelongt, brigitte/N-3746-2017; Ronco, Pierre/AAC-8390-2022	lelongt, brigitte/0000-0002-9308-8798; Piedagnel, Remi/0000-0002-5931-1271; Brenchley, Paul/0000-0003-1290-9919				BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; CASTELLOT JJ, 1987, SEMIN THROMB HEMOST, V13, P489, DOI 10.1055/s-2007-1003525; DAVID G, 1983, J BIOL CHEM, V258, P7338; DROZ D, 1990, AM J PATHOL, V137, P895; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; HOPWOOD JJ, 1978, PEDIATR RES, V12, P52, DOI 10.1203/00006450-197801000-00013; HOPWOOD JJ, 1977, J BIOL CHEM, V252, P4777; HORVAT R, 1986, J CELL BIOL, V102, P484, DOI 10.1083/jcb.102.2.484; IOZZO R V, 1982, Journal of Biological Chemistry, V257, P11135; IOZZO RV, 1985, LAB INVEST, V53, P373; IOZZO RV, 1988, CANCER METAST REV, V7, P39, DOI 10.1007/BF00048277; JOHNSTON LS, 1979, BIOCHIM BIOPHYS ACTA, V583, P81, DOI 10.1016/0304-4165(79)90312-X; KELLER KL, 1980, BIOCHEMISTRY-US, V19, P2529, DOI 10.1021/bi00552a035; KOJIMA J, 1975, CANCER RES, V35, P542; KRAEMER PM, 1972, J CELL BIOL, V55, P713, DOI 10.1083/jcb.55.3.713; LELONGT B, 1988, P NATL ACAD SCI USA, V85, P9047, DOI 10.1073/pnas.85.23.9047; LEVY P, 1990, CANCER RES, V50, P6716; LIOTTA LA, 1983, LAB INVEST, V49, P636; OHKUBO Y, 1983, CANCER RES, V43, P2712; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; PARTHASARATHY N, 1984, J BIOL CHEM, V259, P2749; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; RONCO P, 1990, J CELL PHYSIOL, V145, P222, DOI 10.1002/jcp.1041450206; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SHANLEY DJ, 1983, J BIOL CHEM, V258, P810; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; SUGAHARA K, 1985, J BIOCHEM-TOKYO, V98, P875, DOI 10.1093/oxfordjournals.jbchem.a135367; TAUC M, 1988, J HISTOCHEM CYTOCHEM, V36, P523, DOI 10.1177/36.5.2895788; UNDERHILL CB, 1975, BIOCHEM BIOPH RES CO, V63, P448, DOI 10.1016/0006-291X(75)90708-1; VANDEWALLE A, 1989, J CELL PHYSIOL, V141, P203, DOI 10.1002/jcp.1041410128; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; YANAGISHITA M, 1983, J BIOL CHEM, V258, P2847	33	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23815	23822						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331101				2022-12-25	WOS:A1992JZ23900059
J	CARDARELLI, PM; YAMAGATA, S; TAGUCHI, I; GORCSAN, F; CHIANG, SL; LOBL, T				CARDARELLI, PM; YAMAGATA, S; TAGUCHI, I; GORCSAN, F; CHIANG, SL; LOBL, T			THE COLLAGEN RECEPTOR-ALPHA-2-BETA-1, FROM MG-63 AND HT1080-CELLS, INTERACTS WITH A CYCLIC RGD PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; CELL-ADHESION; ALPHA-2-BETA-1 INTEGRIN; EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR; BINDING-SPECIFICITY; DEPENDENT ADHESION; LAMININ RECEPTOR; DIVALENT-CATIONS; IDENTIFICATION	Several receptors for the extracellular matrix protein collagen have been described which belong to the superfamily of receptors collectively known as integrins. Although several integrins have been shown to interact with extracellular matrix molecules via a common recognition site, arginine-glycine-aspartic Acid (RGD), within the beta1 integrin subfamily, only the fibronectin receptor (alpha5beta1) has been convincingly shown to interact with RGD. In the present study, we tested whether a collagen receptor could interact with RGD. Adhesion of an osteosarcoma cell line, MG-63, to immobilized collagen I was inhibited by the cyclic RGD-containing peptide, C*GRGDSPC* (where C* indicates that Cys participates in disulfide), and not by the linear GRGDSP or the non-RGD-containing cyclic peptide, C*GKGESPC*. Similarly, using collagen-Sepharose affinity chromatography, a heterodimeric protein could be specifically eluted from the column by the cyclic RGD peptide. Immunoprecipitations of the eluted material with monoclonal antibodies showed reactivity with the collagen receptor alpha2beta1 and not alpha3beta1. Our data demonstrate that RGD peptides can interact with the collagen receptor, and the differences seen with the linear and cyclic peptide suggest that the cyclic C*GRGDSPC* has a higher avidity for the receptor than the more flexible linear GRGDSP. In this paper, we provide supportive evidence that one possible mode of collagen interaction with alpha2beta1 is via the RGD recognition sequence.	TANABE SEIYAKU CO LTD,APPL BIOCHEM RES LAB,OSAKA 532,JAPAN	Mitsubishi Tanabe Pharma Corporation	CARDARELLI, PM (corresponding author), TANABE RES LABS,SAN DIEGO,CA 92121, USA.							ADAMSON ED, 1983, COLLAGEN HLTH DISEAS, P218; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; BARANY G, 1980, PEPTIDES ANAL SYNTHE, P3; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; CARDARELLI PM, 1986, P NATL ACAD SCI USA, V83, P2647, DOI 10.1073/pnas.83.8.2647; DEDHAR S, 1987, J CELL BIOL, V104, P585, DOI 10.1083/jcb.104.3.585; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GULLBERG D, 1989, J BIOL CHEM, V264, P12686; Hay E.D., 1981, CELL BIOL EXTRACELLU, P379, DOI [10.1007/978-1-4613-0881-2_13, DOI 10.1007/978-1-4613-0881-2_13]; HRUBY VJ, 1982, LIFE SCI, V31, P189, DOI 10.1016/0024-3205(82)90578-1; HRUBY VJ, 1983, DESIGN SYNTHESIS ORG, P269; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; MILLER EJ, 1983, CONNECTIVE TISSUE BI, P41; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; VONKAMBER B, 1971, HELV CHIM ACTA, V54, P927; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WRIGHT SD, 1987, P NATL ACAD SCI USA, V84, P1965, DOI 10.1073/pnas.84.7.1965	38	81	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23159	23164						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331077				2022-12-25	WOS:A1992JY16300070
J	BAIRD, PN; GROVES, N; HABER, DA; HOUSMAN, DE; COWELL, JK				BAIRD, PN; GROVES, N; HABER, DA; HOUSMAN, DE; COWELL, JK			IDENTIFICATION OF MUTATIONS IN THE WT1 GENE IN TUMORS FROM PATIENTS WITH THE WAGR SYNDROME	ONCOGENE			English	Article							ZINC-FINGER GENE; WILMS-TUMOR; BAND 11P13; HUMAN CHROMOSOME-11; ANIRIDIA; DELETION; HETEROZYGOSITY; ASSOCIATION; REGION; LOCUS	Individuals with constitutional, heterozygous deletions of chromosome region 11p13 are predisposed to the development of Wilms' tumour, indicating the site of the tumour predisposition gene. The WT1 gene is a candidate for this cancer predisposition gene. If this gene is truely involved in tumorigenesis it would be expected to be mutant in tumour tissue from patients with 11p13 deletions. We have used single-stranded conformation polymorphism (SSCP) and polymerase chain reaction sequencing to test this hypothesis in an exon-by-exon analysis of the gene. Four tumours were analysed, two of which were from unilaterally affected individuals and two from a bilaterally affected patient. SSCP analysis identified mutations in the two unilateral tumours which, on sequencing, were shown to involve a 10-bp insertion in exon 7 and a single base pair change in exon 8. Both mutations result in the generation of premature stop codons and the predicted proteins would lack part of the zinc finger motif. Despite complete sequencing of the WT] gene in both of the bilateral tumours, no mutations were identified. These results possibly suggest that WT1 may not be involved in tumorigenesis in all tumours. All four tumours retained heterozygosity in the 11p15 region, making it unlikely that a second recessive oncogene in this re ion was involved in tumorigenicity.	ICRF ONCOL GRP,INST CHILD HLTH,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	University of London; University College London; Massachusetts Institute of Technology (MIT)				Baird, Paul/0000-0002-1305-3502; Cowell, John/0000-0002-2079-5950				BAIRD P, 1991, ONCOGENE, V6, P1147; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1988, ANAL BIOCHEM, V173, P93; COUILLIN P, 1989, HUM GENET, V82, P171, DOI 10.1007/BF00284053; COWELL JK, 1991, ONCOGENE, V6, P595; COWELL JK, 1989, HUM GENET, V82, P123, DOI 10.1007/BF00284042; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P375; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HENRY I, 1989, HUM GENET, V81, P273, DOI 10.1007/BF00279003; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOGG A, 1992, ONCOGENE, V7, P1444; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LEMOINE NR, 1992, IN PRESS J PATHOL; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MORRIS JF, 1991, ONCOGENE, V6, P2339; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PAL N, 1990, ONCOGENE, V5, P1665; PAL N, 1991, ONCOGENE, V252, P800; PAVLETICH NP, 1991, SCIENCE, V252, P800; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PORTEOUS DJ, 1987, P NATL ACAD SCI USA, V84, P5355, DOI 10.1073/pnas.84.15.5355; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; PRRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1980, CANCER GENET CYTOGEN, V2, P131, DOI 10.1016/0165-4608(80)90056-4; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WADEY RB, 1990, ONCOGENE, V5, P901	47	89	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2141	2149						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331933				2022-12-25	WOS:A1992JW66500006
J	HUNT, J; MASSEY, V				HUNT, J; MASSEY, V			PURIFICATION AND PROPERTIES OF MILK XANTHINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; ACTIVE-SITE PROBES; O-2-DEPENDENT TYPES; OXIDASE; REDUCTION; OXIDATION; FLAVIN; MOLYBDENUM; MECHANISM; REDOX	Milk xanthine oxidase (XO) has been prepared in a dehydrogenase form (XDH) by purifying the enzyme in the presence of 2.5 mM dithiothreitol. Unlike XO, which reacts rapidly only with oxygen and not with NAD, the XDH form of the enzyme reacts rapidly with NAD. XDH has a turnover number for the NAD-dependent conversion of xanthine to urate of 380 mol/min/mol at pH 7.5, 25-degrees-C, with a K(m) = less-than-or-equal-to muM for xanthine and a K(m) = 7 muM for NAD, but has very little O2-dependent activity. There is evidence that the two forms of the enzyme have different flavin environments: XDH stabilizes the neutral form of the flavin semiquinone and XO does not. Further, XDH binds the artificial flavin 8-mercapto-FAD in its neutral form, shifting the pK of this flavin by 5 pH units, while XO binds 8-mercapto-FAD in its benzoquinoid anionic form. XDH can be converted back to the XO form by the addition of three to four equivalents of the disulfide-forming reagent 4,4'-dithiodipyridine, suggesting that, in the XDH form of the enzyme, disulfide bonds are broken; this may cause a conformational change which creates a binding site for NAD and changes the protein structure near the flavin.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [T32-GM07767] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1980, ARCH BIOCHEM BIOPHYS, V201, P468, DOI 10.1016/0003-9861(80)90535-4; BARBER MJ, 1973, BIOCHEM J, V163, P279; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; BETCHERLANGE SL, 1979, J BIOL CHEM, V254, P8825; Bray R. C., 1975, ENZYMES, P300; CLEERE WF, 1975, COMP BIOCHEM PHYSIOL, V50, P311, DOI 10.1016/0305-0491(75)90280-1; COUGHLAN MP, 1980, MOLYBDENUM MOLYBDENU, P160; FISH KM, 1990, J BIOL CHEM, V265, P19665; FISHER TL, 1973, J BIOL CHEM, V248, P4293; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; HILLE R, 1981, J BIOL CHEM, V256, P8933; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; KOMAI H, 1969, J BIOL CHEM, V244, P1692; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1989, J BIOL CHEM, V264, P10567; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MAYHEW SG, 1969, J BIOL CHEM, V244, P794; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; NISHINO T, 1989, J BIOL CHEM, V264, P2518; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; RAJAGOPALAN KV, 1967, J BIOL CHEM, V242, P4097; SAITO T, 1987, Yokohama Medical Bulletin, V38, P151; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; SWINGLE SM, 1951, BIOCHEM J, V48, P171, DOI 10.1042/bj0480171; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6	32	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21479	21485						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328233				2022-12-25	WOS:A1992JV01100035
J	WIESE, RJ; UHLANDSMITH, A; ROSS, TK; PRAHL, JM; DELUCA, HF				WIESE, RJ; UHLANDSMITH, A; ROSS, TK; PRAHL, JM; DELUCA, HF			UP-REGULATION OF THE VITAMIN-D RECEPTOR IN RESPONSE TO 1,25-DIHYDROXYVITAMIN-D(3) RESULTS FROM LIGAND-INDUCED STABILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; OSTEOCALCIN GENE; DEPENDENT REGULATION; RIBONUCLEIC-ACID; MESSENGER-RNA; D METABOLITES; CELLS HL-60; INVIVO; IDENTIFICATION; BINDING	Several studies have shown that the 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) receptor protein levels increase in response to 1,25-(OH)2D3. We have studied the mechanism of this regulation in both mouse fibroblasts and rat intestinal epithelial cells. Cell extracts and total RNA were prepared at varying times after addition of 1,25-(OH)2D3. The 1,25-(OH)2D3 receptor protein levels, measured using an immunoradiometric assay, rose significantly 2-3 h posttreatment and had risen 3-fold at 8 h. Concurrently, the 1,25-(OH)2D3 receptor mRNA content, measured using a ribonuclease protection assay, was not altered by 1,25-(OH)2D3 during this time. In cycloheximide-blocked cells, the administration of 1,25-(OH)2D3 markedly reduced the degradation rate of previously formed receptor. The 1,25-(OH)2D3 receptor protein half-life was determined as 4 h in the absence of 1,25-(OH)2D3 and increased to at least 8 h in the presence of 1,25-(OH)2D3. We also measured the 1,25-(OH)2D3 receptor mRNA levels in the duodena and kidney of vitamin D-deficient rats after a single 150-pmol injection of 1,25-(OH)2D3. Again, we found that 1,25-(OH)2D3 receptor mRNA levels were not changed in these tissues after 1,25-(OH)2D3 treatment. Therefore, the elevation of the 1,25-(OH)2D3 receptor protein following 1,25-(OH)2D3 administration is apparently the result of increased receptor protein lifetime and not increased transcription.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK014881] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-14881] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURMESTER JK, 1988, P NATL ACAD SCI USA, V85, P9499, DOI 10.1073/pnas.85.24.9499; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSTA EM, 1987, ENDOCRINOLOGY, V120, P1173, DOI 10.1210/endo-120-3-1173; COSTA EM, 1985, ENDOCRINOLOGY, V117, P2203, DOI 10.1210/endo-117-5-2203; COSTA EM, 1986, BIOCHEM BIOPH RES CO, V137, P742, DOI 10.1016/0006-291X(86)91141-1; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DeLuca H. F. J., 1990, J BONE MINER METAB, V8, P1; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; FINLAY JA, 1990, BIOCHEMISTRY-US, V29, P4914, DOI 10.1021/bi00472a023; GEHRON R, 1986, J BONE MINER RES  S1, V1, P288; HUANG YC, 1989, J BIOL CHEM, V264, P17454; KARASAWA M, 1987, P NATL ACAD SCI USA, V84, P8810, DOI 10.1073/pnas.84.24.8810; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KIZAKI M, 1991, BLOOD, V77, P1238; LEE YS, 1989, J BIOL CHEM, V264, P13701; MAHONEN A, 1991, BIOCHIM BIOPHYS ACTA, V1088, P111, DOI 10.1016/0167-4781(91)90159-J; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; Maniatis T., 1982, MOL CLONING; MCCAIN TA, 1978, FEBS LETT, V86, P65, DOI 10.1016/0014-5793(78)80100-8; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NAVEHMANY T, 1990, J CLIN INVEST, V86, P1968, DOI 10.1172/JCI114931; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; PAN LC, 1987, J BIOL CHEM, V262, P4670; PAN P, 1991, CELL PROLIFERAT, V24, P159, DOI 10.1111/j.1365-2184.1991.tb01146.x; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; SANDGREN ME, 1990, P NATL ACAD SCI USA, V87, P4312, DOI 10.1073/pnas.87.11.4312; SANDGREN ME, 1989, ANAL BIOCHEM, V183, P57, DOI 10.1016/0003-2697(89)90171-1; SILVER J, 1985, P NATL ACAD SCI USA, V82, P4270, DOI 10.1073/pnas.82.12.4270; STROM M, 1989, P NATL ACAD SCI USA, V86, P9770, DOI 10.1073/pnas.86.24.9770; SUDA T, 1970, J NUTR, V100, P1049, DOI 10.1093/jn/100.9.1049; WASSERMA.RH, 1966, SCIENCE, V152, P791, DOI 10.1126/science.152.3723.791; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; 1991, PROMEGA PROTOCOLS AP	35	198	200	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20082	20086						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328192				2022-12-25	WOS:A1992JR85800054
J	ZHANG, L; MCSPADDEN, B; PAKRASI, HB; WHITMARSH, J				ZHANG, L; MCSPADDEN, B; PAKRASI, HB; WHITMARSH, J			COPPER-MEDIATED REGULATION OF CYTOCHROME-C553 AND PLASTOCYANIN IN THE CYANOBACTERIUM SYNECHOCYSTIS-6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; TARGETED MUTAGENESIS; RECIPROCAL FORMATION; ELECTRON-TRANSPORT; SP PCC-6803; GENE; CLONING; ALGAE; METALLOTHIONEIN	In certain cyanobacteria and algae, cytochrome C553 or plastocyanin can serve to carry electrons from the cytochrome bf complex to photosystem I. The availability of copper in the growth medium regulates which protein is present. To investigate copper induced control of gene expression we isolated these proteins from the cyanobacterium Synechocystis 6803. Using immunodetection and optical spectroscopy, the steady state levels of cytochrome c553 and plastocyanin were measured in cells grown at different copper concentrations. The results show that in cells grown in 20-30 nm copper, cytochrome c553 was present, whereas plastocyanin was not detected. The opposite behavior was observed in cells grown in the presence of 1 muM copper; plastocyanin was present, whereas cytochrome c553 could not be detected. Both proteins were present in cells grown in 0.3 muM copper. Northern analysis of total RNA, probed with a gene fragment for cytochrome c553 or the plastocyanin gene, showed that cells grown in the presence of 20-30 nm copper have message for cytochrome c553, but not for plastocyanin, whereas cells grown in 1 muM copper have message for plastocyanin, but not for cytochrome C553. These results demonstrate that copper regulates expression of both of the genes encoding cytochrome c553 and plastocyanin prior to translation in Synechocystis 6803.	UNIV ILLINOIS, DEPT PLANT BIOL, CHICAGO, IL 60680 USA; UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60680 USA; USDA ARS, PHOTOSYNTH RES UNIT, URBANA, IL 61801 USA; WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; United States Department of Agriculture (USDA); Washington University (WUSTL)			Gardener, Brian B McSpadden/C-9844-2009		NIGMS NIH HHS [GM 41841] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; BOHNER H, 1978, FEBS LETT, V85, P337, DOI 10.1016/0014-5793(78)80486-4; Boulter D., 1977, INT REV BIOCH PLANT, V13, P1; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CRAMER WA, 1977, ANNU REV PLANT PHYS, V28, P133, DOI 10.1146/annurev.pp.28.060177.001025; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HILL KL, 1991, J BIOL CHEM, V266, P15060; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; HO KK, 1979, BIOCHIM BIOPHYS ACTA, V545, P236; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; LACY MJ, 1986, J IMMUNOL METHODS, V87, P169, DOI 10.1016/0022-1759(86)90527-2; LAUDENBACH DE, 1990, PLANT CELL, V2, P913, DOI 10.1105/tpc.2.9.913; LI HH, 1992, J BIOL CHEM, V267, P9368; LIGHTBODY JJ, 1967, BIOCHIM BIOPHYS ACTA, V131, P508, DOI 10.1016/0005-2728(67)90010-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; NAKAMURA M, 1992, J BIOCHEM, V111, P219, DOI 10.1093/oxfordjournals.jbchem.a123740; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PAKRASI HB, 1992, PHOTOSYSTEMS STRUCTU, P231; REDDY KJ, 1990, BIOTECHNIQUES, V8, P250; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SANDMANN G, 1980, PLANT SCI LETT, V17, P417, DOI 10.1016/0304-4211(80)90128-5; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; VANDERPLAS J, 1989, MOL MICROBIOL, V3, P275; WHITMARSH J, 1979, BIOPHYS J, V26, P223, DOI 10.1016/S0006-3495(79)85246-7; WHITMARSH J, 1984, ARCH BIOCHEM BIOPHYS, V231, P378, DOI 10.1016/0003-9861(84)90401-6; Whitmarsh J., 1986, ENCY PLANT PHYSL, V19, P508; Whitton B. A., 1970, PHYKOS, V9, P116; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YRUELA I, 1991, J BIOL CHEM, V266, P22847; Zieger R., 1965, BEITR BIOL PFLANZ, V41, P11	37	113	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19054	19059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326543				2022-12-25	WOS:A1992JP59300009
J	ADAMCZEWSKI, M; PAOLINI, R; KINET, JP				ADAMCZEWSKI, M; PAOLINI, R; KINET, JP			EVIDENCE FOR 2 DISTINCT PHOSPHORYLATION PATHWAYS ACTIVATED BY HIGH-AFFINITY IMMUNOGLOBULIN-E RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; MEDIATED SIGNAL TRANSDUCTION; NATURAL-KILLER-CELLS; FC-GAMMA RECEPTOR; T-CELL; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; PHENYLARSINE OXIDE; HISTAMINE-RELEASE	The high affinity receptor for immunoglobulin (Ig) E on mast cells, along with the antigen receptors on T and B cells and Fc receptors for IgG, belongs to a class of receptors which lack intrinsic kinase activity, but activate non-receptor tyrosine and serine/threonine kinases. Receptor engagement triggers a chain of signaling events leading from protein phosphorylation to activation of phosphatidylinositol-specific phospholipase C, an increase in intracellular calcium levels, and ultimately the activation of more specialized functions. IgE receptor disengagement leads to reversal of phosphorylation by undefined phosphatases and to inhibition of activation pathways. Here we show that phenylarsine oxide, a chemical which reacts with thiol groups and has been reported to inhibit tyrosine phosphatases, uncouples the IgE receptor-mediated phosphorylation signal from activation of phosphatidyl inositol metabolism, the increase in intracellular calcium levels, and serotonin release. Phenylarsine oxide inhibits neither the kinases (tyrosine and serine/threonine) phosphorylating the receptor and various cellular substrates nor, unexpectedly, the phosphatases responsible for the dephosphorylation following receptor disengagement. By contrast, it abolishes the receptor-mediated phosphorylation of phospholipase C-gamma-1, but not phospholipase C activity in vitro. Therefore the phosphorylation and activation of phospholipase C likely requires a phenylarsine oxide-sensitive element. Receptor aggregation thus activates at least two distinct phosphorylation pathways: a phenylarsine oxide-insensitive pathway leading to phosphorylation/dephosphorylation of the receptor and of various substrates and a sensitive pathway leading to phospholipase C-gamma-1 phosphorylation.			ADAMCZEWSKI, M (corresponding author), NIAID,MOLEC ALLERGY & IMMUNOL SECT,TWINBROOK 2 BLDG,RM 108,12441 PARKLAWN DR,ROCKVILLE,MD 20852, USA.			PAOLINI, Rossella/0000-0001-7605-1531				ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERNIER M, 1988, J BIOL CHEM, V263, P13626; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; DEANIN GG, 1991, BIOCHEM BIOPH RES CO, V179, P551, DOI 10.1016/0006-291X(91)91406-3; EISEMAN E, 1992, NATURE, V355, P78; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HOOK WA, 1991, J IMMUNOL, V147, P2670; HSI ED, 1989, J BIOL CHEM, V264, P10836; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KOYASU S, 1992, J BIOL CHEM, V267, P3375; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; LIU FT, 1980, J IMMUNOL, V124, P2728; MAYEAMA K, 1988, J IMMUNOL, V140, P3919; MAYEAMA K, 1986, J BIOL CHEM, V261, P2583; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YOUNG JDE, 1987, P NATL ACAD SCI USA, V84, P9175, DOI 10.1073/pnas.84.24.9175; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	53	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18126	18132						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325458				2022-12-25	WOS:A1992JM22300099
J	GURNEY, AL; PARK, EA; GIRALT, M; LIU, JS; HANSON, RW				GURNEY, AL; PARK, EA; GIRALT, M; LIU, JS; HANSON, RW			OPPOSING ACTIONS OF FOS AND JUN ON TRANSCRIPTION OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) GENE - DOMINANT NEGATIVE REGULATION BY FOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; DNA-BINDING DOMAINS; C-FOS; GLUCOCORTICOID RECEPTOR; HEPATOMA-CELLS; PHORBOL-ESTER; PROTEIN COMPLEXES; NERVOUS-SYSTEM; FACTOR AP-1; EXPRESSION	Jun homodimers and Fos/Jun heterodimers bind to the gene for phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) (PEPCK) at three sites within the first 350 base pairs of the promoter. These include CRE-1 (-82 to -90), and P3(II) and P4 (-252 to -258 and -268 to -285, respectively). Over-expression of Jun in HepG2 cells resulted in a 10-15-fold increase in the level of transcription of a chimeric PEPCK (-490 to +73)-CAT gene, while expression of Fos decreased transcription and blocked the induction of transcription from the PEPCK promoter by Jun. The action of Fos and Jun on PEPCK gene transcription involved each of the Fos/Jun-binding sites and was modulated by additional transcriptional regulatory elements within the PEPCK promoter. The ability of Fos to inhibit PEPCK transcription was dependent upon P3(I), a region of the promoter which does not bind Fos/Jun heterodimers, but does bind members of the C/EBP family of transcription factors. Stimulation of PEPCK transcription by 8-Br-cAMP or by overexpression of the catalytic subunit of protein kinase A was inhibited by Fos expression. The inhibitory effects of phorbol esters and protein kinase C on PEPCK gene expression may be mediated through the action of Fos and Jun.			GURNEY, AL (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106, USA.		Giralt, Marta/A-4756-2013	Giralt, Marta/0000-0001-7968-4190	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021859, R01DK021859] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-21859, DK-24451] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BOSCH F, 1990, J BIOL CHEM, V265, P13677; BOSCH F, 1992, J BIOL CHEM, V267, P2888; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAMBIER JC, 1987, NATURE, V327, P629; CHU DTW, 1986, J BIOL CHEM, V261, P6848; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; CORRAL M, 1985, EXP CELL RES, V160, P427, DOI 10.1016/0014-4827(85)90190-9; Curran T, 1988, ONCOGENE HDB, P307; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOD Y, 1988, J BIOL CHEM, V263, P7747; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; Maniatis T., 1982, MOL CLONING; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MCGRANE MM, 1990, J BIOL CHEM, V265, P22372; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MILLAND J, 1990, J AM PHYS SOC, pG340; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, GENE DEV, V2, P687; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SQUINTO SP, 1989, MOL ENDOCRINOL, V3, P433, DOI 10.1210/mend-3-3-433; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	63	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18133	18139						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325459				2022-12-25	WOS:A1992JM22300100
J	ZIEGELIN, G; PANSEGRAU, W; LURZ, R; LANKA, E				ZIEGELIN, G; PANSEGRAU, W; LURZ, R; LANKA, E			TRAK PROTEIN OF CONJUGATIVE PLASMID RP4 FORMS A SPECIALIZED NUCLEOPROTEIN COMPLEX WITH THE TRANSFER ORIGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GEL-ELECTROPHORESIS; ENCODED PRODUCTS; DNA; SEQUENCE; BINDING; NUCLEOTIDE; EXPRESSION; REPRESSOR; CLONING	Conjugative transfer of the self-transmissible IncP Plasmid RP4 requires the product of the RP4 traK gene. By using the phage T7 expression system, the traK gene product was efficiently overproduced and purified to near homogeneity. traK encodes a basic protein (pI = 10.7) of 14.6 kDa that, as shown by DNA fragment retention assay, interacts exclusively with its cognate transfer origin. The apparent equilibrium constant K(app) for the complex of TraK and oriT-DNA was estimated to be 4 nM. Footprinting experiments using DNase I or hydroxyl radicals indicate that several TraK molecules interact specifically with an intrinsically bent region of oriT, covering a range of almost 200 base pairs. The TraK target sequence maps in the leading region adjacent to the relaxation nick site and recognition sequences involved in relaxosome formation but does not overlap them. Specific interactions between TraK and the DNA occur only on one side of the double helix. Electron microscopy of TraK-oriT complexes demonstrates that binding of TraK to its recognition region apparently shrinks the length of the target DNA, suggesting that the nucleic acid becomes wrapped around a core of TraK molecules. Formation of this structure could be favored by the presence of the sequence-directed bend in the TraK recognition region.	MAX PLANCK INST MOLEC GENET,SCHUSTER ABT,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; FURSTE JP, 1989, P NATL ACAD SCI USA, V86, P1771, DOI 10.1073/pnas.86.6.1771; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HALFMAN CJ, 1972, BIOCHEMISTRY-US, V11, P3493, DOI 10.1021/bi00768a025; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; Miller J.H., 1972, EXPT MOL GENETICS; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1988, BIOCHIM BIOPHYS ACTA, V951, P365, DOI 10.1016/0167-4781(88)90108-X; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; PEREZMARTIN J, 1989, J BIOL CHEM, V264, P21334; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1950, J AM CHEM SOC, V72, P535, DOI 10.1021/ja01157a138; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WANG JC, 1982, CELL, V29, P724, DOI 10.1016/0092-8674(82)90433-0; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; WILKINS B, 1992, BACTERIAL CONJUGATIO; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIEGELIN G, 1989, J BIOL CHEM, V264, P11989; Ziegelin G, 1991, DNA Seq, V1, P303, DOI 10.3109/10425179109020786	32	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17279	17286						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324929				2022-12-25	WOS:A1992JL05300083
J	ENGSTROM, U; ENGSTROM, A; ERNLUND, A; WESTERMARK, B; HELDIN, CH				ENGSTROM, U; ENGSTROM, A; ERNLUND, A; WESTERMARK, B; HELDIN, CH			IDENTIFICATION OF A PEPTIDE ANTAGONIST FOR PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF BETA-RECEPTOR; A-CHAIN; KINASE ACTIVATION; HUMAN-FIBROBLASTS; B-CHAIN; BINDING; PURIFICATION; DIMERIZATION; HETERODIMER; ESTABLISHES	A series of peptides derived from the primary sequence of the B-chain of platelet-derived growth factor (PDGF) was analyzed for their ability to inhibit the binding of I-125-PDGF-AA and I-125-PDGF-BB to PDGF alpha-receptors and PDGF beta-receptors, respectively. A 13-amino acid peptide (ANFLVWEIVRKKP), corresponding to amino acids 116-121 and 157-163 in PDGF B-chain, was found to compete with binding to both alpha- and beta-receptors. Modification of this peptide on the tryptophan residue increased its receptor competing activity. The peptide was found to be a receptor antagonist, since it inhibited dimerization and autophosphorylation of PDGF receptors. When analyzed on intact cells, the peptide was found to have, in addition to the specific inhibitory effect at the receptor level, a nonspecific inhibitory effect on [H-3]thymidine incorporation. Our study has identified two regions in PDGF that are of importance for receptor interaction.	LUDWIG INST CANC RES, BOX 595, S-75124 UPPSALA, SWEDEN; BIOMED CTR, DEPT IMMUNOL, S-75123 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, DEPT PATHOL, S-75185 UPPSALA, SWEDEN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital								BETSHOLTZ C, 1984, J CELL PHYSIOL, V118, P203, DOI 10.1002/jcp.1041180213; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; EK B, 1984, J BIOL CHEM, V259, P1145; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HUANG JS, 1982, J BIOL CHEM, V257, P8130; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KING CR, 1985, P NATL ACAD SCI USA, V82, P5295, DOI 10.1073/pnas.82.16.5295; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MERCOLA M, 1988, SCIENCE, V241, P1223, DOI 10.1126/science.3413486; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RONNSTRAND L, 1987, J BIOL CHEM, V262, P2929; SCOFFONE E, 1968, BIOCHEMISTRY-US, V7, P971, DOI 10.1021/bi00843a014; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SPRUGEL KH, 1987, AM J PATHOL, V129, P601; SUNDQVIST B, 1985, MASS SPECTROM REV, V4, P421, DOI 10.1002/mas.1280040403; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	32	56	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16581	16587						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322909				2022-12-25	WOS:A1992JJ45800091
J	PERRINO, BA; FONG, YL; BRICKEY, DA; SAITOH, Y; USHIO, Y; FUKUNAGA, K; MIYAMOTO, E; SODERLING, TR				PERRINO, BA; FONG, YL; BRICKEY, DA; SAITOH, Y; USHIO, Y; FUKUNAGA, K; MIYAMOTO, E; SODERLING, TR			CHARACTERIZATION OF THE PHOSPHATASE-ACTIVITY OF A BACULOVIRUS-EXPRESSED CALCINEURIN-A ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; BOVINE BRAIN CALCINEURIN; CATALYTIC SUBUNIT; CALMODULIN; BINDING; KINASE; DEPHOSPHORYLATION; CLONING; DOMAIN; PHOSPHORYLATION	Calcineurin A was purified by calmodulin-Sepharose affinity chromatography from Sf9 cells infected with recombinant baculovirus containing the cDNA of a rat calcineurin A isoform. The Sf9-expressed calcineurin A has a low basal phosphatase activity in the presence of EDTA (0.9 nmol/min/mg) which is stimulated 3-5-fold by Mn2+. Calmodulin increased the Mn2+ stimulated activity 3-5-fold. Bovine brain calcineurin B increased the A subunit activity 10-15-fold, and calmodulin further stimulated the activity of reconstituted A and B subunits 10-15-fold (644 nmol/min/mg). The K(m) of calcineurin A for P-32-R(II) pep (a peptide substrate (DLDVPIPGRFDRRVSVAAE) for CaN), was 111-mu-M with or without calmodulin, and calmodulin increased the V(max) about 4-fold. The K(m) of reconstituted calcineurin A plus B for P-32-R(II) pep was 20-mu-M, and calmodulin increased the V(max) 18-fold without affecting the K(m). CaN A467-492, a synthetic autoinhibitory peptide (ITSFEEAKGLDRINERMPPRRDAMP) from calcineurin, inhibited the Mn2+/calmodulin-stimulated activities of the reconstituted enzyme and the A subunit with IC50's of 25-mu-M and 90-mu-M, respectively. The reconstitution of the phosphatase activity of an expressed isoform of calcineurin A by purified B subunit and calmodulin may facilitate comparative studies of the regulation of calcineurin A activity by the B subunit and calmodulin.	KUMAMOTO MED SCH, DEPT PHARMACOL, KUMAMOTO 860, JAPAN	Kumamoto University	PERRINO, BA (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA.				NIGMS NIH HHS [GM-41292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; GUPTA RC, 1985, FEBS LETT, V190, P104, DOI 10.1016/0014-5793(85)80437-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HIGUCHI S, 1991, J BIOL CHEM, V266, P18104; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; HOSEY MM, 1986, P NATL ACAD SCI USA, V83, P3733, DOI 10.1073/pnas.83.11.3733; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KING MM, 1987, J BIOL CHEM, V262, P10658; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; Klee CB, 1985, ADV PROTEIN PHOSPHAT, P135; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; MERAT DL, 1985, J BIOL CHEM, V260, P1053; OSTERGAARD HL, 1991, J BIOL CHEM, V253, P1423; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; PERRINO BA, 1990, FASEB J, V4, pA2237; SAITOH Y, 1991, BIOMED RES-TOKYO, V12, P215, DOI 10.2220/biomedres.12.215; SILVA EFD, 1989, BIOCHIM BIOPHYS ACTA, V1009, P293, DOI 10.1016/0167-4781(89)90118-8; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; TAKAISHI T, 1991, BIOCHEM BIOPH RES CO, V174, P393, DOI 10.1016/0006-291X(91)90533-D; WRIGHT DE, 1981, P NATL ACAD SCI-BIOL, V78, P6048, DOI 10.1073/pnas.78.10.6048	32	89	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15965	15969						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322410				2022-12-25	WOS:A1992JG11300105
J	CAMPOSGONZALEZ, R; GLENNEY, JR				CAMPOSGONZALEZ, R; GLENNEY, JR			TYROSINE PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN-KINASE IN CELLS WITH TYROSINE KINASE-NEGATIVE EPIDERMAL GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EGF RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; MAP KINASE; ASSOCIATION; GEL	Epidermal growth factor (EGF) treatment of cells expressing the human EGF receptor (EGFr) results in rapid tyrosine phosphorylation of several cellular proteins including mitogen-activated protein (MAP) kinase. EGF treatment of cells expressing a tyrosine kinase-inactive EGFr failed to induce the tyrosine phosphorylation of endogenous substrates in response to EGF; however, the tyrosine phosphorylation and activation of MAP kinase did occur. This observation indicates that MAP kinase is activated in response to a signal other than the tyrosine kinase activity of the EGFr. Because EGF does not stimulate cells expressing the inactive EGFr to proliferate, phosphorylation of MAP kinase may not be sufficient for the EGF-dependent mitogenesis.	UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky	CAMPOSGONZALEZ, R (corresponding author), UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,COMBS BLDG,RM 227,800 ROSE ST,LEXINGTON,KY 40536, USA.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CAMPOSGONZALEZ R, 1991, CELL REGUL, V2, P663, DOI 10.1091/mbc.2.8.663; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUNG CK, 1989, J BIOL CHEM, V264, P18951; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D	23	68	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14535	14538						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321807				2022-12-25	WOS:A1992JF08800006
J	SCHMIDT, AM; VIANNA, M; GERLACH, M; BRETT, J; RYAN, J; KAO, J; ESPOSITO, C; HEGARTY, H; HURLEY, W; CLAUSS, M; WANG, F; PAN, YCE; TSANG, TC; STERN, D				SCHMIDT, AM; VIANNA, M; GERLACH, M; BRETT, J; RYAN, J; KAO, J; ESPOSITO, C; HEGARTY, H; HURLEY, W; CLAUSS, M; WANG, F; PAN, YCE; TSANG, TC; STERN, D			ISOLATION AND CHARACTERIZATION OF 2 BINDING-PROTEINS FOR ADVANCED GLYCOSYLATION END-PRODUCTS FROM BOVINE LUNG WHICH ARE PRESENT ON THE ENDOTHELIAL-CELL SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED BINDING; LOW-DENSITY LIPOPROTEIN; HUMAN LACTOFERRIN; IDENTIFICATION; ALBUMIN; MACROPHAGES; DEGRADATION; FORMS; COMPLICATIONS; MECHANISM	Nonenzymatic glycosylation of proteins, as occurs at an accelerated rate in diabetes, can lead to the formation of advanced glycosylation end products of proteins (AGEs), which can bind to endothelial cells, thereby altering cellular function in a manner which could contribute to the pathogenesis of diabetic angiopathy. In this report, we describe the isolation of two endothelial cell surface-associated proteins which mediate, at least in part, the interaction of AGEs with endothelium. Based on pilot studies demonstrating AGE binding activity with comparable characteristics in bovine endothelial cell and lung extracts, the material from lung was sequentially subjected to chromatography on hydroxylapatite, fast protein liquid chromatography Mono S, and gel filtration. Two distinct polypeptides, almost-equal-to 35 and almost-equal-to 80 kDa, were purified to homogeneity, each of which bound AGEs as demonstrated by competitive binding assays using cellular binding proteins immobilized on a plastic surface. NH2-terminal sequence analysis indicated that the almost-equal-to 35-kDa protein was novel, whereas the NH2-terminal sequence of the almost-equal-to 80-kDa protein was identical to that of lactoferrin. Immunocytologic studies using polyclonal antibody prepared to each of the purified polypeptides demonstrated the presence of immunoreactive material on the surface of bovine endothelial cells maintained under serum-free conditions. Furthermore, immunoelectron microscopic studies with antibodies to the almost-equal-to 35- and almost-equal-to 80-kDa AGE-binding proteins conjugated to different size colloidal gold particles confirmed the presence of the target antigens on the cell surface and suggested that they were closely associated. IgG purified from polyclonal antisera to either the 35- or 80-kDa AGE-binding proteins blocked the binding of I-125-AGE-albumin to the cell surface. These results indicate that endothelial cells express specific cell surface molecules which mediate AGE-endothelial interaction. These polypeptides represent a novel class of cell surface acceptor molecules for glucose-modified proteins which may promote degradation and/or transcytosis of the ligand, and modulation of cellular function.	HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT PROT BIOCHEM,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT MOLEC GENET,NUTLEY,NJ 07110; UNIV ILLINOIS,DEPT ANIM SCI,URBANA,IL 61801	Roche Holding; Roche Holding; University of Illinois System; University of Illinois Urbana-Champaign	SCHMIDT, AM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,ROVER PHYSIOL RES LAB,NEW YORK,NY 10032, USA.		esposito, ciro/AAC-8023-2020	esposito, ciro/0000-0002-7906-1097; Clauss, Matthias/0000-0001-5180-3899	NHLBI NIH HHS [HL-21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRETT JG, 1988, J CELL BIOL, V106, P2109, DOI 10.1083/jcb.106.6.2109; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; COZZOLINO FM, 1990, CIRCULATION S, V82, P142; DAVID GS, 1974, BIOCHEMISTRY-US, V13, P1014, DOI 10.1021/bi00702a028; DAVIDSON LA, 1989, AM J PHYSIOL, V257, pG930, DOI 10.1152/ajpgi.1989.257.6.G930; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FURMANSKI P, 1989, J EXP MED, V170, P415, DOI 10.1084/jem.170.2.415; GERLACH H, 1989, J EXP MED, V170, P913, DOI 10.1084/jem.170.3.913; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HORIUCHI S, 1985, J BIOL CHEM, V260, P475; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; HUTCHENS TW, 1991, P NATL ACAD SCI USA, V88, P2994, DOI 10.1073/pnas.88.8.2994; Johns EW, 1982, HMG CHROMOSOMAL PROT; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KLOTZ I, 1984, J BIOL CHEM, V258, P11442; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPTON H, 1990, CIRCULATION S, V82, P81; Low M G, 1981, Methods Enzymol, V71 Pt C, P741; LOW MG, 1986, TRENDS BIOCHEM SCI, V11, P212, DOI 10.1016/0968-0004(86)90009-5; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; MORA R, 1992, FASEB J, V6, pA1593; OIMOMI M, 1988, J GERONTOL, V43, pB98, DOI 10.1093/geronj/43.4.B98; PAONESSA G, 1987, NUCLEIC ACIDS RES, V15, P9077, DOI 10.1093/nar/15.21.9077; RADOFF S, 1990, DIABETES, V39, P1510, DOI 10.2337/diabetes.39.12.1510; RADOFF S, 1988, ARCH BIOCHEM BIOPHYS, V263, P418, DOI 10.1016/0003-9861(88)90654-6; REJMAN JJ, 1989, COMP BIOCHEM PHYS B, V93, P929, DOI 10.1016/0305-0491(89)90068-0; ROCHARD E, 1989, FEBS LETT, V255, P201, DOI 10.1016/0014-5793(89)81091-9; SCHMIDT AM, 1991, CIRCULATION S, V84, P456; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; STAHL PD, 1978, P NATL ACAD SCI USA, V75, P1399, DOI 10.1073/pnas.75.3.1399; STERN D, 1986, J CELL BIOL, V102, P1971, DOI 10.1083/jcb.102.5.1971; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	41	705	740	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14987	14997						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321822				2022-12-25	WOS:A1992JF08800073
J	JIN, H; OKSENBERG, D; ASHKENAZI, A; PEROUTKA, SJ; DUNCAN, AMV; ROZMAHEL, R; YANG, Y; MENGOD, G; PALACIOS, JM; ODOWD, BF				JIN, H; OKSENBERG, D; ASHKENAZI, A; PEROUTKA, SJ; DUNCAN, AMV; ROZMAHEL, R; YANG, Y; MENGOD, G; PALACIOS, JM; ODOWD, BF			CHARACTERIZATION OF THE HUMAN 5-HYDROXYTRYPTAMINE-1B RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOCUS; DNA; AMPLIFICATION; POLYMORPHISM; FAMILY; BRAIN; GENE	We report the cloning of a human gene encoding the 5-hydroxytryptamine1B receptor. The receptor has the characteristics of a G-protein-linked receptor and is most homologous to the human 5-HT1D receptor. This human 5-HT receptor gene, most abundantly expressed in striatum, is localized on chromosome 6, at 6q13, and the gene encoding the 5-HT1D receptor is localized on chromosome 1. Radioligand studies indicate that the affinity of [H-3]5-HT is 16 +/- 2 nM. Drug competition studies indicate that the receptor displays high affinity (i.e. < 40 nM) for 5-HT, 5-carboxyamidotryptamine, methiothepin, and metergoline.	UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ONTARIO,CANADA; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL,STANFORD,CA 94305; GENENTECH INC,S SAN FRANCISCO,CA 94080; KINGSTON GEN HOSP,KINGSTON K7L 2V7,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; CTR INVEST DESARROLLO,E-08034 BARCELONA,SPAIN; CSIC,BARCELONA,SPAIN; ADDICT RES FDN,TORONTO M5S 2S1,ONTARIO,CANADA	University of Toronto; Stanford University; Roche Holding; Genentech; Queens University - Canada; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Consejo Superior de Investigaciones Cientificas (CSIC); University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada			Ashkenazi, Avi/ABG-2712-2020; Mengod, Guadalupe/K-5391-2014	Ashkenazi, Avi/0000-0002-6890-4589; Mengod, Guadalupe/0000-0001-7223-7873	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007223] Funding Source: NIH RePORTER; NIDA NIH HHS [1 RO1-DA07223-01] Funding Source: Medline; NINDS NIH HHS [NS 23506-04] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAAS F, 1984, HUM GENET, V67, P301, DOI 10.1007/BF00291357; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; DEMARTINVILLE B, 1982, AM J HUM GENET, V34, P216; DUNCAN AMV, 1988, CYTOGENET CELL GENET, V49, P309, DOI 10.1159/000132684; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V15, P6737, DOI 10.1093/nar/15.16.6737; HARTIG P, 1990, NEUROPSYCHOPHARMACOL, V3, P335; HEURING RE, 1987, J NEUROSCI, V7, P894; HOYER D, 1989, TRENDS PHARMACOL SCI, V10, P130, DOI 10.1016/0165-6147(89)90159-4; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; Maniatis T, 1989, DECONTAMINATION DILU; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MENGOD G, 1991, MOL BRAIN RES, V10, P185, DOI 10.1016/0169-328X(91)90110-J; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NGUYEN T, 1991, GENE, V109, P211, DOI 10.1016/0378-1119(91)90611-E; ODOWD BF, 1991, ENCY HUM BIOL, V1, P81; Osborne N.N., 1982, P7; PALACIOS JM, 1991, SEROTONIN MOL BIOL R, P107; PRICHETT DB, 1988, EMBO J, V7, P4135; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; VOGT M, 1982, BIOL SEROTONERGIC TR, P299; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	28	174	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5735	5738						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1348246				2022-12-25	WOS:A1992HK31800004
J	LEE, SC; OLINS, PO				LEE, SC; OLINS, PO			EFFECT OF OVERPRODUCTION OF HEAT-SHOCK CHAPERONES GROESL AND DNAK ON HUMAN PROCOLLAGENASE PRODUCTION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBULOSE BISPHOSPHATE CARBOXYLASE; CLONING VEHICLES; PROTEINS; GENE; MUTATIONS; SEQUENCE; EXPORT; LAMBDA; CONSTRUCTION; REPLICATION	The effect of overexpression of the heat shock chaperone genes dnaK and groESL on heterologous protein production in Escherichia coli was examined, using a set of related human procollagenase proteins. A diverse range of effects on protein solubility, secretion, and accumulation was observed, and these effects were highly dependent on the particular chaperone/procollagenase pairing involved. Both chaperones caused a large increase in the apparent solubility of a fusion of the LamB signal peptide to procollagenase. GroESL had no effect on the accumulation of mature (secreted) procollagenase, while DnaK suppressed secretion considerably. In the absence of a signal peptide, overexpression of either chaperone resulted in a dramatic increase in both solubility and accumulation of procollagenase. The 10-fold increase in accumulation was associated with an increase in in vivo protein half-life.			LEE, SC (corresponding author), MONSANTO CO, MONSANTO CORP RES, 700 CHESTERFIELD VILLAGE PKWY, ST LOUIS, MO 63198 USA.		Lee, Stephen/C-2394-2011					BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; ELLIS RJ, 1990, ANNU REV BIOCHEM, V61, P321; EMR SD, 1980, NATURE, V285, P82, DOI 10.1038/285082a0; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GREENFIELD L, 1978, P NATL ACAD SCI USA, V75, P4724, DOI 10.1073/pnas.75.10.4724; KLEIN BK, 1991, BIO-TECHNOL, V9, P869, DOI 10.1038/nbt0991-869; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; MALKI A, 1991, MOL GEN GENET, V225, P420, DOI 10.1007/BF00261682; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; OLINS PO, 1989, J BIOL CHEM, V264, P16973; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILIPS GJ, 1990, NATURE, V344, P44; RANDALL LL, 1987, ANNU REV MICROBIOL, V41, P507; RENART J, 1979, P NATL ACAD SCI USA, V76, P3116, DOI 10.1073/pnas.76.7.3116; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SOBERON X, 1980, GENE, V9, P287, DOI 10.1016/0378-1119(90)90328-O; STADER JA, 1990, METHOD ENZYMOL, V185, P166; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	35	111	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2849	2852						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1346610				2022-12-25	WOS:A1992HD15400004
J	MAENZ, DD; CHENU, C; BRETON, S; BERTELOOT, A				MAENZ, DD; CHENU, C; BRETON, S; BERTELOOT, A			PH-DEPENDENT HETEROGENEITY OF ACIDIC AMINO-ACID-TRANSPORT IN RABBIT JEJUNAL BRUSH-BORDER MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-GLUTAMATE; SYSTEM; COTRANSPORT; SERVICE; K+	Initial rates of Na+-dependent L-glutamic and D-aspartic acid uptake were determined at various substrate concentrations using a fast sampling, rapid filtration apparatus, and the resulting data were analyzed by nonlinear computer fitting to various transport models. At pH 6.0, L-glutamic acid transport was best accounted for by the presence of both high (K(m) = 61-mu-M) and low (K(m) = 7.0 mM) affinity pathways, whereaS D-aspartic acid transport was restricted to a single high affinity route (K(m) = 80-mu-M). Excess D-aspartic acid and L-phenylalanine served to isolate L-glutamic acid flux through the remaining low and high affinity systems, respectively. Inhibition studies of other amino acids and analogs allowed us to identify the high affinity pathway as the X(AG)-. system and the low affinity one as the intestinal NBB system. The pH dependences of the high and low affinity pathways of L-glutamic acid transport also allowed us to establish some relationship between the NBB and the more classical ASC system. Finally, these studies also revealed a heterotropic activation of the intestinal X(AG)- transport system by all neutral amino acids but glycine through an apparent activation of V(max).	UNIV MONTREAL,FAC MED,DEPT PHYSIOL,MEMBRANE TRANSPORT RES GRP,CP 6128,SUCCURSALE A,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal								BERTELOOT A, 1986, BIOCHIM BIOPHYS ACTA, V857, P180, DOI 10.1016/0005-2736(86)90346-9; BERTELOOT A, 1986, BIOCHIM BIOPHYS ACTA, V861, P447, DOI 10.1016/0005-2736(86)90453-0; BERTELOOT A, 1984, BIOCHIM BIOPHYS ACTA, V775, P129, DOI 10.1016/0005-2736(84)90163-9; BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BERTELOOT A, 1991, J MEMBRANE BIOL, V122, P111, DOI 10.1007/BF01872635; BERTELOOT A, 1990, COMP PHYSL, V7, P130; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CORCELLI A, 1982, BIOCHIM BIOPHYS ACTA, V689, P97, DOI 10.1016/0005-2736(82)90193-6; DALLASTA V, 1983, J BIOL CHEM, V258, P6371; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6054; GIBSON QH, 1951, BIOCHEM J, V48, P426, DOI 10.1042/bj0480426; HARIG JM, 1987, BIOCHIM BIOPHYS ACTA, V903, P358, DOI 10.1016/0005-2736(87)90226-4; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KOEPSELL H, 1984, J BIOL CHEM, V259, P6548; LAWLESS K, 1987, AM J PHYSIOL, V253, pG637, DOI 10.1152/ajpgi.1987.253.5.G637; LERNER J, 1987, COMP BIOCHEM PHYS B, V87, P443, DOI 10.1016/0305-0491(87)90035-6; LERNER J, 1977, COMP BIOCHEM PHYS A, V57, P11, DOI 10.1016/0300-9629(77)90340-1; MAENZ DD, 1991, BIOCHIM BIOPHYS ACTA, V1069, P250, DOI 10.1016/0005-2736(91)90132-R; MAKOWSKE M, 1982, J BIOL CHEM, V257, P4635; MAKOWSKE M, 1982, J BIOL CHEM, V257, P5663; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; RAJENDRAN VM, 1987, AM J PHYSIOL, V252, pG33, DOI 10.1152/ajpgi.1987.252.1.G33; SCOTT DM, 1978, BIOCHIM BIOPHYS ACTA, V508, P379, DOI 10.1016/0005-2736(78)90340-1; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; WEISS SD, 1978, J MEMBRANE BIOL, V43, P91, DOI 10.1007/BF01869043; WINGROVE TG, 1987, AM J PHYSIOL, V252, pC105, DOI 10.1152/ajpcell.1987.252.1.C105	28	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1510	1516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346136				2022-12-25	WOS:A1992HA48500021
J	IMBODEN, MA; MATTHEWS, JL; LOFQUIST, AK; PAULE, MR				IMBODEN, MA; MATTHEWS, JL; LOFQUIST, AK; PAULE, MR			AN EXONUCLEASE REQUIRING AN INTACT HELICAL STEM FOR SPECIFICITY PRODUCES THE 3' END OF ACANTHAMOEBA-CASTELLANII 5-S RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III; TRANSCRIPTION TERMINATION; NUCLEOTIDE-SEQUENCES; RIBOSOMAL-RNA; 5S; INVITRO; MUTANT; GENE; MATURATION; PRECURSOR	A nuclear extract from Acanthamoeba castellanii which contains all of the components necessary for specific transcription of a 5 S RNA gene was separated into fractions required for specific transcription initiation and an additional fraction needed in the reconstituted system to produce the 3' end characteristic of mature 5 S RNA. The latter fraction contained a novel processing activity characterized by an exonuclease specific for highly structured RNAs, including 5 S RNA. An intact helical stem formed between the 5' and 3' ends of the 5 S RNA precursor determines the 3' nucleotide. In addition, the presence of ATP is required for specific processing. However, the possibility has not been ruled out that ATP inhibits a nonspecific ribonuclease in the extract since processing proceeds into the helical stem in its absence.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523; COLORADO STATE UNIV,CELL & MOLEC BIOL PROGRAM,FT COLLINS,CO 80523	Colorado State University; Colorado State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026059] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26059] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; DALESSIO JM, 1979, J BIOL CHEM, V254, P4085; Detke S., 1976, Molecular mechanisms in the control of gene expression. ICN-UCLA symposia on molecular and cellular biology, Volume 5., P261; DETKE S, 1975, BIOCHIM BIOPHYS ACTA, V383, P67, DOI 10.1016/0005-2787(75)90246-4; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; GUERRIERTAKADA C, 1984, SCIENCE, V223, P285, DOI 10.1126/science.6199841; IMBODEN M, 1986, J MOL BIOL, V188, P393, DOI 10.1016/0022-2836(86)90163-4; JAMES P, 1990, GENETICS, V125, P293; JAMES P, 1991, J BIOL CHEM, V266, P5616; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKAY RM, 1981, NUCLEIC ACIDS RES, V9, P3321, DOI 10.1093/nar/9.14.3321; Maniatis T., 1982, MOL CLONING; PACE NR, 1980, TRANSFER RNA BIOL AS, P155; PAULE MR, 1984, NUCLEIC ACIDS RES, V12, P8161, DOI 10.1093/nar/12.21.8161; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PREISER PR, 1991, J BIOL CHEM, V266, P7509; SPINDLER SR, 1978, J BIOL CHEM, V253, P4669; SPINDLER SR, 1978, J BIOL CHEM, V253, P6242; TELFORD JL, 1979, P NATL ACAD SCI USA, V76, P2590, DOI 10.1073/pnas.76.6.2590; WALDSCHMIDT R, 1990, EUR J BIOCHEM, V194, P167, DOI 10.1111/j.1432-1033.1990.tb19441.x; WATSON JB, 1984, NUCLEIC ACIDS RES, V12, P5369, DOI 10.1093/nar/12.13.5369; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WIGGS MY, 1983, 5 S RNA SEQUENCE ACA; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008; ZWICK MG, 1991, GENE, V101, P153, DOI 10.1016/0378-1119(91)90239-8; ZWICK MG, 1991, NUCLEIC ACIDS RES, V19, P1681, DOI 10.1093/nar/19.7.1681; ZWICK MG, 1989, THESIS COLORADO STAT	32	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24601	24610						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332962				2022-12-25	WOS:A1992KA26300069
J	ZHANG, BX; MUALLEM, S				ZHANG, BX; MUALLEM, S			FEEDBACK INHIBITION OF CA2+ RELEASE BY CA2+ IS THE UNDERLYING MECHANISM OF AGONIST-EVOKED INTRACELLULAR CA2+ OSCILLATIONS IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM POOL; INOSITOL TRISPHOSPHATE; CA-2+ RELEASE; AR42J CELLS; GENERATION; 1,4,5-TRISPHOSPHATE; MOBILIZATION; ACTIVATION; HYDROLYSIS; STORES	Oscillations of free intracellular Ca2+ concentration ([Ca2+]i) are known to occur in many cell types during physiological cell signaling. To identify the basis for the oscillations, we measured both [Ca2+]i and extracellular Ca2+ concentration ([Ca2+]o) to follow the fate of Ca2+ during stimulation of [Ca2+]i oscillations in pancreatic acinar cells. [Ca2+]i oscillations were initiated by either t-butyloxycarbonyl-Tyr(SO3)-Nle-Gly-Tyr-Nle-Asp-2-phenylethyl ester (CCK-J), which mobilized Ca2+ from the inositol 1,4,5-trisphosphate (IP3)-insensitive pool, or low concentration of cholecystokinin octapeptide (CCK-OP), which mobilized Ca2+ from the IP3-sensitive internal pool. Little Ca2+ efflux occurred during the oscillations triggered by CCK-J or CCK-OP in spite of a large average increase in [Ca2+]i. When internal store Ca2+ pumps were inhibited with thapsigargin (Tg) during [Ca2+]i oscillations, a rapid Ca2+ efflux occurred similar to that measured in intensely stimulated, nonoscillatory cells. Tg also stimulated Ca-45 efflux from internal pools of cells stimulated with CCK-J or a low concentration of CCK-OP. Hence, a large fraction of the Ca2+ released during each spike is reincorporated by the internal store Ca2+ pumps. Surprisingly, when the increase in [Ca2+]i during stimulation of oscillations was prevented by loading the cells with 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid, a persistent activation of Ca2+ release and Ca2+ efflux occurred. This was reflected as a persistent increase in [Ca2+]o in cells suspended at low [Ca2+]o or persistent efflux of Ca-45 from internal stores of cells maintained at high [Ca2+]o. Since agonist-stimulated Ca2+ release evidently remains activated when [Ca2+]i is highly buffered, the primary mechanism determining Ca2+ oscillations must include an inhibition of Ca2+ release by [Ca2+]i. Loading the cells with 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid had no apparent effect on the levels or kinetics of IP3 formation in agonist-stimulated cells. This suggests that [Ca2+]i regulated the oscillation by inhibition of Ca2+ release independent of its possible effects on cellular levels of IP3.			ZHANG, BX (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; CHUCK SH, 1986, J BIOL CHEM, V261, P13883; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P97, DOI 10.1016/0143-4160(91)90012-4; FOHR KJ, 1991, J NEUROCHEM, V56, P665, DOI 10.1111/j.1471-4159.1991.tb08201.x; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KEIZER J, 1992, BIOPHYS J, V61, P649, DOI 10.1016/S0006-3495(92)81870-2; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; LYTON J, 1991, J BIOL CHEM, V266, P17067; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MAYER T, 1988, P NATL ACAD SCI USA, V85, P5051; MAYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; Muallem S, 1990, Semin Cell Biol, V1, P305; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; OTTO FW, 1984, AM J PHYSIOL, V246, pR847; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; ROSS J, 1987, ANNU REV BIOPHYS BIO, V16, P401; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; STUENKEL EL, 1989, BIOCHEM BIOPH RES CO, V158, P863, DOI 10.1016/0006-291X(89)92802-7; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZHANG BX, 1992, AM J PHYSIOL, V262, pC1125, DOI 10.1152/ajpcell.1992.262.5.C1125; ZHAO H, 1990, J BIOL CHEM, V265, P14822; ZHAO H, 1990, J BIOL CHEM, V265, P21419; ZHAO H, 1990, J BIOL CHEM, V265, P20856	44	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24387	24393						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332954				2022-12-25	WOS:A1992KA26300040
J	PRONK, GJ; MEDEMA, RH; BURGERING, BMT; CLARK, R; MCCORMICK, F; BOS, JL				PRONK, GJ; MEDEMA, RH; BURGERING, BMT; CLARK, R; MCCORMICK, F; BOS, JL			INTERACTION BETWEEN THE P21(RAS) GTPASE ACTIVATING PROTEIN AND THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GAP-ASSOCIATED PROTEINS; TYROSINE PHOSPHORYLATION; PHENYLARSINE OXIDE; P21RAS ACTIVATION; 3T3-L1 ADIPOCYTES; SH2 DOMAINS; RAS P21; BINDING; CELLS	We investigated the involvement of the p21ras-GTPase activating protein (GAP) in insulin-induced signal transduction. In cells overexpressing the insulin receptor, we did not observe association between GAP and the insulin receptor after insulin treatment nor the phosphorylation of GAP on tyrosine residues. However, after insulin treatment in the presence of the phosphotyrosine phosphatase inhibitor phenylarsine oxide (PAO), 5-10% of GAP was found to be associated with the insulin receptor, and, in addition, a fraction of total GAP was phosphorylated on tyrosine. Using in vitro binding we showed that the N-terminal part of GAP containing the src-homology domains 2 and 3 (SH2-SH3-SH2 region) is involved in binding to the autophosphorylated insulin receptor beta-chain. In vitro binding between GAP and the autophosphorylated insulin receptor occurred independently of PAO pretreatment. These results suggest that GAP can transiently interact with the insulin receptor after insulin treatment, and this interaction is arrested after PAO pretreatment.	UNIV UTRECHT, PHYSIOL CHEM LAB, VONDELLAAN 24A, 3521 GG UTRECHT, NETHERLANDS; ONYX PHARMACEUT, DEPT MOLEC BIOL, RICHMOND, CA 94806 USA	Utrecht University				Medema, Rene/0000-0002-6754-0381				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; FROST SC, 1987, J BIOL CHEM, V262, P9872; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; LIAO K, 1991, J BIOL CHEM, V266, P6544; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; PRONK GJ, 1992, ONCOGENE, V7, P389; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	40	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24058	24063						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331107				2022-12-25	WOS:A1992JZ23900094
J	CANTOR, AB; KORNFELD, S				CANTOR, AB; KORNFELD, S			PHOSPHORYLATION OF ASN-LINKED OLIGOSACCHARIDES LOCATED AT NOVEL SITES ON THE LYSOSOMAL-ENZYME CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; PHOSPHOMANNOSYL RECEPTORS; SACCHAROMYCES-CEREVISIAE; DIRECTED MUTAGENESIS; LIGAND INTERACTIONS; PROTEINASE-A; BINDING; CELLS; PURIFICATION; RECOGNITION	We have examined the phosphorylation of Asn-linked oligosaccharides introduced at seven novel sites on human cathepsin D to determine whether the location of an oligosaccharide on a lysosomal enzyme affects its ability to serve as a substrate for UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (phosphotransferase), the enzyme that catalyzes the initial step in the biosynthesis of mannose 6-phosphate residues. The glycosylation sites were introduced into the cathepsin D cDNA by site-directed mutagenesis and were selected to be widely distributed over the surface of the molecule. When the constructs were expressed in Xenopus oocytes, the oligosaccharides at each glycosylation site were phosphorylated at levels considerably above background (19-70% phosphorylation versus <0.4% for the secretory protein glycopepsinogen). However, oligosaccharides located closer to the essential components of the phosphotransferase recognition domain (lysine 203 and amino acids 265-292) were phosphorylated better than oligosaccharides located further away. Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower. These results demonstrate that there is considerable flexibility in the placement of glycosylation sites on cathepsin D in terms of the ability of the oligosaccharides to serve as substrates for phosphotransferase, although oligosaccharides located closer to the phosphotransferase recognition determinant are preferentially phosphorylated.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)				Cantor, Alan/0000-0002-5136-028X	NCI NIH HHS [CA08759] Funding Source: Medline; NIGMS NIH HHS [GM-07200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHAUDA SBP, 1990, BIOCHEM BIOPH RES CO, V168, P878, DOI 10.1016/0006-291X(90)92403-M; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOEL E, 1986, Proteins Structure Function and Genetics, V1, P363, DOI 10.1002/prot.340010409; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, IN PRESS ANAL BIOCH; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; FAUST PL, 1987, J CELL BIOL, V105, P1947, DOI 10.1083/jcb.105.5.1947; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FISCHER HD, 1982, J BIOL CHEM, V257, P9938; FRITZ LC, 1986, P NATL ACAD SCI USA, V83, P4114, DOI 10.1073/pnas.83.12.4114; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; GRAY GL, 1986, GENE, V48, P41, DOI 10.1016/0378-1119(86)90350-1; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; Maniatis T., 1982, MOL CLONING; MECHLER B, 1982, J BIOL CHEM, V257, P1203; MEUSSDOERFFER F, 1980, J BIOL CHEM, V255, P2087; PINET F, 1985, P NATL ACAD SCI USA, V82, P8503, DOI 10.1073/pnas.82.24.8503; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VARKI A, 1980, J BIOL CHEM, V255, P847; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WARIN V, 1979, CARBOHYD RES, V76, P11, DOI 10.1016/0008-6215(79)80002-6; WEITZ G, 1992, J BIOL CHEM, V267, P10039; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	41	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23357	23363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331083				2022-12-25	WOS:A1992JY16300099
J	MCKENZIE, FR; SEUWEN, K; POUYSSEGUR, J				MCKENZIE, FR; SEUWEN, K; POUYSSEGUR, J			STIMULATION OF PHOSPHATIDYLCHOLINE BREAKDOWN BY THROMBIN AND CARBACHOL BUT NOT BY TYROSINE KINASE RECEPTOR LIGANDS IN CELLS TRANSFECTED WITH M1 MUSCARINIC RECEPTORS - RAPID DESENSITIZATION OF PHOSPHOCHOLINE-SPECIFIC (PC) PHOSPHOLIPASE-D BUT SUSTAINED ACTIVITY OF PC-PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ALPHA-THROMBIN; HAMSTER FIBROBLASTS; HL-60 GRANULOCYTES; DOWN-REGULATION; 2ND MESSENGER; DNA-SYNTHESIS; GROWTH-FACTOR	In order to evaluate the possible contribution of phospholipase D (PLD) stimulation to the mitogenic response, a screening of a variety of different compounds, some of which are known to be potent mitogens, was performed using the well characterized Chinese hamster lung fibroblast (CCL39) cell line. In wild type CCL39 cells, or derivatives expressing high levels of either the human M1 muscarinic receptor (Hm1) or the human epidermal growth factor (EGF) receptor (39M1-81 and 39ER22 clones, respectively), thrombin, a potent mitogen for all three cell types, elicited the rapid activation of PLD (t1/2 activation, 30 s). Carbachol-mediated activation of the Hm1 receptor in the 39M1-81 clone, which is not a mitogenic signal, produced a similarly rapid although greater activation of PLD. Addition of EGF to the 39ER22 clone was able to provoke both a mitogenic response and stimulate PLD, albeit a comparatively small effect. In each case, the stimulation of PLD correlated closely with the ability to stimulate inositol phospholipid breakdown and was entirely dependent on the activation of protein kinase C. Moreover, the ability of both thrombin and carbachol to stimulate PLD was found to be rapidly desensitized, with a similar time course of desensitization (t1/2 desensitization, 90 s). It has recently been reported that an increase in phospholipase C (PLC)-mediated phosphocholine (PC) hydrolysis by either addition of agonist or by extracellular addition of PC-specific PLC enzyme constitutes a mitogenic signal. In this regard, in addition to stimulation of PLD, thrombin and carbachol were both able to stimulate the activity of a phosphocholine-specific phospholipase C (PC-PLC), which did not appear to desensitize within the time course employed. By contrast, EGF was unable to elicit the stimulation of PC-PLC. Ligands such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF), which bind to and activate receptors with intrinsic tyrosine kinase activity, are potent mitogens for CCL39 cells but were unable to stimulate either PLD or PC-PLC activity. Furthermore, exogenous addition of purified PC-PLC enzyme, although able to induce a strong and lasting hydrolysis of PC, was unable to produce a mitogenic signal on its own. On the basis of these results, we conclude that the activation of both PLD and PC-PLC is neither sufficient nor required to produce a mitogenic response.			MCKENZIE, FR (corresponding author), CTR BIOCHIM,UMR 134,PARC VALROSE,F-06108 NICE,FRANCE.							AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BROWN KD, 1987, BIOCHEM J, V245, P631, DOI 10.1042/bj2450631; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, CELL SIGNAL, V3, P273, DOI 10.1016/0898-6568(91)90055-Y; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GO M, 1987, BIOCHEM BIOPH RES CO, V144, P598; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CF, 1990, J BIOL CHEM, V265, P17468; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; KAHAN K, 1992, J BIOL CHEM, V267, P13369; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; L'allemain G, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000255; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEE MH, 1986, J BIOL CHEM, V261, P4867; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MORI T, 1982, J BIOCHEM, V91, P427, DOI 10.1093/oxfordjournals.jbchem.a133714; PAI JK, 1988, J BIOL CHEM, V263, P12472; PAI JK, 1988, J BIOL CHEM, V263, P12474; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PARIS S, 1988, J BIOL CHEM, V263, P11250; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PRICE BD, 1989, J BIOL CHEM, V264, P16638; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	59	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22759	22769						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331066				2022-12-25	WOS:A1992JY16300013
J	NAKA, D; ISHII, T; YOSHIYAMA, Y; MIYAZAWA, K; HARA, H; HISHIDA, T; KITAMURA, N				NAKA, D; ISHII, T; YOSHIYAMA, Y; MIYAZAWA, K; HARA, H; HISHIDA, T; KITAMURA, N			ACTIVATION OF HEPATOCYTE GROWTH-FACTOR BY PROTEOLYTIC CONVERSION OF A SINGLE CHAIN FORM TO A HETERODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; HEPATOPOIETIN-A; MESSENGER-RNA; SCATTER FACTOR; PURIFICATION; IDENTIFICATION; RECEPTOR; SEQUENCE; CDNA; FIBROBLASTS	Hepatocyte growth factor (HGF) is a heterodimeric protein consisting of a heavy chain and a light chain held by a disulfide bond. These chains are produced by endoproteolytic processing from a single chain precursor. In this study, we examined whether the processing is a prerequisite for the mitogenic activity of HGF on hepatocytes in primary culture. Single chain HGF was proteolytically converted to the heterodimeric form during incubation with hepatocytes and was as mitogenic as the heterodimeric form. When the conversion was inhibited by serine-protease inhibitors, the mitogenic activity of single chain HGF was markedly reduced. Furthermore, a mutant resistant to the proteolytic processing, which was prepared by in vitro mutagenesis, completely lost the mitogenic activity. From these results, we concluded that the single chain form of HGF is endoproteolytically processed by a serine-protease and that this processing is a prerequisite for the mitogenic activity of HGF.	KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University	NAKA, D (corresponding author), MITSUBISHI KASEI CORP,RES CTR,BIOSCI LAB,1000 KAMOSHIDA CHO,MIDORI KU,YOKOHAMA 227,JAPAN.		MIYAZAWA, KEIJI/I-9713-2014					BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HERNANDEZ J, 1992, J CELL PHYSIOL, V150, P116, DOI 10.1002/jcp.1041500116; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIMOMURA T, 1992, IN PRESS CYTOTECHNOL; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1989, CANCER RES, V49, P3314	31	207	231	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20114	20119						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328193				2022-12-25	WOS:A1992JR85800059
J	FREUND, R; BRONSON, RT; BENJAMIN, TL				FREUND, R; BRONSON, RT; BENJAMIN, TL			SEPARATION OF IMMORTALIZATION FROM TUMOR-INDUCTION WITH POLYOMA LARGE T-MUTANTS THAT FAIL TO BIND THE RETINOBLASTOMA GENE-PRODUCT	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; ADENOVIRUS E1A PROTEINS; MIDDLE-T; CELL-CYCLE; TRANSCRIPTION FACTOR; SUSCEPTIBILITY GENE; KINASE-ACTIVITY; EMBRYO FIBROBLASTS; SIMIAN VIRUS-40; WILD-TYPE	The mouse polyomavirus encodes a tumor-suppressor gene inactivator in its large T protein and a proto-oncogene activator in its middle T protein. We have used site-directed mutagenesis to selectively inactivate the former function without affecting the latter. Two mutant viruses were constructed to encode altered large T proteins that fail to bind the retinoblastoma tumor-suppressor gene product pRB, along with normal small and middle T proteins. The pRB-binding mutants proved to be defective in immortalization of primary rat embryo fibroblasts by a variety of tests. Yet they proved capable of transforming both primary and established fibroblasts in culture. Most importantly, the inability of these mutants to bind pRB had little effect on their ability to induce tumors in mice. We conclude that induction of multiple tumor types in this system does not depend on large T-pRB interactions but rather on middle T-dependent pathways. In addition, the ability of this virus to immortalize cells in culture is not essential to its ability to induce tumors in the animal.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NCI NIH HHS [R35-CA44343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BENJAMIN T, 1990, VIROLOGY, P317; BENJAMIN TL, 1970, P NATL ACAD SCI USA, V67, P394, DOI 10.1073/pnas.67.1.394; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; DAWE CJ, 1987, AM J PATHOL, V127, P243; DEBENSKY TW, 1984, J VIROL, V50, P779; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUBENSKY TW, 1991, J VIROL, V65, P342, DOI 10.1128/JVI.65.1.342-349.1991; DYSON N, 1989, CANCER CEL, V7, P235; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ECKHART W, 1969, VIROLOGY, V38, P120, DOI 10.1016/0042-6822(69)90133-0; ECKHART W, 1977, VIROLOGY, V77, P589, DOI 10.1016/0042-6822(77)90484-6; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEUTEUN J, 1976, P NATL ACAD SCI USA, V73, P4169; FLUCK MM, 1979, VIROLOGY, V96, P205, DOI 10.1016/0042-6822(79)90185-5; FLUCK MM, 1977, VIROLOGY, V77, P610, DOI 10.1016/0042-6822(77)90486-X; FREUND R, 1991, J VIROL, V65, P335, DOI 10.1128/JVI.65.1.335-341.1991; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; FRIED M, 1965, P NATL ACAD SCI USA, V53, P486, DOI 10.1073/pnas.53.3.486; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SILVER J, 1978, CELL, V15, P485, DOI 10.1016/0092-8674(78)90018-1; STANELONI RJ, 1977, VIROLOGY, V77, P598, DOI 10.1016/0042-6822(77)90485-8; TALMAGE DA, 1992, VIROLOGY, V187, P734, DOI 10.1016/0042-6822(92)90476-6; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	73	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1979	1987						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328987				2022-12-25	WOS:A1992JP42400011
J	MUERHOFF, AS; GRIFFIN, KJ; JOHNSON, EF				MUERHOFF, AS; GRIFFIN, KJ; JOHNSON, EF			THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR MEDIATES THE INDUCTION OF CYP4A6, A CYTOCHROME-P450 FATTY-ACID OMEGA-HYDROXYLASE, BY CLOFIBRIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RETINOIC ACID; BETA-GENE; SUPERFAMILY; CLONING; HORMONE; EXPRESSION; SEQUENCES; BINDING; ELEMENT; MEMBER	Gene transfer experiments indicate that induction by the peroxisome proliferators, clofibric acid and WY-14,643, of luciferase expression driven by the promoter and 5'-flanking sequences of the rabbit cytochrome P450 4A6 gene (CYP4A6) is dependent on cotransfection of expression plasmids for the peroxisome proliferator-activated receptor, PPAR. Activation by PPAR is observed in the absence of the inducers. However, a mutant, PPAR-G (Glu282 --> Gly) activated luciferase expression only in the presence of peroxisome proliferators. Deletion analysis has localized a response element to a 34-base pair segment located 677 base pairs upstream of the CYP4A6 transcription start site that is similar to an element that regulates the response of the rat fatty acyl-CoA oxidase gene to peroxisome proliferators and that binds PPAR.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED,DIV BIOCHEM,NX 4, LA JOLLA, CA 92037 USA	Scripps Research Institute					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NICHD NIH HHS [HD04445] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KRAUPPGRASL B, 1990, CANCER RES, V50, P3701; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MUERHOFF AS, 1992, ARCH BIOCHEM BIOPHYS, V296, P66, DOI 10.1016/0003-9861(92)90545-8; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; POLAND A, 1976, J BIOL CHEM, V251, P4936; RAO MS, 1987, CARCINOGENESIS, V8, P631; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrook J, 1989, MOL CLONING LABORATO; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YOKOTANI N, 1989, J BIOL CHEM, V264, P21665	23	309	316	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19051	19053						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326542				2022-12-25	WOS:A1992JP59300008
J	YAMAGUCHI, A; SOMEYA, Y; SAWAI, T				YAMAGUCHI, A; SOMEYA, Y; SAWAI, T			METAL-TETRACYCLINE/H+ ANTIPORTER OF ESCHERICHIA-COLI ENCODED BY TRANSPOSON TN10 - THE ROLE OF A CONSERVED SEQUENCE MOTIF, GXXXXRXGRR, IN A PUTATIVE CYTOPLASMIC LOOP BETWEEN HELICES 2 AND 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE PROTEIN; NUCLEOTIDE-SEQUENCE; GENE; DETERMINANTS; EFFLUX	The region including the conserved Ser65-Asp66 dipeptide in the tetracycline/H+ antiporter (TET) encoded by transposon Tn10 is thought to play a gating role (Yamaguchi, A., Ono, N., Akasaka, T., Noumi, T., and Sawai, T. (1990) J. Biol. Chem. 265, 15525-15530). The dipeptide is in putative interhelix loop2-3, which also includes the conserved sequence motif, GXXXXRXGRR, found in all TET proteins and sugar/H+ symporters. Through the combination of localized random and site-directed mutagenesis, each residue in loop2-3 was replaced. Among 10 residues in putative loop2-3, the important residues, of which substitution resulted in significant reduction or complete loss of the transport activity, were Gly62, Asp66, Gly69, and Arg70. The defect in the transport activity of the Gly62 and Gly69 substitution mutants corresponded to the steric hindrance by the substituents as to the putative beta-turn structure of the peptide backbone containing these glycines. Of 3 conserved Arg residues, the replacement of only Arg70 caused complete loss of the activity except for replacement with Lys, indicating the importance of a positive charge at this position, which is similar to the essentiality of a negative charge at Asp66. A "charge-neutralizing" intra-loop salt bridge between Asp66 and Arg70 was not likely because the double mutant in which Asp66 and Arg70 were replaced with asparagine and leucine, respectively, showed no transport activity. A triple mutant with only one positive charge at Arg70 in this loop showed about half the wild-type activity, indicating that the polycationic nature of the loop was not critical for the activity. Cys mutants as to the unessential residues in the loop were modifiable with N-ethylmaleimide, except for the Met64 --> Cys and Arg71 --> Cys mutants; however, the modification of only the Ser65 --> Cys mutant caused significant inhibition of the transport activity, indicating that position 65 is a unique position in the structure of loop2-3.			YAMAGUCHI, A (corresponding author), CHIBA UNIV, FAC PHARMACEUT SCI, DIV MICROBIAL CHEM, CHIBA 263, JAPAN.							CHOPRA I, 1986, J ANTIMICROB CHEMOTH, V18, P51, DOI 10.1093/jac/18.Supplement_C.51; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Creighton TE, 1983, PROTEINS STRUCTURES; ECKERT B, 1989, J BIOL CHEM, V264, P11663; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MOYED HS, 1983, J BACTERIOL, V155, P549, DOI 10.1128/JB.155.2.549-556.1983; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; RUBIN RA, 1990, GENE, V87, P7, DOI 10.1016/0378-1119(90)90489-E; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAMAMOTO T, 1981, J BACTERIOL, V145, P808, DOI 10.1128/JB.145.2.808-813.1981	24	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19155	19162						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326546				2022-12-25	WOS:A1992JP59300025
J	JIN, SLC; SWINNEN, JV; CONTI, M				JIN, SLC; SWINNEN, JV; CONTI, M			CHARACTERIZATION OF THE STRUCTURE OF A LOW KM, ROLIPRAM-SENSITIVE CAMP PHOSPHODIESTERASE - MAPPING OF THE CATALYTIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; SITE-DIRECTED MUTAGENESIS; SERTOLI-CELL; REGULATORY SUBUNIT; MOLECULAR-CLONING; DICTYOSTELIUM-DISCOIDEUM; HORMONAL-REGULATION; ESCHERICHIA-COLI; BINDING	Considerable structural similarities are present in a region of approximately 270 amino acids in most known cyclic nucleotide phosphodiesterase (PDE) sequences, opening the possibility that this region encodes the catalytic domain of the enzyme. To test this hypothesis, the structure of a high affinity cAMP PDE (cAMP-PDE) was analyzed by deletion mutations and site-directed mutagenesis. A ratPDE3 cDNA was mutated using a strategy based on fragment amplification by polymerase chain reaction. The effect of the introduced mutations was determined by expressing wild type and mutated proteins in prokaryotic and eukaryotic cells. The level of expression of the PDE protein was monitored by immunoblot analysis using two specific cAMP-PDE polyclonal antibodies and by measuring the PDE activity. After removal of a 99-amino acid region at the carboxyl terminus flanking the conserved domain, the protein retains its catalytic activity even though its K(m) and velocity were changed. Internal deletions at the amino terminus of this PDE showed that the enzyme activity was increased when a 97-amino acid fragment (from Tyr49 to Lys145) was removed. Further deletions within the amino terminus produced inactive proteins. Within the domain that appears essential for catalysis, 1 threonine and 2 serine residues are conserved in all PDEs. Substitutions of the invariant threonine (Thr349) present in the most conserved region with alanine, proline, or serine yielded proteins of the correct size and a level of expression comparable to the wild type PDE. However, in both expression systems used, proteins were completely devoid of the ability to hydrolyze cyclic nucleotides, except when the threonine was substituted with a serine. Conversely, mutations of 2 other conserved serine residues (Ser305 and Ser398) present in the catalytic domain either had no effect or produced changes only in K(m) and V(max), but did not abolish catalytic activity. In addition, 2 histidine residues (His278 and His311) present in proximity to Thr349 appeared to be essential for the structure of the catalytic domain, since any substitution performed in these residues yielded an inactive enzyme. Mutations of a serine residue (Ser295) in the region homologous to the cAMP binding site of the regulatory subunit of the cAMP-dependent protein kinase demonstrated that this region does not have the same function in the two proteins. These data provide direct evidence that a 37-kDa domain, which in part corresponds to the region of conservation in all PDEs, contains the catalytic domain, and that threonine and histidine residues are probably involved in catalysis and/or are essential for the conformation of an active enzyme.	UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	JIN, SLC (corresponding author), GLAXO INC, DIV PHARMACOL, 5 MOORE DR, RES TRIANGLE PK, NC 27709 USA.		Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; Bernard H U, 1979, Methods Enzymol, V68, P482; BUBIS J, 1988, J BIOL CHEM, V263, P9668; CAMPAGNE MMV, 1990, J BIOL CHEM, V265, P5847; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; CHARBONNEAU H, 1987, CALCIUM BINDING PROT, P505; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CONTI M, 1986, ENDOCRINOLOGY, V118, P901, DOI 10.1210/endo-118-3-901; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189, DOI 10.1210/endo-110-4-1189; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; CONTI M, 1983, ENDOCRINOLOGY, V113, P1845, DOI 10.1210/endo-113-5-1845; Conti M., 1990, Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, P243; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; CULP JS, 1985, J BIOL CHEM, V260, P8320; EPSTEIN PM, 1982, ARCH BIOCHEM BIOPHYS, V218, P119, DOI 10.1016/0003-9861(82)90327-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LETRONG H, 1990, BIOCHEMISTRY-US, V29, P10280; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; OGREID D, 1988, J BIOL CHEM, V263, P17397; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SHEPARD HM, 1982, DNA-J MOLEC CELL BIO, V1, P125, DOI 10.1089/dna.1.1982.1.125; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; VANHAASTERT PJM, 1983, EUR J BIOCHEM, V131, P659; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321	43	115	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18929	18939						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326538				2022-12-25	WOS:A1992JN50200102
J	HANSON, PI; SCHULMAN, H				HANSON, PI; SCHULMAN, H			INHIBITORY AUTOPHOSPHORYLATION OF MULTIFUNCTIONAL CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE ANALYZED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CA-2+ CALMODULIN; BINDING DOMAIN; CA-2+-INDEPENDENT ACTIVITY; BIOTINYLATED CALMODULIN; REGULATORY INTERACTIONS; MOLECULAR-CLONING; EXPRESSION SYSTEM; AUTONOMOUS ENZYME; SENSITIVE METHOD	Initial autophosphorylation of multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase) occurs at Thr286 (the "autonomy" site) and converts the kinase from a Ca2+-dependent to a partially Ca2+-independent or autonomous enzyme. After removal of Ca2+/calmodulin, the autonomous kinase undergoes a "burst" of inhibitory autophosphorylation at sites distinct from the autonomy site which may be masked in the presence of bound calmodulin. This burst of Ca2+-independent autophosphorylation blocks the ability of calmodulin to activate the kinase. We have used site-directed mutagenesis to replace putative inhibitory autophosphorylation sites within the calmodulin binding domain of recombinant alpha-CaM kinase with nonphosphorylatable alanines and examined the effects on autophosphorylation, kinase activity, and calmodulin binding. Although prominent Ca2+-independent autophosphorylation occurs within the calmodulin binding domain at Thr305, Thr306, and Ser314 in wild-type alpha-CaM kinase, the inhibitory effect on kinase activity and calmodulin binding is retained in mutants lacking any one of these three sites. However, when both Thr305 and Thr306 are converted to alanines the kinase does not display inhibition of either activity or calmodulin binding. Autophosphorylation at either Thr305 or Thr306 is therefore sufficient to block both binding and activation of the kinase by Ca2+/calmodulin. Thr306 is also slowly autophosphorylated in a basal reaction in the continuous absence of Ca2+/calmodulin. Autophosphorylation of Thr306 by the kinase in either its basal or autonomous state suggests that in the absence of bound calmodulin, the region of the autoregulatory domain surrounding Thr306, rather than the region near the autonomy site, lies nearest the peptide substrate binding site of the kinase.	STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA	Stanford University			Hanson, Phyllis/E-9420-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030179, R01GM030179] Funding Source: NIH RePORTER; NCI NIH HHS [CA09302] Funding Source: Medline; NIGMS NIH HHS [GM30179] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; CONTI MA, 1981, J BIOL CHEM, V256, P3178; FONG YL, 1989, J BIOL CHEM, V264, P16759; GILBERT DG, 1989, ENZYME KINETICS; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; HASHIMOTO Y, 1988, P NATL ACAD SCI USA, V85, P7001, DOI 10.1073/pnas.85.18.7001; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; KING MM, 1988, J BIOL CHEM, V263, P4754; LICKTEIG R, 1988, J BIOL CHEM, V263, P19232; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOU LL, 1989, J NEUROSCI, V9, P2020; MARTENSEN TM, 1989, BIOCHEMISTRY-US, V28, P9243, DOI 10.1021/bi00450a002; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; OLWIN BB, 1983, METHOD ENZYMOL, V102, P148; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SCHULMAN H, 1978, NATURE, V271, P478, DOI 10.1038/271478a0; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SHARMA RK, 1985, P NATL ACAD SCI USA, V82, P2603, DOI 10.1073/pnas.82.9.2603; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; UEDA T, 1977, J BIOL CHEM, V252, P5155; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; YAMAUCHI T, 1989, J BIOL CHEM, V264, P19108	55	172	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17216	17224						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324926				2022-12-25	WOS:A1992JL05300075
J	LEE, AW; NIENHUIS, AW				LEE, AW; NIENHUIS, AW			FUNCTIONAL DISSECTION OF STRUCTURAL DOMAINS IN THE RECEPTOR FOR COLONY-STIMULATING FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; DEPENDENT PROTEIN-KINASE; GLYCOPHORIN-A; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; INSULIN-RECEPTORS; TYROSINE KINASES; TRANSMEMBRANE DOMAIN	Receptor tyrosine kinases (RTKs) transduce external signals to the interior of the cell via a cytoplasmic kinase domain. We demonstrated previously that ligand-induced kinase activation of the colony-stimulating factor-1 receptor (CSF-1R) occurs via receptor oligomerization without propagation of conformational changes through the transmembrane (TM) domain (Lee, A. W., and Nienhuis, A. W. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7270-7274). We have now examined the role of the different subdomains in the metabolic and signaling properties of CSF-1R. Two types of chimeric receptors have been utilized, Glyfms A, with the extracellular and TM domains of glycophorin A (GpA) and the cytoplasmic domain of CSF-1R, and Glyfms B, where only the extracellular domain originates from GpA. Glyfms A was found to exhibit a higher basal level of in vitro kinase activity, an increased associated phosphatidylinositol (PtdIns) 3-kinase activity and to support enhanced cellular mitogenesis, compared with wild-type CSF-1R or to Glyfms B. The constitutive activation of Glyfms A is consistent with the hypothesis that the TM domain may play a role in receptor oligomerization. Cross-linking with anti-GpA antibodies activated the kinase function of Glyfms B leading to an increase in PtdIns 3-kinase association and to the transmission of a mitogenic signal. Our results indicate that an activated kinase domain contains the major determinant for coupling with PtdIns 3-kinase, independent of extracellular and TM sequences and of ligand binding. Both chimeric receptors underwent internalization in the presence of anti-GpA antibodies but were not degraded, including the tyrosine-phosphorylated and kinase-active population. These results suggest that structural determinants in the extracellular domain must be important for targeting internalized receptors for lysosomal degradation.			LEE, AW (corresponding author), NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARSOUM AL, 1989, INT J BIOCHEM, V21, P635, DOI 10.1016/0020-711X(89)90383-2; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; CALBERG K, 1991, EMBO J, V10, P877; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GAHMBERG CG, 1979, J BIOL CHEM, V254, P7442; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREENBERGER J, 1985, P NATL ACAD SCI USA, V80, P2931; HARI J, 1987, J BIOL CHEM, V262, P15341; HARLOW E, 1988, ANTIBODIES LABORATOR; HEFFETZ D, 1986, J BIOL CHEM, V261, P889; HUECKSTEADT T, 1986, J BIOL CHEM, V261, P8655; KAHLES O, 1988, P NATL ACAD SCI USA, V85, P8567; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANGLOIS RG, 1985, J IMMUNOL, V134, P4009; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LEE AWM, 1992, CURR TOP CELL REGUL, V32, P73; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MARSHALL S, 1985, J BIOL CHEM, V260, P4136; MELLMAN I, 1988, J CELL SCI, P45; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORROW B, 1987, J BIOL CHEM, V262, P13812; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, MOL CELL BIOL, V10, P2407, DOI 10.1128/MCB.10.5.2407; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SHERR CJ, 1989, BLOOD, V73, P1786; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; SILVERBERG M, 1976, BIOCHEMISTRY-US, V15, P1448, DOI 10.1021/bi00652a015; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, P NATL ACAD SCI USA, V11, P4698; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947; YAMAKAWA A, 1991, J BIOL CHEM, V266, P17580	71	10	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16472	16483						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322904				2022-12-25	WOS:A1992JJ45800076
J	POMERANCE, M; SCHWEIGHOFFER, F; TOCQUE, B; PIERRE, M				POMERANCE, M; SCHWEIGHOFFER, F; TOCQUE, B; PIERRE, M			STIMULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE BY ONCOGENIC RAS-P21 IN XENOPUS OOCYTES - REQUIREMENT FOR RAS-P21-GTPASE-ACTIVATING PROTEIN-INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; CYCLIC-AMP PHOSPHODIESTERASE; SERINE THREONINE KINASE; ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; RAS PROTEINS; S6 KINASE; LAEVIS OOCYTES; OKADAIC ACID; MAP KINASE	p21ras plays an important role in the control of cell proliferation. The molecular mechanisms implicated are unknown. We report that the injection of oncogenic Lys12 Ras into Xenopus laevis oocytes promoted the activation of mitogen-activated protein kinase (MAP kinase) after a lag of about 90 min. MAP kinase activity was 10-fold higher 4 h after injection of oncogenic Lys12 Ras than after injection of nononcogenic Gly12 Ras. The stimulated MAP kinase activity remained at a plateau for at least 18 h. Maximal stimulation was obtained with 5 ng of Lys12 Ras, which is similar to the amount that elicits germinal vesicle breakdown. DEAE-Sephacel chromatography of extracts from Lys12 Ras-injected oocytes showed one peak of MAP kinase. MAP kinase activation by Lys12 Ras was associated with tyrosine phosphorylation of MAP kinase (p42). As previously shown, the S6-kinase II (likely pp90rsk), which is activated in vitro by MAP kinase, was also activated by oncogenic Lys12 Ras. Lys12 Ras with an additional mutation (Glu38) in the effector region that binds GTPase-activating protein (GAP) did not promote MAP kinase or S6 kinase activations. Thus, GAP may be involved downstream to Ras in these activation processes. Our results indicate that the Ras-GAP complex promotes MAP kinase activation in oocytes. This supports the idea that Ras-GAP controls MAP kinase, a kinase implicated in the action of various stimuli.	RHONE POULENC RORER SA, CTR RECH VITRY, F-94403 VITRY, FRANCE	Sanofi-Aventis	POMERANCE, M (corresponding author), INSERM, U96, UNITE RECH GLANDE THYROIDE & REGULAT HORMONALE, 80 RUE GEN LECLERC, F-94276 LE KREMLIN BICETRE, FRANCE.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CICIRELLI MF, 1988, FEBS LETT, V241, P195, DOI 10.1016/0014-5793(88)81060-3; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ELETR M, 1979, SCIENCE, V205, P1397, DOI 10.1126/science.472755; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ERICKSON F, 1986, J BIOL CHEM, V261, P350; ERICKSON RL, 1991, J BIOL CHEM, V266, P6007; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HACCAFD O, 1991, EUR J BIOCHEM, V192, P633; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; MALLER JL, 1985, CELL DIFFER DEV, V16, P211, DOI 10.1016/0045-6039(85)90570-6; MARTIN TE, 1969, J MOL BIOL, V43, P151, DOI 10.1016/0022-2836(69)90085-0; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; SADLER SE, 1989, J BIOL CHEM, V264, P856; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; SANO M, 1990, J NEUROCHEM, V55, P427, DOI 10.1111/j.1471-4159.1990.tb04154.x; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHORDERET-SLATKINE S, 1972, Cell Differentiation, V1, P179, DOI 10.1016/0045-6039(72)90027-9; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMATA T, 1990, MOL CELL BIOL, V10, P880; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORUDELBAUFFE D, 1988, J NEUROCHEM, V51, P1448, DOI 10.1111/j.1471-4159.1988.tb01110.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VEDA T, 1991, BIOCHEMISTRY-US, V30, P909; WOLFMAN A, 1990, SCIENCE, V248, P247; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	63	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16155	16160						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322893				2022-12-25	WOS:A1992JJ45800029
J	BEERS, EP; MORENO, TN; CALLIS, J				BEERS, EP; MORENO, TN; CALLIS, J			SUBCELLULAR-LOCALIZATION OF UBIQUITIN AND UBIQUITINATED PROTEINS IN ARABIDOPSIS-THALIANA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE MUTANT TS85; ABNORMAL PROTEINS; DEPENDENT PROTEOLYSIS; CONJUGATING ENZYMES; LYSOSOMAL SYSTEM; HIGHER-PLANT; HELA-CELLS; HEAT-SHOCK; DEGRADATION; YEAST	Ubiquitin is a highly conserved, 76-amino acid, eukaryotic protein. Its widely accepted role as a proteolytic cofactor depends on its unique ability to covalently ligate to other cellular proteins. While there is good evidence for the existence of such ubiquitinated proteins in the cytosolic and nuclear compartments, relatively little is known about the presence of free ubiquitin and ubiquitinated proteins in other subcellular compartments. This is especially true of higher plants, which have not previously been the subject of extensive biochemical subcellular localizations of ubiquitinated proteins. We extracted cell wall proteins and purified nuclei, vacuoles, chloroplasts, and microsomes from chlorophyllous tissues of Arabidopsis. Immunoblot analyses were used to compare the profiles of ubiquitinated proteins from purified subcellular fractions to those from unfractionated extracts. Purified nuclei contained, in addition to a complex mixture of high molecular mass ubiquitinated proteins, a strongly immunoreactive 28-kDa protein. In the apoplastic extract, we did not detect any ubiquitinated proteins enriched above the background level of those due to cytosolic contamination. Vacuoles appeared to contribute significantly to the ubiquitinated proteins present in the whole protoplast extract. At least three high molecular mass ubiquitinated proteins were unique to the vacuolar extract. Chloroplast stromal proteins did not react specifically with anti-ubiquitin antibodies. When microsomal ubiquitinated proteins were compared to those found in a whole protoplast extract, a distinct pattern was evident. Microsomal ubiquitinated proteins were not visible in the 10,000 x g supernatant used to prepare the 100,000 x g pellet, indicating that they were probably low abundance proteins in the protoplast extract.	UNIV CALIF DAVIS,DEPT BIOCHEM & BIOPHYS,DAVIS,CA 95616	University of California System; University of California Davis				Callis, Judy/0000-0002-0622-078X				ANDERSEN MW, 1981, FEBS LETT, V132, P210, DOI 10.1016/0014-5793(81)81162-3; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BEERS EP, 1988, PLANT PHYSIOL, V87, P799, DOI 10.1104/pp.87.4.799; BOLLER T, 1979, PLANT PHYSIOL, V63, P1123, DOI 10.1104/pp.63.6.1123; BONNER WM, 1988, UBIQUITIN, P157; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; DELLAPENNA D, 1989, PLANT PHYSIOL, V90, P1372, DOI 10.1104/pp.90.4.1372; DIETZGEN RG, 1991, VIROLOGY, V184, P397, DOI 10.1016/0042-6822(91)90857-8; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FREHNER M, 1987, PLANT PHYSIOL, V84, P1296, DOI 10.1104/pp.84.4.1296; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GASPAR JO, 1990, MOL PLANT MICROBE IN, V3, P182, DOI 10.1094/MPMI-3-182; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZELWOOD D, 1990, VIROLOGY, V177, P352, DOI 10.1016/0042-6822(90)90490-I; HEINEMEYER W, 1991, BIOCHEM SOC T, V19, P724, DOI 10.1042/bst0190724; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOFFMAN NE, 1991, PLANT MOL BIOL, V17, P1189, DOI 10.1007/BF00028735; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KLEMES Y, 1981, J BIOL CHEM, V256, P8436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; LUTHE DS, 1980, PLANT PHYSIOL, V65, P305, DOI 10.1104/pp.65.2.305; MAGNANI M, 1986, J BIOL CHEM, V261, P8327; MAGNANI M, 1991, J BIOL CHEM, V266, P21018; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PICKART CM, 1985, J BIOL CHEM, V260, P7903; RABOY B, 1986, EMBO J, V5, P863, DOI 10.1002/j.1460-2075.1986.tb04296.x; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; Rechsteiner M., 1988, UBIQUITIN; RECORD RD, 1988, PLANTA, V176, P425, DOI 10.1007/BF00397648; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHAEFFER JR, 1988, J BIOL CHEM, V263, P13663; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; Somerville C.R., 1982, METHODS CHLOROPLAST, P129; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VANDERVALK HCPM, 1988, PLANT PHYSIOL, V87, P536, DOI 10.1104/pp.87.2.536; VEIERSKOV B, 1991, PLANT PHYSIOL, V96, P4, DOI 10.1104/pp.96.1.4; VIERSTRA RD, 1985, J BIOL CHEM, V260, P2015; VIERSTRA RD, 1988, BIOCHEMISTRY-US, V27, P3290, DOI 10.1021/bi00409a025; WETTERN M, 1990, EUR J BIOCHEM, V191, P571, DOI 10.1111/j.1432-1033.1990.tb19159.x; YANG JF, 1991, PHYTOCHEMISTRY, V30, P2487, DOI 10.1016/0031-9422(91)85087-G; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZIEGLER P, 1986, PLANT PHYSIOL, V82, P119	70	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15432	15439						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322398				2022-12-25	WOS:A1992JG11300029
J	RIJNBOUTT, S; STOORVOGEL, W; GEUZE, HJ; STROUS, GJ				RIJNBOUTT, S; STOORVOGEL, W; GEUZE, HJ; STROUS, GJ			IDENTIFICATION OF SUBCELLULAR COMPARTMENTS INVOLVED IN BIOSYNTHETIC PROCESSING OF CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; LYSOSOMAL-ENZYMES; MEDIATED ENDOCYTOSIS; HEPG2 CELLS; RAT-LIVER; INTRACELLULAR MOVEMENT; MACROPHAGE ENDOSOMES; BETA-HEXOSAMINIDASE; HUMAN-FIBROBLASTS; HEPATOMA-CELLS	We have assigned the biosynthetic processing steps of cathepsin D to intracellular compartments which are involved in its transport to lysosomes in HepG2 cells. Cathepsin D was synthesized as a 51-kDa proenzyme. After formation of 51-55-kDa intermediates due to processing of N-linked oligosaccharides, procathepsin D was proteolytically processed to an intermediate 44-kDa and the mature 31-kDa enzyme. The intersection of the biosynthetic pathway of cathepsin D with the endocytic pathway was labeled with horseradish peroxidase and monitored biochemically by 3,3'-diaminobenzidine cytochemistry. Horseradish peroxidase was used either as a fluid-phase marker to label the entire endocytic pathway or conjugated to transferrin (Tf) to label endosomes only. Directly after biosynthesis cathepsin D was accessible neither to horseradish peroxidase nor Tf-horseradish peroxidase. Newly synthesized 51-55-kDa species of cathepsin D present in the trans-Golgi reticulum were accessible to both horseradish peroxidase and Tf-horseradish peroxidase. The accessibility of trans-Golgi reticulum to both endocytosed horseradish peroxidase and Tf-horseradish peroxidase was monitored by colocalization with a secretory protein, alpha-1-anti-trypsin. The proteolytic processing of 51-55-kDa to 44-kDa cathepsin D occurred in compartments which were fully accessible to fluid-phase horseradish peroxidase. Tf-horseradish peroxidase had access to only 20% of 44-kDa cathepsin D while it had no access to 31-kDa cathepsin D. In contrast, the 31-kDa species was completely accessible to fluid-phase horseradish peroxidase. We conclude that proteolytic processing of 51-55-kDa to 44-kDa cathepsin D occurs in endosomes, whereas the processing of 44-31-kDa cathepsin D takes place in lysosomes.	UNIV UTRECHT, SCH MED, CELL BIOL LAB, AZU, ROOM H02314, 3584 CX UTRECHT, NETHERLANDS	Utrecht University								BACKER JM, 1990, J BIOL CHEM, V265, P14828; BLEEKEMOLEN JE, 1988, EUR J CELL BIOL, V47, P366; BOWSER R, 1990, J CELL PHYSIOL, V143, P110, DOI 10.1002/jcp.1041430115; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; FARQUHAR MG, 1983, FED PROC, V42, P2407; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; HASILIK A, 1981, EUR J BIOCHEM, V121, P125, DOI 10.1111/j.1432-1033.1981.tb06440.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; JONSSON LMV, 1987, EUR J BIOCHEM, V164, P171, DOI 10.1111/j.1432-1033.1987.tb11008.x; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEIBOLD DM, 1988, J CELL PHYSIOL, V137, P411, DOI 10.1002/jcp.1041370304; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4	47	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15665	15672						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322403				2022-12-25	WOS:A1992JG11300064
J	GONG, MC; COHEN, P; KITAZAWA, T; IKEBE, M; MASUO, M; SOMLYO, AP; SOMLYO, AV				GONG, MC; COHEN, P; KITAZAWA, T; IKEBE, M; MASUO, M; SOMLYO, AP; SOMLYO, AV			MYOSIN LIGHT CHAIN PHOSPHATASE-ACTIVITIES AND THE EFFECTS OF PHOSPHATASE INHIBITORS IN TONIC AND PHASIC SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PIG TAENIA-COLI; OKADAIC ACID; PROTEIN PHOSPHATASE; CELLULAR-REGULATION; CATALYTIC SUBUNIT; FLASH-PHOTOLYSIS; HEAVY-MEROMYOSIN; KINASE; PHOSPHORYLATION	Phosphatase inhibitors microcystin-LR, tautomycin, and okadaic acid caused contraction and increased 20-kDa myosin light chain (MLC20) phosphorylation in Ca2+-free solutions in both phasic and tonic smooth muscle permeabilized with beta-escin, and inhibited the heavy meromyosin (HMM) phosphatase activity of smooth muscle homogenates with the same potency sequence: microcystin-LR > tautomycin > okadaic acid. The sensitivity to all three inhibitors was significantly higher, the half-times of relaxation and dephosphorylation were 4-6 times longer, and the HMM phosphatase and MLC20 kinase activity/smooth muscle cell wet weight was 2.0- and 1.9-fold lower in the tonic, femoral artery, than in the phasic, ileum or portal vein, smooth muscle. Preincubation with 0.2-mu-M inhibitor-2 decreased the HMM phosphatase activity by 35% in the ileum and by 60% in the femoral artery. The results suggest that the HMM phosphatases of smooth muscle have properties common to type 1 protein phosphatases, but are inhibited only partially by high concentrations of inhibitor-2, and that the lower HMM phosphatase activity of tonic smooth muscle may contribute to its greater sensitivity to phosphatase inhibitors and its slower rate of relaxation.	UNIV DUNDEE, DEPT BIOCHEM, MRC, PROT PHOSPHORYLAT GRP, DUNDEE DD1 4HN, SCOTLAND; UNIV VIRGINIA, SCH MED, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL, CLEVELAND, OH 44106 USA	University of Dundee; University of Virginia; University of Virginia; University of Virginia; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038888] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL19242-14] Funding Source: Medline; NIAMS NIH HHS [AR 38888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; BIALOJAN C, 1988, J PHYSIOL-LONDON, V398, P81, DOI 10.1113/jphysiol.1988.sp017030; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLEN M, 1988, BIOCHEM J, V250, P659, DOI 10.1042/bj2500659; CASSIDY P, 1979, J BIOL CHEM, V254, P1148; CHENG XC, 1987, J ANTIBIOT, V40, P907, DOI 10.7164/antibiotics.40.907; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V971, P163, DOI 10.1016/0167-4889(88)90188-7; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V968, P392, DOI 10.1016/0167-4889(88)90032-8; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DISALVO J, 1982, BIOCHEM BIOPH RES CO, V108, P534, DOI 10.1016/0006-291X(82)90861-0; DRISKA SP, 1989, AM J PHYSIOL, V256, pC315, DOI 10.1152/ajpcell.1989.256.2.C315; EDDINGER TJ, 1988, BIOCHEMISTRY-US, V27, P3807, DOI 10.1021/bi00410a043; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; HAEBERLE JR, 1985, J BIOL CHEM, V260, P9965; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HARTSHORNE DJ, 1989, ADV PROTEIN PHOSPHAT, V5, P219; HELPER DJ, 1988, J BIOL CHEM, V263, P15748; HIMPENS B, 1988, J GEN PHYSIOL, V92, P713, DOI 10.1085/jgp.92.6.713; HIRANO K, 1989, BRIT J PHARMACOL, V98, P1261, DOI 10.1111/j.1476-5381.1989.tb12672.x; HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014-5793(91)80745-O; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; HORIUTI K, 1989, J GEN PHYSIOL, V94, P769, DOI 10.1085/jgp.94.4.769; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1987, J BIOL CHEM, V262, P13828; INAGAKI M, 1987, ARCH BIOCHEM BIOPHYS, V254, P136, DOI 10.1016/0003-9861(87)90089-0; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1991, AM J PHYSIOL, V260, pC364, DOI 10.1152/ajpcell.1991.260.2.C364; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; OZAKI H, 1987, N-S ARCH PHARMACOL, V335, P356; PATO MD, 1985, J BIOL CHEM, V260, P2359; PATO MD, 1983, EUR J BIOCHEM, V132, P283, DOI 10.1111/j.1432-1033.1983.tb07360.x; PATO MD, 1983, J BIOL CHEM, V258, P7047; PATO MD, 1983, J BIOL CHEM, V258, P7055; PAUL RJ, 1983, CIRC RES, V53, P342, DOI 10.1161/01.RES.53.3.342; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; RUEGG JC, 1982, BIOCHEM BIOPH RES CO, V106, P1126, DOI 10.1016/0006-291X(82)91229-3; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SHIBATA S, 1982, J PHARMACOL EXP THER, V223, P135; SIEGMAN MJ, 1989, ADV PROTEIN PHOSPHAT, V5, P233; SOMLYO A V, 1969, Microvascular Research, V1, P354, DOI 10.1016/0026-2862(69)90014-4; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; TAKAI A, 1989, BIOCHEM J, V262, P617, DOI 10.1042/bj2620617; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; WALSH MP, 1982, BIOCHEMISTRY-US, V21, P1919, DOI 10.1021/bi00537a034; WERTH DK, 1982, J BIOL CHEM, V257, P7306	59	196	196	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14662	14668						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321813				2022-12-25	WOS:A1992JF08800028
J	STEPHENS, CM; BAUERLE, R				STEPHENS, CM; BAUERLE, R			ESSENTIAL CYSTEINES IN 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE FROM ESCHERICHIA-COLI - ANALYSIS BY CHEMICAL MODIFICATION AND SITE-DIRECTED MUTAGENESIS OF THE PHENYLALANINE-SENSITIVE ISOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID 7-PHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; PURIFICATION; ISOENZYME; KINETICS; GENE	The phenylalanine-sensitive isozyme of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase from Escherichia coli was inactivated by the sulfhydryl modifying reagents 5,5-dithiobis-(2-nitrobenzoate), bromopyruvate, and N-ethylmaleimide and protected from inactivation by the presence of its metal activator, Mn2+, and substrate, phosphoenolpyruvate. Inactivation by 5,5-dithiobis-(2-nitrobenzoate) was correlated with modification of two of the seven cysteine sulfhydryls of the enzyme monomer. The kinetics of 5,5-dithiobis-(2-nitrobenzoate) modification were altered significantly and distinctively by both substrates (phosphoenolpyruvate and erythrose 4-phosphate), by Mn2+, and by L-phenylalanine, suggesting that ligand binding has significant effects on the conformation of the enzyme. Site-directed mutagenesis was used to create multiple substitutions at the two invariant cysteine residues of the polypeptide, Cys-61 and Cys-328. Analysis of purified mutant enzymes indicated that Cys-61 is essential for catalytic activity and for metal binding. Cys-328 was found to be nonessential for catalytic activity, although mutations at this position had significant negative effects on V(max), K(m)Mn, and K(m)PEP.	UNIV VIRGINIA,DEPT BIOL,GILMER HALL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,INST EXTRATERR PHYS,CHARLOTTESVILLE,VA 22901	University of Virginia; University of Virginia; University of Virginia					NIGMS NIH HHS [GM35889, GM07082] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035889] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARDEMIL E, 1990, BIOCHIM BIOPHYS ACTA, V1040, P71, DOI 10.1016/0167-4838(90)90147-8; DAVIES WD, 1982, NUCLEIC ACIDS RES, V10, P4045, DOI 10.1093/nar/10.13.4045; DELEO AB, 1973, J BIOL CHEM, V248, P2344; DOY CH, 1967, BIOCHEM BIOPH RES CO, V26, P187, DOI 10.1016/0006-291X(67)90232-X; DYER WE, 1990, J BIOL CHEM, V265, P1608; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GANEM B, 1978, TETRAHEDRON, V34, P3353, DOI 10.1016/0040-4020(78)80222-1; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HUISMAN OC, 1974, J BIOL CHEM, V249, P6842; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCANDLISS RJ, 1978, J BIOL CHEM, V253, P4259; MELOCHE HP, 1967, BIOCHEMISTRY-US, V6, P2273, DOI 10.1021/bi00860a002; MUDAY GK, 1990, J BACTERIOL, V172, P2259, DOI 10.1128/jb.172.5.2259-2266.1990; NAGANO H, 1970, ARCH BIOCHEM BIOPHYS, V138, P58, DOI 10.1016/0003-9861(70)90284-5; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; PARAVICINI G, 1989, EUR J BIOCHEM, V186, P361, DOI 10.1111/j.1432-1033.1989.tb15217.x; RAY JM, 1988, J BACTERIOL, V170, P5500, DOI 10.1128/jb.170.12.5500-5506.1988; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONER R, 1976, J BIOL CHEM, V251, P5440; SIMPSON RJ, 1976, EUR J BIOCHEM, V70, P509, DOI 10.1111/j.1432-1033.1976.tb11042.x; SRINIVASAN PR, 1959, J BIOL CHEM, V234, P716; STAUB M, 1969, BIOCHIM BIOPHYS ACTA, V178, P599, DOI 10.1016/0005-2744(69)90228-9; STAUB M, 1969, BIOCHIM BIOPHYS ACTA, V178, P588, DOI 10.1016/0005-2744(69)90227-7; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; SUGIMOTO S, 1980, J BIOCHEM-TOKYO, V87, P881, DOI 10.1093/oxfordjournals.jbchem.a132818; VEIRA J, 1987, METHOD ENZYMOL, V153, P67; WELTMAN JK, 1973, J BIOL CHEM, V248, P3173; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	29	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5762	5767						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1348247				2022-12-25	WOS:A1992HK31800010
J	FLETCHER, BS; KUJUBU, DA; PERRIN, DM; HERSCHMAN, HR				FLETCHER, BS; KUJUBU, DA; PERRIN, DM; HERSCHMAN, HR			STRUCTURE OF THE MITOGEN-INDUCIBLE TIS10 GENE AND DEMONSTRATION THAT THE TIS10-ENCODED PROTEIN IS A FUNCTIONAL PROSTAGLANDIN G/H SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; TETRADECANOYL PHORBOL ACETATE; ENDOPEROXIDE SYNTHASE; COMPLEMENTARY-DNA; GROWTH-FACTOR; OSTEOBLASTIC CELLS; ARACHIDONIC-ACID; C-FOS; CYCLOOXYGENASE; MOUSE	The TIS10 cDNA was cloned as a primary response gene transcript whose mRNA rapidly accumulates in 3T3 cells treated with serum, polypeptide growth factors, or phorbol esters. The sequence of the TIS10 cDNA suggested that the gene encodes a protein with strong similarities to prostaglandin G/H synthase/cyclooxygenase (EC 1.14.99.1). Transient transfection into COS-1 cells of an expression vector driving the TIS10 cDNA leads to production and secretion of prostaglandin E2. Microsomes prepared from COS-1 cells transfected with this construct demonstrate both hydroperoxidase and cyclooxygenase activities similar to that demonstrated by cells transfected with a vector encoding the ovine prostaglandin G/H synthase. These data demonstrate that the TIS10 gene encodes a functional prostaglandin synthase/cyclooxygenase distinct from the prostaglandin synthase/cyclooxygenase whose cDNAs and/or genes have previously been cloned from sheep, mouse, and man. The structure of the TIS10 gene, determined by a combination of sequencing of genomic clones and polymerase chain reactions from genomic clones, demonstrates remarkable exon-intron conservation with the human prostaglandin synthase/cyclooxygenase gene. A 1-kilobase sequence located immediately proximal to the start site of transcription of the TIS10 gene can confer phorbol ester and serum inducibility to a luciferase reporter gene following transient transfection into NIH 3T3 cells, suggesting that this region of the gene is responsible for transcriptional regulation of the TIS10 gene by mitogens in fibroblasts.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV NEPHROL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIGMS NIH HHS [GM24797, GM0 8042-08] Funding Source: Medline; PHS HHS [1K11 01815] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797, T32GM008042] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTLERGRALLA E, 1983, BIOCHEM BIOPH RES CO, V111, P194, DOI 10.1016/S0006-291X(83)80135-1; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HONG SCL, 1976, J BIOL CHEM, V251, P776; KUJUBU DA, 1987, ONCOGENE, V1, P257; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUSAKA M, 1988, BIOCHIM BIOPHYS ACTA, V972, P339, DOI 10.1016/0167-4889(88)90210-8; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIM RW, 1987, ONCOGENE, V1, P263; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SAMBROOK J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIPPETTS MT, 1988, MOL CELL BIOL, V8, P4570, DOI 10.1128/MCB.8.10.4570; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSAI AL, 1990, ADV PROSTAGLANDIN TH, V21, P141; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, ONCOGENE, V4, P1263; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445; YOKOTA K, 1986, J BIOL CHEM, V261, P5410; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; YOUNG MR, 1984, J NATL CANCER I, V72, P919	38	507	519	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4338	4344						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1339449				2022-12-25	WOS:A1992HF64200015
J	MURRAYWHELAN, R; SCHLEGEL, W				MURRAYWHELAN, R; SCHLEGEL, W			BRAIN SOMATOSTATIN RECEPTOR-G PROTEIN-INTERACTION - G-ALPHA C-TERMINAL ANTIBODIES DEMONSTRATE COUPLING OF THE SOLUBLE RECEPTOR WITH GI(1-3) BUT NOT WITH G(0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; PITUITARY CELL-MEMBRANES; RAT CEREBRAL-CORTEX; ADENYLATE-CYCLASE; ADRENERGIC-RECEPTOR; CALCIUM CURRENT; TUMOR CELLS; K+ CHANNELS; GH3 CELLS; IDENTIFICATION	Somatostatin (SST) receptors activate potassium channels, stimulate protein phosphatases, inhibit adenylate cyclase and close calcium channels. These multiple effects are controlled by guanine nucleotide binding (G) proteins of the pertussis toxin-sensitive G(i) and G(o) types. In the present study we have identified the G proteins coupling with brain SST receptors. To this end, brain SST receptors were solubilized in G-protein coupled form. Binding of the SST analogue MK 678 to the solubilized receptor was completely inhibited by guanosine 5'-O-thiotriphosphate (IC50 = 100 nM), reflecting decreased receptor affinity for agonist following uncoupling of the receptor and G protein(s). Antibodies raised against specific COOH-terminal peptides of the G proteins Gi(1-3), G(o), and G(z) were used to probe for SST receptor-G protein coupling in this system. Antibodies binding to the COOH-terminal regions of G(i1) and G(i2) (antibody AS) and G(i3) (antibody EC) inhibited binding of I-125-MK 678 (75 pM) by 57 +/- 4% and 48 +/- 5%, respectively. The effects of these antibodies were concentration-dependent and additive, such that in combination AS and EC completely inhibited binding. Antibodies binding to the COOH-terminal region of G(o) (GO) and G(z) (QN) did not affect binding of I-125-MK 678, indicating that neither G(o) nor G(z) are associated with the brain SST receptor. Prelabeling of the receptor with I-125-MK 678 prior to addition of antibody induced the formation of a ''locked conformation'' of the agonist-bound receptor-G protein complex which was insensitive to antibody. In conclusion, G(il) and/or G(i2) and G(i3) are coupled in approximately equal proportions to the brain I-125-MK 678-binding SST receptor, accounting for all of the G protein coupling of this receptor.			MURRAYWHELAN, R (corresponding author), UNIV GENEVA,DEPT MED,FDN RECH MED,64 AV ROSERAIE,CH-1211 GENEVA 4,SWITZERLAND.							BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CODINA J, 1988, J BIOL CHEM, V263, P6746; CZERNIK AJ, 1983, J BIOL CHEM, V258, P5525; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HE HT, 1990, MOL PHARMACOL, V37, P614; HEISLER S, 1982, P NATL ACAD SCI-BIOL, V79, P6502, DOI 10.1073/pnas.79.21.6502; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; KILPATRICK BF, 1983, J BIOL CHEM, V258, P3528; KOCH BD, 1984, ENDOCRINOLOGY, V114, P1784, DOI 10.1210/endo-114-5-1784; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; MARIE JC, 1989, EUR J BIOCHEM, V186, P181, DOI 10.1111/j.1432-1033.1989.tb15193.x; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAIR BG, 1990, J BIOL CHEM, V265, P21317; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAYNOR K, 1989, J PHARMACOL EXP THER, V510, P251; SCHLEGEL W, 1984, CELL CALCIUM, V5, P223, DOI 10.1016/0143-4160(84)90038-1; SCHLEGEL W, 1985, FEBS LETT, V189, P27, DOI 10.1016/0014-5793(85)80835-8; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH SK, 1981, P NATL ACAD SCI-BIOL, V78, P4026, DOI 10.1073/pnas.78.7.4026; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TANAKA S, 1981, BRAIN RES, V208, P219, DOI 10.1016/0006-8993(81)90636-3; TATSUMI H, 1990, J NEUROSCI, V10, P1675; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YAMASHITA N, 1987, AM J PHYSIOL, V253, pE28, DOI 10.1152/ajpendo.1987.253.1.E28; YAMASHITA N, 1986, P NATL ACAD SCI USA, V83, P6198, DOI 10.1073/pnas.83.16.6198; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	42	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2960	2965						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1346612				2022-12-25	WOS:A1992HD15400025
J	ARSHAVSKY, VY; DUMKE, CL; BOWNDS, MD				ARSHAVSKY, VY; DUMKE, CL; BOWNDS, MD			NONCATALYTIC CGMP-BINDING SITES OF AMPHIBIAN ROD CGMP PHOSPHODIESTERASE CONTROL INTERACTION WITH ITS INHIBITORY GAMMA-SUBUNITS - A PUTATIVE REGULATORY MECHANISM OF THE ROD PHOTORESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER-SEGMENT PHOSPHODIESTERASE; FROG PHOTORECEPTOR-MEMBRANES; LIGHT-SENSITIVE CURRENT; VERTEBRATE PHOTORECEPTORS; ACTIVATION MECHANISM; MOLECULAR MECHANISM; RETINAL TRANSDUCIN; SYNTHETIC PEPTIDES; VISUAL EXCITATION	The cGMP phosphodiesterase (PDE) of retinal rods plays a central role in phototransduction. Illumination leads to its activation by a rod G-protein (G(t), transducin), thus causing a decrease in intracellular cGMP concentration, closure of plasma membrane cationic channels gated by cGMP, and development of the photoresponse. The PDE holoenzyme is an alphabetagamma2 tetramer. The alpha- and beta-subunits each contain one catalytic and one, or possibly two, noncatalytic cGMP-binding sites. Two identical gamma-subunits serve as protein inhibitors of the enzyme. Their inhibition is removed when they bind to G(t)-GTP during PDE activation. Here we report that the noncatalytic cGMP-binding sites regulate the binding of PDE(alphabeta) with PDE(gamma) and as a result determine the mechanism of PDE activation by G(t). If the noncatalytic sites are empty, G(t)-GTP physically removes PDE(gamma) from PDE(alphabeta) upon activation. Alternatively, if the noncatalytic sites are occupied by cGMP, G(t)-GTP releases PDE(gamma) inhibitory action but remains bound in a complex with the PDE heterotetramer. The kinetic parameters of activated PDE in these two cases are indistinguishable. This mechanism appears to have two implications for the physiology of photoreceptor cells. First, the tight binding of PDE(gamma) with PDE(alphabeta) when the noncatalytic sites are occupied by cGMP may be responsible for the low level of basal PDE activity observed in dark-adapted cells. Second, occupancy of the noncatalytic sites ultimately controls the rate of PDE inactivation (cf. Arshavsky, V. Yu., and Bownds, M. D. (1992) Nature 357, 416-417), for the GTPase activity that terminates PDE activity is slower when these sites are occupied and G(t) stays in a complex with PDE holoenzyme. In contrast GTPase acceleration is maximal when the noncatalytic sites are empty and G(t)-PDE(gamma) dissociates from PDE(alphabeta). Because cGMP levels are known to decrease upon illumination over a concentration range corresponding to the binding constants of the noncatalytic sites, the binding might be involved in determining the lifetime of activated PDE, after a single flash and/or during dark adaptation.	UNIV WISCONSIN, MOLEC BIOL LAB, MADISON, WI 53706 USA; UNIV WISCONSIN, NEUROSCI TRAINING PROGRAM, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT ZOOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NEI NIH HHS [EY 00463] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000463] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGELSONJK, 1992, INVEST OPHTH VIS SCI, V33, P1103; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; Beavo J., 1990, CYCLIC NUCLEOTIDE PH, P3; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHUMAKOV KM, 1982, EUR J BIOCHEM, V127, P309, DOI 10.1111/j.1432-1033.1982.tb06871.x; CLERC A, 1992, J BIOL CHEM, V267, P6620; COBBS WH, 1985, NATURE, V313, P585, DOI 10.1038/313585a0; COTE RH, 1989, J BIOL CHEM, V264, P15384; CUNNICK JM, 1990, BIOCHEM J, V271, P721, DOI 10.1042/bj2710721; DAWIS SM, 1988, J BIOL CHEM, V263, P8771; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; FAIN GL, 1976, J PHYSIOL-LONDON, V261, P71, DOI 10.1113/jphysiol.1976.sp011549; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P61; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HODGKIN AL, 1988, J PHYSIOL-LONDON, V403, P439, DOI 10.1113/jphysiol.1988.sp017258; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KINCAID RL, 1988, METHOD ENZYMOL, V159, P457; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; Lipkin V M, 1990, Biomed Sci, V1, P305; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P61; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; NICOL GD, 1989, J GEN PHYSIOL, V94, P233, DOI 10.1085/jgp.94.2.233; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; STROOP SD, 1992, ADV SEC MESS PHOSPH, V25, P55; STRYER L, 1987, CHEM SCRIPTA, V27B, P161; STRYER L, 1991, J BIOL CHEM, V266, P10711; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WENSEL TG, 1988, ENZYME DYNAMICS REGU, P103; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; WOODRUFF ML, 1979, J GEN PHYSIOL, V73, P629, DOI 10.1085/jgp.73.5.629; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	67	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24501	24507						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332960				2022-12-25	WOS:A1992KA26300055
J	CANTOR, AB; BARANSKI, TJ; KORNFELD, S				CANTOR, AB; BARANSKI, TJ; KORNFELD, S			LYSOSOMAL-ENZYME PHOSPHORYLATION .2. PROTEIN RECOGNITION DETERMINANTS IN EITHER LOBE OF PROCATHEPSIN-D ARE SUFFICIENT FOR PHOSPHORYLATION OF BOTH THE AMINO AND CARBOXYL LOBE OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-TYPE OLIGOSACCHARIDES; HUMAN CATHEPSIN-D; N-ACETYLGLUCOSAMINYLPHOSPHOTRANSFERASE; AFFINITY-CHROMATOGRAPHY; CELLS	Cathepsin D is a bilobed lysosomal aspartyl protease that contains one Asn-linked oligosaccharide/lobe. Each lobe also contains protein determinants that serve as recognition domains for binding of UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase, the first enzyme in the biosynthesis of the mannose 6-phosphate residues on lysosomal enzymes. In this study we examined whether the location of the protein recognition domain influences the relative phosphorylation of the amino and carboxyl lobe oligosaccharides. To do this, chimeric proteins containing either amino or carboxyl lobe sequences of cathepsin D substituted into a glycosylated form of the homologous secretory protein pepsinogen were expressed in Xenopus oocytes. The amino and carboxyl lobe oligosaccharides were then isolated from the various chimeric proteins and independently analyzed for their mannose 6-phosphate content. This analysis has shown that a phosphotransferase recognition domain located on either lobe of a cathepsin D/glycopepsinogen chimeric molecule is sufficient to allow phosphorylation of oligosaccharides on both lobes. However, phosphorylation of the oligosaccharide on the lobe containing the recognition domain is favored. We also found that the majority of the carboxyl lobe oligosaccharides of cathepsin D acquire two phosphates, whereas the amino lobe oligosaccharides only acquire one phosphate.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)				Cantor, Alan/0000-0002-5136-028X	NCI NIH HHS [CA08759] Funding Source: Medline; NIGMS NIH HHS [GM-07200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen G, 1986, LAB TECHNIQUES BIOCH, P30; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BENYOSEPH Y, 1986, BIOCHEM J, V235, P883, DOI 10.1042/bj2350883; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CANTOR AB, 1992, ANAL BIOCHEM, V205, P23357; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DONG JM, 1990, J BIOL CHEM, V265, P4210; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; GEISELMANN V, 1992, J BIOL CHEM, V267, P13262; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LANG L, 1984, J BIOL CHEM, V259, P4663; LAZZARINO DA, 1989, J BIOL CHEM, V264, P5015; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MONTREUIL J, 1984, PURE APPL CHEM, V56, P859, DOI 10.1351/pac198456070859; NARASIMHAN S, 1979, CAN J BIOCHEM CELL B, V57, P83, DOI 10.1139/o79-011; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; VARKI A, 1980, J BIOL CHEM, V255, P847; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WARIN V, 1979, CARBOHYD RES, V76, P11, DOI 10.1016/0008-6215(79)80002-6; WEITZ G, 1992, J BIOL CHEM, V267, P10039	32	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23349	23356						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331082				2022-12-25	WOS:A1992JY16300098
J	DWYER, LD; CROCKER, PJ; WATT, DS; VANAMAN, TC				DWYER, LD; CROCKER, PJ; WATT, DS; VANAMAN, TC			THE EFFECTS OF CALCIUM SITE OCCUPANCY AND REAGENT LENGTH ON REACTIVITY OF CALMODULIN LYSYL RESIDUES WITH HETEROBIFUNCTIONAL ARYL AZIDES - MAPPING INTERACTION DOMAINS WITH SPECIFIC CALMODULIN PHOTOPROBE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL HELIX; BINDING-SITES; BOVINE BRAIN; TROPONIN-C; CA-2+ PUMP; PROTEINS; TRIFLUOPERAZINE; PHOSPHODIESTERASE; PHOTOCHEMISTRY; MUTATIONS	The relationship of structural and functional moieties on calmodulin is important in all venues of cell activity. In this study, we investigate the effect of lysine modification on calmodulin function. Azidosalicylate reagents containing different "linker arm" lengths, between the photoactive terminus and an amine-reactive N-hydroxysuccinimidyl ester moiety were used to modify calmodulin lysines at three different positions in a calcium-dependent manner. The short cross-linker, (ASNE-2 (where ASNE represents azidosalicylate N-hydroxysuccinimidyl ester), modifies Lys-75, whereas the longer reagent, ASNE-6, modifies lysines 21, 75, and 94. The modification of these different lysines is shown to be calcium-dependent. At 1-100 muM levels of calcium, only Lys-94 is modified, suggesting that modification of this residue is directed by both the binding of calcium to calcium-binding loops III and IV and the hydrophobic pocket exposed between these two loops as a result of calcium binding. At higher calcium concentrations (>200 muM), where sites I and II become filled, modification of Lys-21 or Lys-75 also was observed. All the modified calmodulins were able to stimulate 3',5'-cyclic-nucleotide phosphodiesterase fully although the K(act) for the Lys-75 and Lys-21 derivatives increased 10- and 50-fold, respectively. None of the modifications affected the activation of erythrocyte plasma membrane Ca2+-ATPase. Only the ASNE-6 Lys-75 derivative showed efficient (40%) photocross-linking to the Ca2+-ATPase. The ASNE-2 Lys-75 derivative as well as the ASNE-6 Lys-21 and Lys-94 derivatives did not show efficient calcium-dependent photocross-linking to this enzyme.	UNIV KENTUCKY,MED CTR,COLL MED,DEPT BIOCHEM,MS607,800 ROSE ST,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT CHEM,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021868] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-21868] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON A, 1983, EUR J BIOCHEM, V134, P459, DOI 10.1111/j.1432-1033.1983.tb07589.x; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; Crocker PJ, 1990, BIOCONJUGATE CHEM, V1, P419, DOI 10.1021/bc00006a008; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; DALGARNO DC, 1984, BIOCHIM BIOPHYS ACTA, V791, P164, DOI 10.1016/0167-4838(84)90006-2; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GIEDROC DP, 1985, J BIOL CHEM, V260, P3406; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; IMAI N, 1990, BIOCONJUGATE CHEM, V2, P144; JAFFE CL, 1980, BIOCHEMISTRY-US, V19, P4423, DOI 10.1021/bi00560a007; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMIESON GA, 1979, BIOCHEM BIOPH RES CO, V90, P1048, DOI 10.1016/0006-291X(79)91932-6; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1988, CALMODULIN MOL ASPEC, V5, P35; KLEVIT RE, 1983, METHOD ENZYMOL, V102, P92; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LEYVA E, 1986, J AM CHEM SOC, V108, P3783, DOI 10.1021/ja00273a037; LINSE S, 1991, J BIOL CHEM, V266, P8050; MACKALL J, 1991, BIOCHEMISTRY-US, V30, P7242, DOI 10.1021/bi00243a028; MANN DM, 1988, J BIOL CHEM, V263, P11284; MANN DM, 1989, J BIOL CHEM, V264, P2373; MANN DM, 1987, THESIS U KENTUCKY; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEWTON D, 1985, BIOCHIM BIOPHYS ACTA, V845, P533, DOI 10.1016/0167-4889(85)90222-8; NEWTON DL, 1983, BIOCHEMISTRY-US, V22, P5472, DOI 10.1021/bi00293a003; NIGGLI V, 1987, METHOD ENZYMOL, V139, P791; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; PERSECHINI A, 1991, P NATL ACAD SCI USA, V88, P449, DOI 10.1073/pnas.88.2.449; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS2; SCHUSTER GB, 1987, J AM CHEM SOC, V109, P7803; SHIELDS CJ, 1987, J AM CHEM SOC, V109, P4723, DOI 10.1021/ja00249a047; TORRES MJ, 1986, TETRAHEDRON LETT, V27, P791, DOI 10.1016/S0040-4039(00)84102-7; VANAMAN TC, 1983, METHOD ENZYMOL, V102, P296; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; WALLACE RW, 1983, METHOD ENZYMOL, V102, P39; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WEISS W, 1982, BIOCHEM PHARMACOL, V31, P2217	44	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22606	22615						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1343568				2022-12-25	WOS:A1992JW71900096
J	DORSEUIL, O; VAZQUEZ, A; LANG, P; BERTOGLIO, J; GACON, G; LECA, G				DORSEUIL, O; VAZQUEZ, A; LANG, P; BERTOGLIO, J; GACON, G; LECA, G			INHIBITION OF SUPEROXIDE PRODUCTION IN LYMPHOCYTES-B BY RAC ANTISENSE OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING-PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; CELL-LINES; SURFACE IG; OXIDASE; GENE; ACTIVATION; SUPERFAMILY; GENERATION; SYSTEM	Rac1 and Rac2 gene products are small GTP-binding proteins showing 92% homology to each other. According to recent studies performed in cell-free systems, Rac1 and Rac2 proteins may be involved in the activation of NADPH-oxidase, the superoxide-generating enzymatic complex active in phagocytes. Epstein-Barr virus (EBV) transformed B lymphocytes, which express rac1 and rac2 genes, also efficiently release superoxide anions when triggered by various cell surface stimuli. To investigate the regulatory role of Rac proteins in living cells, we analyzed superoxide production in response to cross-linking of surface immunoglobulins or phorbol ester treatment in human EBV-transformed B lymphocytes pretreated with Rac sense and antisense oligonucleotides. We report here that (i) the rac protein content estimated by immunoblotting can be decreased by 60% in Rac antisense pretreated cells and (ii) a strong (50-60%), dose-dependent inhibition of superoxide production is observed in antisense pretreated cells whereas cells pretreated with sense oligonucleotide are unaffected. The data presented show, for the first time in whole cells, that superoxide production is modulated by the Rac protein content, thus demonstrating the physiological role of Rac proteins in the regulation of NADPH-oxidase.	INST COCHIN GENET MOLEC,INSERM,U257,24 RUE FBG ST JACQUES,F-75014 PARIS,FRANCE; INSERM,U131,F-92140 CLAMART,FRANCE; ASSOC CLAUDE BERNARD,RES CTR,F-92140 CLAMART,FRANCE; INST GUSTAVE ROUSSY,INSERM,U333,F-94805 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; COHENTANUGI L, 1991, EUR J BIOCHEM, V202, P649, DOI 10.1111/j.1432-1033.1991.tb16419.x; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JT, 1989, BIOCHEM J, V262, P373, DOI 10.1042/bj2620373; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LANG P, 1992, J BIOL CHEM, V267, P11677; LECA G, 1990, FEBS LETT, V269, P171, DOI 10.1016/0014-5793(90)81146-F; LECA G, 1991, J IMMUNOL, V146, P3542; MALY FE, 1988, J IMMUNOL, V140, P2334; MOLL J, 1991, ONCOGENE, V6, P863; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SHRECK R, 1991, EMBO J, V10, P2247; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006	23	118	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20540	20542						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328203				2022-12-25	WOS:A1992JT97800005
J	BARDELLI, A; MAINA, F; GOUT, I; FRY, MJ; WATERFIELD, MD; COMOGLIO, PM; PONZETTO, C				BARDELLI, A; MAINA, F; GOUT, I; FRY, MJ; WATERFIELD, MD; COMOGLIO, PM; PONZETTO, C			AUTOPHOSPHORYLATION PROMOTES COMPLEX-FORMATION OF RECOMBINANT HEPATOCYTE GROWTH-FACTOR RECEPTOR WITH CYTOPLASMIC EFFECTORS CONTAINING SH2 DOMAINS	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR SCATTER FACTOR; C-MET; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; PROTEINS; PHOSPHOTYROSINE; IDENTIFICATION; PEPTIDE	Hepatocyte growth factor (HGF), also known as scatter factor (SF), is a polypeptide which induces motility and/or mitogenesis in epithelial cells. The receptor for HGF/SF, p190MET, is a two-chain transmembrane tyrosine kinase encoded by the MET proto-oncogene. To identify the cytoplasmic effectors involved in signal transduction we have produced the human HGF/SF receptor in insect cells (Sf9) by means of a recombinant baculovirus. Two 170-kDa forms of the receptor were synthesized in Sf9 cells: the uncleaved single-chain precursor (which is by far the more abundant) and the proteolytically processed two-chain molecule. Both receptor species are phosphorylated on tyrosine in vivo and are active kinases in vitro. The recombinant receptor binds and phosphorylates in vitro four known cytoplasmic transducers containing src homology region 2 (SH2) domains: the 85-kDa subunit of phosphatidylinositol 3-kinase (Pl 3-kinase), rasGAP, phospholipase-C-gamma (PLC-gamma), and p59Fyn, a tyrosine kinase of the src family. In all cases the association is strictly dependent on tyrosine phosphorylation of the receptor, indicating that it occurs via specific interaction with the SH2 domains. These results show that the HGF/SF receptor has the sequence requirements for binding a spectrum of cytoplasmic transducers whose different combinations in target cells may result in the observed pleiotropic biological response.	UNIV TURIN,DEPT BIOMED SCI & ONCOL,CSO MASSIMO AZEGLIO 52,I-10126 TURIN,ITALY; LUDWIG INST CANC RES,LONDON,ENGLAND	University of Turin; Ludwig Institute for Cancer Research			Maina, Flavio/J-9962-2019; BARDELLI, Alberto/J-9721-2018	Maina, Flavio/0000-0001-6100-4695; BARDELLI, Alberto/0000-0003-1647-5070; Fry, Michael/0000-0001-8518-1370; Comoglio, Paolo/0000-0002-7056-5328				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONZETTO C, 1991, ONCOGENE, V6, P553; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	24	87	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1973	1978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328986				2022-12-25	WOS:A1992JP42400010
J	COURVALIN, JC; SEGIL, N; BLOBEL, G; WORMAN, HJ				COURVALIN, JC; SEGIL, N; BLOBEL, G; WORMAN, HJ			THE LAMIN-B RECEPTOR OF THE INNER NUCLEAR-MEMBRANE UNDERGOES MITOSIS-SPECIFIC PHOSPHORYLATION AND IS A SUBSTRATE FOR P34CDC2-TYPE PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PRIMARY BILIARY-CIRRHOSIS; STEP PURIFICATION; MEVALONIC ACID; CELL-CYCLE; ENVELOPE; INVIVO; IDENTIFICATION; AUTOANTIBODIES; CLEAVAGE; BINDING	The lamin B receptor (LBR) is an integral protein of the inner nuclear membrane that interacts with lamin B in vitro. It contains a 204-amino acid nucleoplasmic amino-terminal domain and a hydrophobic carboxyl-terminal domain with eight putative transmembrane segments. We found cell cycle-dependent phosphorylation of LBR using phosphoamino acid analysis and phosphopeptide mapping of in vivo P-32-labeled LBR immunoprecipitated from chicken cells in interphase and arrested in mitosis. LBR was phosphorylated only on serine residues in interphase and on serine and threonine residues in mitosis. Some serine residues phosphorylated in interphase were not phosphorylated in mitosis. To identify a threonine residue specifically phosphorylated in mitosis and the responsible protein kinase, wild-type and mutant LBR nucleoplasmic domain fusion proteins were phosphorylated in vitro by p34cdc2-type protein kinase. Comparisons of phosphopeptide maps to those of in vivo P-32-labeled mitotic LBR showed that Thr188 is likely to be phosphorylated by this enzyme during mitosis. These phosphorylation/dephosphorylation events may be responsible for some of the changes in the interaction between the nuclear lamina and the inner nuclear membrane that occur during mitosis.	CUNY MT SINAI SCH MED,DEPT MED,BOX 1039,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOL LAB,NEW YORK,NY 10021	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013752] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01790] Funding Source: Medline; NIGMS NIH HHS [GM13752] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELBAUM J, 1990, J BIOL CHEM, V265, P4181; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COURVALIN JC, 1990, J CLIN INVEST, V86, P279, DOI 10.1172/JCI114696; COURVALIN JC, 1990, J EXP MED, V172, P961, DOI 10.1084/jem.172.3.961; EARNSHAW WC, 1991, J CELL SCI, V98, P443; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBBINS E, 1964, J CELL BIOL, V21, P429, DOI 10.1083/jcb.21.3.429; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; ZELIGS JD, 1979, J ULTRA MOL STRUCT R, V66, P53, DOI 10.1016/S0022-5320(79)80065-9	27	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19035	19038						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326541				2022-12-25	WOS:A1992JP59300004
J	SHUMAN, S				SHUMAN, S			2 CLASSES OF DNA END-JOINING REACTIONS CATALYZED BY VACCINIA TOPOISOMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; CLEAVAGE; RECOMBINATION; SITE; SEQUENCE; INVITRO	The ability of a eukaryotic DNA topoisomerase I to catalyze DNA rearrangements was examined in vitro using defined substrates and purified enzyme. Site-specific DNA strand cleavage by vaccinia topoisomerase I across from a nick generated double-strand breaks that could be religated to a heterologous blunt-ended duplex DNA regardless of the sequence of the acceptor molecule. Topoisomerase bound covalently at internal positions could religate the bound strand to an incoming acceptor provided that DNA molecule had sequence homology to the region 3' of the scissile bond. These end-joining reactions suggest two potential modes of topoisomerase-mediated recombination that differ in their requirements for DNA homology.			SHUMAN, S (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; WANG HP, 1991, J VIROL, V65, P2381, DOI 10.1128/JVI.65.5.2381-2392.1991	10	54	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16755	16758						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324909				2022-12-25	WOS:A1992JL05300003
J	DOUCET, JP; PIERCE, GN; HERTZBERG, EL; TUANA, BS				DOUCET, JP; PIERCE, GN; HERTZBERG, EL; TUANA, BS			LOW-MOLECULAR-WEIGHT GTP-BINDING PROTEINS IN CARDIAC-MUSCLE - ASSOCIATION WITH A 32-KDA COMPONENT RELATED TO CONNEXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; GAP JUNCTION PROTEIN; ENDOPLASMIC-RETICULUM; RAS P21; ACTIVATING PROTEIN; SKELETAL-MUSCLE; INTERCELLULAR COMMUNICATION; SUBCELLULAR-FRACTIONS; SARCOLEMMAL VESICLES; POLYACRYLAMIDE GELS	Low molecular weight GTP-binding proteins and their cellular interactions were examined in cardiac muscle. Heart homogenate was separated into various subcellular fractions by differential and sucrose density gradient centrifugation. Various fractions were separated by sodium dodecyl sulfate-gel electrophoresis, blotted to nitrocellulose, and GTP-binding proteins detected by incubating with [alpha-P-32]GTP. Three polypeptides of M(r) 23,000, 26,000, and 29,000 were specifically labeled with [alpha-P-32]GTP in all the fractions examined and enriched in sarcolemmal membranes. The 23-kDa polypeptide was labeled to a higher extent with [alpha-P-32]GTP than the 26- and 29-kDa polypeptides. A polypeptide of M(r) 40,000 was weakly labeled with [alpha-P-32]GTP in the sarcolemmal membrane and tentatively identified as G(i)alpha by immunostaining with anti-G(i)alpha antibodies. Cytosolic GTP-binding proteins were labeled with [alpha-P-32]GTP and their potential sites of interaction investigated using the blot overlay approach. A polypeptide of 32 kDa present in sarcolemmal membranes, intercalated discs, and enriched in heart gap junctions was identified as a major site of interaction. The low molecular weight GTP-binding proteins associated with the 32-kDa polypeptide through a complex involving cytosolic components of M(r) 56,000, 36,000, 26,000, 23,000, and 12,000. A monoclonal antibody against connexin 32 from liver strongly recognized the 32-kDa polypeptide in heart gap junctions, whereas polyclonal antibodies only weakly reacted with this polypeptide. The low molecular weight GTP-binding proteins associated with a 32-kDa polypeptide in liver membranes that was also immunologically related to connexin 32. These results indicate the presence of a subset of low molecular weight GTP-binding proteins in a membrane-associated and a cytoplasmic pool in cardiac muscle. Their association with a 32-kDa component that is related to the connexins suggests that these polypeptides may be uniquely situated to modulate communication at the cell membrane.	UNIV OTTAWA, FAC MED, DEPT PHARMACOL, 451 SMYTH RD, OTTAWA K1H 8M5, ONTARIO, CANADA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT NEUROSCI, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA; UNIV MANITOBA, ST BONIFACE HOSP, RES CTR, DIV CARDIOVASC SCI, WINNIPEG R2H 2A6, MANITOBA, CANADA	University of Ottawa; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Manitoba; Children's Hospital Research Institute of Manitoba				Pierce, Grant/0000-0001-7674-0142	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030667] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30667] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZARNIA R, 1987, MOL CELL BIOL, V7, P946, DOI 10.1128/MCB.7.2.946; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BIELINSKI DF, 1989, J BIOL CHEM, V264, P18363; BOKOCH GM, 1988, FEBS LETT, V227, P66, DOI 10.1016/0014-5793(88)81415-7; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; DAWSON AP, 1989, CELL CALCIUM, V10, P343, DOI 10.1016/0143-4160(89)90060-2; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DOLPHIN AC, 1988, TRENDS NEUROSCI, V11, P287, DOI 10.1016/0166-2236(88)90085-9; DOUCET JP, 1991, J BIOL CHEM, V266, P17613; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; DOUCET JP, 1989, FEBS LETT, V247, P127, DOI 10.1016/0014-5793(89)81254-2; DROBAK BK, 1988, BIOCHEM BIOPH RES CO, V150, P899, DOI 10.1016/0006-291X(88)90713-9; EDELSTEIN NG, 1988, BIOCHEMISTRY-US, V27, P1818, DOI 10.1021/bi00406a003; EGHBALI B, 1990, P NATL ACAD SCI USA, V87, P1328, DOI 10.1073/pnas.87.4.1328; EGHBALI B, 1990, P NATL ACAD SCI USA, V111, pA153; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GREEN CR, 1983, TISSUE CELL, V15, P17, DOI 10.1016/0040-8166(83)90030-7; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HERTZBERG EL, 1984, CELL, V39, P61, DOI 10.1016/0092-8674(84)90191-0; HERTZBERG EL, 1985, GAP JUNCTIONS, P57; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; IKEDA N, 1980, J MOL CELL CARDIOL, V12, P809, DOI 10.1016/0022-2828(80)90082-6; KANTER HL, 1992, CIRC RES, V70, P438, DOI 10.1161/01.RES.70.2.438; KAPLAN S, 1991, J BIOL CHEM, V266, P18934; KLEBER AG, 1986, CIRCULATION, V73, P189, DOI 10.1161/01.CIR.73.1.189; KUTRYK MJB, 1988, J BIOL CHEM, V263, P13167; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LANOIX J, 1989, BIOCHEM J, V262, P497, DOI 10.1042/bj2620497; MANJUNATH CK, 1984, AM J PHYSIOL, V246, pH865, DOI 10.1152/ajpheart.1984.246.6.H865; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MESNIL M, 1986, EXP CELL RES, V165, P391, DOI 10.1016/0014-4827(86)90593-8; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGAHARA H, 1987, BIOCHEM BIOPH RES CO, V149, P686, DOI 10.1016/0006-291X(87)90422-0; NGSEE JK, 1990, J NEUROSCI, V10, P317; NICHOLSON BJ, 1985, J BIOL CHEM, V260, P6514; NICOLSON GL, 1988, P NATL ACAD SCI USA, V85, P473, DOI 10.1073/pnas.85.2.473; PAGE E, 1985, GAP JUNCTIONS, P49; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PAUL DL, 1985, GAP JUNCTIONS, P107; PIERCE GN, 1989, J APPL PHYSIOL, V66, P1715, DOI 10.1152/jappl.1989.66.4.1715; PIERCE GN, 1985, BIOCHIM BIOPHYS ACTA, V818, P109, DOI 10.1016/0005-2736(85)90553-X; PIERCE GN, 1989, J BIOL CHEM, V264, P15344; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; ROBINSON A, 1987, FEBS LETT, V218, P63, DOI 10.1016/0014-5793(87)81019-0; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; VANHAMME L, 1989, EXP CELL RES, V180, P297, DOI 10.1016/0014-4827(89)90234-6; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WILDEY G M, 1989, Journal of Cell Biology, V109, p293A; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMAMOTO T, 1990, BRAIN RES, V508, P313, DOI 10.1016/0006-8993(90)90415-8; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	77	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16503	16508						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322906				2022-12-25	WOS:A1992JJ45800080
J	LIN, SX; YANG, F; JIN, JZ; BRETON, R; ZHU, DW; VAN, LT; LABRIE, F				LIN, SX; YANG, F; JIN, JZ; BRETON, R; ZHU, DW; VAN, LT; LABRIE, F			SUBUNIT IDENTITY OF THE DIMERIC 17-BETA-HYDROXYSTEROID DEHYDROGENASE FROM HUMAN PLACENTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYSTEROID DEHYDROGENASE; AFFINITY-CHROMATOGRAPHY; PURIFICATION; ESTRADIOL-17-BETA; INACTIVATION; PROTEINS	Human placental 17-beta-hydroxysteroid dehydrogenase has been purified with a new rapid procedure based on fast protein liquid chromatography, yielding quantitatively a homogeneous preparation with high specific activity catalyzing the oxidation of 7.2-mu-mol of estradiol/min/mg of enzyme protein at 23-degrees-C, pH 9.2. This preparation was shown to have a subunit mass of 34.5 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis while having a molecular mass of 68 kDa by both Superose-12 gel filtration and native pore gradient gel electrophoresis. When 17-beta-hydroxysteroid dehydrogenase was expressed in HeLa cells or overproduced in insect cells using the baculovirus expression system, both from its cDNA encoding a protein of 34 kDa, the enzyme had the same migration in native and sodium dodecyl sulfate-gel electrophoresis as the purified one from human placenta and eluted from the Superose-12 column at the same elution volume. Moreover, all the above forms of this enzyme have similar specific activity. These results clearly demonstrate the identity of the three enzyme forms. The enzyme produced from the cDNA is expressed as a dimer, and its two subunits are identical. 17-Beta-hydroxysteroid dehydrogenase subunit identity is thus proved. The NH2-terminal analysis revealed a unique sequence of Ala-Arg-Thr-Val-Val-Leu-Ile for the purified enzyme from placenta, further confirming the above conclusion.	UNIV LAVAL, QUEBEC CITY G1V 4G2, QUEBEC, CANADA	Laval University	LIN, SX (corresponding author), CHU LAVAL, RES CTR, MRC, MOLEC ENDOCRINOL GRP, 2705 LAURIER BLVD, QUEBEC CITY G1V 4G2, QUEBEC, CANADA.			Lin, Sheng-Xiang/0000-0001-9149-375X				AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P671; BURNS DJW, 1971, BIOCHEM BIOPH RES CO, V44, P786, DOI 10.1016/0006-291X(71)90779-0; CHIN CC, 1973, STEROIDS, V22, P373; CHIN CC, 1975, J BIOL CHEM, V250, P7682; DESCOMPS B, 1968, B SOC CHIM BIOL, V50, P1681; DUMONT M, 1992, J STEROID BIOCHEM, V41, P605, DOI 10.1016/0960-0760(92)90391-U; GIEGE R, 1986, J CRYST GROWTH, V76, P554, DOI 10.1016/0022-0248(86)90172-7; GIEGE R, 1987, NATO ASI SERIES A, V126, P15; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JARABAK J, 1971, BIOCHEMISTRY-US, V10, P3831, DOI 10.1021/bi00797a005; Jarabak J, 1969, METHOD ENZYMOL, V15, P746, DOI DOI 10.1016/S0076-6879(69)15041-7; KARAVOLAS HJ, 1970, J BIOL CHEM, V245, P4948; KINGSTONRE, 1987, CURRENT PROTOCOLS MO, P911; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER LJ, 1959, J BIOL CHEM, V234, P2609; LANGER LJ, 1958, J BIOL CHEM, V233, P583; LIN SX, 1988, BIOCHEMISTRY-US, V27, P6343, DOI 10.1021/bi00417a022; LIN SX, 1992, PROTEIN EXPRES PURIF, V3, P41; Luu The V, 1989, Mol Endocrinol, V3, P1301; LUU-THE V, 1990, Molecular Endocrinology, V4, P268; MAINATIS T, 1989, MOL CLONING LABORATO; MURDOCK GL, 1986, BIOCHEMISTRY-US, V25, P641, DOI 10.1021/bi00351a019; REED MJ, 1991, J ENDOCRINOL, V129, P163, DOI 10.1677/joe.0.1290163; REED MJ, 1991, J STEROID BIOCHEM, V39, P791, DOI 10.1016/0960-0760(91)90027-3; SIMARD J, 1991, J BIOL CHEM, V266, P14842; SUMMERS MD, 1987, B TEXAS AM U, V1555; THOMAS JL, 1983, J BIOL CHEM, V258, P1500; TOBIAS B, 1982, J BIOL CHEM, V257, P2783; WAHAWISAN R, 1980, STEROIDS, V36, P115, DOI 10.1016/0039-128X(80)90073-2; Warburg O, 1942, BIOCHEM Z, V310, P384; 1989, BCA PROTEIN ASSAY RE; 1990, MINI PROTEAN 2 DUAL; 1982, GEL FILTRATION THERY; 1986, TECHNICAL B SIGM MKR, V137	34	114	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16182	16187						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322895				2022-12-25	WOS:A1992JJ45800033
J	LORIES, V; CASSIMAN, JJ; VANDENBERGHE, H; DAVID, G				LORIES, V; CASSIMAN, JJ; VANDENBERGHE, H; DAVID, G			DIFFERENTIAL EXPRESSION OF CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCANS IN HUMAN MAMMARY EPITHELIAL-CELLS AND LUNG FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN-SULFATE; CORE PROTEINS; EXTRACELLULAR-MATRIX; DISTINCT MEMBRANE; HUMAN SYNDECAN; RECEPTOR; CLONING; FORMS	Treating the liposome-intercalatable heparan sulfate proteoglycans from human lung fibroblasts and mammary epithelial cells with heparitinase and chondroitinase ABC revealed different core protein patterns in the two cell types. Lung fibroblasts expressed heparan sulfate proteoglycans with core proteins of approximately 35, 48/90 (fibroglycan), 64 (glypican), and 125 kDa and traces of a hybrid proteoglycan which carried both heparan sulfate and chondroitin sulfate chains. The mammary epithelial cells, in contrast, expressed large amounts of a hybrid proteoglycan and heparan sulfate proteoglycans with core proteins of approximately 35 and 64 kDa, but the fibroglycan and 125-kDa cores were not detectable in these cells. Phosphatidylinositol-specific phospholipase C and monoclonal antibody (mAb) S1 identified the 64-kDa core proteins as glypican, whereas mAb 2E9, which also reacted with proteoglycan from mouse mammary epithelial cells, tentatively identified the hybrid proteoglycans as syndecan. The expression of syndecan in lung fibroblasts was confirmed by amplifying syndecan cDNA sequences from fibroblastic mRNA extracts and demonstrating the cross-reactivity of the encoded recombinant core protein with mAb 2E9. Northern blots failed to detect a message for fibroglycan in the mammary epithelial cells and in several other epithelial cell lines tested, while confirming the expression of both glypican and syndecan in these cells. Confluent fibroblasts expressed higher levels of syndecan mRNA than exponentially growing fibroblasts, but these levels remained lower than observed in epithelial cells. These data formally identify one of the cell surface proteoglycans of human lung fibroblasts as syndecan and indicate that the expression of the cell surface proteoglycans varies in different cell types and under different culture conditions.	CATHOLIC UNIV LEUVEN, CTR HUMAN GENET, CAMPUS GASTHUISBERG O&N, HEREST 49, B-3000 LOUVAIN, BELGIUM	KU Leuven								Bernfield M, 1989, CURR OPIN CELL BIOL, V1, P953, DOI 10.1016/0955-0674(89)90064-1; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSTER L, 1986, J BIOL CHEM, V261, P2079; DAVID G, 1989, EUR J BIOCHEM, V178, P609, DOI 10.1111/j.1432-1033.1989.tb14489.x; DAVID G, 1985, J BIOL CHEM, V260, P1067; DAVID G, 1989, J CELL BIOL, V108, P1165, DOI 10.1083/jcb.108.3.1165; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; HAYASHI K, 1988, LAB INVEST, V58, P68; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KODA JE, 1985, J BIOL CHEM, V260, P8157; LORIES V, 1987, J BIOL CHEM, V262, P854; LORIES V, 1989, J BIOL CHEM, V264, P7009; LORIES V, 1986, EUR J BIOCHEM, V158, P351, DOI 10.1111/j.1432-1033.1986.tb09758.x; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; SUN XJ, 1989, J BIOL CHEM, V264, P11288; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945	30	105	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1116	1122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1339431				2022-12-25	WOS:A1992GY96000071
J	LEVY, JR; HUG, V				LEVY, JR; HUG, V			REGULATION OF INSULIN-RECEPTOR GENE-EXPRESSION - CELL CYCLE-MEDIATED EFFECTS ON INSULIN-RECEPTOR MESSENGER-RNA STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER REGION; DEGRADATION; MECHANISMS; SEQUENCES; POLY(A); GROWTH; CDNA	Posttranscriptional mechanisms play important roles in insulin receptor gene regulation; variability in cellular insulin receptor number and the growth arrest-mediated increases in insulin receptor mRNA are secondary to changes in insulin receptor mRNA stability. Therefore, further characterization of the pathways and kinetics of insulin receptor mRNA degradation were investigated. The insulin receptor mRNA in the insulin receptor-rich Hep G2 cells is more stable compared with the insulin receptor-sparse MCF-7 cells. Growth arrest results in a significant rise in insulin receptor mRNA in both cell lines. The increase in mRNA is caused by changes in mRNA stability. The half-life of the insulin receptor mRNA in growth-arrested cells is approximately three times that of proliferating cells. The insulin receptor gene contains four polyadenylation sites that produce four species of mRNA of 5.4, 6.9, 8.0, and 9.4 kilobases (kb). The mRNA species are not coordinately regulated. The ratio of the most abundant species (9.4/6.9) is significantly larger in growth-arrested cells compared with proliferating cells. By utilizing a specific cDNA probe for the 9.4-kb mRNA species, it was determined that the diminished 9.4/6.9 ratio in proliferating cells was caused by a more rapid rate of the 9.4-kb mRNA degradation. The kinetics of insulin receptor mRNA degradation were investigated. Insulin receptor mRNA levels were reduced to 56% of their base line within 6 h when growth-arrested cells were stimulated to proliferate; protein inhibition with cycloheximide completely inhibited the decline in insulin receptor mRNA.			LEVY, JR (corresponding author), MCGUIRE VET AFFAIRS MED CTR,DEPT RES,MED SERV 111-P,1201 BROAD ROCK BLVD,RICHMOND,VA 23249, USA.							ARAKI E, 1987, J BIOL CHEM, V262, P16186; CHENG GH, 1989, P NATL ACAD SCI USA, V86, P7002, DOI 10.1073/pnas.86.18.7002; CLEVELAND D W, 1989, New Biologist, V1, P121; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HATADA EN, 1989, J BIOL CHEM, V264, P6741; KAHN CR, 1985, ANNU REV MED, V36, P429; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P1598, DOI 10.1128/MCB.3.9.1598; KIM YK, 1992, J BIOL CHEM, V267, P2723; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAIRDOFFRINGA IA, 1989, NUCLEIC ACIDS RES, V17, P6499, DOI 10.1093/nar/17.16.6499; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEVY JR, 1991, DIABETES, V40, P58, DOI 10.2337/diabetes.40.1.58; LUSCHER B, 1985, P NATL ACAD SCI USA, V82, P4389, DOI 10.1073/pnas.82.13.4389; LUSCHER B, 1987, EMBO J, V6, P1721, DOI 10.1002/j.1460-2075.1987.tb02423.x; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MAMULA PW, 1988, DIABETES, V37, P1241, DOI 10.2337/diabetes.37.9.1241; MCDONALD AR, 1987, DIABETES, V36, P779, DOI 10.2337/diabetes.36.6.779; MCDONALD AR, 1988, J CLIN INVEST, V81, P499, DOI 10.1172/JCI113347; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; MUSCHEL R, 1986, MOL CELL BIOL, V6, P337, DOI 10.1128/MCB.6.1.337; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; ROUILLER DG, 1988, J BIOL CHEM, V263, P13185; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TEWARI M, 1991, MOL ENDOCRINOL, V5, P653, DOI 10.1210/mend-5-5-653; THEIL EC, 1990, J BIOL CHEM, V265, P4771; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	32	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25289	25295						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334088				2022-12-25	WOS:A1992KB60300058
J	JANASWAMI, PM; KALVAKOLANU, DVR; ZHANG, YH; SEN, GC				JANASWAMI, PM; KALVAKOLANU, DVR; ZHANG, YH; SEN, GC			TRANSCRIPTIONAL REPRESSION OF INTERLEUKIN-6 GENE BY ADENOVIRAL E1A PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; NUCLEAR FACTOR; INTERFERON; EXPRESSION; BINDING; DNA; TRANSFORMATION; PRODUCTS; TYPE-5; DIFFERENTIATION	Transcription of interleukin-6 (IL-6) gene in human HepG2 and HeLa cells was induced by treatment with interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), phorbol 12-myristate 13-acetate, or dibutyryl cyclic AMP. These agents enhanced the expression of chloramphenicol acetyltransferase (CAT) activity in cells transfected with chimeric CAT genes driven by the transcriptional regulatory regions of human IL-6 gene. Both induced and basal levels of CAT expression were severely repressed upon co-transfection of expression vectors encoding the adenoviral E1A289R or E1A243R protein. The conserved region 1 of E1A proteins was required for this activity. IL-6-CAT expression could also be induced by co-transfecting expression vectors containing cDNAs of the catalytic subunit of protein kinase A or c-jun. E1A repressed transcriptional induction by these agents as well. Similar inhibition was observed when a CAT gene driven by the NFkappaB element of the IL-6 gene was used as a reporter plasmid. In a cell line stably transfected with the E1A gene, IL-1 or TNF-alpha failed to induce IL-6 mRNA. Electrophoretic mobility shift assays were carried out with nuclear extracts of these cells using, as probes, the NFkappaB element or the multiple regulatory element of the IL-6 gene. With either probe, additional faster migrating DNA-protein complexes were formed in the extracts of E1A-expressing cells as compared with the extracts of the corresponding control cells. Experiments with NFkappaB antibody revealed differences between the different DNA-protein complexes formed in the extract of E1A-expressing cells. These observations suggest that E1A represses IL-6 gene transcription by interfering with the formation of appropriate DNA-protein complexes.	CLEVELAND CLIN FDN, RES INST,DEPT MOLEC BIOL,9500 EUCLID AVE,NC2-104, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NIAID NIH HHS [AI-22510] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022510] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KISHIMOTO T, 1988, BIOESSAYS, V9, P11, DOI 10.1002/bies.950090104; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SEHGAL PB, 1987, SCIENCE, V235, P731, DOI 10.1126/science.3492764; SHENK T, 1991, ADV CANCER RES, V57, P47; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SOGAWA K, 1989, EUR J BIOCHEM, V181, P539, DOI 10.1111/j.1432-1033.1989.tb14757.x; SPERGEL JM, 1991, P NATL ACAD SCI USA, V88, P6472, DOI 10.1073/pnas.88.15.6472; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; TANABE O, 1988, J IMMUNOL, V141, P3875; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; VANDAM H, 1989, ONCOGENE, V4, P1207; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	44	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24886	24891						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332971				2022-12-25	WOS:A1992KA26300108
J	MENENDEZARIAS, L; YOUNG, M; OROSZLAN, S				MENENDEZARIAS, L; YOUNG, M; OROSZLAN, S			PURIFICATION AND CHARACTERIZATION OF THE MOUSE MAMMARY-TUMOR VIRUS PROTEASE EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GLUTATHIONE-S-TRANSFERASE; DEFICIENCY SYNDROME AIDS; CELL LEUKEMIA-VIRUS; HIV-1 PROTEASE; NUCLEOTIDE-SEQUENCE; ASPARTIC PROTEASE; CRYSTAL-STRUCTURE; PROTEINS; GAG	The mouse mammary tumor virus (MMTV) protease gene was cloned into pGEX-2T, an Escherichia coli expression vector containing the glutathione S-transferase coding region of Schistosoma japonicum. The chimeric protein was formed by fusion of the glutathione S-transferase with a hexapeptide which contains a thrombin cleavage site, followed by the MMTV protease. Affinity chromatography on a glutathione-Sepharose 4B column was used to isolate the chimeric protein. After thrombin cleavage, the glutathione S-transferase and the protease were separated by gel filtration chromatography on a Sephadex G-75 column. The overall yield of the protease purification procedure was about 1 mg of protease/liter of culture, and the specific activity was 380 pmol/min.mug of enzyme. Like other retroviral proteases, the MMTV enzyme was active as a dimer, showed maximum activity at pH between 4 and 6, and could be inhibited by pepstatin A and a phosphinic acid derivative HIV-1 protease inhibitor. Enzymatic characterization of this protease reveals its broad specificity, showing a clear preference for the oligopeptide substrate mimicking the cleavage site at the amino-terminal end of the capsid protein (k(cat)/K(m) = 9725.5 M-1.s-1). The chimeric protein was also an active dimer and showed a similar K(m) (17 muM) for such an oligopeptide, although its k(cat) was about 10 times smaller. Autocatalytic processing of the MMTV protease was observed after expression of clones containing the natural cleavage site, as it occurs at the amino-terminal end of the viral protease, instead of the thrombin-sensitive sequence.			MENENDEZARIAS, L (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MOLEC VIROL & CARCINOGENESIS LAB, FREDERICK, MD 21702 USA.		Arias, Luis Menendez/N-7447-2016; Menendez Arias, Luis/G-2436-2016	Arias, Luis Menendez/0000-0002-1251-6640; 	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENNETT RP, 1991, J VIROL, V65, P272, DOI 10.1128/JVI.65.1.272-280.1991; BILLICH S, 1988, J BIOL CHEM, V263, P17905; BOUTELJE J, 1990, ARCH BIOCHEM BIOPHYS, V283, P141, DOI 10.1016/0003-9861(90)90624-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; GIAM CZ, 1988, J BIOL CHEM, V263, P14617; GRANT SK, 1991, BIOCHEMISTRY-US, V30, P8424, DOI 10.1021/bi00098a021; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; GUSTCHINA A, 1991, PROTEINS, V10, P325, DOI 10.1002/prot.340100406; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HIZI A, 1989, J VIROL, V63, P2543, DOI 10.1128/JVI.63.6.2543-2549.1989; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; KEYDAR I, 1984, P NATL ACAD SCI-BIOL, V81, P4188, DOI 10.1073/pnas.81.13.4188; KOBAYASHI M, 1991, FEBS LETT, V293, P106, DOI 10.1016/0014-5793(91)81162-2; KRAUSSLICH HG, 1989, CURRENT COMMUNICATIO; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; LOUIS JM, 1991, EUR J BIOCHEM, V199, P361, DOI 10.1111/j.1432-1033.1991.tb16132.x; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MENENDEZARIAS L, 1992, J BIOL CHEM, V267, P11392; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WONDRAK EM, 1991, FEBS LETT, V280, P344, DOI 10.1016/0014-5793(91)80327-Y; [No title captured]	40	28	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24134	24139						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331110				2022-12-25	WOS:A1992JZ23900105
J	ATTA, M; NORDLUND, P; ABERG, A; EKLUND, H; FONTECAVE, M				ATTA, M; NORDLUND, P; ABERG, A; EKLUND, H; FONTECAVE, M			SUBSTITUTION OF MANGANESE FOR IRON IN RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI - SPECTROSCOPIC AND CRYSTALLOGRAPHIC CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; DIMERIC SMALL SUBUNIT; SUPEROXIDE-DISMUTASE; 3-DIMENSIONAL STRUCTURE; THERMUS-THERMOPHILUS; RADICAL FORMATION; ONE TYROSINE-122; CONCANAVALIN-A; REDUCED FORMS; OXO PROTEINS	Each polypeptide chain of protein R2, the small subunit of ribonucleotide reductase from Escherichia coli, contains a stable tyrosyl radical and two antiferromagnetically coupled oxo-bridged ferric ions. A refined structure of R2 has been recently obtained. R2 can be converted into apoR2 by chelating out the metal cofactor and scavenging the radical. This study shows that apoR2 has a very strong affinity for four stable Mn2+ ions. The manganese-containing form of R2, named Mn-R2, has been studied by EPR spectroscopy and x-ray crystallography. It contains two binuclear manganese clusters in which the two manganese ions occupy the natural iron-binding sites and are only bridged by carboxylates from glutamates 115 and 238. This in turn explains why the spin-exchange interaction between the two ions is very weak and why Mn-R2 is EPR active. Mn-R2 could provide a model for the native diferrous form of protein R2, and a detailed molecular mechanism for the reduction of the iron center of protein R2 is proposed.	UNIV JOSEPH FOURIER, ETUD DYNAM & STRUCT SELECTIV,CNRS,URA 0332,BP 53X, F-38041 GRENOBLE, FRANCE; UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN; LAB MOLEC BIOPHYS, OXFORD OX1 3QU, ENGLAND; SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Stockholm University; University of Oxford; Swedish University of Agricultural Sciences								ANTANAITIS BC, 1987, BIOCHEMISTRY-US, V26, P7932, DOI 10.1021/bi00398a058; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BARYNIN VV, 1986, DOKL AKAD NAUK SSSR+, V288, P877; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BOROVIK AS, 1990, J AM CHEM SOC, V112, P6031, DOI 10.1021/ja00172a019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUTTLAIRE DH, 1980, J BIOL CHEM, V255, P2164; CANESCHI A, 1989, ANGEW CHEM INT EDIT, V28, P1365, DOI 10.1002/anie.198913651; ELGREN TE, 1991, J BIOL CHEM, V266, P19265; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; GEREZ C, 1991, ANGEW CHEM INT EDIT, V30, P1135, DOI 10.1002/anie.199111351; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KHANGULOV SV, 1990, J INORG BIOCHEM, V40, P279, DOI 10.1016/0162-0134(90)80062-3; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LARSSON A, 1988, J BIOL CHEM, V263, P17780; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MARKHAM GD, 1981, J BIOL CHEM, V256, P1903; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; RARDIN RL, 1991, NEW J CHEM, V15, P417; REED GH, 1970, J BIOL CHEM, V245, P662; REED GH, 1972, J BIOL CHEM, V247, P3073; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; Thelander L, 1978, Methods Enzymol, V51, P227; THORP HH, 1991, NEW J CHEM, V15, P479; TOLMAN WB, 1991, J AM CHEM SOC, V113, P152, DOI 10.1021/ja00001a023; WAGNER UG, 1989, J MOL BIOL, V206, P787, DOI 10.1016/0022-2836(89)90586-X; WIEGHARDT K, 1988, J AM CHEM SOC, V110, P7398, DOI 10.1021/ja00230a021; WIEGHARDT K, 1989, ANGEW CHEM INT EDIT, V28, P1153, DOI 10.1002/anie.198911531; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681	43	144	145	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20682	20688						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328209				2022-12-25	WOS:A1992JT97800028
J	POSNER, I; ENGEL, M; LEVITZKI, A				POSNER, I; ENGEL, M; LEVITZKI, A			KINETIC-MODEL OF THE EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR TYROSINE KINASE AND A POSSIBLE MECHANISM OF ITS ACTIVATION BY EGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PHOSPHORYLATION; DOMAIN	The tyrosine kinase activity of the epidermal growth factor receptor (EGFR-TK) was determined at varying poly-Glu6Ala3Tyr1 (GAT) or [Val5]-angiotensin II (AT) and constant ATP concentrations and vice versa. With GAT as substrate, double reciprocal plots intersected practically on the abscissa following EGFR-TK pre-activation with EGF, but below the abscissa without EGF pre-activation. The EGFR-TK inhibitors App(NH)p (5'-adenylyl-beta,gamma-imidodiphosphate) and ADP were competitive with ATP and noncompetitive with GAT. Four families of 1/v vs. 1/[ATP] plots, constructed at different fixed concentrations of ADP and a different constant concentration of GAT for each family, yielded Slope1/ATP replots which intersected to the left of the ordinate and below the abscissa. GAT and AT, as cosubstrates, were competitive with each other and noncompetitive with ATP; 1/v vs. 1/[GAT] or 1/[AT] plots were hyperbolic and reached horizontal asymptotes when v was expressed as the rate of common product formation. All data were subjected to computer best-fit analysis by a program written especially for this purpose. We conclude that (i) the EGFR-TK reaction follows a Sequential Bi-Bi Rapid Equilibrium Random mechanism, and (ii) EGF induces conformational changes in the EGFR-TK active center which lead to marked decreases in the apparent dissociation constants of both substrates of the kinase reaction and a concomitant increase in initial velocities and V(max)(apparent).	HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, CTR COMPUTAT, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem								BRAUN S, 1984, J BIOL CHEM, V259, P2051; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1979, METHOD ENZYMOL, V63, P108; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; Fromm H J, 1979, Methods Enzymol, V63, P42; Fromm H J, 1979, Methods Enzymol, V63, P467; FROMM HJ, 1964, BIOCHIM BIOPHYS ACTA, V81, P413, DOI 10.1016/0926-6569(64)90126-9; GOLDBERG AR, 1984, ADV ENZYME REGUL, V22, P289, DOI 10.1016/0065-2571(84)90019-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU CYJ, 1991, J BIOL CHEM, V266, P21105; HSU CYJ, 1991, J BIOL CHEM, V266, P603; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; Rudolph F B, 1979, Methods Enzymol, V63, P411; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; Segel I. H., 1975, ENZYME KINETICS, P273; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALKER DH, 1987, BIOCHEMISTRY-US, V26, P1428, DOI 10.1021/bi00379a033; WONG TW, 1984, J BIOL CHEM, V259, P3127; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; ZEWE V, 1964, J BIOL CHEM, V239, P1625	25	63	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20638	20647						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328205				2022-12-25	WOS:A1992JT97800023
J	DUESCHER, RJ; ELFARRA, AA				DUESCHER, RJ; ELFARRA, AA			1,3-BUTADIENE OXIDATION BY HUMAN MYELOPEROXIDASE - ROLE OF CHLORIDE-ION IN CATALYSIS OF DIVERGENT PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; CHLORINATING ACTIVITY; BUTADIENE MONOXIDE; EXPOSURE; RATS; CARCINOGENICITY; ACTIVATION; CHLOROPEROXIDASE; EPICHLOROHYDRIN; ENZYME	1,3-Butadiene was oxidized by human myeloperoxidase in the absence of KCl to yield butadiene monoxide (BM) and crotonaldehyde (CA), but at KCl concentrations higher than 50 mM, 1-chloro-2-hydroxy-3-butene (CHB) was the major metabolite detected; metabolite formation was dependent on incubation time, pH, KCl, 1,3-butadiene, and H2O2 concentrations. The data are best explained by 1,3-butadiene being oxidized by myeloperoxidase by two different mechanisms. First, oxygen transfer from the hemoprotein would occur to either C-1 or C-4 of 1,3-butadiene to form an intermediate which may cyclize to form BM or undergo a hydrogen shift to form 3-butenal, an unstable precursor of CA. Further evidence for this mechanism was provided by the inability to detect methyl vinyl ketone, a possible product of an oxygen transfer reaction to C-2 or C-3 of 1,3-butadiene, and by the finding that CA was not simply a decomposition product of BM under assay conditions. In the second mechanism, however, chloride ion is oxidized by myeloperoxidase to HOCl which reacts with 1,3-butadiene to yield CHB. Further evidence for this mechanism was provided by the finding that CHB was readily formed when 1,3-butadiene was added to the filtrate of a myeloperoxidase/H2O2/KCl incubation and when 1,3-butadiene was allowed to react with authentic HOCl. In addition, CHB was not detected when BM or CA was incubated with myeloperoxidase, H2O2, and KCl for up to 60 min, or when 1,3-butadiene and KCl were incubated with chloroperoxidase and H2O2 or with mouse liver microsomes and NADPH, enzyme systems which catalyze 1,3-butadiene oxidation to BM and CA, but unlike myeloperoxidase, do not catalyze chloride ion oxidation to HOCl. These results provide clear evidence for novel olefinic oxidation reactions by myeloperoxidase.	UNIV WISCONSIN,SCH VET MED,DEPT COMPARAT BIOSCI,2015 LINDEN DR W,MADISON,WI 53706; UNIV WISCONSIN,CTR ENVIRONM TOXICOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040375] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40375] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agner K., 1972, STRUCTURE FUNCTION O, P329; BERRY CA, 1991, KIDNEY, V1, P245; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P189, DOI 10.1016/0167-4838(84)90127-4; BRUNNEMANN KD, 1990, CARCINOGENESIS, V11, P1863, DOI 10.1093/carcin/11.10.1863; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; CITTI L, 1984, CARCINOGENESIS, V5, P47, DOI 10.1093/carcin/5.1.47; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DEROBERTIS EDP, 1975, CELL BIOL, P472; EASTMOND DA, 1990, METHOD ENZYMOL, V186, P579; ELFARRA AA, 1991, ARCH BIOCHEM BIOPHYS, V286, P244, DOI 10.1016/0003-9861(91)90036-I; GOODROW T, 1990, CANCER RES, V50, P4818; GREENBERG HL, 1990, BRIT J IND MED, V47, P221; Hallenberg P F, 1978, Methods Enzymol, V52, P521; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; ICHIHARA S, 1986, BIOCHEM PHARMACOL, V35, P3935, DOI 10.1016/0006-2952(86)90007-9; IRONS RD, 1987, CARCINOGENESIS, V8, P1711, DOI 10.1093/carcin/8.11.1711; KADESCH RG, 1946, J AM CHEM SOC, V68, P41, DOI 10.1021/ja01205a013; KLUWE WM, 1983, TOXICOL APPL PHARM, V70, P67, DOI 10.1016/0041-008X(83)90180-1; KREILING R, 1987, ARCH TOXICOL, V61, P7, DOI 10.1007/BF00324541; LASKIN S, 1980, J NATL CANCER I, V65, P751, DOI 10.1093/jnci/65.4.751; LEIDERMAN LJ, 1986, EXP MOL PATHOL, V44, P50, DOI 10.1016/0014-4800(86)90032-8; LIBBY RD, 1992, J BIOL CHEM, V267, P1769; MALLET WG, 1991, CARCINOGENESIS, V12, P521, DOI 10.1093/carcin/12.3.521; MATANOSKI GM, 1990, ENVIRON HEALTH PERSP, V86, P107, DOI 10.2307/3430942; MELNICK RL, 1990, CANCER RES, V50, P6592; OTT MG, 1989, AM J IND MED, V16, P631; OWEN PE, 1987, AM IND HYG ASSOC J, V48, P407, DOI 10.1080/15298668791384959; PEMBER SO, 1983, BLOOD, V61, P1116; Reed C. D., 1959, J CHEM ENG DATA, V4, P294; SHARER JE, 1991, CHEM RES TOXICOL, V4, P430, DOI 10.1021/tx00022a006; SHARER JE, 1992, IN PRESS DRUG METAB; STELMASZYNSKA T, 1974, EUR J BIOCHEM, V45, P305, DOI 10.1111/j.1432-1033.1974.tb03555.x; SUMRELL G, 1964, CAN J CHEM, V42, P2896, DOI 10.1139/v64-428; UETRECHT JP, 1991, CHEM RES TOXICOL, V4, P218, DOI 10.1021/tx00020a015; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6; [No title captured]	37	53	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19859	19865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328183				2022-12-25	WOS:A1992JR85800020
J	TERCERO, JC; RILES, LE; WICKNER, RB				TERCERO, JC; RILES, LE; WICKNER, RB			LOCALIZED MUTAGENESIS AND EVIDENCE FOR POSTTRANSCRIPTIONAL REGULATION OF MAK3 - A PUTATIVE N-ACETYLTRANSFERASE REQUIRED FOR DOUBLE-STRANDED-RNA VIRUS PROPAGATION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACETYLTRANSFERASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; CHORISMATE MUTASE; LACZ FUSIONS; CELL-GROWTH; YEAST; GENE; PROTEIN; DNA	The MAK3 gene of Saccharomyces cerevisiae is necessary for the propagation of the L-A double-stranded RNA virus and its satellites, such as M1 that encodes a killer toxin. We cloned the MAK3 gene based on its genetic map position using physically mapped lambda-clones covering nearly all of the yeast genome. The minimal sequence necessary to complement the mak3-1 mutation contained 3 open reading frames (ORFs). Only one (ORF3) was necessary to complement mak3-1. A deletion insertion mutant of ORF3 grew slowly on nonfermentable carbon sources, an effect not due simply to its loss of L-A. Although ORF3 alone is sufficient for MAK3 activity when expressed from an expression vector, in its native context an additional 669 base pairs 3' to the ORF and complementary to the gene for a non-histone protein are necessary for expression, but not for normal steady state transcript levels. This suggests a posttranscriptional control of MAK3 expression by the 3' region. The MAK3 protein has substantial homology with several N-acetyltransferases with consensus patterns h..h.h...Y..[HK]GI[AG][KR].Lh...h and h.h[DE] ....N..A...Y...GF.........Y...[DE]G, (h = hydrophobic). Mutation of any of the underlined conserved residues (94GI --> AA, 123N --> A, 130Y --> A, 134GF --> SL, 144Y --> A, and 149G --> A) inactivated the gene, supporting the hypothesis that MAK3 encodes an N-acetyltransferase.	WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	TERCERO, JC (corresponding author), NIDDKD, GENET SIMPLE EUKARYOTES SECT, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA.		Bueren, Juan/L-6112-2014	Bueren, Juan/0000-0002-3228-7013				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; BALL SG, 1986, MOL GEN GENET, V205, P326, DOI 10.1007/BF00430446; BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; COHN MS, 1978, J BIOL CHEM, V253, P5225; DIHANICH M, 1989, MOL CELL BIOL, V9, P1100, DOI 10.1128/MCB.9.3.1100; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HITZEMAN RA, 1983, SCIENCE, V219, P620, DOI 10.1126/science.6186023; HONJO M, 1990, J BACTERIOL, V172, P1783, DOI 10.1128/jb.172.4.1783-1790.1990; HORINOUCHI S, 1987, J BACTERIOL, V169, P1929, DOI 10.1128/jb.169.5.1929-1937.1987; ICHO T, 1988, J BIOL CHEM, V263, P1467; ICHO T, 1989, J BIOL CHEM, V264, P6716; ISONO K, 1980, MOL GEN GENET, V177, P645; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LEE FJS, 1989, J BIOL CHEM, V264, P12339; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Maniatis T., 1982, MOL CLONING; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY SP, 1984, MOL CELL BIOL, V4, P761, DOI 10.1128/MCB.4.4.761; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDHEINI T, 1989, J BACTERIOL, V171, P1245, DOI 10.1128/jb.171.3.1245-1253.1989; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAPIRO M, 1990, BINARY, V2, P187; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SOMMER SS, 1982, J BACTERIOL, V150, P545, DOI 10.1128/JB.150.2.545-551.1982; SOMMER SS, 1982, CELL, V31, P429, DOI 10.1016/0092-8674(82)90136-2; STILES JI, 1983, METHOD ENZYMOL, V101, P290; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANAKA S, 1989, MOL GEN GENET, V217, P289, DOI 10.1007/BF02464895; TENOVER FC, 1988, J BACTERIOL, V170, P471, DOI 10.1128/jb.170.1.471-473.1988; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TERCERO JC, 1988, ANAL BIOCHEM, V174, P128, DOI 10.1016/0003-2697(88)90526-X; THRASH C, 1984, J BIOL CHEM, V259, P1375; TYAGI AK, 1984, P NATL ACAD SCI-BIOL, V81, P1149, DOI 10.1073/pnas.81.4.1149; WCKNER RB, 1988, P NATL ACAD SCI USA, V85, P6007; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1976, J MOL BIOL, V105, P427, DOI 10.1016/0022-2836(76)90102-9; WICKNER RB, 1976, GENETICS, V82, P429; WICKNER RB, 1982, P NATL ACAD SCI-BIOL, V79, P4706, DOI 10.1073/pnas.79.15.4706; WICKNER RB, 1991, MOL CELLULAR BIOL YE; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153	54	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20270	20276						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1339437				2022-12-25	WOS:A1992JR85800082
J	BAI, WL; SINGH, B; YANG, YD; ARLINGHAUS, RB				BAI, WL; SINGH, B; YANG, YD; ARLINGHAUS, RB			EVIDENCE FOR INTERACTION BETWEEN V-MOS AND A P34CDC2 ISOFORM, P35CDK	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; MATURATION-PROMOTING FACTOR; PROTEIN-KINASE ACTIVITY; CELL-CYCLE; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; ONCOGENE PRODUCT; XENOPUS OOCYTES; GENE; EGGS	The c-mos gene product (c-Mos) encodes a serine/threonine kinase required for activation of pre-MPF (maturation-promoting factor) to MPF in oocytes undergoing meiosis and also for stabilization of MPF leading to metaphase arrest in unfertilized eggs. In order to determine whether the v-mos gene product (v-Mos) causes neoplastic transformation via interaction with cell cycle control elements, we have searched for proteins that interact with v-Mos. Extracts of NIH3T3 cells transformed by v-Mos encoded by Moloney murine sarcoma virus (Mo-MuSV) were examined by gel filtration by immunoprecipitation with antibodies to a conserved region of p34cdc2, and by binding to beads that contain cross-linked p13scu1, a protein known to bind p34cdc2. Gel filtration detected a 500-kDa complex that contained v-Mos and a p34cdc2 isoform, termed p35cdk. The 500-kDa macromolecular complex also exhibited histone H1 phosphorylation activity, consistent with the presence of a cdc2 isoform. The identity of p35cdk is based on its recognition by anti-cdc2 PSTAIR but not by anti-cdc2 C-terminal antibodies, which detect authentic p34cdc2. Structures containing v-Mos and p35cdk were also detected by experiments involving co-immunoprecipitation of v-Mos with anti-cdc2 PSTAIR antibodies. Furthermore. both v-Mos and the p35cdk co-precipitated with p13scu1-Sepharose beads. Our findings raise the possibility of a v-Mos-p35cdk regulatory interaction in cells transformed by Mo-MuSV.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAI W, 1992, IN PRESS ONCOGENE; BAI WL, 1991, ONCOGENE, V6, P1715; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FREEMAN RS, 1991, MOL CELL BIOL, V11, P1713, DOI 10.1128/MCB.11.3.1713; GALLICK GE, 1984, VIROLOGY, V139, P366, DOI 10.1016/0042-6822(84)90382-9; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HERZOG NK, 1988, ONCOGENE, V3, P225; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIU JX, 1990, ONCOGENE, V5, P171; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1988, ONCOGENE, V3, P79; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEHBER M, 1991, DEV BIOL, V148, P393; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P1423; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	46	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1757	1763						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323818				2022-12-25	WOS:A1992JJ37600012
J	PAGANO, M; DURST, M; JOSWIG, S; DRAETTA, G; JANSENDURR, P				PAGANO, M; DURST, M; JOSWIG, S; DRAETTA, G; JANSENDURR, P			BINDING OF THE HUMAN E2F TRANSCRIPTION FACTOR TO THE RETINOBLASTOMA PROTEIN BUT NOT TO CYCLIN-A IS ABOLISHED IN HPV-16-IMMORTALIZED CELLS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELLULAR PROTEINS; E1A PROTEINS; DNA-BINDING; ADENOVIRUS-E1A; KERATINOCYTES; EXPRESSION; INTERACT	The adenovirus E1A, SV40 large T and papillomavirus E7 proteins immortalize primary cells by virtue of their ability to bind the retinobtastoma gene product (pRB) and other cellular proteins, including cyclin A and the prRB-related protein, p107. It has been demonstrated that these viral oncogene products will prevent the inhibition of positive growth regulators by pRB, one of them being the E2F transcription factor. Here we show that the interactions of pRB and cyclin A with E2F are present also in normal keratinocytes and in primary human fibroblasts. In human keratinocytes immortalized by human papillomavirus 16 (HPV-16), expressing high levels of HPV-16 E7 protein, complexes between E2F and pRB are disrupted. In this cell line, as well as in HeLa cells which express HPV-18 E7, complexes containing E2F and cyclin A are maintained, indicating that this interaction is not sensitive to the viral oncoprotein and that cyclin A can associate with E2F independently of pRB. In vitro binding experiments suggest that the E7 gene product is able to preferentially abolish the interaction of pRB with E2F, leaving the cyclin A complexes intact. Our findings suggest that E7-dependent immortalization of human cells is associated with modifications of E2F multiprotein complexes.	DEUTSCH KREBSFORSCHUNGSZENTRUM,PROJEKTGRP ANGEW TUMORVIROL,NEUENHEIMER FELD 506,W-6900 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); Helmholtz Association; German Cancer Research Center (DKFZ)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; pagano, michele/0000-0003-3210-2442				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTEK J, 1992, ONCOGENE, V7, P101; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOEUF H, 1990, P NATL ACAD SCI USA, V87, P1782, DOI 10.1073/pnas.87.5.1782; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GIARD F, 1991, CELL, V67, P1169; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JANSENDURR P, 1990, J VIROL, V64, P2384, DOI 10.1128/JVI.64.5.2384-2387.1990; JANSENDURR P, 1989, EMBO J, V8, P3365, DOI 10.1002/j.1460-2075.1989.tb08499.x; KUMAR V, 1988, CELL, V55, P507; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROHLFS M, 1991, VIROLOGY, V183, P331, DOI 10.1016/0042-6822(91)90146-3; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL	42	91	91	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1681	1686						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323816				2022-12-25	WOS:A1992JJ37600002
J	TAKEDA, S; NORTH, DL; LAKICH, MM; RUSSELL, SD; WHALEN, RG				TAKEDA, S; NORTH, DL; LAKICH, MM; RUSSELL, SD; WHALEN, RG			A POSSIBLE REGULATORY ROLE FOR CONSERVED PROMOTER MOTIFS IN AN ADULT-SPECIFIC MUSCLE MYOSIN GENE FROM MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE GENE; HEAVY-CHAIN GENE; THYROID-HORMONE; SKELETAL-MUSCLE; MESSENGER-RNA; ACTIN GENE; CARDIAC ACTIN; RAT HINDLIMB; BINDING-SITE; DNA-BINDING	The mouse gene encoding a myosin heavy chain (MHC) protein expressed in type IIB fibers of adult skeletal muscle has been cloned and its promoter isolated. A number of DNA sequence motifs are found within the first 2.5 kilobases of the promoter which are similar to motifs present in the promoters of other muscle-specific genes. One sequence located at approximately-940 base pairs corresponds to the motif called MEF1 which has been shown in other muscle genes to bind the myogenic regulatory factors of which MyoD is one example. The MEF1 site of this adult IIB MHC promoter does indeed bind MyoD although this factor is normally thought to be involved in early muscle cell differentiation. The IIB MHC promoter also has several motifs located in the first 200 base pairs which are strikingly conserved between this mouse gene and several chicken skeletal MHC genes. Of these evolutionarily conserved sequences, two motifs rich in A and T residues appear to be major contributors to the muscle-specific transcriptional activity of the mouse IIB MHC promoter when transfected into quail myogenic and non-myogenic cells. These observations suggest an important functional role for these AT-rich sequence motifs in the regulation of genes of the MHC family.	INST PASTEUR,DEPT MOLEC BIOL,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BANDMAN E, 1985, INT REV CYTOL, V97, P97, DOI 10.1016/S0074-7696(08)62349-9; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; BUTLERBROWNE GS, 1987, J BIOL CHEM, V262, P15188; BUTLERBROWNE GS, 1984, DEV BIOL, V102, P324, DOI 10.1016/0012-1606(84)90197-0; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONDON K, 1990, DEV BIOL, V138, P256, DOI 10.1016/0012-1606(90)90196-P; COX RD, 1991, DEV BIOL, V143, P36, DOI 10.1016/0012-1606(91)90052-5; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS HL, 1988, NERVE MUSCLE CELL TR, P101; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; GOBLET C, 1989, NUCLEIC ACIDS RES, V17, P2144, DOI 10.1093/nar/17.5.2144; GORMAN CM, 1982, MOL CELL BIOL, V2, P1004; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; HARRIS AJ, 1989, DEVELOPMENT, V107, P7251; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KIRSCHBAUM BJ, 1990, J BIOL CHEM, V265, P13974; KROPP KE, 1987, J BIOL CHEM, V262, P16536; LAFRAMBOISE WA, 1991, DEV BIOL, V144, P1, DOI 10.1016/0012-1606(91)90473-G; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI ZL, 1991, J BIOL CHEM, V266, P6562; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MAHDAVI V, 1986, MOL BIOL MUSCLE DEV, P345; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MONTARRAS D, 1983, J BIOL CHEM, V258, P3883; MONTARRAS D, 1991, NEW BIOL, V3, P592; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOULY V, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P651; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; POUTSKA A, 1984, P NATL ACAD SCI USA, V81, P429; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUSSELL SD, 1988, J BIOL CHEM, V263, P6370; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P6296, DOI 10.1128/MCB.11.12.6296; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHEN RQ, 1991, MOL CELL BIOL, V11, P1676, DOI 10.1128/MCB.11.3.1676; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEDMAN HH, 1990, J BIOL CHEM, V265, P3568; TONG SW, 1983, J BIOL CHEM, V258, P3100; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEYDERT A, 1983, J BIOL CHEM, V258, P3867; WHALEN RG, 1985, J EXP BIOL, V115, P43; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; WHALEN RG, 1979, P NATL ACAD SCI USA, V76, P5197, DOI 10.1073/pnas.76.10.5197; WHALEN RG, 1990, DEV BIOL, V141, P24, DOI 10.1016/0012-1606(90)90099-5; WHALEN RG, 1985, J CELL BIOL, V101, P603, DOI 10.1083/jcb.101.2.603; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	73	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16957	16967						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324916				2022-12-25	WOS:A1992JL05300038
J	DAVIDPFEUTY, T; NOUVIANDOOGHE, Y				DAVIDPFEUTY, T; NOUVIANDOOGHE, Y			SLOW TIME-DEPENDENT CELLULAR-TRANSFORMATION INDUCED AT RESTRICTIVE TEMPERATURE BY TS-SRC MUTANTS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-KINASE ACTIVITY; ATP-BINDING SITE; GENE-PRODUCT; MONOCLONAL-ANTIBODIES; CELLS; PP60SRC; PP60V-SRC; LOCALIZATION; PARAMETERS	Cell lines infected with a temperature-sensitive Rous sarcoma virus have been widely used to study the temporal dynamics of various transformation parameters following downshift from the non-permissive temperature to the permissive temperature as it is considered that, at the non-permissive temperature, the infected cells exhibit the morphological and growth characteristics of normal cell whereas, at the permissive temperature, they exhibit characteristics of the transformed state. We show here that the apparently normal state in which tsPA1-infected FR3T3 cells are directed at the restrictive temperature is not a stationary stable state, but rather a transient one which continuously drifts as the cells are grown and passaged at this temperature and which eventually ends up as a new transformed state (T2) with morphological and growth properties definitely different from those belonging to the transformed state (T1) at the permissive temperature. The establishment of the transformed T2 state at the restrictive temperature occurs concomitantly with a steady accumulation of an intracellular pool of pp60v-src in the vicinity of the nucleus, whose traffic towards the plasma membrane is released following downshift to the permissive temperature, leading to the reappearance of transformation parameters characteristic of the transformed T1 state. Our finding raises the possibility that the v-src protein encoded by the tsPA1 mutant of Rous sarcoma virus may induce cellular transformation via two different pathways, leading to two different transformation states, depending on at which temperature the infected cells are grown. Various possible mechanisms that could be involved in the time-dependent establishment of a transformed state by ts-src mutants at the restrictive temperature are discussed.			DAVIDPFEUTY, T (corresponding author), CTR UNIV ORSAY, INST CURIE BIOL, BATIMENT 110, F-91405 ORSAY, FRANCE.							BARAK LS, 1980, P NATL ACAD SCI-BIOL, V77, P980, DOI 10.1073/pnas.77.2.980; BIQUARD J-M, 1970, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences Serie D Sciences Naturelles, V271, P2430; BIQUARD JM, 1972, VIROLOGY, V47, P444, DOI 10.1016/0042-6822(72)90280-2; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GARBER EA, 1982, VIROLOGY, V118, P419, DOI 10.1016/0042-6822(82)90361-0; GIONTI E, 1980, VIROLOGY, V100, P219, DOI 10.1016/0042-6822(80)90515-2; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHLIWA M, 1986, CYTOSKELETON INTRO S, P47; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; WEBER MJ, 1979, CELL, V16, P25, DOI 10.1016/0092-8674(79)90184-3	41	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1611	1623						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321405				2022-12-25	WOS:A1992JE81300018
J	KIM, IG; MCBRIDE, OW; WANG, M; KIM, SY; IDLER, WW; STEINERT, PM				KIM, IG; MCBRIDE, OW; WANG, M; KIM, SY; IDLER, WW; STEINERT, PM			STRUCTURE AND ORGANIZATION OF THE HUMAN TRANSGLUTAMINASE-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BLOOD-COAGULATION FACTOR; HUMAN FACTOR-XIII; KERATINOCYTE TRANSGLUTAMINASE; GUINEA-PIG; ERYTHROCYTE-MEMBRANE; INSITU HYBRIDIZATION; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; EPIDERMAL-CELLS	Membrane-associated transglutaminases (TGase1) have recently been found to be common in mammalian cells, but it is not clear whether these derive from the same or different genes. In order to determine the complexity of this system, we have isolated and characterized the human gene (TGM1). The gene of 14,133 base pairs was found to contain 15 exons spliced by 14 introns. Interestingly, the positions of these introns have been conserved in comparison with the genes of two other transglutaminase-like activities described in the literature, but the TGM1 gene is by far the smallest characterized to date because its introns are relatively smaller. On the other hand, the TGase1 enzyme is the largest known transglutaminase (about 90 kDa), apparently because its gene acquired tracts that encode additional sequences on its amino and carboxyl termini that confer its unique properties. Southern blot analyses of total human genomic DNA cut with several restriction enzymes reveal only one band. Use of human-rodent cell hybrid panels and chromosomal in situ hybridization with biotin-labeled probes revealed that the human TGM1 gene maps to chromosome position 14q11.2-13. Such data suggest there is a single gene copy per haploid human genome. Comparisons of sequence identities and homologies indicate that the transglutaminase family of genes arose by duplications and subsequent divergent evolution from a common ancestor but later became scattered in the human genome. Although our present Southern blot and chromosomal localization studies revealed no restriction fragment length polymorphisms, comparisons of published sequences and our genomic clone indicate there are two sequence variants for TGase1 within the human population. The rare smaller variant contains a two-nucleotide deletion near the 5'-end, uses an alternate initiation codon, and differs from the common larger variant only in the first 15 amino acids. Furthermore, the DNA sequences of intron 14 possess several tracts of dinucleotide repeats that by polymerase chain reaction analysis show wide size polymorphism within the human population. Accordingly, this gene system constitutes a useful polymorphic marker for genetic linkage analyses.	NIAMSD,SKIN BIOL LAB,BLDG 10,RM 9N228,BETHESDA,MD 20892; NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BOARD PG, 1988, CYTOGENET CELL GENET, V48, P25, DOI 10.1159/000132580; CARDINALI M, 1990, CANCER RES, V50, P8010; CHANG SK, 1986, J BIOL CHEM, V261, P8112; CHEN R, 1970, P NATL ACAD SCI USA, V66, P472, DOI 10.1073/pnas.66.2.472; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEYOUNG L, 1984, J INVEST DERMATOL, V82, P275, DOI 10.1111/1523-1747.ep12260366; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENTILE V, 1991, J BIOL CHEM, V266, P478; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOLBROOK KA, 1991, J INVEST DERMATOL, V96, P542; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDEGENT JE, 1985, NATURE, V317, P175, DOI 10.1038/317175a0; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARTINET N, 1990, BIOCHEM J, V271, P305, DOI 10.1042/bj2710305; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; POLAKOWSKA RR, 1991, CYTOGENET CELL GENET, V56, P105, DOI 10.1159/000133060; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; ROTHNAGEL JA, 1984, MOL CELL BIOCHEM, V58, P113, DOI 10.1007/BF00240610; SCHMIDT R, 1988, J INVEST DERMATOL, V90, P475, DOI 10.1111/1523-1747.ep12460936; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	47	99	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7710	7717						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348508				2022-12-25	WOS:A1992HN48500073
J	BRZESKA, H; KULESZALIPKA, D; KORN, ED				BRZESKA, H; KULESZALIPKA, D; KORN, ED			INHIBITION OF ACANTHAMOEBA MYOSIN-I HEAVY-CHAIN KINASE BY CA2+-CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; ACTIN-BINDING; BRUSH-BORDER; DICTYOSTELIUM-DISCOIDEUM; MG2+-ATPASE ACTIVITY; COFACTOR PROTEIN; PLASMA-MEMBRANE; 3RD ISOFORM; C SUBSTRATE; AMINO-ACID	The actin-activated Mg2+-ATPase activity of Acanthamoeba myosins I depends on phosphorylation of their single heavy chains by myosin I heavy chain kinase. Kinase activity is enhanced >50-fold by autophosphorylation at multiple sites. The rate of kinase autophosphorylation is increased approximately 20-fold by acidic phospholipids independent of the presence of Ca2+ and diglycerides. We show in this paper that Ca2+-calmodulin inhibits phospholipid-stimulated autophosphorylation of myosin I heavy chain kinase and hence also inhibits the catalytic activity of unphosphorylated kinase in the presence of phospholipid. Ca2+-calmodulin does not inhibit kinase activity in the absence of phospholipid. Micromolar Ca2+-calmodulin also inhibits binding of myosin I heavy chain kinase to phospholipid vesicles and purified plasma membranes. Proteolytic removal of a 7-kDa NH2-terminal segment from the 97-kDa kinase prevents binding of both calmodulin and phospholipid; therefore, we propose that they bind to the same or overlapping sites. These data provide a mechanism by which Ca2+ could inhibit the actin-activated Mg2+-ATPase activity of the myosin I isozymes in vivo and thus regulate myosin I-dependent motile activities.			BRZESKA, H (corresponding author), NHLBI,CELL BIOL LAB,BETHESDA,MD 20892, USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; ATKINSON M A, 1991, Journal of Cell Biology, V115, p331A; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BAINES IC, 1992, IN PRESS J CELL BIOL; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BARYLKO B, 1991, Journal of Cell Biology, V115, p331A; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BONI LT, 1985, J BIOL CHEM, V260, P819; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1989, J BIOL CHEM, V264, P10243; BRZESKA H, 1983, BIOCHEM BIOPH RES CO, V115, P87, DOI 10.1016/0006-291X(83)90972-5; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; BRZESKA H, 1988, J BIOL CHEM, V263, P427; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CLARKE BJ, 1988, J PROTOZOOL, V35, P408, DOI 10.1111/j.1550-7408.1988.tb04118.x; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1991, EUR J CELL BIOL, V56, P286; COTE GP, 1985, J BIOL CHEM, V260, P4543; DANDREA L, 1991, J CELL BIOL, V115, pA331; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; FUJISAKI H, 1985, J BIOL CHEM, V260, P1183; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GADASI H, 1980, NATURE, V286, P452, DOI 10.1038/286452a0; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOODSON H V, 1990, Journal of Cell Biology, V111, p168A; HAMMER JA, 1983, J BIOL CHEM, V258, P168; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KELLERMAN K, 1991, Journal of Cell Biology, V115, p330A; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KULESZALIPKA D, 1991, J CELL BIOL, V115, P109, DOI 10.1083/jcb.115.1.109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH TJ, 1990, BIOPHYS J, V57, pA536; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; LYNCH TJ, 1990, METHOD ENZYMOL, V196, P12; MARUTA H, 1979, J BIOL CHEM, V254, P3624; MARUTA H, 1977, J BIOL CHEM, V252, P8329; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MCCUBBIN WD, 1979, CAN J BIOCHEM CELL B, V57, P15, DOI 10.1139/o79-002; MCDONALD JR, 1987, BIOCHEM J, V242, P695, DOI 10.1042/bj2420695; MCDONALD JR, 1985, BIOCHEM J, V232, P559, DOI 10.1042/bj2320559; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1973, J BIOL CHEM, V248, P4691; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHERR E H, 1991, Journal of Cell Biology, V115, p331A; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; SPUDICH JA, 1989, CELL REGUL, V1, P1; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; ULSAMER AG, 1971, J CELL BIOL, V51, P193, DOI 10.1083/jcb.51.1.193; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WYLIE DC, 1987, METHOD ENZYMOL, V139, P50; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	70	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23870	23875						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331103				2022-12-25	WOS:A1992JZ23900066
J	SOMMERGRUBER, W; AHORN, H; ZOPHEL, A; MAURERFOGY, I; FESSL, F; SCHNORRENBERG, G; LIEBIG, HD; BLAAS, D; KUECHLER, E; SKERN, T				SOMMERGRUBER, W; AHORN, H; ZOPHEL, A; MAURERFOGY, I; FESSL, F; SCHNORRENBERG, G; LIEBIG, HD; BLAAS, D; KUECHLER, E; SKERN, T			CLEAVAGE SPECIFICITY ON SYNTHETIC PEPTIDE-SUBSTRATES OF HUMAN RHINOVIRUS-2 PROTEINASE-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4F; CYSTEINE PROTEASES; SERINE PROTEASES; ESCHERICHIA-COLI; RNA VIRUSES; POLIOVIRUS; IDENTIFICATION; EXPRESSION; INHIBITION; FAMILIES	Proteinase 2A of human rhinovirus serotype 2 (HRV2 2A) was expressed in Escherichia coli and partially purified; the preparation was used to study various enzymatic parameters. Using a 16-amino acid peptide representing the native cleavage region of HRV2 2A, an apparent K(m) value of 5.4 x 10(-4) mol/liter was determined. A minimum of 9 amino acids (comprising residues P8 to P1') was necessary for cleavage to occur. Proteolysis of substituted peptides was highly tolerant toward changes at P1, P2', and P3' but an absolute requirement for glycine P1' and a high preference for threonine P2 was found. Furthermore, HRV2 2A only cleaved peptide substrates derived from other rhinovirus serotypes and poliovirus that possessed P2 Thr and P1' Gly. Thus, the sequence Thr-X-Gly may form the basis of the cellular cleavage site processed by rhinoviral 2As during viral replication. Studies with various inhibitors support the hypothesis that HRV2 2A belongs to a new class of cysteine proteinases.	BOEHRINGER MANNHEIM GMBH,CTR RES,DEPT CHEM,W-6800 MANNHEIM 31,GERMANY; UNIV VIENNA,INST BIOCHEM,A-1090 VIENNA,AUSTRIA	University of Vienna	SOMMERGRUBER, W (corresponding author), ERNST BOEHRINGER INST ARZNEIMITTELFORSCH,DR BOEHRINGERGASSE 5-11,A-1120 VIENNA,AUSTRIA.		Skern, Tim/AAC-1732-2022	Skern, Tim/0000-0001-8865-5500				ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; GORBALENYA AE, 1986, FEBS LETT, V194, P253, DOI 10.1016/0014-5793(86)80095-3; HANECAK R, 1982, P NATL ACAD SCI-BIOL, V79, P3973, DOI 10.1073/pnas.79.13.3973; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; IVANOFF LA, 1986, P NATL ACAD SCI USA, V83, P5392, DOI 10.1073/pnas.83.15.5392; JEWELL JE, 1990, J VIROL, V64, P1388, DOI 10.1128/JVI.64.3.1388-1393.1990; KOENIG H, 1988, J VIROL, V62, P1243; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LLOYD RE, 1987, J VIROL, V61, P2480, DOI 10.1128/JVI.61.8.2480-2488.1987; MCBRIDE LJ, 1988, BIOTECHNIQUES, V6, P362; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORRISON JM, 1991, VIRUS INDUCED ENZYME, P391; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; RUECKERT RR, 1990, VIROLOGY, V1, P507; Sambrook J, 1989, MOL CLONING LABORATO; SKERN T, 1991, VIROLOGY, V181, P46, DOI 10.1016/0042-6822(91)90468-Q; SOMMERGRUBER W, 1989, VIROLOGY, V169, P68, DOI 10.1016/0042-6822(89)90042-1; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; WIMMER E, 1989, VIRAL PROTEINASES TA; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8	27	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22639	22644						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331062				2022-12-25	WOS:A1992JW71900100
J	BARBER, DL; GANZ, MB				BARBER, DL; GANZ, MB			GUANINE-NUCLEOTIDES REGULATE BETA-ADRENERGIC ACTIVATION OF NA-H EXCHANGE INDEPENDENTLY OF RECEPTOR COUPLING TO G(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; NA+/H+ EXCHANGE; PERTUSSIS TOXIN; PHOSPHOLIPASE-C; PROTEIN-KINASE; GROWTH-FACTOR; HAMSTER FIBROBLASTS; PARATHYROID-HORMONE; PH REGULATION; CELLS	We have previously shown that the beta-adrenergic receptor (beta-AR) stimulates activity of the ubiquitous Na-H exchanger (NHE-1) independently of changes in cAMP accumulation and independently of a cholera toxin-sensitive stimulatory GTP-binding protein (G(s)). To further investigate the potential role of a GTP-binding protein in coupling the beta-AR to NHE-1, we have used a recently available nonhydrolyzable GTP analog, "caged" guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS), to study time-dependent effects of GTP on NHE-1 in intact cells. By monitoring intracellular pH (pH(i)) in cells loaded with the fluorescent pH-sensitive dye, 2,7-biscarboxyethyl-5(6)-carboxyfluorescein, we determined NHE-1 activity in primary cultures of canine enteric endocrine cells, which express an endogenous beta-AR, and in mouse L cells stably transfected with either the wild type hamster beta2-AR or a mutant construct of the hamster beta2-AR containing a deletion in amino acid residues 222-229. This D(222-229)beta2-AR is functionally uncoupled from G(s) and adenylylcyclase. In all three cell types, NaF and GTPgammaS induced an increase in activity of the exchanger, determined by assessing the rate of pH(i) recovery from an acute intracellular acid load (dpH(i)/dt). This increase in pH(i) recovery was dependent on extracellular Na+ and sensitive to the amiloride analog ethylisopropylamiloride. GTPgammaS, but not NaF, also increased beta-adrenergic stimulation of resting NHE-1 activity. The alkalinization in response to isoproterenol was reversed by propranolol in the absence, but not the presence, of GTPgammaS and was completely blocked by GDPbetaS. The ability of guanine nucleotides to regulate beta-adrenergic activation of NHE-1 in cells expressing the mutant D(222-229)beta2-AR suggests that functional coupling of the beta-AR to NHE-1 may be mediated by a GTP-binding protein other than G(s).	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106	University of California System; University of California San Francisco; Case Western Reserve University	BARBER, DL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,HSW 604,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R01DK041371, R29DK040259] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40259, DK41371] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1987, AM J PHYSIOL, V253, pG684, DOI 10.1152/ajpgi.1987.253.5.G684; BARBER DL, 1986, AM J PHYSIOL, V250, pG374, DOI 10.1152/ajpgi.1986.250.3.G374; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BICKER P, 1980, NATURE, V287, P607; BIERMAN AJ, 1990, J CELL PHYSIOL, V142, P441, DOI 10.1002/jcp.1041420302; BORLE AB, 1982, SCIENCE, V217, P252, DOI 10.1126/science.6806904; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; DOLPHIN AC, 1988, PFLUG ARCH EUR J PHY, V411, P628, DOI 10.1007/BF00580858; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GANZ MB, 1989, KIDNEY INT, V35, P298; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; GRINSTEIN S, 1987, J BIOL CHEM, V262, P15277; GRINSTEIN S, 1986, BIOCHIM BIOPHYS ACTA, V889, P301, DOI 10.1016/0167-4889(86)90192-8; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HUANG CL, 1987, J BIOL CHEM, V262, P14134; Johnson G L, 1980, Adv Cyclic Nucleotide Res, V13, P1; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; PARIS S, 1987, J BIOL CHEM, V262, P1977; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PARIS S, 1990, J BIOL CHEM, V265, P11567; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROSS EM, 1978, J BIOL CHEM, V253, P6401; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; SIFFERT W, 1990, J BIOL CHEM, V265, P15441; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1987, J BIOL CHEM, V262, P16439; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VOLPI M, 1985, P NATL ACAD SCI USA, V82, P2708, DOI 10.1073/pnas.82.9.2708; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1989, J MEMBRANE BIOL, V109, P233, DOI 10.1007/BF01870280; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	41	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20607	20612						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328204				2022-12-25	WOS:A1992JT97800019
J	TOBE, K; KADOWAKI, T; HARA, K; GOTOH, Y; KOSAKO, H; MATSUDA, S; TAMEMOTO, H; UEKI, K; AKANUMA, Y; NISHIDA, E; YAZAKI, Y				TOBE, K; KADOWAKI, T; HARA, K; GOTOH, Y; KOSAKO, H; MATSUDA, S; TAMEMOTO, H; UEKI, K; AKANUMA, Y; NISHIDA, E; YAZAKI, Y			SEQUENTIAL ACTIVATION OF MAP KINASE ACTIVATOR, MAP KINASES, AND S6 PEPTIDE KINASE IN INTACT RAT-LIVER FOLLOWING INSULIN INJECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; STIMULATED PROTEIN-KINASE; CHICKEN-EMBRYO FIBROBLASTS; SERINE THREONINE KINASES; SWISS 3T3 CELLS; TYROSINE-PHOSPHORYLATION; RIBOSOMAL PROTEIN-S6; RECEPTOR KINASE; RABBIT LIVER; INVITRO	An insulin-stimulated phosphorylation cascade was examined in rat liver after insulin injection via a portal vein by the use of immune complex kinase assays specific to the mitogen-activated protein (MAP) kinase and S6 kinase II homologue (rsk) kinase. We have prepared an antibody against the peptide consisting of a carboxyl-terminal portion of the extracellular signal-regulated kinase 1 (alphaC92), one of the MAP kinases, and an antibody against the peptide consisting of the carboxyl terminus of the mouse S6 kinase II homologue (alpharsk(m)C). In alphaC92 immune complex assay, maximal activation of rat liver MAP kinases (approximately 4.3-fold) were observed 4.5 min after insulin injection. We also observed an insulin-stimulated MAP kinase activity (approximately 3-fold) in liver extracts from insulin-treated rat in fractions eluted from phenyl-Sepharose with 30-50% ethylene glycol. Kinase assay in myelin basic protein (MBP)-containing gel after sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by denaturation with 6 M guanidine HCl, and renaturation revealed that insulin injection stimulated the kinase activity of the 42- and 44-kDa proteins, which corresponded to the two distinct MAP kinases. In alpharsk(m)C immune complex assay, maximal stimulation (approximately 5-fold) of the S6 peptide (Arg-Arg-Leu-Ser-Ser-Leu-Arg-Ala) kinase activity was observed 7.5 min after insulin injection. In addition, MAP kinases purified from insulin-treated rat liver were able to activate S6 peptide kinase activity in vitro in alpharsk(m)C immunoprecipitates from untreated rat liver, accompanied by the appearance of several phosphorylated bands including a major band at 88 kDa. We also examined whether insulin injection stimulates the MAP kinase activator (Ahn, N. G., Seger, R., Bratlien, R. L., Diltz, C. D., Tonks, N. K., and Krebs, E. G. (1991) J. Biol. Chem. 266, 4220-4227) in rat liver. Using recombinant Xenopus MAP kinase, fractions of Q-Sepharose eluted early in the NaCl gradient were found to have MAP kinase activator activity accompanied by the phosphorylation of 42-kDa recombinant Xenopus MAP kinase. From these data, we demonstrate three tiers of a cascade composed of the MAP kinase activator, MAP kinases, and an S6 peptide kinase activity in rat liver under physiological conditions in the intact animal.	UNIV TOKYO, FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU, TOKYO 113, JAPAN; ASAHI LIFE FDN, INST DIABET CARE & RES, CHIYODA KU, TOKYO 100, JAPAN; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN	University of Tokyo; Asahi Life Foundation; University of Tokyo								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDO A, 1992, J BIOL CHEM, V267, P12788; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRANDT H, 1975, J BIOL CHEM, V250, P8038; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ERICKSON E, 1987, MOL CELL BIOL, V7, P3147; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; IZUMI T, 1988, J BIOL CHEM, V263, P10386; JENO P, 1989, J BIOL CHEM, V264, P1293; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KABURAGI Y, 1991, 73RD ANN M END SOC W, P309; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KLARLUND JK, 1990, J BIOL CHEM, V265, P227; KREBS EG, 1964, BIOCHEMISTRY-US, V3, P1022, DOI 10.1021/bi00896a003; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LEVOINNE A, 1991, EUR J BIOCHEM, V199, P723; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; PELECH SL, 1987, INSULIN INSULIN LIKE, P27; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P1844; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V344, P7150; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WEIEL JE, 1990, ADV SEC MESS PHOSPH, V24, P182; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	56	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21089	21097						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328222				2022-12-25	WOS:A1992JT97800090
J	HATTORI, S; FUKUDA, M; YAMASHITA, T; NAKAMURA, S; GOTOH, Y; NISHIDA, E				HATTORI, S; FUKUDA, M; YAMASHITA, T; NAKAMURA, S; GOTOH, Y; NISHIDA, E			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE AND ITS ACTIVATOR BY RAS IN INTACT-CELLS AND IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MURINE SARCOMA-VIRUS; XENOPUS OOCYTES; STIMULATED PROTEIN; MAP KINASE; PC12 CELLS; TYROSINE PHOSPHORYLATION; GUANINE-NUCLEOTIDES; FIBROBLASTIC CELLS; ONCOGENE PRODUCTS	Mitogen-activated protein (MAP) kinase is a serine/threonine kinase whose function is thought to be essential for the transduction of mitogenic signals. MAP kinase is activated by phosphorylation induced by a variety of extracellular stimuli, and its direct upstream activator has been identified. Using amphibian and mammalian systems, we show here that ras can activate MAP kinase and its activator. Injection of v-Ha-ras p21 into Xenopus immature oocytes activated both MAP kinase and maturation-promoting factor (MPF) activities. The activation of MAP kinase preceded that of MPF, demonstrating that ras activates MAP kinase in an MPF-independent pathway. Moreover, we found that the MAP kinase activator is also activated in ras-injected oocytes. Activation of MAP kinase and its activator occurred also when the v-Ki-ras gene was conditionally induced in rat fibroblastic 3Y1 cells. Furthermore, we observed that ras activated MAP kinase and its activator in a cell-free system prepared from Xenopus oocytes. Using an antibody against the Xenopus 45-kDa MAP kinase activator, we demonstrated that the 45-kDa activator molecule was activated by ras. These findings suggest that the MAP kinase activator/MAP kinase system may be the downstream components of ras signal transduction pathways.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN	University of Tokyo; National Center for Neurology & Psychiatry - Japan			Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/I-7915-2014; Fukuda, Makoto/S-9748-2019	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1985, MOL CELL BIOL, V5, P1449, DOI 10.1128/MCB.5.6.1449; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; KAMATA T, 1990, MOL CELL BIOL, V10, P880, DOI 10.1128/MCB.10.3.880; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P1001; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573	48	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20346	20351						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328197				2022-12-25	WOS:A1992JR85800094
J	OOKAWARA, T; KAWAMURA, N; KITAGAWA, Y; TANIGUCHI, N				OOKAWARA, T; KAWAMURA, N; KITAGAWA, Y; TANIGUCHI, N			SITE-SPECIFIC AND RANDOM FRAGMENTATION OF CU,ZN-SUPEROXIDE DISMUTASE BY GLYCATION REACTION - IMPLICATION OF REACTIVE OXYGEN SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC SUPEROXIDE-DISMUTASE; METAL-CATALYZED OXIDATION; HYDROGEN-PEROXIDE; AMINO-GROUPS; COPPER; INACTIVATION; PROTEIN; GLUCOSYLATION; MECHANISM; GLUCOSE	Site-specific and random fragmentation of human Cu,Zn-superoxide dismutase (Cu,Zn-SOD) was observed following the glycation reaction (the early stage of the Maillard reaction). The fragmentation proceeded in two steps. In the first step, Cu,Zn-SOD was cleaved at a peptide bond between Pro62 and His63, as judged by amino acid analysis and sequencing of fragment peptides, yielding a large (15 kDa) and a small (5 kDa) fragment. In the second step, random fragmentation occurred. The ESR spectrum of the glycated Cu,Zn-SOD suggested that reactive oxygen species was implicated in the both steps of fragmentation. The same fragmentations were seen upon exposure of the enzyme to an H2O2 bolus. Catalase completely blocked both steps of the fragmentation process, whereas EDTA blocked only the second step. Incubation with glucose resulted in a time-dependent release of Cu2+ from the Cu,Zn-SOD molecule. The released CU2+ then likely participated in a Fenton's type of reaction to produce hydroxyl radical, which may cause the nonspecific fragmentation. Evidence that EDTA abolished only the second step of fragmentation induced by an H2O2 bolus supports this mechanism. This is the first report that a site-specific fragmentation of a protein is caused by reactive oxygen species formed by the Maillard reaction.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, 2-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; AMICI A, 1989, J BIOL CHEM, V264, P3341; ARAI K, 1987, J BIOL CHEM, V262, P16969; ARAI K, 1987, BIOCHIM BIOPHYS ACTA, V924, P292, DOI 10.1016/0304-4165(87)90025-0; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; JABUSCH JR, 1980, BIOCHEMISTRY-US, V19, P2310, DOI 10.1021/bi00552a005; JEWETT SL, 1989, EUR J BIOCHEM, V180, P569, DOI 10.1111/j.1432-1033.1989.tb14683.x; KASHIMURA N, 1979, CARBOHYD RES, V70, pC3, DOI 10.1016/S0008-6215(00)83286-3; KAWAKISHI S, 1991, CARBOHYD RES, V211, P167, DOI 10.1016/0008-6215(91)84156-9; KAWAMURA N, 1992, J CLIN ENDOCR METAB, V74, P1352, DOI 10.1210/jc.74.6.1352; KINOSHITA N, 1990, ADV LIF SCI, P443; KITAGAWA Y, 1991, J BIOCHEM-TOKYO, V109, P477, DOI 10.1093/oxfordjournals.jbchem.a123407; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE PROT, P66; LERCH K, 1981, J BIOL CHEM, V256, P1545; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MONNIER VM, 1989, MAILLARD REACTION AG, P1; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NEY KA, 1981, ANAL BIOCHEM, V118, P294, DOI 10.1016/0003-2697(81)90585-6; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SALO DC, 1990, J BIOL CHEM, V265, P11919; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; Taniguchi N., 1989, MAILLARD REACTION AG, P277; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	28	219	227	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18505	18510						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326527				2022-12-25	WOS:A1992JN50200043
J	GOODE, N; HUGHES, K; WOODGETT, JR; PARKER, PJ				GOODE, N; HUGHES, K; WOODGETT, JR; PARKER, PJ			DIFFERENTIAL REGULATION OF GLYCOGEN-SYNTHASE KINASE-3-BETA BY PROTEIN-KINASE-C ISOTYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; PHOSPHORYLATION; ACTIVATION; FAMILY; GENE; EXPRESSION; SEQUENCE; PRODUCT; ALPHA; GAMMA	In cells, stimulation of protein kinase C (PKC) results in the dephosphorylation of specific residues proximal to the DNA binding domain of c-Jun, a major component of the AP-1 transcription factor. Since phosphorylation of this region of c-Jun inhibits interaction with DNA, this pathway may contribute to PKC activation of AP-1. To determine the mechanism(s) underlying this pathway, possible interactions between PKC and proteins implicated in c-Jun regulation are being investigated. Here it is shown that glycogen synthase kinase-3-beta (GSK-3-beta), a serine/threonine kinase that specifically targets the inhibitory c-Jun phosphorylation sites, is phosphorylated in vitro by particular forms of PKC (alpha, beta-1, gamma > beta-2; not epsilon). By contrast, the related GSK-3-alpha is not a substrate for any of these PKC isotypes. Phosphorylation of GSK-3-beta by PKC results in its specific inactivation. These results are consistent with a model in which activation of PKC stimulates c-Jun DNA binding by inhibiting its phosphorylation by GSK-3-beta.	IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research			Woodgett, Jim/F-1087-2010; Parker, Peter j/D-5192-2013	Woodgett, Jim/0000-0003-3731-5797; parker, peter/0000-0002-6218-2933				ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUGHES K, 1991, ADV PROTEIN PHOSPHAT, V7, P483; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; IDO M, 1987, FEBS LETT, V219, P215, DOI 10.1016/0014-5793(87)81219-X; KARIN M, 1991, MOL ASPECTS CELLULAR, V6, P143; KUBO K, 1987, NUCLEIC ACIDS RES, V15, P7179, DOI 10.1093/nar/15.17.7179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PARKER PJ, 1991, METHOD ENZYMOL, V200, P234; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YANG SD, 1991, ADV PROT PHOSPHATASE, V6, P133	39	347	351	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16878	16882						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324914				2022-12-25	WOS:A1992JL05300026
J	LIU, JW; MODRELL, B; ARUFFO, A; MARKEN, JS; TAGA, T; YASUKAWA, K; MURAKAMI, M; KISHIMOTO, T; SHOYAB, M				LIU, JW; MODRELL, B; ARUFFO, A; MARKEN, JS; TAGA, T; YASUKAWA, K; MURAKAMI, M; KISHIMOTO, T; SHOYAB, M			INTERLEUKIN-6 SIGNAL TRANSDUCER GP130 MEDIATES ONCOSTATIN-M SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLONY-STIMULATING FACTOR; MOLECULAR-CLONING; GROWTH-REGULATOR; GM-CSF; RECEPTOR; EXPRESSION; SUBUNIT; CELLS; CDNA	Oncostatin M (OM) is a multifunctional cytokine that is structurally and functionally related to interleukin 6 (IL-6) and leukemia inhibitory factor (LIF). The specific receptor for OM has been demonstrated (by chemical cross-linking) to be a 150-kDa protein in a number of cell lines. The IL-6 signal transducer, gp130, is also an affinity converter for the LIF receptor. It does not bind to either IL-6 or LIF, but associates with the alpha-subunits of the receptors and transduces the signals. We examined the possible involvement of gp130 in OM binding and signaling. We demonstrate that: (a) anti-gp130 monoclonal antibodies (mAbs) block the inhibitory effect of OM on A375 cell growth, (b) the binding and cross-linking of I-125-OM to H2981 cells are completely abolished by anti-gp130 mAbs, (c) the cross-linked OM-receptor complex is immunoprecipitated by anti-gp130 mAbs, and (d) COS-7 cells transfected with the full-length cDNA encoding gp130 exhibit increased OM binding and cross-linking, which are also blocked by anti-gp130 mAbs. Therefore, we conclude that the 150-kDa OM binding protein previously characterized in a variety of cell lines is gp130. OM is the natural ligand for gp130 and gp130 mediates the biological responses of OM.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; TOSOH CORP,BIOTECHNOL RES LAB,KANAGAWA,JAPAN	Bristol-Myers Squibb; Osaka University; Tosoh Corporation			Kishimoto, Tadamitsu/C-8470-2009					ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BROWN TJ, 1991, J IMMUNOL, V147, P2175; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MALIK N, 1992, DNA CELL BIOL, V11, P453, DOI 10.1089/dna.1992.11.453; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	22	155	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16763	16766						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324910				2022-12-25	WOS:A1992JL05300005
J	WANG, JS; TSAI, AL; HELDT, J; PALMER, G; VANWART, HE				WANG, JS; TSAI, AL; HELDT, J; PALMER, G; VANWART, HE			TEMPERATURE-DEPENDENT AND PH-DEPENDENT CHANGES IN THE COORDINATION SPHERE OF THE HEME-C GROUP IN THE MODEL PEROXIDASE N(ALPHA)-ACETYL MICROPEROXIDASE-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; MAGNETIC CIRCULAR-DICHROISM; SPIN-STATE; HORSERADISH-PEROXIDASE; CYTOCHROME-C; OCTAPEPTIDE MICROPEROXIDASE-8; VIBRATIONAL-MODES; FERRICYTOCHROME-C; AQUEOUS-SOLUTION; ALKALINE FORMS	The pH- and temperature-dependent changes in the coordination sphere of the heme c group of N(alpha)-acetyl microperoxidase-8 (Ac-MP-8) have been studied by examining its optical, resonance Raman, electron paramagnetic resonance, and magnetic circular dichroism spectra. An optical titration indicates that Ac-MP-8 exists in three major ionization forms over the pH 1-12 range that are linked by pK(a) values of approximately 3 and 9. The acid form that is present at pH 1.5 exists as a mixture of five- and six-coordinate high-spin species and most likely has water or buffer ions as axial ligand(s). On titration to pH 7, the His18 residue is deprotonated and becomes the proximal ligand to the iron to give a six-coordinate neutral form that has water as the sixth ligand. This form exists in a thermal high-spin intermediate-spin state equilibrium. On raising the pH to 10, an alkaline form is generated which is predominantly a five-coordinate high-spin species. It is formed by ionization of the proximal His18 residue to its imidazolate form with concomitant dissociation of the water ligand at the sixth site. At concentrations of Ac-MP-8 greater than 10-mu-M, some six-coordinate low-spin species are formed that are attributed to a dimer in which a His18 residue from a second molecule of Ac-MP-8 coordinates to the sixth site of another to give a bis-His complex. Raising the pH to 11.5 does not produce an appreciable amount of the six-coordinate complex with hydroxide as the sixth ligand. These studies show that Ac-MP-8 is a good water-soluble model for the peroxidases that exhibits minimal aggregation at concentrations below 10-mu-M in the neutral and alkaline pH regions.	FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,INST MOLEC BIOPHYS,TALLAHASSEE,FL 32306; UNIV TEXAS,HLTH SCI CTR,DIV HEMATOL & ONCOL,HOUSTON,TX 77030; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	State University System of Florida; Florida State University; State University System of Florida; Florida State University; University of Texas System; University of Texas Health Science Center Houston; Rice University					NIGMS NIH HHS [GM21337, GM27276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027276, R37GM021337, R01GM021337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ADAMS PA, 1990, J CHEM SOC CHEM COMM, P97, DOI 10.1039/c39900000097; ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; ARON J, 1986, J INORG BIOCHEM, V27, P227, DOI 10.1016/0162-0134(86)80064-2; ASHER SA, 1977, BIOCHEMISTRY-US, V16, P5849, DOI 10.1021/bi00645a032; ASHER SA, 1979, BIOCHEMISTRY-US, V18, P5377, DOI 10.1021/bi00591a019; BALDWIN DA, 1986, J INORG BIOCHEM, V27, P245, DOI 10.1016/0162-0134(86)80065-4; BALDWIN DA, 1985, FEBS LETT, V183, P309, DOI 10.1016/0014-5793(85)80799-7; BALDWIN DA, 1987, J INORG BIOCHEM, V30, P203, DOI 10.1016/0162-0134(87)80064-8; BELL SEJ, 1990, J CHEM SOC FARADAY T, V86, P4017, DOI 10.1039/ft9908604017; BURKE JM, 1978, J AM CHEM SOC, V100, P6077, DOI 10.1021/ja00487a017; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; CHUANG WJ, 1989, J BIOL CHEM, V264, P14209; DESBOIS A, 1979, BIOCHEMISTRY-US, V18, P1510, DOI 10.1021/bi00575a019; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EHRENBERG A, 1955, ACTA CHEM SCAND, V9, P1193, DOI 10.3891/acta.chem.scand.09-1193; KAJIYOSHI M, 1975, J BIOCHEM-TOKYO, V78, P1087, DOI 10.1093/oxfordjournals.jbchem.a130986; KOBAYASHI N, 1977, BIOCHIM BIOPHYS ACTA, V493, P340, DOI 10.1016/0005-2795(77)90190-8; LAMAR GN, 1990, J BIOL CHEM, V265, P16173; LANIR A, 1979, BIOCHEMISTRY-US, V18, P1656, DOI 10.1021/bi00576a004; LINDER RE, 1980, BIOPHYS CHEM, V12, P143, DOI 10.1016/0301-4622(80)80047-0; MALTEMPO MM, 1979, BIOCHEMISTRY-US, V18, P2935, DOI 10.1021/bi00581a003; MALTEMPO MM, 1974, BIOCHIM BIOPHYS ACTA, V342, P290, DOI 10.1016/0005-2795(74)90084-1; MYER YP, 1990, J PROTEIN CHEM, V9, P379, DOI 10.1007/BF01024613; NOZAWA T, 1976, BIOCHIM BIOPHYS ACTA, V427, P652, DOI 10.1016/0005-2795(76)90209-9; OGOSHI H, 1981, B CHEM SOC JPN, V54, P3414, DOI 10.1246/bcsj.54.3414; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; Palmer G., 1979, PORPHYRINS, P313; REED CA, 1979, J AM CHEM SOC, V101, P2948, DOI 10.1021/ja00505a023; REED RA, 1990, INORG CHEM, V29, P2881, DOI 10.1021/ic00341a003; SITTER AJ, 1988, J BIOL CHEM, V263, P13032; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TU AT, 1968, EXPERIENTIA, V24, P219, DOI 10.1007/BF02152778; TUPPY H, 1955, ACTA CHEM SCAND, V9, P353, DOI 10.3891/acta.chem.scand.09-0353; URRY DW, 1967, J AM CHEM SOC, V89, P5276, DOI 10.1021/ja00996a034; VICKERY L, 1976, J AM CHEM SOC, V98, P351, DOI 10.1021/ja00418a006; VICKERY L, 1976, J AM CHEM SOC, V98, P343, DOI 10.1021/ja00418a005; WANG JS, 1989, J PHYS CHEM-US, V93, P7925, DOI 10.1021/j100360a038; WANG JS, 1991, BIOCHEM BIOPH RES CO, V179, P1320, DOI 10.1016/0006-291X(91)91717-Q; WILSON MT, 1977, EUR J BIOCHEM, V77, P193, DOI 10.1111/j.1432-1033.1977.tb11657.x	40	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15310	15318						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322395				2022-12-25	WOS:A1992JG11300012
J	HARRIS, KW; MITCHELL, RA; WINKELMANN, JC				HARRIS, KW; MITCHELL, RA; WINKELMANN, JC			LIGAND-BINDING PROPERTIES OF THE HUMAN ERYTHROPOIETIN RECEPTOR EXTRACELLULAR DOMAIN EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MURINE INTERLEUKIN-4 RECEPTOR; CELL-LINE; BETA-CHAIN; CLONING; GENE; GROWTH; FAMILY; VIRUS; IDENTIFICATION	We developed an assay to directly measure the ligand binding properties of the cloned human erythropoietin receptor (EpoR). The cDNA encoding the extracellular domain of the human EpoR was amplified by polymerase chain reaction and ligated into the prokaryotic expression vector pGEX3X. Synthesis in Escherichia coli was induced and a soluble glutathione S-transferase fusion protein, EREx, was purified by erythropoietin affinity chromatography. Purified EREx was bound to GSH agarose beads and used in a solid phase ligand binding assay. Specific binding of I-125-erythropoietin to EREx beads was demonstrated. A single affinity class (K(d) = 1.5 nM) of the binding site was evident on Scatchard analysis. The K(d) of this site is quantitatively equivalent to that of the "low" affinity cellular binding site. Kinetic analysis of ligand binding to EREx revealed both the on and off rates to be rapid, with t1/2 of 60 and 40 s, respectively. EREx ligand binding exhibits no obvious metal ion dependence or cross-competition by other hemopoietins. Antibodies to EREx block the binding of erythropoietin to the cellular EpoR. We conclude that the 66-kDa EpoR protein is capable of specific ligand binding and that no covalent modifications or associated molecules are required for this interaction. We speculate that the "high" affinity cellular binding site (K(d) < 0.2 nM) results from the interaction of the EpoR with another molecule, either additional EpoR or associated subunits, that decreases the ligand off rate.	UNIV MINNESOTA, DEPT MED, BOX 480 UMHC, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NHLBI NIH HHS [HL39834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BROUDY VC, 1990, BLOOD, V75, P1622; BROUDY VC, 1988, P NATL ACAD SCI USA, V85, P6513, DOI 10.1073/pnas.85.17.6513; CHENG JB, 1986, J PHARMACOL EXP THER, V236, P126; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1990, PROG CLIN BIOL RES, V352, P153; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DIPERSIO JF, 1991, J BIOL CHEM, V266, P279; ERSLEV A, 1953, BLOOD, V8, P349, DOI 10.1182/blood.V8.4.349.349; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; Harlow E., 1988, ANTIBODIES LABORATOR, P511; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES SS, 1990, BLOOD, V76, P31; KITAMURA T, 1989, BLOOD, V73, P375; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; KRANTZ SB, 1984, P NATL ACAD SCI-BIOL, V81, P7574, DOI 10.1073/pnas.81.23.7574; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PERRINE SP, 1989, BIOCHEM BIOPH RES CO, V164, P857, DOI 10.1016/0006-291X(89)91537-4; SAWYER ST, 1990, PROG CLIN BIOL RES, V352, P145; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHIOZAKI M, 1990, LEUKEMIA RES, V14, P287, DOI 10.1016/0145-2126(90)90137-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPIVAK JL, 1991, BLOOD, V77, P1228; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TSUDA H, 1989, EXP HEMATOL, V17, P211; URDAL DL, 1989, HEMATOPOIETIC GROWTH; WINKELMANN JC, 1990, BLOOD, V76, P24; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675	41	35	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15205	15209						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321832				2022-12-25	WOS:A1992JF08800102
J	VONECHE, V; CALLEBAUT, I; KETTMANN, R; BRASSEUR, R; BURNY, A; PORTETELLE, D				VONECHE, V; CALLEBAUT, I; KETTMANN, R; BRASSEUR, R; BURNY, A; PORTETELLE, D			THE 19-27 AMINO-ACID SEGMENT OF GP51 ADOPTS AN AMPHIPHILIC STRUCTURE AND PLAYS A KEY ROLE IN THE FUSION EVENTS INDUCED BY BOVINE LEUKEMIA-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; INFLUENZA-VIRUS; MONOCLONAL-ANTIBODIES; ENVELOPE GLYCOPROTEIN; PROTEIN; PEPTIDE; TYPE-1; GP120; EPITOPES	Previous results indicate that the external glycoprotein gp51 of bovine leukemia virus plays an important role in the process of cell fusion induced by bovine leukemia virus (Bruck, C., Mathot, S., Portetelle, D., Berte, C., Franssen, J. D., Herion, P., and Burny, A. (1982) Virology 122, 342-352; Voneche, V., Portetelle., D., Kettmann, R., Willems, L., Limbach, K., Paoletti, E., Ruysschaert, J. M., Burny, A., and Brasseur, R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3810-3814) and suggest that a region encompassing residues 23 and 25 of gp51 is involved in this process (Portetelle, D., Couez, D., Bruck, C., Kettmann, R., Mammerickx, M., Van der Maaten, M., Brasseur, R., and Burny, A. (1989) Virology 169, 27-33; Mamoun, R., Morisson, M., Rebeyrotte, N., Busetta, B., Couez, D., Kettmann, R., Hospital, M., and Guillemain, B. (1990) J. Virol. 64, 4180-4188). X-ray diffraction studies performed on envelope glycoproteins of influenza virus indicate that the NH2-terminal part of the external glycoprotein lies very close to the fusion peptide. The same overall structure seems to exist in human immunodeficiency virus as suggested by site-directed mutagenesis followed by syncytia induction assays. Our theoretical studies indicate that a segment expanding between residues 19 and 27 of gp5l probably adopts an amphipathic beta-strand structure. We hypothesize that the amphipathic 19-27 structure of gp51 plays an important role in the process of membrane fusion by interacting with the fusion peptide or with another region of gp30. Mutational analysis disrupting the amphipathy of the 19-27 region strongly altered the fusogenic capacity of the gp51-gp30 complex.	FAC AGRON GEMBLOUX,MICROBIOL LAB,B-5030 GEMBLOUX,BELGIUM; UNIV BRUSSELS,BIOL CHEM LAB,B-1640 RHODE ST GENESE,BELGIUM; UNIV BRUSSELS,MACROMOLEC INTERFACES LAB,B-1050 BRUSSELS,BELGIUM; UNIV LIEGE,B-4000 LIEGE,BELGIUM	University of Liege; University of Liege	VONECHE, V (corresponding author), FAC AGRON GEMBLOUX,MOLEC BIOL & ANIM PHYSIOL LAB,13 AVE MARECHAL JUIN,B-5030 GEMBLOUX,BELGIUM.							BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1029, P267, DOI 10.1016/0005-2736(90)90163-I; BRUCK C, 1984, VIROLOGY, V136, P20, DOI 10.1016/0042-6822(84)90244-7; BRUCK C, 1982, VIROLOGY, V122, P342, DOI 10.1016/0042-6822(82)90234-3; BRUCK C, 1982, VIROLOGY, V122, P353, DOI 10.1016/0042-6822(82)90235-5; BURNY A, 1988, J ACQ IMMUN DEF SYND, V1, P579; BURNY A, 1987, CANCER SURV, V6, P139; BUSETTA B, 1989, BIOCHIM BIOPHYS ACTA, V998, P301, DOI 10.1016/0167-4838(89)90289-6; CALLEBAUT I, 1991, VIROLOGY, V185, P48, DOI 10.1016/0042-6822(91)90752-W; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; FISCHINGER PJ, 1974, J VIROL, V14, P177, DOI 10.1128/JVI.14.1.177-179.1974; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRAVES DC, 1981, J VIROL, V38, P1055, DOI 10.1128/JVI.38.3.1055-1063.1981; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667; HORTH M, 1991, EMBO J, V10, P2747, DOI 10.1002/j.1460-2075.1991.tb07823.x; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MAMOUN RZ, 1990, J VIROL, V64, P4180, DOI 10.1128/JVI.64.9.4180-4188.1990; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MEULEMANS G, 1978, ANN MED VET, V122, P45; RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3; SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	35	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15193	15197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321831				2022-12-25	WOS:A1992JF08800100
J	WRIGHT, CS				WRIGHT, CS			CRYSTAL-STRUCTURE OF A WHEAT-GERM-AGGLUTININ GLYCOPHORIN-SIALOGLYCOPEPTIDE RECEPTOR COMPLEX - STRUCTURAL BASIS FOR COOPERATIVE LECTIN-CELL BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE GLYCOPHORIN; AMINO-ACID SEQUENCE; SIALIC-ACID; MACROMOLECULAR STRUCTURES; PLANT-LECTINS; SUGAR BINDING; ISOLECTIN; SITES; OLIGOSACCHARIDE; RESOLUTION	The crystal structure of wheat germ agglutinin isolectin 1 (WGA1) complexed with a tryptic sialoglycopeptide fragment (T-5) from its erythrocyte receptor glycophorin A, which contains the O-linked tetrasaccharide NeuNAc-alpha-2,3-Gal-beta-1,3-(alpha-2,6-NeuNAc) Gal-NAc-alpha-1-O-Thr, has been determined by molecular replacement techniques and refined at 2.0-angstrom resolution (R = 18.1%). The structure reveals that association between WGA1 dimers, composed of two identical four-domain (A-D) monomers, and T-5 is asymmetric and involves sialic acid binding at three nonequivalent aromatic residue-rich sites. Two independent binding modes are observed. In the dominant ("major") binding mode, the two highest affinity sites are utilized to cross-link neighboring crystallographically related WGA1 dimers. The branched tetrasaccharide has an extended rigid conformation, and its terminal alpha-2,6-NeuNac and alpha-2,3-NeuNAc residues occupy specificity sites in domains B1 (monomer 1) and C2 (monomer 2) on opposing dimers, respectively. This asymmetric selection of binding sites leads to infinite open-ended arrays of interlinked lectin molecules. In the subsidiary "minor" binding mode, only the terminal alpha-2,6-NeuNac, anchored to the aromatic residue-rich binding site in domain A2, is clearly visible. The remaining portion of T-5 is disordered. This structure presents the first evidence for NeuNAc binding in the aromatic residue-rich sites of domains A and C and suggests a preference of WGA for alpha-2,6-linked NeuNAc. Moreover, the unusual asymmetric WGA1-tetrasaccharide association, involving domain binding sites that differ in their binding affinities for NeuNAc, offers explanations for the widely observed cooperative cell binding behavior of WGA.			WRIGHT, CS (corresponding author), VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017992] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17992] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAIR WL, 1974, J BIOL CHEM, V249, P4696; ALLEN AK, 1973, BIOCHEM J, V131, P155, DOI 10.1042/bj1310155; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BRILES EB, 1977, J BIOL CHEM, V252, P1107; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CUATRECA.P, 1973, BIOCHEMISTRY-US, V12, P1312, DOI 10.1021/bi00731a011; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; ETZLER ME, 1985, ANNU REV PLANT PHYS, V36, P209, DOI 10.1146/annurev.pp.36.060185.001233; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GANGULY P, 1979, BIOCHEM BIOPH RES CO, V89, P1154, DOI 10.1016/0006-291X(79)92129-6; GOLDSTEIN IJ, 1986, LECTINS PROPERTIES F, P43; GROB PM, 1983, J BIOL CHEM, V258, P4136; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KETIS NV, 1980, P NATL ACAD SCI-BIOL, V77, P3788, DOI 10.1073/pnas.77.7.3788; KRONIS KA, 1982, BIOCHEMISTRY-US, V21, P3050, DOI 10.1021/bi00256a003; KRONIS KA, 1985, BIOCHEMISTRY-US, V24, P826, DOI 10.1021/bi00325a003; Lis H., 1981, The biochemistry of plants. A comprehensive treatise. Volume 6. Proteins and nucleic acids., P371; LIS H, 1977, ANTIGENS, V4, P465; LOVRIEN RE, 1980, J CELL BIOL, V85, P534, DOI 10.1083/jcb.85.3.534; MANSFIELD MA, 1988, PLANTA, V173, P482, DOI 10.1007/BF00958961; MARCHESI VT, 1972, P NATL ACAD SCI USA, V69, P1445, DOI 10.1073/pnas.69.6.1445; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; NAGATA Y, 1974, J BIOL CHEM, V249, P3116; NICOLSON GL, 1974, INT REV CYTOL, V39, P89, DOI 10.1016/S0074-7696(08)60939-0; OIKAWA T, 1973, NATURE, V241, P256, DOI 10.1038/241256a0; PETERS BP, 1979, BIOCHEMISTRY-US, V18, P5505, DOI 10.1021/bi00591a038; PRIVAT JP, 1974, FEBS LETT, V46, P224, DOI 10.1016/0014-5793(74)80373-X; PRUJANSKY A, 1978, BIOCHIM BIOPHYS ACTA, V508, P137, DOI 10.1016/0005-2736(78)90195-5; QUIOCHO FA, 1988, CURR TOP MICROBIOL, V139, P135; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; REEKE GN, 1988, CURR TOP MICROBIOL, V139, P35; REISNER Y, 1976, EXP CELL RES, V97, P445, DOI 10.1016/0014-4827(76)90640-6; RICE RH, 1975, BIOCHEMISTRY-US, V14, P4093, DOI 10.1021/bi00689a027; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH JJ, 1989, PLANT MOL BIOL, V13, P601, DOI 10.1007/BF00027321; SOBOTTKA SE, 1984, NUCL INSTRUM METH A, V220, P575, DOI 10.1016/0167-5087(84)90325-9; STANLEY P, 1977, P NATL ACAD SCI USA, V74, P5056, DOI 10.1073/pnas.74.11.5056; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; THOMAS DB, 1969, J BIOL CHEM, V244, P5943; TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; WRIGHT CS, 1987, J MOL BIOL, V194, P353, DOI 10.1016/0022-2836(87)90383-4; WRIGHT CS, 1989, J MOL BIOL, V209, P475, DOI 10.1016/0022-2836(89)90011-9; WRIGHT CS, 1980, J MOL BIOL, V141, P267, DOI 10.1016/0022-2836(80)90181-3; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; WRIGHT CS, 1984, J MOL BIOL, V178, P91, DOI 10.1016/0022-2836(84)90232-8; WRIGHT CS, 1987, J MOL BIOL, V194, P501, DOI 10.1016/0022-2836(87)90678-4; WRIGHT CS, 1977, J MOL BIOL, V111, P439, DOI 10.1016/S0022-2836(77)80063-6; WRIGHT CS, 1989, J MOL EVOL, V28, P327, DOI 10.1007/BF02103429; WRIGHT CS, 1984, BIOCHEMISTRY-US, V23, P280, DOI 10.1021/bi00297a017; WRIGHT HT, 1991, J MOL EVOL, V33, P283, DOI 10.1007/BF02100680; WRIGHT HT, 1985, J MOL EVOL, V21, P133, DOI 10.1007/BF02100087	59	127	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14345	14352						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321144				2022-12-25	WOS:A1992JD32500085
J	DANESCH, U; HOECK, W; RINGOLD, GM				DANESCH, U; HOECK, W; RINGOLD, GM			CLONING AND TRANSCRIPTIONAL REGULATION OF A NOVEL ADIPOCYTE-SPECIFIC GENE, FSP27 - CAAT-ENHANCER-BINDING PROTEIN (C/EBP) AND C/EBP-LIKE PROTEINS INTERACT WITH SEQUENCES REQUIRED FOR DIFFERENTIATION-DEPENDENT EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; GROWTH-FACTOR; DEVELOPMENTAL REGULATION; ADIPOSE CONVERSION; MOLECULAR-CLONING; NUCLEAR FACTORS; FAMILY; CELLS; DNA; IDENTIFICATION	We have reported previously the cloning of several cDNAs whose mRNAs are induced during differentiation of the adipogenic cell line TA1. Here we characterize an adipocyte-specific gene, which we refer to as FSP27 (formerly clone 47), that encodes a protein of 27 kDa, the sequence of which is unrelated to any in the current data banks. The FSP27 promoter confers adipocyte-specific expression to a heterologous reporter gene in transfected adipogenic cell lines, e.g. TA1 and 3T3-L1. Analysis of regulatory elements in the FSP27 promoter region indicates the presence of (a) a proximal palindromic sequence that is necessary for adipocyte-specific expression; and (b) a distal differentiation-independent enhancer-like element. The palindromic sequence TTCGAAA is protected from digestion by DNase I using nuclear extracts from TA1 preadipocytes and adipocytes. Heated rat liver nuclear extract, a very abundant source of the transcription factor CAAT-enhancer-binding protein (C/EBP) and related proteins, generates an equivalent footprint over the palindrome. However, C/EBP can account for only a portion of the protein-DNA complexes in TA1 cells because preadipocytes as well as adipocytes contain proteins distinct from C/EBP which interact with the same sequence. We suggest that C/EBP and other C/EBP-like proteins play a critical role in regulating the transcription of the fat-specific gene FSP27.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; SYNTEX INC,INST CANC & DEV BIOL,PALO ALTO,CA 94304	Stanford University; Syntex Corporation				Hoeck, Wolfgang/0000-0001-9142-7103	NIGMS NIH HHS [GM 25821] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025821] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BORCK K, 1976, MOL GEN GENET, V146, P199, DOI 10.1007/BF00268089; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; DANI C, 1990, J CELL BIOCHEM, V43, P103, DOI 10.1002/jcb.240430202; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DILORENZO D, 1991, BIOCHEM BIOPH RES CO, V176, P1326, DOI 10.1016/0006-291X(91)90431-6; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HOECK W, 1989, J BIOL CHEM, V264, P14396; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; KNIGHT DM, 1987, MOL ENDOCRINOL, V1, P36, DOI 10.1210/mend-1-1-36; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAVRE M, 1988, J CELL BIOL, V107, P279, DOI 10.1083/jcb.107.1.279; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PAIK YK, 1988, J BIOL CHEM, V263, P13340; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RINGOLD GM, 1986, J STEROID BIOCHEM, V24, P69, DOI 10.1016/0022-4731(86)90034-8; RO HS, 1991, MOL CELL BIOL, V11, P2303, DOI 10.1128/MCB.11.4.2303; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILKISON WO, 1990, J BIOL CHEM, V265, P477; YANG VW, 1989, P NATL ACAD SCI USA, V86, P3629, DOI 10.1073/pnas.86.10.3629	52	108	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7185	7193						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1339452				2022-12-25	WOS:A1992HM05300111
J	WU, DQ; KATZ, A; LEE, CH; SIMON, MI				WU, DQ; KATZ, A; LEE, CH; SIMON, MI			ACTIVATION OF PHOSPHOLIPASE-C BY ALPHA-1-ADRENERGIC RECEPTORS IS MEDIATED BY THE ALPHA-SUBUNITS OF GQ FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; MOLECULAR-CLONING; SIGNAL TRANSDUCTION; EXPRESSION; SUBTYPES; DIVERSITY; CDNA; CHLORETHYLCLONIDINE; HETEROGENEITY; PHOSPHATE	High efficiency transient transfection of Cos-7 cells was previously used to establish the functional coupling between Galphaq/Galpha11 and phospholipase C beta1 (Wu, D., Lee, C-H., Rhee, S. G., and Simon, M. I. (1992) J. Biol. Chem. 267, 1811-1817). Here the same system was used to study the functional coupling between other guanine nucleotide-binding regulatory protein (G-protein) alpha subunits and phospholipases and to study which Galpha subunits mediate the activation of phospholipase C by the alpha1-adrenergic receptor subtypes, alpha1A, alpha1beta, and alpha1C. We found that Galpha14 and Galpha16 behaved like Galpha11 or Galphaq, i.e. they could activate endogenous phospholipases in Cos-7 cells in the presence of AIFn. The synergistic increase in inositol phosphate release in Cos-7 cells after they were cotransfected with cDNAs encoding Galpha subunits and phospholipase C beta1 indicates that both Galpha16 and Galpha14 can activate phospholipase C beta1. The activation of phospholipase C beta1 was restricted to members of the Gq subfamily of alpha subunits. They activated phospholipase C beta1 but not phospholipase C gamma1, gamma2, or phospholipase C delta3. The cotransfection of Cos-7 cells with cDNAs encoding three different alpha1-adrenergic receptors and Galphaq or Galpha11 leads to an increase in norepinephrine-dependent inositol phosphate release. This indicates that Galphaq or Galpha11 can mediate the activation of phospholipase C by all three subtypes of alpha1-adrenergic receptors. With the same assay system, Galpha16 and Galpha14 appear to be differentially involved in the activation of phospholipase C by the alpha1-adrenergic receptors. The alpha1B subtype receptor gave a ligand-mediated synergistic response in the cells cotransfected with either Galpha14 or Galpha16. However, the alpha1C receptor responded in cells cotransfected with Galpha14 but not Galpha16, and the alpha1A receptor showed little synergistic response in cells transfected with either Galpha14 or Galpha16. The ability of the alpha1A and alpha1C receptors to activate phospholipase C through Galphaq and Galpha11 was also demonstrated in a cell-free system. Clearly Galphaq and Galpha11 can couple all three of the alpha1-adrenergic receptors to activate phospholipase C beta1, however, there are differences in the relative coupling of the Galpha14 and Galpha16 subunits to these receptors.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology	SIMON, MI (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.		Katz, Arieh/F-5836-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN LF, 1991, P NATL ACAD SCI USA, V267, P1430; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAN C, 1987, MOL PHARMACOL, V32, P505; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KRIZ R, 1990, CIBA F SYMP, V150, P112; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MORROW AL, 1986, MOL PHARMACOL, V29, P321; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUZUKI E, 1990, MOL PHARMACOL, V38, P725; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WILSON KM, 1990, J BIOL CHEM, V265, P17601; WU DQ, 1992, J BIOL CHEM, V267, P1811	32	267	273	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25798	25802						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334487				2022-12-25	WOS:A1992KD07300035
J	BAULDRY, SA; ELSEY, KL; BASS, DA				BAULDRY, SA; ELSEY, KL; BASS, DA			ACTIVATION OF NADPH OXIDASE AND PHOSPHOLIPASE-D IN PERMEABILIZED HUMAN NEUTROPHILS - CORRELATION BETWEEN OXIDASE ACTIVATION AND PHOSPHATIDIC-ACID PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROTEIN-KINASE-C; GTP-BINDING PROTEIN; FMET-LEU-PHE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; FLUORIDE-TREATED NEUTROPHILS; SUPEROXIDE-GENERATING SYSTEM; STIMULATED HUMAN-NEUTROPHILS; STAPHYLOCOCCAL ALPHA-TOXIN; SODIUM DODECYL-SULFATE	A major function of human neutrophils (PMN) during inflammation is formation of oxygen radicals through activation of the respiratory burst enzyme, NADPH oxidase. Stimulus-induced production of both phosphatidic acid (PA) and diglyceride (DG) has been suggested to mediate oxidase activity; however, transductional mechanisms and cofactor requirements necessary for activation are poorly defined. We have utilized PMN permeabilized with Staphylococcus aureus alpha-toxin to elucidate the signal pathway involved in eliciting oxidase activity and to investigate whether PA or DG act as second messengers. PMN were permeabilized in cytoplasmic buffer supplemented with ATP and EGTA for 15 min before addition of NADPH and various cofactors. Oxidase activation was assessed by superoxide dismutase inhibitable reduction of ferricytochrome C; PA and DG levels were measured by radiolabeled product formation or by metabolite mass formation. Both superoxide (O2-) and PA formation were initiated by 10 muM GTPgammaS; addition of cytosolic levels of calcium ions (Ca2+, 120 nM) enhanced O2- and PA formation 1.5-2 fold. DG levels showed little change during these treatments. PA formation preceded O2- production and varying GTPgammaS levels had parallel effects on O2- and PA formation. However, while PA formation and oxidase activation occurred in tandem at Ca2+ levels of <1 muM, higher calcium enhanced PA formation but inhibited O2- production. Removal of ATP completely blocked O2- production but had little effect on PA formation; in contrast, if ATP was replaced with ATPgammaS, parallel production of PA and O2- occurred in the absence of other cofactors. Finally, while inhibition of PA production by ethanol pretreatment led to inhibition of O2- formation in PMN treated with GTPgammaS alone, in cells stimulated with a combination of GTPgammaS and Ca2+, ethanol continued to inhibit PA formation but had no effect on O2- production. Our results do not support a role for DG in the signal transduction path leading to oxidase activation and, while we show a close correlation between oxidase activation and PA production under many physiologic conditions, we also demonstrate that PA is not sufficient to induce oxidase activation and O2- formation can occur when PA production is inhibited.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC 27103 USA	Wake Forest University; Wake Forest Baptist Medical Center					NIAID NIH HHS [AI-30142, AI-14929, AI-10732] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030142, R01AI030142, R01AI014929, R01AI010732] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; AHNERTHILGER G, 1985, J BIOL CHEM, V260, P2730; AVIRAM I, 1989, BIOCHEM BIOPH RES CO, V161, P712, DOI 10.1016/0006-291X(89)92658-2; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BADER MF, 1986, J BIOL CHEM, V261, P5777; BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V154, P502, DOI 10.1016/0006-291X(88)90168-4; BASS DA, 1988, J BIOL CHEM, V263, P19610; BASS DA, 1987, J BIOL CHEM, V262, P6643; BAUDRY SA, 1988, J BIOL CHEM, V263, P16787; BAUDRY SA, 1991, J IMMUNOL, V146, P1277; BAUDRY SA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P178; BAULDRY SA, 1992, J BIOL CHEM, V267, P323; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1987, J BIOL CHEM, V262, P4065; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; COCKCROFT S, 1981, BIOCHEM J, V200, P501, DOI 10.1042/bj2000501; COHEN HJ, 1978, J CLIN INVEST, V61, P1088, DOI 10.1172/JCI109008; COX CC, 1986, J IMMUNOL, V136, P4611; COX JA, 1987, J IMMUNOL, V138, P1884; CURNUTTE JT, 1975, BLOOD, V45, P851; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DALE MM, 1987, BRIT J PHARMACOL, V92, P63, DOI 10.1111/j.1476-5381.1987.tb11296.x; DOUGHERTY RW, 1989, J BIOL CHEM, V264, P11263; ENGLISH D, 1991, BLOOD, V77, P2746; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; ENGLISH D, 1989, J IMMUNOL, V143, P1685; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FUJITA I, 1984, BIOCHEM BIOPH RES CO, V120, P318, DOI 10.1016/0006-291X(84)91256-7; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GODFREY RW, 1987, J CELL BIOL, V104, P925, DOI 10.1083/jcb.104.4.925; GOMPERTS BD, 1985, TRENDS BIOCHEM SCI, V10, P414, DOI 10.1016/0968-0004(85)90020-9; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1989, BIOCHEM J, V261, P755, DOI 10.1042/bj2610755; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GRZESKOWIAK M, 1986, BIOCHEM BIOPH RES CO, V135, P785, DOI 10.1016/0006-291X(86)90997-6; HARSHMAN S, 1988, METHOD ENZYMOL, V165, P3; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KESSELS GCR, 1991, J BIOL CHEM, V266, P23152; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; LU DJ, 1990, J BIOL CHEM, V265, P13721; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MCPHAIL LC, 1984, REGULATION LEUKOCYTE, P247; MILLER RT, 1991, KIDNEY INT, V39, P421, DOI 10.1038/ki.1991.53; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NAKASHIMA S, 1987, J BIOCHEM-TOKYO, V101, P1055, DOI 10.1093/oxfordjournals.jbchem.a121948; NAKASHIMA S, 1988, ARCH BIOCHEM BIOPHYS, V261, P375, DOI 10.1016/0003-9861(88)90353-0; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; OHTSUKA T, 1989, J BIOCHEM-TOKYO, V106, P259, DOI 10.1093/oxfordjournals.jbchem.a122841; OLSON SC, 1991, J BIOL CHEM, V266, P17236; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RIDER LG, 1987, J BIOL CHEM, V262, P5603; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROSSI F, 1989, J IMMUNOL, V142, P1652; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; SEIFERT R, 1988, EUR J BIOCHEM, V175, P51, DOI 10.1111/j.1432-1033.1988.tb14165.x; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V677, P512, DOI 10.1016/0304-4165(81)90267-1; SPARKMAN TB, 1985, BIOCHIM BIOPHYS ACTA, V846, P8, DOI 10.1016/0167-4889(85)90103-X; THOMPSON NT, 1990, BIOCHEM J, V271, P209, DOI 10.1042/bj2710209; TRAYNOR AE, 1989, BLOOD, V73, P296; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; WALKER BAM, 1991, J IMMUNOL, V146, P3124; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081	84	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25141	25152						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334083				2022-12-25	WOS:A1992KB60300037
J	LIEBL, EC; MARTIN, GS				LIEBL, EC; MARTIN, GS			INTRACELLULAR TARGETING OF PP60SRC EXPRESSION - LOCALIZATION OF V-SRC TO ADHESION PLAQUES IS SUFFICIENT TO TRANSFORM CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; INSOLUBLE CELLULAR MATRIX; GENE-PRODUCT; PROTEIN-PHOSPHORYLATION; MORPHOLOGICAL TRANSFORMATION; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; PLATELET PROTEIN; PLASMA-MEMBRANE; FOREIGN DNA	To define the effects of pp60v-src activity at different intracellular sites, we have constructed chimeric molecules which target the pp60v-src kinase to specific intracellular locations. pp60v-src was targeted to the nucleus by insertion of the SV40 large T antigen nuclear localization signal. Nuclear pp60v-src was active as a tyrosine kinase and phosphorylated nuclear proteins at tyrosine. However, cells expressing the nuclear pp60v-src were phenotypically normal by a number of criteria, and nuclear src kinase did not induce the expression of an mRNA (CEF-4) whose induction is characteristic of transformation by wild-type v-src. pp60v-src was targeted to perinuclear membranes by fusion to rat growth hormone and vesicular stomatis G protein sequences. Cells expressing this chimeric molecule were phenotypically normal by most criteria. However the perinuclear src protein did induce elevated levels of CEF-4 mRNA, indicating that the v-src kinase expressed at this site induces partial transformation. The v-src and activated c-src kinases were targeted to adhesion plaques by fusion to the talin-binding sequence of vinculin. Cells expressing these fusion proteins were transformed by morphological, physiological and biochemical criteria, although the foci induced by these viruses were distinct from those induced by wild-type v-src. A chimeric protein which targeted c-src to adhesion plaques was not transforming. Thus targeting pp60src to adhesion plaques, although not sufficient to activate the transforming capacity of c-src, is sufficient to allow transformation by v-src.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R37CA017542, R01CA017542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232] Funding Source: NIH RePORTER; NCI NIH HHS [CA09041, CA-17542] Funding Source: Medline; NIGMS NIH HHS [GM07232] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRICK BA, 1990, CANCER RES, V50, P299; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL JC, 1987, NATURE, V325, P552, DOI 10.1038/325552a0; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BRYAN WR, 1958, ACTA UNION INT CONTR, V15, P764; BRZESKI H, 1980, CELL, V22, P513, DOI 10.1016/0092-8674(80)90361-X; BURR JG, 1980, P NATL ACAD SCI USA, V77, P3483; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; CARTER VC, 1986, J CELL BIOL, V103, P2017, DOI 10.1083/jcb.103.5.2017; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hunter E, 1979, Methods Enzymol, V58, P379; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P1005; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; KRUEGER JG, 1984, MOL CELL BIOL, V4, P454, DOI 10.1128/MCB.4.3.454; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARTINSGREEN M, 1990, J CELL BIOL, V101, P581; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROHRSCHNEIDER L, 1985, MOL CELL BIOL, V5, P3097, DOI 10.1128/MCB.5.11.3097; ROHRSCHNEIDER L, 1983, MOL CELL BIOL, V3, P731, DOI 10.1128/MCB.3.4.731; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROYCHOUDHURY R, 1983, GENE, V25, P161, DOI 10.1016/0378-1119(83)90179-8; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SHAWVER LK, 1987, MOL CELL BIOL, V7, P2112, DOI 10.1128/MCB.7.6.2112; SHILO BZ, 1987, TRENDS GENET, V3, P69, DOI 10.1016/0168-9525(87)90178-8; SUDOL M, 1986, NUCLEIC ACIDS RES, V14, P2391, DOI 10.1093/nar/14.5.2391; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1	74	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2417	2428						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334249				2022-12-25	WOS:A1992KA85600006
J	BOUTILLIER, AL; BARTHEL, F; ROBERTS, JL; LOEFFLER, JP				BOUTILLIER, AL; BARTHEL, F; ROBERTS, JL; LOEFFLER, JP			BETA-ADRENERGIC STIMULATION OF CFOS VIA PROTEIN-KINASE A IS MEDIATED BY CAMP REGULATORY ELEMENT BINDING-PROTEIN (CREB)-DEPENDENT AND TISSUE-SPECIFIC CREB-INDEPENDENT MECHANISMS IN CORTICOTROPE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROOPIOMELANOCORTIN GENE-TRANSCRIPTION; ANTERIOR-PITUITARY CELLS; C-FOS; RESPONSIVE ELEMENT; HORMONAL-REGULATION; MESSENGER-RNA; TUMOR-CELLS; CYCLIC-AMP; EXPRESSION; GLUCOCORTICOIDS	Catecholamines stimulate proopiomelanocortin (POMC) gene expression in corticotrope cells, but the molecular mechanisms of these effects are not known. While beta-adrenergic receptors stimulate the protein kinase A (PKA) system, the POMC promoter does not have classical cAMP-response elements (CREs). Therefore, we investigated the induction of the c-fos protooncogene, previously shown to increase POMC transcription in AtT20 cells. In this corticotrope-derived cell line, we show that activation of beta-receptors with isoprenalin (Iso) induces a transient rise in c-fos mRNA levels. Gel mobility shift assays with a labeled AP1 consensus sequence (TGACTCA) showed induction of specific binding activity after Iso treatment. Cotransfection experiments with dominant inhibitory PKA mutants and reporter genes containing c-fos promoter sequences showed that c-fos induction by Iso is entirely dependent on a functional PKA activity. Furthermore, we show that beta-receptor induction of c-fos in corticotrophs is mediated by at least two distinct cAMP-responsive sequences. cAMP regulatory element binding (CREB)-dependent induction is observed on the CRE located at -60 bp on the c-fos promoter. A region located in the vicinity of the dyad symetry element (-290) is also found to mediate tissue-specific cAMP induction. Transcriptional activation by this site, although sensitive to PKA antagonism, is not blocked by CREB mutants.	INST PHYSIOL & CHIM BIOL, 21 RUE RENE DESCARTES, F-67084 STRASBOURG, FRANCE; MT SINAI MED CTR, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai			LOEFFLER, Jean-Philippe/AAS-4401-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2086, DOI 10.1073/pnas.80.7.2086; AFFOLTER HU, 1985, J BIOL CHEM, V260, P5477; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUTELITANO DJ, 1989, ANNU REV PHYSIOL, V51, P715, DOI 10.1146/annurev.physiol.51.1.715; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; CAILLA HL, 1973, ANAL BIOCHEM, V56, P394, DOI 10.1016/0003-2697(73)90205-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1985, FEBS LETT, V193, P54, DOI 10.1016/0014-5793(85)80078-8; EBERWINE JH, 1987, DNA-J MOLEC CELL BIO, V6, P483, DOI 10.1089/dna.1987.6.483; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GAGNER JP, 1987, MOL ENDOCRINOL, V1, P677, DOI 10.1210/mend-1-10-677; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; LOEFFLER JP, 1990, J NEUROCHEM, V54, P1812, DOI 10.1111/j.1471-4159.1990.tb01240.x; LOEFFLER JP, 1986, ENDOCRINOLOGY, V119, P2840, DOI 10.1210/endo-119-6-2840; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; MCKNIGHT GS, 1988, COLD SPRING HARB SYM, V53, P111, DOI 10.1101/SQB.1988.053.01.017; MIYAZAKI K, 1984, ENDOCRINOLOGY, V115, P1933, DOI 10.1210/endo-115-5-1933; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; REISINE TD, 1982, P NATL ACAD SCI USA, V3, P725; ROBERTS JL, 1987, ANN NY ACAD SCI, V512, P275, DOI 10.1111/j.1749-6632.1987.tb24966.x; SABOL SL, 1980, ARCH BIOCHEM BIOPHYS, V203, P37, DOI 10.1016/0003-9861(80)90151-4; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VONDREDEN G, 1988, NEUROENDOCRINOLOGY, V47, P32, DOI 10.1159/000124887; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOUNG SL, 1989, MOL ENDOCRINOL, V3, P15, DOI 10.1210/mend-3-1-15	35	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23520	23526						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331087				2022-12-25	WOS:A1992JZ23900019
J	CHIBALIN, AV; VASILETS, LA; HENNEKES, H; PRALONG, D; GEERING, K				CHIBALIN, AV; VASILETS, LA; HENNEKES, H; PRALONG, D; GEERING, K			PHOSPHORYLATION OF NA,K-ATPASE ALPHA-SUBUNITS IN MICROSOMES AND IN HOMOGENATES OF XENOPUS OOCYTES RESULTING FROM THE STIMULATION OF PROTEIN KINASE-A AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; CATALYTIC SUBUNIT; PHORBOL ESTER; BETA-SUBUNITS; CELLS; TRANSPORT; MEMBRANE; SEQUENCE; NA+,K+-ATPASE; BLADDER	The phosphorylation of the alpha-subunit of Na+/K+-transporting ATPase (Na,K-ATPase) by cAMP-dependent protein kinase (PKA) and protein kinase C (PKC) was characterized in purified enzyme preparations of Bufo marinus kidney and duck salt gland and in microsomes of Xenopus oocytes. In addition, we have examined cAMP and phorbol esters, which are stimulators of PKA and PKC, respectively, for their ability to provoke the phosphorylation of alpha-subunits of Na,K-ATPase in homogenates of Xenopus oocytes. In the enzyme from the duct salt gland, phosphorylation by PKA and PKC occurs on serine and threonine residues, whereas in the enzyme from B. marinus kidney and Xenopus oocytes, phosphorylation by PKA occurs only on serine residues. Phosphopeptide analysis indicates that a site phosphorylated by PKA resides in a 12-kDa fragment comprising the C terminus of the polypeptide. Studies of phosphorylation performed on homogenates of Xenopus oocytes show that not only endogenous oocyte Na,K-ATPase but also exogenous Xenopus Na,K-ATPase expressed in the oocyte by microinjection of cRNA can be phosphorylated in response to stimulation of oocyte PKA and PKC. In conclusion, these data are consistent with the possibility that the alpha-subunit of Na,K-ATPase can serve as a substrate for PKA and PKC in vivo.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, RUE BUGNON 27, CH-1005 LAUSANNE, SWITZERLAND; SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; RUSSIAN ACAD SCI, INST CHEM PHYS, MOSCOW 142432, USSR	University of Lausanne; Swiss Institute Experimental Cancer Research; Russian Academy of Sciences; N.N. Semenov Federal Research Centre for Chemical Physics, Russian Academy of Sciences				Vasilets, Larisa/0000-0001-5980-4423; Chibalin, Alexander/0000-0002-6339-6271				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BEACH RE, 1987, AM J PHYSIOL, V252, pF215, DOI 10.1152/ajprenal.1987.252.2.F215; BERTORELLO A, 1988, AM J PHYSIOL, V254, pF795, DOI 10.1152/ajprenal.1988.254.6.F795; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHIBALIN AV, 1991, BIOL MEMBRANY, V8, P1140; CHIBALIN AV, 1992, IN PRESS J BIOENERG; GEERING K, 1979, BIOCHIM BIOPHYS ACTA, V566, P157, DOI 10.1016/0005-2744(79)90258-4; GEERING K, 1982, J BIOL CHEM, V257, P338; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1985, J BIOL CHEM, V260, P5154; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; HERNANDEZ J, 1992, NEUROCHEM INT, V20, P1, DOI 10.1016/0197-0186(92)90119-C; JAUNIN P, 1992, J BIOL CHEM, V267, P577; LAMB JF, 1990, INT J BIOCHEM, V22, P1365, DOI 10.1016/0020-711X(90)90224-Q; LING L, 1984, J BIOL CHEM, V259, P4089; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; MARDH S, 1983, CURR TOP MEMBR TRANS, V19, P999; MARVER D, 1986, J MEMBRANE BIOL, V94, P205, DOI 10.1007/BF01869716; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAVRAN SS, 1991, J PHARMACOL EXP THER, V256, P297; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSSIER BC, 1987, TRENDS BIOCHEM SCI, V12, P483, DOI 10.1016/0968-0004(87)90235-0; SATOH T, 1990, AM J PHYSIOL, V259, pF425, DOI 10.1152/ajprenal.1990.259.3.F425; SMART JL, 1988, PHARMACOLOGY, V37, P94, DOI 10.1159/000138452; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; VASILETS LA, 1991, SOC GENERAL PHYSL 2, V46; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034	32	116	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22378	22384						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331053				2022-12-25	WOS:A1992JW71900062
J	GUAN, XM; KOBILKA, TS; KOBILKA, BK				GUAN, XM; KOBILKA, TS; KOBILKA, BK			ENHANCEMENT OF MEMBRANE INSERTION AND FUNCTION IN A TYPE IIIB MEMBRANE-PROTEIN FOLLOWING INTRODUCTION OF A CLEAVABLE SIGNAL PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; GLYCOSYLATION; TRANSLOCATION; TOPOGRAPHY; MECHANISMS; SEQUENCE; BINDING; SITES; GENE	The human beta2 adrenergic receptor is a type IIIb membrane protein. It has a putative seven-transmembrane topology but lacks an amino-terminal cleavable signal sequence. The mechanism by which the amino terminus of the beta2 receptor is translocated across the endoplasmic reticulum membrane is unknown. Furthermore, it is not known if translocation as a type IIIb protein is essential for the proper folding. Our studies indicate that conversion of beta2 receptor from a type IIIb to a type IIIa membrane protein by introducing an NH2-terminal cleavable signal sequence enhances translocation of the receptor into the endoplasmic reticulum membrane, thereby facilitating expression of functional receptor.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,DIV CARDIOVASC,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NINDS NIH HHS [5 RO1 NS28471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Blobel G, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 1, P7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; JOU WM, 1980, CELL, V19, P683, DOI 10.1016/S0092-8674(80)80045-6; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU JTY, 1983, J BIOL CHEM, V258, P5255; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; SUMMERS MD, 1987, TEXAS AGR EXP STN B, V1555; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WANG HY, 1989, J BIOL CHEM, V264, P14424; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	18	226	232	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					21995	21998						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331042				2022-12-25	WOS:A1992JW71900003
J	TOMAVO, S; DUBREMETZ, JF; SCHWARZ, RT				TOMAVO, S; DUBREMETZ, JF; SCHWARZ, RT			BIOSYNTHESIS OF GLYCOLIPID PRECURSORS FOR GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS IN A TOXOPLASMA-GONDII CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; DECAY-ACCELERATING FACTOR; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; STRUCTURAL CHARACTERIZATION; THY-1 GLYCOPROTEIN; LEISHMANIA-MAJOR; N-GLYCOSYLATION; PHOSPHATIDYLINOSITOL	Toxoplasmosis, a disease that affects humans and a wide variety of mammals is caused by Toxoplasma gondii, the obligate intracellular coccidian protozoan parasite. Most T. gondii research has focused on the rapidly growing invasive form, the tachyzoite, which expresses five major surface proteins attached to the parasite membrane by glycosylphosphatidylinositol (GPI) anchors. We have recently reported the purification and partial characterization of candidate precursor glycolipids (GPIs) from metabolically labeled parasites and have presented evidence that these GPIs have a linear glycan backbone sequence indistinguishable from the GPI core glycan of the major tachyzoite surface protein, P30. In this report, we describe a cell-free system derived from tachyzoite membranes which is capable of catalyzing GPI biosynthesis. Incubation of the membrane preparations with radioactive sugar nucleotides (GDP-[H-3]mannose or UDP-[H-3]GlcNAc) resulted in incorporation of radiolabel into numerous glycolipids. By using a combination of chemical/enzymatic tests and chromatographic analysis, a series of incompletely glycosylated lipid species and mature GPIs have been identified. We have also established the involvement of Dol-P-mannose in the synthesis of T. gondii GPIs by demonstrating that the incorporation of [H-3]mannose into the mannosylated GPIs is stimulated by dolichylphosphate and inhibited by amphomycin. In addition, increasing the concentration of nonradioactive GDP mannose resulted in a loss of radiolabel from the first easily detectable GPI precursor, GlcN-PI, and a concomittant appearance of the radioactivity into mannosylated glycolipids. Altogether, our data suggest that the GPI core glycan in T. gondii is assembled via sequential glycosylation of phosphatidylinositol, as proposed for the biosynthesis of GPIs in Trypanosoma brucei. In contrast to T. brucei, preliminary experiments indicate that the core glycan of some GPIs synthesized by the T. gondii cell-free system is modified by N-acetylgalactosamine similar to the situation for mammalian Thy-1.	UNIV MARBURG,MED ZENTRUM HYG & MED MIKROBIOL,W-3550 MARBURG,GERMANY; INSERM,U42,F-59650 VILLENEUVE DASCQ,FRANCE	Philipps University Marburg; Institut National de la Sante et de la Recherche Medicale (Inserm)								BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FASEL N, 1989, P NATL ACAD SCI USA, V86, P6858, DOI 10.1073/pnas.86.18.6858; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, J BIOL CHEM, V266, P8392; HARDY MR, 1988, P NATL ACAD SCI USA, V85, P3289, DOI 10.1073/pnas.85.10.3289; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KANG MS, 1978, J BIOL CHEM, V253, P8860; KASPER LH, 1983, J IMMUNOL, V130, P2407; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; NAGEL SD, 1989, J BIOL CHEM, V264, P5569; PFEFFERKORN ER, 1983, CIBA F SYMP, V99, P74; PFEFFERKORN ER, 1978, EXP PARASITOL, V44, P26, DOI 10.1016/0014-4894(78)90077-2; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHWARZ RT, 1982, METHOD ENZYMOL, V83, P432; SHARMA CB, 1974, EUR J BIOCHEM, V46, P35, DOI 10.1111/j.1432-1033.1974.tb03594.x; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TOMAVO S, 1989, MOL CELL BIOL, V9, P4576, DOI 10.1128/MCB.9.10.4576; TOMAVO S, 1992, J BIOL CHEM, V267, P11721; TOMAVO S, 1992, Biochemical Society Transactions, V20, p166S; TOMAVO S, 1991, BIOL CHEM H-S, V372, P769; WALTER EI, 1990, J IMMUNOL, V144, P1030	46	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21446	21458						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328232				2022-12-25	WOS:A1992JV01100031
J	FOSANG, AJ; NEAME, PJ; LAST, K; HARDINGHAM, TE; MURPHY, G; HAMILTON, JA				FOSANG, AJ; NEAME, PJ; LAST, K; HARDINGHAM, TE; MURPHY, G; HAMILTON, JA			THE INTERGLOBULAR DOMAIN OF CARTILAGE AGGRECAN IS CLEAVED BY PUMP, GELATINASES, AND CATHEPSIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; GLOBULAR PROTEIN DOMAINS; 72 KDA PROGELATINASE; LINK-PROTEIN; PROTEOGLYCANS INVITRO; TISSUE INHIBITOR; BINDING REGION; G2 DOMAIN; DEGRADATION; STROMELYSIN	The action of three matrix metalloproteinases (MMPs), 72- and 95-kDa gelatinases (MMP-2 and MMP-9) and PUMP (MMP-7), and a cysteine proteinase, cathepsin B, were investigated on aggrecan the major proteoglycan of cartilage. All the enzymes cleaved aggrecan although the activity of the 95-kDa gelatinase was very low. Specific cleavage sites were investigated following incubation with a purified aggrecan G1-G2 domain fragment (150 kDa). Both gelatinases produced 110-kDa G2 and 56-kDa G1 products by a single cleavage at an Asn-Phe bond within the interglobular domain close to the G1 domain. This was similar to the action of stromelysin (MMP-3) (Fosang, A. J., Neame, P. J., Hardingham, T. E., Murphy, G., and Hamilton, J. A. (1991) J. Biol. Chem. 266, 15579-15582). Cathepsin B also produced two fragments from a single cleavage at a Gly-Val bond only three amino acids C-terminal to the metalloproteinase cleavage site. PUMP cleaved at the metalloproteinase Asn-Phe site, but in addition produced a low yield of a smaller G2 fragment (56 kDa) corresponding to cleavage between Asp441 and Leu442 (human sequence), within the interglobular domain, close to the G2 domain. The apparent difference in size between the two G2 fragments released by PUMP (110 and 56 kDa) was much greater than predicted from the peptide length between the cleavage sites (100 amino acids). However, keratanase digestion greatly reduced the size of the 110-kDa G2 fragment, while producing only a small reduction in size of the 56-kDa product, showing that there was approximately 30-40 kDa of keratan sulfate attached to the interglobular domain between the PUMP cleavage sites. This new structural information on aggrecan may account for the previously observed stiffness of the interglobular domains when viewed by rotary shadowing electron microscopy (Paulsson, M., Morgelin, M., Wiedemann, H., Beardmore-Gray, M., Dunham, D. G., Hardingham, T. E., Heinegard, D., Timpl, R., and Engel, J. (1987) Biochem. J. 245, 763-772). These results show that in spite of a high keratan sulfate content the interglobular domain provides important sites for cleavage by different proteinases, including several members of the matrix metalloproteinase family.	SHRINERS HOSP CRIPPLED CHILDREN,TAMPA,FL 33612; KENNEDY INST,LONDON W6 7DW,ENGLAND; STRANGEWAYS RES LAB,CAMBRIDGE CB1 4RN,ENGLAND	University of Oxford	FOSANG, AJ (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,ROYAL PARADE,PARKVILLE,VIC 3050,AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224; Last, Karena/0000-0002-4396-8404; Fosang, Amanda/0000-0002-5523-5427; Hardingham, Timothy/0000-0001-8271-6763				ALLAN JA, 1991, J CELL SCI, V99, P789; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BAYLISS MT, 1985, BIOCHEM J, V232, P111, DOI 10.1042/bj2320111; BROWN CC, 1989, J BONE JOINT SURG AM, V71A, P580, DOI 10.2106/00004623-198971040-00014; CAMPBELL IK, 1986, BIOCHEM J, V237, P117, DOI 10.1042/bj2370117; CARNEY SL, 1986, ANAL BIOCHEM, V156, P38, DOI 10.1016/0003-2697(86)90150-8; CASE JP, 1990, J IMMUNOL, V145, P3755; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1991, BIOCHEM J, V273, P369, DOI 10.1042/bj2730369; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASTY KA, 1990, ARTHRITIS RHEUM, V33, P388, DOI 10.1002/art.1780330312; LEE X, 1990, J BIOL CHEM, V265, P5950; LEFEBVRE V, 1991, BIOCHIM BIOPHYS ACTA, V1094, P8, DOI 10.1016/0167-4889(91)90020-X; MACIEWICZ RA, 1988, BIOCHEM SOC T, V16, P812, DOI 10.1042/bst0160812; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; MOK MT, 1992, ARCH BIOCHEM BIOPHYS, V292, P442, DOI 10.1016/0003-9861(92)90014-N; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1986, COLLAGEN REL RES, V6, P351; NGUYEN Q, 1992, J CLIN INVEST, V89, P1189, DOI 10.1172/JCI115702; OGATA Y, 1992, J BIOL CHEM, V267, P3581; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; POOLE AR, 1987, J RHEUMATOL, V14, P80; RATCLIFFE A, 1983, BIOCHEM J, V213, P371, DOI 10.1042/bj2130371; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; SAKLATVALA J, 1984, BIOCHEM J, V224, P461, DOI 10.1042/bj2240461; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1990, J BIOL CHEM, V265, P21108; TRECHSEL U, 1982, BIOCHIM BIOPHYS ACTA, V720, P364, DOI 10.1016/0167-4889(82)90113-6; TYLER JA, 1985, BIOCHEM J, V225, P493, DOI 10.1042/bj2250493; VANRANST M, 1991, CYTOKINE, V3, P231, DOI 10.1016/1043-4666(91)90021-5; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J	44	273	283	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19470	19474						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326552				2022-12-25	WOS:A1992JP59300069
J	WILLARD, JM; OSWALD, RE				WILLARD, JM; OSWALD, RE			INTERACTION OF THE FROG BRAIN KAINATE RECEPTOR EXPRESSED IN CHINESE-HAMSTER OVARY CELLS WITH A GTP-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HIPPOCAMPAL-NEURONS; METHYL-D-ASPARTATE; GLUTAMATE RECEPTOR; GUANINE-NUCLEOTIDES; MOLECULAR-CLONING; SUBUNIT; ASTROCYTES; INDUCTION; INVITRO; FAMILY	A protein that binds kainate with high affinity has been purified and cloned from frog brain (Rana pipiens) and has approximately 35% sequence homology with mammalian non-N-methyl-D-aspartate glutamate receptors, some of which have been shown to be ligand-gated ion channels. Frog brain membranes and membranes from Chinese hamster ovary (CHO) cells transfected with the cDNA coding for the frog kainate-binding protein (CHO-4 cells) bound kainate with essentially identical affinity (K(D) values of 1.9 and 2.1 nm, respectively). In both tissues, the affinity for kainate decreased 9-fold in the presence of 100 muM GTPgammaS (guanosine 5'-O-(3-thio)triphosphate). No specific kainate binding to nontransfected CHO cell membranes was observed. GTPgammaS and GDP were effective inhibitors of kainate binding, while cGMP and adenosine 5'-O-(3-thio)triphosphate had no effect in either frog brain membranes or CHO-4 membranes. Pretreatment of CHO-4 cell membranes with pertussis toxin led to a 34% decrease in kainate binding. Kainate increased the binding of [H-3]5'-guanylyl imidodiphosphate by 61%, and the rate of GTP hydrolysis by up to 5-fold. These results indicate that the kainate receptor cloned from frog brain can interact functionally with a G protein present in CHO-4 cell membranes.	CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University								ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BARON BM, 1989, J PHARMACOL EXP THER, V250, P162; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CHERUBINI E, 1990, EPILEPSY RES, V5, P18, DOI 10.1016/0920-1211(90)90062-Z; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FOSTER AC, 1984, BRAIN RES REV, V7, P103, DOI 10.1016/0165-0173(84)90020-1; GARTHWAITE J, 1989, J NEUROCHEM, V53, P1952, DOI 10.1111/j.1471-4159.1989.tb09266.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MILLER RJ, 1991, TRENDS NEUROSCI, V14, P477, DOI 10.1016/0166-2236(91)90054-X; MONAHAN JB, 1988, MOL PHARMACOL, V34, P111; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; NISTRI A, 1991, J PHYSIOL-LONDON, V435, P465, DOI 10.1113/jphysiol.1991.sp018519; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PUCKETT C, 1991, P NATL ACAD SCI USA, V88, P7557, DOI 10.1073/pnas.88.17.7557; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; ROVIRA C, 1990, PFLUG ARCH EUR J PHY, V415, P471, DOI 10.1007/BF00373625; SCHUSTER CM, 1991, SCIENCE, V254, P112, DOI 10.1126/science.1681587; STERNWEIS PC, 1990, TRENDS NEUROSCI, V13, P122, DOI 10.1016/0166-2236(90)90002-R; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WILLARD JM, 1991, J BIOL CHEM, V266, P10196; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZIEGRA CJ, 1992, P NATL ACAD SCI USA, V89, P4134, DOI 10.1073/pnas.89.9.4134; ZIEGRA CJ, 1992, IN PRESS MOL PHARM	37	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19112	19116						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326545				2022-12-25	WOS:A1992JP59300019
J	BIRD, GS; OBIE, JF; PUTNEY, JW				BIRD, GS; OBIE, JF; PUTNEY, JW			SUSTAINED CA(2+) SIGNALING IN MOUSE LACRIMAL ACINAR-CELLS DUE TO PHOTOLYSIS OF CAGED GLYCEROPHOSPHORYL-MYO-INOSITOL 4,5-BISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; 1,4,5-TRISPHOSPHATE; TRISPHOSPHATE; KINETICS; TETRAKISPHOSPHATE; PERMEABILITY; HEPATOCYTES; GLAND; CA-2+	In saponin-permeabilized mouse lacrimal acinar cells, glycerophosphoryl-myo-inositol 4,5-bisphosphate (GPIP2) activated the release of sequestered Ca2+ to the same extent as inositol 1,4,5-trisphosphate ((1,4,5)IP3) but with a potency about 1/10 that of (1,4,5)IP3. In lacrimal gland homogenates, [H-3]GPIP2 was metabolized to two compounds which upon anion exchange high performance liquid chromatography eluted at positions indicating that they were [H-3]GPIP and [H-3]GPIP3. The rate of metabolism of [H-3]GPIP2 was much slower than that of [H-3](1,4,5)IP3, and its rate of phosphorylation was less than 1% of that of [H-3] (1,4,5)IP3. In intact lacrimal cells, photolysis of a microinjected "caged" derivative of GPIP2, 1-(alpha-glycero-phosphoryl)-myo-inositol 4,5-bisphoshhate p4(5)-1-(2-nitrophenyl)ethyl ester, resulted in sustained activation of Ca2+ signaling; i.e. intracellular Ca2+ release followed by increased entry of Ca2+ across the plasma membrane. These findings indicate that caged GPIP2 should provide a useful tool for producing photolytically initiated, sustained activation of intracellular (1,4,5)IP3 receptors. They also provide strong support for the idea that sustained Ca2+ signaling can be achieved in lacrimal acinar cells by activation of intracellular receptors for (1,4,5)IP3 in the absence of stimulated production of inositol 1,3,4,5-tetrakisphoshate.			BIRD, GS (corresponding author), NIEHS, CELLULAR & MOLEC PHARMACOL LAB, CALCIUM REGULAT SECT, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Bird, Gary/AAI-8186-2021; Putney, James/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James/0000-0002-3379-4789				BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GSJ, 1991, BIOCHEM J, V273, P541, DOI 10.1042/bj2730541; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1991, NATURE, V352, P115, DOI 10.1038/352115a0; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; PAROD RJ, 1978, J PHYSIOL-LONDON, V281, P371, DOI 10.1113/jphysiol.1978.sp012428; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1981, PHILOS T ROY SOC B, V296, P37, DOI 10.1098/rstb.1981.0169; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023	21	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17722	17725						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325446				2022-12-25	WOS:A1992JM22300039
J	BEULLENS, M; VAN EYNDE, A; STALMANS, W; BOLLEN, M				BEULLENS, M; VAN EYNDE, A; STALMANS, W; BOLLEN, M			THE ISOLATION OF NOVEL INHIBITORY POLYPEPTIDES OF PROTEIN PHOSPHATASE-1 FROM BOVINE THYMUS NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR-REGULATION; RAT-LIVER; TYPE-1; PURIFICATION; ENCODES; GENE; IDENTIFICATION; PHOSPHOPROTEIN; CHROMATOGRAPHY; DROSOPHILA	Nuclei from bovine thymus contain a high level of partially latent protein phosphatase 1 (PP-1). More than 90% of this PP-1 is associated with the insoluble chromatin/matrix fraction and can be extracted with 0.3 M NaCl. The salt extract also contains three heat- and acid-stable inhibitory proteins of PP-1 that can be resolved on Mono Q. We have purified two of these nuclear inhibitors of PP-1 (NIPP-1a and NIPP-1b) until homogeneity. They are acidic proteins (pI = 4.4) with a molecular mass of 18 kDa (NIPP-1a) and 16 kDa (NIPP-1b) on SDS-PAGE. Judged from the larger molecular mass that was deduced from gel filtration (35 kDa), NIPP-1a and NIPP-1b appear to be asymmetric or dimeric proteins. The nuclear inhibitors totally inhibited the phosphorylase phosphatase activity of PP-1, but even at a 250-fold higher concentration they did not affect the activities of the other major serine/threonine protein phosphatases (PP-2A, PP-2B, and PP-2C). NIPP-1a and NIPP-1b inhibited the catalytic subunit of PP-1 with an extrapolated K(i) of about 1 pM, which is some three orders of magnitude better than the cytoplasmic proteins inhibitor 1/DARPP-32 and modulator. The nuclear inhibitors were not inactivated by incubation with protein phosphatases that inactivate inhibitor 1 and DARPP-32. Unlike modulator, they were not able to convert the catalytic subunit of PP-1 into a MgATP-dependent form. Remarkably, the extent of inhibition of PP-1 by NIPP-1b depended on the nature of the substrate. The phosphorylase phosphatase and casein phosphatase activities of PP-1 were completely blocked by NIPP-1b, whereas the dephosphorylation of basic proteins was either not at all inhibited (histone IIA) or only partially (myelin basic protein). These data may indicate that the acidic NIPP-1b is inactivated through complexation by basic proteins. Indeed, nonphosphorylated histone IIA antagonized the inhibitory effect of NIPP-1b on the casein phosphatase activity of PP-1. Our data show that the nucleus contains specific and potent inhibitory proteins of PP-1 that differ from earlier described cytoplasmic inhibitors. We suggest that these novel proteins may control the activity of nuclear PP-1 on its natural substrate(s).	CATHOLIC UNIV LEUVEN, FAK GENEESKUNDE, AFDELING BIOCHEM, CAMPUS GASTHUISBERG, B-3000 LOUVAIN, BELGIUM	KU Leuven								AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; ANTONIW JF, 1977, BIOCHEM J, V162, P423, DOI 10.1042/bj1620423; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DEJONG L, 1990, CELL BIOL INT REP, V14, P1051, DOI 10.1016/0309-1651(90)90014-P; DOMBRADI V, 1990, FEBS LETT, V275, P39, DOI 10.1016/0014-5793(90)81434-P; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DOPERE F, 1982, BIOCHEM BIOPH RES CO, V104, P443, DOI 10.1016/0006-291X(82)90657-X; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; FRIEDMAN DL, 1986, BIOCHEM BIOPH RES CO, V134, P1372, DOI 10.1016/0006-291X(86)90401-8; GOODWIN GH, 1973, EUR J BIOCHEM, V40, P215, DOI 10.1111/j.1432-1033.1973.tb03188.x; GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x; GOODWIN GH, 1989, PROTEIN PURIFICATION, P97; GORIS J, 1984, ADV ENZYME REGUL, V22, P467, DOI 10.1016/0065-2571(84)90026-8; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; JESSUS C, 1989, BIOCHEM J, V260, P45, DOI 10.1042/bj2600045; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KURET J, 1986, FEBS LETT, V203, P197, DOI 10.1016/0014-5793(86)80741-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERCIER JC, 1968, B SOC CHIM BIOL, V50, P521; MERLEVEDE W, 1985, ADV PROTEIN PHOSPHAT, V1, P1; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; STEWART AA, 1983, EUR J BIOCHEM, V132, P289, DOI 10.1111/j.1432-1033.1983.tb07361.x; TAKAI A, 1991, BIOCHEM J, V275, P233, DOI 10.1042/bj2750233; TSUIKI S, 1988, METHOD ENZYMOL, V159, P437; VANDENHEEDE JR, 1987, FEBS LETT, V211, P190, DOI 10.1016/0014-5793(87)81434-5; VANFLETEREN JR, 1989, ANAL BIOCHEM, V178, P385, DOI 10.1016/0003-2697(89)90657-X; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; YANG SD, 1981, FEBS LETT, V132, P293, DOI 10.1016/0014-5793(81)81182-9	40	116	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16538	16544						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322907				2022-12-25	WOS:A1992JJ45800085
J	EASON, MG; KUROSE, H; HOLT, BD; RAYMOND, JR; LIGGETT, SB				EASON, MG; KUROSE, H; HOLT, BD; RAYMOND, JR; LIGGETT, SB			SIMULTANEOUS COUPLING OF ALPHA-2-ADRENERGIC RECEPTORS TO 2 G-PROTEINS WITH OPPOSING EFFECTS - SUBTYPE-SELECTIVE COUPLING OF ALPHA-2C10, ALPHA-2C4, AND ALPHA-2C2 ADRENERGIC-RECEPTORS TO G(I) AND G(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; HAMSTER OVARY CELLS; ADENYLATE-CYCLASE; PHOSPHOLIPID-VESICLES; CYTOPLASMIC DOMAINS; EXPRESSION; CLONING; IDENTIFICATION; GENE; PHOSPHORYLATION	Coupling of the three alpha-2-adrenergic receptor (alpha-2AR) subtypes to G(i) and G(s) was studied in membranes from transfected CHO cells. We observed that in the presence of low concentrations of the alpha-2AR agonist UK-14304, alpha-2C10 mediated inhibition of adenylyl cyclase activity, whereas at high concentrations of agonist, alpha-2C10 mediated stimulation of adenylyl cyclase activity. We considered that this biphasic response was due to the coupling of alpha-2C10 to both G(i) and G(s). To isolate functional G(s) and G(i) coupling, cells were treated with pertussis toxin or cholera toxin in doses sufficient to fully ADP-ribosylate the respective G-proteins. Following treatment with cholera toxin, agonists elicited only alpha-2C10-mediated inhibition (approximately 50%) of adenylyl cyclase while after pertussis toxin treatment, agonists elicited only alpha-2C10-mediated stimulation (approximately 60%) of adenylyl cyclase. Incubation of membranes with antisera directed against the carboxyl-terminal portion of G(s-alpha) blocked this functional alpha-2AR.G(s) coupling to the same extent as that found for beta-2AR.G(s) coupling. In addition to functional G(s) coupling, we also verified direct, agonist-dependent, physical coupling of alpha-2AR to G(s-alpha). In agonist-treated membranes, an agonist-receptor-G(s-alpha) complex was immunoprecipitated with a specific alpha-2C10 antibody, and the G(s) component identified by both western blots using G(s-alpha) antibody, and cholera toxin mediated ADP-ribosylation. Due to the differences in primary amino acid structure in a number of regions of the alpha-2AR subtypes, we investigated whether G-protein coupling was subtype-selective, using UK-14304 and cells with the same alpha-2AR expression levels (approximately 5 pmol/mg). Coupling to G(i) was equivalent for alpha-2C10, alpha-2C4, and alpha-2C2: 53.4 +/- 8.9% versus 54.9 +/- 1.0% versus 47.6 +/- 3.5% inhibition of adenylyl cyclase, respectively. In marked contrast, distinct differences in coupling to G(s) were found between the three alpha-2AR subtypes: stimulation of adenylyl cyclase was 57.9 +/- 6.3 % versus 30.7 +/- 1.1% versus 21.8 +/- 1.7% for alpha-2C10, alpha-2C4, and alpha-2C2, respectively. Thus, alpha-2AR have the potential to couple physically and functionally to both G(i) and G(s); for G(i) coupling we found a rank order of alpha-2C10 = alpha-2C4 = alpha-2C2, while for G(s) coupling, alpha-2C10 > alpha-2C4 > alpha-2C2.	DUKE UNIV,MED CTR,DEPT MED PULM & NEPHROL,POB 3177,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University; Duke University			liggett, stephen b/E-7453-2012		NHLBI NIH HHS [HL45967] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045967, R01HL045967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CERIONE RA, 1986, J BIOL CHEM, V261, P3901; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DELEAN A, 1981, MOL PHARMACOL, V21, P5; DUMAN RS, 1986, J NEUROCHEM, V47, P800; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GUYER CA, 1990, J BIOL CHEM, V265, P17307; JONES SB, 1991, MOL PHARMACOL, V39, P239; JONES SB, 1990, J PHARMACOL EXP THER, V254, P294; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LIGGETT SB, 1989, BIOCHEM BIOPH RES CO, V165, P257, DOI 10.1016/0006-291X(89)91063-2; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIMBIRD LE, 1985, RECEPTORS, V2, P281; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRADER CD, 1987, J BIOL CHEM, V262, P16439; ULLRICH S, 1984, J BIOL CHEM, V259, P4111	31	327	331	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15795	15801						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322406				2022-12-25	WOS:A1992JG11300082
J	SCHOEPPER, B; WEGNER, A				SCHOEPPER, B; WEGNER, A			GELSOLIN BINDS TO POLYMERIC ACTIN AT A LOW RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-GELSOLIN; DEOXYRIBONUCLEASE-I; RATE CONSTANTS; SMOOTH-MUSCLE; POINTED ENDS; BARBED ENDS; F-ACTIN; FILAMENTS; COMPLEX; CALCIUM	Association of gelsolin with actin filament subunits was investigated by the decrease of the fluorescence intensity of a 7-nitro-2-oxa-1,3-diazole (NBD) label covalently linked to gelsolin. The rate constant of this reaction was found to be 4 x 10(3) M-1 s-1. Binding of NBD-labeled gelsolin to monomeric actin proceeds at a similar low rate. The rate of association of gelsolin that was unmodified to actin filament subunits was estimated too. Unmodified gelsolin was added to a mixture of actin filaments and actin-DNase I complex. The fractions of gelsolin that bound to actin filament subunits or to actin-DNase I complex depended on the relative rates of these two competing reactions. In this way it was possible to estimate the rate constant of association of unmodified gelsolin with actin filament subunits (2 x 10(4) M-1 s-1 ). Thus, gelsolin associates with actin filament subunits at a rate that is considerably slower than diffusion-controlled and similar to the rate of binding of gelsolin to monomeric actin.	RUHR UNIV BOCHUM,INST PHYSIOL CHEM,W-4630 BOCHUM,GERMANY	Ruhr University Bochum								ABODERIN AA, 1973, BIOCHIM BIOPHYS ACTA, V328, P20, DOI 10.1016/0005-2795(73)90325-5; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; COLOMBO R, 1991, J MOL BIOL, V217, P401, DOI 10.1016/0022-2836(91)90742-O; COUE M, 1986, J BIOL CHEM, V261, P1588; COUE M, 1985, J BIOL CHEM, V260, P5033; DETMERS P, 1981, J BIOL CHEM, V256, P99; DOI Y, 1991, EUR J BIOCHEM, V199, P277, DOI 10.1111/j.1432-1033.1991.tb16121.x; EDGAR AJ, 1990, J MUSCLE RES CELL M, V11, P323, DOI 10.1007/BF01766670; HINSSEN H, 1984, FEBS LETT, V166, P90, DOI 10.1016/0014-5793(84)80051-4; ITO H, 1990, J CHROMATOGR-BIOMED, V526, P397, DOI 10.1016/S0378-4347(00)82523-2; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KONDO H, 1976, J BIOCHEM-TOKYO, V79, P159, DOI 10.1093/oxfordjournals.jbchem.a131043; KURTH MC, 1984, J BIOL CHEM, V259, P7473; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LIND SE, 1982, J CLIN INVEST, V69, P1384, DOI 10.1172/JCI110578; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNHERZ HG, 1980, EUR J BIOCHEM, V104, P367, DOI 10.1111/j.1432-1033.1980.tb04437.x; NISHIDA E, 1981, J BIOCHEM-TOKYO, V89, P1655, DOI 10.1093/oxfordjournals.jbchem.a133363; NODES BR, 1987, J BIOL CHEM, V262, P5422; NORBERG R, 1979, EUR J BIOCHEM, V100, P575, DOI 10.1111/j.1432-1033.1979.tb04204.x; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; PORTE F, 1986, EUR J BIOCHEM, V154, P87, DOI 10.1111/j.1432-1033.1986.tb09362.x; REES MK, 1967, J BIOL CHEM, V242, P4449; SCHOEPPER B, 1991, EUR J BIOCHEM, V202, P1127, DOI 10.1111/j.1432-1033.1991.tb16480.x; SELVE N, 1986, EUR J BIOCHEM, V155, P397, DOI 10.1111/j.1432-1033.1986.tb09504.x; SELVE N, 1986, J MOL BIOL, V187, P627, DOI 10.1016/0022-2836(86)90341-4; SELVE N, 1986, EUR J BIOCHEM, V160, P379, DOI 10.1111/j.1432-1033.1986.tb09982.x; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WEBER A, 1991, BIOCHEMISTRY-US, V30, P9327, DOI 10.1021/bi00102a027; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WEIGT C, 1990, FEBS LETT, V260, P266, DOI 10.1016/0014-5793(90)80119-4; WEIGT C, 1991, BIOCHEMISTRY-US, V30, P10700, DOI 10.1021/bi00108a014; WOODRUM DT, 1975, J CELL BIOL, V67, P231, DOI 10.1083/jcb.67.1.231; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	38	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13924	13927						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321131				2022-12-25	WOS:A1992JD32500024
J	SINGH, TKA; SCRABA, DG; RYAN, RO				SINGH, TKA; SCRABA, DG; RYAN, RO			CONVERSION OF HUMAN LOW-DENSITY-LIPOPROTEIN INTO A VERY LOW-DENSITY LIPOPROTEIN-LIKE PARTICLE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PARTICLE; MANDUCA-SEXTA; APOLIPOPHORIN-III; TRANSFER PROTEIN; TOBACCO HORNWORM; INSECT; HEMOLYMPH; INTERCONVERSIONS; DIACYLGLYCEROL; LIPOPHORIN	The lipid substrate specificity of Manduca sexta lipid transfer particle (LTP) was examined in in vitro lipid transfer assays employing high density lipophorin and human low density lipoprotein (LDL) as donor/acceptor substrates. Unesterified cholesterol was found to exchange spontaneously between these substrate lipoproteins, and the extent of transfer/exchange was not affected by LTP. By contrast, transfer of labeled phosphatidylcholine and cholesteryl ester was dependent on LTP in a concentration-dependent manner. Facilitated phosphatidylcholine transfer occurred at a faster rate than facilitated cholesteryl ester transfer; this observation suggests that either LTP may have an inherent preference for polar lipids or the accessibility of specific lipids in the donor substrate particle influences their rate of transfer. The capacity of LDL to accept exogenous lipid from lipophorin was investigated by increasing the high density lipophorin:LDL ratio in transfer assays. At a 3:1 (protein) ratio in the presence of LTP, LDL became turbid (and aggregated LDL were observed by electron microscopy) indicating LDL has a finite capacity to accept exogenous lipid while maintaining an overall stable structure. When either isolated human non B very low density lipoprotein (VLDL) apoproteins or insect apolipophorin III (apoLp-III) were included in transfer experiments, the sample did not become turbid although lipid transfer proceeded to the same extent as in the absence of added apolipoprotein. The reduction in sample turbidity caused by exogenous apolipoprotein occurred in a concentration-dependent manner, suggesting that these proteins associate with the surface of LDL and stabilize the increment of lipid/water interface created by LTP-mediated net lipid transfer. The association of apolipoprotein with the surface of modified LDL was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, and scanning densitometry revealed that apoLp-III bound to the surface of LDL in a 1:14 apoB:apoLp-III molar ratio. Electron microscopy showed that apoLp-III-stabilized modified LDL particles have a larger diameter (29.2 +/- 2.6 nm) than that of control LDL (22.7 +/- 1.9 nm), consistent with the observed changes in particle density, lipid, and apolipoprotein content. Thus LTP-catalyzed vectorial lipid transfer can be used to introduce significant modifications into isolated LDL particles and provides a novel mechanism whereby VLDL-LDL interrelationships can be studied.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,328 HERITAGE BLDG,EDMONTON T6G 2S2,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta; University of Alberta					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034786] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 34786] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1976, J BIOL CHEM, V251, P3823; ANDO S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P289, DOI 10.1016/0005-2760(90)90029-W; AVIRAM M, 1991, J BIOL CHEM, V266, P11567; BISGAIER CL, 1991, J LIPID RES, V32, P21; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAIT A, 1984, BIOCHIM BIOPHYS ACTA, V795, P314, DOI 10.1016/0005-2760(84)90081-X; DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509; GRANOT E, 1985, BIOCHIM BIOPHYS ACTA, V833, P308, DOI 10.1016/0005-2760(85)90203-6; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; KEZDY FJ, 1978, LIPOPROTEIN MOL, P83; KLEINMAN Y, 1988, J LIPID RES, V29, P729; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P112, DOI 10.1016/0005-2760(91)90238-D; MORTON RE, 1990, EXPERIENTIA, V46, P552, DOI 10.1007/BF01939693; PRASAD SV, 1986, J BIOL CHEM, V261, P558; RYAN RO, 1990, J BIOL CHEM, V265, P10551; RYAN RO, 1990, J LIPID RES, V31, P1725; RYAN RO, 1990, J BIOL CHEM, V265, P546; RYAN RO, 1990, FEBS LETT, V267, P305, DOI 10.1016/0014-5793(90)80950-N; RYAN RO, 1986, J BIOL CHEM, V261, P563; RYAN RO, 1990, J LIPID RES, V31, P871; RYAN RO, 1988, J BIOL CHEM, V263, P14140; RYAN RO, 1986, BIOCHEM BIOPH RES CO, V136, P260, DOI 10.1016/0006-291X(86)90903-4; SCHONFELD G, 1985, METABOLISM, V34, P45, DOI 10.1016/S0026-0495(85)80009-3; SILVER ET, 1990, J BIOL CHEM, V265, P22487; SINGH TKA, 1991, ARCH BIOCHEM BIOPHYS, V286, P376, DOI 10.1016/0003-9861(91)90054-M; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TALL AR, 1986, J LIPID RES, V27, P361; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; VAKAKIS N, 1983, BIOCHIM BIOPHYS ACTA, V751, P280, DOI 10.1016/0005-2760(83)90285-0; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; VANHEUSDEN MC, 1989, J BIOL CHEM, V264, P17287; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WELLS MA, 1985, INSECT BIOCHEM, V15, P565, DOI 10.1016/0020-1790(85)90116-7; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	37	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9275	9280						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1343558				2022-12-25	WOS:A1992HR85400087
J	WU, CA; ZECHNER, EL; HUGHES, AJ; FRANDEN, MA; MCHENRY, CS; MARIANS, KJ				WU, CA; ZECHNER, EL; HUGHES, AJ; FRANDEN, MA; MCHENRY, CS; MARIANS, KJ			COORDINATED LEADING-STRAND AND LAGGING-STRAND SYNTHESIS AT THE ESCHERICHIA-COLI DNA-REPLICATION FORK .4. RECONSTITUTION OF AN ASYMMETRIC, DIMERIC DNA POLYMERASE-III HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION COMPLEX; GAMMA-SUBUNIT; GENE-PRODUCT; BETA-SUBUNIT; PROTEIN MACHINES; EPSILON-SUBUNIT; PRIMED TEMPLATE; SIZE CLASSES; IDENTIFICATION; PURIFICATION	Individually purified subunits have been used to reconstitute the action of the Escherichia coli DNA polymerase III holoenzyme (Pol III HE) at a replication fork formed in the presence of the primosome, the single-stranded DNA binding protein, and a tailed form II DNA template. Complete activity, indistinguishable from that of the intact DNA Pol III HE, could be reproduced with a combination of the DNA polymerase III core (Pol III core), the gamma.delta-complex, and the beta-subunit. Experiments where the Pol III core in reaction mixtures containing active replication forks was diluted suggested that the lagging-strand Pol III core remained associated continuously with the replication fork through multiple cycles of Okazaki fragment synthesis. Since the lagging-strand Pol III core must dissociate from the 3' end of the completed Okazaki fragment, this suggests that its association with the fork is via protein-protein interactions, lending credence to the idea that it forms a dimeric complex with the leading-strand Pol III core. An asymmetry in the action of the subunits was revealed under conditions (high ionic strength) that were presumably destabilizing to the integrity of the replication fork. Under these conditions, tau acted to stimulate DNA synthesis only when the primase was present (i.e. when lagging-strand DNA synthesis was ongoing). This stimulation was reflected by an inhibition of the formation of small Okazaki fragments, suggesting that, within the context of the model developed to account for the temporal order of steps during a cycle of Okazaki fragment synthesis, the presence of tau-accelerated the transit of the lagging-strand Pol III core from the 3' end of the completed Okazaki fragment to the 3' end of the new primer.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	Cornell University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WU, CA (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.			Zechner, Ellen L./0000-0003-2035-1898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; ALBERTS BM, 1985, TRENDS GENET, V1, P26, DOI 10.1016/0168-9525(85)90011-3; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BURGERS PMJ, 1983, J BIOL CHEM, V258, P7669; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; CHANDLER M, 1975, J MOL BIOL, V94, P127, DOI 10.1016/0022-2836(75)90410-6; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HENSON JM, 1979, GENETICS, V92, P1041; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KOADIRA M, 1983, MOL GEN GENET, V192, P80; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; MAKI H, 1985, J BIOL CHEM, V260, P2982; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6547; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1988, BIOCHIM BIOPHYS ACTA, V951, P240, DOI 10.1016/0167-4781(88)90092-9; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; MCHENRY CS, 1987, ICN UCLA S MOL CELLU, V47, P47; MCHENRY CS, 1989, ICN UCLA S MOL CELLU, V127, P115; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; OBERFELDER R, 1987, J BIOL CHEM, V262, P4190; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WELCH MM, 1982, J BACTERIOL, V152, P351; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P1053, DOI 10.1073/pnas.73.4.1053; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P1764, DOI 10.1073/pnas.70.6.1764; WICKNER W, 1974, J BIOL CHEM, V249, P6244; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045; ZECKNER EL, 1909, J BIOL CHEM, V267, P4054	49	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4064	4073						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1346785				2022-12-25	WOS:A1992HE60700076
J	MACNULTY, EE; MCCLUE, SJ; CARR, IC; JESS, T; WAKELAM, MJO; MILLIGAN, G				MACNULTY, EE; MCCLUE, SJ; CARR, IC; JESS, T; WAKELAM, MJO; MILLIGAN, G			ALPHA-2-C10 ADRENERGIC-RECEPTORS EXPRESSED IN RAT-1 FIBROBLASTS CAN REGULATE BOTH ADENYLYLCYCLASE AND PHOSPHOLIPASE-D-MEDIATED HYDROLYSIS OF PHOSPHATIDYLCHOLINE BY INTERACTING WITH PERTUSSIS TOXIN-SENSITIVE GUANINE NUCLEOTIDE-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 BU1 CELLS; K+-CHANNEL; ALPHA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; KINASE-C; GENERATION; ACTIVATION; SUBTYPES; GI2; IDENTIFICATION	The alpha-2-C10 adrenergic receptor from human platelets was expressed permanently in Rat-1 fibroblasts. A series of clones that varied in expression of the receptor from 0 to 3.5 pmol/mg of membrane protein were isolated. We have demonstrated recently in cells of one of these clones (1C) that the alpha-2-C10 receptor interacts directly with two distinct pertussis toxin-sensitive G-proteins, G(i)2 and G(i)3 (Milligan, G., Carr, C., Gould, G. W., Mullaney, I., and Lavan, B. E. (1991) J. Biol. Chem. 266, 6447-6455). High affinity GTPase activity in membranes of cells from the various clones was stimulated by the addition of the alpha-2-adrenergic agonist UK14304, defining that the receptor coupled productively to the G-protein signaling system. Maximal stimulation of high affinity GTPase activity correlated with the levels of receptor expressed. Clones expressing the receptor also demonstrated agonist-mediated inhibition of adenylylcyclase. Furthermore, the alpha-2-C10 receptor in one clone (1C), but not other clones, promoted a marked stimulation in the generation of water-soluble products derived from phosphatidylcholine. The concentration of UK14304 required to produce half-maximal regulation of GTPase activity (20-30 nM), of forskolin-amplified adenylylcyclase activity (30-40 nM), and of choline generation (30-40 nM) were similar. Transphosphatidylation experiments with cells of clone 1C indicated that the receptor-mediated hydrolysis of phosphatidylcholine was via the action of a phospholipase D. All of these effects were attenuated by pretreatment of the cells with pertussis toxin. Dose-effect curves of pertussis toxin-treatment demonstrated similar effective concentrations of the toxin in causing endogenous ADP-ribosylation of both G(i)2 and G(i)3, inhibition of receptor-stimulated GTPase activity, and phospholipase D activity. Receptor activation of phospholipase D activity was not dependent upon prior phospholipase C-dependent activation of protein kinase C, as alpha-2-adrenergic stimulation of inositol phosphate production was negligible and the presence of the selective protein kinase C inhibitor RO-31-8220, at concentrations up to 10-mu-M, had no effect on UK14304-mediated production of phosphatidylbutanol. These results demonstrate that expression of the alpha-2-C10 receptor in a heterologous system can result in receptor regulation of signaling elements that appear not to be primary targets for the receptor in vivo. Such results are important in respect to recent observations that transfection of a single defined receptor into separate cell lines can lead to the regulation of distinct effector systems (Vallar, L., Muca, C., Magni, M., Albert, P., Bunzow, J., Meldolesi, J. and Civelli, O. (1990) J. Biol. Chem. 265, 10320-10326). Here, we demonstrate that differences in the signaling pathways activated by a defined receptor can be recorded in individual clones and show for the first time a direct alpha-2-adrenergic regulation of a phospholipase D activity.	UNIV GLASGOW,DEPT BIOCHEM,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT PHARMACOL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; University of Glasgow			Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Wakelam, Michael/0000-0003-4059-9276	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; CODINA J, 1988, J BIOL CHEM, V263, P6746; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; FAIN JN, 1988, FASEB J, V2, P2569, DOI 10.1096/fasebj.2.10.2838362; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LIMBIRD LE, 1988, ALPHA 2 ADRENERGIC R; MACNULTY EE, 1990, BIOCHEM J, V272, P761, DOI 10.1042/bj2720761; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1989, CELL SIGNAL, V1, P411, DOI 10.1016/0898-6568(89)90027-2; MILLIGAN G, 1987, BIOCHEM J, V245, P501, DOI 10.1042/bj2450501; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MILLIGAN G, 1987, BIOCHIM BIOPHYS ACTA, V929, P197, DOI 10.1016/0167-4889(87)90176-5; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MILLIGAN G, 1989, PROG GROWTH FACTOR R, V1, P171; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PLEVIN R, 1990, BIOCHEM J, V268, P605, DOI 10.1042/bj2680605; POUYSSEGUR J, 1990, G PROTEINS, P555; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; VALLAR L, 1990, J BIOL CHEM, V265, P10320; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	36	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2149	2156						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346392				2022-12-25	WOS:A1992HB53200009
J	VIITANEN, PV; LORIMER, GH; SEETHARAM, R; GUPTA, RS; OPPENHEIM, J; THOMAS, JO; COWAN, NJ				VIITANEN, PV; LORIMER, GH; SEETHARAM, R; GUPTA, RS; OPPENHEIM, J; THOMAS, JO; COWAN, NJ			MAMMALIAN MITOCHONDRIAL CHAPERONIN-60 FUNCTIONS AS A SINGLE TOROIDAL RING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; MAJOR ANTIGEN; PROTEIN; GROES; PURIFICATION; BACTERIAL; SEQUENCE; PLANT	Chaperonins are thought to participate in the process of protein folding in bacteria and in eukaryotic mitochondria and chloroplasts. While some chaperonins are relatively well characterized, the structures of the mammalian chaperonins are unknown. We have expressed a mammalian mitochondrial chaperonin 60 in Escherichia coli and purified the recombinant protein to homogeneity. Structural and biochemical analyses of this protein establish a single toroidal structure of seven subunits, in contrast to the homologous bacterial, fungal, and plant chaperonin 60s, which have double toroidal structures comprising two layers of seven identical subunits each. The recombinant mammalian chaperonin 60, together with the mammalian chaperonin 10 (but not with bacterial chaperonin 10), facilitates the formation of catalytically active ribulose-bisphosphate carboxylase from an unfolded state in the presence of K+ and MgATP. Analysis of the partial reactions involved in this in vitro reconstitution reveals that the single toroid of chaperonin 60 can form stable complexes with both unfolded or partially folded [S-35]ribulose-bisphosphate carboxylase and mitochondrial (but not bacterial) chaperonin 10 in the presence of MgATP. We conclude that the minimal functional unit of chaperonin 60 is a single heptameric toroid.	DUPONT CO,DEPT CENT RES & DEV,EXPTL STN,WILMINGTON,DE 19880; DUPONT MERCK PHARMACEUT CO,BIOTECHNOL RES,WILMINGTON,DE 19880; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA; NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	DuPont; DuPont; McMaster University; New York University; New York University				Oppenheim, Joel/0000-0002-6920-5624				BAIRD PN, 1988, NUCLEIC ACIDS RES, V16, P9047, DOI 10.1093/nar/16.18.9047; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; Ellis R J, 1990, Semin Cell Biol, V1, P1; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GUTTERIDGE S, 1989, BIOCHEM J, V260, P711, DOI 10.1042/bj2600711; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUTCHISON EG, 1989, EMBO J, V8, P1484; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; PIERCE J, 1986, ARCH BIOCHEM BIOPHYS, V245, P483, DOI 10.1016/0003-9861(86)90241-9; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, IN PRESS BIOCHEMISTR; VIITANEN PV, 1991, IN PRESS PROTEIN SCI; VODKIN MH, 1988, J BACTERIOL, V170, P1227, DOI 10.1128/jb.170.3.1227-1234.1988; WEBB R, 1990, J BACTERIOL, V172, P5079, DOI 10.1128/jb.172.9.5079-5088.1990	35	182	193	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					695	698						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1346131				2022-12-25	WOS:A1992GY96000005
J	MARK, MR; LOKKER, NA; ZIONCHECK, TF; LUIS, EA; GODOWSKI, PJ				MARK, MR; LOKKER, NA; ZIONCHECK, TF; LUIS, EA; GODOWSKI, PJ			EXPRESSION AND CHARACTERIZATION OF HEPATOCYTE GROWTH-FACTOR RECEPTOR-IGG FUSION PROTEINS - EFFECTS OF MUTATIONS IN THE POTENTIAL PROTEOLYTIC CLEAVAGE SITE ON PROCESSING AND LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MET PROTO-ONCOGENE; TYROSINE KINASE; SCATTER FACTOR; C-MET; EPITHELIAL-CELLS; MUTAGENESIS; MIGRATION; PRECURSOR; LINES	The receptor for hepatocyte growth factor (HGF) is the product of the c-met proto-oncogene, a membrane-spanning tyrosine kinase receptor. To facilitate analysis of HGF and its receptor (HGFr), we expressed and purified a chimeric protein containing the extracellular domain (ECD) of the HGFr fused to the constant region of IgG heavy chain. This soluble form of the HGFr (sHGFr) bound HGF with an affinity similar to that of the authentic, membrane-associated receptor. The sHGFr also neutralized the binding of HGF to the HGFr expressed on A549 cells. Like the mature form of the HGFr, sHGFr is a heterodimer which arises by proteolytic processing within the ECD. In order to characterize the requirements for proteolytic processing of the ECD and the effects of cleavage on ligand binding, we expressed sHGFr variants containing amino acid substitutions in the putative processing site. Replacement of the P1 or P4 arginine, but not the P3 lysine, with alanine inhibited conversion to the alpha/beta heterodimer. This suggests that maturation is mediated by furin or a furin-like protease. Finally, we showed that processing of the sHGFr into the alpha/beta form is not required for high affinity binding to either pro- or mature HGF.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT METAB,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	GODOWSKI, PJ (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CACHIANES G, 1992, IN PRESS TECHNIQUE; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAMOW SM, 1990, BIOCHEMISTRY-US, V29, P9885, DOI 10.1021/bi00494a019; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CWIKEL BJ, 1987, J BIOL CHEM, V262, P14235; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; GIORDANO S, 1989, ONCOGENE, V4, P1383; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALLBOOK F, 1988, MOL CELL BIOL, V8, P452, DOI 10.1128/MCB.8.1.452; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; MCCUNE J, 1988, JCELL, V50, P55; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROSEN EM, 1990, EXP CELL RES, V186, P22, DOI 10.1016/0014-4827(90)90205-O; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; THORNE BA, 1989, J BIOL CHEM, V264, P3545; VERWEIJ CL, 1988, J BIOL CHEM, V263, P7921; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	41	70	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26166	26171						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334493				2022-12-25	WOS:A1992KD07300086
J	KNAUS, UG; HEYWORTH, PG; KINSELLA, BT; CURNUTTE, JT; BOKOCH, GM				KNAUS, UG; HEYWORTH, PG; KINSELLA, BT; CURNUTTE, JT; BOKOCH, GM			PURIFICATION AND CHARACTERIZATION OF RAC-2 - A CYTOSOLIC GTP-BINDING PROTEIN THAT REGULATES HUMAN NEUTROPHIL NADPH OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; GUANINE-NUCLEOTIDES; ACTIVATING PROTEIN; PLASMA-MEMBRANE; IDENTIFICATION; CLONING; EXPRESSION; COMPONENTS	Human neutrophils and other phagocytes generate superoxide anion (O2-) as a means of destroying ingested microorganisms. O2- is produced by an NADPH-consuming oxidase composed of membrane and cytosolic components. Activation of the NADPH oxidase is absolutely dependent upon GTP, indicating the requirement for a GTP-binding protein in this process. We have utilized a five-step chromatographic procedure to isolate a GTP-binding protein from human neutrophil cytosol which can stimulate NADPH oxidase activity in a cell-free assay. Oxidase enhancing activity was shown to coisolate with this GTP-binding component, which was purified to apparent homogeneity. The GTP-binding protein was identified as Rac 2 by immunological reactivity and amino acid sequencing. Thus, Rac 2 appears to be a third cytosolic component required for human neutrophil NADPH oxidase activation. Recombinant Rac 2 was shown to bind guanine nucleotides in a Mg2+-dependent fashion. GDP dissociation rates were determined and shown to be regulated by the free Mg2+ concentration. Rac 2 was found to possess the highest rate of intrinsic GTP hydrolysis of any of the characterized members of the Ras superfamily. The biochemical properties of Rac 2 indicate it is likely to be subject to regulatory cofactors in vivo.	Scripps Res Inst, DEPT IMMUNOL & CELL BIOL, IMM-14, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; NATL UNIV IRELAND UNIV COLL DUBLIN, MATER HOSP, CTR CARDIOVASC RES DEPT MED & EXPTL THERAPEUT, DUBLIN 4, IRELAND	Scripps Research Institute; Scripps Research Institute; Mater Misericordiae University Hospital; University College Dublin				Kinsella, B. Therese/0000-0003-3072-941X	NCRR NIH HHS [RR00833] Funding Source: Medline; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BOKOCH GM, 1988, FEBS LETT, V227, P66, DOI 10.1016/0014-5793(88)81415-7; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1992, CLIN RES ABSTR, V40, P351; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FRECH M, 1990, J BIOL CHEM, V265, P6353; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, J BIOL CHEM, V266, P20840; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MURAO S, 1989, J BIOL CHEM, V264, P8356; MURAO S, 1990, CELL GROWTH DIFFER, V1, P447; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; QUILLIAM LA, 1992, SIGNAL TRANSDUCTION, V3, P25; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEIFERT R, 1986, FEBS LETT, V205, P161, DOI 10.1016/0014-5793(86)80886-9; SHAAG D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P405, DOI 10.1016/0167-4838(90)90044-G; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	48	170	173	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23575	23582						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331090				2022-12-25	WOS:A1992JZ23900026
J	BAVIK, CO; BUSCH, C; ERIKSSON, U				BAVIK, CO; BUSCH, C; ERIKSSON, U			CHARACTERIZATION OF A PLASMA RETINOL-BINDING PROTEIN MEMBRANE-RECEPTOR EXPRESSED IN THE RETINAL-PIGMENT EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR; VITAMIN-A; CELLS; IDENTIFICATION; HOMOLOGY; SIMILARITY; TRANSPORT; MECHANISM; CLONING; FAMILY	A specific membrane receptor for plasma retinol-binding protein (RBP) is expressed in the retinal pigment epithelium (RPE). When chemically cross-linking RBP to RPE membranes, an 86-kDa RBP.RBP receptor complex is formed, and a 63-kDa protein was identified as the RBP-binding membrane protein (Bavik, C.-O., Eriksson, U., Allen, R., and Peterson, P. (1991) J. Biol. Chem. 266,14978-14985). To explore in more detail the characteristics of this membrane receptor, we have generated a monoclonal antibody, A52, to the 63-kDa protein (p63). A52 binds the 86-kDa RBP.RBP receptor complex and p63. Several lines of evidence suggest that p63 is not a regular integral membrane protein, and it occurs in different forms. One form is firmly attached to membranes, is part of a high molecular weight complex, and is able to bind RBP. The other form of p63 can be removed from membranes by treatment with an alkaline buffer and is unable to bind RBP. Both forms of p63 contain extensive hydrophobic domains and are found in the detergent phase upon extraction with Triton X-114. The expression of p63 is restricted to RPE, and immunohistochemical localization of tissue sections from bovine retina showed highest expression in the basolateral portion of RPE cells. Immunofluorescence localization, using isolated RPE cells, showed that p63 is exposed on the cell surface of newly isolated RPE cells.	UNIV HOSP UPPSALA,DEPT PATHOL,S-75122 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	BAVIK, CO (corresponding author), LUDWIG INST CANC RES,STOCKHOLM BRANCH,POB 60202,S-10401 STOCKHOLM,SWEDEN.							BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BOK D, 1976, EXP EYE RES, V22, P395, DOI 10.1016/0014-4835(76)90177-9; Bok D., 1979, RETINAL PIGMENT EPIT, P148; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUSCH C, 1990, METHOD ENZYMOL, V189, P315; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; ERIKSSON U, 1986, CANCER RES, V46, P717; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GJOEN T, 1987, J BIOL CHEM, V262, P10926; GODOVAC-ZIMMERMANN J, 1985, BIOL CHEM H-S, V366, P431, DOI 10.1515/bchm3.1985.366.1.431; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HELLER J, 1975, J BIOL CHEM, V250, P3613; HOLMDAHL R, 1985, J IMMUNOL METHODS, V83, P379, DOI 10.1016/0022-1759(85)90260-1; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KATOH M, 1982, ACTA HISTOCHEM CYTOC, V15, P68, DOI 10.1267/ahc.15.68; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCGUIRE B, 1981, ENDOCRINOLOGY, V108, P180; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RASK L, 1979, FEBS LETT, V104, P55, DOI 10.1016/0014-5793(79)81084-4; RASK L, 1976, J BIOL CHEM, V251, P6360; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; SCHMALE H, 1990, NATURE, V343, P366, DOI 10.1038/343366a0; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P571; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	39	122	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23035	23042						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331074				2022-12-25	WOS:A1992JY16300052
J	RYTOMAA, M; MUSTONEN, P; KINNUNEN, PKJ				RYTOMAA, M; MUSTONEN, P; KINNUNEN, PKJ			REVERSIBLE, NONIONIC, AND PH-DEPENDENT ASSOCIATION OF CYTOCHROME-C WITH CARDIOLIPIN-PHOSPHATIDYLCHOLINE LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; CONFORMATIONAL-CHANGES; FERRICYTOCHROME-C; ESCHERICHIA-COLI; DNAA PROTEIN; MITOCHONDRIAL-MEMBRANES; PHOSPHOLIPID MONOLAYERS; CHARGED INTERFACES; INITIATION PROTEIN; APOCYTOCHROME-C	Membrane association of cytochrome c (cyt c) was monitored by the efficiency of resonance energy transfer from a pyrene-fatty acid containing phospholipid derivative (1-palmitoyl-2[6-(pyren-1-yl)]hexanoyl-sn-glycero-3-phosphocholine (PPHPC)) to the heme of cyt c. Liposomes consisted of 85 mol% egg phosphatidylcholine (egg PC), 10 mol% cardiolipin, and 5 mol% PPHPC. Cardiolipin was necessary for the membrane binding of cyt c over the pH range studied, from 4 to 7. In accordance with the electrostatic nature of the membrane association of cyt c at neutral pH both 2 mM MgCl2 and 80 mM NaCl dissociated cyt c from the vesicles completely. At neutral pH also adenine nucleotides in millimolar concentrations were able to displace cyt c from liposomes, their efficiency decreasing in the sequence ATP > ADP > AMP. In addition, both CTP and GTP were equally effective as ATP. The detachment of cyt c from liposomes by nucleotides is likely to result from a competition between cardiolipin and the nucleotides for a common binding site in cyt c. When pH was decreased to 4 there was a small yet significant increase in the apparent affinity of cyt c to cardiolipin containing liposomes. Notably, at pH 4 the above nucleotides as well as NaCl and MgCl2 were no longer able to dissociate cyt c and, on the contrary, they slightly enhanced the quenching of pyrene fluorescence by cyt c. The above results do suggest that the membrane association of cyt c at acidic pH was nonionic and presumably due to hydrogen bonding. The pH-dependent binding of cyt c to membranes was fully reversible. Accordingly, in the presence of sufficient concentrations of either nucleotides or salts rapid detachment and membrane association of cyt c could be induced by varying pH between neutral and acidic values, respectively.	UNIV HELSINKI,DEPT MED CHEM,SILTAVUORENPENGER 10A,SF-00170 HELSINKI 17,FINLAND	University of Helsinki								BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; DEJONGH HHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P105, DOI 10.1016/0005-2736(90)90442-Q; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; HAVERSTICK DM, 1989, BIOPHYS J, V55, P677, DOI 10.1016/S0006-3495(89)82866-8; HEIMBURG T, 1991, BIOCHEMISTRY-US, V30, P9084, DOI 10.1021/bi00101a025; HILDEBRANDT P, 1989, BIOCHEMISTRY-US, V28, P6710, DOI 10.1021/bi00442a026; HILDEBRANDT P, 1989, BIOCHEMISTRY-US, V28, P6722, DOI 10.1021/bi00442a027; HOCHMAN JH, 1982, P NATL ACAD SCI-BIOL, V79, P6866, DOI 10.1073/pnas.79.22.6866; JORI G, 1974, PHOTOCHEM PHOTOBIOL, V19, P337, DOI 10.1111/j.1751-1097.1974.tb06521.x; KAIHOVAARA P, 1991, BIOCHEMISTRY-US, V30, P8380, DOI 10.1021/bi00098a015; KIMELBERG HK, 1969, BIOCHEM BIOPH RES CO, V34, P784, DOI 10.1016/0006-291X(69)90248-4; KONTTILA R, 1988, BIOCHEMISTRY-US, V27, P7443, DOI 10.1021/bi00419a040; KOZARAC Z, 1988, FEBS LETT, V229, P372, DOI 10.1016/0014-5793(88)81159-1; LEE S, 1989, ARCH BIOCHEM BIOPHYS, V271, P188, DOI 10.1016/0003-9861(89)90269-5; MACDONALD PM, 1987, BIOCHEMISTRY-US, V26, P6292, DOI 10.1021/bi00393a050; MITCHELL P, 1983, FEBS LETT, V151, P167, DOI 10.1016/0014-5793(83)80063-5; MOSIOR M, 1992, BIOCHEMISTRY-US, V31, P1767, DOI 10.1021/bi00121a026; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; NICHOLLS P, 1973, T BIOCHEM SOC, V1, P372; QUINN PJ, 1969, BIOCHEM J, V115, P65, DOI 10.1042/bj1150065; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SJOSTRAND FS, 1983, CONCEPTS MEMBRANE ST, V1, P83; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3871, DOI 10.1021/bi00230a010; STEINEMANN A, 1971, J MEMBRANE BIOL, V4, P74, DOI 10.1007/BF02431963; STELLWAGEN E, 1975, BIOCHEMISTRY-US, V14, P5135, DOI 10.1021/bi00694a018; SZEBENI J, 1988, BIOCHIM BIOPHYS ACTA, V932, P153, DOI 10.1016/0005-2728(88)90150-8; VANDERKOOI J, 1973, ARCH BIOCHEM BIOPHYS, V154, P219, DOI 10.1016/0003-9861(73)90052-0; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; WALTHAM MC, 1986, BIOCHIM BIOPHYS ACTA, V862, P451, DOI 10.1016/0005-2736(86)90250-6; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	38	151	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22243	22248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331048				2022-12-25	WOS:A1992JW71900041
J	ROSS, TS; MAJERUS, PW				ROSS, TS; MAJERUS, PW			IDENTIFICATION OF A PHOSPHODIESTERASE THAT CONVERTS INOSITOL CYCLIC 1/2-PHOSPHATE TO INOSITOL 2-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-2-CYCLIC PHOSPHATE 2-PHOSPHOHYDROLASE; 1,2-CYCLIC PHOSPHATE; 2-INOSITOLPHOSPHOHYDROLASE; PHOSPHOLIPIDS	Inositol 2-phosphate (Ins(2)P) has been identified in several cell types. The cellular levels of Ins(2)P appear to be directly correlated with the levels of inositol 1:2-cyclic phosphate (cIns(1:2)P) (Ross, T. S., Wang, F. P., and Majerus, P. W. (1992) J. Biol. Chem. 267, 19919-19923). In this study we have detected an enzyme in extracts from CV-1 cells and rat cerebellum that converts cIns(1:2)P to Ins(2)P and inositol I-phosphate. This enzyme (designated cyclic hydrolase II) is not the same protein previously designated cIns(1:2)P 2-phosphohydrolase (cyclic hydrolase I). The products, heat inactivation curves, pH optima, and metal dependence of these two activities are different, and the two activities were separated by DEAE and gel filtration chromatography. Mixing of cyclic hydrolase I with cyclic hydrolase II does not effect the activity of either. The K(m) of the CV-1 cyclic hydrolase II for D-cIns(1:2)P is 10 muM. The enzyme is approximately 55 kDa as estimated by gel filtration analysis in the presence of sodium chloride and 120 kDa in its absence.			ROSS, TS (corresponding author), WASHINGTON UNIV,DIV HEMATOL ONCOL,ST LOUIS,MO 63130, USA.			Ross, Theodora/0000-0002-9166-1802	NHLBI NIH HHS [HLBI 14147, HLBI 16634] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL016634, R01HL016634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1960, J BIOL CHEM, V235, P769; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DAWSON RMC, 1973, BIOCHEM J, V134, P59, DOI 10.1042/bj1340059; DAWSON RMC, 1972, BIOCHEM J, V127, P113, DOI 10.1042/bj1270113; EISENBER.F, 1967, J BIOL CHEM, V242, P1375; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; KIM JW, 1989, BIOCHEM BIOPH RES CO, V163, P177, DOI 10.1016/0006-291X(89)92117-7; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; RAGAN CI, 1988, BIOCHEM J, V249, P143, DOI 10.1042/bj2490143; ROSS TS, 1992, J BIOL CHEM, V267, P19919; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1986, J BIOL CHEM, V261, P1119; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184	16	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19924	19928						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328187				2022-12-25	WOS:A1992JR85800031
J	NEUBERT, TA; JOHNSON, RS; HURLEY, JB; WALSH, KA				NEUBERT, TA; JOHNSON, RS; HURLEY, JB; WALSH, KA			THE ROD TRANSDUCIN ALPHA SUBUNIT AMINO TERMINUS IS HETEROGENEOUSLY FATTY ACYLATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; GAMMA-SUBUNIT; ACID SEQUENCE; PHOTORECEPTOR-MEMBRANES; MASS-SPECTROMETRY; OUTER SEGMENTS; CDNA SEQUENCE; MYRISTOYLATION	Rod transducin (T(r)), a heterotrimeric GTP-binding protein composed of alpha, beta, and gamma-subunits, couples photolysis of rhodopsin to the activation of cyclic GMP phosphodiesterase in the vertebrate visual signal transduction cascade. To determine if T-alpha(r) is covalently modified, we analyzed tryptic fragments of bovine retinal T-alpha(r) using electrospray mass spectrometry, liquid chromatography/mass spectrometry, tandem mass spectrometry, and gas chromatography. A novel heterogeneous fatty acylation was detected at the NH2 terminus. Four types of NH2-terminal tryptic fragments of T-alpha(r) were isolated, and each contained either a lauroyl (C12:0), myristoyl (C14:0), (cis-DELTA-5)-tetradecaenoyl (C14:1) or (cis,cis-DELTA-5,DELTA-8)-tetradecadienoyl (C14:2) fatty acyl residue amide-linked to the NH2-terminal glycine residue. NH2-terminal fatty acylation does not anchor T-alpha(r) permanently in the membrane, since T-alpha(r) used in these experiments was eluted without detergent from rod outer segment membranes.	UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL EYE INSTITUTE [R01EY006641] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040990] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0553] Funding Source: Medline; NEI NIH HHS [R01 EY006641, EY06641] Funding Source: Medline; NHLBI NIH HHS [HL40990] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HO YK, 1989, CURR TOP CELL REGUL, V30, P171; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LIPKIN VM, 1987, RETINAL PROTEINS, P39; McConnell D.G., 1984, FED PROC, V43, P1585; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; OVCHINNIKOV YA, 1985, FEBS LETT, V179, P107, DOI 10.1016/0014-5793(85)80201-5; PAPPAS JJ, 1966, TETRAHEDRON LETT, P4273; SANFORD J, 1991, J BIOL CHEM, V266, P9570; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; WENSEL T G, 1992, Biophysical Journal, V61, pA98; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	30	164	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18274	18277						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326520				2022-12-25	WOS:A1992JN50200007
J	CHEN, LH; KENYON, GL; CURTIN, F; HARAYAMA, S; BEMBENEK, ME; HAJIPOUR, G; WHITMAN, CP				CHEN, LH; KENYON, GL; CURTIN, F; HARAYAMA, S; BEMBENEK, ME; HAJIPOUR, G; WHITMAN, CP			4-OXALOCROTONATE TAUTOMERASE, AN ENZYME COMPOSED OF 62 AMINO-ACID-RESIDUES PER MONOMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; DIENELACTONE HYDROLASE; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-PUTIDA; META-CLEAVAGE; TRIOSEPHOSPHATE ISOMERASE; PLASMID; PROTEIN; GENE	The xylH gene encoding 4-oxalocrotonate tautomerase (4-OT) has been located on a subclone of the Pseudomonasputida mt-2 TOL plasmid pWW0 and inserted into an Escherichia coli expression vector. Severalof the genes of the metafission pathway encoded by pWW0 have been cloned in E. coli, but the overexpression of their gene products has met with limited success. By utilizing the E. coli alkaline phosphatase promoter (phoA) coupled with the proper positioning of a ribosome-binding region, we are able to express functional 4-OT in yields of at least 10 mg of pure enzyme/liter of culture. 4-OT has been previously characterized and shown to be an extremely efficient catalyst (Whitman, C. P., Aird, B. A., Gillespie, W. R., and Stolowich, N. J. (1991) J. Am. Chem. Soc. 113,3154-3162). Kinetic and physical characterization of the E. coli-expressed protein show that it is identical with that of the 4-OT isolated from P. putida. The functional unit is apparently a pentamer of identical subunits, each consisting of only 62 amino acid residues. This is the smallest enzyme subunit reported to date. The amino acid sequence, determined in part from automated Edman degradation and also deduced from the primary sequence of xylH, did not show homology with any of the sequences in the current data bases nor with any of the sequences of enzymes that catalyze similar reactions. We propose that the active site of 4-OT may be established by an overlap of subunits and comprised of amino acid residues belonging to several, if not all, of the subunits.	UNIV TEXAS, COLL PHARM, DIV MED CHEM, AUSTIN, TX 78712 USA; UNIV GENEVA, DEPT MED BIOCHEM, CH-1211 GENEVA 4, SWITZERLAND; UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of Texas System; University of Texas Austin; University of Geneva; University of California System; University of California San Francisco				Harayama, Shigeaki/0000-0003-2103-7796	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017323, R01AR017323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041239, R01GM040570, R01GM041239] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 17323] Funding Source: Medline; NIGMS NIH HHS [GM 40570, GM 41239] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; ANDREWS AT, 1986, ELECTROPHORESIS THEO, P134; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P7; FRANTZ B, 1987, J BACTERIOL, V169, P704, DOI 10.1128/jb.169.2.704-709.1987; FREIFELDER D, 1982, PHYSICAL BIOCH, P455; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; HARAYAMA S, 1989, J BACTERIOL, V171, P6251, DOI 10.1128/jb.171.11.6251-6258.1989; HARAYAMA S, 1990, MOL GEN GENET, V221, P113, DOI 10.1007/BF00280375; HARAYAMA S, 1984, J BACTERIOL, V160, P251, DOI 10.1128/JB.160.1.251-255.1984; HAWKINSON DC, 1991, BIOCHEMISTRY-US, V30, P6956, DOI 10.1021/bi00242a021; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8441, DOI 10.1021/bi00098a023; KULIOPULOS A, 1987, P NATL ACAD SCI USA, V84, P8893, DOI 10.1073/pnas.84.24.8893; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapworth A, 1901, J CHEM SOC, V79, P1265, DOI 10.1039/ct9017901265; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENN FM, 1991, GENE, V104, P91, DOI 10.1016/0378-1119(91)90470-V; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; OLLIS DL, 1985, J BIOL CHEM, V260, P9818; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; ROPER DI, 1990, FEBS LETT, V266, P63, DOI 10.1016/0014-5793(90)81507-K; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOLTEN JD, 1991, SCIENCE, V253, P182, DOI 10.1126/science.1853203; SCHWAB JM, 1990, CHEM REV, V90, P1203, DOI 10.1021/cr00105a007; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SMITH SL, 1979, J BIOL CHEM, V254, P6222; STONE D, 1979, J BIOL CHEM, V254, P857; STRAUS D, 1985, P NATL ACAD SCI USA, V82, P2014, DOI 10.1073/pnas.82.7.2014; WHITMAN CP, 1991, J AM CHEM SOC, V113, P3154, DOI 10.1021/ja00008a052; ZOLG JW, 1981, NUCLEIC ACIDS RES, V9, P697, DOI 10.1093/nar/9.3.697	35	84	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17716	17721						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1339435				2022-12-25	WOS:A1992JM22300038
J	SCIMECA, JC; NGUYEN, TT; FILLOUX, C; VANOBBERGHEN, E				SCIMECA, JC; NGUYEN, TT; FILLOUX, C; VANOBBERGHEN, E			NERVE GROWTH FACTOR-INDUCED PHOSPHORYLATION CASCADE IN PC12 PHEOCHROMOCYTOMA CELLS - ASSOCIATION OF S6 KINASE-II WITH THE MICROTUBULE-ASSOCIATED PROTEIN-KINASE, ERK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; TYROSINE PHOSPHORYLATION; SIGNALING COMPLEX; SWISS 3T3-CELLS; SKELETAL-MUSCLE; INSULIN; ACTIVATION; INVITRO; MECHANISM; AUTOPHOSPHORYLATION	Microtubule-associated protein (MAP) kinases form a group of serine/threonine kinases stimulated by various growth factors such as nerve growth factor (NGF) and hormones such as insulin. Interestingly, MAP kinases are thought to participate in a protein kinase cascade leading to cell growth as they have been shown to phosphorylate and activate ribosomal protein S6 kinase. To further evaluate the interactions between the different components of this cascade, we looked at the possible coprecipitation of MAP kinase activator(s) or MAP kinase substrate(s) with MAP kinase. Using antipeptides to the C terminus of the M(r) 44,000 MAP kinase, ERK1, and cell extracts from unstimulated or NGF-treated PC12 cells, we obtained in addition to MAP kinase itself coprecipitation of a protein with a M(r) in the 90,000 range. We further show that this protein is a protein kinase since it becomes phosphorylated on serine residues, after sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transfer to a polyvinylidene difluoride membrane. In vitro phosphorylation performed before sodium dodecyl sulfate-polyacrylamide gel electrophoresis demonstrates NGF-sensitive phosphorylation of this 90-kDa protein on both serine and threonine; the serine phosphorylation is likely to be due to autophosphorylation, and the threonine phosphorylation due to phosphorylation by the copurifying MAP kinase. Furthermore, immunoprecipitation of this 90-kDa protein was obtained with antibodies to S6 kinase II. Finally, using in situ chemical cross-linking, we were able to demonstrate in intact cells the occurrence of an anti-ERK1 immunoreactive species with a molecular mass of approximately 125,000 compatible with a complex between ERK1 and a 90-kDa S6 kinase. Taken together, our observations demonstrate that the 44-kDa MAP kinase is associated, in intact PC12 cells, with a protein kinase which is very likely to be S6 kinase II. In conclusion, our data represent strong evidence for a physiological role of the MAP kinase-S6 kinase cascade in PC12 cells. Finally, our antipeptides provide us with a powerful tool to search for additional physiologically relevant substrates for MAP kinase, a key integrator enzyme for growth factors and hormones.			SCIMECA, JC (corresponding author), FAC MED NICE,INSERM,U145,F-06107 NICE 2,FRANCE.		Scimeca, Jean-Claude/P-3830-2016	Scimeca, Jean-Claude/0000-0003-3773-6110				AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HARI J, 1987, ENDOCRINOLOGY, V120, P829, DOI 10.1210/endo-120-2-829; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	27	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17369	17374						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324933				2022-12-25	WOS:A1992JL05300095
J	OLDERSHAW, KA; RICHARDSON, A; TAYLOR, CW				OLDERSHAW, KA; RICHARDSON, A; TAYLOR, CW			PROLONGED EXPOSURE TO INOSITOL 1,4,5-TRISPHOSPHATE DOES NOT CAUSE INTRINSIC DESENSITIZATION OF THE INTRACELLULAR CA2+-MOBILIZING RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE; CA-2+ RELEASE; TRISPHOSPHATE; HEPATOCYTES; CELLS; DECAVANADATE; PHOSPHATES; INHIBITION; STORES	The rapid release of Ca2+ from intracellular stores stimulated with inositol 1,4,5-trisphosphate (InsP3) has required superfusion or stopped-flow techniques to resolve the kinetics of Ca2+ mobilization and made it difficult to determine whether the InSP3 receptor desensitizes during prolonged stimulation. Here we have overloaded the intracellular Ca2+ stores of permeabilized rat hepatocytes by incubating them with ATP and Ca-45(2+) in the presence of pyrophosphate, which precipitates Ca2+ within the lumen of the stores. Subsequent ATP removal initiated slow Ca-45(2+) efflux that followed zero-order kinetics, allowing us to examine the effects of InSP3 over a prolonged time course. InsP3 produced a concentration-dependent increase in the C-45(2+) efflux rate that was sustained for several min. The rate rapidly returned to the unstimulated level after the addition of decavanadate, a competitive antagonist of InsP3 at its receptor. Prior incubation with a submaximal concentration of InSP3 (1-mu-M) did not affect the subsequent enhanced rate of Ca-45(2+) efflux stimulated by a higher, but still submaximal, concentration of InSP3 (3-mu-M). We conclude that prolonged exposure to InsP3 does not desensitize the InsP3 receptor and that intrinsic receptor desensitization cannot provide an explanation for the quantal responses to InsP3 observed in several cell types.	UNIV CAMBRIDGE, DEPT PHARMACOL, TENNIS COURT RD, CAMBRIDGE CB2 1QJ, ENGLAND	University of Cambridge			Richardson, Alan/E-7615-2010; Richardson, Alan/I-4631-2015; Taylor, Colin/G-2447-2010	Richardson, Alan/0000-0003-1825-3375; Taylor, Colin/0000-0001-7771-1044				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOHR KJ, 1989, BIOCHEM J, V262, P83; FOHR KJ, 1991, CELL CALCIUM, V12, P735, DOI 10.1016/0143-4160(91)90042-D; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LESLIE BA, 1988, CELL CALCIUM, V9, P9, DOI 10.1016/0143-4160(88)90033-4; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, BIOCHEM J, V282, P306, DOI 10.1042/bj2820306; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PALADE P, 1989, MOL PHARMACOL, V36, P673; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PIETRI F, 1990, J BIOL CHEM, V265, P17478; STRUPISH J, 1991, Molecular Neuropharmacology, V1, P111; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TAYLOR CW, 1989, BIOCHEM J, V259, P645, DOI 10.1042/bj2590645	22	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16312	16316						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322898				2022-12-25	WOS:A1992JJ45800051
J	SANJOSE, E; BENGURIA, A; GELLER, P; VILLALOBO, A				SANJOSE, E; BENGURIA, A; GELLER, P; VILLALOBO, A			CALMODULIN INHIBITS THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; BINDING PROTEINS; EGF RECEPTOR; A431 CELLS; PHOSPHORYLATION; GENE	We demonstrate in this report that the epidermal growth factor (EGF) receptor from rat liver can be isolated by calmodulin affinity chromatography by binding in the presence of Ca2+ and elution with a Ca2+-chelating agent. The bulk of the EGF receptor is not eluted by a NaCl gradient in the presence of Ca2+. We ascertained the identity of the isolated receptor by immunoblot and immunoprecipitation using a polyclonal antibody against an EGF receptor from human origin. The purified receptor is autophosphorylated in tyrosine residues in an EGF-stimulated manner, and EGF-dependent phosphorylation of serine residues was also detected. Both the EGF and the transforming growth factor-alpha stimulate the tyrosine-directed protein kinase activity of the isolated receptor with similar affinities. Furthermore, we demonstrate that calmodulin inhibits the EGF-dependent tyrosine-directed protein kinase activity associated to the receptor in a concentration-dependent manner. This inhibition is partially Ca2+ dependent and is not displaced by increasing the concentration of EGF up to an EGF/calmodulin ratio of 10 (mol/mol). In addition, calmodulin was phosphorylated in an EGF-stimulated manner in the presence of a basic protein (histone) as cofactor and in the absence, but not in the presence, of Ca2+.	CSIC, INST INVEST BIOMED, ARTURO DUPERIER 4, E-28029 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Villalobo, Antonio/O-9621-2019; Villalobo, Antonio/K-2902-2017; Benguria, Alberto/M-9911-2014	Villalobo, Antonio/0000-0002-4200-374X; Benguria, Alberto/0000-0002-5536-566X				ANDERSON WB, 1985, CURR TOP CELL REGUL, V27, P455; BROWN AE, 1976, BIOCHIM BIOPHYS ACTA, V426, P418, DOI 10.1016/0005-2736(76)90387-4; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; GRAVES CB, 1985, SCIENCE, V230, P827, DOI 10.1126/science.3904001; GRAVES CB, 1986, J BIOL CHEM, V261, P429; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOSE ES, 1990, J BIOL CHEM, V265, P20653; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MEANS AR, 1980, NATURE, V285, P73, DOI 10.1038/285073a0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; PANDIELLA A, 1987, BIOCHEM BIOPH RES CO, V149, P145, DOI 10.1016/0006-291X(87)91616-0; PANDIELLA A, 1988, BIOCHEM J, V254, P223, DOI 10.1042/bj2540223; PARKER PJ, 1984, J BIOL CHEM, V259, P9906; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SACKS DB, 1988, J BIOL CHEM, V263, P2377; SACKS DB, 1989, BIOCHEM J, V263, P803, DOI 10.1042/bj2630803; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1989, BIOCHEM CELL BIOL, V67, P703, DOI 10.1139/o89-105; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZHAO D, 1991, BIOCHEM J, V277, P445, DOI 10.1042/bj2770445	31	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15237	15245						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321833				2022-12-25	WOS:A1992JF08800107
J	STIRDIVANT, SM; AHERN, JD; OLIFF, A; HEIMBROOK, DC				STIRDIVANT, SM; AHERN, JD; OLIFF, A; HEIMBROOK, DC			RETINOBLASTOMA PROTEIN-BINDING PROPERTIES ARE DEPENDENT ON 4 CYSTEINE RESIDUES IN THE PROTEIN-BINDING POCKET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELL-CYCLE; TRANSCRIPTION FACTOR; ENCODED PROTEIN; RB PROTEIN; EXPRESSION; PHOSPHORYLATION; SUBSTITUTION	The retinoblastoma gene product (pRB) participates in regulating mammalian cell replication. The mechanism responsible for pRB's growth regulatory activity is uncertain. However, pRB is known to bind viral transforming proteins including the papilloma virus E7 protein, cellular proteins, and DNA. pRB contains a critical domain termed the "binding pocket" which is required for binding activities. This binding pocket contains 8 cysteine residues. A naturally occurring mutation affecting one of these cysteines is known to eliminate pRB's protein and DNA binding activities. To investigate the cysteine residues in pRB's binding pocket, each residue was mutated to alanine, phenylalanine, or serine. These mutant genes were used to prepare pRBs harboring specific amino acid substitutions. Individual mutations at positions 407, 553, 666, and 706 depressed pRB binding to E7 protein, DNA, and a conformation-specific anti-pRB antibody, XZ133. Combinations of these inhibitory mutations exhibited additive inhibitory effects on pRB's binding properties. Mutations at positions 438, 489, 590, 712, and 853 did not affect pRB binding to E7 protein, DNA, or the XZ133 antibody. Combination of these five neutral mutations yielded a pRB species with full E7 protein, DNA, and XZ133 binding activities. These studies indicate that the cysteine residues at positions 407, 553, 666, and 706 contribute to the E7 protein and DNA binding properties of pRB and appear to do so by maintaining pRB's normal conformation.	MERCK SHARP & DOHME LTD,DEPT CANC RES,BLDG 16,RM 101,W POINT,PA 19486	Merck & Company								BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; JONES RE, 1992, J BIOL CHEM, V267, P908; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; PATRICK DR, 1992, J BIOL CHEM, V267, P6910; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	32	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14846	14851						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321820				2022-12-25	WOS:A1992JF08800053
J	HARDING, PP; DUESTER, G				HARDING, PP; DUESTER, G			RETINOIC ACID ACTIVATION AND THYROID-HORMONE REPRESSION OF THE HUMAN ALCOHOL-DEHYDROGENASE GENE ADH3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ELEMENT; LIVER ALCOHOL; HEPATOCELLULAR-CARCINOMA; BETA-GENE; RECEPTOR; IDENTIFICATION; EXPRESSION; REGION; CELLS; TRANSCRIPTION	Mammalian alcohol dehydrogenase (ADH) catalyzes the oxidation of retinol to retinaldehyde, the rate-limiting step in the synthesis of retinoic acid. There exists a family of ADH isozymes encoded by unique genes, and it is unclear which isozymes are most important for regulation of retinoic acid synthesis during differentiation or development. A region in the human ADH3 promoter from -328 to -272 base pairs was shown previously to function as a retinoic acid response element (RARE), prompting an hypothesis for a positive feedback mechanism controlling retinoic acid synthesis (Duester, G., Shean, M. L., McBride, M. S., and Stewart, M. J. (1991) Mol. Cell. Biol. 11, 1638-1646). The ADH3 RARE contains three direct AGGTCA repeats which constitute the critical nucleotides of RAREs present in other genes. We dissected the ADH3 RARE and determined that receptor binding as well as transactivation are dependent upon only the two downstream AGGTCA motifs separated by 5 base pairs, a structure noticed previously for a RARE in the promoter for the retinoic acid receptor-beta (RAR-beta) gene. ADH3 and RAR-beta RAREs functioned similarly in transfection assays, suggesting that the feedback mechanisms controlling ADH3 and RAR-beta utilize a common RARE. We also found that the normal functioning of the ADH3 RARE was abrogated by thyroid hormone receptor in the presence of thyroid hormone. A negative thyroid hormone response element in the human ADH3 promoter was found to colocalize with the RARE. Since ADH production in rat liver is known to be repressed by thyroid hormone, these findings suggest that human ADH production may also be subject to thyroid hormone repression and that the mechanism involves an interference with retinoic acid induction.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; COLORADO STATE UNIV, DEPT BIOCHEM, FT COLLINS, CO 80523 USA	Sanford Burnham Prebys Medical Discovery Institute; Colorado State University					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K02AA000119, R01AA007261] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07261, K02 AA00119] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CRABB DW, 1986, BIOCHEM PHARMACOL, V35, P1527, DOI 10.1016/0006-2952(86)90120-6; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DUESTER G, 1986, J BIOL CHEM, V261, P2027; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Duester G., 1991, LIVER PATHOLOGY ALCO, P375; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HILLBOM ME, 1970, BIOCHEM PHARMACOL, V19, P2097, DOI 10.1016/0006-2952(70)90308-4; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; ISRAEL Y, 1975, J PHARMACOL EXP THER, V192, P565; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; li T K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P427; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Maxam A M, 1980, Methods Enzymol, V65, P499; MEZEY E, 1971, EXP MOL PATHOL, V15, P148, DOI 10.1016/0014-4800(71)90095-5; MEZEY E, 1981, GASTROENTEROLOGY, V80, P566; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; Sambrook J, 1989, MOL CLONING LABORATO; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SMITH M, 1986, ADV HUM GENET, V15, P249; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEWART MJ, 1991, J BIOL CHEM, V266, P11594; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; YOSHIDA A, 1991, PROG NUCLEIC ACID RE, V40, P255; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	55	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14145	14150						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321136				2022-12-25	WOS:A1992JD32500057
J	KO, K; KO, ZW				KO, K; KO, ZW			CARBOXYL-TERMINAL SEQUENCES CAN INFLUENCE THE INVITRO IMPORT AND INTRAORGANELLAR TARGETING OF CHLOROPLAST PROTEIN PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B PROTEIN; TRANSIT PEPTIDE; FOREIGN PROTEIN; ISOLATED-MITOCHONDRIA; THYLAKOID MEMBRANE; BINDING PROTEIN; TRANSLOCATION; PLASTOCYANIN; INTEGRATION; ENVELOPE	The transit peptide of the lumenal 33-kDa oxygen-evolving polypeptide (OEE1) is capable of directing the import and targeting of the foreign protein dihydrofolate reductase (DHFR) to the thylakoid lumen. The import results from the first part of this study indicate that methotrexate cannot block the import or intraorganellar targeting of OEE1-DHFR in chloroplasts in contrast to that reported for the import of cytochrome oxidase subunit IV (COXIV)-DHFR in mitochondria. These results suggest that the fusion of the OEE1 transit sequence to DHFR affected the protein's methotrexate binding properties. We further examined and compared the transport characteristics of a number of carboxyl-terminal truncated native chloroplast precursors to determine whether carboxyl domains contribute to the import and intraorganellar targeting mechanism of these proteins. The plastid precursors chosen for this study are targeted to one of the following chloroplast compartments: the stroma, the thylakoid membrane, and the lumen. In most cases, removal of carboxyl domains had a dramatic effect on one or more stages of the translocation pathway, such as import, processing, and intraorganellar targeting. The effects of carboxyl deletions varied from precursor to precursor and were dependent on the extent of the deletion. These combined results suggest that carboxyl domains in the mature part of the proteins can influence the function of the transit peptide, and as a result play an important role in determining the import and targeting competence of chloroplast precursors.			KO, K (corresponding author), QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA.							ANDERSON CM, 1991, FEBS LETT, V280, P383, DOI 10.1016/0014-5793(91)80337-3; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1985, J BIOL CHEM, V260, P3691; DEBOER D, 1991, EMBO J, V10, P2765, DOI 10.1002/j.1460-2075.1991.tb07825.x; DEBOER D, 1988, EMBO J, V7, P2631, DOI 10.1002/j.1460-2075.1988.tb03115.x; DELLACIOPPA G, 1988, EMBO J, V7, P1299, DOI 10.1002/j.1460-2075.1988.tb02944.x; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; KAVANAGH TA, 1988, MOL GEN GENET, V215, P38, DOI 10.1007/BF00331300; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KO K, 1990, PLANT MOL BIOL, V14, P217, DOI 10.1007/BF00018562; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KOHORN BD, 1989, PLANT CELL, V1, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LUBBEN TH, 1988, PHOTOSYNTH RES, V17, P173, DOI 10.1007/BF00047688; MEADOWS JW, 1989, FEBS LETT, V253, P244, DOI 10.1016/0014-5793(89)80968-8; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NESS SA, 1987, P NATL ACAD SCI USA, V84, P6692, DOI 10.1073/pnas.84.19.6692; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANDENBROECK G, 1988, PLANT SCI, V58, P171, DOI 10.1016/0168-9452(88)90006-4; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VERNER K, 1989, EMBO J, V8, P1491, DOI 10.1002/j.1460-2075.1989.tb03533.x; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WASMANN CC, 1986, MOL GEN GENET, V205, P446, DOI 10.1007/BF00338081; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	40	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13910	13916						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321129				2022-12-25	WOS:A1992JD32500022
J	BOCHKAREVA, ES; LISSIN, NM; FLYNN, GC; ROTHMAN, JE; GIRSHOVICH, AS				BOCHKAREVA, ES; LISSIN, NM; FLYNN, GC; ROTHMAN, JE; GIRSHOVICH, AS			POSITIVE COOPERATIVITY IN THE FUNCTIONING OF MOLECULAR CHAPERONE GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENATURED RHODANESE; ESCHERICHIA-COLI; ATP HYDROLYSIS; PROTEIN; PURIFICATION; ASSOCIATION; CARBOXYLASE	In the presence of its partner, GroES, the tetradecameric molecular chaperone GroEL binds 14 ATP molecules, half of which are hydrolyzed in a cooperative manner. Moreover GroEL can bind, with a positive cooperativity, more than two molecules of nonfolded protein rhodanese. The role of the cooperative mechanism in the functioning of GroEL is discussed.	ACAD SCI USSR,INST PROT RES,PUSHCHINO 142292,USSR; SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LAB,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021	Russian Academy of Sciences; Memorial Sloan Kettering Cancer Center								BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DAHLQUIST FW, 1974, FEBS LETT, V49, P267, DOI 10.1016/0014-5793(74)80527-2; EHRESMAN.B, 1973, ANAL BIOCHEM, V54, P454, DOI 10.1016/0003-2697(73)90374-6; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GATENBY AA, 1990, TRENDS BIOTECHNOL, V8, P354, DOI 10.1016/0167-7799(90)90224-L; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROWITZ P, 1986, J BIOL CHEM, V261, P5652; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HORWICH AL, 1990, TRENDS BIOTECHNOL, V8, P126, DOI 10.1016/0167-7799(90)90153-O; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1123; TANDON S, 1986, J BIOL CHEM, V261, P5615; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Westley J, 1981, Methods Enzymol, V77, P285	30	151	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6796	6800						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348056				2022-12-25	WOS:A1992HM05300052
J	ROCH, JM; SHAPIRO, IP; SUNDSMO, MP; OTERO, DAC; REFOLO, LM; ROBAKIS, NK; SAITOH, T				ROCH, JM; SHAPIRO, IP; SUNDSMO, MP; OTERO, DAC; REFOLO, LM; ROBAKIS, NK; SAITOH, T			BACTERIAL EXPRESSION, PURIFICATION, AND FUNCTIONAL MAPPING OF THE AMYLOID-BETA/A4 PROTEIN-PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; ESCHERICHIA-COLI; NEXIN-II; SECRETED FORM; GENE; DEGRADATION; DOMAIN; BRAIN	The secreted form of Alzheimer amyloid beta/A4 protein precursor (APP) has been shown to be involved in cell growth regulation (Saitoh, T., Sundsmo, M., Roch, J.M., Kimura, N., Cole, G., Schubert, D., Oltersdorf, T., and Schenk, D. B. (1989) Cell 58, 615-622). Using a strong prokaryotic expression system, we expressed, in Escherichia coli, peptide fragments covering different regions of the secreted form of APP-695. The longest of these fragments (KB75, 572 amino acids from Val-20 to Ile-591), which contained neither the Kunitz-type protease inhibitor (KPI) domain nor the amyloid beta/A4-protein domain, was purified and shown to be biologically active in terms of growth regulation. Two other APP fragments (KB48, 316 amino acids from Val-20 to Met-335; and RB17, 150 amino acids from Thr-296 to Pro-445), overlapping by only 40 amino acids at a close site C-terminal to the KPI insertion site, were also active. Furthermore, a chemically synthesized 40-residue peptide corresponding to this region of overlap also stimulated the growth of A-1 fibroblasts. These results establish the presence of growth-promoting activity in the secreted form of APP-695 and suggest that the site of this activity of APP-695 lies within a 40-amino acid domain next to the KPI insertion site.	UNIV CALIF SAN DIEGO, DEPT NEUROSCI, 0624, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Robakis, Nikolaos/AAA-1838-2021		NATIONAL INSTITUTE ON AGING [P50AG005131] Funding Source: NIH RePORTER; NIA NIH HHS [AG05131] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BAKER TA, 1984, P NATL ACAD SCI-BIOL, V81, P6779, DOI 10.1073/pnas.81.21.6779; BODMER S, 1990, BIOCHEM BIOPH RES CO, V171, P890, DOI 10.1016/0006-291X(90)91229-L; BUELL G, 1985, NUCLEIC ACIDS RES, V13, P1923, DOI 10.1093/nar/13.6.1923; COLE GM, 1990, BIOCHEM BIOPH RES CO, V170, P288, DOI 10.1016/0006-291X(90)91272-T; COLE GM, 1991, NEUROBIOL AGING, V12, P85, DOI 10.1016/0197-4580(91)90046-M; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DUVOISIN RM, 1986, GENE, V45, P193, DOI 10.1016/0378-1119(86)90254-4; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FLOOD JF, 1991, P NATL ACAD SCI USA, V88, P3363, DOI 10.1073/pnas.88.8.3363; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GORSKI K, 1985, CELL, V43, P461, DOI 10.1016/0092-8674(85)90176-X; GOTTESMAN S, 1978, J BACTERIOL, V133, P844, DOI 10.1128/JB.133.2.844-851.1978; HIGGINS GA, 1990, P NATL ACAD SCI USA, V87, P3032, DOI 10.1073/pnas.87.8.3032; JOACHIM C, 1991, AM J PATHOL, V138, P373; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KRISCH HM, 1974, J MOL BIOL, V88, P89, DOI 10.1016/0022-2836(74)90296-4; KRISCH HM, 1977, VIROLOGY, V78, P87, DOI 10.1016/0042-6822(77)90080-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1990, INT CONGR SER, V884, P179; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SCHUBERT D, 1989, BIOCHEM BIOPH RES CO, V162, P83, DOI 10.1016/0006-291X(89)91965-7; SCHUBERT D, 1988, SCIENCE, V241, P223, DOI 10.1126/science.2968652; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SIMON LD, 1978, NATURE, V275, P424, DOI 10.1038/275424a0; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; UEDA K, 1989, ANN NEUROL, V25, P246, DOI 10.1002/ana.410250307; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WHITSON JS, 1990, NEUROSCI LETT, V110, P319, DOI 10.1016/0304-3940(90)90867-9; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1990, P NATL ACAD SCI USA, V87, P9020, DOI 10.1073/pnas.87.22.9020	57	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2214	2221						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346393				2022-12-25	WOS:A1992HB53200017
J	CHOI, SY; SCHERER, BJ; SCHNIER, J; DAVIES, MV; KAUFMAN, RJ; HERSHEY, JWB				CHOI, SY; SCHERER, BJ; SCHNIER, J; DAVIES, MV; KAUFMAN, RJ; HERSHEY, JWB			STIMULATION OF PROTEIN-SYNTHESIS IN COS CELLS TRANSFECTED WITH VARIANTS OF THE ALPHA-SUBUNIT OF INITIATION-FACTOR EIF-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; FACTOR-II; PHOSPHORYLATION STATE; RABBIT RETICULOCYTES; MESSENGER-RNAS; HELA-CELLS; TRANSLATION; INHIBITION; MECHANISM; EXPRESSION	The role of eukaryotic initiation factor 2 (eIF-2) phosphorylation in translational control has been demonstrated in vivo by overexpressing variant forms of eIF-2-alpha that are not phosphorylated. COS-1 cells transiently transfected with expression vectors for human eIF-2-alpha contain 10-20-fold more eIF-2-alpha-subunit than the endogenous COS cell eIF-2 trimeric complex. Expression of the variant form of eIF-2-alpha, Ser51Asp, where Asp replaces Ser51, causes inhibition of protein synthesis, whereas the Ser48Asp variant does not. When either Ser48 or Ser51 is replaced by Ala, the variants stimulate dihydrofolate reductase synthesis when the eIF-2-alpha-kinase, DAI, is activated. In order to elucidate these mechanisms, we have separated eIF-2 trimeric complexes from free overexpressed eIF-2-alpha-subunits by fast protein liquid chromatography Superose chromatography. Pulse-labeled cells transfected with wild-type or variant DNAs produced eIF-2 preparations with greater than 10-fold higher specific radioactivity in the alpha-subunit compared to the gamma-subunit, thus demonstrating that the human eIF-2-alpha produced from the plasmids readily exchanges into COS cell eIF-2 complexes. Both wild-type and Ser48Ala variant forms of the free 2-alpha-subunit, further purified by MonoQ chromatography, are poor substrates for the heme-regulated eIF-2-alpha-kinase, HRI, but are good substrates for double-stranded RNA-activated inhibitor in vitro; the Ser51Ala variant subunit is not phosphorylated by either kinase. None of the purified free eIF-2-alpha subunits inhibits phosphorylation of eIF-2 in vitro, even at up to 8-fold molar excess. Examination of the extent of eIF-2-alpha-phosphorylation in the COS cell eIF-2 complexes by two-dimensional polyacrylamide gel electrophoresis shows that the stimulation of dihydrofolate reductase synthesis by the Ser51Ala variant is most readily explained by failure of eIF-2 to be phosphorylated. Stimulation by the Ser48Ala variant appears to occur by mitigation of the effect of phosphorylation at Ser51 since the double variant, Ser48AlaSer51Asp, inhibits protein synthesis less than the single variant Ser51Asp. The evidence argues strongly against there being a second site of phosphorylation involved in translational repression.	UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616; GENET INST,CAMBRIDGE,MA 02140	University of California System; University of California Davis					NIGMS NIH HHS [GM22135, GM07377] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, T32GM007377] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EY PL, 1986, METHOD ENZYMOL, V121, P497; GRACE M, 1984, P NATL ACAD SCI-BIOL, V81, P5379, DOI 10.1073/pnas.81.17.5379; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOWE JG, 1983, J BIOL CHEM, V258, P1954; JACKSON RJ, 1985, BIOCHIM BIOPHYS ACTA, V826, P224, DOI 10.1016/0167-4781(85)90010-7; JACKSON RJ, 1990, TRANSLATION EUKARYOT, P193; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KRAMER G, 1990, FEBS LETT, V267, P181, DOI 10.1016/0014-5793(90)80919-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SAMUEL CE, 1984, J BIOL CHEM, V259, P13415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; WONG ST, 1982, J BIOL CHEM, V257, P5231	29	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					286	293						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1346129				2022-12-25	WOS:A1992GY43900048
J	LUO, ZJ; SINGH, IS; FUJIHIRA, T; ERLICHMAN, J				LUO, ZJ; SINGH, IS; FUJIHIRA, T; ERLICHMAN, J			CHARACTERIZATION OF A MINIMAL PROMOTER ELEMENT REQUIRED FOR TRANSCRIPTION OF THE MOUSE TYPE-II-BETA REGULATORY SUBUNIT (RII-BETA) OF CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIC CELLS; MOLECULAR-CLONING; BOVINE BRAIN; IMMUNOGLOBULIN ENHANCER; BINDING-PROTEINS; SKELETAL-MUSCLE; CDNA STRUCTURE; RECEPTOR GENE; HUMAN TESTIS; DNA-BINDING	The 5'-flanking DNA of the mouse RIIbeta subunit of the cAMP-dependent protein kinase gene was characterized by transient transfection of RIIbeta-CAT constructs into mouse neuroblastoma cells (NB2a) and Chinese hamster ovary (CHO) cells and by gel mobility shift and footprinting assays. The minimal promoter of the RIIbeta gene was composed of two adjacent functional elements. A 3'-element which supported enhanced CAT activity was located between base pairs (bp) -267/-168 from the translation initiation start site. CAT plasmids containing these RIIbeta sequences showed 12- and 16-fold increased CAT activity in the NB2a and CHO cells, respectively, compared to the basic CAT vector. Plasmids containing 20 additional bp 5' to the -267/-168 fragment showed 2-fold more CAT activity than the shorter fragment in NB2a cells, while CAT activity in CHO cells was nearly the same for both constructs. CAT plasmids containing only this 20-bp fragment showed 9- and 13-fold increased CAT activity in NB2a and CHO cells, respectively. The core promoter of the RIIbeta gene lacked classical TATA and CAT sequences, but contained 3 copies of the Spl core consensus sequence. Gel mobility shift assays using P-32-labeled 5'-flanking DNA containing bp -291/-49 and nuclear extracts from NB2a and CHO cells displayed several retarded bands in the gels suggesting complex formation with nuclear DNA-binding factors. Unlabeled DNA containing bp -291/-49 blocked the appearance of all retarded bands. Competition using an oligonucleotide corresponding to the Sp1 DNA-binding site effectively blocked the appearance of the two more slowly migrating bands but did not affect the major rapidly migrating bands. DNase I footprinting analysis using purified Sp1 protein confirmed that Sp 1 could bind to the Sp1 sites. Methylation interference and mutational analysis showed that one of the faster migrating bands was the result of factor binding to the DNA sequence adjacent to the Sp1 sites. Additional tissue-specific nuclear-binding factor sequences were detected upstream of the core promoter. Our data suggest that the core promoter of the RIIbeta gene can initiate transcription from the DNA around the Sp1 sites but that there are tissue-specific nuclear factor-binding sites located distal to the Sp1 sites.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,1300 MORRIS PARK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				LUO, ZHIJUN/0000-0001-8105-5289	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027736] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-27736] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1991, J BIOL CHEM, V266, P3944; BEEBE SJ, 1986, ENZYMES, V17, P43; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS RE, 1990, J BIOL CHEM, V265, P8152; HARTL FT, 1983, J BIOL CHEM, V258, P3950; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JAHNSEN T, 1986, J BIOL CHEM, V261, P6637; JAHNSEN T, 1985, J BIOL CHEM, V260, P5980; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KURTEN RC, 1988, ENDOCRINOLOGY, V123, P2408, DOI 10.1210/endo-123-5-2408; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATCHMAN DS, 1990, BIOCHEM J, V270, P281, DOI 10.1042/bj2700281; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LEISER M, 1986, J BIOL CHEM, V261, P1904; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; RUBIN CS, 1983, POSTTRANSLATIONAL CO, P81; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SINGH IS, 1991, BIOCHEM BIOPH RES CO, V178, P221, DOI 10.1016/0006-291X(91)91802-J; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; STEIN JC, 1985, J BIOL CHEM, V260, P991; TASKEN KA, 1992, ENDOCRINOLOGY, V130, P1271, DOI 10.1210/en.130.3.1271; TASKEN KA, 1991, MOL ENDOCRINOL, V5, P21, DOI 10.1210/mend-5-1-21; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WELDON SL, 1985, J BIOL CHEM, V260, P6440; WIEMANN S, 1991, J BIOL CHEM, V266, P5140	57	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24738	24747						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332964				2022-12-25	WOS:A1992KA26300088
J	YASUMOTO, K; OKAMOTO, S; MUKAIDA, N; MURAKAMI, S; MAI, M; MATSUSHIMA, K				YASUMOTO, K; OKAMOTO, S; MUKAIDA, N; MURAKAMI, S; MAI, M; MATSUSHIMA, K			TUMOR-NECROSIS-FACTOR-ALPHA AND INTERFERON-GAMMA SYNERGISTICALLY INDUCE INTERLEUKIN-8 PRODUCTION IN A HUMAN GASTRIC-CANCER CELL-LINE THROUGH ACTING CONCURRENTLY ON AP-1 AND NF-KB-LIKE BINDING-SITES OF THE INTERLEUKIN-8 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; MONONUCLEAR-CELLS; INFILTRATING LYMPHOCYTES; SELECTIVE DEPLETION; MONOCLONAL-ANTIBODY; DISTANT SITE; T-CELL; EXPRESSION; IMMUNE; RATS	Interleukin 8 (IL-8) is a novel cytokine which possesses neutrophil chemotactic and activating activities in addition to chemotactic activity for basophils and T lymphocytes. It has been shown that IL-8 is produced by a variety of human somatic cells including monocytes/macrophages, dermal fibroblasts, vascular endothelial cells, keratinocytes, mesangeal cells, and several types of tumor cell lines. We have examined here whether or not human gastric cancer cell lines produce IL-8 in vitro. The production of IL-8 protein was detected by enzyme-linked immunosorbent assay in the culture supernatants derived from eight of nine human gastric cancer cell lines stimulated with either interleukin 1alpha (IL-1alpha), tumor necrosis factor alpha (TNFalpha), or TNFalpha plus interferon gamma (IFNgamma). In some of the gastric cancer cell lines such as MKN 45 and KATO, TNFalpha plus IFNgamma synergistically induced the production of IL-8. In MKN 45 cells, synergistic increase of the steady state level of IL-8 mRNA by TNFalpha plus IFNgamma was not inhibited by cycloheximide treatment. Scatchard analysis revealed that IFNgamma changed neither the number nor the affinity constant of TNFalpha binding sites on a gastric cancer cell line, suggesting that the synergism was a post-receptor event. Furthermore, synergistic induction of chloramphenicol acetyltransferase activity by TNFalpha plus IFNgamma was observed in MKN 45 that were transiently transfected with chimeric chloramphenicol acetyltransferase reporter genes driven by the transcriptional regulatory region of human IL-8 gene. Through the mutation of the regulatory region of the IL-8 gene, both AP-1- and NF-kB-like factor binding elements were presumed to be involved in conferring the responsiveness to TNFalpha plus IFNgamma. Moreover, gel retardation analyses revealed that TNFalpha and IFNgamma synergistically induced the binding of NF-kB like as well as AP-1 like proteins bound to these sites. These results indicated that IFNgamma synergistically enhanced TNFalpha-induced IL-8 production in a human gastric cancer cell line through synergistic activation of transcription factors without up-regulating TNFalpha receptor.	KANAZAWA UNIV, CANC RES INST, DEPT PHARMACOL, 13-1 TAKARA MACHI, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, DEPT BIOPHYS, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, DEPT SURG, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University; Kanazawa University; Kanazawa University			Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBINA T, 1990, JPN J CANCER RES, V81, P1307, DOI 10.1111/j.1349-7006.1990.tb02695.x; EBINA T, 1991, JPN J CANCER RES, V82, P1292, DOI 10.1111/j.1349-7006.1991.tb01795.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hojo H., 1997, NIIGATA IGAKKAI ZASS, V91, P737; HUNG CD, 1991, HUMAN CELL S, V4, P51; IBAYASHI Y, 1985, J IMMUNOL, V134, P648; IOACHIM HL, 1976, J NATL CANCER I, V57, P465, DOI 10.1093/jnci/57.3.465; ITOH K, 1986, CANCER RES, V46, P3011; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P5183, DOI 10.1073/pnas.87.13.5183; KIKUCHI K, 1976, ANN NY ACAD SCI, V276, P188, DOI 10.1111/j.1749-6632.1976.tb41646.x; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; KRADIN RL, 1989, LANCET, V1, P577; KUDO C, 1991, J IMMUNOL, V147, P2196; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE SH, 1984, J IMMUNOL, V133, P1083; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSHIMA K, 1992, CHEM IMMUNOL, V51, P236; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIDORIKAWA Y, 1990, CANCER RES, V50, P6243; MINAMOTO T, 1990, CANCER-AM CANCER SOC, V66, P945, DOI 10.1002/1097-0142(19900901)66:5<945::AID-CNCR2820660523>3.0.CO;2-X; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; ROSENBERG SA, 1988, ANN SURG, V208, P121, DOI 10.1097/00000658-198808000-00001; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; SAWAGUCHI K, 1991, HUMAN CELL S, V4, P50; SAWAGUCHI S, 1989, HUMAN CELL S, V2, P87; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIJUBO N, 1989, J IMMUNOL, V142, P2961; SHIMOKAWARA I, 1982, CANCER, V49, P1456, DOI 10.1002/1097-0142(19820401)49:7<1456::AID-CNCR2820490724>3.0.CO;2-#; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; UEDE T, 1985, J IMMUNOL, V135, P3243; UNDERWOOD JCE, 1974, BRIT J CANCER, V30, P538, DOI 10.1038/bjc.1974.233; VOSE BM, 1979, INT J CANCER, V24, P579, DOI 10.1002/ijc.2910240510; WATANABE H, 1976, CANCER, V38, P232, DOI 10.1002/1097-0142(197607)38:1<232::AID-CNCR2820380135>3.0.CO;2-4; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; YAMAKI T, 1988, J IMMUNOL, V140, P4388; YAMANO S, 1989, HUMAN CELL S, V2, P93; ZACHARIAE COC, 1992, IN PRESS INVEST DERM	46	430	435	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22506	22511						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331059				2022-12-25	WOS:A1992JW71900081
J	CHEN, ML; TSAI, CN; LIANG, CL; SHU, CH; HUANG, CR; SULITZEANU, D; LIU, ST; CHANG, YS				CHEN, ML; TSAI, CN; LIANG, CL; SHU, CH; HUANG, CR; SULITZEANU, D; LIU, ST; CHANG, YS			CLONING AND CHARACTERIZATION OF THE LATENT MEMBRANE-PROTEIN (LMP) OF A SPECIFIC EPSTEIN-BARR-VIRUS VARIANT DERIVED FROM THE NASOPHARYNGEAL CARCINOMA IN THE TAIWANESE POPULATION	ONCOGENE			English	Article							EPITHELIAL-CELLS; DNA; TRANSFORMATION; ANTIBODIES; SEQUENCES; AMPLIFICATION; TRANSCRIPTION; REPLICATION; ANTIGENS; REGION	A DNA fragment containing Epstein-Barr virus (EBV) terminal fragment sequence was obtained from a genomic library of nasopharyngeal carcinoma (NPC). One of the clones (clone 1510) contained the gene encoding latent membrane protein (LMP). Sequence analysis revealed that this gene had 95% homology with the LMP sequence of the B95-8 strain. Among the sequence variations, there was a change from G to T at nucleotide position 169 426, resulting in the loss of an XhoI site in exon 1 of the LMP gene. A pair of primers bracketing the XhoI site were designed to synthesize the EBV DNA fragment from nucleotides 169 081-169 577 by using the polymerase chain reaction (PCR) method. The PCR products were then subject to XhoI digestion and to DNA sequencing analysis. This restriction enzyme site polymorphism along with the sequence variations were also observed in 50 biopsy tissues as well as in the throat washings of 6 out of 20 healthy individuals that we examined, indicating that the EBV strain predominantly existing in these biopsy tissues was different from strains of B95-8, Jijoye or nude mouse passaged cells (C15) with an African origin, but closely resembled other nude mouse passaged CAO cells which were originally derived from China. Balb/c 3T3 cells carrying this NPC-LMP gene showed a transformed cell morphology and were tumorigenic in nude mice. The relationship between this unique type of EBV and NPC has yet to be established.	CHANG GUNG MED COLL,DEPT MICROBIOL & IMMUNOL,259 WEN HWA IST RD,TAOYUAN 33332,TAIWAN; NATL YANG MING MED COLL,GRAD INST MICROBIOL & IMMUNOL,SHIH PAI 11221,TAIWAN; VET GEN HOSP TAIPEI,DEPT OTOLARYNGOL,TAIPEI 11217,TAIWAN; HEBREW UNIV JERUSALEM,HADASSAH MED CTR,DEPT IMMUNOL,JERUSALEM,ISRAEL	Chang Gung University; Hebrew University of Jerusalem; Hadassah University Medical Center			Tsai, Chi neu/C-3373-2011; Tsai, Chi-Neu/AAZ-2558-2020	Tsai, Chi neu/0000-0002-5940-0696; Tsai, Chi-Neu/0000-0002-5940-0696; Chang, Yu-Sun/0000-0002-6457-3890				BAICHWAL VR, 1989, ONCOGENE, V4, P67; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHANG YS, 1990, J CLIN MICROBIOL, V28, P2398, DOI 10.1128/JCM.28.11.2398-2402.1990; CHANG YS, 1990, LEUKEMIA RES, V14, P309, DOI 10.1016/0145-2126(90)90157-5; CHANG YS, 1991, NUCLEIC ACIDS RES, V20, P139; DAMBAUGH T, 1980, P NATL ACAD SCI-BIOL, V77, P2999, DOI 10.1073/pnas.77.5.2999; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DESGRANGES C, 1975, INT J CANCER, V16, P7, DOI 10.1002/ijc.2910160103; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANTO DW, 1985, TRANSPLANTATION, V39, P461, DOI 10.1097/00007890-198505000-00001; HENLE G, 1971, JNCI-J NATL CANCER I, V46, P861; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE W, 1970, J NATL CANCER I, V44, P225; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; KLEIN G, 1980, P NATL ACAD SCI USA, V77, P6162; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MILLER G, 1973, P NATL ACAD SCI USA, V70, P4006; RAABTRAUB N, 1983, J VIROL, V48, P580, DOI 10.1128/JVI.48.3.580-590.1983; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHU CH, 1991, IN PRESS J VIROL MET; SIXBEY JW, 1983, NATURE, V306, P480, DOI 10.1038/306480a0; SIXBEY JW, 1989, LANCET, V2, P761; SMITH PR, 1992, J VIROL, V66, P706, DOI 10.1128/JVI.66.2.706-714.1992; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988	40	187	203	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2131	2140						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331932				2022-12-25	WOS:A1992JW66500005
J	YASUDA, K; RENSDOMIANO, S; BREDER, CD; LAW, SF; SAPER, CB; REISINE, T; BELL, GI				YASUDA, K; RENSDOMIANO, S; BREDER, CD; LAW, SF; SAPER, CB; REISINE, T; BELL, GI			CLONING OF A NOVEL SOMATOSTATIN RECEPTOR, SSTR3, COUPLED TO ADENYLYLCYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; PITUITARY-CELLS; RAT-BRAIN; DESENSITIZATION; SUBTYPES; ANALOGS; PROTEIN; CAMP; SMS-201-995; SPECIFICITY	The gene encoding a novel mouse somatostatin receptor termed mSSTR3 was isolated and characterized. The sequence of mSSTR3 shows 46 and 47% identity with mSSTR1 and mSSTR2, respectively. mSSTR3 binds somatostatin-14 and somatostatin-28 with high affinity, but shows very low affinity for the somatostatin analogs MK-678 and SMS-201-995. In addition, mSSTR3 is coupled to pertussis toxin-sensitive G proteins and mediates somatostatin inhibition of forskolin-stimulated and dopamine D1 receptor-stimulated cAMP formation, indicating that it is coupled to adenylylcyclase. The pharmacological properties of mSSTR3 and its ability to couple with adenylylcyclase distinguish SSTR3 from the other cloned somatostatin receptors and indicates that it mediates biological functions different from SSTR1 or SSTR2. In situ hybridization indicates that SSTR3 mRNA is widely distributed in the mouse brain, and its expression in the nucleus of the lateral olfactory tract and in the piriform cortex, the primary olfactory cortex in the rodent brain, suggests that SSTR3 may participate in the processing and modulation of primary sensory information.	UNIV CHICAGO,HOWARD HUGHES MED INST,5841 S MARYLAND AVE,MC1028,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,COMM NEUROBIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Pennsylvania			Saper, Clifford/L-3815-2019		NIDDK NIH HHS [DK-20595, DK-42086] Funding Source: Medline; NIMH NIH HHS [MH-45533] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, P60DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER DL, 1989, J BIOL CHEM, V264, P21038; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; CARPENTER MB, 1987, HDB CLIN NEUROLOGY, P1; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; MAHY N, 1988, J PHARMACOL EXP THER, V246, P779; MAHY N, 1988, J PHARMACOL EXP THER, V247, P390; MALM D, 1991, ACTA PHYSIOL SCAND, V143, P305, DOI 10.1111/j.1748-1716.1991.tb09237.x; MARKSTEIN R, 1989, NEUROSCI LETT, V104, P13, DOI 10.1016/0304-3940(89)90321-2; MARTIN JL, 1991, NEUROSCIENCE, V41, P581, DOI 10.1016/0306-4522(91)90351-N; MORIIZUMI T, 1991, NEUROSCI LETT, V132, P69, DOI 10.1016/0304-3940(91)90435-V; PITTMAN QJ, 1981, BRAIN RES, V221, P402, DOI 10.1016/0006-8993(81)90791-5; PLESS J, 1986, SCAND J GASTROENTERO, V21, P54, DOI 10.3109/00365528609087432; PRESKY DH, 1988, J BIOL CHEM, V263, P714; Price J. L., 1987, HDB CHEM NEUROANATOM, V5, P279; PRIESTLEY T, 1992, NEUROPHARMACOLOGY, V31, P103, DOI 10.1016/0028-3908(92)90018-K; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAYNOR K, 1989, J PHARMACOL EXP THER, V251, P510; RAYNOR K, 1991, MOL PHARMACOL, V40, P248; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; REISINE T, 1984, J PHARMACOL EXP THER, V229, P14; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH MA, 1984, MOL CELL ENDOCRINOL, V37, P311, DOI 10.1016/0303-7207(84)90101-1; SPANN BM, 1991, J COMP NEUROL, V311, P375, DOI 10.1002/cne.903110308; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TALLENT M, 1992, MOL PHARMACOL, V41, P452; THEVENIAU M, 1992, P NATL ACAD SCI USA, V89, P4314, DOI 10.1073/pnas.89.10.4314; TOTTERDELL S, 1984, J NEUROCYTOL, V13, P593, DOI 10.1007/BF01148081; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VEBER DF, 1984, LIFE SCI, V34, P1371, DOI 10.1016/0024-3205(84)90009-2; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017; WANG H, 1990, NEUROSCIENCE, V342, P335; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; YAJIMA Y, 1986, J BIOL CHEM, V261, P2684; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	44	336	349	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20422	20428						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328199				2022-12-25	WOS:A1992JR85800105
J	DURR, JA; HENSEN, J; SCHRIER, RW				DURR, JA; HENSEN, J; SCHRIER, RW			HIGH SPECIFIC ACTIVITY I-125 LABELED AND S-35 LABELED VASOPRESSIN ANALOGS WITH HIGH-AFFINITY FOR THE V1 AND V2 VASOPRESSIN ISORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROHYPOPHYSEAL HORMONES; 8-LYSINE VASOPRESSIN; BINDING-SITES; RECEPTOR; PURIFICATION; ANTAGONISTS	Since iodination of the tyrosine residue in the pressin ring of vasopressins abolishes binding to the V2 (renal) isoreceptor, the low specific activity tritiated vasopressins have been the only radioligands available for this receptor. Alternative vasopressin radioligands are described in the present study. N-tert-Butoxycarbonyl-(N-t-Boc) I-125-tyrosine or [S-35]methionine were conjugated to the 8th amino acid of lysine- (LVP) or deamino-ornithine-vasopressin via active succinimidyl esters. Following the purification on C-18 reverse-phase high pressure liquid chromatography, t-Boc removal, and a second high pressure liquid chromatography purification, specific activities of 2200 and 1300 Ci/mmol were obtained for the I-125 and the S-35-labeled ligands, respectively. These vasopressin analogues, conjugated outside the pressin ring, were found to bind with high affinity to the V1A (Vascular) and V2 vasopressin isoreceptors (K(d) less-than-or-equal-to 10(-9) M) and to retain the full biological activity of intact vasopressin. The present study demonstrates the possibility of producing high specific activity radioligands with high affinity for the V1A and V2 Vasopressin isoreceptors by conjugating labeled moieties to the 8th amino acid of vasopressin analogues. Since these new radioligands have specific activities much higher than the tritiated ligands (1300-2200 versus 10-30 Ci/mmol), they should provide considerable advantages in the future study of the physiology and biochemistry of the AVP receptors.			DURR, JA (corresponding author), UNIV COLORADO,SCH MED,DEPT MED,DIV RENAL DIS,BOX C-281,DENVER,CO 80262, USA.				NIDDK NIH HHS [DK 38468, DK 19928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928, R29DK038468] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASSOIAN RK, 1980, ANAL BIOCHEM, V103, P70, DOI 10.1016/0003-2697(80)90238-9; BURLET C, 1980, J PHYSIOL-PARIS, V76, P249; DILLINGHAM MA, 1986, SCIENCE, V231, P1572, DOI 10.1126/science.3006248; FAHRENHOLZ F, 1986, EUR J BIOCHEM, V161, P321, DOI 10.1111/j.1432-1033.1986.tb10450.x; FAHRENHOLZ F, 1985, EUR J BIOCHEM, V152, P589, DOI 10.1111/j.1432-1033.1985.tb09236.x; FLOURET G, 1977, BIOCHEMISTRY-US, V16, P2119, DOI 10.1021/bi00629a011; GEORGOUSSI Z, 1990, BIOCHIM BIOPHYS ACTA, V1055, P69, DOI 10.1016/0167-4889(90)90092-R; GUILLON G, 1984, MOL PHARMACOL, V26, P241; HAVRAN RT, 1969, J AM CHEM SOC, V91, P2696, DOI 10.1021/ja01038a048; HECHTER O, 1978, J BIOL CHEM, V253, P3230; JARD S, 1981, J PHYSIOL-PARIS, V77, P621; JARD S, 1987, MOL PHARMACOL, V32, P369; JI I, 1985, ANAL BIOCHEM, V151, P348, DOI 10.1016/0003-2697(85)90186-1; KIM JK, 1977, KIDNEY INT, V12, P172, DOI 10.1038/ki.1977.98; LANGONE JL, 1981, METHOD ENZYMOL, V71, P112; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDT BF, 1978, INT J PEPT PROT RES, V12, P258; MOORE ML, 1984, BIOCHEM BIOPH RES CO, V121, P878, DOI 10.1016/0006-291X(84)90759-9; MOREL F, 1983, RECENT PROG HORM RES, V39, P271; MOREL F, 1976, METHODS PHARM RENAL, P297; MORRIS BJ, 1976, CLIN CHIM ACTA, V73, P213, DOI 10.1016/0009-8981(76)90328-4; MUJAIS SK, 1986, J CLIN INVEST, V77, P315, DOI 10.1172/JCI112293; PRADELLE.P, 1972, FEBS LETT, V26, P189, DOI 10.1016/0014-5793(72)80570-2; RAGGENBASS M, 1987, P NATL ACAD SCI USA, V84, P7778, DOI 10.1073/pnas.84.21.7778; RATTRAY M, 1990, MOL BRAIN RES, V7, P249, DOI 10.1016/0169-328X(90)90035-C; Roy C, 1981, Ann N Y Acad Sci, V372, P92, DOI 10.1111/j.1749-6632.1981.tb15463.x; ROY C, 1981, J BIOL CHEM, V256, P3415; ROY C, 1975, J BIOL CHEM, V250, P3157; ROY C, 1982, INSERM S, V21, P41; SMIGEL M, 1977, J BIOL CHEM, V252, P3689; STASSEN FL, 1987, MOL PHARMACOL, V31, P267; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244; WALTER R, 1967, AM J MED, V42, P653, DOI 10.1016/0002-9343(67)90087-3; WATSON S, 1991, TRENDS PHARMS CI S1, V12, P28; WEITZMAN RE, 1978, AM J PHYSIOL, V235, pE591, DOI 10.1152/ajpendo.1978.235.6.E591; YAMASHIRO D, 1967, P NATL ACAD SCI USA, V57, P1058, DOI 10.1073/pnas.57.4.1058	36	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18453	18458						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326525				2022-12-25	WOS:A1992JN50200036
J	ZHANG, B; ROTH, RA				ZHANG, B; ROTH, RA			THE INSULIN RECEPTOR-RELATED RECEPTOR - TISSUE EXPRESSION, LIGAND-BINDING SPECIFICITY, AND SIGNALING CAPABILITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-I RECEPTOR; HAMSTER OVARY CELLS; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; PROTEIN; PHOSPHORYLATION; SUBSTRATE; REGIONS; DOMAIN	In 1989, Shier and Watt identified a gene which was predicted to encode a new member of the insulin receptor (IR) family, and they called it the insulin receptor-related receptor (IRR) (Shier, P., and Watt, V. M. (1989) J. Biol. Chem. 264, 14605-14608). However, the tissues expressing this receptor, its ligand binding specificity and its signaling capability have remained unknown. In the present studies we report Northern blot analyses and polymerase chain reaction data, which indicate that the IRR mRNA is expressed in a variety of tissues, including the human kidney, heart, skeletal muscle, liver, and pancreas. In order to examine the ligand(s) recognized by IRR, we constructed a chimeric receptor with the extracellular domain of the IR replaced with that of IRR. This chimera was found not to bind radioactively labeled insulin, insulin-like growth factor I (IGF-I), or IGF-II. These ligands and relaxin, the only other known member of the mammalian insulin family, also failed to stimulate the tyrosine kinase activity of this chimeric receptor. A second chimeric receptor with the extracellular domain of IR and the kinase domain of IRR was also constructed and utilized to study the signaling capabilities of the kinase domain of IRR. This chimera exhibited high affinity insulin binding and insulin-stimulated tyrosine kinase activity. The kinase domains of the IR and IRR were found capable of phosphorylating the same spectrum of exogenous and endogenous substrates. However, Chinese hamster ovary (CHO) cells stably overexpressing the kinase domain of IRR exhibited elevated basal thymidine incorporation and 2-deoxyglucose uptake compared with CHO cells and CHO cells overexpressing wild-type IR. We conclude that: 1) IRR is expressed in the human kidney, heart, skeletal muscle, liver, and pancreas, 2) IRR does not appear to be the receptor of any known member of the insulin family, and 3) the tyrosine kinase of IRR appears to be similar to that of IR in both the spectrum of substrates phosphorylated and the biological responses stimulated.	STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA	Stanford University					NIDDK NIH HHS [DK 34926, DK 4175] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIN JE, 1991, J BIOL CHEM, V266, P15587; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS L, 1986, P NATL ACAD SCI USA, V83, P8137, DOI 10.1073/pnas.83.21.8137; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1987, P NATL ACAD SCI USA, V84, P5101, DOI 10.1073/pnas.84.15.5101; ELLIS L, 1986, COLD SPRING HARB SYM, V51, P773, DOI 10.1101/SQB.1986.051.01.090; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GERAERTS WPM, 1991, CURRENT ASPECTS NEUR, V3, P255; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HERBST R, 1991, J BIOL CHEM, V266, P19908; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAMMERS R, 1991, METHOD ENZYMOL, V198, P225; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MARUYAMA K, 1988, AGR BIOL CHEM TOKYO, V52, P3035, DOI 10.1080/00021369.1988.10869178; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROTH RA, 1983, BIOCHEM BIOPH RES CO, V115, P245, DOI 10.1016/0006-291X(83)90996-8; ROTH RA, 1991, MODERN CONCEPTS INSU, P505; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SCHWABE C, 1990, COMP BIOCHEM PHYS B, V96, P15, DOI 10.1016/0305-0491(90)90335-Q; SHIER P, 1990, CYTOGENET CELL GENET, V54, P80, DOI 10.1159/000132963; SHIER P, 1989, J BIOL CHEM, V264, P14605; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMURA S, 1983, BIOCHEM BIOPH RES CO, V113, P80, DOI 10.1016/0006-291X(83)90434-5; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	44	84	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18320	18328						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326521				2022-12-25	WOS:A1992JN50200015
J	CHAKRABORTY, T; MARTIN, JF; OLSON, EN				CHAKRABORTY, T; MARTIN, JF; OLSON, EN			ANALYSIS OF THE OLIGOMERIZATION OF MYOGENIN AND E2A PRODUCTS INVIVO USING A 2-HYBRID ASSAY SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOOP-HELIX PROTEINS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; HETERO-OLIGOMERIZATION; REGULATORY PROTEIN; LEUCINE ZIPPER; MYOD; DOMAIN; EXPRESSION; ENHANCER	Members of the helix-loop-helix (HLH) family of proteins bind DNA and activate transcription as homo- and heterodimers. Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47. We describe a method for detection of protein-protein interactions among HLH proteins in vivo in which dimerization through the HLH motif reconstructs a hybrid transcription factor containing the DNA-binding domain of yeast GAL4 linked to one HLH motif and the activation domain of VP-16 linked to another. We have used this assay to investigate whether myogenin forms homomeric or heteromeric complexes in vivo and to determine whether growth factors and oncogenes that inhibit myogenesis influence myogenin's ability to dimerize. The results show that myogenin heterodimerizes with E12 and E47 in vivo, but it does not homodimerize to a measurable extent. Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.	UNIV TEXAS, MD ANDERSON CANC CTR,DEPT BIOCHEM,BOX 117, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039849, R01AR040339] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39849, AR40339] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FARMER K, 1992, J BIOL CHEM, V267, P5631; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN H, 1992, J BIOL CHEM, V267, P4773; MARTIN JF, 1992, J BIOL CHEM, V267, P10956; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	47	16	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17498	17501						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325437				2022-12-25	WOS:A1992JM22300006
J	SCHEIBE, RJ; WAGNER, JA				SCHEIBE, RJ; WAGNER, JA			RETINOIC ACID REGULATES BOTH EXPRESSION OF THE NERVE GROWTH-FACTOR RECEPTOR AND SENSITIVITY TO NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; HIGH-AFFINITY RECEPTORS; NGF RECEPTOR; TERATOCARCINOMA CELLS; MOLECULAR-CLONING; TRK PROTOONCOGENE; NEURITE OUTGROWTH; GENE-TRANSFER; DEVELOPMENTAL EXPRESSION; TYROSINE PHOSPHORYLATION	In PC12 cells, retinoic acid (RA) stimulates the expression of p75NGFR, a component of the nerve growth factor (NGF) receptor, as indicated by a rapid increase in p75NGFR mRNA, an increase in the binding of I-125-labeled NGF to p75NGFR, and an increase in the binding of NGF to low affinity sites. RA-treated cells are more sensitive to NGF, but not to either fibroblast growth factor or phorbol 12-myristate 13-acetate, showing that RA has a specific effect on the responsiveness of PC12 cells to NGF. Exposure to RA leads neither to an increase in the expression of mRNA for trk, another component of the NGF receptor, nor to an increase in binding to high affinity receptors, suggesting that an increase in the expression of p75NGFR is sufficient to make cells more sensitive to NGF. This work suggests that, in addition to having direct effects on gene expression, RA can indirectly modulate differentiation of neurons by modifying their expression of cell surface receptors to peptide growth factors.	CORNELL UNIV, SCH MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10021 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Cornell University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA022427, R01CA040929] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40929, CA 22427] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BLOCK T, 1983, J NEUROCHEM, V40, P1654, DOI 10.1111/j.1471-4159.1983.tb08139.x; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BUXSER S, 1990, J BIOL CHEM, V265, P12701; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ERIKSSON U, 1986, CANCER RES, V46, P717; EVELETH DD, 1988, NEURON, V1, P929, DOI 10.1016/0896-6273(88)90150-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HASKELL BE, 1987, CELL TISSUE RES, V247, P67, DOI 10.1007/BF00216548; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANDRETH GE, 1987, NEUROCHEM RES, V12, P943, DOI 10.1007/BF00966317; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEVI-MONTALCINI R, 1968, Physiological Reviews, V48, P535; MADEN M, 1989, DEV BIOL, V135, P124, DOI 10.1016/0012-1606(89)90163-2; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REES JL, 1989, BIOCHEM J, V259, P917, DOI 10.1042/bj2590917; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SEEGER RC, 1977, CANCER RES, V37, P1364; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STONER CM, 1989, CANCER RES, V49, P1497; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUTTER A, 1979, J BIOL CHEM, V254, P5972; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; VALE RD, 1985, METHOD ENZYMOL, V109, P21; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; WAGNER JA, 1986, J CELL BIOL, V103, P1363, DOI 10.1083/jcb.103.4.1363; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	67	63	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17611	17616						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325442				2022-12-25	WOS:A1992JM22300023
J	HASHIMOTO, Y; OGIHARA, A; NAKANISHI, S; MATSUDA, Y; KUROKAWA, K; NONOMURA, Y				HASHIMOTO, Y; OGIHARA, A; NAKANISHI, S; MATSUDA, Y; KUROKAWA, K; NONOMURA, Y			2 THROMBIN-ACTIVATED CA2+ CHANNELS IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; SMOOTH-MUSCLE CELLS; INOSITOL 1,4,5-TRISPHOSPHATE; FREE CALCIUM; CA-2+; RELEASE; MEMBRANES; KINETICS; PHOSPHORYLATION; TRIPHOSPHATE	The regulation of extracellular Ca2+ entry into fura-2-loaded human platelets was examined following stimulation with thrombin. In the presence of external Ca2+, stimulation of platelets with thrombin resulted in a rapid increase, followed by a plateau, in intracellular Ca2+ concentration ([Ca2+]i). Pretreatment with wortmannin, a specific inhibitor of myosin light chain kinase, suppressed only the plateau phase and had no effect on the initial rapid increase in [Ca2+]i. In Ca2+-free EGTA buffer, thrombin induced a transient and relatively small increase in [Ca2+]i caused by Ca2+ release from internal stores. When Ca2+ was added subsequently to the Ca2+-free medium within 10 min after thrombin activation, a marked increase in [Ca2+]i was seen, reflecting thrombin-stimulated external Ca2+ entry. With the Ca2+-free medium, wortmannin did not affect either the Ca2+ mobilization from the internal stores or the rapid external Ca2+ entry at early time points (within 5 s) after thrombin stimulation, whereas it significantly inhibited Ca2+ entry when Ca2+ was added later (at 3 min). Wortmannin inhibition of this late Ca2+ entry and that of 20-kDa myosin light chain phosphorylation after thrombin stimulation were dose- and preincubation time-dependent and correlated well with each other. These results suggest that two different channels are responsible for Ca2+ entry in human platelets at the early and late phases of thrombin stimulation and that the channel responsible for the late phase of Ca2+ entry may be activated by a mechanism involving myosin light chain kinase.	KYOWA HAKKO KOGYO,RES LABS,MACHIDA,TOKYO 194,JAPAN; NIHON UNIV,SCH MED,DEPT INTERNAL MED 3,ITABASHI KU,TOKYO 173,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN	Kyowa Kirin Ltd; Nihon University; University of Tokyo	HASHIMOTO, Y (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 1,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.							ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ADUNYAH SE, 1985, BIOCHEM BIOPH RES CO, V128, P1274, DOI 10.1016/0006-291X(85)91078-2; ADUNYAH SE, 1986, J BIOL CHEM, V261, P3122; AUTHI KS, 1985, BIOCHEM J, V230, P247, DOI 10.1042/bj2300247; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRASS LF, 1985, J BIOL CHEM, V260, P5172; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; HASHIMOTO Y, 1985, BIOCHIM BIOPHYS ACTA, V841, P283, DOI 10.1016/0304-4165(85)90070-4; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1984, P NATL ACAD SCI-BIOL, V81, P7431, DOI 10.1073/pnas.81.23.7431; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OROURKE FA, 1985, J BIOL CHEM, V260, P956; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; ROGERS JC, 1989, BIOCHEM BIOPH RES CO, V164, P419, DOI 10.1016/0006-291X(89)91736-1; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TAKEUCHI K, 1989, TOHOKU J EXP MED, V159, P23, DOI 10.1620/tjem.159.23; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	28	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17078	17081						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324922				2022-12-25	WOS:A1992JL05300055
J	HUANG, MN; HUNG, HL; STANFIELDOAKLEY, SA; HIGH, KA				HUANG, MN; HUNG, HL; STANFIELDOAKLEY, SA; HIGH, KA			CHARACTERIZATION OF THE HUMAN BLOOD-COAGULATION FACTOR-X PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ENHANCER BINDING-PROTEIN; ALBUMIN GENE; FACTOR-IX; TRANSCRIPTION FACTOR; HEPATOMA-CELLS; HEMOPHILIA-B; DNA; PROTHROMBIN; HORMONE	Blood coagulation Factor X is a serine protease required for both the intrinsic and extrinsic pathways of coagulation. The gene for Factor X spans 27 kilobases and is located on chromosome 13, in close proximity to the gene encoding Factor VII. Expression of Factor X is restricted to the liver. We have characterized the human Factor X promoter by mapping the start sites of transcription and carrying out a functional analysis of the promoter. The first 279 base pairs (bp) of 5'-flanking sequence upstream from the first AUG are sufficient to confer maximal promoter activity in HepG2 cells. Protein-binding sites within the 279-bp fragment are defined using gel mobility shift assays. Mutagenesis of two specific sequences within the 279-bp fragment (CCAAT at -120 to -116, and ACTTTG at -56 to -51), results in loss of ability to bind proteins from a HepG2 nuclear extract, and profound reduction in promoter activity of the 279-bp fragment. We conclude that these two protein-binding sites are critical for the activity of the Factor X promoter.	UNIV N CAROLINA, DEPT MED, DIV HEMATOL, CAMPUS BOX 7035, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			High, Katherine A./AAB-9322-2020		NHLBI NIH HHS [KO8-HL01922, P01-HL06350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001922, P01HL006350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSON DS, 1984, EMBO J, V3, P1053, DOI 10.1002/j.1460-2075.1984.tb01926.x; BANCROFT JD, 1990, GENE, V95, P253, DOI 10.1016/0378-1119(90)90368-2; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAIR DS, 1984, BLOOD, V64, P194; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUANG MN, 1990, BIOTECHNIQUES, V9, P710; JAGADEESWARAN P, 1989, GENE, V84, P517, DOI 10.1016/0378-1119(89)90529-5; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; REITSMA PH, 1989, BLOOD, V73, P743; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Sharp P A, 1980, Methods Enzymol, V65, P750; SHINICHI A, 1987, METHOD ENZYMOL, V151, P38; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291	32	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15440	15446						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322399				2022-12-25	WOS:A1992JG11300030
J	JACKIW, V; HUNZICKERDUNN, M				JACKIW, V; HUNZICKERDUNN, M			LUTEINIZATION-ASSOCIATED CHANGES IN PROTEIN STABILITY OF THE REGULATORY SUBUNIT OF THE TYPE-I CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN GRANULOSA-CELLS; BOVINE CARDIAC-MUSCLE; CATALYTIC SUBUNIT; MOLECULAR-CLONING; MESSENGER-RNA; CYCLIC-AMP; HUMAN TESTIS; HORMONAL-REGULATION; SKELETAL-MUSCLE; CDNA STRUCTURE	The purpose of this study was to determine how RI-alpha, the R subunit of the type I cAMP-dependent protein kinase, is regulated in rabbit ovarian follicles in response to the preovulatory luteinizing hormone surge. When soluble extracts from rabbit preovulatory follicles and 7-day-old corpora lutea were photoaffinity-labeled with 8-N3-[P-32]cAMP, 3-fold more RI-alpha was detected in corpora lutea than in follicles. Based on DEAE-cellulose chromatography, both type I holoenzyme and free RI-alpha increased during luteinization. Western blot analysis of soluble extracts obtained from follicles and corpora lutea at various time points after human chorionic gonadotropin (hCG) injection revealed a 6-10-fold increase in RI-alpha protein by 5 h after hCG injection. However, based on Northern blot analysis and solution hybridization/RNase protection assays, this increase in RI-alpha protein was not due to an increase in RI-alpha mRNA. These results suggested that RI-alpha subunit levels were post-transcriptionally regulated. Half-life determinations indicated a 2.1-fold increase in the stability of RI-alpha when follicles were incubated in the presence of hCG. The effect of hCG on the stability of RI-alpha could also be mimicked by forskolin, thus suggesting that a rise in cAMP levels in follicles during the luteinizing hormone surge plays a role in RI-alpha subunit stability. We conclude that RI-alpha protein is stabilized in follicles by hCG treatment and the consequent rise in follicular cAMP levels.	NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011356] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-11356, HD-21921] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAVO JA, 1982, HDB EXPT PHARM, V581, P363; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTLEY MS, 1984, J BIOL CHEM, V259, P6001; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; DRUBIN DG, 1984, J CELL BIOL, V98, P1090, DOI 10.1083/jcb.98.3.1090; ERLICHMAN J, 1984, J BIOL CHEM, V259, P289; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUNZICKERDUNN M, 1978, ENDOCRINOLOGY, V103, P420, DOI 10.1210/endo-103-2-420; HUNZICKERDUNN M, 1978, ENDOCRINOLOGY, V103, P441, DOI 10.1210/endo-103-2-441; HUNZICKERDUNN M, 1984, ENDOCRINOLOGY, V115, P302, DOI 10.1210/endo-115-1-302; HUNZICKERDUNN M, 1981, J BIOL CHEM, V256, P2185; HUNZICKERDUNN M, 1985, J BIOL CHEM, V260, P3360; HUNZICKERDUNN M, 1991, J BIOL CHEM, V266, P7166; HUNZICKERDUNN M, 1978, ENDOCRINOLOGY, V103, P431, DOI 10.1210/endo-103-2-431; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JAHNSEN T, 1986, J BIOL CHEM, V261, P6637; JAHNSEN T, 1985, J BIOL CHEM, V260, P5980; KAPOOR CL, 1979, J BIOL CHEM, V254, P2427; KERLAVAGE AR, 1980, J BIOL CHEM, V255, P8483; KNUTSEN HK, 1991, ENDOCRINOLOGY, V129, P2496, DOI 10.1210/endo-129-5-2496; KURTEN RC, 1988, ENDOCRINOLOGY, V123, P2408, DOI 10.1210/endo-123-5-2408; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LIU AYC, 1987, BIOCHEM BIOPH RES CO, V148, P350, DOI 10.1016/0006-291X(87)91117-X; LORIMER IAJ, 1987, J BIOL CHEM, V262, P17200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; MAIZELS ET, 1990, SERONO S, P54; Maniatis T, 1982, MOL CLONING LABORATO; MARSH JM, 1973, BIOCHIM BIOPHYS ACTA, V304, P197, DOI 10.1016/0304-4165(73)90128-1; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OYEN O, 1987, BIOL REPROD, V37, P947, DOI 10.1095/biolreprod37.4.947; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; POTTER RL, 1979, J BIOL CHEM, V254, P2413; RANGELALDAO R, 1979, J BIOL CHEM, V254, P2499; RATOOSH SL, 1987, J BIOL CHEM, V262, P7306; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; Rudolph S A, 1979, Adv Cyclic Nucleotide Res, V10, P107; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; STEINBERG RA, 1984, ARCH BIOCHEM BIOPHYS, V234, P546, DOI 10.1016/0003-9861(84)90302-3; SUDGEN PH, 1976, BIOCHEM J, V159, P423; TASKEN KA, 1991, MOL ENDOCRINOL, V5, P21, DOI 10.1210/mend-5-1-21; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WELDON SL, 1985, J BIOL CHEM, V260, P6640; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WIEMANN S, 1991, J BIOL CHEM, V266, P5140	61	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14335	14344						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321143				2022-12-25	WOS:A1992JD32500084
J	WILKIN, DJ; EDWARDS, PA				WILKIN, DJ; EDWARDS, PA			CALCIUM IONOPHORE TREATMENT IMPAIRS THE STEROL-MEDIATED SUPPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE, 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A SYNTHASE, AND FARNESYL DIPHOSPHATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; DENSITY LIPOPROTEIN RECEPTOR; PROTEIN KINASE-C; COORDINATE REGULATION; PHORBOL ESTER; RAT-LIVER; GENE; TRANSCRIPTION; EXPRESSION; SEQUENCE	We report that the sterol-mediated suppression of the mRNA levels of three cholesterogenic enzymes, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, HMG-CoA synthase, and farnesyl diphosphate (FPP) synthetase is partially overcome by the calcium ionophore A23187. Addition of A23187 to the human monocytic leukemia cell line THP-1 in the presence of fetal calf serum led to rapid increases in mRNA concentration of up to 40-fold for HMG-CoA synthase and 15-fold for HMG-CoA reductase with little or no change in FPP synthetase mRNA levels. Treatment of HepG2 cells with A23187 resulted in approximately 2-4-fold increases in the mRNA levels for these three enzymes. The increases in HMG-CoA synthase and HMG-CoA reductase mRNAs were maximal after treatment of THP-1 cells with 10-mu-g/ml A23187 for 3 h. The stimulation was blocked by actinomycin D but not by cycloheximide treatment. Ionophore treatment had no effect on the half-lives of the mRNAs for HMG-CoA reductase and HMG-CoA synthase. Surprisingly, the addition of A23187 to THP-1 cells incubated in the presence of 25-hydroxycholesterol and mevalonic acid also led to significant increases in the mRNA levels for HMG-CoA reductase and HMG-CoA synthase. Finally, the stimulation of these mRNA levels by A23187 was reduced in cells in which protein kinase C had been inactivated by preincubation of the cells with a phorbol ester. Taken together, these data suggest that A23187 treatment results in increased transcription of HMG-CoA reductase, HMG-CoA synthase, and, in some cell types, FPP synthetase by a mechanism that does not involve de novo protein synthesis. We speculate that A23187 treatment results in the modification of a trans-acting factor(s) which is common for the transcription of all these genes.	UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	WILKIN, DJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NCRR NIH HHS [RR 865] Funding Source: Medline; NHLBI NIH HHS [IT 32 HL-07412, HL-30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007412, P01HL030568] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BROWN MS, 1980, J LIPID RES, V21, P505; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE CF, 1987, PLASMA LIPOPROTEINS, P261; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; MEHRABIAN M, 1986, J BIOL CHEM, V261, P6249; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; POMPIDOU A, 1987, BIOCHEM BIOPH RES CO, V148, P435, DOI 10.1016/0006-291X(87)91130-2; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SKALNIK DG, 1985, J BIOL CHEM, V260, P1991; SMITH JR, 1988, J BIOL CHEM, V263, P18480; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TSUCHIYA S, 1982, CANCER RES, V42, P1530; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	23	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2831	2836						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346397				2022-12-25	WOS:A1992HB53200107
J	BARANSKI, TJ; CANTOR, AB; KORNFELD, S				BARANSKI, TJ; CANTOR, AB; KORNFELD, S			LYSOSOMAL-ENZYME PHOSPHORYLATION .1. PROTEIN RECOGNITION DETERMINANTS IN BOTH LOBES OF PROCATHEPSIN D-MEDIATE ITS INTERACTION WITH UDP-GLCNAC-LYSOSOMAL ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-D; N-ACETYLGLUCOSAMINE; OLIGOMERIC PROTEINS; OLIGOSACCHARIDES; GLYCOPROTEINS; BIOSYNTHESIS; FIBROBLASTS; INTERFACES; TRANSPORT; SURFACE	We have investigated the nature of a protein domain that is shared among lysosomal hydrolases and is recognized by UDP-GlcNAc:lysosomal enzyme N-acetyl-glucosamine-1-phosphotransferase, the initial enzyme in the biosynthesis of mannose 6-phosphate residues. Previously, elements of this recognition domain were identified using a chimeric protein approach. The combined substitution of two regions (amino acids 188-230, particularly lysine 203, and 265-292) from the carboxyl lobe of the lysosomal hydrolase cathepsin D into the homologous positions of the related secretory protein glycopepsinogen was sufficient to confer recognition by phosphotransferase and subsequent phosphorylation of the oligosaccharides when this chimeric protein was expressed in Xenopus oocytes. (Baranski, T. J., Faust, P. L., and Kornfeld, S. (1990) Cell 63, 281-291). The current study demonstrates that when these two regions are replaced in cathepsin D by the homologous glycopepsinogen amino acids, the resultant chimeric molecule is poorly phosphorylated. However, when either of these regions is substituted individually, the chimeric molecules are well phosphorylated. The phosphorylation of these latter chimeric proteins is dependent on the presence of procathepsin D amino lobe elements. By analyzing a series of chimeric proteins that contain all eight combinations of three consecutive segments of the entire amino lobe of procathepsin D, it was found that multiple regions of the amino lobe of cathepsin D enhance phosphorylation of the chimeric proteins. These elements may be part of an extended carboxyl lobe recognition domain or comprise a second independent recognition domain.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)				Cantor, Alan/0000-0002-5136-028X	NCI NIH HHS [CA08759] Funding Source: Medline; NIGMS NIH HHS [GM-07200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; LODISH HF, 1988, J BIOL CHEM, V263, P2107; Maniatis T., 1982, MOL CLONING; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; STEIN M, 1957, METHOD ENZYMOL, V3, P154; TAKAHASHI T, 1981, METHOD ENZYMOL, V80, P565; TANG J, 1978, NATURE, V271, P618, DOI 10.1038/271618a0; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P847; WAHEED A, 1982, J BIOL CHEM, V257, P2322	27	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23342	23348						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331081				2022-12-25	WOS:A1992JY16300097
J	NANDA, A; GUKOVSKAYA, A; TSENG, J; GRINSTEIN, S				NANDA, A; GUKOVSKAYA, A; TSENG, J; GRINSTEIN, S			ACTIVATION OF VACUOLAR-TYPE PROTON PUMPS BY PROTEIN-KINASE-C - ROLE IN NEUTROPHIL PH REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; CYTOPLASMIC PH; NA+/H+ EXCHANGE; PLASMA-MEMBRANE; TRANSPORT; CELLS; INHIBITOR; IONOPHORE; OXIDASE; ATPASES	Activated neutrophils undergo a large burst of metabolic acid generation, yet maintain their cytosolic pH (pH(i)) within physiological limits. To analyze the underlying regulatory mechanisms, pH(i) was measured fluorimetrically in suspensions of human neutrophils. In acid loaded but otherwise unstimulated cells, pH(i) recovered rapidly via Na+/H+ exchange. Upon Na+ removal, recovery from an imposed acid load was negligible. Phorbol ester activation of acidified cells induced a rapid recovery of pH(i) partly due to a Zn2+-sensitive H+-conductive pathway. A third component of the regulatory response was apparent in Na+-free media containing Zn2+. Acid extrusion through this alternate pathway was voltage sensitive and capable of translocating H+ equivalents against their electrochemical gradient. This active H+ transport was inhibited by N-ethylmaleimide, by N,N'-dicyclohexylcarbodiimide and by nanomolar doses of bafilomycins A1 or B1, suggesting the involvement of vacuolar (V)-type H+ pumps. Cytosolic alkalinization was accompanied by extracellular acidification, indicative of translocation of H+ equivalents across the surface membrane and consistent with the sensitivity of the alkalinization to changes in plasma membrane potential. The activity of the V-type H+ pumps was virtually undetectable in resting cells, becoming apparent only after treatment with phorbol esters or other, chemically unrelated agonists of protein kinase C. These H+ pumps are likely to play a role in pH(i) homeostasis during the metabolic burst that accompanies neutrophil activation during infection and inflammation.	HOSP SICK CHILDREN, RES INST, DIV CELL BIOL, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Gukovskaya, Anna/0000-0003-3737-5335				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BIDANI A, 1990, AM J PHYSIOL, V28, pC586; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BONNANO JA, 1991, AM J PHYSIOL, V260, pC618; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CALA PM, 1986, CURR TOP MEMBR TRANS, V26, P79; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; GRINSTEIN S, 1989, METHOD ENZYMOL, V173, P777; GURICH RW, 1989, AM J PHYSIOL, V257, pF777, DOI 10.1152/ajprenal.1989.257.5.F777; GURICH RW, 1991, J CLIN INVEST, V87, P1547, DOI 10.1172/JCI115167; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; NANDA A, 1991, Cellular Physiology and Biochemistry, V1, P65, DOI 10.1159/000154595; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SAWYER RG, 1991, ANN SURG, V213, P253, DOI 10.1097/00000658-199103000-00013; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; SIMCHOWITZ L, 1985, J BIOL CHEM, V260, P3248; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; WRIGHT DG, 1977, AM J PATHOL, V87, P273; ZHANG K, 1992, J BIOL CHEM, V267, P14539; ZHANG K, 1992, J BIOL CHEM, V267, P9701	33	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22740	22746						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331065				2022-12-25	WOS:A1992JY16300010
J	AKIYAMA, M; CROOKE, E; KORNBERG, A				AKIYAMA, M; CROOKE, E; KORNBERG, A			THE POLYPHOSPHATE KINASE GENE OF ESCHERICHIA-COLI - ISOLATION AND SEQUENCE OF THE PPK GENE AND MEMBRANE LOCATION OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; PROMOTERS; MAP	Polyphosphate kinase (PPK) catalyzes the reversible transfer of the terminal phosphate of ATP to form a long-chain polyphosphate (polyP) (Ahn, K., and Kornberg, A. (1990) J. Biol. Chem. 265, 11734-11739). The Escherichia coli gene (ppk) encoding PPK has been cloned, sequenced, and overexpressed (about 100-fold). The gene possesses an open reading frame for 687 amino acids (mass of 80,278 Da). PPK has been purified from overproducing cells after release from attachment to the cell outer membrane; the purified soluble PPK reassociates with cell membrane fractions. About 850 molecules of PPK are found in a wild type cell.			AKIYAMA, M (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM007581, R01GM007581] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07581] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KH, 1990, J BIOL CHEM, V265, P11734; AIBA H, 1981, J BIOL CHEM, V256, P1905; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANSORGE W, 1983, ELECTROPHORESIS 82, P235; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BAYER MH, 1982, J BACTERIOL, V149, P758, DOI 10.1128/JB.149.2.758-767.1982; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CSONKA LN, 1980, J BACTERIOL, V143, P529, DOI 10.1128/JB.143.1.529-530.1980; DIRHEIMER G, 1968, B SOC CHIM BIOL, V50, P1933; HARE JF, 1974, P NATL ACAD SCI USA, V71, P4843, DOI 10.1073/pnas.71.12.4843; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; ITO K, 1980, J BIOL CHEM, V255, P2123; KASSAVETIS GA, 1982, EMBO J, V1, P107, DOI 10.1002/j.1460-2075.1982.tb01132.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V20, P215, DOI 10.1016/0006-3002(56)90280-3; KORNBERG SR, 1957, BIOCHIM BIOPHYS ACTA, V26, P294, DOI 10.1016/0006-3002(57)90008-2; Kulaev IS, 1979, BIOCH INORGANIC POLY; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; OHTAKE H, 1985, WATER RES, V19, P1587, DOI 10.1016/0043-1354(85)90404-X; Osborn M J, 1974, Methods Enzymol, V31, P642; PEPIN CA, 1987, J BIOL CHEM, V262, P5223; REUSCH RN, 1989, P SOC EXP BIOL MED, V191, P377; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; Sambrook J, 1989, MOL CLONING LABORATO; SMITH JM, 1987, J BIOL CHEM, V262, P10565; SZYMONA M, 1977, ACTA BIOCHIM POL, V24, P133; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315	29	176	190	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22556	22561						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331061				2022-12-25	WOS:A1992JW71900088
J	SHAH, MM; GROVER, TA; BARR, DP; AUST, SD				SHAH, MM; GROVER, TA; BARR, DP; AUST, SD			ON THE MECHANISM OF INHIBITION OF THE VERATRYL ALCOHOL OXIDASE ACTIVITY OF LIGNIN PEROXIDASE H2 BY EDTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE-ROT FUNGUS; PHANEROCHAETE-CHRYSOSPORIUM; ENVIRONMENTAL-POLLUTANTS; STEADY-STATE; OXALIC-ACID; COMPOUND-II; OXIDATION; DEGRADATION; OXYGEN; PURIFICATION	The mechanism of inhibition of the veratryl alcohol oxidase activity of lignin peroxidase H2 (LiPH2) by EDTA was investigated. It was found that EDTA was decarboxylated and that cytochrome c, nitro blue tetrazolium, ferric iron, and molecular oxygen were reduced in a reaction mixture containing LiPH2, H2O2, veratryl alcohol, and EDTA. The reductive activity observed with LiPH2 followed first order kinetics with respect to the concentration of EDTA. Stoichiometry studies showed that in the presence of sufficient EDTA, 1.7 mol of ferric iron were reduced per mole of H2O2 added to the reaction mixture. Superoxide- and EDTA-derived radicals were detected by ESR spin trapping upon incubation of LiPH2 with H2O2, veratryl alcohol, and EDTA. The K(m) values of veratryl alcohol and H2O2 remained the same for both the oxidative and reductive activities of LiPH2. Reductive activity was also observed with LiPH2 and EDTA using other free radical mediators in the place of veratryl alcohol, such as 1,4-dimethoxybenzene, 1,2,3- and 1,2,4-trimethoxybenzenes, and 1,2,4,5-tetramethoxybenzene. EDTA reduced the cation radical of 1,2,4,5-tetramethoxybenzene formed by LiPH2 in the presence of H2O2. Hence, it is proposed that the apparent inhibition of the veratryl alcohol oxidase activity of LiPH2 by EDTA is due to the reduction of the veratryl alcohol cation radical intermediate back to veratryl alcohol by EDTA. The reduction of cytochrome c, nitro blue tetrazolium, ferric ion, and molecular oxygen appears to be mediated by the EDTA radical formed by reduction of the veratryl alcohol cation radical.	UTAH STATE UNIV, CTR BIOTECHNOL, LOGAN, UT 84322 USA	Utah System of Higher Education; Utah State University					NIEHS NIH HHS [ES04922] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004922] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKAMATSU Y, 1990, FEBS LETT, V269, P261, DOI 10.1016/0014-5793(90)81169-O; ANDERSON NH, 1971, J CHEM SOC B, P993, DOI 10.1039/j29710000993; ARJMAND M, 1985, J AGR FOOD CHEM, V33, P1055, DOI 10.1021/jf00066a011; AUST SD, 1990, MICROB ECOL, V20, P197, DOI 10.1007/BF02543877; BANERJEE RK, 1989, J BIOL CHEM, V264, P9188; BANERJEE RK, 1986, J BIOL CHEM, V261, P592; BARLEV SS, 1981, BIOCHEM BIOPH RES CO, V99, P373, DOI 10.1016/0006-291X(81)91755-1; BARR DP, 1992, ARCH BIOCHEM BIOPHYS, V298, P480, DOI 10.1016/0003-9861(92)90438-3; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUMPUS JA, 1985, SCIENCE, V228, P1434, DOI 10.1126/science.3925550; DEMELO PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P34; FAISON BD, 1983, APPL ENVIRON MICROB, V46, P1140, DOI 10.1128/AEM.46.5.1140-1145.1983; FIFE DJ, 1979, PHOTOCHEM PHOTOBIOL, V29, P43, DOI 10.1111/j.1751-1097.1979.tb09257.x; FORNEY LJ, 1982, J BIOL CHEM, V257, P1455; GILARDI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P129, DOI 10.1016/0167-4838(90)90055-K; GOLD MH, 1983, PHOTOCHEM PHOTOBIOL, V38, P617; GREENWALD RA, 1985, CRC HDB METHODS OXYG, P121; GROVER TA, 1987, FREE RADICAL BIO MED, V3, P27, DOI 10.1016/0891-5849(87)90036-0; HAEMMERLI SD, 1986, J BIOL CHEM, V261, P6900; HALL PL, 1980, ENZYME MICROB TECH, V2, P170, DOI 10.1016/0141-0229(80)90043-5; HAMMEL KE, 1986, J BIOL CHEM, V261, P6948; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; HARVEY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P59, DOI 10.1016/0167-4838(89)90062-9; HEELIS PF, 1982, CHEM SOC REV, V11, P15, DOI 10.1039/cs9821100015; KELLEY RL, 1986, J BACTERIOL, V166, P269, DOI 10.1128/jb.166.1.269-274.1986; KERNSTEN PJ, 1985, J BIOL CHEM, V260, P2609; KIRK TK, 1978, ARCH MICROBIOL, V117, P277, DOI 10.1007/BF00738547; METODIEWA D, 1992, ARCH BIOCHEM BIOPHYS, V296, P27, DOI 10.1016/0003-9861(92)90540-D; PHILIP JK, 1987, J BACTERIOL, V169, P2195; POPP JL, 1991, ARCH BIOCHEM BIOPHYS, V288, P145, DOI 10.1016/0003-9861(91)90176-J; POPP JL, 1990, BIOCHEMISTRY-US, V29, P10475, DOI 10.1021/bi00498a008; SAWYER DT, 1984, OXYGEN RADICALS CHEM; SHAH MM, 1991, ARCH BIOCHEM BIOPHYS, V290, P173, DOI 10.1016/0003-9861(91)90604-H; SHIMADA MF, 1981, ARCH MICROBIOL, V1129, P321; SHOEMAKER HE, 1990, RECL TRAV CHIM PAY B, V109, P255; TAKAO S, 1965, APPL MICROBIOL, V13, P732, DOI 10.1128/AEM.13.5.732-737.1965; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; TUISEL H, 1990, ARCH BIOCHEM BIOPHYS, V279, P158, DOI 10.1016/0003-9861(90)90476-F; TUISEL H, 1991, ARCH BIOCHEM BIOPHYS, V293, P287; WARIISHI H, 1991, J BIOL CHEM, V266, P20694; WAYNER DDM, 1988, J AM CHEM SOC, V110, P132, DOI 10.1021/ja00209a021; YAMAZAKI I, 1960, ARCH BIOCHEM BIOPHYS, V86, P294, DOI 10.1016/0003-9861(60)90421-5	43	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21564	21569						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328238				2022-12-25	WOS:A1992JV01100048
J	LEMAS, MV; TAKEYASU, K; FAMBROUGH, DM				LEMAS, MV; TAKEYASU, K; FAMBROUGH, DM			THE CARBOXYL-TERMINAL-161 AMINO-ACIDS OF THE NA,K-ATPASE ALPHA-SUBUNIT ARE SUFFICIENT FOR ASSEMBLY WITH THE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; NA+-K+-ATPASE; SKELETAL-MUSCLE; INTRACELLULAR-TRANSPORT; SODIUM-PUMP; SARCOPLASMIC-RETICULUM; EXPRESSION; NA+,K+-ATPASE; CELLS; CA-2+-ATPASE	Chimeric cDNAs encoding regions of the Na,K-ATPase alpha-subunit and a sarcoplasmic reticulum Ca2+-ATPase were constructed and expressed together with the avian Na,K-ATPase beta-subunit cDNA in COS-1 cells to determine which regions of the alpha-subunit are required for assembly with the beta-subunit. Assembly was assayed by immune precipitation of the chimeric subunit with a monoclonal antibody to the avian beta-subunit. A chimera composed of the amino-terminal two-thirds of the Na,K-ATPase and carboxyl-terminal one-third of the Ca2+-ATPase did not assemble with the avian beta-subunit. In contrast, the reciprocal chimera, containing the carboxyl-terminal one-third of the Na,K-ATPase, assembled with the beta-subunit. A third chimera, in which 161 amino acids of the Na,K-ATPase carboxyl terminus replaced the corresponding amino acids of the Ca2+-ATPase carboxyl terminus, also assembled with the beta-subunit. These results suggest that the aminoacyl residues of the Na,K-ATPase alpha-subunit critical for subunit assembly lie within the carboxyl-terminal 16% of the sequence.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR BIOTECHNOL, COLUMBUS, OH 43210 USA	Johns Hopkins University; Ohio State University; Ohio State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044373, R21GM044373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-27867] Funding Source: Medline; NIGMS NIH HHS [GM-44373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; FAMBROUGH DM, 1983, J BIOL CHEM, V258, P3926; FAMBROUGH DM, 1988, TRENDS NEUROSCI, V11, P325, DOI 10.1016/0166-2236(88)90096-3; FAMBROUGH DM, 1983, COLD SPRING HARB SYM, V48, P297, DOI 10.1101/SQB.1983.048.01.032; FAMBROUGH DM, 1992, IN PRESS CURR TOP ME, V40; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAPRIELIAN Z, 1987, DEV BIOL, V124, P490, DOI 10.1016/0012-1606(87)90502-1; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; KAWAKAMI K, 1988, J BIOCHEM-TOKYO, V103, P54, DOI 10.1093/oxfordjournals.jbchem.a122239; KONE BC, 1990, SODIUM PUMP RECENT D, V46, P263; KURT AE, 1992, P NATL ACAD SCI USA, V89, P2834; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LUCKIE DB, 1992, BIOPHYS J, V62, P220, DOI 10.1016/S0006-3495(92)81807-6; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NOGUCHI S, 1990, BIOCHIM BIOPHYS ACTA, V1023, P247, DOI 10.1016/0005-2736(90)90420-S; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; TAKEYASU K, 1990, AM J PHYSIOL, V259, pC619, DOI 10.1152/ajpcell.1990.259.4.C619; TAKEYASU K, 1989, CURR TOP MEMBR TRANS, V34, P143; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009	38	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20987	20991						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328216				2022-12-25	WOS:A1992JT97800075
J	PEPPER, MS; MATSUMOTO, K; NAKAMURA, T; ORCI, L; MONTESANO, R				PEPPER, MS; MATSUMOTO, K; NAKAMURA, T; ORCI, L; MONTESANO, R			HEPATOCYTE GROWTH-FACTOR INCREASES UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (U-PA) AND U-PA RECEPTOR EXPRESSION IN MADIN-DARBY CANINE KIDNEY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; C-MET; INVITRO; IDENTIFICATION; MORPHOGENESIS; INDUCTION; MONOCYTES; BINDING	We have recently demonstrated that fibroblast-conditioned medium induces Madin-Darby canine kidney (MDCK) epithelial cells to form branching tubules when grown in three-dimensional collagen or fibrin gels (Montesano, R., Schaller, G., and Orci, L. (1991) Cell 66, 697-711), and that this morphogenetic effect is mediated by hepatocyte growth factor (HGF), also known as scatter factor (Montesano, R., Matsumoto, K., Nakamura, T., and Orci, L. (1991) Cell 67, 901-908). In fibrin gels, this effect is inhibited by addition of exogenous serine protease inhibitors, which suggests a role for plasminogen activators (PAs) in the matrix remodeling required for tubulogenesis. In the studies reported in this paper, we have investigated the effect of fibroblast-conditioned medium (CM) and HGF on the production of PAs by MDCK cells. We have found that urokinase-type PA (u-PA) activity and mRNA are increased 4.9-fold by CM from human MRC-5 fibroblasts, which has tubulogenic activity, but not by CM from human Detroit-550 fibroblasts, which lacks tubulogenic activity. The u-PA inductive property of MRC-5 CM was completely inhibited by preincubation with antibodies to recombinant human HGF (rhHGF). Exogenously added rhHGF also increased u-PA activity and mRNA 5.9-fold in MDCK cells, with an optimal effect at approximately 10 ng/ml. MRC-5 CM also increased u-PA receptor mRNA 34.9-fold in MDCK cells, an effect which was inhibited by 71% by preincubating the CM with antibodies to rhHGF, and which was mimicked by exogenously added rhHGF (31.3-fold increase). These results demonstrate that HGF, which induces tubulogenesis by MDCK cells in vitro, also increases u-PA and u-PA receptor expression in these cells. Taken together with our previous observations, this suggests that the resulting increase in extracellular proteolysis, appropriately localized to the cell surface, is required for epithelial morphogenesis.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN	Kyushu University	PEPPER, MS (corresponding author), UNIV GENEVA,MED CTR,DEPT MORPHOL,INST HISTOL & EMBRYOL,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.		Pepper, Michael S./M-6143-2014	Pepper, Michael S./0000-0001-6406-2380				Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSO N, 1986, J BIOL CHEM, V261, P9309; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHALOPOULOS GK, 1992, HEPATOLOGY, V15, P149, DOI 10.1002/hep.1840150125; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSALLI JD, 1977, CELL, V11, P695, DOI 10.1016/0092-8674(77)90086-1; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	34	215	218	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20493	20496						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328201				2022-12-25	WOS:A1992JR85800115
J	FALCONE, G; PROVENZANO, C; ALEMA, S; TATO, F				FALCONE, G; PROVENZANO, C; ALEMA, S; TATO, F			TRANSFORMATION OF NIH3T3 CELLS BY ROUS-SARCOMA VIRUS OCCURS WITH HIGH-EFFICIENCY IN THE ABSENCE OF PROVIRAL REARRANGEMENTS OR AMPLIFICATION	ONCOGENE			English	Article							RAT-CELLS; INTEGRATION SITES; RETROVIRUS INTEGRATION; GENE AMPLIFICATION; DNA; EXPRESSION; CHROMATIN; REGIONS; MAP	NIH3T3 cells could be transformed by a mammaltropic strain of Rous sarcoma virus (RSV) with an efficiency 10(3) times greater than that observed in Balb/c 3T3 cells or other mammalian cell lines and almost identical to that of chick embryo fibroblasts. In infected NIH3T3 cells a single, properly integrated, provirus was sufficient to induce focus formation; moreover, kinase activity of pp60v-src and tyrosine phosphorylation of cellular proteins could be detected very soon after infection in the majority of cells. On the other hand, in transformed foci from RSV-infected Balb/c 3T3 cells both rearrangements and amplification of proviral sequences were frequently detected. Accordingly, expression of pp60v-src and ensuing tyrosine phosphorylation of cellular proteins occurred, at high levels, only in a minority of the infected cells. Furthermore, by using a murine retrovirus carrying the v-src oncogene and an independent selectable marker, we found that Balb/c 3T3 cells were transformed with a 100-fold lower efficiency than NIH3T3 cells, yet the majority of infected untransformed Balb/c 3T3 cells expressed active pp60v-src. These findings are consistent with the existence in most mammalian cell lines of a major restriction to v-src-induced transformation, operating at the level of proviral expression, that is apparently absent in NIH3T3 cells.	UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-00185 ROME,ITALY	Sapienza University Rome	FALCONE, G (corresponding author), CNR,IST BIOL CELLULARE,VIALE MARX 43,I-00137 ROME,ITALY.		Falcone, Germana/A-3735-2016	Falcone, Germana/0000-0002-3508-7623; Alema, Stefano/0000-0002-9869-6354				AKROYD J, 1987, ONCOGENE, V1, P347; ALTANER C, 1970, VIROLOGY, V70, P118; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOETTIGER D, 1975, J VIROL, V15, P108, DOI 10.1128/JVI.15.1.108-114.1975; BOETTIGER D, 1974, VIROLOGY, V62, P522, DOI 10.1016/0042-6822(74)90412-7; BOULTER CA, 1988, ONCOGENE, V2, P207; CHISWELL DJ, 1982, NUCLEIC ACIDS RES, V10, P3967, DOI 10.1093/nar/10.13.3967; CHISWELL DJ, 1982, VIROLOGY, V116, P428, DOI 10.1016/0042-6822(82)90137-4; COPELAND NG, 1979, CELL, V17, P993, DOI 10.1016/0092-8674(79)90338-6; DENG CT, 1977, VIROLOGY, V76, P313, DOI 10.1016/0042-6822(77)90305-1; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; FINCHAM VJ, 1991, J VIROL, V65, P461, DOI 10.1128/JVI.65.1.461-463.1991; GILLESPIE DAF, 1985, CELL, V41, P279, DOI 10.1016/0092-8674(85)90081-9; GILMER TM, 1987, CANCER RES, V47, P4663; GREEN AR, 1986, EMBO J, V5, P707, DOI 10.1002/j.1460-2075.1986.tb04271.x; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniatis T, 1989, DECONTAMINATION DILU; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARIANI BD, 1984, J BIOL CHEM, V259, P1901; MOOSLEHNER K, 1990, J VIROL, V64, P3056, DOI 10.1128/JVI.64.6.3056-3058.1990; ROGUEL N, 1986, BIOCHIM BIOPHYS ACTA, V908, P12; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; RYNDITCH A, 1991, GENE, V106, P165, DOI 10.1016/0378-1119(91)90196-I; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; TATO F, 1978, VIROLOGY, V88, P71, DOI 10.1016/0042-6822(78)90111-3; VARMUS HE, 1975, SPR COLD HARB S QUAN, V39, P118; WEISS R, 1985, RNA TUMOR VIRUSES MO; Wyke J A, 1975, Cold Spring Harb Symp Quant Biol, V39 Pt 2, P897; WYKE JA, 1980, VIROLOGY, V106, P217, DOI 10.1016/0042-6822(80)90246-9	31	9	9	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1913	1920						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328985				2022-12-25	WOS:A1992JP42400003
J	CHEIFETZ, S; BELLON, T; CALES, C; VERA, S; BERNABEU, C; MASSAGUE, J; LETARTE, M				CHEIFETZ, S; BELLON, T; CALES, C; VERA, S; BERNABEU, C; MASSAGUE, J; LETARTE, M			ENDOGLIN IS A COMPONENT OF THE TRANSFORMING GROWTH-FACTOR-BETA RECEPTOR SYSTEM IN HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING-PROTEINS; SURFACE PROTEINS; IDENTIFICATION; EXPRESSION; PURIFICATION; ANTIGEN; CLONING; KINASE	Endoglin, a dimeric membrane glycoprotein expressed at high levels on human vascular endothelial cells, shares regions of sequence identity with beta-glycan, a major binding protein for transforming growth factor-beta (TGF-beta) that co-exists with TGF-beta receptors I and II in a variety of cell lines but is low or absent in endothelial cells. We have examined whether endoglin also binds TGF-beta and demonstrate here that the major TGF-beta1-binding protein co-existing with TGF-beta receptors I and II on human umbilical vein endothelial cells is endoglin, as determined by specific immunoprecipitation of endoglin affinity-labeled with I-125-TGF-beta. Furthermore, endoglin ectopically expressed in COS cells binds TGF-beta1. Competition affinity-labeling experiments showed that endoglin binds TGF-beta1 (K(D) approximately 50 pM) and TGF-beta3 with high affinity but fails to bind TGF-beta2. This difference in affinity of endoglin for the TGF-beta isoforms is in contrast to beta-glycan which recognizes all three isoforms. TGF-beta however is binding with high affinity to only a small fraction of the available endoglin molecules, suggesting that some rate-limiting event is required to sustain TGF-beta binding to endoglin.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,BOX 116,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN; HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,TORONTO M5G LX8,ONTARIO,CANADA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Bellón, Teresa/ABF-4916-2020; Calés, Carmela/AAB-1595-2019; Bernabeu, Carmelo/L-3226-2014; Bernabeu, Carmelo/P-4662-2019	Bellón, Teresa/0000-0002-0138-6879; Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Cales, Carmela/0000-0002-6987-2259; Massague, Joan/0000-0001-9324-8408				ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BUHRING HJ, 1991, LEUKEMIA, V5, P841; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; Fafeur V, 1990, GROWTH FACTORS, V3, P237, DOI 10.3109/08977199009043908; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; GOUGOS A, 1988, J IMMUNOL, V141, P1935; GOUGOS A, 1992, J INT IMMUNOL, V4, P83; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MACKAY K, 1990, J BIOL CHEM, V265, P9351; MACKAY K, 1991, J BIOL CHEM, V266, P9907; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MERWIN JR, 1991, AM J PATHOL, V138, P37; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; QUACKENBUSH EJ, 1985, J IMMUNOL, V134, P1276; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1992, J BIOL CHEM, V267, P1048; WANG XF, 1991, CELL, V67, P796	31	706	739	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19027	19030						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326540				2022-12-25	WOS:A1992JP59300002
J	OH, Y; MATALON, S; KLEYMAN, TR; BENOS, DJ				OH, Y; MATALON, S; KLEYMAN, TR; BENOS, DJ			BIOCHEMICAL-EVIDENCE FOR THE PRESENCE OF AN AMILORIDE BINDING-PROTEIN IN ADULT ALVEOLAR TYPE-II PNEUMOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER MEMBRANE-VESICLES; EPITHELIAL SODIUM-CHANNEL; ISOLATED RAT LUNG; ION-TRANSPORT; NA+ CHANNELS; CELLS; LOCALIZATION; ANTIBODIES; ANALOGS; ABSORPTION	An amiloride binding protein in adult rat and rabbit alveolar type II (ATII) cells was characterized using three different antibodies against epithelial Na+ channel proteins. We found that 1) polyclonal antibodies raised against epithelial Na+ channel proteins from bovine kidney cross-react with a 135-kDa protein in ATII membrane vesicles on Western blots; 2) using the photoreactive amiloride analog, 2'-methoxy-5'-nitrobenzamil (NMBA), in combination with anti-amiloride antibodies, we found that NMBA specifically labeled the same M(r) protein; and 3) monoclonal anti-idiotypic antibodies directed against anti-amiloride antibodies also recognized this same M(r) protein on Western blots. We also demonstrated a low benzamil affinity binding site (apparent K(d) = 370 nM) in rabbit ATII cell membranes and both high and low benzamil affinity binding sites (apparent K(d) = 6 nM and 230 nM) in bovine kidney membranes using [H-3]Br-benzamil as a ligand. Pharmacological inhibitory profiles for displacing bound [H-3]Br-benzamil were also different between ATII cells and bovine kidneys. These observations indicate that adult ATII pneumocytes express a population of epithelial Na+ channels having a low affinity to benzamil and amiloride and a pharmacological inhibitory profile different from that in bovine kidney.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT ANESTHESIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL 35294; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; VET AFFAIRS MED CTR,PHILADELPHIA,PA 19104	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031197, R01HL031197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK037206] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31197] Funding Source: Medline; NIDDK NIH HHS [DK-37206] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMSON IYR, 1974, LAB INVEST, V30, P35; ASHER C, 1987, J BIOL CHEM, V262, P8566; BARBRY P, 1989, BIOCHEMISTRY-US, V28, P3744, DOI 10.1021/bi00435a018; BASSET G, 1987, J PHYSIOL-LONDON, V384, P325, DOI 10.1113/jphysiol.1987.sp016457; BASSET G, 1987, J PHYSIOL-LONDON, V384, P311, DOI 10.1113/jphysiol.1987.sp016456; Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1992, IN PRESS REV PHYSL B; BRIDGES RJ, 1988, AM J PHYSIOL, V254, pC484, DOI 10.1152/ajpcell.1988.254.4.C484; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC67, DOI 10.1152/ajpcell.1989.256.1.C67; BROWN D, 1989, AM J PHYSIOL, V256, pF366, DOI 10.1152/ajprenal.1989.256.2.F366; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; CHEEK JM, 1989, AM J PHYSIOL, V256, pC688, DOI 10.1152/ajpcell.1989.256.3.C688; CRAPO JD, 1978, LAB INVEST, V39, P640; DOBBS LG, 1990, AM J PHYSIOL, V258, pL134, DOI 10.1152/ajplung.1990.258.4.L134; EVANS MJ, 1975, EXP MOL PATHOL, V22, P142, DOI 10.1016/0014-4800(75)90059-3; GARTY H, 1984, J MEMBRANE BIOL, V82, P269, DOI 10.1007/BF01871636; GOODMAN BE, 1987, J APPL PHYSIOL, V62, P2460, DOI 10.1152/jappl.1987.62.6.2460; HACKNEY CM, 1991, SCANNING MICROSCOPY, V5, P741; HAIES DM, 1981, AM REV RESPIR DIS, V123, P533; KLEYMAN TR, 1986, AM J PHYSIOL, V250, pC165, DOI 10.1152/ajpcell.1986.250.1.C165; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P51; MASON RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6033, DOI 10.1073/pnas.79.19.6033; MATALON S, 1991, AM J PHYSIOL, V260, pL90, DOI 10.1152/ajplung.1991.260.2.L90; MATALON S, 1991, AM J PHYSIOL, V261, pC727, DOI 10.1152/ajpcell.1991.261.5.C727; MATALON S, 1992, AM J PHYSIOL, V262, pC1228, DOI 10.1152/ajpcell.1992.262.5.C1228; MORAN A, 1988, J BIOL CHEM, V263, P19586; NIELSON DW, 1990, AM J PHYSIOL, V258, pL215, DOI 10.1152/ajplung.1990.258.4.L215; NIJJAR MS, 1980, BIOCHIM BIOPHYS ACTA, V600, P238, DOI 10.1016/0005-2736(80)90429-0; OH Y, 1992, IN PRESS AMILORIDE I; SARIBANSOHRABY S, 1986, BIOCHEMISTRY-US, V25, P4639, DOI 10.1021/bi00364a028; SIMON SA, 1992, IN PRESS J ELECTRON; SMITH PR, 1991, ANNU REV PHYSIOL, V53, P509, DOI 10.1146/annurev.ph.53.030191.002453; SORSCHER EJ, 1988, AM J PHYSIOL, V255, pC835, DOI 10.1152/ajpcell.1988.255.6.C835; TIERNEY DF, 1989, AM J PHYSIOL, V257, pL1, DOI 10.1152/ajplung.1989.257.2.L1; TOUSSON A, 1989, J CELL SCI, V93, P349; [No title captured]	41	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18498	18504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326526				2022-12-25	WOS:A1992JN50200042
J	REPASKE, DR; SWINNEN, JV; JIN, SLC; VANWYK, JJ; CONTI, M				REPASKE, DR; SWINNEN, JV; JIN, SLC; VANWYK, JJ; CONTI, M			A POLYMERASE CHAIN-REACTION STRATEGY TO IDENTIFY AND CLONE CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE CDNAS - MOLECULAR-CLONING OF THE CDNA-ENCODING THE 63-KDA CALMODULIN-DEPENDENT PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY CAMP PHOSPHODIESTERASE; AMINO-ACID-SEQUENCE; DROSOPHILA DUNCE+ GENE; PROTEOLYTIC ACTIVATION; MESSENGER-RNA; ALPHA-SUBUNIT; BOVINE BRAIN; IDENTIFICATION; PHYTOHEMAGGLUTININ; ISOZYMES	Multiple isozymes of cyclic nucleotide phosphodiesterases (PDEs) are expressed simultaneously in mammalian tissues. To identify and clone these PDEs, a polymerase chain reaction (PCR) strategy was developed using degenerate oligonucleotide primers designed to hybridize with highly conserved PDE DNA domains. Both known and novel PDEs were cloned from rat liver, the mouse K30a-3.3 lymphoma cell line, and a human hypothalamus cDNA library, demonstrating that these PCR primers can be used to amplify the cDNA of multiple PDE isozymes. One unique mouse PDE clone was found to encode a polypeptide identical with the corresponding portion of the bovine brain 63-kDa calmodulin-dependent PDE as reported in the companion article (Bentley, J. K., Kadlecek, A., Sherbert, C. H., Seger, D., Sonnenburg, W. K., Charbonneau, H., Novack, J. P., and Beavo, J. A. (1992) J. Biol. Chem. 267, 18676-18682). This mouse clone was used as a probe to screen a rat brain cDNA library for a full-length clone. The conceptual translation of the nucleotide sequence of the resulting rat clone has an open reading frame of 535 amino acids and maintains a high degree of homology with the bovine 63-kDa calmodulin-dependent PDE, indicating that this protein is likely to be the rat homolog of the 63-kDa calmodulin-dependent PDE. Expression of the full-length clone in Escherichia coli yielded a cGMP hydrolyzing activity that was stimulated severalfold by calmodulin. Northern blot analysis demonstrated that the mRNA encoding this PDE is highly expressed in rat brain and also in the S49.1 T-lymphocyte cell line. These data demonstrate that the PCR method described is a viable strategy to isolate cDNA clones of known and novel members of different families of PDE isozymes. Molecular cloning of these PDEs will provide valuable tools for investigating the roles of these isozymes in regulation of intracellular concentrations of the cyclic nucleotides.	UNIV N CAROLINA, DEPT PEDIAT, REPROD BIOL LABS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DIV PEDIAT ENDOCRINOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Swinnen, Johannes V/AAA-2214-2022; Repaske, David/W-5603-2019; Repaske, David/E-3939-2011	Swinnen, Johannes V/0000-0002-7720-5077; Repaske, David/0000-0002-5417-0967; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007129] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline; NIDDK NIH HHS [5 T32 DK07129] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; Beavo J., 1990, CYCLIC NUCLEOTIDE PH, P3; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BROTHERS VM, 1982, J BIOL CHEM, V257, P9349; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; EPSTEIN PM, 1984, ADV CYCLIC NUCL PROT, V16, P303; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P117; Gillespie P.G., 1990, CYCLIC NUCLEOTIDE PH, P163; HOUSLAY MD, 1990, CYCLIC NUCLEOTIDE PH, P185; HURWITZ RL, 1990, J BIOL CHEM, V265, P8901; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; RALPH P, 1973, J IMMUNOL, V110, P1470; RALPH P, 1973, J NATL CANCER I, V51, P883, DOI 10.1093/jnci/51.3.883; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; TANAKA T, 1991, SEC MESS PHOSPHOPROT, V13, P87; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TRONG HL, 1990, BIOCHEMISTRY-US, V29, P10280, DOI 10.1021/bi00496a018; Wang J.H., 1990, CYCLIC NUCLEOTIDE PH, P19	38	55	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18683	18688						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326532				2022-12-25	WOS:A1992JN50200067
J	NISHIKAWA, A; IHARA, Y; HATAKEYAMA, M; KANGAWA, K; TANIGUCHI, N				NISHIKAWA, A; IHARA, Y; HATAKEYAMA, M; KANGAWA, K; TANIGUCHI, N			PURIFICATION, CDNA CLONING, AND EXPRESSION OF UDP-N-ACETYLGLUCOSAMINE - BETA-D-MANNOSIDE BETA-1,4N-ACETYLGLUCOSAMINYLTRANSFERASE-III FROM RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULL-LENGTH CDNA; GLYCOPROTEIN-SYNTHESIS; LINKED OLIGOSACCHARIDES; LIVER CARCINOGENESIS; HEPATOMA TISSUES; MESSENGER-RNA; SUGAR CHAINS; HEN OVIDUCT; CELLS; SEQUENCE	UDP-N-acetylglucosamine:beta-D-mannoside beta-1,4N-acetylglucosaminyltransferase III (GnT-III: EC 2.4.1.144) catalyzes the addition of N-acetylglucosamine in beta-1-4 linkage to the beta-linked mannose of the trimannosyl core of N-linked sugar chains. The enzyme has been purified over 153,000-fold in 1.5% yield from a Triton X-100 extract of rat kidney by fractionation procedures utilizing QAE-Sepharose, Cu2+-chelating Sepharose, and affinity chromatography on UDP-hexanolamine and substrate-conjugated Sepharose. The purified protein migrates as one major and one minor band with apparent molecular masses of 62 kDa and 52 kDa, respectively. The purified enzyme was digested with trypsin, and the amino acid sequences of four peptides were determined. Oligonucleotide primers were designed according to those amino acid sequences and used in the polymerase chain reaction. Screening for the cDNA for GnT-III was carried out by plaque hybridization using a rat kidney cDNA library (lambda-gt10) and a polymerase chain reaction product as the probe. Rat kidney GnT-III has 536 amino acids and three putative N-glycosylation sites. There is no sequence homology to other previously cloned glycosyltransferases, but the enzyme appears to be a type II transmembrane protein like the other glycosyltransferases. The GnT-III activity in transiently transfected COS-1 cells was found to be about 500-3600-fold as compared to that in non- or mock-transfected cells.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN; INST MOLEC & CELLULAR BIOL,DIV MOLEC BIOL,SUITA,OSAKA 565,JAPAN; MIYAZAKI MED COLL,DEPT BIOCHEM,MIYAZAKI 88916,JAPAN	Osaka University; University of Miyazaki			Taniguchi, Naoyuki/I-4182-2014; Nishikawa, Atsushi/E-6766-2013; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Nishikawa, Atsushi/0000-0003-4325-1160; 				BAENZIGER J, 1974, J BIOL CHEM, V249, P7260; BARKER R, 1972, J BIOL CHEM, V247, P7135; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; CARVER JP, 1981, BIOCHEMISTRY-US, V20, P6600, DOI 10.1021/bi00526a013; CARVER JP, 1987, PURE APPL CHEM, V59, P1465, DOI 10.1351/pac198759111465; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FUJII S, 1990, J BIOL CHEM, V265, P6009; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; IRIMURA T, 1981, BIOCHEMISTRY-US, V20, P560, DOI 10.1021/bi00506a018; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOENDERMAN AHL, 1987, FEBS LETT, V222, P42, DOI 10.1016/0014-5793(87)80188-6; KOENDERMAN AHL, 1989, EUR J BIOCHEM, V181, P651, DOI 10.1111/j.1432-1033.1989.tb14772.x; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NARASIMHAN S, 1986, CARBOHYD RES, V149, P65, DOI 10.1016/S0008-6215(00)90370-7; NARASIMHAN S, 1985, BIOCHEMISTRY-US, V24, P1694, DOI 10.1021/bi00328a019; NARASIMHAN S, 1988, BIOCHEM CELL BIOL, V66, P889, DOI 10.1139/o88-101; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; PASCALE R, 1989, CARCINOGENESIS, V10, P961, DOI 10.1093/carcin/10.5.961; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WIENSTEIN J, 1987, J BIOL CHEM, V262, P17735; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAMASHITA K, 1983, CANCER RES, V43, P5059	48	176	183	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18199	18204						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325461				2022-12-25	WOS:A1992JM22300109
J	ELIAS, P; GUSTAFSSON, CM; HAMMARSTEN, O; STOW, ND				ELIAS, P; GUSTAFSSON, CM; HAMMARSTEN, O; STOW, ND			STRUCTURAL ELEMENTS REQUIRED FOR THE COOPERATIVE BINDING OF THE HERPES-SIMPLEX VIRUS ORIGIN BINDING-PROTEIN TO ORIS RESIDE IN THE N-TERMINAL PART OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; VIRAL-DNA REPLICATION; TYPE-1 ORIGIN; SV40 ORIGIN; UL9 PROTEIN; SEQUENCE; ANTIGEN; SITES; SP1; INITIATION	The origin binding protein (OBP) of herpes simplex virus type 1 is required to activate a viral origin of replication in vivo. We have used intact OBP as well as a truncated form of the protein expressed in Escherichia coli to investigate the protein-protein interactions, as well as the protein-DNA interactions involved in the formation of a nucleoprotein complex at a viral origin of replication (oriS) in vitro. The salient findings demonstrate that the N-terminal part of OBP is required for the cooperative binding of OBP to three sites (boxes I, II, and III) within oriS. A detailed model for the interaction of OBP with the viral origins of replication oriS and oriL is presented.	INST VIROL,MRC,VIROL UNIT,GLASGOW G11 5JR,SCOTLAND	University of Glasgow	ELIAS, P (corresponding author), UNIV GOTEBORG,DEPT MED BIOCHEM,MEDICINAREGATAN 9,S-41390 GOTHENBURG,SWEDEN.		Hammarsten, Ola/A-2791-2012	Gustafsson, Claes/0000-0003-3531-8468				ARNDTJOVIN DJ, 1975, EUR J BIOCHEM, V54, P411, DOI 10.1111/j.1432-1033.1975.tb04151.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; DABROWSKI CE, 1991, J VIROL, V65, P3140, DOI 10.1128/JVI.65.6.3140-3150.1991; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB S, 1991, J VIROL, V65, P2829, DOI 10.1128/JVI.65.6.2829-2838.1991; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HERNANDEZ TR, 1991, J VIROL, V65, P1649, DOI 10.1128/JVI.65.3.1649-1652.1991; HODGMAN TC, 1988, NATURE, V333, P578, DOI 10.1038/333578a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; Kornberg A., 1992, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; RABKIN SD, 1991, P NATL ACAD SCI USA, V88, P10946, DOI 10.1073/pnas.88.23.10946; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STOW ND, 1983, VIROLOGY, V130, P427, DOI 10.1016/0042-6822(83)90097-1; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; WONG SW, 1991, J VIROL, V65, P2601, DOI 10.1128/JVI.65.5.2601-2611.1991; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	35	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17424	17429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324937				2022-12-25	WOS:A1992JL05300103
J	JORDANOV, J; COURTOISVERNIQUET, F; NEUBURGER, M; DOUCE, R; DIAKUN, G				JORDANOV, J; COURTOISVERNIQUET, F; NEUBURGER, M; DOUCE, R; DIAKUN, G			STRUCTURAL INVESTIGATIONS BY EXTENDED X-RAY ABSORPTION FINE-STRUCTURE SPECTROSCOPY OF THE IRON CENTER OF MITOCHONDRIAL ACONITASE IN HIGHER-PLANT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DOUBLE-RESONANCE SPECTROSCOPY; SULFUR CLUSTERS; AZOTOBACTER-VINELANDII; DESULFOVIBRIO-GIGAS; <4FE-4S>+ CLUSTER; FERREDOXIN-II; EXAFS; PROTEINS; BINDING; INACTIVATION	We have obtained iron K-edge extended x-ray absorption fine structure spectra of the plant mitochondrial aconitase in its active state, in the presence (aconitase (+)) and absence (aconitase (-)) of the substrate citrate. Analysis of the data indicates that oxygens are present in the first coordination shell, at an average Fe-O distance of 1.96/1.98 angstrom (aconitase (+)/aconitase(-)). Part of these oxygens is provided by the citrate, which binds at 1.99 angstrom from the iron in aconitase (+). The second shell (sulfur) contribution is split and is consistent with Fe-S distances of 2.30/2.29 and 2.56/2.59 angstrom, and the third shell (iron) is consistent with an Fe-Fe distance of 2.83/2.84 angstrom. Both Fe-S and Fe-Fe distances are longer than similar distances found in most Fe-S centers. A strong scattering at approximately 5 angstrom has been identified as originating from an iron atom which is near to, but not part of, the Fe-S cluster. These data indicate that active plant mitochondrial aconitase contains a novel type of iron center.	CEN,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,F-38041 GRENOBLE,FRANCE; CEN,DEPT RECH FONDAMENTALE MAT CONDENSEE,F-38041 GRENOBLE,FRANCE; SERC,DARESBURY LAB,WARRINGTON WA4 4AD,CHESHIRE,ENGLAND	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); STFC Daresbury Laboratory				Courtois, Florence/0000-0003-0357-9401				ANTONIO MR, 1982, J BIOL CHEM, V257, P6646; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BLACKBURN NJ, 1983, BIOCHEM J, V213, P765, DOI 10.1042/bj2130765; BROUQUISSE R, 1987, PLANT PHYSIOL, V84, P1402, DOI 10.1104/pp.84.4.1402; BROUQUISSE R, 1985, PLANT PHYSIOL, V81, P247; CARTER CW, 1977, J BIOL CHEM, V252, P7802; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; Fansler B., 1969, METHODS ENZYMOL, V13, P26; FUKUYAMA K, 1988, J MOL BIOL, V199, P183, DOI 10.1016/0022-2836(88)90388-9; GARRATT RC, 1986, BIOCHEM J, V233, P479, DOI 10.1042/bj2330479; GURMAN SJ, 1984, J PHYS C SOLID STATE, V17, P143, DOI 10.1088/0022-3719/17/1/019; JOYNER RW, 1987, J PHYS C SOLID STATE, V20, P4005, DOI 10.1088/0022-3719/20/25/028; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENT TA, 1985, J BIOL CHEM, V260, P6871; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KISSINGER CR, 1991, J MOL BIOL, V219, P693, DOI 10.1016/0022-2836(91)90665-S; LINDAHL PA, 1987, INORG CHEM, V26, P3912, DOI 10.1021/ic00270a018; MARONEY MJ, 1991, J AM CHEM SOC, V113, P3962, DOI 10.1021/ja00010a044; MCREE DE, 1986, J BIOL CHEM, V261, P277; PERUTZ MF, 1982, NATURE, V295, P535, DOI 10.1038/295535a0; POGANIUCH P, 1991, J AM CHEM SOC, V113, P4645, DOI 10.1021/ja00012a037; RAO CP, 1986, INORG CHEM, V25, P428, DOI 10.1021/ic00224a011; STEPHENS PJ, 1985, P NATL ACAD SCI USA, V82, P5661, DOI 10.1073/pnas.82.17.5661; TEO BK, 1979, J AM CHEM SOC, V101, P5624, DOI 10.1021/ja00513a029; VANDERHOEK MJ, 1986, NUCL INSTRUM METH A, V246, P380, DOI 10.1016/0168-9002(86)90113-0; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10533, DOI 10.1021/bi00498a016	30	4	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16775	16778						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324911				2022-12-25	WOS:A1992JL05300008
J	RUSCITTI, T; POLAYES, DA; KARU, AE; LINN, S				RUSCITTI, T; POLAYES, DA; KARU, AE; LINN, S			SELECTIVE IMMUNONEUTRALIZATION OF THE MULTIPLE ACTIVITIES OF ESCHERICHIA-COLI DNA-POLYMERASE-I SUPPORTS THE MODEL FOR SEPARATE ACTIVE-SITES AND INDICATES A COMPLEX 5' TO 3' EXONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; BINDING; CULTURES; SERUM; FORM	DNA polymerase I (pol I) from Escherichia coli has three well-defined activities: DNA polymerase, 3'-5' exonuclease, and 5'-3' exonuclease. We have raised monoclonal antibodies to pol I which selectively neutralize each of these three activities, thus supporting the model of separate active sites for each activity, heretofore exclusively demonstrated with proteolytic fragments of pol I. Antibodies from each class could bind pol I in the presence of antibodies of another class, indicating the existence of significant spatial separation between each of the three sites. In addition, several of the neutralizing antibodies were able to distinguish particular activities of the 5'-3' exonuclease. One of them, for example, inhibited the RNase H activity but not the DNase activity. Two other antibodies could, in addition to inhibiting the polymerase and the 3'-5' exonuclease, either stimulate or inhibit the 5'-3' exonuclease depending upon the assay conditions, particularly the ionic strength.			RUSCITTI, T (corresponding author), UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019020, R01GM030415, R01GM019020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19020, GM30415] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P9586, DOI 10.1021/bi00451a006; BERNARDI F, 1979, J MOL BIOL, V129, P93, DOI 10.1016/0022-2836(79)90062-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUTLAG D, 1969, BIOCHEM BIOPH RES CO, V37, P982, DOI 10.1016/0006-291X(69)90228-9; CATALANO CE, 1989, BIOCHEMISTRY-US, V28, P4374, DOI 10.1021/bi00436a038; COOPER PK, 1982, MOL GEN GENET, V185, P189, DOI 10.1007/BF00330785; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FREEMANWITTIG MJ, 1986, BIOCHIM BIOPHYS ACTA, V867, P107, DOI 10.1016/0167-4781(86)90070-9; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; HARLOW E, 1988, ANTIBODIES LABORATOR, P311; ISCOVE NN, 1978, J EXP MED, V147, P923, DOI 10.1084/jem.147.3.923; ITOH T, 1979, COLD SPRING HARB SYM, V43, P409, DOI 10.1101/SQB.1979.043.01.047; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KARU AE, 1985, J IMMUNOL METHODS, V76, P145, DOI 10.1016/0022-1759(85)90487-9; KLENOW H, 1970, P NATL ACAD SCI USA, V65, P168, DOI 10.1073/pnas.65.1.168; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V21, P197, DOI 10.1016/0006-3002(56)90127-5; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LACKEY D, 1985, J BIOL CHEM, V260, P3178; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LINN S, 1976, P NATL ACAD SCI USA, V73, P2818, DOI 10.1073/pnas.73.8.2818; MORENO MR, 1985, ANAL BIOCHEM, V151, P466; NIWA O, 1981, P NATL ACAD SCI-BIOL, V78, P7024, DOI 10.1073/pnas.78.11.7024; PAPANICOLAOU C, 1984, BIOCHIMIE, V66, P115, DOI 10.1016/0300-9084(84)90199-8; ROSS M, 1990, BIOTECHNIQUES, V9, P532; STEITZ TA, 1992, J CELL BIOCH B S, V16, P3; SUGASAWARA RJ, 1985, J IMMUNOL METHODS, V79, P263, DOI 10.1016/0022-1759(85)90106-1; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; Voller A., 1976, MANUAL CLIN IMMUNOLO	31	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16806	16811						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324912				2022-12-25	WOS:A1992JL05300014
J	WEBER, DJ; BHATNAGAR, SK; BULLIONS, LC; BESSMAN, MJ; MILDVAN, AS				WEBER, DJ; BHATNAGAR, SK; BULLIONS, LC; BESSMAN, MJ; MILDVAN, AS			NMR AND ISOTOPIC EXCHANGE STUDIES OF THE SITE OF BOND-CLEAVAGE IN THE MUTT REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTATOR GENE; NUCLEOSIDE TRIPHOSPHATASE; PYROPHOSPHORYL GROUP; MOLECULAR-CLONING; IDENTIFICATION	The MutT protein, which prevents AT --> CG transversions during DNA replication, hydrolyzes nucleoside triphosphates to yield nucleoside monophosphates and pyrophosphate. The hydrolysis of dGTP by the MutT protein in (H2O)-O-18-enriched water, when monitored by high resolution P-31 NMR spectroscopy at 242.9 MHz, showed O-18 labeling of the pyrophosphate product, as manifested by a 0.010 +/- 0.002 ppm upfield shift of the pyrophosphate resonance, and no labeling of the dGMP product. This establishes that the reaction proceeds via a nucleophilic substitution at the beta-phosphorus of dGTP with displacement of dGMP as the leaving group. No exchange of P-32-labeled dGMP into dGTP was detected, indicating that water attacks dGTP directly or, less likely, an irreversibly formed pyrophosphoryl-enzyme intermediate. No exchange of P-32-labeled pyrophosphate into dGTP was observed, consistent with nucleophilic substitution at the beta-phosphorus of dGTP. Only six enzymes, all synthetases, have previously been shown to catalyze nucleophilic substitution at the beta-phosphorus of nucleoside triphosphate substrates. The MutT protein is the first hydrolase shown to do so.	JOHNS HOPKINS UNIV, SCH MED, SCH MED, DEPT BIOL CHEM, 725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University			Weber, David J/B-5349-2011	Weber, David J/0000-0002-8824-1110	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028616, R37DK028616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28616] Funding Source: Medline; NIGMS NIH HHS [GM18649, F32 GM13324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; BERMAN K, 1967, BIOCHIM BIOPHYS ACTA, V141, P214, DOI 10.1016/0304-4165(67)90270-X; BERTANI LE, 1961, J BIOL CHEM, V236, pPC67; BHATNAGAR SK, 1990, J BACTERIOL, V172, P2802, DOI 10.1128/jb.172.5.2802-2803.1990; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; COHN M, 1959, J CELL COMPAR PHYSL, V54, P17, DOI 10.1002/jcp.1030540405; COOPER RA, 1967, BIOCHEM J, V105, pC49; COX EC, 1973, GENETICS, V73, P67; EVANS HJ, 1968, P NATL ACAD SCI USA, V61, P1448, DOI 10.1073/pnas.61.4.1448; GIROIR IE, 1987, J BIOL CHEM, V262, P130; KAZIRO Y, 1961, J BIOCHEM-TOKYO, V49, P472, DOI 10.1093/oxfordjournals.jbchem.a127330; KHORANA HG, 1958, J BIOL CHEM, V230, P941; LI TM, 1978, J BIOL CHEM, V253, P3918; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Mildvan A.S., 1970, ENZYMES, P445; MILLER GA, 1975, ARCH BIOCHEM BIOPHYS, V171, P732, DOI 10.1016/0003-9861(75)90086-7; MILNER Y, 1972, P NATL ACAD SCI USA, V9, P2463; ROSCOE DH, 1969, VIROLOGY, V38, P520, DOI 10.1016/0042-6822(69)90172-X; Saenger W., 1984, PRINCIPLES NUCLEIC A, P76; SCHLOMAI J, 1978, J BIOL CHEM, V253, P3305; SHIOTA T, 1969, BIOCHEMISTRY-US, V8, P5022, DOI 10.1021/bi00840a052; SY J, 1973, P NATL ACAD SCI USA, V70, P306, DOI 10.1073/pnas.70.2.306; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; ZIMMERMAN S, 1961, J BIOL CHEM, V236, P1480	27	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16939	16942						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324915				2022-12-25	WOS:A1992JL05300035
J	HIGMAN, MA; BOURGEOIS, N; NILES, EG				HIGMAN, MA; BOURGEOIS, N; NILES, EG			THE VACCINIA VIRUS MESSENGER-RNA (GUANINE-N7-)-METHYLTRANSFERASE REQUIRES BOTH SUBUNITS OF THE MESSENGER-RNA CAPPING ENZYME FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PURIFICATION; VIRIONS; TRANSCRIPTION; POLYMERASE; INITIATION; PROTEINS; GENES; ACID	Plasmid vectors capable of expressing the large and small subunits of the vaccinia virus mRNA capping enzyme were constructed and used to transform Escherichia coli. Conditions for the induction of the dimeric enzyme or the individual subunits in a soluble form were identified, and the capping enzyme was purified to near homogeneity. Proteolysis of the capping enzyme in bacteria yields a 60-kDa product shown previously to possess the mRNA triphosphatase and guanyltransferase activities (Shuman, S. (1990) J. Biol. Chem. 265, 11960-11966) was isolated and shown by amino acid sequence analysis to be derived from the NH2 terminus of D1R. The individual subunits lacked methyltransferase activity when assayed alone. However, mixing the D1R and D12L subunits permitted reconstitution of the methyltransferase activity, and this appearance in activity accompanied the association of the subunits. In contrast, mixing the D12L subunit with the D1R-60K proteolytic fragment failed to yield methyltransferase activity or result in a physical association of the two proteins. These results demonstrate that the methyltransferase active site requires the presence of the D12L subunit with the carboxyl-terminal portion of the D1R subunit. Furthermore, since the mRNA triphosphatase and guanyltransferase active sites reside in the NH2-terminal domain of the D1R subunit, and the methyltransferase activity is found in the carboxyl-terminal portion of this subunit and D12L, there must be at least two separate active sites in this enzyme.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [AI28824] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; CONG PJ, 1992, J BIOL CHEM, V267, P16424; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FURUICHI Y, 1989, METHOD ENZYMOL, V180, P164; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KATES JR, 1967, P NATL ACAD SCI USA, V57, P314, DOI 10.1073/pnas.57.2.314; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; MOSS B, 1975, J BIOL CHEM, V250, P4722; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PAOLETTI E, 1974, J BIOL CHEM, V249, P3273; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TUTAS DJ, 1977, J BIOL CHEM, V252, P3092; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6069, DOI 10.1073/pnas.84.17.6069; [No title captured]	29	58	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16430	16437						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322902				2022-12-25	WOS:A1992JJ45800070
J	AUBERTFOUCHER, E; FONT, B; EICHENBERGER, D; GOLDSCHMIDT, D; LETHIAS, C; VANDERREST, M				AUBERTFOUCHER, E; FONT, B; EICHENBERGER, D; GOLDSCHMIDT, D; LETHIAS, C; VANDERREST, M			PURIFICATION AND CHARACTERIZATION OF NATIVE TYPE-XIV COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX COLLAGEN; EXTRACELLULAR-MATRIX; II COLLAGEN; PROTEINS; MOLECULE; DOMAIN; IDENTIFICATION; CARTILAGE; CLONING; CDNA	A new molecule, type XIV collagen, with domains homologous to type IX and XII collagens has been recently discovered in pepsin extracts of fetal bovine tissues (Dublet, B., and van der Rest, M. (1991) J. Biol. Chem. 266, 6853-6858). In the present study, we describe the purification and the characterization of the intact native form of this newly discovered collagen. By using only two chromatographic steps we were able to obtain pure type XIV collagen. Furthermore, minor modifications of the protocol allowed us to perform the simultaneous large scale purification of type XII and type XIV collagens from the same tissue. Intact type XIV collagen migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as two bands of 220 and 290 kDa (reducing conditions). After collagenase treatment, a single band of 190 kDa is observed, which represents the large non-collagenous domain of the molecule (NC3). Rotary shadowing electron micrographs of intact type XIV collagen show a cross-shaped structure formed by a thin tail attached through a central globule to three identical "fingers." These properties are similar to those previously described for intact chicken type XII collagen (Dublet, B., Oh, S., Sugrue, S. P., Gordon, M. K., Gerecke, D. R., Olsen, B. R., and van der Rest, M. (1989) J. Biol. Chem. 264, 13150-13156), but the two molecules are different gene products and have charge and glycosylation differences. Finally, we show that the three chains of purified type XIV collagen have an apparent molecular mass of approximately 220 kDa and are not cross-linked to each other by bonds other than disulfide bridges. The same observation was made for type XII collagen. In both cases, the 290-kDa migrating band in SDS-PAGE is due to incomplete denaturation in electrophoresis sample buffer in the absence of urea.	ECOLE NORMALE SUPER LYON, 46 ALLEE DITALIE, F-69364 LYON, FRANCE; CNRS, UPR 412, INST BIOL & CHEM PROT, F-69364 LYON, FRANCE; UNIV LYON 1, F-69622 VILLEURBANNE, FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUBLET B, 1990, ANN NY ACAD SCI, V580, P436, DOI 10.1111/j.1749-6632.1990.tb17953.x; DUBLET B, 1989, J BIOL CHEM, V264, P13150; DUBLET B, 1991, J BIOL CHEM, V266, P6853; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; GORDON MK, 1989, CONNECT TISSUE RES, V20, P179, DOI 10.3109/03008208909023886; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSENMAYER TF, 1982, IMMUNOCHEMISTRY EXTR, V1, P179; LUNSTRUM G P, 1991, Journal of Cell Biology, V115, p106A; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANDERREST M, 1990, BIOCHIMIE, V72, P473, DOI 10.1016/0300-9084(90)90071-N; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	23	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15759	15764						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322405				2022-12-25	WOS:A1992JG11300077
J	FRIDMAN, R; FUERST, TR; BIRD, RE; HOYHTYA, M; OELKUCT, M; KRAUS, S; KOMAREK, D; LIOTTA, LA; BERMAN, ML; STETLERSTEVENSON, WG				FRIDMAN, R; FUERST, TR; BIRD, RE; HOYHTYA, M; OELKUCT, M; KRAUS, S; KOMAREK, D; LIOTTA, LA; BERMAN, ML; STETLERSTEVENSON, WG			DOMAIN-STRUCTURE OF HUMAN 72-KDA GELATINASE TYPE-IV COLLAGENASE CHARACTERIZATION OF PROTEOLYTIC ACTIVITY AND IDENTIFICATION OF THE TISSUE INHIBITOR OF METALLOPROTEINASE-2 (TIMP-2) BINDING REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; RHEUMATOID SYNOVIAL FIBROBLASTS; BRONCHIAL EPITHELIAL-CELLS; MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; EXPRESSION; PURIFICATION; ACTIVATION; STROMELYSIN; INVASION	The 72-kDa gelatinase/type IV collagenase, a metalloproteinase thought to play a role in metastasis and in angiogenesis, forms a noncovalent stoichiometric complex with the tissue inhibitor of metalloproteinase-2 (TIMP-2), a potent inhibitor of enzyme activity. To define the regions of the 72-kDa gelatinase responsible for TIMP-2 binding, a series of NH2- and COOH-terminal deletions of the enzyme were constructed using the polymerase chain reaction technique. The full-length and the truncated enzymes were expressed in a recombinant vaccinia virus mammalian cell expression system (Vac/T7). Two truncated enzymes ending at residues 425 (DELTA-426-631) and 454 (DELTA-455-631) were purified. Like the full-length recombinant 72-kDa gelatinase, both COOH-terminally truncated enzymes were activated with organomercurial and digested gelatin and native collagen type IV. In contrast to the full-length enzyme, DELTA-426-631 and DELTA-455-631 enzymes were less sensitive to TIMP-2 inhibition requiring 10 mol of TIMP-2/mol of enzyme to achieve maximal inhibition of enzymatic activity. The activated but not the latent forms of the DELTA-426-631 and DELTA-455-631 proteins formed a complex with TIMP-2 only when excess molar concentrations of inhibitor were used. We also expressed the 205-amino acid COOH-terminal fragment, DELTA-1-426, and found that it binds TIMP-2. In addition, a truncated version of the 72-kDa gelatinase lacking the NH2-terminal 78 amino acids (DELTA-1-78) of the proenzyme retained the ability to bind TIMP-2. These studies demonstrate that 72-kDa gelatinases lacking the COOH-terminal domain retain full enzymatic activity but acquire a reduced sensitivity to TIMP-2 inhibition. These data suggest that both the active site and the COOH-terminal tail of the 72-kDa gelatinase independently and cooperatively participate in TIMP-2 binding.	MEDIMMUNE,GAITHERSBURG,MD 20878; NCI,PATHOL LAB,BETHESDA,MD 20892	AstraZeneca; Medimmune; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	FRIDMAN, R (corresponding author), MOLEC ONCOL INC,19 FIRSTFIELD RD,GAITHERSBURG,MD 20878, USA.		Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808	NATIONAL CANCER INSTITUTE [R43CA056257] Funding Source: NIH RePORTER; NCI NIH HHS [1R43CA56257-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BROWN PD, 1990, CANCER RES, V50, P6184; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CAWSTON TE, 1983, BIOCHEM J, V211, P313, DOI 10.1042/bj2110313; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DECLERCK YA, 1991, CANCER RES, V51, P2151; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KOLKENBROCK H, 1991, EUR J BIOCHEM, V198, P775, DOI 10.1111/j.1432-1033.1991.tb16080.x; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SELTZER JL, 1990, J BIOL CHEM, V265, P20409; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TRYGGVASON K, 1980, BIOCHEMISTRY-US, V19, P1284, DOI 10.1021/bi00548a003; URA H, 1989, CANCER RES, V49, P4615; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	40	210	219	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15398	15405						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322396				2022-12-25	WOS:A1992JG11300024
J	LUSSKA, A; WU, L; WHITLOCK, JP				LUSSKA, A; WU, L; WHITLOCK, JP			SUPERINDUCTION OF CYP1A1 TRANSCRIPTION BY CYCLOHEXIMIDE - ROLE OF THE DNA-BINDING SITE FOR THE LIGANDED AH RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P1-450 GENE-TRANSCRIPTION; DIOXIN-RESPONSIVE ENHANCER; MOUSE HEPATOMA-CELLS; PROTEIN-SYNTHESIS; WILD-TYPE; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; ACTIVATION; EXPRESSION; MECHANISM; INDUCTION	Nuclear run-off experiments reveal that four distinct DNA domains, each of which contains a binding site for the liganded Ah receptor, can mediate the super-induction of transcription by 2,3,7.8-tetrachlorodibenzo-p-dioxin plus cycloheximide. Superinduction requires substantial inhibition of protein synthesis by cycloheximide. Gel retardation analyses of nuclear extracts and methylation protection studies in intact cells reveal no evidence for cycloheximide-sensitive protein-DNA interactions that might mediate the superinduction response. These observations suggest the existence of a labile protein(s) that acts to inhibit the function of the dioxin-responsive receptor/enhancer regulatory system via protein-protein interactions.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R35CA053887, R01CA053887] Funding Source: NIH RePORTER; NCI NIH HHS [CA53887] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DURRIN LK, 1989, MOL CELL BIOL, V9, P5733, DOI 10.1128/MCB.9.12.5733; ELFERINK CJ, 1990, J BIOL CHEM, V265, P5718; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FISHER JM, 1989, MOL CARCINOGEN, V1, P216, DOI 10.1002/mc.2940010403; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIMBROUGH RD, 1989, HALOGENATED BIPHENYL, P1; KLEIN E, 1988, THESIS STANFORD U; LILIENFELD DE, 1989, EPIDEMIOL REV, V11, P28, DOI 10.1093/oxfordjournals.epirev.a036044; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; WEN LP, 1990, P NATL ACAD SCI USA, V87, P8545, DOI 10.1073/pnas.87.21.8545; WHITLOCK JP, 1973, J BIOL CHEM, V248, P6114; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	42	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15146	15151						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321828				2022-12-25	WOS:A1992JF08800094
J	ROSENBERG, AH; PATEL, SS; JOHNSON, KA; STUDIER, FW				ROSENBERG, AH; PATEL, SS; JOHNSON, KA; STUDIER, FW			CLONING AND EXPRESSION OF GENE-4 OF BACTERIOPHAGE-T7 AND CREATION AND ANALYSIS OF T7 MUTANTS LACKING THE 4A-PRIMASE HELICASE OR THE 4B-HELICASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; ESCHERICHIA-COLI; LAC REPRESSOR; NUCLEOTIDE-SEQUENCE; REPLICATION INVITRO; CLONED FRAGMENTS; DNA; PROTEIN; PRIMASE; SYSTEM	T7 gene 4, which is required for DNA replication, specifies two proteins whose coding sequences overlap in the same reading frame: the 4A protein, a 566-amino acid primase/helicase, and the 4B protein, a 503-amino acid helicase whose initiation codon is the 64th codon of the 4A protein. To study better the individual functions of these two overlapping proteins, we made clones that express both 4A and 4B proteins, only 4B protein, or only what we refer to as the 4A' protein, in which methionine 64 is replaced by leucine, thereby eliminating the 4B initiation codon. These clones provide considerably more gene 4 protein for biochemical analysis than do infected cells. They can also be used to isolate and propagate T7 gene 4 deletion mutants, and we have made T7 mutants which lack all gene 4 coding sequences, or which express 4A' protein but no 4B protein, or 4B protein but no 4A protein. Analysis of these phage mutants shows that 4A' protein without any 4B protein can support essentially normal replication and growth, whereas 4B protein without any 4A protein supports little replication or growth. Apparently, the primase activity of the 4A protein is essential for replication, but the 4B protein is dispensable, presumably because the 4A protein also supplies helicase activity. The mutation at amino acid 64 of 4A' appears to have little effect on 4A function. The rate of replication during normal T7 infection appears to be limited by the amount of gene 4 protein, but too high a level of either 4A or 4B protein is inhibitory to growth.	PENN STATE UNIV,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	ROSENBERG, AH (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613, R01GM021872, F32GM013135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44613, GM21872, GM13135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CAMPBELL JL, 1978, P NATL ACAD SCI USA, V75, P2276, DOI 10.1073/pnas.75.5.2276; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DEUSCHLE U, 1986, P NATL ACAD SCI USA, V83, P4134, DOI 10.1073/pnas.83.12.4134; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; DUNN JJ, 1984, J MOL BIOL, V175, P111; FISCHER H, 1980, J BIOL CHEM, V255, P7956; GIORDANO TJ, 1989, GENE, V84, P209, DOI 10.1016/0378-1119(89)90494-0; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; KOLODNER R, 1978, J BIOL CHEM, V253, P566; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MCALLISTER WT, 1981, J MOL BIOL, V153, P527, DOI 10.1016/0022-2836(81)90406-X; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NAKAMURA K, 1982, EMBO J, V1, P771, DOI 10.1002/j.1460-2075.1982.tb01244.x; PATEL SS, 1992, J BIOL CHEM, V267, P15013; RICHARDSON CC, 1987, UCLA S MOL CELL BIOL, V47, P151; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SILBERSTEIN S, 1975, J MOL BIOL, V96, P1, DOI 10.1016/0022-2836(75)90178-3; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; STUDIER FW, 1981, J MOL BIOL, V153, P493, DOI 10.1016/0022-2836(81)90404-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; STUDIER FW, 1973, J MOL BIOL, V79, P227, DOI 10.1016/0022-2836(73)90002-8	34	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15005	15012						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321823				2022-12-25	WOS:A1992JF08800075
J	SEGER, R; AHN, NG; POSADA, J; MUNAR, ES; JENSEN, AM; COOPER, JA; COBB, MH; KREBS, EG				SEGER, R; AHN, NG; POSADA, J; MUNAR, ES; JENSEN, AM; COOPER, JA; COBB, MH; KREBS, EG			PURIFICATION AND CHARACTERIZATION OF MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATOR(S) FROM EPIDERMAL GROWTH FACTOR-STIMULATED A431 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; POLYACRYLAMIDE GELS; SWISS 3T3-CELLS; S6 KINASE; INSULIN; PHOSPHORYLATES; INVITRO; ACID	Two peaks of mitogen-activated protein (MAP) kinase activator activity are resolved upon ion exchange chromatography of cytosolic extracts from epidermal growth factor-stimulated A431 cells. Two forms of the activator (1 and 2) have been purified from these peaks, using chromatography on Q-Sepharose, heparin-agarose, hydroxylapatite, ATP-agarose, Sephacryl S-300, Mono S, and Mono Q. The two preparations each contained one major protein band with an apparent molecular mass of 46 or 45 kDa, respectively, on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Evidence identifying the MAP kinase activators as the 46- and 45-kDa proteins is presented. Using inactive mutants of MAP kinase as potential substrates, it was found that each preparation of MAP kinase activator catalyzes phosphorylation of the regulatory residues, threonine 188 and tyrosine 190, of Xenopus MAP kinase. These results support the concept that the MAP kinase activators are protein kinases. These MAP kinase kinases demonstrate an apparent high degree of specificity toward the native conformation of MAP kinase, although slow autophosphorylation on serine, threonine, and tyrosine residues and phosphorylation of myelin basic protein on serine and threonine residues is detected as well.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473; Posada, James/0000-0003-3582-9612	NIDDK NIH HHS [DK 42528] Funding Source: Medline; NIGMS NIH HHS [GM 42508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; AHN NG, 1992, IN PRESS J NEUROCHEM; AHN NG, 1992, IN PRESS CIBA F; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; WU T, 1991, P NATL ACAD SCI USA, V88, P9508	41	342	348	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14373	14381						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321146				2022-12-25	WOS:A1992JD32500089
J	KILBOURNE, EJ; NANKOVA, BB; LEWIS, EJ; MCMAHON, A; OSAKA, H; SABBAN, DB; SABBAN, EL				KILBOURNE, EJ; NANKOVA, BB; LEWIS, EJ; MCMAHON, A; OSAKA, H; SABBAN, DB; SABBAN, EL			REGULATED EXPRESSION OF THE TYROSINE-HYDROXYLASE GENE BY MEMBRANE DEPOLARIZATION - IDENTIFICATION OF THE RESPONSIVE ELEMENT AND POSSIBLE 2ND MESSENGERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DOPAMINE-BETA-HYDROXYLASE; PC12 PHEOCHROMOCYTOMA CELLS; PROTEIN-KINASE-C; CYCLIC-AMP; SYMPATHETIC NEURONS; FOS; TRANSCRIPTION; RNA; JUN	Prolonged depolarization has been used as a model of adaptive changes in the expression of various proteins, such as ion channels and neurotransmitter biosynthetic enzymes, in response to increased trans-synaptic activity in the nervous system. In depolarized PC12 cells, tyrosine hydroxylase (TH) mRNA levels increased severalfold (Kilbourne, E. J., and Sabban, E. L. (1990) Mol. Brain Res. 8, 121-127). In this study, membrane depolarization caused an increase in the expression of the reporter gene chloramphenicol acetyltransferase (CAT), under transcriptional control of the 5' region of the rat TH gene. These results indicate that membrane depolarization leads to increased transcription of the TH gene. Protein kinase C inhibitors had no effect on the induction of TH mRNA by depolarization, as well as the increase in formation of CAT under control of the upstream region of the TH gene. The depolarization responsive element in the TH gene was mapped to the region containing the cAMP responsive element. This region of the TH gene also increased CAT activity in response to the calcium ionophore, ionomycin. Interestingly, combined treatment with cAMP analogs and membrane depolarization had a greater effect than either alone on TH mRNA levels, as well as on CAT activity in PC12 cells transfected with the plasmid containing the cAMP responsive element.	NEW YORK MED COLL,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	New York Medical College; Oregon Health & Science University				Nankova, Bistra/0000-0002-3997-4369	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869, K04NS001121] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01121, NS28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAETGE EE, 1981, P NATL ACAD SCI-BIOL, V78, P1269, DOI 10.1073/pnas.78.2.1269; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BLACK IB, 1987, SCIENCE, V236, P1263, DOI 10.1126/science.2884727; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CHALAZONITIS A, 1980, J PHARMACOL EXP THER, V213, P139; CHEN RF, 1967, J BIOL CHEM, V242, P173; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; D'MELLO SR, 1989, J NEUROSCI RES, V23, P31, DOI 10.1002/jnr.490230105; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FAUCONBIGUET N, 1989, NEUROSCI LETT, V104, P189; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALL FL, 1988, J BIOL CHEM, V263, P4460; HARRINGTON CA, 1987, NUCLEIC ACIDS RES, V15, P2363, DOI 10.1093/nar/15.5.2363; HEFTI F, 1982, J NEUROSCI, V2, P1554; ILARIA R, 1985, J NEUROSCI METH, V15, P165, DOI 10.1016/0165-0270(85)90053-6; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KILBOURNE EJ, 1991, J NEUROSCI METH, V40, P193, DOI 10.1016/0165-0270(91)90068-B; KVETNANSKY R, 1970, ENDOCRINOLOGY, V87, P744, DOI 10.1210/endo-87-4-744; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MCMAHON A, 1992, IN PRESS J NEUROCHEM; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; OLASMAA M, 1991, J NEUROCHEM B, V57, P20; OTTEN U, 1977, BRAIN RES, V133, P291, DOI 10.1016/0006-8993(77)90765-X; RABE CS, 1982, J CYCLIC NUCLEOTIDE, P371; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RAYNAUD B, 1987, DEV BIOL, V119, P305, DOI 10.1016/0012-1606(87)90036-4; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SABBAN EL, 1992, STRESS : NEUROENDOCRINE AND MOLECULAR APPROACHES, VOLS 1 AND 2, P325; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLING M, 1989, P NATL ACAD SCI USA, V86, P302; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STACHOWIAK MK, 1990, J BIOL CHEM, V265, P4694; STACHOWIAK MK, 1987, BRAIN RES, V359, P256; STUDELSKA DR, 1990, SOC NEUROSCI, V16; TANK AW, 1986, MOL PHARMACOL, V30, P497; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRAYNOR AE, 1984, DEV BRAIN RES, V14, P197; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	63	127	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7563	7569						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348505				2022-12-25	WOS:A1992HN48500053
J	LYTLE, C; FORBUSH, B				LYTLE, C; FORBUSH, B			THE NA-K-CL COTRANSPORT PROTEIN OF SHARK RECTAL GLAND .2. REGULATION BY DIRECT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 BUMETANIDE BINDING; SQUID GIANT-AXON; NA/K/2CL COTRANSPORT; CO-TRANSPORT; CELLS; DEPHOSPHORYLATION; STIMULATION; INHIBITION; MECHANISM; SECRETION	We determined the relationship between the activation state and phosphorylation state of the Na-K-Cl cotransport protein in tubules isolated from the shark rectal gland, a prototypic chloride-secreting epithelium. In response to cAMP-dependent secretagogues (e.g. vasoactive intestinal peptide, adenosine, and forskolin) or osmotically induced changes in cell volume, the activation state of the cotransport protein (assessed from measurements of loop diuretic binding) increased 5-10 fold. The response was temporally associated with a comparable increase (3-9 fold) in cotransport protein phosphorylation. Graded changes in cotransporter activation evoked proportional changes in cotransporter phosphorylation. Under the conditions of our experiments, the 195-kDa cotransporter was the only membrane protein whose phosphorylation state increased conspicuously in response to both cAMP and cell shrinkage. Both stimuli promoted phosphorylation of the cotransport protein at serine and threonine residues. One of the cAMP-sensitive phosphoacceptors was found within a segment of the cotransport protein comprised of a sequence (Phe-Gly-His-Asn-Thr*-Ile-Asp-Ala-Val-Pro) that corresponds to a segment of the Na-K-Cl cotransport protein predicted by cDNA analysis, where the phosphoacceptor (Thr*) is threonine 189. Incubation of rectal gland tubules with K-252a or H-8, structurally different protein kinase inhibitors, rendered the cotransporter insensitive to both cAMP and cell shrinkage. We conclude that the rectal gland Na-K-Cl cotransport protein is regulated by direct reversible phosphorylation at serine and threonine sites.	MT DESERT ISL BIOL LAB,SALSBURY COVE,ME 04672	Mount Desert Island Biological Laboratory	LYTLE, C (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Lytle, Christian/0000-0001-5442-1546	NIDDK NIH HHS [DK17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTAMIRANO AA, 1988, AM J PHYSIOL, V254, pC582, DOI 10.1152/ajpcell.1988.254.4.C582; BREITWIESER GE, 1990, AM J PHYSIOL, V258, pC749, DOI 10.1152/ajpcell.1990.258.4.C749; BURGER JW, 1960, SCIENCE, V131, P760; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FORBUSH B, 1988, BIOPHYS J, V53, pA222; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; GREGER R, 1988, COMP BIOCHEM PHYS A, V90, P733, DOI 10.1016/0300-9629(88)90692-5; GREGER R, 1984, PFLUG ARCH EUR J PHY, V402, P376, DOI 10.1007/BF00583938; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; KACHINTORN U, 1992, AM J PHYSIOL, V262, pC15, DOI 10.1152/ajpcell.1992.262.1.C15; KAJI D, 1991, FASEB J, V5, pA739; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, Biophysical Journal, V61, pA384; MARSHALL J, 1991, J BIOL CHEM, V266, P22749; OGRADY SM, 1988, AM J PHYSIOL, V254, pC115, DOI 10.1152/ajpcell.1988.254.1.C115; PALFREY HC, 1980, J EXP BIOL, V89, P103; PALFREY HC, 1980, B MT DESERT ISL BIOL, V20, P146; PEWITT EB, 1990, J BIOL CHEM, V265, P14364; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHUTTLEWORTH TJ, 1983, AM J PHYSIOL, V245, pR894, DOI 10.1152/ajpregu.1983.245.6.R894; SILVA P, 1977, AM J PHYSIOL, V233, pF298, DOI 10.1152/ajprenal.1977.233.4.F298; SILVA P, 1992, B MT DESERT ISL BIOL, V31, P65; TORCHIA J, 1992, J BIOL CHEM, V267, P25444; TORCHIA J, 1991, AM J PHYSIOL, V261, pC543, DOI 10.1152/ajpcell.1991.261.3.C543; WELSH MJ, 1983, AM J PHYSIOL, V245, pF640, DOI 10.1152/ajprenal.1983.245.5.F640; Xu Jianchao, 1992, Journal of General Physiology, V100, p39A	33	251	252	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25438	25443						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334094				2022-12-25	WOS:A1992KB60300080
J	BRUBAKER, PL; LEE, YC; DRUCKER, DJ				BRUBAKER, PL; LEE, YC; DRUCKER, DJ			ALTERATIONS IN PROGLUCAGON PROCESSING AND INHIBITION OF PROGLUCAGON GENE-EXPRESSION IN TRANSGENIC MICE WHICH CONTAIN A CHIMERIC PROGLUCAGON-SV40 T-ANTIGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET CELL-LINE; GLUCAGON GENE; PEPTIDE-I; PRO-OPIOMELANOCORTIN; DEPENDENT PATHWAY; INSULIN RELEASE; RAT INTESTINE; PANCREAS; PROHORMONE; PITUITARY	The proglucagon gene is expressed in A cells of the pancreas and L cells of the large and small intestine. Transgenic mice expressing SV40 large T antigen under the control of proglucagon regulatory sequences develop neuroendocrine carcinoma of the large intestine. To determine the consequences of coexpression of SV40 large T antigen and proglucagon in different cell types, the levels of proglucagon mRNA transcripts and proglucagon-derived peptides were determined in tumor-bearing transgenic mice and in age-matched paired controls. Plasma levels of proglucagon-derived peptides (glicentin, oxyntomodulin, and glucagon, as determined by high pressure liquid chromatography and radioimmunoassay) were markedly elevated in association with tumor growth (p < 0.001). Northern blot analysis demonstrated that the increased concentration of proglucagon-derived peptides was associated with significant inhibition of the endogenous proglucagon gene in pancreas, and to a lesser extent, small intestine. Concomitantly, the concentrations of proglucagon-derived peptides fell to 1-10% of control values in pancreas (p < 0.001) and to 62% of control values in small intestine (p < 0.001). Analysis of proglucagon-derived peptides in mice of different ages demonstrated that tumor growth was associated with a switch in the post-translational processing of proglucagon. Compared with normal mouse intestine, tumors contained increased proportions of glucagon and glucagon-like peptide-1(7-37) relative to glicentin, oxyntomodulin, and glucagon-like peptide-1(1-37). The results of these studies provide evidence for humorally-mediated tissue-specific inhibition of proglucagon gene expression.	UNIV TORONTO, BANTING & BEST DIABET CTR, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT MED, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University of Toronto; University of Toronto	BRUBAKER, PL (corresponding author), UNIV TORONTO, DEPT PHYSIOL, RM 3366, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA.		Drucker, Daniel J/A-4092-2010					ALARCON C, 1991, HORM METAB RES, V23, P290, DOI 10.1055/s-2007-1003677; BATAILLE D, 1988, ANN NY ACAD SCI, V527, P168; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRUBAKER PL, 1987, ENDOCRINOLOGY, V120, P1976, DOI 10.1210/endo-120-5-1976; BRUBAKER PL, 1988, ENDOCRINOLOGY, V123, P220, DOI 10.1210/endo-123-1-220; BRUBAKER PL, 1989, ENDOCRINOLOGY, V124, P3003, DOI 10.1210/endo-124-6-3003; BRUBAKER PL, 1991, ENDOCRINOLOGY, V128, P3175, DOI 10.1210/endo-128-6-3175; CANNY BJ, 1988, NEUROENDOCRINOLOGY, V48, P603, DOI 10.1159/000125069; DRUCKER DJ, 1990, CANCER, V65, P1762, DOI 10.1002/1097-0142(19900415)65:8<1762::AID-CNCR2820650817>3.0.CO;2-Q; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; DRUCKER DJ, 1988, ENDOCRINOLOGY, V123, P1861, DOI 10.1210/endo-123-4-1861; DRUCKER DJ, 1991, ENDOCRINOLOGY, V128, P394, DOI 10.1210/endo-128-1-394; DRUCKER DJ, 1986, J BIOL CHEM, V261, P9637; FALOONA GR, 1974, METHOD HORM RADIOIMM, P317; FEHMANN HC, 1991, ENDOCRINOLOGY, V128, P2880, DOI 10.1210/endo-128-6-2880; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FUKUSHIMA H, 1981, ENDOCRINOL JAPON, V28, P575; HEDING LG, 1971, DIABETOLOGIA, V7, P10, DOI 10.1007/BF02346248; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOLST JJ, 1983, DIABETOLOGIA, V24, P359; KAWAI K, 1989, ENDOCRINOLOGY, V124, P1768, DOI 10.1210/endo-124-4-1768; KERVRAN A, 1990, REGUL PEPTIDES, V31, P41, DOI 10.1016/0167-0115(90)90194-2; KERVRAN A, 1987, ENDOCRINOLOGY, V121, P704, DOI 10.1210/endo-121-2-704; KOMATSU R, 1989, DIABETES, V38, P902, DOI 10.2337/diabetes.38.7.902; KREYMANN B, 1987, LANCET, V2, P1300; LEE YC, 1992, J BIOL CHEM, V267, P10705; LIU EY, 1990, ENDOCRINOLOGY, V126, P110; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOJSOV S, 1990, J BIOL CHEM, V265, P8001; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; MURPHY GJ, 1987, BIOCHEM J, V243, P39, DOI 10.1042/bj2430039; NOEL G, 1991, ENDOCRINOLOGY, V129, P1317, DOI 10.1210/endo-129-3-1317; OCONNOR KJ, 1976, BIOCHEM J, V156, P265, DOI 10.1042/bj1560265; OHNEDA A, 1986, DIABETOLOGIA, V29, P397, DOI 10.1007/BF00903352; PATZELT C, 1984, P NATL ACAD SCI-BIOL, V81, P5007, DOI 10.1073/pnas.81.16.5007; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1986, ENDOCRINOLOGY, V119, P2833, DOI 10.1210/endo-119-6-2833; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; SCHMIDT WE, 1985, DIABETOLOGIA, V28, P704, DOI 10.1007/BF00291980; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; TANAKA R, 1979, ENDOCRINOL JAPON, V26, P59; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; ZAKARIAN S, 1989, NATURE, V339, P553, DOI 10.1038/339553a0	49	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20728	20733						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328210				2022-12-25	WOS:A1992JT97800035
J	MIKI, T; FUJII, H; KAKINUMA, K				MIKI, T; FUJII, H; KAKINUMA, K			EPR SIGNALS OF CYTOCHROME-B558 PURIFIED FROM PORCINE NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; ELECTRON-PARAMAGNETIC RESONANCE; 2 CYTOSOLIC COMPONENTS; NADPH OXIDASE; SPIN-RESONANCE; SUPEROXIDE PRODUCTION; RESPIRATORY BURST; PLASMA-MEMBRANE; SYSTEM; OXIDOREDUCTASE	Cytochrome b558 of pig blood neutrophils was partially purified, and its EPR spectra were measured. The cytochrome b558 was solubilized from membranes with the detergent n-heptyl-beta-thioglucoside and purified by DEAE-Sepharose and heparin-Sepharose chromatographies. The small and large subunits of cytochrome b558 were detected on gel by immunoblotting. A solution of the purified, undenatured cytochrome b558 at 85-108 muM concentration was obtained. The concentrated cytochrome b558 showed an EPR signal at a g value of 3.26 with a bandwidth of 100 G at 10 K. Addition of 2 mM KCN had no effect on the low spin signal at g = 3.26 but caused disappearance of a minor high spin signal. The cyanide-insensitive signal at g = 3.26 disappeared completely on reduction with Na2S2O4. These results suggest that the g = 3.26 signal is characteristic of the low spin heme in cytochrome b558 of neutrophils.	TOKYO METROPOLITAN INST MED SCI,DEPT INFLAMMAT RES,HONKOMAGOME 3-18-22,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science								BABIOR BM, 1984, BLOOD, V64, P959; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CHIBA T, 1990, BIOCHEM BIOPH RES CO, V173, P376, DOI 10.1016/S0006-291X(05)81068-X; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; FRIDEN H, 1990, BIOCHIM BIOPHYS ACTA, V1041, P207, DOI 10.1016/0167-4838(90)90067-P; FUJII H, 1992, IN PRESS BIOCH BIOPH; GABELLINI N, 1986, EUR J BIOCHEM, V154, P569, DOI 10.1111/j.1432-1033.1986.tb09437.x; GABIG TG, 1982, J BIOL CHEM, V257, P4114; HATATANAKA A, 1987, FEBS LETT, V214, P279, DOI 10.1016/0014-5793(87)80070-4; HURST JK, 1991, J BIOL CHEM, V266, P1627; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; KAKINUMA K, 1986, J BIOL CHEM, V261, P9426; KAKINUMA K, 1989, 3RD P INT C BIOPH 19; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKERT M, 1985, P NATL ACAD SCI USA, V82, P3144, DOI 10.1073/pnas.82.10.3144; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MIKI T, 1992, J BIOL CHEM, V267, P18695; NUGENT JHA, 1989, BIOCHEM J, V264, P921, DOI 10.1042/bj2640921; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; WAKEYAMA H, 1982, BIOCHEM J, V205, P593, DOI 10.1042/bj2050593; WALKER FA, 1984, J AM CHEM SOC, V106, P6888, DOI 10.1021/ja00335a003	34	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19673	19675						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326560				2022-12-25	WOS:A1992JP59300097
J	UMBARGER, KO; YAMAZAKI, M; HUTSON, LD; HAYASHI, F; YAMAZAKI, A				UMBARGER, KO; YAMAZAKI, M; HUTSON, LD; HAYASHI, F; YAMAZAKI, A			HETEROGENEITY OF THE RETINAL G-PROTEIN TRANSDUCIN FROM FROG ROD PHOTORECEPTORS - BIOCHEMICAL-IDENTIFICATION AND CHARACTERIZATION OF NEW SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CYCLIC-GMP PHOSPHODIESTERASE; CGMP PHOSPHODIESTERASE; ADP-RIBOSYLATION; PERTUSSIS TOXIN; OUTER SEGMENTS; GAMMA-SUBUNITS; ALPHA-SUBUNIT; VISUAL EXCITATION; CYCLASE	Transducin, a retinal G-protein, has been shown to exist as heterotrimers of alpha (39,000), beta (36,000), and gamma (approximately 7,000) subunits. Blue Sepharose CL-6B column chromatography of a transducin preparation extracted with a metal-free, low salt buffer containing GTP showed three distinct alpha and two distinct betagamma activities in frog (Rana catesbiana) rod outer segment. The binding of a hydrolysis-resistant GTP analog in these alpha fractions was proportional to the amount of the M(r) 39,000 protein. The first alpha was eluted in a complex with an inhibitory subunit of cGMP phosphodiesterase, but alpha subunits in the second and the third fractions were not complexed with any proteins. Two-dimensional gel electrophoresis and characterization with regard to the interaction with the inhibitory subunit of cGMP phoshodiesterase suggested that the first and the second alphas were the same protein; however, the third alpha showed different characters as follows. We designated alpha in the first two fractions as alpha1, and alpha in the third fraction as alpha2. Nonlinear regression analysis for the binding of a hydrolysis-resistant GTP analog to both alpha subunits revealed a single class of GTP binding sites with an apparent stoichiometry of 1 mol of GTP/mol of alpha. Compared with alpha1, alpha2 required larger amounts of rhodopsin and betagamma for the binding of a hydrolysis-resistant GTP analog. Alpha2 also showed less binding with the inhibitory subunit of cGMP phosphodiesterase. Both alpha1 and alpha2 complexed with betagamma or betadelta (described below) were substrates for pertussis toxin-dependent ADP-ribosylation. The protein profiles of two betagamma fractions revealed that the main fraction was composed of a betagamma complex; however, the second active fraction was composed of beta complexed with delta (M(r) 12,000). Compared with betagamma, betadelta stimulated GTP binding to alpha1 at approximately 10-fold higher concentration. Two-dimensional gel electrophoresis revealed five beta and two gamma isoforms in betagamma. Only one beta isoform was present in betadelta. The diversity of transducin subunits may reflect different signaling pathways in visual signal transduction.	WAYNE STATE UNIV, SCH MED,KRESGE EYE INST,DEPT OPHTHALMOL, 4717 ST ANTOINE ST, DETROIT, MI 48201 USA; LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA; WAYNE STATE UNIV, SCH MED, DEPT PHARMACOL, DETROIT, MI 48201 USA	Wayne State University; United States Department of Energy (DOE); Los Alamos National Laboratory; Wayne State University					NATIONAL EYE INSTITUTE [R01EY007546, R01EY009631] Funding Source: NIH RePORTER; NEI NIH HHS [EY09631, EY07546] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUKADA Y, 1986, PHOTOBIOCH PHOTOBIOP, V11, P269; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GRUNWALD GB, 1986, SCIENCE, V231, P856, DOI 10.1126/science.3080807; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; HILDEBRANDT JD, 1985, J BIOL CHEM, V260, P4867; HO YK, 1989, CURR TOP CELL REGUL, V30, P171; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LIEBMAN PA, 1968, VISION RES, V8, P761, DOI 10.1016/0042-6989(68)90128-4; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MANNING DR, 1984, J BIOL CHEM, V259, P749; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; NEUBERT TA, 1992, INVEST OPHTH VIS SCI, V33, P872; OKABE K, 1990, J BIOL CHEM, V265, P12854; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; VANDOP C, 1984, J BIOL CHEM, V259, P23; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1992, ADV SEC MESS PHOSPH, V25, P135; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9324	38	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19494	19502						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326554				2022-12-25	WOS:A1992JP59300073
J	BENTLEY, JK; KADLECEK, A; SHERBERT, CH; SEGER, D; SONNENBURG, WK; CHARBONNEAU, H; NOVACK, JP; BEAVO, JA				BENTLEY, JK; KADLECEK, A; SHERBERT, CH; SEGER, D; SONNENBURG, WK; CHARBONNEAU, H; NOVACK, JP; BEAVO, JA			MOLECULAR-CLONING OF CDNA-ENCODING A 63-KDA CALMODULIN-STIMULATED PHOSPHODIESTERASE FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; RAT-BRAIN; SUBSTRATE-SPECIFICITY; RNA-POLYMERASE; EXPRESSION; SEQUENCE; IDENTIFICATION; LOCALIZATION; ISOZYMES	Partially degenerate oligonucleotides based on peptide sequence were used to isolate cDNA to a 63-kDa bovine brain calmodulin-stimulated phosphodiesterase (CaM-PDE) isozyme. A 412-base pair polymerase chain reaction fragment was obtained and used along with the oligonucleotides to isolate several cDNAs each encoding sequence identical to known peptide sequences from the 63-kDa CaM-PDE. The largest cDNA contained a full-length open reading frame (ORF) encoding a 534 amino acid, 61,005-dalton protein. It had 59% amino acid identity to the 61-kDa bovine brain CaM-PDE and included a carboxyl-terminal conserved domain containing the PDE catalytic domain consensus sequences. The NH2-terminal region fits the criteria for a calmodulin-binding domain. When its expression was driven by a cytomegalogvirus promoter on a pCDM8 vector in COS-7 cells, the cDNA encoded a catalytically active, calmodulin-stimulated PDE. Northern analysis of RNA from several tissues with a probe containing much of the conserved PDE catalytic domain showed only a single band of 4.0 kilobases. Hybridization was seen in mRNA from several regions of the central nervous system with the greatest signal in basal ganglia. Strong signals also were seen in other tissues including kidney papilla and adrenal medulla. Antisense RNA probes were used in RNase-protection assays to look for evidence of multiple 63-kDa CaM-PDE transcripts. A catalytic domain probe was fully protected by RNA from cerebral cortex, basal ganglia, cerebellum, hippocampus, adrenal medulla, and kidney papilla. However, a probe to the NH2-terminal region was fully protected only by brain and adrenal medullary RNA indicating the likelihood of one or more isozyme(s) divergent in this region in the kidney papilla.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University of Washington; University of Washington Seattle; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Bentley, John Kelley/0000-0001-8865-7979	NEI NIH HHS [EY 08197] Funding Source: Medline; NIDDK NIH HHS [DK 21723] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSIELLO DA, 1984, SEMIN NEPHROL, V4, P134; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Beavo JA, 1990, CYCLIC NUCLEOTIDE PH, P1; BELTZ GA, 1983, METHOD ENZYMOL, V100, P266; BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; BILLINGSLEY ML, 1990, DEV BRAIN RES, V53, P253, DOI 10.1016/0165-3806(90)90015-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7981; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDWARDS RM, 1981, AM J PHYSIOL, V240, pF311, DOI 10.1152/ajprenal.1981.240.4.F311; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; HURWITZ RL, 1990, J BIOL CHEM, V265, P8901; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINCAID RL, 1987, P NATL ACAD SCI USA, V84, P1118, DOI 10.1073/pnas.84.4.1118; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LUDVIG N, 1991, NEUROSCIENCE, V44, P491, DOI 10.1016/0306-4522(91)90072-V; MARRIOTT D, 1988, J NEUROCHEM, V50, P616, DOI 10.1111/j.1471-4159.1988.tb02955.x; MORRIS CE, 1986, GENE, V41, P193, DOI 10.1016/0378-1119(86)90098-3; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHARMA RK, 1991, BIOCHEMISTRY-US, V30, P5963, DOI 10.1021/bi00238a021; SHARMA RK, 1985, P NATL ACAD SCI USA, V82, P2603, DOI 10.1073/pnas.82.9.2603; SHARMA RK, 1984, J BIOL CHEM, V259, P9248; SHENOLIKAR S, 1985, BIOCHEMISTRY-US, V24, P672, DOI 10.1021/bi00324a020; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SMITH WL, 1989, ADV EXP MED BIOL, V259, P131; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; SONNENBURG WK, 1992, IN PRESS CYCLIC GMP; TIRRELL JG, 1983, ARCH BIOCHEM BIOPHYS, V222, P380, DOI 10.1016/0003-9861(83)90534-9	40	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18676	18682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326531				2022-12-25	WOS:A1992JN50200066
J	REALINI, CA; ALTHAUS, FR				REALINI, CA; ALTHAUS, FR			HISTONE SHUTTLING BY POLY(ADP-RIBOSYLATION)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA EXCISION REPAIR; ADP-RIBOSYLATION; MAMMALIAN-CELLS; POLYMERASE; INVITRO; RIBOSE; ACTIVATION; BREAKS; INHIBITION; MOLECULES	We have found that two nuclear enzymes, i.e. poly(ADP-ribose) polymerase (EC 2.4.2.30) and poly(ADP-ribose) glycohydrolase, may cooperate to function as a histone shuttle mechanism on DNA. The mechanism involves four distinct reaction intermediates that were analyzed in a reconstituted in vitro system. In the first step, the enzyme poly(ADP-ribose) polymerase is activated in the presence of histone-DNA complexes and converts itself into a protein carrying multiple ADP-ribose polymers. These polymers attract histones that dissociate from the DNA as a histone-polymer-polymerase complex. The DNA assumes the electrophoretic mobility of free DNA and becomes susceptible to nuclease digestion (second step). In the third step, poly(ADP-ribose) glycohydrolase degrades ADP-ribose polymers and thereby eliminates the binding sites for histones. In the fourth step, histones reassociate with DNA, and the histone-DNA complexes exhibit the electrophoretic mobilities and nuclease susceptibilities of the original complexes prior to dissociation. Our results are compatible with the view that the poly(ADP-ribosylation) system acts as a catalyst of nucleosomal unfolding of chromatin in DNA excision repair.	UNIV ZURICH, TIERSPITAL, INST PHARMACOL & BIOCHEM, WINTERTHURERSTR 260, CH-8057 ZURICH, SWITZERLAND	University of Zurich								Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; BERGER NA, 1981, BIOCHEMISTRY-US, V20, P3610, DOI 10.1021/bi00515a047; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN JJ, 1981, BIOCHEM BIOPH RES CO, V98, P268, DOI 10.1016/0006-291X(81)91898-2; COHEN JJ, 1982, BIOCHEMISTRY-US, V21, P4931, DOI 10.1021/bi00263a016; COLE GA, 1991, BIOCHEM BIOPH RES CO, V180, P504, DOI 10.1016/S0006-291X(05)81093-9; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HATAKEYAMA K, 1986, J BIOL CHEM, V261, P4902; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JUAREZSALINAS H, 1982, J BIOL CHEM, V257, P607; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT WM, 1989, DNA REPAIR MECHANISM, P667; LOEB LA, 1969, J BIOL CHEM, V244, P1672; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MALANGA M, 1992, Experientia (Basel), V48, pA82; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MATHIS G, 1990, CARCINOGENESIS, V11, P1237, DOI 10.1093/carcin/11.7.1237; MATHIS G, 1987, BIOCHEM BIOPH RES CO, V143, P1049, DOI 10.1016/0006-291X(87)90358-5; MCCURRY LS, 1981, J BIOL CHEM, V256, P551; NAEGELI H, 1989, J BIOL CHEM, V264, P14382; NAEGELI H, 1991, J BIOL CHEM, V266, P10596; OHASHI Y, 1983, P NATL ACAD SCI-BIOL, V80, P3604, DOI 10.1073/pnas.80.12.3604; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PANZETER PL, 1990, NUCLEIC ACIDS RES, V18, P2194, DOI 10.1093/nar/18.8.2194; PEACOCK AC, 1967, BIOCHEMISTRY-US, V6, P1818, DOI 10.1021/bi00858a033; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; SIDIK K, 1992, CARCINOGENESIS, V13, P135, DOI 10.1093/carcin/13.1.135; SMERDON MJ, 1989, NATO ADV SCI I A-LIF, V182, P271; THOMASSIN H, 1990, NUCLEIC ACIDS RES, V18, P4691, DOI 10.1093/nar/18.16.4691; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; van Holde KE., 1989, SPRINGER SERIES MOL; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P3471	43	165	167	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18858	18865						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326536				2022-12-25	WOS:A1992JN50200092
J	CONG, PJ; SHUMAN, S				CONG, PJ; SHUMAN, S			METHYLTRANSFERASE AND SUBUNIT ASSOCIATION DOMAINS OF VACCINIA VIRUS MESSENGER-RNA CAPPING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE INTERMEDIATE; ESCHERICHIA-COLI; GUANYLYLTRANSFERASE; TRANSCRIPTION; MECHANISM	RNA triphosphatase, RNA guanylyltransferase, and RNA (guanine-N7-)-methyltransferase activities are associated with the vaccinia virus mRNA capping enzyme, a heterodimeric protein containing polypeptides of M(r) 95,000 and 31,000. Although the RNA triphosphatase and RNA guanylyltransferase domains have been localized to a M(r) 59,000 fragment of the capping enzyme large subunit, the location of the methyltransferase domain within the protein and the catalytic role of individual subunits in methyl group transfer remain unclear. In the present work, through the study of methyltransferase activity of truncated forms of capping enzyme translated in vitro in a rabbit reticulocyte lysate, we have localized the methyltransferase domain to a complex consisting of the small subunit and the carboxyl-terminal portion of the large subunit. The M(r) 31,000 subunit translated alone was not sufficient for methyltransferase activity. This requirement for both subunits may explain the tight physical association of the two polypeptides in vivo. We have recreated the association of the large and small enzyme subunits in vitro through the translation of synthetic mRNAs encoding the two polypeptides. Study of the ability of deleted versions of the large subunit to bind the small subunit, as detected by co-immunoprecipitation, defined a 347-amino acid carboxyl-terminal region of the large subunit that was sufficient for heterodimerization. Colocalization within the large subunit of the methyltransferase and subunit association domains suggests that dimerization of the subunits may be required for methyltransferase activity.			CONG, PJ (corresponding author), SLOAN KETTERING MEM CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.				NIGMS NIH HHS [GM 42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; LUO Y, 1991, J BIOL CHEM, V266, P13303; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; TOYAMA R, 1983, EMBO J, V2, P2195, DOI 10.1002/j.1460-2075.1983.tb01723.x; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x	17	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16424	16429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322901				2022-12-25	WOS:A1992JJ45800069
J	LI, L; LIN, K; CORREIA, JJ; PILKIS, SJ				LI, L; LIN, K; CORREIA, JJ; PILKIS, SJ			LYSINE-356 IS A CRITICAL RESIDUE FOR BINDING THE C-6 PHOSPHO GROUP OF FRUCTOSE 2,6-BISPHOSPHATE TO THE FRUCTOSE-2,6-BISPHOSPHATASE DOMAIN OF RAT-LIVER 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC GLUCONEOGENESIS; ESCHERICHIA-COLI; SUBSTRATE CYCLE; EXPRESSION; 2-KINASE; INTERMEDIATE; GLYCOLYSIS; SEQUENCE; ENZYME; KINASE	Lysine 356 has been implicated by protein modification studies as a fructose-2,6-bisphosphate binding site residue in the 6-phosphofructo-2-kinase domain of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (Kitajima, S., Thomas, H., and Uyeda, K. (1985) J. Biol. Chem. 260, 13995-14002). However, Lys-356 is found in the fructose-2,6-bisphosphatase domain (Bazan, F., Fletterick, R., and Pilkis, S. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86,9642-9646). In order to ascertain whether Lys-356 is involved in fructose-2,6-bisphosphatase catalysis and/or domain/domain interactions of the bifunctional enzyme, Lys-356 was mutated to Ala, expressed in Escherichia coli, and then purified to homogeneity. Circular dichroism experiments indicated that the secondary structure of the Lys-356-Ala mutant was not significantly different from that of the wild-type enzyme. The K(m) for fructose 2,6-bisphosphate and the K(i) for the noncompetitive inhibitor, fructose 6-phosphate, for the fructose-2,6-bisphosphatase of the Lys-356-Ala mutant were 2700- and 2200-fold higher, respectively, than those of the wild-type enzyme. However, the maximal velocity and the K(i) for the competitive product inhibitor, inorganic phosphate, were unchanged compared to the corresponding values of the wild-type enzyme. Furthermore, in contrast to the wild-type enzyme, which exhibits substrate inhibition, there was no inhibition by substrate of the Lys-356-Ala mutant. In the presence of saturating substrate, inorganic phosphate, which acts by relieving fructose-6-phosphate and substrate inhibition, is an activator of the bisphosphatase. The K(a) for inorganic phosphate of the Lys-356-Ala mutant was 1300-fold higher than that of the wild-type enzyme. The kinetic properties of the 6-phosphofructo-2-kinase of the Lys-356-Ala mutant were essentially identical with that of the wild-type enzyme. The results demonstrate that: 1) Lys-356 is a critical residue in fructose-2,6-bisphosphatase for binding the 6-phospho group of fructose 6-phosphate/fructose 2,6-bisphosphate; 2) the fructose 6-phosphate binding site is responsible for substrate inhibition; 3) Inorganic phosphate activates fructose-2,6-bisphosphatase by competing with fructose 6-phosphate for the same site; and 4) Lys-356 is not involved in 6-phosphofructo-2-kinase substrate/product binding or catalysis.	SUNY STONY BROOK, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, JACKSON, MS 39216 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Mississippi; University of Mississippi Medical Center					NIDDK NIH HHS [DK 38354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P57; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1982, BIOCHEM BIOPH RES CO, V106, P794, DOI 10.1016/0006-291X(82)91780-6; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3096; HERS HG, 1982, BIOCHEM J, V206, P1; KITAJIMA S, 1985, J BIOL CHEM, V260, P3995; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; LI L, 1992, J BIOL CHEM, V267, P4386; LIN K, 1992, J BIOL CHEM, V267, P6556; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIN K, 1992, IN PRESS J BIOL CHEM, V267; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1982, MOL CELL ENDOCRINOL, V25, P245, DOI 10.1016/0303-7207(82)90082-X; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; PILKIS SJ, 1990, FRUCTOSE 2 6 BISPHOS; PILKIS SJ, 1981, ENZYMES, V16, P3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STEWART HB, 1986, J BIOL CHEM, V261, P8793; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1989, P NATL ACAD SCI USA, V86, P7316, DOI 10.1073/pnas.86.19.7316; TAULER A, 1988, P NATL ACAD SCI USA, V85, P6642, DOI 10.1073/pnas.85.18.6642; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; WINN SL, 1983, PHILOS T R SOC LON B, V293, P121	34	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16669	16675						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322913				2022-12-25	WOS:A1992JJ45800103
J	LEEBEEK, FWG; KARIYA, K; SCHWABE, M; FOWLKES, DM				LEEBEEK, FWG; KARIYA, K; SCHWABE, M; FOWLKES, DM			IDENTIFICATION OF A RECEPTOR-BINDING SITE IN THE CARBOXYL TERMINUS OF HUMAN INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; AMINO-ACIDS; HUMAN IL-6; PROTEIN; INTERFERON-BETA-2; MUTAGENESIS; EXPRESSION	To identify a receptor binding site of human interleukin-6 (IL-6), we created a library of IL-6 variants with single amino acid substitutions in the last 15 residues (171-185) in the COOH terminus of IL-6. Twenty-seven IL-6 variants were tested for biological activity on a human hepatoma and a mouse hybridoma cell line. Most variants were additionally tested in a receptor binding assay using a human myeloma cell line. Several single amino acid substitutions in the COOH terminus of IL-6 were found to decrease biological activity significantly. This is especially seen in variants with amino acid substitutions that alter the postulated amphipathical alpha-helix structure between residues 178 and 183. The two highly conserved Arg residues at positions 180 and 183 seem to play a very important role in biological activity. The loss of biological activity in all inactive variants is completely paralleled by a decrease of IL-6 receptor binding, as determined by competition binding experiments. One mutant (Leu171) displayed a higher activity on human cells and a higher binding affinity to the receptor and can be considered an IL-6 agonist. It is concluded that the amphipathical alpha-helix structure in the COOH terminus of IL-6 is critical for ligand receptor interaction. Furthermore, the region between residues Ser178 and Arg183 (Ser-Leu-Arg-Ala-X-Arg) is identified as a receptor binding site in the COOH terminus of human IL-6.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NHLBI NIH HHS [HL31012] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL031012, R01HL031012] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BATAILLE R, 1991, BLOOD S, V78, pA129; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; CHEN L, 1988, P NATL ACAD SCI USA, V85, P8037, DOI 10.1073/pnas.85.21.8037; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DINARELLO CA, 1991, BLOOD, V77, P1627; FALTYNEK CR, 1986, J IMMUNOL, V136, P4134; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; HACK CE, 1989, BLOOD, V74, P1704; HIBI M, 1991, CELL, V63, P1049; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HORII Y, 1989, J IMMUNOL, V143, P3949; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; IDA N, 1989, BIOCHEM BIOPH RES CO, V165, P728, DOI 10.1016/S0006-291X(89)80027-0; IKEBUCHI K, P NATL ACAD SCI USA, V84, P9305; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; JAMBOU RC, 1988, P NATL ACAD SCI USA, V139, P4116; JANIN J, 1976, J MOL BIOL, V100, P197, DOI 10.1016/S0022-2836(76)80148-9; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KLEIN B, 1991, BLOOD, V78, P1198; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KUGA T, 1989, BIOCHEM BIOPH RES CO, V159, P103, DOI 10.1016/0006-291X(89)92410-8; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOKKER NA, 1991, J BIOL CHEM, V266, P10624; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; RENNICK D, 1989, BLOOD, V73, P1828; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SNOUWAERT J, 1987, NUCLEIC ACIDS RES, V15, P8293, DOI 10.1093/nar/15.20.8293; SNOUWAERT JN, 1991, J BIOL CHEM, V266, P23097; SNOUWAERT JN, 1991, J IMMUNOL, V146, P585; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XG, 1989, BLOOD, V74, P11; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	53	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14832	14838						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321818				2022-12-25	WOS:A1992JF08800051
J	PATEL, KD; ZIMMERMAN, GA; PRESCOTT, SM; MCINTYRE, TM				PATEL, KD; ZIMMERMAN, GA; PRESCOTT, SM; MCINTYRE, TM			NOVEL LEUKOCYTE AGONISTS ARE RELEASED BY ENDOTHELIAL-CELLS EXPOSED TO PEROXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; MYOCARDIAL REPERFUSION INJURY; PLASMA-MEMBRANE VESICULATION; FREE-RADICAL GENERATION; INDUCED LUNG INJURY; ISCHEMIA-REPERFUSION; FACTOR ACETYLHYDROLASE; NEUTROPHIL ADHERENCE; INTESTINAL ISCHEMIA; RAT-LIVER	Reactive oxygen species do not activate isolated neutrophils, yet in vivo, such oxidants promote their adhesion to, and subsequent migration through, the vascular wall. We show human endothelial cells exposed to t-butylhydroperoxide shed large, sealed membrane vesicles that contained potent neutrophil agonists. This activity migrated on TLC like platelet-activating factor (PAF). Since neutrophils have a receptor for this phospholipid, which recognizes its unique characteristics including the short sn-2 acetyl residue, we examined the effect of PAF receptor antagonists and PAF acetylhydrolase on this activity. Structurally unrelated PAF receptor antagonists blocked neutrophil stimulation by vesicular phospholipids, and digestion with PAF acetylhydrolase, which is specific for short sn-2 residues, destroyed this activity. However, metabolic labeling, inhibition of synthesis, phospholipase A, digestion, and high performance liquid chromatographic studies demonstrated that the vesicles did not contain PAF. Instead, the bioactivity migrated on high performance liquid chromatography like the phospholipids generated by oxidative fragmentation of synthetic arachidonoyl phosphatidylcholine that we have shown previously (Smiley, P. L., Stremler, K. E., Prescott, S. M., Zimmerman, G. A., and McIntyre, T. M. (1991) J. Biol. Chem. 266, 11104-11110) to stimulate neutrophils through their receptor for PAF. Thus, peroxide treatment of endothelial cells fragments cellular phosphatidylcholines, forming novel PAF-like phospholipids, and induces the shedding of membrane vesicles that contain these bioactive phospholipids.	UNIV UTAH, SCH MED, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INS, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT MED, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Patel, Kamala D/AAX-1245-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044513, R01HL035828, R01HL044525, R37HL044525] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35828, HL44525, HL44513] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER JE, 1988, P NATL ACAD SCI USA, V85, P2786, DOI 10.1073/pnas.85.8.2786; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BERTI F, 1990, J CARDIOVASC PHARM, V16, P727, DOI 10.1097/00005344-199011000-00006; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1989, TRENDS PHARMACOL SCI, V10, P23, DOI 10.1016/0165-6147(89)90103-X; DELMAESTRO RF, 1982, INT J MICROCIRC, V1, P105; DELMAESTRO RF, 1980, ACTA PHYSIOL SCAND, P43; DREYER WJ, 1989, CIRC RES, V65, P1751, DOI 10.1161/01.RES.65.6.1751; GASIC AC, 1991, CIRCULATION, V84, P2154, DOI 10.1161/01.CIR.84.5.2154; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GO LO, 1988, AM J PHYSIOL, V255, pH1188, DOI 10.1152/ajpheart.1988.255.5.H1188; GOLDMAN G, 1990, ANN SURG, V211, P196, DOI 10.1097/00000658-199002000-00012; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; GROVES RW, 1991, BRIT J DERMATOL, V124, P117, DOI 10.1111/j.1365-2133.1991.tb00419.x; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; INGRAHAM LM, 1982, BLOOD, V59, P1259; JAESCHKE H, 1990, FASEB J, V4, P3355, DOI 10.1096/fasebj.4.15.2253850; JANOS F, 1989, BIOCHEM BIOPH RES CO, V158, P353; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; KLAUSNER JM, 1989, SURGERY, V105, P192; KLAUSNER JM, 1988, ANN SURG, V208, P761, DOI 10.1097/00000658-198812000-00015; KOHLER HR, 1990, ULTRASTRUCT PATHOL, V14, P513; KUBES P, 1990, AM J PHYSIOL, V259, pG300, DOI 10.1152/ajpgi.1990.259.2.G300; LASKY LA, 1991, J CELL BIOCHEM, V45, P139, DOI 10.1002/jcb.240450204; LEMASTERS JJ, 1983, J CELL BIOL, V97, P778, DOI 10.1083/jcb.97.3.778; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; LOPEZFARRE A, 1988, BIOCHEM BIOPH RES CO, V152, P129, DOI 10.1016/S0006-291X(88)80689-2; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MCEVER RP, 1991, THROMB HAEMOSTASIS, V65, P223; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MEEUSEN E, 1987, IMMUNOLOGY, V61, P321; MOLDOVAN NI, 1987, EXP CELL RES, V170, P499, DOI 10.1016/0014-4827(87)90324-7; MORGAN BP, 1987, J IMMUNOL, V138, P246; MUELLER HW, 1991, BIOCHEM BIOPH RES CO, V176, P1557, DOI 10.1016/0006-291X(91)90465-J; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; ROMASCHIN AD, 1990, AM J PHYSIOL, V259, pH116, DOI 10.1152/ajpheart.1990.259.1.H116; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; SATOUCHI K, 1985, BIOCHEM BIOPH RES CO, V128, P1409, DOI 10.1016/0006-291X(85)91097-6; SCHMELING DJ, 1989, SURGERY, V106, P195; SCOTT RE, 1979, J CELL SCI, V35, P229; SCOTT RE, 1979, J CELL SCI, V35, P245; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; SPRAGG RG, 1991, LUNG SCI F, P2003; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; VERCELLOTTI GM, 1988, BLOOD, V71, P1100; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; WRIGHT SD, 1988, J CELL SCI, P99; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	62	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15168	15175						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321830				2022-12-25	WOS:A1992JF08800097
J	KONG, SK; CHOCK, PB				KONG, SK; CHOCK, PB			PROTEIN UBIQUITINATION IS REGULATED BY PHOSPHORYLATION - AN INVITRO STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; HISTONES; IDENTIFICATION; DISAPPEARANCE; PURIFICATION; MECHANISM; ISOZYMES; SPLEEN; ENZYME; CELLS	Protein ubiquitination has been implicated in ATP-dependent protein turnover and in a number of biological processes in eukaryotic cells. The ubiquitination activating enzyme, E1, and ubiquitin carrier protein, E2, are two essential enzymes in the protein ubiquitination machinery. Using purified E1 and E2 from rabbit reticulocytes and various protein kinases, which include cAMP-dependent protein kinase, protein kinase C, and protein tyrosine kinase, we demonstrated that E1 is phosphorylated by protein kinase C, with a stoichiometry of 0.65 mol of phosphate/mol of E1, and one of the E2 isoforms, E2(32kDa), is phosphorylated by protein tyrosine kinase to 2 eq of phosphate/mol of protein. Phosphorylation of E1 causes a 2- fold enhancement of its activity as monitored by ubiquitin-dependent ATP half arrow left over half arrow right PP(i) exchange. When 1 eq of phosphate was incorporated into E2(32kDa), a 2.4-fold activation was also observed for its activity to catalyze the ubiquitination of histone H2A. The regulatory significance of this finding is discussed.			KONG, SK (corresponding author), NHLBI,BIOCHEM LAB,BETHESDA,MD 20892, USA.							CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOYER A, 1980, J BIOL CHEM, V255, P7525; COOK J, 1988, Biofactors, V1, P133; COOK JC, 1991, P NATL ACAD SCI USA, V88, P11388, DOI 10.1073/pnas.88.24.11388; COOK JC, 1991, BIOCHEM BIOPH RES CO, V174, P564, DOI 10.1016/0006-291X(91)91454-K; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; KONG SK, 1988, J BIOL CHEM, V263, P14523; KONG SK, 1987, J BIOL CHEM, V262, P2597; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; MATSUI SI, 1979, P NATL ACAD SCI USA, V76, P6386, DOI 10.1073/pnas.76.12.6386; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MUELLER RD, 1985, J BIOL CHEM, V260, P5147; PICKART CM, 1988, J BIOL CHEM, V263, P15076; SCHAFFNER M, 1990, CELL, V63, P1129; SHACHTER E, 1986, ENZYMES A, V17, P21; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TOKUDA M, 1987, BIOCHEMISTRY-US, V26, P5226, DOI 10.1021/bi00391a002; WANG CY, 1988, BIOCHEMISTRY-US, V27, P1254, DOI 10.1021/bi00404a027; WU RS, 1981, J BIOL CHEM, V256, P5916	31	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14189	14192						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321138				2022-12-25	WOS:A1992JD32500063
J	MOONEY, RA; BORDWELL, KL				MOONEY, RA; BORDWELL, KL			DIFFERENTIAL DEPHOSPHORYLATION OF THE INSULIN-RECEPTOR AND ITS 160-KDA SUBSTRATE (PP160) IN RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FACTOR-I STIMULATE; HUMAN-PLACENTA; 3T3-L1 ADIPOCYTES; KINASE-ACTIVITY; PERMEABILIZED ADIPOCYTES; ENDOGENOUS SUBSTRATE; DIABETIC RATS; INTACT-CELLS; PHOSPHORYLATION	A permeabilized rat adipocyte model was developed which permitted an examination of: 1) insulin receptor autophosphorylation, 2) phosphorylation of a putative insulin receptor substrate of 160 kDa, pp160, and 3) the dephosphorylation reactions associated with each of these phosphoproteins. Rat adipocytes, preincubated with [P-32]orthophosphate for 2 h, were exposed to insulin (10(-7) M) at the time of digitonin permeabilization. Phosphorylation of pp160 and autophosphorylation of the insulin receptor increased as a function of Mn2+ concentration in the media with near maximum responses at 10 mM. Maximum response was at least as large as the intact cell response to 10(-7) M insulin. In contrast, magnesium did not increase phosphorylation of pp160 although an increase in receptor autophosphorylation was observed. Autophosphorylation was preserved at digitonin concentrations of 20-100-mu-g/ml, but pp160 phosphorylation was negligible beyond 40-mu-g/ml. Our previous work demonstrated that the insulin receptor was associated with a phosphotyrosine phosphatase activity in permeabilized adipocytes (Mooney, R., and Anderson, D. (1989) J. Biol. Chem. 264,6850-6857). The current permeabilized adipocyte model made possible an examination of the effects of phosphotyrosine phosphatase inhibitors, including several divalent metal cations (Zn2+, Co2+, and Ni2+), vanadate, and molybdate on both net phosphorylation of pp160 and autophosphorylation of the insulin receptor. Zn2+ at 100-mu-M, Ni2+ at 1 mM and Co2+ at 1 or 5 mM increased insulin-dependent phosphorylation of pp160 at least 5-fold and autophosphorylation 2-fold. At higher concentrations of Zn2+ (1 mM) and Ni2+ (5 mM), however, no increase in phosphorylation of pp160 was observed and autophosphorylation was inhibited. Vanadate (I mM) and molybdate (100-mu-M) increased insulin-dependent phosphorylation of pp160 by 3-fold when tested separately and 7-fold in combination. Insulin receptor autophosphorylation was increased 50% by each and 3-fold when the agents were combined. Dephosphorylation of pp 1 60 and the insulin receptor was analyzed directly by permeabilizing prelabeled insulin-treated adipocytes in the presence of EDTA (10 mM). Dephosphorylation of pp 1 60 was especially rapid with a t1/2 of approximately 10 s. The t1/2 for the insulin receptor was 37 s. Zn2+ at 1 mM (a concentration that inhibited the insulin receptor kinase) was a strong inhibitor of dephosphorylation, prolonging the rate of PP160 dephosphorylation more than 12-fold and insulin receptor dephosphorylation 3-fold. Inhibition by Zn2+ was reversible with EDTA. These results demonstrate that phosphorylation by the insulin receptor tyrosine kinase of its substrate, pp160, is acutely sensitive to modulation by phosphotyrosine phosphatase activity. The observation that pp160 is more rapidly dephosphorylated and more sensitive to phosphatase inhibitors than the insulin receptor may suggest a phosphatase-dependent mechanism for rapid reversal of insulin signal propagation and is consistent with a role for pp160 in insulin signal transduction.			MOONEY, RA (corresponding author), UNIV ROCHESTER, SCH MED & DENT, DEPT PATHOL & LAB MED, ROCHESTER, NY 14642 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038138] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38138] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICHARD SM, 1988, ENDOCRINOLOGY, V123, P2048, DOI 10.1210/endo-123-4-2048; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DEGANI H, 1981, BIOCHEMISTRY-US, V20, P5795, DOI 10.1021/bi00523a023; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EZAKI O, 1989, J BIOL CHEM, V264, P16118; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; KOWALSKI A, 1983, BIOCHEM BIOPH RES CO, V117, P885, DOI 10.1016/0006-291X(83)91679-0; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUSTIN K, 1982, COMMENTS INORG CHEM, V2, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; MACHICAO F, 1987, BIOCHEM J, V243, P797, DOI 10.1042/bj2430797; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MOONEY RA, 1983, EUR J BIOCHEM, V136, P603, DOI 10.1111/j.1432-1033.1983.tb07783.x; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; MOONEY RA, 1989, BIOCHEM BIOPH RES CO, V162, P1200, DOI 10.1016/0006-291X(89)90801-2; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; PANG DT, 1985, J BIOL CHEM, V260, P7131; PANG DT, 1985, J BIOL CHEM, V260, P5126; PETRUZZELLI LM, 1982, P NATL ACAD SCI-BIOL, V79, P6792, DOI 10.1073/pnas.79.22.6792; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SMITH JB, 1983, P NATL ACAD SCI-BIOL, V80, P6162, DOI 10.1073/pnas.80.20.6162; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAMURA S, 1983, BIOCHEM BIOPH RES CO, V113, P80, DOI 10.1016/0006-291X(83)90434-5; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	43	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14054	14060						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321133				2022-12-25	WOS:A1992JD32500044
J	KIM, HS; KELLY, RE; EVANS, DR				KIM, HS; KELLY, RE; EVANS, DR			THE STRUCTURAL ORGANIZATION OF THE HAMSTER MULTIFUNCTIONAL PROTEIN CAD - CONTROLLED PROTEOLYSIS, DOMAINS, AND LINKERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMYL-PHOSPHATE SYNTHETASE; INITIATES PYRIMIDINE BIOSYNTHESIS; CARBONIC-PHOSPHORIC ANHYDRIDE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; DIHYDROOROTASE DOMAIN; MAMMALIAN-CELLS; YEAST GENE; URA2 GENE	CAD is a multidomain protein that catalyzes the first three steps in mammalian de novo pyrimidine biosynthesis. The 243-kDa polypeptide consists of four functional domains; glutamine amidotransferase (GLNase), carbamyl phosphate synthetase (CPSase), aspartate transcarbamylase (ATCase), and dihydroorotase (DHOase). Controlled proteolysis of hamster CAD was found to cleave the molecule into 18 fragments which successively accumulate and disappear during the course of digestion. Each fragment was isolated and partially sequenced to determine its location in the polypeptide chain. Proteolysis was found to usually occur at the junctions between the domains and subdomains identified by sequence homology. All proteases of low to moderate specificity cleaved the molecule in a similar fashion. The rate of proteolysis widely varied and the interdomain regions were not always accessible to proteases. Each of the major functional domains is postulated to consist of subdomains. The duplicated halves of the CPSase domain (116 kDa) have a homologous structure consisting of 11-, 25-26-, and 21-22-kDa subdomains. Prolonged digestion cleaved the DHOase domain (36.6 kDa) into two stable species suggesting that this region is comprised of 11.5- and 15.0-kDa subdomains. Similarly, proteolysis of the 21-kDa catalytic subdomain of the GLNase domain (40 kDa) indicated a bilobal structure consisting of 12.3- and 8.5-kDa chain segments. The connecting region between the two ATCase subdomains (16.4 and 18 kDa) was not cleaved. Copurification of many of the domains showed that they remain associated by noncovalent interactions even after the connecting segments have been cleaved. The chain segments, the linkers, which connect the domains and subdomains were conserved in length but not in sequence, were predicted to be relatively hydrophilic and flexible but did not show a tendency to assume a particular secondary structure. These studies provide a more detailed map of the structural organization of the CAD polypeptide.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Wayne State University					NCI NIH HHS [CA-27674] Funding Source: Medline; NIGMS NIH HHS [GM-47399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; BEIN K, 1991, J BIOL CHEM, V266, P3791; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; HAGER SE, 1967, J BIOL CHEM, V242, P5674; HAGER SE, 1967, J BIOL CHEM, V242, P5667; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KILSTRUP M, 1988, EUR J BIOCHEM, V176, P421, DOI 10.1111/j.1432-1033.1988.tb14299.x; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KRAUHS E, 1982, ANAL BIOCHEM, V119, P153, DOI 10.1016/0003-2697(82)90679-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; MORI M, 1975, J BIOCHEM, V78, P239; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERS SG, 1978, J BIOL CHEM, V253, P800; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; ROSE GD, 1979, J MOL BIOL, V134, P447, DOI 10.1016/0022-2836(79)90363-2; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUMBSBY PC, 1984, BIOCHEM J, V217, P435; SCULLY JL, 1991, PROTEINS, V9, P191, DOI 10.1002/prot.340090305; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; SOUCIET JL, 1987, MOL GEN GENET, V207, P314, DOI 10.1007/BF00331595; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; WERNER M, 1985, EUR J BIOCHEM, V146, P371, DOI 10.1111/j.1432-1033.1985.tb08663.x; ZALKIN H, 1980, MULTIFUNCTIONAL PROT, P123	46	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7177	7184						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348059				2022-12-25	WOS:A1992HM05300110
J	KURLAND, IJ; ELMAGHRABI, MR; CORREIA, JJ; PILKIS, SJ				KURLAND, IJ; ELMAGHRABI, MR; CORREIA, JJ; PILKIS, SJ			RAT-LIVER 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE - PROPERTIES OF PHOSPHO-FORMS AND DEPHOSPHO-FORMS AND OF 2 MUTANTS IN WHICH SER32 HAS BEEN CHANGED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; AMINO-ACID-SEQUENCE; FRUCTOSE 2,6-BISPHOSPHATE; ISOCITRATE DEHYDROGENASE; ACTIVE-SITE; PHOSPHORYLATION; ENZYME; PHOSPHOFRUCTOKINASE-2; INACTIVATION; ACTIVATION	The mechanism by which cAMP-dependent protein kinase-catalyzed phosphorylation modulates the activities of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase was examined after site-specific mutation of the cAMP-dependent phosphorylation site (Ser32) to aspartic acid or alanine. The mutant and wild-type enzymes were overexpressed in Escherichia coli in a rich medium to levels as high as 30 mg/liter and were then purified to homogeneity. The kinetic properties of the Ser32-Ala mutant were identical with the dephosphorylated wild-type bifunctional enzyme. Mutation of Ser32 to aspartic acid mimicked several effects of cAMP-dependent phosphorylation: there was an increase in the K(m) for fructose 6-phosphate for 6-phosphofructo-2-kinase and an increase in the maximal velocity of fructose-2,6-bisphosphatase. Fructose-2,6-bisphosphatase activity of the Ser32-Asp mutant was 75% that of the phosphorylated wild-type enzyme, the mutant's kinase reaction had an identical dependence on fructose 6-phosphate, while its maximum velocity was only 60% that of the phosphorylated wild-type enzyme over a wide pH range. Furthermore, catalytic subunit-catalyzed in vitro phosphorylation of the Ser32-Ala mutant on Ser33 increased the K(m) for fructose 6-phosphate by 4-fold for the 6-phosphofructo-2-kinase. The results support the hypothesis that Ser32 is an important residue in the regulation of the activities of the bifunctional enzyme and that phosphorylation of Ser32 can be functionally substituted by aspartic acid. The results suggest a role for negative charge in the effect of phosphorylation.	UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	University of Mississippi; University of Mississippi Medical Center	KURLAND, IJ (corresponding author), SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794, USA.				NIDDK NIH HHS [DK 38354, T32DK07521] Funding Source: Medline; NIGMS NIH HHS [GM 41117] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521, R01DK038354, R37DK038354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041117] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZAN F, 1989, P NATL ACAD SCI USA, V86, P9643; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P57; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1987, J BIOL CHEM, V262, P11714; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FERSHT A, 1985, ENZYME STRUCTURE MEC, P109; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KEMP RG, 1990, FRUCTOSE 2 6 BISPHOS, P17; KOUNTZ PD, 1985, ARCH BIOCHEM BIOPHYS, V238, P531, DOI 10.1016/0003-9861(85)90197-3; KREBS EG, 1986, ENZYMES, V13, P3; LALOUX M, 1985, EUR J BIOCHEM, V148, P155, DOI 10.1111/j.1432-1033.1985.tb08819.x; LI L, 1992, IN PRESS J BIOL CHEM; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUS F, 1988, J BIOL CHEM, V263, P6058; MURRAY KJ, 1984, J BIOL CHEM, V259, P7673; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; PILKIS SJ, 1987, ENZYMES, V18, P3; SAMBROOK J, 1986, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STEWART HB, 1986, J BIOL CHEM, V261, P8793; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1989, P NATL ACAD SCI USA, V86, P7316, DOI 10.1073/pnas.86.19.7316; TAULER A, 1990, J BIOL CHEM, V265, P15617; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V101, P1078; GRAPHPAD INPLOT PROG	40	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4416	4423						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1339450				2022-12-25	WOS:A1992HF64200026
J	CHERIFI, Y; PIGEON, C; LEROMANCER, M; BADO, A; REYLDESMARS, F; LEWIN, MJM				CHERIFI, Y; PIGEON, C; LEROMANCER, M; BADO, A; REYLDESMARS, F; LEWIN, MJM			PURIFICATION OF A HISTAMINE-H3 RECEPTOR NEGATIVELY COUPLED TO PHOSPHOINOSITIDE TURNOVER IN THE HUMAN GASTRIC CELL-LINE HGT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROGENIC MICROVASCULAR LEAKAGE; RAT-BRAIN; SOMATOSTATIN RECEPTOR; MOLECULAR-CLONING; H-3; INHIBITION; LIGANDS; AIRWAYS; BINDING; CONTRACTIONS	The histamine H-3 receptor agonist (R)alpha-methylhistamine (MeHA) inhibited, in a nanomolar range, basal and carbachol-stimulated inositol phosphate formation in the human gastric tumoral cell line HGT1-clone 6. The inhibition was reversed by micromolar concentrations of the histamine H-3 receptor antagonist thioperamide and was sensitive to cholera or pertussis toxin treatment. Using [H-3]N(alpha)-MeHA as specific tracer, high affinity binding sites were demonstrated with a B(max) of 54 +/- 3 fmol/mg of protein and a K(D) of either 0.61 +/- 0.04 or 2.2 +/- 0.4 nM, in the absence or presence of 50 muM GTP[gamma]S, respectively. The binding sites were solubilized by Triton X-100 and prepurified by gel chromatography. They were separated from the histamine H-2 receptor sites by filtration through Sepharose-famotidine and finally retained on Sepharose-thioperamide. The purified sites concentrated in one single silver-stained protein band of 70 kDa in SDS-polyacrylamide gel electrophoresis. They specifically bound [H-3]N(alpha)-MeHA with a K(D) of 1.6 +/- 0.1 nM and a B(max) of 12,000 +/- 750 pmol/mg of protein. This corresponds to a 90,225-fold purification over cell lysate and a purity degree of 84%. Binding was competitively displaced by N(alpha)-MeHA (IC50 = 5.8 +/- 0.7 nM), (R)alpha-MeHA (IC50 = 9 +/- 1 nM), and thioperamide (IC50 = 85 +/- 10 nM), but not by famotidine (H-2 antagonist) or by mepyramine (H-1 antagonist). These findings provide the first evidence for solubilization, purification, and molecular mass characterization of the histamine H-3 receptor protein and for the negative coupling of this receptor phosphatidylinositol turnover through a so far unidentified G protein.			CHERIFI, Y (corresponding author), HOP BICHAT,UNITE RECH GASTROENTEROL,INSERM,U10,170 BLVD NEY,F-75877 PARIS 18,FRANCE.			Le Romancer, Muriel/0000-0002-8491-4015; BADO, Andre/0000-0002-8007-1460				ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; ARRANG JM, 1990, EUR J PHARM-MOLEC PH, V188, P219, DOI 10.1016/0922-4106(90)90005-I; ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; BADO A, 1992, AM J PHYSIOL, V262, pG56, DOI 10.1152/ajpgi.1992.262.1.G56; BADO A, 1991, AM J PHYSIOL, V260, pG631, DOI 10.1152/ajpgi.1991.260.4.G631; BERTACCINI G, 1991, ITAL J GASTROENTEROL, V23, P378; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERET AM, 1985, AGENTS ACTIONS, V17, P436; CHEW CS, 1980, AM J PHYSIOL, V238, pG312, DOI 10.1152/ajpgi.1980.238.4.G312; FELDMAN M, 1990, NEW ENGL J MED, V323, P1672; GANTZ I, 1991, BIOCHEM BIOPH RES CO, V178, P1386, DOI 10.1016/0006-291X(91)91047-G; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GARBARG M, 1989, EUR J PHARMACOL, V164, P1, DOI 10.1016/0014-2999(89)90225-2; GESPACH C, 1984, BIOCHEM BIOPH RES CO, V120, P641, DOI 10.1016/0006-291X(84)91304-4; GESPACH C, 1988, EUR J CLIN INVEST, V19, P1; HILL SJ, 1990, PHARMACOL REV, V42, P45; ICHINOSE M, 1990, J APPL PHYSIOL, V68, P21, DOI 10.1152/jappl.1990.68.1.21; ICHINOSE M, 1989, BRIT J PHARMACOL, V97, P13, DOI 10.1111/j.1476-5381.1989.tb11917.x; ICHINOSE M, 1989, EUR J PHARMACOL, V174, P49, DOI 10.1016/0014-2999(89)90872-8; KORTE A, 1990, BIOCHEM BIOPH RES CO, V168, P979, DOI 10.1016/0006-291X(90)91125-C; LABOISSE CL, 1982, CANCER RES, V42, P1541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIN MJM, 1992, THERAPIE, V47, P93; LEWIN MJM, 1988, CONTROL ACID SECRETI, P3; LIN JS, 1990, BRAIN RES, V523, P325, DOI 10.1016/0006-8993(90)91508-E; LINARD C, 1992, REGUL PEPTIDES, V41, P219, DOI 10.1016/0167-0115(92)90115-B; LWIN MJM, 1991, SCAND J GASTROE S180, V26, P53; MENKVELD GJ, 1990, EUR J PHARMACOL, V186, P343, DOI 10.1016/0014-2999(90)90458-I; POLI E, 1991, LIFE SCI, V48, P63; REYLDESMARS F, 1991, CR ACAD SCI III-VIE, V312, P221; REYLDESMARS F, 1989, J BIOL CHEM, V264, P18789; REYLDESMARS F, 1986, REGUL PEPTIDES, V16, P207, DOI 10.1016/0167-0115(86)90020-0; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; SCHLICKER E, 1988, N-S ARCH PHARMACOL, V337, P588; SCHWARTZ JC, 1990, AGENTS ACTIONS, V30, P13, DOI 10.1007/BF01968988; SOLL AH, 1987, PHYSL GASTROINTESTIN, P883; SOUMARMON A, 1974, BIOCHIM BIOPHYS ACTA, V339, P403, DOI 10.1016/0005-2736(74)90167-9; TRZECIAKOWSKI JP, 1987, J PHARMACOL EXP THER, V243, P874; WEST RE, 1990, J NEUROCHEM, V55, P1612, DOI 10.1111/j.1471-4159.1990.tb04946.x; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	41	53	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25315	25320						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334091				2022-12-25	WOS:A1992KB60300062
J	HENRY, NL; SAYRE, MH; KORNBERG, RD				HENRY, NL; SAYRE, MH; KORNBERG, RD			PURIFICATION AND CHARACTERIZATION OF YEAST RNA POLYMERASE-II GENERAL INITIATION FACTOR-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIE; PROMOTER INVITRO; PROTEINS; BINDING; CLONING; SUBUNIT; MOTIFS; LIVER; DNA	Yeast RNA polymerase II general initiation factor g was purified to near homogeneity on the basis of its function in a reconstituted transcription system. Polypeptides of 30, 54, and 105 kDa co-purified with transcriptional activity, forming a complex with a mass of 300 kDa as judged by gel filtration, but only 100 kDa based on sedimentation in glycerol gradients, suggesting an elongated shape. Transcription activity could be reconstituted after separation of the three polypeptides under denaturing conditions; the 54- and 105-kDa subunits were both essential, while the 30-kDa subunit was slightly stimulatory. Factor g was required for initiation at all promoters tested, including those from Saccharomyces cerevisiae, Schizosaccharomyces pombe, and adenovirus. Factor g can stably associate with RNA polymerase II, as shown by co-sedimentation in a glycerol gradient.			HENRY, NL (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY JW, 1991, J BIOL CHEM, V266, P17771; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1989, J BIOL CHEM, V264, P8913; GERARD M, 1991, J BIOL CHEM, V266, P20940; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	28	58	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23388	23392						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331085				2022-12-25	WOS:A1992JY16300103
J	CIOE, L; MUKHOPADHYAY, S; ROVERA, G				CIOE, L; MUKHOPADHYAY, S; ROVERA, G			SELECTIVE-INHIBITION OF PROLIFERATION IN V-ABL-TRANSFORMED AND BCR-ABL-TRANSFORMED CELLS BY A NUCLEOSIDE ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; PHILADELPHIA-CHROMOSOME; GENE-PRODUCT; GRANULOCYTIC DIFFERENTIATION; KINASE-ACTIVITY; LINE; EXPRESSION; 9-(2-HYDROXYETHOXYMETHYL)GUANINE; INTERLEUKIN-3; SEQUENCE	The nucleoside analog acyclovir (9-[2-hydroxyethoxy)methyl]guanine or acycloguanosine; ACV) inhibited the in vitro transformation of NIH 3T3 cells by Abelson murine leukemia virus and the proliferation of abl- and bcr-abl-transformed hemopoietic murine cell lines. This effect is selective since ACV at the same concentration had no effect on the src and Ha-ras transformation of NIH 3T3 cells or on the proliferation of hemopoietic cells transformed by those oncogenes. The inhibitory effect on proliferation of abl-transformed cells correlated with the extent of ACV triphosphate formation and incorporation into cellular DNA that was greater than that in normal or other oncogene-transformed cells. The increased ACV triphosphate formation might be due to a higher level of 5'-nucleotidase, the enzyme responsible for trace levels of ACV phosphorylation in uninfected cells.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NATIONAL CANCER INSTITUTE [P30CA010815, P01CA052009] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52009, CA 10815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORELLI E, 1988, P NATL ACAD SCI USA, V85, P7572; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; FYFE JA, 1978, J BIOL CHEM, V253, P8721; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; ISCOVE NN, 1971, BLOOD-J HEMATOL, V37, P1; JACKSON P, 1989, EMBO J, V8, P49; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KELLER PM, 1985, J BIOL CHEM, V260, P8664; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KRUGER A, 1991, ONCOGENE, V6, P245; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LARSSON A, 1981, ANTIVIR RES, V1, P55, DOI 10.1016/0166-3542(81)90032-2; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAVILIO F, 1989, ONCOGENE, V4, P301; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REDDY EP, 1988, ONCOGENE HDB, P3; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROVERA G, 1987, ONCOGENE, V1, P29; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V21, P129, DOI 10.1016/0165-4608(86)90039-7; SCHER CD, 1975, P NATL ACAD SCI USA, V72, P1932; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SEGEL IH, 1975, BEHAVIOR ANAL RAPID, P810; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STEMBERG K, 1986, J BIOL CHEM, V261, P2134; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WITTE ON, 1980, NATURE, V332, P2269; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	38	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22178	22182						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331046				2022-12-25	WOS:A1992JW71900031
J	SCOTT, DJ; DEAN, DR; NEWTON, WE				SCOTT, DJ; DEAN, DR; NEWTON, WE			NITROGENASE-CATALYZED ETHANE PRODUCTION AND CO-SENSITIVE HYDROGEN EVOLUTION FROM MOFE PROTEINS HAVING AMINO-ACID SUBSTITUTIONS IN AN ALPHA-SUBUNIT FEMO COFACTOR-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; KLEBSIELLA-PNEUMONIAE NITROGENASE; AZOTOBACTER-VINELANDII NITROGENASE; ELECTRON-PARAMAGNETIC RESONANCE; SUBSTRATE REDUCTION PROPERTIES; CONSERVED CYSTEINE RESIDUES; SITE-DIRECTED MUTAGENESIS; WILD-TYPE; VANADIUM-NITROGENASE; BETA-SUBUNIT	Unlike wild type, certain Mo-dependent nitrogenases, which are expressed in non-N2-fixing mutant strains of Azotobacter vinelandii and have single amino acid substitutions within a region of the MoFe protein alpha-subunit proposed to encompass an FeMo cofactor-binding domain, are able to catalyze the reduction of acetylene by both two and four electrons to yield ethylene and ethane, respectively (Scott, D. J., May, H. D., Newton, W. E., Brigle, K. E., and Dean, D. R. (1990) Nature 343, 188-190). Although the V-dependent nitrogenase is also able to catalyze the reduction of acetylene to the same two- and four-electron products (Dilworth, M. J., Eady, R. R., Robson, R. L., and Miller, R. W. (1987) Nature 327, 167-168), we find that ethane formation from acetylene catalyzed by the altered Mo-dependent nitrogenases occurs by a different mechanism, which is distinguished by: (i) an increased sensitivity to CO; (ii) the absence of a lag; and (iii) no temperature dependence of product distribution among ethylene and ethane during acetylene reduction. An altered MoFe protein, which was purified from one such mutant strain having the alpha-subunit glutaminyl 191 residue substituted by lysyl, exhibited both a changed S = 3/2 EPR spectrum and changes in the distribution of electrons to various products when compared to wild type. Also, unlike wild type, this altered MoFe protein catalyzed proton reduction that is inhibited by carbon monoxide (CO). Because proton reduction catalyzed by a nitrogenase that has a FeMo cofactor with citrate rather than homocitrate as its organic constituent (Liang, J., Madden, M., Shah, V. K., and Burris, R. H. (1990) Biochemistry 29, 8577-8581) is also inhibited by CO, the possibility arose that changes in the polypeptide environment of FeMo cofactor might have caused a rearrangement in its molecular structure or composition. However, this possibility was ruled out by biochemical reconstitution studies (using FeMo cofactor isolated from both the wild-type and altered MoFe proteins), which were monitored by EPR spectroscopy and resulting catalytic activity.	VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & NUTR, BLACKSBURG, VA 24061 USA; USDA ARS, WESTERN REG RES CTR, BERKELEY, CA 94710 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA	Virginia Polytechnic Institute & State University; United States Department of Agriculture (USDA); Virginia Polytechnic Institute & State University					NIDDK NIH HHS [DK-37255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALT HG, 1982, ANGEW CHEM INT EDIT, V21, P78, DOI 10.1002/anie.198200781; ASHBY GA, 1987, BIOCHEM J, V247, P547, DOI 10.1042/bj2470547; BISHOP PE, 1980, P NATL ACAD SCI-BIOL, V77, P7342, DOI 10.1073/pnas.77.12.7342; Bishop PE, 1992, BIOL NITROGEN FIXATI, P736; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BRIGLE KE, 1987, P NATL ACAD SCI USA, V84, P7066, DOI 10.1073/pnas.84.20.7066; Bulen W., 1965, NONHEMA IRON PROTEIN, P261; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURNS R. C., 1965, BIOCHIM BIOPHYS ACTA, V105, P437; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DEAN DR, 1990, MOL MICROBIOL, V4, P1505, DOI 10.1111/j.1365-2958.1990.tb02061.x; DEAN DR, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P95; DILWORTH MJ, 1991, BIOCHEM J, V277, P465, DOI 10.1042/bj2770465; DILWORTH MJ, 1988, BIOCHEM J, V249, P745, DOI 10.1042/bj2490745; DILWORTH MJ, 1987, NATURE, V327, P167, DOI 10.1038/327167a0; EADY RR, 1987, BIOCHEM J, V244, P197, DOI 10.1042/bj2440197; EIDSNESS MK, 1986, J AM CHEM SOC, V108, P2746, DOI 10.1021/ja00270a039; EULER WB, 1984, BIOCHEMISTRY-US, V23, P3021, DOI 10.1021/bi00308a027; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAGEMAN RV, 1980, BIOCHIM BIOPHYS ACTA, V591, P63, DOI 10.1016/0005-2728(80)90220-0; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; HALES BJ, 1986, BIOCHEMISTRY-US, V25, P7253, DOI 10.1021/bi00371a001; HARDY RWF, 1965, BIOCHEM BIOPH RES CO, V20, P539, DOI 10.1016/0006-291X(65)90431-6; HARRIS GS, 1990, J BIOL CHEM, V265, P15909; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HEDMAN B, 1988, J AM CHEM SOC, V110, P3798, DOI 10.1021/ja00220a013; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KENT HM, 1990, MOL MICROBIOL, V4, P1497, DOI 10.1111/j.1365-2958.1990.tb02060.x; KENT HM, 1989, BIOCHEM J, V264, P257, DOI 10.1042/bj2640257; KURTZ DM, 1979, P NATL ACAD SCI USA, V76, P4986, DOI 10.1073/pnas.76.10.4986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG JH, 1990, BIOCHEMISTRY-US, V29, P8577, DOI 10.1021/bi00489a011; LOWE DJ, 1984, BIOCHEM J, V224, P877, DOI 10.1042/bj2240877; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MAY HD, 1991, BIOCHEM J, V277, P457, DOI 10.1042/bj2770457; MCLEAN PA, 1987, J AM CHEM SOC, V109, P943, DOI 10.1021/ja00237a075; MCLEAN PA, 1981, NATURE, V292, P655, DOI 10.1038/292655a0; MCLEAN PA, 1989, BIOCHEMISTRY-US, V28, P9402, DOI 10.1021/bi00450a023; MORTENSON LE, 1973, BIOCHIM BIOPHYS ACTA, V292, P422, DOI 10.1016/0005-2728(73)90048-0; MUNCK E, 1975, BIOCHIM BIOPHYS ACTA, V400, P32, DOI 10.1016/0005-2795(75)90124-5; NAGATANI HH, 1974, J BACTERIOL, V120, P697, DOI 10.1128/JB.120.2.697-701.1974; NAKAMURA A, 1972, J AM CHEM SOC, V94, P1886, DOI 10.1021/ja00761a017; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; PAU RN, 1989, J BACTERIOL, V171, P124, DOI 10.1128/jb.171.1.124-129.1989; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBERTS GP, 1978, J BACTERIOL, V136, P267, DOI 10.1128/JB.136.1.267-279.1978; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBSON RL, 1986, NATURE, V322, P388, DOI 10.1038/322388a0; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; SMITH BE, 1973, BIOCHEM J, V135, P331, DOI 10.1042/bj1350331; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; THOMANN H, 1987, J AM CHEM SOC, V109, P7913, DOI 10.1021/ja00259a067; THOMANN H, 1991, P NATL ACAD SCI USA, V88, P6620, DOI 10.1073/pnas.88.15.6620; TRUE AE, 1990, J AM CHEM SOC, V112, P651, DOI 10.1021/ja00158a024; WHERLAND S, 1981, BIOCHEMISTRY-US, V20, P5132, DOI 10.1021/bi00521a006; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4	66	65	68	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20002	20010						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328190				2022-12-25	WOS:A1992JR85800042
J	DEEG, MA; MURRAY, NR; ROSENBERRY, TL				DEEG, MA; MURRAY, NR; ROSENBERRY, TL			IDENTIFICATION OF GLYCOINOSITOL PHOSPHOLIPIDS IN RAT-LIVER BY REDUCTIVE RADIOMETHYLATION OF AMINES BUT NOT IN H4IIE HEPATOMA-CELLS OR ISOLATED HEPATOCYTES BY BIOSYNTHETIC LABELING WITH GLUCOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; VARIANT SURFACE GLYCOPROTEINS; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; MEMBRANE ANCHOR; LEISHMANIA-MAJOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; INSULIN MEDIATORS; PRECURSOR; PROTEINS	The identification of free glycoinositol phospholipids (GPIs) following biosynthetic labeling with [H-3]glucosamine in cultured cells has been reported by several laboratories. We applied this procedure to two of the cell types used in these studies, H4IIE hepatoma cells and isolated hepatocytes, but were unable to detect a [H-3]glucosamine-containing lipid that met any of the criteria for GPIs, including sensitivity to phosphatidylinositol-specific phospholipase C (PIPLC) or GPI-specific phospholipase D. Part of the difficulty in radiolabeling a GPI by this procedure was the rapid metabolic conversion of [H-3]glucosamine to galactosamine and neutral or anionic derivatives. A PIPLC-sensitive radiolabeled lipid was detected only after 16 h of labeling. The water-soluble fragments released from this lipid by PIPLC corresponded largely to myoinositol 1,2-cyclic phosphate and myo-inositol 1-phosphate, products expected from PIPLC cleavage of phosphatidylinositol or lyso-phosphatidylinositol. In an alternative approach that we introduce here, free GPIs in lipid extracts from rat liver plasma membranes were labeled by reductive radiomethylation. This procedure, which radiomethylates primary and secondary amines, has been shown to label a glucosamine residue adjacent to inositol in all GPIs characterized to date. The labeled extracts were fractionated by two-dimensional thin-layer chromatography, and a cluster of polar labeled lipids were assigned as GPIs based upon the following observations. 1) They were cleaved by PIPLC, 2) after hydrolysis in 6 N HCl, both radiomethylated glucosamine and a glucosamine-inositol conjugate were identified by cation exchange chromatography, and 3) hydrolysis in 4 M trifluoroacetic acid generated a fragment consistent with glucosamine-inositol-phosphate. These results illustrate new criteria for the identification of GPIs. The labeled GPIs also contained radiomethylated ethanolamine, another component found in GPI anchors of proteins and in mature lipid precursors of GPI anchors, suggesting that the liver plasma membrane GPIs retained considerable structural homology to GPI anchors.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NIDDK NIH HHS [DK 08441, DK38181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181, F32DK008441] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARR K, 1984, BIOCHEMISTRY-US, V23, P5581, DOI 10.1021/bi00318a031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS EP, 1984, FEBS LETT, V169, P293, DOI 10.1016/0014-5793(84)80336-1; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DOERING TL, 1990, J BIOL CHEM, V265, P611; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FATEMI SH, 1987, J BIOL CHEM, V262, P4728; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, J BIOL CHEM, V266, P8392; GAULTON GN, 1991, DIABETES, V40, P1297, DOI 10.2337/diabetes.40.10.1297; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; HAAS R, 1985, ANAL BIOCHEM, V148, P154, DOI 10.1016/0003-2697(85)90640-2; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; HANSON BA, 1980, J LIPID RES, V21, P309; HARMS E, 1973, EUR J BIOCHEM, V32, P254, DOI 10.1111/j.1432-1033.1973.tb02605.x; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; IGARASHI Y, 1987, BIOCHEM BIOPH RES CO, V145, P249, DOI 10.1016/0006-291X(87)91313-1; LARNER J, 1988, COLD SPRING HARB SYM, V53, P965, DOI 10.1101/SQB.1988.053.01.111; LEE HC, 1992, BIOCHEMISTRY-US, V31, P3236, DOI 10.1021/bi00127a027; MACAULAY SL, 1990, BIOCHEM J, V271, P427, DOI 10.1042/bj2710427; MALEY F, 1959, BIOCHIM BIOPHYS ACTA, V31, P577, DOI 10.1016/0006-3002(59)90047-2; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; MATO JM, 1987, J BIOL CHEM, V262, P2131; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MERIDA I, 1988, FEBS LETT, V236, P251, DOI 10.1016/0014-5793(88)80325-9; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; PERELMAN A, 1989, EUR J BIOCHEM, V182, P203, DOI 10.1111/j.1432-1033.1989.tb14818.x; PUOTI A, 1991, J BIOL CHEM, V266, P21051; RAY TK, 1969, J BIOL CHEM, V244, P5528; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROMERO G, 1991, CELL BIOL INT REP, V15, P827, DOI 10.1016/0309-1651(91)90036-I; ROSENBERRY TL, 1989, METHOD CELL BIOL, V32, P231; ROSS GAM, 1990, ANN REV CELL BIOL, V6, P1; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SALTIEL AR, 1988, AM J PHYSIOL, V255, pC1, DOI 10.1152/ajpcell.1988.255.1.C1; SEYFRED MA, 1984, J BIOL CHEM, V259, P7659; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; SUZUKI S, 1991, J BIOL CHEM, V266, P8115; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; THAKKAR JK, 1990, J BIOL CHEM, V265, P5475; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; VARELA I, 1990, EUR J BIOCHEM, V188, P213, DOI 10.1111/j.1432-1033.1990.tb15392.x	52	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18581	18588						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326529				2022-12-25	WOS:A1992JN50200053
J	HOSODA, K; NAKAO, K; TAMURA, N; ARAI, H; OGAWA, Y; SUGA, S; NAKANISHI, S; IMURA, H				HOSODA, K; NAKAO, K; TAMURA, N; ARAI, H; OGAWA, Y; SUGA, S; NAKANISHI, S; IMURA, H			ORGANIZATION, STRUCTURE, CHROMOSOMAL ASSIGNMENT, AND EXPRESSION OF THE GENE ENCODING THE HUMAN ENDOTHELIN-A RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CDNA; SEQUENCE; RAT; PROMOTER; CELLS; DNA; PROTEINS; REGIONS; SITES	We have isolated and characterized the gene for the human endothelin-A receptor. Southern blot analyses demonstrated a single copy gene for the receptor. The gene spans more than 40 kilobases and contains eight exons and seven introns. Intron 1 exists in the 5'-noncoding region, and introns 2-7 occur in the coding region. The locations of introns 2-7 exist before or after the regions encoding the membrane-spanning domains. The transcription start site, determined by primer extension experiments, is 502 base pairs upstream of the methionine initiation codon. The 5'-flanking region lacks a typical TATA box but contains a potential SP-1-binding site 27 base pairs upstream of the transcription start site. Using human-rodent somatic hybrid cell DNA, the gene was assigned to human chromosome 4. Northern blot analyses revealed a 4.3-kilobase mRNA in a wide variety of human tissues, at the highest level in the aorta and at a substantial level in the cultured human mesangial cells. This is the first report of cloning of a gene for a member of the endothelin receptor family. The present study should give a clue to the discovery of possible disorders of the endothelin-A receptor, as well as facilitate the elucidation of the mechanisms by which the gene expression is regulated.	KYOTO UNIV,SCH MED,DEPT MED,DIV 2,54 SHOGOIN KAWAHARA CHO,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,SCH MED,INST IMMUNOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University				Ogawa, Yoshihiro/0000-0002-0834-2836				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; LEE ME, 1990, J BIOL CHEM, V265, P10446; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; Nayler W G, 1990, Trends Pharmacol Sci, V11, P96, DOI 10.1016/0165-6147(90)90188-E; NICOSIA RF, 1990, LAB INVEST, V63, P115; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sambrook J, 1989, MOL CLONING LABORATO; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WARNER TD, 1989, EUR J PHARMACOL, V159, P325, DOI 10.1016/0014-2999(89)90167-2; WATANABE H, 1989, BIOCHEM BIOPH RES CO, V161, P1252, DOI 10.1016/0006-291X(89)91377-6; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	41	165	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18797	18804						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326535				2022-12-25	WOS:A1992JN50200083
J	SNOW, JW; GLICK, JM; PHILLIPS, MC				SNOW, JW; GLICK, JM; PHILLIPS, MC			THE PHASE-BEHAVIOR OF CHOLESTERYL ESTERS IN INTRACELLULAR INCLUSIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; TISSUE-CULTURE CELLS; ATHEROSCLEROTIC LESIONS; PHYSICAL STATE; LIPID DEPOSITS; FOAM CELLS; METABOLISM; MACROPHAGES; DISPERSIONS; MODEL	Differential scanning calorimetry and polarizing light microscopy have been used to investigate kinetic and thermodynamic properties of the phase behavior of cholesteryl ester contained in Fu5AH rat hepatoma cells and J774 murine macrophages. These cultured cells store cholesteryl esters as cytoplasmic inclusions of approximately 1-mu-m diameter and thus are models of the foam cells characteristic of atherosclerotic plaque. Simple binary mixtures of cholesteryl palmitate and cholesteryl oleate, the predominant cholesteryl esters in cellular inclusions in both cell types serve as models to explain important aspects of the phase behavior of these inclusions. Although inclusions should exist as stable crystals at 37-degrees-C under conditions of thermodynamic equilibrium, microscopic examination of cells indicates that inclusions exist as metastable liquid crystals at 37-degrees-C for extended periods of time. Using an analytical model based on nucleation theory, we predict that the cholesteryl ester inclusions should be liquid-crystalline in the cytoplasm of living cells. This may not be true either for lysosomal cholesteryl ester or for extracellular cholesteryl ester present in advanced atherosclerotic plaque where fusion of droplets can enhance the possibility of crystallization. The enhanced metastability of the relatively fluid liquid-crystalline state in cellular inclusions should result in increased activity of the neutral cholesteryl ester hydrolase in living cells.	MED COLL PENN, DEPT PHYSIOL BIOCHEM, PHILADELPHIA, PA 19129 USA	Drexel University	SNOW, JW (corresponding author), PHILADELPHIA COLL PHARM & SCI, DEPT CHEM, PHILADELPHIA, PA 19104 USA.			Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL 22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN SJ, 1984, J BIOL CHEM, V259, P3844; BILLHEIMER JT, 1983, J LIPID RES, V24, P1646; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CARROLL RM, 1981, J LIPID RES, V22, P359; CROLL DH, 1985, BIOCHEMISTRY-US, V24, P7971, DOI 10.1021/bi00348a020; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Eyring H., 1963, MODERN CHEM KINETICS; GINSBURG GS, 1984, PROG LIPID RES, V23, P135, DOI 10.1016/0163-7827(84)90002-X; GLICK JM, 1983, J BIOL CHEM, V258, P3425; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Hatch F T, 1968, Adv Lipid Res, V6, P1; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KATZ SS, 1977, J CLIN INVEST, V59, P1045, DOI 10.1172/JCI108727; KROON PA, 1981, J BIOL CHEM, V256, P5332; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; LUPU F, 1987, ATHEROSCLEROSIS, V67, P127, DOI 10.1016/0021-9150(87)90273-5; MAHLBERG FH, 1990, BIOCHIM BIOPHYS ACTA, V1045, P291, DOI 10.1016/0005-2760(90)90133-I; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; MINOR LK, 1989, J LIPID RES, V30, P189; NOBLE RP, 1968, J LIPID RES, V9, P693; OLIVER MJ, 1975, J CRYST GROWTH, V30, P343, DOI 10.1016/0022-0248(75)90010-X; PITOT H. C., 1964, NAT CANCER INST MONOGR, V13, P229; RALPH P, 1975, J IMMUNOL, V114, P898; ROTHBLAT GH, 1977, EXP MOL PATHOL, V26, P318, DOI 10.1016/0014-4800(77)90059-4; ROTHBLAT GH, 1974, LIPIDS, V9, P526, DOI 10.1007/BF02532500; SKODA W, 1963, J COLL SCI IMP U TOK, V18, P568, DOI 10.1016/0095-8522(63)90049-7; SMALL DM, 1974, SCIENCE, V185, P222, DOI 10.1126/science.185.4147.222; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SMALL DM, 1986, HDB LIPID RES, V4, P395; SNOW J, 1990, BIOCHEMISTRY-US, V29, P2464, DOI 10.1021/bi00462a005; SNOW JW, 1988, BIOCHEMISTRY-US, V27, P3640, DOI 10.1021/bi00410a018; TURNBULL D, 1949, J CHEM PHYS, V17, P71, DOI 10.1063/1.1747055; TURNBULL D, 1952, J CHEM PHYS, V20, P411, DOI 10.1063/1.1700435; WERB Z, 1972, J EXP MED, V135, P21, DOI 10.1084/jem.135.1.21; YAUYOUNG AO, 1982, BIOCHIM BIOPHYS ACTA, V710, P181, DOI 10.1016/0005-2760(82)90148-5	38	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18564	18572						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326528				2022-12-25	WOS:A1992JN50200051
J	RANDAZZO, PA; NORTHUP, JK; KAHN, RA				RANDAZZO, PA; NORTHUP, JK; KAHN, RA			REGULATORY GTP-BINDING PROTEINS (ADP-RIBOSYLATION-FACTOR, G(T), AND RAS) ARE NOT ACTIVATED DIRECTLY BY NUCLEOSIDE DIPHOSPHATE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; ADENYLATE-CYCLASE; TRIPHOSPHATE CONFORMATION; TUMOR-METASTASIS; ESCHERICHIA-COLI; BOUND GDP; P21; CELLS; GS; RHODOPSIN	The expression of nucleoside diphosphate kinase (NDK) genes has been implicated as a negative regulator of murine and human tumor metastases and is critical to proper development in Drosophilia melanogaster. Molecular mechanisms for the role(s) of NDK in these complex processes have not yet been elucidated, but several reports have suggested that these and many other signal transduction pathways may be activated by NDK acting directly on a regulatory GTP-binding protein(s). To test this hypothesis, we examined the ability of NDK to catalyze the phosphorylation of the GDP bound to the following three members of the superfamily of regulatory GTP-binding proteins: G(t), Ha-ras p21, and ARF. We have found no evidence to support the hypothesis that NDK can directly activate any GTP-binding protein. Rather, evidence is presented which clearly shows that all of the GTP formed upon incubation of GTP-binding proteins with NDK is the result of NDK utilizing free GDP as substrate. The GDP bound to the regulatory proteins is not a substrate for NDK under conditions in which free nucleotides are rapidly and efficiently phosphorylated. The importance of appropriate controls for dissociation of GDP from the regulatory proteins both during the NDK reaction and during the analysis of product is demonstrated. We believe there is currently no experimental evidence to support the hypothesis that NDK can directly activate a regulatory GTP-binding protein.	NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BIOL CHEM LAB,BETHESDA,MD 20892; NIMH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				Agarwal R P, 1978, Methods Enzymol, V51, P376; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BRANDT DR, 1985, J BIOL CHEM, V260, P266; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; HAMEL E, 1984, J BIOL CHEM, V259, P1060; JACOBS M, 1979, EUR J BIOCHEM, V99, P613, DOI 10.1111/j.1432-1033.1979.tb13294.x; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIKKAWA S, 1991, J BIOL CHEM, V266, P12795; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KIMURA N, 1983, J BIOL CHEM, V258, P2609; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LACOMBE M L, 1992, Trends in Pharmacological Sciences, V13, P46, DOI 10.1016/0165-6147(92)90020-7; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MANNE V, 1984, P NATL ACAD SCI-BIOL, V81, P6953, DOI 10.1073/pnas.81.22.6953; MOURAD N, 1966, J BIOL CHEM, V241, P271; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OHTSUKI K, 1985, BIOCHEM INT, V11, P719; OHTSUKI K, 1987, BIOCHIM BIOPHYS ACTA, V929, P231, DOI 10.1016/0167-4889(87)90248-5; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; OTERO AS, 1988, SCIENCE, V242, P443, DOI 10.1126/science.3051383; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PENNINGROTH SM, 1977, J MOL BIOL, V115, P643, DOI 10.1016/0022-2836(77)90108-5; POE M, 1985, J BIOL CHEM, V260, P3906; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SEIFERT R, 1988, EUR J BIOCHEM, V175, P51, DOI 10.1111/j.1432-1033.1988.tb14165.x; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; WEISS O, 1989, J BIOL CHEM, V264, P21066; WIELAND T, 1989, FEBS LETT, V245, P189, DOI 10.1016/0014-5793(89)80219-4; WIELAND T, 1991, EUR J PHARM-MOLEC PH, V208, P17, DOI 10.1016/0922-4106(91)90046-K	48	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18182	18189						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325460				2022-12-25	WOS:A1992JM22300107
J	SPRING, DJ; CHENLIU, LW; CHATTERTON, JE; ELOVSON, J; SCHUMAKER, VN				SPRING, DJ; CHENLIU, LW; CHATTERTON, JE; ELOVSON, J; SCHUMAKER, VN			LIPOPROTEIN ASSEMBLY - APOLIPOPROTEIN-B SIZE DETERMINES LIPOPROTEIN CORE CIRCUMFERENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LIVER-CELL; ELECTRON-MICROSCOPY; RAT-LIVER; PLASMA; LINE; CHOLESTEROL; APOPROTEIN; PROTEIN; B-100	Apolipoprotein B (apoB) is an essential structural protein for the two triglyceride-rich lipoproteins synthesized by humans: chylomicrons and very low density lipoproteins. Although much is known about the role of apoB in clearance of lipoproteins from the circulation, relatively little is known about its role in the assembly of nascent lipoproteins. Therefore, we have investigated the relationship between the length of various N-terminal apoB fragments and the characteristics of the lipoproteins with which these fragments were associated. After the addition of puromycin, HepG2 cells secreted a discrete series of C-terminally truncated apoB fragments on lipoprotein particles including apoB25, apoB29, apoB31, apoB33, apoB36, apoB38, apoB42, apoB45, apoB49, apoB51, apoB55, apoB70, and apoB80. Also, using plasmids encoding apoB26, apoB33, apoB37, apoB42, and apoB48, C-terminally truncated apoB fragments were expressed and secreted after transient transfection of HepG2 cells. Lipoproteins bearing the metabolically labeled apoB fragments were isolated from the cell culture media and characterized in terms of size, density, flotation coefficient, and composition. Lipoprotein radii, calculated from their flotation coefficients and buoyant densities, were used to derive the circumference of the non-polar core of each lipoprotein species. When plotted as a function of apoB size, core circumference defined a straight line of near-zero intercept. The slope of this line was approximately 1 angstrom of core circumference/1 kDa of apoB molecular mass. A model for the mechanism of lipoprotein assembly in HepG2 cells, consistent with the concept that apoB size determines lipoprotein core circumference, is proposed.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; WADSWORTH VET ADM MED CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Spring, Denise J./0000-0002-4593-0901	NHLBI NIH HHS [HL07386, HL28481] Funding Source: Medline; NIGMS NIH HHS [1 P41 GM 27556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58; BUSCH SJ, 1989, LIFE SCI, V45, P615, DOI 10.1016/0024-3205(89)90047-7; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; CHATTERTON JE, 1991, J BIOL CHEM, V266, P5955; CHEN GC, 1989, J BIOL CHEM, V264, P14369; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CLAUDE A, 1970, J CELL BIOL, V47, P745, DOI 10.1083/jcb.47.3.745; FISHER WR, 1971, BIOCHEMISTRY-US, V10, P1622, DOI 10.1021/bi00785a019; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; GULIKKRZYWICKI T, 1979, J MOL BIOL, V131, P475, DOI 10.1016/0022-2836(79)90003-2; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HAUSER H, 1972, Z PHYSL CHEM, V353, P1579; JANERO DR, 1983, J BIOL CHEM, V258, P4496; JONES AL, 1967, J LIPID RES, V8, P429; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; LABELLE M, 1991, BIOCHIM BIOPHYS ACTA, V1046, P288; LEE DM, 1987, BIOCHEM BIOPH RES CO, V144, P210, DOI 10.1016/S0006-291X(87)80497-7; LUZZATI V, 1979, J MOL BIOL, V131, P435, DOI 10.1016/0022-2836(79)90002-0; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PHILLIPS ML, 1989, J LIPID RES, V30, P415; POLLARD H, 1969, P NATL ACAD SCI USA, V64, P304, DOI 10.1073/pnas.64.1.304; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; SMALL D, 1978, HDB LIPID RES, P386; SPRING DJ, 1992, J LIPID RES, V33, P233; STEELE JCH, 1979, J BIOL CHEM, V254, P1639; THRIFT RN, 1986, J LIPID RES, V27, P236; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1991, J BIOL CHEM, V266, P3300	35	129	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14839	14845						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321819				2022-12-25	WOS:A1992JF08800052
J	URADE, R; NASU, M; MORIYAMA, T; WADA, K; KITO, M				URADE, R; NASU, M; MORIYAMA, T; WADA, K; KITO, M			PROTEIN-DEGRADATION BY THE PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C-ALPHA FAMILY FROM RAT-LIVER ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL-MEMBRANES; DISULFIDE-ISOMERASE; IDENTIFICATION; SEQUENCE; BINDING; CARBOXYLESTERASES; PURIFICATION; INVIVO; ER	A 60-kDa protein homologous to phosphoinositide-specific phospholipase C-alpha was purified to apparent homogeneity on sodium dodecyl sulfate-polyacrylamide gel electrophoresis from the rough endoplasmic reticulum of rat liver through three sequential chromatographies on DEAE Toyopearl 650, AF-heparin Toyopearl 650M, and TSK gel G3000SW. The purified protein was monomeric, with an M(r) of 60,000. Eight types of protein were further separated from the 60-kDa protein and named ER60A-ER60H according to the order of their elution from a TSK gel DEAE-5PW column. They were essentially identical in terms of immunochemical properties and the NH2-terminal amino acid sequence. The partial amino acid sequence of ER60F showed homology to that of phosphoinositide-specific phospholipase C-alpha. ER60A-ER60H showed no phosphoinositide-specific phospholipase C activity. However, ER60A-ER60H catalyzed cleavage of themselves and the endoplasmic reticulum proteins protein disulfide-isomerase and calreticulin. Proteolytic degradation was inhibited by p-chloromercuribenzoate. These results indicate that ER60A-ER60H comprise a group of endoplasmic reticulum resident proteins and show thiol group-related proteolytic activity.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University								BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CHUN KT, 1990, J BIOL CHEM, V265, P22004; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAUGEJORDEN SM, 1991, J BIOL CHEM, V266, P6015; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; KASCHNITZ R, 1969, ANAL BIOCHEM, V30, P148; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KLAUSNER RD, 1991, CELL, V113, P997; KOCH GLE, 1987, J CELL SCI, V87, P491; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACER DRJ, 1988, J CELL SCI, V91, P61; MARTIN JL, 1991, BIOCHEM BIOPH RES CO, V178, P679, DOI 10.1016/0006-291X(91)90161-Y; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MILLS ENC, 1983, BIOCHEM J, V213, P245, DOI 10.1042/bj2130245; MOORE S, 1963, J BIOL CHEM, V238, P235; MORIYAMA T, 1990, J BIOCHEM-TOKYO, V108, P414, DOI 10.1093/oxfordjournals.jbchem.a123215; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MURTHY KK, 1990, NUCLEIC ACIDS RES, V18, P4933, DOI 10.1093/nar/18.16.4933; MURTHY LR, 1991, ANAL BIOCHEM, V193, P299, DOI 10.1016/0003-2697(91)90025-O; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TOMPKINS TA, 1991, J BIOL CHEM, V266, P4228	35	110	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15152	15159						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321829				2022-12-25	WOS:A1992JF08800095
J	EKI, T; MATSUMOTO, T; MURAKAMI, Y; HURWITZ, J				EKI, T; MATSUMOTO, T; MURAKAMI, Y; HURWITZ, J			THE REPLICATION OF DNA CONTAINING THE SIMIAN VIRUS-40 ORIGIN BY THE MONOPOLYMERASE AND DIPOLYMERASE SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-III HOLOENZYME; LARGE TUMOR-ANTIGEN; SV40 ORIGIN; T-ANTIGEN; INVITRO REPLICATION; HELICASE ACTIVITY; ESCHERICHIA-COLI; PROTEIN COMPLEX; PRIMED DNA	The influence of DNA polymerase (pol) alpha and DNA primase on SV40 DNA replication was examined in both the monopolymerase and dipolymerase systems. The synthesis of oligoribonucleotides in the monopolymerase and dipolymerase systems, followed by pulse labeling with deoxynucleoside triphosphates, yielded short Okazaki fragments approximately 35 nucleotides in length that were chased into full-length Okazaki fragments with time. In the presence of activator 1 and proliferating cell nuclear antigen (PCNA), but no pol-delta, these short fragments hardly increased in size with time. DNA fragments of similar size (approximately 35 nucleotides) were previously observed in SV40 replication reactions carried out with crude extracts of HeLa cells in the presence of antibodies directed against PCNA (Bullock, P. A., Seo, Y. S., and Hurwitz, J. (1991) Mol. Cell. Biol. 11, 2350-2361). Thus, the pol alpha-primase complex appears to act processively for only a short distance. At high levels of pol-alpha and primase, both short and long DNA products were formed in both systems. In the presence of limiting amounts of pol-alpha and excess primase, the monopolymerase system inefficiently yielded longer length Okazaki fragments than those formed with excess pol-alpha and primase, whereas the dipolymerase system yielded both short and long DNA fragments. In the presence of limiting amounts of primase and excess pol-alpha, long products were formed in both systems, and virtually no short products accumulated. Thus, the ratio between the polymerase and primer ends available controls the size of the nascent product DNA strands. We examined whether PCNA, the T4 phage-encoded gene product 45 (T4 gp45), and the Escherichia coli beta-subunit of DNA polymerase III (dnaN gene product) supported SV40 DNA replication and the elongation of single-stranded DNA-binding protein-coated singly primed DNA in reactions catalyzed by pol-delta, T4 DNA pol, and E. coli DNA pol III*, respectively. In the presence of T4 gp44/62 and T4 gp32 (but not human single-stranded DNA-binding protein isolated from HeLa cells), T4 DNA pol was weakly activated by PCNA and the beta-subunit in lieu of T4 gp45 in the elongation of singly primed phi-X174 DNA. However, the other systems were specific for their analogous auxiliary factors. This specificity indicates the importance of protein-protein interactions.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034559, R01GM034559] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34559] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; EKI T, 1991, J BIOL CHEM, V266, P3087; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; IKEDA JE, 1981, P NATL ACAD SCI-BIOL, V78, P884, DOI 10.1073/pnas.78.2.884; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kornberg A., 1992, DNA REPLICATION; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; NETHANEL T, 1990, J VIROL, V62, P2867; PIPERNO JR, 1978, J BIOL CHEM, V253, P5180; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	36	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7284	7294						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348504				2022-12-25	WOS:A1992HN48500017
J	CHUANG, TT; SALLESE, M; AMBROSINI, G; PARRUTI, G; DEBLASI, A				CHUANG, TT; SALLESE, M; AMBROSINI, G; PARRUTI, G; DEBLASI, A			HIGH EXPRESSION OF BETA-ADRENERGIC-RECEPTOR KINASE IN HUMAN PERIPHERAL-BLOOD LEUKOCYTES - ISOPROTERENOL AND PLATELET-ACTIVATING-FACTOR CAN INDUCE KINASE TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; BETA-2-ADRENERGIC RECEPTOR; DESENSITIZATION; AGONIST; PROTEIN; PURIFICATION; INHIBITION; RHODOPSIN; PATHWAYS; FAMILY	Receptor phosphorylation is a key step in the process of desensitization of the beta-adrenergic and other related receptors. A selective kinase (called beta-adrenergic receptor kinase, beta-ARK) has been identified which phosphorylates the agonist-occupied form of the receptor. Recently the bovine beta-ARK cDNA has been cloned and the highest levels of specific mRNA were found in highly innervated tissues. It was proposed that beta-ARK may be primarily active on synaptic receptors. In the present study, the cDNA of human beta-ARK was cloned and sequenced. The sequence was very similar to that of the bovine-beta-ARK (the overall amino acid homology was 98%). Very high levels of beta-ARK mRNA and kinase activity were found in peripheral blood leukocytes and in several myeloid and lymphoid leukemia cell lines. Since agonist-induced beta-ARK translocation is considered the first step involved in beta-ARK-mediated homologous desensitization, we screened a number of G-protein-coupled receptor agonists for their ability to induce beta-ARK translocation. In human mononuclear leukocytes, beta-AR agonist isoproterenol and platelet-activating factor were able to induce translocation of beta-ARK from cytosol to membrane. After 20 min of exposure to isoproterenol (10-mu-M), the cytosolic-beta-ARK activity decreased to 61% of control, while membrane-associated beta-ARK activity increased to 170%. 20-min exposure to platelet-activating factor (1-mu-M) reduced the cytosolic-beta-ARK activity to 42% of control with concomitant increase in membrane-beta-ARK activity to 214% of control. The high levels of beta-ARK expression in human peripheral blood leukocytes together with the ability of isoproterenol and platelet-activating factor to induce beta-ARK translocation, suggest a role for beta-ARK in modulating some receptor-mediated immune functions.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Sallese, Michele/J-5347-2016	Sallese, Michele/0000-0002-2555-3571				BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1991, FEBS LETT, V283, P122, DOI 10.1016/0014-5793(91)80568-N; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CROUCH MF, 1989, J BIOL CHEM, V264, P584; DEBLASI A, 1986, J LAB CLIN MED, V107, P86; DELMASCHIO A, 1989, GINKGOLIDES CHEM BIO, V2, P83; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Maniatis T., 1982, MOL CLONING; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MAZER B, 1991, J IMMUNOL, V146, P1914; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; Roszman T., 1991, PROG NEUROENDOCRINIM, V4, P69; SCHWERTSCHLAG US, 1988, J BIOL CHEM, V263, P13791; SELIGMANN BE, 1982, J BIOL CHEM, V257, P6280; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	34	126	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6886	6892						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1339451				2022-12-25	WOS:A1992HM05300067
J	MEIJER, AJ; BAQUET, A; GUSTAFSON, L; VANWOERKOM, GM; HUE, L				MEIJER, AJ; BAQUET, A; GUSTAFSON, L; VANWOERKOM, GM; HUE, L			MECHANISM OF ACTIVATION OF LIVER-GLYCOGEN SYNTHASE BY SWELLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; CELL-VOLUME REGULATION; PHOSPHORYLASE-A; AMINO-ACIDS; MEMBRANE; STIMULATION; GLUCOSE; PHOSPHATASE; METABOLISM; SYNTHETASE	The mechanism linking the stimulation of liver glycogen synthesis to swelling induced either by amino acids or hypotonicity was studied in hepatocytes, in gel-filtered liver extracts, and in purified preparations of particulate glycogen to which glycogen-metabolizing enzymes are bound. High concentrations of KCl, but not of potassium glutamate, were found to inhibit glycogen synthesis in permeabilized hepatocytes. Similarly, physiological concentrations (30-50 mM) of Cl- ions were also found to inhibit synthase phosphatase in vitro, whereas 10-20 mM Cl- ions, a concentration found in swollen hepatocytes, did not inhibit synthase phosphatase. Synthase phosphatase activity was more sensitive to inhibition by Cl- ions at low (0.1%) than at high (1%) concentrations of glycogen. By contrast, 10 mm glutamate and aspartate, a concentration observed in hepatocytes incubated with glutamine or proline, stimulated synthase phosphatase in vitro. Therefore, it is proposed that the fall in intracellular Cl- concentration as well as the increase in intracellular glutamate and aspartate concentrations, that are observed in swollen hepatocytes in the presence of amino acids, are responsible, at least in part, for the stimulation of synthase phosphatase and, hence, of glycogen synthesis.	UNIV AMSTERDAM,ACAD MED CTR,EC SLATER INST BIOCHEM RES,1105 AZ AMSTERDAM,NETHERLANDS; CATHOLIC UNIV LOUVAIN,SCH MED,METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM	University of Amsterdam; Academic Medical Center Amsterdam; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; BAKKERGRUNWALD T, 1983, BIOCHIM BIOPHYS ACTA, V731, P239, DOI 10.1016/0005-2736(83)90014-7; BAQUET A, 1990, J BIOL CHEM, V265, P955; BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; Bernt E., 1974, METHODS ENZYMATIC AN, P1704, DOI [10.1016/B978-0-12-091304-6.50017-3, DOI 10.1016/B978-0-12-091304-6.50017-3]; CHEN KS, 1985, J BIOL CHEM, V260, P4683; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG290, DOI 10.1152/ajpgi.1990.258.2.G290; DEWULF H, 1970, EUR J BIOCHEM, V15, P1; FITZ JG, 1989, AM J PHYSIOL, V257, pG961, DOI 10.1152/ajpgi.1989.257.6.G961; GRAF J, 1988, RENAL PHYSIOL BIOCH, V11, P202; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HOWARD LD, 1987, J MEMBRANE BIOL, V100, P53, DOI 10.1007/BF02209140; HUE L, 1978, BIOCHEM J, V176, P791, DOI 10.1042/bj1760791; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; KATZ J, 1976, P NATL ACAD SCI USA, V73, P3433, DOI 10.1073/pnas.73.10.3433; KATZ J, 1979, BIOCHEM J, V180, P389, DOI 10.1042/bj1800389; KRISTENSEN LO, 1986, AM J PHYSIOL, V251, pG575, DOI 10.1152/ajpgi.1986.251.5.G575; LANG F, 1989, PFLUG ARCH EUR J PHY, V413, P209, DOI 10.1007/BF00583532; LAVOINNE A, 1987, BIOCHEM J, V248, P429, DOI 10.1042/bj2480429; MEIJER AJ, 1985, EUR J BIOCHEM, V148, P189, DOI 10.1111/j.1432-1033.1985.tb08824.x; MOULE SK, 1987, BIOCHEM J, V241, P737, DOI 10.1042/bj2410737; MOULE SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P383, DOI 10.1016/0304-4157(90)90016-6; MVUMBI L, 1985, BIOCHEM J, V232, P697, DOI 10.1042/bj2320697; MVUMBI L, 1987, BIOCHEM J, V246, P367, DOI 10.1042/bj2460367; NOBES CD, 1989, BIOCHIM BIOPHYS ACTA, V987, P115, DOI 10.1016/0005-2736(89)90462-8; PLOMP PJAM, 1990, EUR J BIOCHEM, V191, P237, DOI 10.1111/j.1432-1033.1990.tb19115.x; ROGNSTAD R, 1986, BIOCHEM ARCH, V2, P185; STALMANS W, 1976, CURR TOP CELL REGUL, V11, P51; STALMANS W, 1971, EUR J BIOCHEM, V18, P582, DOI 10.1111/j.1432-1033.1971.tb01279.x; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V181, P278, DOI 10.1016/0003-9861(77)90506-9	33	104	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5823	5828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1348248				2022-12-25	WOS:A1992HK31800019
J	HINCHMAN, SK; HENIKOFF, S; SCHUSTER, SM				HINCHMAN, SK; HENIKOFF, S; SCHUSTER, SM			A RELATIONSHIP BETWEEN ASPARAGINE SYNTHETASE-A AND ASPARTYL TRANSFER-RNA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; EXPRESSION; MOTIFS; GENES	A highly conserved protein motif characteristic of Class II aminoacyl tRNA synthetases was found to align with a region of Escherichia coli asparagine synthetase A. The alignment was most striking for aspartyl tRNA synthetase, an enzyme with catalytic similarities to asparagine synthetase. To test whether this sequence reflects a conserved function, site-directed mutagenesis was used to replace the codon for Arg298 of asparagine synthetase A, which aligns with an invariant arginine in the Class II aminoacyl tRNA synthetases. The resulting genes were expressed in E. coli, and the gene products were assayed for asparagine synthetase activity in vitro. Every substitution of Arg298, even to a lysine, resulted in a loss of asparagine synthetase activity. Directed random mutagenesis was then used to create a variety of codon changes which resulted in amino acid substitutions within the conserved motif surrounding Arg298. Of the 15 mutant enzymes with amino acid substitutions yielding soluble enzyme, t3 with changes within the conserved region were found to have lost activity. These results are consistent with the possibility that asparagine synthetase A, one of the two unrelated asparagine synthetases in E. coli, evolved from an ancestral aminoacyl tRNA synthetase.	UNIV FLORIDA, J HILLIS MILLER HLTH CTR,COLL MED, DEPT BIOCHEM & MOLEC BIOL,BOX J 245, GAINESVILLE, FL 32610 USA; FRED HUTCHINSON CANC RES CTR, HOWARD HUGHES MED INST, SEATTLE, WA 98104 USA	State University System of Florida; University of Florida; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute				Henikoff, Steven/0000-0002-7621-8685	NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029009] Funding Source: NIH RePORTER; NCI NIH HHS [CA28725] Funding Source: Medline; NIGMS NIH HHS [GM29009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSELME J, 1989, GENE, V84, P481, DOI 10.1016/0378-1119(89)90524-6; BAIROCH A, 1990, PROSITE DICT PROTEIN; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; CEDAR H, 1969, J BIOL CHEM, V244, P4112; CEDAR H, 1969, J BIOL CHEM, V244, P4122; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FETT R, 1991, J BIOL CHEM, V266, P1448; GATTI DL, 1991, J MOL BIOL, V218, P557, DOI 10.1016/0022-2836(91)90701-7; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HUMBERT R, 1980, J BACTERIOL, V142, P212, DOI 10.1128/JB.142.1.212-220.1980; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MEHLHAFF PM, 1985, BIOCHEMISTRY-US, V24, P1104, DOI 10.1021/bi00326a006; NAKAMURA M, 1981, NUCLEIC ACIDS RES, V9, P4669, DOI 10.1093/nar/9.18.4669; RAVEL JM, 1970, METHODS ENZYMOL    A, V17, P722; REITZER LJ, 1982, J BACTERIOL, V151, P1299, DOI 10.1128/JB.151.3.1299-1313.1982; RUOLD MA, 1989, SCIENCE, V246, P1135; SARTAR G, 1990, BIOTECHNIQUES, V8, P404; SCOFIELD MA, 1990, J BIOL CHEM, V265, P12895; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANHEEKE G, 1989, J BIOL CHEM, V264, P5503; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; ZALKIN H, 1977, J BIOL CHEM, V252, P5341; ZEWLER C, 1982, J MOL BIOL, V155, P63	28	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					144	149						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1346128				2022-12-25	WOS:A1992GY43900028
J	KATO, J; SUZUKI, H; IKEDA, H				KATO, J; SUZUKI, H; IKEDA, H			PURIFICATION AND CHARACTERIZATION OF DNA TOPOISOMERASE-IV IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRAGENIC PALINDROMIC SEQUENCES; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; ATTACHMENT SITES; REVERSE GYRASE; S-CEREVISIAE; GYRB GENE; RECOMBINATION; YEAST; REPLICATION	The subunits of topoisomerase IV (topo IV), the ParC and ParE proteins in Escherichia coli, were purified to near homogeneity from the respective overproducers. They revealed type II topoisomerase activity only when they were combined with each other. In the presence of Mg2+ and ATP, topo IV was capable of relaxing a negatively or positively supercoiled plasmid DNA or converting the knotted P4 phage DNA, whether nicked or ligated, to a simple ring. However, supercoiling activity was not detected. The topoisomerase activity was not detectable when the purified ParC and ParE proteins were combined with the purified GyrB and GyrA proteins, respectively. This is consistent with the result that neither a parC nor a parE mutation was compensated by transformation with a plasmid carrying either the gyrA or the gyrB gene. Simultaneous introduction of both the gyrA and gyrB plasmids corrected the phenotypic defect of parC and parE mutants. The results suggest that DNA gyrase can substitute for topo IV at least in some part of the function for chromosome partitioning. Antisera were prepared against the purified ParC, ParE, GyrA, and GyrB proteins and used to investigate cellular localization of these gene products. ParC protein was found to be specifically associated with inner membranes only in the presence of DNA. This result suggests that one of the functions of topo IV might be to anchor chromosomes on membranes as previously proposed for eukaryotic topoisomerase II.	KANAGAWA UNIV, DEPT APPL BIOL, HIRATSUKA, KANAGAWA 25912, JAPAN	Kanagawa University	KATO, J (corresponding author), UNIV TOKYO, INST MED SCI, DEPT MOLEC BIOL, PO TAKANAWA, TOKYO 108, JAPAN.							ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AGUILERA A, 1990, MOL CELL BIOL, V10, P1439, DOI 10.1128/MCB.10.4.1439; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DORMAN CJ, 1989, MOL MICROBIOL, V3, P531, DOI 10.1111/j.1365-2958.1989.tb00199.x; FUTAI M, 1973, BIOCHEMISTRY-US, V12, P2468, DOI 10.1021/bi00737a016; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GILSON E, 1990, NUCLEIC ACIDS RES, V18, P3941, DOI 10.1093/nar/18.13.3941; GUSTAFSSON P, 1983, EMBO J, V2, P27, DOI 10.1002/j.1460-2075.1983.tb01375.x; HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9; HIROTA Y, 1968, COLD SPRING HARB SYM, V33, P677, DOI 10.1101/SQB.1968.033.01.077; HIROTA Y, 1971, BIOMEMBRANE, V2, P13; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HUSSAIN K, 1987, MOL MICROBIOL, V1, P259, DOI 10.1111/j.1365-2958.1987.tb01932.x; INADA T, 1989, J BACTERIOL, V171, P5017, DOI 10.1128/jb.171.9.5017-5024.1989; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1989, MOL GEN GENET, V217, P178, DOI 10.1007/BF00330959; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; MILLER CA, 1990, CELL, V62, P127, DOI 10.1016/0092-8674(90)90246-B; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; NORRIS V, 1986, J BACTERIOL, V168, P494, DOI 10.1128/jb.168.2.494-504.1986; SAKAKIBARA Y, 1976, J MOL BIOL, V108, P569, DOI 10.1016/S0022-2836(76)80137-4; Sambrook J, 1989, MOL CLONING LABORATO; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAHLE E, 1988, EMBO J, V7, P1889, DOI 10.1002/j.1460-2075.1988.tb03022.x; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012; YANG Y, 1988, P NATL ACAD SCI USA, V85, P8850, DOI 10.1073/pnas.85.23.8850; YASUDA S, 1983, J BACTERIOL, V154, P1153, DOI 10.1128/JB.154.3.1153-1161.1983	45	165	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25676	25684						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334483				2022-12-25	WOS:A1992KD07300015
J	KAMIBAYASHI, C; LICKTEIG, RL; ESTES, R; WALTER, G; MUMBY, MC				KAMIBAYASHI, C; LICKTEIG, RL; ESTES, R; WALTER, G; MUMBY, MC			EXPRESSION OF THE A-SUBUNIT OF PROTEIN PHOSPHATASE-2A AND CHARACTERIZATION OF ITS INTERACTIONS WITH THE CATALYTIC AND REGULATORY SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; LIGHT CHAIN KINASE; DNA-REPLICATION INVITRO; MEDIUM TUMOR-ANTIGEN; MOLECULAR-CLONING; CELLULAR-REGULATION; SEQUENCE-ANALYSIS; CDNA; PURIFICATION; FORMS	The alpha form of the A subunit of human protein phosphatase 2A was expressed in insect cells following infection with a recombinant baculovirus. Aalpha was expressed as a soluble protein that comprised approximately 10% of total cellular protein. The expressed Aalpha subunit was purified by chromatography on amino-hexyl-Sepharose and Mono Q with a yield of 2 mg/500-ml culture. The recombinant protein had the same apparent molecular mass as the bovine cardiac protein and was devoid of myosin light chain phosphatase activity. Biological activity of expressed A was assessed by assays of complex formation with the catalytic (C) and B subunits, purified from bovine cardiac tissue, and by inhibition of phosphatase activity. Purified Aalpha had a high apparent affinity for C (IC50 = 0.10 nM) and bound with a stoichiometry of 1 mol of A/mol of C. Interaction of Aalpha with the catalytic subunit caused a maximal inhibition of myosin light chain and phosphorylase phosphatase activities of 50 and 79%, respectively. The AC complex prepared by reconstitution of recombinant Aalpha with C had the same electrophoretic mobility in nondenaturing polyacrylamide gels and the same elution volume when chromatographed on a size exclusion column as the native AC complex purified from cardiac muscle. Similar chromatographic profiles were also observed for the heterotrimer reconstituted from recombinant Aalpha, purified B and C, and the native bovine cardiac heterotrimeric holoenzyme. Cross-linking of the native enzyme and the reconstituted hetero-trimer generated the same pattern of high molecular weight species. Immunological analyses of these complexes demonstrated that distinct cross-linked forms composed of ABC, AC, AB, and BC were obtained. These results suggest that each of the three subunits of protein phosphatase 2A forms direct contacts with both of the others.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA054726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NCI NIH HHS [CA54726] Funding Source: Medline; NHLBI NIH HHS [HL31107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; BLISS CI, 1970, STATISTICS BIOL; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; IMAOKA T, 1980, BIOCHIM BIOPHYS ACTA, V612, P73, DOI 10.1016/0005-2744(80)90280-6; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; KITAGAWA Y, 1988, BIOCHEM BIOPH RES CO, V157, P821, DOI 10.1016/S0006-291X(88)80323-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; NUNNALLY MH, 1985, J BIOL CHEM, V260, P1020; ORGAD S, 1990, FEBS LETT, V275, P44, DOI 10.1016/0014-5793(90)81435-Q; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARIS H, 1984, J BIOL CHEM, V259, P7510; PATO MD, 1986, J BIOL CHEM, V261, P3770; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sambrook J, 1989, MOL CLONING LABORATO; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SILVA OBDC, 1987, FEBS LETT, V226, P176; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAMARU S, 1980, EUR J BIOCHEM, V104, P347; THOEN C, 1987, EUR J BIOCHEM, V163, P503, DOI 10.1111/j.1432-1033.1987.tb10897.x; TUNG HYL, 1984, EUR J BIOCHEM, V145, P57, DOI 10.1111/j.1432-1033.1984.tb08521.x; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USUI H, 1988, J BIOL CHEM, V263, P3752; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	49	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21864	21872						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328247				2022-12-25	WOS:A1992JV01100093
J	KIMURA, S; NAKAMURA, H; HASHIMOTO, T; OOBATAKE, M; KANAYA, S				KIMURA, S; NAKAMURA, H; HASHIMOTO, T; OOBATAKE, M; KANAYA, S			STABILIZATION OF ESCHERICHIA-COLI RIBONUCLEASE HI BY STRATEGIC REPLACEMENT OF AMINO-ACID-RESIDUES WITH THOSE FROM THE THERMOPHILIC COUNTERPART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED PROTEIN THERMOSTABILITY; SITE-DIRECTED MUTAGENESIS; L-LACTATE DEHYDROGENASES; DISULFIDE BOND; RNASE-H; ENGINEERING THERMOSTABILITY; MESOPHILIC BACTERIA; STABILITY; BINDING; GENE	Thermus thermophilus ribonuclease H is exceptionally stable against thermal and guanidine hydrochloride denaturations as compared to Escherichia coli ribonuclease HI (Kanaya, S., and Itaya, M. (1992) J. Biol. Chem. 267, 10184-10192). The identity in the amino acid sequences of these enzymes is 52%. As an initial step to elucidate the stabilization mechanism of the thermophilic RNase H, we examined whether certain regions in its amino acid sequence confer the thermostability. A variety of mutant proteins of E. coli RNase HI were constructed and analyzed for protein stability. In these mutant proteins, amino acid sequences in loops or terminal regions were systematically replaced with the corresponding sequences from T. thermophilus RNase H. Of the nine regions examined, replacement of the amino acid sequence in each of four regions (R4-R7) resulted in an increase in protein stability. Simultaneous replacements of these amino acid sequences revealed that the effect of each replacement on protein stability is independent of each other and cumulative. Replacement of all four regions (R4-R7) gave the most stable mutant protein. The temperature of the midpoint of the transition in the thermal unfolding curve and the free energy change of unfolding in the absence of denaturant of this mutant protein were increased by 16.7-degrees-C and 3.66 kcal/mol, respectively, as compared to those of E. coli RNase HI. These results suggest that individual local interactions contribute to the stability of thermophilic proteins in an independent manner, rather than in a cooperative manner.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN				Nakamura, Haruki/O-4028-2014					ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BIRO J, 1990, FEBS LETT, V275, P130, DOI 10.1016/0014-5793(90)81456-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P863; CARUTHERS MH, 1985, SCIENCE, V230, P281, DOI 10.1126/science.3863253; Crouch R. J., 1982, NUCLEASES, P211; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IMANAKA T, 1986, NATURE, V324, P695, DOI 10.1038/324695a0; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1991, EUR J BIOCHEM, V198, P437, DOI 10.1111/j.1432-1033.1991.tb16033.x; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIMURA S, 1992, EUR J BIOCHEM, V206, P337, DOI 10.1111/j.1432-1033.1992.tb16932.x; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MILLER HI, 1973, J BIOL CHEM, V248, P2621; Miller J. H., 1972, EXPT MOL GENETICS, P433; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; OSHIMA T, 1986, PROTEIN ENG APPLICAT, P81; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; PANTOLIANO MW, 1989, BIOCHEMISTRY-US, V28, P7205, DOI 10.1021/bi00444a012; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; STEARMAN RS, 1988, BIOCHEMISTRY-US, V27, P7571, DOI 10.1021/bi00419a059; SUZUKI Y, 1989, J BIOL CHEM, V264, P18933; TAKAGI H, 1990, J BIOL CHEM, V265, P6874; TOGAYA M, 1989, J BIOL CHEM, V264, P990; TOMA S, 1991, BIOCHEMISTRY-US, V30, P97, DOI 10.1021/bi00215a015; WATANABE K, 1991, J BIOL CHEM, V266, P24287; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YUTANI K, 1991, PROTEINS, V9, P90, DOI 10.1002/prot.340090203; ZULLI F, 1990, BIOL CHEM H-S, V371, P655, DOI 10.1515/bchm3.1990.371.2.655; ZULLI F, 1991, BIOL CHEM H-S, V372, P363, DOI 10.1515/bchm3.1991.372.1.363	50	69	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21535	21542						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328237				2022-12-25	WOS:A1992JV01100044
J	LEE, YS; MARKS, AR; GURECKAS, N; LACRO, R; NADALGINARD, B; KIM, DH				LEE, YS; MARKS, AR; GURECKAS, N; LACRO, R; NADALGINARD, B; KIM, DH			PURIFICATION, CHARACTERIZATION, AND MOLECULAR-CLONING OF A 60-KDA PHOSPHOPROTEIN IN RABBIT SKELETAL SARCOPLASMIC-RETICULUM WHICH IS AN ISOFORM OF PHOSPHOGLUCOMUTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHANNEL RYANODINE RECEPTOR; AMINO-ACID-SEQUENCE; CALCIUM RELEASE; COMPLEMENTARY-DNA; CA2+ TRANSPORT; MUSCLE TRIADS; CALMODULIN; CDNA; COMPLEX	A 60-kDa substrate of calmodulin-dependent protein kinase in rabbit "heavy" skeletal sarcoplasmic reticulum (SR) was characterized by purification and cDNA cloning. Purification was achieved by column chromatography using DEAE-Sephacel, heparin-agarose, and hydroxylapatite in 0.5% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonic acid (CHAPS). Analyses of amino acid sequence and composition indicated that the CHAPS-soluble 60-kDa protein is an isoform of phosphoglucomutase (PGM). cDNAs encoding two isoforms of PGM were isolated from rabbit skeletal muscles. The translated amino acid sequences show that the isoforms, PGM1 and PGM2, differ in the N-terminal 77 amino acids and that PGM2 is identical to the 60-kDa protein in the SR. Northern blot analysis showed that the size of the mRNA encoding PGM2 is 2.4 kilobases. The PGM enzyme activity was markedly inhibited in SR membranes, while perturbation of the membranes with CHAPS or guanidine-HCl recovered the enzyme activity. KCl (0.15-1 M) led to a partial recovery of the enzyme activity suggesting that the charge interaction is not the primary force for PGM-SR interaction. PGM is localized in the heavy fraction of SR, where calsequestrin and Ca2+ release channel are enriched. Our results demonstrate that an isoform of PGM localized in junctional skeletal SR is the 60-kDa substrate of calmodulin-dependent protein kinase.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV CARDIOL,FARMINGTON,CT 06030; CHILDRENS HOSP MED CTR,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	University of Connecticut; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute					NHLBI NIH HHS [HL 33026] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033026] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BURN P, 1988, TRENDS BIOCHEM SCI, V13, P79, DOI 10.1016/0968-0004(88)90043-6; CAMPBELL KP, 1982, J BIOL CHEM, V257, P1238; CASWELL A H, 1989, Biophysical Journal, V55, p478A; CHIESI M, 1982, J BIOL CHEM, V257, P984; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; DAWSON DM, 1975, ISOZYMES, V1, P381; ENTMAN ML, 1980, J BIOL CHEM, V255, P6245; ENTMAN ML, 1976, J BIOL CHEM, V251, P3140; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HEILMEYER LMG, 1990, MOL CELL BIOCHEM, V99, P111; HORL WH, 1978, BIOCHEMISTRY-US, V17, P759; IKEMOTO N, 1974, J BIOL CHEM, V249, P649; KIM DH, 1983, J BIOL CHEM, V258, P9662; KIM DH, 1986, J BIOL CHEM, V261, P1674; KORZA G, 1988, J BIOL CHEM, V263, P3486; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1969, J BIOL CHEM, V244, P910; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1984, ADV CYCLIC NUCL PROT, V17, P393; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MEYER F, 1970, J BIOL CHEM, V245, P6642; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OTSU K, 1990, J BIOL CHEM, V265, P13472; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; RAY WJ, 1983, J BIOL CHEM, V258, P9166; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; Sambrook J, 1989, MOL CLONING LABORATO; SATO H, 1988, ARCH BIOCHEM BIOPHYS, V260, P443, DOI 10.1016/0003-9861(88)90468-7; SEILER S, 1984, J BIOL CHEM, V259, P8550; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; VALE MGP, 1988, J BIOL CHEM, V263, P12872; WADDELL ID, 1991, BIOCHEM J, V275, P133, DOI 10.1042/bj2750133; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	43	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21080	21088						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328221				2022-12-25	WOS:A1992JT97800089
J	CHAO, TSO; BYRON, KL; LEE, KM; VILLEREAL, M; ROSNER, MR				CHAO, TSO; BYRON, KL; LEE, KM; VILLEREAL, M; ROSNER, MR			ACTIVATION OF MAP KINASES BY CALCIUM-DEPENDENT AND CALCIUM-INDEPENDENT PATHWAYS - STIMULATION BY THAPSIGARGIN AND EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; SIGNAL-REGULATED KINASES; SERINE THREONINE KINASES; TYROSINE PHOSPHORYLATION; HUMAN-FIBROBLASTS; SWISS 3T3-CELLS; FACTOR RECEPTOR; TUMOR PROMOTER; 3T3-L1 CELLS; INSULIN	In order to determine the effect of calcium mobilization on mitogen-activated protein (MAP) kinase activation, we have treated human foreskin fibroblasts (HSWP cells) and human epidermal carcinoma (A431) cells with thapsigargin. Intracellular free calcium was monitored by single cell image analysis using fura-2 and correlated with MAP kinase stimulation as assessed by immunoprecipitation, kinase renaturation assays and immunoblotting. Thapsigargin stimulated the 44- and 42-kDa MAP kinase isozymes in both cell types with kinetics that were slightly delayed relative to enzyme stimulated by epidermal growth factor. Removal of external calcium did not significantly affect the activation of the MAP kinases by thapsigargin-indicating that intracellular calcium mobilization is sufficient to stimulate the enzymes. However, treatment of cells with EGTA under conditions which deplete both intra- and extracellular calcium inhibited stimulation by thapsigargin but not epidermal growth factor. Stimulation of the MAP kinases by the calcium ionophore ionomycin paralleled the activation observed with thapsigargin in both calcium-containing and calcium-free conditions. These results indicate that there are at least two independent pathways for stimulation of MAP kinase: one that is dependent on intracellular calcium mobilization, and one that is mediated by the tyrosine kinase epidermal growth factor receptor and is calcium-independent.	UNIV CHICAGO,BEN MAY INST,5841 S MARYLAND AVE,M-C 6027,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	University of Chicago; University of Chicago				Byron, Kenneth/0000-0002-3875-9667	NCI NIH HHS [CA35541] Funding Source: Medline; NIGMS NIH HHS [GM28359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BESTERMAN JM, 1986, J BIOL CHEM, V261, P723; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRON KL, 1989, J BIOL CHEM, V264, P18234; BYRON KL, 1992, J BIOL CHEM, V267, P108; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HUGHES AR, 1991, MOL PHARMACOL, V40, P254; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MULDOON LL, 1987, AM J PHYSIOL, V253, pC219, DOI 10.1152/ajpcell.1987.253.2.C219; NEL AE, 1990, J IMMUNOL, V145, P971; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POLLACK S, 1991, BIOCHEM J, V276, P481, DOI 10.1042/bj2760481; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, J BIOL CHEM, V263, P12721; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TOBE K, 1991, J BIOL CHEM, V266, P24793	38	255	256	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19876	19883						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328184				2022-12-25	WOS:A1992JR85800023
J	AMIN, AA; HURWITZ, J				AMIN, AA; HURWITZ, J			POLAR ARREST OF THE SIMIAN-VIRUS 40 TUMOR ANTIGEN-MEDIATED REPLICATION FORK MOVEMENT INVITRO BY THE TUS PROTEIN-TERB COMPLEX OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 DNA-REPLICATION; LARGE-T-ANTIGEN; CELL NUCLEAR ANTIGEN; POLYMERASE-ALPHA; ENZYMATIC-SYNTHESIS; TERMINATOR PROTEIN; ACCESSORY PROTEINS; PURIFIED PROTEINS; HELICASE ACTIVITY; BINDING PROTEIN	The effect of the tus protein-terB sequence complex of Escherichia coli on the movement of the SV40 large tumor antigen (T antigen)-mediated replication fork during SV40 DNA replication in vitro has been examined. In the monopolymerase and dipolymerase systems, the tus protein-terB complex efficiently blocked the replication fork movement in a polar fashion, as observed in prokaryotic replication systems. With crude cytosolic extracts of HeLa cells, the same polarity of fork arrest was observed, but the block of replication fork movement was inefficient. These results indicate that the structure of the prokaryotic tus protein-terB complex allows it to block replication fork movement in an orientation-dependent manner. We also show that the tus protein-terB complex blocks the 3' --> 5' helicase action of T antigen in a polar fashion, using substrates comprised of single-stranded M13 DNA with either a 52-base pair (bp) or 29-bp duplex containing the terB sequence. The tus protein-terB complex formed on the 52-bp duplex was less effective than the complex formed on the 29-bp duplex in blocking the helicase action of T antigen. With the 52-bp duplex substrate, T antigen movement was only partially (30%) blocked by the tus protein-terB sequence complex in the active orientation, whereas the E. coli dnaB helicase moving 5' --> 3' was blocked more than 90% by the complex in the active orientation. However, with the shorter 29-bp duplex substrate, the complex blocked the T antigen helicase activity about 75%, whereas the dnaB helicase activity was completely blocked. Altogether, these results suggest that the T antigen helicase activity, when coupled to DNA replication, is more susceptible to arrest by the tus protein-terB complex than the T antigen functioning as a helicase alone.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NIGMS NIH HHS [5R0 GM34559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034559, R01GM034559] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1991, J BIOL CHEM, V266, P3087; EKI T, 1992, J BIOL CHEM, V267, P7284; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HORIUCHI T, 1988, CELL, V54, P515, DOI 10.1016/0092-8674(88)90073-6; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KUEMPEL PL, 1989, CELL, V59, P581, DOI 10.1016/0092-8674(89)90001-9; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LOEBER G, 1991, J VIROL, V65, P3167, DOI 10.1128/JVI.65.6.3167-3174.1991; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; SEO YS, 1991, J BIOL CHEM, V266, P13161; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL MH, 1988, EMBO J, V7, P3149; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TACK LC, 1987, J BIOL CHEM, V262, P6339; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1987, PHILOS T ROY SOC B, V317, P439, DOI 10.1098/rstb.1987.0071; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	53	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18612	18622						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326530				2022-12-25	WOS:A1992JN50200057
J	PAYET, MD; DUPUIS, G				PAYET, MD; DUPUIS, G			DUAL REGULATION OF THE N-TYPE K+ CHANNEL IN JURKAT LYMPHOCYTES-T BY PROTEIN KINASE-A AND KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SENSITIVE ION CHANNELS; POTASSIUM CHANNEL; SIGNAL TRANSDUCTION; CHLORIDE CHANNELS; CHOLERA-TOXIN; CELLS; MODULATION; FAMILY; INTERLEUKIN-2; PHOSPHATASES	We have measured the activity of the n type K+ channel present in human (Jurkat) T lymphocytes using the patch clamp technique in the whole-cell configuration. We report that protein kinase A (PKA) and protein kinase C (PKC) modulate, in a dual manner, the K+ conductance in these cells. Activation of PKA decreases the amplitude of the current, as previously reported (Bastin, B., Payet, M. D., and Dupuis, G. (1990) Cell. Immunol. 128, 385-399), and this is also the case for 12-O-tetradecanoylphorbol-13-acetate-dependent activation of PKC. In contrast, inhibitors of PKC (H7, staurosporine, polymixin B, and anti-PKC antibody) increase the current amplitude. Of importance, down-regulation of PKC or its inhibition prevented the PKA-dependent inhibition of the K+ channels. Addition of alkaline phosphatase via the patch pipette increased the K+ conductance under basal conditions and reversed the inhibition produced by PKA. The dual modulation of K+ channels in Jurkat T cells is in agreement with the presence of consensus sequences in the primary structure of the n type K+ channel.	UNIV SHERBROOKE, FAC MED, DEPT BIOCHEM, SHERBROOKE J1H 5N4, QUEBEC, CANADA	University of Sherbrooke	PAYET, MD (corresponding author), UNIV SHERBROOKE, FAC MED, DEPT PHYSIOL & BIOPHYS, SHERBROOKE J1H 5N4, QUEBEC, CANADA.							Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; ATTALI B, 1992, J BIOL CHEM, V267, P8650; BASTIN B, 1990, CELL IMMUNOL, V128, P385, DOI 10.1016/0008-8749(90)90035-P; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CAI YC, 1992, DNA CELL BIOL, V11, P163, DOI 10.1089/dna.1992.11.163; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHOQUET D, 1987, SCIENCE, V235, P1211, DOI 10.1126/science.2434998; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DEUTSCH C, 1986, J PHYSIOL-LONDON, V372, P405, DOI 10.1113/jphysiol.1986.sp016016; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; DUPUIS G, 1989, J PHYSIOL-LONDON, V412, P135, DOI 10.1113/jphysiol.1989.sp017608; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; ICHINOSE M, 1991, BRAIN RES, V549, P146, DOI 10.1016/0006-8993(91)90611-X; IMBODEN JB, 1986, P NATL ACAD SCI USA, V83, P5673, DOI 10.1073/pnas.83.15.5673; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KRAUSE D, 1988, PFLUG ARCH EUR J PHY, V412, P133, DOI 10.1007/BF00583742; LAI CY, 1980, CRC CR REV BIOCH MOL, V9, P171, DOI 10.3109/10409238009105434; LAI WS, 1990, BIOCHEM J, V267, P23, DOI 10.1042/bj2670023; LEWIS RS, 1990, ANNU REV PHYSIOL, V52, P415; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MALDONADO D, 1991, FASEB J, V5, P2965, DOI 10.1096/fasebj.5.14.1721593; MARY D, 1987, J IMMUNOL, V139, P1179; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; ROTHERMEL JD, 1984, J BIOL CHEM, V259, P5294; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; TAMIR A, 1991, IMMUNOL LETT, V27, P95, DOI 10.1016/0165-2478(91)90134-V; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WALSH KB, 1991, AM J PHYSIOL, V261, pC1081, DOI 10.1152/ajpcell.1991.261.6.C1081; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WIENER E, 1989, J BIOL CHEM, V264, P4324; WITTKA R, 1991, FEBS LETT, V286, P193, DOI 10.1016/0014-5793(91)80972-6; YAZAWA K, 1990, J PHYSIOL-LONDON, V421, P135, DOI 10.1113/jphysiol.1990.sp017937; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	47	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18270	18273						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326519				2022-12-25	WOS:A1992JN50200006
J	TSAI, AL; PALMER, G; KULMACZ, RJ				TSAI, AL; PALMER, G; KULMACZ, RJ			PROSTAGLANDIN-H SYNTHASE - KINETICS OF TYROSYL RADICAL FORMATION AND OF CYCLOOXYGENASE CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; PEROXIDASE REACTION; ENDOPEROXIDE SYNTHETASE; VESICULAR GLAND; HYDROPEROXIDE; SPECTROSCOPY; PURIFICATION; BIOSYNTHESIS; SUBSTRATE; ENZYME	Hydroperoxides are known to induce the formation of tyrosyl free radicals in prostaglandin (PG) H synthase. To evaluate the role of these radicals in cyclooxygenase catalysis we have analyzed the temporal correlation between radical formation and substrate conversion during reaction of the synthase with arachidonic acid. PGH synthase reacted with equimolar levels of arachidonic acid generated sequentially the wide doublet (34 G peak-to-trough) and wide singlet (32 G peak-to-trough) tyrosyl radical signals previously reported for reaction with hydroperoxide. The kinetics of formation and decay of the doublet signal corresponded reasonably well with those of cyclooxygenase activity. However, the wide singlet free radical signal accumulated only after prostaglandin formation had ceased, indicating that the wide singlet is not likely to be an intermediate in cyclooxygenase catalysis. When PGH synthase was reacted with 25 equivalents of arachidonic acid, the wide doublet and wide singlet radical signals were not observed. Instead, a narrower singlet (24 G peak-to-trough) tyrosyl radical was generated, similar to that found upon reaction of indomethacin-treated synthase with hydroperoxide. Only about 11 mol of prostaglandin were formed per mol of synthase before complete self-inactivation of the cyclooxygenase, far less than the 170 mol/mol synthase produced under standard assay conditions. Phenol (0.5 mM) increased the extent of cyclooxygenase reaction by only about 50%, in contrast to the 460% stimulation seen under standard assay conditions. These results indicate that the narrow singlet tyrosyl radical observed in the reaction with high levels of arachidonate in this study and by Lassmann et al. (Lassmann, G., Odenwaller, R., Curtis, J. F., DeGray, J. A., Mason, R. P., Marnett, L. J., and Eling, T. E. (1991) J. Biol. Chem. 266 20045-20055) is associated with abnormal cyclooxygenase activity and is probably nonphysiological. In titrations of the synthase with arachidonate or with hydroperoxide, the loss of enzyme activity and destruction of heme were linear functions of the amount of titrant added. Complete inactivation of cyclooxygenase activity was found at about 10 mol of arachidonate, ethyl hydrogen peroxide, or hydrogen peroxide per mol of synthase heme; maximal bleaching of the heme Soret absorbance peak was found with 10 mol of ethyl hydroperoxide or 20 mol of either arachidonate or hydrogen peroxide per mol of synthase heme. The peak concentration of the wide doublet tyrosyl radical did not change appreciably with increased levels of ethyl hydroperoxide. In contrast, higher levels of hydroperoxide gave higher levels of the wide singlet radical species, in parallel with enzyme inactivation. We conclude that the wide doublet tyrosyl radical species is kinetically competent for participation in cyclooxygenase catalysis, whereas both the wide and narrow singlet free radical species are probably involved in self-inactivation processes.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University	TSAI, AL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,6431 FANNIN ST,HOUSTON,TX 77030, USA.				NIGMS NIH HHS [GM21337, GM30509] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021337, R01GM021337, R01GM030509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; BALLOU DP, 1974, ANAL CHEM, V46, P1248, DOI 10.1021/ac60345a034; BARRY BA, 1990, J BIOL CHEM, V265, P20139; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ELING TE, 1986, J BIOL CHEM, V261, P5023; GRAFF G, 1982, METHOD ENZYMOL, V86, P376; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1985, BIOCHEM BIOPH RES CO, V130, P918, DOI 10.1016/0006-291X(85)90504-2; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; KULMACZ RJ, 1989, PROSTAGLANDINS, V38, P277, DOI 10.1016/0090-6980(89)90133-0; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; ZHANG XH, 1992, BIOCHEMISTRY-US, V31, P2528, DOI 10.1021/bi00124a013	27	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17753	17759						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325448				2022-12-25	WOS:A1992JM22300045
J	BIESALSKI, HK; DOEPNER, G; TZIMAS, G; GAMULIN, V; SCHRODER, HC; BATEL, R; NAU, H; MULLER, WEG				BIESALSKI, HK; DOEPNER, G; TZIMAS, G; GAMULIN, V; SCHRODER, HC; BATEL, R; NAU, H; MULLER, WEG			MODULATION OF MYB GENE-EXPRESSION IN SPONGES BY RETINOIC ACID	ONCOGENE			English	Article							HORMONE RESPONSE ELEMENTS; AMINO-TERMINAL REGION; DNA-BINDING DOMAIN; AGGREGATION FACTOR; VITAMIN-A; GEODIA-CYDONIUM; C-MYB; DIFFERENTIAL EXPRESSION; ONCOGENE PRODUCTS; PROTEIN	We demonstrate that the cells of the sponge Geodia cydonium are equipped with the basic elements required for a retinoic acid (RA)-dependent response pathway; RA was identified and quantitated, the cellular RA-binding protein (CRABP) was detected and the nuclear RA receptor (RAR) was found. In the isolated cell system the level of CRABP, but not of RAR, is strongly induced after incubating the cells for 10 h with the homologous aggregation factor. In induced cells incubation with 0.3-mu-M RA results in a strong down-regulation of the c-myb (or c-myb-related) proto-oncogene (M(r) 63 000; mRNA 3.3 kb). We postulate that this pathway is also functionally active and that R.A acts as a natural morphogen.	UNIV MAINZ, INST PHYSIOL CHEM, MOLEK BIOL ABT, DUESBERGWEG 6, W-6500 MAINZ, GERMANY; FREE UNIV BERLIN, INST TOXIKOL & EMBRYONALPHARMAKOL, W-1000 BERLIN 33, GERMANY; RUDJER BOSKOVIC INST, CTR ORGAN CHEM & BIOCHEM, YU-41001 ZAGREB, CROATIA; INST RUDER BOSKOVIC, CTR MARINE RES, YU-552210 ROVINJ, CROATIA	Johannes Gutenberg University of Mainz; Free University of Berlin; Rudjer Boskovic Institute; Rudjer Boskovic Institute			Müller, W. E. G./AAR-8651-2020; Tzimas, Giannis/R-5550-2019	Müller, W. E. G./0000-0002-8223-3689; Tzimas, Giannis/0000-0002-4073-7256; Schroder, Heinz C./0000-0003-0992-6427				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BACHMANN M, 1986, P NATL ACAD SCI USA, V83, P7770, DOI 10.1073/pnas.83.20.7770; Battey, 1986, BASIC METHODS MOL BI; Biesalski H. K., 1990, METHOD ENZYMOL, V189, P83; BIESALSKI HK, 1990, INT J VITAM NUTR RES, V60, P4; BIESALSKI HK, 1989, J CLIN CHEM CLIN BIO, V27, P65; BIESALSKI HK, 1990, J MICRONUTR ANAL, V7, P97; BIESALSKI HK, 1992, PROGR RETINOIDS; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BOROJEVIC R, 1964, Z ZELLFORSCH MIK ANA, V64, P708, DOI 10.1007/BF01258544; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CARBALLEIRA NM, 1991, COMP BIOCHEM PHYS B, V100, P489, DOI 10.1016/0305-0491(91)90209-V; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONRAD J, 1982, J CELL BIOCHEM, V19, P395, DOI 10.1002/jcb.240190408; DESUTTER D, 1977, ROUX ARCH DEV BIOL, V181, P151, DOI 10.1007/BF00848439; DIEHLSEIFERT B, 1989, TISSUE CELL, V21, P25, DOI 10.1016/0040-8166(89)90018-9; DOEPNER G, 1992, IN PRESS DRUG RES; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DUNHAM P, 1983, P NATL ACAD SCI-BIOL, V80, P4756, DOI 10.1073/pnas.80.15.4756; ECKHOFF C, 1989, TOXICOL LETT, V48, P171, DOI 10.1016/0378-4274(89)90172-0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GERLACH T, 1989, AM J CLIN NUTR, V50, P1029, DOI 10.1093/ajcn/50.5.1029; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Goodwin TW, 1984, BIOCH CAROTENOIDS, VII; GRAMZOW M, 1989, CELL, V59, P939, DOI 10.1016/0092-8674(89)90616-8; GRAMZOW M, 1986, J CELL BIOL, V102, P1344, DOI 10.1083/jcb.102.4.1344; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HARLOW E, 1988, ANTIBODIES LABORATOR; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JANICKBUCKNER D, 1991, FASEB J, V5, P320, DOI 10.1096/fasebj.5.3.2001792; JETTEN AM, 1990, METHOD ENZYMOL, V189, P248; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LITAN R, 1991, IN PRESS BIOMEDICINE; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIGITA M, 1990, MICROBIOL IMMUNOL, V34, P937, DOI 10.1111/j.1348-0421.1990.tb01072.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOSCONA AA, 1963, P NATL ACAD SCI USA, V49, P742, DOI 10.1073/pnas.49.5.742; MULLER WEG, 1990, ELECTRON MICROSC REV, V3, P97, DOI 10.1016/0892-0354(90)90016-L; MULLER WEG, 1982, INT REV CYTOL, V77, P129, DOI 10.1016/S0074-7696(08)62466-3; MULLER WEG, 1976, J CELL SCI, V21, P227; MULLER WEG, 1978, DIFFERENTIATION, V10, P45, DOI 10.1111/j.1432-0436.1978.tb00944.x; MULLER WEG, 1987, J BIOL CHEM, V262, P9850; MULLER WEG, 1973, EXP CELL RES, V80, P95, DOI 10.1016/0014-4827(73)90279-6; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1989, DEVELOPMENT, V107, P133; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PEARCE JC, 1986, J CHROMATOGR, V353, P371, DOI 10.1016/S0021-9673(01)87107-7; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBITZKI A, 1990, EUR J BIOCHEM, V192, P499, DOI 10.1111/j.1432-1033.1990.tb19253.x; ROSSON D, 1987, ANN NY ACAD SCI, V511, P219, DOI 10.1111/j.1749-6632.1987.tb36250.x; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SCHRODER HC, 1988, BIOCHEM J, V252, P777, DOI 10.1042/bj2520777; SCHRODER HC, 1989, LABORATORY MANUAL; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TAKENAWA T, 1980, LAB INVEST, V42, P490; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WEIGELE M, 1973, BIOCHEM BIOPH RES CO, V50, P352, DOI 10.1016/0006-291X(73)90847-4; WEINBAUM G, 1973, NATURE, V244, P510, DOI 10.1038/244510a0; WEISSENFELS N, 1985, ZOOMORPHOLOGY, V105, P12, DOI 10.1007/BF00312068; WELLNER U, 1985, LECTURE NOTES MED IN, V25, P579; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WOLF G, 1991, NUTR REV, V49, P1, DOI 10.1111/j.1753-4887.1991.tb07349.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	83	35	35	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1765	1774						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323819				2022-12-25	WOS:A1992JJ37600013
J	JACKSON, TR; STEPHENS, LR; HAWKINS, PT				JACKSON, TR; STEPHENS, LR; HAWKINS, PT			RECEPTOR SPECIFICITY OF GROWTH FACTOR-STIMULATED SYNTHESIS OF 3-PHOSPHORYLATED INOSITOL LIPIDS IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I PHOSPHATIDYLINOSITOL KINASE; PHOSPHOLIPASE-C; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHOSPHOINOSITIDE KINASES; ACTIVATED NEUTROPHILS; HUMAN PLATELETS; A431 CELLS; G-PROTEINS; PDGF	We have investigated synthesis of 3-phosphorylated inositol lipids in growth factor-stimulated Swiss 3T3 cells. Those growth factors tested which act via tyrosine kinase-containing receptors (platelet-derived growth factor (PDGF), insulin growth factor I (IGF-I), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF)) caused the rapid synthesis of [P-32]PtdIns(3,4)P2 and [P-32]PtdIns(3,4,5)P3 (PtdIns is phosphatidylinositol) in [P-32]P(i)-prelabeled cells and the appearance of an inositol lipid 3-OH kinase in antiphosphotyrosine immunoprecipates. In contrast, those growth factors tested which act via G-protein-coupled receptors (bombesin, vasopressin, prostaglandin E1) were unable to stimulate either of the above responses. Furthermore, while PDGF was able to increase the formation of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 in streptolysin-permeabilized cells, guanosine 5'-3-(thio)triphosphate and guanyl-5'-yl imidodiphosphate were not. These results suggest that Swiss 3T3 cells possess the machinery for tyrosine kinase but not G-protein-mediated activation of PtdIns(4, 5)P2 3-OH kinase; a situation which is the inverse to that recently described for human neutrophils. The tyrosine kinase-containing receptors differed markedly in their relative abilities to elevate the levels of [P-32] PtdIns(3,4,5)P3 (ranked in the order PDGF greater-than-or-equal-to IGF-I > EGF > bFGF), [P-32]Ptd-OH (PDGF > EGF > bFGF; undetectable for IGF-I), and [P-32]PtdIns4P (EGF > bFGF > PDGF; undetectable for IGF-I) in [P-32]P(i)-prelabeled cells. These differences are epitomized by IGF-I, which was the joint most powerful stimulus for [P-32]ptdIns(3,4,5)P3 formation, but was unable to stimulate a measurable accumulation of [P-32]Ptd-OH (and hence, by deduction, was unable to stimulate phospholipase C). These results indicate that there is a differential ability among the tyrosine kinase-containing receptors present in a single cell to recruit phospholipase C and PtdIns(4, 5)P2 3-OH kinase into their signalling complexes and further emphasizes the notion that the rapid synthesis of PtdIns(3,4,5)P3 may be a signalling event.			JACKSON, TR (corresponding author), INST ANIM PHYSIOL & GENET RES, DEPT BIOCHEM, CAMBRIDGE CB2 4AT, ENGLAND.			Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487				ALLEN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P277; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BLAKELEY DM, 1989, BIOCHEM J, V258, P177, DOI 10.1042/bj2580177; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN KD, 1983, BIOCHEM J, V212, P465, DOI 10.1042/bj2120465; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COCHET C, 1991, J BIOL CHEM, V266, P637; CORPS AN, 1988, BIOCHEM J, V252, P119, DOI 10.1042/bj2520119; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; EBERLE M, 1990, J BIOL CHEM, V265, P16725; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FOLCH J, 1949, J BIOL CHEM, V177, P497; FOLCH J, 1957, J BIOL CHEM, V226, P497; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HARDEN TK, 1991, BIOCHEM SOC T, V19, P342, DOI 10.1042/bst0190342; HESKETH TR, 1988, J BIOL CHEM, V263, P11879; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LOGAN A, 1991, CELL SIGNAL, V3, P171; MILLER ES, 1990, BIOCHEM BIOPH RES CO, V173, P289, DOI 10.1016/S0006-291X(05)81055-1; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOLAN RD, 1991, BIOCHEM BIOPH RES CO, V174, P524, DOI 10.1016/0006-291X(91)91448-L; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALMER S, 1986, BIOCHEM J, V238, P491, DOI 10.1042/bj2380491; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TALMAGE DA, 1989, CELL, V59, P5; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VADNAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995, DOI 10.1016/0006-291X(89)92320-6; Vallance SJ, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104813; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VERHEIJDEN GF, 1990, CELL REGUL, V1, P615, DOI 10.1091/mbc.1.9.615; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	63	122	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16627	16636						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322911				2022-12-25	WOS:A1992JJ45800098
J	ROTMAN, EI; DEJONGH, KS; FLORIO, V; LAI, Y; CATTERALL, WA				ROTMAN, EI; DEJONGH, KS; FLORIO, V; LAI, Y; CATTERALL, WA			SPECIFIC PHOSPHORYLATION OF A COOH-TERMINAL SITE ON THE FULL-LENGTH FORM OF THE ALPHA-1-SUBUNIT OF THE SKELETAL-MUSCLE CALCIUM-CHANNEL BY CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SIZE FORMS; DIHYDROPYRIDINE RECEPTOR; CYCLIC-AMP; 1,4-DIHYDROPYRIDINE RECEPTOR; ANTAGONIST RECEPTOR; BINDING POLYPEPTIDE; TRANSVERSE TUBULES; CATALYTIC SUBUNIT; IDENTIFICATION; MODULATION	The primary (alpha-1) subunit of purified skeletal muscle dihydropyridine-sensitive calcium channels is present in full-length (212 kDa) and truncated (190 kDa) forms which are both phosphorylated by cAMP-dependent protein kinase (cA-PK) in vitro. In the present study, phosphorylation of the purified calcium channel by cA-PK followed by immunoprecipitation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and two-dimensional phosphopeptide mapping revealed differential phosphorylation of the related 190- and 212-kDa forms. The 190-kDa form of the alpha-1 subunit was phosphorylated on three major and three minor tryptic phosphopeptides; the 212-kDa form was phosphorylated on all six of these phosphopeptides plus two that were unique. Time course experiments showed that a single site on the COOH-terminal portion of the full-length form of the alpha-1 subunit is most intensely and rapidly (within 10 s) phosphorylated. Phosphorylation occurs almost exclusively on this COOH-terminal site unless harsh conditions such as treatment with denaturing detergents are employed to expose phosphorylation sites within the 190-kDa segment of the molecule. Elution of phosphopeptides from the second dimension chromatograph followed by immunoprecipitation with an anti-peptide antibody (anti-CP1) directed against the COOH-terminal amino acid sequence enabled us to identify this major phosphorylation site as serine 1854. The nearby consensus sites for cA-PK phosphorylation at serines 1757 and 1772 were phosphorylated only after denaturation or proteolytic cleavage. Phosphorylation of serine 1854 may play a pivotal role in the regulation of calcium channel function by cA-PK.			ROTMAN, EI (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA.		Mackie, Ken/E-3384-2013		NINDS NIH HHS [R01-NS22625] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022625] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; BRUM G, 1983, PFLUG ARCH EUR J PHY, V398, P147, DOI 10.1007/BF00581064; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; CURTIS BM, 1986, BIOCHEMISTRY-US, V25, P3077, DOI 10.1021/bi00359a002; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FERNANDEZ JL, 1980, BIOCHIM BIOPHYS ACTA, V599, P552, DOI 10.1016/0005-2736(80)90199-6; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P4290, DOI 10.1073/pnas.85.12.4290; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1990, J BIOL CHEM, V265, P20839; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MUSZYNSKA G, 1986, BIOCHEMISTRY-US, V25, P6850, DOI 10.1021/bi00370a018; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; OCALLAHAN CM, 1988, BIOCHEMISTRY-US, V27, P6071, DOI 10.1021/bi00416a036; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID A, 1985, J BIOL CHEM, V260, P3041; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SIEBER M, 1987, EUR J BIOCHEM, V167, P117, DOI 10.1111/j.1432-1033.1987.tb13311.x; STRIESSNIG J, 1990, J BIOL CHEM, V265, P363; STRIESSNIG J, 1987, FEBS LETT, V212, P247, DOI 10.1016/0014-5793(87)81354-6; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; VAGHY PL, 1987, J BIOL CHEM, V262, P14337	40	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16100	16105						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322891				2022-12-25	WOS:A1992JJ45800021
J	CHEN, TM; DEFENDI, V				CHEN, TM; DEFENDI, V			FUNCTIONAL INTERACTION OF P53 WITH HPV18 E6, C-MYC AND H-RAS IN 3T3 CELLS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CERVICAL-CARCINOMA; SV40-TRANSFORMED CELLS; BIOLOGICAL-ACTIVITIES; CELLULAR ONCOGENE; TRANSFORMING GENE; ESCHERICHIA-COLI; SIMIAN VIRUS-40; DNA	Wild-type (wt) p53 has been suggested to be the product of a tumor-suppressor gene. Recently, it has been shown that the E6 oncoproteins of human papillomavirus (HPV) types 16 and 18, like the SV40 large T antigen, are physically associated with wt p53. We have investigated the functional interaction of wt p53 with the viral oncogene products of HPV16 and 18 and with cellular oncogenes by transfection of NIH3T3 cells with p53 wt alone or with several oncogene(s). We found that over-expression of HPV18 E6, c-myc or activated H-ras, like SV40 large T, can partially overcome the growth-inhibitory effect of wt p53 in NIH3T3 cells, while HPV16 E6 and E7, HPV18 E7, k-fgf, c-fos and mutant (mt) p53 do not. Further studies indicate that HPV18 E6 and c-myc can overcome the antiproliferative effect, but not the antitransforming effect, of wt p53, while activated H-ras can overcome both the antiproliferative and antitransforming effects of wt p53. These data show evidence of a functional interaction between HPV18 E6 and wt p53, and suggest that the cooperation of HPV E6 and cellular oncogenes c-myc and H-ras, which are activated in several cases of human cervical cancers, may be necessary to overcome completely the anti-oncogenic function of p53 in the development of these tumors.	NYU MED CTR, DEPT PATHOL, 550 1ST AVE, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				defendi, vittorio/0000-0002-0707-6900				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BOURHIS J, 1990, J CLIN ONCOL, V8, P1789, DOI 10.1200/JCO.1990.8.11.1789; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; CROOK T, 1989, P NATL ACAD SCI USA, V86, P5713, DOI 10.1073/pnas.86.15.5713; CROOK T, 1991, ONCOGENE, V6, P873; DAVID YB, 1988, ONCOGENE, V3, P179; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MILLER AD, 1984, CELL, V36, P51; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PECORARO G, 1991, AM J PATHOL, V138, P1; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; QUARTO N, 1989, ONCOGENE RES, V5, P101; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIOU G, 1988, ONCOGENE, V3, P329; RIOU G, 1990, LANCET, V335, P1171; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TUCK SP, 1989, ONCOGENE RES, V4, P81; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0	55	40	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1541	1547						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321402				2022-12-25	WOS:A1992JE81300010
J	LI, Y; JAISWAL, AK				LI, Y; JAISWAL, AK			REGULATION OF HUMAN NAD(P)H-QUINONE OXIDOREDUCTASE GENE - ROLE OF AP1 BINDING-SITE CONTAINED WITHIN HUMAN ANTIOXIDANT RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; PLANAR AROMATIC-COMPOUNDS; QUINONE REDUCTASE; TRANSCRIPTIONAL REGULATION; DT-DIAPHORASE; NAD(P)H-MENADIONE OXIDOREDUCTASE; PHENOLIC ANTIOXIDANTS; MESSENGER-RNA; NQO1 GENE	Deletion mutagenesis and transfection studies into hepatic (mouse hepatoma (Hepa- 1) and human hepatoblastoma (Hep-G2)) and nonhepatic (HeLa) cells indicated that high levels of expression of the human NAD(P)H:quinone oxidoreductase gene in tumor cells and its induction by beta-naphthoflavone and 3-(2)-tert-butyl-4-hydroxyanisole are mediated by human antioxidant response element (hARE) located in the region between -470 and -445. The hARE, when attached to the thymidine kinase promoter and transfected into several mammalian cells, expressed high levels of the chloramphenicol acetyltransferase gene that was inducible by beta-naphthonavone and 3-(2)-tert-butyl-4-hydroxyanisole. Nucleotide sequence analysis of the hARE revealed the presence of a recognition site for binding to the AP1 protein. Mutation of the AP1 binding site located within the hARE resulted in the loss of expression and induction upon transfection into various cell types. Band shift and competition assays with hARE and nuclear extracts from control and beta-naphthoflavone-treated Hepa-1, Hep-G2 and HeLa cells indicated specific interaction of regulatory protein(s) to the hARE. The supershift assays using antibodies against specific proteins of the AP1 family identified Jun-D and c-Fos as two members in the hARE-protein complex observed in band shift assays.	FOX CHASE CANC INST,DEPT PHARMACOL,7701 BURHOLME AVE,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; DAVIES LG, 1980, BASIC METHODS MOL BI, P244; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P334, DOI 10.1016/0003-9861(84)90206-6; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P343, DOI 10.1016/0003-9861(84)90207-8; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; IYANAGI T, 1987, CHEM SCRIPTA, V27A, P31; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN LF, 1987, CANCER LETT, V36, P341, DOI 10.1016/0304-3835(87)90028-0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PROCHASKA HJ, 1987, J BIOL CHEM, V262, P1931; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBERTSON JA, 1986, J BIOL CHEM, V261, P5794; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAL GD, 1989, BIOTECHNIQUES, V7, P514; SCHLAGER JJ, 1990, INT J CANCER, V45, P403, DOI 10.1002/ijc.2910450304; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TALALAY P, 1982, ADV ENZYME REGUL, V20, P287, DOI 10.1016/0065-2571(82)90021-8; WILLIAMS JB, 1986, J BIOL CHEM, V261, P5524; WILLIAMS JB, 1984, ARCH BIOCHEM BIOPHYS, V232, P408, DOI 10.1016/0003-9861(84)90556-3	40	332	337	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15097	15104						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1340765				2022-12-25	WOS:A1992JF08800087
J	OHMICHI, M; PANG, L; DECKER, SJ; SALTIEL, AR				OHMICHI, M; PANG, L; DECKER, SJ; SALTIEL, AR			NERVE GROWTH-FACTOR STIMULATES THE ACTIVITIES OF THE RAF-1 AND THE MITOGEN-ACTIVATED PROTEIN-KINASES VIA THE TRK PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; C-RAF; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; NGF RECEPTOR; PC-12 CELLS; V-RAF; SERINE; ONCOGENE; INSULIN	Nerve growth factor (NGF) binds to two structurally unrelated transmembrane proteins on the surface of PC-12 cells, a 75-kDa glycoprotein with a short cytoplasmic sequence, and the trk protooncogene (pp140c-trk), a protein tyrosine kinase activated by NGF. Immediately after binding to cells, NGF induces changes in serine/threonine phosphorylation of several proteins. We have explored the relative roles of these two NGF binding proteins in mediating the activation of two intracellular kinases that may be responsible for some of these phosphorylations. The raf-1 protooncogene is a serine/threonine kinase activated by several growth factors and oncogenic proteins. Treatment of PC-12 cells with NGF increases the serine and threonine phosphorylation of raf-1 in an anti-raf-1 immunoprecipitate kinase assay. This increased phosphorylation observed in vitro is dose-dependent and transient and is accompanied by the NGF-dependent shift in the mobility of immunoblotted raf-1 on SDS sodium dodecyl sulfate-polyacrylamide gel electrophoresis, an effect thought to reflect phosphorylation. NGF-dependent activation of raf-1 is not dependent on protein kinase C, since prolonged exposure to phorbol esters under conditions that cause down-regulation of cellular protein kinase C activity has no effect on the NGF response. Expression of pp140c-trk in 3T3 fibroblasts (3T3-c-trk), as evidenced by cross-linking of I-125-NGF to the 140-kDa protein, permits the NGF-dependent activation of raf-1 kinase, detected in the immunoprecipitate kinase assay, anti-raf immunoblot shift on gel electrophoresis, and incorporation of [P-32]orthophosphate into the raf-1 protein. The concentration dependence of raf-1 activation is identical in 3T3-c-trk and PC-12 cells, despite the absence of the 75-kDa NGF binding protein in 3T3-c-trk cells. NGF is without effect in untransfected 3T3 cells or in Chinese hamster ovary cells overexpressing p75, although raf-1 is present in these cells. Similarly, the NGF-dependent activation of mitogen-activated protein (MAP) kinase is detected in 3T3-c-trk cells, but not in untransfected 3T3 or Chinese hamster ovary cells overexpressing p75. As described for raf-1 activation, the NGF dose responses for MAP kinase activation in 3T3-c-trk and PC-12 cells are virtually superimposable. These data indicate that the activation of these two serine/threonine kinases by NGF is mediated solely by binding to and activating the pp140c-trk receptor.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019		NATIONAL CANCER INSTITUTE [R01CA037754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK033804, R01DK033804] Funding Source: NIH RePORTER; NCI NIH HHS [CA37754] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALETTA JM, 1988, J CELL BIOL, V106, P1573, DOI 10.1083/jcb.106.5.1573; BERG MM, 1991, P NATL ACAD SCI USA, V86, P1756; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; DECKER SJ, 1984, MOL CELL BIOL, V4, P1719; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KY, 1985, MOL PHARMACOL, V28, P220; LEE RM, 1991, J BIOL CHEM, V266, P10351; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARGOLIS B, 1990, MOL CELL BIOL, V4, P571; MATSUDA Y, 1987, J BIOL CHEM, V262, P2832; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1991, CELL REGUL, V2, P691, DOI 10.1091/mbc.2.9.691; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAWLAND EA, 1987, J BIOL CHEM, V262, P7504; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VULLIET PR, 1989, J BIOL CHEM, V264, P16292	44	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14604	14610						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321811				2022-12-25	WOS:A1992JF08800020
J	BRASS, LF; VASSALLO, RR; BELMONTE, E; AHUJA, M; CICHOWSKI, K; HOXIE, JA				BRASS, LF; VASSALLO, RR; BELMONTE, E; AHUJA, M; CICHOWSKI, K; HOXIE, JA			STRUCTURE AND FUNCTION OF THE HUMAN PLATELET THROMBIN RECEPTOR - STUDIES USING MONOCLONAL-ANTIBODIES DIRECTED AGAINST A DEFINED DOMAIN WITHIN THE RECEPTOR N-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-LINE	Based upon its recently cloned nucleotide sequence, the human platelet thrombin receptor is thought to be formed by a single polypeptide chain with seven transmembrane domains and an extracellular N terminus that can be cleaved by thrombin. As yet, however, little is known from studies of the receptor protein itself. To obtain such information, we have prepared monoclonal antibodies against a peptide corresponding to receptor residues Ser42 through Phe55, the domain immediately distal to the site of cleavage by thrombin. By flow cytometry, all of the antibodies reacted with the thrombin-responsive megakaryoblastic CHRF-288 and HEL cell lines, but not with the T-lymphoid Sup-T1 cell line. Functionally, the antibodies inhibited platelet responses to alpha-thrombin, gamma-thrombin, and trypsin, but had no effect on platelet activation by ADP, epinephrine, or the thromboxane analog U46619. Radioiodinated antibody bound to almost-equal-to 1,800 sites/platelet, a value similar to the reported number of moderate affinity thrombin binding sites per platelet. On Western blots, the antibodies recognized a 66-kDa protein in platelet, HEL, and CHRF-288 membranes. The discrepancy between this apparent size and the predicted mass of the receptor suggests that, as with other G protein-coupled receptors, one or more of the potential sites for N-linked glycosylation have been utilized. Therefore, these results suggest that: 1) the cloned thrombin receptor is involved in a broad range of platelet responses to thrombin, as well as gamma-thrombin and trypsin; 2) as predicted, the N terminus of the receptor is accessible on the platelet surface; 3) the moderate affinity thrombin binding site noted in earlier studies may be the receptor; 4) potentially as much as one third of the mass of the receptor is carbohydrate.	UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania	BRASS, LF (corresponding author), UNIV PENN,DEPT MED,HEMATOL ONCOL SECT,SILVERSTEIN 7,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRASS LF, 1992, BIOCHEM J, V281, P73, DOI 10.1042/bj2810073; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; FROST GH, 1991, BIOCHEM BIOPH RES CO, V180, P349, DOI 10.1016/S0006-291X(05)81299-9; FUGMAN DA, 1990, BLOOD, V75, P1252; GAGNON AW, 1991, BLOOD, V78, P1247; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRECO NJ, 1991, P SOC EXP BIOL MED, V198, P792; GRIFFITH L, 1991, BLOOD, V78, P1753; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; LIU LW, 1991, J BIOL CHEM, V266, P16977; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; RANDS E, 1990, J BIOL CHEM, V265, P10759; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; SEILER SM, 1992, BIOCHEM BIOPH RES CO, V182, P1296, DOI 10.1016/0006-291X(92)91873-O; SMITH SD, 1984, CANCER RES, V44, P5657; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	25	182	186	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13795	13798						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321125				2022-12-25	WOS:A1992JD32500002
J	KAHLE, P; HERTEL, C				KAHLE, P; HERTEL, C			NERVE GROWTH-FACTOR (NGF) RECEPTOR ON RAT GLIAL-CELL LINES - EVIDENCE FOR NGF INTERNALIZATION VIA P75(NGFR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; HIGH-AFFINITY RECEPTORS; SCHWANN-CELLS; BINDING-PROPERTIES; EXPRESSION; ASSOCIATION; DEGRADATION; CONVERSION; TRANSPORT; NEURONS	Two types of nerve growth factor (NGF) receptors have been described: high affinity (class I) and low affinity (class II). Biological responses to NGF are thought to be mediated by class I receptors, whereas the role of class II receptors is less clear. While some neuronal cells express both receptor types, only class II receptors have been detected on glial cells. Two glial cell lines, peripheral Schwannoma D6P2T and central 33B glioma cells, were employed to investigate the properties of class II receptors in the absence of class I receptors. These cell lines were found to express NGF receptors identified as class II by a low nanomolar dissociation constant, rapid dissociation kinetics at 4-degrees-C, and trypsin sensitivity. The receptor was found to bind brain-derived neurotrophic factor with similar affinity as NGF. The responsible binding molecule appeared in sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a heterogeneously glycosylated protein of 60-80 kDa with a tendency to aggregate. All receptor bands affinity-labeled with radioiodinated NGF were immunoprecipitated with anti-p75NGFR antibody, but not with anti-p140prototrk antiserum. In these cells, which express p75NGFR as only NGF receptor, a time- and temperature-dependent appearance of a nondisplaceable, trypsin-resistant, acid wash-stable ligand fraction, followed by an increase of trichloroacetic acid-soluble radiolabel in the medium was observed. This sequestration resembled receptor-mediated internalization with subsequent degradation of NGF. Whether this ligand processing indicates a functional role of p75NGFR in glial cells remains to be shown.	F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,GRENZACHERSTR 124,CH-4002 BASEL,SWITZERLAND	Roche Holding								BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; DISTEFANO PS, 1988, J NEUROSCI, V8, P231; FIELDS KL, 1975, P NATL ACAD SCI USA, V72, P1296, DOI 10.1073/pnas.72.4.1296; FIELDS KL, 1985, NEUROSCIENCE, V15, P877, DOI 10.1016/0306-4522(85)90085-5; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HERTEL C, 1983, BIOCHEM J, V216, P669, DOI 10.1042/bj2160669; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; IMADA M, 1978, DEV BIOL, V66, P97, DOI 10.1016/0012-1606(78)90276-2; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KASAIAN MT, 1988, J BIOL CHEM, V263, P5083; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LAYER PG, 1983, J BIOL CHEM, V258, P3012; LEMKE G, 1988, DEVELOPMENT, V102, P499; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; PERIOSO PM, 1988, AM J PATHOL, V132, P152; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAIVICH G, 1991, NEURON, V7, P151, DOI 10.1016/0896-6273(91)90083-C; RAKOWICZSZULCZYNSKA EM, 1989, MOL CARCINOGEN, V2, P47, DOI 10.1002/mc.2940020108; Rodbard D, 1975, Methods Enzymol, V37, P3; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SAAD B, 1991, J CELL BIOL, V115, P473, DOI 10.1083/jcb.115.2.473; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SEILHEIMER B, 1987, EMBO J, V6, P1611, DOI 10.1002/j.1460-2075.1987.tb02408.x; SONNENFELD KH, 1986, CANCER RES, V46, P1446; STACH RW, 1984, J NEUROSCI RES, V11, P215, DOI 10.1002/jnr.490110302; TANIUCHI M, 1985, J CELL BIOL, V101, P1100, DOI 10.1083/jcb.101.3.1100; TANIUCHI M, 1988, J NEUROSCI, V8, P664; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VALE RD, 1985, METHOD ENZYMOL, V109, P21; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; YAN Q, 1988, J NEUROSCI, V8, P3481; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x; ZIMMERMANN A, 1983, EMBO J, V2, P879, DOI 10.1002/j.1460-2075.1983.tb01517.x	50	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13917	13923						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321130				2022-12-25	WOS:A1992JD32500023
J	DARMOUL, D; LACASA, M; BARICAULT, L; MARGUET, D; SAPIN, C; TROTOT, P; BARBAT, A; TRUGNAN, G				DARMOUL, D; LACASA, M; BARICAULT, L; MARGUET, D; SAPIN, C; TROTOT, P; BARBAT, A; TRUGNAN, G			DIPEPTIDYL PEPTIDASE-IV (CD-26) GENE-EXPRESSION IN ENTEROCYTE-LIKE COLON CANCER CELL-LINES HT-29 AND CACO-2 - CLONING OF THE COMPLETE HUMAN CODING SEQUENCE AND CHANGES OF DIPEPTIDYL PEPTIDASE-IV MESSENGER-RNA LEVELS DURING CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; ASPARAGINE-LINKED OLIGOSACCHARIDES; INTESTINAL EPITHELIAL-CELLS; SUCRASE-ISOMALTASE; AMINOPEPTIDASE-IV; POSTNATAL-DEVELOPMENT; MICROVILLAR MEMBRANE; CARCINOMA-CELLS; TRANSGENIC MICE; RAT	A cDNA (DPCR1) specific for human intestinal dipeptidyl peptidase IV (DPP IV) has been isolated. This 1.7-kilobase cDNA, together with a previously published partial sequence, covers the entire open reading frame of human DPP IV plus 67 base pairs of the 3'-untranslated end. Human DPP IV is a 766-amino acid polypeptide with a high degree of homology with the rat liver protein. The characterization of this molecular probe allowed us to definitively confirm the identity of DPP IV with CD 26, a mouse thymocyte activation antigen, a conclusion strengthened by the fact that we observed identical patterns on Southern blot of human genomic DNA hybridized either with human DPP IV or mouse CD 26 cDNA probe. Using this new tool, we have investigated the expression of DPP IV during the onset of enterocytic differentiation of two cultured human colon cancer cell lines, HT-29 and Caco-2. Whatever the cell line and the culture conditions, DPP IV expression strictly correlates with the presence of a differentiated phenotype, as shown by enzyme activity and the steady state amount of the protein measured by indirect immunofluorescence and Western blot. Accordingly, DPP IV biosynthesis exclusively increases in cells that display an enterocytic differentiation. Neither the glycosylation nor the stability of the protein appear to be dependent on the state of enterocytic differentiation. The DPP IV mRNA level remains very low in undifferentiated cell populations and specifically increases in cells that undergo an enterocytic differentiation. These results strongly suggest that DPP IV gene expression is controlled at the transcriptional or posttranscriptional level during intestinal differentiation.	INSERM,U178,UNITE RECH DIFFERENCIAT CELLULAIRE INTESTINALE,16 AVE PAUL VAILLANT COUTURIEN,F-94807 VILLEJUIF,FRANCE; INST RECH SCI CANC,CNRS,UPR 72,F-94801 VILLEJUIF,FRANCE; CNRS,INSERM,CTR IMMUNOL,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Baricault, Laurent/G-3396-2017; Darmoul, Dalila/M-5812-2018; Marguet, Didier/B-9946-2008; Marguet, Didier/AGO-5421-2022	Darmoul, Dalila/0000-0002-1206-0655; Marguet, Didier/0000-0003-3198-5095; Krejbich Trotot, Pascale/0000-0001-7329-1716				BARTON RW, 1990, J LEUKOCYTE BIOL, V48, P291, DOI 10.1002/jlb.48.4.291; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BOOTH AG, 1979, BIOCHEM J, V179, P397, DOI 10.1042/bj1790397; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANTRET I, 1988, CANCER RES, V48, P1936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG YS, 1985, CANCER RES, V45, P2976; CLEVELAND D W, 1989, New Biologist, V1, P121; DANIELSEN EM, 1989, J BIOL CHEM, V264, P13726; DANIELSEN EM, 1982, BIOCHEM J, V202, P647, DOI 10.1042/bj2020647; DARMOUL D, 1990, ANN HUM GENET, V54, P191, DOI 10.1111/j.1469-1809.1990.tb00377.x; DARMOUL D, 1991, EXPERIENTIA, V47, P1211, DOI 10.1007/BF01918387; DARMOUL D, 1991, AM J PHYSIOL, V24, pG6763; DAVID R, 1979, BIOCHEM J, V179, P379; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; FELLER AC, 1982, BRIT J HAEMATOL, V51, P227, DOI 10.1111/j.1365-2141.1982.tb02775.x; FOLTZERJOURDAINNE C, 1989, AM J PHYSIOL, V257, pG496, DOI 10.1152/ajpgi.1989.257.4.G496; FREUND JN, 1991, GASTROENTEROLOGY, V100, P388, DOI 10.1016/0016-5085(91)90207-2; FREUND JN, 1989, FEBS LETT, V248, P39, DOI 10.1016/0014-5793(89)80427-2; FREUND JN, 1990, CELL MOL BIOL, V36, P729; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; FUKASAWA KM, 1978, BIOCHIM BIOPHYS ACTA, V535, P161, DOI 10.1016/0005-2795(78)90042-9; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORRELL MD, 1991, CELL IMMUNOL, V134, P205, DOI 10.1016/0008-8749(91)90343-A; GORVEL JP, 1991, GASTROENTEROLOGY, V101, P618, DOI 10.1016/0016-5085(91)90517-O; GRAND RJ, 1976, GASTROENTEROLOGY, V70, P790; GRUBER M, 1988, CELL IMMUNOL, V113, P423, DOI 10.1016/0008-8749(88)90039-1; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HANSKI C, 1985, BIOL CHEM H-S, V366, P1169, DOI 10.1515/bchm3.1985.366.2.1169; HARTEL S, 1988, HISTOCHEMISTRY, V89, P151, DOI 10.1007/BF00489918; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HEGEN M, 1990, J IMMUNOL, V144, P2908; HONG WJ, 1989, EXP CELL RES, V182, P256, DOI 10.1016/0014-4827(89)90296-6; JACK HM, 1988, EMBO J, V7, P1041, DOI 10.1002/j.1460-2075.1988.tb02911.x; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEPER LL, 1990, AM J PHYSIOL, V258, pG52, DOI 10.1152/ajpgi.1990.258.1.G52; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; LINDBERG T, 1966, CLIN SCI, V30, P505; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS PS, 1982, MOL CLONING LABORATO, P205; MATSUMOTO H, 1990, GASTROENTEROLOGY, V98, P1199, DOI 10.1016/0016-5085(90)90334-W; MESSER M, 1966, ANAL BIOCHEM, V14, P372; NAGATSU T, 1976, ANAL BIOCHEM, V74, P466, DOI 10.1016/0003-2697(76)90227-X; NEUTRA MR, 1980, IN VITRO EPITHELIA B, P261; NOREN O, 1989, FEBS LETT, V259, P107, DOI 10.1016/0014-5793(89)81506-6; OGATA S, 1989, J BIOL CHEM, V264, P3596; OGIERDENIS E, 1989, J CELL BIOCHEM, V41, P13, DOI 10.1002/jcb.240410103; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; PINTO M, 1982, BIOL CELL, V44, P193; PINTO M, 1983, BIOL CELL, V47, P322; RAUL F, 1977, CELL TISSUE RES, V176, P167; ROUSSET M, 1989, J CELL PHYSIOL, V141, P627, DOI 10.1002/jcp.1041410322; SAHARA N, 1981, HISTOCHEMISTRY, V72, P229, DOI 10.1007/BF00517136; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SHAPIRO VA, 1986, J GEODYN, V5, P221, DOI 10.1016/0264-3707(86)90007-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TAUC M, 1989, HISTOCHEMISTRY, V91, P17, DOI 10.1007/BF00501905; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P1476; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; TRUGNAN G, 1991, J BIOL CHEM, V266, P20849; WICE BM, 1985, J BIOL CHEM, V260, P139; YOSHIMOTO T, 1978, J BIOL CHEM, V253, P3708; YOSHIMOTO T, 1982, J BIOCHEM, V92, P275, DOI 10.1093/oxfordjournals.jbchem.a133924; YOSHIOKA M, 1991, INT J CANCER, V47, P916, DOI 10.1002/ijc.2910470622; ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105; ZWEIBAUM A, 1984, INT J CANCER, V34, P591, DOI 10.1002/ijc.2910340502; ZWEIBAUM A, 1991, GASTROINTESTINAL SYS, V4, P223; ZWEIBAUM A, 1988, MAMMALIAN BRUSH BORD, P63	78	162	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4824	4833						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1347043				2022-12-25	WOS:A1992HF64200081
J	TAYLOR, KL; POHL, J; KINKADE, JM				TAYLOR, KL; POHL, J; KINKADE, JM			UNIQUE AUTOLYTIC CLEAVAGE OF HUMAN MYELOPEROXIDASE - IMPLICATIONS FOR THE INVOLVEMENT OF ACTIVE-SITE MET409	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL MYELOPEROXIDASE; CHROMATOGRAPHIC FORMS; EOSINOPHIL PEROXIDASE; HEMI-MYELOPEROXIDASE; REDUCTIVE CLEAVAGE; MOLECULAR-CLONING; SUBUNIT STRUCTURE; GRANULOCYTES; LEUKOCYTES; RESONANCE	Myeloperoxidase (MPO) is a functionally important component of the normal human neutrophil host defense system. This enzyme possesses a dimeric structure composed of two heavy subunit (55-63 kDa)/light subunit (10-15 kDa) protomers, each of which is associated with a heme-like prosthetic group. In addition, MPO species of approximately 38 and 22 kDa have been reported by many different investigators, but their nature and mode of origin are not understood. In the present study, we demonstrate that when MPO is heated under nonreducing, denaturing conditions, these two species are produced via a novel autolytic cleavage of the heavy subunit. The 38-kDa species was isolated by fast-protein liquid chromatography and identified by sequencing as the carboxyl-terminal portion of the heavy subunit, and the cleavage was shown to occur exclusively between Met409 and Pro410. In order to further characterize this unusual cleavage reaction, the 22-kDa species was digested with endoproteinase Asp-N, and the peptide corresponding to its carboxyl terminus was isolated and analyzed by sequencing and mass spectrometry. These data indicated that during cleavage of the heavy subunit, Met409 was converted to homoserine lactone. Thus, the cleavage appeared to formally resemble the cyanogen bromide-dependent cleavage of Met-X peptide bonds. Recent x-ray crystallographic data for canine MPO have indicated that Met409 is in close proximity to the heme-like prosthetic group of MPO. Our studies suggest that interaction of Met409 with this group leads to the formation of a methionyl sulfonium derivative which undergoes intramolecular rearrangement with subsequent peptide cleavage under nonreducing conditions. This derivative may be, at least in part, responsible for the unusual spectral characteristics and enzymatic properties of the enzyme. The primary structure of the 22-kDa MPO species is also reported, and direct evidence is provided for asparagine-linked oligosaccharide moieties at two of the three predicted glycosylation sites.	EMORY UNIV, SCH MED, MICROCHEM FACIL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, WINSHIP CANC CTR, ATLANTA, GA 30322 USA	Emory University; Emory University	TAYLOR, KL (corresponding author), EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA.				NCI NIH HHS [R01 CA-22294] Funding Source: Medline; NIDCR NIH HHS [F32 DE-05541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGNER K, 1958, ACTA CHEM SCAND, V12, P89, DOI 10.3891/acta.chem.scand.12-0089; ANDERSEN MR, 1982, ARCH BIOCHEM BIOPHYS, V214, P273, DOI 10.1016/0003-9861(82)90031-5; ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; BABCOCK GT, 1985, BIOCHIM BIOPHYS ACTA, V828, P58, DOI 10.1016/0167-4838(85)90009-3; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V791, P75, DOI 10.1016/0167-4838(84)90283-8; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHANG Y, 1970, BIOCHIM BIOPHYS ACTA, V215, P88, DOI 10.1016/0304-4165(70)90390-9; EGLINTON DG, 1982, BIOCHIM BIOPHYS ACTA, V703, P187, DOI 10.1016/0167-4838(82)90047-4; FELBERG NT, 1972, ARCH BIOCHEM BIOPHYS, V148, P407, DOI 10.1016/0003-9861(72)90158-0; GLOSSMANN H, 1971, J BIOL CHEM, V246, P6339; GROSS E, 1962, J BIOL CHEM, V237, P1856; HARRISON JE, 1977, BIOCHIM BIOPHYS ACTA, V493, P247, DOI 10.1016/0005-2795(77)90181-7; HARRISON JE, 1978, BIOCHIM BIOPHYS ACTA, V536, P341, DOI 10.1016/0005-2795(78)90492-0; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HASILIK A, 1984, EMBO J, V3, P2671, DOI 10.1002/j.1460-2075.1984.tb02192.x; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HURST JK, 1990, PEROXIDASES CHEM BIO, P37; IKEDASAITO M, 1989, J BIOL CHEM, V264, P4559; IWAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P688, DOI 10.1093/oxfordjournals.jbchem.a122330; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KOEFFLER HP, 1985, BLOOD, V65, P484; KUN SC, 1986, BLOOD, V68, P1411; LAWSON WB, 1961, J AM CHEM SOC, V83, P1509, DOI 10.1021/ja01467a051; MATHESON NR, 1981, BIOCHEMISTRY-US, V20, P325, DOI 10.1021/bi00505a015; MIYASAKI KT, 1986, ARCH BIOCHEM BIOPHYS, V246, P751, DOI 10.1016/0003-9861(86)90332-2; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; NAIDER F, 1972, BIOCHEMISTRY-US, V11, P3208, DOI 10.1021/bi00767a011; NAUSEEF WM, 1986, BLOOD, V67, P1504; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; NAUSEEF WM, 1987, BLOOD, V70, P1143; ODAJIMA T, 1972, BIOCHIM BIOPHYS ACTA, V284, P368, DOI 10.1016/0005-2744(72)90132-5; ODAJIMA T, 1980, J BIOCHEM-TOKYO, V87, P379, DOI 10.1093/oxfordjournals.jbchem.a132758; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; OLSEN RL, 1984, BIOCHEM J, V222, P701, DOI 10.1042/bj2220701; OLSSON I, 1972, SCAND J HAEMATOL, V9, P483; PEMBER SO, 1982, FEBS LETT, V140, P103, DOI 10.1016/0014-5793(82)80530-9; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; SCHULTZ J, 1962, ARCH BIOCHEM BIOPHYS, V96, P465, DOI 10.1016/0003-9861(62)90321-1; SCHULTZ J, 1983, BIOCHEMISTRY, V22; SIBBETT SS, 1984, BIOCHEMISTRY-US, V23, P3007, DOI 10.1021/bi00308a025; SPITZNAGEL JK, 1974, LAB INVEST, V30, P774; SVENSSON BE, 1987, BIOCHEM J, V242, P673, DOI 10.1042/bj2420673; TAYLOR KL, 1990, J BIOL CHEM, V265, P15938; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; WATERFIELD MD, 1986, PRACTICAL PROTEIN CH, pCH13; WRIGHT J, 1987, BIOCHIM BIOPHYS ACTA, V915, P68, DOI 10.1016/0167-4838(87)90126-9; WU NC, 1975, FEBS LETT, V60, P141, DOI 10.1016/0014-5793(75)80437-6; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	51	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25282	25288						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334087				2022-12-25	WOS:A1992KB60300057
J	TELERMAN, A; DODEMONT, H; DEGRAEF, C; GALAND, P; BAUWENS, S; VANOOSTVELDT, P; AMSON, RB				TELERMAN, A; DODEMONT, H; DEGRAEF, C; GALAND, P; BAUWENS, S; VANOOSTVELDT, P; AMSON, RB			IDENTIFICATION OF THE CELLULAR PROTEIN ENCODED BY THE HUMAN WILMS-TUMOR (WT1) GENE	ONCOGENE			English	Note							HUMAN CHROMOSOME-11; PHYSICAL MAP; PRODUCT; DELETION; BINDING; REGION; GROWTH; LOCUS	A putative tumor-suppressor gene (wt1) located at chromosome 11p13 and involved in Wilms' tumor development has recently been identified as a zinc finger polypeptide-encoding gene. The purpose of this study was to characterize the protein encoded by the human wt1 gene. The region spanning the entire zinc finger domain was amplified by polymerase chain reaction (PCR) and subcloned in the pATH 3 expression vector. Polyclonal antibodies against the fused TrpE-WT protein were raised. These antibodies immunoprecipitated a 49- to 51-kDa protein from hematopoietic tumor cells labeled in vivo with [S-35]methionine. Subcellular fractionation and immunohistochemistry followed by confocal microscopy indicated that the Wilms' tumor gene product (WT1) is mainly localized within the nucleus.	FREE UNIV BRUSSELS,SCH MED,INST INTERDISCIPLINARY RES,CAMPUS ERASME,BLDG C,ROUTE LENNIK 808,B-1070 BRUSSELS,BELGIUM; MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM,W-3400 GOTTINGEN,GERMANY; FREE UNIV BRUSSELS,SCH MED,CYTOL & EXPTL ONCOL LAB,B-1050 BRUSSELS,BELGIUM; STATE UNIV GHENT,GENET LAB,B-9000 GENT,BELGIUM; STATE UNIV GHENT,BIOCHEM LAB,B-9000 GENT,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Max Planck Society; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ghent University; Ghent University								AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; AMSON RB, 1989, ONCOGENE, V4, P243; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; GALAND P, 1989, CELL TISSUE KINET, V22, P383, DOI 10.1111/j.1365-2184.1989.tb00223.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383	19	21	28	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2545	2548						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334252				2022-12-25	WOS:A1992KA85600023
J	MARTIN, DW; SACHS, JR				MARTIN, DW; SACHS, JR			CROSS-LINKING OF THE ERYTHROCYTE (NA+,K+)-ATPASE - CHEMICAL CROSS-LINKERS INDUCE ALPHA-SUBUNIT-BAND-3 HETERODIMERS AND DO NOT INDUCE ALPHA-SUBUNIT HOMODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+)-DEPENDENT ADENOSINE-TRIPHOSPHATASE; PREDOMINANT TRANSMEMBRANE POLYPEPTIDE; CELL-MEMBRANES; ANION TRANSPORT; BAND-3 PROTEIN; SODIUM; PUMP; POTASSIUM; CROSSLINKING; MECHANISM	Earlier studies (Periyasamy, S. M., Huang, W.-H., and Askari, A. (1983) J. Biol. Chem. 258,9878-9885) suggested that Cu2+ and o-phenanthroline induced the formation of cross-linked homodimers between alpha-subunits of the erythrocyte (Na+,K+)-ATPase. This was interpreted as indicating that alpha-subunits existed in close proximity in native erythrocyte membranes. The alpha-subunit and band 3 monomers have similar molecular weights (M(r) approximately 100,000) and exist in the membrane in molar ratios of approximately 1:3000 alpha-subunit:band 3. We explored the possibility that alpha-subunit and band 3 could be induced to form heterodimeric structures in the presence of cross-linking reagents. Using methods similar to those employed in the above-cited reference we demonstrated that cross-linked dimers containing phosphorylated alpha-subunits had proteolytic sensitivity that was inconsistent with the formation of alpha-subunit homodimers and fully consistent with heterodimer formation between alpha-subunit and band 3. The data also indicated that alpha-subunit-band 3 heterodimer formation is dependent on the conformational state of the (Na+,K+)-ATPase. Using the appropriate reagents we obtained cross-linked products which were consistent with heterodimer formation between alpha- and beta-subunits of the (Na+,K+)-ATPase. Our data argue against a close association between pairs of (Na+,K+)-ATPase alpha-subunits in the human red cell membrane.			MARTIN, DW (corresponding author), SUNY STONY BROOK, DEPT MED, STONY BROOK, NY 11794 USA.				NIDDK NIH HHS [DK-19185] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019185] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1980, BIOCHEM BIOPH RES CO, V93, P448, DOI 10.1016/0006-291X(80)91098-0; ASKARI A, 1980, BIOCHEMISTRY-US, V19, P1132, DOI 10.1021/bi00547a015; ASKARI A, 1988, NA PLUS K PLUS PUM A, P149; AVRUSH J, 1972, P NATL ACAD SCI USA, V69, P1216, DOI 10.1073/pnas.69.5.1216; BENDER WW, 1971, J MOL BIOL, V58, P783, DOI 10.1016/0022-2836(71)90040-4; BLOSTEIN R, 1968, J BIOL CHEM, V243, P1957; BUXBAUM E, 1990, EUR J BIOCHEM, V193, P355, DOI 10.1111/j.1432-1033.1990.tb19346.x; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; FOSSEL ET, 1981, BIOCHIM BIOPHYS ACTA, V649, P557, DOI 10.1016/0005-2736(81)90160-7; GAFFNEY BJ, 1985, BIOCHIM BIOPHYS ACTA, V822, P289, DOI 10.1016/0304-4157(85)90012-7; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1988, NA PLUS K PLUS PUM A, P435; HOFFMAN JF, 1969, J GEN PHYSIOL, V54, pS343; HUANG WH, 1981, BIOCHIM BIOPHYS ACTA, V645, P54, DOI 10.1016/0005-2736(81)90511-3; HUANG WH, 1979, FEBS LETT, V101, P67, DOI 10.1016/0014-5793(79)81297-1; HUANG WH, 1988, METHOD ENZYMOL, V156, P345; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JI TH, 1979, BIOCHIM BIOPHYS ACTA, V559, P39, DOI 10.1016/0304-4157(79)90007-8; JOINER CH, 1978, J PHYSIOL-LONDON, V283, P155, DOI 10.1113/jphysiol.1978.sp012494; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KAPLAN JH, 1985, J GEN PHYSIOL, V85, P123, DOI 10.1085/jgp.85.1.123; KNAUF PA, 1974, J GEN PHYSIOL, V63, P305, DOI 10.1085/jgp.63.3.305; KYTE J, 1975, J BIOL CHEM, V250, P7443; MARINETTI GV, 1974, BIOCHEM BIOPH RES CO, V61, P30, DOI 10.1016/0006-291X(74)90529-4; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; MIDDAUGH CR, 1983, MOL CELL BIOCHEM, V50, P115; NORBY JG, 1991, SOC GEN PHY, V46, P173; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROBINSON JD, 1979, BIOCHIM BIOPHYS ACTA, V549, P145, DOI 10.1016/0304-4173(79)90013-2; SACHS JR, 1980, J PHYSIOL-LONDON, V302, P219; SKOU JC, 1969, BIOCHIM BIOPHYS ACTA, V185, P198, DOI 10.1016/0005-2744(69)90295-2; STECK TL, 1978, BIOCHEMISTRY-US, V17, P1216, DOI 10.1021/bi00600a013; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; STECK TL, 1972, MEMBRANE RESEARCH, P71; WANG K, 1974, J BIOL CHEM, V249, P8005	40	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23922	23929						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331105				2022-12-25	WOS:A1992JZ23900074
J	KIMURA, S; KANAYA, S; NAKAMURA, H				KIMURA, S; KANAYA, S; NAKAMURA, H			THERMOSTABILIZATION OF ESCHERICHIA-COLI RIBONUCLEASE HI BY REPLACING LEFT-HANDED HELICAL LYS(95) WITH GLY OR ASN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MALATE-DEHYDROGENASE; CRYSTAL-STRUCTURE; SEQUENCE-ANALYSIS; STABILITY; RESIDUES; PROTEINS; MUTAGENESIS; RESOLUTION; CLONING	From the systematic replacements of amino acid residues of Escherichia coli ribonuclease HI with those of its thermophilic counterpart, the basic protrusion domain including region 6 (R6) from residues 91 to 95 was found to increase the structural stability of the mutant protein (Kimura, S., Nakamura, H., Hashimoto, T., Oobatake, M., and Kanaya, S. (1992) J. Biol. Chem. 267, 21535-21542). Further mutagenesis concentrating in the R6 region has revealed that replacements of Lys95 at the left-handed structure with Gly or Asn essentially enhances the protein stability. Gly and Asn substitutions stabilize the protein up to 1.9 kcal/mol and 0.9 kcal/mol in the free energy changes of unfolding, respectively. We propose that the amino acid substitution of left-handed non-Gly residue with Gly or Asn residue can be used as one of the general strategies to enhance protein stability, when such a non-Gly residue itself does not seriously contribute to protein stability.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN				Nakamura, Haruki/O-4028-2014					[Anonymous], INTRO PROTEIN STRUCT; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BETZEL C, 1988, ACTA CRYSTALLOGR B, V44, P163, DOI 10.1107/S010876818700939X; BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; Crouch R. J., 1982, NUCLEASES, P211; HEADGORDON T, 1991, J AM CHEM SOC, V113, P5989, DOI 10.1021/ja00016a010; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; JOH T, 1987, J BIOL CHEM, V262, P15127; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIMURA S, 1992, J BIOL CHEM, V267, P21535; KIMURA S, 1992, EUR J BIOCHEM, V206, P337, DOI 10.1111/j.1432-1033.1992.tb16932.x; KOYAMA Y, 1990, J BACTERIOL, V172, P3490, DOI 10.1128/jb.172.6.3490-3495.1990; KWON ST, 1988, EUR J BIOCHEM, V173, P491, DOI 10.1111/j.1432-1033.1988.tb14025.x; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MENENDEZARIAS L, 1989, J MOL BIOL, V206, P397, DOI 10.1016/0022-2836(89)90488-9; NICHOLSON H, 1989, J MOL BIOL, V210, P181, DOI 10.1016/0022-2836(89)90299-4; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; THORNTON JM, 1988, BIOESSAYS, V8, P63, DOI 10.1002/bies.950080205; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZIMMERMAN SS, 1977, MACROMOLECULES, V10, P1, DOI 10.1021/ma60055a001	28	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22014	22017						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331044				2022-12-25	WOS:A1992JW71900008
J	PARDY, K; ADAN, RAH; CARTER, DA; SEAH, V; BURBACH, JPH; MURPHY, D				PARDY, K; ADAN, RAH; CARTER, DA; SEAH, V; BURBACH, JPH; MURPHY, D			THE IDENTIFICATION OF A CIS-ACTING ELEMENT INVOLVED IN CYCLIC 3',5'-ADENOSINE-MONOPHOSPHATE REGULATION OF BOVINE VASOPRESSIN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION ANALYSIS; MESSENGER-RNA REGULATION; HYPOTHALAMIC NUCLEI; OSMOTIC STIMULATION; C-FOS; TRANSCRIPTION FACTORS; SOMATOSTATIN GENE; RAT HYPOTHALAMUS; BRATTLEBORO RAT; AMP	Cyclic adenosine 3',5'-monophosphate (cAMP) has been implicated as an intracellular messenger mediating osmotic regulation of expression of the gene encoding the neuropeptide vasopressin (VP) in the hypothalamus. We have used a heterologous transient transfection system to demonstrate that cAMP regulates the bovine VP gene promoter following transfection into CV1 cells. Mutational analysis identified a bovine VP cAMP-responsive element (BVP-CRE) 120-112 base-pairs upstream of the start of transcription. DNase I footprint analysis using nuclear protein extract from CV1 cells showed protection at the site of the BVP-CRE. Protection of the BVP-CRE was also observed using purified AP1 protein, while there was a weak interaction with the BVP-CRE using purified rat CREB protein. Nuclear proteins purified from the rat supraoptic nucleus bind to the BVP-CRE. As transgenic mouse studies have shown that the bovine VP gene is subject to appropriate physiological regulation in the mouse hypothalamus (Ang, H. L., Funkhouser, J., Carter, D. A., Ho, M. Y., and Murphy, D. (1991) Soc. Neurosci. Abstr. 513, 12), these data indicate a role for the BVP-CRE element in mediating VP gene expression in vivo. These data demonstrate that cAMP regulates bovine VP gene expression in vitro via a cis-acting element within the VP promoter, and this activation may be mediated by members of the AP1/ATF/CREB family of transcription factors.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,NEUROPEPTIDE LAB,SINGAPORE 0511,SINGAPORE; UNIV UTRECHT,RUDOLF MAGNUS INST,3521 GD UTRECHT,NETHERLANDS	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Utrecht University			Carter, David/A-4479-2010; Murphy, David/C-3967-2012	Carter, David/0000-0002-8419-3975; Murphy, David/0000-0003-2946-0353				ANG HL, 1991, SOC NEUR ABSTR; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBACH JPH, 1986, J NEUROCHEM, V47, P1814, DOI 10.1111/j.1471-4159.1986.tb13093.x; BURBACH JPH, 1984, NEUROENDOCRINOLOGY, V39, P582; CARTER DA, 1990, CELL MOL NEUROBIOL, V10, P435, DOI 10.1007/BF00711185; CARTER DA, 1989, BRAIN RES, V487, P350, DOI 10.1016/0006-8993(89)90839-1; CECCATELLI S, 1989, P NATL ACAD SCI USA, V86, P9569, DOI 10.1073/pnas.86.23.9569; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINK JS, 1991, J BIOL CHEM, V266, P3882; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERMAN JP, 1991, MOL ENDOCRINOL, V5, P1447, DOI 10.1210/mend-5-10-1447; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; LIGHTMAN SL, 1987, J PHYSIOL-LONDON, V394, P23, DOI 10.1113/jphysiol.1987.sp016858; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MAJZOUB JA, 1983, J BIOL CHEM, V258, P4061; Maxam A M, 1980, Methods Enzymol, V65, P499; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MOHR E, 1990, FEBS LETT, V260, P305, DOI 10.1016/0014-5793(90)80130-B; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MURPHY D, 1990, MOL ENDOCRINOL, V4, P1051, DOI 10.1210/mend-4-7-1051; MURPHY D, 1987, AM J PATHOL, V129, P552; OEDING P, 1990, J NEUROENDOCRINOL, V2, P859, DOI 10.1111/j.1365-2826.1990.tb00652.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SAMBROOK J, 1987, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN TG, 1986, NEUROENDOCRINOLOGY, V44, P222, DOI 10.1159/000124649; SHERMAN TG, 1988, J NEUROSCI, V8, P3785; SHERMAN TG, 1986, J NEUROSCI, V6, P1685; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; UHL GR, 1985, P NATL ACAD SCI USA, V82, P5555, DOI 10.1073/pnas.82.16.5555; VERBEECK MAE, 1990, FEBS LETT, V272, P89, DOI 10.1016/0014-5793(90)80455-R; YOUNG WS, 1987, MOL ENDOCRINOL, V1, P884, DOI 10.1210/mend-1-12-884; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZINGG HH, 1986, J BIOL CHEM, V261, P2956	43	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21746	21752						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1339438				2022-12-25	WOS:A1992JV01100076
J	SHATTIL, SJ; CUNNINGHAM, M; WIEDMER, T; ZHAO, J; SIMS, PJ; BRASS, LF				SHATTIL, SJ; CUNNINGHAM, M; WIEDMER, T; ZHAO, J; SIMS, PJ; BRASS, LF			REGULATION OF GLYCOPROTEIN-IIB-IIIA RECEPTOR FUNCTION STUDIED WITH PLATELETS PERMEABILIZED BY THE PORE-FORMING COMPLEMENT PROTEINS C5B-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPIIB-IIIA; FIBRINOGEN RECEPTOR; MONOCLONAL-ANTIBODY; ACTIVATED PLATELETS; KINASE INHIBITORS; IIB/IIIA COMPLEX; PLASMA-MEMBRANE; BINDING DOMAIN; FACTOR-VA; EXPRESSION	Recent evidence suggests that the cytoplasmic domains of platelet glycoprotein (GP) IIb-IIIa are involved in the agonist-initiated transformation of this integrin into a receptor for fibrinogen. To identify intracellular reactions that regulate the receptor function of GP IIb-IIIa, membrane-impermeable agonists and antagonists were introduced into the platelet by permeabilizing the plasma membrane with the pore-forming complement proteins C5b-9. Platelet responses were then analyzed by flow cytometry. Non-lytic concentrations of C5b-9 caused permeabilization of the platelet plasma membrane, as determined by uptake of a water-soluble fluorescent tracer dye. The complement pores were large enough to permit the entry of fluorescein isothiocyanate (FITC)-labeled oligopeptides in a size-dependent manner. Under conditions of low external Ca2+, C5b-9 treatment per se did not activate GP IIb-IIIa, as measured by binding of the activation-dependent antibody FITC-PAC1. However, FITC-PAC1 binding to C5b-9-permeabilized platelets was stimulated by a thrombin receptor agonist acting at the cell surface and by guanosine 5'-O-(thiotriphosphate), a membrane-impermeable activator of G proteins. Permeabilization also permitted the entry of cyclic AMP and the peptide, RFARKGALRQKNV, a pseudo-substrate inhibitor of protein kinase C. Each of these inhibited agonist-induced FITC-PAC1 binding to permeabilized platelets but not to intact platelets. Agonist-induced GP IIb-IIIa activation in permeabilized platelets was also inhibited by tyrphostin-23, a protein tyrosine kinase inhibitor. Thus, C5b-9 can be used to permeabilize the plasma membrane to permit the selective entry of small peptides and other bioactive compounds into permeabilized platelets. Results obtained with these platelets indicate that GP IIb-IIIa receptor function is regulated by a network of signaling reactions involving G proteins, serine/threonine kinases, and tyrosine kinases.	UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; OKLAHOMA MED RES FDN, OKLAHOMA CITY, OK 73104 USA	University of Pennsylvania; University of Pennsylvania; Oklahoma Medical Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL036061, R37HL036061, P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL40387, HL36946, HL36061] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; ABRAMS CS, 1990, BLOOD, V75, P128; ANDO B, 1989, BLOOD, V73, P462; ANDO B, 1988, J BIOL CHEM, V263, P11907; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAMSON HN, 1991, J BIOL CHEM, V266, P16219; Brass L F, 1991, Prog Hemost Thromb, V10, P127; BRASS LF, 1982, J BIOL CHEM, V257, P4000; BRASS LF, 1985, J BIOL CHEM, V260, P5172; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHEN Y, 1991, BLOOD, V78, P279; CHUNG DL, 1991, ANTICANCER RES, V11, P1373; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FISHER GJ, 1985, BIOCHEM BIOPH RES CO, V129, P958, DOI 10.1016/0006-291X(85)91984-9; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRABER SE, 1982, J BIOL CHEM, V257, P4606; HERSEY SJ, 1990, ANNU REV PHYSIOL, V52, P345; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; ISRAELS SJ, 1985, THROMB RES, V40, P499, DOI 10.1016/0049-3848(85)90287-7; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LEVITZKI A, 1991, TRENDS PHARMACOL SCI, V12, P171, DOI 10.1016/0165-6147(91)90538-4; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1987, ANN NY ACAD SCI, V509, P177, DOI 10.1111/j.1749-6632.1987.tb30994.x; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PONCZ M, 1987, J BIOL CHEM, V262, P8476; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHATTIL SJ, 1986, BLOOD, V68, P1224; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SIMS PJ, 1980, J IMMUNOL, V125, P2617; SIMS PJ, 1983, BIOCHIM BIOPHYS ACTA, V732, P541, DOI 10.1016/0005-2736(83)90230-4; SIMS PJ, 1989, J BIOL CHEM, V264, P19228; SIMS PJ, 1991, IMMUNOL TODAY, V12, P338, DOI 10.1016/0167-5699(91)90012-I; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SIMS PJ, 1981, P NATL ACAD SCI-BIOL, V78, P1838, DOI 10.1073/pnas.78.3.1838; SMYTH SS, 1991, BLOOD, V78, P278; TORTI M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P20, DOI 10.1016/0005-2736(91)90141-T; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1991, THROMB HAEMOSTASIS, V65, P202; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; WIEDMER T, 1987, J BIOL CHEM, V262, P13674; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	64	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18424	18431						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326524				2022-12-25	WOS:A1992JN50200032
J	FROLAND, WA; ANDERSSON, KK; LEE, SK; LIU, Y; LIPSCOMB, JD				FROLAND, WA; ANDERSSON, KK; LEE, SK; LIU, Y; LIPSCOMB, JD			METHANE MONOOXYGENASE COMPONENT-B AND REDUCTASE ALTER THE REGIOSELECTIVITY OF THE HYDROXYLASE COMPONENT-CATALYZED REACTIONS - A NOVEL ROLE FOR PROTEIN-PROTEIN INTERACTIONS IN AN OXYGENASE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS-BATH; METHYLOSINUS-TRICHOSPORIUM OB3B; ALKANE HYDROXYLATION; MONO-OXYGENASE; SATURATED-HYDROCARBONS; CYTOCHROME P-450CAM; UTILIZING BACTERIA; GENE-CLUSTER; IRON CENTER; PURIFICATION	The soluble methane monooxygenase (MMO) system, consisting of reductase, component B, and hydroxylase (MMOH), catalyzes NADH and O2-dependent monooxygenation of many hydrocarbons. MMOH contains 2-mu-(H or R)oxo-bridged dinuclear iron clusters thought to be the sites of catalysis. Although rapid NADH-coupled turnover requires all three protein components, three less complex systems are also functional: System I, NADH, O2, reductase, and MMOH; System II, H2O2 and oxidized MMOH; System III, MMOH reduced nonenzymatically by 2e- and then exposed to O2 (single turnover). All three systems give the same products, suggesting a common reactive oxygen species. However, the distribution of products observed for most substrates that are hydroxylated in more than one position is different for each system. For several of these substrates, addition of component B to Systems I, II, or III causes the product distributions to shift dramatically. These shifts result in identical product distributions for Systems I and III in which MMOH passes through the 2e- reduced state ([Fe(II)-Fe(II)]) during catalysis. In contrast, System II (in which MMOH probably does not become reduced) generally gives a unique product distribution. It is proposed that changes in MMOH structure occurring upon diiron cluster reduction and/or component complex formation cause substrates to be presented differently to the activated oxygen species. Kinetic studies show that component B strongly activates System I and, in most cases, strongly deactivates System II. The effect of component B on product distribution of System I (and III) occurs at <5% of the MMOH concentration, while nearly stoichiometric concentrations are required to maximize the rate of System I. This shows that component B has at least two roles in catalysis. EPR monitored titration of reduced MMOH ([Fe(II).Fe(II)]) with component B suggests that the effect of substoichiometric component B on product distribution is due to hysteresis in the MMOH conformational changes.	UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, 4-225 MILLARD HALL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities			Andersson, K Kristoffer/F-9624-2010	Lipscomb, John/0000-0002-8158-5594	NIGMS NIH HHS [GM40466, GM08277, R01 GM040466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040466, T32GM008277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KK, 1991, NEW J CHEM, V15, P411; ANDERSSON KK, 1981, BIOCHEM BIOPH RES CO, V98, P311, DOI 10.1016/0006-291X(81)91904-5; Anthony C., 1982, BIOCH METHYLOTROPHS; ATKINS WM, 1989, J AM CHEM SOC, V111, P2715, DOI 10.1021/ja00189a057; BARTON DHR, 1990, P NATL ACAD SCI USA, V87, P3401, DOI 10.1073/pnas.87.9.3401; BARTON DHR, 1986, NEW J CHEM, V10, P387; BARTON DHR, 1992, J AM CHEM SOC, V114, P2147, DOI 10.1021/ja00032a032; CARDY DLN, 1991, MOL MICROBIOL, V5, P335, DOI 10.1111/j.1365-2958.1991.tb02114.x; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COOK BR, 1986, J AM CHEM SOC, V108, P7281, DOI 10.1021/ja00283a024; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; ENHALT DH, 1978, PAGEOPH, V116, P452; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FROMMER U, 1970, H-S Z PHYSIOL CHEM, V351, P903, DOI 10.1515/bchm2.1970.351.2.903; GREEN J, 1989, J BIOL CHEM, V264, P17698; GROVES JT, 1983, J AM CHEM SOC, V105, P6243, DOI 10.1021/ja00358a009; GROVES JT, 1983, J AM CHEM SOC, V105, P5791, DOI 10.1021/ja00356a016; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; HENDRICH MP, 1992, J BIOL CHEM, V267, P261; HIGGINS IJ, 1980, NATURE, V286, P561, DOI 10.1038/286561a0; HOA GHB, 1990, BIOCHEMISTRY-US, V29, P6810, DOI 10.1021/bi00481a008; HRYCAY EG, 1976, EUR J BIOCHEM, V61, P43, DOI 10.1111/j.1432-1033.1976.tb09995.x; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KITAJIMA N, 1988, J CHEM SOC CHEM COMM, P485, DOI 10.1039/c39880000485; Leak D. J., 1987, BIOCATALYSIS, V1, P23; LEISING RA, 1990, INORG CHEM, V29, P2553, DOI 10.1021/ic00339a003; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; LIU KE, 1991, J BIOL CHEM, V266, P12836; MANSUY D, 1982, TETRAHEDRON LETT, V23, P2781, DOI 10.1016/S0040-4039(00)87457-2; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; MURCH BP, 1986, J AM CHEM SOC, V108, P5027, DOI 10.1021/ja00276a065; PATEL RN, 1987, J BACTERIOL, V169, P2313, DOI 10.1128/jb.169.5.2313-2317.1987; RATAJ MJ, 1991, J BIOL CHEM, V266, P18684; ROSENZWEIG AC, 1991, IND UNIV C, P69; SHEU C, 1990, J AM CHEM SOC, V112, P1936, DOI 10.1021/ja00161a045; SHEU CH, 1989, J AM CHEM SOC, V111, P8030, DOI 10.1021/ja00202a063; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STANLEY SH, 1983, BIOTECHNOL LETT, V5, P487, DOI 10.1007/BF00132233; Trotman-Dickenson A. F., 1965, ADVAN FREE RADICAL C, V1, P1; VINCENT JB, 1988, J AM CHEM SOC, V110, P6898, DOI 10.1021/ja00228a057; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WHITTENB.R, 1970, J GEN MICROBIOL, V61, P205, DOI 10.1099/00221287-61-2-205; WOODLAND MP, 1984, J BIOL CHEM, V259, P53	49	147	147	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17588	17597						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325441				2022-12-25	WOS:A1992JM22300020
J	VENTURA, F; ROSA, JL; AMBROSIO, S; PILKIS, SJ; BARTRONS, R				VENTURA, F; ROSA, JL; AMBROSIO, S; PILKIS, SJ; BARTRONS, R			BOVINE BRAIN 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE - EVIDENCE FOR A NEURAL-SPECIFIC ISOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER 6-PHOSPHOFRUCTO-2-KINASE; AMINO-ACID-SEQUENCE; FRUCTOSE 2,6-BISPHOSPHATE; HEPATIC GLUCONEOGENESIS; GENE-EXPRESSION; PROTEIN-KINASE; HEART; GLYCOLYSIS; PHOSPHORYLATION; ENZYMES	Bovine brain 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase was purified to homogeneity and characterized. This bifunctional enzyme is a homodimer with a subunit molecular weight of 120,000, which is twice that of all other known bifunctional enzyme isozymes. The kinase/bisphosphatase activity ratio was 3.0. The K(m) values for fructose 6-phosphate and ATP of the 6-phosphofructo-2-kinase were 27 and 55-mu-M, respectively. The K(m) for fructose 2,6-bisphosphate and the K(i) for fructose 6-phosphate for the bisphosphatase were 70 and 20-mu-M, respectively. Physiologic concentrations of citrate had reciprocal effects on the enzyme's activities, i.e. inhibiting the kinase (K(i) of 35-mu-M) and activating the bisphosphatase (K(a) of 16-mu-M). Phosphorylation of the brain enzyme was catalyzed by the cyclic AMP-dependent protein kinase with a stoichiometry of 0.9 mol of phosphate/mol of subunit and at a rate similar to that seen with the liver isozyme. In contrast to the liver isozyme, the kinetic properties of the brain enzyme were unaffected by cyclic AMP-dependent protein kinase phosphorylation, and also was not a substrate for protein kinase C. The brain isozyme formed a labeled phosphoenzyme intermediate and cross-reacted with antibodies raised against the liver isozyme. However, the NH2-terminal amino acid sequence of a peptide generated by cyanogen bromide cleavage of the enzyme had no identity with any known bifunctional enzyme sequences. These results indicate that a novel isozyme, which is related to other 6-phosphofructose-2,6-bisphosphatase isozymes, is expressed specifically in neural tissues.	UNIV BARCELONA,DEPT CIENCIES FISIOL HUMANES & NUTR,UNITAT BIOQUIM,CAMPUS BELLVITGE,E-08907 LHOSPITALET LLOBR,SPAIN; SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	University of Barcelona; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/K-9700-2014; Ambrosio, Santiago/ABC-8753-2021; Ventura, Francesc/ABG-2285-2020	Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Bartrons, Ramon/0000-0001-9349-5847	NIDDK NIH HHS [DK-38354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBROSIO S, 1991, J NEUROCHEM, V57, P200, DOI 10.1111/j.1471-4159.1991.tb02116.x; BARTRONS R, 1983, BIOCHEM J, V136, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; DARVILLE MI, 1991, FEBS LETT, V288, P91, DOI 10.1016/0014-5793(91)81009-W; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ELMAGHRABI MR, 1980, J BIOL CHEM, V255, P668; FOE LG, 1985, J BIOL CHEM, V260, P726; FRANCOIS J, 1988, EUR J BIOCHEM, V171, P599, DOI 10.1111/j.1432-1033.1988.tb13830.x; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; KITAMURA K, 1989, J BIOL CHEM, V264, P9799; KITAMURA K, 1988, J BIOL CHEM, V263, P9027; KRETSCHMER M, 1991, BIOCHEMISTRY-US, V30, P10663, DOI 10.1021/bi00108a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE AJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P258, DOI 10.1016/0003-9861(91)90617-R; LEMAIGRE FP, 1991, MOL CELL BIOL, V11, P1099, DOI 10.1128/MCB.11.2.1099; LIVELY MO, 1988, J BIOL CHEM, V263, P839; MARKER AJ, 1989, J BIOL CHEM, V264, P7000; NEWSHOLME EA, 1977, BIOCHEM J, V166, P123, DOI 10.1042/bj1660123; PAUWELS PJ, 1984, NEUROSCI LETT, V46, P173, DOI 10.1016/0304-3940(84)90437-3; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; RIDER MH, 1985, BIOCHEM J, V231, P193, DOI 10.1042/bj2310193; RIDER MH, 1986, BIOCHEM J, V240, P57, DOI 10.1042/bj2400057; RUDERMAN NB, 1974, BIOCHEM J, V138, P1; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1991, BIOCHEM BIOPH RES CO, V180, P470, DOI 10.1016/S0006-291X(05)81088-5; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VENTURA F, 1991, BIOCHEM J, V276, P455, DOI 10.1042/bj2760455; VORA S, 1985, BIOCHEM J, V229, P333, DOI 10.1042/bj2290333; WALL SR, 1989, FEBS LETT, V257, P211, DOI 10.1016/0014-5793(89)81536-4; YAMAMOTO M, 1990, J NEUROCHEM, V54, P592, DOI 10.1111/j.1471-4159.1990.tb01912.x	39	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17939	17943						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325453				2022-12-25	WOS:A1992JM22300070
J	CAMERON, KE; RESNIK, J; WEBSTER, NJG				CAMERON, KE; RESNIK, J; WEBSTER, NJG			TRANSCRIPTIONAL REGULATION OF THE HUMAN INSULIN-RECEPTOR PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE; BINDING-PROTEIN; MESSENGER-RNAS; CELLS; EXPRESSION; SEQUENCE; REGION; INITIATOR; ELEMENT; MOUSE	The ability of the human insulin receptor promoter to direct expression of a linked chloramphenicol acetyltransferase gene was assessed in transient transfections into HepG2 and Hela cells. A 5'-deletional analysis of the promoter showed that regions between -646 and -489 were important for the activity of the proximal promoter. In addition, a possible negative regulatory element was identified between -1311 and -877 and a positive element between -1823 and -1311. DNase I footprint and gel retardation analysis showed that multiple factors bind to the human insulin receptor promoter. In particular, DNase I protection patterns were observed over the Sp1 sites at -620 to -599 and -438 to -392, a TC box at -533, four homopyrimidine/homopurine sites clustered around -1150, and a site at -1420 that contains the motif TGGCCC which has been shown to bind the liver-specific transcription factor LF-A1.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; VET ADM MED CTR,DEPT VET AFFAIRS,MED RES SERV,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego			Webster, Nick/AAI-8410-2021					ARAKI E, 1991, J BIOL CHEM, V266, P3944; ARAKI E, 1987, J BIOL CHEM, V262, P16186; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; IWAMA N, 1989, DIABETOLOGIA, V32, P877, DOI 10.1007/BF00297453; KAHN CR, 1985, ANNU REV MED, V36, P429; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LEVY JR, 1991, DIABETES, V40, P58, DOI 10.2337/diabetes.40.1.58; MACE HAF, 1983, NATURE, V304, P555, DOI 10.1038/304555a0; MAMULA PW, 1990, DIABETES CARE, V13, P288, DOI 10.2337/diacare.13.3.288; MAMULA PW, 1988, DIABETES, V37, P1241, DOI 10.2337/diabetes.37.9.1241; MCKEON C, 1991, BIOCHEM BIOPH RES CO, V174, P721, DOI 10.1016/0006-291X(91)91477-T; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFFER JD, 1989, MOL CELL BIOL, V9, P355, DOI 10.1128/MCB.9.2.355; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SIBLEY E, 1989, P NATL ACAD SCI USA, V86, P9732, DOI 10.1073/pnas.86.24.9732; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TANG A, 1989, ONCOGENE, V4, P401; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TEWARI M, 1991, MOL ENDOCRINOL, V5, P653, DOI 10.1210/mend-5-5-653; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209	41	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17375	17383						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324934				2022-12-25	WOS:A1992JL05300096
J	LAMA, J; CARRASCO, L				LAMA, J; CARRASCO, L			EXPRESSION OF POLIOVIRUS NONSTRUCTURAL PROTEINS IN ESCHERICHIA-COLI-CELLS - MODIFICATION OF MEMBRANE-PERMEABILITY INDUCED BY 2B AND 3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; RNA-POLYMERASE; PURIFICATION; GENOME; REPLICATION; TRANSLATION; SEQUENCE; PEPTIDES; CDNA; GENE	The poliovirus nonstructural proteins 2B, 2C, 2C3A, 2C3AB, 3A, and 3AB have been cloned and efficiently expressed in Escherichia coli cells. Each individual protein, or combinations of some of them, were cloned using polymerase chain reaction techniques and correspond to the genuine poliovirus protein plus an additional methionine. The system used to express them uses pET vectors containing the promoter of gene 10 of phage T7. Expression of protein 2C in BL21(DE3) pLysS cells, which express the T7 lysozyme, is not toxic, and the bacteria synthesize this protein for several hours after induction. In contrast, the expression of proteins 2B, 3A, or 3AB is not tolerated by BL21(DE3) pLysS cells which could make them only for a limited period of time. Protein 3AB was particularly toxic and induced a rapid lysis of the recombinant clone after its induction with isopropyl-1-thio-beta-D-galactopyranoside alone or with both isopropyl-1-thio-beta-D-galactopyranoside and rifampicin. Further analyses showed that 3AB induced profound modifications in membrane permeability to o-nitrophenyl-beta-D-galactopyranoside, labeled uridine, and nonpermeant translation inhibitors. Cloning and expression of proteins 2B, 3A, and 3AB in BL21(DE3) cells that do not contain the T7 lysozyme lead to a more sustained expression of these proteins without detectable cell lysis. Changes in permeability to low molecular weight compounds such as radioactive uridine, o-nitrophenyl-beta-D-galactopyranoside, and hygromycin B readily appeared upon induction of 2B, 3A, and 3AB. Our results indicate that the poliovirus nonstructural polypeptides 2B and 3A (or 3AB) are lytic for the bacteria. In fact, both proteins 2B and 3A contain hydrophobic domains in a potential amphipathic helix; this is one characteristic shared with a number of membrane-active peptides.			LAMA, J (corresponding author), UNIV AUTONOMA MADRID, CTR BIOL MOLEC, CANTO BLANCO, E-28049 MADRID, SPAIN.		Carrasco, Luis/E-2435-2012; Carrasco, Luis/H-3001-2017	Carrasco, Luis/0000-0003-3833-8835				AGAWA Y, 1991, J BIOL CHEM, V266, P20218; BAUM EZ, 1991, VIROLOGY, V185, P140, DOI 10.1016/0042-6822(91)90762-Z; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1976, NATURE, V264, P807, DOI 10.1038/264807a0; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CARRASCO L, 1987, MECHANISM VIRAL TOXI, P1; CARRASCO L, 1983, ANTIBIOTICS, V6, P279; CASTRILLO JL, 1988, J GEN VIROL, V69, P583, DOI 10.1099/0022-1317-69-3-583; CONTRERAS A, 1979, J VIROL, V29, P114, DOI 10.1128/JVI.29.1.114-122.1979; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; GARRETT J, 1981, MOL GEN GENET, V182, P326, DOI 10.1007/BF00269678; GARRETT JM, 1982, J VIROL, V44, P886, DOI 10.1128/JVI.44.3.886-892.1982; GOESSENS WHF, 1988, EMBO J, V7, P867, DOI 10.1002/j.1460-2075.1988.tb02886.x; GUINEA R, 1989, J BIOL CHEM, V264, P21923; GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; INNIS AM, 1989, PCR PROTOCOLS GUIDE; Koch G., 1985, MOL BIOL POLIOVIRUS; LACAL JC, 1983, J GEN VIROL, V64, P787, DOI 10.1099/0022-1317-64-4-787; LI JP, 1988, J VIROL, V62, P4016, DOI 10.1128/JVI.62.11.4016-4021.1988; LOPEZRIVAS A, 1987, J GEN VIROL, V68, P335, DOI 10.1099/0022-1317-68-2-335; Maniatis T., 1982, MOL CLONING; MINOR PD, 1986, J GEN VIROL, V67, P1283, DOI 10.1099/0022-1317-67-7-1283; MUNOZ A, 1983, EUR J BIOCHEM, V137, P623, DOI 10.1111/j.1432-1033.1983.tb07871.x; MUNOZ A, 1985, VIROLOGY, V146, P203, DOI 10.1016/0042-6822(85)90004-2; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; PAGE GS, 1988, J VIROL, V62, P1781, DOI 10.1128/JVI.62.5.1781-1794.1988; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1989, J VIROL, V63, P441, DOI 10.1128/JVI.63.1.441-444.1989; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887; ROTHSTEIN MA, 1988, VIROLOGY, V164, P301, DOI 10.1016/0042-6822(88)90542-9; SEMLER BL, 1988, RNA GENETICS, P23; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAHARA Y, 1989, GENE, V79, P249; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TRONO D, 1988, SCIENCE, V241, P445, DOI 10.1126/science.2839901; URZAINQUI A, 1989, BIOCHEM BIOPH RES CO, V158, P263, DOI 10.1016/S0006-291X(89)80207-4; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WIMMER E, 1987, J CELL SCI, P251; YOUNG KD, 1982, J VIROL, V44, P993, DOI 10.1128/JVI.44.3.993-1002.1982; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	48	101	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15932	15937						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322409				2022-12-25	WOS:A1992JG11300100
J	CARTER, AN; DOWNES, CP				CARTER, AN; DOWNES, CP			PHOSPHATIDYLINOSITOL 3-KINASE IS ACTIVATED BY NERVE GROWTH-FACTOR AND EPIDERMAL GROWTH-FACTOR IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; TYROSINE PHOSPHORYLATION; INOSITOL 3-PHOSPHATE; RECEPTOR; PROTEIN; TRANSFORMATION; POLYPHOSPHOINOSITIDES; DIFFERENTIATION	The effects of nerve growth factor (NGF) and epidermal growth factor (EGF) on the regulation of phosphatidylinositol 3-kinase (PtdIns 3-kinase) activity were assessed in rat pheochromocytoma (PC12) cells. Both NGF and EGF induced a rapid activation of PtdIns 3-kinase as assessed by a dramatic rise in growth factor-induced PtdIns 3-kinase activity found in antiphosphotyrosine immunoprecipitates. The intracellular levels of two of the lipid products of PtdIns 3-kinase, phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) and phosphatidylinositol 3,4-bisphosphate PtdIns(3,4)P2), also rose dramatically, exhibiting time courses very similar to the appearance of PtdIns 3-kinase in immunoprecipitates. The activation of PtdIns 3-kinase is, therefore, a common event in the signal transduction processes elicited by growth factors stimulating distinct cellular end points in PC12 cells, namely the NGF-induced neuronal differentiation and EGF-stimulated mitogenesis. Thus the intracellular products of this enzyme may function in early biochemical events that are common components of the pathways controlling both differentiation and proliferation.			CARTER, AN (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.							ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COCHET C, 1991, J BIOL CHEM, V266, P637; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MILLER ES, 1990, BIOCHEM BIOPH RES CO, V173, P289, DOI 10.1016/S0006-291X(05)81055-1; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; QUI MS, 1991, J CELL BIOL, V115, P795; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VADNAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995, DOI 10.1016/0006-291X(89)92320-6; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	38	142	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14563	14567						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321809				2022-12-25	WOS:A1992JF08800013
J	YU, FX; SUN, HQ; JANMEY, PA; YIN, HL				YU, FX; SUN, HQ; JANMEY, PA; YIN, HL			IDENTIFICATION OF A POLYPHOSPHOINOSITIDE-BINDING SEQUENCE IN AN ACTIN MONOMER-BINDING DOMAIN OF GELSOLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DEOXYRIBONUCLEASE-I; CAPPING PROTEIN; PLASMA GELSOLIN; HUMAN-PLATELET; PROFILIN; INHIBITION; FILAMENTS; COFILIN	Gelsolin is an actin filament-severing and -capping protein that has profound effects on actin filament organization and assembly. It is activated by Ca2+ and inhibited by polyphosphoinositides (PPI). We have previously shown that PPI inhibit actin filament severing by the amino-terminal half of gelsolin and hypothesized that this is mediated through inhibition of actin filament side binding (by domains II-III of gelsolin), a requisite first step in severing. In this paper, we report that the subsequent step in severing, which is mediated by an actin monomer binding site located in domain I of gelsolin, is also regulated by PPI. We used deletional mutagenesis and a synthetic peptide to locate the sequence required for high affinity PPI binding in domain I. Our results show that the PPI-binding sequence has a basic charge distribution that is also present in the PPI-regulated actin filament side binding domain, and the two gelsolin PPI-binding sites have similar PPI-binding affinities. In addition, a similar motif is present in several other PPI-binding proteins, including a highly conserved region in the phospholipase C family. We propose that the sequences identified in gelsolin may represent a consensus for PPI binding in a variety of proteins.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV EXPTL MED,BOSTON,MA 02115	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29113] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMPE C, 1988, FEBS LETT, V228, P17, DOI 10.1016/0014-5793(88)80575-1; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; BUBB MR, 1991, J BIOL CHEM, V266, P3820; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; ISENBERG G, 1991, J MUSCLE RES CELL M, V142, P4319; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1992, IN PRESS J BIOL CHEM, V267; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WAY M, 1992, J CELL BIOL, V116, P1135, DOI 10.1083/jcb.116.5.1135; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; XIAN W, 1992, FASEB J, V6, pA87; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1990, FEBS LETT, V264, P78, DOI 10.1016/0014-5793(90)80769-F; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269	38	213	218	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14616	14621						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1321812				2022-12-25	WOS:A1992JF08800022
J	STEELE, MI; LORENZ, D; HATTER, K; PARK, A; SOKATCH, JR				STEELE, MI; LORENZ, D; HATTER, K; PARK, A; SOKATCH, JR			CHARACTERIZATION OF THE MMSAB OPERON OF PSEUDOMONAS-AERUGINOSA PAO ENCODING METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE AND 3-HYDROXYISOBUTYRATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE DEHYDROGENASE; SEQUENCE-ANALYSIS; CLONING; PUTIDA; GENE; DNA; PURIFICATION; CONSTRUCTION; EXPRESSION; VECTOR	A 5417-base pair (bp) region of Pseudomonas aeruginosa PAO chromosomal DNA containing the mmsAB operon and an upstream regulatory gene (mmsR) has been cloned and characterized: The operon contains two structural genes involved in valine metabolism: mmsA, which encodes methylmalonate-semialdehyde dehydrogenase; and mmsB, which encodes 3-hydroxy-isobutyrate dehydrogenase. mmsA and mmsB share the same orientation and are separated by a 16-bp noncoding region. The transcriptional start site for the operon has been pinpointed to a cytidine residue located 77 bp from the translational start site of the operon. mmsR is located on the opposite strand and begins 134 bp from the translational start site of mmsA. MmsR has been identified as a member of the XylS/AraC family of transcriptional regulators and appears to act as a positive regulator of the mmsAB operon. Sequence comparison of MmsA to other proteins in the data bases revealed that MmsA belongs to the aldehyde dehydrogenase (NAD+) superfamily. MmsB shares a 44% amino acid identity with 3-hydroxyisobutyrate dehydrogenase from rat liver. Mutants with insertionally inactivated mmsR, mmsA, and mmsB grow slowly on valine/isoleucine medium and exhibit reduced enzyme activity in cell-free extracts compared to P. aeruginosa PAO.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma - Norman	STEELE, MI (corresponding author), UNIV OKLAHOMA, HLTH SCI CTR, DEPT PEDIAT, POB 26901, OKLAHOMA CITY, OK 73190 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000873] Funding Source: NIH RePORTER; NIAID NIH HHS [AI00873] Funding Source: Medline; NIDDK NIH HHS [DK27137] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIBA H, 1981, J BIOL CHEM, V256, P1905; BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BANNERJEE D, 1970, J BIOL CHEM, V245, P1828; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOYD LA, 1991, GENE, V103, P45, DOI 10.1016/0378-1119(91)90389-S; BURTON RM, 1953, J BIOL CHEM, V202, P873; CLEWELL DB, 1970, BIOCHEMISTRY-US, V9, P4428; DEBARBOUILLE M, 1983, J BACTERIOL, V153, P1221; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; GOLDBERG JB, 1984, J BACTERIOL, V158, P1115, DOI 10.1128/JB.158.3.1115-1121.1984; GOODWIN GW, 1989, J BIOL CHEM, V264, P14965; HASEGAWA J, 1981, AGR BIOL CHEM TOKYO, V45, P2805, DOI 10.1080/00021369.1981.10864958; HATTER K, 1988, METHOD ENZYMOL, V166, P389; HEMPEL J, 1989, ENZYMOLOGY MOL BIOL, P3; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HSU LC, 1991, J BIOL CHEM, V266, P12257; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUPIECKI FP, 1960, BIOCH PREP, V7, P69; LEI SP, 1985, J BACTERIOL, V164, P717, DOI 10.1128/JB.164.2.717-722.1985; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LINDAHL R, 1990, ENZYMOLOGY MOL BIOL, P1; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARSHALL VD, 1972, J BACTERIOL, V110, P1073, DOI 10.1128/JB.110.3.1073-1081.1972; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; RAMOS JL, 1990, NUCLEIC ACIDS RES, V18, P2149, DOI 10.1093/nar/18.8.2149; ROBINSON WG, 1963, METHOD ENZYMOL, V6, P549, DOI 10.1016/0076-6879(63)06220-0; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROUGRAFF PM, 1989, J BIOL CHEM, V264, P5899; ROUGRAFF PM, 1988, J BIOL CHEM, V263, P327; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHELNESS GS, 1984, J BIOL CHEM, V259, P9929; SOKATCH JR, 1981, J BACTERIOL, V148, P639, DOI 10.1128/JB.148.2.639-646.1981; TU GC, 1988, J BIOL CHEM, V263, P1218; TU GC, 1988, J BIOL CHEM, V263, P1212; WEINER H, 1990, ENZYMOLOGY MOL BIOL, P13; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	42	65	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13585	13592						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1339433				2022-12-25	WOS:A1992JB74600077
J	MOEN, CJA; SNOEK, M; HART, AAM; DEMANT, P				MOEN, CJA; SNOEK, M; HART, AAM; DEMANT, P			SCC-1, A NOVEL COLON CANCER SUSCEPTIBILITY GENE IN THE MOUSE - LINKAGE TO CD44 (LY-24, PGP-1) ON CHROMOSOME-2	ONCOGENE			English	Article							COLORECTAL CARCINOMAS; MUTATIONS; MODEL; MAPS; ARM	Mutations of proto-oncogenes and tumor-suppressor genes lead to neoplastic development. Some germline mutations of these genes increase the tumor susceptibility of their carriers, but the relationship between genes controlling tumor susceptibility and the known oncogenes and tumor-suppressor genes remains unelucidated. Moreover, as tumor susceptibility in mouse is controlled by multiple genes, their identification has been virtually impossible. We therefore developed a new system, the recombinant congenic strains (RCS), which separates individual susceptibility genes into different RC strains, thus facilitating their analysis. To map genes controlling the development of colon cancer, we used the Balb/c-c-STS (CcS/Dem) RC strains. Owing to several unidentified genes, Balb/cHeA mice are relatively resistant and STS/A mice highly susceptible to 1,2-dimethylhydrazine-(DMH)-induced colon adenocarcinomas. Each CcS/Dem strain carries a different subset of about 12.5% of genes of the STS strain on the Balb/c background, and individual STS susceptibility genes became segregated into different RC strains. Using CcS-19, one of the highly susceptible RC strains, we mapped a novel colon tumor susceptibility gene, Scc-1, different from the oncogenes and tumor-suppressor genes known to be involved in colon tumorigenesis, in the vicinity of CD44 (Ly-24, Pgp-1) on chromosome 2. The mapping of the Scc-1 gene indicates that the RCS system can be used to map and study the presently unknown genes which control cancer development.	NETHERLANDS CANC INST, DIV MOLEC GENET, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV RADIOTHERAPY, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; Davisson MT, 1989, GENETIC VARIANTS STR, P432; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DEMANT P, 1989, ADV CANCER RES, V53, P117; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLEISZER D, 1988, CURR TOP MICROBIOL, V137, P243; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HESTON WE, 1963, METHODOLOGY MAMMALIA, P247; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; LANDER ES, 1989, GENETICS, V121, P185; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MOCK B, 1987, NUCLEIC ACIDS RES, V15, P4700, DOI 10.1093/nar/15.11.4700; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; MURPHY ED, 1966, BIOL LABORATORY MOUS; NADEAU J, 1990, MOUSE GENOME, V87, P55; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; WATKINS PC, 1987, DNA-J MOLEC CELL BIO, V6, P205, DOI 10.1089/dna.1987.6.205; WETSEL RA, 1987, BIOCHEMISTRY-US, V26, P737, DOI 10.1021/bi00377a013; [No title captured]	26	57	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					563	566						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347918				2022-12-25	WOS:A1992HK00500024
J	LADRAM, A; BULANT, M; NICOLAS, P				LADRAM, A; BULANT, M; NICOLAS, P			CHARACTERIZATION OF RECEPTORS FOR THYROTROPIN-RELEASING HORMONE-POTENTIATING PEPTIDE ON RAT ANTERIOR-PITUITARY MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE PRO-TRH; PANCREATIC-ISLETS; IMMUNOCYTOCHEMICAL DISTRIBUTION; CONNECTING PEPTIDES; PRECURSOR PEPTIDES; XENOPUS-LAEVIS; BRAIN; IDENTIFICATION; LOCALIZATION; PREPRO-TRH-(160-169)	Previous studies (Bulant, M., Delfour, A., Vaudry, H., and Nicolas, P. (1 988) J. Biol. Chem. 2 63, 17189-17196; Bulant, M., Roussel, J. P., Astier, H., Nicolas, P., and Vaudry, H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4439-4443) have shown that post-translational processing of rat thyrotropin-releasing hormone prohormone (pro-TRH) generates, besides thyrotropin-releasing hormone (TRH), a connecting decapeptide corresponding to prepro-TRH-(160-169), i.e. Ser-Phe-Pro-Trp-Met-Glu-Ser-Asp-Val-Thr. This peptide, which is named TRH-potentiating peptide (Ps4), is co-localized with TRH in the median eminence nerve endings and is involved in potentiation of the action of TRH on thyrotropin hormone release by pituitary in vitro and in vivo. To characterize the receptor(s) for TRH-potentiating peptide in the pituitary, a highly potent and metabolically stable derivative of Ps4, [I-Tyr0]Ps4, was radioiodinated. Binding of [I-125-Tyr-0]Ps4 to rat pituitary membrane homogenates was specific, saturable, reversible, and linear with membrane protein concentration. Equilibrium measurements performed over a large range of concentrations revealed a single homogeneous population of high affinity binding sites (K(d) = 0.22 nM; B(max) = 517 fmol/mg of membrane proteins). Several naturally occurring neuropeptides and hormones, including TRH, did not compete with [I-125-Tyr0]Ps4 in the binding, which suggests the binding sites are specific to Ps4. Using C-terminal deletion analogs of [Tyr0]Ps4, we further showed the critical role the C-terminal residues Thr10, Val9, and Asp8 play in conferring high binding affinity and selectivity. Binding site tissue distribution and cross-reactivity binding studies suggest that the action of TRH-potentiating peptide is mediated through interaction with a specific pituitary cell-surface receptor which differ from those for TRH. [I-Tyr0]Ps4 reported in this paper, through its high binding affinity and specificity, its very low nonspecific binding, its high resistance to enzymatic degradation, and its high potentiating action in vitro should allow further progress in understanding the in vivo physiological function of Ps4.	UNIV PARIS 07, INST JACQUES MONOD, BIOACTIVAT PEPTIDE LAB, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE	UDICE-French Research Universities; Universite Paris Cite	BULANT, M (corresponding author), UNIV PARIS 07, INST JACQUES MONOD, BIOACTIVAT PEPTIDE LAB, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE.		Nicolas, Pierre/C-7908-2009					ARATANSPIRE S, 1984, ENDOCRINOLOGY, V114, P2369, DOI 10.1210/endo-114-6-2369; BOLER J, 1969, BIOCHEM BIOPH RES CO, V37, P705, DOI 10.1016/0006-291X(69)90868-7; BULANT M, 1990, ENDOCRINOLOGY, V127, P1978, DOI 10.1210/endo-127-4-1978; BULANT M, 1988, J BIOL CHEM, V263, P17189; BULANT M, 1992, FEBS LETT, V296, P292, DOI 10.1016/0014-5793(92)80307-3; BULANT M, 1990, P NATL ACAD SCI USA, V87, P4439, DOI 10.1073/pnas.87.12.4439; BURGUS R, 1969, CR ACAD SCI D NAT, V269, P1870; CARR FE, 1990, 72ND ANN M END SOC, P807; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COCKLE SM, 1990, FEBS LETT, V264, P253, DOI 10.1016/0014-5793(90)80261-G; COCKLE SM, 1987, EUR J BIOCHEM, V165, P693, DOI 10.1111/j.1432-1033.1987.tb11496.x; DUTOUR A, 1989, PEPTIDES, V10, P523, DOI 10.1016/0196-9781(89)90136-8; GAY DD, 1981, INT J PEPT PROT RES, V18, P107; GKONOS PJ, 1989, MOL ENDOCRINOL, V3, P2101, DOI 10.1210/mend-3-12-2101; HOKFELT T, 1989, ANN NY ACAD SCI, V553, P76; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KUCHLER K, 1990, J BIOL CHEM, V265, P11731; LECHAN RM, 1986, SCIENCE, V231, P159, DOI 10.1126/science.3079917; LECHAN RM, 1987, ENDOCRINOLOGY, V121, P1879, DOI 10.1210/endo-121-5-1879; LEDUQUE P, 1989, ENDOCRINOLOGY, V125, P1492, DOI 10.1210/endo-125-3-1492; LEE SL, 1988, J BIOL CHEM, V263, P16604; LIAO N, 1988, NEUROPEPTIDES, V11, P107, DOI 10.1016/0143-4179(88)90078-9; LIAO N, 1988, NEUROSCI LETT, V85, P24, DOI 10.1016/0304-3940(88)90422-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINO E, 1978, P NATL ACAD SCI USA, V75, P4265, DOI 10.1073/pnas.75.9.4265; NICOLAS P, 1986, BIOCHEM BIOPH RES CO, V140, P565, DOI 10.1016/0006-291X(86)90769-2; RICHTER K, 1984, EMBO J, V3, P617, DOI 10.1002/j.1460-2075.1984.tb01857.x; ROUSSEL JP, 1991, NEUROENDOCRINOLOGY, V54, P559, DOI 10.1159/000125960; VALENTIJN K, 1991, NEUROSCIENCE, V44, P223, DOI 10.1016/0306-4522(91)90263-N; WICKLER C, 1991, 73RD ANN M END SOC, P417; WU P, 1988, REGUL PEPTIDES, V22, P347, DOI 10.1016/0167-0115(88)90111-5; WU P, 1988, BRAIN RES, V456, P22, DOI 10.1016/0006-8993(88)90342-3; WU P, 1987, ENDOCRINOLOGY, V121, P108, DOI 10.1210/endo-121-1-108; YAMADA M, 1990, MOL ENDOCRINOL, V4, P551, DOI 10.1210/mend-4-4-551	34	16	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25697	25702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334484				2022-12-25	WOS:A1992KD07300018
J	SUSA, M; KEELER, M; VARTICOVSKI, L				SUSA, M; KEELER, M; VARTICOVSKI, L			PLATELET-DERIVED GROWTH-FACTOR ACTIVATES MEMBRANE-ASSOCIATED PHOSPHATIDYLINOSITOL 3-KINASE AND MEDIATES ITS TRANSLOCATION FROM THE CYTOSOL - DETECTION OF ENZYME-ACTIVITY IN DETERGENT-SOLUBILIZED CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; SIGNAL TRANSDUCTION; BOVINE BRAIN; RAT-LIVER; PROTEIN; POLYPHOSPHOINOSITIDES; TRANSFORMATION; PURIFICATION; FIBROBLASTS; PI3-KINASE	Phosphatidylinositol 3-kinase (PI 3-kinase) activity has been detected in immune complexes with active protein tyrosine kinases, and its products have been measured in intact cells in response to growth stimuli. Both methods do not directly evaluate whole cell PI 3-kinase enzymatic activity. We have developed a sensitive method to measure PI 3-kinase activity in diluted, detergent-containing whole cell extracts and used this method to determine total, soluble, and membrane-associated PI 3-kinase activity in PDGF-stimulated NIH 3T3 fibroblasts. PDGF stimulation induced a 1.4-fold increase in total Nonidet P-40-extractable PI 3-kinase activity, which occurred within 1 min and was maintained above basal levels at 10 min. At the same time, PI 3-kinase activity in the soluble fraction decreased 30-50%. However, membrane-bound PI 3-kinase activity increased 2.4-fold at 1 min and 3.1-fold at 5 min. Translocation of the p85 PI 3-kinase subunit to the membrane was maximal at 10 min. These results suggest that PDGF-mediated activation of PI 3-kinase in membrane fraction results from initial intrinsic enzymatic activation followed by translocation from the cytosol.	TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT BIOMED RES,736 CAMBRIDGE ST,BOSTON,MA 02135					Varticovski, Lyuba/0000-0002-5105-9008	NCI NIH HHS [R29CA53094] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053094] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHANG J, 1992, J BIOL CHEM, V267, P4686	29	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22951	22956						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331070				2022-12-25	WOS:A1992JY16300039
J	YU, K; MORIOKA, H; FRITZE, LMS; BEELER, DL; JACKMAN, RW; ROSENBERG, RD				YU, K; MORIOKA, H; FRITZE, LMS; BEELER, DL; JACKMAN, RW; ROSENBERG, RD			TRANSCRIPTIONAL REGULATION OF THE THROMBOMODULIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING PROTEINS; AMP-INCREASING AGENTS; LEUKEMIA-CELL LINES; ENDOTHELIAL-CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; VASCULAR ENDOTHELIUM; ENHANCED EXPRESSION; RNA-POLYMERASE; PROMOTER	The transcriptional start sites of the endogenous human thrombomodulin (TM) gene and transiently expressed TM promoter/CAT gene constructs were defined by nuclease S1 mapping which showed two closely spaced sites at +1 and +6, respectively. Transient expression and in vitro transcription assays of 5' and internal deletion mutants of the TM promoter/CAT gene constructs reveal that the region from -72 to -29 exhibits a positive acting domain which is essential for transcriptional activity, whereas the region from -373 to -225 possesses two positive acting subdomains, -343 to -277 and -245 to -225, which together augment transcriptional activity by about 40%. Electrophoretic mobility shift assays with a duplex oligonucleotide corresponding to -72 to -29 and DNase I footprinting experiments show two specific interaction products which individually or cooperatively protect the DNA sequence from about -60 to -30. These components are essential for TM gene transcription since affinity fractionation of nuclear extracts with a duplex oligonucleotide corresponding to -72 to -29 depletes the above interaction products and specifically inhibits in vitro transcription activity of the promoter, whereas addition of the eluted components specifically restores in vitro transcription activity of the promoter. Electrophoretic mobility shift assays with duplex oligonucleotides corresponding to -294 to -215, as well as -373 to -295 and DNase I footprinting experiments show two specific interaction products which individually bind to the two subdomains but not -72 to -29 and protect the coding and noncoding strands from -245 to -225, and the noncoding strand from -337 to -314, respectively. Transient expression studies reveal that the TM promoter construct starting at -51 and including the TATA box is responsive to TNF only in cell lines exhibiting sensitivity of the endogenous receptor gene to cytokine, whereas other promoter constructs possessing a TATA box sequence are insensitive to TNF in all cell types. Based upon the above data, the regulatory events involved in TNF-dependent transcriptional regulation of the TM gene can be defined with the experimental tools and conceptual framework developed by the present investigation.	MIT,DEPT BIOL,E25-229,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NHLBI NIH HHS [HL 33014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battey, 1986, BASIC METHODS MOL BI; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOFFA MC, 1987, J HISTOCHEM CYTOCHEM, V35, P1267, DOI 10.1177/35.11.2821107; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; CONWAY EM, 1992, J CELL PHYSIOL, V151, P604, DOI 10.1002/jcp.1041510321; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDGAL CJS, 1983, P NATL ACAD SCI USA, V80, P3734; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIROKAWA K, 1990, J BIOCHEM-TOKYO, V108, P839, DOI 10.1093/oxfordjournals.jbchem.a123290; IMADA S, 1982, J BIOL CHEM, V257, P9108; IMADA S, 1990, DEV BIOL, V140, P113, DOI 10.1016/0012-1606(90)90058-Q; ITO T, 1990, THROMB RES, V58, P615, DOI 10.1016/0049-3848(90)90307-X; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LEE ME, 1990, J BIOL CHEM, V265, P10446; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MCCACHREN SS, 1991, BLOOD, V78, P3128; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RAJAGOPALAN V, 1992, BLOOD, V80, P153; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SOFF GA, 1991, BLOOD, V77, P515; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x	42	37	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23237	23247						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331078				2022-12-25	WOS:A1992JY16300082
J	LIUZZI, M; PATERSON, MC				LIUZZI, M; PATERSON, MC			ENZYMATIC ANALYSIS OF OLIGONUCLEOTIDES CONTAINING CYCLOBUTANE PYRIMIDINE PHOTODIMERS WITH A CLEAVED INTRADIMER PHOSPHODIESTER LINKAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; ISOMERIC TRITHYMIDYLATES; MICROCOCCUS-LUTEUS; DIMERS; REPAIR; INHIBITION; EXCISION	Our recent studies indicate that enzymatic hydrolysis of the intradimer phosphodiester linkage constitutes an early reaction in processing UV light-induced cis-syn-cyclobutane pyrimidine dimers in cultured human fibroblasts. Before characterizing the resultant modified dimer sites in cellular DNA, it is necessary to establish experimental conditions that can distinguish backbone-nicked from intact dimers. We thus constructed a model substrate, i.e. p(dT)10<>p(dT)10 containing a dimer with a ruptured sugar-phosphate bond, and determined the products of its reaction with snake venom phosphodiesterase and alkaline phosphatase, an enzymatic digestion mixture known to release dimers from UV-treated poly(dA) . poly(dT) within trinucleotides with the photoproduct intact at the 3'-end (d-TpT<p>T). The model substrate was prepared by (i) end labeling p(dT)9 using terminal deoxynucleotidyltransferase and [H-3]thymine-labeled TTP; and (ii) annealing the chromatographically purified p(dT)10 oligomers to poly(dA) followed by UV (290 nm)-induced ligation. Photoligated 20-mers with one radioactive and modified internal dimer were isolated and enzymatically digested. High performance liquid chromatographic analysis of the reaction products revealed a novel trithymidylate with its backbone severed at the 3'-terminus (d-TpT<>dT), demonstrating that this procedure could discriminate between intact and modified dimers. The procedure was then exploited to show that (i) Escherichia coli DNA photolyase can monomerize, albeit inefficiently, backbone-ruptured dimers; and (ii) phage T4 polynucleotide kinase can catalyze the phosphorylation of d-TpT<>dT, thus facilitating the development of a sensitive postlabeling assay suitable for modified dimer detection under biologically relevant conditions.	CROSS CANC INST, DEPT MED, MOLEC ONCOL PROGRAM, EDMONTON T6G 1Z2, ALBERTA, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2E1, ALBERTA, CANADA	University of Alberta; University of Alberta								[Anonymous], 1985, DNA REPAIR; CADET J, 1983, J CHROMATOGR, V280, P99, DOI 10.1016/S0021-9673(00)91543-7; CARRIER WL, 1981, DNA REPAIR A, V1, P1; DEERING RA, 1963, BIOCHIM BIOPHYS ACTA, V68, P526; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; LABELLE M, 1982, PHOTOCHEM PHOTOBIOL, V36, P319, DOI 10.1111/j.1751-1097.1982.tb04381.x; LEWIS RJ, 1982, NATURE, V298, P393, DOI 10.1038/298393a0; LIUZZI M, 1987, BIOCHEMISTRY-US, V26, P3315, DOI 10.1021/bi00386a011; LIUZZI M, 1989, J BIOL CHEM, V264, P6355; LIUZZI M, 1988, J CELL BIOCH A S, V12, P271; MOORE P, 1979, NATURE, V278, P664, DOI 10.1038/278664a0; PATERSON MC, 1987, J CELL SCI, P161; PATERSON MC, 1992, ADP RIBOSYLATION REA, P97; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR GB, 1987, TRENDS BIOCHEM SCI, V12, P259, DOI 10.1016/0968-0004(87)90130-7; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHOTT H, 1984, EUR J BIOCHEM, V143, P613, DOI 10.1111/j.1432-1033.1984.tb08414.x; SETLOW RB, 1964, BIOCHIM BIOPHYS ACTA, V91, P446, DOI 10.1016/0926-6550(64)90075-1; SMITH CA, 1990, ADV MUTAGENESIS RES, V1, P153; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WEINFELD M, 1989, J BIOL CHEM, V264, P6364; WEINFELD M, 1986, BIOCHEMISTRY-US, V25, P2656, DOI 10.1021/bi00357a055; WEINFELD M, 1988, NUCLEIC ACIDS RES, V16, P5693, DOI 10.1093/nar/16.12.5693	28	4	4	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22421	22427						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331055				2022-12-25	WOS:A1992JW71900068
J	HALABAN, R; RUBIN, JS; FUNASAKA, Y; COBB, M; BOULTON, T; FALETTO, D; ROSEN, E; CHAN, A; YOKO, K; WHITE, W; COOK, C; MOELLMANN, G				HALABAN, R; RUBIN, JS; FUNASAKA, Y; COBB, M; BOULTON, T; FALETTO, D; ROSEN, E; CHAN, A; YOKO, K; WHITE, W; COOK, C; MOELLMANN, G			MET AND HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR SIGNAL TRANSDUCTION IN NORMAL MELANOCYTES AND MELANOMA-CELLS	ONCOGENE			English	Article							AUTOCRINE MOTILITY FACTOR; TYROSINE KINASE RECEPTOR; HUMAN GASTRIC-CARCINOMA; C-MET; MOLECULAR-CLONING; MURINE MELANOCYTES; EPITHELIAL-CELLS; REGULATED KINASES; TRANSFORMING GENE; PROTEIN-KINASES	The proto-oncogene c-MET encodes a transmembrane tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF stimulates the proliferation and motility of various cell types. Because HGF/SF is also a melanocyte mitogen, we investigated the biological role of HGF/SF, including c-Met expression, activation and signal transduction, in normal and malignant human melanocytes. We show that HGF/SF is mitogenic in the presence of synergistic factors, such as basic fibroblast growth factor (bFGF) and mast cell growth factor (MGF) and that, by itself, it stimulates the motility of normal human melanocytes. The ligand also maintained high levels of tyrosinase activity and melanin content in theses cells. Signal transduction by HGF/SF included phosphorylation of tyrosyl residues on c-Met, a cascade of tyrosine phosphorylations on several other proteins and activation of microtubule-associated protein kinase/extracellular signal-regulated kinase. Met expression and activity are normal in human melanomas, and constitutive activity of HGF/SF in retrovirally infected autonomously proliferative mouse melanocytes is insufficient to confer the malignant phenotype. Our findings suggest that activation of Met in response to HGF/SF may contribute to malignant progression synergistically with the aberrant expression of bFGF in malignant melanocytes and that, in addition, the peptide may promote dispersion of factor-dependent melanocytes from early stages of primary melanomas to ectopic sites.	NCI,FREDERICK CANC RES & DEV,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PATHOL,WINSTON SALEM,NC 27103; YALE UNIV,SCH MED,DEPT RADIAT THERAPY,NEW HAVEN,CT 06510; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; YALE UNIV,SCH MED,DEPT PLAST SURG,NEW HAVEN,CT 06510; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University; Wake Forest Baptist Medical Center; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yale University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HALABAN, R (corresponding author), YALE UNIV,SCH MED,DEPT DERMATOL,333 CEDAR ST,POB 3333,NEW HAVEN,CT 06510, USA.		Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew Man-Lok/0000-0001-9923-5464; Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NCI NIH HHS [5-R29-CA44542] Funding Source: Medline; NIAMS NIH HHS [1RO1-AR39848] Funding Source: Medline; NIDDK NIH HHS [DK 34128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALBINO AP, 1991, CANCER RES, V51, P4815; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BEAN MA, 1975, CANCER RES, V35, P2902; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BHARGAVA J, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1043; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; FALETTO DL, 1992, ONCOGENE, V7, P1149; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREGORY J, 1989, J BIOL CHEM, V264, P18377; HALABAN R, 1992, J IMMUNOTHER, V12, P154, DOI 10.1097/00002371-199210000-00002; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1991, Critical Reviews in Oncogenesis, V2, P247; HALABAN R, 1988, ONCOGENE RES, V3, P177; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; HALABAN R, 1977, EXP CELL RES, V108, P119, DOI 10.1016/S0014-4827(77)80017-7; HALABAN R, 1991, CANCER METAST REV, V10, P129, DOI 10.1007/BF00049410; HERLYN M, 1985, CANCER RES, V45, P5670; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; JAMBROSIC J, 1989, INT J CANCER, V44, P1117, DOI 10.1002/ijc.2910440630; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEE RM, 1992, J BIOL CHEM, V267, P1088; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1988, P NATL ACAD SCI USA, V85, P2667, DOI 10.1073/pnas.85.8.2667; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SILLETTI S, 1991, CANCER RES, V51, P3507; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; WATANABE H, 1991, J BIOL CHEM, V266, P13442; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILSON RE, 1989, CANCER RES, V49, P711; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	73	179	183	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2195	2206						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331934				2022-12-25	WOS:A1992JW66500012
J	CREPIN, KM; DECLOEDT, M; VERTOMMEN, D; FORET, D; MICHEL, A; RIDER, MH; ROUSSEAU, GG; HUE, L				CREPIN, KM; DECLOEDT, M; VERTOMMEN, D; FORET, D; MICHEL, A; RIDER, MH; ROUSSEAU, GG; HUE, L			MOLECULAR-FORMS OF 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE EXPRESSED IN RAT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED BOVINE HEART; ESCHERICHIA-COLI; LIVER 6-PHOSPHOFRUCTO-2-KINASE; FRUCTOSE 2,6-BISPHOSPHATE; PLASMID VECTORS; MESSENGER-RNAS; CLONING; PROTEIN; DNA; SEQUENCE	The rat cDNA for the muscle-type (M) isozyme of 6-phosphofructo-2-kinase(PFK-2)/fructose-2,6-bisphosphatase (FBPase-2) contains two putative translation initiation sites. To determine whether the M isozyme expressed in rat skeletal muscle corresponds to the short (PFK2M-sf) or the long (PFK2M-lf) isoform, we have expressed them in Escherichia coli. A third construction was also expressed in which the second ATG codon was deleted (PFK2M-lfDELTAATG) to ensure that initiation started at the first ATG. The properties of these recombinant proteins were compared with those of the PFK-2/FBPase-2 present in rat skeletal muscle and liver. The recombinant proteins displayed PFK-2 and FBPase-2 activities and the M(r) values of the subunits measured by SDS-polyacrylamide gel electrophoresis were compatible with the calculated ones. The purified recombinant lf form contained not only the expected If band (54,500 M(r)) but also the sf band (52,000 M(r)), indicating that the expression system could synthesize the long and the short isoforms from the same mRNA. The kinetic properties of the recombinant sf form were not different from those of the rat muscle enzyme. By contrast, lfDELTAATG PFK-2 displayed a higher K(m) for its substrates and a lower V(max). Immunoblotting with an antibody directed against the long isoform revealed a 54,500 M(r) band both in the If and the lfDELTAATG recombinant, but no band in rat skeletal muscle extracts. In these extracts, one band of 52,000 and a minor one of 54,500 M(r) were detected by an anti PFK-2/FBPase-2 antibody. The 54,500 M(r) band was recognized by an antibody directed against the L isozyme, suggesting that a small amount of the latter is expressed in skeletal muscle. Thus, the M isozyme differs from the L isozyme by replacement of the first 32 amino acids of the L isozyme by an unrelated nonapeptide.	CATHOLIC UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM; UNIV MONS,FAC SCI,BIOL CHEM LAB,B-7000 MONS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; University of Mons				Vertommen, Didier/0000-0001-7648-8282				BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; BOLLAG DM, 1991, PROTEIN METHODS, P118; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; KITAMURA K, 1989, J BIOL CHEM, V264, P9799; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARCHAND MJ, 1992, BIOCHEM J, V285, P413, DOI 10.1042/bj2850413; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; REMAUT E, 1987, METHOD ENZYMOL, V153, P416; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RIDER MH, 1984, FEBS LETT, V176, P484, DOI 10.1016/0014-5793(84)81223-5; RIDER MH, 1985, BIOCHEM J, V231, P193, DOI 10.1042/bj2310193; RIDER MH, 1986, BIOCHEM J, V240, P57, DOI 10.1042/bj2400057; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; TANIYAMA M, 1988, BIOCHEM BIOPH RES CO, V157, P949, DOI 10.1016/S0006-291X(88)80966-5; van Schaftingen E., 1984, METHODS ENZYMATIC AN, P335; VANSCHAFTINGEN E, 1986, EUR J BIOCHEM, V159, P359; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21698	21704						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1328243				2022-12-25	WOS:A1992JV01100069
J	GAFVELS, ME; COUKOS, G; SAYEGH, R; COUTIFARIS, C; STRICKLAND, DK; STRAUSS, JF				GAFVELS, ME; COUKOS, G; SAYEGH, R; COUTIFARIS, C; STRICKLAND, DK; STRAUSS, JF			REGULATED EXPRESSION OF THE TROPHOBLAST ALPHA-2-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN - DIFFERENTIATION AND CAMP MODULATE PROTEIN AND MESSENGER-RNA LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANCY; BINDING; SYNCYTIOTROPHOBLAST; IDENTIFICATION; CLEARANCE; ANTIGEN; INVITRO	The alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2MR/LRP) has several ligands including activated alpha2-macroglobulin, pregnancy zone protein, and very low density lipoproteins enriched with apolipoprotein E. The diversity of ligands suggests a role for the alpha2MR/LRP in a variety of processes including tissue remodeling and lipoprotein metabolism. We examined alpha2MR/LRP in placental trophoblasts, invasive cells that also function in lipid transport and cholesterol metabolism. Alpha2MR/LRP protein was localized by immunohistochemistry in the syncytiotrophoblast of term placenta. Cytotrophoblasts did not stain prominently. Alpha2MR/LRP (protein and message) in primary cultures of human trophoblast cells increased as cytotrophoblasts differentiated into syncytiotrophoblast. 8-Bromo-cAMP prevented this increase and suppressed alpha2MR/LRP expression. The cyclic nucleotide had similar suppressive effects on alpha2MR/LRP in BeWo choriocarcinoma cells. In contrast, low density lipoprotein receptor gene expression was increased. We conclude that: 1) there is a differentiation-dependent pattern of alpha2MR/LRP expression in the human trophoblast; 2) cAMP negatively regulates alpha2MR/LRP; 3) there is an inverse relationship between alpha2MR/LRP and low density lipoprotein receptor gene expression in trophoblast cells.	AMER RED CROSS LABS, BIOCHEM LAB, ROCKVILLE, MD 20855 USA	American Red Cross	GAFVELS, ME (corresponding author), UNIV PENN, SCH MED, DEPT OBSTET & GYNECOL, 778 CLIN RES BLDG, 422 CURIE BLVD, PHILADELPHIA, PA 19104 USA.		Coukos, George/ABG-7389-2020	Coukos, George/0000-0001-8813-7367	NICHD NIH HHS [HD-06274, HD-29946] Funding Source: Medline; NIGMS NIH HHS [GM-42581] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029946, P01HD006274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUTIFARIS C, 1991, DEVELOPMENT, V113, P767; Daiter E, 1992, REPROD MED REV, V1, P83; FURUHASHI M, 1989, MOL ENDOCRINOL, V3, P1252, DOI 10.1210/mend-3-8-1252; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V883, P400, DOI 10.1016/0304-4165(86)90276-X; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAINI IM, 1990, J BIOL CHEM, V265, P19441; JENSEN PH, 1988, PLACENTA, V9, P463, DOI 10.1016/0143-4004(88)90019-7; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARRE J, 1991, LAB INVEST, V65, P3; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; POTTER JM, 1979, AM J OBSTET GYNECOL, V133, P165, DOI 10.1016/0002-9378(79)90469-1; RINDLER MJ, 1991, PLACENTA, V12, P615, DOI 10.1016/0143-4004(91)90496-3; Sambrook J, 1989, MOL CLONING LABORATO; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WICE B, 1990, EXP CELL RES, V186, P306, DOI 10.1016/0014-4827(90)90310-7	28	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21230	21234						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328226				2022-12-25	WOS:A1992JT97800111
J	HOLMES, SE; SINGER, MF; SWERGOLD, GD				HOLMES, SE; SINGER, MF; SWERGOLD, GD			STUDIES ON P40, THE LEUCINE ZIPPER MOTIF-CONTAINING PROTEIN ENCODED BY THE 1ST OPEN READING FRAME OF AN ACTIVE HUMAN LINE-1 TRANSPOSABLE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL; SEQUENCE; FAMILY; CELLS; END; DNA	Full-length human LINE-1 retrotransposons encode p40 proteins with varying electrophoretic mobilities under denaturing conditions. The p40 expressed from the first open reading frame in the LINE-1 copy designated L1.2A co-electrophoreses with the endogenous p40 in human teratocarcinoma cells. This finding is consistent with previous data indicating that L1.2A is an active element. The amino acid sequence in the central region of the L1.2A p40 accounts, at least in part, for its characteristic mobility. This region includes sequences which can, in principle, form a leucine zipper.	NCI,BIOCHEM LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT PEDIAT & MED,BALTIMORE,MD 21205; CARNEGIE INST WASHINGTON,WASHINGTON,DC 20005	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Carnegie Institution for Science								BRATTHAUER GL, 1992, ONCOGENE, V7, P507; DEMERS GW, 1989, J MOL EVOL, V29, P3, DOI 10.1007/BF02106177; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FURANO AV, 1988, NUCLEIC ACIDS RES, V16, P9215, DOI 10.1093/nar/16.19.9215; GRIMALDI G, 1984, EMBO J, V3, P1753, DOI 10.1002/j.1460-2075.1984.tb02042.x; HODGES R S, 1988, Peptide Research, V1, P19; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; LIEBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARINAS MG, 1977, J MOL BIOL, V85, P309; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MATHIAS SL, 1992, THESIS J HOPKINS U B; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SHEHEE WR, 1987, J MOL BIOL, V196, P757, DOI 10.1016/0022-2836(87)90402-5; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718	27	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19765	19768						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328181				2022-12-25	WOS:A1992JR85800004
J	RAISHER, BD; GULICK, T; ZHANG, ZF; STRAUSS, AW; MOORE, DD; KELLY, DP				RAISHER, BD; GULICK, T; ZHANG, ZF; STRAUSS, AW; MOORE, DD; KELLY, DP			IDENTIFICATION OF A NOVEL RETINOID-RESPONSIVE ELEMENT IN THE PROMOTER REGION OF THE MEDIUM CHAIN ACYL-COENZYME-A DEHYDROGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; ACID RECEPTOR; COA DEHYDROGENASE; THYROID-HORMONE; MOLECULAR CHARACTERIZATION; MITOCHONDRIAL PROTEINS; BINDING PROTEIN; I GENE; EXPRESSION; DEFICIENCY	To study the mechanisms involved in regulation of nuclear genes encoding mitochondrial enzymes in oxidative energy pathways, the promoter region of the medium-chain acyl-CoA dehydrogenase (MCAD) gene was analyzed. A series of hexamer sequences known to bind and confer responsiveness to a subset of members of the nuclear receptor superfamily of transcription factors was identified. Cotransfection of an MCAD promoter-chloramphenicol acetyltransferase (CAT) reporter plasmid with retinoic acid receptor (RAR)alpha, beta, or retinoid X receptor alpha (RXRalpha) resulted in 10-15-fold transcriptional activation in response to retinoic acid. The retinoic acid-induced activation was 3-4-fold higher with RXRalpha than with either RARalpha or RARbeta. Deletional analysis confirmed that a region between -341 and -308 base pairs upstream of the MCAD gene cap site conferred the RA-responsive transcriptional activation to homologous and heterologous promoters. Gel mobility shift assays demonstrated that the MCAD RARE interacted directly with overexpressed receptors. Mutational analysis of the RARE delineated three hexamer binding sequences with unique orientation and spacing compared to other reported retinoid responsive elements. These results indicate that the MCAD gene promoter region contains a novel regulatory element that interacts with members of the retinoid receptor family, with preferential activation by RXRalpha. This element likely plays a role in the transcriptional regulation of this gene and perhaps others involved in oxidative energy metabolism.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,660 S EUCLID AVE,BOX 8086,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Kelly, Daniel/ABG-2056-2021					ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUSIBEL FM, 1987, CURRENT PROTOCOLS MO, V2, P1612; Beinert H., 1963, ENZYMES, P447; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BONDMATTHEWS B, 1988, GENE, V62, P289, DOI 10.1016/0378-1119(88)90566-5; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; DORSMAN JC, 1988, NUCLEIC ACIDS RES, V16, P7287, DOI 10.1093/nar/16.15.7287; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREGERSEN N, 1991, HUM GENET, V86, P545; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATSUBARA Y, 1990, BIOCHEM BIOPH RES CO, V171, P498, DOI 10.1016/0006-291X(90)91421-N; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SAMBROOK J, 1989, MOL CLONING LABORATO, P114; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STANLEY CA, 1983, PEDIATR RES, V17, P872; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG ZF, 1992, BIOCHEMISTRY-US, V31, P81, DOI 10.1021/bi00116a013	45	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20264	20269						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1328196				2022-12-25	WOS:A1992JR85800081
J	MANGUES, R; SEIDMAN, I; GORDON, JW; PELLICER, A				MANGUES, R; SEIDMAN, I; GORDON, JW; PELLICER, A			OVEREXPRESSION OF THE N-RAS PROTOONCOGENE, NOT SOMATIC MUTATIONAL ACTIVATION, ASSOCIATED WITH MALIGNANT-TUMORS IN TRANSGENIC MICE	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; HA-RAS; EXPRESSION; GENE; TRANSFORMATION; DNA; TUMORIGENESIS; INVIVO; CELLS	We have produced transgenic mice that carry a foreign gene construct consisting of the N-ras proto-oncogene driven by the mouse mammary tumor virus (MMTV) long terminal repeat. Overexpression of the normal N-ras gene is associated with development of hyperplasias and tumors in a variety of tissues. The tumors are clearly malignant, as evidenced by the presence of metastatic lesions. Extensive analysis of the foreign ras gene in these tumors by use of polymerase chain reaction and sequencing demonstrates in all cases the absence of somatically acquired mutations at those codons normally associated with activation of the ras genes. Thus, these tumors develop from overexpression of the proto-oncogene rather than the presence of the mutated oncogene. These data demonstrate that overexpression of a proto-oncogene of the ras family can predispose cells in vivo to fully malignant behavior.	NYU MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; CUNY MT SINAI SCH MED, DEPT GERIATR & ADULT DEV, CTR MOLEC BIOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA	New York University; New York University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Pellicer, Angel/0000-0002-5062-0692; Mangues, Ramon/0000-0003-2661-9525	NCI NIH HHS [CA 50434, CA 42103, CA 36327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042103, R01CA036327, R01CA050434, R37CA036327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUERRERO I, 1984, SCIENCE, V225, P1041, DOI 10.1126/science.6089339; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HIGUCHI R, 1988, NATURE, V332, P543, DOI 10.1038/332543a0; HOFLER H, 1988, VIRCHOWS ARCH B, V55, P355; MANGUES R, 1990, ONCOGENE, V5, P1491; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH A, 1990, ONCOGENE, V5, P1195; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SOUYRI M, 1989, J VIROL, V63, P3944, DOI 10.1128/JVI.63.9.3944-3953.1989; SPANDIDOS DA, 1984, BRIT J CANCER, V49, P681, DOI 10.1038/bjc.1984.108; TANAKA T, 1986, CANCER RES, V46, P1465; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x	25	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					2073	2076						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328989				2022-12-25	WOS:A1992JP42400024
J	HAMA, H; WILSON, TH				HAMA, H; WILSON, TH			PRIMARY STRUCTURE AND CHARACTERISTICS OF THE MELIBIOSE CARRIER OF KLEBSIELLA-PNEUMONIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CATION SPECIFICITY; TRANSPORT-SYSTEM; NUCLEOTIDE-SEQUENCE; SUGAR; GENE; NA+; LI+; REPLACEMENT; COTRANSPORT	The melB gene coding for the melibiose carrier of Klebsiella pneumoniae was cloned and sequenced. There were two potential translation initiation sites. It was predicted that the melibiose carrier consists of 471 (or 467) amino acid residues. Seventy-eight percent of the 471 amino acids were identical to the Escherichia coli melibiose carrier. Sugar transport characteristics were studied using an E. coli mel- mutant expressing cloned K. pneumoniae melB gene. Accumulation of melibiose via the K. pneumoniae melibiose carrier was not stimulated by adding NaCl or LiCl which stimulates melibiose accumulation via the E. coli melibiose carrier. Lactose was accumulated only in the presence of LiCl. TMG (methyl-1-thio-beta-D-galactopyranoside) was accumulated in the absence of added NaCl or LiCl. The accumulation was stimulated by LiCl but not by NaCl. Rapid H+ uptake was observed when melibiose or TMG was added to cell suspensions. These results suggest that the preferred cation couplings via K. pneumoniae melibiose carrier are H+-melibiose, Li+-lactose, and H+/Li+-TMG. This coupling spectrum is quite different from that of the E. coli melibiose carrier. It is of special interest that the K. pneumoniae melibiose carrier seems to be lacking the ability to recognize Na+ which is a preferred coupling cation of the E. coli melibiose carrier for all known sugar substrates. Further investigation of these two carriers may give us insight into the Na+ recognition site.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIDDK NIH HHS [DK05736] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005736, R01DK005736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11649; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOTFIELD MC, 1988, J BIOL CHEM, V264, P11643; BOTFIELD MC, 1989, THESIS HARVARD U CAM; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HANATANI M, 1984, J BIOL CHEM, V259, P1807; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; LILJESTROM PL, 1987, NUCLEIC ACIDS RES, V15, P2213, DOI 10.1093/nar/15.5.2213; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MCMORROW I, 1988, BIOCHIM BIOPHYS ACTA, V945, P315, DOI 10.1016/0005-2736(88)90494-4; MIZUSHIMA K, 1992, IN PRESS MOL GEN GEN; NIIYA S, 1982, J BIOL CHEM, V257, P8902; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; REEVE ECR, 1973, GENET RES, V21, P273, DOI 10.1017/S001667230001346X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIOTA S, 1985, J BACTERIOL, V162, P106, DOI 10.1128/JB.162.1.106-109.1985; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; TSUCHIYA T, 1985, ANN NY ACAD SCI, V456, P342, DOI 10.1111/j.1749-6632.1985.tb14884.x; TSUCHIYA T, 1983, J BIOL CHEM, V258, P2765; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; TSUCHIYA T, 1977, BIOCHEM BIOPH RES CO, V76, P26, DOI 10.1016/0006-291X(77)91663-1; WEBSTER C, 1987, GENE, V59, P253, DOI 10.1016/0378-1119(87)90333-7; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WILSON TH, 1982, MEMBRANES TRANSPORT, V2, P33; YAZYU H, 1984, J BIOL CHEM, V259, P4320; YAZYU H, 1985, J BACTERIOL, V162, P933, DOI 10.1128/JB.162.3.933-937.1985	31	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18371	18376						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1339436				2022-12-25	WOS:A1992JN50200023
J	MIKI, T; YOSHIDA, LS; KAKINUMA, K				MIKI, T; YOSHIDA, LS; KAKINUMA, K			RECONSTITUTION OF SUPEROXIDE-FORMING NADPH OXIDASE ACTIVITY WITH CYTOCHROME-B558 PURIFIED FROM PORCINE NEUTROPHILS - REQUIREMENT OF A MEMBRANE-BOUND FLAVIN ENZYME FOR RECONSTITUTION OF ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; POLYACRYLAMIDE GELS; GENERATING OXIDASE; PHAGOCYTIC-CELLS; FATTY-ACIDS; C REDUCTASE; ACTIVATION; BINDING	Cytochrome b558 of pig blood neutrophils was purified from the membranes of resting cells to examine its ability to reconstitute superoxide (O2-)-forming NADPH oxidase activity in a cell-free assay system containing cytosol and fatty acid. The membrane-associated cytochrome b558 was solubilized with a detergent, n-heptyl beta-thioglucoside, and purified by DEAE-Sepharose, heparin-Sepharose, and Mono Q column chromatography. The final preparation of cytochrome containing 11.5 nmol of protoheme/mg of protein gave bands of the large and small subunits on immunoblotted gel. The cell-free system with the purified cytochrome alone as a membrane component showed little O2--generating activity in the absence of exogenous FAD. However, the system showed high O2--generating activity of 31.8 mol/s/mol of cytochrome b558 (52.5% of the original O2--generating activity of the solubilized membranes) in the presence of a nitro blue tetrazolium (NBT) reductase fraction that was separated from the cytochrome b fraction by heparin-Sepharose chromatography. Heat treatment of the NBT reductase fraction resulted in loss of the O2--generating activity in the reconstituted system. The O2--forming activity of the reconstituted system was markedly decreased by removal of FAD from the NBT reductase fraction and was restored by readdition of FAD to the FAD-depleted reductase. The reconstituted system containing purified cytochrome b558 plus the NBT reductase showed approximately 100 times higher O2--generating activity than a system containing rabbit liver NADPH-cytochrome P-450 reductase instead. These results suggest that both the FAD-dependent NBT reductase and cytochrome b558 are required as membrane redox components for O2--forming NADPH oxidase activity. The present data are discussed in comparison with previously reported results on reconstituted systems containing added free FAD.	TOKYO METROPOLITAN INST MED SCI,DEPT INFLAMMAT RES,HONKOMAGOME 3-18-22,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1990, SEMIN HEMATOL, V27, P247; BALLOU D, 1969, BIOCHEM BIOPH RES CO, V36, P898, DOI 10.1016/0006-291X(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CHIBA T, 1990, BIOCHEM BIOPH RES CO, V173, P376, DOI 10.1016/S0006-291X(05)81068-X; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; FUJII H, 1991, BIOCHIM BIOPHYS ACTA, V1095, P201, DOI 10.1016/0167-4889(91)90100-C; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GROVER TA, 1981, ARCH BIOCHEM BIOPHYS, V212, P105, DOI 10.1016/0003-9861(81)90348-9; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KAKINUMA K, 1978, BIOCHIM BIOPHYS ACTA, V538, P50, DOI 10.1016/0304-4165(78)90251-9; KAKINUMA K, 1986, J BIOL CHEM, V261, P9426; KAKINUMA K, 1987, J BIOL CHEM, V262, P12316; KISHORE GM, 1979, BIOCHEM BIOPH RES CO, V87, P518, DOI 10.1016/0006-291X(79)91826-6; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MICHELSON AM, 1977, SUPEROXIDE SUPEROXID, P87; MISRA HP, 1972, J BIOL CHEM, V247, P188; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARKINSON JF, 1988, J BIOENERG BIOMEMBR, V20, P653, DOI 10.1007/BF00762547; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TU SC, 1981, ARCH BIOCHEM BIOPHYS, V209, P423, DOI 10.1016/0003-9861(81)90299-X; UMEI T, 1991, J BIOL CHEM, V266, P6019; WAKEYAMA H, 1982, BIOCHEM J, V205, P593, DOI 10.1042/bj2050593; YOSHIDA LS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P245	39	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18695	18701						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1326533				2022-12-25	WOS:A1992JN50200069
J	BOISE, LH; GORSE, KM; WESTIN, EH				BOISE, LH; GORSE, KM; WESTIN, EH			MULTIPLE MECHANISMS OF REGULATION OF THE HUMAN C-MYB GENE DURING MYELOMONOCYTIC DIFFERENTIATION	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; MOUSE ERYTHROLEUKEMIA-CELLS; PROTO-ONCOGENE PRODUCT; MESSENGER-RNA; TRANS-ACTIVATION; V-MYB; EXPRESSION; PROLIFERATION; TRANSCRIPTION; SEQUENCE	Alterations in expression of c-myb can have profound effects on the growth and differentiation of hematopoietic cells. Thus, it is important to understand the mechanisms by which c-myb is regulated during hematopoietic cell differentiation. Previous studies pertaining to the regulation of c-myb have been carried out with the avian and murine forms of the gene; the current studies were designed to determine the mechanisms of regulation of the human form of c-myb. Transcriptional analysis by nuclear run-on assays revealed that an attenuation of transcription was the means of primary regulation during retinoic acid- and vitamin D3-induced differentiation of HL-60 cells, while other mechanisms in addition to attenuation were active during dimethyl sulfoxide (DMSO)- and phorbol ester-induced differentiation. Densitometric analysis of the changes in c.myb transcription caused by phorbol ester suggested that the c-myb promoter may be down-regulated during phorbol ester-induced differentiation of HL-60. Additional studies exhibited post-transcriptional regulation by phorbol ester. DMSO was also shown to regulate c-myb at the post-transcriptional level. Interestingly, the post-transcriptional regulation of c-myb by DMSO required continuous transcription. This requirement was shared for c-myc but not ornithine decarboxylase expression. The transcriptional dependency of c-myb post-transcriptional regulation did not equate to translational dependency, thus a novel post-transcriptional regulatory mechanism may control c-myb gene expression. The multiple levels of regulation of c-myb suggest the importance of proper control for hematopoietic cell differentiation.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University			Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007087] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 07087] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; Dalla-Favera R, 1983, Haematol Blood Transfus, V28, P247; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYWARD WS, 1989, MOL CELL BIOL, V9, P837; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	36	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1817	1825						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323820				2022-12-25	WOS:A1992JJ37600018
J	FIORE, S; RYEOM, SW; WELLER, PF; SERHAN, CN				FIORE, S; RYEOM, SW; WELLER, PF; SERHAN, CN			LIPOXIN RECOGNITION SITES - SPECIFIC BINDING OF LABELED LIPOXIN-A4 WITH HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTE RECEPTORS; ARACHIDONIC-ACID; LEUKOTRIENE-B4 RECEPTORS; STIMULATED NEUTROPHILS; LIGAND-BINDING; LUNG MEMBRANES; G-PROTEINS; METABOLISM; RESPONSES; RELEASE	Lipoxin A4 stimulates rapid lipid remodeling and a pertussis toxin-sensitive release of arachidonic acid in Polymorphonuclear leukocytes (PMN) (Nigam, S., Fiore, S., Luscinskas, F. W., and Serhan, C. N. (1990) J. Cell. Physiol. 143, 512-523) and has been shown to inhibit leukocyte responses in several systems. To examine the basis underlying these actions, we have prepared [11,12-H-3]lipoxin A4 (LXA4) and characterized its interactions with human PMN. Time course studies (0-90 min) with intact PMN demonstrated cell association of H-3 label which was specific and reversible. PMN bound [H-3]LXA4 with a K(d) of 0.5 +/- 0.3 nm, representing approximately 1,830 sites/PMN, and the Hill plot value of 1.9 suggests cooperative binding. [H-3]LXA4 binding was stereoselective since neither leukotriene B4 (LTB4), lipoxin B4 (LXB4), (6S)-LXA4, 11-trans-LXA4, nor SKF 104353 competed for [H-3]LXA4-specific binding while LTD4 and LTC4 partially competed. Subcellular fractionation revealed that specific binding with [H-3]LXA4 was associated with membrane (42.1%)-, granule (34.5%)-, and nuclear (23.3%)-enriched fractions, a distribution distinct from that of [14,15-H-3] LTB4 binding. [11,12-H-3]LXA4-specific binding was modulated by guanosine analogs, suggesting the involvement of G proteins. A fluorescent LXA4 derivative (methyl-7-methoxycoumarin-LXA4) competed with [H-3]LXA4 binding to intact PMN and showed specific and reversible binding as monitored by flow cytometric analysis. These results indicate that PMN possess specific recognition sites for LXA4 which may mediate its actions.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV HEMATOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV INFECT DIS, BOSTON, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NIAID NIH HHS [AI22571, AI20241] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020241, R01AI022571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R29GM038765, R01GM038765] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; BAUD L, 1987, IMMUNOLOGY, V62, P53; BERGMEYER HU, 1963, METHOD ENZYMAT AN, P737; BOEYNAEMS JM, 1975, J CYCLIC NUCL PROT, V1, P123; BOYUN A, 1986, SCAND J CLIN LAB S97, V21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASSEUR R, 1988, BIOCHIM BIOPHYS ACTA, V960, P245, DOI 10.1016/0005-2760(88)90070-7; BREZINSKI DA, 1991, BIOL MASS SPECTROM, V20, P45, DOI 10.1002/bms.1200200202; CANNISTRA SA, 1990, J BIOL CHEM, V265, P12656; CANONICO PG, 1978, J RETICULOENDOTH SOC, V24, P115; Dahlen S E, 1988, Adv Exp Med Biol, V229, P107; DAHLEN SE, 1991, LIPOXYGENASES THEIR, P235; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DUNGES W, 1977, ANAL CHEM, V49, P442; FALCONE RC, 1990, J PHARMACOL EXP THER, V255, P565; GOLDMAN DW, 1987, FASEB J, V46, P200; GRANDORDY BM, 1990, BIOCHEM BIOPH RES CO, V167, P1022, DOI 10.1016/0006-291X(90)90625-W; HAVUNJIAN RH, 1990, J BIOL CHEM, V265, P22181; HEDQVIST P, 1989, ACTA PHYSIOL SCAND, V137, P571, DOI 10.1111/j.1748-1716.1989.tb08805.x; HERRMANN T, 1988, J CHROMATOGR-BIOMED, V428, P237, DOI 10.1016/S0378-4347(00)83914-6; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; IYENGAR R, 1980, J BIOL CHEM, V255, P312; LEE TH, 1989, CLIN SCI, V77, P195, DOI 10.1042/cs0770195; LINDHART K, 1974, METHOD ENZYMAT AN, P856; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MIGLER R, 1978, BIOCHEM MED METAB B, V19, P16, DOI 10.1016/0006-2944(78)90003-0; MONG S, 1990, METHOD ENZYMOL, V187, P421; MONG S, 1987, MOL PHARMACOL, V32, P223; MONG S, 1991, LIPOXYGENASES THEIR, P185; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NICOLAOU KC, 1985, J AM CHEM SOC, V107, P7515, DOI 10.1021/ja00311a048; NIGAM S, 1990, J CELL PHYSIOL, V143, P512, DOI 10.1002/jcp.1041430316; OFLAHERTY JT, 1990, J CELL PHYSIOL, V142, P299, DOI 10.1002/jcp.1041420212; Palmblad J, 1988, Adv Exp Med Biol, V229, P137; PARIS S, 1990, J BIOL CHEM, V265, P11567; RODBELL M, 1974, J BIOL CHEM, V249, P59; ROSSI AG, 1989, PROSTAGLANDINS, V37, P641, DOI 10.1016/0090-6980(89)90102-0; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAAF TK, 1983, ADV PROSTAG THROMB L, V11, P313; SERHAN CN, 1990, METHOD ENZYMOL, V187, P167; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P951, DOI 10.1016/0006-291X(82)90615-5; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; STENKE L, 1991, BIOCHEM BIOPH RES CO, V180, P255, DOI 10.1016/S0006-291X(05)81285-9; TODA M, 1985, ADV PROSTAG THROMB L, V14, P427; UESAKA H, 1987, BIOCHEM BIOPH RES CO, V143, P552, DOI 10.1016/0006-291X(87)91389-1; VOTTA B, 1990, BIOCHEM J, V265, P841, DOI 10.1042/bj2650841; WALKER BAM, 1991, LAB INVEST, V64, P105; WALSH CE, 1981, J BIOL CHEM, V256, P7228; Wasserman MA, 1991, LIPOXYGENASES THEIR, P1; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; WRIGHT DG, 1977, AM J PATHOL, V87, P273; YAMAZAKI M, 1989, P NATL ACAD SCI USA, V86, P5791, DOI 10.1073/pnas.86.15.5791	56	122	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16168	16176						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322894				2022-12-25	WOS:A1992JJ45800031
J	JONES, KS; COLEMAN, J; MERKEL, GW; LAUE, TM; SKALKA, AM				JONES, KS; COLEMAN, J; MERKEL, GW; LAUE, TM; SKALKA, AM			RETROVIRAL INTEGRASE FUNCTIONS AS A MULTIMER AND CAN TURN OVER CATALYTICALLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-DELTA RESOLVASE; HIV-1 PROTEASE; DNA; RECOMBINATION; ENZYME; VIRUS	A number of studies have demonstrated that the retroviral protein integrase (IN) alone is sufficient to carry out two discrete steps required for retroviral integration: the endonucleolytic processing of viral DNA ends and the cleavage and joining of host DNA to the processed viral DNA termini. Little is known about the biochemical and biophysical mechanisms involved in these reactions. Here, we employ in vitro assays of Rous sarcoma virus IN to demonstrate for the first time that IN is capable of multiple turnover in both the processing and joining reactions. The turnover number calculated for the processing reaction is 0.26 cleavages/min/mol of IN. Our steady state kinetic studies indicate that both the processing and joining activities require a multimeric form of IN. Ultracentrifugation analyses reveal a substrate-independent reversible equilibrium among the monomeric, dimeric, and tetrameric forms of this protein. From these results we conclude that the minimal functional unit for both the processing and joining of each viral DNA end is an IN dimer.	UNIV NEW HAMPSHIRE, DEPT BIOCHEM, DURHAM, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	JONES, KS (corresponding author), FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA.		Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NCI NIH HHS [CA-47486, CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R35CA047486] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CHRISTOPHERSON RI, 1979, ANAL BIOCHEM, V100, P184, DOI 10.1016/0003-2697(79)90130-1; ENGLEMAN A, 1991, CELL, V67, P1211; Friedberg E C, 1980, Methods Enzymol, V65, P191; GATES CA, 1988, P NATL ACAD SCI USA, V85, P4628, DOI 10.1073/pnas.85.13.4628; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KATZ RA, 1992, IN PRESS P NATL ACAD; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KOTLER M, 1989, P NATL ACAD SCI USA, V85, P4185; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P839; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; Laue T. M, 1981, THESIS U CONNECTICUT; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LAUE TM, 1992, IN PRESS ANAL ULTRAC; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; MCMEEKIN TL, 1952, SCIENCE, V116, P142, DOI 10.1126/science.116.3006.142; PERLMANN GE, 1948, J AM CHEM SOC, V70, P2719, DOI 10.1021/ja01188a027; ROARK DE, 1969, ANN NY ACAD SCI, V164, P245, DOI 10.1111/j.1749-6632.1969.tb14043.x; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SCHRAMM HJ, 1991, BIOCHEM BIOPH RES CO, V179, P847, DOI 10.1016/0006-291X(91)91895-J; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; SKALKA AM, 1988, GENETIC RECOMBINATIO, P701; TERRY R, 1988, J VIROL, V62, P2358, DOI 10.1128/JVI.62.7.2358-2365.1988; VARMUS HE, 1985, RNA TUMOR VIRUSES, V2, P75; WEAST RC, 1986, HDB CHEM PHYSICS, V67; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x; YPHANTIS DA, 1987, BIOCHEMISTRY-US, V26, P5422, DOI 10.1021/bi00391a031; YPHANTIS DA, 1956, J PHYS CHEM-US, V60, P623; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	36	134	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16037	16040						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322888				2022-12-25	WOS:A1992JJ45800009
J	SAKAKI, T; AKIYOSHISHIBATA, M; YABUSAKI, Y; OHKAWA, H				SAKAKI, T; AKIYOSHISHIBATA, M; YABUSAKI, Y; OHKAWA, H			ORGANELLA-TARGETED EXPRESSION OF RAT-LIVER CYTOCHROME-P450C27 IN YEAST - GENETICALLY ENGINEERED ALTERATION OF MITOCHONDRIAL-P450 INTO A MICROSOMAL FORM CREATES A NOVEL FUNCTIONAL ELECTRON-TRANSPORT CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NADPH-CYTOCHROME-P450 REDUCTASE; VITAMIN-D3 25-HYDROXYLASE; ENDOPLASMIC-RETICULUM; GENE; CDNA; DEHYDROGENASE; PURIFICATION; ORIENTATION; PROTEINS	A modified rat cytochrome P450c27, whose mitochondrial targeting signal had been replaced by a possible microsomal targeting signal of bovine cytochrome P450c17, was expressed in yeast. The modified P450c27 hemoprotein was correctly localized on yeast microsomes and exhibited the P450c27-dependent monooxygenase activity by addition of bovine adrenodoxin (ADX) and NADPH-adrenodoxin reductase (ADR). Considering the previous observation that P450c27 with its own mitochondrial targeting signal was imported into yeast mitochondria (Akiyoshi-Shibata, M., Usui, E., Sakaki, T., Yabusaki, Y., Noshiro, M., Okuda, K., and Ohkawa, H. (1991) FEBS Lett. 280, 367-370), it is now suggested that the destination of P450c27 to either mitochondria or microsomes in yeast depends solely on the amino-terminal targeting signal. In addition, the modified P450c27 was simultaneously expressed in yeast with mature forms of bovine ADX and ADR. The recombinant yeast produced the P450 on the microsomes and mature forms of ADX and ADR in the cytoplasm, and showed the monooxygenase activity. Accordingly, a novel type of functional electron transport chain has been established between the cytoplasm and the microsomes in yeast.			SAKAKI, T (corresponding author), SUMITOMO CHEM CO LTD, TAKARAZUKA RES CTR, BIOTECHNOL LAB, 4-2-1 TAKATSUKASA, TAKARAZUKA, HYOGO 665, JAPAN.							AKIYOSHISHIBATA M, 1991, DNA CELL BIOL, V10, P613, DOI 10.1089/dna.1991.10.613; AKIYOSHISHIBATA M, 1991, FEBS LETT, V280, P367, DOI 10.1016/0014-5793(91)80333-X; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; EDWARDS RJ, 1991, BIOCHEMISTRY-US, V30, P71, DOI 10.1021/bi00215a011; HITZEMAN RA, 1980, J BIOL CHEM, V255, P2073; IMURA T, 1987, AGR BIOL CHEM TOKYO, V51, P1641, DOI 10.1080/00021369.1987.10868270; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUMOTO O, 1988, J BIOL CHEM, V263, P14256; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MURAKAMI H, 1986, DNA-J MOLEC CELL BIO, V5, P1, DOI 10.1089/dna.1986.5.1; MURAKAMI H, 1990, J BIOCHEM, V108, P859, DOI 10.1093/oxfordjournals.jbchem.a123293; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OHYAMA Y, 1991, J BIOCHEM-TOKYO, V63, P389; OKUDA K, 1988, J BIOL CHEM, V263, P18138; OMURA T, 1964, J BIOL CHEM, V239, P2370; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAKI T, 1984, J BIOCHEM-TOKYO, V96, P117, DOI 10.1093/oxfordjournals.jbchem.a134803; SAKAKI T, 1990, DNA CELL BIOL, V9, P603, DOI 10.1089/dna.1990.9.603; SAKAKI T, 1991, PHARMACOGENETICS, V1, P86, DOI 10.1097/00008571-199111000-00005; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; SAKAKI T, 1987, DNA-J MOLEC CELL BIO, V6, P31, DOI 10.1089/dna.1987.6.31; SAKAKI T, 1985, J BIOCHEM-TOKYO, V98, P167, DOI 10.1093/oxfordjournals.jbchem.a135255; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; VERGERES G, 1989, BIOCHEMISTRY-US, V28, P3650, DOI 10.1021/bi00435a005; YABUSAKI Y, 1991, FRONTIERS BIOTRANSFO, V4, P169; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	30	55	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16497	16502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1322905				2022-12-25	WOS:A1992JJ45800079
J	KATAFUCHI, T; MIZUNO, T; HAGIWARA, H; ITAKURA, M; ITO, T; HIROSE, S				KATAFUCHI, T; MIZUNO, T; HAGIWARA, H; ITAKURA, M; ITO, T; HIROSE, S			MODULATION BY NACL OF ATRIAL-NATRIURETIC-PEPTIDE RECEPTOR LEVELS AND CYCLIC-GMP RESPONSIVENESS TO ATRIAL-NATRIURETIC-PEPTIDE OF CULTURED VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICULATE GUANYLATE-CYCLASE; DOWN-REGULATION; BINDING-SITES; PURIFICATION; ACTIVATION; LUNG	Type C atrial natriuretic peptide (ANP) receptor levels in cultured vascular endothelial cells were found to be very sensitive to NaCl and shown to be inversely related to the magnitude of ANP-induced cGMP response of the cells. Endothelial cells from bovine carotid artery were subcultured in Eagle's minimum essential medium supplemented with 10% fetal bovine serum (MEM-FBS) and in MEM-FBS plus 25 and 50 mm NaCl. Determination, after several passages, of ANP receptor levels in these cells by I-125-ANP binding assay and affinity labeling revealed a marked reduction in the number of type C receptor in the NaCl-treated cells, whereas type A receptor density was not affected. RNase protection assay to estimate the levels of type C receptor mRNA indicated that the reduction occurred at a pre-translational level. In spite of the decrease in type C receptor number and no significant change in type A receptor (i.e. particulate guanylate cyclase) levels, cGMP response of the NaCl-treated cells to ANP was greatly exaggerated; this sensitization was also observed in membrane preparations. Simple masking of type C ANP receptor with C-ANF (des-[Gln18,Ser19,Gly20,Leu21,Gly22]ANP), a ring-deleted ANP analog, did not produce any sensitization of the cGMP response to ANP; therefore, the above phenomenon cannot simply be explained by the clearance function of the type C receptor. Although whether the type C receptor depletion is directly related to the sensitization of the type A receptor/cyclase is not known, the phenomenon reported and characterized here will serve as a useful basis for elucidating ANP receptor regulation and activation.			KATAFUCHI, T (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MEGURO KU,TOKYO 152,JAPAN.							BALLERMANN BJ, 1985, J CLIN INVEST, V76, P2049, DOI 10.1172/JCI112207; BAXTER JD, 1988, BIO-TECHNOL, V6, P529, DOI 10.1038/nbt0588-529; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHABRIER PE, 1988, J BIOL CHEM, V263, P13199; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; FULLER F, 1988, J BIOL CHEM, V263, P9395; GARBERS DL, 1989, J BIOL CHEM, V264, P9103; GAUQUELIN G, 1988, AM J PHYSIOL, V255, pF621, DOI 10.1152/ajprenal.1988.255.4.F621; HIRATA Y, 1985, BIOCHEM BIOPH RES CO, V128, P538, DOI 10.1016/0006-291X(85)90080-4; HIRATA Y, 1989, EUR J PHARMACOL, V164, P603, DOI 10.1016/0014-2999(89)90273-2; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUNO T, 1986, J BIOL CHEM, V261, P5817; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; LEITMAN DC, 1986, BIOCHIM BIOPHYS ACTA, V885, P74, DOI 10.1016/0167-4889(86)90040-6; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LYNCH DR, 1986, P NATL ACAD SCI USA, V83, P3357; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; NEEDLEMAN P, 1989, ANNU REV PHARMACOL, V29, P23, DOI 10.1146/annurev.pa.29.040189.000323; OHUCHI S, 1989, BIOCHEM BIOPH RES CO, V158, P603, DOI 10.1016/S0006-291X(89)80092-0; PAUL AK, 1987, SCIENCE, V235, P1224, DOI 10.1126/science.2881352; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SAHEKI T, 1991, J BIOL CHEM, V266, P11122; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFRIN EL, 1991, AM J PHYSIOL, V260, pH58, DOI 10.1152/ajpheart.1991.260.1.H58; SCHIFFRIN EL, 1986, HYPERTENSION, V8, P141; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104; TAKAYANAGI R, 1986, J HYPERTENS, V4, pS303; UCHIDA K, 1989, BIOCHEM J, V263, P671, DOI 10.1042/bj2630671	31	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7624	7629						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348507				2022-12-25	WOS:A1992HN48500061
J	GRAF, R; MATTERA, R; CODINA, J; ESTES, MK; BIRNBAUMER, L				GRAF, R; MATTERA, R; CODINA, J; ESTES, MK; BIRNBAUMER, L			A TRUNCATED RECOMBINANT ALPHA SUBUNIT OF GI3 WITH A REDUCED AFFINITY FOR BETA-GAMMA DIMERS AND ALTERED GUANOSINE 5'-3-O-(THIO)TRIPHOSPHATE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; AMINO-TERMINAL REGION; STIMULATORY G-PROTEIN; ADENYLATE-CYCLASE; K+ CHANNELS; PURIFICATION; RECEPTOR; NI; LIGANDS; SYSTEM	The baculovirus-based expression system was adapted to express a subunits of the complete (alpha(i3)) and an amino-terminally truncated (alpha(i3)') form of G(i3) and of two complete forms of G(s) (alpha(s-L) and alpha(s-S)). Subunits encoded in full length cDNAs were obtained with yields of 40-60 mg of recombinant protein/liter of cells, of which alpha(i3) was between 30 and 50% soluble, but alpha(s) subunits were only 5-10% soluble. Only the complete alpha(i3) was myristoylated. Alpha(i3) was purified in four steps. The purified protein bound 0.8-0.9 mol of guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) per mol of protein and had one predominant contaminant which was identified as a truncated form that begins with methionine 18 instead of methionine 1. Both the full length alpha(i3) and the truncated alpha(i3)' formed trimers with human erythrocyte betagamma as seen by their migration in sucrose density gradients and by an increased rate of ADP ribosylation by pertussis toxin, but compared to alpha(i3), alpha(i3)' interacted with betagamma with a reduced affinity and dissociated upon warming. At 32-degrees-C, only full length alpha(i3) was ADP-ribosylated; at 4-degrees-C, alpha(i3) and alpha(i3)' were both ADP-ribosylated, with the truncated form requiring approximately 200-fold higher concentrations of betagamma. A genetically engineered alpha(i3)' (alpha(i3)[18-354]) was also expressed in Sf9 cells. Yields, assessed as saturable GTPgammaS binding sites, were 3-5 mg per liter. Scatchard analysis showed that truncation of the amino terminus interferes with the ability of Mg2+ to promote high affinity binding of GTPgammaS. We conclude that the G protein alpha subunit amino terminus is not essential for interaction with betagamma dimers, but rather is important in determining the affinity of the alpha subunit for both the betagamma dimers and guanine nucleotide.	BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	Baylor College of Medicine	GRAF, R (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.			Graf, Rolf/0000-0001-7449-7302	NHLBI NIH HHS [HL-45198] Funding Source: Medline; NICHD NIH HHS [HD-09581] Funding Source: Medline; NIDDK NIH HHS [DK-19318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009581] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019318, R37DK019318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CODINA J, 1984, J RECEPTOR RES, V4, P411, DOI 10.3109/10799898409042565; CODINA J, 1984, J BIOL CHEM, V259, P5871; CODINA J, 1988, J BIOL CHEM, V263, P6746; CODINA J, 1991, J RECEPTOR RES, V11, P587, DOI 10.3109/10799899109066429; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; ESTES MK, 1987, J VIROL, V61, P1488, DOI 10.1128/JVI.61.5.1488-1494.1987; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P1271; HILDEBRANDT JD, 1983, NATURE, V302, P706, DOI 10.1038/302706a0; HUFF RM, 1986, J BIOL CHEM, V261, P1105; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KOHNKEN RE, 1989, J BIOL CHEM, V264, P20688; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; Maniatis T., 1982, MOL CLONING; MATTERA R, 1989, J BIOL CHEM, V264, P465; MATTERA R, 1986, J BIOL CHEM, V261, P11174; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OLATE J, 1988, J BIOL CHEM, V263, P10394; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SUNYER T, 1984, J BIOL CHEM, V259, P5447; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9	33	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24307	24314						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332951				2022-12-25	WOS:A1992KA26300028
J	ABDULLAH, M; HUGHES, PJ; CRAXTON, A; GIGG, R; DESAI, T; MARECEK, JF; PRESTWICH, GD; SHEARS, SB				ABDULLAH, M; HUGHES, PJ; CRAXTON, A; GIGG, R; DESAI, T; MARECEK, JF; PRESTWICH, GD; SHEARS, SB			PURIFICATION AND CHARACTERIZATION OF INOSITOL-1,3,4-TRISPHOSPHATE 5 6-KINASE FROM RAT-LIVER USING AN INOSITOL HEXAKISPHOSPHATE AFFINITY COLUMN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; 1,3,4-TRISPHOSPHATE PHOSPHORYLATION; AVIAN ERYTHROCYTES; ACINAR-CELLS; 1,3,4,6-TETRAKISPHOSPHATE; TETRAKISPHOSPHATE; 1,3,4,5-TETRAKISPHOSPHATE; 1,4,5-TRISPHOSPHATE; PHOSPHATES	The metabolism of inositol 1,3,4-trisphosphate is a pivotal branch point of inositol phosphate turnover; its dephosphorylation replenishes cellular inositol pools, its phosphorylation at the 6-position supports the synthesis of inositol pentakisphosphate, and its phosphorylation at the 5-position produces inositol 1,3,4,5-tetrakisphosphate Shears, S. B. (1989) J. Biol. Chem. 264, 19879-19886). In order to increase understanding of the control of inositol-1,3,4-trisphosphate kinase activity, the enzyme was highly purified from rat liver by precipitation with polyethylene glycol, MonoQ ion-exchange chromatography, heparin-agarose affinity chromatography, and a novel affinity chromatography procedure that utilized Affi-Gel resin to which InSP6 was coupled (Marecek, J. F., and Prestwich, G. D. (1991) Tetrahedron Lett. 32, 1863-1866). The final purification was about 26,000-fold, with a 6% yield. This final preparation performed both 5- and 6-kinase activities in the ratio of approximately 1:5. The affinity of the enzyme for inositol 1,3,4-trisphosphate was 0.04 muM, the highest yet determined for an inositol phosphate kinase. Both inositol 1,3,4,5-tetrakisphosphate and inositol 1,3,4,6-tetrakisphosphate were competitive inhibitors of the kinase (K(i) values of 2-4 muM). The enzyme was determined to have a molecular mass of 36 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Kinase activity was unaffected by Ca2+/calmodulin, protein kinase A, or protein kinase C.	NIEHS, INOSITOL LIPID SECT, CELLULAR & MOLEC PHARMACOL LAB, RES TRIANGLE PK, NC 27709 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND; SUNY STONY BROOK, DEPT CHEM, STONY BROOK, NY 11794 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); MRC National Institute for Medical Research; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NINDS NIH HHS [NS 29632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLA T, 1987, J BIOL CHEM, V262, P9952; BALLA T, 1989, J BIOL CHEM, V264, P13605; BANSAL VS, 1990, J BIOL CHEM, V265, P1806; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; DESAI T, 1992, CARBOHYD RES, V228, P65, DOI 10.1016/S0008-6215(00)90549-4; GAWLER DJ, 1991, BIOCHEM J, V276, P163, DOI 10.1042/bj2760163; HANSEN CA, 1988, FEBS LETT, V236, P53, DOI 10.1016/0014-5793(88)80284-9; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIRATA M, 1990, BIOCHEM BIOPH RES CO, V168, P379, DOI 10.1016/0006-291X(90)91719-9; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; INHORN RC, 1988, J BIOL CHEM, V263, P14559; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; IVORRA I, 1991, BIOCHEM J, V273, P317, DOI 10.1042/bj2730317; KING WG, 1990, BIOCHEM J, V270, P125, DOI 10.1042/bj2700125; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SY, 1990, J BIOL CHEM, V265, P9434; LI GD, 1992, J BIOL CHEM, V267, P4349; MARECEK JF, 1991, TETRAHEDRON LETT, V32, P1863, DOI 10.1016/S0040-4039(00)85982-1; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; PITTET D, 1989, J BIOL CHEM, V264, P18489; PRESTWICH GD, 1991, ACS SYM SER, V463, P122; PRESTWICH GD, 1991, J AM CHEM SOC, V113, P1822, DOI 10.1021/ja00005a055; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; SHEARS SB, 1987, BIOCHEM J, V246, P139, DOI 10.1042/bj2460139; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; 1989, BIOCHEM J, V258, P1	34	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22340	22345						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1331051				2022-12-25	WOS:A1992JW71900056
J	PENNICA, D; LAM, VT; MIZE, NK; WEBER, RF; LEWIS, M; FENDLY, BM; LIPARI, MT; GOEDDEL, DV				PENNICA, D; LAM, VT; MIZE, NK; WEBER, RF; LEWIS, M; FENDLY, BM; LIPARI, MT; GOEDDEL, DV			BIOCHEMICAL-PROPERTIES OF THE 75-KDA TUMOR-NECROSIS-FACTOR RECEPTOR - CHARACTERIZATION OF LIGAND-BINDING, INTERNALIZATION, AND RECEPTOR PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL-SURFACE RECEPTORS; FACTOR TNF RECEPTOR; PROTEIN KINASE-C; HIGH-AFFINITY BINDING; MOLECULAR-CLONING; SOLUBLE FORM; FACTOR-ALPHA; MONOCLONAL-ANTIBODIES; ACTIVATION MOLECULE	An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2. Ligand binding analysis revealed high affinity binding (K(d) = 0.2 nM) with approximately 94,000 +/- 7,500 sites/cell for I-125-TNF-alpha and approximately 5-fold lower affinity for TNF-beta (K(d) = 1.1 nM) with 264,000 +/- 2,000 sites/cell. Cross-linking of I-125-TNF-alpha and I-125-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules. Immunoprecipitation of TNF-R2 from P-32-labeled 293/TNF-R2 cells demonstrated that the receptor is phosphorylated. The majority (97%) of P-32i incorporation was found in serine residues with a very low level of incorporation (3%) in threonine residues. TNF-alpha treatment of 293/TNF-R2 cells did not significantly affect the degree or pattern of phosphorylation. Cell surface-bound I-125-TNF-alpha was slowly internalized by the 293/TNF-R2 cell line with a t1/2 = 25 min. Shedding of the extracellular domain of TNF-R2 was induced by 4beta-phorbol 12-myristate 13-acetate but not by TNF-alpha or TNF-beta.	GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	PENNICA, D (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ADERKA D, 1991, CANCER RES, V51, P5602; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HATEKAYEMA M, 1989, CELL, V59, P837; HAYAKAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P323, DOI 10.1016/0003-9861(91)90047-M; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1991, LAB INVEST, V64, P724; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOETSCHER H, 1992, TUMOR NECROSIS FACTO, P160; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MIYATA A, 1985, BIOCHEM BIOPH RES CO, V129, P248, DOI 10.1016/0006-291X(85)91429-9; MOSSELMANS R, 1988, J IMMUNOL, V141, P3096; NAUME B, 1991, J IMMUNOL, V146, P3045; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PORTEU F, 1991, J BIOL CHEM, V266, P18846; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN BY, 1985, J EXP MED, V162, P1099, DOI 10.1084/jem.162.3.1099; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEED B, 1987, P NATL ACAD SCI USA, V84, P8573; SHALABY MR, 1990, J EXP MED, V172, P15617; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH RA, 1992, TUMOR NECROSIS FACTO, P131; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WATANABE N, 1989, CANCER IMMUNOL IMMUN, V28, P157; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOSHIE O, 1986, J BIOCHEM-TOKYO, V100, P531, DOI 10.1093/oxfordjournals.jbchem.a121744	73	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21172	21178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1328224				2022-12-25	WOS:A1992JT97800102
J	NAKANISHI, A; IMAJOHOHMI, S; FUJINAWA, T; KIKUCHI, H; KANEGASAKI, S				NAKANISHI, A; IMAJOHOHMI, S; FUJINAWA, T; KIKUCHI, H; KANEGASAKI, S			DIRECT EVIDENCE FOR INTERACTION BETWEEN COOH-TERMINAL REGIONS OF CYTOCHROME-B558 SUBUNITS AND CYTOSOLIC 47-KDA PROTEIN DURING ACTIVATION OF AN O2(-)-GENERATING SYSTEM IN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; DEPENDENT SUPEROXIDE PRODUCTION; ADENINE-DINUCLEOTIDE PHOSPHATE; CHRONIC GRANULOMATOUS-DISEASE; NADPH OXIDASE; FATTY-ACIDS; LEUKOCYTES; NUCLEOTIDE; COMPONENT	Cytochrome b558 in phagocytes is a transmembrane protein composed of large and small subunits and considered to play a key role in O2- generation during the respiratory burst. The COOH-terminal regions of the cytochrome subunits protrude to the cytoplasmic side and are assumed to be the sites for association with cytosolic components to form an active O2--generating complex (Imajoh-Ohmi, S., Tokita, K., Ochiai, H., Nakamura, M., and Kanegasaki, S. (1992) J. Biol. Chem. 267, 180-184). We show here that two synthetic peptides corresponding to the COOH-terminal region of each subunit inhibit NADPH-dependent oxygen uptake induced by sodium dodecyl sulfate (SDS) in a cell-free system consisting of plasma membrane and cytosol. The inhibition was observed when either peptide was added to the system before, but not after, the activation with SDS suggesting that interaction between the COOH-terminal regions of the cytochrome subunits and cytosolic components is important for the assembly and the activity of the O2--generating system. Using the cross-linking reagent dimethyl 3,3'-dithiobis-propionimidate, we found that the cytosolic 47-kDa protein, an essential component of the O2--generating system, interacted with the synthetic peptides in the presence of SDS. In addition to the 47-kDa protein, a 17-kDa protein was found to be associated with the peptide corresponding to the COOH-terminal region of the small subunit. These results indicate that the cytosolic COOH-terminal regions of cytochrome b558 subunits are the binding sites for both the cytosolic 47-kDa protein and the 17-kDa protein and that the binding takes place during activation of the system.	UNIV TOKYO,INST MED SCI,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Kanegasaki, Shiro/AAM-4921-2021					BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DOUSSIERE J, 1988, BIOCHEM BIOPH RES CO, V152, P993, DOI 10.1016/S0006-291X(88)80382-6; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, BLOOD REV, V3, P94, DOI 10.1016/0268-960X(89)90004-0; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SMITH RM, 1991, BLOOD, V77, P673; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TANAKA T, 1987, BIOCHEM BIOPH RES CO, V144, P606, DOI 10.1016/S0006-291X(87)80009-8; TANAKA T, 1988, J BIOL CHEM, V263, P13670; UMEI T, 1991, J BIOL CHEM, V266, P6019; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563	28	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19072	19074						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326544				2022-12-25	WOS:A1992JP59300012
J	ULMER, JB; BURKE, CJ; SHI, CY; FRIEDMAN, A; DONNELLY, JJ; LIU, MA				ULMER, JB; BURKE, CJ; SHI, CY; FRIEDMAN, A; DONNELLY, JJ; LIU, MA			PORE FORMATION AND MITOGENICITY IN BLOOD-CELLS BY THE CLASS-2 PROTEIN OF NEISSERIA-MENINGITIDIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; MATRIX PORIN; GENE; PERMEABILITY; GONORRHOEAE; SEQUENCE	The class 2 outer membrane protein (MIEP) of Neisseria meningitidis has recently been shown to be mitogenic for lymphocytes (Liu, M. A., Friedman, A., Tai, J., Martinez, D., Deck, R. R., Hawe, L. A., Shieh, J. T.-C., Jenkins, T. D., Donnelly, J. J., and Oliff, A. 1. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4633-4637. In this study, a possible connection between MIEP's mitogenicity and its possible action as a porin was investigated. MIEP, purified from the bacterial outer membrane protein complex under denaturing conditions, caused a modest but specific release of ions (Rb-86) from both erythrocytes and lymphocytes, ultimately resulting in cell lysis. The dose-response of MIEP on erythrocyte lysis was qualitatively similar to a known porin (protein I from Neisseria gonorrhoeae) but was much less efficient. Induction or preservation of native structure in MIEP increased pore formation, resulting in levels comparable to that of the protein I porin. These observations suggest that native MIEP, free of the other outer membrane proteins of Neisseria meningitidis, can efficiently form pores in cells, but that denatured MIEP is variably and marginally effective. However, pore formation by MIEP was not related to its mitogenicity in lymphocytes, based on: (i) native MIEP was not mitogenic; (ii) denatured MIEP was highly mitogenic; and (iii) denatured MIEP was mitogenic at concentrations below the threshold level for pore formation. Therefore, mitogenicity is dependent upon MIEP being in a denatured, monomeric state and is masked by native conformation.	MERCK RES LABS,DEPT PHARMACEUT RES,W POINT,PA 19486	Merck & Company	ULMER, JB (corresponding author), MERCK RES LABS,DEPT CANC RES,BLDG 16-3,W POINT,PA 19486, USA.							AHONKAI VI, 1990, PEDIATRICS, V85, P668; BARLOW AK, 1989, MOL MICROBIOL, V3, P131, DOI 10.1111/j.1365-2958.1989.tb01802.x; BLAKE MS, 1982, INFECT IMMUN, V36, P277, DOI 10.1128/IAI.36.1.277-283.1982; DIHANICH M, 1990, EXPERIENTIA, V46, P146, DOI 10.1007/BF02027310; DONNELLY JJ, 1990, J IMMUNOL, V145, P3071; DORNMAIR K, 1990, J BIOL CHEM, V265, P18907; DORSET DL, 1983, J MOL BIOL, V165, P701, DOI 10.1016/S0022-2836(83)80275-7; EISELE JL, 1990, J BIOL CHEM, V265, P10217; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FRASCH CE, 1978, J BACTERIOL, V136, P1127, DOI 10.1128/JB.136.3.1127-1134.1978; FRASCH CE, 1986, CLIN INVEST MED, V9, P101; GELFAND EW, 1990, LIGANDS RECEPTORS SI, P359; HANCOCK REW, 1987, J BACTERIOL, V169, P929, DOI 10.1128/jb.169.3.929-933.1987; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; Levitt D, 1990, CURR OPIN CELL BIOL, V2, P689, DOI 10.1016/0955-0674(90)90112-R; LIU MA, 1992, P NATL ACAD SCI USA, V89, P4633, DOI 10.1073/pnas.89.10.4633; LYNCH EC, 1984, BIOPHYS J, V45, P104, DOI 10.1016/S0006-3495(84)84127-2; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARKOVICHOUSLEY Z, 1986, BIOCHIM BIOPHYS ACTA, V869, P158, DOI 10.1016/0167-4838(86)90290-6; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; MURAKAMI K, 1989, INFECT IMMUN, V57, P2318, DOI 10.1128/IAI.57.8.2318-2323.1989; NAKAE T, 1979, J BIOL CHEM, V254, P1457; PARR TR, 1986, J BACTERIOL, V165, P523, DOI 10.1128/jb.165.2.523-526.1986; PERUTZ MF, 1968, NATURE, V219, P29, DOI 10.1038/219029a0; TSAI CM, 1981, J BACTERIOL, V146, P69, DOI 10.1128/JB.146.1.69-78.1981; WEISS A, 1987, ADV IMMUNOL, P1; YOSHIHARA E, 1991, J BIOL CHEM, V266, P952	29	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19266	19271						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1326549				2022-12-25	WOS:A1992JP59300040
J	KESSLER, D; HERTH, W; KNAPPE, J				KESSLER, D; HERTH, W; KNAPPE, J			ULTRASTRUCTURE AND PYRUVATE FORMATE-LYASE RADICAL QUENCHING PROPERTY OF THE MULTIENZYMATIC ADHE PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ALCOHOL-DEHYDROGENASE; ZYMOMONAS-MOBILIS; ADENINE-DINUCLEOTIDE; ACETYL-COA; HYPOPHOSPHITE; CLONING; ENZYME; ANALOG; GENE	The AdhE protein of Escherichia coli is a homopolymer of 96-kDa subunits harboring three Fe2+-dependent catalytic functions: acetaldehyde-CoA dehydrogenase, alcohol dehydrogenase, and pyruvate formatelyase (PFL) deactivase. By negative staining electron microscopy, we determined a helical assembly of 20-60 subunits into rods of 45-120 nm in length. The subunit packing is widened along the helix axis when Fe2+ and NAD are present. Chymotrypsin dissects the AdhE polypeptide between Phe762 and Ser763, thereby retaining the alcohol dehydrogenase activity on the NH2-terminal core, but destroying all other activities. PFL deactivation, i.e. quenching of the glycyl radical in PFL by the AdhE protein, was examined with respect to cofactor involvements (Fe2+, NAD, and CoA). This process is coupled to NAD reduction and requires the intact CoA sulfhydryl group. Pyruvate and NADH are inhibitors that affect the steady-state level of the radical form of PFL in a reconstituted interconversion cycle. Studies of cell cultures found that PFL deactivation in situ is initiated at redox potentials of greater-than-or-equal-to +100 mV. Our results provide insights into the structure/function organization of the AdhE multienzyme and give a rationale for how its PFL radical quenching activity may be suppressed in situ to enable effective glucose fermentation.	UNIV HEIDELBERG,INST BIOL CHEM,NEUENHEIMER FELD 501,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; CONWAY T, 1987, J BACTERIOL, V169, P2591, DOI 10.1128/jb.169.6.2591-2597.1987; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISHER TL, 1973, J BIOL CHEM, V248, P4293; GOODLOVE PE, 1989, GENE, V85, P209, DOI 10.1016/0378-1119(89)90483-6; HARVEY HE, 1955, ANAL CHEM, V27, P26; KESSLER D, 1991, FEBS LETT, V281, P59, DOI 10.1016/0014-5793(91)80358-A; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATAYOSHI S, 1989, J GEN MICROBIOL, V135, P525; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PLAGA W, 1988, EUR J BIOCHEM, V178, P445, DOI 10.1111/j.1432-1033.1988.tb14468.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STANDRING DN, 1980, BIOCHEMISTRY-US, V19, P2811, DOI 10.1021/bi00553a042; TSE P, 1989, J AM CHEM SOC, V111, P8703, DOI 10.1021/ja00205a021; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WILLIAMSON VM, 1987, MOL GEN GENET, V209, P374, DOI 10.1007/BF00329668; WIMPENNY JW, 1971, BIOCHIM BIOPHYS ACTA, V253, P352, DOI 10.1016/0005-2728(71)90039-9	22	98	99	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18073	18079						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325457				2022-12-25	WOS:A1992JM22300091
J	NIRANJANAKUMARI, S; GOPINATHAN, KP				NIRANJANAKUMARI, S; GOPINATHAN, KP			DNA POLYMERASE-DELTA FROM THE SILK GLANDS OF BOMBYX-MORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CALF THYMUS; AUXILIARY PROTEIN; HUMAN-FIBROBLASTS; REPAIR SYNTHESIS; HELA-CELLS; RAT-LIVER; 2 FORMS; ALPHA; PURIFICATION	The silk gland of Bombyx mori is a terminally differentiated tissue in which DNA replication continues without cell or nuclear division during larval development. DNA polymerase-delta activity increases in the posterior and middle silk glands during the development period, reaching maximal levels in the middle of the fifth instar larvae. The enzyme has been purified to homogeneity by a series of column chromatographic and affinity purification steps. It is a multimer comprising of three heterogeneous subunits, M(r) 170,000, 70,000, and 42,000. An auxiliary protein from B. mori silk glands, analogous to the proliferating cell nuclear antigen, enhances the processivity of the enzyme and stimulates catalytic activity by 3-fold. This auxiliary protein has also been purified to homogeneity. It is a dimer comprised of a single type M(r) 40,000 subunit. Polymerase-delta possesses an intrinsic 3' --> 5' exonuclease activity which participates in proofreading by mismatch match repair during DNA synthesis and is devoid of any primase activity. DNA polymerase-delta activity could be further distinguished from polymerase-alpha from the same tissue based on its sensitivity to various inhibitors and polyclonal antibodies to the individual enzymes. Like DNA polymerase-alpha, polymerase-delta is also tightly associated with the nuclear matrix. The polymerase alpha-primase complex could be readily separated from polymerase-delta (exonuclease) in the purification protocol adopted. DNA polymerase-delta from B. mori silk glands resembles the mammalian delta-polymerases. Considering that both DNA polymerase-delta and -alpha are present in nearly equal amounts in this highly replicative tissue and their close association with the nuclear matrix, the involvement of both the enzymes in the chromosomal endoreplication process in B. mori is strongly implicated.	INDIAN INST SCI,DEPT MICROBIOL & CELL BIOL,BANGALORE 560012,KARNATAKA,INDIA; INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								BAUER GA, 1988, J BIOL CHEM, V263, P917; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNES JJ, 1985, BIOCHEM BIOPH RES CO, V132, P628, DOI 10.1016/0006-291X(85)91179-9; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; DECKER RS, 1987, J BIOL CHEM, V262, P10863; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; DRESLER SL, 1986, NUCLEIC ACIDS RES, V14, P7093, DOI 10.1093/nar/14.17.7093; FOCHER F, 1988, NUCLEIC ACIDS RES, V16, P6279, DOI 10.1093/nar/16.14.6279; FRY M, 1986, ANIMAL CELL DNA POLY; GAGE LP, 1974, CHROMOSOMA, V45, P27; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HAMMOND RA, 1987, BIOCHEMISTRY-US, V26, P6817, DOI 10.1021/bi00395a035; HOLMES AM, 1974, EUR J BIOCHEM, V43, P487, DOI 10.1111/j.1432-1033.1974.tb03436.x; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Lee M Y, 1981, Prog Nucleic Acid Res Mol Biol, V26, P83; LEE MYWT, 1987, BIOCHEMISTRY-US, V26, P1076, DOI 10.1021/bi00378a014; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE MYWT, 1985, NUCLEIC ACIDS RES, V13, P8623, DOI 10.1093/nar/13.23.8623; LONGIARU M, 1979, NUCLEIC ACIDS RES, V6, P3369, DOI 10.1093/nar/6.10.3369; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MECHALI M, 1980, J BIOL CHEM, V255, P2114; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NIRANJANAKUMARI S, 1991, EUR J BIOCHEM, V202, P431; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OHASHI M, 1978, BIOCHEM BIOPH RES CO, V82, P1084, DOI 10.1016/0006-291X(78)90298-X; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; REYLAND ME, 1988, J BIOL CHEM, V263, P6518; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TAN CK, 1986, J BIOL CHEM, V261, P2310; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006	35	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17531	17539						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1325438				2022-12-25	WOS:A1992JM22300012
J	ADLER, V; POLOTSKAYA, A; WAGNER, F; KRAFT, AS				ADLER, V; POLOTSKAYA, A; WAGNER, F; KRAFT, AS			AFFINITY-PURIFIED C-JUN AMINO-TERMINAL PROTEIN-KINASE REQUIRES SERINE THREONINE PHOSPHORYLATION FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC INHIBITOR; MONOCYTIC DIFFERENTIATION; REGULATORY DOMAIN; FOS; EXPRESSION; ACTIVATION; INDUCTION; ONCOGENE	The addition of phorbol esters to U937 leukemic cells stimulates the phosphorylation of c-Jun on serines 63 and 73. To isolate the protein kinase which stimulates this phosphorylation, we have used heparin-Sepharose chromatography followed by affinity chromatography over glutathione-Sepharose beads bound with a fusion protein of glutathione S-transferase and amino acids 5-89 of c-Jun (GST-c-Jun). Using this procedure we purify a 67-kDa protein which is capable of phosphorylating GST-c-Jun as well as the complete c-Jun protein. By making mutations in serines 63 and 73 and then creating a fusion protein with GST (GST-c-Jun mut), we demonstrate that this protein kinase specifically phosphorylates these sites in the c-Jun amino terminus. Treatment of purified c-Jun amino-terminal protein kinase (cJAT-PK) with phosphatase 2A inhibits its ability to phosphorylate GST-c-Jun. This inactivated enzyme can be reactivated by phosphorylation with protein kinase C (PKC), although PKC is not capable of phosphorylating the GST-c-Jun substrate. Because v-Jun cannot be phosphorylated in vivo, we compared the ability of cJAT-PK to bind to GST-v-Jun or GST-c-Jun mut. The cJAT-PK bound 50-fold better to GST-c-Jun mut than GST-v-Jun suggesting that the delta-domain which is missing in v-Jun plays a role in binding the cJAT-PK. These results suggest that there is a protein kinase cascade mediated by protein phosphatases and PKC which regulates c-Jun phosphorylation.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA-42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; FRANKLIN CC, IN PRESS P NATL ACAD; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; WILLIAM F, 1990, J BIOL CHEM, V265, P18166	22	103	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17001	17005						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324919				2022-12-25	WOS:A1992JL05300044
J	MAIZELS, ET; MILLER, JB; CUTLER, RE; JACKIW, V; CARNEY, EM; MIZUNO, K; OHNO, S; HUNZICKERDUNN, M				MAIZELS, ET; MILLER, JB; CUTLER, RE; JACKIW, V; CARNEY, EM; MIZUNO, K; OHNO, S; HUNZICKERDUNN, M			ESTROGEN MODULATES CA2+-INDEPENDENT LIPID-STIMULATED KINASE IN THE RABBIT CORPUS-LUTEUM OF PSEUDOPREGNANCY - IDENTIFICATION OF LUTEAL ESTROGEN-MODULATED LIPID-STIMULATED KINASE AS PROTEIN-KINASE C-DELTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; STEROL CARRIER PROTEIN-2; 2 DISTINCT CLASSES; 17 BETA-ESTRADIOL; CORPORA-LUTEA; RAT-BRAIN; DEPENDENT PHOSPHORYLATION; SIGNAL TRANSDUCTION; PKC-EPSILON; FAMILY	Rabbit corpora lutea were tested for the presence of phosphorylative responses sensitive to estrogen. Luteal Ca2+-independent lipid-stimulated kinase activity was detected by phosphorylation of the endogenous substrate, p76. Estrogen treatment, by way of estradiol-17-beta implant, increased levels of the lipid-stimulated phosphoprotein 2-3-fold throughout pseudopregnancy. Midpseudopregnant rabbit luteal extracts were further evaluated to determine the identity of the lipid-stimulated kinase. Results of low pH-activated phosphorylation were consistent with the identification of p76 as an autophosphorylated member of the protein kinase C (PKC) family. Partial purification of the luteal lipid-stimulated kinase was performed using sequential DEAE-cellulose/hydroxylapatite chromatographies and using gel filtration. Western immunoblot with type-specific anti-PKC-delta antiserum showed coelution of kinase p76 activity with immunoreactive PKC-delta. Immunoblot analysis confirmed that luteal levels of PKC-delta were increased by estrogen treatment.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA; UNIV ILLINOIS, SCH MED, DEPT OBSTET & GYNECOL, CHICAGO, IL 60612 USA; YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, YOKOHAMA 236, JAPAN	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Yokohama City University			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Maizels, Evelyn/0000-0001-9072-1095	NICHD NIH HHS [HD-11356, HD-28472] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028472, R01HD011356] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKITA Y, 1990, J BIOL CHEM, V265, P354; ALESSENKO A, 1992, BIOCHEM BIOPH RES CO, V182, P1333, DOI 10.1016/0006-291X(92)91879-U; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENDER EM, 1978, ENDOCRINOLOGY, V103, P1937, DOI 10.1210/endo-103-5-1937; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BIGNON E, 1989, BIOCHEM BIOPH RES CO, V163, P1377, DOI 10.1016/0006-291X(89)91131-5; BILL CH, 1983, BIOL REPROD, V28, P608, DOI 10.1095/biolreprod28.3.608; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DEMANNO DA, 1992, IN PRESS MOL CELL EN; GADSBY JE, 1983, ENDOCRINOLOGY, V113, P2255, DOI 10.1210/endo-113-6-2255; GSCHWENDT M, 1989, BIOCHEM BIOPH RES CO, V164, P974, DOI 10.1016/0006-291X(89)91765-8; GSCHWENDT M, 1986, BIOCHEM BIOPH RES CO, V137, P766, DOI 10.1016/0006-291X(86)91145-9; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HOLT JA, 1975, ENDOCRINOLOGY, V97, P76, DOI 10.1210/endo-97-1-76; HOLT JA, 1988, ENDOCRINOLOGY, V122, P1948, DOI 10.1210/endo-122-5-1948; HOLT JA, 1985, ENDOCRINOLOGY, V117, P2462, DOI 10.1210/endo-117-6-2462; HOLT JA, 1989, BIOL REPROD, V40, P201, DOI 10.1095/biolreprod40.2.201; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1986, J BIOL CHEM, V261, P4781; HUNZICKERDUNN M, 1984, ENDOCRINOLOGY, V115, P302, DOI 10.1210/endo-115-1-302; KEYES PL, 1967, ENDOCRINOLOGY, V80, P938, DOI 10.1210/endo-80-5-938; KEYES PL, 1990, ENDOCRINOLOGY, V127, P1186, DOI 10.1210/endo-127-3-1186; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KILEY S, 1990, J BIOL CHEM, V265, P15704; LEACH KL, 1988, ADV 2ND MESSENGER A, V21, P182; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maizels E T, 1989, J Reprod Fertil Suppl, V37, P311; MAIZELS E T, 1987, Biology of Reproduction, V36, P124; MAIZELS ET, 1990, BIOCHIM BIOPHYS ACTA, V1054, P285, DOI 10.1016/0167-4889(90)90099-Y; MAIZELS ET, 1983, ENDOCRINOLOGY, V112, P1895, DOI 10.1210/endo-112-6-1895; MAIZELS ET, 1991, REGULATORY PROCESSES, P54; MCFADDEN PN, 1989, J BIOL CHEM, V264, P12765; MCLEAN MP, 1989, ENDOCRINOLOGY, V125, P1337, DOI 10.1210/endo-125-3-1337; MILLER JB, 1983, BIOL REPROD, V29, P620, DOI 10.1095/biolreprod29.3.620; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELECH SL, 1991, J BIOL CHEM, V266, P8696; RAO MC, 1987, ENDOCRINOLOGY, V120, P1010, DOI 10.1210/endo-120-3-1010; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; STEINSCHNEIDER A, 1991, ENDOCRINOLOGY, V128, P263, DOI 10.1210/endo-128-1-263; STEINSCHNEIDER A, 1989, ENDOCRINOLOGY, V125, P569, DOI 10.1210/endo-125-1-569; SU HD, 1985, BIOCHEM PHARMACOL, V34, P3649; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C	58	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17061	17068						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324921				2022-12-25	WOS:A1992JL05300052
J	RICHARDS, OC; YU, P; NEUFELD, KL; EHRENFELD, E				RICHARDS, OC; YU, P; NEUFELD, KL; EHRENFELD, E			NUCLEOTIDE BINDING BY THE POLIOVIRUS RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; COLI DNA-POLYMERASE; ESCHERICHIA-COLI; CROSS-LINKING; ELECTROPHORETIC TRANSFER; FUNCTIONAL TOPOGRAPHY; POLYACRYLAMIDE GELS; ENZYMATIC-ACTIVITY; SUBSTRATE-BINDING; VIRAL CDNA	Cross-linking of ribonucleoside triphosphates (NTPs) to specific binding sites on the poliovirus RNA-dependent RNA polymerase has been performed by ultraviolet irradiation and by reduction of oxidized nucleotide-protein complexes. The latter method approached a cross-linking efficiency of 1 NTP/molecule of enzyme. Nucleotide competition experiments suggested that the same binding site is occupied by all NTPs. Analysis of peptides produced by proteinase Glu-C and trypsin digestion and labeled with [P-32]GTP indicated that a lysine residue between Met-189 and Lys-228 in the polymerase was cross-linked to NTP. Nucleotide binding was exploited for rapid purification of the enzyme by GTP-agarose affinity chromatography. In addition, a set of cloned, modified polymerase molecules with reduced or absent polymerization activity was analyzed for binding efficiency to a GTP-agarose column. Some mutations eliminated GTP binding, whereas others generated proteins with varying affinities for GTP. Incubation of the poliovirus polymerase with high concentrations of NTP, particularly GTP, resulted in a dramatic protection against heat denaturation and activity loss. These data suggest that nucleotide binding results in an alteration of the enzyme conformation or the stabilization of an ordered conformation.	UNIV UTAH, DEPT CELLULAR VIRAL & MOLEC BIOL, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah				Neufeld, Kristi/0000-0003-3653-9385	NATIONAL CANCER INSTITUTE [P30CA042014, T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017386, R37AI017386] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09602, CA 42014] Funding Source: Medline; NIAID NIH HHS [AI 17386] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; BASU A, 1988, J BIOL CHEM, V263, P1648; BASU A, 1990, J BIOL CHEM, V265, P17162; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU A, 1989, J BIOL CHEM, V264, P8746; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS CC, 1989, J VIROL, V63, P4866, DOI 10.1128/JVI.63.11.4866-4874.1989; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P23; CLERTANT P, 1982, J BIOL CHEM, V257, P6300; FRISCHAUF AM, 1973, BIOCHEM BIOPH RES CO, V53, P1227, DOI 10.1016/0006-291X(73)90596-2; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; HANNA MM, 1989, METHOD ENZYMOL, V180, P383; HARTMANN GR, 1988, BIOL CHEM H-S, V369, P775; HEY TD, 1986, J VIROL, V58, P790, DOI 10.1128/JVI.58.3.790-796.1986; JABLONSKI SA, 1991, J VIROL, V65, P4565, DOI 10.1128/JVI.65.9.4565-4572.1991; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KELLY S, 1990, J BIOL CHEM, V265, P7787; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORROW CD, 1987, P NATL ACAD SCI USA, V84, P6050, DOI 10.1073/pnas.84.17.6050; NANDURI VB, 1990, BIOCHEMISTRY-US, V29, P5258, DOI 10.1021/bi00474a006; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; NEUFELD KL, 1991, VIRUS RES, V19, P173, DOI 10.1016/0168-1702(91)90044-V; OBERSTE MS, 1988, NUCLEIC ACIDS RES, V16, P10338; PANDEY V, 1987, BIOCHEMISTRY-US, V26, P2033, DOI 10.1021/bi00381a036; PANDEY V, 1988, J BIOL CHEM, V263, P3744; PANDEY VN, 1987, BIOCHEMISTRY-US, V26, P7744, DOI 10.1021/bi00398a031; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RICHARDS OC, 1987, VIROLOGY, V161, P348, DOI 10.1016/0042-6822(87)90127-9; RIVA M, 1990, J BIOL CHEM, V265, P16498; ROTHSTEIN MA, 1988, VIROLOGY, V164, P301, DOI 10.1016/0042-6822(88)90542-9; RUSH J, 1990, J BIOL CHEM, V265, P4821; Sambrook J, 1989, MOL CLONING LABORATO; SEMLER BL, 1988, RNA GENETICS, P23; SPERLING J, 1976, BIOCHEMISTRY-US, V15, P1489, DOI 10.1021/bi00652a020; SUN S, 1990, J VIROL, V64, P5093, DOI 10.1128/JVI.64.10.5093-5105.1990; TIRUMALAI RS, 1991, BIOCHEMISTRY-US, V30, P6436, DOI 10.1021/bi00240a014; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDYKE TA, 1980, J VIROL, V35, P732, DOI 10.1128/JVI.35.3.732-740.1980	43	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17141	17146						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1324924				2022-12-25	WOS:A1992JL05300065
J	FONDA, ML				FONDA, ML			PURIFICATION AND CHARACTERIZATION OF VITAMIN-B(6)-PHOSPHATE PHOSPHATASE FROM HUMAN ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEIGHT ACID-PHOSPHATASE; HUMAN SERUM-ALBUMIN; PYRIDOXAL 5'-PHOSPHATE; ALKALINE-PHOSPHATASE; PROTEIN-BINDING; VITAMIN-B6 METABOLISM; RAT-LIVER; PLASMA; LOCALIZATION; PYRIDOXAL-5'-PHOSPHATE	Human erythrocytes rapidly convert vitamin B-6 to pyridoxal-P and contain soluble phosphatase activity which dephosphorylates pyridoxal-P at a pH optimum of 6-6.5. This phosphatase was purified 51,000-fold with a yield of 39% by ammonium sulfate precipitation and chromatography on DEAE-Sepharose, Sephacryl S-200, hydroxylapatite, and reactive yellow 86-agarose. Sephacryl S-200 chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that the enzyme was a dimer with a molecular mass of approximately 64 kDa. The phosphatase required Mg2+ for activity. It specifically catalyzed the removal of phosphate from pyridoxal-P, pyridoxine-P, pyridoxamine-P, 4-pyridoxic acid-P, and 4-deoxypyridoxine-P at pH 7.4. Nucleotide phosphates, phosphoamino acids, and other phosphorylated compounds were not hydrolyzed significantly nor were they effective inhibitors of the enzyme. The phosphatase showed Michaelis-Menten kinetics with its substrates. It had a K(m) of 1.5-mu-M and a V(max) of 3.2-mu-mol/min/mg with pyridoxal-P. The V(max)/K(m) was greatest with pyridoxal-P > 4-pyridoxic acid-P > pyridoxine-P > pyridoxamine-P. The phosphatase was competitively inhibited by the product, inorganic phosphate, with a K(i) of 0.8 mM, and weakly inhibited by pyridoxal. It was also inhibited by Zn2+, fluoride, molybdate, and EDTA, but was not inhibited by levamisole, L-phenylalanine, or L(+)-tartrate. These properties of the purified enzyme suggest that it is a unique acid phosphatase that specifically dephosphorylates vitamin B-6-phosphates.			FONDA, ML (corresponding author), UNIV LOUISVILLE, SCH MED, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA.				NIAAA NIH HHS [AA06861] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006861] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON BB, 1980, GUT, V21, P192, DOI 10.1136/gut.21.3.192; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; COBURN SP, 1986, METHOD ENZYMOL, V122, P102, DOI 10.1016/0076-6879(86)22155-2; Coburn SP, 1988, CLIN PHYSL APPLICATI, P65; COLEMAN JE, 1983, ADV ENZYMOL RAMB, V55, P381; COLEMAN RA, 1980, J HISTOCHEM CYTOCHEM, V28, P115, DOI 10.1177/28.2.7354210; DISSING J, 1990, BIOCHIM BIOPHYS ACTA, V1041, P232, DOI 10.1016/0167-4838(90)90277-M; EBADI M, 1979, INT J BIOCHEM, V10, P705, DOI 10.1016/0020-711X(79)90216-7; Ebadi M., 1986, VITAMIN B6 PYRIDOXAL, P449; FONDA M, 1987, BIOCH VITAMIN B6, P399; FONDA ML, 1982, AM J CLIN NUTR, V35, P1391, DOI 10.1093/ajcn/35.6.1391; FONDA ML, 1991, ARCH BIOCHEM BIOPHYS, V288, P79, DOI 10.1016/0003-9861(91)90167-H; FONDA ML, 1990, ANN NY ACAD SCI, V585, P483, DOI 10.1111/j.1749-6632.1990.tb28082.x; FONDA ML, 1989, ALCOHOL CLIN EXP RES, V13, P804, DOI 10.1111/j.1530-0277.1989.tb00426.x; FUJIMOTO S, 1984, J BIOCHEM, V96, P1079, DOI 10.1093/oxfordjournals.jbchem.a134925; HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009-8981(90)90031-M; HENDERSON JM, 1986, HEPATOLOGY, V6, P464, DOI 10.1002/hep.1840060324; HILL DW, 1979, ANAL CHEM, V51, P1338, DOI 10.1021/ac50044a055; KYAW A, 1980, BIOCHEM MED METAB B, V24, P27, DOI 10.1016/0006-2944(80)90083-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE H, 1971, BIOCHIM BIOPHYS ACTA, V242, P519, DOI 10.1016/0005-2744(71)90144-6; LI TK, 1974, BIOCHEM BIOPH RES CO, V61, P677, DOI 10.1016/0006-291X(74)91010-9; LUMENG L, 1980, J CLIN INVEST, V66, P688, DOI 10.1172/JCI109906; LUMENG L, 1974, J CLIN INVEST, V53, P693, DOI 10.1172/JCI107607; LUMENG L, 1974, J LAB CLIN MED, V84, P334; LUMENG L, 1975, J BIOL CHEM, V250, P8126; LUMENG L, 1986, HEPATOLOGY, V6, P330; MIDDLETON HM, 1986, GASTROENTEROLOGY, V91, P343, DOI 10.1016/0016-5085(86)90567-6; MURAKAMI K, 1986, CHEM PHARM BULL, V34, P3320; NATTA CL, 1984, AM J CLIN NUTR, V40, P235, DOI 10.1093/ajcn/40.2.235; RAIBAUD O, 1974, FEBS LETT, V40, P41, DOI 10.1016/0014-5793(74)80889-6; REYNOLDS RD, 1991, AM J CLIN NUTR, V53, P698, DOI 10.1093/ajcn/53.3.698; ROSE ZB, 1981, ARCH BIOCHEM BIOPHYS, V208, P602, DOI 10.1016/0003-9861(81)90549-X; SARASWATHI S, 1963, J NEUROCHEM, V10, P127, DOI 10.1111/j.1471-4159.1963.tb11473.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH GP, 1981, BIOCHIM BIOPHYS ACTA, V661, P287, DOI 10.1016/0005-2744(81)90017-6; SMITH GP, 1981, CLIN CHIM ACTA, V114, P257, DOI 10.1016/0009-8981(81)90398-3; SPATER HW, 1978, J HISTOCHEM CYTOCHEM, V26, P809, DOI 10.1177/26.10.31396; STOCK A, 1966, BIOCHEM Z, V344, P353; WADA H, 1961, J BIOL CHEM, V236, P2089; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILSON PD, 1983, HISTOCHEM J, V15, P257, DOI 10.1007/BF01006240; ZECHER R, 1980, BIOCHEM J, V191, P117, DOI 10.1042/bj1910117	43	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15978	15983						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1322411				2022-12-25	WOS:A1992JG11300107
J	WANG, J; ZINDY, F; CHENIVESSE, X; LAMAS, E; HENGLEIN, B; BRECHOT, C				WANG, J; ZINDY, F; CHENIVESSE, X; LAMAS, E; HENGLEIN, B; BRECHOT, C			MODIFICATION OF CYCLIN-A EXPRESSION BY HEPATITIS-B VIRUS-DNA INTEGRATION IN A HEPATOCELLULAR-CARCINOMA	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; PROTEIN-KINASE; M-PHASE; SCHIZOSACCHAROMYCES-POMBE; TRANSGENIC MICE; G1 PHASE; CDC2	We have previously reported the identification of a hepatitis B virus (HBV) DNA integration in an intron of the cyclin A gene in an early hepatocellular carcinoma (HCC) and the isolation of human cyclin A cDNA. We have now constructed a cDNA library from the tumor and isolated several hybrid HBV-cyclin A cDNAs from it. The hybrid cDNAs encode an HBV-cyclin A fusion protein. In the chimeric protein, the N-terminus of cyclin A, including the signals for cyclin degradation, is deleted and replaced by viral PreS2/S sequences, transcription being initiated from the viral PreS2/S promoter. This chimeric protein is undegradable in an in vitro cyclin degradation assay. Northern blot analyses showed strong expression of the hybrid transcripts in the tumor, while cyclin A- or HBV-specific transcripts were not detected in the non-tumorous liver of the same patient. Thus, HBV DNA integration in the cyclin A gene resulted in a strong expression of hybrid HBV-cyclin A transcripts encoding a stabilized cyclin A. This chimeric protein may play an important role in the development of the tumor.	CHU NECKER ENFANTS MALAD, INSERM, U75, 156 RUE VAUGIRARD, F-75730 PARIS 15, FRANCE; INST PASTEUR, HYBRIDOTEST, F-75724 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Lamas, Eugenia/L-9654-2018	Lamas, Eugenia/0000-0001-7677-9442				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GANEM D, 1990, NATURE, V347, P230, DOI 10.1038/347230b0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; INES J, 1991, CELL, V66, P1071; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	46	138	145	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1653	1656						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321406				2022-12-25	WOS:A1992JE81300024
J	DAHL, MK; MSADEK, T; KUNST, F; RAPOPORT, G				DAHL, MK; MSADEK, T; KUNST, F; RAPOPORT, G			THE PHOSPHORYLATION STATE OF THE DEGU RESPONSE REGULATOR ACTS AS A MOLECULAR SWITCH ALLOWING EITHER DEGRADATIVE ENZYME-SYNTHESIS OR EXPRESSION OF GENETIC COMPETENCE IN BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; MUTATIONS; PHOSPHOTRANSFER; PROTEINS; SYSTEMS	Two classes of mutations were identified in the degS and degU regulatory genes of Bacillus subtilis, leading either to deficiency of degradative enzyme synthesis (degS or degU mutations) or to a pleiotropic phenotype which includes overproduction of degradative enzymes and the loss of genetic competence (degS(Hy) or degU(Hy) mutations). We have shown previously that the DegS protein kinase and the DegU response regulator form a signal transduction system in B. subtilis. We now demonstrate that the DegS protein kinase also acts as a DegU phosphatase. We present evidence that the DegU response regulator has two active conformations: a phosphorylated form which is necessary for degradative enzyme synthesis and a nonphosphorylated form required for expression of genetic competence. The degU146-encoded response regulator, allowing expression of genetic competence, has been purified and seems to be modified within the putative phosphorylation site (D56-->N) since it is no longer phosphorylated by DegS. Both the degU146 mutation as well as the degS220 mutation, which essentially abolishes DegS protein kinase activity, lead to deficiency of degradative enzyme synthesis, indicating the requirement of phosphorylated DegU for the expression of this phenotype. We also purified the degU32(Hy)-encoded protein and showed that this response regulator is phosphorylated by the DegS protein kinase in vitro. In addition, the phosphorylated form of the degU32(Hy)-encoded protein presented a strongly increased stability as compared with the wild type DegU protein, thus leading to hyperproduction of degradative enzymes in vivo.			DAHL, MK (corresponding author), INST PASTEUR,CNRS,CNRS,URA 1300,UNITE BIOCHIM MICROBIENNE,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; AMORY A, 1987, J BACTERIOL, V169, P324, DOI 10.1128/jb.169.1.324-333.1987; AYUSAWA D, 1975, J BACTERIOL, V124, P459, DOI 10.1128/JB.124.1.459-469.1975; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DAHL MK, 1991, J BACTERIOL, V173, P2539, DOI 10.1128/jb.173.8.2539-2547.1991; DUBNAU D, 1991, MICROBIOL REV, V55, P395, DOI 10.1128/MMBR.55.3.395-424.1991; Gibson T., 1984, THESIS U CAMBRIDGE C; HENNER DJ, 1988, J BACTERIOL, V170, P5102, DOI 10.1128/jb.170.11.5102-5109.1988; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; KUNST F, 1988, J BACTERIOL, V170, P5093, DOI 10.1128/jb.170.11.5093-5101.1988; KUNST F, 1974, BIOCHIMIE, V56, P1481; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; MSADEK T, 1991, J BACTERIOL, V173, P2366, DOI 10.1128/JB.173.7.2366-2377.1991; MSADEK T, 1990, J BACTERIOL, V172, P824, DOI 10.1128/jb.172.2.824-834.1990; MUKAI K, 1990, J BIOL CHEM, V265, P20000; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; ROGGIANI M, 1990, J BACTERIOL, V172, P4056, DOI 10.1128/jb.172.7.4056-4063.1990; Sambrook J, 1989, MOL CLONING LABORATO; Silhavy T.J., 1984, EXPT GENE FUSIONS; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANAKA T, 1988, J BACTERIOL, V170, P3593, DOI 10.1128/jb.170.8.3593-3600.1988; TANAKA T, 1991, J BACTERIOL, V173, P5507, DOI 10.1128/jb.173.17.5507-5515.1991; YANG M, 1986, J BACTERIOL, V166, P113, DOI 10.1128/jb.166.1.113-119.1986	26	133	143	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14509	14514						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1321152				2022-12-25	WOS:A1992JD32500109
J	JALLAL, B; SCHLESSINGER, J; ULLRICH, A				JALLAL, B; SCHLESSINGER, J; ULLRICH, A			TYROSINE PHOSPHATASE INHIBITION PERMITS ANALYSIS OF SIGNAL TRANSDUCTION COMPLEXES IN P185HER2/NEU-OVEREXPRESSING HUMAN TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; PROTO-ONCOGENE; NEU ONCOGENE; PDGF RECEPTOR; HUMAN-BREAST; KINASE RECEPTOR; GENE-PRODUCT; SI-LOCUS; PHOSPHORYLATION	The HER2/neu gene encodes a receptor tyrosine kinase that is highly homologous to the epidermal growth factor receptor. Overexpression of the receptor in mammary and ovarian carcinoma correlates with poor patient prognosis. To determine how the overexpression of a normal receptor leads to the generation of an oncogenic signal, we compared the patterns of tyrosine phosphorylation in tumor-derived human cell lines expressing high levels of p185HER2/neu. In intact SKBR3 cells, basal phosphorylation of p185HER2/neu was not detected. However, pretreatment of cells with the tyrosine phosphatase inhibitor, sodium orthovanadate, led to the detection of phosphotyrosine on phospholipase C-gamma (PLC-gamma), GTPase-activating protein but not on the RAF-1 kinase. Strikingly, PLC-gamma was detected in a complex which contained multiple tyrosine-phosphorylated polypeptides. This complex was detected only in cytoplasmic fractions and had a distinct composition in different p185HER2/neu-overexpressing cell lines. Although GTPase-activating protein has been found previously in association with proteins of 190 and 62 kDa in fibroblasts, in SKBR3 cells it was found associated with multiple additional tyrosine-phosphorylated polypeptides. These experiments show that SKBR3 cells possess high levels of protein tyrosine phosphatase that can act upon p185HER2/neu. Moreover, they reveal, for the first time, the presence of PLC-gamma and GTPase-activating protein in cytosolic complexes containing a variety of other tyrosine-phosphorylated polypeptides. These observations suggest novel possibilities for the specific definition of receptor-generated signals in tumor cells.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; New York University								ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERGER MS, 1988, CANCER RES, V48, P1238; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENDLY BM, 1990, CANCER RES, V50, P1550; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARLEY JM, 1987, ONCOGENE, V1, P423; VEUTER DJ, 1987, LANCET, V2, P69; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZHOU DJ, 1987, CANCER RES, V47, P6123; ZIPPEL R, 1989, EUR J CELL BIOL, V50, P428; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	59	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4357	4363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1347042				2022-12-25	WOS:A1992HF64200018
